Entries |
Document | Title | Date |
20080200342 | Device, Array, And Methods For Disease Detection And Analysis - A device and array coupled to capture molecules are provided. Specifically, the device and array can be used for detecting the presence and concentration of biomarkers in a sample from a subject. The device and array can also allow the use of a method for scoring a sample for, e.g., the purpose of diagnosing a disease. The method can also be advantageous to applications where there is a need to accurately determine the disease stage of a subject for the purpose of making therapeutic decisions. | 08-21-2008 |
20080200343 | Fluidics Devices - The invention relates to fluidics as used in medical and diagnostic equipment and relates further to means for purifying, abstracting, filtering, detecting and/or measuring analytes in liquid samples. | 08-21-2008 |
20080200344 | Protein chips for HPV detection - Embodiments of the invention provide methods, assays, and kits for detecting HPV infection, including infection by various HPV genotypes, early and/or late HPV-associated or HPV-specific proteins or antibodies. Detection of HPV DNAs, genomes, and/or oncoproteins by protein chips immunological assays can be used in early clinical screening for HPV infection and general diagnosis for cervical cancer and can be advantageous performed in a multiplexed test. Comparative detection of altered levels of HPV proteins and host proteins can performed in one or more assays. The polypeptides, recombinant proteins, antibodies, nucleic acids, and various detection methods thereof are particularly useful for diagnosing carcinomas of the uterine cervix and those at risk of developing cervical cancer. | 08-21-2008 |
20080207462 | DNA fragments array from biomining microorganisms and method for detection of them - Microorganisms are used in large-scale heap or tank aeration processes for the commercial extraction of a variety of metals from their ores or concentrates. These include copper, cobalt, gold and, in the past, uranium. The metal solubilization processes are considered to be largely chemical with the microorganisms providing the chemicals and the space (exopolysaccharide layer) where the mineral dissolution reactions occur. Temperatures at which these processes are carried out can vary from ambient to 80° C. and the types of organisms present depends to a large extent on the process temperature used. Irrespective of the operation temperature, biomining microbes have several characteristics in common. One shared characteristic is their ability to produce the ferric iron and sulfuric acid required to degrade the mineral and facilitate metal recovery. Other characteristics are their ability to grow autotrophically, their acid-tolerance and their inherent metal resistance or ability to acquire metal resistance. Although the microorganisms that drive the process have the above properties in common, biomining microbes usually occur in consortia in which cross-feeding may occur such that a combination of microbes including some with heterotrophic tendencies may contribute to the efficiency of the process. The remarkable adaptability of these organisms is assisted by several of the processes being continuous-flow systems that enable the continual selection of microorganisms that are more efficient at mineral degradation. Adaptability is also assisted by the processes being open and non-sterile thereby permitting new organisms to enter. This openness allows for the possibility of new genes that improve cell fitness to be selected from the horizontal gene pool. Characteristics that biomining microorganisms have in common and examples of their remarkable adaptability are described. | 08-28-2008 |
20080207463 | APPARATUS AND METHOD FOR PERFORMING LIGAND BINDING ASSAYS ON MICROARRAYS IN MULTIWELL PLATES - An apparatus and method for real time, label-free imaging and quantitation of binding events at an array of positions are provided. Total internal reflection from a planar side wall of a well of a multiwell plate is used to create an evanescent field in the plane of a pattern of ligands immobilized on the wall. Embodiments include imaging and multiple analyte detection and quantitation of a single wall of a single well as well as the simultaneous imaging and multiple analyte detection and quantitation of a number of wells. | 08-28-2008 |
20080207464 | Amplification of Nucleric Acids with Magnetic Detection - The present invention describes a method of amplifying nucleic acids and determining the amount of amplified nucleic acids using magnetic detection. The detection can be performed during the amplification process of the nucleic acid. During the detection, the amplified nucleic acid is bound to a sensor via a biological molecule. | 08-28-2008 |
20080207465 | Assay systems with adjustable fluid communication - Systems, including apparatus and methods, for performing assays with adjustable fluid communication between samples. | 08-28-2008 |
20080214406 | Look-Through Mutagenesis For Developing Altered Polypeptides With Enhanced Properties - A method of mutagenesis by which a predetermined amino acid is introduced into each and every position of a selected set of positions in a preselected region (or several different regions) of a polypeptide to produce a library of polypeptide analogs is disclosed. The method is based on the premise that certain amino acids play a crucial role in the structure and function of proteins and thus is capable of identifying and distinguishing functional amino acid residues (“hot spots”) from non-functional amino acids residues (“cold spots”) within a polypeptide or portion thereof. Libraries can be generated which contain only desired polypeptide analogs and are of reasonable size for screening. The libraries can be used to study the role of specific amino acids in polypeptide structure and function and to develop new or improved polypeptides such as antibodies, antibody fragments, single chain antibodies, enzymes, and ligands. | 09-04-2008 |
20080214407 | METHOD AND SYSTEM FOR QUANTIFICATION OF A TARGET COMPOUND OBTAINED FROM A BIOLOGICAL SAMPLE UPON CHIPS - A method quantifies a target compound selected from the group consisting of a polynucleotide or a protein present in a sample solution. The method includes putting into contact a target compound with a capture probe and detecting signals resulting from the binding between the target compound and its corresponding capture probe and resulting from the printed detection molecule in the different discrete regions. The method obtains a detection curve of the detected signals of the detection molecule and converts the signal obtained from the target compound bound to a specific capture probe into a concentration value and quantifies the target compound by converting the concentration value into a target amount using a target concentration curve. | 09-04-2008 |
20080214408 | IN SITU ASSEMBLY OF PROTEIN MICROARRAYS - The invention provides a microarray and methods for producing a protein microarray. The array comprises multiple nucleic acid molecules immobilized on a substrate, each comprising (i) a protein-binding domain and (ii) a nucleic acid sequence encoding a fusion protein comprising a polypeptide of interest and a DNA-binding protein that binds the protein-binding domain, and one or more fusion proteins produced from the multiple nucleic acid molecules. Each fusion protein is immobilized on the substrate via binding to a nucleic acid sequence comprising the protein-binding domain present on the nucleic acid molecule from which the fusion protein is produced or on the substrate. The invention also provides a method of analyzing protein interactions with, for example, other proteins, lipids and drugs. | 09-04-2008 |
20080220979 | Rapid Method To Detect Nucleic Acid Molecules - This invention relates to the field of detecting nucleic acid molecules using microarrays. The invention provides a method for detecting a target nucleic acid molecule in a biological sample by hybridizing a cell lysate directly probes immobilized on microarrays without any nucleic acid purification. | 09-11-2008 |
20080220980 | Method to Measure Dynamic Internal Calibration True Dose Response Curves - A method of determining an amount of analyte in a sample solution is provided. The method involves the use of an assay device that has a substantially planar assay surface. The surface has a plurality of calibration dots a test dot printed thereon. The calibration dots contain pre-determined quantities of the analyte while the test dot includes a capture antibody for binding to the analyte. The analyte is mixed into a solution having a sample antibody for the analyte, where the antibody is labeled with a detectable marker. The sample solution is introduced into the loading portion of the assay device for delivery to said reading portion. The next step is to measure the intensity of detectable marker in the calibration dots. With the data obtained, one then prepares a calibration curve correlating the amount of analyte in said calibration dots to said intensity of detectable marker. The intensity of detectable marker in the test dot can be measures and the amount of analyte present in said test dot calculated by comparing the intensity of detectable marker to the amount of analyte corresponding to the intensity in said calibration curve. | 09-11-2008 |
20080220981 | Chimeric binding peptide library screening method - There is described a method of isolating nucleotide sequences encoding target peptides from DNA libraries using DNA binding proteins to link the peptide to the sequence which encodes it. DNA libraries are prepared from cells encoding the protein of interest, or from synthetic DNA, and inserted into, or adjacent to, a DNA binding protein in an expression vector to create a chimeric fusion protein. Incorporation of the vector DNA into a carrier package, during expression of the chimeric fusion protein, results in the production of a peptide display carrier package (PDCP) displaying the DNA-bound fusion protein on the external surface of the carrier package. Employment of affinity purification techniques results in the PDCP particles containing sequences encoding the desired peptide to be selected and the desired nucleotide sequences obtained therefrom. | 09-11-2008 |
20080220982 | Nanoparticle Probes for Capture, Sorting and Placement of Targets - A nanoparticle probe is attached to a substrate to capture targets. The nanoparticle probe includes a specific binding agent that specifically binds to a target biomolecule. The biomolecule can be associated with a cell, for example expressed on the cell's surface, such that the cell is bound to the probe immobilized on the substrate. The nanoparticle probes can be applied to the substrate in a layer, for example in the form of a spot, and multiple spots can be applied to the substrate to form patterns or arrays of the spots on the substrate. The nanoparticle probe presents a binding surface on which oriented specific binding agents (such as antibodies or nucleic acids) can be attached. In particular examples the nanoparticle is spaced slightly from the substrate, for example by a linker, to provide a probe with improved contact with a liquid in which target biomolecules or cells are suspended. The probes can be applied to the substrate in identifiable locations, either by applying the nanoparticle probes to the substrate at a predetermined address or using a nanoparticle probe that emits a signal to identify its location. Particular examples of such probes are semiconductor nanocrystals such as quantum dots, which emit fluorescence of a particular color. The nanoparticle probes can sort biomolecules or cells of different types or subtypes, and maintain them in a substantially fixed location on the substrate where they can be studied for prolonged periods of time. | 09-11-2008 |
20080227652 | Dna Array for Analyzing Dna Methylation, Method of Producing the Same and Method of Analyzing Dna Methylation - A method of producing a DNA array for analyzing a DNA modification (for example, methylation), comprising (1) preparing a mixture of DNA fragments in which a modified base (for example, methylated cytosine) or a base (for example, cytosine) is exposed, (2) bringing the mixture of DNA fragments into contact with an antibody specific to the modified base (for example, methylated cytosine) or the base (for example, cytosine), and separating the mixture into a group consisting of DNA fragments which form an immunocomplex and another group consisting of DNA fragments which do not react with the antibody, or a group consisting of DNA fragments showing a high affinity for the antibody and another group consisting of DNA fragments showing a low affinity for the antibody, (3) identifying all or part of DNA fragments contained in each of the DNA fragment groups, and (4) arranging one or more nucleic acids capable of hybridizing with any one of the identified DNA fragments on a substrate, is disclosed. | 09-18-2008 |
20080227653 | Expression monitoring by hybridization to high density oligonucleotide arrays - The present invention provides methods for comparing and identifying differences in nucleic acid sequences using a plurality of sequence specific recognition reagents (i.e., probes comprising a nucleic acid complementary to a nucleic acid sequence in collections to be compared) bound to a solid surface. | 09-18-2008 |
20080227654 | Method for sequencing nucleic acid molecules - The present invention is directed to a method of sequencing a target nucleic acid molecule having a plurality of bases. In its principle, the temporal order of base additions during the polymerization reaction is measured on a molecule of nucleic acid, i.e. the activity of a nucleic acid polymerizing enzyme on the template nucleic acid molecule to be sequenced is followed in real time. The sequence is deduced by identifying which base is being incorporated into the growing complementary strand of the target nucleic acid by the catalytic activity of the nucleic acid polymerizing enzyme at each step in the sequence of base additions. A polymerase on the target nucleic acid molecule complex is provided in a position suitable to move along the target nucleic acid molecule and extend the oligonuelcotide primer at an active site. A plurality of labelled types of nucleotide analogs are provided proximate to the active site, with each distinguishable type of nucleotide analog being complementary to a different nucleotide in the target nucleic acid sequence. The growing nucleic acid strand is extended by using the polymeras to add a nucleotide analog to the nucleic acid strand at the active site, where the nucleotide analog being added is complementary to the nucleotide of the target nucleic acid at the active site. The nucleotide analog added to the oligonucleotide primer as a result of the polymerizing step is identified. The steps of providing labelled nucleotide analogs, polymerizing the growing nucleic acid strand, and identifying the added nucleotide analog are repeated so that the nucleic acid strand is further extended and the sequence of the target nucleic acid is determined. | 09-18-2008 |
20080234137 | Assay Method for Group Transfer Reactions - The present invention relates to methods for detecting, quantifying and high throughput screening of donor-products and the catalytic activities generating the donor-products in group-transfer reactions. The invention further provides immunoassays, antibodies and kits that may be used to practice the methods of the invention. | 09-25-2008 |
20080234138 | TP53 gene expression and uses thereof - The present invention is drawn to diagnosis, prognosis and treatment of multiple myeloma. In this regard, the present invention discloses importance of down-regulation of TP3 gene in multiple myeloma and its use as an independent progostic indicator of multiple myeloma. Additionally, the present invention also discloses novel-TP53 associated genes and demonstrates the clinical relevance of these alterations to disease progression. | 09-25-2008 |
20080234139 | Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling - Provided herein are methods for diagnosing and treating multiple myeloma based on statistical analysis of and subsequent increasing/inhibiting expression of subgroups of plasma cells and B cell genes. Also provided are methods for a developmental stage-based classification for multiple myeloma using hierarchical clustering analysis of plasma cell and B cell nucleic acids and for discriminating among normal, hyperplastic and malignant using gene expression array data and statistical analysis thereof. In addition methods for determining the risk of developing bone disease in a test individual by examining expression levels of a WNT signaling antagonist, such as DKK1, are provided. A kit comprising anti-DKK1 antibodies and detection reagents for measuring DKK1 protein levels also is provided. | 09-25-2008 |
20080242552 | MOLECULAR RECOGNITION OF MATERIALS - The present invention includes methods for selective binding of inorganic materials and the compositions that made up of the selecting agent and the target materials. One form of the present invention is a method for selecting crystal-binding peptides with binding specificity including the steps of contacting one or more amino acid oligomers with one or more single-crystals of a semiconductor material so that the oligomers may bind to the crystal and eluting the bound amino acid oligomers from the single-crystals. | 10-02-2008 |
20080242553 | Devices and methods for biochip multiplexing - The invention is directed to devices that allow for simultaneous multiple biochip analysis. In particular, the devices are configured to hold multiple cartridges comprising biochips comprising arrays such as nucleic acid arrays, and allow for high throughput analysis of samples. | 10-02-2008 |
20080242554 | NUCLEOTIDE PRIMER SET AND NUCLEOTIDE PROBE FOR DETECTING GENOTYPE OF METHYLENE TETRAHYDROFOLATE REDUCTASE (MTHFR) - There is provided is a nucleotide primer set for LAMP amplification used for detecting genotypes of single-nucleotide polymorphisms C677T and A1298C of an MTHFR gene. There is also provided a nucleotide probe for detecting an amplification product amplified by the primer set according to the present invention. There is also provided a method of detecting the genotypes of the single-nucleotide polymorphisms C677T and A1298C in the MTHFR gene, by using the primer set according to the present invention. | 10-02-2008 |
20080242555 | MULTIPLEX NUCLEIC ACID REACTIONS - The invention is directed to a variety of multiplexing methods used to amplify and/or genotype a variety of samples simultaneously. | 10-02-2008 |
20080242556 | METHODS OF MACROMOLECULAR ANALYSIS USING NANOCHANNEL ARRAYS - Methods of analyzing features such as the physical size of macromolecules or biomarkers along large genomic DNA molecules were disclosed as well as the devices for carrying out such high throughput analysis in a massively parallel fashion. Methods of fabricating such devices are also disclosed. | 10-02-2008 |
20080248962 | Adhesive Bead For Immobilization of Biomolecules and Method For Fabricating a Biochip Using the Same - The present invention relates to an adhesive bead for immobilizing biomolecules and a method for fabricating a biochip using the same, and more particularly, relates to an adhesive bead functioning both as a solid support immobilizing biomolecules and an adhesive to the surface of a biochip substrate, and a method for fabricating a biochip, the method comprising the steps of immobilizing biomolecules to the adhesive bead to prepare an aqueous suspension of beads on which biomolecules are fixed and fixing the aqueous suspension on a substrate. The adhesive beads of the present invention can be directely immobilized on a biochip without additional equipment and treatment process due to the dual functions of a solid support immobilizing biomolecules and an adhesive to the surface of a substrate. | 10-09-2008 |
20080248963 | Hybridization Method - A hybridization method is provided in which an efficient hybridization reaction can be carried out. Further, there are provided, using this hybridization method, a method for detecting a target gene with high sensitivity and a signal amplifying method for markedly improving the detection sensitivity of the target gene. There is provided a hybridization method comprising the use of oligonucleotides in a reaction solution, the method comprising forming partially a reaction temperature region in the reaction solution and performing a hybridization reaction in the reaction temperature region. | 10-09-2008 |
20080248964 | METHOD AND A SYSTEM FOR DETERMINATION OF PARTICLES IN A LIQUID SAMPLE - The present invention relates to a method for the assessment of quantity and quality parameters of biological particles in a liquid analyte material. The method comprises applying a volume of a liquid sample to an exposing domain from which exposing domain electromagnetic signals from the sample in the domain can pass to the exterior, and exposing, onto an array of active detection elements such as CCD-elements, a spatial representation of electromagnetic signals having passed from the domain, the representation being detectable as an intensity by individual active detection elements, under conditions permitting processing of the intensities detected by the array of detection elements during the exposure in such a manner that representations of electromagnetic signals from the biological particles are identified as distinct from representations of electromagnetic signals from background signals. The size of the volume of the liquid sample is sufficiently large to permit the assessment of the quantity and quality parameters to fulfill a predetermined requirement to the statistical quality of the assessment based on substantially one exposure. | 10-09-2008 |
20080248965 | METHOD AND A SYSTEM FOR DETERMINATION OF PARTICLES IN A LIQUID SAMPLE - The present invention relates to a method for the assessment of quantity and quality parameters of biological particles in a liquid analyte material. The method comprises applying a volume of a liquid sample to an exposing domain from which exposing domain electromagnetic signals from the sample in the domain can pass to the exterior, and exposing, onto an array of active detection elements such as CCD-elements, a spatial representation of electromagnetic signals having passed from the domain, the representation being detectable as an intensity by individual active detection elements, under conditions permitting processing of the intensities detected by the array of detection elements during the exposure in such a manner that representations of electromagnetic signals from the biological particles are identified as distinct from representations of electromagnetic signals from background signals. The size of the volume of the liquid sample is sufficiently large to permit the assessment of the quantity and quality parameters to fulfill a predetermined requirement to the statistical quality of the assessment based on substantially one exposure. | 10-09-2008 |
20080248966 | METHOD AND A SYSTEM FOR DETERMINATION OF PARTICLES IN A LIQUID SAMPLE - The present invention relates to a method for the assessment of quantity and quality parameters of biological particles in a liquid analyte material. The method comprises applying a volume of a liquid sample to an exposing domain from which exposing domain electromagnetic signals from the sample in the domain can pass to the exterior, and exposing, onto an array of active detection elements such as CCD-elements, a spatial representation of electromagnetic signals having passed from the domain, the representation being detectable as an intensity by individual active detection elements, under conditions permitting processing of the intensities detected by the array of detection elements during the exposure in such a manner that representations of electromagnetic signals from the biological particles are identified as distinct from representations of electromagnetic signals from background signals. The size of the volume of the liquid sample is sufficiently large to permit the assessment of the quantity and quality parameters to fulfill a predetermined requirement to the statistical quality of the assessment based on substantially one exposure. | 10-09-2008 |
20080254997 | Kit, Device and Method For Analyzing Biological Substance - The invention provides an analytical device insusceptible to inactivation or other influences even when exposed to a thermal load or organic compounds contained in an adhesive in the process for manufacturing the same and, more over, allowing an immunological substance or the like to be readily immobilized at a site in the microchannel passage therein. | 10-16-2008 |
20080254998 | Polymer Particle - A support comprising functional groups supported therein that specifically react with an aldehyde group of a sugar chain, and a polymer particle and a glycochip to which the support is applied, and uses thereof. | 10-16-2008 |
20080254999 | Linear nucleic acid and sequence therefor - Nucleic acids and sequences therefor are disclosed that are characterized by a reduction or lack of internal secondary structure, are capable of hybridizing with a complementary nucleic acid and do not hybridise with non-complementary nucleic acids (eg. do not cross-hybridise or form dimers) under low stringency hybridisation conditions. In particular, the nucleotide sequences enable use of these nucleic acids, without reduction in target hybridisation efficiency with increasing nucleic acid length. The nucleic acids may be used with analyte capture systems, for example medical, veterinary and agricultural diagnostic applications. In particular, the nucleic acid may be used as irrelevant binding pairs in an analyte capture system, such as an array or lateral flow assay. | 10-16-2008 |
20080255000 | Method Evolved for Recognition and Testing of Age Related Macular Degeneration (Mert-Armd) - Methods for predicting an individual's genetic risk for developing ARMD is disclosed, as are arrays and kits which can be used to practice the method. The method includes screening for mutations and/or polymorphisms in ARMD-associated molecules, such as CFH, LOC387715, BF, C2, ABCR, Fibulin 5, VMD2, TLR4, CX3CR1, CST3, MnSOD, MEHE, paraoxonase, APOE, ELOVL4 and hemicentin-1. | 10-16-2008 |
20080261821 | Mechanism-Based Crosslinkers - The present invention provides novel mechanism-based crosslinkers useful in covalently linking a kinase and an interactor. | 10-23-2008 |
20080261822 | Non-invasive prenatal genetic diagnosis using transcervical cells - A non-invasive, risk-free method of prenatal diagnosis is provided. According to the method of the present invention transcervical specimens are subjected to trophoblast-specific immuno-staining followed by FISH, PRINS, Q-FISH and/or MCB analyses and/or other DNA-based genetic analysis in order to determine fetal gender and/or identify chromosomal and/or DNA abnormalities in a fetus. Also provided is a method of in situ chromosomal, DNA and/or RNA analysis of a prestained specimen by incubating the prestained specimen in ammonium hydroxide. Also provided is a method of identifying embryonic cells according to a nucleus/cytoplasm ratio of at least 1:1 and the presence of at least variably condensed chromatin. | 10-23-2008 |
20080261823 | Fluorescent Nucleoside Analogs That Mimic Naturally Occurring Nucleosides - The present invention provides fluorescent nucleoside analogs with conjugated membered heterocycles, including furan and thiophene. The fluorescent nucleoside analogs maintain structural similarity to naturally occurring nucleoside bases, mimicking shape, size, hybridization, and recognition properties. Incorporation of the fluorescent cyclic compounds confers specific photophysical characteristics including a bathochromic (red) shift of the absorption spectrum to minimize absorption overlap with naturally occurring nucleoside bases, and a shift to the long emission wavelength in the visible range. The invention also provides for various methods of synthesizing the fluorescent nucleoside analogs and incorporating the fluorescent analogs in DNA, RNA, or oligomer synthesis. Further, methods of detecting the fluorescent nucleoside analogs in an oligonucleotide or oligomer are provided. The subject compounds are useful as probes in the study of the structure and dynamics of nucleic acids and their complexes with proteins. | 10-23-2008 |
20080261824 | Rationale, methods, and assays for identifying novel taste cell genes and salty taste receptor targets and assays using these identified genes or gene products - This invention relates to novel rationale and methods for identifying taste-specific genes, including genes involved in salty taste perception, especially human salty taste perception, but also genes involved in sweet, bitter, umami, and sour taste perception, and genes involved in other taste cell or taste receptor related activities such as digestive function and digestive related diseases, taste cell turnover, immunoregulation of the oral and digestive tract, and metabolic regulation such as in diabetes and obesity, the genes identified using these methods, and assays for identifying taste modulators (enhancers or blockers) and potential therapeutics using these genes. These compounds have potential application in modulating (enhancing or blocking) taste perception, especially salty taste perception and as potential therapeutics. In addition, this invention relates to novel methods for identifying taste-specific genes that can be used as markers for different taste cell types, including sweet, bitter, umami, sour, salt, and other taste cells in mammals as well as assays that measure the activity of the sweet, bitter, umami, or sour receptor in the presence of these genes to identify modulators of sweet, bitter, umami, and sour taste and to identify therapeutics especially for treating digestive or metabolic disorders, taste loss, and oral infections. Further, the invention provides specific methods of purifying, enriching, isolating or marking desired taste cell subtypes or lineages such as sweet, umami, bitter, salty, sour, fat or stem cells et al. e.g., by use of FACS, magnetic beads or other selection methods that purify, enrich, mark, or eliminate such as by use of labeled cytotoxins, cells that express or do not express one or more taste specific genes. | 10-23-2008 |
20080261825 | METHOD OF IMMOBILIZING MEMBRANE-ASSOCIATED MOLECULES - The present invention relates to methods of immobilizing membrane-associated molecules within a sol-gel matrix. The membrane-associated molecule is embedded in the bilayer of a liposome. The molecule-liposome assembly remains functionally intact when it is immobilized within a protein and membrane-compatible sol-gel derived from polyol silane precursors or sodium silicate. The activity and stability of the entrapped membrane-associated molecule was significantly improved in macroporous silica. | 10-23-2008 |
20080261826 | Manufacture And Use Of Non-Standard Size Microarray Slides - Methods and devices are disclosed for microarray analysis. In one embodiment a method is disclosed for processing a non-standard size slide having an array of chemical compounds attached to a surface of the slide. A sample is exposed to the surface of the non-standard size slide wherein components in the sample bind to the chemical compounds on the surface of the slide. The sample and the slide are incubated under conditions for carrying out the binding reactions, and the surface of the non-standard size slide is examined for the results of the binding reactions. Prior to the exposing step or the incubating step or the examining step, the non-standard size slide is placed into a slide holder comprising a slide-holding section a slide-holding section adapted to dispose the non-standard size slide to a processing instrument in a manner similar to that for a standard size slide. The non-standard size slide may also include an identifier such as a bar code. | 10-23-2008 |
20080269064 | Method and Kit for Detecting Components in a Sample - Methods and a kit for use in the detection of a component in a sample on a solid support are disclosed which use a conjugate and polymer having metal particles of diameter in the nanometer range (that is between 0.1 and 500 nm). Methods and a kit for detection of a component in a sample on a solid support which have a conjugate and optionally a polymer bound to one or more supermagnetic particles are also disclosed. The methods and kits may be used for enhancing in vivo imaging and microscopy. | 10-30-2008 |
20080269065 | Conformationally Constrained Analytical Probes - There is disclosed probes bearing partial metal chelators that in some embodiments are conformationally constrained. In certain embodiments such probes are useful in methods for the detection of a specific target molecule. These target molecules may include oligonucleotides, peptides, proteins, polysaccharides, or small molecules. There is further disclosed the use of probes with partial metal chelators engaged in a coordination complex with one another that imposes a structural constraint in the probe and increases the specificity factor of the probe. | 10-30-2008 |
20080269066 | Method and Array for the Replication and Analysis of Nucleic Acids - The invention includes a method and array for replicating and analyzing one or a plurality of different target sequences in nucleic acid samples. The different reactions for replicating the target sequences occur simultaneously on an array with selectively heatable array elements with their reaction surfaces, some of which have been modified differently, and in the sample solution disposed thereabove. The target sequences are analyzed using molecular detection on reaction surfaces of said array that have been modified with probe strands. The target strands are replicated and analyzed simultaneously, successively, or alternately. | 10-30-2008 |
20080269067 | Companion diagnostic assays for cancer therapy - A method for classifying cancer patients as eligible to receive cancer therapy comprising determination of the presence or absence in a patient tissue sample of chromosomal copy number gain at chromosomal locus 18q21-q22. The classification of cancer patients based upon the presence or absence of 18q21-q22 gain allows selection of patients to receive chemotherapy, such as therapy with a Bcl-2 family inhibitor, and for monitoring patient response to therapy. | 10-30-2008 |
20080269068 | MULTIPLEX DECODING OF SEQUENCE TAGS IN BARCODES - Methods and compositions for performing multiplex reactions are provided. | 10-30-2008 |
20080274909 | Kits and Reagents for Use in Diagnosis and Prognosis of Genomic Disorders - The invention provides articles of manufacture which are arrays, reagents, kits, and methods for diagnosis and/or prognosis of diseases with genomic aberrations. The methods of the invention identify differences between DNA samples from normal and disease tissues that are ascertained using comparative genomic hybridization (CGH) with microarrays of genomic fragments covering the whole genome of an organism, or microarrays containing subsets of the genome that are identified by the methods herein, for example, the long arm of chromosome 2 associated with prostate cancer. The detected genomic aberrations, are correlated to specific clinical outcomes, such that specific patterns of genomic aberration—disease association are identified in the majority of samples. The invention also provides genomic DNA arrays encompassing regions, the aberration of which was correlated to specific disease outcomes, for diagnosis/prognosis of such diseases. | 11-06-2008 |
20080274910 | Method of Detecting Early Immune Activation - Provided are methods of diagnosing an early immune activation by detecting T-cell immune response cDNA 7 (TIRC7); in particular, TIRC7 as an early biomarker for the detection of transplant rejection in a non-invasive diagnostic methods is described that replaces biopsy intervention with a simple diagnostic method for monitoring after transplantation and furthermore, kits for uses in such methods of diagnosis are provided. | 11-06-2008 |
20080274911 | Gene expression profiling based identification of genomic signature of high-risk multiple myeloma and uses thereof - The present invention discloses a method of applying novel bioinformatics and computational methodologies to data generated by high-resolution genome-wide comparative genomic hybridization and gene expression profiling on CD138-sorted plasma cells from a cohort of 92 newly diagnosed multiple myeloma patients treated with high dose chemotherapy and stem cell rescue. The results revealed that gains the q arm and loss of the p arm of chromosome 1 were highly correlated with altered expression of resident genes in this chromosome, with these changes strongly correlated with 1) risk of death from disease progression, 2) a gene expression based proliferation index, and 3) a recently described gene expression-based high-risk index. Importantly, we also found a strong correlation between copy number gains of 8q24, and increased expression of Argonate 2 (AGO2) a gene coding for a master regulator of microRNA expression and maturation, also being significantly correlated with outcome. Our novel findings significantly improve our understanding of the genomic structure of multiple myeloma and its relationship to clinical outcome. | 11-06-2008 |
20080280772 | Salivary Mrna Profiling, Biomarkers and Related Methods and Kits of Parts - A method to detect a biomarker in saliva wherein the biomarker is an extracellular mRNA, comprises detecting the extracellular mRNA in the cell-free saliva; transcriptome analysis of saliva comprises detecting a transcriptome pattern in the cell-free saliva; a method to detect genetic alterations in an organ or in a gene in the organ by analyzing saliva, comprises detecting a transcriptome pattern and/or the mRNA profiling of the gene in cell-free saliva; a method to diagnose an oral or systemic pathology disease or disorder in a subject, comprises: detecting profile of a biomarker associated with the pathology disease or disorder, in particular mRNA and/or protein, in cell-free saliva and/or serum; kits comprising identifier for at least one biomarker for performing at least one of the methods; and use of salivary biomarker salivary and/or serum mRNAs as biomarkers for oral and/or systemic pathology, disease or disorder. | 11-13-2008 |
20080280773 | Method of Nucleotide Detection - The invention relates to an additive which can be added to buffers used in nucleotide detection processes and improved methods of nucleic acid sequencing using this additive. In particular the invention relates to use of the additive to improve the efficiency of fluorescence-based multiple cycle nucleic acid sequencing reactions. | 11-13-2008 |
20080280774 | Methods and Systems for Diagnosis, Prognosis and Selection of Treatment of Leukemia - The present invention provides methods, systems and equipment for the prognosis, diagnosis and selection of treatment of AML or other types of leukemia. Genes prognostic of clinical outcome of leukemia patients can be identified according to the present invention. Leukemia disease genes can also be identified according to the present invention. These genes are differentially expressed in PBMCs of AML patients relative to disease-free humans. These genes can be used for the diagnosis or monitoring the development, progression or treatment of AML. | 11-13-2008 |
20080280775 | Determination of Antibiotic Resistance in Staphylococcus Aureus - The present invention relates to the detection of antibiotic resistance determinants in | 11-13-2008 |
20080280776 | Method and apparatus for detection of molecules using a sensor array - Apparatus and methods for detecting molecules in a fluidic environment are provided, including nanodevices and methods for fabricating, functionalizing, and operating such nanodevices. At least one of the methods includes selective heating of nanodevices in an array. | 11-13-2008 |
20080280777 | Method for determining the effects of external stimuli on biological pathways in living cells - The present invention describes methods for carrying out experiments on living cells, including making measurements of the operation transcriptional regulatory processes and indicators of the kinds of processes operating in the cell in response to external stimuli. Image analysis allows for gathering data concerning the flow of information through a cell's genomic regulatory network as it is executing a programmatic change in its activities as a function of said stimuli. The method also allows collection of data of the results of the information-processing in the cell by observing the decisions the cell makes when modulating cellular process activities. | 11-13-2008 |
20080280778 | Binding reagents that contain small epitope binding molecules - The invention provides binding reagents that contain a plurality of linked small epitope binding molecules that each recognizes a small epitope, such as small epitope antibodies. The combination of small epitope binding molecules in a binding reagent specifically recognizes and binds to a molecule of interest. The binding reagents may be used for such purposes as detection, quantification, identification, and purification of molecules of interest. | 11-13-2008 |
20080287309 | Methods for Discovering Antibodies Specific to Cancer Cells and Antibodies Discovered Thereby - This disclosure relates to methods for selecting antibodies having desirable characteristics from a population of diverse antibodies. More specifically, this disclosure provides methods for identifying antibodies which bind to cancer cells, but which do not bind to human red blood cells, white blood cells or normal tissue cells. Antibodies of the disclosure can be used for therapeutic and/or diagnostic purposes. | 11-20-2008 |
20080287310 | Human Sweet and Umami Taste Receptor Variants - Identified herein are different forms of sweet and umami receptor encoding sequences that occur in different human populations. In particular, there are provided several single nucleotide polymorphisms (SNPs) that occur within the exons/coding sequence (and are therefore coding SNPs, cSNPs) of one of the three T1R genes. Some SNPs cause amino acid substitutions, while others introduce a chain termination codon, rendering a truncated product. Differences in these genes are believed to affect the sense of taste of individuals, such that individuals with different SNPs (or different haplotypes) are believed to perceive the taste of sweet or umami (e.g., glutamate) substances differently than the rest of the population. The ability to assay this allelic information is useful in the development of flavorings and flavor enhancers, as it can be used to define groups and populations who perceive tastes differently. This in turn allows the taste preferences of these groups to be addressed at the molecular level. | 11-20-2008 |
20080287311 | Membrane-Translocating Peptides - A method is provided for selecting membrane-translocating peptides (MTPs) from a peptide display library that are capable of crossing or penetrating a lipid membrane. A plurality of nucleic acid constructs that encode displayed peptides are expressed, resulting in the formation of a plurality of nucleic acid-peptide complexes, each complex comprising at least one displayed peptide associated with the corresponding nucleic acid construct encoding the displayed peptide; the complexes are exposed to a population of membrane-encapsulated compartments, allowing a translocating reaction to occur; complexes that remain unassociated with the membrane are removed; optionally complexes that are associated with the membrane are removed; and internalised nucleic acid-peptide complexes are recovered. The membrane-encapsulated compartments may be artificial vesicles such as liposomes, or populations of one or more cell types. | 11-20-2008 |
20080287312 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 2 and mutated sequences thereof. | 11-20-2008 |
20080287313 | Reactive chips and methods for detecting bindings of target substances utilizing the chips - A novel chip capable of reducing a reaction period, applying wide-ranging target substance, preventing a mismatch binding efficiently and enabling a highly accurate detection is provided. Thus, an inventive reactive chip has the capture probe ( | 11-20-2008 |
20080293580 | Methods for Detecting and Measuring Specific Nucleic Acid Sequences - The invention provides novel oligonucleotides and methods of using the same for detection or measurement of specific nucleic acid molecules. The invention also features nucleic acid arrays comprising the oligonucleotides of the invention. An oligonucleotide of the invention comprises (1) a reporter-binding sequence capable of hybridizing to a fluorrophore-labeled reporter sequence and (2) a hairpin-forming sequence capable of forming a stem-loop. Formation of the stem-loop modifies (e.g., quenching) the fluorescence signals of the reporter sequence when the reporter sequence is hybridized to the oligonucleotide. This can be achieved, for example, by bringing one or more guanine based in the oligonucleotide into close proximity to the fluorophore(s) of the reporter sequence by virtue of the formation of the stem-loop. Disruption of the stem-loop, such as by hybridization of a target sequence to at least part of the hairpin-forming sequence, produces a detectable change in the fluorescence signals. | 11-27-2008 |
20080293581 | Rna Expression Microarrays - Provided are microarrays comprising spots comprising mixtures of cDNA molecules, the cDNA mixture being complementary and substantially quantitatively proportional to a mixture of mRNA molecules present in a cell or group of cells. Also provided are methods for determining expression of a gene in a cell or group of cells using the invention microarrays. Additionally provided are methods of determining the difference in expression of a first gene between a first cell or group of cells and a second cell or group of cells, using the invention microarrays. Also provided are microarrays comprising short RNAs, and methods of using these microarrays for detecting and quantifying microarrays in cells. | 11-27-2008 |
20080293582 | Markers and Methods for Assessing and Treating Ulcerative Colitis and Related Disorders Using a 43 Gene Panel - A method for prognostic or diagnostic assessment of a gastrointestinal-related disorder, such as ulcerative colitis, in a subject correlates the presence, absence, and/or magnitude of a gene in a sample with a reference standard to determine the presence and/or severity of the disorder, and/or the response to treatment for the disorder. The method enables identification of the effectiveness of candidate therapies. | 11-27-2008 |
20080293583 | Methods for diagnosing mood disorders - The present invention relates generally to the fields of neuroscience, proteomics and mood disorders. More particularly, the present invention relates to the identification of a group of proteins modulated in subjects with a mood disorder; methods for detecting or screening mRNA encoding these proteins and methods for diagnosing mood disorders. | 11-27-2008 |
20080293584 | Fluorescent silica nano-particle, fluorescent nano-material, and biochip and assay using the same - Colloidal silica particles containing a fluorescent dye compound, composed of a silica particle containing a silica component and a fluorescent dye compound chemically bound or adsorbed thereto, | 11-27-2008 |
20080293585 | 5'/3' Ratioing Procedure for Detection of Gene Rearrangements - The present invention relates to methods and kits useful for the detection of gene rearrangements and the diagnosis of a propensity to develop a disease condition caused by the gene rearrangements, wherein two PCR products are prepared from the 5′ side and from the 3′ side of a putative breakpoint of the gene of interest, and the ratio of the two products are measured. | 11-27-2008 |
20080293586 | FLUORESCENT PROBES FOR DNA DETECTION BY HYBRIDIZATION WITH IMPROVED SENSITIVITY AND LOW BACKGROUND - Minor groove binder-oligonucleotide probes are provided along with methods for their use wherein the probes have an attached fluorophore which, in an unhybridized form exhibits very low background signal. | 11-27-2008 |
20080293587 | Method of Screening a Biological Target for Weak Interactions Using Weak Affinity Chromatography - The present invention relates to a method of screening a biological target for transient weak interactions between the target and a library of ligands. The method includes the provision of a composition comprising a biological target and the provision of a plurality of stationary phases from such a composition. A plurality of ligand compositions is transported to the stationary phases to establish contacts between the ligands and the biological targets. Zonal retardation information are collected for each ligand, downstream of the stationary phases in order to select ligands with dissociation constants (Kd) in the range of 0.01 to 10 mM, exhibiting weak affinity to the target. | 11-27-2008 |
20080293588 | NANODISK CODES - The invention relates to nanodisk codes and methods of using the nanodisk codes in encoding and detection schemes. In one aspect, the invention relates to nanodisk codes having a binary encoding scheme and functionalized such that the encoding of the nanodisk codes is detectable. | 11-27-2008 |
20080293589 | Multiplex locus specific amplification - Methods are provided for amplifying a plurality of pre-selected target sequences from a complex background of nucleic acids. The targets are selected for amplification using splint oligonucleotides that are used to modify the ends of the fragments. The fragments have known end sequences and the splints are designed to be complementary to the ends. In one aspect the splint brings the ends of the fragment together and the ends are joined to form a circle. In another aspect the splint is used to add a common priming site to the ends of the target fragments. Specific loci are amplified and can be subsequently analyzed. | 11-27-2008 |
20080293590 | Multianalyte assay method - A plurality of groups of colorimetrically distinguishable metal nanoparticles are prepared to label specific analytes whose presence in a sample is under investigation, each group for specific analytes. After being mixed with the sample so that labeling can occur if the analyte or analytes are present, the sample is exposed to a sensor having probes for the analytes under investigation. Binding of any of the analytes present will carry the metal nanoparticle as well, which then enables colorimetric detection of each label to determine which if any of the analytes is present in the sample. In an alternative method the probes can be labeled with colorimetrically distinguishable metal nanoparticle labels and any binding events can be detected colorimetrically. | 11-27-2008 |
20080300141 | Neoepitope Detection of Disease Using Protein Arrays - A biosensor for use in detecting the presence of diseases, the biosensor comprising a detector for detecting a presence of at least one marker indicative of a specific disease. A method of determining efficacy of a pharmaceutical for treating a disease or staging disease by administering a pharmaceutical to a sample containing markers for a disease, detecting the amount of at least one marker of the disease in the sample, and analyzing the amount of the marker in the sample, whereby the amount of marker correlates to pharmaceutical efficacy or disease stage. Markers for gynecological disease selected from the list in Table 8. An immuno-imaging agent comprising labeled antibodies, whereby the labeled antibodies are isolated and reactive to proteins overexpressed in vivo. Informatics software for analyzing the arrays of claim | 12-04-2008 |
20080300142 | Methods, Reagents and Kits for Detection of Nucleic Acid Molecules - Methods, reagents and kits are provided for the production and use in detection assays of labeled nucleic acid molecules wherein a labeling molecule is attached directly to the 3′ end of the nucleic acid molecules. | 12-04-2008 |
20080300143 | ENDOGENOUS ANTISENSE RNA EXPRESSION ANALYSIS SYSTEM - Provided is a novel endogenous antisense RNA expression analysis system capable of comprehensively and highly-precisely detecting endogenous antisense RNA including noncoding antisense RNA. A probe set containing one or more probes designed for an antisense strand sequence (Artificial Antisense Sequence: AFAS) under the conditions optimal for hybridization, by artificially defining an antisense strand of known cDNA; a microarray containing the AFAS probe set; detection method of endogenous antisense RNA wherein the microarray and RNA labeling by random priming are combined, and the like. | 12-04-2008 |
20080300144 | Sensor for Biomolecules and a Method for Preparing and Using the Same - Disclosed is a method of preparing a sensor for the analysis of a sample fluid, said sample fluid containing one or more target molecules. The method comprises the steps of applying a non-activated porous organic polymer membrane with probes in the form of an array of probe locations, said probes being able to specifically bind to said one or more target molecules. Furthermore, the method comprises the steps of blocking areas remaining free of probes of said porous organic polymer membrane with one or more blocking substances and forcing the sample fluid repeatedly in one or two directions through the pores of said porous organic polymer membrane. Also disclosed is a sensor for the analysis of a sample fluid. | 12-04-2008 |
20080305959 | Laser microdissection and microarray analysis of breast tumors reveal estrogen receptor related genes and pathways - About 70% to 80% of breast cancers express estrogen receptor-α (ERα), and estrogens play important roles in the development and growth of hormone-dependent tumors. Together with lymph node metastasis, tumor size and histological grade, ER status is considered one of the prognostic factors in breast cancer, and an indicator for hormonal treatment. 147 genes and 112 genes with significant P-value and having significant differential expression between ER+ and ER− tumors were identified from the LCM data set and bulk tissue data set, respectively. 61 genes were found to be common in both data sets, while 85 genes were unique to the LCM data set and 51 genes were present only in the bulk tumor data set. Pathway analysis with the 85 genes using Gene Ontology suggested that genes involved in endocytosis, ceramide generation, Ras/ERK/Ark cascade, and JAT-STAT pathway may play roles related to ER. The gene profiling with LCM-captured tumor cells provides a unique approach to characterize and study epithelial tumor cells and to gain an insight into signaling pathways associated with ER. | 12-11-2008 |
20080305960 | Sequences for Differential Diagnostic of Ehrlichia Ruminantium and Use Thereof - The invention provides genes that are unique either to | 12-11-2008 |
20080305961 | Method of Generating Translationally Active Linear Dna Molecules and Use Thereof in Array Formats - This invention provides a method for producing expressionally and translationally active linear DNA molecules that can be used as protein expression cassettes and are useful for high throughput protein expression and analysis in living cells. The method comprises a PCR amplification using two primers complementary to the sequences flanking the DNA sequence of interest, such as a cDNA, an open reading frame or a gene, that exists in expression vectors. The resultant PCR product contains a promoter, the DNA sequence of interest, and a termination sequence. The invention further provides different uses of these translationally active DNA cassettes, such as in proteome arrays. | 12-11-2008 |
20080305962 | Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies - The invention provides novel compositions, methods and uses, for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia and cancer. The invention further relates to genes that are differentially expressed in tissue of cancer patients versus those of normal “healthy” tissue. Differentially expressed genes for the identification of patients which are likely to respond to chemotherapy are also provided. The present invention relates to methods for prognosis the prediction of therapeutic success in cancer therapy. In a preferred embodiment of the invention it relates to methods for prediction of therapeutic success of combinations of signal transduction inhibitors, therapeutic antibodies, radio- and chemotherapy. The methods of the invention are based on determination of expression levels of 48 human genes which are differentially expressed prior to the onset of anti-cancer chemotherapy. The methods and compositions of the invention are most useful in the investigation of advanced colorectal cancer, but are useful in the investigation of other types of cancer and therapies as well. | 12-11-2008 |
20080305963 | Conductimetric biosensor device, method and system - A multi-array membrane strip biosensor device ( | 12-11-2008 |
20080312093 | Method for detecting cancer and a method for suppressing cancer - An object of the invention is to find a cancer-associated gene to be used as an index for detecting canceration of cells and degree of malignancy of cancer, so as to provide a method for detecting cancer using the cancer-associated gene as an index and provide a method of suppressing/treating cancer using the cancer-associated gene as essential part. According to the present invention, specific genes which are amplified or deleted in gastric carcinoma as compared with normal cell have been collectively found, and a method for detecting cancer using amplification or deletion of these cancer-associated genes as an index is provided. Further, cancer can be suppressed by introducing a gene which is deleted in cancer cells among these cancer-associated genes into cancer and inhibiting the transcription product of the gene amplified. | 12-18-2008 |
20080312094 | MUTATED AQP, METHOD FOR DETECTING CANCER USING THE SAME, DNA CHIP HAVING OLIGONUCLEOTIDES OF SAID MUTATED AQP SEQUENCE - The present invention relates to mutation genes of the AQP (aquaporin), a method for detecting cancer using mutations and expressions of the AQP and a DNA chip possessing oligonucleotides of mutated AQP base sequence. In case of the present method for detecting cancer and DNA chip using the AQP's mutations and expressions, it is highly accurate, rapid and effective in cancer diagnosis. | 12-18-2008 |
20080312095 | VACCINE DESIGN METHODOLOGY - Systems and methodologies for efficient vaccine design are disclosed herein. A methodology for efficient vaccine design in accordance with one or more embodiments disclosed herein may be operable to receive a graph having vertices corresponding to epitope sequences present in the pathogen population, weights for respective vertices corresponding to respective frequencies with which corresponding epitope sequences appear in the pathogen population, and directed edges that connect vertices that correspond to overlapping epitope sequences. Such a methodology may also be operable to determine a candidate vaccine sequence of overlapping epitope sequences by identifying a path though the graph corresponding to a series of connected vertices and directed edges that maximizes the total weight of the vertices in the path for a desired vaccine sequence length. | 12-18-2008 |
20080312096 | Predictive and Therapeutic Markers in Ovarian Cancer - Cancer markers may be developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genes in the human chromosomal regions, 8q24, 11q13, 20q11-q13, were found to be amplified indicating in vivo drug resistance in diseases such as ovarian cancer. Diagnosis and assessment of amplification levels certain genes shown to be amplified, including PVT1, can be useful in prediction of poor outcome of patient's response and drug resistance in ovarian cancer patients with low survival rates. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically ovarian cancer. Therapeutics to inhibit amplification and inhibitors of one of these genes, PVT1, target drug resistance in ovarian cancer patients with low survival rates is described. | 12-18-2008 |
20080312097 | Immunological assay and chip - The present invention provides an immunological assay suitable to be carried out on a chip. After an antigen-antibody complex in which an antigen | 12-18-2008 |
20080312098 | Use of a Gip Promoter Polymorphism - The use of the single nucleotide polymorphism (SNP) at position −(97) of the GIP gene for the identification of a cardiovascular disease or of an increased risk for developing a cardiovascular disease in a biological sample taken from an individual to be examined. | 12-18-2008 |
20080312099 | Microarray, System, and Method for Detecting, Identifying, and Quantitating Micro-Rnas - Micro-RNA (miRNA) microarrays useful for detecting, identifying and quantitating miRNAs in a sample include oligonucleotide probes that specifically bind miRNAs. Exemplary miRNA microarray can be specific for miRNAs of human, canine, mouse, rat, or another species. | 12-18-2008 |
20080318797 | PROCESS FOR SCREENING OF A BINDING PEPTIDE SPECIFIC FOR SPECIFIC RNA AND RNA BINDING PEPTIDES THEREFROM - The present invention relates to a screening method for RNA specific binding peptide using alpha-helical peptides. The screening method for RNA specific binding peptide of the present invention using alpha-helical peptides enables the selection of a peptide having strong binding capacity to a specific RNA having particular morphology and nucleotide sequence and the investigation of functions of RNA using the selected peptides, and is very useful for the production of a new drug using synthetic peptide having more powerful and specific binding capacity to RNA than those of natural peptides. | 12-25-2008 |
20080318798 | Antigen Detection - The present invention relates to methods of detecting specific cell surface antigens present in a sample of cells being tested and in particular blood group antigens, which methods do not employ the addition of extrinsic labels to detect said cell surface antigens. Typically detection is carried out using an intrinsic fluorescence capability of the cells being tested. | 12-25-2008 |
20080318799 | Method of Quantifying the G Protein-Coupled Receptor (Gpcr)/G Protein Coupling Using a Cell Membrane Array - The invention relates to a method for quantifying G protein-coupled receptor (GPCR)-G protein binding by means of using a cell membrane array, which comprises (i) putting an unlabeled candidate compound in contact with a cell membrane array in the presence of labeled GTP or of a labeled, non-hydrolyzable analog thereof, in conditions allowing the interaction between said compound and said GPCR present in said cell membranes, and between said labeled GTP or analog thereof and said G protein present in said membranes; (ii) washing; and (iii) quantifying the signal obtained due to the binding of the labeled GTP (or analog) to said G protein. It is applicable in the analysis of the interaction between compounds and cell membrane receptor proteins and of the intracellular signaling mechanisms triggering this interaction mechanism mediated by said compounds. | 12-25-2008 |
20080318800 | METHODS AND COMPOSITIONS FOR DETECTING AUTOIMMUNE DISORDERS - The invention provides methods and compositions useful for detecting autoimmune disorders. | 12-25-2008 |
20080318801 | METHOD AND KIT FOR EVALUATING RNA QUALITY - The present invention relates to a method for analyzing and rapidly determining the quality of a test RNA of unknown quality utilizing a novel quantitative reverse transcription-polymerase chain reaction (RT-PCR) based method. The present invention is based on normalizing the 3′ end of the house-keeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to the relative abundance of the 5′ end of GAPDH MRNA in the test RNA. The present invention is particularly useful in pre-screening postmortem tissue samples for microarray experiments and for evaluating large quantities of samples which would be time consuming and expensive to analyze by methods currently in use. | 12-25-2008 |
20080318802 | METHODS AND COMPOSITIONS FOR TAGGING AND IDENTIFYING POLYNUCLEOTIDES - The invention provides methods and compositions for attaching oligonucleotide tags to polynucleotides for the purpose of carrying out analytical assays in parallel and for decoding the oligonucleotide tags of polynucleotides selected in such assays. Words, or subunits, of oligonucleotide tags index submixtues in successively more complex sets of submixtures (referred to herein as “tiers” of submixtures) that a polynucleotide goes through while successive words are added to a growing tag. By identifying each word of an oligonucleotide tag, a series of submixtures is identified including the first submixture that contains only a single polynucleotide, thereby providing the identity of the selected polynucleotide. The analysis of the words of an oligonucleotide tag can be carried out in parallel, e.g. by specific hybridization of the oligonucleotide tag to its tag complement on an addressable array; or such analysis can be carried out serially by successive specific hybridizations of labeled word complements, or the like. | 12-25-2008 |
20090005257 | Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire - The invention relates to polypeptides that unfold reversibly (e.g., unfolds when heated and refolds when cooled), to repertoires containing polypeptides that unfold reversibly and to libraries that contain polypeptides that unfold reversibly or nucleic acids that encode polypeptides that unfold reversibly. The invention further relates to processes for producing a library enriched in polypeptides that unfold reversibly or nucleic acids encoding polypeptides that unfold reversibly, processes for selecting and/or isolating polypeptides that unfold reversibly, and to methods for producing a polypeptide that unfolds reversibly. | 01-01-2009 |
20090005258 | Diagnosis of Metastases in Hnscc Tumours - The invention relates to the detection or prediction of metastases of head and neck squamous cell carcinoma (HNSCC) with the use of gene expression profiles. A gene signature has been identified which is able to detect or predict the occurrence of these metastases better than current clinical methods. Part of the invention are micro-arrays comprising this signature and methods for performing the detection and/or prediction. | 01-01-2009 |
20090005259 | Random array DNA analysis by hybridization - The invention relates to methods and devices for analyzing single molecules, i.e. nucleic acids. Such single molecules may be derived from natural samples, such as cells, tissues, soil, air and water without separating or enriching individual components. In certain aspects of the invention, the methods and devices are useful in performing nucleic acid sequence analysis by probe hybridization. | 01-01-2009 |
20090005260 | MULTIPLEX DATA COLLECTION AND ANALYSIS IN BIOANALYTE DETECTION - Method and device to collect multiplex data simultaneously in analyte detection and analyze the data by experimentally trained software (machine-learning) is disclosed. Various ways (magnetic particles and microcoils) are disclosed to collect multiple reporter (tag) signals. Multiplex detection can increase the biomolecule analysis efficiency by using small sample size and saving assay reagents and time. Machine learning and data analysis schemes are also disclosed. Multiple affinity binding partners, each labeled by a unique reporter, are contacted with a sample and a single spectrum is taken to detect multiple reporter signals. The spectrum is deconvoluted by experimentally trained software to identify multiple analytes. | 01-01-2009 |
20090005261 | PURIFICATION OF IMMUNOGLOBULINS USING AFFINITY CHROMATOGRAPHY AND PEPTIDE LIGANDS - An immunoglobulin binding peptide having the general formula, from amino terminus to carboxy terminus, of Z-R | 01-01-2009 |
20090005262 | Methods, Compositions and Compound Assays for Inhibiting Amyloid-Beta Protein production - A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a GPCR polypeptide, or fragment thereof, and measuring a compound-GPCR property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including second messenger and/or amyloid beta peptide levels. Therapeutic methods, and pharmaceutical compositions including effective amyloid-beta precursor processing-inhibiting amounts of GPCR expression inhibitors, are useful for treating conditions involving cognitive impairment such as Alzheimers Disease. | 01-01-2009 |
20090005263 | Signal Amplification of Biorecognition Events Using Photopolymerization in the Presence of Air - The present invention discloses an inexpensive and non-enzymatic signal amplification technique on both DNA and protein microarrays. The technique is uses photo-initiated polymerization and is conducted directly on the microarray. A capture molecule is bound to the desired surface. The target molecule then binds to the capture molecule. A label sequence with a bound photo initiator binds to the target molecule. Polymerization is activated using a wave length of light corresponding to the wave length needed to activate the chosen photo initiator. This new non-enzymatic method can be applied to the rapid detection of any biological pathogen via either microarray or ELISA platforms. Influenza is described herein as an example application of the technology. | 01-01-2009 |
20090011946 | Use of Sequence Specific Polymers in Chemical Detection - A method for chemical detection is provided. In one aspect, the method comprises exposing a sample to a sequence specific polymer under conditions such that an analyte in the sample binds to the polymer. Binding of the analyte to the sequence specific polymer results in a change in a property of the sequence specific polymer that is transduced to a response transduction medium, which generates a detectable response. Another aspect provides a detection device comprising the sequence specific polymer and response transduction medium. | 01-08-2009 |
20090011947 | Detection Chip and Method for Detecting Substance Using Same - A detection chip comprises a substrate and a well-shaped reaction portion formed in the substrate, in which the well-shaped reaction portion comprises a bottom portion having a planar shape and a side portion the width between which is widen from the bottom portion toward an opening portion. | 01-08-2009 |
20090011948 | Structured Substrates for Optical Surface Profiling - This disclosure provides methods and devices for the label-free detection of target molecules of interest. The principles of the disclosure are particularly applicable to the detection of biological molecules (e.g., DNA, RNA, and protein) using standard SiO | 01-08-2009 |
20090011949 | Methods and devices based upon a novel form of nucleic acid duplex on a surface - Provided herein are biomolecular hybridization devices comprising a substrate with a permanently and covalently attached surface of functional groups and an adsorbed monolayer of unmodified, single-stranded oligonucleotides all of which are 10 to about 24 bases in length as a saturated film of constrained oligonucleotides on the surface via direct non-covalent phosphate-surface adsorptive contact of substantially all phosphate groups of each oligonucleotide. The constrained oligonucleotides are effective to dissociably hybridize to a complementary single-stranded nucleic acid with asymmetric, non-helical base pairing and without oligonucleotide dissociation from the surface of the device. Also, provided are methods for hybridizing solution-state target nucleic acids to probe nucleic acids and for identifying a nucleotide sequence to which a nucleotide-binding protein binds using the biomolecular hybridization devices. | 01-08-2009 |
20090011950 | METHOD FOR DETECTING ORAL SQUAMOUS-CELL CARCINOMA AND METHOD FOR SUPPRESSING THE SAME - An object of the present invention is to provide a method for detecting cancer through identification of genes exhibiting characteristic behavior in the cases of cancer such as oral squamous-cell carcinoma, and a cell growth inhibitor. The present invention provides a method for detecting cancer, which comprises detecting canceration including malignancy of a specimen through detection of at least one alteration of a gene existing in a chromosomal region 1q21, 2q24. 1-q24.2, 3p13, 7p11.2, 10p12.1, 11p5.4, 11p15.2, 11p13.3, 11q22, 11q23.3, 12p13, 12q24.31, 13q33.3-q34, 12q24.1, 19q13, or 22q12.1 in the specimen. | 01-08-2009 |
20090018027 | Method for Producing Chemical Microarrays - A method of producing a microarray, the microarray itself and the use of the microarray for detecting interactions between probe molecules and analyte molecules from a sample is provided. The method comprises the steps of synthesis, in two or more stages, of probe molecules on a polymeric support, bonds being formed between the probe molecules and the polymeric support; dispersion of the polymeric support having the synthetic probe molecules, | 01-15-2009 |
20090018028 | Self-Assembled Nucleic Acid Nanoarrays and Uses Therefor - The present invention provides self-assembling, finite nucleic acid tiling arrays, and methods for their synthesis and use, which overcome a major hurdle in self-assembled DNA nanostructures, and therefore have numerous potential applications for nanofabrication of complex structures and useful devices, as further disclosed herein. | 01-15-2009 |
20090018029 | Methods and Compositions Comprising Non-Natural Amino Acids - Disclosed herein are methods of detecting non-natural amino acids and polypeptides that include at least one non-natural amino acid. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of functionalities, including but not limited to oxime, carbonyl, and/or hydroxylamine groups. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, and methods for detecting such polypeptides. | 01-15-2009 |
20090018030 | Polymorphisms in the human genes for OCT1 and their use in diagnostic and therapeutic applications - The present invention relates to a polymorphic OCT1 polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing cells capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide or the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or drug or an inhibitor are also encompassed by the present invention. In addition, the invention relates to methods for producing of a pharmaceutical composition and to methods of diagnosing a disease. Further, the invention relates to a method of detection of the polynucleotide of the invention. Furthermore, comprised by the present invention are a diagnostic and a pharmaceutical composition. Even more, the invention relates to uses of the polynucleotides, genes, vectors, polypeptides or antibodies of the invention. Finally, the invention relates to a diagnostic kit. | 01-15-2009 |
20090023592 | SYSTEM FOR IDENTIFYING AND ANALYZING EXPRESSION OF ARE-CONTAINING GENES - The present invention relates to a gene discovery system and gene expression systems specific for genes encoding ARE-containing mRNAs. In one aspect, the present invention relates to computational methods of selecting coding sequences of ARE-genes from databases using aone or more ARE search sequences. The ARE search sequences are from 10 to 80 nucleotides in length and comprise a sequence which is encompassed by one of the following two sequences: (a) WU/T(AU/TU/TU/TA)TWWW, SEQ ID NO. 1, wherein none or one of the nucleotides outside of the parenthesis is replaced by a different nucleotide, and wherein W represents A, U. or T; and (b) U/T(AU/TU/T/U/T)n, SEQ ID NO. 2, wherein n indicates that the search sequence comprises from 3 to 12 of the tetrameric sequences contained within the parenthesis. The method comprises extracting from the databases, those nucleic acids whose protein coding sequences are upstream and contiguous with a 3′untranslated region (UTR) that comprises one of the ARE search sequences. The present invention also relates to methods of selectively amplifying RNA and cDNA molecules using primers derived from and complementary to the consensus 5′ sequence motifs and primers derived from and complementary to the ARE search sequence. The present invention also relates to methods of selectively amplifying ARE genes which employ a 3′ primer which is from 15 to 50 nucleotides and length and comprises from 2 to 10 pentamers having the sequence TAAAT. The pentameric sequences in the primers are either overlapping or non-overlapping. The 3′ primers are used in the reverse transcription step of the methods, the polymerase chain reaction (PCR) amplification step of the methods, or in both the reverse transcription step and the PCR amplification step of the methods. The present invention also relates to methods of making libraries which comprise portions of the ARE genes that are selectively amplified by the present methods and to methods of making microarrays which comprise probes that hybridize under stringent conditions to portions of the protein coding sequences of the ARE genes that are selectively amplified by the present methods. The present invention also relates to libraries and the microarrays that are made by such methods. | 01-22-2009 |
20090023593 | In situ cloning from pathological tissue specimens - The present invention pertains to methods related to cloning nucleic acids from biological samples, particularly pathological tissue samples. This method includes hybridizing a population of oligonucleotide sequence probes comprising degenerate sequence tags to a fixed tissue, isolating the hybridized oligonucleotide sequence probes and amplifying the sequence tags in the hybridized oligonucleotide sequence probes. This method can be utilized to identify genes associated with disease and to quantitate the expression of disease-related transcripts. The method can also be used to identify truncated mRNAs. | 01-22-2009 |
20090023594 | REAGENTS FOR LABELLING NUCLEIC ACIDS AND USES THEREOF - The present invention relates to labelling kits containing novel non-natural nucleotide monomers and to methods of making and using such compounds. The invention further relates to a method of detecting the presence of a nucleic acid, e.g., RNA, of interest in a sample, the method having the following steps: providing the sample; ligating a nucleic acid of interest with a labelling reagent according to the instant invention; providing a nucleic acid array having probes directed to the nucleic acid of interest; hybridizing the labelled nucleic acid fragments to said nucleic acid array; and determining the extent of hybridization to said probes to determine the presence of the nucleic acid of interest. | 01-22-2009 |
20090023595 | METHOD FOR MEASURING A TARGET SUBSTANCE AND A KIT FOR MEASURING A TARGET SUBSTANCE - The method for measuring the concentration of a target substance in a sample solution by fluorescence polarization method comprises steps of mixing the sample solution with a fluorescently labeled substance capable of binding to the target substance, dispensing the resulting mixture in micro-chambers of a micro-chamber array, measuring a value of fluorescence polarization or anisotropy with respect to each of the micro-chambers, and determining the concentration of the target substance in the sample solution on the basis of the measurement results. | 01-22-2009 |
20090023596 | In Vitro Model Of Latent Mycobacterial Infection - A method of inducing latency in | 01-22-2009 |
20090023597 | Single Nucleotide Polymorphism Detection from Unamplified Genomic DNA - The present invention provides methods, compositions and systems for the specific and selective detection of multiple single nucleotide polymorphisms (SNPs) from genomic DNA. Importantly, the inventive systems and methods eliminate the need for costly, time- and labor-intensive gene amplification that is generally carried out prior to SNP detection. Also provided are kits useful to perform the inventive methods. | 01-22-2009 |
20090029864 | Method For Screening Toxin Neutralizing Peptide, STX2 Inhibiting Peptide And Verotoxin Neutralizing Agent - A screening method comprises the following steps;
| 01-29-2009 |
20090029865 | IDENTIFICATION OF MOLECULAR SEQUENCE SIGNATURES AND METHODS INVOLVING THE SAME - Novel means and methods for analyzing hybridization data derived from hybridization assays between a target nucleic acid and differently sequenced polynucleotide probes involve selecting probe sets that define reference sequences for sequence signatures and deriving useful data about the nature of the target nucleic acid molecule based on its hybridization to the probes. The methods are useful for determining whether the target contains a nucleic acid or polypeptide sequence signature, whether the target encodes a member of a gene family, or whether the target is derived from one of any number of genes. | 01-29-2009 |
20090029866 | Libraries of oligomers labeled with different tags - A method of making a set of labelled compounds by the use of a preferably particulate support, comprises dividing the support into lots, performing a different chemical reaction on each lot of the support, e.g. to couple a chemical moiety to that lot of the support, tagging a fraction of each lot of the support with a different label, and combining the said lots of the support. The steps are repeated several times, preferably to build up oligomer molecules carrying labels which identify the nature and position of a monomer unit of the oligomer, and which are releasable from the support. Preferred labels, which are releasable from the compounds by cleavage to provide charged groups for analysis by mass spectrometry, are groups of the trityl (trimethylphenyl) family. Also claimed are libraries of these labels and their use in assays and nucleic acid analysis methods. | 01-29-2009 |
20090029867 | DNA purification and analysis on nanoengineered surfaces - A microfluidic device for isolating genomic DNA from human leukocytes, simultaneously capturing and measuring the DNA for simplifying genetic analysis. The device contains a fluid inlet port, a fluid outlet port, and a DNA binding channel in contact with the fluid inlet port wherein at least a portion of at least one surface within the DNA binding channel is modified with a binding reagent such that DNA is preferentially bound to the surface. | 01-29-2009 |
20090029868 | Expression signature in peripheral blood for detection of aortic aneurysm - We hypothesized that gene expression patterns in peripheral blood cells may correlate with TAA disease status, and carried out a comprehensive gene expression survey on peripheral blood cells obtained from TAA patients and normal individuals. A distinct gene expression profile in peripheral blood cells can classify TAA patients from normal individuals. The genes provided by the present teachings define a set of diagnostic markers, thus providing a blood-based gene expression test to facilitate early detection of TAA disease. Methods of distinguishing ascending from descending TAA are also provided, as are methods of distinguishing familial from sporadic TAA. | 01-29-2009 |
20090029869 | SURFACE MODIFICATION, LINKER ATTACHMENT, AND POLYMERIZATION METHODS - The present invention relates to surface modifications and linker attachments. For example, the present invention provides surface modification and linker chemistry that facilitates manufacture and use of microarrays, including nucleic acid and protein microarrays. The present invention also relates to array spotting through non-aqueous liquids. | 01-29-2009 |
20090029870 | Particle Analyzing Systems and Methods Using Acoustic Radiation Pressure - The present invention comprises methods and systems that use acoustic radiation pressure. | 01-29-2009 |
20090029871 | METHOD FOR SIMULTANEOUSLY PERFORMING MULTIPLE AMPLIFICATION REACTIONS - An automated analyzer for performing multiple diagnostic assays simultaneously includes multiple stations, or modules, in which discrete aspects of the assay are performed on fluid samples contained in reaction receptacles. The analyzer includes stations for automatically preparing a specimen sample, incubating the sample at prescribed temperatures for prescribed periods, performing an analyte isolation procedure, and ascertaining the presence of a target analyte. An automated receptacle transporting system moves the reaction receptacles from one station to the next. The analyzer further includes devices for carrying a plurality of specimen tubes and disposable pipette tips in a machine-accessible manner, a device for agitating containers of target capture reagents comprising suspensions of solid support material and for presenting the containers for machine access thereto, and a device for holding containers of reagents in a temperature controlled environment and presenting the containers for machine access thereto. A method for performing an automated diagnostic assay includes an automated process for isolating and amplifying a target analyte. The process is performed by automatically moving each of a plurality of reaction receptacles containing a solid support material and a fluid sample between stations for incubating the contents of the reaction receptacle and for separating the target analyte bound to the solid support from the fluid sample. An amplification reagent is added to the separated analyte after the analyte separation step and before a final incubation step. | 01-29-2009 |
20090036321 | Methods for predicting the course of a malignant disease - The present invention relates to methods of predicting the course of malignant disease and more specifically to methods which use SERPINE2 as a prognostic indicator of disease in cancer patients. | 02-05-2009 |
20090036322 | Leukocyte Adsorbing Material - A novel polyurethane material having excellent leukocyte adsorption capacity. When exposed to a labelled sugar chain solution LDF1 for 2 hours, it exhibits an adsorption amount of 400,000 or more. The polyurethane is composed of (A) a diisocyanate compound structural unit, (B) a polymer diol compound structural unit, and (C) a chain extender structural unit, preferably containing a tertiary amino group. | 02-05-2009 |
20090036323 | STRATEGIES FOR HIGH THROUGHPUT IDENTIFICATION AND DETECTION OF POLYMORPHISMS - The invention relates to a method for the high throughput identification of single nucleotide polymorphisms by performing a complexity reduction on two or more samples to yield two or more libraries, sequencing at least part of the libraries, aligning the identified sequences and determining any putative single nucleotide polymorphisms, confirming any putative single nucleotide polymorphism, generating detection probes for the confirmed single nucleotide polymorphisms, subjection a test sample to the same complexity reduction to provide a test library and screen the test library for the presence or absence of the single nucleotide polymorphisms using the detection probe. | 02-05-2009 |
20090036324 | ARRAYS, SUBSTRATES, DEVICES, METHODS AND SYSTEMS FOR DETECTING TARGET MOLECULES - Arrays and substrates comprising a material, in particular capture agents and/or detectable targets, attached to the substrates along substantially parallel lines forming a barcoded pattern and related methods and systems. | 02-05-2009 |
20090042733 | Process for detecting or quantifying nucleic acids in a library - This invention provides novel compositions and processes for analyte detection, quantification and amplification. Nucleic acid arrays and libraries of analytes are usefully incorporated into such compositions and processes. Universal detection elements, signaling entities and the like are employed to detect and if necessary or desirable, to quantify analytes. Amplification of target analytes are also provided by the compositions and processes of this invention. | 02-12-2009 |
20090042734 | Probe Array and Method for Producing Probe Array - An object of the present invention is to provide a probe array having partitioned array regions with uniform surface chemical properties. The probe array of the present invention includes a substrate having a plurality of partitioned array regions where many probes are immobilized and a separator attached to the substrate and including partitions partitioning the array regions. The above object can be achieved by attaching the separator including the partitions capable of partitioning instead of forming hydrophobic regions on a surface of the substrate by printing or chemical treatment. | 02-12-2009 |
20090042735 | Methods and Compositions Related to Nucleic Acid Detection - Disclosed are compositions and a method for detection of nucleic acid sequences based on competitive displacement. | 02-12-2009 |
20090048117 | MODULATION OF IMMUNE SYSTEM FUNCTION BY MODULATION OF POLYPEPTIDE ARGININE METHYLTRANSFERASES - The instant invention pertains to, e.g., method of identifying a compound that modulates cytokine production or T cell receptor-mediated signaling, by identifying modulators of the expression and/or activity or PRMT polypeptides. The invention further pertains to methods for identifying a compound that modulates cytokine production in a non-T cell, by identifying compounds that modulate the expression and/or activity of NIP45. Methods for modulating cytokine production in cells by modulating the expression and/or activity of at least one molecule selected from the group consisting of: NIP45, PRMT1, and NFAT are also provided. The invention also pertains to methods for modulating the relative number of Th1 or Th2 cells is modulated and to methods of treating a subject that would benefit from the modulation of cytokine production comprising contacting an immune cell from the subject with an agent that modulates PRMT 1 expression and/or activity in the immune cell. | 02-19-2009 |
20090048118 | Oligonucleotides, Arrays Thereof for Detecting Microorganisms, and an Apparatus, a Method and a Kit for Detecting Microorganisms - The present invention relates to an instrument, a method and a kit for detecting a microorganism contaminating a subject test sample, which enables one to quickly and accurately identify the microorganism with an easy operation. The instrument for detecting a microorganism according to the present invention relates to a microarray type instrument in which oligonucleotides prepared based on nucleotide sequences specific to the species and genus to which the subject microorganism belongs have been immobilized onto a surface of a substrate. Based on the presence or absence of hybridization of the probes prepared from the test sample with the oligonucleotides immobilized onto the surface of the substrate, the present invention makes it possible to detect and/or identify the microorganism in the test sample easily, quickly and accurately. | 02-19-2009 |
20090048119 | Method to determine single nucleotide polymorphisms and mutations in nucleic acid sequence - A genotyping method and a prepared oligomicroarray as device is to determine single nucleotide polymorphism (SNP) and mutations are provided. The method uses two specific APEX-2 primers per each SNP or mutations to be determined. The same primers are used in amplification phase (primer extension and PCR with universal primer) and in the single base extension phase on an array. All SNP-containing sequences can be genotyped and amplified in one reaction tube and visualized on a microarray. | 02-19-2009 |
20090048120 | ATOMIC FORCE MICROSCOPE AS AN ANALYZING TOOL FOR BIOCHIP - The present application discloses a method for detecting a presence of target ligand in a fluid medium which includes the steps of: (i) contacting the fluid medium with a solid substrate that includes an array of dendrons on its surface, wherein each of the dendron includes a central atom, a probe that is attached to the central atom optionally through a linker, and a base portion attached to the central atom and having a plurality of termini that are attached to the surface of the solid support; and (ii) determining the presence of a probe-target ligand complex by measuring binding force between the bound ligand and detection molecule tethered to the tip of an atomic force microscope (“AFM”), which detection molecule has affinity for the ligand, wherein measurement of an increase in force between the probe-target ligand complex and the detection molecule by AFM indicates the presence of the probe-target ligand complex. | 02-19-2009 |
20090054248 | CONNEXIN 40 TISSUE SPECIFIC GENE MUTATIONS - A method of detecting cardiac arrhythmia in a patient is described. This method involves determining whether there is a mutation in the nucleotide sequence, the amino acid sequence, or both, of connexin40 obtained from a patient. The mutation may be localized within the transmembrane domain of connexin40. Furthermore, there is described a method of identifying a compound for the treatment of cardiac arrhythmia. This method involves providing a cell culture that is characterized by having impaired intracellular trafficking, impaired electrical coupling, reduced gap junction plaque formation, reduced intracellular coupling, or a combination thereof, when compared to a wild-type cell. A compound is added to the cell culture, and restoration of intracellular trafficking, electrical coupling, gap junction plaque formation, intracellular coupling, or a combination thereof, is monitored. | 02-26-2009 |
20090054249 | DNA FRAGMENTS ARRAY FROM BIOMINING MICROORGANISMS AND METHOD FOR DETECTION OF THEM - The present invention discloses an array of DNA fragments from biomining microorganisms and a method to identify readily and simultaneously said microorganisms in a sample. This method is a useful tool in biomining, in every circumstance where a global understanding of the present microbiological diversity is required, or simply to assess the presence of some microorganism with biomining relevance, either on the mineral, or in a bioleaching heap, in the biomining laboratory or in any other circumstance involving biomining microorganisms. | 02-26-2009 |
20090054250 | Methods to create fluorescent biosensors using aptamers with fluorescent base analogs - The present invention provides improved methods for generating fluorescent aptamer polynucleotides, novel polynucleotides, and methods for use thereof. | 02-26-2009 |
20090054251 | Diagnosis of Autoimmune Disease - Methods and compositions for diagnosing and treating autoimmune disease, e.g., acute disseminated encephalomyelitis (ADEM), are described. | 02-26-2009 |
20090054252 | Hemopexin-Like Structure as New Polypeptide-Scaffold - The invention concerns a method for the generation of a polypeptide with specific binding properties to a predetermined target molecule which are not naturally inherent to that polypeptide. At the same time an optimization of the binding specifity and a process of production are described. The invention further concerns a method for the identification and modification of specific amino acid positions within a polypeptide scaffold. | 02-26-2009 |
20090054253 | Markers and Methods for Assessing and Treating Ulcerative Colitis and Related Disorders Using 66 Gene Panel - A method for prognostic or diagnostic assessment of a gastrointestinal-related disorder, such as ulcerative colitis, in a subject correlates the presence, absence, and/or magnitude of a gene in a sample with a reference standard to determine the presence and/or severity of the disorder, and/or the response to treatment for the disorder. The method enables identification of the effectiveness of candidate therapies. | 02-26-2009 |
20090054254 | Method for Preparing Immunoglobulin Libraries - The invention relates to the generation of immunoglobulin libraries and the identification and production of immunoglobulins having a specific functionality of interest. | 02-26-2009 |
20090054255 | MICROFLUIDIC DEVICES AND METHODS - Contemplated microfluidic devices and methods are drawn to protein arrays in which distinct and detergent-containing antigen preparations are deposited onto an optical contrast layer in a non-specific and non-covalent manner. Detection of binding a is carried out using a dye that precipitates or agglomerates to so form a visually detectable signal at a dynamic range of at least three orders of magnitude. | 02-26-2009 |
20090054256 | METHOD EVOLVED FOR RECOGNITION OF THROMBOPHILIA (MERT) - Methods for predicting an individual's genetic risk for developing venous thrombosis in diverse ethnic populations is disclosed, as are arrays and kits which can be used to practice the method. The method includes screening for mutations, polymorphisms, or both, in at least eight venous thrombosis-related molecules, such as antithrombin III, protein C, protein S, fibrinogen, factor V, prothrombin (factor II), methylenetetrahydrofolate reductase (MTHFR), and angiotensin I-converting enzyme (ACE) molecules which are associated with venous thrombosis. | 02-26-2009 |
20090054257 | METHOD OF IMPROVING T CELL RECEPTORS - A method of increasing the affinity and/or decreasing the off-rate of a given TCR specific for a given target pMHC, comprising creating a plurality of TCRs having an α chain CDR2 sequence and/or a β chain CDR2 sequence different from the corresponding CDR2 sequence(s) of the given TCR but having the same α and β CDR1 and CDR3 sequences as the given TCR, determining the affinity and/or off-rate of members of said plurality of TCRs for the target pMHC, and selecting one or more members having at least a 10-fold greater affinity for the target pMHC than the given TCR and/or a 10-fold slower off-rate for the target pMHC than the given TCR. | 02-26-2009 |
20090054258 | Nucleic Acid Labeling Methods - In one aspect of the invention, a method is provided for end-labeling RNA (total RNA, mRNA, cRNA or fragmented RNA). In one aspect of the present invention, T4 RNA ligase is used to attach a 3′-labeled AMP or CMP donor to an RNA acceptor molecule. In another embodiment, a pyrophosphate molecule 3′-AppN-3′-linker-detectable moiety is used as donor molecule. | 02-26-2009 |
20090062137 | Methods For Identification, and Compounds Useful For The Treatment Of Degenerative & Inflammatory Diseases - The present invention relates to in vivo and in vitro methods, agents and compound screening assays for inhibiting extra-cellular matrix degradation, including joint degenerative inhibiting and/or anti-inflammatory pharmaceutical compositions, and the use thereof in treating and/or preventing a disease involving extra-cellular matrix degradation in a subject. | 03-05-2009 |
20090062138 | Array-based method for performing SNP analysis - An array-based method for performing SNP analysis is provided. In certain embodiments, the method may comprise: a) contacting a labeled genomic sample with an array comprising a first SNP-detecting oligonucleotide and a second SNP-detecting oligonucleotide that differ from each other by a single nucleotide, under hybridization conditions that provide binding equilibrium; and b) evaluating a SNP of said labeled genomic sample by comparing: i. binding of the labeled genomic sample to the first SNP-detecting oligonucleotide and ii. binding of the labeled genomic sample to said second SNP-detecting oligonucleotide. | 03-05-2009 |
20090062139 | PHYTASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM - The invention provides isolated and recombinant phytase enzymes. In one aspect, the phytases are produced by modification of the wild type appA of | 03-05-2009 |
20090062140 | METHOD FOR IDENTIFYING CELLS BASED ON DNA REPLICATION DOMAIN TIMING PROFILES - Methods for identifying and/or distinguishing a homogeneous population of cells based on their replication domain timing profile using high resolution genomic arrays or sequencing procedures are provided. These methods may be used to compare the replication timing profile for a population of cells to another replication timing profile(s), a replication timing fingerprint, and/or one or more informative segments of a replication timing fingerprint, which may be simultaneously or previously determined and/or contained in a database, to determine whether there is a match between them. Based on such information, the identity of the population of cells may be determined, or the identity of the population of cells may be distinguished from other populations of cells or cell types. Methods for determining a replication timing fingerprint for particular cell types are also provided. | 03-05-2009 |
20090062141 | METHOD FOR EVALUATING DRUG CANDIDATES - Two-dimensional and/or three-dimensional polymeric or extended solid arrays, such as arrays of a polydiacetylene backbone, are used to evaluate the organic/water partition coefficient or oral absorptivity or transcellular permeability of a compound by monitoring the change in the fluorescence or phosphorescence of the array upon exposure to the compound and comparing it to a known change in fluorescence or phosphorescence, respectively. The method can also be used to evaluate the ability of a compound to bind to a protein. | 03-05-2009 |
20090062142 | Methods for enhancing bacterial cell display of proteins and peptides - Methods of making and using bacterial display polypeptide libraries using circularly permuted OmpX (CPX) variants are disclosed. The invention further relates to methods for enhancing the display of proteins and peptides at the surface of bacteria by optimizing linkers and incorporating mutations at positions 165 and 166 of CPX. | 03-05-2009 |
20090069190 | METHODS FOR HLA TYPING - The present invention relates to methods for reducing the ambiguity in human leukocyte antigen (HLA) allele identification. In particular, the methods comprise using target specific oligonucleotide (TSO) techniques to determine a first set of possible HLA alleles. The methods further comprise using sequence-based typing (SBT) to obtain a second set of possible HLA alleles. The two sets of the possible HLA alleles are then combined to determine at least one common allele identified in the both the TSO and SBT assays, thus reducing the ambiguity associated with current HLA typing procedures. | 03-12-2009 |
20090069191 | Rapid Comparative Genome Hybridization - Disclosed is a method for performing nucleic acid hybridization assays, such as assays used for detecting and mapping chromosomal or genetic abnormalities associated with various diseases or associated with predisposition to various diseases. In a particular aspect, the present method relates to the use of rapid nucleic acid hybridization methods for comparing nucleic acid segments of one genome to corresponding nucleic acid segments in another genome(s). | 03-12-2009 |
20090069192 | Microarray device for DNA recognition, apparatus using the microarray device, and corresponding method of operation - There is described a microarray device ( | 03-12-2009 |
20090069193 | METHOD OF PROVIDING A PATTERN OF BIOLOGICAL-BINDING AREAS FOR BIOLOGICAL TESTING - The present invention provides a method of forming one or more biological-binding areas on a substrate for biological-testing. The method includes activating at least a portion of a glass-ceramic substrate comprising glass and one or more metal containing compounds. The one or more metal containing compounds have a range of diameters that are less than about 300 nanometers in diameter and are spaced an average distance of at least one-half the midpoint of the diameter range apart. The one or more metals include compounds selected from metal oxides, metal nanoparticles, metal alloys, and atomic metals. The glass-ceramic substrate is heated to a temperature near the glass transformation temperature to form one or more metal nanoparticles in one or more ceramic biological-binding areas. The glass-ceramic substrate is etched to expose one or more metal. One or more biological molecules are contacted with one or more ceramic biological-binding areas to provide one or more biological testing areas with an increased binding area as compared to un-activated areas. | 03-12-2009 |
20090069194 | COPY NUMBER VARIATION DETERMINATION, METHODS AND SYSTEMS - The present invention methods and systems for determining copy number variation of a target polynucleotide in a genome of a subject including amplification based techniques. Methods can include pre-amplification of the sample followed by distribution of sample and a plurality of reaction volumes, quantitative detection of a target polynucleotide and a reference polynucleotide, and analysis so as to determine the relative copy number of the target polynucleotide sequence in the genome of the subject. | 03-12-2009 |
20090069195 | COMPOSITIONS AND METHODS FOR ARRAY-BASED NUCLEIC ACID HYBRIDIZATION - The invention provides compositions and methods for generating a molecular profile of genomic DNA by hybridization of labeled nucleic acid representing the genomic DNA to immobilized nucleic acid probes, e.g., arrays or biochips. | 03-12-2009 |
20090075831 | METHOD FOR DIFFERENTIATING BETWEEN THE NON-INFECTIOUS AND INFECTIOUS CAUSES OF MULTIPLE ORGAN FAILURE - The present invention relates to the use of gene expression profiles obtained in vitro from patient samples for differentiating between the non-infectious and infectious causes of multiple organ failure. The invention also relates to a method for measuring gene expression profiles in vitro and the use of said gene expression profiles and/or of the probes used therein for screening active substances against the non-infectious and/or infectious causes of multiple organ failure. | 03-19-2009 |
20090075832 | Compositions and Methods for Classifying Biological Samples - The present invention relates to autoantibodies and the detection thereof with peptide epitopes. The invention also relates to autoantibody patterns and their correlation with biological class distinctions. | 03-19-2009 |
20090075833 | ADRB2 CANCER MARKERS - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ADRB2 markers for cancer. | 03-19-2009 |
20090075834 | Aptamers and methods for their in vitro selection and uses thereof - The present method is an improved in vitro selection protocol that relies on magnetic separations for DNA aptamer production that is relatively easy and scalable without the need for expensive robotics. The ability of aptamers selected by this method to recognize and bind their target protein with high affinity and specificity, and detail their uses in a number of assays is also described. Specific TTF1 and His6 aptamers were selected using the method described, and shown to be useful for enzyme-linked assays, Western blots, and affinity purification. | 03-19-2009 |
20090075835 | METHODS AND SYSTEMS FOR THE DETECTION OF MICRODELETION AND MICRODUPLICATION SYNDROMES - Methods for diagnosing the presence or absence of a genetic disorder in a patient are provided, wherein the genetic disorder is associated with a chromosomal abnormality at 1q41q42 and/or 16p11.2p12.2, and wherein the genetic disorder is not Fryns syndrome or congenital diaphragmatic hernia (CDH). Materials, such as microarrays for use in microarray CGH, and kits for use in such methods are also provided. | 03-19-2009 |
20090082214 | CONJUGATE PROBES AND OPTICAL DETECTION OF ANALYTES - This invention relates to conjugate probes and optical detection of analytes. More specifically, this invention relates to conjugate probes which are used to form an array for a biosensor employing optical detection of analytes. | 03-26-2009 |
20090082215 | GENE EXPRESSION PROFILING FROM FFPE SAMPLES - Methods and compositions relating to the generation and use of gene expression data from tissue samples that have been fixed and embedded are provided. The data can electronically stored and implemented as well as used to augment diagnosis and treatment of diseases. | 03-26-2009 |
20090082216 | Metallic nanostructures self-assembly, and testing methods - The invention provides method for metallic nanonstructures self-assembly methods and materials testing. Preferred embodiment methods permit for the formation of individual nanonstructures and arrays of nanostructrues. The nanostructures formed can have a metal alloy crystal structure. Example structures include slender wires, rectangular bars, or plate-like structures. Tips can be shaped, single layer and multiple layer coatings can be formed, tips can be functionalized, molecules can be adhered, and many testing methods are enabled. | 03-26-2009 |
20090082217 | Selection of nucleic acid-based sensor domains within nucleic acid switch platform - The invention relates to a method (preferably a high throughput method) for screening for functional aptamer-regulated, ligand-responsive nucleic acids, or “ampliSwitches,” and uses thereof. The subject method not only applies to large molecules, such as proteins, but also applies to relatively small ligands, such as those with molecular weight of no more than 5 kDa, 3 kDa, or 1 kDa. | 03-26-2009 |
20090082218 | 3'-Based sequencing approach for microarray manufacture - Methods are described to derive design sequences for the production of nucleic acid microarrays. The present methods use high throughput 3′ sequencing of transcripts in a tissue sample or diseased state to design probes for nucleic acid microarrays. Also described are nucleic acid microarrays that possess probes directed to the extreme 3′ end of transcripts in a tissue. These microarrays preferably represent alternate polyadenylation sequences that are specific to the tissue from which the transcripts are derived. Also described are methods of using the microarrays directed to the extreme 3′ end of the transcript for evaluating gene expression in a tissue where there are reduced false positive and false negative results. | 03-26-2009 |
20090088330 | Methods And Kits For Producing Labeled Target Nucleic Acids For Use In Array Based Hybridization Applications - Methods for producing labeled probe nucleic acids from genomic nucleic acid template are provided. In some embodiments of the subject methods, a plurality of sequence-specific primers are employed to enzymatically generate a set of labeled target nucleic acids corresponding to coding regions of genes from a genomic template via a primer extension protocol. The subject methods find use in a variety of different applications, and can be used, for example, in the preparation of labeled probe nucleic acids for use in array based comparative genomic hybridization applications. Also provided are kits for use in practicing the subject methods. | 04-02-2009 |
20090088331 | INFLUENZA VIRUS NUCLEIC ACID MICROARRAY AND METHOD OF USE - The present invention relates generally to methods of detecting and identifying known and unknown viruses using hybridization microarrays to essentially all known influenza virus nucleotide sequences of at least one type that infect at least one species, the sequencing of nucleotides which hybridize to the microarrays and analysis of the hybridized sequences with existing databases, thus identifying existing or new subtypes of viruses. The present invention also relates to methods of use of the microarrays of the invention for the detection of influenza viruses, including variant influenza viruses. The method includes the use of a non-specific PCR amplification method to amplify sample nucleic acids. | 04-02-2009 |
20090088332 | Multiplex Digital Immuno-Sensing Using a Library of Photocleavable Mass Tags - This invention provides methods, compositions and kits for immunosensing using photocleavable mass tags. | 04-02-2009 |
20090088333 | TARGET MOLECULE EVALUATION METHOD AND APPARATUS - AC potential is applied between a substrate electrode provided on a substrate and a counter electrode, a sample is brought into contact with a probe molecule bound to the substrate electrode, and a fluorescent signal obtained from a fluorescent marker provided on the probe molecule is observed to evaluate a target molecule in the sample that has bound to the probe molecule, wherein the target molecule is evaluated by measuring a signal intensity and/or a signal amplitude. | 04-02-2009 |
20090088334 | METHOD OF HIGH SENSITIVE IMMUNOASSAY - An object of the present invention is to provide a method of high sensitive immunoassay using immunoagglutination reaction by antigen-antibody reaction for quantification of a biological substance. The present invention provides a method for assaying an antigen comprising assaying agglutination which is generated by contacting an antigen with a carrier on which antibodies are supported, wherein the carrier on which antibodies are supported comprises a plurality of types of monoclonal antibodies that recognize different epitopes of an antigen supported thereon via simultaneous sensitization to the carrier. | 04-02-2009 |
20090088335 | NUCLEIC ACID SEQUENCING BY SINGLE-BASE PRIMER EXTENSION - The present invention pertains to a method for determining a sequence of contiguous bases within a polynucleotide, the method relying on single-base primer extension using labeled dideoxynucleotide terminators. The primers are immobilized to solid supports (e.g. microspheres or two-dimensional arrays), allowing for the identification of the labeled terminator incorporated into each primer. | 04-02-2009 |
20090088336 | MODULAR POINT-OF-CARE DEVICES, SYSTEMS, AND USES THEREOF - The present invention provides devices and systems for use at the point of care. The methods devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device are modular to allow for flexibility and robustness of use with the disclosed methods for a variety of medical applications. | 04-02-2009 |
20090088337 | RET-Based Analyte Detection - Compositions and methods for Resonance Energy Transfer (RET) Based Detection of analyte binding are provided. | 04-02-2009 |
20090088338 | MULTI-CHANNEL MICROARRAY APPARATUS AND METHODS - A multi-channel microarray reader has a light source carried by a first supporting stage, a second supporting stage having a plurality of reaction assembly receiving positions, each position to receive a reaction assembly, wherein each reaction assembly includes a reaction chamber and an optical substrate to support a microarray chip, and wherein the reaction chamber and the optical substrate encapsulate a buffer solution. The reader also includes an imaging sensor positioned to detect fluorescence emitted from a single microarray chip and a motion control module to position at least one of the first and second supporting stages to cause a selected microarray chip to receive energy emitted from the light source and to position the imaging sensor to receive fluorescence from that microarray chip. | 04-02-2009 |
20090093372 | METHODS FOR INCREASING DEFINITIVE ENDODERM PRODUCTION - Disclosed herein are methods for increasing the production of definitive endoderm cells from pluripotent stem cells. Also disclosed herein are agents capable of increasing definitive endoderm cell production. | 04-09-2009 |
20090093373 | DNA MICRO-ARRAY HAVING STANDARD PROBE AND KIT INCLUDING THE ARRAY - To provide a DNA micro-array having a nucleic acid probe immobilized on a substrate, which is used to detect a molecule of a target nucleic acid contained in a sample and has a substantially complementary base sequence to the target base sequence of the nucleic acid molecule, including at least one probe selected from the group consisting of: at least one internal standard probe for assay of PCR of the target nucleic acid; at least one external standard probe for a detection operation and assay of an amount of the probe; and a probe for measurement of the amount or density of the nucleic acid probe, formed by the same method as the nucleic acid probe. | 04-09-2009 |
20090099029 | Methods and substrates for conducting assays - The present invention relates to methods of conducting kinase assays using a myelin basic protein subtrate and a tyrosine kinase. Also provided herein are compositions that include myelin basic protein and a tyrosine kinase. Illustrative embodiments of these assays are performed on a microarray. In another embodiment, provided herein is a universal substrate that includes myelin basic protein. | 04-16-2009 |
20090099030 | Method of detecting mutations in the gene encoding cytochrome P450-2C9 - The present invention describes a method for the simultaneous identification of two or more mutations located in the gene encoding Cytochrome P450-2C9. Multiplex detection is accomplished using multiplexed tagged allele specific primer extension (ASPE) and hybridization of such extended primers to a probe, preferably an addressable anti-tagged support. | 04-16-2009 |
20090099031 | Genetic package and uses thereof - The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications. | 04-16-2009 |
20090099032 | HIGHLY SENSITIVE PROTEOMIC ANALYSIS METHODS, AND KITS AND SYSTEMS FOR PRACTICING THE SAME - Methods of determining whether a sample includes one or more analytes, particularly proteinaceous analytes, of interest are provided. In the subject methods, an array of binding agents, where each binding agent includes an epitope binding domain of an antibody, is contacted with the sample. In many embodiments, contact occurs in the presence of a metal ion chelating polysaccharide, e.g., a pectin. Following contact, the presence of binding complexes on the array surface are detected and the resultant data is employed to determine whether the sample includes the one or more analytes of interest. Also provided are kits, systems and other compositions of matter for practicing the subject methods. The subject methods and compositions find use in a variety of applications, including proteomic applications such as protein expression analysis, e.g., differential protein expression profiling. | 04-16-2009 |
20090099033 | In vitro screening and evolution of proteins - The present invention provides a composition which links genotype and phenotype and provides a method for in vitro protein evolution and screening using said composition. The invention also facilitates the identification and isolation of proteins with selected properties from large pools of proteins. The composition and method of the invention can be used with eukaryotic (both mammalian and plant) and prokaryotic translation systems. | 04-16-2009 |
20090099034 | Reagents and Methods for miRNA Expression Analysis and Identification of Cancer Biomarkers - This invention provides methods for amplifying, detecting, measuring, and identifying miRNAs from biological samples, particularly limited amounts of a biological sample. miRNAs that are differentially expressed in tumor samples and normal tissues are useful as cancer biomarkers for cancer diagnostics. | 04-16-2009 |
20090099035 | OLIGONUCLEOTIDE ARRAYS FOR HIGH RESOLUTION HLA TYPING - Arrays of HLA Class I oligonucleotide probes on a solid support are provided, wherein the probes are sufficient to represent at least 80% of the known polymorphisms in exons 2 and 3 of the HLA Class I locus. | 04-16-2009 |
20090099036 | METHODS AND COMPOSITIONS FOR SCREENING GLYCAN STRUCTURES - The present invention relates to methods and compositions for screening of glycan structures. In particular, the present invention provides methods and compositions for global profiling of glycoprotein states by utilizing a glycoprotein microarray format. | 04-16-2009 |
20090105083 | Ligand Screening and Discovery - Disclosed is a method that includes: (i) providing a plurality of initial nucleic acid cassettes that include: a) a first coding region encoding a first immunoglobulin variable domain, b) a second coding region encoding a second immunoglobulin variable domain, and c) a ribosomal binding site disposed between the first and second coding regions for translation of the second polypeptide in a first expression system, wherein the first and second coding regions are in the same translational orientation; (ii) modifying each nucleic acid cassette of the plurality in a single reaction mixture so that it is functional in a second expression system, wherein the first and second region remain physically attached during the modifying; (iii) introducing each modified nucleic acid cassette into a mammalian cell to produce a mixture of transfected cells; and (iv) expressing each modified nucleic acid cassette in the transfected cells. | 04-23-2009 |
20090105084 | Nucleic acid molecule encoding a novel estrogen receptor beta variant - This invention relates to an isolated nucleotide fragment of a novel estrogen receptor, in particular, a novel ERβ variant protein and isolated nucleic acid fragment comprising the coding regions of the genes encoding such variant proteins. Also provided are vectors, host cells, and methods for producing the novel ERβ variant protein. The invention further relates to method of obtaining such nucleotide fragment and the method of determining the presence of such ERβ variant protein in a sample. | 04-23-2009 |
20090105085 | ARRAY OF NUCLEOTIDIC SEQUENCES FOR THE DETECTION AND IDENTIFICATION OF GENES THAT CODIFY PROTEINS WITH ACTIVITIES RELEVANT IN BIOTECHNOLOGY PRESENT IN A MICROBIOLOGICAL SAMPLE, AND METHOD FOR USING THIS ARRAY - The present invention makes known an array of nucleotididc sequences for rapidly and simultaneously identifying the presence of certain genes that codify proteins with activities relevant in biotechnology, present in a microbiological sample, and the method for using this array in the identification of the said genes. Specifically, genes that codify for proteins relevant in Biofilm formation, in CO | 04-23-2009 |
20090105086 | Methods of selecting internalizing antibodies - This invention provides methods of selecting antibodies that are internalized into target cells. The methods generally involve contacting target cells with one or more members of an antibody phage display library. The members of the phage display library are also contacted with cells of a subtractive cell line. The target cells are then washed to remove the subtractive cell line cells and members of the phage display library that are non-specifically bound or weakly bound to the target cells. The target cells are cultured under conditions where members of the phage display library can be internalized if bound to an internalizing marker and internalized members of the phage display library are then identified. | 04-23-2009 |
20090105087 | MICROELECTRONIC DEVICE WITH CONTROLLABLE REFERENCE SUBSTANCE SUPPLY - The invention relates to microelectronic device ( | 04-23-2009 |
20090111702 | Methods of determining allergen response using microarray immunoassay techniques - The present invention is directed to materials and methods that may be used in diagnosing and/or characterizing allergies. More specifically, the specification describes methods and compositions for making and using a plurality of peptides having allergen epitopes that may be used in immunoassays e.g., microarray-based immunoassays to predict the severity of an allergic response. | 04-30-2009 |
20090111703 | SUBSTRATE INDEPENDENT COPOLYMERS FOR BIOFUNCTIONALIZATION - The present invention provides crosslinked epoxy-functional copolymer films and microarrays built from the crosslinked epoxy-functional copolymer films. Microarrays incorporating the copolymers include a substrate on which a film of the crosslinked epoxy-functional copolymer is disposed and target molecules bound to the copolymer film. The crosslinked polymer films are well-suited for use as scaffolds for target molecules in microarrays because they provide a high density of binding sites for the target molecules, are mechanically stable, and may be coated onto a wide range of substrates. | 04-30-2009 |
20090111704 | PANEL FOR THE DETECTION AND DIFFERENTIATION OF RENAL CORTICAL NEOPLASMS - The present invention provides a novel, highly sensitive and specific probe panel which detects the type of renal cortical neoplasm present in a biopsy sample. As such, the invention permits diagnosis of the predominant subtypes of renal cortical neoplasms without the use of invasive methods. The present invention further provides a molecular cytogenetic method for detecting and analyzing the type of renal cortical neoplasm present in a renal biopsy sample. | 04-30-2009 |
20090111705 | SELECTION OF DNA ADAPTOR ORIENTATION BY HYBRID CAPTURE - Aspects described and claimed herein provide methods to insert multiple DNA adaptors into a population of circular target DNAs at defined positions and orientations with respect to one another by employing selective capture of defined molecules. The resulting multi-adaptor constructs are then used in massively-parallel nucleic acid sequencing techniques. | 04-30-2009 |
20090111706 | SELECTION OF DNA ADAPTOR ORIENTATION BY AMPLIFICATION - Aspects described and claimed herein provide methods to insert multiple DNA adaptors into a population of circular target DNAs at defined positions and orientations with respect to one another by employing amplification procedures. The resulting multi-adaptor constructs are then used in massively-parallel nucleic acid sequencing techniques. | 04-30-2009 |
20090111707 | MARKERS FOR THE PREDICTION OF OUTCOME OF ANTHRACYCLINE TREATMENT - The present invention relates to methods for predicting the outcome of anthracycline treatment of cell proliferative disorder patients. This is achieved by determining the expression level of at least one gene selected from the group consisting of PITX2; TFF1 and PLAU. The invention also relates to sequences, oligonucleotides and antibodies which can be used within the described methods. | 04-30-2009 |
20090111708 | POLYNUCLEOTIDES ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION AND METHODS FOR EVALUATING PATIENT RISK - The present invention provides for certain polynucleotide sequences that have been correlated to AMD. These polynucleotides are useful as diagnostics, and are preferably used to fabricate an array, useful for screening patient samples. The array is used as part of a laboratory information management system, to store and process additional patient information in addition to the patient's genomic profile. As described herein, the system provides an assessment of the patient's risk for developing AMD, risk for disease progression, and the likelihood of disease prevention based on patient controllable factors. | 04-30-2009 |
20090111709 | Affinity Measurements Using Frameless Multiplexed Microarrays - The present invention relates to novel methods of the quantitative detection of molecules in an array. In particular, the present invention relates to methods for molecular detection assays performed on solid surfaces. The present invention provides improved methods for the high throughput analysis of molecular interactions and quantitative detection. In another aspect, the invention relates to a method of measuring protein interactions on a solid surface that is useful for the determination of equilibrium binding and rate constants. In yet another aspect, the invention relates to predicting a molecules utility in a detection assay. | 04-30-2009 |
20090118134 | Template Fixed Beta-Hairpin Loop Mimetics and Their Use in Phage Display - Template-fixed β-hairpin mime tics of the general formula R | 05-07-2009 |
20090118135 | METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS - An assay for determining compounds that inhibit activity of a BCl-2 protein, or affect conversion of Bcl-2 from an antiapoptotic to a proapoptotic form are described. In addition, compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and related Bcl-2 family members are identified. | 05-07-2009 |
20090118136 | ASSAY FOR DETECTING NUCLEOTIDE SEQUENCES IN GENETICALLY MODIFIED CROPS AND PLANTS USING OPTICAL THIN-FILM BIOSENSOR CHIPS - A process for detecting at least one DNA sequence using an optical thin-film biosensor chip includes the steps of placing a sample to be tested in contact with at least one capture probe attached to an optical thin-film biosensor chip; incubating the sample in the presence of an enzyme and a substrate; identifying a change in the color of the sample; and detecting the sample comprises at least one DNA sequence. | 05-07-2009 |
20090118137 | COMPETITIVE OLIGONUCLEOTIDES - The present invention generally relates to competitive oligonucleotides and, in some embodiments, to competitive oligonucleotides for use in comparative genomic hybridization (CGH) and related techniques. One aspect is generally directed to a blocking composition constructed and arranged to be used in an assay of a nucleic acid. The blocking composition may comprise oligonucleotides comprising sequences selected to hybridize to the nucleic acid used in the assay. Another aspect is generally directed to performing CGH assays and similar techniques on genomic DNA, in the absence of a Cot-1 fraction, such that the genomic DNA does not substantially cross-hybridize. Yet other aspects of the invention are directed to devices or kits for making or using competitive oligonucleotides, methods of promoting such competitive oligonucleotides, or the like. | 05-07-2009 |
20090124509 | Protein-biochip for validating binding agents - The invention relates to an arrangement of proteins containing at least one cDNA-expression library and to the use thereof as a protein-biochip, in particular for validating binding agents and protein binding agents and to a method for determining in a simultaneous manner quantitative variables. | 05-14-2009 |
20090124510 | Quantitative Determination of Proteins from Formalin-Fixed Tissue - The invention relates to a method with which proteins from formalin-fixed biological samples can be dissolved and subsequently quantified. The method makes it possible to extract intact full-length proteins from the samples and to conduct a subsequent analysis thereof. | 05-14-2009 |
20090124511 | ANTIBODY COMPLEXES AND METHODS FOR IMMUNOLABELING - The present invention provides labeling reagents and methods for labeling primary antibodies and for detecting a target in a sample using an immuno-labeled complex that comprises a target-binding antibody and one or more labeling reagents. The labeling reagents comprise monovalent antibody fragments or non-antibody monomeric proteins whereby the labeling proteins have affinity for a specific region of the target-binding antibody and are covalently attached to a label. Typically, the labeling reagent is an anti-Fc Fab or Fab′ fragment that was generated by immunizing a goat or rabbit with the Fc fragment of an antibody. The present invention provides for discrete subsets of labeling reagent and immuno-labeled complexes that facilitate the simultaneous detection of multiple targets in a sample wherein the immuno-labeled complexes are distinguished by i) a ratio of label to labeling reagent, or ii) a physical property of said label, or iii) a ratio of labeling reagent to said target-binding antibody, or iv) by said target-binding antibody. This is particularly useful for fluorophore labels that can be attached to labeling reagents and subsequently immuno-labeled complexes in ratios for the detection of multiple targets. | 05-14-2009 |
20090124512 | DNA ARRAY ANALYSIS AS A DIAGNOSTIC FOR CURRENT AND EMERGING STRAINS OF INFLUENZA - Embodiments herein provide for methods, compositions and apparati for detection and/or diagnosis of virus types, subtypes and/or strains. In particular embodiments, the virus is an influenza virus. The apparatus may include a microarray with attached capture probes, designed to bind to oligonucleotides capable of binding at least a portion of a nucleic acid sequence of one or more target genes in a broad array of influenza types, subtypes or strains. The compositions may include isolated nucleic acids as capture probes, target sequences and/or tagged label probes, of use for diagnosis and/or detection of influenza virus. | 05-14-2009 |
20090124513 | Multiplex Biosensor - This invention relates to CMOS SAW-based biosensor devices for detecting analytes and biomolecules of interest. | 05-14-2009 |
20090124514 | SELECTION PROBE AMPLIFICATION - Multiple unique selection probes are provided in a single medium. Each selection probe has a sequence that is complementary to a unique target sequence that may be present in a sample under consideration. For example, each selection probe may be complementary to a sequence that includes one of the SNPs used to genotype an organism. Single-stranded selection probes anneal or hybridize with sample sequences having the unique target sequences specified by the selection probe sequences. Sequences from the sample that do not anneal or hybridize with the selection probes are separated from the bound sequences by an appropriate technique. The bound sequences can then be freed to provide a mixture of isolated target sequences, which can be used as needed for the application at hand. | 05-14-2009 |
20090131266 | Nucleic Acid-Like Proteins - Provided are recombinant pentapeptide repeat family proteins comprising at least one mutation of an i | 05-21-2009 |
20090131267 | USE OF POLYMERS FOR INCREASING THE SIGNAL INTENSITY WHEN CARRYING OUT DETECTION REACTIONS - The present invention relates to increasing the signal intensity while simultaneously reducing unspecific background binding when carrying out detection reactions, in particular immunoassays by using polyvinyl derivatives. | 05-21-2009 |
20090131268 | Methods for Genotyping Polymorphisms - The invention provides method for genotyping specific sets of polymorphisms in a single multiplex reaction. The polymorphisms are selected to be of interest in detecting genetic variation that alters individuals' metabolism, distribution, extretion and transport of pharmacological compounds. In preferred aspects the genotyping employs a multiplex hybridization-based assay. In some aspects combinations of methods are employed to allow the combination of polymorphisms to be interrogated. The invention also provides nucleic acid standards for validating the performance of such hybridization-based assays. | 05-21-2009 |
20090131269 | Highly multiplexed particle-based assays - Methods are provided for detecting and optionally quantitating multiple analytes, including nucleic acid and/or polypeptide analytes, in particle-based assays that can be highly multiplexed. Compositions, systems, and kits related to the methods are also featured. | 05-21-2009 |
20090137411 | Methods and biochips for detecting small molecule compounds - The present invention discloses methods for detection of small molecule compounds and its specific biochips. Biochips of the present invention comprise a solid support and carrier-linked small molecules immobilized onto the solid support. The invention also provides methods and kits for detection of small molecule compounds using the biochips of the invention. | 05-28-2009 |
20090137412 | CHROMOGENIC IN SITU HYBRIDIZATION METHODS, KITS, AND COMPOSITIONS - The present invention relates to chromogenic (calorimetric) in situ hybridization (CISH) and nucleic acid probes useful for in situ hybridization. Specifically, the present invention provides methods, kits, and compositions for performing bright field cancer diagnostics employing chromogenic in situ hybridization (e.g. to detect gene amplifications, gene translocations, and chromosome polysomy). In preferred embodiments, the present invention provides CISH methods, kits and compositions for detecting HER2 gene status. | 05-28-2009 |
20090137413 | Manipulation of Microparticles In Microfluidic Systems - Arrays of flowable or fixed particle sets are used in microfluidic systems for performing assays and modifying hydrodynamic flow. Also provided are assays utilizing flowable or fixed particle sets within a microfluidic system, as well as kits, apparatus and integrated systems comprising arrays and array members. | 05-28-2009 |
20090137414 | Single molecule arrays for genetic and chemical analysis - Random arrays of single molecules are provided for carrying out large scale analyses, particularly of biomolecules, such as genomic DNA, cDNAs, proteins, and the like. In one aspect, arrays of the invention comprise concatemers of DNA fragments that are randomly disposed on a regular array of discrete spaced apart regions, such that substantially all such regions contain no more than a single concatemer. Preferably, such regions have areas substantially less than 1 μm | 05-28-2009 |
20090137415 | SUBTRACTIVE SEPARATION AND AMPLIFICATION OF NON-RIBOSOMAL TRANSCRIBED RNA (nrRNA) - The invention provides a method of separating non-ribosomal transcribed RNA (nrRNA) fragments from ribosomal RNA (rRNA) and rRNA fragments. The method comprises (i) providing a sample comprising rRNA, rRNA fragments, and nrRNA fragments, and (ii) providing a plurality of probes. The probes hybridize to RNA targeting sequences of at least 50% of the contiguous regions of the rRNA and to rRNA fragments comprising the rRNA targeting sequences. The method further comprises (iii) adding the plurality of probes to the sample, (iv) hybridizing the probes to the rRNA and rRNA fragments to form rRNA-probe complexes and rRNA fragment-probe complexes, and (v) separating the rRNA-probe complexes and rRNA fragment-probe complexes. The invention also provides a method of amplifying an nrRNA fragment, a method of analyzing nrRNA expression, a method of determining the level of nrRNA in a sample, and a kit and system useful in any of the foregoing methods. | 05-28-2009 |
20090137416 | Isolating Cells Expressing Secreted Proteins - A method of detecting and isolating cells that produce a secreted protein of interest (POI) that has a T cell receptor variable domain, comprising: a) constructing a cell line transiently or stably expressing a cell surface capture molecule, which binds the POI, by transfecting the cell line with a nucleic acid that encodes such cell surface capture molecule; b) transfecting said cell simultaneously or subsequently with a second nucleic acid that encodes a POI wherein such POI is secreted; c) detecting the surface-displayed POI by contacting the cells with a detection molecule, which binds the POI; and d) isolating cells based on the detection molecule. | 05-28-2009 |
20090137417 | Microarray-Based Gene Copy Number Analyses - This invention contemplates an accurate and efficient estimation of gene copy number using oligonucleotide microarrays. The method integrates gene copy number data obtained from perfect match and mismatch probe sequence structure intensities and probe binding affinities. In one embodiment, an accurate determination of single nucleotide polymorphisms (SNPs) sequences is obtained. In another embodiment, an accurate detection and determination of DNA copy number alteration is obtained. In another embodiment, an accurate estimation for RNA gene expression is obtained. | 05-28-2009 |
20090137418 | DNA MICROARRAY HAVING HAIRPIN PROBES TETHERED TO NANOSTRUCTURED METAL SURFACE - A sensor chip and detection device are disclosed. The sensor chip includes a substrate, at least a portion of which is covered by a metal nanoparticle film; a first nucleic acid molecule that is characterized by being able to (i) self-anneal into a hairpin conformation and (ii) hybridize specifically to a target nucleic acid molecule, the first nucleic acid molecule having first and second ends, which first end is tethered to the metal nanoparticle film; and a first fluorophore bound to the second end of the first nucleic molecule. When the first nucleic acid molecule is in the hairpin conformation, the metal nanoparticle film substantially quenches fluorescent emissions by the first fluorophore, and when the first nucleic acid molecule is in a non-hairpin conformation fluorescent emissions by the first fluorophore are surface plasmon-enhanced. | 05-28-2009 |
20090137419 | Sequencing of surface immobilized polymers utilizing microfluorescence detection - Means for simultaneous parallel sequence analysis of a large number of biological polymer macromolecules. Apparatus and methods may use fluorescent labels in repetitive chemistry to determine terminal monomers on solid phase immobilized polymers. Reagents which specifically recognize terminal monomers are used to label polymers at defined positions on a solid substrate. | 05-28-2009 |
20090143236 | Method of detecting cancer cell acquiring drug-resistance - It is an object of the present invention to find out a novel gene marker by which a drug-resistant cancer cell can be detected and provide a means of efficiently and comprehensively detecting a drug-resistant cancer cell using this marker. In the present invention, gene amplifications or deletions have been analyzed in cancer cell strains resistant to drugs, which are anticancer drugs having particularly serious side effects and being administered to cancer patients at a high frequency (namely, camptothecins, cisplatins, etoposides, adriamycins (ADM), and cytosine arabinosides), and parent cancer cell strains. As a result, it was found out that the acquisition of drug-resistance to an anticancer drug in a test cancer cell can be detected by detecting amplification of one or more genes selected from ABC transporter genes and BCL2 family genes consisting of ABCA3 gene, ABCB6 gene, ABCB8 gene, ABCB10 gene, ABCC4 gene, ABCC9 gene, ABCD3 gene, ABCD4 gene, ABCE1 gene, ABCF2 gene, BCL2L2, BCL2L10, BCL2L1, and BCL2A1 which are novel gene markers relating to the acquisition of drug resistance of cancer cells. | 06-04-2009 |
20090143237 | Methods, kits and compositions pertaining to fluorescence quenching using pna probes - Disclosed for instance, are methods suitable for the detection, identification and/or quantitation of nucleic acid target sequences using probes. Suitable probes include those consisting of peptide nucleic acid (PNA) or locked nucleic add (LNA) units. Binding of the probes to adjacent target sequences results in fluorescent quenching. Analysis of changes in the fluorescent signal is used to detect, identify or quantitate a target sequence in a sample. The invention is more specifically directed to methods for improving the sensitivity, specificity and/or reliability of diagnostic tests using suitable probes. It is particularly well-suited for real-time PCR and related amplification reaction. | 06-04-2009 |
20090143238 | Oligonucleotide matrix and methods of use - The present invention relates broadly to compositions and methods for performing nucleic acid analysis. In particular the invention relates to a universal oligonucleotide probe set and a hybridization matrix or array for performing analysis of nucleic acids from any source. The oligonucleotide matrix of the present invention provides up to approximately 10 | 06-04-2009 |
20090143239 | FLUORESCENCE BASED BIOSENSOR - A novel biosensor comprises at least one fluorophore and at least two quenchers, and is capable of selectively and specifically detecting the presence of an ion in the presence of other ions. | 06-04-2009 |
20090143240 | Novel Methods for Genome-Wide Location Analysis - The invention relates to improved methods of identifying the genomic regions to which a protein of interest binds, and in particular, to methods that use tiled arrays. The invention also provides methods of identifying the transcriptional rate of the gene in a cell. The invention also relates to methods of performing genome-wide location analysis, and ChIP-CHIP analysis, using histones and modified histones. | 06-04-2009 |
20090143241 | ANTIBACTERIAL AND PLASMID ELIMINATION AGENTS - Inhibitors of the tmRNA pathway have antibacterial activity with broad species specificity, including | 06-04-2009 |
20090143242 | ALIEN SEQUENCES - The present invention provides sequences and reagents for preparing microarrays with internal controls. Specifically, the present invention defines and provides sequences that are not present in the hybridizing mRNA or cDNA, and therefore can be used both as hybridization controls and for inter-spot normalization. | 06-04-2009 |
20090143243 | MICROARRAY SYSTEM WITH IMPROVED SEQUENCE SPECIFICITY - The invention provides a novel array method for nucleic acid sequence detection with improved specificity which allows for detection of genetic variation, from simple SNPs (where the variation occurs at a fixed position and is of limited allelic number) to more complex sequence variation patterns (such as with multigene families or multiple genetic strains of an organism where the sequence variation between the individual members is neither fixed nor consistent). The array is comprised of short, synthetic oligonucleotide probes attached to a solid surface which are hybridized to single-stranded targets. Single stranded targets can be produced using a method that employs primers modified on the 5′ end to prohibit degradation by a 5′-exonuclease that is introduced to degrade the unprotected strand. The invention further provides for printing buffers/solutions for the immobilization of oligonucleotide probes to an array surface. The invention also provides hybridization and wash buffers and conditions to maximize hybridization specificity and signal intensity, and reduce hybridization times. | 06-04-2009 |
20090149336 | Indexed library of cells containing genomic modifications and methods of making and utilizing the same - Methods and vectors (both DNA and retroviral) are provided for the construction of a Library of mutated cells. The Library will preferably contain mutations in essentially all genes present in the genome of the cells. The nature of the Library and the vectors allow for methods of screening for mutations in specific genes, and for gathering nucleotide sequence data from each mutated gene to provide a database of tagged gene sequences. Such a database provides a means to access the individual mutant cell clones contained in the Library. The invention includes the described Library, methods of making the same, and vectors used to construct the Library. Methods are also provided for accessing individual parts of the Library either by sequence or by pooling and screening. The invention also provides for the generation of non-human transgenic animals which are mutant for specific genes as isolated and generated from the cells of the Library. | 06-11-2009 |
20090149337 | Use of an Extraction Control in a Method of Extracting Nucleic Acids - The present invention relates to a method of ensuring the effectiveness of the extraction workup from a biological sample of nucleic acid. The inventive method is able to distinguish between possible defects in the extraction of nucleic acid from a sample and possible defects in a subsequent amplification step. The present invention also relates to a packaged array for extracting nucleic acid from a biological sample. | 06-11-2009 |
20090149338 | SYSTEM FOR DETECTING PROTEIN-PROTEIN INTERACTIONS - A method of detecting protein interactions is described wherein reporter protein fragments are genetically fused at internal positions of suspected interacting proteins. When proteins interact, the fluorescent fragments are brought close enough together to form a functional reporter protein providing visible confirmation of interaction. | 06-11-2009 |
20090149339 | Methods of Identifying Modulators of Interaction Between PDZ Domain Proteins and PL Proteins - The invention provides reagents and methods for inhibiting or enhancing interactions between proteins in hematopoietic cells and other cells involved in the mediation of an immune response. Reagents and methods provided are useful for treatment of a variety of diseases and conditions mediated by immune system cells. | 06-11-2009 |
20090149340 | Encoded microparticles - Microparticles including spatially coded microparticles, systems for imaging and methods of detecting such microparticles as well as using the same in bioassays are provided. | 06-11-2009 |
20090149341 | METHODS FOR DETECTING TARGET ANALYTES AND ENZYMATIC REACTIONS - A microsphere-based analytic chemistry system and method for making the same is disclosed in which microspheres or particles carrying bioactive agents may be combined randomly or in ordered fashion and dispersed on a substrate to form an array while maintaining the ability to identify the location of bioactive agents and particles within the array using an optically interrogatable, optical signature encoding scheme. A wide variety of modified substrates may be employed which provide either discrete or non-discrete sites for accommodating the microspheres in either random or patterned distributions. The substrates may be constructed from a variety of materials to form either two-dimensional or three-dimensional configurations. In a preferred embodiment, a modified fiber optic bundle or array is employed as a substrate to produce a high density array. The disclosed system and method have utility for detecting target analytes and screening large libraries of bioactive agents. | 06-11-2009 |
20090149342 | Method for reduction of nonspecific binding in nucleic acid assays, nucleic acid synthesis and multiplex amplification reactions - The methods of the present invention described herein may be carried out to reduce unintended binding of probes to target and/or template nucleic acids, to increase the accuracy and efficiency in nucleic acid assays, nucleic acid synthesis and multiplex amplification reactions. | 06-11-2009 |
20090149343 | HISTONES - A histone microarray comprising a substrate support functionalised with at least two probe molecules each comprising a sequence derived from a histone protein, or isoform, or variant, or modification thereof. A histone microarray in which probe molecules have sequences derived from different histone proteins. The histone microarray of the invention can be used in methods for screening and characterising antibodies exhibiting binding specificity for histones and to specific histone modifications, as well as methods for screening and characterising the effects of histone modifications on the activity and binding of histone specific enzymes and binding proteins. | 06-11-2009 |
20090156415 | REAL-TIME PCR OF TARGETS ON A MICRO-ARRAY - The present invention relates to a method and apparatus for monitoring on a micro-array a PCR amplification of a nucleotide molecule being present in a solution. The method includes the steps of: providing a support having fixed upon its surface a microarray having at least a capture molecule being immobilized in specifically localized areas of the support and a reaction chamber; introducing a solution containing the nucleotide molecule into the reaction chamber and reagents for nucleotide molecule amplification and labelling; submitting the solution to at least 2 thermal cycles having at least 2 and preferably 3 different temperature steps in order to obtain labelled target nucleotide molecule by PCR amplification; performing at least a measurement of the labelled target nucleotide molecule in at least one thermal cycle by incubating the labelled target nucleotide molecule under conditions allowing a specific binding between the target nucleotide molecule and its corresponding capture molecule and measuring the light emission from the bound labelled target nucleotide molecule in response to excitation light with the solution being present in the chamber and containing the labelled target nucleotide molecule. The surface of emission for a localized area is between about 0.1 μm | 06-18-2009 |
20090156416 | Hybrid Molecular Probe - A system and method for analyzing a substance, in particular RNA in vivo, comprising a hybrid molecular probe, said probe comprising two single-stranded nucleic acid sequences tethered together with a polyethylene glycol polymer and fluorophores attached to either end of the sequences. When a probe of the invention hybridizes to a target substance (such as a target RKA sequence), fluorescence resonance energy transfer occurs between the two fluorophores to generate a visible signal. | 06-18-2009 |
20090156417 | Library From Toxin Mutants, And Methods Of Using Same - This application relates to libraries of ABx toxin mutants, in which a peptide insert is introduced into the protease-sensitive loop of the A-chain sequence to alter the type of cells to which toxic species are delivered. Said libraries are used in the development of therapeutics targeted against specific cell types. | 06-18-2009 |
20090156418 | MARKERS AND METHODS FOR ASSESSING AND TREATING CROHN'S DISEASE AND RELATED DISORDERS - A method for assessment of the suitability of and/or effectiveness of a target therapy for a gastrointestinal-related disorder, such as Crohn's disease, in a subject evaluates the presence, absence, and/or magnitude of expression of one or more genes in a 10-member gene panel in a sample. The method enables identification of the effectiveness of target therapies prior to or after starting a patient on such therapies. | 06-18-2009 |
20090156419 | HYBRIDIZATION METHODS USING NATURAL BASE MISMATCHES - The present invention provides an improved nucleic acid hybridization process employing a modified oligonucleotide probe comprising naturally occurring nucleotide bases. At least one nucleotide in the modified oligonucleotide is artificially mismatched relative to the control nucleic acid in addition to any mismatches arising from a variant nucleic acid target containing a sequence variation. The artificial mismatch and the sequence variation positions are separated from one another on the oligonucleotide by six to nine nucleotide positions. | 06-18-2009 |
20090156420 | Method for detecting cancer - To provide a method for selecting a marker gene useful for cancer classification; a method for classifying cancer using the gene; a method for detecting cancer; a kit usable for the classification method or detection method; and a DNA array carrying the gene. According to the present invention, there can be obtained a gene, wherein expression of the above gene is altered independently from genes each of which expression is altered specifically during cell proliferation and expression level of the above gene is specifically altered depending on every type of cancer samples to be tested, whereby the classification or detection of cancer can be carried out conveniently and quickly without giving surgical treatment. Therefore, the present invention is useful for the diagnosis, the treatment, and the like of cancer. | 06-18-2009 |
20090156421 | ASSAYS AND METHODS FOR EVALUATING MULTIMERIC COMPLEXES - Assays, e.g., homogenous assays, and methods for identifying, quantifying and/or monitoring the formation and/or stability of a multimeric complex, e.g., a ternary complex are disclosed. The methods and assays of the invention can be used to identify and/or evaluate agents (e.g., proteins, peptides, antibody molecules, and small and large molecules) that interfere with and/or inhibit the formation of a multimeric complex (e.g., a ternary complex) or that disrupt a previously formed complex. | 06-18-2009 |
20090156422 | DEVICE AND METHOD TO DETECT ANALYTES - The present invention relates to a device for and method of detecting analytes in samples, using optimized concentrations of Fc receptor-antibody complexes being immobilized on solid supports. | 06-18-2009 |
20090156423 | METHOD AND DEVICE FOR INTEGRATED SYNTHESIS AND ANALYSIS OF ANALYTES ON A SUPPORT - Methods and devices provide integrated synthesis of a support for analyte determination and the analyte determination. Preferred embodiments involve particles immobilized on the surface of a support to which receptors are coupled location-specifically, time-specifically or both on pre-determined positions on the support. | 06-18-2009 |
20090156424 | USE OF MASS LABELED PROBES TO DETECT TARGET NUCLEIC ACIDS USING MASS SPECTROMETRY - The invention relates to the use of mass labeled probes to characterise nucleic acids by mass spectrometry. Thus the invention provides methods of detecting the presence of a target nucleic acid in a sample, using a circularising probe in which a mass tag is present in the probe. Further methods of detecting the presence of a target nucleic acid are provided, which in contrast use a probe detection sequence in the circularising probe, wherein the probe detection sequence is detected with a probe attached to a mass tag. Methods for determining a genetic profile from the genome of an organism also form part of the invention. | 06-18-2009 |
20090156425 | METHODS FOR DETECTING TARGET ANALYTES AND ENZYMATIC REACTIONS - A microsphere-based analytic chemistry system and method for making the same is disclosed in which microspheres or particles carrying bioactive agents may be combined randomly or in ordered fashion and dispersed on a substrate to form an array while maintaining the ability to identify the location of bioactive agents and particles within the array using an optically interrogatable, optical signature encoding scheme. A wide variety of modified substrates may be employed which provide either discrete or non-discrete sites for accommodating the microspheres in either random or patterned distributions. The substrates may be constructed from a variety of materials to form either two-dimensional or three-dimensional configurations. In a preferred embodiment, a modified fiber optic bundle or array is employed as a substrate to produce a high density array. The disclosed system and method have utility for detecting target analytes and screening large libraries of bioactive agents. | 06-18-2009 |
20090163370 | Competitive N-Hybrid System - The invention relates to a method for identifying highly affinous ligands comprising the following steps: a) creating a bank for a mutagenized first hybrid protein comprising a plurality of mutants; b) expression of a first hybrid protein in a host with a second hybrid protein, one of the hybrid proteins comprising the DNA binding domain of a transcription factor and a bait protein and the other hybrid protein comprising the activation domain for a transcription factor and a prey protein; c) allowing the binding reaction between the first and second hybrid protein in order to form a complex with a functional transcription factor in the host cell under reaction conditions, which are such that the balance of the binding reaction is offset on the side of the hybrid proteins; d) detecting the binding reaction by detecting a reporter gene expressed via the functional transcription factor; e) optionally repeating one or more steps from a) to d); f) selection of a mutant. | 06-25-2009 |
20090163371 | Anchor-Assisted Fragment Selection and Directed Assembly - The invention provides methods for compound and lead generation and discovery. In particular, the present invention provides a method for generating compounds and for selecting compounds that bind to a target. The present invention provides a way by which anchors (e.g., weak binders) and anchor-scaffold conjugates can be evolved into new generations of compounds having improved target binding and other desired pharmaceutical properties through control of both synthetic input and selection criteria. | 06-25-2009 |
20090163372 | Nucleolipids and use thereof, and devices for nucleic acid analysis - The invention relates to a method for isolating and/or identifying known or unknown, nucleic acid sequences (target sequences) which are marked, optionally, with reporter groups, by base specific hybridisation with, essentially, complementary sequences, which belong to a library or sequences. The sample sequences are characterised in that they support, on one of the termini thereof (5′-ends or 3′-ends, preferably on 5′-ends), a single double or multi-chained lipid part, which spreads in a monomolecular layer on a liquid gas or liquid-liquid phase boundary layer. The invention also relates to a system for detecting or isolating nucleic acids. | 06-25-2009 |
20090163373 | Method of Drug Design - The invention provides a method of identifying biologically active compounds comprising: (a) designing a first library of compounds of formula (1) to scan molecular diversity wherein each compound of the library has at least two pharmacophoric groups R1 to R5 as defined below and wherein compound of the library has same number of pharmacophoric groups; (b) assaying the first library of compounds in one or more biological assay(s); and (c) designing a second library wherein each compound of the second library contains one or more additional pharmacophoric group with respect to the first library; such that the/each component of the first and second library is a compound of formula (1). | 06-25-2009 |
20090163374 | Process for Determining One or More Analytes in Samples of Biological Origin Having Complex Composition, and Use Thereof - The present invention relates to a process for detecting one or more analytes in one or more samples of biological origin having complex composition. The present invention also relates to a microarray for quantitative determination of one or more analytes in samples of biological origin having complex composition which are immobilized in measurement ranges of microarray, and also to a quantitative detection method based thereon. | 06-25-2009 |
20090163375 | Use of Photopolymerization for Amplification and Detection of a Molecular Recognition Event - The invention provides methods to detect molecular recognition events. The invention also provides methods to detect the presence of or identify a target species based on its interaction with one or more probe species. The methods of the invention are based on amplification of the signal due to each molecular recognition event. The amplification is achieved through photopolymerization, with the polymer formed being associated with the molecular recognition event. In one aspect, a fluorescent polymer, a magnetic polymer, a radioactive polymer or an electrically conducting polymer can form the basis of detection and amplification. In another aspect, a polymer gel swollen with a fluorescent solution, a magnetic solution, a radioactive solution or an electrically conducting solution can form the basis of detection and amplification. In another aspect, detectable particles can be included in the polymer formed. In another aspect, sufficient polymer forms to be detectable by visual inspection. | 06-25-2009 |
20090163376 | KETOL-ACID REDUCTOISOMERASE USING NADH - Methods for the evolution of NADPH binding ketol-acid reductoisomerase enzymes to acquire NADH binding functionality are provided. Specific mutant ketol-acid reductoisomerase enzymes isolated from | 06-25-2009 |
20090163377 | DETECTION AND/OR QUANTIFICATION METHOD OF TARGET MOLECULES ON A SOLID SUPPORT - The invention relates a method for detecting and/or quantifying different target molecules being bound at different locations (spots) of a surface of an optically transparent solid support having a refractive index n | 06-25-2009 |
20090163378 | MULTIPLEX MICROPARTICLE SYSTEM - Arrays of microparticle populations, each population labeled with a single fluorescent dye, are provided for use in multiplex assays. The populations form a virtual multidimensional array wherein each microparticle is identified by fluorescence intensity in two different fluorescence detection channels. The arrays are useful in a variety of assays, including multiplex, multi-analyte assays for the simultaneous detection of two or more analytes by, for example, flow cytometry, and a labeling reagents in, for example, microscopy. The use of singly-dyed microparticles to form multidimensional arrays greatly simplifies the creation of multiplex assays. | 06-25-2009 |
20090170716 | ELECTRONIC SENSING FOR NUCLEIC ACID SEQUENCING - Methods for sequencing nucleic acids are presented. Sequencing is accomplished through the detection of a redox active species that is indicative of nucleotide incorporation. In embodiments of the invention, an electrochemical signal indicative of nucleotide incorporation is amplified through cycling before it is detected. Arrays are provided that are capable of massively parallel nucleic acid sequence determination. | 07-02-2009 |
20090170717 | RE-SEQUENCING PATHOGEN MICROARRAY - The present invention relates to pathogen detection and identification by use of DNA resequencing microarrays. The present invention also provides resequencing microarray chips for differential diagnosis and serotyping of pathogens present in a biological sample. The present invention further provides methods of detecting the presence and identity of pathogens present in a biological sample. | 07-02-2009 |
20090170718 | High-stringency screening of target-binding partners using a microfludic device - The invention provides a method of screening a library of candidate agents by contacting the library with a target in a reaction mixture under a condition of high stringency, wherein the target includes a tag that responds to a controllable force applied to the tag, and passing the members of the library through a microfluidic device in a manner that exposes the library members to the controllable force, thereby displacing members of the library that are bound to the target relative to their unbound counterparts. Kits and systems for use with the methods of the invention are also provided. | 07-02-2009 |
20090170719 | SUPERIOR HYBRIDIZATION PROBES AND METHODS FOR THEIR USE IN DETECTION OF POLYNUCLEOTIDE TARGETS - We describe new hybridization probes and methods for their use in detection, identification, and quantitation of polynucleotides such as RNA and DNA. Ordinary short oligonucleotide probes usually provide higher sequence-specificity but lower efficacy of hybridization than longer ordinary polynucleotide probes where both are fully complementary to the target polynucleotide. Our new polynucleotide probes combine the hybridization efficacy of long probes with the sequence-specificity of short probes. The polynucleotide probes contain a target binding domain and a binding enhancer domain, where the binding enhancer domain does not for stable structures under hybridizing conditions with the target binding domain or its corresponding target. These binding enhancer domains are able to improve the hybridization features of the target binding domain as well as the signal-to-noise ratio for target detection. Detection methods based on these probes allow fast, accurate, and sensitive detection of target polynucleotides (either qualitatively or quantitatively) and can be easily multiplexed. | 07-02-2009 |
20090170720 | MOLECULAR TARGETS AND COMPOUNDS, AND METHODS TO IDENTIFY THE SAME, USEFUL IN THE TREATMENT OF JOINT DEGENERATIVE AND INFLAMMATORY DISEASES - The application discloses methods for identifying and using compounds that inhibit extra-cellular matrix (ECM) degradation and inflammation, using a polypeptide sequence including SEQ ID NO: 17-127 (hereinafter “TARGETS”) and fragments thereof, expression inhibitory agents such as antisense polynucleotide, a ribozyme, and a small interfering RNA (siRNA), comprising a nucleic acid sequence complementary to, or engineered from, a naturally occurring polynucleotide sequence encoding a polypeptide of SEQ ID NO: 17-127, useful in pharmaceutical compositions comprising said agent, for the treatment, or prevention, of chronic joint degenerative and/or inflammatory diseases such as rheumatoid arthritis. | 07-02-2009 |
20090176653 | ZINC FINGER DOMAIN LIBRARIES - Disclosed are libraries of chimeric zinc finger domains. The libraries can include two or more zinc finger domains from naturally occurring proteins, e.g., mammalian proteins and particularly human proteins. Useful chimeric zinc finger domains can be identified from the library. Also disclosed are the amino acid sequences of zinc finger domains that recognize particular sites. | 07-09-2009 |
20090176654 | Universal fibronectin type III binding-domain libraries - Walk-through mutagenesis and natural-variant combinatorial fibronectin Type III (FN3) polypeptide libraries are described, along with their method of construction and use. Also disclosed are a number of high binding affinity polypeptides selected by screening the libraries against a variety of selected antigens. | 07-09-2009 |
20090176655 | Methylation detection - A method of identifying nucleic acid molecules differentially methylated in a disease comprises steps of incubating fragmented DNA, from a disease cell, with a reagent which specifically binds to methylated DNA to thus concentrate methylated DNA fragments, incubating fragmented DNA, from a disease cell related to the disease cell utilised in step (a) in which DNA methyltransferase expression and/or activity has been inhibited, with a reagent which specifically binds to methylated DNA to thus concentrate methylated DNA fragments and comparing the methylated DNA fragments obtained in steps (a) and (b) to identify nucleic acid molecules differentially methylated in the disease. A method of detecting a predisposition to, or the incidence of, colorectal cancer in a sample comprises detecting an epigenetic change in at least one gene selected from RASGRF2, SCNN1B, HOXD1, PLK2 and BHLHB9 wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, colorectal cancer. | 07-09-2009 |
20090176656 | TISSUE REJECTION - This document relates to methods and materials involved in detecting tissue injury and/or rejection (e.g., injury and/or rejection of transplanted tissue). For example, this document relates to methods and materials involved in the early detection of kidney tissue injury. | 07-09-2009 |
20090176657 | BINDING AND FUNCTIONAL ASSAYS THAT USE THE T1R3 RECEPTOR TO SCREEN FOR TASTE MODULATORY COMPOUNDS - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed. | 07-09-2009 |
20090176658 | Real Time Binding Analysis of Antigens on a Biosensor Surface - The invention provides methods for detecting interactions between phage and antigen or antigen and antibody using biosensors. | 07-09-2009 |
20090186772 | Markers and Methods for Assessing and Treating Ulcerative Colitis and Related Disorders Using a 19 Gene Panel - A method for assessment of the suitability of a target therapy for a gastrointestinal-related disorder, such as ulcerative colitis, in a subject evaluates the presence, absence, and/or magnitude of expression of one or more genes in a 19- or 5-member gene panel in a sample. The method enables identification of the effectiveness of target therapies prior to starting a patient on such therapies. | 07-23-2009 |
20090186773 | Methods For Predicting The Response Of Multiple Sclerosis Patients To Interferon Theraphy And Diagnosing Multiple Sclerosis - The present invention relates to a method of diagnosing a predisposition of a multiple sclerosis (MS) patient for responsiveness to a treatment of MS by administration of interferon-α (IFN-α) and/or interferon-β (IFN-β) and means to perform the method. Furthermore, the invention relates to a method of diagnosing a predisposition of a patient for developing multiple sclerosis (MS) and corresponding means. | 07-23-2009 |
20090186774 | SEPSIS DETECTION MICROARRAY - The invention relates to the early detection of sepsis and the use of particular sets of biomarkers. Combinations of biomarkers representing changes in expression levels of specific genes are provided and, in particular, the use of microarrays to detect such changes of expression and to provide early diagnostic information is provided. | 07-23-2009 |
20090186775 | Method and device for dual array hybridization karyotype analysis - A method, a device and a platform for a dual assay, co-hybridization of labeled nucleic acid molecules utilizing two independent microarray platforms are provided herein. The dual hybridization method and device, including for example, each of a BAC based array and an oligonucleotide array provide simultaneous replication and/or validation of data for a single assay sample and in the same container, using two or more microarray slides. | 07-23-2009 |
20090192047 | Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers - Mitochondrial DNA deletions useful for the detection of cancers and sun exposure are provided. In particular, methods and kits for detecting mitochondrial DNA deletions for the early detection, diagnosis and progression of prostate cancer, sun exposure and non-melonoma skin cancer are provided. | 07-30-2009 |
20090192048 | METHOD OF PRODUCING A MULTIMERIC CAPTURE AGENT FOR BINDING A LIGAND - The current invention relates to a method of fabricating a multimeric capture agent for binding a ligand, the capture agent comprising at least first and second monomers units, the first monomer unit further comprising a first ligand-binding moiety, a first reactive group and an attachment moiety, the second monomer unit further comprising a second ligand-binding moiety, and a second reactive group, wherein the reactive groups may be the same or different for each monomer unit, the method comprising the steps of; a) reacting the first monomer unit with the second monomer unit such that reactive groups present on the monomer units react to form a multimeric capture agent. b) immobilising the first monomer unit on a substrate via the attachment moiety, wherein, step a) can be performed before, simultaneously with, or subsequently to step b). | 07-30-2009 |
20090192049 | Proteolipid Membrane and Lipid Membrane Biosensor - The invention provides compositions and methods for detection of interaction of molecules. | 07-30-2009 |
20090197772 | Compartmentalised combinatorial chemistry by microfluidic control - The invention describes a method for the synthesis of compounds comprising the steps of: (a) compartmentalising two or more sets of primary compounds into microcapsules; such that a proportion of the microcapsules contains two or more compounds; and (b) forming secondary compounds in the microcapsules by chemical reactions between primary compounds from different sets; wherein one or both of steps (a) and (b) is performed under microfluidic control; preferably electronic microfluidic control The invention further allows for the identification of compounds which bind to a target component of a biochemical system or modulate the activity of the target, and which is co-compartmentalised into the microcapsules. | 08-06-2009 |
20090197773 | Bioreaction Execution System and Bioreaction Execution Method, DNA Chip, Information Processing System and Information Processing Method, Program, and Recording Medium - This invention relates to a bioreaction execution system and bioreaction execution method capable of producing electric fields in a flow channel, into which a solution with a target gene contained therein is dropped, on a DNA chip and causing the target gene to electrophoretically migrate, the DNA chip, an information processing system and information processing method, a program, and a recording medium. An AC supply unit | 08-06-2009 |
20090197774 | METHOD FOR DIAGNOSING THROMBOEMBOLIC DISORDERS AND CORONARY HEART DISEASE - The present invention refers to a method for the in vitro diagnosis of thromboembolic and/or coronary heart diseases, wherein the nucleotide at position 470 of a nucleic acid coding for the human EGLN2 protein or the amino acid at position 58 of the human EGLN2 protein of a sample of a person is determined. | 08-06-2009 |
20090197775 | NUCLEASE ON CHIP - The present invention pertains to a method for determining point mutations on micro-arrays/biochips using a nuclease capable to selectively digest hybridized DNA strands into two DNA fragments, said hybridized DNA strands containing a nucleotide mismatch or nucleotide deletion. The occurrence and/or location of such DNA fragments are indicative for a point mutation. | 08-06-2009 |
20090197776 | Liquid Tissue Preparation From Histopathologically Processed Biological Samples, Tissues and Cells - The current invention provides a method for directly converting histopathologically processed biological samples, tissues, and cells into a multi-use biomolecule lysate. This method allows for simultaneous extraction, isolation, solublization, and storage of all biomolecules contained within the histopathologically processed biological sample, thereby forming a representative library of said sample. This multi-use biomolecule lysate is dilutable, soluble, capable of being fractionated, and used in any number of subsequent experiments. | 08-06-2009 |
20090203533 | Methods and Kits for Predicting and Monitoring Direct Response to Cancer Therapy - The invention provides novel compositions, methods and uses, for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia and breast cancer. The invention further relates to genes that are differentially expressed in breast tissue of breast cancer patients versus those of normal “healthy” tissue. Differentially expressed genes for the identification of patients which are likely to respond to chemotherapy are also provided. | 08-13-2009 |
20090203534 | EXPRESSION PROFILES FOR PREDICTING SEPTIC CONDITIONS - A rapid, safe method for predicting sepsis, or a condition similar to sepsis, in a mammal is disclosed, which comprises the following steps:
| 08-13-2009 |
20090203535 | ACOUSTIC WAVE TRANSDUCER SUBSTRATE AND MEASUREMENTS USING THE SAME - An acoustic wave transducer substrate is provided, the substrate having a surface with a plurality of growth promotion sites for promoting the accumulation of polypeptide molecules at said sites. The growth-promotion sites are preferably for promoting fibril formation. The invention also provides a method of screening a candidate compound for an effect on fibril growth, including the steps of: providing an acoustic wave transducer substrate having a surface with a plurality of growth promotion sites for promoting the accumulation of polypeptide molecules at said sites; causing oscillation of the substrate; contacting the substrate surface with a sample fluid comprising polypeptide molecules and a candidate compound; and measuring one or more parameters of the substrate oscillation to monitor the accumulation of said polypeptide molecules of interest in the presence and absence of said candidate compound. Alteration of the accumulation of said polypeptide molecules of interest in the presence of said candidate compound as compared with that in the absence of said candidate compound indicates that the candidate compound has an effect of fibril growth. | 08-13-2009 |
20090203536 | Assay supports comprising a peg support, said support attached from a peg solution in cloud point (theta solvent) conditions - Assay supports, such as microarrays and similar devices, and methods of use and manufacture thereof, are described. The assay support is capable of assaying binding and/or activity of a bioactive entity, such as a bioactive molecule or a cell. Analytical and diagnostic uses of the supports are also described. | 08-13-2009 |
20090203537 | NUCLEAR RECEPTOR ASSAY - The present invention relates to methods for measuring compound efficacy and potency on nuclear receptor-co-regulator interaction, comprising the steps of (a) co-incubating at least one nuclear receptor and at least one compound under conditions that allow interaction; (b) co-incubating the nuclear receptor-compound mixture of step (a) with an array of co-regulators, under conditions that allow compound modulated receptor-co-regulator interaction; (c) determination of compound-modulated receptor-co-regulator interaction in function B of co-regulator concentration, and (d) determination of compound-modulated receptor-co-regulator interaction in function of compound concentration; wherein steps (c) and (d) are performed in a single assay. | 08-13-2009 |
20090203538 | Method of classifying antibody, method of identifying antigen, method of obtaining antibody or antibody set, method of constructing antibody panel and antibody or antibody set and use of the same - It is intended to provide a method whereby a plural number of antibodies against cell surface antigens are quickly classified and to provide a method whereby antigens of the thus classified antibodies are quickly identified. Further, it is intended to provide a method of promoting the utilization of the useful data obtained by the above methods. Furthermore, it is intended to provide an antibody which is effective in treating or diagnosing cancer. Namely, a method of classifying antibodies which comprises: (1) the step of preparing a plural number of antibodies respectively recognizing cell surface antigens; (2) the step of bringing each of these antibodies into contact with a cell of the same species; (3) the step of analyzing each of the cells having been treated in the step (2) by flow cytometry and thus obtaining data indicating the reactivity of each antibody with its cell surface antigen; and (4) the step of comparing the thus obtained data and classifying the individual antibodies depending on the similarity. A method of identifying antigens which further comprises: (5) the step of selecting one to several antibodies from each antibody group formed in the step (4) and identifying antigens thereof; and (6) on the assumption that antigens of the antibodies belonging to a single antibody group are the same or highly related to one another, making relations between the antigens having been identified in the step (5) and the antibody groups to thereby identify the antigens. An antibody against HER1, an antibody against HER2, an antibody against CD46, an antibody against ITGA3, an antibody against ICAM1, an antibody against ALCAM, an antibody against CD147, an antibody against C1qR, an antibody against CD44, an antibody against CD73, an antibody against EpCAM and an antibody against HGFR, each obtained by using the above methods. | 08-13-2009 |
20090203540 | Methods and Systems for Quality Control Metrics in Hybridization Assays - The present invention provides methods and systems for performing quality control metrics in hybridization assays. In particular, the present invention provides for quality control metrics for nucleic acid enrichment on hybridization assay formats, such as microarray assays. | 08-13-2009 |
20090203541 | MSP AND ITS DOMAINS AS FRAMEWORKS FOR NOVEL BINDING MOLECULES - Disclosed are compositions and methods relating to the use of MSP94 proteins and its domains as frameworks for novel binding molecules, including screening assays for the identification of novel binding molecules. | 08-13-2009 |
20090209432 | Detecting targets using nucleic acids having both a variable region and a conserved region - The invention relates to nucleic acid molecules for use in detecting a target nucleic acid molecule which is a member of a class of nucleic acid molecules and which is characterised by a specific variant region, said nucleic acid molecule comprising (i) a nucleic acid stem region which comprises a nucleic acid interaction site directed to a conserved region of the class of which said target nucleic acid molecule is member, or part thereof and which conserved region is located proximally to a variant region; operate y linked to (ii) a nucleic acid recognition region comprising at least two nucleotides. The nucleic acids are used in arrays and are an efficient means of screening molecules exhibiting a unique nucleotide sequence within a randomly varying population. The invention is useful in monitoring the effectiveness of therapeutic drug therapies and the progression of medical conditions, characterised by the presence of clonal populations of cells, particularly clonal lymphocyte populations. | 08-20-2009 |
20090209433 | METHOD FOR SCREENING AND SELECTING LIGANDS - The present invention provides a method for screening of ligands wherein the target is a membrane protein, which is reconstituted into a membrane environment, using the surface plasmon resonance (SPR) technology. In particular, the target is a VDAC protein. | 08-20-2009 |
20090209434 | Probe-antiprobe compositions and methods for DNA or RNA detection - The invention provides novel compositions and methods for detecting unlabeled nucleic acid targets using labeled polynucleotide probes and partially complementary antiprobes. The interaction of probes, antiprobes and targets result in signaling changes that indicate target frequency. This novel detection mechanism is called a DNA detection switch, and it enable end-point detection, microarray detection and real-time PCR detection of a variety of nucleic acid targets including microbial species and subspecies, drug resistant mutants, and pathogenic strains. | 08-20-2009 |
20090209435 | Methods of screening for TRPM4b modulators - The invention relates, in part, to methods useful in identifying molecules, that bind TRPM4b, which modulate TRPM4b ion channel activity, and/or which alter expression of TRPM4b within cells. The TRPM4b channels as described herein contain TRPM4b polypeptides, which are in turn encoded by TRPM4b nucleic acids. The ion channels described herein are preferably formed in HEK-293 cells from one or more novel TRPM4b polypeptides, which exhibit one or more of the unique TRPM4b properties described herein. | 08-20-2009 |
20090209436 | HYDROGEL LABELED PRIMER EXTENSION METHOD FOR MICROARRAYS - A method for fabricating hydrogel based microarrays by a nanostamping process is provided. A method of manufacturing a patterned hydrogel array is provided comprising the steps of contacting a patterned substrate with a hydrogel substrate to form a substrate complex, wherein the patterned substrate comprises a surface, a first polymer attached to the surface, and a second polymer reversibly attached to the first polymer, the hydrogel substrate comprises a polymer matrix and a plurality of attachment sites along the polymer matrix capable of attaching the second polymer, binding at least one attachment site to the second polymer, disassociating the dimer; and separating the substrate complex to obtain a patterned hydrogel array having a second polymer attached to an attachment site. Methods where the second polymer is synthesized using the first polymer as template are provided. Hydrogel arrays manufactured according to the methods of the invention are provided. | 08-20-2009 |
20090215637 | Method of detecting mutations in the gene encoding cytochrome P450-2D6 - The present invention describes a method for the simultaneous identification of two or more mutations located in the gene encoding Cytochrome P450-2D6. Multiplex detection is accomplished using multiplexed tagged allele specific primer extension (ASPE) and hybridization of such extended primers to a probe, preferably an addressable anti-tagged support. | 08-27-2009 |
20090215638 | ANTIBIOTIC SUSCEPTIBILITY AND VIRULENCE FACTOR DETECTION IN PSEUDOMONAS AERUGINOSA - The present invention relates in general to the detection of antibiotic resistance determinants in | 08-27-2009 |
20090215639 | Method of Producing Human IgG Antibodies with Enhanced Effector Functions - A method for generating human IgG | 08-27-2009 |
20090215640 | METHODS FOR IDENTIFYING LIGANDS FOR STEM CELLS AND CELLS DERIVED THEREFROM - The present invention provides methods for the identification of novel ligands to pluripotent stem cells such as human embryonic stem cells, human embryo-derived cells, and from cells differentiated from such cells, and the use of such ligands in identifying differentiation conditions, purifying cells, and for eliminating such cells from mixtures of varied cell types. The invention also provides methods for the identification of target progenitor cells and cells identified thereby. | 08-27-2009 |
20090215641 | Gene involved in occurrence/recurrence of hcv-positive hepatocelluar carcinoma - The present invention relates to a method for screening a gene involved in early recurrence of HCV-positive hepatocellular carcinoma associated with chronic hepatitis, comprising: determining an expression level of a gene in a noncancerous site from each of early and late recurrent cases of HCV-positive hepatocellular carcinoma associated with chronic hepatitis; and selecting a gene whose expression is increased in the early recurrent case compared with that in the late recurrent case. The present invention can provide a gene involved in recurrence of hepatocellular carcinoma. | 08-27-2009 |
20090215642 | Methods and Compositions for Assessing Alterations in Gene Expression Patterns in Clinically Normal Tissues Obtained from Heterozygous Carriers of Mutant Genes Associated with Cancer and Methods of Use Thereof - Compositions, kits, and methods are provided for assessing alterations in gene expression in heterozygous carriers of mutant genes associated with cancer. | 08-27-2009 |
20090215643 | Highly Visible Chromosome-Specific Probes and Related Methods - Disclosed are chromosome-specific synthetic oligonucleotides and labeled probe compositions, as well as related methods for preparing and using such compositions. Also disclosed are kits for utilization in methods for preparing or using the labeled probes. | 08-27-2009 |
20090221431 | Digital bio disc (dbd), dbd driver apparatus, and assay method using the same - An aspect of embodiment relates to a digital bio disc (DBD) including new valve control means and fluid movement system, a digital bio disc (DBD) driver apparatus, and an assay method using the same. More particularly, an aspect of embodiment relates to a DBD with a lab-on-a-chip for various diagnostic assays, nucleic acid hybridization assays, or immunoassays, a DBD driver apparatus integrated with a controller for controlling the DBD and a general optical disc (CD or DVD), and an assay method using the same. | 09-03-2009 |
20090221432 | Compositions, methods and systems for inferring bovine breed - Provided herein are methods to discover and use single nucleotide polymorphisms (SNP) for identifying breed, or line and breed, or line composition of a bovine subject. The present invention further provides specific nucleic acid sequences, SNPs, and SNP patterns that can be used for identifying breed or breed combinations for Angus, Holstein, Limousin, Brahman, Hereford, Simmental, Gelbvieh, Charolais and Beefmaster breeds. These patterns can be utilized to manage animals in a feedlot to obtain optimum performance based on known characteristics of specific breeds and identify animals for breeding in selection programs. In another aspect, these patterns can be used to ensure labeling on breed specific branded products. | 09-03-2009 |
20090221433 | SMALL MOLECULE PRINTING - The present invention provides compositions and methods to facilitate the identification of compounds that are capable of interacting with a biological macromolecule of interest. In one aspect, a composition is provided that comprises an array of one or more types of chemical compounds attached to a solid support using isocyanate or isothiocyanate chemistry, wherein the density of the array of compounds is at least 1000 spots per cm | 09-03-2009 |
20090221434 | USE OF PARTICULATE LABELS IN BIOANALYTE DETECTION METHODS - New applications for the use of distinguishable particulate labels available in a variety of hues and sized in the submicron range are described. These applications include profiling of cellular components, obtaining secretion patterns, identifying a multiplicity of components in chromatographic or electrophoretic techniques and identification of desired immunoglobulin secreting cells. | 09-03-2009 |
20090221435 | MICROARRAY FOR DETECTING AND QUANTIFYING MICRORNA - A microarray can be configured for hybridizing with short nucleic acids, such as miRNA or siRNA, contained within a sample. Such a microarray includes a polynucleotide trap coupled to a substrate of a microarray site. The polynucleotide trap includes a probe that selectively hybridizes with short nucleic acid sequences, and a linker that is coupled to the substrate and configured to extend the probe from the substrate. Additionally, the polynucleotide trap can include an enhancer that hybridizes with the linker in order to enhance functionality of the probe. The linker and/or enhancer are configured to inhibit the probe from interacting with the linker or substrate. This can include the linker and/or enhancer being configured to have a minimal secondary structure so as to present the probe region for hybridizing with the target polynucleotide and inhibit the linker region or probe region from interacting with the substrate. | 09-03-2009 |
20090221436 | PROCESS FOR DETERMINING TARGET FUNCTION AND IDENTIFYING DRUG LEADS - The present invention relates to methods for using chemical ligands to determine target function and identify drug leads. | 09-03-2009 |
20090221437 | Transcriptome microarray technology and methods of using the same - Arrays containing a transcriptome of a diseased tissue and methods of using the arrays for diagnosis, prognosis, screening, and identification of disease are provided herein. The transcriptome arrays from diseased tissue are useful for diagnosis of a disease by analysis of the genetic profile of a tissue sample specific to a disease state. The genetic profiles are then correlated with data on the effectiveness of specific therapeutic agents. Correlating expression profiles to the effectiveness of therapeutic agents provides a way to screen and select further patients predicted to respond to those therapeutic agents, thereby minimizing needless exposure to ineffective therapy. | 09-03-2009 |
20090221438 | METHODS AND SYSTEMS FOR UNIFORM ENRICHMENT OF GENOMIC REGIONS - The present invention provides methods and compositions for the enrichment of target nucleic acids in a microarray system. In particular, the present invention provides methods and compositions for uniform enrichment of target nucleic acid molecules in a microarray format. The present invention also provides for intentionally non-uniform enrichment among target nucleic acid molecules. | 09-03-2009 |
20090221439 | COMBINATORIAL ARTIFICIAL RECEPTORS INCLUDING TETHER BUILDING BLOCKS - The present invention relates to artificial receptors, arrays or microarrays of artificial receptors or candidate artificial receptors, methods of and compositions for making them, and methods of using them. Each artificial receptor includes a plurality of building block compounds. In an embodiment, at least one of the building blocks includes a tether moiety. The tether can provide spacing or distance between the recognition element and the support or scaffold to which the building block is immobilized. A tether moiety can have any of a variety of characteristics or properties including flexibility, rigidity or stiffness, ability to bond to another tether moiety, and the like. | 09-03-2009 |
20090239757 | Control Sequences Responding to AMP and Uses Thereof - The present invention relates to a method of identifying control sequences responding to antimicrobial peptides (AMPs), to host cells expressing an AMP and comprising a control sequence of the invention operable linked to a reporter, and to a method of screening for novel AMPs or AMP-variants having improved antimicrobial activity. Particularly the present invention relates to DNA control sequences, wherein the transcriptional profiles of said control sequences are regulated by the presence of an antimicrobial polypeptide expressed inside the host cell. | 09-24-2009 |
20090239758 | METHODS, MICROARRAY, AND KITS FOR DETECTION OF DRUG RESISTANCE GENES IN GRAM-NEGATIVE BACTERIA - The present invention provides kits and microarrays containing primer pairs for amplifying drug resistance genes and/or probes for detection of drug resistance genes. Also provided are methods of detecting drug resistance genes using kits and microarrays described herein. | 09-24-2009 |
20090239759 | MULTIPLEXED MOLECULAR ANALYSIS SYSTEMS - A method and apparatus for analyzing molecular structures within a sample substance using an array having a plurality of test sites upon which the sample substance is applied. The invention is also directed to a method and apparatus for constructing molecular arrays having a plurality of test sites. The invention allows for definitive high throughput analysis of multiple analytes in complex mixtures of sample substances. A combinatorial analysis process is described that results in the creation of an array of integrated chemical devices. These devices operate in parallel, each unit providing specific sets of data that, when taken as a whole, give a complete answer for a defined experiment. This approach is uniquely capable of rapidly providing a high density of information from limited amounts of sample in a cost-effective manner. | 09-24-2009 |
20090239760 | Method for the Identification of New Leads for Drug Candidates - Disclosed is a method for producing new leads for drug candidates. The method employs a combinatorial approach for identifying high affinity ligands. The target may be unknown and/or may include one or more unknown binding sites. A method involving a combined screening and synthesis method for bi-site inhibitors is disclosed comprising: 1) determining if there is sufficient proximity between ligands binding to different sites of a target: e.g. by using spin-labelled ligands quenching can be measured with NMR if a first ligand and second allosteric ligand are in proximity 2) connecting both ligands having linkers, via in situ synthesis in the presence of the protein scaffold (e.g. target guided synthesis combined with fragment based self assembly). Click chemistry is a preferred embodiment here. Also disclosed are kits used in context of this method, leads discovered by the method and their use in drug development. Leads for drugs acting on myelin associated glycoprotein (MAG) have been identified and synthesised. | 09-24-2009 |
20090239761 | Protein arrays and uses thereof - The inventors herein describe methods for the production of a functional human, animal, plant or microbe protein arrays and methods to assay for interactions between the proteins on the array with molecules of interest, for example, using such arrays to determine the in vitro metabolite profile of any drug. Such protein arrays can be used, for example, to assay, in a parallel fashion, the protein products of DNA sequences encoding drug metabolizing enzymes (DMES) to obtain a toxicology profile. Also described herein is a novel DME expression and purification strategy using detergents and not requiring an ultra-centrifugation step. | 09-24-2009 |
20090239762 | APTAMERS THAT BIND ABNORMAL CELLS - A new aptamer approach for the recognition of specific small cell lung cancer (SCLC) cell surface molecular markers relies on cell-based systematic evolution of ligands by exponential enrichment (cell-SELEX) to evolve aptamers for whole live cells that express a variety of surface markers representing molecular differences among cancer cells. When applied to different lung cancer cells including those from patient samples, these aptamers bind to SCLC cells with high affinity and specificity in different assay formats. When conjugated with magnetic and fluorescent nanoparticles, the aptamer nano-conjugates could effectively extract SCLC cells from mixed cell media for isolation, enrichment, and sensitive detection. | 09-24-2009 |
20090239763 | MARKERS FOR BREAST CANCER - Correlations between polymorphisms and breast cancer are provided. Methods of diagnosing, prognosing, and treating breast cancer are provided. Systems and kits for diagnosis, prognosis and treatment of breast cancer are provided. Methods of identifying breast cancer modulators are also described. | 09-24-2009 |
20090239764 | ARRAY-BASED TRANSLOCATION AND REARRANGEMENT ASSAYS - Methods for detecting genomic rearrangements are provided. In one embodiment, methods are provided for the use of paired end tags from restriction fragments to detect genomic rearrangements. Sequences from the ends of the fragments are brought together to form ditags and the ditags are detected. Combinations of ditags are detected by an on-chip sequencing strategy that is described herein, using inosine for de novo sequencing of short segments of DNA. In another aspect, translocations are identified by using target specific capture and analysis of the captured products on a tiling array. | 09-24-2009 |
20090239765 | GENES WHOSE EXPRESSION IS INCREASED IN RESPONSE TO STIMULATION BY CORTICOTROPIN-RELEASING HORMONE - The present invention relates generally to therapy and diagnosis of depression. In particular this invention relates to the polypeptides as well as to the polynucleotides encoding these polypeptides, wherein said polypeptides are shown to play a central role in mediating the endocrine response to corticotropin releasing hormone. These polypeptides and polynucleotides are useful in the diagnosis, treatment and/or prevention of depression. | 09-24-2009 |
20090239766 | METHOD FOR THE IDENTIFICATION OF HUMAN IMMUNODEFICIENCY VIRUS RELATED ANTIBODIES IN BLOOD - This invention discloses using SPR technology to simultaneously and qualitatively measure the presence of HIV related antibodies in a serum sample for the diagnosis of HIV infection. It also discloses an efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of HIV related antigens used for the diagnosis of HIV infection. | 09-24-2009 |
20090247418 | OPTICAL DETECTION FOR ELECTRONIC MICROARRAYS - Embodiments of the invention provide methods for detecting molecular recognition events electronically and optically. Methods according to embodiments of the invention provide a nucleic acid molecule that hybridizes to a first probe nucleic acid molecule attached to an electronic detector wherein the second nucleic acid molecule comprises two regions. The two regions of the second nucleic acid molecule consist of a region that is complementary to the probe nucleic acid and a distal region that is not complementary to the first probe nucleic acid molecule. The hybridization reaction is detected electronically. A third nucleic acid molecule having an attached optically detectable label is hybridized to the distal region of the second nucleic acid molecule and the label is detected optically. Methods according to embodiments of the invention are useful, for example, to validate and quantify electronic detection methods. | 10-01-2009 |
20090247419 | METHOD FOR CONFIRMING POSITIONS ON WHICH PROBES ARE IMMOBILIZED IN NUCLEIC ACID ARRAY - The present invention provides a method for confirming immobilization conditions of nucleic acid probes immobilized on a nucleic acid array, comprising the steps of:
| 10-01-2009 |
20090247420 | METHOD FOR ENCODING AND SCREENING COMBINATORIAL LIBRARIES - A method of screening a library comprising: (i) providing either (a) a library comprising more than one copy of different library members, each copy of a different library member attached to a different releasable tag through a releasable covalent bond; where a plurality of tags uniquely encode each library member; or (b) a library comprising one or more copies of a library member attached to a support, with a plurality of tags uniquely encoding each library member; or (c) a library comprising different library members, each different library member attached to a plurality of tags uniquely encoding the different library member; (ii) providing a target compound with tethered sensitizer in specific binding proximity to the library, allowing specific binding of the target compound with tethered sensitizer to a selected library member; (iii) exciting the tethered sensitizer with excitation photoradiation, whereby the releasable tags attached to the selected library member are released; and (iv) detecting the releasable tags. | 10-01-2009 |
20090247421 | DIVERSE CHEMICAL LIBRARIES BOUND TO SMALL PARTICLES WITH PARAMAGNETIC PROPERTIES - The present invention provides diverse chemical libraries bound to small particle with paramagnetic properties. Typically, the chemical structures comprise a plurality of different chemical moieties, the particles are paramagnetic and have a diameter between about 100 nm and about 10 microns, the chemical structures bound to each particular particle have substantially the same structure and the combinatorial library comprises at least 100,000 different chemical structures. | 10-01-2009 |
20090247422 | In SITU Induced Antigen Technology (ISIAT) for Identification of Polynucleotides Expressed during Infection or Colonization - The invention provides compositions and methods for identifying polynucleotides and polypeptides expressed by a microbe during infection or colonization. The invention also provides compositions and methods for identifying polynucleotides and polypeptides expressed by a host organism in response to a disease state. The invention also provides methods and compositions for the diagnosis, treatment, prevention, and amelioration of diseases and infections caused by microbes. | 10-01-2009 |
20090247423 | Compositions and Methods Relating to Elutable Carbohydrate-Binding Proteins - Compositions and methods are provided for creating and identifying mutant carbohydrate-binding proteins that reversibly bind to carbohydrate substrates under conditions where the native protein remains bound. Examples of modified chitin-binding domains are provided which can be eluted from chitin in the presence of a reducing agent or at a pH within the range of 5-10. | 10-01-2009 |
20090247424 | DETECTION ASSAY DEVICES AND METHODS OF MAKING AND USING THE SAME - An article such as a biomolecular detector or biosensor having a nonfouling surface thereon includes:(a) a substrate having a surface portion; (b) a linking layer on the surface portion; and (c) a polymer layer formed on the linking layer; and (d) a first member of a specific binding pair (e.g., a protein, peptide, antibody, nucleic acid, etc.) bound to the polymer layer. Methods of making and using the articles are also described. | 10-01-2009 |
20090253583 | Hematological Cancer Profiling System - A system for profiling lymphoma is provided that is based on the identification of sets of genes, which are characterized in that changes in expression of each gene within a set of genes can be correlated to one or more features of a specific lymphoma. The lymphoma profiling system provides for sets of “lymphoma profiling” genes and further provides for combinations of polynucleotide probes derived from one or more of the lymphoma profiling sets. These combinations of polynucleotide probes can be provided in solution or as an array. The combination of probes and the arrays can be used for disease prognosis, diagnosis, staging or grading, treatment management, monitoring of disease progression, predicting disease outcome or complications, and the like. | 10-08-2009 |
20090253584 | Method for the determination of the DNA methylation level of a CPG position in identical cells within a tissue sample - Aspects of the present invention relate to the determination of the DNA methylation level at one or more CpG position within cells of a defined type in a tissue sample. This methylation level is deduced from the total DNA methylation level of all cells of the sample and from the content of said cells of interest. In aspects of the invention, the cell content is determined by means of histopatholoy, staining methods, antibodies, expression analysis or DNA methylation analysis. | 10-08-2009 |
20090253585 | Identification of Genetic Polymorphic Variants Associated With Somatosensory Disorders and Methods of Using the Same - Methods of predicting effective pharmacological therapies for a subject afflicted with a somatosensory disorder by determining a genotype of the subject with or without determination of psychosocial and/or neurological assessments of the subject are provided. Methods of predicting susceptibility of a subject to develop somatosensory disorders by determining a genotype of the subject with or without determination of psychosocial and/or neurological assessments of the subject are further provided. | 10-08-2009 |
20090253586 | SUBSTRATES FOR MULTIPLEXED ASSAYS AND USES THEREOF - The present invention relates to novel methodologies for performing multiplexed assays for biological molecules such as proteins and nucleic acids. In particular, the present invention provides multiplexed assays using precipitating reagents and optically clear nitrocellulose-coated solid supports. | 10-08-2009 |
20090253587 | Integrated Biosensor and Simulation System for Diagnosis and Therapy - BioMEMS/NEMS appliance biologically monitors an individual, using biosensors to detect cellular components. Data is simulated or analyzed using systems-biology software, which provides diagnostic or therapeutic guidance. | 10-08-2009 |
20090258790 | IDENTIFYING ANTIGEN CLUSTERS FOR MONITORING A GLOBAL STATE OF AN IMMUNE SYSTEM - Method, system and an article of manufacture for clustering and thereby identifying predefined antigens reactive with undetermined immunoglobulins of sera derived from patient subjects in need of diagnosis of disease or monitoring of treatment. | 10-15-2009 |
20090258791 | Fluid Based Analysis of Multiple Analytes by a Sensor Array - A system for the rapid characterization of multi-analyte fluids, in one embodiment, includes a light source, a sensor array, and a detector. The sensor array is formed from a supporting member into which a plurality of cavities may be formed. A series of chemically sensitive particles are, in one embodiment positioned within the cavities. The particles may be configured to produce a signal when a receptor coupled to the particle interacts with the analyte. Using pattern recognition techniques, the analytes within a multi-analyte fluid may be characterized. | 10-15-2009 |
20090258792 | Prostate Cancer Glycan Markers and Autoantibody Signatures - Disclosed are methods for probing the immunogenic sugar moieties of prostate cancer cells. The methods detect a number of glyco-epitopes that are highly and differentially expressed among prostate cancers of various Gleason grades. The glyco-epitopes exist on the surfaces of prostate cells. The methods also comprise the detection of autoantibodies in prostate cancer subjects. The antibodies bound to a glyco-motif of N-glycans that is normally “cryptic.” This target is highly expressed in prostate cancers. Lectins and antibodies that detect these glyco-epitopes that expressed in prostate cancer tissues include | 10-15-2009 |
20090258793 | TARGET-SPECIFIC COMPOMERS AND METHODS OF USE - Provided herein are libraries of nucleic acid species each comprising a transcription unit having a promoter region operatively linked to a coding sequence. The coding sequence of each nucleic acid species encodes a RNA cleavage substrate comprising a unique compomer species and a cleavage site. Each compomer species has a molecular mass distinguishable from the molecular mass of other compomer species in the library, and cleavage at a cleavage site releases a polynucleotide comprising the compomer species from the RNA cleavage substrate. | 10-15-2009 |
20090264303 | Polypeptides having a functional domain of interest and methods of identifying and using same - Novel polypeptides having functional domains of interest are described, along with DNA sequences that encode the same. A method of identifying these polypeptides by means of a sequence-independent (that is, independent of the primary sequence of the polypeptide sought), recognition unit-based functional screen is also disclosed. Various applications of the method and of the polypeptides identified are described, including their use in assay kits for drug discovery, modification, and refinement. | 10-22-2009 |
20090264304 | NORMALIZED NUCLEIC ACID LIBRARIES AND METHODS OF PRODUCTION THEREOF - The present invention relates generally to methods for producing normalized nucleic acid libraries in which each member of the library can be isolated with approximately equivalent probability. In particular, the present methods comprise subtractive hybridization of a nucleic acid library with haptenylated (e.g., biotinylated, avidinated or streptavidinated) nucleic acid molecules that are complementary to one or more of the nucleic acid molecules of the library, such that the variation in the abundances of the individual nucleic acid molecules in the library is reduced. The invention also relates to production of normalized nucleic acid libraries (particularly cDNA libraries) in which contaminating nucleic acid molecules have been reduced or eliminated, and to normalized nucleic acid libraries produced by such methods. | 10-22-2009 |
20090264305 | Polynucleotide Marker Genes and their Expression, for Diagnosis of Endotoxemia - The present invention discloses disease-associated molecules and assays, which are useful for diagnosing and assessing those animals with endotoxemia, and determining those animals at risk of developing endotoxemia or its sequelae. The invention has practical use in the early diagnosis of disease, in monitoring an animal's immune response to the disease, and in enabling better treatment and management decisions to be made in clinically and sub-clinically affected animals. | 10-22-2009 |
20090264306 | DNA METHYLATION BIOMARKERS IN LYMPHOID AND HEMATOPOIETIC MALIGNANCIES - Differential Methylation Hybridization (DMH) was used to identify novel methylation markers and methylation profiles for hematopoieetic malignancies, leukemia, lymphomas, etc. (e.g., non-Hodgkin's lymphomas (NHL), small B-cell lymphomas (SBCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), etc.). Particular aspects provide novel biomarkers for NHL and subtypes thereof (e.g., MCL, B-CLL/SLL, FL, DLBCL, etc.), AML, ALL and MM, and further provide non-invasive tests (e.g. blood tests) for lymphomas and leukemias. Additional aspects provide markers for diagnosis, prognosis, monitoring responses to therapies, relapse, etc., and further provide targets and methods for therapeutic demethylating treatments. Further aspects provide cancer staging markers, and expression assays and approaches comprising idealized methylation and/or patterns” (IMP and/or IEP) and fusion of gene rankings. | 10-22-2009 |
20090264307 | ARRAY-BASED POLYMORPHISM MAPPING AT SINGLE NUCLEOTIDE RESOLUTION - Disclosed herein is a system useful for detecting sequence differences (e.g., single-nucleotide polymorphisms) between genomes using data from a single hybridization with a genomic DNA microarray, such as a whole-genome array. The methods described herein can be used to detect, simply and inexpensively, differences in sequence among the genomes of individual members of a species, for example. In examples described herein, the system and methods were used to detect a variety of spontaneous single base-pair substitutions, insertions and deletions, and most (>90%) of the approximately 30,000 known single-nucleotide polymorphisms between two | 10-22-2009 |
20090264308 | BIOSENSOR SOLID SUBSTRATE WITH INTEGRATED TEMPERATURE CONTROL AND A METHOD TO MAKE THE SAME - This invention provides a biosensor solid or hydrogel substrate comprising one or more temperature indicating agents, each of said one or more temperature indicating agents operating by changing its optical properties and being deposited in and/or at the surface of the biosensor solid or hydrogel substrate as one or more layers and/or spots | 10-22-2009 |
20090270265 | Molecular Characteristics of Non-Small Cell Lung Cancer - We used hierarchical clustering to examine gene expression profiles generated by serial analysis of gene expression (SAGE) in a total of nine normal lung epithelial cells and non-small cell lung cancers (NSCLC). Separation of normal and tumor samples, as well as histopathological subtypes, was evident using the 3,921 most abundant transcript tags. This distinction remained when just 115 highly differentially expressed transcript tags were used. Furthermore, these 115 transcript tags clustered into groups that were suggestive of the unique biological and pathological features of the different tissues examined. Adenocarcinomas were characterized by high-level expression of small airway-associated or immunologically related proteins, while squamous cell carcinomas overexpressed genes involved in cellular detoxification or antioxidation. The messages of two p53-regulated genes, p21 | 10-29-2009 |
20090270266 | Method for Electrocatalytic Protein Detection - The present invention provides a method of detecting an analyte in a sample with probe-modified electrodes and measuring an electrocatalytic signal generated by a binding of an analyte in the sample to a probe. | 10-29-2009 |
20090270267 | Composition and method for diagnosing esophageal cancer and metastasis of esophageal cancer - This invention relates to a composition, kit, or DNA chip comprising polynucleotides and antibodies as probes for detecting, determining, or predicting the presence or metastasis of esophageal cancer, and to a method for detecting, determining, or predicting the presence or metastasis of esophageal cancer using the same. | 10-29-2009 |
20090270268 | Methods for Obtaining Immortalized Antibody Secreting Cells - The present Invention provides novel methods for immortalizing cells that secrete antibodies of one or more specific isotypes. Polyclonal, oligoclonal, and monoclonal populations of cells obtained using the methods of the Invention can be screened on the basis of the functional and/or binding activities of the antibodies they secrete, for example directed to antigens of human or viral origin having medical interest, in cell culture conditions. Using these methods, human B cells that secrete antibodies binding human Cytomegalovirus, Herpes Simplex Virus, or HSP60 protein have been efficiently immortalized with Epstein-Barr virus. | 10-29-2009 |
20090270269 | NANO-SCALE FLUORO-BIOSENSORS EXHIBITING A LOW FALSE ALARM RATE FOR RAPID DETECTION OF BIOLOGICAL CONTAMINANTS - A sensing system incorporating a nano-scale fluoro-biosensor for detection of specifically targeted bio-contaminants (targets). Select embodiments use fluorescent nanoparticles such as quantum dots (QD) conjugated to antibody fragments to form a sensor for a specific bio-contaminant based on fluorescent resonance energy transfer (FRET). A quenching dye may be used to label an analog, while a specific antibody is covalently bonded to a hydrophilic QD. Coupling of QD labeled antibodies and quencher labeled analogs provides enough proximity to produce appreciable FRET-based quenching. Any addition of the target displaces the dye-labeled bacteria, eliminating FRET-based quenching and results in a concentration-dependent increase in QD photoluminescence. Applications include rapid detection and identification, with a high degree of specificity and sensitivity, of a broad range of targets, including viral contaminants, e.g., in less than about three minutes. By using QDs of varying wavelengths the system may be adapted into a multiplexing immuno-assay. | 10-29-2009 |
20090270270 | METHOD FOR DETECTING INTRAGENIC LARGE REARRANGEMENTS - The invention relates to methods for detecting at least one intragenic large rearrangement in a gene of interest, mapping the rearrangement breakpoint and diagnosing a genetic disease in a subject. | 10-29-2009 |
20090270271 | 3' Biased Detection of Nucleic Acids - The invention provides materials and methods for the detection of nucleic acid expression via the 3′ portion of expressed sequences. Embodiments of the invention include the use of microarrays comprising nucleic acid probes that are complementary to the 3′ end of expressed sequences and by the use of quantitative PCR (Q-PCR) based amplification of sequences found at or near the 3′ end of expressed sequences. The invention may be used to detect the presence of expressed nucleic acids encoding particular gene products (sequences present in a “transcriptome”). | 10-29-2009 |
20090270272 | ASSESSING RISK OF DISEASE PROGRESSION IN RHEUMATOID ARTHRITIS PATIENTS - Disclosed is an in vitro method aiding in the further assessment of patients suffering from rheumatoid arthritis. The method especially is used in assessing whether an RA patient is at risk of disease progression. The method is for example practiced by analyzing biochemical markers, comprising measuring in a sample the concentration of at least C-reactive protein (CRP) and interleukin-6 and correlating the concentrations determined to the likelihood of an underlying rapidly progressing form of RA. A patient at high risk of a rapidly progressing disease might be a patient in need for treatment or if already treated in need for a different and more effective treatment. The invention also relates to the use of a marker panel comprising C-reactive protein and interleukin-6 in the assessment of a patient with rheumatoid arthritis and it teaches a protein array device and kit, respectively, for performing the method of the invention. | 10-29-2009 |
20090270273 | ARRAY STRUCTURES FOR NUCLEIC ACID DETECTION - Devices formed as optically readable substrates are provided having a high feature density (e.g., attachment or deposition sites) in arrays comprising macromolecules, specifically amplicons, and devices and methods are provided for analysis of target nucleic acids having an undetermined sequence. High density arrayed nucleic acids are provided which are amenable to individual or multiple nucleotide interrogation, and which are particularly useful to determine the nucleotide sequence of a complex target nucleic acid sequence | 10-29-2009 |
20090270274 | BIOCHIPS AND RELATED AUTOMATED ANALYZERS AND METHODS - The present invention provides biochips that include: (a) a plurality of cards, each card having a plurality of card apertures extending therethrough, each respective card aperture having one or more cross sectional areas; and (b) a plurality of gaskets, at least one gasket residing intermediate two neighboring cards, each gasket having a plurality of gasket apertures extending therethrough. At least some of the gasket apertures have an area that is greater than that of at least one adjacent card aperture. Different sets of the gasket apertures and card apertures define a plurality of fluidic flow channels. Also provided herein are methods of making and using biochips. | 10-29-2009 |
20090275481 | Anchored Transferrin Fusion Protein Libraries - Fusion proteins comprising a transferrin moiety, a stalk moiety, and cell wall linking member and peptide libraries thereof are disclosed. The present invention includes a method of screening peptide libraries displayed in fusion proteins expressed by host cells. The fusion proteins of the present invention include transferrin fusion proteins capable of expression in yeast. | 11-05-2009 |
20090275482 | Normalization Probes for Comparative Genome Hybridization Arrays - A method of selecting a set of normalization probes for use on a comparative genome hybridization array is provided. In certain embodiments, the method includes: a) selecting a first region of a genome to be evaluated by comparative genome hybridization to produce data; b) selecting a second region of the genome for normalization of the data, and c) selecting from a set of candidate probes a sub-set of normalization probes that detect the second region. | 11-05-2009 |
20090275483 | QUANTITATIVE MICROARRAY OF INTACT GLYCOLIPID CD1D INTERACTION AND CORRELATION WITH CELL-BASED CYTOKINE PRODUCTION - The protein CD1d binds self and foreign glycolipids for presentation to CD1-restricted T cells by means of TCR recognition, and activates T | 11-05-2009 |
20090275484 | QUANTITATIVE ANALYSIS OF CARBOHYDRATE-PROTEIN INTERACTIONS USING GLYCAN MICROARRAYS: DETERMINATION OF SURFACE AND SOLUTION DISSOCIATION CONSTANTS - A method, system and device to identify, study and/or mimic carbohydrate-protein interactions on cell surfaces and in solution measured by a glycan microarray. In some instances the method, system and device uses very small quantities of carbohydrate as low as attomol. In some instances the system, method and device is high-throughput. The small quantity sensitivity may allow for close placement of carbohydrate array members wherein due to close proximity multivalent interactions with proteins may be identified. | 11-05-2009 |
20090280994 | NUCLEIC ACID LIBRARY OR PROTEIN OR PEPTIDE LIBRARY - The invention relates to a nucleic acid library or protein or peptide library in the form of a two-dimensionally resolved grid-type arrangement with a plurality of grid elements. Every grid element contains, on the statistical average, a defined number of nucleic acid types or protein or peptide types having a respective specific sequence structure. The inventive library is further characterized in that the grid elements are configured as capillary hollow spaces. The capillary axes of said capillary hollow spaces are in parallel to one another and the openings of different capillary hollow spaces are arranged in a grid area. The invention further relates to various uses of such a library. | 11-12-2009 |
20090280995 | METHOD OF DIAGNOSIS - Provided are methods, kits and arrays for use in determining whether a scar of interest is keloid or non-keloid in nature. These determine keloid or non-keloid nature based on comparison of gene expression in the scar of interest with expression in a control sample. If expression of at least one gene, selected from the group of genes set out in Table 1, is increased in a sample representative of gene expression in the scar of interest compared to expression of the same gene (or genes) in the control sample this indicates that the scar of interest comprises a keloid. | 11-12-2009 |
20090280996 | DELTA 17 DESATURASE AND ITS USE IN MAKING POLYUNSATURATED FATTY ACIDS - The present invention relates to Δ17 desaturases, which have the ability to convert ω-6 fatty acids into their ω-3 counterparts (i.e., conversion of arachidonic acid [20:4, ARA] to eicosapentaenoic acid [20:5, EPA]). Isolated nucleic acid fragments and recombinant constructs comprising such fragments encoding Δ17 desaturases along with a method of making long-chain polyunsaturated fatty acids (PUFAs) using these Δ17 desaturases in oleaginous yeast are disclosed. | 11-12-2009 |
20090286690 | Modified Nucleic Acid Probes - Oligonucleotide analogue arrays attached to solid substrates and methods related to the use thereof are provided. The oligonucleotide analogues hybridize to nucleic acids with either higher or lower specificity than corresponding unmodified oligonucleotides. Target nucleic acids which comprise nucleotide analogues are bound to oligonucleotide and oligonucleotide analogue arrays. | 11-19-2009 |
20090286691 | Oligonucleotide for Detection of Bacteria Associated with Sepsis and Microarrays and Method for Detection of the Bacteria Using the Oligonucleotide - The present invention relates to oligonucleotides for detection of sepsis-causing bacteria and a detection method using the oligonucleotides, more particularly to a microarry comprising at least one of gram positive bacteria-specific and gram negative bacteria-specific oligonucleotides, sepsis-causing bacteria's genus-specific and species-specific oligonucleotides designed from the ITS target region which is hypervariable base sequence of sepsis-causing bacteria as probes, and a detection method and a diagnosis kit by using the same. | 11-19-2009 |
20090286692 | Cartridge and Method for Sample Analysis - The invention provides a cartridge containing an addressable array for detecting the presence of one or more target analytes in a fluid sample. The cartridge comprises (i) a housing defining a sample inlet, an optical cell, an outlet, a first conduit in fluidic communication with the sample inlet and the optical cell, and a second conduit in fluidic communication with the outlet and the optical cell, (ii) an addressable array disposed within the optical cell; and (iii) a reagent dried upon a fluid contacting surface of at least one of the sample inlet and the first conduit, such that, when a fluid sample is applied to the fluid inlet, the fluid sample mobilizes and transports the reagent to the optical cell. The invention also provides a method of detecting one or more analytes in a fluid sample of interest. | 11-19-2009 |
20090286693 | MICROARRAYS OF TAGGED COMBINATORIAL TRIAZINE LIBRARIES - Triazine linkers can be used to prepare universal small molecule chips for functional proteomics and sensors. These triazine linker compounds are prepared by making a first building block by adding a first amine by reductive amination of triazine, making a second building block by adding a second amine to cyanuric chloride, and combining the first and second building blocks by aminating the first building block onto one of the chloride positions of the second building block. These triazine linkers are then linked to a substrate for determining binding affinity of proteins. | 11-19-2009 |
20090286694 | NUCLEIC ACID ARRAY WITH RELEASEABLE NUCLEIC ACID PROBES - A process is provided for identifying a complementary target nucleic acid. The process includes the hybridization of a nucleic acid probe to a carrier to form a nucleic acid probe-carrier complex. The complex is placed in a compartment bounded by a media permeable to the nucleic acid probe and exclusive of both the carrier and the complex. The complex is then denatured, with the nucleic acid probe transported through the media and into contact with the target nucleic acid. The nucleic acid probe hybridizes to the complementary target nucleic acid to yield a probe-target double stranded complex. A non-complementary nucleic acid probe, independent probe-target complex is returned to the compartment and given an opportunity to rehybridize to the carrier. A determination as to whether at least one of the complementary target nucleic acid or the carrier is present as a complex provides information as to probe sequences complementary to the target nucleic acid. | 11-19-2009 |
20090291855 | METHOD FOR CONFIRMING THE EXPOSURE ON CHRYSENE - The present invention relates to a method for confirming the exposure on chrysene using a DNA fragment whose expression is increased or decreased specifically when it is exposed to chrysene. The method of the present invention is effective in determination of risk by chrysene and monitoring the chrysene exposure, so that it can be effectively used as a tool for examining the mechanism of chrysene induced toxicity. | 11-26-2009 |
20090291856 | DIAGNOSTIC TEST FOR CARDIOMYOPATHY - Methods and compositions relating to diagnosing and treating cardiomyopathy and particularly relating to methods and compositions for diagnosing and treating arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) are described. Provided are methods for screening for, diagnosing or detecting a risk of developing arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) comprising detecting the presence of a transmembrane protein 43 (TMEM43) disease associated variant in a sample of a subject, wherein the presence of a TMEM43 disease variant is indicative that the subject has ARVD/C or an increased risk of developing ARVD/C compared to an individual having wild type TMEM43. | 11-26-2009 |
20090298704 | Wireless CMOS Biosensor - System and methods for detection and measurement of interactions in microarrays or within a human body are described. The system includes a CMOS sensor which can be placed in a fluidic environment, and is capable of measuring DNA interactions and protein binding kinetics, as well as cellular interactions and signals within the body. The sensor can be placed in close proximity with the sample and eliminates the need for optics, and in some embodiments is a wireless device. | 12-03-2009 |
20090298705 | METHODS AND ASSAYS FOR OVERSULFATED GLYCOSAMINOGLYCANS - Methods and assays for oversulfated glycosaminoglycans are provided. In an embodiment, the present disclosure provides a method for detecting oversulfated glycosaminoglycan (OS-GAG) in a heparin sample. The method comprises placing the heparin sample onto a support comprising immobilized heparin and contacting the heparin sample on the support with a binding compound that attaches to the heparin and forms a heparin-binding compound complex. The binding compound also has a greater affinity for attaching to the OS-GAG than to the heparin in the heparin sample and forms an OS-GAG-binding compound complex. The method can further comprise detecting an amount of the heparin-binding compound complex on the support, and determining an amount of OS-GAG in the heparin sample based on the amount of the heparin-binding compound complex on the support. | 12-03-2009 |
20090298706 | METHOD FOR CELL SURFACE DISPLAYING OF TARGET PROTEINS USING BACILLUS ANTHRACIS EXOSPORIUM - The present invention relates to a method for expressing a target protein on the surface of a microorganism using | 12-03-2009 |
20090298707 | SPARSE MATRIX SYSTEM AND METHOD FOR IDENTIFICATION OF SPECIFIC LIGANDS OR TARGETS - In certain embodiments, this invention pertains to the creation of “Sparse Matrix” libraries of compounds. The sparse matrix libraries of this invention typically span an n-dimensional parameter (property) space at extremely sparse intervals and thereby provide a relatively small library of compounds (e.g., a library of about 200 or fewer compounds) that can be used to quickly and efficiently screen the compound parameter space for one or more desired physical, chemical, or biological properties (e.g., binding specificity, binding avidity, γtoxicity, solubility, mobility, cell permeability, serum half-life, biocompatibility, etc.). | 12-03-2009 |
20090298708 | 2'-DEOXY-2'-FLUORO-BETA-D-ARABINONUCLEOSIDE 5'-TRIPHOSPHATES AND THEIR USE IN ENZYMATIC NUCLEIC ACID SYNTHESIS - The invention relates to arabinose modified nucleoside 5′ triphosphates and to the biosynthesis and amplification of oligonucleotides containing and/or from templates containing arabinose modified nucleosides. The invention further relates to methods of generating modified oligonucleotide libraries for use in selection strategies, such as SELEX. The arabinose modified oligonucleotides of the invention are useful for modulating target nucleic acid expression, such as RNA. | 12-03-2009 |
20090298709 | Assays for determining telomere length and repeated sequence copy number - Methods of detecting copy number of a repeated sequence element, including methods of determining telomere length, are provided. The methods can be multiplexed for detection of repeated sequence element copy number on two or more nucleic acid targets simultaneously. Compositions, kits, and systems related to the methods are also described. | 12-03-2009 |
20090305902 | Double-Tiled and Multi-Tiled Arrays and Methods Thereof - Described herein are multi-tiling methods that increases the number of features present on an array and methods of making and using the multi-tiled arrays. The arrays are useful, for example, for transcriptional profiling and genomic studies. | 12-10-2009 |
20090305903 | METHODS AND COMPOSITIONS FOR DIAGNOSIS, MONITORING AND DEVELOPMENT OF THERAPEUTICS FOR TREATMENT OF ATHEROSCLEROTIC DISEASE - Polynucleotide sequences are provided that correspond to genes that are differentially expressed in atherosclerotic disease conditions. Methods for using these sequences to detect gene expression and/or for transcriptional profiling in mammals are also provided. The polynucleotide sequences of the invention may be used, for example, to diagnose atherosclerotic disease, to monitor extent of progression or efficacy of treatment or to assess prognosis of atherosclerotic disease, and/or to identify compounds effective to treat an atherosclerotic disease condition. | 12-10-2009 |
20090305904 | APOPTOSIS MODULATOR BCL-B AND METHODS FOR MAKING AND USING SAME - A novel human member of the Bcl-2 family Bcl-B has been identified, which is closest in amino-acid sequence homology to the Boo (Diva) protein. The Bcl-B protein is widely expressed in adult human tissues. The Bcl-B protein modulates apoptosis. Bcl-B also binds Bcl-2. BCl-XL, and Bax but not Bak. Bcl-B displays a unique pattern of selectivity for binding and regulating the function of other members of the Bcl-2 family. | 12-10-2009 |
20090312192 | METHOD FOR FUNCTIONALISING A HYDROPHOBIC SUBSTRATE - The current invention relates to a method of functionalising a substrate comprising immobilising at least one multimeric peptide on the substrate, wherein, the at least one multimeric peptide comprises at least first and second peptide chains, the first peptide chain comprising at least one hydrophobic amino acid residue and at least one functionalising moiety, wherein the at least one hydrophobic amino acid residue and at least one functionalising moiety are positioned in the peptide primary structure so as to result in a hydrophobic face, and a substantially non hydrophobic face comprising the functionalising moiety, and wherein, contacting the peptide with the substrate causes the peptide to be immobilised thereon. | 12-17-2009 |
20090312193 | MICROARRAY HYBRIDIZATION ASSAY METHODS - An assay method suitable for use in microarray hybridization of a target sample can include providing a microarray having probes, hybridizing the probes to a target sample and random primers each having an arbitrary sequence, ligating a free terminal of each of the probes to one end of each of the random primers in the probe side, removing the target sample hybridized to each of the probes, and measuring the intensity of the remaining random primers. | 12-17-2009 |
20090318302 | MICROFLUIDIC SELECTION OF LIBRARY ELEMENTS - Disclosed herein is a microfluidic device comprising a chip; a flow channel being disposed in the chip; the flow channel being in communication with an entry port and an exit port; the flow channel being operative to permit the flow of a library from the entry port to the exit port; a substrate; the substrate being disposed upon the chip; the substrate being operative to act as an upper wall for the flow channels; and a plurality of receptors; the plurality of receptors being disposed on the substrate; the plurality of receptors being operative to interact with an element from the library. | 12-24-2009 |
20090318303 | MICROFLUIDIC SELECTION OF LIBRARY ELEMENTS - Disclosed herein is a system comprising a chip; a flow channel disposed in the chip; the flow channel being in communication with an entry port and an exit port; the flow channel being operative to permit the flow of a library from the entry port to the exit port; a substrate; the substrate being disposed upon the chip; the substrate being operative to act as an upper wall for the flow channel; and a receptor; the receptor being disposed on the substrate; the receptor being operative to interact with a component from the library. | 12-24-2009 |
20090318304 | Efficient Shotgun Sequencing Methods - Methods are provided for efficient shotgun sequencing to allow efficient selection and sequencing of nucleic acids of interest contained in a library. The nucleic acids of interest can be defined any time before or after preparation of the library. One example of nucleic acids of interest is missing or low confidence genome sequences resulting from an initial sequencing procedure. Other nucleic acids of interest include subsets of genomic DNA, RNA or cDNAs (exons, genes, gene sets, transciptomes). By designing an efficient (simple to implement, speedy, high specificity, low cost) selection procedure, a more complete sequence is achieved with less effort than by using highly redundant shotgun sequencing in an initial sequencing procedure | 12-24-2009 |
20090318305 | METHODS FOR SELECTIVELY CAPTURING AND AMPLIFYING EXONS OR TARGETED GENOMIC REGIONS FROM BIOLOGICAL SAMPLES - In one aspect, the present invention relates to a method for selectively capturing and/or amplifying exons or targeted genomic regions from biological samples. In one embodiment, the method includes the steps of obtaining DNA templates for the targeted genomic region, cloning the DNA templates into cloning vectors to form template DNA clones, constructing libraries of the template DNA clones that cover at least the targeted genomic regions, generating hybridization probes from the DNA template clones in the libraries, capturing the targeted genomic DNA regions by hybridizing the targeted genomic DNA samples (fragmented either mechanically or enzymatically) with the generated hybridization probes, and eluting the captured genomic fragments by using conditions for releasing and separating the bound DNA from the hybridization probes. | 12-24-2009 |
20090325813 | Methods and kits for quantitative oligonucleotide analysis - Aspects of the disclosure are generally directed to methods, probes, probe compositions and kits for detecting or quantifying target oligonucleotides. In some embodiments, there are provided methods for determining the level of target oligonucleotides, such as a small RNA (e.g., miRNA), in a sample. In some embodiments, the methods comprise analyzing hybridization of target oligonucleotides to a test microarray; analyzing hybridization of a known amount of reference oligonucleotides (having the same sequences as the target oligonucleotides) to a calibration microarray; and determining the level of the target oligonucleotides in the sample by comparing the hybridization of the target oligonucleotides with the hybridization of the reference oligonucleotides. | 12-31-2009 |
20090325814 | BIOMOLECULE DETECTION REAGENT AND METHOD FOR DETECTING BIOMOLECULE USING THE SAME - A biomolecule detection reagent comprising a semiconductor nanoparticle aggregate, wherein each semiconductor nanoparticle, constituting the semiconductor nanoparticle aggregate, has detection molecules binding specifically with biomolecules on its surface, and a standard deviation of numbers of the detection molecules existing on each semiconductor nanoparticle, is 5% or less. | 12-31-2009 |
20090325815 | PRODUCTION OF ANTI-SELF ANTIBODIES FROM ANTIBODY SEGMENT REPERTOIRES AND DISPLAYED ON PHAGE - Methods are disclosed for the production of anti-self antibodies and antibody fragments, being antibodies or fragments of a particular species of mammal which bind self antigens of that species. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Anti-self antibody fragments are selected by binding with a self antigen from said species of mammal. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding antigen. Nucleic acid libraries used may be derived from rearranged V-gene sequences of unimmunised mammal. Synthetic or artificial libraries are described and shown to be useful. | 12-31-2009 |
20100009860 | Device and method for analysis of interactions between biomolecules - The present invention relates to a device for the analysis of interactions between biomolecules comprising a support, on which a plurality of biomolecules are immobilized on the surface of a support material in a regular or irregular manner by a linker, whereby two biomolecules are bound to each linker. Further, the present invention relates to a method for the detection of interactions between biopolymers immobilized on a surface comprising the steps of providing a device of one of the preceding claims, adjusting a defined distance between two biopolymers immobilized on the surface and detection of a signal generated by the interaction between the two biopolymers. | 01-14-2010 |
20100009861 | BREAST CANCER PROGNOSTICS - A method of providing a prognosis of breast cancer is conducted by analyzing the expression of a group of genes. Gene expression profiles in a variety of medium such as microarrays are included as are kits that contain them. | 01-14-2010 |
20100009862 | BIOMOLECULE SENSOR, METHOD FOR MANUFACTURING THE SAME, BIOMOLECULE DETECTION METHOD, AND BIOMOLECULE DETECTION SYSTEM - The present invention aims to improve detecting accuracy and reproducibility of a biomolecule sensor. The biomolecule sensor of the present invention includes single probe molecules orderly aligned and fixed on grid points on the surface of a substrate. Accordingly, in the biomolecule sensor of the present invention: probe molecules for detecting a biomolecule are orderly aligned and separately fixed; blocking for preventing non-specific adsorption is applied to a region other than the region of the probe molecules for detecting a biomolecule; and fluorescence enhancement is achieved by metal microparticles. | 01-14-2010 |
20100009863 | METHOD FOR ENGINEERING T-CELL RECEPTORS - The present invention provides a method for engineering a T-cell receptor domain polypeptide comprising at least one modification in a structural loop region of said T-cell receptor domain polypeptide and determining the binding of said T-cell receptor domain polypeptide to an epitope of an antigen, wherein the unmodified T-cell receptor domain polypeptide does not significantly bind to said epitope, comprising the steps of providing a nucleic acid encoding a T-cell receptor domain polypeptide comprising at least one structural loop region, modifying at least one nucleotide residue of at least one of said structural loop regions, transferring said modified nucleic acid in an expression system, expressing said modified T-cell receptor domain polypeptide, contacting the expressed modified T-cell receptor domain polypeptide with said epitope and determining whether said modified T-cell receptor domain polypeptide binds to said epitope. The present invention also covers modified T cell receptor domain polypeptides obtained by said method and their use and libraries containing said modified T cell receptor domain polypeptides. | 01-14-2010 |
20100009864 | Method for analysing amplified nucleic acids - An example embodiment of the present invention discloses a method for analyzing nucleic acids in a microfluidic device. The method includes the following steps: a) nucleic acids are amplified in a first chamber in the microfluidic device; b) the amplified nucleic acids are brought into contact with an additive including: i) monovalent cations and ii) an Mg2+ ion-binding agent, the additive being provided in a second chamber in the microfluidic device; and c) the amplified nucleic acids are hybridized on at least one probe oligonucleotide. | 01-14-2010 |
20100009865 | OLIGONUCLEOTIDE ARRAYS - The present invention provides for oligonucleotide arrays wherein the oligonucleotides comprise six-membered sugar-ring nucleosides, especially tetrahydropyran nucleosides, more specifically altritol nucleosides. The present invention also provides for the use of said oligonucleotide arrays for detecting target molecules in samples (diagnostic or experimental use). The present invention also provides for a method of detecting target molecules in samples by using said oligonucleotide arrays comprising six-membered sugar-ring nucleosides. | 01-14-2010 |
20100009866 | Surface Display of Whole Antibodies in Eukaryotes - Methods for display of recombinant whole immunoglobulins or immunoglobulin libraries on the surface of eukaryote host cells, including yeast and filamentous fungi, are described. The methods are useful for screening libraries of recombinant immunoglobulins in eukaryote host cells to identify immunoglobulins that are specific for an antigen of interest. | 01-14-2010 |
20100009867 | MULTI-MODAL ION EXCHANGE CHROMATOGRAPHY RESINS - The present invention relates to a method of preparing a library of resins which are useful in chromatography, which method comprises creating a diversity of multi-modal ion exchange resins; and providing the diversity in a parallel system in which each resin is presented separated from the other resin(s). | 01-14-2010 |
20100016172 | Nucleic acid binding assay materials and methods - The invention provides reliable, reusable materials, system and methods for use in nucleic acid binding assays between a nucleic-acid binding assay molecule and a robust unimolecular target. In a preferred embodiment, the target is a nucleic acid-containing molecule, L | 01-21-2010 |
20100016173 | MATERNAL SERUM BIOMARKERS FOR DETECTION OF PRE-ECLAMPSIA - The present invention concerns the identification and detection of maternal serum biomarkers of pre-eclampsia and associated complications, gestational hypertension and placental insufficiency using global proteomic approaches. The invention further concerns the identification of maternal serum biomarkers for detection of pre-eclampsia and associated complications, gestational hypertension and placental insufficiency during early gestation. | 01-21-2010 |
20100016174 | METHOD AND APPARATUS FOR DETECTING BIO-CHIP BY USING PHASE-CHANGE - A biochip and a biochip scanning method and apparatus using phase changes are provided, wherein a laser beam is radiated to a biochip having immobilized probes placed thereon to cause a phase change in a phase change layer located under the biochip and the reflectance on the phase change layer according to the phase change is detected to allow reproduction or recording of bio information on the biochip. A phase change biochip and a phase change detection method using phase changes based on resistance detection are also provided, wherein the resistance between two electrodes connected respectively to both ends of a phase change layer including a bio spot where a phase change occurs is measured so that it is possible to easily detect phase changes in the biochip based on changes in the resistance. | 01-21-2010 |
20100016175 | QUANTUM DOT-ENCODED BEAD SET FOR CALIBRATION AND QUANTIFICATION OF MULTIPLEXED ASSAYS, AND METHODS FOR THEIR USE - Control beads are disclosed that allow for improved quantitation of analytes in multiplexed bead assays. The control beads have a range of concentrations of calibration moieties that provide for the preparation of a titration curve. The titration curve can be used to quantify the concentration of the analytes. The titration curve can be used to correlate the signal obtained from a bead with the concentration (or absolute number of molecules) of the analyte bound to the bead. | 01-21-2010 |
20100022402 | Methods and Compositions for the In Vitro High-Throughput Detection of Protein/Protein Interactions - The present invention relates to methods and compositions for the identification and/or assessment of protein/protein interactions, and in particular to methods and compositions for accomplishing the high-throughput detection of interactions of proteins displayed on the surfaces of lambdoid bacteriophage particles. | 01-28-2010 |
20100022403 | METHODS FOR FRAGMENTATION AND LABELING OF NUCLEIC ACIDS - The invention provides methods, compositions, and kits for fragmentation and labeling of nucleic acids. More particularly, the invention relates to methods for fragmentation of nucleic acids to produce fragments with 3′ end hydroxyl groups within a desired size range. In methods of the invention, nucleic acids are fragmented at abasic sites to produce fragments with blocked 3′ ends. The 3′ ends are unblocked to produce polynucleotide fragments with hydroxyl groups at their 3′ ends. Methods, kits, and compositions for carrying out fragmentation of a polynucleotide template in a single reaction mixture to yield fragments with 3′-hydroxyl ends within the desired size range are disclosed. | 01-28-2010 |
20100022404 | Gene/protein marker for prediction or diagnosis of pharmacological efficacy of aurora a inhibitor - [PROBLEMS] To provide: a gene marker or a protein marker for detecting whether or not an Aurora A inhibitor acts in a living body in an Aurora A-specific manner when the Aurora A inhibitor is administered to the living body; and a method for predicting or diagnosing the pharmacological efficacy of an Aurora A inhibitor by using the gene marker or the protein marker [MEANS FOR SOLVING PROBLEMS] A gene/protein marker for use in the prediction or diagnosis of the pharmacological efficacy of an Aurora A inhibitor, wherein the gene is a gene selected from the group consisting of Aurora B, Histone H3, BIRC5, PRC1, DLG7, TACC3 and KNTC2 or a gene having substantially the same function as that of the gene; and a method for predicting or diagnosing the pharmacological efficacy of an Aurora A inhibitor by using the gene/protein marker. | 01-28-2010 |
20100022405 | Methods and Kits for Sense RNA Synthesis - Methods and kits are provided for performing multiple rounds of sense RNA synthesis. The sense RNA molecules can be used in various research and diagnostic applications, such as gene expression studies involving nucleic acid microarrays. | 01-28-2010 |
20100022406 | Methods and Systems for Universal Carrier Screening - Provided herein are methods, systems, and devices for genetic screening. The genetic screening of two or more individuals can be utilized to predict the phenotype of a child from the group of individuals. Also disclosed is prediction of a phenotype of a child from a subset of biological relatives, such as a potential mother and father, before conception. In many instances, the methods, systems and devices herein are utilized to predict the probability of a child developing a rare genetic disease. | 01-28-2010 |
20100022407 | MICROARRAYS AND USES THEREFOR - Methods of using microarrays to simplify analysis and characterization of genes and their function are provided. Such methods can be used to identify and characterize antibodies having binding affinity for a specific target antigen. A method of determining gene expression at the protein level by contacting an array of characterized or uncharacterized antibodies on a solid surface with one or more proteins and identifying the antibodies to which said protein(s) binds also is provided. This method can be used to compare the protein expression in two different populations of cells, such as normal cells and cancer cells or resting cells and stimulated cells. In addition, a method of determining gene expression at the protein level by contacting a microarray of nucleic acid samples derived from a variety of different sources with one or more nucleic acid probes then identifying the sample or samples to which the probe binds is provided. | 01-28-2010 |
20100022408 | ADDRESSABLE ANTIBODY ARRAYS AND METHODS OF USE - Systems and assay methods are disclosed for detecting an autoantibody in a sample. In certain instances, the systems and methods employ a mass tag releasably connected to an antigen. The tag is thereafter released for detection. A tag can be detected by mass spectrometry or in certain instances the tag is fluorescent. Methods for diagnosing a disease or disorder in a subject are also disclosed. | 01-28-2010 |
20100022409 | METHOD OF NUCLEIC ACID ANALYSIS TO ANALYZE THE METHYLATION PATTERN - Methods and kits are disclosed for determining the methylation of nucleic acids. The methods and kits can be used for the diagnosis and prognosis of diseases. The method and kits can be used to identify biomarkers. The method and kits relate to fragmenting a nucleic acid sample, ligating adaptors to the ends of the nucleic fragments obtained, amplifying the fragments that include both adaptors using specific primers based on the adaptors, labeling of the amplified fragments by in vitro transcription and determining the methylation state of the sample. | 01-28-2010 |
20100029494 | Macromolecular Nucleotide Compounds And Methods For Using The Same - The invention relates to novel classes of nucleotides that can be used as substrates for enzymes, e.g. for labeling nucleic acids. | 02-04-2010 |
20100029495 | Mass labels - Provided is a set of mass labels, each mass label in the set comprising a mass marker moiety attached via a cleavable linker to a mass normalisation moiety, each mass label in the set having a common mass; wherein the set comprises a plurality of groups of mass labels, the mass of the mass marker moiety being the same for mass labels within a group, the mass of the mass marker moiety being different between groups; the mass marker moiety is capable of fragmentation into two or three fragments; and the mass of at least one fragment of the mass marker moiety differs between mass labels within a group. | 02-04-2010 |
20100029496 | Multiplexed lateral flow microarray assay for detection of citrus pathogens Xylella fastidiosa and Xanthomonas axonopodis PV citri - The invention provides highly sensitive and specific assays for the major citrus pathogens | 02-04-2010 |
20100029497 | METHOD FOR ENGINEERING IMMUNOGLOBULINS - The present invention relates to a method for engineering an immunoglobulin comprising a variable domain and at least one modification in at least two structural loops of said immunoglobulin and determining the binding of said immunoglobulin to an epitope of an antigen, wherein the unmodified immunoglobulin does not significantly bind to said epitope, comprising the steps of: providing a nucleic acid encoding an immunoglobulin comprising at least two structural loops, modifying at least one nucleotide residue of each of said structural loops, transferring said modified nucleic acid in an expression System, expressing said modified immunoglobulin, contacting the expressed modified immunoglobulin with an epitope, and determining whether said modified immunoglobulin binds to said epitope, immunoglobulins produced by such a method and libraries of immunoglobulins. | 02-04-2010 |
20100029498 | SELECTION OF NUCLEIC ACIDS BY SOLUTION HYBRIDIZATION TO OLIGONUCLEOTIDE BAITS - Methods of selection of nucleic acids using solution hybridization, methods of sequencing nucleic acids including such selection methods, and products for use in the methods are disclosed. | 02-04-2010 |
20100029499 | Artificial Protein Scaffolds - The present invention provides proteins having one or more similarities to the artificial protein Top7 or to a Top7 derivative. Proteins of the invention have one or more loops that are longer than the corresponding loops of Top7, and/or that bind to a preselected target molecule. The invention also provides nucleic acids and cells useful in producing the proteins and methods for their use. | 02-04-2010 |
20100029500 | OLIGONUCLEOTIDE ARRAYS TO MONITOR GENE EXPRESSION AND METHODS FOR MAKING AND USING SAME - The present invention provides an oligonucleotide array capable of identifying genes and related pathways involved with the induction of a particular phenotype by a cell line, e.g., the genes and related pathways involved with the induction of transgene expression by the cell line. The invention is particularly useful when there is little or no information about the genome of the cell line being studied, because it provides methods for identifying consensus sequences for known and previously undiscovered genes, and for designing oligonucleotide probes to the identified consensus sequences. Additionally, when the array is to be used to determine optimal conditions for expression of a transgene by the cell line, the invention teaches methods of including oligonucleotide probes to transgene sequences in the array. The invention also provides methods of using the array to identify genes and related pathways involved with the induction of a particular cell line phenotype. The invention also provides novel polynucleotides of undiscovered genes (i.e., a gene that had not been sequenced and/or shown to be expressed by CHO cells) and novel polynucleotides involved with the induction of a particular cell phenotype, e.g., increased survival when grown under stressful culture conditions, increased transgene expression, decreased production of an antigen, etc. These novel polynucleotides are termed novel CHO sequences and differential CHO sequences, respectively. The invention also provides genetically engineered expression vectors, host cells, and transgenic animals comprising the novel nucleic acid molecules of the invention. The invention additionally provides antisense and RNAi molecules to the nucleic acid molecules of the invention. The invention further provides methods of using the polynucleotides of the invention. | 02-04-2010 |
20100029501 | METHOD OF IDENTIFYING MICRO-RNA TARGETS - The present invention provides methods of identifying an mRNA target of a microRNA. The present invention further provides kits and systems for carrying out a subject method. | 02-04-2010 |
20100029502 | Self-Assembly of Molecules Using Combinatorial Hybridization - Simple and convenient methods for arranging molecules of interest in a pre-determined pattern are described. The methods use combinatorial hybridization based on interactions between complementary nucleic acid sequences to arrange the molecules of interest. The resulting arrangements, kits containing the components used in the methods, and methods of using the resulting arrangements are also disclosed. | 02-04-2010 |
20100029503 | ANALYSIS CHIP AND ANALYSIS METHOD - This invention is directed to an analysis chip comprising a substrate having a surface on which a selective binding substance is immobilized; a cover member adhered to the substrate; and particles movably contained or injected in a void between the substrate and the cover member; wherein the surfaces of the particles are coated with a surfactant. By this invention, generation of bubbles which inhibit the selective reaction between the test substance and the immobilized selective binding substance is suppressed, thereby reducing the deviation of data, suppressing the lowering of sensitivity, and promoting the reproducibility of the measurement. | 02-04-2010 |
20100029504 | DETECTING PAX2 FOR THE DIAGNOSIS OF BREAST CANCER - A method for monitoring breast conditions in a subject is disclosed. The method comprises determining a Paired Box 2 gene-to-beta defensin- | 02-04-2010 |
20100035760 | Nucleic Acid molecules and Collections Thereof, Their Application and Modification - The invention provides a method for characterising a sample comprising nucleic acid derived from a cell. The method comprises determining whether a sample comprises at least a minimal sequence of at least one new microRNA (miRNA) according to the invention or a mammalian ortholog thereof and characterizing the sample on the basis of the presence or absence of the miRNA. The invention further provides nucleic acid molecules and collections thereof and their use in therapeutic and diagnostic applications. The invention furthermore provides a method for identifying a miRNA molecule or a precursor molecule thereof. | 02-11-2010 |
20100035761 | High-throughput rna structure analysis - The presently disclosed subject matter relates to technology and methods for analyzing the structure of RNA molecules. More particularly, the presently disclosed subject matter is directed to methods of, compositions for, and computer program products for RNA structure analysis through alkoxide-selective 2′-hydroxyl acylation analyzed by primer extension. | 02-11-2010 |
20100035762 | Prognostic Methods in Colorectal Cancer - Prognostic method in colorectal cancer based on the determination of the expression levels of the EphB4 gene in tumours of patients afflicted by this disease. The levels can be used as a marker for the probability of the recurrence of the cancer in the patient and for the prognostics of the sensitivity that the tumours present to treatment with 5-fluorouracil, allowing to establish the more adequate therapeutic strategy for every patient. | 02-11-2010 |
20100035763 | METHOD OF SCREENING SINGLE CELLS FOR THE PRODUCTION OF BIOLOGICALLY ACTIVE AGENTS - This invention generally relates to a methods, devices and kits for screening single cells for the production of one or more biologically active agents of interest, such as a protein, nucleic acid, or a protein and the nucleic acid encoding same. | 02-11-2010 |
20100035764 | METHODS AND COMPOSITIONS FOR MONITORING T CELL RECEPTOR DIVERSITY - The present invention provides an array for use in a method of monitoring T cell diversity. The array comprises a substrate having a plurality of capture probes that can specifically bind to a nucleic acid molecule corresponding to a T cell receptor (TCR) gene family selected from the group consisting of the TCR gene families listed in Table 1. In one format, the system has one or more oligonucleotide capture probes wherein each probe is selected from the group consisting of SEQ ID NO: 1-41. Further provided are methods for monitoring T cell diversity in a subject following, for example, allogeneic hematopoietic stem cell transplantation, or other treatment or therapy that contributes to an alteration in T cell population and/or diversity. Compositions of the invention include arrays, computer readable media, and kits for use in the methods of the invention. | 02-11-2010 |
20100035765 | Protein and Antibody Profiling Using Small Molecule Microarrays - Aspects of the present invention describe methodology by which arrays of synthetic molecules can be created and employed for various types of proteomics profiling experiments. The most important of these from a clinical standpoint are the visualization of antibody and T cell binding patterns, which could be employed as a tool for monitoring the state of the immune system of a patient. This may be a generally useful tool for the diagnosis of many types of disease states. Similar techniques are employed to detect the post-translational modification of specific proteins, a tool for the visualization of induction of signal transduction pathways in cells and tissues treated with drugs. Finally, aspects of the invention teache a method for the creation of simpler arrays with less than 100 features that are, nonetheless, effective for protein profiling experiments. | 02-11-2010 |
20100041562 | MICROFLUIDIC MICROARRAY ASSEMBLIES AND METHODS OF MANUFACTURING AND USING - Microarray devices fabricated using microfluidic reagent distribution techniques are provided. As described herein, the invention encompasses microfluidic microarray assemblies (MMA) and subassemblies and methods for their manufacture and use. In one embodiment first and second channel plates are provided which may be sealed to a test chip in consecutive steps. Each channel plate includes microfluidic channels configured in a predetermined reagent distribution pattern. For example, the first channel plate may have a radial (linear) reagent distribution pattern and the second channel plate may have a spiral (curved) reagent distribution pattern, or vice versa. In one embodiment the first channel plate is connected to the test chip and at least one first reagent is distributed on the test chip in a first predetermined reagent pattern. The first reagent is then immobilized on the test chip. Next, the first channel plate is removed, the second channel plate is connected to the test chip and at least one second reagent is distributed on the test chip in a second predetermined reagent pattern. The first and second reagent patterns intersect to define a plurality of microarray test positions on the test chip. In one embodiment, the first reagent may comprise a plurality of separate probes each distributed to selected test position(s) of the microarray and the second reagent may comprise a plurality of test samples each distributed to selected test position(s) of the microarray. Positive or negative reactions between the probes (or other first reagent) and test samples (or other second reagent) may then be detected at the microarray test positions. For example, hybridization between selected nucleic acid probes and selected nucleic acid samples may be detected at particular test positions. The invention thus provides an efficient means to fabricate high density multi-probe, multi-sample microarrays. Preferably the test chips and channel plates are circular and centrifugal force is used to achieve fluid flow through the microfluidic channels, such as by rotating the MMA in a disc spinner. | 02-18-2010 |
20100041563 | METHODS FOR IDENTIFICATION OF ALLELES - The invention provides a method for identification of alleles. In this method, genomic DNA is used as target. Multiple allele-specific PCR amplification are carried out with a group of primers comprising one or more allele-specific primers for a target gene, a universal primer, and a common primer; and a DNA polymerase without 5′ to 3′ exonuclease activity. The PCR products are hybridized with tag probes immobilized on a DNA chip. Results are determined based on the signal intensity and the position of the probe immobilized on the array. Each allele-specific primer comprises a unique tag sequence at the 5′ end. Each tag probe immobilized on the DNA chip comprises a sequence identical to its corresponding tag sequence; and each tag probe hybridizes only with the complementary sequence in the PCR amplification product. | 02-18-2010 |
20100041564 | METHOD FOR ESTABLISHING THE SOURCE OF INFECTION IN A CASE OF FEVER OF UNCLEAR AETIOLOGY - Use of gene expression profiles obtained in vitro from a patient's sample for establishing the local infection of a “fever of unknown origin”, wherein the gene expression profiles are specific for local inflammations of a “fever of unknown origin”, such as peritonitis, pneumonia, endocarditis or infections of the urea tract. | 02-18-2010 |
20100041565 | BLOOD TYPING - A blood testing method for use in the detection of a disease, wherein at least one characteristic antibody or complement factor is bound to a subject's red blood cells, comprises providing a microarray wherein a plurality of binding agents therefor are immobilised on a substrate at discrete pre-defined positions; and contacting a blood sample therewith. The presence of bound red blood cells is then detected. | 02-18-2010 |
20100041566 | ARRAYS AND METHODS FOR GUIDED CELL PATTERNING - Guided cell patterning arrays for single cell patterning, methods for making the arrays, and methods for using the arrays. | 02-18-2010 |
20100041567 | Antibody-Based Protein Microarray to Detect Long-Term Stress In Animal Tissues - A method for determining ‘stress profiles’ of wildlife by measuring the expression of a plurality of stress-activated proteins is herein described. | 02-18-2010 |
20100041568 | TRIPODAL CYCLOHEXANE DERIVATIVES AND THEIR USE AS CARBOHYDRATE RECEPTORS - A tri-podal compound according to formula (I) wherein, each Z is the same and is a substituted or unsubstituted N-heteroaromatic single-, multiple-, or fused-ring; and each A is the same, and can represent a direct bond between the cyclohexane ring and Z, or a carboxamide group (—C(O)—N(H)—). Use of the compounds in combinatorial libraries, methods of making the tripodal compounds, sensor devices for detecting carbohydrate targets, and methods of using the tripodal compounds to detect carbohydrate targets in a sample are also disclosed. | 02-18-2010 |
20100048411 | SUBSTRATE FOR THE GROWTH OF CULTURED CELLS IN THREE DIMENSIONS - We describe a cell culture substrate comprising a polymerised high internal phase emulsion polymer adapted and modified for use in the routine culture of cells in three dimensions; typically mammalian cells and the use of the substrate in a cell culture system for investigation and analysis of proliferation, differentiation and function of cells. | 02-25-2010 |
20100048412 | DETECTION OF PROTEASE AND PROTEASE ACTIVITY USING A SINGLE NANOSCRESCENT SERS PROBE - This invention pertains to the in vitro detection of proteases using a single peptide-conjugate nanocrescent surface enhanced Raman scattering (SERS) probes with at least nanomolar sensitivity. The probe enables detection of proteolytic activity in extremely small volume and at low concentration. In certain embodiments the probes comprise an indicator for the detection of an active protease, where the indicator comprises a nanocrescent attached to a peptide, where said peptide comprises a recognition site for the protease and a Raman tag attached to the peptide. | 02-25-2010 |
20100048413 | OB FOLD DOMAINS - Provided herein are modified OB-fold domains having desired properties; methods of producing libraries of modified OB-fold domains; the libraries of modified OB-fold domains produced by such methods; methods for screening such libraries of modified OB-fold domains for desired biological activities; and the modified OB-fold domains identified from such libraries. Provided herein are modified OB-fold domains obtainable from | 02-25-2010 |
20100048414 | NOVEL METHODS FOR PREDICTING AND TREATING TUMORS RESISTANT TO DRUG, IMMUNOTHERAPY, AND RADIATION - The present invention relates to methods for prognosis, diagnosis, and treatment of malignant tumors that were treatment resistant. The present invention provides methods of prognosis and diagnosis of multidrug resistant tumors through detection of the expression levels of nuclear co-repressor 2 (“N-CoR2”), histone deacetylases 3 (“HDAC3”), and their associated gene expression biomarkers. The present invention also provides methods of sensitizing tumors to anti-tumor therapeutics by disrupting HDAC3 activation, abrogating the N-CoR2-HDAC3 interaction, inhibiting the activity of either protein, or by down-regulating the expression of either protein. | 02-25-2010 |
20100048415 | METHOD FOR THE DETECTION OF INTERFERON-ASSOCIATED ANGIOSTATIC TUMORSTAGES IN COLORECTAL CARCINOMA - The present invention is directed to a microarray for the detection of an angiostatic tumor stage/tumor area of colorectal carcinoma in a patient, wherein the microarray comprises gene probes capable of specifically hybridizing to predefined nucleic acids. The invention is further directed to an inhibitor or modulator of one or more of these nucleic acids, as well as to a pharmaceutical composition, comprising those inhibitors or modulators. In a further aspect, the present invention is directed to an ex vivo method for the diagnosis of an angiostatic tumor stage/tumor area in a patient suffering from a colorectal carcinoma. In a further aspect the invention is directed to predict the response of patients with colorectal carcinoma but also other diseases to therapy. | 02-25-2010 |
20100048416 | ENCODED MICROSPHERE - There is disclosed a method for encoding a microsphere comprising the steps of i) providing a layer of a polyionic polymer to the microsphere, ii) coating the layer with quantum dots, iii) providing a layer of a transparent polyionic polymer to the coated polymer layer and iv) coating the transparent layer with the same and/or different quantum dots and, optionally, repeating steps iii) and iv) whereby to characterise the microsphere by the wavelength and/or intensity of its photoemission spectrum on excitation at a predetermined wavelength of incident light. | 02-25-2010 |
20100048417 | NOVEL BACILLUS 029cel CELLULASE - The present invention provides a novel cellulase nucleic acid sequence, designated 029cel, and the corresponding 029cel amino acid sequence. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding 029cel, recombinant 029cel proteins and methods for producing the same. | 02-25-2010 |
20100056386 | Rationally Designed, Synthetic Antibody Libraries and Uses Therefor - The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system, with or without DH segments derived from other species, and are based on rational design informed by examination of publicly available databases of antibody sequences. | 03-04-2010 |
20100056387 | ASSAYS - A method for assaying a sample for each of multiple analytes is described. The method includes contacting an array of spaced-apart test zones with a liquid sample (e.g., whole blood). The test zones are disposed within a channel of a microfluidic device. The channel is defined by at least one flexible wall and a second wall which may or may not be flexible. Each test zone comprising a probe compound specific for a respective target analyte. The microfluidic device is compressed to reduce the thickness of the channel, which is the distance between the inner surfaces of the walls within the channel. The presence of each analyte is determined by optically detecting an interaction at each of multiple test zones for which the distance between the inner surfaces at the corresponding location is reduced. The interaction at each test zone is indicative of the presence in the sample of a target analyte. | 03-04-2010 |
20100056388 | NUCLEIC ACID ARRAY HAVING FIXED NUCLEIC ACID ANTI-PROBES AND COMPLEMENTARY FREE NUCLEIC ACID PROBES - A process for identifying a complementary nucleic acid probe to a target nucleic acid involves forming an array of spots where each spot of the array has an immobilized nucleic acid anti-probe to which is hybridized a nucleic acid probe. The array of the anti-probe-probe complex is denatured. The nucleic acid probes are then moved into a target chamber that includes a target nucleic acid. Hybridization conditions are established to form double-stranded complexation between the target nucleic acid and nucleic acid probes in instances where the target nucleic acid has a sequence complementary. The nucleic acid probes noncomplementary to the target nucleic acid are allowed to rehybridize with anti-probes. Determining whether the anti-probe spots exposed to nucleic acid probes noncomplementary to the target nucleic acid are single stranded after exposure to noncomplementary nucleic acid probes provides information as to target nucleic acid sequence. | 03-04-2010 |
20100056389 | Molecularly Imprinted Microspheres Prepared Using precipitation Polymerisation - Molecularly imprinted microspheres comprising specific binding site are described. These microspheres can be obtained by a method comprising polymerising functional monomers and crosslinkers in a reaction solvent in the presence of print molecules as templates in a surfactant-free precipitation polymerisation process. The print molecules used are capable of forming non-covalent, reversible covalent or semi-covalent interactions with said functional monomers. There is also disclosed the use of said microspheres in different applications. | 03-04-2010 |
20100062948 | USE OF PROBES FOR UNBOUND METABOLITES - Methods of determining levels of unbound metabolites are disclosed. Probes derived from fatty acid binding protein muteins are described that bind preferentially to a number of unbound metabolites including oleate, stearate, linoleate, palmitate, arachidonate and unconjugated bilirubin. A profile for a patient is determined using one or more of the described probes. The profile is useful in diagnosis of disease, particularly myocardial infarction, non-alcoholic fatty liver disease (NAFLD), diabetes, stroke, sepsis and neonatal jaundice. The responses of multiple probes to a test sample are used to classify the degree of acute coronary syndrome by comparison to multi-probe profiles generated from unstable angina, non ST elevation myocardial infarction, and ST elevation myocardial infarction. | 03-11-2010 |
20100069253 | Impedance Spectroscopy Measurement of DNA - An impedance spectroscopy system and method are provided for quantitatively measuring DNA. The method provides a transducer having electrode surfaces exposed to a shared local environment. The electrode surfaces are functionalized with an oligonucleotide to interact with a predetermined DNA target. A DNA sample solution is introduced into the local environment. The solution includes nucleotides, polymerase enzyme, and primers. The DNA sample is thermocycled to promote a first DNA target polymerase chain reaction (PCR). Then, capacitance is measured between a pair of transducer electrodes, and in response to measuring the capacitance, a determination is made of the presence of first DNA amplicons in the DNA sample. Typically, a number of thermocycles are performed and capacitance measurements are made after each cycle, so that an amplicon growth rate can be determined. | 03-18-2010 |
20100069254 | Cell Culture Model for Demyelination/Remyelination - A research model for monitoring demyelination or remyelination in a sample of cells that comprises providing cells, typically CNS cells, and contacting cells with a demyelination solution such as one that includes one of hexachlorophene and/or lysophosphatidylcholine. | 03-18-2010 |
20100069255 | METHOD FOR IDENTIFYING THERAPEUTICAL TARGETS IN SECONDARY TUMORS, THE USE OF THEREOF AND MEANS FOR IDENTIFYING, LABELLING AND TARGETING SECONDARY TUMORS - In comparison with primary tumors, where the organ by itself is the starting point of the malignant degeneration, metastases inherit a different emergence. The molecular causes leading to secondary liver malignancies are unknown so far. The aim of the present invention is therefore to make available an easy and efficient method for identifying therapeutical targets in secondary tumors, the use of novel therapeutical targets identified by the method for screening and determining beneficial means and/or drugs, and means and drugs for identifying, labeling and treating secondary metastases in the liver made up of or derived from tumor cells of the colon. In principle, expression of transcription factors is studied in the primary tumor, the secondary tumor and in the healthy organ, wherein the secondary tumor is formed, according to the invention, in particular of transcription factors being enriched in the healthy tissue of the organ, wherein the secondary tumor is formed, e.g. expression of liver enriched transcription factors HNF6 and/or Foxa2 or of NGN3, HSP105B, HSP10, HNF1β, C/EBP is studied, such as by reverse transcription polymerase chain reaction, by gene chip analysis, by Western blotting technique, by studying the DNA binding of liver enriched transcription factors by electromobility shift assay (EMSA) or by genomic sequencing of therapeutical targets, such as of HNF6. | 03-18-2010 |
20100069256 | Markers and Methods for Assessing and Treating Ulcerative Colitis and Related Disorders Using a 20 Gene Panel - A method for assessment of the suitability of a target therapy for a gastrointestinal-related disorder, such as ulcerative colitis, in a subject evaluates the presence, absence, and/or magnitude of expression of one or more genes in a 20- or 5-member gene panel in a sample. The method enables identification of the effectiveness of target therapies prior to starting a patient on such therapies. | 03-18-2010 |
20100069257 | POROUS SAMPLE TESTING DEVICE AND METHODS - Described are devices and methods for parallel testing of formulations on various substrates. | 03-18-2010 |
20100069258 | Hydrophilic Labels for Biomolecules - Compounds, compositions, and methods for optical, including fluorescence optical, determinations useful in labeling biomolecules such as protein and deoxyribonucleic acid for their detection and quantitation. The compounds are diastereomeric cyanines with high hydrophilicity and other desirable properties. | 03-18-2010 |
20100075862 | HIGH SENSITIVITY DETERMINATION OF THE CONCENTRATION OF ANALYTE MOLECULES OR PARTICLES IN A FLUID SAMPLE - The present invention relates to methods, systems, and kits for detecting, quantifying and/or analyzing a fluid sample comprising molecules or particles at low concentration. In certain embodiments, the methods for detection and/or quantifying analyte molecules in a sample comprise capturing a plurality of analyte molecules on a substrate (e.g., an array comprising a plurality of reaction vessels). The substrate may then be exposed to additional reaction components such as at least one binding ligand. The substrate may additionally be exposed to a precursor labeling agent molecule, wherein the precursor labeling agent molecule, in some cases, is converted to a labeling agent molecule, which may be detected, either directly or indirectly, which determination may be related to the presence of and/or may be employed to quantify the analyte molecules. Although the various aspects of the present invention may use a number of different assay formats, in one embodiment, the assays are conducted in a plurality of reaction vessels defined, at least in part, by the distal ends of fiber optic strands. | 03-25-2010 |
20100075863 | ROTARY ARRAY MODULE FOR MULTIPLEXING SPOT-BASED OPTICAL READOUTS - An apparatus for multiplexing detection of one or more of a plurality of target molecules in a liquid sample includes a sample chamber adapted to receive a liquid sample containing one or more target molecules and a rotary array disposed in the sample chamber. The rotary array includes a plurality of spots, with each spot including at least one probe molecule selected to bind to a particular region of a target molecule. The apparatus also includes an optical detector capable of determining if a target molecule has bound to one of the probe molecules as the array rotates within the sample chamber. | 03-25-2010 |
20100075864 | MEASUREMENT OF COMPLEMENT ACTIVATION PRODUCTS ON ANTIGEN ARRAYS - The basis of the present invention is that antigens on an antigen array can initiate complement activation both by antibody-dependent or -independent way. The systems and methods disclosed herein can be used in methods of diagnosing and monitoring particular autoimmune disorders and infections. The invention relates to a new diagnostic method, utilizing an antigen array for simultaneously identifying different antigens capable of activating the complement system, in a quantitative fashion; to multiplex immunoassays utilizing antigen arrays, and more particularly to systems, methods and kits for qualitative and quantitative detection of antigens activating complement in a biological sample, via the measurement of complement components deposited on antigen arrays. The invention employs the functional complement system in the biological sample tested, thereby the information gained relates to antigen recognition properties and functional consequences in the organism from which the sample was taken and relies on the ability of antigen recognition molecules, primarily antibodies to activate the complement system in the sample tested, upon binding to elements of an antigen array. | 03-25-2010 |
20100075865 | MICROARRAY SYSTEM AND A PROCESS FOR PRODUCING MICROARRAYS - A process for making a micro-array. The process comprises the step of depositing a population of microbeads on a substrate having at least one fiducial. The population being comprised of at least two sub-populations, preferably multiple sub-populations, each comprising a known active agent capable of specific binding with at least one target analyte. The said subpopulations are deposited sequentially and at discrete periods of each other. The process also comprises the step of making images of the substrate after deposition of each subpopulation. The images are then compared using the fiducial as a reference to thereby determine the location of each microbead and to identify the subpopulation, and its known active agent, based on differences between each image. Also disclosed in a system for using the microarray. | 03-25-2010 |
20100075866 | METHODS FOR IDENTIFYING AND MONITORING DRUG SIDE EFFECTS - The present invention relates generally to methods for identifying drug side effects by detecting perturbations in organ-specific molecular blood fingerprints. The invention further relates to methods for identifying drug-specific organ-specific molecular blood fingerprints. As such, the present invention provides compositions comprising organ-specific proteins, detection reagents for detecting such proteins, and panels and arrays for determining organ-specific molecular blood fingerprints. | 03-25-2010 |
20100081581 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 46 to 48 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium. | 04-01-2010 |
20100087327 | PARTICLES - A coated magnetic particle comprising an optionally porous magnetic polymer particle of a matrix polymer, said polymer particle having on a surface and/or in the pores thereof superparamagnetic crystals, said coated particle having a coat formed of a coating polymer, wherein said coated magnetic particle is essentially non-autofluorescent. | 04-08-2010 |
20100087328 | BRM EXPRESSION AND RELATED DIAGNOSTICS - The present invention relates to methods and compounds for causing BRM re-expression in cells, such as cancer cells, that have lost BRM expression. In particular, the present invention relates to screening methods for identifying BRM expression-promoting compounds. The present invention also relates to methods of accessing cancer risk through the identification of polymorphisms in the BRM promoter. | 04-08-2010 |
20100087329 | Enzymatic Labeling of RNA - Methods are described in which a sample containing RNA is contacted with an enzyme having an RNA ligation activity in the presence of a labeled substrate to provide labeled RNA. Methods of performing an array analysis of a labeled RNA sample are also described. | 04-08-2010 |
20100087330 | BREAST CANCER GENE ARRAY - The present invention relates to a method for prognosing or classifying cancer subtypes in a subject with breast cancer. Methods and biomarkers are disclosed that are useful for prognosing or classifying ESR1, PGR and ERBB2 breast cancer subtypes. | 04-08-2010 |
20100087331 | METHOD OF NUCLEIC ACID ANALYSIS - A method of nucleic acid analysis includes the stages of synthesizing a first complementary DNA strand from a messenger RNA using compound primers, synthesizing a second DNA strand, labeling by in vitro transcription of an RNA polymerase, and determining the presence of splicing events in the sample. The present invention has application, for example, in analyzing differential splicing events and in diagnosing diseases. | 04-08-2010 |
20100093553 | Solid Substrate Comprising Array of Dendrons and Methods for Using the Same - The present invention provides solid supports comprising a surface bound array of dendrons and methods for using the same. | 04-15-2010 |
20100093554 | Methods for identifying biomarkers, autoantibody signatures, and stratifying subject groups using peptide arrays - Peptide arrays and uses thereof for diagnostics, therapeutics and research. Ultra high density peptide arrays are generated using photolithography, such as using photoresist techniques. | 04-15-2010 |
20100093555 | Enzymes resistant to photodamage - Provided are compositions comprising modified DNA polymerases that exhibit improved photostability compared to the parental polymerases from which they were derived. Provided are methods for generating enzymes, such as DNA polymerases, with the aforementioned phenotype. Provided are methods of using polymerases with increased resistance to photodamage to make a DNA or to sequence a DNA template. | 04-15-2010 |
20100093556 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CANCER - The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides gene expression profiles and signatures associated with solid tumor stem cells, as well as novel stem cell cancer markers useful for the diagnosis, characterization, prognosis and treatment of solid tumor stem cells. More particularly, the present invention identifies two profiles of cancer stem cells useful for the diagnosis, characterization, and treatment of cancer and cancer metastases. The invention also provides a variety of reagents such as stem cell gene signatures for use in the diagnosis and management of cancer. | 04-15-2010 |
20100093557 | Assay Membrane and Method of Use Thereof - The present invention provides a microporous membrane for detecting at least one target analyte in a sample. The membrane includes an array that comprises at least one capture element and the at least one control element printed on the membrane surface, the at least one capture element corresponding to and being able to bind a target analyte, the plurality of control elements, when present including: i) at least one fiduciary marker, ii) at least one negative control to monitor background signal, iii) at least one negative control to monitor assay specificity, iv) at least one positive colorimetric control, v) at least one positive control to monitor assay performance or any combination thereof. | 04-15-2010 |
20100093558 | CANCER BIOMARKERS - Provided is a biomarker for detecting cancer, in particular prostate cancer in a male subject, the biomarker comprising at least one homeodomain containing transcription factor, such as a HOX peptide or EN-2 peptide, or a fragment thereof. The use of said biomarker in detecting and/or treating prostate cancer is provided, together with methods and kits therefor. | 04-15-2010 |
20100093559 | Microfluidic Array Device and System for Simultaneous Detection of Multiple Analytes - (A1+A3, B1−B3, C1−C3) Disclosed herein are microfluidic devices having an array of microfluidic valves and other components to meet the requirement of an antibody array for analyte detection. The microfluidic valves disclosed herein enable simultaneous detection of multiple analytes in a sample. One embodiment exemplified herein pertains to a microarray that is in the format of a sandwich assay, each of which comprises a capture antibody, analyte, and secondary detection antibody conjugated with a fluorescent dye or an enzyme or another moiety to facilitate detection. Methods of using microfluidic valves in an array for simultaneously detecting multiple analytes is also disclosed. | 04-15-2010 |
20100093560 | COMBINED AUTOMATED PARALLEL SYNTHESIS OF POLYNUCLEOTIDE VARIANTS - The present disclosure relates to methods for efficient synthesis, cloning, transformation and screening of large diverse libraries of polynucleotide variants comprising well-defined nucleotide differences relative to a reference polynucleotide. | 04-15-2010 |
20100099575 | NOVEL POLYPEPTIDE SCAFFOLDS AND USE THEREOF - Novel peptide having a sequence according to SEQ. ID. No. 1, SEQ. ID. No. 2 and/or SEQ. ID. No. 3 are disclosed and also polypeptide scaffold consisting of a four helix bundle formed of two dimerized helix-loop-helix motifs, said helix-loop-helix motifs having sequences according to SEQ. ID. No. 1, SEQ. ID. No. 2 and/or SEQ. ID. No. 3 which may comprise a fluorescent probe at the side chain of Lys15 and a ligand with affinity for a target molecule at the side chain of Lys8 or Lys34. | 04-22-2010 |
20100105567 | NOVEL CAPTURE AGENTS FOR BINDING A LIGAND - The current invention relates to a multimeric capture agent for binding a ligand, the multimeric capture agent comprising at least first and second peptide chains, wherein said first and second peptide chains each comprise a chain of 2 to 50 amino acids, each of said amino acids being substantially enantiomerically pure, and wherein said at least first and second peptide chains are covalently linked. | 04-29-2010 |
20100105568 | METHOD FOR DETECTION OF COMPOUND INTERACTING WITH MOLECULE LOCATED ON CELL MEMBRANE - The present invention aims to provide a convenient and low-cost method for detection of a wide variety of compounds interacting with a target molecule located on a cell membrane, using a living cell without need of separating the cell membrane or the like from the cell. The present invention also aims to provide a kit for carrying out the method of the present invention. The method for detection of the compound interacting with the molecule located on the cell membrane in the present invention comprises steps of, allowing a compound having a moiety capable of binding selectively to the molecule located on the cell membrane and a radicalization-promoting moiety, to act on the cell; further allowing a compound having a group capable of being radicalized by the radicalization-promoting moiety and a labeling group, to act on the cell; and identifying the interacting compound bound by the compound radicalized by the radicalization-promoting moiety. | 04-29-2010 |
20100105569 | Methods of RNA Display - The present invention features improved methods of in vitro RNA display to allow reliable expression and selection of scFv antibody molecules from expression libraries. The improved methods, in part, involve the use of mildly reducing conditions, which favor of scFv intra-chain disulphide bond and thus correct folding of the scFv antibody molecules. Although particularly suited to expression and selection of scFv antibody molecules, the methods of the invention are also expedient for in vitro RNA display of all classes of protein. | 04-29-2010 |
20100105570 | Multi-Chamber Pretreatment Reactor for High Throughput Screening of Biomass - The disclosure provides reactors for rapid pretreatment of multiple biomass samples in a simple, process-driven, high throughput screening assay. This disclosure also provides methods and systems for rapid, high-throughput pretreatment and subsequent enzyme hydrolysis testing of multiple biomass samples. | 04-29-2010 |
20100105571 | Protein Signature/Markers for the Detection of Adenocarcinoma - The present invention provides a method for determining the presence of pancreatic adenocarcinoma in an individual and/or for determining the survival time of an individual afflicted with pancreatic adenocarcinoma comprising the steps of: (a) providing a serum or plasma sample to be tested; and (b) determining a protein signature of the test sample by measuring the presence and/or amount in the test sample of one or more selected proteins; wherein the presence and/or amount in the test sample of one or more proteins selected from the group defined in Table 1 is indicative of the presence of pancreatic adenocarcinoma. The invention also provides an array and a kit suitable for use in the methods of the invention. | 04-29-2010 |
20100113296 | Methods And Kits For Nucleic Acid Analysis - Methods for analyzing a mixture of polynucleotides are provided. In some embodiments, a plurality of detection primers comprising target-specific segments complementary to regions in said polynucleotides are employed to generate a library of 3′-end labeled detection primers after hybridization with said mixture of polynucleotides, the detection primers optionally including unique barcode sequences. The labeled detection primers can be enriched and subjected to microarray and/or sequencing analysis. The subject methods can be used, for example, in comparative genomic hybridization, gene expression analysis, methylation analysis, copy-number variation, genome partitioning and other applications. Also provided are kits for use in practicing the subject methods. | 05-06-2010 |
20100113297 | METHOD FOR PREDICTING THE OCCURRENCE OF METASTASIS IN BREAST CANCER PATIENTS - The present invention relates to the prognosis of the progression of breast cancer in a patient, and more particularly to the prediction of the occurrence of metastasis in one or more tissue or organ of patients affected with a breast cancer. | 05-06-2010 |
20100113298 | DETECTION OF RNA WITH MICRO-ARRAYS - A method for the detection and quantification of RNA via micro-arrays, wherein a first DNA molecule is added to a RNA-pool to be tested, which first DNA molecule is complementary to at least a first segment of a RNA of interest, as well as a second DNA molecule complementary to a second segment of the RNA of interest, which second segment is different from said first segment and further has at the 3′ and 5′ ends specific nucleotide sequences, which are not complementary to the RNA of interest. The DNA molecules are contacted with the RNA-pool under conditions allowing hybridization of complementary strands. Afterwards all RNA molecules are removed to which said first DNA molecule has not hybridized. After releasing of the second DNA molecules, they are contacted with an array having at specific locations thereof probes specific for particular nucleotide sequences. | 05-06-2010 |
20100113299 | GENE AND GENE EXPRESSED PROTEIN TARGETS DEPICTING BIOMARKER PATTERNS AND SIGNATURE SETS BY TUMOR TYPE - Provided herein are methods and systems for identifying a therapeutic for an individual, such as a therapeutic not previously identified for treating the individual. The therapeutic can be identified by molecular profiling, such as determining the biomarker patterns or signature sets of a biological sample of an individual. | 05-06-2010 |
20100113300 | T CELL RECEPTOR DISPLAY - A proteinaceous particle, for example a bacteriophage, ribosome or cell, displaying on its surface a T-cell receptor (TCR). The displayed TCR is preferably a heterodimer having a non-native disulfide bond between constant domain residues. Such display particles may be used for the creation of diverse TCR libraries for the identification of high affinity TCRs. Several high affinities are disclosed. | 05-06-2010 |
20100113301 | METHOD FOR THE IDENTIFICATION AND/OR THE QUANTIFICATION OF A TARGET COMPOUND OBTAINED FROM A BIOLOGICAL SAMPLE UPON CHIPS - The present invention is related to a method for the identification and/or the quantification of a target compound obtained from a sample, preferably a biological sample, comprising the steps of putting into contact the target compound with a capture molecule in order in order to allow a specific binding between said target compound with a capture molecule, said capture molecule being fixed upon a surface of a solid support according to an array comprising a density of at least 20 discrete regions per cm | 05-06-2010 |
20100120627 | GENEMAP OF THE HUMAN GENES ASSOCIATED WITH PSORIASIS - The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to psoriasis disease and/or their response to a particular drug or drugs. | 05-13-2010 |
20100120628 | GENEMAP OF THE HUMAN GENES ASSOCIATED WITH ADHD - The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to ADHD disease and/or their response to a particular drug or drugs. | 05-13-2010 |
20100125043 | GLYCAN DATA MINING SYSTEM - The present invention provides a system for analyzing glycans and their interaction partners. The inventive system is particularly useful in the identification and analysis of glycoprotein binding interactions. | 05-20-2010 |
20100130373 | MAPPING OF GENOMIC INTERACTIONS - The present invention relates to genomic analysis. In particular, the present invention provides methods and compositions for mapping genomic interactions. | 05-27-2010 |
20100130374 | HIGH-THROUGHPUT DIAGNOSTIC TESTING USING ARRAYS - The present invention relates to arrays comprising between 2 and 12.000 nucleic acid molecules, comprising a first set of nucleic acid molecules that comprise a nucleotide sequence that is able to hybridize to a gene that is used for normalization. The array may further comprise a second set of nucleic acid molecules that comprise nucleic acid sequences capable of hybridizing to nucleic acid molecules that are expressed in clinical relevant samples such as, for example, breast tissue. The invention further relates to a method for normalizing data. Further provided are methods of using an array according to the invention for distinguishing clinical samples. | 05-27-2010 |
20100130375 | APOLIPOPROTEIN AII ASSAY METHOD FOR THE IN VITRO DIAGNOSIS OF COLORECTAL CANCER - The present invention relates to a method for the in vitro diagnosis of colorectal cancer by determining the presence of the Apolipoprotein AII tumor marker in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer. | 05-27-2010 |
20100130377 | PREDICTING CANCER OUTCOME - This document provides methods and materials related to assessing prostate cancer in mammals. For example, this document provides nucleic acids and polypeptides that can be analyzed to determine whether a male mammal having prostate cancer is susceptible to a good or poor outcome. | 05-27-2010 |
20100130378 | MICROARRAY-BASED LINEAGE ANALYSIS AS A DIAGNOSTIC FOR CURRENT AND EMERGING STRAINS OF INFLUENZA B - Embodiments herein provide for methods, compositions and apparatus for detection and/or diagnosis of pathogenic virus lineage and/or strains. In some embodiments, the virus is influenza Type B virus. In other embodiments, an apparatus may include a microarray with attached capture probes, designed to bind to nucleic acid sequences from a single gene in a broad array of influenza strains. In some embodiments, compositions may include isolated nucleic acid sequences of use as capture probes, target sequences and/or label probe sequences, for diagnosis of and/or detection of influenza virus. | 05-27-2010 |
20100130379 | Weighted Chemiluminescent Chip array Method for Multiple Marker Detection - A gene chip for chemiluminescent detection is obtained. The chip uses multiple markers. Weighted scores are given to genes separately according to their influences on forming a cancer. The present invention provides an objective and accurate disease assistant diagnosis with a low cost, a high sensitivity and a good performance. The present invention can be widely applied to personal medical behaviors, like clinical diagnosis, treatment filtration, prognosis review, preventive medicine, etc. | 05-27-2010 |
20100137152 | Absolute PCR Quantification - The present application provides methods and devices for absolute quantification of polymerase chain reaction target nucleic acids. In particular, the methods and devices of the present application provide for splitting a nucleic acid sample to be analyzed into small, isolated volumes, conducting the method of polymerase chain reaction (PCR) on said volumes, detecting PCR amplification products, analyzing said detected PCR amplification products, performing absolute quantification of the PCR target and presenting said quantification results. | 06-03-2010 |
20100137153 | Cisplatin-resistance marker for ovarian tumor - Disclosed is a cisplatin-resistance marker for determining whether ovarian tumor cells of interest are resistant to cisplatin. | 06-03-2010 |
20100137154 | GENOME ANALYSIS USING A METHYLTRANSFERASE - A method of genome analysis is provided. In certain embodiments, the method may comprise: labeling the test genome using a first site-specific methyltransferase to produce a labeled test genome comprising a label; and analyzing the labeled test genome to determine if the test genome comprises a sequence alteration relative to a reference sequence. In certain embodiments, the method may comprise: evaluating binding of the labeled test genome to an array of probes, or observing a pattern of labeling along the labeled test genome. | 06-03-2010 |
20100137155 | BIOSENSOR, METHOD FOR FABRICATING THE SAME, DETECTING METHOD UTILIZING THE SAME - A biosensor capable of highly sensitive detection of a recognition target substance while having structural stability is provided at low cost. The biosensor is for capturing and detecting a recognition target substance and includes a linker made of a hydrocarbon compound having two or more particular functional groups, a peptide serving as a molecular recognition substance directly bonded to one particular functional group of the linker, and a support directly bonded to the other particular functional group of the linker. Preferably, the particular functional groups each are a reaction product functional group of an epoxy group and an amino group. The peptide is an artificially synthesized peptide including three or more consecutive amino acid sequences, among amino acid sequences of a natural immunoglobulin, that exist in a part corresponding to a hypervariable area of the natural immunoglobulin. | 06-03-2010 |
20100137156 | CONSTRUCTION AND USE OF A FUNCTIONALLY HUMAN ANTIBODY LIBRARY WITH MAXIMIZED REPERTOIRE DIVERSITY - Immunoglobulin libraries are provided that contain randomly assembled FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4 sequences of heavy or light chain immunoglobulin variable regions. The libraries exhibit a degree of repertoire diversity not found in natural immune systems and can be used to express novel immunoglobulins. The libraries can be used for screening antibodies with the target specificity of interest. The resultant antibodies can be fully human and non-immunogenic. | 06-03-2010 |
20100137157 | METHOD OF FABRICATION OF PHOTONIC BIOSENSOR ARRAYS - This invention relates to a method for the fabrication of photonic biosensor arrays and applications of arrays produced by the method in the biomedical field. A method for the fabrication of a biosensor array for plasmon resonance-based sensing of a plurality of different biological targets simultaneously, the method comprising: (i) providing a transparent substrate; ii) providing seed metallic nanoparticles in the form of a colloid; (iii) depositing said colloid as discrete metallic islands on the transparent substrate, each of said metallic islands comprising a plurality of metallic nanoparticles; (iv) washing the substrate in order to remove unadhered material; (v) developing the substrate in a growth solution, which solution comprises a salt of the same metal which is present in the form of discrete metallic islands on the substrate, a reducing agent, a capping agent and optionally a surfactant; (vi) washing the developed substrate; and (vii) functionalising each of said metallic islands with a different functionalising molecule using a common chemical process to attach said different functionalising molecules to said metallic islands. | 06-03-2010 |
20100137158 | GFABS: GFP-based biosensors possessing the binding properties of antibodies - A family of GFP scaffolds capable of accommodating two proximal, randomized binding loops is disclosed. GFP-based binders binding with nanomolar affinity are developed from a library of these GFP scaffolds. | 06-03-2010 |
20100137159 | Simple Tests for Rapid Detection of Canine Parvovirus Antigen and Antibodies - Slide agglutination tests (SATs) and slide inhibition tests (SITs) provide rapid detection, quantitation and strain identification of red blood cell (RBC) agglutinating viruses such as canine parvovirus (CPV) in biological samples. The tests are rapid, low-cost, and easy to use. These tests do not require any expensive equipment and can thus be used to monitor infections and antibody titers under field conditions. The tests can be modified to detect results using fluorescence (FSAT). FSAT is useful for rapid high-throughput screening (HTS) of libraries of small molecules and/or chemical compounds to identify antiviral compounds useful for the treatment of diseases caused by emerging hemaglutinating viruses that infect animals and humans. | 06-03-2010 |
20100137160 | Method and Device for Analyzing Biomolecules With Track - Etched Polymeric Layers - The present disclosure provides methods, devices and kits that permit large numbers of target biomolecules to be detected simultaneously in samples originating from a multi-sample holder, such as a multi-well plate. One specific example method is a method of making multiple substantial replicas of a biomolecular content of a multi-well sample holder. Devices and kits for carrying out the described methods are also provided. | 06-03-2010 |
20100144543 | Epigenetic silencing of tumor suppressor genes - Provided are methods of identifying a compound that binds to or modulates an activity of a CTCF polypeptide or CTCF polypeptide complex. Also provided are methods of monitoring a cancer state of a cell by detecting a chromatin boundary proximal to a tumor suppressor gene of the cell and by monitoring the formation of a gene-specific CTCF polypeptide complex in the cell. In addition, methods of selecting a treatment or determining a prognosis for a cancer related disease are provided. Provided are recombinant cells comprising recombinant CTCF genes, recombinant cells comprising CTCF knock downs or knock outs, and recombinant laboratory animals comprising CTCF knock downs or knock outs. | 06-10-2010 |
20100144544 | FLUORESCENCE LABELLING - Fluorescence Labelling This invention generally relates to techniques for fluorescence labelling, and to methods, apparatus and computer program code for processing fluorescence signal data. A method of determining respective first and second degree-of-labelling signals for different respective first and second fluorophores associated with a common entity, the method comprising: determining a first fluorescence signal from said first and second fluorophores under first conditions; determining a second fluorescence signal from said first and second fluorophores under second conditions different to said first conditions; and determining said first and second degree-of-labelling signals for said first and second fluorophores from said first and second fluorescence signals; and wherein said determining of said first and second degree-of-labelling signals is responsive to at least one coupling value (c | 06-10-2010 |
20100144545 | Arrays, Systems, and Methods of Using Genetic Predictors of Polycystic Diseases - Embodiments of the present disclosure encompass resequencing and comparative genomic hybridization arrays for identifying inherited polycystic diseases. The arrays allow identification of one or more of the following features: SNPs, deletions, duplications, mutations, unstable repeats, and the like that can be used to determine if a host has a polycystic disease such as ADPKD. | 06-10-2010 |
20100152054 | SCREENING ASSAYS AND METHODS - Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody. | 06-17-2010 |
20100152055 | Composition and method for diagnosing kidney cancer and for predicting prognosis for kidney cancer patient - This invention relates to a composition, kit, DNA chip, and use thereof for detecting, diagnosing, and predicting metastasis of kidney cancer and/or for predicting the prognosis for kidney cancer, comprising one or a plurality of polynucleotides selected from the group consisting of polynucleotides, mutants thereof or fragments thereof, the expression levels of which vary in kidney cancer cells from a patient with a poor prognosis when compared with that in kidney cancer cells from a patient with a good prognosis; or antibodies or fragments thereof that bind specifically to polypeptides, mutants thereof or fragments thereof, the expression levels of which vary in the similar manner. | 06-17-2010 |
20100152056 | SYSTEMS AND METHODS FOR NUCLEASE-ASSISTED SELECTION AND ACQUISITION OF SINGLE STRANDED DNA OLIGOMER/POLYMER APTAMERS/LIGANDS - A method for identifying aptamers that bind to target molecules may include contacting an oligonucleotide library with target molecule and digesting unbound oligonucleotides with one or more endonucleases, one or more exonucleases, or one or more endonucleases in combination with one or more exonucleases. A method for identifying aptamers may further include optionally subjecting selected aptamers to one or more rounds of selection under conditions of increased stringency. A method for identifying aptamers may include yet further amplifying selected aptamers. The described methods may be performed in a screen for identifying aptamers either alone or in combination with other methods typically employed in the art for selecting aptamers (such as, e.g., SELEX). Also contemplated herein are systems and kits for accomplishing the above. | 06-17-2010 |
20100152057 | HIGH-SENSITIVITY NANOSCALE WIRE SENSORS - The present invention generally relates to nanoscale wire devices and methods for use in determining analytes suspected to be present in a sample. The invention provides a nanoscale wire that has improved sensitivity, as the carrier concentration in the wire is controlled by an external gate voltage, such that the nanoscale wire has a Debye screening length that is greater than the average cross-sectional dimension of the nanoscale wire when the nanoscale wire is exposed to a solution suspected of containing an analyte. This Debye screening length (lambda) associated with the carrier concentration (p) inside nanoscale wire is adjusted by adjusting the gate voltage applied to an FET structure, such that the carriers in the nanoscale wire are depleted. | 06-17-2010 |
20100152058 | CANCER MARKERS - The invention relates to methods of diagnosis and prognosis of cancer, and in particular NSCLC, the methods comprising determining the expression level of one or more genes. In some embodiments the invention relates to prognosis of early stage NSCLC. | 06-17-2010 |
20100152059 | Method for screening biomolecules - A method for screening biomolecues molecules is disclosed. One embodiment of the method includes inoculating an expression library or a portion of the expression library into an animal, monitoring the relative abundance of individual members of the expression library; and analyzing molecules expressed by members that show significantly reduced relative abundance after inoculation into the animal. Also disclosed is an expression vector and an expression library employing the vector. | 06-17-2010 |
20100152060 | ASSAY SOLUTION COMPOSITIONS AND METHODS FOR GPCR ARRAYS - Buffered assay solutions for performing 1) binding or 2) functional assays on GPCR arrays, along with methods for their use are described. The buffered assay solution has an underlying composition having: a buffer reagent with a pH in the range of about 6.5 to about 7.9; an inorganic salt of either a monovalent or divalent species, at a concentration from about 1 mM to about 500 mM; and optionally a combination of: c) a blocker reagent at a concentration of about 0.01 wt. % to about 2 wt. % of the composition, or d) protease-inhibitor at a concentration of about 0.001 mM to about 100 mM. In an embodiment for functional assay uses, the composition is modified to also include a GTP-analogue, a guanosine 5′-diphosphate (GDP) salt, and/or an anti-oxidant reagent. | 06-17-2010 |
20100152061 | Oligonucleotide Primer Set For Amplifying Target Sequence(S) Of Norovirus, Oligonucleotide Probe Or Probe Set Specifically Hybridizing With Target Sequence(S) Of Norovirus, Microarray Immobilized With The Probe Or Probe Set, And Method Of Detecting Norovirus Using The Probe Or Probe Set - Provided are an oligonucleotide primer set for amplifying at least one target sequence of the genomic RNA of norovirus, an oligonucleotide probe or probe set specifically hybridizing with at least one target sequence of the genomic RNA of norovirus, a microarray immobilized with the probe or probe set, and a method of detecting norovirus using the probe or probe set. | 06-17-2010 |
20100160173 | METHOD OF DETECTING INTERACTIONS ON A MICROARRAY USING NUCLEAR MAGNETIC RESONANCE - Methods of using nuclear magnetic resonance (NMR) to detect the interaction of target substances with probes present at locations of a microarray are disclosed, and in particular methods of detecting the interaction of target substances present in fluids with an array comprising one or more probes present or locatable, e.g. in the case of a bead array, on a substrate at one or more locations. The methods are based on detecting the changes in the NMR signal arising from spin-carrying molecules present in a fluid in the vicinity of the probes that occur when target substances interact with probes in the array. | 06-24-2010 |
20100160174 | PROTEIN TRANSDUCING DOMAIN/DEAMINASE CHIMERIC PROTEINS, RELATED COMPOUNDS, AND USES THEREOF - Disclosed are compositions for chimeric proteins comprising a protein transduction domain and a deaminase domain, mimetics or analog thereof, and uses of same. | 06-24-2010 |
20100160175 | Catalysis of the cis/trans-isomerisation of secondary amide peptide compounds - The present invention is based on the finding that the cis/trans isomerisation of secondary amide peptide bonds in oligo- and polypeptides can be catalytically promoted. This catalysis is effected by enzymes which are hereinafter called “secondary amide peptide bond cis/trans isomerases (APIases). It can be assumed that the APIase activity plays a central role in a number of pathophysiological processes. Thus, the invention relates to pharmaceutical compositions comprising substances which inhibit APIase activity. | 06-24-2010 |
20100160176 | RAT GENE EXPRESSION PROFILING OF DRUG TRANSPORTERS, CYTOCHROME P450s, TRANSFERASES AND NUCLEAR XENOBIOTIC RECEPTORS FOR PREDICTING DRUG EFFECTS - The disclosure describes materials and methods for detecting the expression of genes and generating a gene expression profile from drug-treated rat primary cells or established rat cell lines using a unique combination of rat cytochrome p450 enzyme, nuclear xenobiotic receptor, transferase and transporter gene sequences. The materials include sets of primers, PCR amplicons and arrays. The methods include hybridization assays. Assays for the detection of the expression of the genes are also provided. In addition, the disclosure provides the use of the materials and methods in drug screening assays and, specifically, the detection of potential drug-drug interaction(s). | 06-24-2010 |
20100160177 | DIAGNOSTIC METHOD BASED ON LARGE SCALE IDENTIFICATION OF POST-TRANSLATIONAL MODIFICATION OF PROTEINS - Methods for the large scale identification of post-translational modification states of proteins and enzyme activities for carrying out post-translational modification reactions involve the analysis of functional extracts from fresh and frozen samples using protein arrays. The methods and kits of the present invention can be used to analyze and characterize compounds for their effects on post-translational modifications and their pathways. The methods and kits can also be used to diagnose and characterize a wide variety of diseases and medical conditions, including cancer, neurodegenerative diseases, immune diseases, infectious diseases, genetic diseases, metabolic conditions, and drug effects using cells or body fluids of a patient. | 06-24-2010 |
20100160178 | SYSTEM AND METHOD FOR PRESENTING DNA BINDING SPECIFICITIES USING SPECIFICITY LANDSCAPES - A system and method for analyzing DNA binding specificities is provided. The potential binding motifs are compared to a plurality of DNA sequences. The DNA sequences are plotted within a specificity landscape, which provides details otherwise unavailable, relating to binding affinities and binding specificities of the motif-sequence combination. | 06-24-2010 |
20100160179 | Method of detecting target substance - Provided are a method of detecting a target substance whereby the detection sensitivity in the PALSAR method can be improved and multiple genes can be simultaneously detected, and a kit for detection. The method of detecting a target substance is a method of detecting a target substance by forming a signal probe polymer using one or more sets of paired dimer-forming probes for forming dimer probes or dimer probes, one or more kinds of crosslinking probes, and one or more kinds of assist probes, in which a dimer-forming probe includes a 5′-side region, a central region, and a 3′-side region, a crosslinking probe includes two regions, i.e., a 5′-side region and a 3′-side region, the 5′-side region of the dimer-forming probe is complementary to either 5′-side region of a crosslinking probe, the 3′-side region of the dimer-forming probe is complementary to either 3′-region of a crosslinking probe, and an assist probe includes a region complementary to the 5′-side region in one of paired dimer-forming probes, a region complementary to the 3′-side region in the other, and a target region capable of binding to the target substance. | 06-24-2010 |
20100167943 | System and Method for Hybridization Slide Processing - A system for the automated hybridization of a plurality of microarray slides. The system comprises an enclosure with a wash basin having an open top end, a lower carrier rotor disposed within the wash basin on a support axle for receiving a plurality of microarray slide substrates, and an upper clamp rotor disposed above the lower carrier rotor on the support axle for receiving a plurality of disposable mixers. The system is further configured so that lowering the upper clamp rotor to engage with the lower carrier rotor couples the plurality of mixers to the plurality of slide substrates to form a plurality of sealed reaction chambers, and raising the upper clamp rotor to disengage from the lower carrier rotor de-couples the plurality of mixers from the plurality of slide substrates to unseal the plurality of reaction chambers. | 07-01-2010 |
20100167944 | Compositions and Methods for the Detection of Topoisomerase II Complexes with DNA - Compositions, methods, and kits for detecting DNA topoisomerase II-DNA complexes are disclosed. | 07-01-2010 |
20100167945 | DRUG SELECTION FOR BREAST CANCER THERAPY USING ANTIBODY-BASED ARRAYS - The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments. | 07-01-2010 |
20100167946 | PHOTONIC BIOSNESOR ARRAYS - This invention relates to photonic biosensor arrays in particular employing plasmon resonance based sensing, and to methods and apparatus for reading such arrays. A biosensor array for plasmon resonance-based sensing of a plurality of different biological targets simultaneously, the array comprising a transparent substrate having a surface bearing a plurality of assay spots for plasmon resonance sensing, each of said assay spots comprising a discrete metallic island, a said metallic island comprising a plurality of metallic nanoparticles to which are attached functionalising molecules for binding to a said biological target, different said islands bearing different said functionalising molecules for binding to different ones of said biological targets, and wherein total internal reflection of light at said surface at a wavelength at or near a said plasmon resonance results in scattering of said light away from said surface, said scattering being modulated by said binding of said biological targets. | 07-01-2010 |
20100167947 | Polymorphisms in Genes Affecting Ace-Related Disorders and Uses Thereof - A method for predicting a subject's risk factors for ACE-related disorders includes detecting the allelic status of one or more polymorphisms in a nucleic acid sample of the subject. | 07-01-2010 |
20100167948 | MicroRNA Expression Profiling of Cerebrospinal Fluid - The present invention is directed to assay methods in which the levels of certain specific microRNAs are determined in the cerebrospinal fluid of a subject. These methods may be used in the diagnosis or monitoring of neurological diseases, especially brain tumors. | 07-01-2010 |
20100167949 | DNA-BASED ANALYSIS METHODS AND APPARATUS FOR HUMAN IDENTIFICATION - Methods and apparatus for determining a human identification by analyzing DNA in a biological sample. DNA in the biological sample selectively binds to one or more probes in an array of probes within a DNA authentication cell. The array of probes is genetically designed to match a pattern of single nucleotide polymorphisms (SNPs) in DNA of a particular individual or a group of individuals. A microcontroller receives the results of the DNA analysis from the DNA authentication cell and determines whether the biological sample matches or does not non-match the particular individual or group of individuals for which the array of probes was designed. An indication of the match or non-match is displayed to a user and optionally is transmitted to a remote computer using one or more wired or wireless communication networks. | 07-01-2010 |
20100167950 | MICROARRAY CHIP AND METHOD OF FABRICATING FOR THE SAME - The present invention provides a microarray chip for use in the analysis of various sample types. The microarray chips disclosed herein generally comprise a substrate covered with a coating material comprising a photoresist material, wherein the coating material is patterned to comprise a plurality of microstructures such as microwells and/or microcolumns. Methods for preparing and utilizing the microarray chips of the invention are further provided. The microarray chips of the instant invention find particular use in high-throughput assays. | 07-01-2010 |
20100173792 | Self-addressable self-assembling microelectronic systems and devices for molecular biological analysis and diagnostics - A method for analyzing nucleic acid obtained from a cell sample on a platform is described. A platform having a cell selector, a nucleic acid selector, and an array of microlocations, wherein at least one microlocation has an associated capture sequence, is provided. The cell selector is contacted with a cell sample, wherein a portion of the cells remain associated with the cell selector. At least a portion of cells associated with the cell selector are lysed to release a nucleic acid sample. The nucleic acid selector is then contacted with the nucleic acid sample, such that a portion of the nucleic acid sample remains associated with the nucleic acid selector. The associated nucleic acid sample is then released from the nucleic acid selector and then is contacted with the array of microlocations, such that at least a portion of the released nucleic acid sample hybridizes with the capture sequence. | 07-08-2010 |
20100173793 | PEPTIDE / PROTEIN IDENTIFICATION USING PHOTOREACTIVE CARRIERS FOR THE IMMOBILISATION OF THE LIGANDS - The invention provides a method of identifying a peptide or protein capable of binding a ligand which comprises: (i) providing a support, the support comprising a photoreactive group; (ii) reacting the photoreactive group with a ligand to attach the ligand to the support and produce a supported ligand; (iii) providing an expression library comprising a plurality of members, each member expressing a different peptide or protein; (iv) screening the expression library to identify one or more peptides or proteins which bind to the ligand; (v) isolating the member or each member of the library which expresses a peptide or protein which binds to the ligand; and (vi) identifying the peptide or protein which binds to the ligand. Supported photo-reactive compounds are disclosed comprising a photo-reactive group attached to a support via a spacer and a dendritic group, the dendritic group comprising attached thereto, optionally via a spacer, at least one further photo-reactive group and/or a second functional group. Compounds comprising photo-reactive groups attached to a support and a protein resistant group attached to the support are also provided, together with kits for carrying out the method of the invention. | 07-08-2010 |
20100173794 | DEVICE FOR AMPLIFICATION AND DETECTION OF NUCLEIC ACIDS - A device is provided which is suitable for use in the amplification and detection of nucleic acids. The device comprises a simple tube comprising a compartment ( | 07-08-2010 |
20100173795 | HIV and Hepatitis C Microarray to Detect Drug Resistance - The invention provides arrays and probes for resequencing gene sequences of HIV and HCV using an array of probes complementary to a set of reference sequences, and to each possible single nucleotide substitution of the reference sequences, and for identifying known mutations in HIV and HCV gene sequences associated with resistance to antiviral therapy. Methods of identifying mutations in HIV and HCV sequences, methods of characterizing HIV and HCV isolates, and methods of evaluating and optimizing a patient's antiviral therapy regimen are also provided. | 07-08-2010 |
20100173796 | PROCESS FOR SCREENING OF A BINDING AMPHIPHILIC PEPTIDES SPECIFIC FOR HAIRPIN RNA - The present invention relates to a screening method of an amphiphilic peptide specifically binding to hairpin RNA, more precisely a screening method of an amphiphilic peptide having specificity and strong binding strength to target hairpin RNA using peptide library comprising those peptides having modifications of both hydrophilic face and hydrophobic face. The method of the present invention provides a screening method of an amphiphilic peptide which is specific to hairpin RNA. So, the peptide selected by the method of the present invention can be effectively used for the study of hairpin RNA functions and for the production of a novel drug using an artificial peptide binding to a hairpin RNA target. | 07-08-2010 |
20100173797 | CLINICALLY INTELLIGENT DIAGNOSTIC DEVICES AND METHODS - The invention relates to the clinically intelligent design of diagnostic devices (such as microarrays) and methods of making and using such devices in differential diagnoses of specific clinical symptoms or sets of symptoms. In one aspect, the devices include various probes used to perform parallel screening of a number of analytes. The probes are clustered on the devices based on known clinical presentations of symptoms associated with specific diseases and disorders. | 07-08-2010 |
20100173798 | BIOCHIP IN WHICH HYBRIDIZATION CAN BE MONITORED, APPARATUS FOR MONITORING HYBRIDIZATION ON BIOCHIP AND METHOD OF MONITORING HYBRIDIZATION ON BIOCHIP - A biochip for monitoring hybridization is provided. The biochip includes a transparent substrate and a first probe region. The first probe region is disposed on the transparent substrate and has a plurality of analytical probes. The plurality of analytical probes are configured to bond to a sample having a fluorescence material. The plurality of analytical probes are used in analyzing the sample using fluorescence detection. The biochip further includes a second probe region disposed on the transparent substrate and having a plurality of monitoring probes used in monitoring hybridization according to a surface plasmon resonance in the second probe region. The biochip further includes a thin metal layer disposed between the second probe region and the transparent substrate. | 07-08-2010 |
20100173799 | METHOD FOR GENERATION OF IMMUNOGLOBULIN SEQUENCES - The present invention relates to a method for generating immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored. The invention also provides immunoglobulin sequences obtainable by the method of the invention. Specifically, the present invention relates to the generation of immunoglobulin sequences by use of DNA vaccination. More specifically, the present invention relates to generation of immunoglobulin sequences in camelids, preferably directed against cell-associated antigens, in particular antigens with multiple transmembrane spanning domains, including GPCRs and ion channels, by DNA vaccination. Furthermore, the present invention relates to said immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored, such as e.g. GPCRs and ion channels, more preferably ion channels. | 07-08-2010 |
20100179068 | Assays - A method for assaying a sample for each of multiple analytes is described. The method includes contacting an array of spaced-apart test zones with a liquid sample (e.g., whole blood). The test zones disposed within a channel of a microfluidic device. The channel is defined by at least one flexible wall and a second wall which may or may not be flexible. Each test zone comprising a probe compound specific for a respective target analyte. The microfluidic device is compressed to reduce the thickness of the channel, which is the distance between the inner surfaces of the walls within the channel. The presence of each analyte is determined by optically detecting an interaction at each of multiple test zones for which the distance between the inner surfaces at the corresponding location is reduced. The interaction at each test zone is indicative of the presence in the sample of a target analyte. | 07-15-2010 |
20100179069 | METHOD AND APPARATUS FOR CONDUCTING HIGH-THROUGHPUT MICRO-VOLUME EXPERIMENTS - An apparatus and a method for conducting high-throughput micro-volume dialysis-based experiments are disclosed. The apparatus includes a microfluidic base plate comprising one or more through-holes, each of the one or more through-holes being interconnected through a microfluidic channel. Each through-hole is covered by a dialysis membrane. Further, the two ends of the microfluidic channel are connected to a sample inlet port and a sample outlet port respectively. The apparatus further includes a microtiter plate comprising multiple wells. The microtiter plate is attached to the microfluidic base plate in such a way that at least one well overlies at least one through-hole, with the dialysis membrane in between. The method for conducting the high-throughput micro-volume dialysis-based experiments comprises adding reagents into the wells overlying the through-holes, and loading micro-volume samples into the through-holes. The reagents get diffused from the wells, through the dialysis membrane, and into the through-holes for reaction. | 07-15-2010 |
20100179070 | DNA Damage Testing - The invention relates to a method of for detecting DNA damage in a tissue sample. The method includes the steps of exposing sample DNA to a tagged DNA-damage binding factor and then shearing the DNA to produce fragments. After separating damaged from undamaged DNA, the two are amplified and differentially labeled. The labeled fragments can be immobilised on a microarray allowing the location and extent of any DNA damage to be determined. | 07-15-2010 |
20100184610 | METHOD OF PROGNOSIS - Provided are methods, kits and arrays for use in determining susceptibility to keloid formation. These determine susceptibility based on comparison of gene expression in a patient of interest with expression in a control sample. If expression of at least one gene, selected from the group of genes set out in Table 1, is decreased in a sample representative of gene expression in the patient compared to expression of the same gene (or genes) in the control sample this is indicative of a susceptibility to keloid formation. | 07-22-2010 |
20100184611 | ENCODED SELF-ASSEMBLING CHEMICAL LIBRARIES (ESACHEL) - The invention concerns a chemical compound comprising a chemical moiety (p) capable of performing a binding interaction with a target molecule (e.g. a biological target) and further comprising an oligonucleotide (b) or functional analogue thereof. In a first embodiment according to the invention, the chemical compound is characterized in that the oligonucleotide (b) or functional analogue comprises at least one self-assembly sequence (b | 07-22-2010 |
20100184612 | NOVEL TRIPLE TAG SEQUENCE AND METHODS OF USE THEREOF - The present disclosure relates to novel triple tag sequences that may comprise a 6× histidine tag, a c-myc tag and a V5 tag. The present disclosure also provides polynucleotides, proteins, vectors and host cells that comprise the triple tag sequence of the present disclosure, including libraries of such polynucleotides, proteins, vectors and host cells. The novel triple tag sequences of the present disclosure may be used in phage display vectors and phage libraries and in methods for detection, screening, capture, purification, quantitation, and/or recovery of proteins of interest to which they are linked. Proteins of interest include antibodies such as single chain antibodies, single chain antibodies, and Fab fragments of antibodies or peptides such as non-antibody peptides. | 07-22-2010 |
20100184613 | Proteome Epitope Tags and Methods of Use Thereof in Protein Modification Analysis - Disclosed are methods for reliably detecting the presence of proteins, including proteins with various post-translational modifications (phosphorylation, glycosylation, methylation, acetylation, etc.) in a sample by the use of one or more capture agents that recognize and interact with recognition sequences uniquely characteristic of a protein or a set of proteins (Proteome Epitope Tags, or PETs) in the sample. Arrays comprising these capture agents or PETs are also provided. | 07-22-2010 |
20100184614 | MICROARRAY SYSTEMS AND METHODS FOR IDENTIFYING DNA-BINDING PROTEINS - Disclosed are methods for identifying double-stranded nucleic acid protein binding sites and double-stranded nucleic acid binding proteins. The method can include contacting a sample with at least one partially double-stranded nucleic acid probe under conditions that permit binding of double-stranded binding proteins and partially double-stranded nucleic acid probes. In particular examples, the partially double-stranded nucleic acid probes include a first portion of single-stranded nucleic acid at least about 15 nucleotides in length with a unique index sequence and a second portion of double-stranded nucleic acid greater than about 8 base pairs in length with a potential binding site for a double-stranded nucleic acid binding protein. The protein bound partially double-stranded nucleic acid probe can then be isolated and detected by hybridization to a nucleic acid indexing probe. Also disclosed are kits and devices for carrying out the methods. | 07-22-2010 |
20100184615 | Display of Binding Agents - The present invention relates to a method of preparing a genetic package displaying oligomers of modular antibody domains binding to a target and to a scaffold ligand as well as to vectors and libraries of genetic packages produced thereby. The invention further relates to methods of selecting suitable linker sequences for use in such oligomer display. | 07-22-2010 |
20100184616 | SPATIALLY CONTROLLED ILLUMINATION OF BIOLOGICAL SAMPLE ARRAY THROUGH WEDGE-SHAPED SUPPORT - Two-dimensional samples or sample arrays such as electrophoresis gels and microplates, containing fluorescently labeled species, are illuminated by an illumination device that includes a slab of non-autofluorescing or low-autofluorescing material shaped to receive excitation light from one or more edges and to distribute the light to emerge from an upper surface of the slab at a uniform intensity along the length and width of the upper surface. | 07-22-2010 |
20100184617 | CHARACTERIZATION OF MICROARRAYS BY NANOGOLD STAINING - Methods for determining the quality of a biomolecular microarray to determine suitability of the microarray for performing specific binding reactions, such as hybridization, are provided. Methods are based on staining a microarray with a solution of detectable nanoparticles that reversibly stain the biomolecules through an electrostatic interaction to select microarrays that meet quality standards for hybridization reactions. A gold nanoparticle solution based staining method for DNA microarrays is provided. Destaining methods allowing multiple rounds of hybridization of nanogold stained microarrays are provided. Microarrays selected by methods of the invention are provided. | 07-22-2010 |
20100184618 | DNA LIGATION ON RNA TEMPLATE - Disclosed are methods and compositions for detection and amplification of nucleic acids, wherein two DNA strands hybridized to an RNA strand are ligated. In one aspect, the disclosed methods include removal of an energy source, such as ATP, upon charging a ligase to form an enzyme-AMP intermediate, and then adding substrate, which results in one complete round of RNA-templated DNA ligation. In another aspect, the ligation reaction is accomplished by use of a mixture of at least two different ligase enzymes. The disclosed methods and compositions for RNA-templated DNA ligation may be particularly useful for detection of RNA sequence variants, for example RNA splice variants, and for quantitative expression analysis. | 07-22-2010 |
20100184619 | METHOD FOR ANALYZING ORGANELLE-LOCALIZED PROTEIN AND MATERIAL FOR ANALYSIS - A method for analyzing an organelle-localized protein, which enables one to determine whether or not a test protein localizes to an organelle, comprising the steps of: (a) a step of introducing a fusion peptide (a), which comprises one half-peptide of an intein, one half-peptide of a fluorescent protein and an organelle-targeting signal peptide, into a eukaryotic cell; (b) a step of introducing a test protein bound to a fusion peptide (b), which comprises the other half-peptide of the fluorescent protein and the other half-peptide of the intein, into the eukaryotic cell; and (c) a step of detecting fluorescence signal emitted by the fluorescent protein, and a material for analysis to be used in such method are provided. | 07-22-2010 |
20100184620 | METHOD OF BIOLOGICAL AND MEDICAL DIAGNOSTICS USING IMMUNE PATTERNS OBTAINED WITH ARRAYS OF PEPTIDE PROBES - Immune-chips, which are arrays of peptides probes are used to obtain a pattern which characterizes the global immune reactivity status of the human or other organism, are described. The peptide probes participate in immune reactions with antibodies and immune receptors of the investigated organisms to generate an immune pattern on the chip, which are detected and stored as patterns in databases. The patterns are then compared with other patterns observed with the same array and obtained under physiological, pathological and experimental conditions from the same or other organisms. The comparison is used to classify the state of the investigated organisms based on similarity to other observed states. The immune chips and the obtained patterns can be used for clinical diagnosis and biological studies, such as the investigation of similarities between physiological, pathological or experimental processes. | 07-22-2010 |
20100190653 | Nucleotide sequences encoding alanine racemase from coryneform - The invention relates to an isolated polynucleotide having a polynucleotide sequence which codes for the alr gene, and a host-vector system having a coryneform host bacterium in which the alr gene is present in attenuated form and a vector which carries at least the alr gene according to SEQ ID No 1, and the use of polynucleotides which comprise the sequences according to the invention as hybridization probes. | 07-29-2010 |
20100190654 | NANOARRAYS AND METHODS AND MATERIALS FOR FABRICATING SAME - A nanoarray includes a fluoropolymer array defining a plurality of cavities where each cavity has a predetermined shape and is less than about 5 micrometers in a broadest cross-sectional dimension. The nanoarray also includes a composition discretely contained in each cavity, where the composition includes a linking group for coupling with a modifying group. The nanoarray can be fabricated from fluoropolyether or perfluoropolyether. | 07-29-2010 |
20100190655 | FUSION POLYPEPTIDE FOR DETECTION OF CONSERVED COMBINATORIAL OR COMPOSITE EPITOPES IN NON-CONSERVED PROTEINS - The present invention provides multiepitope-binding fusion polypeptides for use in a method for the detection of the presence of human immunodeficiency virus, HIV, in a biological sample. The present invention also provides a method for producing multiepitope-binding fusion polypeptides. | 07-29-2010 |
20100190656 | Breast Cancer Specific Markers and Methods of Use - The present invention relates to breast cancer biomarkers useful for the detection, diagnosis and therapeutic treatment of breast cancer. | 07-29-2010 |
20100190657 | Oligonucleotide-tagged semiconductor nanocrystals for microarray and fluorescence in situ hybridization - Methods for assaying a sample for a probe polynucleotide are provided. The methods comprise forming a complex between a target on a substrate, the probe polynucleotide that binds to the target, and a conjugate comprising a semiconductor nanocrystal that binds to the probe polynucleotide by way of a tag sequence on the probe polynucleotide. The complex is formed when the probe polynucleotide is present in the sample. The methods are useful in any technique in which the detection of a target that can bind to a probe polynucleotide is desired, for example in fluorescence in situ hybridization. The methods are particularly useful in multiplex settings such as hybridization to microarrays where a plurality of targets are present. Assay complexes produced by such methods and kits useful for performing such methods are also provided. | 07-29-2010 |
20100190658 | COLORIMETRIC ASSAY FOR THE VISUAL DETECTION OF PRIMARY AND SECONDARY AMINES - The present invention concerns a novel method and kit system for the detection of solid-phase bound primary amines, secondary amines, or thiol groups comprising adding a fluid to said substrate and further comprising adding a novel reagents to said substrate and recording a colour reaction on said substrate that comprise said amine or said thiol groups. The method and kit of present invention can be used for the quantitative determination of organic substituents with primary or secondary amines or with thiol groups immobilized on or in insoluble materials. | 07-29-2010 |
20100197515 | DETECTING TARGET MOLECULES IN A SAMPLE - The invention relates to detection the presence of a target molecule in a sample, wherein the sample is contacted with a substrate, the substrate subsequently being washed in a wash step. In particular, the invention relates to a method of detecting the presence of a target molecule in a sample, the method comprising: (a) contacting the sample ( | 08-05-2010 |
20100197516 | DETECHIP: MOLECULAR COLOR AND FLUORESCENT SENSORY ARRAYS FOR SMALL MOLECULES - A small molecule detection device including a chamber, a carrier within the chamber, and a dye in combination with the carrier is disclosed. The dye is capable of interacting with a small molecule target to produce a detectable change in color, fluorescence, mass uptake, refractive index, extinction coefficient, or solubility. A method of using the device is also disclosed. | 08-05-2010 |
20100197517 | REACTION BUFFER FOR MICROARRAY - Embodiments of the present invention relate to a buffer composition for an integrated nucleic acid amplification and hybridization reaction. The buffer comprise about 50-20 OmM of a salt, about 10-30 mM Tris-HCI, about 2-10M Water soluble magnesium salt, about 0.05-1.5% surfactant, about 0.05-0.15 mg/ml stabilizing protein about 50-300 nM of one or more primers, about 20-15 OuM of one or more dNTPs, about 5-15% glycerine, about 0.5-1.5% formamide and at least about 5 unit/ml polymerase. | 08-05-2010 |
20100197518 | Methods for Diagnosing Ischemia - This invention provides methods and compositions for diagnosing ischemia, ischemia reference expression profiles, and methods for identifying compounds for treating or preventing ischemia. | 08-05-2010 |
20100197519 | KETOL-ACID REDUCTOISOMERASE USING NADH - Methods for the evolution of NADPH specific ketol-acid reductoisomerase enzymes to acquire NADH specificity are provided. Specific mutant ketol-acid reductoisomerase enzymes isolated from | 08-05-2010 |
20100197520 | METHOD OF ANALYZING A TARGET NUCLEIC ACID SEQUENCE - Provided is a method of analyzing a target nucleic acid sequence by using an elongation reaction and a ligation reaction. | 08-05-2010 |
20100204051 | Hereditary Hemochromatosis Gene - The invention relates generally to the gene, and mutations thereto, that are responsible for the disease hereditary hemochromatosis (HH). More particularly, the invention relates to the identification, isolation, and cloning of the DNA sequence corresponding to the normal and mutant HH genes, as well as the characterization of their transcripts and gene products. The invention also related to methods and the like for screening for HH homozygotes and further relates to HH diagnosis, prenatal screening and diagnosis, and therapies of HH disease, including gene therapeutics, protein and antibody based therapeutics, and small molecule therapeutics. | 08-12-2010 |
20100204052 | Protein scaffolds and uses thereof - The present invention provides thrombospondin, thyroglobulin and trfoil/PD monomer domains and multimers comprising the monomer domains are provided. Methods, compositions, libraries and cells that express one or more library member, along with kits and integrated systems, are also included in the present invention. | 08-12-2010 |
20100204053 | ASSAYS FOR THE IDENTIFICATION OF COMPOUNDS THAT MODULATE BONE FORMATION AND MINERALIZATION - This invention demonstrates that KRC molecules have multiple important functions as modulating agents in regulating a wide variety of cellular processes including bone formation and mineralization. TGF-β signaling in osteoblasts promotes the formation of a multimeric complex between KRC, Runx2, Smad3, and the E3 ubiquitin ligase, WWP1 which inhibits Runx2 function due to the ability of WWP1 to promote Runx2 polyubiquitination and proteasome-dependent degradation. Furthermore, KRC and WWP1 form a complex with RSK2 which inhibits RS K2 function due to the ability of WWP1 to promote RSK2 ubiquitination. Methods for identifying modulators of KRC activity are provided. Methods for modulating an immune response, bone formation and mineralization and KRC-associated disorders using agents that modulate KRC expression and/or activity are also provided. | 08-12-2010 |
20100204054 | METHODS FOR IDENTIFYING INHIBITORS OF BOTULINUM NEUROTOXINS - A system and method for identifying a botulinum neurotoxin inhibitor employing a botulinum neurotoxin substrate complex having a peptide substrate, preferably SNAP-25, a reporter domain on one side of said peptide substrate and an immobilization domain on the opposite side of said peptide substrate. The botulinum neurotoxin inhibitor is identified by its ability to decrease the relative amount of cleaved complex, detected through measuring a decrease in complex bound to a solid support. The method of the present invention also utilizes novel cells that express a botulinum neurotoxin substrate complex. The methods of the present invention are adapted for cell based screening to monitor the catalytic activity of a BoNT in living cells and to identify molecules that inhibit the catalytic activity of a BoNT in living cells. Also provided are novel stable cell lines that express the botulinum toxin substrate complex and viral vectors capable of efficiently expressing an active light chain of the BoNT within mammalian cells. | 08-12-2010 |
20100204055 | AUTOANTIBODY DETECTION SYSTEMS AND METHODS - Autoantibodies in biological samples such as serum can result from changes to biomolecules (e.g., proteins, polysaccharides, and lipids) that are associated with disease. Such autoantibodies are useful biomarkers because they frequently appear early in disease and are readily accessible, particularly in biological fluids such as blood and serum. CT antigens are particularly useful for detecting autoantibodies correlated with cancer. Numerous population-based profiles for pluralities of different autoantibody species, at least some of which are specifically reactive with CT antigens, allow for simultaneous assessment of multiple disease-associated analytes is a single test, which can be more effective in diagnostics and drug development than individual profiles. The instant invention provides autoantibody detection array devices that include a plurality of independently selected autoantibody-reactive reagent species, such as full-length CT antigens or the antigenic portions thereof, disposed on a substrate. Such arrays can be used to screen biological samples taken from patients or other subjects for diagnostic, drug development, and other applications. | 08-12-2010 |
20100204056 | QUALITY-CONTROL AND ALIGNMENT ELEMENT FOR ASSAY SUBSTRATES - A method for fabricating and assessing the quality of printing on substrates used for chemical or biological array testing, and method for ascertaining relative consistency of the deposit reproducibility is described. Generally, the method involves: providing a substrate, providing a solution mixture of a capture moiety and a colorant; depositing an amount of said solution mixture onto said substrate, monitoring the substrate such that the visible indicator colorant manifests in a co-extensive fashion as with the capture moiety on the substrate. In another aspect, the invention relates to a sensor or assay device comprising a physical complex of a number of capture agents and an amount of colorants adhere to least a part of a surface of a substrate. | 08-12-2010 |
20100204057 | SUBSTRATE FOR MICROARRAY, METHOD OF MANUFACTURING MICROARRAY USING THE SAME AND METHOD OF OBTAINING LIGHT DATA FROM MICROARRAY - Provided is a substrate that is used to produce a microarray, wherein the substrate includes; a fiducial mark disposed on the substrate, and a probe immobilization region disposed on the substrate, wherein a surface of the first fiducial mark is a hydrophobic and a probe immobilization compound is immobilized on the probe immobilization region. | 08-12-2010 |
20100204058 | Profiling for Determination of Response to Treatment for Inflammatory Disease - The present invention relates to compositions and methods for treating, characterizing, and diagnosing autoimmune diseases or other inflammatory diseases. In particular, the present invention provides gene expression profiles as well as novel TKI Responsive Signature(s) useful for the diagnosis, characterization, prognosis and treatment of autoimmune disease or other inflammatory diseases. | 08-12-2010 |
20100204059 | CDR-Anchored Amplification Method - A method of obtaining nucleic acid encoding a plurality of antibodies is provided. In certain embodiments, the method comprises obtaining from an immunized animal nucleic acid encoding the amino acid sequence of the heavy and light chains of a second antibody that binds to the antigen as a first antibody and differs in amino acid sequence to the first antibody, wherein the obtaining is done by amplification using: i. a first primer pair that includes oligonucleotides are complementary to CDR-encoding regions first antibody. | 08-12-2010 |
20100204060 | HYPOXIA-INDUCIBLE PROTEIN 2 (HIG 2), A DIAGNOSTIC MARKER FOR CLEAR CELL RENAL CELL CARCINOMA - The present invention provides a method for inhibiting growth of a cancer cell, particularly a renal cell carcinoma, by contacting the cell with a composition composed of an HIG2 siRNA or HIG2 antibody. Methods of diagnosing renal cell cancer are also provided within the present invention. | 08-12-2010 |
20100210471 | AUTISM ASSOCIATED GENETIC MARKERS - The present disclosure relates to the identification of a subject that is affected with, or predisposed to, autism or to one or more autism spectrum disorders (ASD). The present disclosure includes methods related to the association of certain genetic markers with autism and/or ASD. More particularly, the present disclosure is related to methods and diagnostic tests for diagnosing or predicting ASD in an individual. | 08-19-2010 |
20100210472 | SPATIAL POSITIONING OF SPECTRALLY LABELED BEADS - Devices, systems, kits, and methods for detecting and/or identifying a plurality of spectrally labeled bodies well-suited for performing multiplexed assays. By spectrally labeling the beads with materials which generate identifiable spectra, a plurality of beads may be identified within the fluid. Reading of the beads is facilitated by restraining the beads in arrays, and/or using a focused laser. | 08-19-2010 |
20100210474 | HETEROCYCLIC SCAFFOLDS USEFUL FOR PREPARATION OF COMBINATORIAL LIBRARIES, LIBRARIES AND METHODS FOR PREPARATION THEREOF - Disclosed are heterocyclic scaffolds useful, for example, for solid-phase organic synthesis of combinatorial libraries and methods for the preparation thereof. Also disclosed are libraries, including combinatorial libraries, and methods for preparation thereof. Exemplified are the following scaffolds (I): | 08-19-2010 |
20100216656 | METHODS OF ENZYMATIC DISCRIMINATION ENHANCEMENT AND SURFACE-BOUND DOUBLE-STRANDED DNA - Methods for discriminating between fully complementary hybrids and those that differ by one or more base pairs and libraries of unimolecular, double-stranded oligonucleotides on a solid support. In one embodiment, the present invention provides methods of using nuclease treatment to improve the quality of hybridization signals on high density oligonucleotide arrays. In another embodiment, the present invention provides methods of using ligation reactions to improve the quality of hybridization signals on high density oligonucleotide arrays. In yet another embodiment, the present invention provides libraries of unimolecular or intermolecular, double-stranded oligonucleotides on a solid support. These libraries are useful in pharmaceutical discovery for the screening of numerous biological samples for specific interactions between the double-stranded oligonucleotides, and peptides, proteins, drugs and RNA. In a related aspect, the present invention provides libraries of conformationally restricted probes on a solid support. The probes are restricted in their movement and flexibility using double-stranded oligonucleotides as scaffolding. The probes are also useful in various screening procedures associated with drug discovery and diagnosis. The present invention further provides methods for the preparation and screening of the above libraries. | 08-26-2010 |
20100216657 | PCR-FREE SAMPLE PREPARATION AND DETECTION SYSTEMS FOR HIGH SPEED BIOLOGIC ANALYSIS AND IDENTIFICATION - Provided herein are biologic sample preparation and analysis systems that are rapid, portable, robust detection system for multiplexed detection of bio-threats, and which can be ruggedized to operate in harsh environments. A new method of detection called Combinatorial Probe Analysis (CPA), which provides an exponential increase in detection reliability, has been incorporated into these systems. This type of analysis greatly reduces false positives and false negatives; in addition it is reusable and eliminates special storage requirements for reagents. Specific technical advancements in the optimization of hybridization assays for nucleic acid detection on porous polymer monoliths (PPM) are also disclosed. Performing rapid and complete solubilization of viruses, vegetative bacteria and bacterial spores with an ultra high temperature solubilization protocol is also described. The systems provided herein provides the ability to perform rapid highly multiplexed analysis of a variety of bioagents, including bacteria viruses, and protein biotoxins. The systems and assays described herein are perform completely automated sample preparation and analysis, in a time frame of five minutes or less. The assay is simple in design allowing users in personal protective equipment to easily operate the system. The disclosed systems are robust, simple to use, and address the goals of the first responder community. | 08-26-2010 |
20100216658 | Modified Nucleic Acid Nanoarrays and Uses Therefor - The present invention provides finite, addressable, and self-assembling nucleic acid tiling arrays, and methods for their use. | 08-26-2010 |
20100216659 | METHODS AND COMPOSITIONS FOR INDENTIFYING BINDING PARTNERS FROM LIBRARIES OF BIOMOLECULES - The present invention provides methods for identifying cognate binding pairs from two libraries of biomolecules (e.g., polypeptides). The methods typically involve displaying a first library of candidate biomolecules (e.g., receptors or epitopes) on a first replicable genetic package (e.g., a cell surface display platform) and displaying a second library of candidate biomolecules (e.g., ligands) on a second replicable genetic package (e.g., a phage display platform), contacting the first library with the second library, and then selecting members of the first library to which a member of the second library is bound. Also provided in the invention are compositions and kits for carrying out the methods of the invention. | 08-26-2010 |
20100216660 | NOVEL METHODS FOR FUNCTIONAL ANALYSIS OF HIGH-THROUGHPUT EXPERIMENTAL DATA AND GENE GROUPS IDENTIFIED THEREFROM - The present invention relates generally to groups of genes that can be used to diagnose and differentiate between types of specific diseases such as breast cancer. The groups of genes can be further used to develop diagnostic kits for the specific diseases. The diagnostic kits can also differentiate between sub-categories of a disease to help identify the appropriate treatment regimen for a patient. | 08-26-2010 |
20100216661 | Diagnostic Assay - The present invention relates to mimotopes of blood group antigens, methods for identifying mimotopes of blood group antigens and methods for identifying antibodies to blood group antigens using said mimotopes. | 08-26-2010 |
20100216662 | Inhibition of Placenta Growth Factor (PLGF) Mediated Metastasis and/or Angiogenesis - The present invention concerns methods and compositions for inhibiting angiogenesis and/or tumor growth, survival and/or metastasis. In particular embodiments, the methods and compositions may concern ligands against placenta growth factor (P1GF), such as BP-1, BP-2, BP-3 or BP-4. Some methods may comprise administering one or more P1GF ligands, alone or in combination with one or more other agents, such as chemotherapeutic agents, other anti-angiogenic agents, immunotherapeutic agents or radioimmunotherapeutic agents to a subject. The P1GF ligands are effective to inhibit angiogenesis, tumor cell motility, tumor metastasis, tumor growth and/or tumor survival. In certain embodiments, P1GF ligands may be administered to subjects to ameliorate other angiogenesis related conditions, such as macular degeneration. In some embodiments, P1GF expression levels may be determined by any known method to select those patients most likely to respond to P1GF targeted therapies. | 08-26-2010 |
20100216663 | NOVEL PROTEINS WITH TARGETED BINDING - Methods for identifying discrete monomer domains and immuno-domains with a desired property are provided. Methods for generating multimers from two or more selected discrete monomer domains are also provided, along with methods for identifying multimers possessing a desired property. Presentation systems are also provided which present the discrete monomer and/or immuno-domains, selected monomer and/or immuno-domains, multimers and/or selected multimers to allow their selection. Compositions, libraries and cells that express one or more library member, along with kits and integrated systems, are also included in the present invention. | 08-26-2010 |
20100216664 | Method - The present invention relates, in one aspect, to a method for determining the severity of a disease attributed to at least one genetic mutation in one or more of the genes encoding haemoglobin polypeptide chains, comprising the steps of: (a) providing a sample from said subject; and (b) determining the presence of one or more diagnostic markers:
| 08-26-2010 |
20100216665 | DETECTION OF IMMOBILIZED NUCLEIC ACID - The present invention provides methods for determining the presence of immobilized nucleic acid employing unsymmetrical cyanine dyes that are derivatives of thiazole orange, a staining solution and select fluorogenic compounds that are characterized as being essentially non-genotoxic. The methods comprise immobilizing nucleic acid, single or double stranded DNA, RNA or a combination thereof, on a solid or semi solid support, contacting the immobilized nucleic acid with an unsymmetrical cyanine dye compound and then illuminating the immobilized nucleic acid with an appropriate wavelength whereby the presence of the nucleic acid is determined. The cyanine dye compounds are typically present in an aqueous staining solution comprising the dye compound and a tris acetate or tris borate buffer wherein the solution facilitates the contact of the dye compound and the immobilized nucleic acid. Typically the solid or semi-solid support is selected from the group consisting of a polymeric gel, a membrane, an array, a glass bead, a glass slide, and a polymeric microparticle. Preferably, the polymeric gel is agarose or polyacrylamide. The methods employing the non-genotoxic compounds represent an improvement over commonly used methods employing ethidium bromide wherein the present methods retain the advantages of ethidium bromide, ease of use and low cost, but without the disadvantageous, known mutagen requiring special handling and waste procedures. | 08-26-2010 |
20100222226 | Biochip - To provide an electronic component mounting system and an electronic component mounting method which can prevent a mounting failure due to positional error in a height direction of a substrate and ensure mounting quality. The electronic component mounting system includes a plurality of electronic component mounting devices connected to one another and mounts an electronic component on a substrate to manufacture a mounting substrate. A print test device for testing the substrate after solder printing measures a height position of a height measurement point set on the upper surface of the substrate | 09-02-2010 |
20100222227 | RAPID GENOTYPING ANALYSIS AND THE DEVICE THEREOF - The present invention describes methods of performing rapid nucleic acid detection using a flow through process. The methods comprise single-step signal amplification and/or a one-step hybridization protocol. Using the flow through hybridization process, the present invention provides a more efficient, faster and less expensive genotyping method. This invention further provides a Single Nucleotide Polymorphism (SNP)-based DNA fingerprinting method for rapid and accurate genotyping, identification as well as DNA analyses of genetic materials from human beings and other different organisms. In addition this invention also discloses devices for rapid and sensitive analysis of target analysts. | 09-02-2010 |
20100222228 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING IRRITABLE BOWEL SYNDROME - The present invention relates generally to therapy and diagnosis of disorders associated with chronic visceral hypersensitivity (CVH), and in particular irritable bowel syndrome (IBS). In particular, this invention relates to the polypeptides as well as to the polynucleotides encoding these polypeptides, wherein said polypeptides are shown to be associated with CVH. These polypeptides and polynucleotides are useful in the diagnosis, treatment and/or prevention of disorders associated with CVH, in particular in the diagnosis, treatment and/or prevention of disorders associated with IBS. | 09-02-2010 |
20100222229 | Gene Expression Markers for Breast Cancer Prognosis - The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer. | 09-02-2010 |
20100222230 | DIAGNOSTIC AND PROGNOSTIC METHODS FOR RENAL CELL CARCINOMA - The present invention provides methods for diagnosis and prognosis of renal cell carcinoma (RCC) using expression analysis of one or more groups of genes, and a combination of expression analysis from a biological sample from the subject. The methods of the invention provide a method for superior detection accuracy for RCC as compared to any other currently available method for RCC diagnostic or prognosis. The invention also provides kits for diagnosis and prognosis of RCC using expression analysis. | 09-02-2010 |
20100222231 | USE OF ANTISENSE OLIGONUCLEOTIDE LIBRARIES FOR IDENTIFYING GENE FUNCTION - A method for identifying one or more genes involved in a phenotype of cells, tissues or organisms, comprising the steps of contacting cells, tissues or organisms which exhibit the phenotype with a library of antisense oligonucleotides and performing a primary phenotypic assay to determine which antisense oligonucleotides in the library attenuate the phenotype. These antisense oligonucleotides correspond to genes involved in the phenotype. The method may be used to identify genes involved in various disease states. | 09-02-2010 |
20100222232 | ENRICHMENT AND SEQUENCE ANALYSIS OF GENOMIC REGIONS - The present invention provides novel methods for reducing the complexity of preferably a genomic sample for further analysis such as direct DNA sequencing, resequencing or SNP calling. The methods use pre-selected immobilized oligonucleotide probes to capture target nucleic acid molecules from a sample containing denatured, fragmented (genomic) nucleic acids for reducing the genetic complexity of the original population of nucleic acid molecules. | 09-02-2010 |
20100222233 | AFFINITY CAPTURE OF PEPTIDES BY MICROARRAY AND RELATED METHODS - The invention provides methods of detecting polypeptides in a sample. The method can include the steps of cleaving polypeptides in a test sample to generate peptides; adding a predetermined amount of isotopically labeled peptide standards to the cleaved test sample, wherein the peptide standards correspond to peptides cleaved with the same reagent used to cleave the test sample; contacting the cleaved test sample containing peptide standards with an array of immobilized binding agents specific for the peptide standards; washing the array to remove unbound peptides, thereby retaining affinity captured sample peptides and standard peptides; analyzing the affinity captured peptides using mass spectrometry; and determining the presence of bound test peptides and standard peptides. The method can further include the step of quantifying the amount of the test peptides by comparing the ratio of test peptide to corresponding standard peptide. | 09-02-2010 |
20100227769 | GRATING-BASED SENSOR COMBINING LABEL-FREE BINDING DETECTION AND FLUORESCENCE AMPLIFICATION AND READOUT SYSTEM FOR SENSOR - A grating-based sensor is disclosed that has a grating structure constructed and designed for both evanescent resonance (ER) fluorescence detection and label-free detection applications. Some embodiments are disclosed which are optimized for ER detection in an air mode, in which the sample is dry. Other embodiments are optimized for ER detection in liquid mode, in which the sample is suspended in liquid medium such as water. One and two-dimensional gratings are also disclosed, including gratings characterized by unit cells with central posts, central holes, and two-level, two-dimensional gratings. A readout system for such sensors is also disclosed. One embodiment includes a first light source optimized for collecting label-free detection data, a second light source optimized for collecting ER fluorescence amplification data, and at least one detector. In one embodiment, the detector is an imaging system and includes a CCD camera for collecting both ER and label-free data. In other embodiments, the at least one detector takes the form of a spectrometer for collection of label-free data and a photomultiplier for collecting ER data. In other embodiments, a single light source such as a tunable laser or broad band light source is used. | 09-09-2010 |
20100227770 | Brownian microbarcodes for bioassays - An encoded microparticle, methods for using the same in bioassays, and a method of making the same are provided herein. | 09-09-2010 |
20100227771 | METHODS FOR DETECTION OF TARGET ON RESPONSIVE POLYMERIC BIOCHIPS - Methods and tools (e.g., kits, articles of manufacturing, support and arrays) for the solid-phase detection of a target molecule using a cationic polymer and nucleic acid probe complex is provided herewith. These methods and tools allows for the reagentless, ultrasensitive and specific detection of nucleic acids, proteins and other molecules of interest and are based on a labeled complex made of specific capture probes and a polythiophene derivative. | 09-09-2010 |
20100227772 | DETERMINING THE INTERACTION BETWEEN NUCLEIC ACIDS AND NUCLEIC ACID BINDING MOLECULES - The present invention refers to methods for determining the interaction between a nucleic acid molecule and a nucleic acid binding molecule. The methods of the invention are particularly suitable for the analysis of genes associated with pathologic disorders and for the identification of novel therapeutic agents. | 09-09-2010 |
20100227773 | Device and method for determining multiple analytes - A device includes a planar optical waveguide, as part of a sensor platform, and, connected to the platform directly or by means of a sealing medium, a sealing layer. The sealing layer forms either directly or by means of a sealing medium a tightly sealing layer. The sealing layer includes a multitude of recesses at least open towards the sensor platform, which form a corresponding multitude of sample compartments in a 2-dimensional arrangement. Each of the sample compartments has different biological or biochemical recognition elements, for the specific recognition and binding of different analytes, immobilized in five or more discrete measurement areas, wherein the measurement areas are in optical interaction with excitation light emanating from the optical waveguide, as part of the sensor platform which forms a demarcation of the sample compartments, and wherein the sample compartments are operable to be cleared from received sample or reagent solutions and to then receive, optionally without washing steps, further sample or reagent solutions, which are supplied to the same sample compartments. | 09-09-2010 |
20100227774 | Method For Generating and Selecting Antibodies Against Target Protein - Compositions are provided that comprise antibody against membrane proteins such as chemokine receptors. In particular, monoclonal human antibodies against human CXCR4 are provided that are capable of inhibiting HIV infection and chemotaxis in human breast cancer cells. The antibodies can be used as prophylactics or therapeutics to prevent and treat HIV infection and cancer, for screening drugs, and for diagnosing diseases or conditions associated with interactions with chemokine receptors. | 09-09-2010 |
20100227775 | IMMUNOASSAYS AND KITS FOR THE DETECTION OF NGAL - The present invention relates to NGAL immunoassays and kits, and to methods of using glycosylated mammalian NGAL and antibodies that bind to mammalian NGAL in immunoassays and kits. Among other things, the methods and kits can be employed to determine the amount of human NGAL monomer in a test sample, as well as to determine the proportion of human NGAL monomer to human NGAL dimer contained in a test sample. | 09-09-2010 |
20100234237 | BIO DISC, BIO-DRIVER APPARATUS, AND ASSAY METHOD USING THE SAME - A bio-disc device including new valve control means and fluid movement system, a bio-driver apparatus in which a controller disc including a controller for the bio-disc is installed, and an assay method using the same, which are suitable for labs-on-a-chips for various diagnostic assays, nucleic acid hybridization assays, and immunoassays, are provided. The bio-driver apparatus is compatible with general optical discs, including audio CDs, CD-Rs, game CDs, DVDs, etc., and the assay method is compatible with general optical disc drivers, including CD-ROMs, DVD players, etc. Thus, the bio-driver apparatus and the assay method offer and economical and convenient alternative to existing products. In addition, the bio-driver apparatus can be readily and easily applied in connection with a computer for remote diagnosis via the Internet. | 09-16-2010 |
20100234238 | METHOD FOR PROFILING KINASE INHIBITORS - The present invention is concerned with method for pharmacologically profiling compounds using an array of substrates, in particular kinase substrates, immobilized on a porous matrix. This method was found particular useful in the prediction of drug response, i.e. to enable the distinction between responders and non-responders in the treatment of cells, tissues, organs or warm-blooded animals with the compound to be tested, and in compound differentiation. | 09-16-2010 |
20100234239 | METHODS AND COMPOSITIONS FOR IDENTIFYING, CLASSIFYING AND MONITORING SUBJECT HAVING BCL-2 FAMILY INHIBITOR-RESISTANT TUMORS AND CANCERS - The invention is directed to methods and kits that allow for identifying, classifying, and monitoring cancer patients for Bcl-2 family inhibitor therapies. The methods and compositions of the invention are directed to determining amplification of Bcl-x | 09-16-2010 |
20100234240 | SURFACE MODIFICATION - The invention relates to a carrier comprising at least one substrate, which has a coating in at least certain regions produced from individual modules by plasma polymerisation, and the coating has one or more free spaces in at least certain regions for accommodating at least one solution containing a biological sample. | 09-16-2010 |
20100234241 | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES - MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers. | 09-16-2010 |
20100240543 | Method of isolating analytes from a sample - The current invention is a capture-particle comprising: a) a molecular sieve portion; and b) an analyte binding portion; wherein the molecular sieve portion, analyte binding portion or both further comprise a cross-linked region having modified porosity. Capture particles wherein the molecular sieve portion, analyte binding portion or both comprise pore dimensions sufficient to exclude molecules larger than about 60 kDa. These particles are useful in purification and diagnostic methods. Kits comprising the capture particles are also described. | 09-23-2010 |
20100240544 | Aptamer biochip for multiplexed detection of biomolecules - The embodiments of the invention relate to an in situ generated and self-addressed aptamer biochip for the multiplexed detection of biomolecules. The inventive aptamer biochip uses sets of complementary probes to permit in situ generation and immobilization of aptamers on the aptamer biochip surface to form an addressable aptamer array. These aptamer biochip arrays can be used for detecting multiple biomolecules, especially those for disease signature pattern analysis. | 09-23-2010 |
20100240545 | BIOMARKERS FOR INFLAMMATION OF THE LIVER - The invention relates to a method for the diagnostic investigation of biological samples from a person for inflammation of the liver, in particular hepatic fibrosis and/or cirrhosis of the liver, where the sample is investigated for one or more proteins as markers of inflammation of the liver, in particular hepatic fibrosis and/or cirrhosis of the liver, where a concentration of the proteins which is elevated or decreased by comparison with the healthy state indicates the presence of an inflammation of the liver, in particular a hepatic fibrosis and/or cirrhosis of the liver. The proteins are selected from the group of ER6Q, vimentin, actin alpha 1 skeletal muscle protein, hMFAP 4, tropomyosin, PTGES 2, amyloid P component, transgelin, calponin 1, homo sapiens p20 protein, 17 kDa M myosin light chain, H chain H Igg B12, prolyl 4-hydroxylase, beta subunit methylenetetrahydrofolate dehydrogenase 1, PRO2619, aldehyde dehydrogenase 1, fibrinogen alpha chain preproprotein, fructose-bisphosphate aldolase B, argininosuccinate synthetase, Eefla2, AT P 5 A1, alpha-2 actin, regucalcin, serum albumin, mitochondrial malate dehydrogenase, mitochondrial acetoacetyl-CoA thiolase or in each case a partial sequence thereof. | 09-23-2010 |
20100240546 | USE OF BIOMARKERS FOR THE DIAGNOSIS AND PROGNOSIS OF LUNG CANCER - A method for identifying, diagnosing, and monitoring cancerous lung tissues in a subject may include measuring the expression of at least one biomarker in a biological sample in the subject, and comparing the expression against a normal value. When a differential expression of the at least one biomarker between the biological sample and the normal value is more than 1.5-fold, the lung tissue sample is cancerous. The at least one biomarker is selected from the group consisting of peroxiredoxin I, peroxiredoxin II, peroxiredoxin III, peroxiredoxin IV, peroxiredoxin VI, chaperonin, amyloid-P-component, annexin V, dihydropyrimidinase-like 2 protein, glutamate carboxypeptidase, 2,3-bisphosphoglycerate mutase, thymidine phosphorylase, prolyl-4 hydroxylase, selenium binding protein 1, β-mitochondrial ATP synthase H | 09-23-2010 |
20100240547 | METHODS FOR SELECTING PROTEIN BINDING MOIETIES - Methods, compositions, and apparatuses for the identification of binding moieties that bind to targets are provided. Vectors encoding potential binding moieties are also provided. In certain embodiments, methods are provided for the presentation of potential binding moieties by cells, the selection of binding moieties that bind targets, and the amplification of the nucleic acids encoding the binding moieties. | 09-23-2010 |
20100240548 | Genotyping Dihydropyrimidine Dehydrogenase Deficiency - The invention provides compositions and methods relating to a multiplex test which detects all relevant genetic risk markers associated with DPD deficiency in one single reaction test. | 09-23-2010 |
20100240549 | SPECIFIC AMPLIFICATION OF TUMOR SPECIFIC DNA SEQUENCES - The present invention provides methods for cancer detection and diagnosis. The present invention provides a method of selectively amplifying hypomethylated tumor DNA sequences derived from a subject for detection of cancer. This method utilizes differential methylation to allow for the selective amplification of tumor specific sequences from DNA mixtures that contain a high proportion of normal host DNA. The invention also provides methods of using the amplified tumor DNA sequences for evaluation of methylation. | 09-23-2010 |
20100240550 | METHODS FOR SIMULTANEOUS GENERATION OF FUNCTIONAL LIGANDS - The present invention relates to methods for generating functional biomolecules, particularly to methods for generating multiple functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to methods for generating functional biomolecules, particularly to functional nucleic acids, that bind with functional activity to another biomolecule, such as a receptor molecule. In one exemplary aspect of the invention, generation of functional biomolecules may be performed against multiple targets simultaneously within a single system, such as the generation of functional nucleic acid ligands within a single reaction volume. In general, a plurality of targets may be disposed within in a single reaction volume and a library of biomolecules, such as a nucleic acid library, may be applied to the reaction volume. The members of the library that do not bind to any of the plurality of targets under given conditions may then be partitioned, such as by washing. The remaining members of the library may then be marked and/or tagged, such as to identify the particular target or targets to which the member of the library binds. The binding members of the library may then be isolated and, by virtue of the marking or tagging, be matched to a particular target or targets. | 09-23-2010 |
20100240551 | Detection Of Rho Proteins - The present invention provides methods of detecting activated Rho GTPase proteins by contacting a solid support with a sample comprising an activated Rho GTPase protein. The solid support is linked to an activated Rho GTPase binding peptide. The activated Rho GTPase protein remains associated with the solid support during the detection. | 09-23-2010 |
20100248975 | Fluorogenic peptide substrate arrays for highly multiplexed, real-time monitoring of kinase activities - The embodiments of the invention relate to a biomolecule microarray comprising a plurality of different polypeptides, where the polypeptides contain a kinase recognition sequence connected via a linker sequence to a metal binding amino acid that undergoes chelation enhanced fluorescence upon binding to a divalent cation. The embodiments further relate to kits comprising the microarray, and methods of using the microarray to screen for kinase activity, and to screen for inhibitors of kinase activity. | 09-30-2010 |
20100248976 | G-PROTEIN COUPLED RECEPTOR KINASE-5 POLYMORPHISM - The present invention is directed to compositions and methods relating to a G-protein coupled receptor kinase-5 polymorphism. The methods include, for example: detecting enhanced desensitization of the beta adrenergic receptor signaling pathway in an individual, assessing partial protection against heart failure progression in an individual, and assessing an individual's response to beta-blocker therapy. The compositions include polynucleotides or fragments thereof of a nucleotide sequence encoding for a G-protein receptor kinase-5 molecule with a thymine at amino acid position 122 and oligonucleotide primers that hybridize thereto. | 09-30-2010 |
20100248977 | Immobilizing an Entity in a Desired Orientation on a Support Material - The present invention relates to the identification and selection of attachment molecules that attach/immobilize an entity having a detectable activity or property on a support in an orientation that provides a detectable activity or property, and to surfaces made of the attachment molecules. | 09-30-2010 |
20100248978 | METHOD FOR IDENTIFYING THE INTERACTION PARTNER OF AN ACTIVE AGENT - The present invention is related to a method for identifying an interaction partner of an active agent, comprising the following steps:
| 09-30-2010 |
20100248979 | REVERSED FLOW THROUGH PLATFORM FOR RAPID ANALYSIS OF TARGET ANALYTES WITH INCREASED SENSITIVITY AND SPECIFICITY AND THE DEVICE THEREOF - A reversed flow-through device for rapid analysis of target analytes and method thereof, comprises one or more reaction chambers, each of which comprises one or more membranes for immobilizing capture molecules; controlling elements that can be regulated to maintain the reaction chamber in controlled conditions; connecting elements for connection to a power supply and control unit that can regulate and maintain the controlled conditions; and liquid delivery elements capable of accepting and removing solution, wherein the solution is maintained in a flow direction that flows against gravitational force, thereby providing higher sensitivity of analytes detection. | 09-30-2010 |
20100248980 | Method for Selective Labeling and Detection of Target Nucleic Acids Using Immobilized Peptide Nucleic Acid Probes - Disclosed are a method for selective labeling of target nucleic acids on an array having nucleic acid analogue, e.g. PNA (peptide nucleic acid), probes immobilized on a support or supports, comprising adding to the array a detectable label and an agent for introducing the label into the target nucleic acids, after hybridization between the target nucleic acids and the nucleic acid analogue probes, and a method for detection of target nucleic acids using the same. | 09-30-2010 |
20100248981 | SYSTEM AND METHODS FOR PROCESSING MICROARRAYS - A device, method and system for ensuring proper orientation and installation of trays for processing biological sensors in an automated and flexible system are provided. The system comprises an instrument handling robot that transfers a plurality of arrays mounted on pegs on a strip to liquid reaction stations. In particular, the method comprises a first orientation marking on a tray and a second orientation marking on a deck, indicating the proper station in which the tray is placed for a specific process. | 09-30-2010 |
20100248982 | Apparatus and Method for Mixing a Film of Fluid - A method and apparatus is provided for mixing a film of fluid, particularly a film of chemical, biochemical, or biological fluids undergoing a reaction. The apparatus comprises a means for nucleating a bubble using a discrete heat source, such as a resistor, and moving the bubble in the fluid by creating a temperature gradient, thereby mixing the fluid. | 09-30-2010 |
20100248983 | METHOD FOR DIAGNOSING A GENETIC ALTERATION ASSOCIATED WITH A CHROMOSOMAL LOCUS - Methods and apparatuses for selecting and arranging clinically relevant chromosomal loci allow an exemplary diagnostic array to simultaneously test for numerous genetic alterations that occur in many different parts of the human genome. Clinically irrelevant or ineffective loci are eliminated. One implementation increases reliability and accuracy by dividing the base-pair sequence of each chromosomal locus into segments and then assigning nucleic acid clones for comparative genomic hybridization to each different segment. The segments may overlap for increased resolution and control. Clones representing segments that are adjacent on a native chromosome are placed in non-adjacent target areas of the array to avoid interfering hybridization reactions. Arrangement motifs within an array may be redundantly repeated for high availability and increased reliability and accuracy of results. Techniques, hardware, software, logic engines, loci collections, and diagnostic arrays are described. | 09-30-2010 |
20100248984 | METHOD FOR PRECISE GENETIC TESTING BY GENOMIC HYBRIDIZATION - Methods and apparatuses for selecting and arranging clinically relevant chromosomal loci allow an exemplary diagnostic array to simultaneously test for numerous genetic alterations that occur in many different parts of the human genome. Clinically irrelevant or ineffective loci are eliminated. One implementation increases reliability and accuracy by dividing the base-pair sequence of each chromosomal locus into segments and then assigning nucleic acid clones for comparative genomic hybridization to each different segment. The segments may overlap for increased resolution and control. Clones representing segments that are adjacent on a native chromosome are placed in non-adjacent target areas of the array to avoid interfering hybridization reactions. Arrangement motifs within an array may be redundantly repeated for high availability and increased reliability and accuracy of results. Techniques, hardware, software, logic engines, loci collections, and diagnostic arrays are described. | 09-30-2010 |
20100248985 | METHOD FOR PRECISE GENETIC DIAGNOSIS - Methods and apparatuses for selecting and arranging clinically relevant chromosomal loci allow an exemplary diagnostic array to simultaneously test for numerous genetic alterations that occur in many different parts of the human genome. Clinically irrelevant or ineffective loci are eliminated. One implementation increases reliability and accuracy by dividing the base-pair sequence of each chromosomal locus into segments and then assigning nucleic acid clones for comparative genomic hybridization to each different segment. The segments may overlap for increased resolution and control. Clones representing segments that are adjacent on a native chromosome are placed in non-adjacent target areas of the array to avoid interfering hybridization reactions. Arrangement motifs within an array may be redundantly repeated for high availability and increased reliability and accuracy of results. Techniques, hardware, software, logic engines, loci collections, and diagnostic arrays are described. | 09-30-2010 |
20100261615 | ATOMIC FORCE MICROSCOPE AS AN ANALYZING TOOL FOR BIOCHIP - The present application discloses a method for detecting a presence of target ligand in a fluid medium which includes the steps of: (i) contacting the fluid medium with a solid substrate that includes an array of dendrons on its surface, wherein each of the dendron includes a central atom, a probe that is attached to the central atom optionally through a linker, and a base portion attached to the central atom and having a plurality of termini that are attached to the surface of the solid support; and (ii) determining the presence of a probe-target ligand complex by measuring binding force between the bound ligand and detection molecule tethered to the tip of an atomic force microscope (“AFM”), which detection molecule has affinity for the ligand, wherein measurement of an increase in force between the probe-target ligand complex and the detection molecule by AFM indicates the presence of the probe-target ligand complex. | 10-14-2010 |
20100261616 | Capturing Sequences Adjacent to type-IIs restriction sites for Genomic Library Mapping - The present invention relates to novel methods for sequencing and mapping genetic markers in polynucleotide sequences using Type-IIs restriction endonucleases. The methods herein described result in the “capturing” and determination of specific oligonucleotide sequences located adjacent to Type-IIs restriction sites. The resulting sequences are useful as effective markers for use in genetic mapping, screening and manipulation. | 10-14-2010 |
20100261617 | GENE EXPRESSION SIGNATURE FOR THE PROGNOSIS, DIAGNOSIS, AND THERAPY OF PROSTATE CANCER AND USES THEREOF - Provided is a method for monitoring the presence and/or progression of prostate tumor in an individual, by measuring the expression level of marker genes out of a novel signature of 39 genes. The invention further discloses a data base and array comprising said identified marker genes for prognosing the tumor progression in an individual suffering from prostate cancer. | 10-14-2010 |
20100267573 | Methods for In Vivo Identification of Endogenous mRNA Targets of MicroRNAs - A method of generating a gene expression profile of noncoding regulatory RNA (ncRNA; e.g. a microRNA) in a cell in vivo, is carried out by: (a) partitioning from a cell at least one mRNA-protein (RNP) complex, the RNP complex comprising: (i) an RNA binding protein (RNABP) or RNA associated protein, (ii) at least one mRNA bound to or associated with said protein, and (iii) at least one ncRNA bound to or associated with said protein, and then (b) identifying at least one ncRNA in-at least one RNP complex, thereby to produce a gene expression profile comprising the identity of an ncRNA in an RNP complex. | 10-21-2010 |
20100267574 | PREDICTING LUNG CANCER SURVIVAL USING GENE EXPRESSION - The present invention provides a plurality of biomarkers for predicting survival of a subject with a lung cancer. More specifically, the present invention relates to methods of predicting survival of a subject with a lung cancer, a kit for predicting survival of a subject with a lung cancer, and an array for predicting survival of a subject with lung cancer. | 10-21-2010 |
20100267575 | GENE ARRAY TECHNIQUE FOR PREDICTING RESPONSE IN INFLAMMATORY BOWEL DISEASES - Disclosed are methods for classifying individuals having or suspected of having an inflammatory bowel disease, such as Crohn's Disease or Ulcerative Colitis, as “responders” or “non-responders” to first-line treatment, generally comprising the steps of a) obtaining, a biological sample from the individual, b) isolating mRNA from the biological sample c) determining a gene expression profile from the biological sample; and d) comparing the gene expression profile of the individual to a reference gene expression profile or other suitable control such that changes in expression can be used to stratify individuals and predict efficacy of first-line therapy. A gene expression system is further provided for carrying out these methods. | 10-21-2010 |
20100267576 | Compositions And Methods For Identifying And Treating Subjects At Risk Of Developing Type 2 Diabetes - Disclosed herein are compositions and methods for the identification of a subject at risk for developing type 2 diabetes. Also disclosed is a therapeutic target for the prevention and treatment of type 2 diabetes. | 10-21-2010 |
20100267577 | Methods for high throughput and quantitative proteome analysis - The invention provides methods for identifying and quantifying polypeptides in a sample. The methods include the steps of labeling peptides in a polypeptide sample with an isotope tag; adding a plurality of peptide standards to the polypeptide sample, wherein the peptide standards are labeled with an isotopically distinct version of the isotope tag; resolving the labeled sample and standard peptides into a plurality of fractions; analyzing the resolved fractions using mass spectrometry; identifying an isotope-tagged sample peptide in an analyzed fraction; and determining the amount of the identified isotope-tagged sample peptide in the analyzed fraction by comparison to the amount of isotope tagged standard peptide in the same fraction. | 10-21-2010 |
20100267578 | PROBE DENSITY SELF-CONSIDERATIONS AND ELONGATION OF COMPLEMENTARY LOOPED PROBES WHERE PROBES ARE ATTACHED TO A SOLID PHASE - In a multiplexed assay method carried out in solution, wherein the solution contains nucleic acid targets and, wherein several different types of oligonucleotide probes, each type having a different sequence in a region designated as a target binding domain, are used to detect the nucleic acid targets, said assay method including a method for increasing the effective concentration of the nucleic acid targets at the surface of a bead to which the oligonucleotide probes are bound, by one or more of the following steps: | 10-21-2010 |
20100267579 | BIOCHEMICAL REACTION CASSETTE AND DETECTION APPARATUS FOR BIOCHEMICAL REACTION CASSETTE - A biochemical reaction cassette comprises: a substrate carrying probes immobilized thereon, the probes being adapted to be specifically bound to a target substance; a reaction space forming member for forming a reaction space with the substrate; an elastic member; and an anchor member for supporting the substrate so as to keep it movable relative to the reaction space forming member by way of the elastic member. | 10-21-2010 |
20100267580 | METHOD FOR DETECTION OF A DISEASE-SPECIFIC COMBINATORIAL MOLECULAR PATTERN MOTIF IN A TISSUE SAMPLE OF A PATIENT'S SKIN - The invention relates to a method for detection of a disease-specific combinatorial molecular pattern motif in a tissue sample of a patient's skin and/or a tissue sample of skin-neighboured-mucosa, wherein the spatial arrangement of epitopes in the sample is captured for identifying the disease-specific combinatorial molecular pattern motif. The invention moreover relates to compositions and kits comprising antibodies and/or ligands which can be employed for the performance of the method. | 10-21-2010 |
20100267581 | HIGH THROUGHPUT INTEGRATED MICROFLUIDIC SYSTEM AND DEVICE - A microfluidic system and device capable of high throughput which includes a multi-channel micro-column having a high surface area material having at least one affinity reagent bound thereto contained within a housing. The structure of the housing and/or the multi-channel micro-column is of a sufficient size and configuration to enable capture and purification of an analyte contained within a sample and one or more of binding of a reporter molecule to the analyte and a substrate chemical reaction with the analyte to all take place within the housing and/or the multi-channel micro-column. | 10-21-2010 |
20100267582 | DIFFERENTIAL EXPRESSION OF MOLECULES ASSOCIATED WITH ACUTE STROKE - Methods are provided for evaluating a stroke, for example for determining whether a subject has had an ischemic stroke, determining the severity or likely neurological recovery of a subject who has had an ischemic stroke, and determining a treatment regimen for a subject who has had an ischemic stroke, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes screening for expression in ischemic stroke related genes (or proteins), such as white blood cell activation and differentiation genes (or proteins), genes (or proteins) related to hypoxia, genes (or proteins) involved in vascular repair, and genes (or proteins) related to a specific peripheral blood mononuclear cell (PBMC) response to the altered cerebral microenvironment. Also provided are methods of identifying one or more agents that alter the activity (such as the expression) of an ischemic stroke-related molecule. | 10-21-2010 |
20100273667 | Cell culture well-plates having inverted colloidal crystal scaffolds - A three dimensional inverted colloidal crystal scaffold is described which comprises a substrate having at least one well. The scaffold also includes a three dimensional matrix comprising a transparent biocompatible polymeric network containing microspherical voids. The microspherical voids are each connected to at least one other void through inter-connecting pores. Additionally, an apparatus for producing such a colloidal crystal scaffold is described. Methods for making the inverted colloidal crystal scaffold, for using the scaffold and for identifying the effects of a drug, pharmaceutical or toxin on a living cell using the inverted colloidal crystal scaffold are also disclosed. | 10-28-2010 |
20100273668 | USE OF AN ENDOPLASMIN FRAGMENT AND DERIVATIVES THEREOF AS BIOMARKER FOR COLORECTAL ADENOMA AND/OR CARCINOMA; METHOD FOR DETECTION AND TEST SYSTEM - The present invention is directed to a method for detecting colorectal adenoma and/or colorectal carcinoma comprising the steps: a) providing an isolated sample material which has been taken from an individual, b) determining the level of an endoplasmin fragment or a derivative thereof in said isolated sample material, c) comparing the determined level of an endoplasmin fragment or a derivative thereof with one or more reference values. The invention is further directed to a method for discriminating between colorectal adenoma and colorectal carcinoma as well as to a method for monitoring the development and/or course of colorectal adenoma and/or colorectal carcinoma and/or the treatment of colorectal adenoma and/or colorectal carcinoma. Moreover, the invention is directed to a test system and an array for use in these methods. Furthermore, the invention is directed to the use of an endoplasmin fragment as a biomarker for a detection of colorectal adenoma and/or colorectal carcinoma in an individual. Further, the invention is directed to a method for determining the effectiveness of a compound in the treatment colorectal adenoma and/or colorectal carcinoma. | 10-28-2010 |
20100273669 | METHOD FOR SELECTING A PEPTIDE OR POLYPEPTIDE WHICH BINDS TO A TARGET - A method for selecting a peptide or polypeptide which binds to a target is provided. The method is based on protein splicing and phage display. | 10-28-2010 |
20100273670 | DETECTION OF ANTIVIRAL RESISTANCE IN INFLUENZA A USING DNA MICROARRAY - Embodiments of the present invention relate to compositions, methods and apparatus for detection of antiviral agent resistance or sensitivity of a virus. In some embodiments, antiviral agent resistance or sensitivity of influenza types, such as A, B and C may be identified. In more embodiments, sub-types such as the hemagglutinin (HA) and neuraminidase (NA) of influenza A may be analyzed for antiviral agent resistance or sensitivity. In a particular embodiment, the various strains of influenza virus may be analyzed for resistance or sensitivity using DNA microarray analysis designed to target a gene segment. In various embodiments, a microarray-based assay system with capture and detection (label) probes may be utilized to identify a change in a gene segment that confers resistance or sensitivity to an antiviral agent of an influenza strain. | 10-28-2010 |
20100273671 | METHOD FOR THE DETERMINATION AND THE CLASSIFICATION OF RHEUMATIC CONDITIONS - Methods for the determination and the classification of a rheumatic condition in a synovial sample of a subject afflicted with a rheumatic condition are disclosed. Methods include the steps of determining in the level of expression of at least 20 genes or gene fragments in the synovial sample and identifying whether the level of expression of the genes in the sample correlates with the presence of a rheumatic condition. Kits are also described for the determination and the classification of rheumatic conditions which contain a low density microarray having probes suitable for hybridizing with at least 20 genes or gene fragments. On the basis of the hybridization results, the rheumatic condition is determined. | 10-28-2010 |
20100273672 | METHOD AND DEVICE FOR HIGH SENSITIVITY AND QUANTITATIVE DETECTION OF CHEMICAL/BIOLOGICAL MOLECULES - A sensor for detecting the presence of predetermined chemical/biological molecules, the sensor having a MOSFET device ( | 10-28-2010 |
20100273673 | THE METHODS FOR DETECTING MOLECULAR INTERACTIONS - The present invention relates to methods for dynamically detecting the interactions between various materials including bioactive molecules and for detecting target molecules. More specifically, the present invention relates to a method for dynamically detecting bait-prey interactions and a method for easily detecting target molecules which blocks or activates the interactions, the method comprising: allowing a material capable of forming a nano-assembly matrix, a bait and a prey to interact with each other, and analyzing whether a nano-assembly matrix is formed by the interaction between the bait and the prey in vitro or in vivo; or allowing a material capable of forming a nano-assembly matrix, a bait and a prey to interact with each other, inducing the formation of a nano-assembly matrix by a mediator (regulator) material in vitro or in vivo, and then analyzing whether the prey and the bait co-localizes on the nano-assembly matrix. | 10-28-2010 |
20100273674 | METHOD FOR THE ANALYSIS OF OVARIAN CANCER DISORDERS - The invention relates to a method for the analysis of ovarian cancer disorders, comprising determining the genomic methylation status of one or more CpG dinucleotides in a sequence selected from the group of sequences according to SEQ ID NO. 1 to 10 and/or SEQ ID NO. 50 to SEQ ID NO. 60. Optionally, additionally following steps are performed, the one or more results from the methylation status test is input into a classifier that is obtained from a Diagnostic Multi Variate Model, calculating a likelihood as to whether the sample is from a normal tissue or an ovarian cancer tissue and/or, calculating an associated p-value for the confidence in the prediction. | 10-28-2010 |
20100273675 | Methods for detecting fetal abnormality - The invention relates to a method of identifying fetal abnormality from a maternal blood sample by capturing an image of a fetal nucleated red blood cell obtained from the maternal blood sample; inputting probe intensities for a plurality of nucleic acid probes that bind fetal nucleic acids of interest; analyzing the probe intensities; and generating a diagnostic output according to results of the analysis. In some embodiments, the probes are specific to a chromosome. | 10-28-2010 |
20100273676 | HIGH THROUGHPUT SCREENS FOR SMALL-MOLECULE INHIBITORS OF THE NUCLEAR RECEPTOR-LIKE PATHWAY REGULATING MULTIDRUG RESISTANCE IN FUNGI - The present invention relates to the identification of molecular mechanisms associated with multidrug resistance (MDR) in fungal infections. More specifically, fungi harbor a nuclear receptor-like pathway controlling MDR, which represents a novel therapeutic target for the treatment of MDR in pathogenic fungi such as | 10-28-2010 |
20100273677 | PROTEIN ANALYSIS - A method of analysing the interaction between a mixture of molecular components and a group of binding agents includes the following steps. (i) Separating the molecular components in the mixture into a plurality of fractions on the basis of a physical parameter. (ii) Providing a plurality of different binding agents. (iii) Contacting the binding agents with at least two of the fractions and detecting the binding of the molecular components in each fraction to the binding agents. (iv) Detecting the presence of a plurality of the molecular components by the binding of the molecular components to the binding agents. | 10-28-2010 |
20100273678 | METHOD AND KIT TO PERFORM A PCR AMPLIFICATION AND MICRO-ARRAY DETECTION IN THE SAME MEDIUM AND/OR SAME CHAMBER - An amplification and micro-array detection method is performed in a same buffer and/or in a same reaction chamber. A kit for an amplification of multiple nucleotide targets, uses low primer concentration. | 10-28-2010 |
20100279884 | PRIMERS, PROBES, MICROARRAY, AND METHOD FOR SPECIFIC DETECTION OF NINE RESPIRATORY DISEASE-ASSOCIATED BACTERIAL SPECIES - Provided herein are a primer set capable of amplifying target sequence(s) of nine respiratory disease-associated bacterial species, a probe set specifically hybridizing with the target sequence(s), a microarray comprising the probe set, and a method of detecting one or more of the nine respiratory disease-associated bacterial species using the probe set. | 11-04-2010 |
20100279885 | OLIGONUCLEOTIDE MICROARRAY FOR IDENTIFICATION OF PATHOGENS - A method for detecting a target nucleic acid of a pathogen in a test sample, the method comprising preparing a target nucleic acid detecting reagent and contacting the target nucleic acid detecting reagent with an oligonucleotide microarray. A kit for detecting a target nucleic acid of a pathogen in a test sample is also described. The kit comprises at least one primer pair and an oligonucleotide microarray comprising at least one probe. | 11-04-2010 |
20100279886 | TWO-DIMENSIONAL PHOTONIC BANDGAP STRUCTURES FOR ULTRAHIGH-SENSITIVITY BIOSENSING - The present invention relates to two-dimensional photonic crystal arrays and their use in biological sensor chips, including those in the form of microfluidic devices. Methods of making the two-dimensional photonic crystals and biological sensor chips are described herein, as are uses of these devices to detect biological targets in samples. | 11-04-2010 |
20100279887 | NONLINEAR MAGNETOPHORETIC SEPARATION OF BIOLOGICAL SUBSTANCES - A method of separating a target biological analyte from a mixture of substances in a fluid sample employs nonlinear magnetophoresis. Magnetic particles having the capacity to bind to the target analyte are contacted with the fluid sample so that the analyte is immobilized on the surface of at least some of the particles. The magnetic particles are provided adjacent an array of micromagnets patterned on a substrate so that the particles are attracted the micromagnets. The magnetic particles are then subjected to a traveling magnetic field operating at or above a frequency effective to sweep those particles not bound to analyte to an adjacent micromagnet. Those magnetic particles bound to analyte have a larger size or smaller magnetic moment that prevents them from being moved to adjacent micromagnets, thereby affording separation of the analyte. | 11-04-2010 |
20100279888 | COMPOSITIONS AND METHODS OF DETECTION - The present invention relates generally to the field of diagnostic and detection assays. More particularly, the present invention provides methods and reagents including biochips for detecting the presence of, or distinguishing between, one or more analytes in a sample. | 11-04-2010 |
20100279889 | Population scale HLA-typing and uses thereof - The present invention provides a portable system for real-time population-scale HLA genotyping and/or allelotyping in a field environment and methods of such population-scale HLA genotyping. The individual components of the system are portable to and operable within a field environment thereby providing high throughput with real-time geno- or allelotyping. Also provided are HLA gene-specific primers and HLA allele-specific or single nucleotide polymorphism-specific hybridization probes. In addition the present invention provides a microarray comprising the hybridization probes. Further provided is a kit comprising the HLA gene-specific primers and the microarray. | 11-04-2010 |
20100279890 | FUSION GENE MICROARRAY - The present invention relates to a microarray comprising a chimeric probe for an intergenic exon-to-exon junction of a fusion gene and at least two intragenic probes for a fusion gene partner of the fusion gene. The invention further relates to a method of detecting a fusion gene and a kit suitable for detecting fusion genes. | 11-04-2010 |
20100279891 | Proteome-Wide Quantification of Small Molecule Binding to Cellular Target Proteins - This invention relates to methods for the evaluation and/or quantification of the binding affinity of small molecules or other compounds to target components contained within an analyte, such as target proteins contained within the proteome of a cell or tissue. | 11-04-2010 |
20100279892 | METHODS TO DETERMINE IF A SUBJECT WILL RESPOND TO A BCR-ABL INHIBITOR - Methods are provided for determining if a subject of interest will respond to treatment with BCR-ABL inhibitor, comprising. The method includes quantitating expression of a plurality of genes in CD34+ cells isolated from the subject. Expression of the plurality of genes in the subject of interest is compared to a control. Altered expression of the plurality of genes in as compared to the control indicates that the subject of interest will respond to treatment with the BCR-ABL inhibitor. Arrays are also provided. | 11-04-2010 |
20100285981 | Devices and methods for biochip multiplexing - The invention is directed to devices that allow for simultaneous multiple biochip analysis. In particular, the devices are configured to hold multiple cartridges comprising biochips comprising arrays such as nucleic acid arrays, and allow for high throughput analysis of samples. | 11-11-2010 |
20100285982 | IMMUNOGENIC PEPTIDES OF INFLUENZA VIRUS - Peptides and polypeptides that elicit immunogenic responses in a mammal; especially neutralizing antibodies, against human and avian influenza strains H1N1, H3N2, H5N1 and H7N7 are disclosed Immunogenic compositions including these peptides, and polypeptides are also provided. Compositions including these peptides and polypeptides with or without adjuvants are disclosed. Nucleic acids and expression cassettes encoding these peptides and polypeptides are also disclosed. Methods of inhibiting infection by influenza, with or without cell entry, are also disclosed using these peptides and polypeptides. | 11-11-2010 |
20100285983 | OPTICAL DISCS FOR ANALYZING BIOMOLECULES - The present invention describes optical discs on which polymer molecules can be analyzed. There is a method for determining a plurality of characteristics of a target molecule, the target molecule being localized on an optical substrate comprising pits and lands, comprising the steps of:
| 11-11-2010 |
20100285984 | ASSESSING T CELL REPERTOIRES - This document provides methods and materials related to assessing T cell repertoires. For example, amplification methods and materials that can be used to assess the diversity of a mammal's T cell repertoire are provided. | 11-11-2010 |
20100285985 | Methods and Systems for the Generation of Plurality of Security Markers and the Detection Therof - This invention pertains to methods for generating large quantities of DNA security markers by combinatorial variation techniques using polymorphic fragment length DNA for unique identification security marker applications such as explosive ink used in dye/smoke pack and cash carrying boxes. | 11-11-2010 |
20100285986 | SINGLE-STEP MULTIPLEX IMMUNOASSAY - The present invention relates to a system and a method for the immunological detection of several substances or a substance having several features in one step, the detection reaction being based on an immunological sandwich type method and being in particular characterized in that it can easily be carry out and is designed as a “one-pot method”, which means that all detection steps are carried out in one reaction batch without any wash steps and with only one addition of reagents. | 11-11-2010 |
20100285987 | PEPTIDE NUCLEIC ACID PROBES FOR DETECTION, IDENTIFICATION AND/OR QUANTITATION OF PSEUDOMONAS (SENSU STRICTO) - Disclosed is a PNA probe that includes a nucleobase sequence suitable for the detection, identification and/or quantitation of | 11-11-2010 |
20100285988 | Gamma-Secretase Substrates And Methods Of Use - Polypeptide substrates based on modifications or fragments of the various APP isoforms, assay methods based on the use of these substrates, and screening methods directed toward identifying inhibitors of γ-secretase activity. The assay methods and the screening methods are adapted for use in high throughput multi-well plate assay apparatuses. In many embodiments the substrate polypeptides are labeled for ease of detection, and/or may bind specific ligands that themselves are labeled. Generally the labels promote high specificity as well as high sensitivity of detection. These features render the assay and screening methods that employ the labeled substrates especially suited for use in high throughput assay formats. This disclosure further identifies small polypeptides based on a subsequence motif of Aβ that are shown herein to be potent inhibitors of the activity of γ-secretase. | 11-11-2010 |
20100285989 | DETECTION OF ANALTYES USING METAL NANOPARTICLE PROBES AND DYNAMIC LIGHT SCATTERING - Disclosed herein are systems and methods for detecting Chemical Species, Biomolecules and Biotargets (Analytes) using receptor functionalized metal nanoparticles and Dynamic Light Scattering. | 11-11-2010 |
20100292089 | SELECTION OF HUMAN MONOCLONAL ANTIBODIES BY MAMMALIAN CELL DISPLAY - The application provides a method of isolating a eukaryotic cell expressing an antibody of desired specificity, preferably a monoclonal single chain antibody (scFv). The application further provides methods which allow to clone the variable regions of said antibody from that isolated eukaryotic cell and to recombinantly produce antibodies comprising said variable regions as fusion protein with a purification tag, eg. as Fc-fusion, as a Fab fragment, or as whole antibodies, such as IgG, IgE, IgD, IgA and IgM. Said methods also allows to recombinantly produce antibodies with desired specificity in a fully species specific form, preferably as fully human antibodies. | 11-18-2010 |
20100292090 | PROGNOSTIC MARKERS AND THERAPEUTIC TARGETS FOR LUNG CANCER - The present invention provides a diagnostic marker to detecting lung cancer. In particular, the present invention provides lung cancer marker genes i.e. KIF4A, MAPJD, NPTX, or FGFR1OP. The present invention further provides methods and kit for identifying compounds for treating lung cancer as well as methods for predicting a prognosis or diagnosis of lung cancer. In particular, the present invention provides methods and kits for identifying inhibitors of the interaction between KIF4A/ZNF549, KIF4A/ZNF553, MAPJD/MYC, or FGFR1OP/WRNIP1 which find utility in the treatment and prevention of lung. Alternatively, the present invention provides MAPJD associated with HAT complex as therapeutic target. | 11-18-2010 |
20100292091 | MARA FAMILY HELIX-TURN-HELIX DOMAINS AND THEIR METHODS OF USE - An important advance in the battle against drug resistance by elucidating the domains of MarA which are critical in mediating its function. Accordingly, MarA family protein helix-turn-helix domains, mutant MarA family protein helix-turn-helix domains and methods of their use, for example, in screening assays to identify compounds which are useful as antiinfective agents and in screening assays to identify loci which are involved in mediating antibiotic resistance are described. | 11-18-2010 |
20100292092 | ANTIBODY FORMULATIONS - This invention relates to a method for high throughput protein formulations. | 11-18-2010 |
20100292093 | BREAST CANCER PROFILES AND METHODS OF USE THEREOF - This invention relates to the identification and use of gene expression profiles, patterns, suitable for the identification of breast cancer patient populations with an inherited predisposition to breast and ovarian cancer. The gene expression patterns may be embodied in nucleic acid expression, protein expression, or other expression formats and may be used in the study and/or determination of optimal treatment, cancer prevention, patient and family identification, and other uses. The invention also pertains to the identification of patients with sporadic breast cancer, where a similar biology to that of hereditary breast cancer is caused by alternative mechanisms such as epigenetic modification of BRCA1 or somatic mutation of other genes. | 11-18-2010 |
20100292094 | METHOD OF DIAGNOSING NEOPLASMS - The present invention relates generally to nucleic acid molecules, the RNA and protein expression profiles of which are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules, the expression profiles of which are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or an adenocarcinoma. The expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening a subject for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in the expression profile of one or more nucleic acid molecule markers. | 11-18-2010 |
20100292095 | HUMAN MONOCLONAL ANTIBODIES DIRECTED TO SIALYL LEWIS C, SIALYL TN AND N GLYCOLYLNEURAMINIC ACID EPITOPES AND A METHOD OF ANALYSIS OF STEM CELLS COMPRISING SAID EPITOPES - This invention relates to antibody engineering technology. More particularly, the present invention relates to human IgM antibodies and derivatives thereof, which have novel binding specificity with regard to several oligosaccharide sequences and/or xenoantigenic sialic acid residue. The present invention also relates to processes for making and engineering such novel saccharide and/or NeuGc-binding monoclonal antibodies and to methods for using these antibodies and derivatives thereof in the field of immunodiagnostics, enabling qualitative and quantitative determination of xenoantigenic NeuGc in biological and raw material samples, as well as in immunotherapy, enabling blocking of xenoantigenic NeuGc in patients. | 11-18-2010 |
20100292096 | STRAIN AND SPECIES-SPECIFIC BORRELIA PROTEIN ARRAY - Methods of assessing a sample for the presence of antibodies to certain proteins of | 11-18-2010 |
20100292097 | Complexity Management of Genomic DNA - The presently claimed invention provides for novel methods and kits for reducing the complexity of a nucleic acid sample by providing non-gel based methods for amplification of a subset of the sequences in a sample. In a preferred embodiment, amplification of a subset can be accomplished by digesting a sample with two or more restriction enzymes and ligating adaptors to the fragments so that only a subset of the fragments can be amplified. The invention further provides for analysis of the above amplified sample by hybridization to an array, which may be specifically designed to interrogate the desired fragments for particular characteristics, such as, for example, the presence or absence of a polymorphism. | 11-18-2010 |
20100292098 | PROCESS FOR DETERMINING ONE OR MORE ANALYTES IN SAMPLES OF BIOLOGICAL ORIGIN HAVING COMPLEX COMPOSITION, AND USE THEREOF - The present invention relates to a process for detecting one or more analytes in one or more samples of biological origin having complex composition. The present invention also relates to a microarray for quantitative determination of one or more analytes in samples of biological origin having complex composition which are immobilized in measurement ranges of microarray, and also to a quantitative detection method based thereon. | 11-18-2010 |
20100298155 | Antibodies specific to antigens of bartonella henselae and use of these antigens in immunoassays - Disclosed are antibodies that bind to the antigenic proteins GroES, RpIL, GroEL, SodB, UbiG, the ABC transporter, and an expressed antigenic protein of unknown function (the “BepA” protein) of | 11-25-2010 |
20100298156 | GENE EXPRESSION MARKERS OF TUMOR RESISTANCE TO HER2 INHIBITOR TREATMENT - The present invention concerns markers of resistance of HER2 expressing tumors to treatment with HER2 inhibitors, such as HER2 antibodies, including trastuzumab. | 11-25-2010 |
20100298157 | PHOSPHOPROTEOMIC EVALUATION OF DIABETES AND OBESITY - A subject's likelihood of responding to bariatric surgery can be assessed by measuring the phosphorylation state of certain proteins found in white adipose tissue (WAT). In particular, measuring the phosphorylation state of particular proteins can predict a patient's likelihood of resolving diabetes mellitus following bariatric surgery. In addition, evaluating the phosphorylation state of certain proteins forecasts a patient's capacity to reduce excess body weight and/or waist size following bariatric surgery. Such tests are valuable tools for managing the diseases of diabetes and obesity and determining who would most likely benefit from bariatric surgical procedures such as gastic bypass surgery. | 11-25-2010 |
20100298158 | Compositions, Kits, and Methods for Identification, Assessment, Prevention, and Therapy of Cancer - The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human cancer. A variety of chromosomal regions (MCRs) and markers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the MCRs and/or alterations in the amount, structure, and/or activity of one or more of the markers is correlated with the presence of cancer. | 11-25-2010 |
20100298159 | Diagnostic methods for acute ischemic disease using activated hepcidin as an indicator - An objective of the present invention is to provide methods of testing for acute ischemic diseases using active hepcidin as an indicator, methods for determining the timing to administer an agent for treating the disease, and kits for these methods. | 11-25-2010 |
20100298160 | METHOD AND TOOLS FOR PROGNOSIS OF CANCER IN ER-PATIENTS - A gene or protein set includes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 possibly 100, 105, 110 genes or proteins or the entire set or antibodies (or hypervariable portion thereof) directed against the proteins encoded by these genes. | 11-25-2010 |
20100298161 | BIOMARKERS FOR LIVER INJURY - Fourteen markers not previously known to be associated with liver injury have been identified. Methods to diagnose a subject for liver injury using these markers are described. | 11-25-2010 |
20100298162 | DEVELOPMENT AND USE OF CYSTEINE-LABELED FLUORESCENT PROBES OF UNBOUND ANALYTES - A method for high throughput discovery of proteins fluorescently labeled at a cysteine residue and that undergo a change in fluorescence ratio at 2 wavelengths upon binding an unbound analyte is described. Probes are disclosed which are labeled at a cysteine residue and also probes labeled at both cysteine and lysine with two different fluorophores. These probes are useful for characterization and measurement of hydrophobic species in a fluid sample, particularly characterization and measurement of levels of unbound free fatty acids. A profile of unbound free fatty acids can be determined for an individual which can be used to determine the individual's relative risk for disease. | 11-25-2010 |
20100298163 | MICROFLUIDIC MICROARRAY SYSTEM AND METHOD FOR THE MULTIPLEXED ANALYSIS OF BIOMOLECULES - A microfluidic system for fluid transfer to a microarray includes a liquid transfer needle having a fluid conduit therein within which is defined a withholding pressure P | 11-25-2010 |
20100298164 | STRUCTURE-BASED APPROACH TO DESIGN OF INHIBITORS OF PROTEIN-PROCESSIVITY FACTOR INTERACTIONS - A method for the structure-based identification and selection of inhibitors of processivity factor binding to protein is disclosed herein. Characterization of the protein/processivity factor interface is given. Methods for the structure-based inhibition of processivity factor binding to protein are also given. One embodiment includes a class of peptidomimetics that mimic helical portions of proteins. In addition, methods of treatment of various diseases are given, using the inhibitors of the invention. | 11-25-2010 |
20100298165 | BIOARRAY CHIP REACTION APPARATUS AND ITS MANUFACTURE | 11-25-2010 |
20100304985 | METHODS AND COMPOSITIONS FOR DETERMINING WHETHER A SUBJECT CARRIES A DISEASE ASSOCIATED GENE MUTATION COMMON IN JEWISH POPULATIONS - Methods are provided for determining whether a subject carries a disease associated gene mutation common in Jewish populations. In practicing the subject methods, an array comprising a plurality of associated gene mutation probes is contacted with a nucleic acid sample from the subject, and the presence of any resultant surface bound target nucleic acids is detected to determine whether the subject carries an disease associated gene mutation common in Jewish populations. In addition, reagents and kits thereof that find use in practicing the subject methods are provided. | 12-02-2010 |
20100304986 | MECHANICALLY ACTUATED DIAGNOSTIC DEVICE - Disclosed are mechanically-actuated devices for transporting fluids within a microfluidic circuit and performing diagnostic operations on a sample. Also disclosed are related methods for performing sample analysis effected by the motion of an actuator proximate to a microfluidic system. | 12-02-2010 |
20100304987 | METHODS AND KITS FOR DIAGNOSIS AND/OR PROGNOSIS OF THE TOLERANT STATE IN LIVER TRANSPLANTATION - The long-term survival of transplanted grafts critically depends on the life-long administration of immunosuppressive drugs to prevent graft rejection. These drugs are very effective at preventing graft rejection, but they are also associated with severe side effects. Inventors have selected a set of genes whose expression characterizes the tolerant state in liver transplantation in humans. Based on the expression level profile of this set of genes, inventors provide a non-invasive method to assess diagnosis and/or prognosis of the tolerant state in liver transplantation in humans, and kits to perform it. These kits are simpler and cheaper than others based on a great number of genes, such as commercial microarrays with thousands of probes. | 12-02-2010 |
20100304988 | DIAGNOSTIC OF IMMUNE GRAFT TOLERANCE - The present invention concerns a method for the in vitro diagnosis of a graft tolerant phenotype, comprising: determining from a grafted subject biological sample an expression profile comprising, or consisting of, 8 genes, and optionally at least one among 41 further genes, identified in the present invention as differentially expressed between graft tolerant subjects and subjects in chronic rejection, optionally measuring other parameters, and determining the presence or absence of a graft tolerant phenotype from said expression profile and optional other parameters. Said method may further comprise, if said subject is diagnosed as a graft non-tolerant subject, diagnosing from the expression profile if said subject is developing chronic rejection. The invention further concerns kits and oligonucleotide microarrays suitable to implement said method. | 12-02-2010 |
20100304989 | Molecular profiling of tumors - Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease. | 12-02-2010 |
20100304990 | RULER ARRAYS - The invention in some aspects relates to methods for measuring distances between locations in a nucleic acid. The invention relates to methods of genetic analysis useful for detecting genomic alterations. In some aspects, the invention relates to methods for detecting genomic insertions, deletions, and inversions. | 12-02-2010 |
20100304991 | METHOD OF SELECTING APTAMERS - The present invention is a method for the identification of one or more aptamers to at least one target molecule, the method comprising: selecting candidate aptamer sequences that bind to a target molecule, assigning to the bound sequences a measure (fitness function) of each sequence's aptameric potential, allowing evolution of some or all of the sequences to create a new mixture of candidate sequences, and repeating the method with the newly created candidate aptamer pool until the aggregate aptameric potential of the candidate pool reaches a plateau, wherein sequences present in the final pool are optimal aptamers to the target molecule. | 12-02-2010 |
20100304992 | DIAGNOSIS KIT AND CHIP FOR BLADDER CANCER USING BLADDER CANCER SPECIFIC METHYLATION MARKER GENE - The present invention relates to a kit and nucleic acid chip for diagnosing bladder cancer using a bladder cancer-specific marker gene. More particularly, the invention relates to a kit and nucleic acid chip for diagnosing bladder cancer, which can detect the promoter methylation of a bladder cancer-specific gene, the promoter or exon region of which is methylated specifically in transformed cells of bladder cancer. The use of the diagnostic kit or nucleic acid chip of the invention enables diagnosis of bladder cancer at an early stage of transformation, thus enabling early diagnosis of bladder cancer, and can diagnose bladder cancer in a more accurate and rapid manner compared to a conventional method. | 12-02-2010 |
20100304993 | BIOMARKERS FOR THE DETECTION OF EARLY STAGE OVARIAN CANCER - The present invention provides methods and compositions for detecting early stage ovarian cancer in a patient. Also, methods for evaluating the ovarian cancer state of a patient are described herein. These methods involve the detection, analysis, and classification of biomarkers in biological samples. | 12-02-2010 |
20100304994 | Oligonucleotide Paints - Novel methods for making high resolution oligonucleotide paints are provided. Novel, high resolution oligonucleotide paints are also provided. | 12-02-2010 |
20100304995 | Arrays and Methods for Reverse Genetic Functional Analysis - Provided are methods, kits and arrays for carrying out relative measurement of an analyte of interest in a biological sample. As specifically exemplified, there is an array of stabilized, desiccated cDNA preparations, each at a defined location within the array, where those cDNAs were prepared from cells treated with a particular condition believed to modulate at least one gene of interest. Detection can be via Real Time Polymerase Chain Reaction using an appropriate reaction mixture and primers specific for a coding sequence of interest, and a greater relative amount of a RT PCR product from a control preparation reflects greater gene expression in response to the test condition whereas a lower amount of RT PCR product reflects an inhibitory effect on expression of the coding sequence of interest as a result of the application of the test condition. | 12-02-2010 |
20100304996 | B CELL SIGNATURE ASSOCIATED WITH TOLERANCE IN TRANSPLANT RECIPIENTS - The present invention provides methods for predicting the development of tolerance to a transplant, such as a kidney, using molecular markers that have different expression patterns in tolerant transplant recipients, as compared to non-tolerant or healthy, non-recipient controls. | 12-02-2010 |
20100304997 | METHOD FOR DETECTING ABNORMAL SPOTS OF NUCLEIC ACID MICROARRAY - A method carries out a nucleic acid analysis using a nucleic acid microarray. A probe nucleic acid including a probe sequence (a′) complementary to a target sequence (a) and a sequence (b′) which is different from the probe sequence (a′) is immobilized on the nucleic acid microarray. The method includes hybridizing the nucleic acid microarray and a labeled abnormality detecting nucleic acid (B) containing a sequence (b) which can be bound to the sequence (b′), obtaining a labeled amount value (Fc1) of the labeled abnormality detecting nucleic acid (B) from a spot (X1), and determining, based on the measured labeled amount value (Fc1), as to whether or not the spot (X1) is an abnormal spot unsuitable for detecting the target nucleic acid. | 12-02-2010 |
20100304998 | Chemical Proteomic Assay for Optimizing Drug Binding to Target Proteins - Disclosed herein are methods related to drug development. The methods typically include steps whereby an existing drug is modified to obtain a derivative form or whereby an analog of an existing drug is identified in order to obtain a new therapeutic agent that preferably has a higher efficacy and fewer side effects than the existing drug. | 12-02-2010 |
20100304999 | SYSTEM AND METHOD FOR ANTIGEN STRUCTURE-INDEPENDENT DETECTION OF ANTIGENS CAPTURED ON ANTIBODY ARRAYS - The present invention provides a system and method for detecting antigens captured on an antibody array. The method comprises the following steps of providing the antibody array having at least two antibodies, contacting the antibody array with a sample containing at least one antigen that may be captured by the antibodies disposed on the antibody array, and detecting the at least one antigen captured by the antibody array with a detecting agent that specifically binds to the antigen-bound antibodies on the antibody array, thereby the at least one antigen captured by the antibody array can be detected independent of the structures of the antigens. In a preferred embodiment, C1q is used as the detecting agent to detect antigen-bound antibodies. | 12-02-2010 |
20100305000 | METHOD AND USE OF MICROARRAY TECHNOLOGY AND PROTEOGENOMIC ANALYSIS TO PREDICT EFFICACY OF HUMAN AND XENOGRAPHIC CELL, TISSUE AND ORGAN TRANSPLANT - The present invention is directed to systems and proteogenomic methods for predicting the success of the transplant of a cell, tissue, or organ by providing a means to determine the quality of the cell, tissue, or organ to be transplanted. In one embodiment, the present invention uses samples from the preservation solution to obtain phenomic fingerprints correlated with transplant pre-operative and post-operative data as a pre-operative tissue diagnostic and procedural success predictive indicator. | 12-02-2010 |
20100311602 | Sequencing method - The present invention relates, e.g., to a method for isolating a DNA molecule of interest in a form suitable for sequencing at least a portion of the DNA by a high throughput sequencing method, comprising (a) digesting a double-stranded (ds) DNA molecule with two different restriction enzymes, A and B, to generate a ds form of the DNA molecule of interest, which is bounded by the two restriction enzyme cleavage products, and (b) attaching to each end of the DNA molecule of interest an adaptor molecule which comprises at one end a restriction enzyme cleavage site that is compatible with the restriction enzyme A or the restriction enzyme B cleavage product, and which also comprises a sequence and/or element that allows the DNA of interest to be sequenced with a high throughput sequencing apparatus. The method can be adapted for sequencing DNA with a variety of high throughput sequencing apparatuses, including machines manufactured by the 454, Illumina (Solexa Sequencing technology) and ABI (SOLiD™ Sequencing technology) companies. A method is also described for sequencing regulatory elements within a cell, comprising subjecting a collection of ds DNA molecules that are enriched for regulatory elements and that are generated by digestion with two restriction enzymes, A and B, which generate sticky ends, to an isolation method of the invention, and sequencing the collection of ds DNA molecules with a high throughput sequencing apparatus. | 12-09-2010 |
20100311605 | SENSING PLATFORM - A sensing platform includes: a plurality of metal nanoparticles; a plurality of aggregate inducers each comprising first and second functional groups different from each other, and the first functional group of the aggregate inducers being in contact with the metal nanoparticles; and a plurality of recognition molecules for binding the metal nanoparticles and for interacting with a target to recognize the target, wherein the second functional group of the aggregate inducers is free from being in contact with the metal nanoparticles, and is used to induce the metal nanoparticles to aggregate after the recognition molecules interact with the target. | 12-09-2010 |
20100311606 | PHARMACOGENOMIC CELL LINE PANEL AND USE THEREOF - Materials and methods for evaluating cellular response to therapeutic agents. | 12-09-2010 |
20100311607 | METHOD FOR RAPID IDENTIFICATION OF MICROORGANISMS - The present invention relates, in general, to probes, methods, and kits used to determine the presence or absence of a microorganism in a sample. The probes, methods, and kits comprise at least one capture probe and/or at least one detector probe. | 12-09-2010 |
20100311608 | METHOD TO PREPARE MAGNETIC BEADS CONJUGATED WITH SMALL COMPOUNDS - It is an object of the present invention to provide a method for stably and efficiently binding a compound to magnetic beads. The present invention relates to a method for producing compound-bound magnetic beads, which comprises: allowing a compound to come into contact with magnetic beads, on the surface of each of which a photoreactive compound has bound; extending the magnetic beads together with the compound on a support; and applying light to the magnetic beads to form a covalent bond between the photoreactive compound and the compound. | 12-09-2010 |
20100317538 | MICROANALYSIS MEASURING APPARATUS AND MICROANALYSIS MEASURING METHOD USING THE SAME - This invention provides a measuring apparatus for microanalysis, which can be simply manufactured and can realize a number of analyses and measurements in a small analyte amount and particularly can analyze and measure a number of analytes having different concentrations and different analytes in a simultaneous and easy manner, and a measurement method of microanalysis using the apparatus. The measuring apparatus for microanalysis is characterized by comprising detection parts of m lines and n rows in communication with a micropassage for a waste solution, chambers of m lines and n rows in communication with the respective detection parts through a mixing flow passage, n first micropassages in communication with the respective line chambers through a passive valve, m second micropassages in communication with respective row chambers through a passive valve, and third micropassages in communication with the respective chambers for supplying gas and/or a washing solution. | 12-16-2010 |
20100317539 | Library of Engineered-Antibody Producing Cells - A method for producing a library of engineered-antibody producing cells is provided. In certain cases, the method includes isolating nucleic acid sequences encoding IgH variable regions and IgL variable regions from a plurality of antibody producing cells, and introducing the nucleic acids into host cells to obtain cells that produce antibodies comprising non-naturally paired IgH and IgL variable chains. | 12-16-2010 |
20100317540 | METHODS FOR PRODUCING MEMBERS OF SPECIFIC BINDING PAIRS - A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA. Using this method libraries of DNA encoding respective chains of such multimeric sbp members may be combined, thereby obtaining a much greater genetic diversity in the sbp members than could easily be obtained by conventional methods. | 12-16-2010 |
20100317541 | Method of Determining the Probability of a Therapeutic Response in Cancer Chemotherapy With Cardiac Glycoside - A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the α subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside. | 12-16-2010 |
20100317542 | Methods For Detecting Biomarkers - Methods of amplifying nucleic acid on a solid support are described. Beads and template, each in known concentrations, are employed so a range of template to bead ratios can be exploited. Where the beads contain primers, the template can be amplified. After amplification, non-covalently bound template is removed, so as to leave beads with extended primers (or beads with primers that were not extended). | 12-16-2010 |
20100317543 | METHINE-SUBSTITUTED CYANINE DYE COMPOUNDS - Cyanine dye compounds having a substituted methine moiety that are nucleic acid stains, particularly for fluorescent staining of RNA, including compounds having the formula | 12-16-2010 |
20100323904 | Transcription chip - A transcription chip comprising a substrate and, immobilized thereon, at least one polynucleotide including an element sequence to which a transcription factor can be bound. | 12-23-2010 |
20100323905 | Vhh for the Diagnosis, Prevention and Treatment of Diseases Associated with Protein Aggregates - The present invention provides heavy chain variable domain antibodies (VHH) for preventing and/or dissolving aggregates. VHH of the invention are preferably used in the treatment of human diseases that are associated with the formation of aggregates in the body. The invention further provides, among others, means and methods for selecting and using VHH. | 12-23-2010 |
20100323906 | NANOPLASMONIC MOLECULAR RULER FOR NUCLEASE ACTIVITY AND DNA FOOTPRINTING - This invention provides a nanoplasmonic molecular ruler, which can perform label-free and real-time monitoring of nucleic acid (e.g., DNA) length changes and perform nucleic acid footprinting. In various embodiments the ruler comprises a nucleic acid attached to a nanoparticle, such that changes in the nucleic acid length are detectable using surface plasmon resonance. The nanoplamonic ruler provides a fast and convenient platform for mapping nucleic acid -protein interactions, for nuclease activity monitoring, and for other footprinting related methods. | 12-23-2010 |
20100323907 | FROZEN CELL AND TISSUE MICROARRAYS - The invention is directed to a new composition for making a housing block for cryosectioning comprising agarose and optimal cutting temperature medium. The invention is further directed to new methods for making a frozen section microarray of fresh non-fixed frozen cell or tissue samples that undergo only one freeze-thaw cycle before being used in a biological assay. | 12-23-2010 |
20100323908 | Methods and Compositions For Diagnosing Osteoarthritis In A Feline - Methods, compositions and kits for diagnosing osteoarthritis in a feline are disclosed. The methods of the invention comprise detecting differential expression of at least one biomarker in a body sample. preferably a blood sample, where the biomarker is differentially expressed in osteoarthritis. | 12-23-2010 |
20100323909 | DIAGNOSTIC ASSAY FOR TRYPANOSOMA CRUZI INFECTION - A sensitive, multicomponent diagnostic test for infection with | 12-23-2010 |
20100323910 | DNA Microarray for Quantitative Detection of Microbial Processes in the Oilfield - A DNA microarray having correctly designed target nucleotide sequences bound thereto generates a quantifiable signal when the microarray hybridizes a field sample nucleotide sequence that indicates a microbial process in a field sample from an oilfield, for instance from downhole. Such DNA microarrays may be designed and manufactured to detect microbial production of hydrogen sulfide, organic acids, surfactants, and gases as well as thermophilic bacterial activity. The field sample nucleotide sequences may be tagged with a fluorescent molecular label, so that the DNA microarrays may generate signals, such as fluorescent signals that may be measured and quantified to provide a more accurate way to correlate bacterial processes in the oilfield than presently available methods. | 12-23-2010 |
20100323911 | DETECTION OF WORSENING RENAL DISEASE IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS - Methods for the detection of active lupus nephritis (LN) and worsening renal disease activity and/or active LN in patients diagnosed with systemic lupus erythematosus, using a panel of biomarkers including transferrin (Tf), ceruloplasmin (Cp), alpha-1-acid glycoprotein (AGP1), lipocalin-like prostaglandin D synthetase (L-PGDS), and urinary neutrophil gelatinase associated lipocalin (UNGAL). | 12-23-2010 |
20100323912 | REAL-TIME ANALYTICAL METHODS AND SYSTEMS - The present invention is generally directed to compositions, methods, and systems for performing single-molecule, real-time analysis of a variety of different biological reactions, and for determining various characteristics of the different biological reactions. The ability to analyze such reactions provides an opportunity to study those reactions as well as to potentially identify factors and/or approaches for impacting such reactions, e.g., to stimulate, enhance, or inhibit such reactions. | 12-23-2010 |
20100323913 | Purification and Concentration of Proteins and DNA from a Complex Sample Using Isotachophoresis and a Device to Perform the Purification - A method of simultaneously co-purifying and concentrating nucleic acid and protein targets is described. The method includes automation of the entire sample preparation process, performed by having an analyst add a sample into a device that performs all of the steps necessary to prepare a sample for analysis. The method provides for samples that are not split during the sample preparation process and where common purification methods can be used for purifying multiple analytes. | 12-23-2010 |
20100323914 | Enzymatic Methods for Genotyping on Arrays - Disclosed are methods for enzymatic genotyping of polymorphisms on solid supports. In one aspect the method includes hydrolysis of a nucleotide comprising a label on an array-bound probe by a 5′ to 3′ exonuclease activity specific for single-stranded DNA. If there is target-probe sequence mismatch at the polymorphic position (the labeled nucleotide in the probe), the labeled nucleotide is hydrolyzed from the probe by the exonuclease. The presence of a detectable signal on the array is indicative of the identity of the nucleotide at the polymorphic position in the target. In another aspect, the queried position on the probe may be a labeled ribonucleotide, and if there is a sequence mismatch at the polymorphic position on the probe, the labeled ribonucleotide will be hydrolyzed from the nucleic acid by the activity of an exoribonuclease enzyme specific for single-stranded sequences. | 12-23-2010 |
20100323915 | Porous Substrate Plates And The Use Thereof - A substrate plate or device adapted for use with biological or chemical assays is disclosed. The device may take the form of a multi-well plate having a three-dimensional, porous layer as part of a support surface within each well for immobilizing probe species. The porous layer is characterized as having a plurality of interconnected voids defined by a matrix of contiguous solid material. A method and its variants are also described. | 12-23-2010 |
20100331198 | Photo-generated carbohydrate arrays and the rapid identification of pathogen-specific antigens and antibodies - The invention relates to novel photo-generated carbohydrate arrays and methods of their use to detect the presence of one or more agents in a sample. The invention also relates to a high-throughput strategy to facilitate the identification and immunological characterization of pathogen-specific carbohydrates, including those of | 12-30-2010 |
20100331199 | METHOD FOR THE DETECTION AND/OR ENRICHMENT OF ANALYTE PROTEINS AND/OR ANALYTE PEPTIDES FROM A COMPLEX PROTEIN MIXTURE - The present invention relates to a method for the detection and/or enrichment of a large number of different analyte proteins and/or analyte peptides from a sample mixture which includes proteins and/or peptides. The method includes the following steps: a) provision of the sample mixture and, where appropriate, fragmentation of the proteins contained therein into defined peptides, b) provision of first binding molecules which are specific for a peptide epitope of at least one of the various analyte proteins and/or analyte peptides, whereby the peptide epitope includes up to a maximum of five, preferably two to three, amino acids, c) incubation of the first binding molecules with the sample mixture, and d) detection and/or enrichment of the analyte proteins and/or analyte peptides bound to the first binding molecules. The invention also relates to binding molecules which are specific for the terminal peptide epitope of various peptide analytes, whereby the terminal peptide epitope includes the free NH | 12-30-2010 |
20100331200 | POST TRANSLATIONAL MODIFICATION PATTERN ANALYSIS - This invention relates to methods and apparatus for detecting the pattern of post translational modification in a protein or in a plurality of proteins in a sample. One or more target proteins are subjected to predetermined proteolysis to yield plural peptide fragments comprising potential post translational modification sites. The fragments and the state of such sites are analyzed to yield a post translational pattern for the protein or proteins. | 12-30-2010 |
20100331201 | PROTEIN BIOCHIP FOR THE DIFFERENTIAL SCREENING OF PROTEIN-PROTEIN INTERACTIONS - The present invention relates to a system of protein binders containing at least one protein binder presented in at least one native form and at least one non-native form and its use including a method for discrimination and/or differential screening of suitable protein binders in native and non-native form. | 12-30-2010 |
20100331202 | NANOTUBE STRUCTURES HAVING A SURFACTANT BILAYER INNER WALL COATING - Nanotubes and nanotube array structures comprise (a) a nanotube having an inner wall portion; and (b) a bilayer coating formed on the inner wall portions, with the bilayer coating comprised of surfactants. A secondary compound such as a protein, peptide or nucleic acid may be associated with the bilayer coating. The structures are useful for, among other things, affinity purification, catalysis, and as biochips. | 12-30-2010 |
20100331203 | AROMATASE EXPRESSION PREDICTS SURVIVAL IN WOMEN WITH NON-SMALL CELL LUNG CANCER - The present invention relates to the discovery that the level of aromatase polypeptide expression in non-small cell lung carcinomas can be used for example to provide information useful in prognostic and therapeutic methodologies in women having or suspected of having this cancer. | 12-30-2010 |
20100331204 | METHODS AND SYSTEMS FOR ENRICHMENT OF TARGET GENOMIC SEQUENCES - The present invention provides methods and systems for targeted nucleic acid sequence enrichment in a sample. In particular, the present invention provides for enriching for targeted nucleic acid sequences during hybridizations in hybridization assays by first depleting non-target nucleic acid sequences. | 12-30-2010 |
20100331205 | Method and Apparatus for the Identification and Handling of Particles - The present invention refers to the optimised selection and isolation, within a respective population, of elements of interest and/or utility for a series of subsequent operations. The invention concerns a method comprising the phases of: a) identifying, for each particle, at least one of a plurality of characteristic parameters; b) selecting the particles of interest, comparing for each of these the at least one parameter with a respective reference parameter. It furthermore comprises the phases of c) storing, for each of said particles, the at least one parameter identified; d) processing the value of a function of said stored parameter, associating the function with a criterion for selection of the particles of interest chosen from a group of possible selection criteria; e) establishing for each particle a threshold criterion to be used as reference parameter. The threshold criterion is established on a time by time basis according to the result of the above processing. | 12-30-2010 |
20100331206 | COMPOSITIONS AND METHODS FOR EARLY PREGNANCY DIAGNOSIS - Pregnancy-associated glycoproteins (PAGs) are structurally related to the pepsins, thought to be restricted to the hoofed (ungulate) mammals and characterized by being expressed specifically in the outer epithelial cell layer (chorion/trophectoderm) of the placenta. By cloning expressed genes from ovine and bovine placental cDNA libraries, the inventors estimate that cattle, sheep, and most probably all ruminant Artiodactyla, possess possibly 100 or more PAG genes, many of which are placentally expressed. The PAGs are highly diverse in sequence, with regions of hypervariability confined largely to surface-exposed loops. Selected PAG that are products of the invasive binucleate cells, expressed highly in early pregnancy at the time of trophoblast invasion and expressed weakly, if at all, in late gestation are useful in the early diagnosis of pregnancy. In a preferred embodiment, the invention relates to immunoassays for detecting these PAGs. | 12-30-2010 |
20100331207 | METHODS OF DETECTING NUCLEIC ACID WITH MICROARRAY AND PROGRAM PRODUCT FOR USE IN MICROARRAY DATA ANALYSIS - The invention provides a method of detecting, with a microarray, a target nucleic acid containing a base sequence to which a nucleic acid-binding protein binds, obtaining a signal from a correction probe not containing any sequence complementary to the base sequence to which the nucleic acid-binding protein binds for being used as a background to correct a signal obtained from a detection probe hybridizing to the target nucleic acid, as well as a computer program product for enabling a computer to detect, with a microarray, a target nucleic acid containing a base sequence to which a nucleic acid-binding protein binds. | 12-30-2010 |
20100331208 | Cell Display Of Antibody Libraries - The present invention relates to a viral vector encoding for a library of antibodies or antibody fragments that are displayed on the cell membrane when expressed in a cell. The present invention provides cells comprising the viral vector nucleic acids and methods of screening the libraries for antibodies or antibody fragments with desired characteristics. | 12-30-2010 |
20100331209 | MARKERS AND METHODS FOR ASSESSING AND TREATING SEVERE OR PERSISTANT ASTHMA AND TNF RELATED DISORDERS - A method for assessment of the suitability of and/or effectiveness of a target therapy for a TNF-mediated-related disorder, such as severe or persistent asthma, in a subject evaluates the presence, absence, and/or magnitude of expression of one or more genes corresponding to contacting the sample with a panel of nucleic acid segments consisting of at least a portion of at least one member from the group consisting of the nucleotide sequences corresponding to at least one of TNFRSF1A SNP rs4149581 (SEQ ID NO:1), TNFRSF1 B SNP rs3766730 (SEQ ID NO:2) or TNFRSFI B SNP rs590977 (SEQ ID NO:3) SNPs which results in a determination that one or more of said SNPs in a sample are in linkage disequilibrium (LD). The method enables identification of the effectiveness of target therapies prior to or after starting a patient on such therapies. | 12-30-2010 |
20110003701 | System and method for improved processing of nucleic acids for production of sequencable libraries - An embodiment of an adaptor element for efficient target processing is described that comprises a semi-complementary double stranded nucleic acid adaptor comprising a non-complementary region and a complementary region, where the non-complementary region comprises a first amplification primer site and a second amplification primer site and the complementary region comprises a sequencing primer site and one or more inosine species. | 01-06-2011 |
20110003702 | Methods, systems, and kits for identification of osteoinductive peptides - Methods and systems for obtaining and identifying ligands that bind to cells and effect differentiation and/or support growth are provided herein. Several ligands were identified as proof of efficacy of the methods and systems, and amino acid sequences of compositions that effect differentiation of osteoblasts are thereby obtained. | 01-06-2011 |
20110003703 | Nucleic Acid Hybridization and Detection Using Enzymatic Reactions on a Microarray - Embodiments are directed to a methods and systems for nucleic acid detection using enzymatic reactions on a microarray. In one embodiment, a probe comprising a probe nucleotide sequence and a substantially homogenous sequence extender portion is provided on the surface of a microarray. The probe nucleotide sequence is hybridized to the complementary target nucleotide sequence. A solution containing enzymes and detection elements is applied to the hybridized probe structure. The enzyme determines the composition of the nucleotide structure of the extender and creates a complementary homogenous sequence extender structure between the target nucleotide sequence and the microarray surface structure. The detection elements in the solution are bound to the extender structure, thus allowing detection using an appropriate detector system. | 01-06-2011 |
20110003704 | USE OF MICROVESICLES IN DIAGNOSIS AND PROGNOSIS OF MEDICAL DISEASES AND CONDITIONS - The presently disclosed subject matter is directed to methods of aiding diagnosis, prognosis, monitoring and evaluation of a disease or other medical condition in a subject by detecting a biomarker in microvesicles isolated from a biological sample from the subject. | 01-06-2011 |
20110003705 | NOVEL METHOD FOR GENERATING AND SCREENING AN ANTIBODY LIBRARY - The invention relates to a method for generating a DNA sequence coding for the heavy chain or the light chain of at least one antibody from RNA from a cell capable of producing an antibody. More particularly, the invention relates to the generation of a monoclonal antibody library. The invention also relates to the use of an antibody library for screening monoclonal antibodies, preferably human antibodies for treating cancer. | 01-06-2011 |
20110003706 | PROLIFERATION MARKERS IN CLINICAL PRACTICE AND THEIR USE FOR BREAST CANCER PROGNOSIS OR DIAGNOSIS - A method for assessing the proliferative state of cells in a human or non-human biological sample uses Chromatin Assembly Factor-1 (CAF-1) subunits as proliferation markers. The method can be used for breast cancer prognosis or diagnosis, and monitoring tumor response in therapy. | 01-06-2011 |
20110003707 | Highly Sensitive Biomarker Panels - Cardiovascular disease, e.g., congestive heart failure, is often first diagnosed after the onset of clinical symptoms, eliminating potential for early intervention. The invention provides a multi-marker immunoassay, including cardiac pathology and vascular inflammation biomarkers, yielding a more sensitive assay for early detection of CHF in plasma. A panel consisting of cardiac pathology (cTnI, BNP) and vascular inflammation (IL-6, TNFα, IL-17a) biomarkers provided a sensitivity of 94% for association with CHF. | 01-06-2011 |
20110003708 | BIOMARKERS FOR THE PREDICTION OF RENAL INJURY - The present invention relates to means and methods for predicting the onset of renal injury based on measuring the expression of polynucleotides and proteins, particularly on measuring the expression of sets of novel as well as known polynucleotides and proteins, and to kits utilizing same. | 01-06-2011 |
20110003709 | REAGENTS AND METHODS FOR USE IN CANCER DIAGNOSIS, CLASSIFICATION AND THERAPY - Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer. | 01-06-2011 |
20110003710 | SELECTIN LIGANDS USEFUL IN THE DIAGNOSIS AND TREATMENT OF CANCER - The present invention provides methods and compositions useful in the diagnosis and treatment of cancer. More specifically, the present invention provides compositions and methods of use comprising a targeting composition comprising a solid substrate, an antibody composition, and optionally a chemotherapeutic agent. | 01-06-2011 |
20110009280 | MULTI-CHAIN EUKARYOTIC DISPLAY VECTORS AND USES THEREOF - A eukaryotic expression vector capable of displaying a multi-chain polypeptide on the surface of a host cell is provided, such that the biological activity of the multi-chain polypeptide is exhibited at the surface of the host cell. Such a vector allows for the display of complex biologically active polypeptides, e.g., biologically active multi-chain polypeptides such as immunoglobulin Fab fragments. The present invention describes and enables the successful display of a multi-chain polypeptide on the surface of a eukaryotic host cell. Preferred vectors are described for expressing the chains of a multi-chain polypeptide in a host cell separately and independently (e.g., under separate vector control elements, and/or on separate expression vectors, thus forming a matched vector set). The use of such matched vector sets provides flexibility and versatility in the generation of eukaryotic display libraries, for example the ability to generate and to display multi-chain polypeptides by combining and recombining vectors that express variegations of the individual chains of a multi-chain polypeptide. Entire repertoires of novel chain combinations can be devised using such vector sets. | 01-13-2011 |
20110009281 | METHODS FOR CREATING AND IDENTIFYING FUNCTIONAL RNA INTERFERENCE ELEMENTS - The invention relates to the control of gene expression. Specifically, the invention provides compositions and methods for the production and use of recombinant nucleic acid molecules that have the ability to specifically downregulate an expressed target gene in vivo. In some aspects, the invention provides methods for producing a hairpin DNA molecule where part of the molecule is derived from an mRNA that is a target for a small interfering RNA (siRNA) derived from the hairpin. In other aspects, the invention provides synthetic hairpin adapter oligonucleotides that are used in the construction of siRNA-producing cassettes. In other aspects, the invention provides methods for testing for the presence or absence of specific inhibitory activity of an RNAi trigger molecule, and in still other aspects, the invention provides methods for identifying an active RNAi trigger molecule from a library of RNAi trigger molecules. In still other aspects, the invention provides methods for identifying a polynucleotide from a plurality of candidate target polynucleotides that is specifically targeted by an RNAi trigger molecule. In other aspects, the invention provides epi-allelic series of hypomorphic RNAi trigger molecules specific for any gene of interest, where the series of RNAi trigger molecules have a variety of uses including analysis of gene function and drug target development. | 01-13-2011 |
20110009282 | HIGH THROUGHPUT SCREENING METHOD AND APPARATUS FOR ANALYSING INTERACTIONS BETWEEN SURFACES WITH DIFFERENT TOPOGRAPHY AND THE ENVIRONMENT - The invention is directed to a high throughput screening method for analyzing and interaction between a surface of a material and an environment. The screening method of the invention comprises: providing a micro-array comprising said material and having a multitude of units at least part of which have different topography; contacting at least part of said multitude of units with said environment; and screening said micro-array for an interaction between one or more of said units and said environment. | 01-13-2011 |
20110009283 | IDENTIFICATION OF TOXIN LIGANDS - The disclosure relates to a method and system of screening for ligands which specifically bind to receptors. The method comprises expressing at least one receptor. The at least one receptor is contacted with a sample comprising at least one ligand. Whether the ligand selectively binds to the receptor is determined. | 01-13-2011 |
20110009284 | GENE RELATING TO ESTIMATION OF POSTOPERATIVE PROGNOSIS FOR BREAST CANCER - It is intended to provide a system of predicting the postoperative prognosis in a patient with breast cancer from the viewpoint of gene expression based on the data obtained by genome-wide and comprehensive analysis on gene expression in breast cancer. Expression of human genes is comprehensively analyzed by using a DNA microarray and gene expression functions in various breast cancer conditions are compared, thereby establishing a system of predicting the postoperative prognosis of breast cancer. | 01-13-2011 |
20110009285 | METHOD OF DIAGNOSING A PROGRESSIVE DISEASE - A method of determining the risk of progressive renal disease in a patient, by measuring a parameter related to a marker selected from the group of IL1RN, ISG15, LIFR, C6, IL32 and any combination thereof, in a sample of said patient. | 01-13-2011 |
20110009286 | MOLECULAR IN VITRO DIAGNOSIS OF BREAST CANCER - The invention relates to the use of a multiplicity of polynucleotide probe sets, the multiplicity of polynucleotide probe sets consisting in a combination of pools of polynucleotide probe sets, each polynucleotide probe set containing at least one polynucleotide probe chosen among a library of nucleic acid sequences, the polynucleotide probes involved in the combination of pools of polynucleotide probe sets of the multiplicity of polynucleotide probe sets being such that each polynucleotide probe specifically hybridizes with one gene, and/or at least one of its variants when present, for determining the variation of expression at least 12 genes, and their variants when present, in order to diagnose the benign or malignant state of a breast tumor. | 01-13-2011 |
20110009287 | PURIFICATION OF MONOCLONAL ANTIBODIES - Methods and compositions for efficiently purifying monoclonal antibodies and identifying pairs of antibodies compatible in sandwich immunoassays are provided. | 01-13-2011 |
20110009288 | METHODS AND REAGENTS FOR THE EARLY DETECTION OF MELANOMA - An assay for identifying early stage malignant melanocyte in biopsy tissues is provided by determining whether differential expression of a particular gene indicative of melanoma exceed a cut-off value. | 01-13-2011 |
20110009289 | METHODS OF USING AN ARRAY OF POOLED PROBES IN GENETIC ANALYSIS - The invention provides arrays of polynucleotide probes having at least one pooled position. A typical array comprises a support having at least three discrete regions. A first region bears a pool of polynucleotide probes comprising first and second probes. A second region bears the first probe without the second probe and a third region bears the second probe without the first probe. A target nucleic acid having segments complementary to both the first and second probes shows stronger normalized binding to the first region than to the aggregate of binding to the second and third regions due to cooperative binding of pooled probes in the first region. The invention provides methods of using such arrays for e.g., linkage analysis, sequence analysis, and expression monitoring. | 01-13-2011 |
20110015084 | Methods for Identifying Genetic Linkage - The present invention provides a high-throughput system for determining linkage of distinct polynucleotides and determining the sequence of polynucleotides that are linked to the distinct polynucleotides. The methods are particularly useful for analyzing transgenes in a transformed host organism. The disclosed methods provide for the detection of linkage between distinct transgenic polynucleotides in transformed hosts and sequencing of DNA regions linked to the distinct transgenic polynucleotides. Methods for identifying a transgenic plant containing a transgene insertion in an undesirable genomic location are also disclosed. | 01-20-2011 |
20110015085 | Repetitive Sequence-Free DNA Libraries - A method of creating a repetitive sequence-free DNA library comprising the steps of providing a DNA library, providing an amplification mixture from the DNA library, and adding a repetitive sequence fraction DNA to the amplification mixture to produce the repetitive sequence-free DNA library. The invention also provides a method of creating a whole chromosome painting probe comprising the steps of providing a DNA library, providing an amplification mixture from the DNA library, adding a repetitive sequence fraction DNA to the amplification mixture to produce the repetitive sequence-free DNA library, and labeling the repetitive sequence-free DNA library to produce the whole chromosome painting probe. The invention also provides a method of in-situ hybridization comprising the steps of providing a DNA library, providing an amplification mixture from the DNA library, adding a repetitive sequence fraction DNA to the amplification mixture to produce the repetitive sequence-free DNA library, labeling the repetitive sequence-free DNA library to produce the whole chromosome painting probe, and using the painting probe in in-situ hybridization. | 01-20-2011 |
20110015086 | PROGRAMMABLE OLIGONUCLEOTME MICRO ARRAY - A programmable probe design of DNA micro array and detection methodology is provided. DNA probes, which are complemented with the target DNA, are designed and classified into groups according to optimum hybridization temperature. The probes are arrayed by the group and immobilized on the substrate surface of the DNA micro array. The control system, imaging system and temperature control system are programmed to cooperate with each other during the detection process. This design increases the detection capabilities of the parallel-analysis system. | 01-20-2011 |
20110015087 | DETECTION OF ENDOMETRIAL SECRETION MARKERS FOR ASSESSMENT OF ENDOMETRIOSIS - The present invention refers to a group of biomarkers and to non-invasive in vitro methods for the diagnosis or prognosis of endometriosis, as well as to a kit to perform said methods. | 01-20-2011 |
20110015088 | BIOCATALYTIC SOLGEL MICROARRAYS - A system and method for conducting high-throughput interactions between test compositions and analytes, comprising one or more test compositions, and a plurality of independent micromatrices, wherein each said micromatrix encapsulates at least one said test composition; and said micromatrices are made of a material that is permeable to an analyte. | 01-20-2011 |
20110015089 | Methods and apparatus for the detection and differentiation of non-sialated proteins from sialated proteins in a fluid sample - The present invention is directed to methods and devices for detection of cerebrospinal fluid leaks by detection of the CSF protein beta-2 transferrin. The microfluidic devices and methods of the invention combine capture and specific labeling of transferrin from a sample with a subsequent step of isoelectric focusing to separate transferrin isoforms for detection. Microfluidic channels and chambers are patterned on a substrate, designed so that on one region (i.e., a microfluidic channel or chamber) of the substrate transferrin is selectively captured from the sample and labeled, and in a second region of the susbstrate, transferrin isoforms are separated using isoelectric focusing. Detection of two transferrin bands, indicating the presence of beta-2-transferrin, indicates the presence of CSF in the sample. The devices and methods of the invention provide a safe, efficient, and ultrarapid modality with high specificity and sensitivity for the detection of CSF in the acute care setting. | 01-20-2011 |
20110015090 | Markers of Acute Myeloid Leukemia Stem Cells - Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets. | 01-20-2011 |
20110015091 | ASSAY MODULES HAVING ASSAY REAGENTS AND METHODS OF MAKING AND USING SAME - We describe assay modules (e.g., assay plates, cartridges, multi-well assay plates, reaction vessels, etc.), processes for their preparation, and method of their use for conducting assays. Reagents may be present in free form or supported on solid phases including the surfaces of compartments (e.g., chambers, channels, flow cells, wells, etc.) in the assay modules or the surface of colloids, beads, or other particulate supports. In particular, dry reagents can be incorporated into the compartments of these assay modules and reconstituted prior to their use in accordance with the assay methods. A desiccant material may be used to maintain and stabilize these reagents in a dry state. | 01-20-2011 |
20110015092 | MARKERS FOR BREAST CANCER - Correlations between polymorphisms and breast cancer are provided. Methods of diagnosing, prognosing, and treating breast cancer are provided. Systems and kits for diagnosis, prognosis and treatment of breast cancer are provided. Methods of identifying breast cancer modulators are also described. | 01-20-2011 |
20110021365 | Nucleic Acid Binding Compounds Containing Pyrazolo[3,4-D]Pyrimidine Analogues of Purin-2,6-Diamine and Their Uses - The present invention is in the field of nucleic acid binding compounds comprising 7-substituted 7-deaza-8aza-2,6-diamino-purine bases, compounds useful for the preparation of such compounds, various uses thereof and methods for the determination of nucleic acids using said compounds in the field of diagnostics. | 01-27-2011 |
20110021366 | EVALUATING GENETIC DISORDERS - The present invention relates to genetic analysis and evaluation utilizing copy-number variants or polymorphisms. The methods utilize array comparative genomic hybridization and PCR assays to identify the significance of copy number variations in a human or non-human animal subject or subject group. | 01-27-2011 |
20110021367 | DIAGNOSIS AND MONITORING OF MYCOBACTERIUM TUBERCULOSIS INFECTION - Disclosed are methods for detecting protein complexes of sigma factors and interacting proteins in a sample containing | 01-27-2011 |
20110021368 | METHODS FOR THRESHOLD DETERMINATION IN MULTIPLEXED ASSAYS - Methods for determination of threshold values of signatures comprised in an assay are described. Each signature enables detection of a target. The methods determine a probability density function of negative samples and a corresponding false positive rate curve. A false positive criterion is established and a threshold for that signature is determined as a point at which the false positive rate curve intersects the false positive criterion. A method for quantitative analysis and interpretation of assay results together with a method for determination of a desired limit of detection of a signature in an assay are also described. | 01-27-2011 |
20110021369 | SINGLE CELL BASED REPORTER ASSAY TO MONITOR GENE EXPRESSION PATTERNS WITH HIGH SPATIO-TEMPORAL RESOLUTION - The invention relates to a double-stranded polynucleotide comprising on its positive strand considered from its 5′ end to its 3′ end, (i) a promoter of a gene of interest or several promoters of various genes of interest selected among genes which are endogenous to a determined cell, and, (ii) one or several barcode(s) wherein each barcode contains at least one barcode unit formed of at least one, especially of multiple, recognition binding sites each binding site being composed of a nucleotide sequence, and wherein each of said barcode(s) is under the control of at least one of said promoter(s) for transcription. It further concerns use of said polynucleotide to monitor gene expression patterns in living cells, especially in single cells, with a rapid and high spatio-temporal resolution. | 01-27-2011 |
20110021370 | SALIVARY PROTEIN BIOMARKERS FOR HUMAN ORAL CANCER - The present invention relates to the identification of novel oral cancer and periodontal disease biomarkers. Further, the present invention provides novel methods of diagnosing and for providing a prognosis for oral cancer and periodontal disease. The present invention additionally provides novel methods of distinguishing between oral cancer and periodontal disease. Finally, kits are provided that find use in the practice of the methods of the invention. | 01-27-2011 |
20110021371 | DNA MICROARRAY BASED IDENTIFICATION AND MAPPING OF BALANCED TRANSLOCATION BREAKPOINTS - Methods for detecting and mapping chromosomal rearrangements associated with various diseases using comparative genomic hybridization are disclosed. Included are methods to identify translocation partners of known genomic loci and to determine translocation breakpoints. These methods may be used in the prognosis, diagnosis, and determination of predisposition to diseases that involve chromosomal rearrangements. | 01-27-2011 |
20110021372 | Compositions and methods for detection and isolation of phosphorylated molecules - The present invention relates to phosphate-binding compounds that find use in binding, detecting and isolating phosphorylated target molecules including the subsequent identification of target molecules that interact with phosphorylated target molecules or molecules capable of being phosphorylated. A binding solution is provide that comprises a phosphate-binding compound, an acid and a metal ion wherein the metal ion simultaneously interacts with an exposed phosphate group on a target molecule and the metal chelating moiety of the phosphate-binding compound forming a bridge between the phosphate-binding compound and a phosphorylated target molecule resulting in a ternary complex. The binding solution of the present invention finds use in binding and detecting immobilized and solubilized phosphorylated target molecules, isolation of phosphorylated target molecules from a complex mixture and aiding in proteomic analysis wherein kinase and phosphatase substrates and enzymes can be identified. | 01-27-2011 |
20110021373 | ANTIBODY CATEGORIZATION BASED ON BINDING CHARACTERISTICS - Methods for categorizing antibodies based on their epitope binding characteristics are described. Methods and systems for determining the epitope recognition properties of different antibodies are provided. Also provided are data analysis processes for clustering antibodies on the basis of their epitope recognition properties and for identifying antibodies having distinct epitope binding characteristics. | 01-27-2011 |
20110021374 | NMR DEVICE FOR DETECTION OF ANALYTES - This invention relates generally to detection devices having one or more small wells each surrounded by, or in close proximity to, an NMR micro coil, each well containing a liquid sample with magnetic nanoparticles that self-assemble or disperse in the presence of a target analyte, thereby altering the measured NMR properties of the liquid sample. The device may be used, for example, as a portable unit for point of care diagnosis and/or field use, or the device may be implanted for continuous or intermittent monitoring of one or more biological species of interest in a patient. | 01-27-2011 |
20110021375 | Sphingosine 1-Phosphate Receptor Gene, SPPR - A novel sphingosine 1-phosphate receptor gene, herein termed sppr, and its splice variants. Sppr is up-regulated in LGL and is useful, for example, in the diagnosis and treatment of certain lymphoproliferative, neurodegenerative and autoimmune diseases. | 01-27-2011 |
20110021376 | Method for Analyzing a Glycomolecule - The invention relates generally the structural analysis of glycomolecule-containing macromolecules, such as those that occur either attached to proteins (proteoglycans, glycoproteins), lipids, or as free saccharides. | 01-27-2011 |
20110028336 | MIPOL1-ETV1 GENE REARRANGEMENTS - Compositions and methods associated with recurrent MIPOL1-ETV1 genetic rearrangements that are useful for cancer diagnosis and therapy are disclosed. | 02-03-2011 |
20110028337 | NUCLEOBASE CHARACTERISATION - The present invention provides modified nucleobase compounds, modified nucleic acid mimetic compounds and various uses thereof. In addition, the invention provides methods for nucleobase characterisation, SNP characterisation and nucleic acid sequencing. | 02-03-2011 |
20110028338 | SIGNATURES OF RADIATION RESPONSE - The present invention relates, in general, to gene expression profiles, and in particular, to a peripheral blood gene expression profile of an environmental exposure, ionizing radiation. The invention further relates to methods of screening patients for radiation exposure based on gene expression profiling and to kits suitable for use in such methods. | 02-03-2011 |
20110028339 | METHODS AND COMPOSITIONS RELATED TO MICROSCALE SAMPLE PROCESSING AND EVALUATION - Embodiments of the invention include gels and blots comprising electrophoretically separated samples amenable to scanning at 20 micron resolution and methods of using such compositions. | 02-03-2011 |
20110028340 | POLYNUCLEOTIDE ANALYSIS USING COMBINATORIAL PCR - The invention comprises a two-step process for analysis of polynucleotides by chain extension of multiple polynucleotide primers attached to solid supports by first performing PCR of the samples in the presence of multiple oligonucleotides in solution, the oligonucleotides of both sets being similar or identical. This produces immobilized single-strand polynucleotides containing genetic sequence data derived from sample molecules. In a second step, support-bound polynucleotides are interrogated by hybridization with a single labeled oligonucleotide probe or by second-strand synthesis with a primer-dependent polymerase using an oligonucleotide primer and nucleotide monomers, in which either or both of the primer and nucleotide monomers are labeled. Incorporation of label demonstrates the presence of two separate defined-sequence primers within the sample polynucleotide. The presence or absence within the sample of the multiple combinations of primers is demonstrable in a single experiment by use of suitable apparatus, such as an oligonucleotide array. | 02-03-2011 |
20110028341 | METHODS, DEVICES, AND SYSTEMS FOR CHEMILUMINESCENCE-BASED MICROFLUIDIC CELL COUNTING - A chemiluminescence-based detection system and method for counting blood cells by capturing and isolating target blood cells flowing through a microfluidic chip and detecting light emitted by the captured target blood cells. | 02-03-2011 |
20110028342 | Combinatorial Affinity Selection - In one aspect of the invention, methods for analyzing nucleic acid sample are provided. In a preferred embodiment, nucleic acids are selected using affinity matrices prior hybridization with a microarray. | 02-03-2011 |
20110028343 | Biomarkers of Ovarian Cancer - The invention is directed to assays for biomarkers associated with ovarian cancer that can be used diagnostically. It includes glass or plastic plates or slides on which the biomarkers have been immobilized and kits containing these plates or slides. | 02-03-2011 |
20110028344 | BIOMARKERS FOR ENDOMETRIAL DISEASE - This patent application discloses and describes a list of proteins that are found to be differentially expressed between normal endometrial epithelial cells and early stage cancerous endometrial epithelial cells. These proteins can be used either individually or in specific combinations in diagnostic and prognostic protein assays on various biological samples from endometrial cancer patients, or individuals suspected on having endometrial cancer. In addition, these proteins are also differentially expressed between normal endometrial epithelial cells and epithelial cells of other types of endometrial disease, and thus such diseases can be diagnosed using assays based on these proteins. The full length intact proteins can be assayed or peptides derived from these proteins can be assayed as reporters for these proteins. These proteins can also be identified as “companion diagnostic” proteins, wherein they are not only differentially expressed for use as diagnostic and prognostic indicators of endometrial cancer and other endometrial diseases, but the same proteins are also targets for therapeutic intervention of endometrial cancer and other endometrial diseases. | 02-03-2011 |
20110034344 | RESPONSE GENE TO COMPLEMENT 32 (RGC-32) IN DISEASE - The invention relates to antibodies that bind to a fragment of the Response Gene to Complement-32 (RGC-32), as well as methods of using these antibodies. Particular methods of using the antibodies of the present invention include, but are not limited to, methods of detecting RGC-32 in a sample, methods of assaying cell proliferation, as well as methods of detecting and/or monitoring the progression of abnormal conditions in a subject, where the disease states are associated with the presence or absence of RGC-32. | 02-10-2011 |
20110034345 | METHODS FOR DIAGNOSIS OF MACULOPATHIES - The present disclosure provides methods for diagnosing a maculopathy. Specifically, the methods are based on determination of a level of at least one biological marker of a maculopathy in a bodily fluid sample of an individual (e.g. blood sample) and comparing the level of the assayed biological marker with the level of prior determined cut off standards. The level of the biological marker provides information regarding the state of the individual, such as whether the individual has the assayed maculopathy, is predisposed to develop said maculopathy, is responsive to treatment, and others. | 02-10-2011 |
20110034346 | GENE EXPRESSION PROFILING FROM FFPE SAMPLES - Methods and compositions relating to the generation and use of gene expression data from tissue samples that have been fixed and embedded are provided. The data can electronically stored and implemented as well as used to augment diagnosis and treatment of diseases. | 02-10-2011 |
20110034347 | Signatures Associated with Rejection or Recurrence of Cancer - Methods and tools for assessing the prognosis for patients following treatment of primary tumors are provided. The methods involve identifying immune-related genetic markers whose differential expression patterns at tumor lesions are indicative of either tumor recurrence or recurrence-free survival. The methods and tools of the invention assist physicians by providing objective decision-making tools for planning patient treatment protocols. | 02-10-2011 |
20110039715 | INFLUENZA B VIRUS DETECTION METHOD AND KIT THEREFOR - The invention provides oligonucleotide(s) for simple, specific and/or sensitive test(s) for the presence of Influenza virus. In particular, the present invention provides oligonucleotide(s) for test(s) for the Influenza B virus. Kit(s) comprising the oligonucleotide(s) for use as probe(s) and/or primer(s) useful in the test(s) are also provided. | 02-17-2011 |
20110039716 | Analysis of Single Nucleotide Polymorphisms Using a Nicking Endonuclease - A method of genome analysis is provided. In certain embodiments, the method comprises: a) contacting a double-stranded genomic DNA with a site-specific nicking endonuclease that recognizes a sequence comprising a single nucleotide polymorphism (SNP), in which the endonuclease nicks the genomic DNA at a nick site only if a first allele of the SNP is present; b) denaturing the genomic sample; c) contacting the denatured genomic sample with an array comprising a first probe and a second probe, in which nicking results in less binding of the denatured sample to the first probe relative to a sample that is not nicked; and d) comparing the amount of hybridization to the first probe to the amount of hybridization to said second probe, in which decreased binding of the denatured genomic samples to the first probe relative to the second probe indicates that the first allele of the SNP is present. | 02-17-2011 |
20110039717 | METHODS AND SYSTEMS FOR DETECTING AND/OR SORTING TARGETS - Provided herein are methods and systems for detecting and/or sorting targets in a sample based on the combined use of polynucleotide-encoded protein and substrate polynucleotides. The polynucleotide-encoded protein is comprised of a protein that specifically binds to a predetermined target and of an encoding polynucleotide that specifically binds to a substrate polynucleotide, wherein the substrate polynucleotide is attached to a substrate. | 02-17-2011 |
20110039718 | METHODS FOR IDENTIFICATION OF JAK KINASE INTERACTING MOLECULES AND FOR THE PURIFICATION OF JAK KINASES - The present invention relates to immobilization compounds and methods useful for the identification of JAK interacting compounds or for the purification or identification of JAK. | 02-17-2011 |
20110039719 | METHODS AND NUCLEIC ACIDS FOR THE ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS - The invention provides methods, nucleic acids and kits for detecting, or for detecting and distinguishing between or among liver cell proliferative disorders or for detecting, or for detecting and distinguishing between or among colorectal cell proliferative disorders. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of and differentiation between said class of disorders, thereby enabling the improved diagnosis and treatment of patients. | 02-17-2011 |
20110039720 | DEVICE AND METHOD FOR PARALLEL QUANTITATIVE ANALYSIS OF MULTIPLE NUCLEIC ACIDS - The present invention relates to a process for conducting real-time PCR, and to a device for conducting the method of the present invention. The invention is especially suited for the simultaneous identification and quantification of nucleic acids present in a sample, e.g. a biological sample. Further, this invention describes a method for simultaneous quantitative analysis of multiple nucleic acid sequences in a single compartment by using an integrated nucleic acid microarray combined with a highly surface-specific readout device. The invention relates to a device wherein a surface which is either part of the chamber surface or a surface that is created in the reaction chamber, such as bead surface, is coated with capture probes and in the same chamber, a PCR reaction takes place. | 02-17-2011 |
20110039721 | METHOD FOR PREDICTION ABOUT CARCINOGENICITY OF SUBSTANCE IN RODENT - Disclosed is a method for predicting about the carcinogenicity of a substance of interest in a rodent, which comprises the steps of: administering a solution of the substance to a test group and administering a solvent used in the solution to a control group; extracting mRNA from each of the test group and the control group, and measuring the expression level of mRNA for each of genes obtained by selecting at least one gene from (A) genes each comprising a nucleotide sequence depicted in any one of SEQ ID NOs: 1 to 5, (B) genes each comprising a nucleotide sequence depicted in any one of SEQ ID NOs: 6 to 8 and (C) genes each comprising a nucleotide sequence depicted in any one of SEQ ID NOs: 9 to 32; determining whether or not a significant difference in the level of mRNA expressed from the gene is observed between the test group and the control group; and determining that the substance has carcinogenicity when a significant difference in the level of the expression of mRNA from any one of the genes is observed between the test group and the control group and the direction of increase or decrease in the level of the expression of mRNA from any one of the genes is the same as the tendency which is previously defined for each gene. | 02-17-2011 |
20110039722 | LIBRARIES, ARRAYS AND THEIR USES FOR TARGETED AFFINITY ENHANCEMENT - The present disclosure relates to methods and materials for enhancing the binding affinity of an antibody by means of generating a library or an array of targeted amino acid changes (e.g., mutations) at one or more positions in an antibody variable domain. The present disclosure relates to libraries or arrays and their uses for enhancing antibody affinity. The present disclosure relates to methods and materials for mutagenesis, including for the generation of novel or improved antibody variable domains and libraries or arrays of mutant antibody variable domains or nucleic acids encoding such mutant or modified variable domains. | 02-17-2011 |
20110039723 | MALIGNANCY-RISK SIGNATURE FROM HISTOLOGICALLY NORMAL BREAST TISSUE - The invention provides for malignancy-risk gene signatures that predict the risk of developing breast cancer, the recurrence of breast cancer, and/or the metastasis of breast cancer. These signatures have numerous clinical applications including assessing risk of breast cancer development following routine breast biopsy, assessing the need for adjuvant radiotherapy after lumpectomy, and determining the need for completion mastectomy following lumpectomy for the breast cancer patient and other treatment plans that are personalized for the patient. | 02-17-2011 |
20110039724 | METHOD FOR DETECTING CHROMOSOMAL ANEUPLOIDY - The present invention relates to a new, non-invasive method for detecting chromosomal aneuploidy by analyzing a sample from a pregnant woman. The detection is based on the ratio between the amount of a fetal methylation marker located on a chromosome relevant to the aneuploidy and the amount of a fetal genetic marker located on a reference chromosome, offering improved accuracy. | 02-17-2011 |
20110039725 | DYNAMIC ARRAY ASSAY METHODS - High throughput methods are used that combine the features of using a matrix-type microfluidic device, labeled nucleic acid probes, and homogenous assays to detect and/or quantify nucleic acid analytes. The high throughput methods are capable of detecting nucleic acid analyes with high PCR and probe specificity, producing a low fluorescence background and therefore, a high signal to noise ratio. Additionally, the high throughput methods are capable of detecting low copy number nucleic acid analyte per cell. | 02-17-2011 |
20110039726 | POLYNUCLEOTIDES FOR USE AS TAGS AND TAG COMPLEMENTS, MANUFACTURE AND USE THEREOF - A family of minimally cross-hybridizing nucleotide sequences, methods of use, etc. A specific family of 210 24mers is described. | 02-17-2011 |
20110039727 | POLYNUCLEOTIDES FOR USE AS TAGS AND TAG COMPLEMENTS, MANUFACTURE AND USE THEREOF - A family of minimally cross-hybridizing nucleotide sequences, methods of use, etc. A specific family of 210 24 mers is described. | 02-17-2011 |
20110039728 | Polynucleotides for Use as Tags and Tag Complements, Manufacture and Use Thereof - A family of minimally cross-hybridizing nucleotide sequences, methods of use, etc. A specific family of 210 24mers is described. | 02-17-2011 |
20110045997 | METHOD AND PRODUCT FOR "IN VITRO" GENOTYPING WITH APPLICATIONS IN ANTI-AGEING MEDICINE - The invention relates to an “in vitro” method for determining the global genetic risk a subject has of developing a pathology associated with aging. Said method is based on the combination of particular genetic risks of developing common pathologies associated with aging. Said particular genetic risks are determined from the results obtained from the simultaneous genotyping of certain genetic variations associated with said pathologies associated with aging and the main objective of which is the use thereof in anti-aging medicine. | 02-24-2011 |
20110045998 | CANDIDATE GENES AND BLOOD BIOMARKERS FOR BIPOLAR MOOD DISORDER, ALCOHOLISM AND STRESS DISORDER - Analysis of the gene expression changes identified a series of novel candidate genes and blood biomarkers for bipolar disorder, alcoholism and stress disorder. These are used for diagnosing the disorders, predicting and monitoring response to treatment. A novel treatment for these co-morbid disorders, DHA (Docosahexaenoic acid—an omega-3 fatty acid) was identified, using these genes and biomarkers, as well as the transgenic animal model. | 02-24-2011 |
20110045999 | IDENTIFICATION OF NOVEL SUBGROUPS OF HIGH-RISK PEDIATRIC PRECURSOR B ACUTE LYMPHOBLASTIC LEUKEMIA, OUTCOME CORRELATIONS AND DIAGNOSTIC AND THERAPEUTIC METHODS RELATED TO SAME - The present invention relates to the identification of genetic markers patients with high risk B-precursor acute lymphoblastic leukemia (B-ALL) and associated methods and their relationship to therapeutic outcome. The present invention also relates to diagnostic, prognostic and related methods using these genetic markers, as well as kits which provide microchips and/or immunoreagents for performing analysis on leukemia patients. | 02-24-2011 |
20110046000 | METHODS TO INCREASE THE PHOTOSTABILITY OF DYES - The presently disclosed subject matter provides dyes having an improved photostability, biosensors comprising such dyes, and methods of use thereof, including methods for detecting target molecules in a sample under test and for live-cell imaging. The dyes can include a binding member, including a biomolecule or fragments thereof, which can interact with target molecules of interest and can be specific to a given conformational state or covalent modification, e.g., phosphorylation, of the target molecule. The presently disclosed dyes can be used for detecting changes in the binding, conformational change, or posttranslational modification of the target molecule. | 02-24-2011 |
20110046001 | Multiplex Assay for Respiratory Viruses - A method of detecting the presence of a plurality of respiratory viruses using a multiplexed diagnostic assay is disclosed. The method provides a plurality of oligonucleotides that each is specific for a specific respiratory virus. A multiplex PCR is run using the oligonucleotides, which produces double-stranded products. The method also provides a plurality of extension oligonucleotides that each is specific for a specific double-stranded product. Each extension oligonucleotide also has a distinct second portion having a unique sequence. A primer extension reaction is run using the extension oligonucleotides, which produces single-stranded products. The single-stranded products are hybridized to a solid carrier. | 02-24-2011 |
20110046002 | Seven Gene Breast Cancer Predictor - The invention provides a molecular marker set that can be used for prognosis of breast cancer in a patient using histologically normal tissue. The invention also provides methods for evaluating prognosis of breast cancer in a patient based on a molecular molecular signature. | 02-24-2011 |
20110046003 | ALPHA-SELECTIVE SIALYL PHOSPHATE DONORS FOR PREPARATION OF SIALOSIDES AND SIALOSIDE ARRAYS FOR INFLUENZA VIRUS DETECTION - A novel N-acetyl-5-N,4-O-carbonyl-protected dibutyl sialyl phosphate donor for sialylation of both primary and sterically hindered secondary acceptors to prepare sialosides with high yield and α-selectivity is disclosed. Methods for making disaccharide building blocks comprising α(2→3), α(2→6), α(2→8), α(2→8)/α(2→9) alternate, and α(2→9) sialosides are provided. methods for one-pot synthesis of complex sialosides are disclosed. Libraries of sialosides and methods for using the libraries for detection and receptor binding analysis of surface glycoproteins or pathogens and cancer cells are disclosed. Methods for distinguishing between hemagglutinin (HA) from various strains of influenza are provided. | 02-24-2011 |
20110046004 | Magnetic-nanoparticle conjugates and methods of use - The present invention provides novel compositions of binding moiety-nanoparticle conjugates, aggregates of these conjugates, and novel methods of using these conjugates, and aggregates. The nanoparticles in these conjugates can be magnetic metal oxides, either monodisperse or polydisperse. Binding moieties can be, e.g., oligonucleotides, polypeptides, or polysaccharides. Oligonucleotide sequences are linked to either non-polymer surface functionalized metal oxides or with functionalized polymers associated with the metal oxides. The novel compositions can be used in assays for detecting target molecules, such as nucleic acids and proteins, in vitro or as magnetic resonance (MR) contrast agents to detect target molecules in living organisms. | 02-24-2011 |
20110046005 | METHOD AND NUCLEIC ACIDS FOR THE ANALYSIS OF COLON CELL PROLIFERATIVE DISORDERS - Provided are methods and nucleic acids for detecting, differentiating or distinguishing between colon cell proliferative disorders by analysis of one or more of the genes Versican, TPEF, H-Cadherin, Calcitonin, and EYA4. Further provided are novel nucleic acid sequences useful for the cell proliferative disorder specific analysis of said genes as well as methods, assays and kits thereof. | 02-24-2011 |
20110046006 | MEANS AND METHODS FOR TYPING A CELL ISOLATE OF AN INDIVIDUAL SUFFERING FROM A PSYCHIATRIC DISORDER OR AT RISK OF SUFFERING THERE FROM - The present invention relates to a method for typing a cell isolate of an individual suffering from a pychiatric disorder, or at risk for suffering there from, the method comprising providing an RNA sample from a cell isolate from said individual; determining RNA levels for a set of genes in said RNA sample, wherein said set of genes comprises at least two of the genes listed in Table 9; and typing said isolate on the basis of the levels of RNA determined for said set of genes. | 02-24-2011 |
20110046007 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 2 and mutated sequences thereof. | 02-24-2011 |
20110046008 | SCREENING ASSAYS AND METHODS - Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody. | 02-24-2011 |
20110046009 | METHODS FOR DETECTING DNA METHYLATION USING ENCODED PARTICLES - Methods for detecting the methylation status of a target genomic locus are provided. Methods described allow for simultaneous assay of multiple cytosines in a target genomic locus. Assays of multiple cytosines in a target genomic locus provide detection of an aggregate cytosine methylation state of the target genomic locus. Methods to detect methylation of a genomic locus associated with a disease or disorder characterized by aberrant methylation of the genomic locus, such as, but not limited to, Fragile X mental retardation syndrome, Prader-Willi syndrome, Angelman sydrome, Beckwith-Wiedemann syndrome, and Russell-Silverman syndrome, diabetes, cancer, multiple sclerosis or schizophrenia are described herein. | 02-24-2011 |
20110046010 | POLYNUCLEOTIDES FOR USE AS TAGS AND TAG COMPLEMENTS, MANUFACTURE AND USE THEREOF - A family of minimally cross-hybridizing nucleotide sequences, methods of use, etc. A specific family of 210 24 mers is described. | 02-24-2011 |
20110053788 | DETECTION OF TARGET ANALYTES USING PARTICLES AND ELECTRODES - The invention relates to the use of particles comprising binding ligands and electron transfer moieties (ETMs). Upon binding of a target analyte, a particle and a reporter composition are associated and transported to an electrode surface. The ETMs are then detected, allowing the presence or absence of the target analyte to be determined. | 03-03-2011 |
20110053789 | MIRCOARRAY METHODS - The present invention provides a method for identifying a microarray probe set capable of identifying a member of a group of related nucleotide sequences, the method comprising the steps of providing a candidate probe set comprising at least one probe capable of differentially hybridizing to two or more members of the group of related nucleotide sequences, testing reactivity of the probe set against two or more members of the group of related nucleotide sequences, and observing the degree of difference in the patterns of reactivity of the probe set for the two or more members of the group of related nucleotide sequences. | 03-03-2011 |
20110053790 | METHOD AND KIT FOR DETECTION OF MICROORGANISM - A live cell of microorganism in a test sample is detected by the following steps of: a) adding a cross-linker capable of cross-linking a DNA by irradiation with light having a wavelength of 350 nm to 700 nm to the test sample; b) irradiating the test sample to which the cross-linker is added with light having a wavelength of 350 nm to 700 nm; c) removing the cross-linker contained in the test sample irradiated with light; d) adding a medium to the test sample from which the cross-linker is removed and incubating the test sample; e) adding again the cross-linker capable of cross-linking a DNA by irradiation with light having a wavelength of 350 nm to 700 nm to the incubated test sample; f) irradiating the test sample to which the cross-linker is added with light having a wavelength of 350 nm to 700 nm; g) extracting a DNA from the test sample and amplifying a target region of the extracted DNA by a nucleic acid amplification method; and h) analyzing the amplified product. | 03-03-2011 |
20110053791 | METHOD FOR DETECTING OR DETERMINING ABNORMAL PRION PROTEIN ASSOCIATED WITH TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY IN BLOOD-DERIVED SPECIMEN OR BODY FLUID-DERIVED SPECIMEN - A pretreatment method of a specimen used for detecting or determining abnormal prion protein (PrPres) associated with transmissible spongiform encephalopathy (TSE), wherein
| 03-03-2011 |
20110053792 | MICROARRAY FOR EXPRESSION ANALYSIS OF CELLULAR GLYCOSYLATION MECHANISM - The present invention relates to a support onto which a set of probes is applied wherein the set comprises: (a) probes capable of specifically hybridising with nucleic acids encoding fucosyltransferases; (b) probes capable of specifically hybridising with nucleic acids encoding galactosyltransferases; (c) probes capable of specifically hybridising with nucleic acids encoding N-acetylglucosaminyltransferases; (d) probes capable of specifically hybridising with nucleic acids encoding N-acetylgalactosaminyltransferases; (e) probes capable of specifically hybridising with nucleic acids encoding sialyltransferases; (f) probes capable of specifically hybridising with nucleic acids encoding sugar sulfotransferases; (g) probes capable of specifically hybridising with nucleic acids encoding lectins; (h) probes capable of specifically hybridising with nucleic acids encoding selectins; (i) probes capable of specifically hybridising with nucleic acids encoding fucosidases; (j) probes capable of specifically hybridising with nucleic acids encoding neuraminidases (sialidases); (k) probes capable of specifically hybridising with nucleic acids encoding nucleotide sugar epimerases; (l) probes capable of specifically hybridising with nucleic acids encoding sugar kinases; (m) probes capable of specifically hybridising with nucleic acids encoding sugar epimerases; (n) probes capable of specifically hybridising with nucleic acids encoding sugar transporters; and (o) probes capable of specifically hybridising with nucleic acids encoding enzymes of the fucose or sialic acid metabolism. The invention further relates to a kit which comprises the probes of the invention and the use of the support or the kit of the invention for the quantitative determination of expression profiles in a sample obtained from a cell, a tissue or an organism. The present invention further relates to a diagnostic composition and the use of the set of probes of the invention for the preparation of diagnostic compositions or of a diagnostic apparatus for the diagnosis of tumours, inflammatory and/or neurological diseases. | 03-03-2011 |
20110053793 | METHODS AND PRODUCTS FOR IDENTIFYING STRAINS OF BACTERIA - Methods for identifying strains of bacteria, particularly methods for serotyping | 03-03-2011 |
20110053794 | NANOSTRUCTURED SUBSTRATES FOR SURFACE ENHANCED RAMAN SPECTROSCOPY (SERS) AND DETECTION OF BIOLOGICAL AND CHEMICAL ANALYTES BY ELECTRICAL DOUBLE LAYER (EDL) CAPACITANCE - Provided according to embodiments of the invention are nanostructured surfaces that include a substrate; and an array of metallic nanopillar islands on the substrate, wherein each metallic nanopillar island includes a metal base layer on the substrate and a plurality of metallic nanopillars on the metal base layer, and wherein portions of the substrate between adjacent metallic nanopillar islands are free of the metal base layer. Also provided according to some embodiments of the invention are nanostructured surfaces that include a non-conductive substrate; and at least one nanoelectrode defined within the non-conductive substrate, wherein the at least one nanoelectrode is sized and/or shaped to immobilize an analyte or a probe molecule. Also provided are apparatuses and methods for SERS and detection of analytes or biological binding by EDL capacitance. | 03-03-2011 |
20110053795 | Osmolyte Mixture for Protein Stabilization - An osmolyte composition comprising 4 M glycerol and 4M urea for stabilizing previously transient protein folding intermediates as long-lived stable forms. A method to search for other possible stabilizing osmolyte mixtures using a screening array is also provided. These additional osmolyte mixtures may complement or augment the successful 4M glycerol/4 M urea mixture. | 03-03-2011 |
20110053796 | MODIFIED STEFIN A SCAFFOLD PROTEINS - The invention provides novel scaffold proteins for the display of peptides such as peptide aptamers. The novel scaffold proteins are modifications of Stefin A or STM (a variant of Stefin A) and are useful as scaffold proteins and as display systems. | 03-03-2011 |
20110059854 | DIAGNOSTIC AND PROGNOSTIC TESTS - The invention provides methods for diagnosing biological states or conditions based on ratios of gene expression data from tissue samples, such as cancer tissue samples. The invention also provides sets of genes that are expressed differentially in malignant pleural mesothelioma. These sets of genes can be used to discriminate between normal and malignant tissues, and between classes of malignant tissues. Accordingly, diagnostic assays for classification of tumors, prediction of tumor outcome, selecting and monitoring treatment regimens and monitoring tumor progression/regression also are provided. | 03-10-2011 |
20110059855 | Use of adiponectin for the diagnosis and/or treatment of presbycusis - The present invention relates to mutations located within the gene coding for adiponectin, said mutations being associated with presbycusis. The present invention further relates to adiponectin polynucleotides comprising such mutations, to adiponectin polypeptides encoded by such polynucleotides, and to methods of diagnosing and/or treating presbycusis using adiponectin polynucleotides, adiponectin polypeptides and/or ADIPOR2 polypeptides. | 03-10-2011 |
20110059856 | IN VITRO DIAGNOSTIC METHOD FOR THE DIAGNOSIS OF SOMATIC AND OVARIAN CANCERS - Method of using one element chosen among a nucleic acid molecule, a fragment of the nucleic acid molecule and a variant of the nucleic acid molecule for the in vitro or ex vivo diagnosis of any type of somatic or ovarian cancers, wherein at least one of any of the above described elements is abnormally expressed in cancer cells of at least one type of the somatic or ovarian cancers, and wherein each type of somatic or ovarian cancer cells abnormally expresses at least one of the above described elements. | 03-10-2011 |
20110059857 | MARKERS OF ACUTE KIDNEY FAILURE - The present invention relates to the method of determining the risk of acute kidney injury comprising determining the amount of a marker selected from VCAN, NRP1, CCL2, CCL19, COL3A1, GZMM or any combination thereof in a sample. | 03-10-2011 |
20110059858 | NEW BIOMARKER FOR DIAGNOSIS, PREDICTION AND/OR PROGNOSIS OF SEPSIS AND USES THEREOF - The present invention provides kits and methods for the diagnosis, prognosis and prediction of sepsis in a subject using the expression level of the TREML-1 biomarker as an indication of the condition of the patient, alone or in combination with further sepsis markers. | 03-10-2011 |
20110059859 | Molecule Detecting System - The invention disclosed here has several key elements: direct probe-on-sensor detection, mesh probe, and mesh reporter. Furthermore, the mesh probe and reporter shall have some physical cross-linking between the polymer backbone(s), either covalently or non-covalently. In combination, this invention enables one to build an ultra-sensitive, low-cost, and highly portable system for molecular detection. Among its many potential applications is a direct detection of nucleic acids in crude lysate in a multiplex format, without the requirements for nucleic acids extraction and amplification. Such an improvement is likely to change the practice of genotyping and gene expression profiling done in a clinic setting. Another application is an ultrasensitive ELIZA assay in a multiplex format. | 03-10-2011 |
20110065594 | Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual - A method for determining a plurality of proteins for discriminating and positively identifying an individual based from a biological sample. The method may include profiling a biological sample from a plurality of individuals against a protein array including a plurality of proteins. The protein array may include proteins attached to a support in a preselected pattern such that locations of the proteins are known. The biological sample may be contacted with the protein array such that a portion of antibodies in the biological sample reacts with and binds to the proteins forming immune complexes. A statistical analysis method, such as discriminant analysis, may be performed to determine discriminating proteins for distinguishing individuals. Proteins of interest may be used to form a protein array. Such a protein array may be used, for example, to compare a forensic sample from an unknown source with a sample from a known source. | 03-17-2011 |
20110065595 | Method and Test Kit for the Rapid Identification and Characterization of Cells - The invention relates to a rapid method for the characterization and identification of prokaryotic or eukaryotic cells present in a test sample, using an enzyme characterizing a specific strain of cells as a dual marker for cell viability in the presence of a cell inhibitory agent, and as a structural marker for cell identification. The method of the invention is based on change in the enzymatic activity of the enzyme in a tested sample in the presence of different cell inhibitory agents and/or different recognition-agents, preferably, antibodies. The invention further provides kits for rapid characterization and identification of prokaryotic or eukaryotic cells present in a test sample. | 03-17-2011 |
20110065596 | DIRECTED EVOLUTION USING PROTEINS COMPRISING UNNATURAL AMINO ACIDS - The invention provides methods and compositions for screening polypeptide libraries that include variants comprising unnatural amino acids. In addition, the invention provides vector packaging systems and methods for packaging a nucleic acid in a vector. Compositions of vectors produced by the methods and systems are also provided | 03-17-2011 |
20110065597 | SINGLE MOLECULE PROTEOMICS WITH DYNAMIC PROBES - Methods are disclosed utilizing single-molecule proteomics with dynamic probes to accomplish a variety of protein analytic applications. A panel of probes, when used in combination, can resolve and quantify a proteome in a simple assay detecting transient binding to single protein targets. | 03-17-2011 |
20110065598 | Methods and Devices for Detecting Diabetic Nephropathy and Associated Disorders - Methods and devices for diagnosing, monitoring, or determining diabetic nephropathy or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining diabetic nephropathy or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described. | 03-17-2011 |
20110065599 | Methods and Devices for Detecting Kidney Damage - Methods and devices for diagnosing, monitoring, or determining kidney damage in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining kidney damage using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described. | 03-17-2011 |
20110065600 | SEQUENCES ASSOCIATED WITH TDP-43 PROTEINOPATHIES AND METHODS OF USING THE SAME - Nucleic acids and peptides and methods of using thereof to identify subjects at risk for a TDP-43 proteinopathy are disclosed An array is also disclosed which contains the nucleic acids and peptides | 03-17-2011 |
20110065601 | IDENTIFICATION OF DISCRIMINANT PROTEINS THROUGH ANTIBODY PROFILING, METHODS AND APPARATUS FOR IDENTIFYING AN INDIVIDUAL - A method for determining a plurality of proteins for discriminating and positively identifying an individual based from a biological sample. The method may include profiling a biological sample from a plurality of individuals against a protein array including a plurality of proteins. The protein array may include proteins attached to a support in a preselected pattern such that locations of the proteins are known. The biological sample may be contacted with the protein array such that a portion of antibodies in the biological sample reacts with and binds to the proteins forming immune complexes. A statistical analysis method, such as discriminant analysis, may be performed to determine discriminating proteins for distinguishing individuals. Proteins of interest may be used to form a protein array. Such a protein array may be used, for example, to compare a forensic sample from an unknown source with a sample from a known source. | 03-17-2011 |
20110065602 | METHOD FOR DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF - The present invention relates generally to the identification of biomarkers of conditions including disease and non disease conditions as well as identifying compositions of biomarkers. The invention further provides a method of diagnosing disease, monitoring disease progression, and differentially diagnosing disease. The invention further provides for kits useful in diagnosing, monitoring disease progression and differentially diagnosing disease. | 03-17-2011 |
20110065603 | Method for a Highly Sensitive Detection and Quantification of Biomolecules Using Secondary Ion Mass Spectrometry (SIMS) and Related Technologies - The present invention relates to a method for detecting and quantifying the presence or absence of a number of biomolecules in a sample using the SIMS technique and arrays for use in said method. | 03-17-2011 |
20110065604 | Element Defined Sequence Complexity Reduction - A method for providing defined mixtures of nucleic acids is described. In certain embodiments, the method uses oligonucleotide probes attached to a solid support as a sequence-specific affinity agent to isolate and facilitate the amplification of defined nucleic acid fragment mixtures. | 03-17-2011 |
20110065605 | METHOD FOR BIOMARKER AND DRUG-TARGET DISCOVERY FOR PROSTATE CANCER DIAGNOSIS AND TREATMENT AS WELL AS BIOMARKER ASSAYS DETERMINED THEREWITH - The invention relates to a method for the determination of a cancer diagnostic/therapeutic biomarker assay and drug-targets including the following steps: (a) identification of potential candidate protein/peptide biomarkers and drug-targets based on the measurement of protein/peptide constituent concentrations in tissue sample proteomes as well as serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and qualitatively selecting as potential candidate protein/peptide biomarkers those which show a pronounced differential behaviour between healthy and cancerous sample proteomes; (b) optional verification of the potential candidate protein/peptide biomarkers as identified in step (a) by quantitative mass spectrometric measurement of the potential candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and selecting as candidate protein/peptide biomarkers those which show a mass-spectrometrically measurable quantitative differential behaviour between healthy and cancerous sample proteomes; (c) validation of the candidate protein/peptide biomarkers as identified in step (a), or as optionally verified in step (b), by mass spectrometric measurement and/or antibody-based assays such as an Enzyme-Linked Immunosorbent Assay (ELISA) determination of the candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy human individuals as well as from cancerous human individuals and selecting as protein/peptide biomarkers those which show a mass-spectrometrically measurable and/or antibody-based assay detectable differential behaviour between healthy and cancerous sample proteomes; (d) application of statistical methods to uncover single or groups of protein/peptide biomarkers as validated in step (c) as signatures for the detection of patients with cancer. The invention furthermore relates to specific biomarker assays for the highly reliable diagnosis of cancer, specifically of localized or non-localized prostate cancer, using human serum, plasma or any other derivatives of blood, or blood itself. | 03-17-2011 |
20110071038 | Assay devices and methods for the detection of analytes - The present invention relates to devices and methods for performing assays, especially for determining the presence and/or amount of one or more analytes. In particular, the invention relates to a device for the detection of analytes, comprising a reversibly compressible matrix located between a first surface and a second surface, wherein the second surface is located opposite to the first surface, and wherein the distance between the first surface and the second surface is variable. The invention also relates to a corresponding method using such a device for the detection of one or more species of analytes. | 03-24-2011 |
20110071039 | Automated Diagnostic Workstation - A flexible diagnostic workstation comprises is equipped to read label information on well strips of loaded well plates and on loaded reagent kit holders, automatically perform the pre-analytical steps of an immuno-assay which consists of a sequence of operations in accordance with scheduled test requirements for each microwell, read the results according to either a standard singleplex ELISA or multiplex test format as indicated by the well strip label, and report the results. | 03-24-2011 |
20110071040 | MASS- AND PROPERTY-TUNED VARIABLE MASS LABELING REAGENTS AND ANALYTICAL METHODS FOR SIMULTANEOUS PEPTIDE SEQUENCING AND MULTIPLEXED PROTEIN QUANTIFICATION USING THEREOF - The present invention provides variable mass labeling reagents, a set of the variable mass labeling reagents, and a multiplexed set of variable mass labeling reagents. | 03-24-2011 |
20110071041 | METHOD AND COMPOSITION FOR DISEASE DIAGNOSIS ACCORDING TO SACCHARIDE BINDING - Disclosed is a method for characterizing carbohydrate polymer by identifying at least two binding agents that bind to the carbohydrate polymer. Binding is preferably determined by contacting the carbohydrate polymer with substrate that contains a plurality of first saccharide-binding agents affixed at predetermined locations on the substrate. The carbohydrate polymer is allowed to contact the substrate under conditions that allow for formation of a first complex between the first saccharide-binding agent and the carbohydrate polymer. A second saccharide-binding agent, which preferably includes a label, is also contacted with the carbohydrate polymer under conditions that allow for formation of a second complex between the second binding agent and the first complex. Identification of the first and second binding agent allows for characterization of the polysaccharide. | 03-24-2011 |
20110071042 | BIOMARKERS FOR DETERMINING SENSITIVITY OF BREAST CANCER CELLS TO HER2-TARGETED THERAPY - The present invention provides compositions and methods for detecting the expression and/or activation states of components of signal transduction pathways in cells such as tumor cells. Information on the expression and/or activation states of components of signal transduction pathways derived from use of the present invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments. | 03-24-2011 |
20110071043 | Methods For Characterizing Antibody Binding Affinity And Epitope Diversity in Food Allergy - Methods for performing epitope mapping, and for characterizing the antibody binding affinity and epitope diversity of antibodies in a sample using peptide microarray are provided. In some aspects, methods are provided for the specific characterization of IgE and IgG4. Also disclosed are methods for diagnosing whether a milk-allergic individual will outgrow his or her allergy based on the characterization of the individual's milk allergen-specific IgE antibodies. | 03-24-2011 |
20110071044 | MICROARRAY AND METHOD OF DESIGNING NEGATIVE CONTROL PROBES - According to one aspect, a microarray for nucleic acid detection includes a substrate, a negative control probe group immobilized on a first region of the substrate and provided with a plurality of first probes having different sequences, and a second probe immobilized on a second region of the substrate and containing a sequence complementary to a target nucleic acid. | 03-24-2011 |
20110071045 | NOVEL METHOD FOR THE SELECTION OF SPECIFIC AFFINITY BINDERS BY HOMOGENEOUS NONCOMPETITIVE ASSAY - The invention generally relates to the field of immunochemistry including antibody therapy, diagnostics, and basic research and specifically relates to the area of selecting affinity molecules such as natural antibodies, including artificial antibodies, antibody mimics, and aptamers. The invention relates particularly to a method of selecting affinity molecules using a homogeneous noncompetitive assay in a high throughput process. | 03-24-2011 |
20110071046 | MATRIX SCREENING METHOD - The invention concerns a method which can be used to screen two or more repertoires of molecules against one another and/or to create combinatorial repertoires by combining two or more repertoires. In particular, the invention relates to a method whereby two repertoires of molecules can be screened such that all members of the first repertoire are tested against all members of the second repertoire for functional interactions. Furthermore, the invention relates to the creation and screening of antibody repertoires by combining a repertoire of heavy chains with a repertoire of light chains such that antibodies formed by the all combinations of heavy and light chains can be screened against one or more target ligands. | 03-24-2011 |
20110071047 | PROMOTER DETECTION AND ANALYSIS - An array-based method for promoter detection and analysis is provided. Promoter sequence candidates are analyzed simultaneously in one reaction vial utilizing a plurality of vectors, each comprising a unique TAG sequence wherein transcriptional products are tagged as they are synthesized, in such a way that one specific transcript is labeled with only one type of tag, and one tag labels only one type of transcript. The transcriptional output is analyzed on conventional arrays or by real-time RT PCR. | 03-24-2011 |
20110071048 | BIOMOLECULE SUBSTRATE, AND TEST AND DIAGNOSIS METHODS AND APPARATUSES USING THE SAME - An object of the present invention is to provide a test apparatus for testing a DNA substrate on which a plurality of DNA fragments for testing are arranged, wherein absolute precision is not required. The above-described problem was solved by providing a substrate on which a plurality of biomolecule spots containing a group of biomolecules (e.g., DNA, etc.) of a specific type are formed, where the pattern or position of the DNA spot is changed depending on specific data so that information of the specific data is recorded on the substrate. | 03-24-2011 |
20110071049 | METHODS AND COMPOSITIONS FOR TRANSLATIONAL PROFILING AND MOLECULAR PHENOTYPING - Methods and compositions are provided for translational profiling and molecular phenotyping of specific tissues, cells and cell subtypes of interest. The methods provided herein facilitate the analysis of gene expression in the selected subset present within a heterogeneous sample. | 03-24-2011 |
20110071050 | COLLECTION OF MICRO SCALE DEVICES - A collection of one or more microfluidic devices which together carry a plurality of microchannel structures each of which comprises a reaction microcavity in which there is a solid phase with an immobilized affinity ligand L, characterized in that (i) the plurality is divided into sets of microchannel structures, and (ii) the affinity ligand L is directed to the same counterpart (binder, B) independent of set, and (iii) the sets differ in a) the capacity per reaction microcavity and/or the capacity/unit volume of the solid phase in a reaction microcavity for binder B, and/or b) the base matrix of the solid phase between the sets but are equal within each set. | 03-24-2011 |
20110071051 | BIOCHIP FOR FRATIONATING AND DETECTING ANALYTES - The present invention relates to a bio chip for fractionating and detecting analytes, such as proteins, protein-complexes, metabolites, glycoproteins, peptides, DNA, RNA, lipids, fatty acids, carbohydrates and/or other ampholytes. | 03-24-2011 |
20110077164 | EXPRESSION PROFILING PLATFORM TECHNOLOGY - The present invention relates to an efficient mAb panel-based expression profiling technology platform suitable for global and accurate measurement of proteins, peptides and metabolites in complex mixtures. The platform is comprised of new and well established technologies that are coupled in a unique fashion to provide a novel platform technology for (i) the discovery of differentially displayed elements of complex protein, peptide and metabolite mixtures and (ii) the development of robust mAb based assays that detect the differentially expressed elements. | 03-31-2011 |
20110077165 | MITIGATION OF Cot-1 DNA DISTORTION IN NUCLEIC ACID HYBRIDIZATION - A novel method of suppressing non-specific cross-hybridization between repetitive elements present in nucleic acid probes and corresponding repetitive elements in the target nucleic acid by using DNA synthesized to contain a plurality of repetitive elements while avoiding low and single copy sequences. | 03-31-2011 |
20110077166 | SURFACE ATTACHMENT - Provided is a method of attaching a substance to a surface, which method comprises contacting a surface comprising amine reactive groups with a substance labelled with a peptide tag such that the substance is covalently attached to the surface via the peptide tag, wherein the peptide tag comprises one or more histidine residues, one of which is a terminal histidine residue having a free N-terminal amino group. Also provided is a method of processing or analysis which comprises a method of attaching a substance to a surface as detailed above and comprises one or more further steps of processing or analysing the substance. The present invention further provides a method of processing or analysis comprising the steps of:
| 03-31-2011 |
20110077167 | AUTOMATED ANALYSIS OF MULTIPLEXED PROBE-TARGET INTERACTION PATTERNS: PATTERN MATCHING AND ALLELE IDENTIFICATION - Disclosed are methods and algorithms (and their implementation) supporting the automated analysis and interactive review and refinement (“redaction”) of the analysis within an integrated software environment, for automated allele assignments. The implementation, preferably with a software system and a program referred to as the Automated Allele Assignment (“AAA”) program, provides a multiplicity of functionalities including: data management by way of an integrated interface to a portable database to permit visualizing, importing, exporting and creating customizable summary reports; system configuration (“Set-up”) including user authorization, training set analysis and probe masking; Pattern Analysis including string matching and probe flipping; and Interactive Redaction combining real-time database computations and “cut-and-paste” editing, generating “warning” statements and supporting annotation. It also includes a thresholding function, a method of setting thresholds, a method of refining thresholds by matching an experimental binary string (“reaction pattern”) setting for that probe, probe masking of signals produced by probes which do not contribute significantly to discriminating among alleles. | 03-31-2011 |
20110077168 | METHODS FOR DISTINGUISHING BETWEEN SPECIFIC TYPES OF LUNG CANCERS - The present invention provides nucleic acid sequences that are used for identification, classification and diagnosis of lung cancers. The present invention further provides microRNA molecules, as well as various nucleic acid molecules relating thereto or derived therefrom, associated with specific types of lung cancers. | 03-31-2011 |
20110082047 | GENOME-WIDE SCREENING FOR SNPs AND MUTATIONS RELATED TO DISEASE CONDITIONS - The present invention provides a genome-wide methodology for identifying single nucleotide polymorphisms and mutations related to disease conditions, such as cancer. Specifically, the invention provides methods for detecting genome-wide mutations by successively amplifying sequence differences between two sample populations. | 04-07-2011 |
20110082048 | Systematic Evaluation of Sequence and Activity Relationships Using Site Evaluation Libraries For Engineering Multiple Properties - The present invention provides methods for protein engineering. Specifically, the invention provides methods utilizing site evaluation libraries to design libraries that optimize two or more properties of a protein. | 04-07-2011 |
20110082049 | METHOD AND SYSTEM FOR AUTOMATED IMAGE ANALYSIS IN CANCER CELLS - A method of screening for the presence and/or extent of a pathology in a subject, the pathology characterized by an abnormal chromosomal component in a cell of the subject, comprising the steps of: contacting a biological sample comprising cell nuclei from said subject with, one or more distinguishable labeled probes directed to at least one chromosomal sequence that characterizes the abnormality under conditions that promote hybridization of the one or more probes to the at least one sequence, automatically obtaining a representation of the one or more distinguishable labels hybridized to the chromosomal sequences, automatically analyzing the distribution and intensity of binding of the one or more labels in the representation to determine the presence and/or extent of an abnormal chromosomal component; and automatically reporting results of the analysis; wherein the steps are carried out without intervention by a human. | 04-07-2011 |
20110082050 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE MUTATIONS - The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. The mutations include duplication of exons including duplication of exons 6b through 10. Methods of identifying if an individual contains the exons 6b through 10 duplication are provided as well as nucleic acid fragments that contain the junction site of the duplicated segment. The detection of additional mutations in the CFTR gene are also provided. | 04-07-2011 |
20110086768 | TRANSFERRIN FUSION PROTEIN LIBRARIES - Fusion proteins comprising a transferrin moiety and integrin binding domain and peptide libraries thereof are disclosed. The present invention includes a method of screening transferrin and integrin peptide libraries displayed in fusion proteins expressed by host cells. The fusion proteins of the present invention include transferrin fusion proteins capable of expression in yeast. | 04-14-2011 |
20110086769 | METHODS AND GENOTYPING PANELS FOR DETECTING ALLELES, GENOMES, AND TRANSCRIPTOMES - Disclosed are methods and genotyping panels for detecting alleles, genomes, and transcriptomes in admixtures of two individuals. | 04-14-2011 |
20110086770 | Combinatorial Libraries Based on C-type Lectin-like Domain - This invention relates to polypeptide libraries comprising polypeptides having a C-type lectin domain (CTLD) with a randomized loop region, as well as nucleic acid libraries comprising nucleic acid molecules encoding such polypeptides. The invention also relates to methods for generating the randomized polypeptides and the polypeptide libraries. The invention further relates to methods of screening the polypeptide and nucleic acid libraries based on the specific binding of the modified CTLDs to a target molecule of interest. The invention also relates to polypeptides derived from such libraries that bind to target molecules of interest. | 04-14-2011 |
20110086771 | Biochip - Improved biochips comprise a matrix layer coupled to a substrate, wherein the matrix layer includes a plurality of ligands in a plurality of predetermined positions and wherein ligands bind to an anti-ligand disposed in a sample fluid. Preferred matrix layers are multi-functional matrix layers that reduce autofluorescence, incident-light-absorption, charge-effects, and/or surface unevenness of the substrate, and contemplated biochips may comprise additional matrix layers. Contemplated biochips may be useful in detection and/or quantification of various anti-ligands, including polypeptides, polynucleotides, carbohydrates, pharmacologically active molecules, bacterial or eukaryotic cells, and/or viruses. | 04-14-2011 |
20110086772 | MULTIPLEX (+/-) STRANDED ARRAYS AND ASSAYS FOR DETECTING CHROMOSOMAL ABNORMALITIES ASSOCIATED WITH CANCER AND OTHER DISEASES - Multiplex (+/−) stranded analyses, such as array comparative genomic hybridization (aCGH), are provided for detecting chromosomal rearrangements associated with cancer and other diseases. For example, an illustrative multiplex array for CGH includes discrete plus (+) strand and minus (−) strand DNA probes, complementary to each other but separable on the CGH array. The minus (−) strand DNA probes recover diagnostic information lost to conventional microarrays, since many genes transcribe from the minus (−) strand. In an illustrative system, patient and control DNA samples are prepared for CGH by amplification and labeling using comprehensive primers that generate both plus (+) strands and minus (−) strands of DNA in the samples. The breakpoints of a translocated chromosome may be detected on a multiplex microarray by DNA probes of one polarity, while DNA copy number changes associated with the translocation region may be detected by corresponding DNA probes of the complementary polarity. Related methods for identifying translocation partner genes are also provided. | 04-14-2011 |
20110086773 | DIAGNOSTIC METHODS FOR ORAL CANCER - The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose oral cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3, chromosome 5 and chromosome 6 using FISH analysis of probes targeted to 3q and/or 5p and/or 11q. | 04-14-2011 |
20110086774 | Protein Detection Via Nanoreporters - The invention provides methods, compositions, kits and devices for the detection of proteins. In some embodiments, the invention allows for multiplexed protein detection. | 04-14-2011 |
20110086775 | H+-Gated Ion Channel - The invention relates to an isolated or recombinant Na | 04-14-2011 |
20110086776 | PROCESS AND METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE - The present invention concerns methods and compositions usable for diagnosing Alzheimer's disease in mammals, in particular humans. It particularly describes serum markers for Alzheimer's disease and their use in diagnostic methods. It also concerns tools and/or kits usable for implementing these methods (reagents, probes, primers, antibodies, chips, cells, etc.), their preparation and their use. The invention is usable to detect the presence or progression of Alzheimer's disease in mammals, including in the early phase, as well as for predicting the efficacy of an Alzheimer's disease treatment. | 04-14-2011 |
20110086777 | METHOD FOR AUTISM PREDICTION - The present invention relates to a method for evaluating the level of risk for a subject to develop autism, or an autism spectrum disorder, which method comprises determining the number of risk alleles in autism-associated gene loci in a sample of a subject, wherein the more risk alleles are detected within said gene loci combined, the more increased is the risk of developing autism or an autism-spectrum disorder. | 04-14-2011 |
20110092380 | IMPROVED MOLECULAR-BIOLOGICAL PROCESSING EQUIPMENT - The invention relates to improved molecular-biological processing equipment and an improved method of processing biological samples. The invention combines the provision of biologically functional molecules such as nucleic acids and peptides and of derivatives or analogs of these two classes of molecules in miniaturized flow cells with the sequential addition of reagents or fluids and serves for the processing of biological samples, such as proteins, nucleic acids, biogenic small molecules such as e.g. metabolites, viruses or cells, which for this purpose are introduced into the miniaturized flow cells. The invention further relates to methods and to the use of the molecular-biological processing equipment according to the invention for the detection and/or for the isolation of nucleic acids; for sequencing; for point mutation analysis; for the analysis of genomes and/or chromosomes; for the production of synthetic nucleic acids; for the production of arrays of primers, probes and/or antisense molecules; and other analytical and synthetic methods. | 04-21-2011 |
20110092381 | DETECTION OF PLURALITY OF TARGETS IN BIOLOGICAL SAMPLES - Methods for detecting a plurality of targets in a biological sample are provided. The method comprises contacting the biological sample with a plurality of target-binding probes to form a plurality of target-bound probes, covalently attaching at least one of the target-bound probes to the biological sample, and observing the signals from the target-bound probes sequentially. An associated kit and device for detection of the plurality of targets are also provided. | 04-21-2011 |
20110092382 | Modified Nucleic Acid Probes - Oligonucleotide analogue arrays attached to solid substrates and methods related to the use thereof are provided. The oligonucleotide analogues hybridize to nucleic acids with either higher or lower specificity than corresponding unmodified oligonucleotides. Target nucleic acids which comprise nucleotide analogues are bound to oligonucleotide and oligonucleotide analogue arrays. | 04-21-2011 |
20110092383 | Method For Diagnosing Multiple Sclerosis - Disclosed is a method for diagnosing multiple sclerosis and more particularly to a method for diagnosing multiple sclerosis by measuring levels of antibodies to glycans in a biological sample. | 04-21-2011 |
20110092384 | COMPOSITIONS AND METHODS FOR PRODUCING CODED PEPTOID LIBRARIES - Embodiments of the invention are directed to a one-bead-two-compound method for the creation of encoded cyclic peptoid libraries. This scheme is useful for the creation of cyclic peptoid microarrays since only the cyclic peptoid, not the linear encoding molecule, contains an attachment residue and thus can be spotted onto an activated substrate. | 04-21-2011 |
20110092385 | COMPOSITIONS AND METHODS TO DETECT INFLUENZA VARIANTS - Methods and kits used in the detection of variants of the Influenza virus are disclosed, including variants that are resistant to treatment with antiviral compositions. | 04-21-2011 |
20110092386 | ISOLATING BIOLOGICAL MODULATORS FROM BIODIVERSE GENE FRAGMENT LIBRARIES - The present invention provides a method for identifying a modulator or mediator of a biological activity, which activity includes antigenicity and/or immunogenicity, said method comprising the step of:
| 04-21-2011 |
20110092387 | Expression profiling using microarrays - The invention provides novel compositions and methods for the analysis of gene expression (e.g., expression profiling) using microarray-based technology. In some embodiments of the invention, the novel methods use gene-specific as well as universal amplification primers during sample preparation, and the methods permit the simultaneous analysis of multiple samples on the same microarray. Furthermore, some embodiments of the invention incorporate barcode sequences into the amplified products, thereby permitting the use of generic arrays and generic labeled probes. | 04-21-2011 |
20110092388 | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF BREAST CANCER - The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided. | 04-21-2011 |
20110092389 | METHODS OF DETECTING TARGETS ON AN ARRAY - The invention relates to methods of detecting a target analyte in a biological sample using composite microsphere arrays having first and second assay locations. Preferred target analytes include nucleic acid, and more specifically, nucleic acid having one or more single nucleotide polymorphisms (SNPs). | 04-21-2011 |
20110098187 | SYSTEMS AND METHODS FOR DEVELOPING DIAGNOSTIC TESTS BASED ON BIOMARKER INFORMATION FROM LEGACY CLINICAL SAMPLE SETS - Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 μL or less of a legacy clinical sample. | 04-28-2011 |
20110098188 | BLOOD BIOMARKERS FOR PSYCHOSIS - A plurality of biomarkers determine the diagnosis of psychosis based on the expression levels in a sample such as blood. Subsets of biomarkers predict the diagnosis of delusion or hallucination. The biomarkers are identified using a convergent functional genomics approach based on animal and human data. Methods and compositions for clinical diagnosis of psychosis are provided. | 04-28-2011 |
20110098189 | METHOD OF DIAGNOSING NEOPLASMS - II - The present invention relates generally to nucleic acid molecules in respect of which changes to the DNA or to the RNA or protein expression profiles are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to the DNA or to the RNA or protein expression profiles are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or an adenocarcinoma. The DNA or the expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening a subject for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in the DNA or the RNA or protein expression profile of one or more nucleic acid molecule markers. | 04-28-2011 |
20110098190 | SIRT4 ACTIVITIES - Methods of screening for compounds that modulate the expression or activity of Sirt4 are provided. Also provided are methods of modulating insulin secretion, treating metabolic disorders, and treating neurodegenerative disorders by modulating the expression or activity of Sirt4. | 04-28-2011 |
20110098191 | IN VITRO METHODS FOR DETECTING RENAL CANCER - The present invention refers to an in vitro method for detecting the presence of renal cancer in an individual, for determining the stage, malignancy or severity of said carcinoma in the individual or for monitoring the effect of the therapy administered to an individual having said cancer; to the search, identification, development and assessment of the efficacy of compounds for therapy for said cancer in an attempt to develop new drugs; as well as to agents inducing Plexin-131 protein expression and/or activity, or to agents inhibiting the effects of Plexin-B1 protein expression and/or activity repression. | 04-28-2011 |
20110098192 | METHODS FOR ASSESSING LIVER PATHOLOGIES - The present invention provides a new method for detecting or monitoring a liver disease in a subject that has no indication of any liver pathologies, by measuring the amount of concentration of albumin mRNA in an acellular blood sample from the subject, and then comparing the amount or concentration of albumin mRNA with a standard control. | 04-28-2011 |
20110098193 | Methods and Systems for Medical Sequencing Analysis - Disclosed are methods of identifying elements associated with a trait, such as a disease. The methods can comprise, for example, identifying the association of a relevant element (such as a genetic variant) with a relevant component phenotype (such as a disease symptom) of the trait, wherein the association of the relevant element with the relevant component phenotype identifies the relevant element as an element associated with the trait, wherein the relevant component phenotype is a component phenotype having a threshold value of severity, age of onset, specificity to the trait or disease, or a combination, wherein the relevant element is an element having a threshold value of importance of the element to homeostasis relevant to the trait, intensity of the perturbation of the element, duration of the effect of the element, or a combination. The disclosed methods are based on a model of how elements affect complex diseases. The disclosed model is based on the existence of significant genetic and environmental heterogeneity in complex diseases. Thus, the specific combinations of genetic and environmental elements that cause disease vary widely among the affected individuals in a cohort. The disclosed model is an effective, general experimental design and analysis approach for the identification of causal variants in common, complex diseases by medical sequencing. Also disclosed herein are methods of identifying an inherited trait in a subject. The disclosed methods compare a reference sequence from a subject to a library of sequences that contain each mutation. For a given mutation, a normal sequence read aligns best to the normal library sequence. A read having the mutation aligns best to the mutant library sequence. The disclosed model and the disclosed methods based on the model can be used to generate valuable and useful information. | 04-28-2011 |
20110098194 | METHOD FOR DETECTING AND QUANTIFYING A MOLECULE INCLUDING AT LEAST ONE PROTONATED GROUP ON A SOLID SUBSTRATE - The present invention relates to a method for detecting and optionally quantifying at least one molecule comprising at least one protonated group such as an amine function immobilized at the surface of the solid substrate, said method being a reversible, direct and colorimetric method that uses a coloring agent. The present invention also relates to various uses of said method and the solutions used during said method. | 04-28-2011 |
20110098195 | METHOD FOR THE IN VITRO DETECTION AND DIFFERENTIATION OF PATHOPHYSIOLOGICAL CONDITIONS - The invention relates to a method for the in vitro detection and/or differentiation and/or progress observation of pathophysiological conditions with the aid of sample nucleic acids, including determination of gene activities by means of a plurality of polynucleotides, determination of gene activities of at least one internal reference gene, and formation of an index value from the single determined normalized gene activities of a multigene biomarker indicating the pathophysiological condition. | 04-28-2011 |
20110098196 | Multiplex Screening for Pathogenic Hypertrophic Cardiomyopathy Mutations - This invention relates to a new method of screening for hypertrophic cardiomyopathy. In certain embodiments, the invention comprises a method of screening for hypertrophic cardiomyopathy comprising detecting the presence or absence of at least one pathogenic HCM mutation by mutation detection assay in a sample from a subject to be tested for hypertrophic cardiomyopathy. | 04-28-2011 |
20110098197 | Method for Specific Covalent Coupling of Antibody Using a Photoactivable Protein G Variant - The present invention relates to a protein G variant comprising a mutated Fc binding domain, which is prepared by substituting cysteine for specific residues of the Fc-binding domain of protein G, and a method for preparing the same. Further, the present invention relates to a protein G variant comprising a cysteine mutated Fc binding domain that is site-selectively modified with a UV cross-linker. Further, the present invention relates to a method for UV cross-linking the protein G variant with antibody. The present invention relates to a protein G variant-antibody conjugate that is prepared by the above method. Further, the present invention provides a method for screening or analyzing antigens using the conjugate. Furthermore, the present invention provides a biochip or biosensor fabricated by linking the protein G variant to the surface of a solid support, and a method for fabricating the same. In addition, the present invention provides a method for immobilizing antibodies and analyzing antigens using the biochip or biosensor. | 04-28-2011 |
20110105346 | Universal fingerprinting chips and uses thereof - The present invention discloses a designing strategy for constructing a set of probes useful for analyzing all or most prokaryotic and eukaryotic genomes. A set of capture probes with optimal fingerprinting properties and highly representative of all possible sequences of an organism can be selected by six sequential steps. Fingerprinting potential of such probes is validated by phylogenetic analysis, which generates results that strongly correlate with phylogenetic trees produced by sequence alignment. The probes generated by the instant methods can be used for detecting an organism, for establishing phylogenetic relationships between different organisms, for detection of single nucleotide polymorphisms and a wide variety of other applications that require genetic analysis. | 05-05-2011 |
20110105347 | CORN POLYMORPHISMS AND METHODS OF GENOTYPING - Polymorphic corn DNA loci useful for genotyping between at least two varieties of corn. Sequences of the loci are useful for providing the basis for designing primers and probe oligonucleotides for detecting polymorphisms in maize DNA. Polymorphisms are useful for genotyping applications in corn. The polymorphic markers are useful to establish marker/trait associations, e.g. in linkage disequilibrium mapping and association studies, positional cloning and transgenic applications, marker-aided breeding and marker-assisted selection, hybrid prediction and identity by descent studies. The polymorphic markers are also useful in mapping libraries of DNA clones, e.g. for corn QTLs and genes linked to polymorphisms. | 05-05-2011 |
20110105348 | Method for detecting an analyte in a sample - The present invention relates to a method for detecting an analyte in a sample comprising the steps of
| 05-05-2011 |
20110105349 | USE OF A MONOPHOSPHATE ESTER OF A PHTHALEIN COMPOUND AS A SUBSTRATE FOR TARTRATE-RESISTANT ACID PHOSPHATASE B5 (TRAP 5B) - The present invention relates to the use of a monophosphate ester of a phthalein compound as a substrate for Tartrate-Resistant Acid Phosphotase (TRAP). The substrate is used in assays for obtaining a measure of the amount of TRAP 5 | 05-05-2011 |
20110105350 | DIAGNOSIS OF SEPSIS - Methods for predicting the development of sepsis in a subject at risk for developing sepsis are provided. In one method, features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. In one method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods of diagnosing sepsis in a subject are provided. In one such method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set. | 05-05-2011 |
20110105351 | Multiplex branched-chain DNA assays - Methods of detecting two or more nucleic acids in a multiplex branched-chain DNA assay are provided. Different nucleic acids are captured through cooperative hybridization events on different, identifiable subsets of particles or at different selected positions on a spatially addressable solid support. Compositions, kits, and systems related to the methods are also described. | 05-05-2011 |
20110105352 | METHOD FOR MEASURING CHROMOSOME, GENE OR SPECIFIC NUCLEOTIDE SEQUENCE COPY NUMBERS USING SNP ARRAY - The present invention relates to a method for measuring the copy number of a chromosome, gene or specific nucleotide sequence, comprising the steps of: (a) mixing a homozygous DNA with a test sample DNA; (b) analyzing the DNA mixture by means of SNP array; and (c) determining the copy number of a chromosome, gene, or specific nucleotide sequence by measuring the difference in signal output from the homozygous DNA and the test sample DNA. | 05-05-2011 |
20110105353 | Fetal Genomic Analysis From A Maternal Biological Sample - Systems, methods, and apparatus for determining at least a portion of fetal genome are provided. DNA fragments from a maternal sample (maternal and fetal DNA) can be analyzed to identify alleles at certain loci. The amounts of DNA fragments of the respective alleles at these loci can be analyzed together to determine relative amounts of the haplotypes for these loci and determine which haplotypes have been inherited from the parental genomes. Loci where the parents are a specific combination of homozygous and heterozygous can be analyzed to determine regions of the fetal genome. Reference haplotypes common in the population can be used along with the analysis of the DNA fragments of the maternal sample to determine the maternal and paternal genomes. Determination of mutations, a fractional fetal DNA concentration in a maternal sample, and a proportion of coverage of a sequencing of the maternal sample can also be provided. | 05-05-2011 |
20110105354 | Methods and Apparatus for Conducting Multiple Measurements on a Sample - Multiplexed test measurements are conducted using an assay module having a plurality of assay domains. In preferred embodiments, these measurements are conducted in assay modules having integrated electrodes with a reader apparatus adapted to receive assay modules, induce luminescence, preferably electrode induced luminescence, in the wells or assay regions of the assay modules and measure the induced luminescence. | 05-05-2011 |
20110105355 | BORRELIA BURGDORFERI CELL ENVELOPE PROTEIN ARRAY - Methods of assessing a sample for the presence of antibodies to cell envelope proteins of | 05-05-2011 |
20110105356 | COMPOSITIONS AND METHODS FOR PROVIDING SUBSTANCES TO AND FROM AN ARRAY - Methods, kits, systems, and multilayer transfer media for transferring a substance to and from an array are disclosed herein. Also disclosed herein are methods of detecting a substance that has been transferred to an array. | 05-05-2011 |
20110105357 | METHOD FOR ANALYSIS USING NUCLEIC ACID MICROARRAY - An analytical method aided with a nucleic acid microarray, the nucleic acid microarray having a spot (X 1) onto which a first probe nucleic acid is immobilized, the method includes: allowing a labeled sample nucleic acid (A 1) of a sample to be tested to hybridize with the first probe nucleic acid; providing the spot (X 1) with a labeled verification nucleic acid (B) that has a sequence capable of hybridizing with at least a part of the first probe nucleic acid and is labeled with a label different from the labeled sample nucleic acid (A 1), and allowing the labeled verification nucleic acid (B) to hybridize with at least the first probe nucleic acid at all spots; measuring a labeled quantity value (F 1) of the labeled sample nucleic acid (A 1); and measuring a labeled quantity value (Fc 1) of the labeled verification nucleic acid (B). | 05-05-2011 |
20110105358 | SINGLE MOLECULE REAL TIME SEQUENCER, NUCLEIC ACID ANALYZER AND SINGLE MOLECULE REAL TIME SEQUENCING METHOD - An object of the present invention relates to selectively control an extension reaction within a desired area in a substrate. In the present invention, an oligo probe arranged with a caged compound at the terminal thereof is immobilized to a reaction field area in the substrate. After pouring a reaction solution into a flow cell including the reaction field area, the reaction field area alone is irradiated with light to associate the photodegradation-active protecting group at the terminal of the oligo probe that has been immobilized in the reaction field area and thus to selectively control initiation of a polymerase extension reaction. In the flow cell, a plural number of the reaction field areas are arranged at constant interval on the substrate. The flow cell immobilized to a moving stage is moved by a distance equal to the interval between the adjacent reaction field areas and then light irradiation is carried out to measure the extension reaction continuously. By repeating these operations, the base extension reaction is stably measured in the flow cell without using complicated channels or without replacing the reaction solution. | 05-05-2011 |
20110111969 | NOVEL METHOD FOR SIMULTANEOUS DETECTION AND DISCRIMINATION OF BACTERIAL, FUNGAL, PARASITIC AND VIRAL INFECTIONS OF EYE AND CENTRAL NERVOUS SYSTEM - The present invention relates to the diagnostic methods for identification of the single causative agent or more than one causative agent of ocular and nervous system infections among many probable pathogens, which can cause the infection. All the pathogens affecting a discrete area of eye or nervous system generally cause same clinical manifestations or syndromes. The present invention relates to detection and discrimination of the pathogen among the set of probable pathogens in a single test without resorting to a battery of tests each being directed at detection of one pathogen. The current invention aims at the syndrome based diagnostic replacing the diagnostics based on detection of individual pathogens. | 05-12-2011 |
20110111970 | MICROCHIP FOR IDENTIFYING PHELLINUS SPECIES AND THE METHOD THEREOF - The developed oligonucleotide microchip for simultaneous, rapid identification of multiple crucial forest | 05-12-2011 |
20110111971 | METHODS FOR DETECTION OF GENETIC DISORDERS - The invention provides a method useful for detection of genetic disorders. The method comprises determining the sequence of alleles of a locus of interest, and quantitating a ratio for the alleles at the locus of interest, wherein the ratio indicates the presence or absence of a chromosomal abnormality. The present invention also provides a non-invasive method for the detection of chromosomal abnormalities in a fetus. The invention is especially useful as a non-invasive method for determining the sequence of fetal DNA. The invention further provides methods of isolation of free DNA from a sample. | 05-12-2011 |
20110111972 | SELECTIVITY PROFILING OF PI3K INTERACTING MOLECULES AGAINST MULTIPLE TARGETS - The present invention relates to methods wherein a PI3K interacting compound is identified by incubating a PI3K containing protein preparation with phenyl thiazole ligand 1. | 05-12-2011 |
20110111973 | BROAD SPECIFICITY AFFINITY ARRAYS: A QUALITATIVE APPROACH TO COMPLEX SAMPLE DISCRIMINATION - Described is a method for discriminating complex biological samples using an array of discrete biological sensing elements immobilized onto a solid support in which constituents bound to the sensor array is directly determined by measuring the mass increase on the surface; data analysis of said method is performed using neutral network or statical based pattern recognition techniques. In a preferred embodiment the liquid sample is tested for the presence of soluble constituent(s) by contacting said sample with said sensor array under specific conditions, removing unbound sample constituent(s), determining the mass increase on the surface and comprising said mass increase data with a reference standard using pattern recognition software. | 05-12-2011 |
20110111974 | Short Duplex Probes for Enhanced Target Hybridization - The present disclosure is directed to compositions and methods for detecting or associating with a target polynucleotide. | 05-12-2011 |
20110111975 | PROBE FOR NUCLEIC ACID SEQUENCING AND METHODS OF USE - A nanoprobe for sequencing of nucleic acid molecules is provided, as well as methods for using the nanoprobe. In particular examples, the probe includes a polymerizing agent and one or more molecular linkers that carry a chemical moiety capable of reversibly binding to the template strand of a nucleic acid molecule, without being detached from the linker, by specifically binding with a complementary nucleotide in the target nucleic acid molecule. The reversible binding of the chemical moiety on the linker with a complementary nucleotide in the target nucleic acid molecule is indicated by emission of a characteristic signal that indicates pairing of the chemical moiety on the linker with its complementary nucleotide. An example of such a chemical moiety is a nonhydrolyzable nucleotide analog. In particular examples, the polymerizing agent and the chemical moiety are associated with a tag, such as a donor fluorophore and acceptor fluorophore characteristic of the particular type of chemical moiety. | 05-12-2011 |
20110111976 | MICRORNA BIOMARKERS OF TISSUE INJURY - One aspect of the invention generally relates to use of tissue enriched miRNAs as biomarker to estimate tissue damage in a fluid sample. In a second aspect, methods are provided for monitoring a subject who is exposed or might have been exposed to an agent that has a risk of causing tissue injury. In a third aspect, methods are provided for identifying an agent as having a risk of causing tissue injury to a vertebrate subject. In a fourth aspect, kits are provided for practicing the methods of above-listed aspects. The contents of this ABSTRACT are not intended to in anyway limit the scope of the inventions claimed herein. | 05-12-2011 |
20110111977 | HIGH THROUGHPUT SCREENING METHOD AND USE THEREOF TO IDENTIFY A PRODUCTION PLATFORM FOR A MULTIFUNCTIONAL BINDING PROTEIN - Methods of identifying and expressing an antibody variant are disclosed wherein the method comprises identifying a binding region in an antibody, fusing the binding region to a plurality of scaffolds of antibody constant regions to obtain antibody fragment variants, expressing the antibody fragment variants in organisms to form constructs and expressing the constructs carried by the organisms to form induced cultures, wherein the organisms are expressed in HTP mode. | 05-12-2011 |
20110111978 | DIVERSE CHEMICAL LIBRARIES BOUND TO SMALL PARTICLES WITH PARAMAGNETIC PROPERTIES - The present invention provides diverse chemical libraries bound to small particle with paramagnetic properties. Typically, the chemical structures comprise a plurality of different chemical moieties, the particles are paramagnetic and have a diameter between about 100 nm and about 10 microns, the chemical structures bound to each particular particle have substantially the same structure and the combinatorial library comprises at least 100,000 different chemical structures. | 05-12-2011 |
20110111979 | Prostate Cancer-Related Compositions, Methods and Kits Based on DNA Microarray Proteomics Platforms - The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer, The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue. | 05-12-2011 |
20110118134 | Biomarkers for insulin sensitizer drug response - The invention provides compositions and methods for determining insulin sensitizer drug response in a subject. The invention also provides compositions and methods for treating a subject according to insulin sensitizer drug response. | 05-19-2011 |
20110118135 | Mutations in Contaction Associated Protein 2 (CNTNAP2) are Associated with Increased Risk for Ideopathic Autism - The present invention provides compositions and methods for the examination of cells, tissues, and fluids, collectively known as body samples, to identify human subjects at-risk of developing Autism Spectrum Disorder by detecting a chromosomal abnormality or variant in the CNTNAP2 gene, the AUTS2 gene, or both. | 05-19-2011 |
20110118136 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions - Capture compounds and collections thereof and methods using the compounds for the analysis of biomolecules are provided. In particular, collections, compounds and methods are provided for analyzing complex protein mixtures, such as the proteome. The compounds are multifunctional reagents that provide for the separation and isolation of complex protein mixtures. Each compound has the formula: | 05-19-2011 |
20110118137 | USE OF MASS LABELED PROBES TO DETECT TARGET NUCLEIC ACIDS USING MASS SPECTROMETRY - The invention relates to the use of mass labeled probes to characterise nucleic acids by mass spectrometry. Thus the invention provides methods of detecting the presence of a target nucleic acid in a sample, using a circularising probe in which a mass tag is present in the probe. Further methods of detecting the presence of a target nucleic acid are provided, which in contrast use a probe detection sequence in the circularising probe, wherein the probe detection sequence is detected with a probe attached to a mass tag. Methods for determining a genetic profile from the genome of an organism also form part of the invention. | 05-19-2011 |
20110118138 | SOLID PHASE MULTI-ANALYTE ASSAY - Compositions and methods for detecting the presence and/or amount of one or more analytes, including analytes such as drugs of abuse, are provided. The compositions include two or more analytes associated with a solid phase, e.g., a particle or a multiwell plate. The compositions and methods also allow the simultaneous, tandem, or serial determination of the presence and/or amount of two or more analytes of interest in a sample. | 05-19-2011 |
20110118139 | Manipulation of Microparticles In Microfluidic Systems - An array of transportable particle sets is used in a microfluidic device for performing chemical reactions in the microfluidic device. The microfluidic device comprises a main channel and intersecting side channels, the main channel and side channels forming a plurality of intersections. The array of particle sets is disposed in the main channel, and the side channels are coupled to reagents. As the particle sets are transported through the intersections of the main channel and the side channels, reagents are flowed through the side channels into contact with each array member (or selected array members), thereby providing a plurality of chemical reactions in the microfluidic system. | 05-19-2011 |
20110118140 | METHODS FOR IDENTIFICATION, AND COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES - The present invention relates to in vivo and in vitro methods, agents and compound screening assays for inhibiting extra-cellular matrix degradation, including joint degenerative inhibiting and/or anti-inflammatory pharmaceutical compositions, and the use thereof in treating and/or preventing a disease involving extra-cellular matrix degradation in a subject. | 05-19-2011 |
20110118141 | Disease Specific Diagnostic Aid - A disease specific panel having at least one primary test for different analytes that are relevant for either early detection of a primary disease or management of patients already diagnosed with said primary disease. The panel also includes at least one secondary test which is relevant for detection of a co-morbid condition or complications of the primary disease. Generally, the primary and secondary tests are disposed on a support surface. The disease specific panel is different from the prior art creening tests in that there are no tests included in the panel whose results are not relevant or do not relate to either primary disease or a co-morbid condition or complications of the primary disease. The disease specific panel may also include systems and methods utilizing algorithms for creating and outputting diagnostic aids, as well as warnings about the presence of possible sample interferants, especially those commonly associated with the subject disease of the panel. | 05-19-2011 |
20110124516 | Polymer Particles and Uses Thereof - The present invention relates to polymer particles and uses thereof. The polymer particle may comprise a polymer selected from poly-beta-amino acids, polylactates, polythioesters and polyesters. In particular the present invention relates to functionalised polymer particles, processes of production and uses thereof. The methods, polymer particles and fusion proteins of the present invention have utility in diagnostics, protein production, biocatalyst immobilisation, and drug delivery. | 05-26-2011 |
20110124517 | Process for Determining the Genotype from a Biological Sample Containing Nucleic Acids of Different Individuals - The present Invention relates to a process for determining the genotype of one or more individuals from a biological sample which contains nucleic acids from different individuals, in particular a process for determining the number of copies of a predetermined sequence, in which first using at least two subquantities of the biological sample of different concentrations, in each case at least one amplification reaction is carried out, subsequently the number of the different amplification products obtained for each of the at least two subquantities is determined and compared with one another, and finally the amplification products which were obtained only for one defined subquantity and/or those amplification products which were obtained for all subquantities, are characterized. In addition, the present invention relates to a kit for carrying out the process according to the invention. | 05-26-2011 |
20110124518 | METHODS AND COMPOSITIONS FOR THE ANALYSIS OF BIOLOGICAL MOLECULES - Provided herein are compositions and methods for analysis of nucleic acids, including, methods and compositions for genotyping, haplotyping, sequencing and performing other genetic and epigenetic analyses on nucleic acids, for example. In some embodiments, methods and compositions suitable for whole-genome sequencing on single molecules of nucleic acid are provided. In some embodiments, analysis of single molecules of nucleic acid are performed in conjunction with nanopores and/or nanopore devices. | 05-26-2011 |
20110124519 | METHOD OF ASSESSING KIDNEY FUNCTION IN A HUMAN SUBJECT - A method of assessing kidney function in a human subject to aid in the diagnosis of renal tubule diseases or conditions specific to a particular renal tubule region, comprises contacting a urine sample from said subject with a panel of capture molecules, each capture molecule being capable of binding to a specific biomarker from at least one of the four major regions of the renal tubule, in particular the proximal, distal, collecting duct and loop of Henle regions, the detection of one or more biomarkers in the urine sample being indicative of damage in a corresponding region of the renal tubule. The method facilitates inter alia the non-invasive detection of renal tubule damage and serves as a prognostic method to determine the level of tubule damage and monitor the effectiveness of therapeutic treatment. | 05-26-2011 |
20110124520 | Compositions and Methods for Spatial Separation and Screening of Cells - The invention provides a method for isolating particular members from a library of variant cells in individual microreactors, wherein the phenotype of the biomolecule secreted by the cell is evaluated on the basis of multiple parameters, including substrate specificity and kinetic efficiency. | 05-26-2011 |
20110124521 | Use of MiR-26 Family as a Predictive Marker for Hepatocellular Carcinoma and Responsiveness to Therapy - It is disclosed herein that expression of microRNA-26 is decreased in hepatocellular (HCC) tumor tissue relative to non-cancerous tissue, and that a low level of microRNA-26 is associated with a poor clinical outcome. It is also disclosed herein that a low expression level of microRNA-26 is correlated with a favorable response to interferon (IFN)-α therapy in HCC patients. Thus, provided herein is a method of predicting the clinical outcome of a patient diagnosed with HCC comprising detecting the level of microRNA-26 expression in a sample obtained from the patient. Also provided is a method of selecting a patient diagnosed with HCC as a candidate for IFN-α therapy, comprising detecting the level of microRNA-26 expression in a sample obtained from the patient. A method of identifying therapeutic agents for the treatment of HCC, comprising screening candidate agents in vitro to select an agent that increases expression of microRNA-26 in HCC cells are also provided. Further provided are methods of treating a patient diagnosed with HCC and expressing a low level of miR-26, wherein treatment comprises IFN-α therapy. | 05-26-2011 |
20110130299 | PLASTIDIAL MICROARRAY - The present invention relates to a plastidial microarray comprising a solid support which comprises a multiplicity of elemental sites, each elemental site comprising several copies of the same nucleic acid probe, said probe being single-stranded, comprising between 50 and 70 nucleotides and corresponding to a sense oligonucleotide in a chloroplastid gene of | 06-02-2011 |
20110130300 | ASSAY FOR DIAGNOSING STREPTOCOCCUS PNEUMONIAE - Assays for detecting anti-streptococcal antibodies in biological samples using one or more streptococcal antigens are described herein. Various combinations of antigens may be used in the assays. For example, one or more of Ply, PhtD, PhtE, LytB and PcpA may be utilized. Additional streptococcal antigens may also be used. The assays may also be used in combination with assays that detect streptococcal nucleic acids. | 06-02-2011 |
20110130301 | Settings for recombinant adenoviral-based vaccines - Described are of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, described are assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting. | 06-02-2011 |
20110130302 | BIOLOGICAL PATHWAYS ASSOCIATED WITH CHEMOTHERAPY OUTCOME FOR BREAST CANCER - The present invention provides methods for preparing drug response and/or resistance profiles for breast tumor specimens, or cells derived therefrom. The drug response and/or resistance profiles are useful for determining effective chemotherapeutic agents for treatment of the tumor or cell to thereby individualize patient therapy. In other aspects, the invention provides a method for identifying a pathway or gene expression signature indicative of a breast cancer cell's sensitivity to a chemotherapeutic agent, which is useful for identifying a population response rate, or patient sub-population likely to respond to the drug candidate. | 06-02-2011 |
20110130303 | IN VITRO DIAGNOSIS/PROGNOSIS METHOD AND KIT FOR ASSESSMENT OF TOLERANCE IN LIVER TRANSPLANTATION - In vitro diagnosis/prognosis method and kit, for assessment of tolerance in liver transplantation. The present invention refers to the study of peripheral blood transcriptional patterns from 80 liver transplant recipients and 16 non-transplanted healthy individuals employing either oligonucleotide microarrays and/or quantitative real-time PCR to design a clinically applicable molecular test. This has resulted in the discovery and validation of several gene signatures comprising a modest number of genes capable of identifying tolerant and non-tolerant recipients with high accuracy. The marker genes are KLRF1, SLAMF7, NKG7, IL2RB, KLRB1, FANCG, GNPTAB, CLIC3, PSMD14, ALG8, CX3CR1, RGS 3. Multiple peripheral blood lymphocyte subsets contribute to the tolerance-associated transcriptional patterns with NK and γdelta T cells exerting a predominant influence. The invention concludes that transcriptional profiling of peripheral blood can be employed to identify liver transplant recipients who can discontinue immunosuppressive therapy and that innate immune cells are likely to play a major role in the maintenance of operational tolerance in liver transplantation. | 06-02-2011 |
20110136687 | METHOD FOR DETERMINING THE DEGREE OF METHYLATION OF DEFINED CYTOSINES IN GENOMIC DNA IN THE SEQUENCE CONTEXT OF 5'-CpG-3' - A method is described for the detection of the degree of methylation of a specific cytosine in the sequence context 5′-CpG-3′ of a genomic DNA sample. In the first step, the genomic DNA is chemically treated in such a way that the cytosine bases are converted to uracil, but not the 5-methylcytosine bases. Then segments of the genomic DNA which contain the said specific cytosine are amplified, whereby the amplified products are given a detectable label and in the following steps the extent of hybridization of the amplified products on two classes of oligonucleotides is determined by detection of the label of the amplified products, and a conclusion is made on the extent of methylation of said specific cytosine in the genomic DNA sample from the ratio of the labels detected on the two classes of oligonucleotides as a consequence of the hybridization. | 06-09-2011 |
20110136688 | RECOMBINANT BACTERIOPHAGE AND METHODS FOR THEIR USE - Modified forms of naturally occurring bacteriocins, such as the R-type pyocins of | 06-09-2011 |
20110136689 | Dual Expression Vector System for Antibody Expression in Bacterial and Mammalian Cells - The present invention provides a dual expression vector, and methods for its use, for the expression and secretion of a full-length polypeptide of interest in eukaryotic cells, and a soluble domain or fragment of the polypeptide in bacteria. When expressed in bacteria, transcription from a bacterial promoter within a first intron and termination at the stop codon in a second intron results in expression of a fragment of the polypeptide, e.g., a Fab fragment, whereas in mammalian cells, splicing removes the bacterial regulatory sequences located in the two introns and generates the mammalian signal sequence, allowing expression of the full-length polypeptide, e.g., IgG heavy or light chain polypeptide. The dual expression vector system of the invention can be used to select and screen for new monoclonal antibodies, as well as to optimize monoclonal antibodies for binding to antigenic molecules of interest. | 06-09-2011 |
20110136690 | METHODS FOR IDENTIFYING AND MONITORING DRUG SIDE EFFECTS - The present invention relates generally to methods for identifying drug side effects by detecting perturbations in organ-specific molecular blood fingerprints. The invention further relates to methods for identifying drug-specific organ-specific molecular blood fingerprints. As such, the present invention provides compositions comprising organ-specific proteins, detection reagents for detecting such proteins, and panels and arrays for determining organ-specific molecular blood fingerprints. | 06-09-2011 |
20110143953 | Synthetic Antibodies - The present invention provides methods for synthetic antibodies, methods for making synthetic antibodies, methods for identifying ligands, and related methods and reagents. | 06-16-2011 |
20110143955 | Protein Capture, Detection and Quantitation - This invention is related to the area of the capture, detection and quantitation of proteins. In particular, it relates to making and using recombinant antibodies bound to oligonucleotides and using such complexes for analytic purposes. These techniques are designed to permit multiplexed detection and quantitation of very large numbers of proteins. | 06-16-2011 |
20110143956 | Diagnostic Kits and Methods for SCD or SCA Therapy Selection - Variations in certain genomic sequences useful as genetic markers of Sudden Cardiac Death (“SCD”) or Sudden Cardiac Arrest (“SCA”) risk are described. Novel diagnostic kits, DNA microarrays, and methods employing these genetic markers are used in assessing the risk of SCD or SCA. Methods of distinguishing patients having an increased susceptibility to SCD or SCA, through use of these markers, alone or in combination with other markers, are also provided. Further, methods of detecting a polymorphism associated with SCD or SCA are taught. | 06-16-2011 |
20110143957 | SUBTRACTIVE SINGLE LABEL COMPARATIVE HYBRIDIZATION - Provided are methods of determining differences between nucleic acids in a test sample and a reference sample. In certain embodiments the methods are used for detecting and mapping chromosomal or genetic abnormalities associated with various diseases or with predisposition to various diseases, or to detecting the phenomena of large scale copy number variants. In particular, provided are advanced methods of performing array-based comparative hybridization that allow reproducibility between samples and enhanced sensitivity by using the same detectable label for both test sample and reference sample nucleic acids. Invention methods are useful for the detection or diagnosis of particular disease conditions such as cancer, and detecting predisposition to cancer based on detection of chromosomal or genetic abnormalities and gene expression level. Invention methods are also useful for the detection or diagnosis of hereditary genetic disorders or predisposition thereto, especially in prenatal samples. | 06-16-2011 |
20110143958 | Methods of Identifying Modulators of Ubiquitin Ligases - Methods for identifying ubiquitin ligases and ubiquitin ligase modulators are disclosed. The methods comprise combining the components of a ubiquitylation reaction and using proteins that contain motifs that recognize ubiquitylated sites in the detection of ubiquitylation. | 06-16-2011 |
20110143959 | COMPOSITIONS AND METHODS FOR DETERMINING THE PROGNOSIS OF BLADDER UROTHELIAL CANCER - Described herein are compositions and methods for the prediction of bladder cancer risk of invasiveness. The compositions are microRNA molecules associated with the prognosis of bladder cancer, as well as various nucleic acid molecules relating thereto or derived therefrom. | 06-16-2011 |
20110152110 | Set of Tumour-Markers - The present invention provides a set of moieties specific for tumor markers, in particular of follicular thyroid carcinoma (FTC) and papillary thyroid carcinoma (PTC) as well as a method for identifying markers of any genetic disease. | 06-23-2011 |
20110152111 | MULTIPLEX NUCLEIC ACID ANALYSIS USING ARCHIVED OR FIXED SAMPLES - The present invention is directed to compositions and methods for multiplex analyses of nucleic acids from archival tissues. | 06-23-2011 |
20110152112 | DIAGNOSIS AND TREATMENT OF REVERSE CHOLESTEROL TRANSPORT DEFICIENCY-RELATED DISEASES - The present invention provides compositions and methods to assess the state of a reverse cholesterol transport (RCT). In one aspect of the invention provides methods, compositions and kits for diagnosing a subject with deficient reverse cholesterol transport (RCT). In another aspect, the present invention provides a method of identifying responders to RCT treatment. In yet another aspect, the present invention provides a method of treating a subject with RCT deficiency. Also provided by the present invention is a method for drug screening and/or assessing risk of toxicity associated with RCT treatments. | 06-23-2011 |
20110152113 | GENOMIC FINGERPRINT OF BREAST CANCER - The present invention relates to in vitro methods for determining the prognosis of a subject diagnosed with breast cancer developing metastasis or for selecting suitable treatment for said subject. Particularly, the invention relates to a signature of genes the expression of which is correlated with the prognosis of a subject who has been diagnosed with breast cancer. | 06-23-2011 |
20110152114 | SHORT CYCLE METHODS FOR SEQUENCING POLYNUCLEOTIDES - The invention provides methods for sequencing a polynucleotide comprising stopping an extension cycle in a sequence by synthesis reaction before the reaction has run to near or full completion. | 06-23-2011 |
20110152115 | METHODS FOR IDENTIFYING, DIAGNOSING, AND PREDICTING SURVIVAL OF LYMPHOMAS - The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information is useful in developing the appropriate therapeutic approach for use with a particular subject. | 06-23-2011 |
20110152116 | NANOASSAYS - The present invention provides assays of nanometer-level dimension. | 06-23-2011 |
20110152117 | METHODS OF DETERMINING EFFICACY OF TREATMENTS OF DISEASES OF THE BOWEL - Novel methods of determining efficacy of a treatment of inflammatory diseases of the bowel in mammals are provided. The methods are of use in screening and determining the efficacy of treatments of inflammatory diseases of the bowel, and for determining the efficacy response of individual sufferers of inflammatory diseases of the bowel to a given regime. Kits for carrying out the method are also provided. | 06-23-2011 |
20110152118 | METHOD AND SYSTEM FOR DETERMINATION OF MOLECULAR INTERACTION PARAMETERS - A method of determining kinetic parameters for a reversible molecular interaction between a ligand immobilized to a solid support surface and a binding partner to the ligand in solution, comprises sequentially, without intermediate regeneration or renewal of the immobilized ligand, flowing a plurality of fluid volumes containing different known concentrations of the binding partner over the solid support surface, monitoring the momentary amount of binding partner bound to the solid support surface related to time and solution concentration of binding partner and collecting the binding data, and determining the kinetic parameters by globally fitting a predetermined kinetic model for the interaction between the binding partner and the immobilized ligand to the collected binding data, which model allows for mass transport limitation at the solid support surface. An analytical system for carrying out the method, a computer program, a computer program product and a computer system for performing the method are also disclosed. | 06-23-2011 |
20110152119 | Quantification Method of Biochemical Substances Using Ion Scattering Spectroscopy and Specific-Binding Efficiency Quantification Method of Biochemical Substances Using Ion Scattering Spectroscopy - A method for direct quantification of the areal density (number per surface area of a substrate) of an analyte including a biochemical substance bound on the surface of a substrate and for direct quantification of the binding efficiency of biochemical substances is disclosed. Specifically, the areal density of an analyte including a biochemical substance bound on the surface of a substrate, and the binding efficiency between a first biochemical substance fixed on the substrate surface and a second biochemical substance is measured by ion scattering spectroscopy (ISS). | 06-23-2011 |
20110152120 | METHOD OF CHARACTERIZING ANTIBODIES - A method of characterizing a population of antibodies to an antigen comprises contacting a sensor surface having the antigen immobilized thereto with a sample containing the antibody population to bind antibodies to the surface, and detecting dissociation of antibodies from the sensor surface during a dissociation phase when sample no longer contacts the surface. Based on the dissociation behaviour, the antibody population is characterized in terms of subpopulations of more and less stable antibodies, respectively. The method may be used to determine the immunogenicity of drug by monitoring the appearance of anti-drug antibodies in a patient over time, and determining any shift in proportions between more stable and less stable antibodies. | 06-23-2011 |
20110152121 | APPARATUS AND METHOD FOR MULTIPLE IMMUNOASSAYS ON A CHIP - Provided are a multiple immunoassay apparatus on a chip in which a structure comprising multiple microfluidic channels is associated with a tissue sample, which allows immunohistochemical reactions to be conducted therein, to examine various markers specific for certain diseases, and a method for performing multiple immunoassays using the same. The multiple immunoassay apparatus comprises: at least one antibody-introducing unit through which at least one antibody is introduced into the apparatus; at least one reaction unit in which the antibody reacts with a sample in an immunohistochemical pattern; and at least one fluid outlet through which a fluid including the antibody is discharged outside the apparatus. | 06-23-2011 |
20110160072 | METHOD OF DIAGNOSING NEOPLASMS - The present invention relates generally to a nucleic acid molecule, the RNA and protein expression profiles of which are indicative of the onset, predisposition to the onset and/or progression of a large intestine neoplasm. More particularly, the present invention is directed to a nucleic acid molecule, the expression profiles of which are indicative of the onset and/or progression of a colorectal neoplasm, such as an adenoma or an adenocarcinoma. The expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenomas and adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening a subject for the onset, predisposition to the onset and/or progression of a large intestine neoplasm by screening for modulation in the expression profile of said nucleic acid molecule markers. | 06-30-2011 |
20110160073 | SYSTEMS AND METHODS FOR FLUORESCENCE DETECTION WITH A MOVABLE DETECTION MODULE - A fluorescence detection apparatus for analyzing samples located in a plurality of wells in a thermal cycler and methods of use are provided. In one embodiment, the apparatus includes a support structure attachable to the thermal cycler and a detection module movably mountable on the support structure. The detection module includes one or more channels, each having an excitation light generator and an emission light detector both disposed within the detection module. When the support structure is attached to the thermal cycler and the detection module is mounted on the support structure, the detection module is movable so as to be positioned in optical communication with different ones of the plurality of wells. The detection module is removable from the support structure to allow easy replacement. | 06-30-2011 |
20110160074 | Capture Ligand Controls, Blocking Probes, Masking Probes and Methods of Using the Same - The invention, depending on aspect and embodiment, relates to capture probe controls, and capture and signal probe configurations and combinations of configurations that can facilitate accurate and efficient multiplex analyte detection, especially in electrochemical detection schemes. | 06-30-2011 |
20110160075 | Diagnostic assay for orientia tsutsugamushi by detection of responsive gene expression - The inventive subject matter relates to a method for the diagnosis of | 06-30-2011 |
20110160076 | Methods for producing uniquely specific nucleic acid probes - Disclosed herein are uniquely specific nucleic acid probes and methods for their use and production. The disclosed probes have reduced or eliminated background signal while reducing or eliminating the use of blocking DNA during hybridization. In one example, probes are produced by a method that includes joining at least a first binding region and a second binding region in a pre-determined order and orientation, wherein the first binding region and second binding region are complementary to uniquely specific nucleic acid sequences, wherein the uniquely specific nucleic acid sequences are represented only once in a genome of an organism and wherein the first binding region and the second binding region include about 20% or less of a genomic target nucleic acid molecule. In particular examples, the binding regions (“uniquely specific binding regions”) are complementary to non-contiguous portions of the genomic target nucleic acid. Methods of using the disclosed probes and kits including the probes and/or reagents for producing or using the probes are also disclosed. | 06-30-2011 |
20110160077 | SEQUENCING METHODS USING ENZYME CONFORMATION - Systems and methods are provided for single-molecule sequencing of template nucleic acids in which the signal from a label attached to a polymerase enzyme is used to monitor conformational changes in the polymerase which occur while labeled nucleotides or nucleotide analogs are added to a growing nucleic acid chain which is complementary to the template nucleic acid. The signal indicative of the conformational state of the enzyme is used to determine with higher confidence when true nucleotide or nucleotide analog incorporation events occur, allowing for the improved quality of base calls and sequence determination. | 06-30-2011 |
20110160078 | Digital Counting of Individual Molecules by Stochastic Attachment of Diverse Labels - Compositions, methods and kits are disclosed for high-sensitivity single molecule digital counting by the stochastic labeling of a collection of identical molecules by attachment of a diverse set of labels. Each copy of a molecule randomly chooses from a non-depleting reservoir of diverse labels. Detection may be by a variety of methods including hybridization based or sequencing. Molecules that would otherwise be identical in information content can be labeled to create a separately detectable product that is unique or approximately unique in a collection. This stochastic transformation relaxes the problem of counting molecules from one of locating and identifying identical molecules to a series of binary digital questions detecting whether preprogrammed labels are present. The methods may be used, for example, to estimate the number of separate molecules of a given type or types within a sample. | 06-30-2011 |
20110160079 | TOOL FOR DIAGNOSIS AND PROGNOSIS OF MATURE B-CELL NEOPLASMS - The present invention provides a microarray useful as a tool in the diagnosis and/or prognosis of certain types of cancers, particularly mature B-cell neoplasms. The microarray can include a plurality of genomic regions represented thereon, the genomic regions corresponding to regions wherein alterations, such as copy number alterations, at such locations correlate to specific, identifiable cancers, particularly mature B-cell neoplasms. The invention further provides methods of diagnosing and providing prognosis certain types of cancer, particularly mature B-cell neoplasms. The methods can comprise contacting a sample to a microarray according to the invention, allowing any genetic material in the sample to hybridize to the genomic regions on the microarray, analyzing the hybridizations, and correlating the hybridizations to certain cancer types, particularly mature B-cell neoplasms. | 06-30-2011 |
20110160080 | Diagnosis of Melanoma and Solar Lentigo by Nucleic Acid Analysis - The present invention provides methods for diagnosing melanoma and/or solar lentigo in a subject by analyzing nucleic acid molecules obtained from the subject. The present invention also provides methods for distinguishing melanoma from solar lentigo and/or dysplastic nevi and/or normal pigmented skin. The methods include analyzing expression or mutations in epidermal samples, of one or more skin markers. The methods can include the use of a microarray to analyze gene or protein profiles from a sample. | 06-30-2011 |
20110160081 | FUNCTIONAL COMPLEMENTATION ASSAY FOR DEFINED GPCR OLIGOMERS - The present invention is directed to, inter alia, a biological reagent that includes a complex having a first GPCR and a second GPCR linked to a G-protein, the linkage between the second GPCR and the G-protein being of a length, which pre-vents productive interaction between the G-protein and the second GPCR, wherein the first GPCR and the second GPCR linked to the G-protein alone are incapable of producing a signal when presented with a ligand. The invention also provides methods of producing such a biological reagent, as well as methods of determining oligomeric GPCR interactions, methods of identifying compounds that have an effect on GPCR oligomers, methods of identifying a compound capable of interacting with GPCR oligomers, methods of identifying a compound having the ability to modulate binding between a GPCR oligomer and its ligand, and methods for evaluating differential G-protein coupling. | 06-30-2011 |
20110160082 | Mobility-Modified Nucleobase Polymers and Methods of Using Same - The present invention relates generally to nucleobase polymer functionalizing reagents, to mobility-modified sequence-specific nucleobase polymers, to compositions comprising a plurality of mobility-modified sequence-specific nucleobase polymers, and to the use of such polymers and compositions in a variety of assays, such as, for example, for the detection of a plurality of selected nucleotide sequences within one or more target nucleic acids. The mobility-modifying polymers of the present invention include phosphoramidite reagents which can be joined to other mobility-modifying monomers and to sequence-specific oligonucleobase polymers via uncharged phosphate triester linkages. Addition of the mobility-modifying phosphoramidite reagents of the present invention to oligonucleobase polymers results in unexpectedly large effects the mobility of those modified oligonucleobase polymers, especially upon capillary electrophoresis in non-sieving media. | 06-30-2011 |
20110160083 | HIGH SPATIAL RESOLUTION IMAGING OF A STRUCTURE OF INTEREST IN A SPECIMEN - For imaging of a structure, the structure is marked with a substance which can be converted by a switching signal from a first into a second state, and which provides an optical measurement signal in one of its states, only. The switching signal is applied such that at least 10% of the molecules of the substance being in the measurement signal providing state are at a distance from their closest neighbors, which is greater than the spatial resolution limit of imaging the specimen onto a sensor array, which in turn is greater than an average distance between the molecules of the substance. From an intensity distribution of the measurement signal recorded with the sensor array, the position is only determined for those molecules of the substance which are at a distance from their closest neighboring molecules in the measurement signal providing state, which is greater than the spatial resolution limit. | 06-30-2011 |
20110160084 | Protein Chips for HPV Detection - Embodiments of the invention provide methods, assays, and kits for detecting HPV infection, including infection by various HPV genotypes, early and/or late HPV-associated or HPV-specific proteins or antibodies. Detection of HPV DNAs, genomes, and/or oncoproteins by protein chips immunological assays can be used in early clinical screening for HPV infection and general diagnosis for cervical cancer and can be advantageous performed in a multiplexed test. Comparative detection of altered levels of HPV proteins and host proteins can performed in one or more assays. The polypeptides, recombinant proteins, antibodies, nucleic acids, and various detection methods thereof are particularly useful for diagnosing carcinomas of the uterine cervix and those at risk of developing cervical cancer. | 06-30-2011 |
20110160085 | BIOMARKERS FOR ANTI-TNF TREATMENT IN ULCREATIVE COLITIS AND RELATED DISORDERS - Methods and kits for the assessment of the suitability of and/or effectiveness of a target therapy for a TNF mediated-related disorder, such as ulcerative colitis, in a subject, which methods and kits evaluate the presence, absence, and/or magnitude of expression of two or more genes up or down regulated in association with anti-TNF responders in inflammatory gastrointestinal disorders, such as ulcerative colitis | 06-30-2011 |
20110160086 | GENE EXPRESSION SIGNATURE FOR CLASSIFICATION OF KIDNEY TUMORS - The present invention provides a method for classification of kidney tumors through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA expression framework allows optimization of treatment, and determination of specific therapy. | 06-30-2011 |
20110166033 | Method and Apparatus for Forming of an Automated Sampling Device for the Detection of Salmonella Enterica Utilizing an Electrochemical Aptamer Biosensor - An aptamer-based solid-state electrochemical biosensor for label-free detection of | 07-07-2011 |
20110166034 | CAPTURE AGENTS AND RELATED METHODS AND SYSTEMS FOR DETECTING AND/OR SORTING TARGETS - Polynucleotide-encoded capture agents for target detection and in particular modular polynucleotide-capture agents comprising a target binding component, a scaffold component and an encoding component formed by standardized molecular units that can be coupled and decoupled in a controlled fashion, and related compositions methods and systems. | 07-07-2011 |
20110166035 | NOVEL DIAGNOSTIC METHOD - Provided herein are methods, compositions, and kits related to the detection and diagnosis of a neurodegenerative disorder, such as Alzheimer's disease. Various aspects use the oligomeric state of fragments of amyloid β as a biomarker and further concerns a novel method to determine the oligomeric state of fragments of amyloid β in biological samples. | 07-07-2011 |
20110166036 | MODULATION OF THE VPS10P-DOMAIN FOR THE TREATMENT OF CARDIOVASCULAR DISEASE - The present invention relates to methods for modulating the activity of one or more Vps10p-domain receptors selected from the group consisting of Sortilin, SorLA, SorCS1, SorCS2 and SorCS3, in an animal and methods for preparation of a medicament for the treatment of abnormal plasma lipid concentrations and associated diseases and/or disorders. The modulation is carried out by inhibiting or promoting the binding of ligands to the Vps10p-domain receptor. In vitro and in vivo methods for screening for agents capable of modulation of said Vps10p-domain receptor activity are also provided. The invention furthermore relates to methods of altering expression of said receptors in vivo. | 07-07-2011 |
20110166037 | Analysis of methylation using nucleic acid arrays - Arrays for genome-wide analysis of methylation are disclosed. IN a preferred aspect arrays comprising a plurality of probes complementary to a plurality of identified CpG islands in the human, mouse and rat genome are disclosed. The arrays may be used to detect methylation within cpG islands in samples from human, mouse and rat genomes. | 07-07-2011 |
20110172110 | TRACERS AND ASSEMBLY FOR LABELING CHEMICAL OR BIOLOGICAL MOLECULES METHODS AND KITS USING THE SAME - An improved process to create an arbitrarily large number of distinguishable particles allows more flexibility in experimental design and related efficiencies of scale. Novel enhanced tracers, for example, Shape Encoded Particles (SEP's) function as indicator means, such as probe-carriers in massively multiplexed assays. Shape encoded identity provides an elegantly simple tracking mechanism, whereby binding/reaction probes coupled to SEP's surfaces can be monitored, viewed, imaged or otherwise utilized leveraging off of the generation of millions of distinct, for example, approximately 100×100×10 micron squared silicon flakes fabricated using conventional MEMS techniques. Plethoric related applications, and contemplated strategies for benefiting from the novel enhanced SEP's and their respective enabling technologies are disclosed, ranging from pearl cultering seed elements to uniquely identify resulting jewelry pieces to an improved parallel stem cell differentiation screening assays. | 07-14-2011 |
20110172111 | SOLID PHASE SEQUENCING OF BIOPOLYMERS - This invention relates to methods for detecting and sequencing target nucleic acid sequences, to mass modified nucleic acid probes and arrays of probes useful in these methods, and to kits and systems which contain these probes. Useful methods involve hybridizing the nucleic acids or nucleic acids which represent complementary or homologous sequences of the target to an array of nucleic acid probes. These probes comprise a single-stranded portion, an optional double-stranded portion and a variable sequence within the single-stranded portion. The molecular weights of the hybridized nucleic acids of the set can be determined by mass spectroscopy, and the sequence of the target determined from the molecular weights of the fragments. Nucleic acids whose sequences can be determined include DNA or RNA in biological samples such as patient biopsies and environmental samples. Probes may be fixed to a solid support such as a hybridization chip to facilitate automated molecular weight analysis and identification of the target sequence. | 07-14-2011 |
20110172112 | Combination of Marker Genes for Characterizing a Lactobacillus Sakei Strain - The present invention relates to a new combination of marker genes for characterizing a | 07-14-2011 |
20110172113 | ABERRANT MITOCHONDRIAL DNA, ASSOCIATED FUSION TRANSCRIPTS AND HYBRIDIZATION PROBES THEREFOR - The present invention provides novel mitochondrial fusion transcripts and the parent mutated mtDNA molecules that are useful for predicting, diagnosing and/or monitoring cancer. Hybridization probes complementary thereto for use in the methods of the invention are also provided. | 07-14-2011 |
20110172114 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES - The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases. | 07-14-2011 |
20110172115 | CHARACTERISING PLANAR SAMPLES BY MASS SPECTROMETRY - The present invention is directed to probes and methods for the imaging of specimens such as tissue samples or other biological specimens or arrays using mass spectrometry (MS). In one aspect, there is provided a method for analysing a specimen comprising the steps of contacting the specimen with probe molecules each of which includes one or more mass tags coupled to each probe molecule via a first cleavable linker, contacting the specimen with a Matrix-assisted Laser Desorption lonisation (MALDI) matrix or similar material, irradiating a portion of the specimen with a laser beam to release ions from the specimen, selecting released ions with mass-to-charge ratios corresponding to the mass tags or derivatives of the mass tags, and recording the amount and type of ions selected together with the location of the portion of the specimen. The irradiation, selection and recording steps are then repeated on a different portion of the specimen. | 07-14-2011 |
20110172116 | Functional Porous Substrates For Attaching Biomolecules - A substrate comprising a microporous microstructure, an interlayer over at least a portion of the microstructure and a functional layer attached to the interlayer, the functional layer having functional sites with a density of at least 50 nanomoles/cm | 07-14-2011 |
20110172117 | MULTIPLEXED GENOMIC GAIN AND LOSS ASSAYS - Encoded bead multiplex assays for chromosomal gains and losses are provided that provide the benefits of complex, large template DNA sources, such as BAC DNA, as the probe material without bead networking or other assay performance problems. Reagents for assaying DNA are described herein which include a plurality of encoded particles having attached amplicons amplified from a template DNA sequence. Each individual attached amplicon includes a nucleic acid sequence identical to a random portion of the template DNA sequence, wherein the amplicons together represent substantially the entire template DNA and wherein the nucleic acid sequence identical to a random portion of the template DNA sequence of each individual amplicon is shorter than the entire template DNA. | 07-14-2011 |
20110172118 | ALTERNATIVE SUBSTRATES AND FORMATS FOR BEAD-BASED ARRAY OF ARRAYS - The present disclosure relates to composite arrays of various formats for simultaneous processing of multiple samples. Methods of making and using such arrays are also disclosed. | 07-14-2011 |
20110172119 | NUCLEIC ACID SAMPLE ENRICHMENT FOR SEQUENCING APPLICATIONS - The present invention relates to the field of molecular biology, and more specifically to methods for reducing the complexity of a nucleic acid sample. | 07-14-2011 |
20110177960 | Microarray for monitoring gene expression in multiple strains of Streptococcus pneumoniae - The present invention features an array capable of monitoring gene expression patterns of multiple strains of | 07-21-2011 |
20110177961 | Method of Diagnosing Active Mycobacterium Tuberculosis with Detecting Chip - The present disclosure diagnoses mycobacterium tuberculosis, not mycobacterium tuberculosis complex only. Specific target genes are selected from regions of difference of mycobacterium tuberculosis. After hybridization with labeling substances, sputum samples are processed through color developments separately for obtaining images to be analyzed automatically. Thus, the present disclosure rapidly diagnoses mycobacterium tuberculosis in the sputum samples with a simple operation and a low cost. | 07-21-2011 |
20110177962 | SUCCESSIVE SAMPLING DEVICE AND ASSOCIATED METHOD - A method of determining a number of a solution constituent includes introducing a first number of solution constituents to a first test location, establishing a first binding environment for the introduced first number of solution constituents, creating a first residual number of solution constituents by binding a first plurality of solution constituents, establishing a second binding environment for the first residual number of solution constituents, creating a second residual number of solution constituents by binding a second plurality of solution constituents from the first residual number of solution constituents, obtaining a first signal associated with the bound first plurality of solution constituents, obtaining a second signal associated with the bound second plurality of solution constituents, and determining a second number of a constituent of interest based upon the obtained first signal and the obtained second signal. | 07-21-2011 |
20110177963 | Variation in the CHI3L1 Gene Influences Serum YKL-40 Levels, Asthma Risk and Lung Function - The present invention is based on the discovery that a single nucleotide polymorphism (SNP) present the chitinase 3-like 1 gene (CHI3L1) encoding YKL-40 or a regulatory domain of the CHI3L1 gene, is associated with elevated YKL-40 levels, as well as an increased risk for developing a lung disorder, including asthma, bronchial hyperresponsivity, and/or reduced lung function. | 07-21-2011 |
20110177964 | CHEMOSENSORY ARRAYS - A chemosensor array, a method of detecting ligands in a chemical mixture and a chemosensor system are provided. Chemosensor array designs are also provided. | 07-21-2011 |
20110177965 | COMPOSITIONS AND METHODS FOR PROGNOSIS OF GASTRIC CANCER - Described herein are compositions and methods for survival prediction in gastric cancer patients after surgical operation. The compositions are microRNA molecules associated with the prognosis of gastric cancer, as well as various nucleic acid molecules relating thereto or derived therefrom. | 07-21-2011 |
20110177966 | METHOD FOR PREDICTING THE RESPONSE TO A TREATMENT WITH ANAKINRA - The invention relates to a method for predicting the response of a patient to a treatment with anakinra, said method comprising a step of measuring the expression level of 7 genes in a biological sample of said patient, wherein said genes are GT-F2F2, CCT3, CROT, HNRPA3, ARL15, TMED5, and NRG3. | 07-21-2011 |
20110177967 | METHODS AND COMPOSITIONS USING SPLICING REGULATORY PROTEINS INVOLVED IN TUMOR SUPPRESSION - Methods and compositions for diagnosis and prognosis of mammalian carcinoma or cancer derived from primary epithelial cells and tissue fibrosis are designed using newly identified epithelial cell-type specific splicing factors ESRP1 and ESRP2, which have roles in tumor suppression. Diagnostic reagents for the detection of these splicing factors in nucleotide or protein form are useful in such methods. Therapeutic compositions can provide epithelial cells with these factors to maintain FGFR2 and assist in suppressing metastasis. A high throughput splicing assay to identify compounds that change splicing events is described. RNCP1 is also identified as a splicing factor and a diagnostic for conditions characterized by inappropriate FGFR2-splicing. | 07-21-2011 |
20110177968 | MicroRNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF LUNG CANCER USING MIR-17-3P - The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of lung cancer. The invention also provides methods of identifying anti-lung cancer agents. | 07-21-2011 |
20110177969 | THE ROLE OF IL17RD AND THE IL23-1L17 PATHWAY IN CROHN'S DISEASE - The present invention relates to methods of diagnosing susceptibility to Crohn's Diseaese by determining the presence or absence of susceptibility variants at the IL17RD locus. in one embodiment, the present invention provides a method of diagnosing and/or predicting susceptibility to Crohn's Disease by determining the presence or absence of an interaction between IL17RD Block 2 Haplotype 2 and IL23R Block 2 Haplotype 2 and/or IL12RB2 Haplotype 4, where the presence of an interaction between IL17RD Block 2 Haplotype 2 and IL23R Block 2 Haplotype 2 and/or IL12RB2 Haplotype 4 is indicative of susceptibility to Crohn's Disease. | 07-21-2011 |
20110177970 | METHODS FOR PREDICTING OR MONITORING WHETHER A PATIENT AFFECTED BY A CANCER IS RESPONSIVE TO A TREATMENT WITH A MOLECULE OF THE TAXOID FAMILY - The present invention concerns in vitro methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family based on a resistance expression signature, kits for performing the methods, and methods for screening or identifying a compound suitable for improving the treatment of a cancer with a molecule of the taxoid family or for reducing the resistance development during the treatment of a cancer with the molecule of the taxoid family. | 07-21-2011 |
20110183860 | Protein Aggregation Domains and Methods of Use Thereof - Using the Sup35 prion proteins of two distantly related yeast species, it is established that prion replication is initiated by small elements of primary sequence, which can be identified using arrays of short peptides. Subtle differences in replication elements govern the formation of distinct aggregate conformations (prion strains) and also determine their species-specific seeding activities. A Sup35 chimera that promiscuously forms prions in more than one species does so by virtue of carrying the replication element of each species. Mutations or conditions that cause the chimera to assemble into distinct prion strains favor recognition of distinct replication elements. Therefore, subtle differences in small sequences that constitute prion replication elements encode important determinants of prion propagation and transmission. The protein aggregation domains, methods for identification thereof, and polypeptides and higher order aggregates including the protein interaction domains, as well as arrays including peptides derived from an aggregation-prone polypeptide are provided. | 07-28-2011 |
20110183861 | METHODS TO STABILIZE PROTEINS AND POLYPEPTIDES - Methods of modifying and in particular stabilizing proteins and polypeptides by which a predetermined amino acid is introduced into selected positions of said protein or polypeptide to produce a small group of mutants. The methods are based on the premise that certain amino acids play a crucial role in the stability of proteins or polypeptides. Generated mutants can then be further analysed for stability and/or function, e.g. affinity. Furthermore, appropriate mutants may be combined to result in further optimized proteins or polypeptides. In addition, stabilized example polypeptides and suitable methods to identify and/or analyse de-stabilized or stabilized proteins or polypeptides are provided. The methods can be used to study the role of specific amino acids in protein structure and function and to develop new or improved, e.g. stabilized proteins and polypeptides such as antibodies and single variable domains. | 07-28-2011 |
20110183862 | MOLECULAR SIGNATURE OF LIVER TUMOR GRADE AND USE TO EVALUATE PROGNOSIS AND THERAPEUTIC REGIMEN - The present invention concerns a method to determine the gene expression profile on a sample previously obtained from a patient diagnosed for a liver tumor, comprising assaying the expression of a set of genes in this sample and determining the gene expression profile (signature). In a particular embodiment, said method enables to determine the grade of the liver tumor, such as hepatoblastoma (HB) or a hepatocellular carcinoma (HCC). The invention is also directed to kits comprising a plurality of pairs of primers or a plurality of probes specific for a set of genes, as well as to solid support or composition comprising a set of probes specific for a set of genes. These methods are useful to determine the grade of a liver tumor in a sample obtained from a patient, to determine the risk of developing metastasis and/or to define the therapeutic regimen to apply to a patient. | 07-28-2011 |
20110183863 | PROTEIN SCREENING METHODS - The invention provides methods and compositions useful for identifying polypeptides with desired characteristics in vitro. | 07-28-2011 |
20110183864 | METHOD FOR LUNG CANCER EARLY DETECTION AND PROGNOSIS - The present invention provides method for the prognosis or detection of lung cancer, notably for early detection of lung cancer, as well as a kit and a (micro) array suitable for said method. | 07-28-2011 |
20110183865 | Lipoxygenase - The inventors have found a novel fungal lipoxygenase from | 07-28-2011 |
20110183866 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CANCER - The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides gene expression profiles and signatures associated with solid tumor stem cells, as well as novel stem cell cancer markers useful for the diagnosis, characterization, prognosis and treatment of solid tumor stem cells. More particularly, the present invention identifies two profiles of cancer stem cells useful for the diagnosis, characterization, and treatment of cancer and cancer metastases. The invention also provides a variety of reagents such as stem cell gene signatures for use in the diagnosis and management of cancer. | 07-28-2011 |
20110190148 | METHOD OF OBTAINING ANTIBODIES OF INTEREST AND NUCLEOTIDES ENCODING SAME - The invention is a methodology which makes it possible to select from a very large number of cells, a single cell or cells of interest and obtain specific information from those cells in a rapid and efficient manner. As an example of the methodology, a large number of antibody producing cells such as plasma cells are separated so that these individual antibody producing plasma cells are placed in individual wells. The cells are allowed to produce antibodies and the antibodies in the wells are then contacted with a protein bound to a solid surface such as a well top. The protein universally and specifically binds antibodies in the wells. The surface or well tray top includes addresses configured such that each address is specifically related to one of the individual wells containing a cell producing antibodies. | 08-04-2011 |
20110190149 | NEOEPITOPE DETECTION OF DISEASE USING PROTEIN ARRAYS - A biosensor for use in detecting the presence of diseases, the biosensor comprising a detector for detecting a presence of at least one marker indicative of a specific disease. A method of determining efficacy of a pharmaceutical for treating a disease or staging disease by administering a pharmaceutical to a sample containing markers for a disease, detecting the amount of at least one marker of the disease in the sample, and analyzing the amount of the marker in the sample, whereby the amount of marker correlates to pharmaceutical efficacy or disease stage. Markers for gynecological disease. An immuno-imaging agent comprising labeled antibodies, whereby the labeled antibodies are isolated and reactive to proteins overexpressed in vivo. Informatics software for analyzing the arrays, the software including analyzing means for analyzing the arrays. | 08-04-2011 |
20110190150 | ISOLATION OF NUCLEIC ACID FROM MOUTH EPITHELIAL CELLS - The present invention is directed to a scraping instrument for collection of a biological sample, and a non-invasive method for obtaining nucleic acid from buccal mucosa epithelial cells using the scraping instrument. Such nucleic acid can be used for example for gene expression profiling, including to assess lung disease risk associated with airway pollutants. | 08-04-2011 |
20110190151 | METHODS OF DIAGNOSING CHRONIC CARDIAC ALLOGRAFT REJECTION - The present invention relates to methods of diagnosing chronic rejection of a cardiac allograft using genomic expression profiling, proteomic expression profiling, or a combination of genomic and proteomic expression profiling. | 08-04-2011 |
20110190152 | PLURIPOTENCY ASSOCIATED EPIGENETIC FACTOR - A method for controlling the pluripotent phenotype of a cell comprising modulating the expression or activity of a ESET/SETDB1 polypeptide, or a homologue thereof, within the cell is provided. Pluripotent cells, cultures of such cells and methods for reprogramming somatic cells to a pluripotent phenotype comprising expressing a ESET/SETDB1 polypeptide in the cells, either alone or in combination with other pluripotency factors, are further provided. Methods for identifying modulators of pluripotency and their use in treating cancer or cancer stem cells are also provided. | 08-04-2011 |
20110190153 | SYSTEM AND METHOD FOR HYBRIDIZATION SLIDE PROCESSING | 08-04-2011 |
20110190154 | METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF CHEMICALLY SYNTHESIZED NUCLEIC ACIDS - This application describes an antibody that specifically binds to a synthetic oligomer (e.g., an oligonucleotide or oligopeptide) having a organic protecting group covalently bound thereto, which antibody does not bind to that synthetic oligomer when the organic protecting group is not covalently bound thereto. Methods of making and using such antibodies are also disclosed, along with cells for making such antibodies and articles carrying immobilized oligomers that can be used in assay procedures with such antibodies. | 08-04-2011 |
20110190155 | MARKER GENES BASED ON AMIODARONE TREATMENT FOR SCREENING OF DRUG INDUCING PULMONARY TOXICITY AND SCREENING METHODS USING THE SAME - The present invention relates to a marker gene for screening of drug candidates inducing pulmonary toxicity and a screening method using the same, more precisely a marker gene up- or down regulated by amiodarone which is a drug inducing pulmonary toxicity and a method for screening drug candidates inducing pulmonary toxicity using the same. The marker gene of the present invention can be effectively used for monitoring and identifying drugs or chemical having high risk of inducing pulmonary toxicity and can be used as an effective tool for examining the mechanism of amiodarone which causes pulmonary toxicity and side effects. | 08-04-2011 |
20110190156 | MOLECULAR SIGNATURES FOR DIAGNOSING SCLERODERMA - The present invention features methods for classifying, determining severity, and predicting clinical endpoints of scleroderma based upon the expression of selected biomarker genes. | 08-04-2011 |
20110190157 | Biomarkers for Diagnosis and Treatment of Chronic Lymphocytic Leukemia - A molecular classification procedure based on activity levels of modules in protein networks, wherein the proteins are biomarkers for chronic lymphocytic leukemia (CLL), and method for use of the subnetworks to distinguish between patients at low or high risk of progression of their disease. | 08-04-2011 |
20110190158 | Method of nucleic acid sequence detection and nucleic acid sequence detection substrate - According to an aspect of the present invention, a pair of oligonucleotide strands are anchored onto the surface of a substrate by immobilizing one of the ends thereof onto the substrate. Each of the immobilized oligonucleotide strands is bound to a target nucleic acid sequence (single-stranded) having complementary sequences thereto to form a cross-linked structure on the substrate, thereby forming a finely reticulated space. Ligands are captured by this reticulated space through physical adsorption and caused to color with active substances reactive to the ligands. As a result of this, the present invention is capable of highly sensitively detecting even an exceedingly small concentration of a particular target nucleic acid sequence to be detected, at low cost and for a short time. | 08-04-2011 |
20110190159 | MULTI-CHAIN EUKARYOTIC DISPLAY VECTORS AND USES THEREOF - A eukaryotic expression vector capable of displaying a multi-chain polypeptide on the surface of a host cell is provided, such that the biological activity of the multi-chain polypeptide is exhibited at the surface of the host cell. Such a vector allows for the display of complex biologically active polypeptides, e.g., biologically active multi-chain polypeptides such as immunoglobulin Fab fragments. The present invention describes and enables the successful display of a multi-chain polypeptide on the surface of a eukaryotic host cell. Preferred vectors are described for expressing the chains of a multi-chain polypeptide in a host cell separately and independently (e.g., under separate vector control elements, and/or on separate expression vectors, thus forming a matched vector set). The use of such matched vector sets provides flexibility and versatility in the generation of eukaryotic display libraries, for example the ability to generate and to display multi-chain polypeptides by combining and recombining vectors that express variegations of the individual chains of a multi-chain polypeptide. Entire repertoires of novel chain combinations can be devised using such vector sets. | 08-04-2011 |
20110190160 | MicroRNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF LUNG CANCER USING MIR-21 - The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of lung cancer. The invention also provides methods of identifying anti-lung cancer agents. | 08-04-2011 |
20110190161 | Methylation Profile of Cancer - The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides methods of identifying methylation patterns in genes associated with specific cancers. | 08-04-2011 |
20110195852 | METHODS FOR DETERMINING THE CONCENTRATION OF AN ANALYTE IN SOLUTION - Disclosed is a method for measuring the concentration of an analyte or analytes in a solution. Although the methods can be conducted using a number of different assay formats, in one embodiment, the assays are conducted in reaction vessels defined, at least in part, by the distal ends of fiber optic strands. | 08-11-2011 |
20110195853 | Array with Extended Dynamic Range and Associated Method - A system and method of quantitating the concentration of a molecule of interest in one embodiment includes establishing a plurality of test environments at a plurality of test sites, each of the plurality of test environments associated with one of a plurality of response curves, each of the plurality of response curves different from the other of the plurality of response curves, storing a combined response curve resulting from a summation of the plurality of response curves, exposing the plurality of test sites to a sample having a concentration of a molecule of interest, obtaining a plurality of quantitation signals, each of the plurality of quantitation signals associated with one of the plurality of test sites, associating a summation of the plurality of quantitation signals with the stored combined response curve, and generating a signal related to the concentration of the molecule of interest based upon the association. | 08-11-2011 |
20110195854 | DETECTING AND MONITORING INFLAMMATORY NEUROPATHY - The invention relates to detection and/or monitoring of inflammatory neuropathy using markers that specifically indicate the presence of inflammatory neuropathy, for example, allograft inflammatory factor 1 (AIF1), lymphatic hyaluronan receptor (LYVE-1), FYN binding protein (FYB), myeloid/lymphoid or mixed-lineage leukemia, translocated to, 3 (MLLT3), purinergic receptor P2Y, G-protein coupled, 1 (P2RY1) or a combination thereof. According to the invention, skin biopsies can be used for assessing the expression of these markers. | 08-11-2011 |
20110195855 | SYSTEMS AND METHODS FOR IMPROVING BIOMARKER AVAILABILITY - Systems and Methods for Improving Biomarker Availability. In at least one embodiment of a computer-implemented method of improving diagnostic marker availability, the method comprises the steps of introducing a predetermined diagnostic marker for cancer into a plurality of detection sites of a detection platform, introducing a stabilization agent into each of the plurality of detection sites containing the predetermined diagnostic marker for cancer, introducing a detection agent into each of the plurality of detection sites having a stabilized diagnostic agent, determining a binding characteristic of the detection agent and the stabilized diagnostic agent in each of the plurality of detection sites with a processor, and computationally comparing the binding characteristic among each of the plurality of detection sites with the processor, wherein the comparison of binding characteristics is capable of determining the stabilizing agent with the greater effect on the binding characteristic between the detection agent and the diagnostic agent. | 08-11-2011 |
20110195856 | METHODS OF DETERMINING STABILIZATION COMPOUNDS FOR PREDICTIVE BIOMARKERS - Methods of determining stabilization compounds for predictive biomarkers. According to at least one embodiment of a method of the present disclosure, the method comprises introducing a diagnostic marker and a stabilization agent to a detection platform, mixing the diagnostic marker and stabilization agent, and determining their binding characteristics. | 08-11-2011 |
20110195857 | SYSTEMS FOR ANALYZING STABILIZED BIOMARKERS - Systems for analyzing stabilized biomarkers. In at least one embodiment of a system for the detection of a diagnostic marker of the present disclosure, the system comprises a detection platform comprising a plurality of detection wells housed in a solid matrix, wherein the detection wells contain a plurality of diagnostic markers and at least one competitor molecule, wherein the plurality of diagnostic markers and at least one control molecule are each bound to a paramagnetic particle. An embodiment of the system of the present disclosure further comprises a detection system capable of receiving the detection platform, exerting a magnetic field upon a surface of the detection platform, and determining at least one characteristic of the diagnostic marker. | 08-11-2011 |
20110195858 | SYSTEMS AND METHODS OF ANALYZING BIOMARKER LEVELS - Systems and methods of analyzing biomarker levels. In at least one embodiment of a method of analyzing biomarker levels, the method comprises the steps of combining a body fluid comprising a diagnostic marker with a stabilization agent for an incubation period, introducing the stabilized body fluid into a detection platform, combining a detection agent with the stabilized body fluid, determining an interaction characteristic of the detection agent and the diagnostic marker of the stabilized body fluid using a detection device in communication with a processor, comparing the interaction characteristic with a plurality of indexed interaction records contained on a database in communication with the processor to determine an identity and concentration of the detection marker, generating a report of the identity and concentration of the detection marker in the body fluid, and delivering the report to a recipient. | 08-11-2011 |
20110195859 | SYSTEMS AND METHODS FOR THE DETECTION OF BIOMARKERS - System and methods for the detection of biomarkers. In at least one embodiment of a system for the detection of a diagnostic marker in a body fluid of the present disclosure, the system comprises a diagnostic device comprising a plurality of test wells, wherein each test well is capable of containing at least one detection agent, a detection device capable of interacting with the diagnostic device, wherein the detection device is capable of detecting an interaction between the at least one detection agent and a diagnostic marker in at least one of the plurality of test wells, and a stabilization agent contained within at least one of the plurality of test wells, the stabilization agent capable of completely or substantially preventing the degradation or inactivation of the detection agent or the diagnostic marker. | 08-11-2011 |
20110195860 | FIBROUS ASSEMBLIES FOR ANTIBODY PRESENTATION, AND MULTIPLEXED ANTIGENIC ANALYSIS USING SAME - Biofunctionalized fibers including a fiber platform and a histidine-tagged protein and, optionally, an antibody. Chitosan is a fiber useful as the fiber platform. The fiber platform may be treated with nickel or may be directly linked to the histidine-tagged protein e.g., histidine-tagged streptococcal IgG-binding protein, protein G, protein G3T, GFP or RFP. The resulting biofunctionalized fibers can be assembled into protein fiber assemblies by a variety of biofabrication methods. The fiber assemblies, e.g., in the form of woven fabrics, are useful for (i) antigen capture; (ii) immunoanalysis, and/or (iii) multiplexed analysis. In one fabrication, each fiber of a fiber assembly presents a specific antibody, and mixing and matching of fibers, for example by weaving of fabrics from various antibody-presenting fibers, allows for multiple antigens to be captured simultaneously for multiplexed analysis. | 08-11-2011 |
20110195861 | METHOD OF DETECTING AUTO-ANTIBODIES FROM PATIENTS SUFFERING FROM RHEUMATOID ARTHRITIS, A PEPTIDE AND AN ASSAY KIT - A liposomal composition, preferably a vaccine, comprising liposomes formed of liposome forming compounds, containing coentrapped polysaccharide antigen and T-cell dependent protein carrier, such as tetanus toxoid or diphtheria toxin modified to render it non-toxic. The invention is of use in the production of vaccines against | 08-11-2011 |
20110195862 | DEVICES, METHODS AND SYSTEMS FOR TARGET DETECTION - Polymer arrays suitable to perform quantitative and qualitative detection as well as sorting of a target molecules and related devices methods and systems. | 08-11-2011 |
20110195863 | Loss of Function mutations in KCNJ10 cause SeSAME, a human syndrome with sensory, neurological, and renal deficits - The invention includes a method of identifying a human subject at-risk of developing SeSAME syndrome. The invention also includes a method of diagnosing a human subject afflicted with SeSAME syndrome. The invention further includes a method of identifying a therapeutic agent that modulates a given KCNJ10 mediated K | 08-11-2011 |
20110195864 | Assays for determining telomere length and repeated sequence copy number - Methods of detecting copy number of a repeated sequence element, including methods of determining telomere length, are provided. The methods can be multiplexed for detection of repeated sequence element copy number on two or more nucleic acid targets simultaneously. Compositions, kits, and systems related to the methods are also described. | 08-11-2011 |
20110201511 | SYSTEM AND METHOD FOR AUTOMATED BIOPARTICLE RECOGNITION - The invention relates to a method for identifying the source of shed bioparticles and an apparatus that implements the method. The method involves collecting a sample of bioparticles from the environment, selecting from that sample the bioparticles most effective in identifying their source, and gathering data from those bioparticles to form bioparticle signatures. The bioparticle signatures are then processed into a multi-dimensional vector which is then compared to the multi-dimensional vector derived from a standard using a pattern recognition strategy that identifies the source. The apparatus has a particle collection device to collect the sample, a transfer device that selects information-rich bioparticles and a detector that restricts the movement of the information-rich bioparticles. The restricted movement is then translated into a bioparticle signature. | 08-18-2011 |
20110201512 | Biomarkers Indicative of Colon Cancer and Metastasis and Diagnosis and Screening Therapeutics Using the Same - The present invention relates to a method for detecting a colon cancer in a human, comprising the steps of: (a) providing a biological sample from the human; and (b) detecting the level of a ATAD2 nucleic acid or a ATAD2 protein in the biological sample, relative to the level of the ATAD2 nucleic acid or the ATAD2 protein in a control sample from a normal human, wherein an increased level of the ATAD2 nucleic acid or the ATAD2 protein in the biological sample compared to the control sample indicates that the human has the colon cancer. The biomarker of this invention was identified using normal colon tissue, colon cancer tissue and metastatic cancer tissue derived from a colon cancer patient. Therefore, the accuracy and reliability of the present biomarker for colon cancer and/or metastasis are much more significantly improved. In addition, the biomarker of this invention permits to identify and predict colon cancer or metastasis in an accurate manner. | 08-18-2011 |
20110201513 | PROTEIN SPLICE VARIANT / ISOFORM DISCRIMINATION AND QUANTITATIVE MEASUREMENTS THEREOF - The invention relates to methods, reagents and apparatus for detecting protein isoforms (e.g., those due to alternative splicing, or different disease protein isoforms or degradation products) in a sample, including using combinations of capture agents, each combination being unique to the splicing variant to be detected/measured. | 08-18-2011 |
20110201514 | Methods Using 06-Alkylguanine-DNA Alkytransferase - A method of using O | 08-18-2011 |
20110201515 | COMPOSITIONS AND METHODS FOR THE DETECTION OF SMALL RNAS - The invention provides compositions and methods for the detection of small RNA molecules in a multiplexed reaction. The assays and kits described herein are applicable for the identification, diagnosing, and monitoring of disorders including, but not limited to cancer, developmental and degenerative disease, neurological disorders, and stem cell disorders. | 08-18-2011 |
20110201516 | ASSAY FOR DETECTING CLOSELY-RELATED SEROTYPES OF HUMAN PAPILLOMAVIRUS (HPV) - A real time Taq-Man PCR assay for detecting multiple serotypes of human papillomavirus (HPV) wherein the number of serotypes detected exceeds the number of colorimetric channels for detection. A biological sample is combined with three oligonucleotide primer/probe sets such that the probes and primers anneal to a target sequence. Each primer/probe set is at least preferential for a specific serotype of an organism. The first and second primer/probe sets are degenerate with respect to each other. The third primer/probe set is not degenerate with respect to the first and second primer/probe sets and discriminates for a third serotype. The third primer/probe set has a signal moiety that emits signal at a wavelength that is the same or different from the wavelength emitted by the signal moiety of the degenerate primer/probe set probes. The target sequences, if present, are amplified and detected. | 08-18-2011 |
20110201517 | AUTOANTIGEN BIOMARKERS FOR EARLY DIAGNOSIS OF LUNG ADENOCARCINOMA - Provided herein are novel panels of biomarkers for the detection and diagnosis of lung adenocarcinoma, and methods and kits for detecting these biomarkers in samples of individuals suspected of having the disease. Also provided are methods of monitoring the progression of lung adenocarcinoma and methods of monitoring the efficacy of a treatment. | 08-18-2011 |
20110201518 | HEALTHY KIDNEY BIOMARKERS - The invention provides novel healthy kidney biomarkers useful in the monitoring of renal function and in the prognosis and diagnosis of renal dysfunctions, especially those related to graft rejection. The invention further relates to methods for aiding in the evaluation, and design of personalized therapies in transplantation nephrology. | 08-18-2011 |
20110201519 | Methods and Compositions for Determining a Graft Tolerant Phenotype in a Subject - Methods are provided for determining whether a subject has a graft tolerant phenotype. In practicing the subject methods, the expression of at least 5 genes in a sample from the subject, e.g., a blood sample, is assayed to obtain a gene expression result for the at least 5 genes. The obtained gene expression result for the at least 5 genes is then employed to determine whether the subject has a graft tolerant phenotype. Also provided are compositions, systems and kits that find use in practicing the subject methods. The methods and compositions find use in a variety of applications, including the determination of an immunosuppressive therapy regimen. | 08-18-2011 |
20110201520 | COMPOSITION AND METHOD FOR DIAGNOSING ESOPHAGEAL CANCER AND METASTASIS OF ESOPHAGEAL CANCER - This invention relates to a composition, kit, or DNA chip comprising polynucleotides and antibodies as probes for detecting, determining, or predicting the presence or metastasis of esophageal cancer, and to a method for detecting, determining, or predicting the presence or metastasis of esophageal cancer using the same. | 08-18-2011 |
20110201521 | MULTIPLEXED ANALYSIS FOR DETERMINING A SERODIAGNOSIS OF VIRAL INFECTION - Clinical samples can be analyzed using microparticles to determine the serodiagnosis of a viral infection from two candidate viral infections of the same viral group. Serodiagnosis can be determined via a pooled population of subsets of microparticles, with the particles in the pooled population having a bound viral group-reactive antibody and the particles in each subset having at least one characteristic classification parameter that distinguishes between subsets. Viral antigens of antibodies of interest in the same viral-class as the viral group-reactive antibody can be bound to the viral group-reactive antibody on the microparticles, and subsequently exposed to a clinical sample. Binding and labeling can be used. Automated analysis of data from multiplexed flow analysis can determine the presence or absence of antibodies of interest in the sample, thereby diagnosing for two candidate viral infections in a single assay. | 08-18-2011 |
20110201522 | ARRAY FLUORESCENCE EQUALIZATION METHOD - The present invention provides a method for fluorescence intensity equalization. The method involves providing an assay device having at least one immobilized array of molecular probes that bind to an analyte bound to a fluorescent marker; providing drying apparatus comprising an aspiration tube having open first and second ends, the second end of the aspiration tube being connected a vacuum source for applying a vacuum through said tube; placing the first end of the aspiration tube in proximity of said at least one immobilized array of molecular probes; and applying a vacuum through said aspiration tube for removing vapor from said at least one immobilized array of molecular probes. The application of the present invention provides for more reliable fluorescent signal intensity readings due to a reduction in signal quenching factors. | 08-18-2011 |
20110207619 | ARRANGEMENT FOR PROCESSING A PLURALITY OF SAMPLES FOR ANALYSIS - An arrangement is provided in at least one embodiment, having a magazine for supplying a plurality of microfluidic devices. The microfluidic devices each contain at least one element/device for binding at least one biological molecule, wherein the at least one element/device for binding the at least one biological molecule can be moved relative to the microfluidic device. A sample presumably containing biological molecules to be examined is introduced into the microfluidic device. The biological molecule to be examined is bound by the at least one element/device for binding the biological molecule. In at least one embodiment, the at least one element/device for binding the at least one biological molecule, or the substrate-molecule complex, can then be moved in the microfluidic device, e.g. in accordance with a predetermined reaction sequence, for example by means of a magnetic field. The microfluidic device is transported through the arrangement. | 08-25-2011 |
20110207620 | Methods and Systems for Inferring Traits to Breed and Manage Non-Beef Livestock - Methods and systems are provided for managing non-beef livestock subjects in order to maximize their individual potential performance and the value of a product from the non-beef livestock subjects, and to maximize profits obtained in marketing the non-beef livestock subjects. The methods and systems draw an inference of a trait of a non-beef livestock subject by determining the nucleotide occurrence of at least one non-beef livestock SNP that is determined to be associated with the trait. The inference is used in methods of the present invention to establish the economic value of a non-beef livestock subject, to improve profits related to selling beef from a non-beef livestock subject; to manage non-beef livestock subjects, to sort non-beef livestock subjects; to improve the genetics of a non-beef livestock population by selecting and breeding of non-beef livestock subjects, to clone a non-beef livestock subject with a specific trait, to track meat or another commercial product of a non-beef livestock subject; and to diagnose a health condition of a non-beef livestock subject. Certain embodiments of the present invention provide methods, systems, and kits are directed to inferences of a trait related to milk or a dairy product in a livestock subject. | 08-25-2011 |
20110207621 | Assays Based on Liquid Flow over Arrays - Flow-through assay reaction chamber ( | 08-25-2011 |
20110207622 | SALIVARY BIOMARKERS FOR LUNG CANCER DETECTION - Presented herein are biomarkers related to lung cancer. The presently identified salivary biomarkers create the basis for a lung cancer detection bioassay with sensitivity and specificity. Means and methods for evaluating the data generated using multiple biomarkers in order to validate findings and further use of the multiplexed lung cancer assay in clinical, diagnostic and therapeutic uses is also included. | 08-25-2011 |
20110207623 | METHODS FOR DETECTION AND QUANTIFICATION OF ANALYTES IN COMPLEX MIXTURES - The invention provides a diverse population of uniquely labeled probes, containing about thirty or more target specific nucleic acid probes each attached to a unique label bound to a nucleic acid. Also provided is a method of producing a population of uniquely labeled nucleic acid probes. The method consists of (a) synthesizing a population of target specific nucleic acid probes each having a different specifier; (b) synthesizing a corresponding population of anti-genedigits each having a unique label, the population having a diversity sufficient to uniquely hybridize to genedigits within the specifiers, and (c) hybridizing the populations of target nucleic acid probes to the anti-genedigits, to produce a population in which each of the target specific probes is uniquely labeled. Also provided is a method of detecting a nucleic acid analyte. The method consists of (a) contacting a mixture of nucleic acid analytes under conditions sufficient for hybridization with a plurality of target specific nucleic acid probes each having a different specifier; (b) contacting the mixture under conditions sufficient for hybridization with a corresponding plurality of anti-genedigits each having a unique label, the plurality of anti-genedigits having a diversity sufficient to uniquely hybridize to genedigits within the specifiers, and (c) uniquely detecting a hybridized complex between one or more analytes in the mixture, a target specific probe, and an anti-genedigit. | 08-25-2011 |
20110207624 | METHODS AND SYSTEMS FOR NUCLEIC ACID SEQUENCING VALIDATION, CALIBRATION AND NORMALIZATION - A system for performing quality control for nucleic acid sample sequencing is disclosed. The system comprises a set of solid supports, each solid support having attached thereto a plurality of nucleic acid sequences, wherein the set comprises plural groups of solid supports and each group contains solid supports having the same nucleic acid sequences attached thereto. The nucleic acid sequences of each group differ from each other. The nucleic acid sequences are synthetically derived, and the nucleic acids sequences are designed such that the nucleic acid sequences produce a predefined pattern of detectable signals during a sequencing run. A method of preparing a quality control for performing nucleic acid sample sequencing, a method of validating a nucleic acid sequencing instrument during a nucleic acid sequencing experiment, and a method of processing nucleic acid sequencing data during a nucleic acid sequencing experiment are also disclosed. | 08-25-2011 |
20110207625 | PIRNA AND USES RELATED THERETO - The invention relates to small single stranded RNAs and analogs thereof (collectively “piRNA” herein), compositions comprising such piRNAs, and their uses in regulating target gene expression or as markers for certain disease states. | 08-25-2011 |
20110207626 | METHOD FOR DETECTING CHROMOSOME DEFICIENCIES FOR CONGENITAL ABNORMALITY - An object the present invention is to analyze human chromosomes in terms of the presence of a duplication or deletion so as to determine the cause of a multiple congenital anomaly syndrome accompanying mental retardation, to thereby provide a method for determining whether or not a human subject has the syndrome. The present invention includes detecting a hemizygote deletion in the region 10q24.31-10q25.1 of a human chromosome of a human subject, to thereby determine whether or not the subject has a multiple congenital anomaly syndrome accompanying mental retardation. The detection is preferably carried out by hybridizing a reference nucleic acid fragment including a part of the 10q24.31-10q25.1 region with a nucleic acid fragment of a specimen, and detecting a signal attributed to the hemizygote deletion of the 10q24.31-10q25.1 region. | 08-25-2011 |
20110207627 | EX VIVO THERAPEUTICS SCREENING OF LIVING BONE MARROW CELLS FOR MULTIPLE MYELOMA - Methods of selecting a treatment for a patient with multiple myeloma are provided. Prior to commencing a treatment regime, bone marrow aspirates are isolated from a patient and incubated with one or more candidate therapeutics. The methods identify the therapy or combination of therapies most likely to yield the best results for a particular individual. In addition to improving clinical outcome, such theranostic evaluations dramatically reduce health care costs, by avoiding ineffective therapies. Screening assays for identifying treatments for multiple myeloma also are provided. | 08-25-2011 |
20110207628 | OPEN-READING-FRAME (ORF) PHAGE DISPLAY - A dual display phage system for the identification of protein interaction networks and therapeutic targets. | 08-25-2011 |
20110207629 | PREDICTING CARDIOVASCULAR EVENTS AND RENAL FAILURE IN TYPE 1 DIABETICS - The present invention relates to a method for predicting or assessing the risk of a type 1 diabetes patient to suffer from a cardiovascular event and/or terminal renal failure and/or death. The method is based on the determination of adiponectin and optionally a natriuretic peptide in a sample of a subject suffering from type 1 diabetes. Moreover, the present invention pertains to a method for predicting the risk of a cardiovascular event, mortality or terminal renal failure for a subject suffering from type 1 diabetes based on the determination of adiponectin and optionally a natriuretic peptide in a sample of the subject. Also encompassed by the present invention are devices and kits for carrying out the aforementioned methods. | 08-25-2011 |
20110207630 | METHOD FOR TESTING AND QUALITY CONTROLLING OF NUCLEIC ACIDS ON A SUPPORT - The present invention relates to a method for testing nucleic acids on a support, comprising the immobilization of one or more nucleic acids via crosslinking, wherein each of the immobilized nucleic acids includes a stretch of nucleotides of only one basetype, the provision of labeled oligonucleotides complementary to said stretch of nucleotides, and the determination of a value indicative for the condition of said nucleic acids. The present invention further relates to a kit for testing nucleic acids on a support comprising an array of nucleic acids immobilized on a solid support, wherein each of the immobilized nucleic acids includes a stretch of nucleotides of only one basetype and a labeled oligonucleotide complementary to said stretch of nucleotides. The invention additionally concerns the use of a labeled oligonucleotide complementary to a stretch of nucleotides of only one basetype for testing the condition of nucleic acids immobilized on a solid support. | 08-25-2011 |
20110212848 | ULTRA-SENSITIVE DETECTION OF MOLECULES OR PARTICLES USING BEADS OR OTHER CAPTURE OBJECTS - The present invention relates to systems and methods for detecting analyte molecules or particles in a fluid sample and in some cases, determining a measure of the concentration of the molecules or particles in the fluid sample. Methods of the present invention may comprise immobilizing a plurality of analyte molecules or particles with respect to a plurality of capture objects. At least a portion of the plurality of capture objects may be spatially separated into a plurality of locations. A measure of the concentration of analyte molecules in a fluid sample may be determined, at least in part, on the number of reaction vessels comprising an analyte molecule immobilized with respect to a capture object. In some cases, the assay may additionally comprise steps including binding ligands, precursor labeling agents, and/or enzymatic components. | 09-01-2011 |
20110212849 | BIOMARKERS FOR PREDICTING THE DEVELOPMENT OF CHRONIC AUTOIMMUNE DISEASES - The invention relates to a method for determining whether an individual has an increased risk of developing symptoms of a chronic autoimmune disease comprising determining in a sample of said individual the levels of expression products of a collection of genes and determining whether the expression products are present at a level that is different when compared to the level of the same expression products of a control. Said collection of genes are selected from the group consisting of genes involved in the cellular process of (i) IFN-mediated immunity, (ii) hematopoiesis, (iii) B-cell mediated immunity and/or (iv) cytokine mediated immunity, wherein higher levels of expression products of genes involved in IFN-mediated immunity, hematopoiesis and cytokines are predictive for an increased risk and wherein higher levels of expression products of genes involved in the cellular process of B-cell mediated immunity are predictive for a decreased risk. | 09-01-2011 |
20110212850 | USING PHYLOGENETIC PROBES FOR QUANTIFICATION OF STABLE ISOTOPE LABELING AND MICROBIAL COMMUNITY ANALYSIS - Herein is described methods for a high-sensitivity means to measure the incorporation of stable isotope labeled substrates into RNA following stable isotope probing experiments (SIP). RNA is hybridized to a set of probes such as phylogenetic microarrays and isotope incorporation is quantified such as by secondary ion mass spectrometer imaging (NanoSIMS). | 09-01-2011 |
20110212851 | SALIVARY TRANSCRIPTOMIC AND PROTEOMIC BIOMARKERS FOR BREAST CANCER DETECTION - Presented herein are biomarkers related to breast cancer. The presently identified salivary biomarkers create the basis for a breast cancer detection bioassay with sensitivity and specificity. Means and methods for evaluating the data generated using multiple biomarkers in order to validate findings and further use of the multiplexed breast cancer assay in clinical, diagnostic and therapeutic uses is also included. | 09-01-2011 |
20110212852 | COMPOSITIONS AND METHODS TO DETECT ATOPOBIUM VAGINAE NUCLEIC ACID - The disclosed invention include nucleic acid oligomers that may be used as amplification oligomers, including primers, as capture probes for sample preparation, and detection probes for detection of 16S rRNA from | 09-01-2011 |
20110212853 | NOVEL DIAGNOSTIC METHOD - A method of monitoring treatment of an inflammatory disease or an inflammatory associated disease with the use of the ratio of N-terminal pyroglutamate modified MCP-1 (MCP-1 N1pE):total concentration of MCP-1 within a biological sample as a biomarker, and a method for determining the proportion of N-terminal pyroglutamate modified MCP-1 in relation to the total concentration of MCP-1 in biological samples. Also disclosed are a diagnostic kit and a method for screening a glutaminyl cyclase (QC) inhibitor or measuring the effectiveness of a glutaminyl cyclase (QC) inhibitor. | 09-01-2011 |
20110212854 | METHODS AND COMPOSITIONS FOR DIAGNOSIS, STRATIFICATION, AND MONITORING OF ALZHEIMER'S DISEASE AND OTHER NEUROLOGICAL DISORDERS IN BODY FLUIDS - The inventors have discovered a collection of proteinaceous biomarkers (“AD biomarkers) which can be measured in peripheral biological fluid samples to aid in the diagnosis of neurodegenerative disorders, particularly Alzheimer's disease and mild cognitive impairment (MCI). The invention further provides methods of identifying candidate agents for the treatment of Alzheimer's disease by testing prospective agents for activity in modulating AD biomarker levels. | 09-01-2011 |
20110212855 | Genetic Variants Predictive of Cancer Risk - The invention discloses genetic variants that have been determined to be susceptibility variants of cancer. Methods of disease management, including determining increased susceptibility to cancer, methods of predicting response to therapy and methods of predicting prognosis of cancer using such variants are described. The invention further relates to kits useful in the methods of the invention. | 09-01-2011 |
20110212856 | HUMAN T2R RECEPTORS RECOGNIZING A CLASS OF BITTER MOLECULES FROM COFFEE - The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds, i.e., chlorogenic lactone compounds that contribute at least partially to the bitter taste of many coffee beverages. The present invention further relates to the use of these receptors in assays for identifying ligands that modulate the activation of these taste receptors by chlorogenic lactones and related compounds and which may be used as additives and/or removed from foods, beverages and medicinals in order to modify (block) T2R-associated bitter taste. A preferred embodiment is the use of the identified compounds as additives in coffee and coffee-flavored foods, beverages and medicinals. | 09-01-2011 |
20110212857 | Multiplexed Assay Using Encoded Solid Support Matrices - In a multiplexed assay, each molecule of a plurality of molecules is attached to a support matrix with a substrate adapted for attachment and/or synthesis of molecules and an integrally-formed memory device with an optically-encoded identifier to uniquely identify the molecule attached to the substrate. The molecules are exposed to one or more processing conditions then placed within the path of an optical detector adapted to read the optically-encoded identifier and measure biochemical processes on each support matrix. The support matrices may besingulated to be read by the optical detector one at a time. | 09-01-2011 |
20110218115 | TEST PROBES, COMMON OLIGONUCLEOTIDE CHIPS, NUCLEIC ACID DETECTION METHOD, AND THEIR USES - High-throughput detection for the interesting base or the mutation site in the nucleic acid sample can be achieved by the linear test probe pairs P1 and P2. The test probe pairs P1 and P2 respectively comprise either of the flanking complementary sequences which are adjacent to the interesting base or the mutation site in the nucleic acid sample. When the test probe pairs P1, P2 are annealed and hybridized to the nucleic acid sample, a gap will be generated at the interesting base or the mutation site position between the probe pairs and the sample. Divide the annealed hybrid sample into four equal reaction systems to which add dATP, dTTP, dCTP, dGTP, respectively. The test probe pairs P1 and P2 will be ligated into one single probe when adding the complementary nucleotide system under the DNA polymerase or ligase. After purified and amplified, the generated single probes are hybridized to the corresponding area in a common oligonucleotide microarray. The generated single probe will give a signal in the hybrid area, and therefore detect and analyze the hybrid signal to determine the base type or the mutation genotype at the detection position. The invention can be applied to the re-sequencing the target nucleic acid sequence, the detection and analysis for the mutation, insertion, or deletion sites of a known nucleic acid sequence, and the genotyping of the pathogenic microorganism. | 09-08-2011 |
20110218116 | BIOMARKERS OF OSTEOARTHRITIS - Biomarkers, biomarker panels and methods for diagnosing osteoarthritis (OA) are disclosed, using measurement of the expression level of certain polypeptides in a test sample from a subject, including MCP1, IL8, KC, MMP2, MMP3, IL6, MMP1, RANTES, MMP9, IL1B, Apolipoprotein A1, Apolipoprotein E, DCN, CILP and COMP. Related methods for monitoring OA treatment efficacy, diagnostic reagents, and kits are also described. | 09-08-2011 |
20110218117 | Enhanced Immunosorbent Spot Test Device and Method of Using Same - A device used for immunosorbent spot testing. The present invention makes use of a membrane and carrier to test for a multiplex of analytes and is read visually without the use of an optical reader. The membrane comprises of a plurality of specific analyte detectors which each contain a calibrated antigen. The calibrated antigen comprises of a plurality of binding sites which bind a plurality of specific analyte to be tested for. The bound specific analyte is marked with conjugate and further bound with chromogen to provide a visual indiciator as a result of presence of the specific analyte. | 09-08-2011 |
20110224090 | SINGLE NUCLEOTIDE POLYMORPHIC MARKERS OF TGFBetaRIII GENE FOR DIAGONISIS OF HEPATOCELLULAR CARCINOMA - The present invention relates to diagnostic markers for hepatocellar carcinoma and a method for predicting and diagnosing susceptibility to hepatocellular carcinoma, and more particularly, to polymorphic markers for the diagnosis of hepatocellular carcinoma based on polymorphisms present in exons of the TGFβRIII gene represented by SEQ ID No. 1, a diagnostic composition for hepatocellular carcinoma using the same, a diagnostic kit, a microarray, and a method for diagnosing hepatocellular carcinoma. The polymorphic markers for the diagnosis of hepatocellular carcinoma according to the present invention are genetic markers useful to diagnose genetic susceptibility specific to hepatocellular carcinoma. With these markers, susceptibility to hepatocellular carcinoma can be comprehensively determined. | 09-15-2011 |
20110224091 | METHOD AND DEVICE FOR DETECTING CELLULAR TARGETS IN BODILY SOURCES USING CARBON NANOTUBE THIN FILM - A device and method detect cellular targets in a bodily source by utilizing a biofunctional pad comprised of a thin film of carbon nanotubes (CNT's). When antibodies are absorbed by the CNT's, cellular targets having markers matching the antibodies may be detected in a bodily source placed upon the biofunctional pad by measuring the conductivity of the thin film using conductive contacts electrically coupled to the thin film, as the binding of the receptors in the cellular targets to the antibodies changes the free energy in the thin film. In many respects, the device functions as a Field Effect Transistor (FET) with the bodily source, e.g., blood, acting as a polyelectrolyte liquid gate electrode to create a varying electrostatic charge or capacitance in the thin film based upon the binding of cellular targets in the source to the antibodies present on the biofunctional pad. | 09-15-2011 |
20110224092 | METHOD AND APPARATUS FOR COMBINED ELECTROCHEMICAL SYNTHESIS AND DETECTION OF ANALYTES - Described are devices and methods for detecting binding on an electrode surface. In addition, devices and methods for electrochemically synthesizing polymers and devices and methods for synthesizing and detecting binding to the polymer on a common integrated device surface are described. | 09-15-2011 |
20110224093 | RESONANT MAGNETIC DISKS FOR BIOANALYTE DETECTION - Embodiments of the invention relate generally to ferromagnetic microdisks, methods of detecting target bioanalyte using ferromagnetic microdisks, and kits (such as for using in the laboratory setting) containing the reagents necessary to make, and/or use ferromagnetic microdisks for bioanalyte detection, depending on the user's planned application. The methods and products allow the fabrication of ferromagnetic microdisks, and their use in the detection of biological molecules with high sensitivity, little or no signal decay, improved safety, convenience, and lowered cost for use and disposal. | 09-15-2011 |
20110224094 | METHOD FOR IDENTIFYING AND SELECTING DRUG CANDIDATES FOR COMBINATORIAL DRUG PRODUCTS - A method for identifying and selecting chemical entities that contributes to a functional effect in the development of new combinatorial drugs. The combinations of two or more chemical compounds show a synergistic effect. The compounds can be e.g. antibodies, antibiotics, anti-cancer agents, anti-AIDS agents, anti-growth factors, antiviral agents, soluble receptors, cytokines, RNAi's, vaccines and mixtures thereof. The method comprises a) providing n samples each comprising a chemical entity, b) mixing 2 or more of the n samples in all possible combinations, c) subjecting this mixture to a functional assay in order to identify entities contributing to the functional effect. The steps a-c are repeated on the chemical entities from step c which contribute to the functional effect. | 09-15-2011 |
20110230363 | METHODS, KITS, AND COMPOSITIONS USEFUL IN SELECTING AN ANTIBIOTIC TO TREAT MRSA - The present invention provides a method, a kit and composition for determining MRSA and other | 09-22-2011 |
20110230364 | METHODS FOR IDENTIFYING MODULATORS OF APOPTOSIS - The invention provides a method of identifying an effective compound that modulates the binding of Humanin to Bax or Bid. The invention also provides a method of identifying an effective compound that modulates an activity of Bax or Bid. In addition, the invention provides a method of identifying a Humanin-like compound that binds to Bax or Bid or modulates an activity of Bax or Bid, or inhibits the apoptotic activity of Bax or Bid. The invention further provides an isolated polypeptide containing a mitochondrial-derived form of Humanin (SEQ ID NO:3) or a functional fragment thereof where the fragment contains the methionine at position 16 of SEQ ID NO:3. | 09-22-2011 |
20110230365 | Mutations Associated With Cystic Fibrosis - The present invention provides novel mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that can be used for a more accurate diagnosis of cystic fibrosis (CF) and CF related disorders. Methods for testing a sample obtained from a subject to determine the presence of one or more mutations in the CFTR gene are provided wherein the presence of one or more mutations indicates that the subject has CF or a CF related disorder, or is a carrier of a CFTR mutation. | 09-22-2011 |
20110230366 | Genetic Variants Useful for Risk Assessment of Thyroid Cancer - The invention discloses genetic variants that have been determined to be susceptibility variants of thyroid cancer. Methods of disease management, including determining increased susceptibility to thyroid cancer, methods of predicting response to therapy and methods of predicting prognosis of thyroid cancer using such variants are described. The invention further relates to kits useful in the methods of the invention. | 09-22-2011 |
20110230367 | Amphiphilic Peptides Promoting Production of Target miRNA and Method of Regulating Production of Target miRNA - The present invention relates to an amphiphilic peptide capable of promoting target miRNA production and a method for regulating the production of target miRNA using the same. In detail, the amphiphilic peptide of the present invention binds strongly and specifically to hairpin-shaped target miRNA. The specific binding affinity induces the Dicer enzyme activity, therefore specifically increase the production of target miRNA. The present invention can be effectively used for regulating the amount of target miRNA produced in vivo, for the study of miRNA functions and for producing therapeutic drug for target miRNA related disease. | 09-22-2011 |
20110237447 | METHOD OF DETERMINING CHROMATIN STRUCTURE - A method of determining chromatin structure is described. The method comprises the steps of (i) fragmenting a nucleotide sequence at multiple HSs; and (ii) analysing fragments formed in step (i) from a plurality of sequences. In a preferred aspect, the present invention provides a method of determining chromatin structure in a nucleic acid sample comprising the steps of (i) treating the sample to fragment the nucleic acid therein at multiple HSs; and (ii) analysing fragments formed in step (i) from a plurality of genes. | 09-29-2011 |
20110237448 | CARBOHYDRATE BINDING MODULE WITH AFFINITY FOR INSOLUBLE XYLAN - The present disclosure relates to isolated polynucleotides with two polynucleotide sequences linked within one open reading frame, in which the first polynucleotide sequence encodes a peptide that binds to a carbohydrate. The present disclosure also relates to vectors and genetically modified host cells containing such isolated polynucleotides and polypeptides encoded by such isolated polynucleotides. The present disclosure further relates to methods of increasing the ability of a recombinant protein to bind to a carbohydrate and methods of identifying a protein having an ability to bind to a carbohydrate. | 09-29-2011 |
20110237449 | Methods and Compositions for Nucleic Acid Purification - Methods of capturing two or more nucleic acids simultaneously from a single sample are provided. Different nucleic acids are captured through cooperative hybridization events on a substrate, or different subsets of particles, or at different selected positions on a spatially addressable solid support. Methods described include enrichment and purification of nucleic acids prior to downstream steps including sequencing of target nucleic acids. Compositions, kits, and systems related to the methods are also described. | 09-29-2011 |
20110237450 | METHODS AND SYSTEMS OF USING EXOSOMES FOR DETERMINING PHENOTYPES - Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin. | 09-29-2011 |
20110237451 | COMPETITIVE N-HYBRID SYSTEM - A method of identifying high-affinity ligands, comprising the following steps:
| 09-29-2011 |
20110237452 | MARKER FOR DIAGNOSIS OF EXPOSURE TO ELECTROMAGNETIC RADIATION AND DIAGNOSTIC KIT COMPRISING THE SAME - Disclosed are a composition for the diagnosis of exposure to electromagnetic radiation, comprising an agent capable of measuring the expression level of the diagnostic marker, a diagnosis kit comprising the same, a method for detecting the diagnostic marker, and a method for the diagnosis of exposure to electromagnetic radiation. The diagnostic markers are very useful for monitoring and diagnosing exposure to electromagnetic fields, and can be used as instruments by which physiological mechanisms incurred upon electromagnetic radiation exposure are examined. | 09-29-2011 |
20110237453 | MARKER FOR DIAGNOSIS OF EXPOSURE TO ELECTROMAGNETIC RADIATION AND DIAGNOSTIC KIT COMPRISING THE SAME - Disclosed are a composition for the diagnosis of exposure to electromagnetic radiation, comprising an agent capable of measuring the expression level of the diagnostic marker, a diagnosis kit comprising the same, a method for detecting the diagnostic marker, and a method for the diagnosis of exposure to electromagnetic radiation. The diagnostic markers are very useful for monitoring and diagnosing exposure to electromagnetic fields, and can be used as instruments by which physiological mechanisms incurred upon electromagnetic radiation exposure are examined. | 09-29-2011 |
20110237454 | MARKER FOR DIAGNOSIS OF EXPOSURE TO ELECTROMAGNETIC RADIATION AND DIAGNOSTIC KIT COMPRISING THE SAME - Disclosed are a composition for the diagnosis of exposure to electromagnetic radiation, comprising an agent capable of measuring the expression level of the diagnostic marker, a diagnosis kit comprising the same, a method for detecting the diagnostic marker, and a method for the diagnosis of exposure to electromagnetic radiation. The diagnostic markers are very useful for monitoring and diagnosing exposure to electromagnetic fields, and can be used as instruments by which physiological mechanisms incurred upon electromagnetic radiation exposure are examined. | 09-29-2011 |
20110237455 | ARRAY ANALYSIS FOR ONLINE DETECTION - The invention provides a method and kit for performing the analysis of a microarray surface having immobilized capture molecules used for detection and/or quantification of one or multiple target biological molecules labelled with a fluorophore and being present in a solution comprising a light absorbing agent that has an absorption band which overlaps the emission and/or absorption band of the fluorophore and is not a quencher molecule of the label of the target molecules. | 09-29-2011 |
20110237456 | BIOMARKERS FOR DRUG-INDUCED ELONGATED QT INTERVAL AND TORSADES DE POINTES - The present invention provides a method for predicting the risk of a patient for developing adverse drug reactions, particularly drug-induced prolonged QT interval or TdP. The invention also provides a method of identifying a subject afflicted with, or at risk of, developing TdP. In some aspects, the methods comprise analyzing at least one genetic marker, wherein the presence of the at least one genetic marker indicates that the subject is afflicted with, or at risk of, developing TdP. | 09-29-2011 |
20110237457 | METHOD AND SYSTEM OF PARTICLE-COUPLED PHAGE EPITOPE - The present disclosure provides compositions and methods for using phage epitopes to profile the immune response. The phage epitopes can be used to detect one or more antibodies from a sample. Furthermore, the present disclosure provides methods and compositions for detecting a cancer based on the detection of one or more antibodies. In one embodiment, the antibody is an autoantibody. | 09-29-2011 |
20110237458 | DRUG DISCOVERY METHOD - A method of obtaining information about a chemically active area of a target molecule, for example for drug discovery, comprising:
| 09-29-2011 |
20110237459 | Multiplexed Assay Using Encoded Solid Support Matrices - In a multiplexed assay, each molecule of a plurality of molecules is attached to a support matrix with a substrate adapted for attachment and/or synthesis of molecules and an integrally-formed memory device with an optically-encoded identifier to uniquely identify the molecule attached to the substrate. The molecules are exposed to one or more processing conditions then placed within the path of an optical detector adapted to read the optically-encoded identifier and measure biochemical processes on each support matrix. The support matrices may be singulated to be read by the optical detector one at a time. | 09-29-2011 |
20110245093 | FUNCTIONAL PROTEIN ARRAYS - The present invention relates to a method for producing a protein array starting from DNA (or mRNA) in which a number of native, functional proteins, domains or peptides are produced in parallel by in in vitro synthesis using a cell free system for transcription and translation. The products are immobilised in a gridded format on a surface, using an isolation sequence tag incorporated into the proteins. | 10-06-2011 |
20110245094 | DETECTION OF MICROBIAL NUCLEIC ACIDS - The present invention features, inter alia, compositions and methods useful for identifying one or more types of microorganisms, if and when present, in a sample or plurality of samples (e.g., in one or more samples tested in parallel). More specifically, the present compositions and methods can be used in, e.g., determining whether a subject has a microbial infection (e.g., a bacterial, fungal, protozoal, or viral infection), determining the identity of the microbe(s) causing the infection, and/or determining, or helping to determine, an appropriate anti-microbial treatment regimen for a subject identified as having an infection (e.g., an appropriate antibiotic, anti-fungal, anti-viral, or other treatment regimen). | 10-06-2011 |
20110245095 | FAST ASSIGNMENT OF ADEQUATE CHEMOTHERAPY WITH LATINUM BASED DRUGS FOR CANCER PATIENTS BASED ON THE IDENTIFICATION OF CONSTITUTIONAL BRCAL MUTATIONS - A new method to improve therapy outcome depending on a particular constitutional genotype have been disclosed. Subject of invention allows to synthesize DNA and identification of germline BRCA1 genetic abnormalities which are correlated with a significantly increased clinical response to chemotherapy based on platinum derived drugs in cancer patients. | 10-06-2011 |
20110245096 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES - The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases. | 10-06-2011 |
20110245097 | METHODS AND SYSTEMS FOR EXTENDING DYNAMIC RANGE IN ASSAYS FOR THE DETECTION OF MOLECULES OR PARTICLES - Described herein are systems and methods for extending the dynamic range of assay methods and systems used for determining the concentration of analyte molecules or particles in a fluid sample. In some embodiments, a method comprises spatially segregating a plurality of analyte molecules in a fluid sample into a plurality of locations. At least a portion of the locations may be addressed to determine the percentage of said locations containing at least one analyte molecule. Based at least in part on the percentage, a measure of the concentration of analyte molecules in the fluid sample may be determined using an analog, intensity-based detection/analysis method/system and/or a digital detection/analysis method/system. In some cases, the assay may comprise the use of a plurality of capture objects. | 10-06-2011 |
20110245098 | Polymeric carriers for immunohistochemistry and in situ hybridization - Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays. | 10-06-2011 |
20110245099 | Compositions And Methods For Immunodominant Antigens of Mycobacterium Tuberculosis - Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen | 10-06-2011 |
20110245100 | GENERATION OF ANTIBODIES TO AN EPITOPE OF INTEREST - The invention provides methods of obtaining antibodies to an epitope of interest based on an anti-hapten focused library. | 10-06-2011 |
20110245101 | CO-LOCALIZATION AFFINITY ASSAYS - The invention provides a new assay format for high throughput molecular binding studies at a single molecule level. The invention enables creation of binding event identifiers in a highly parallel way. Individual binding events occur between two agents of a binding pair, e.g., a protein-based binding pair or a binding pair comprising a protein and a chemical moiety. The binding event identifier created through the binding of the two binding agents is unique to that pair, and identification of the binding event identifier is indicative of the binding of these specific may be assessed through a readout that is digital in nature. The invention enables very large sets of thousands or more of different binding agents or potential binding agents to be assayed simultaneously, resolving millions or more of potential interactions, and distinguishing specific interactions from those that are less specific. | 10-06-2011 |
20110245102 | Gene Expression Profiling of EGFR Positive Cancer - The present invention concerns prognostic markers associated with EGFR positive cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed tissue samples of EGFR-expressing cancer, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor. | 10-06-2011 |
20110245103 | PREDICTING RESPONSE TO A HER INHIBITOR - The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. | 10-06-2011 |
20110251081 | METHODS AND COMPOSITIONS FOR DETERMINING GENE FUNCTION - The invention relates to methods and systems (e.g., computer systems and computer program products) for characterizing cellular constituents, particularly genes and gene products. In particular, the invention provides methods for assigning or determining the biological function of uncharacterized genes and gene products by using “response profiles,” i.e., measurements of pluralities of cellular constituents in cells having a modified gene or gene product, as phenotypic markers for the gene or gene product. Methods are provided for clustering such response profiles so that similar or correlated response profiles are organized into the same cluster. The invention also provides databases or “compendiums” of response profiles to which the response profile of an uncharacterized gene or gene product can compared. | 10-13-2011 |
20110251082 | BIOMARKERS FOR BREAST CANCER - The present invention uses 2-dimensional differential gel electrophoresisgel (2D-DIGE) and mass spetrum techniques to identify breast cancer biomarkers in transformed breast cells. In summary, the present invention identifies numerous putative breast cancer markers from various stages of breast cancer. The results of the invention aids in developing proteins identified as useful diagnostic and therapeutic candidates on breast cancer research. | 10-13-2011 |
20110251083 | Multiplexed Amplification of Short Nucleic Acids - The present teachings provide methods, compositions, and kits for reverse transcribing and amplifying small nucleic acids such as micro RNAs. High levels of multiplexing are provided by the use of a zip-coded stem-loop reverse transcription primer, along with a PCR-based pre-amplification reaction that comprises a zip-coded forward primer. Detector probes in downstream decoding PCRs can take advantage of the zip-code introduced by the stem-loop reverse transcription primer. In some embodiments, further amplification is achieved by cycling the reverse transcription reaction. The present teachings also provide compositions and kits useful for performing the reverse transcription and amplification reactions described herein. | 10-13-2011 |
20110251084 | System for the Detection of a Biological Pathogen and Use Thereof - The invention features compositions and methods that are useful for the detection of a target analyte, such as a pathogen, in a sample. | 10-13-2011 |
20110251085 | IN VITRO METHOD TO DETERMINE WHETHER A DRUG CANDIDATE ACTIVE AGAINST A TARGET PROTEIN IS ACTIVE AGAINST A VARIANT OF SAID PROTEIN - The present invention relates to the field of virology. More precisely, the invention provides a method of determining the ability of a test compound to modulate the biological activity of a variant of a target protein, wherein said test compound is previously known to modulate the biological activity of said protein. This invention is useful to determine whether a drug candidate, such as anti-viral compounds (eg. against hepatitis C virus: NS5B, NS3), active against a target protein is active against a variant of said protein (eg. polymorphisms, genotypes or mutants). | 10-13-2011 |
20110251086 | NEUROBLASTOMA PROGNOSTIC MULTIGENE EXPRESSION SIGNATURE - The current invention relates to new tools and methods enabling neuroblastoma patient stratification into prognostic favorable or unfavorable groups. The invention is based on the re-analysis of published gene expression data-sets studying neuroblastoma tumors generating different prognostic gene lists. The overlapping gene lists were subsequently tested for their prognostic power on both the published tumor samples and on an unseen large set of unpublished samples, greatly increasing the statistical power of prognostic analyses. In addition, expression analysis of miRNAs in neuroblastoma tumors with different prognosis was performed. By doing this, the inventors could establish a neuroblastoma prognostic classifier with highly improved prognostic power, which is independent from the tumor sample set used to establish it. This classifier and its related prognostic tools and methods are thus perfectly suitable for routine clinical assessment of neuroblastoma prognosis. | 10-13-2011 |
20110251087 | PROGNOSTIC AND DIAGNOSTIC METHOD FOR CANCER THERAPY - The present invention relates to methods for the diagnosis and prognosis of aggressive forms of cancer using a combination of gene expression signatures. | 10-13-2011 |
20110251088 | LARIAT APTAMER: APTAMER CANDIDATE EXCLUSION BY NUCLEASE DIGESTION - A method for identifying aptamers that bind to target molecules may include contacting an oligonucleotide library with target molecule and digesting unbound oligonucleotides with one or more endonucleases, one or more exonucleases, or one or more endonucleases in combination with one or more exonucleases. The unbound oligonucletides lend themselves to nuclease digestion because their flanking sequences are complementary and form predictable, terminal, secondary structure (a Lariat Aptamer). Bound molecules (aptamers) are protected from nuclease digestion and become enriched. A method for identifying aptamers may further include optionally subjecting selected aptamers to one or more rounds of selection under conditions of increased stringency. A method for identifying aptamers may include yet further amplifying selected aptamers. The described methods may be performed in a screen for identifying aptamers either alone or in combination with other methods typically employed in the art for selecting aptamers (such as, e.g., SELEX). Also contemplated herein are systems and kits for accomplishing the above. | 10-13-2011 |
20110251089 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES - The present invention provides a method of synthesizing libraries of molecules which include an encoding oligonucleotide tag. | 10-13-2011 |
20110251090 | PANCREATIC CANCER RELATED GENE TTLL4 - The present invention relates to the roles played by TTLL4 genes in pancreatic cancer carcinogenesis and features a method for treating or preventing pancreatic cancer by administering a double-stranded molecule against one or more of the TTLL4 genes or a composition, vector or cell containing such a double stranded molecule. Also, disclosed are methods of identifying compounds for treating and preventing pancreatic cancer, using as an index their effect on the over-expression of TTLL4 in the pancreatic cancer cell. | 10-13-2011 |
20110251091 | THYROID TUMORS IDENTIFIED - The invention relates to methods and kits for detecting thyroid cancer by detecting differences in the expression of genes that are differentially expressed in thyroid cancer cells. | 10-13-2011 |
20110251092 | Use of Photopolymerization for Amplification and Detection of a Molecular Recognition Event - The invention provides methods to detect molecular recognition events. The invention also provides methods to detect the presence of or identify a target species based on its interaction with one or more probe species. The methods of the invention are based on amplification of the signal due to each molecular recognition event. The amplification is achieved through photopolymerization, with the polymer formed being associated with the molecular recognition event. In one aspect, a fluorescent polymer, a magnetic polymer, a radioactive polymer or an electrically conducting polymer can form the basis of detection and amplification. In another aspect, a polymer gel swollen with a fluorescent solution, a magnetic solution, a radioactive solution or an electrically conducting solution can form the basis of detection and amplification. In another aspect, detectable particles can be included in the polymer formed. In another aspect, sufficient polymer forms to be detectable by visual inspection. | 10-13-2011 |
20110251093 | ANALYSIS, SECURE ACCESS TO, AND TRANSMISSION OF ARRAY IMAGES - Systems and methods are provided the autocentering, autofocusing, acquiring, decoding, aligning, analyzing and exchanging among various parties, images, where the images are of arrays of signals associated with ligand-receptor interactions, and more particularly, ligand-receptor interactions where a multitude of receptors are associated with microparticles or microbeads. The beads are encoded to indicate the identity of the receptor attached, and therefore, an assay image and a decoding image are aligned to effect the decoding. The images or data extracted from such images can be exchanged between de-centralized assay locations and a centralized location where the data are analyzed to indicate assay results. Access to data can be restricted to authorized parties in possession of certain coding information, so as to preserve confidentiality. | 10-13-2011 |
20110251094 | BIOMARKERS FOR HYPERTENSIVE DISORDERS OF PREGNANCY - The application discloses new biomarkers for hypertensive disorders of pregnancy and particularly preeclampsia; methods for the diagnosis, prediction, prognosis and/or monitoring said disorders based on measuring said biomarkers; and kits and devices for measuring said biomarker and/or performing said methods. | 10-13-2011 |
20110251095 | MARA FAMILY HELIX-TURN-HELIX DOMAINS AND THEIR METHODS OF USE - An important advance in the battle against drug resistance by elucidating the domains of MarA which are critical in mediating its function. Accordingly, MarA family protein helix-turn-helix domains, mutant MarA family protein helix-turn-helix domains and methods of their use, for example, in screening assays to identify compounds which are useful as antiinfective agents and in screening assays to identify loci which are involved in mediating antibiotic resistance are described. | 10-13-2011 |
20110251096 | Health Test for a Broad Spectrum of Health Problems - Provided herein are methods and devices for the detection of conditions or disorders by detecting altered levels of stress response pathway biomarkers. Also provided are methods and reagents for identifying panels of biomarkers associated with a condition or disorder. | 10-13-2011 |
20110251097 | DIAGNOSTIC KIT OF COLON CANCER USING COLON CANCER RELATED MARKER AND DIAGNOSTIC METHOD THEREOF - The present invention relates to a composition for diagnosing colon cancer. The composition comprises at least one marker for measuring an mRNA or protein expression level of at least one gene specific for colon cancer. It can screen the genes which are overexpressed specifically only in colon cancer tissues or blood. The present invention can quantitatively analyze both the mRNA expression levels of the genes and the expression levels of the proteins encoded by the gene at the same time, thereby diagnosing colon caner of an early stage with a high level of reliability. | 10-13-2011 |
20110251098 | Biomarkers in Peripheral Blood Mononuclear Cells for Diagnosing or Detecting Lung Cancers - Methods and compositions are provided for diagnosing or detecting a condition, e.g., lung disease in a mammalian subject by use of a micro-RNA expression level or an expression level profile of multiple miRNA in the peripheral blood mononuclear cells (PBMC) of the subject which is characteristic of COPD or NSCLC. Detection of changes in expression in specific miRNA biomarkers from that of a reference sample or miRNA expression profile are correlated with non-small cell lung cancer (NSCLC) and/or COPD and permit differentiation among healthy subjects, subjects with COPD and subjects with adenocarcinoma or squamous cell carcinoma. | 10-13-2011 |
20110251099 | SERUM MARKERS PREDICTING CLINICAL RESPONSE TO ANTI-TNFa ANTIBODIES IN PATIENTS WITH ANKYLOSING SPONDYLITIS - The invention provides tools for management of patients diagnosed with ankylosing spondylitis and prior to the initiation of therapy with an anti-TNFalpha agent. The tools are specific markers and algorithms of predicting response to therapy based on standard clinical primary and secondary end-points using serum marker concentrations. In one embodiment the baseline level of leptin or osteocalcin is used to predict the response at Week 14 after the initiation of therapy. In another embodiment, the change in a serum protein biomarker after 4 weeks of therapy is used such as complement component 3. | 10-13-2011 |
20110251100 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASE AND RELATED DISORDERS - The present invention features biomarkers capable of diagnosing inflammatory bowel disease and methods of using such biomarkers to diagnose and selecting treatments for inflammatory bowel diseases. | 10-13-2011 |
20110251101 | COMBINATORIAL DECODING OF RANDOM NUCLEIC ACID ARRAYS - Methods disclosed herein relate to identification of nucleotides in a nucleotide sequence. | 10-13-2011 |
20110257024 | APPLICATION OF SURFACE PLASMON RESONANCE TECHNOLOGY FOR DETECTING AND GENOTYPING HPV - The present invention discloses using SPR technology to simultaneously and qualitatively detect different HPV genotypes. It also discloses an efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of HPV specific DNA probes used for the detection of different HPV genotypes. | 10-20-2011 |
20110257025 | METHOD FOR TUMOR CLASSIFICATION - The present invention relates to methods for identifying classification markers for tumors by monitoring the activity of protein kinases. By acquiring a phosphorylation profile of diseased and control tissue samples the method of the present invention provides classification procedures using phosphorylation patterns enabling the distinction between different types and/or sub-types of tumors. Specific classification markers for tumors can be identified enabling tumor classification, diagnosis, prognosis and/or prediction of the clinical outcome of a therapy. | 10-20-2011 |
20110257026 | DNA INTERCALATOR DETECTION - A DNA intercalator detection system can include a filtration unit a control sample conditioner operably coupled with the filtration unit and an analytic unit operably coupled with the filtration unit and control sample conditioner and having an electronic chemical array (ECA) reaction component. A data processing unit is operably coupled with the analytic unit and configured to compare and determine a difference between electronic data of a test sample and a conditioned control sample from the ECA reaction component. The difference provides an indication of whether or not a DNA intercalator is present in the test sample. | 10-20-2011 |
20110257028 | Method for selectively binding a substrate to sorbents by way of at least bivalent bonds - A method for the manufacture of at least one sorbent having at least two different groups, which are capable of binding, for the selective binding of a substrate, characterized in that it comprises the steps (i) to (ii):
| 10-20-2011 |
20110257029 | BIOMARKERS FOR PANCREATIC CANCER AND DIAGNOSTIC METHODS - Methods and related kits for differentiating pancreatic cancer from a benign pancreatic disease. The method includes assaying a patient biological sample for a total level of CA 19-9 antigen and for a glycan level in specific mucin(s), and comparing the total level of CA 19-9 antigen and the glycan level in the specific mucin(s) to statistically validated thresholds, wherein a different level of total CA 19-9 antigen in the patient biological sample as compared to a statistically validated threshold and a different level of glycan level in the specific mucin(s) as compared to statistically validated thresholds indicate pancreatic cancer in the patient rather than a benign pancreatic disease. | 10-20-2011 |
20110257030 | Biomarker-Based Methods For Formulating Compositions That Improve Skin Quality And Reduce The Visible Signs Of Aging In Skin For Individuals In A Selected Population - In various embodiments, provided are methods for selecting and formulating compositions for treating and maintaining the quality of skin in a select population, wherein a composition is selected for use in a personal care product based on its demonstrated biological effect to improve skin quality in the population as evidenced by one or more biomarker changes that correlate with improvement as evidenced by one or more objective measurements of skin health in the population. | 10-20-2011 |
20110257031 | Nucleic acid, biomolecule and polymer identifier codes - Provided herein are systems, compositions and methods for tracking, sorting and/or identifying sample polynucleotides using nucleic acid barcodes. The barcodes provided herein are oligonucleotides that are designed to be uniquely identifiable. The nucleic acid barcodes have properties that permit them to be sequenced with high accuracy and/or reduced error rates. In some embodiments, the nucleic acid barcodes are designed to have certain nucleotide sequences that make up overlapping dibase color positions (also called color positions). The order of the overlapping dibase color positions can be determined using fluorophore-encoded dibase probes in a fluorophore color calling scheme to give high fidelity reads. | 10-20-2011 |
20110257032 | MODULAR GLYCAN ARRAYS - The present invention provides methods and systems for functionally analyzing glycans and their interaction partners. Among other things, the invention provides modular glycan arrays in which different glycan populations are associated with different discrete solid phase particles. Provided arrays offer many advantages over available systems for assessing glycan binding interactions. | 10-20-2011 |
20110257033 | POLYMER-NANOSTRUCTURE COMPOSITION FOR SELECTIVE MOLECULAR RECOGNITION - A composition can include a complex, where the complex includes a photoluminescent nanostructure and a polymer free from selective binding to an analyte, the polymer adsorbed on the photoluminescent nanostructure, and a selective binding site associated with the complex. | 10-20-2011 |
20110257034 | METHODS FOR IDENTIFYING GENES WHICH PREDICT DISEASE OUTCOME FOR PATIENTS WITH COLON CANCER - Closures for containers and methods for using same are provided. In a general embodiment/the present disclosure provides a closure having a top portion ( | 10-20-2011 |
20110257035 | IDENTIFICATION OF SIGNATURE GENES ASSOCIATED WITH HEPATOCELLULAR CARCINOMA - The present invention relates to, for example, (1) a novel method for identification of clinically useful serum and/or tumor biomarkers and expression signatures that can be used for detection, prognostication and guidance for the treatment of patients with hepatocellular carcinoma (HCC); and (2) discovery of an expression signature that can be used to monitor and/or study the efficacy of a chemotherapeutic regimen, such as, for example, sorafenib (solely or in combination with other agents). The present invention also provides a method for predicting clinical outcomes, such as, for example, overall survival (OS), time to progression (TTP) and/or likelihood of benefitting from a chemotherapeutic treatment (i.e., sorafenib) in HCC patients based on the analysis of such biomarkers. | 10-20-2011 |
20110263445 | Multidentate Arrays - A method of evaluating for the presence of a target polynucleotide in a sample, using an addressable array of multiple polynucleotide probes linked to a substrate. The sample is exposed to the array and a set of polynucleotide target probes, such that target polynucleotide which may be present will bind to a predetermined feature of the array through multiple target probes of the set by forming at respective target regions on a target molecule, simultaneous hybrids with anti-target regions of the multiple target probes. A binding pattern on the array is observed and the presence of the target polynucleotide evaluated based on the observed binding pattern. Kits using such arrays, and methods for selecting target probes are further provided. | 10-27-2011 |
20110263446 | KIT USEFUL FOR DETECTING, SEPARATING AND/OR CHARACTERIZING A MOLECULE OF INTEREST - A kit for separating and/or characterizing at least one molecule A of interest, the kit including: (i) a compound having the general formula: B—(R) | 10-27-2011 |
20110263447 | METHOD FOR THE PROGNOSIS AND DIAGNOSIS OF TYPE II DIABETES IN CRITICAL PERSONS - This invention is based on the characterization of a set of genes, changes in expression thereof having predictive value on the susceptibility or predisposition to type II diabetes (T2D) in critical persons, in particular in persons having a higher risk in developing T2D such as overweight, obese and pre-diabetic persons. The invention provides in vitro methods for diagnosing, prediction of clinical course, subdiagnosis (based on a Risk Score), prediction and efficacy of treatments for T2D, in critical persons. The genes, and gene products of the present invention are also useful in identifying treatment methods and agents for prevention and/or treatment of T2D onset in critical persons. | 10-27-2011 |
20110263448 | Interferon Response in Clinical Samples (IRIS) - The present invention relates to a specific set of genes useful for determining the efficacy of a treatment against multiple sclerosis (MS). Further, the invention provides an array of these genes useful for evaluating efficacy of a MS treatment. Also provided are methods for evaluating efficacy of an MS treatment and a method for detecting neutralizing antibodies in patient response to interferonβ-1B treatment of MS. | 10-27-2011 |
20110263449 | IN VITRO METHOD AND KIT FOR PROGNOSIS OR PREDICTION OF RESPONSE BY PATIENTS WITH RHEUMATOID ARTHRITIS TO TREATMENT WITH TNF-ALPHA FACTOR BLOCKING AGENTS - In vitro method and kit for prognosis or prediction of the response of rheumatoid patients to treatment with TNF-α factor blocking agents, which comprises determining, in a blood sample from said patients, the expression level of at least one of the eight genes selected from the group: HLA-DRB3, EAT2, GNLY, CAMP, SLC2A3, IL2RB, MXD4 and TLR5 or combinations thereof and comparing said expression level to the expression values obtained from responsive and non-responsive patients who showed responsiveness to the treatment and those who showed non-responsiveness thereto. | 10-27-2011 |
20110263450 | ALZHEIMER'S DISEASE BIOMARKERS - The invention provides a biomarker for qualifying Alzheimer's disease status, the biomarker being detectable in a biological sample containing blood cellular elements and being derived from amyloid precursor protein or amyloid β peptide. Particularly the biomarker includes an Aβ 1-42 or Aβ 1-43 species (monomer) and, or an Aβ 1-42 dimer. An alternative or additional biomarker includes an APP cathepsin D cleavage product or includes a biomarker identifiable by a peak of molecular weight of about 9962 or 9980 Daltons when identified by SELDI-TOF MS utilising antibody WO2. | 10-27-2011 |
20110263451 | BIOLOGICAL MARKERS PREDICTIVE OF RHEUMATOID ARTHRITIS RESPONSE TO LYMPHOTOXIN ANTAGONISTS - The present invention relates to a soluble lymphotoxin (solLT) and methods of using the solLT as a biomarker in the treatment of autoimmune disease. More particularly, the present invention relates to soluble lymphotoxin alpha-beta (solLTαβ) and methods of using this solLTαβ as a biomarker in the treatment of rheumatoid arthritis (RA). | 10-27-2011 |
20110263452 | PLATELET ANALYSIS - The present invention relates to a method, including a diagnostic method, for characterising platelets. More particularly, the invention relates to methods for characterising platelets by immobilising platelets on a substrate for detection and subsequent characterisation, and to devices on which such a method may be practiced. The method comprises the steps of:—a.contacting a substrate that includes a plurality of discrete platelet- binding zones having a surface area of 7850 μm | 10-27-2011 |
20110263453 | NUCLEIC ACID QUANTIFICATION PRODUCTS AND PROCESSES - Described herein are products and processes for nucleic acid quantification, which are in part useful for detecting and determining the nucleotide sequence of rare nucleic acids (i.e., low copy number nucleic acids) in a sample. Such products and processes are useful for reducing the dynamic range among different nucleic acid species. | 10-27-2011 |
20110269635 | SYSTEMS AND METHODS FOR HIGH-THROUGHPUT SCREENING USING LIGHT SCATTERING - Systems and methods for high-throughput screening can be used to determine whether binding occurs between different molecular species. Some systems compare measurements obtained from a static light scattering detector relative to a first solution that includes a target molecular species, a second solution that includes a test molecular species, and a third solution that includes a mixture of the target and test molecular species. | 11-03-2011 |
20110269636 | MATERIALS AND METHODS FOR IDENTIFYING PATIENTS AT HEIGHTEN RISK FOR DEVELOPING HER2+ RELATED BRAIN TUMORS - Aspects of the invention include methods for identifying patients with HER2+ cancers that are at a heightened risk for developing brain metastasis within three years of having been diagnosed with HER2+ cancer. Some embodiments are methods that include the steps of contacting at least a portion of the tumor tissue from patients with probes that interact with the products of a set of thirteen genes that are expressed in these patients at markedly higher levels than in similarly situated patients that are not a heightened risk for developing brain metastasis within this three year window. In some embodiments the tissue samples are assayed from the presence of RNA indicative of the expression of member of a set of 13 genes identified as being differentially expressed in patients with and without a heightened risk for developing brain metastasis. | 11-03-2011 |
20110269637 | Method for Predicting Clinical Outcome of Patients With Non-Small Cell Lung Carcinoma - The invention provides an in vitro method for predicting clinical outcome of a patient affected with a non-small cell lung carcinoma (NSCLC), which method comprises determining the expression level of at least 8 genes in a biological sample of said patient. | 11-03-2011 |
20110269638 | Genes associated with post relapse survival and uses thereof - Provided are methods, systems and kits for predicting post-relapse survival of a cancer patient and for identifying cancer genes predictive of the post-relapse survival of the patient. Values representing gene expression levels of a group of genes associated with survival of the cancer cells are determined using gene expression profiling platforms and a plurality of probe sets that hybridize to one or more of the genes in the group. A predictive model establishes a predictive value based on the weighted contribution of each gene associated with survival of the cancer cells to risk of death for the cancer patient and imports expression values of the genes in the group that is indicative of a risk of death for the relapsed patient. Using global gene expression profiling and statistical analysis, expression of cancer cell genes at baseline and at first relapse that are involved in interaction of cancer cells with cells in their microenvironment, can be used to identify genes that are predictive of post-relapse survival. | 11-03-2011 |
20110269639 | Detection of Johnsongrass and Its Hybrid Seed - Methods for detecting the presence or amount of Johnsongrass or Johnsongrass hybrid genetic material in a biological sample, preferably the detection of the presence or amount of Johnsongrass or Johnsongrass hybrid seed in a seed sample, are disclosed. The methods involve detection of certain nucleic acid sequences, namely Johnsongrass detection sequences, optionally through a primer-based amplification process, such as PCR. Also disclosed are isolated polynucleotides, replication compositions and kits for carrying out the detection methods. | 11-03-2011 |
20110269640 | PROBES FOR DETECTING MUTATIONS OF kRas GENE, LIQUICHIP AND DETECTION METHODS THEREOF - Nucleic acid probes for detecting kRas gene mutations, liquid chips and detection methods thereof are provided. The liquid chips for detecting kRas gene mutations comprise: microspheres coupled with wild-type and mutant-type probes, each of which is amino-substituted at 5′-terminal, specific for kRas codons 12, 13 and/or 61, and primers for amplifying the target sequence biotin-labeled at the terminal which are enriched with mutant alleles of kRas codons 12, 13 and/or 61 to be detected. The detection methods are rapid and accurate, and the processes of the methods are easy to perform. The liquid chip can be used to detect mutations of kRas as assistance to early diagnosis of pancreatic cancer, and can be used to prognose efficiency of the molecular targeted therapy to choose right medicine accurately clinically and avoiding economic loss and time loss caused by unnecessary treatment. | 11-03-2011 |
20110269641 | METHODS AND SYSTEMS FOR CONTROLLING LIQUIDS IN MULTIPLEX ASSAYS - Methods and systems for venting a well that receives a liquid. The method includes providing a microplate including a well that has a cavity with an open inlet and a closed end. The cavity extends between the open inlet and the closed end. The cavity is defined by a wall surface having a cross-sectional contour that includes at least one continuous section and at least one discontinuity section. The method also includes depositing a liquid into the open inlet of the well. The liquid enters the cavity and flows toward the closed end to at least partially fill the well. The liquid flows along the continuous section of the wall surface and remains separated from the discontinuity section of the wall surface, thereby maintaining a gas exhaust path along a spacing between the liquid and the discontinuity section as the liquid flows toward the closed end. | 11-03-2011 |
20110269642 | MODULAR ASSAY PLATES, READER SYSTEMS AND METHODS FOR TEST MEASUREMENTS - Luminescence test measurements are conducted using an assay module having integrated electrodes with a reader apparatus adapted to receive assay modules, induce luminescence, preferably electrode induced luminescence, in the wells or assay regions of the assay modules and measure the induced luminescence. | 11-03-2011 |
20110275526 | GLYCOSYL TRANSFERASE FROM CHINESE HAMSTER AND RELATED METHODS - A glycosyl transferase from Chinese hamster and related methods are described. | 11-10-2011 |
20110275527 | Predictive Toxicology for Biological Systems - Methods and apparatus to identify a potential toxicity of a therapy in a biological system are described. In one embodiment, a method uses a computer model that represents a set of biological processes of the biological system. The method includes executing the computer model to identify a first set of biological processes contributing to the occurrence of a toxic state of the biological system. The method also includes identifying a set of biological assays based on the first set of biological processes and testing the therapy in the set of biological assays to identify a second set of biological processes modified by the therapy. The method further includes identifying the potential toxicity of the therapy based on the second set of biological processes. | 11-10-2011 |
20110275528 | MARKER SEQUENCES FOR INFLAMMATORY PROSTATE DISEASES, PROSTATE CARCINOMA AND THEIR USE - The present invention relates to novel marker sequences for inflammatory prostate diseases, prostate carcinoma and the diagnostic use thereof together with a method for screening of potential active substances for inflammatory prostate diseases, prostate carcinoma by means of these marker sequences. Furthermore, the invention relates to a diagnostic device containing such marker sequences for inflammatory prostate diseases, prostate carcinoma, in particular a protein biochip and the use thereof. | 11-10-2011 |
20110275529 | IDENTIFICATION AND CHARACTERISATION OF RECOMBINANT VIRAL GENE THERAPY VECTORS - The present invention refers to a method for identifying or characterising a recombinant viral vector, particularly a recombinant adeno-associated virus (AAV) vector. | 11-10-2011 |
20110275530 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF EPITHELIAL CANCERS - Methods for detecting, diagnosing and monitoring an epithelial cancer in a patient are described comprising measuring in a sample from the patient EpICD polypeptides and EpICD polynucleotides. The invention also provides kits and compositions for carrying out the methods of the invention. | 11-10-2011 |
20110275532 | USE OF NON-NUCLEOPHILIC ADDITIVES FOR REDUCTION OF SURFACE MORPHOLOGICAL ANOMALIES IN PROBE ARRAYS - The present invention relates to a formulations and methods for coupling a reactant (or probe precursor) to a functionalized surface for purposes of forming an arrayed sensor. This method includes the steps of: providing a surface having a reactive functional group; and introducing onto the surface, at a plurality of discrete locations, two or more compositions of the invention, which include a different reactant (probe precursor) and a non-nucleophilic additive, wherein such introduction is carried out under conditions effective to allow for covalent binding of the reactant to the surface via the reactive functional group. This results in a probe-functionalized array that substantially overcomes the problem of surface morphological anomalies on the array surface. Use of the resulting arrays in various detection systems is also encompassed. | 11-10-2011 |
20110275533 | Micro-RNAs as Markers for Tumor Progression - Disclosed are methods for diagnosing cancer or dysplasia in a sample of tissue, involving testing cells of the sample to assess whether miR-196a expression in cells of the sample is greater than a reference, wherein a greater expression of miR-196a in cells of the sample compared to the reference is indicative of cancer or dysplasia. The cancer or dysplasia may be esophageal cancer or esophageal dysplasia. Also disclosed are method for diagnosing cancer or dysplasia in a sample of tissue, comprising testing cells of the sample to assess whether the expression of ANXA1, KRT5, SPRR2C, or S100A9 in cells of the sample is reduced compared to a reference control, wherein said reduced expression in cells of the sample compared to the reference control is indicative of cancer or dysplasia. Also disclosed are kits and methods involving kits for the diagnosis of cancer or dysplasia. | 11-10-2011 |
20110275534 | MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Ovarian Cancer Using a Real-Time PCR Platform - Methods and compositions for the diagnosis, prognosis and/or treatment of ovarian cancer are disclosed. | 11-10-2011 |
20110275535 | Yeast Display Systems - The present invention relates to the field of protein display libraries and library screening. In preferred embodiments, the present invention provides a three component system for display comprising a cell surface molecule, an adapter molecule and a display molecule. | 11-10-2011 |
20110275536 | BIOMARKER FOR DIAGNOSIS, PREDICTION AND/OR PROGNOSIS OF ACUTE HEART FAILURE AND USES THEREOF - The application discloses Quiescin Q6 as a new biomarker for acute heart failure; methods for predicting, diagnosing and/or prognosticating acute heart failure based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. | 11-10-2011 |
20110275537 | METHOD OF BIOLOGICAL AND MEDICAL DIAGNOSTICS USING IMMUNE PATTERNS OBTAINED WITH ARRAYS OF PEPTIDE PROBES - Immune-chips, which are arrays of peptides probes are used to obtain a pattern which characterizes the global immune reactivity status of the human or other organism, are described. The peptide probes participate in immune reactions with antibodies and immune receptors of the investigated organisms to generate an immune pattern on the chip, which are detected and stored as patterns in databases. The patterns are then compared with other patterns observed with the same array and obtained under physiological, pathological and experimental conditions from the same or other organisms. The comparison is used to classify the state of the investigated organisms based on similarity to other observed states. The immune chips and the obtained patterns can be used for clinical diagnosis and biological studies, such as the investigation of similarities between physiological, pathological or experimental processes. | 11-10-2011 |
20110281744 | METHOD OF IDENTIFYING COMPOUNDS THAT MODULATE REGULATION OF IRON RESPONSE ELEMENTS - The invention features methods for identifying compounds that inhibit binding between iron response elements (IREs) and iron response proteins (IRPs). These compounds are potentially useful for treating or preventing diseases, in particular cancer, but also including anemia, neurodegenerative diseases, inflammation and iron overload. The methods are based on contacting a candidate compound in an in vitro system and monitoring the binding of an IRE to an IRP. In addition, the invention features methods of treating or preventing a proliferative disease, such as cancer, using the compounds of the invention. | 11-17-2011 |
20110281745 | SCREENING ASSAYS AND METHODS - Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody. | 11-17-2011 |
20110281746 | METHODS AND COMPOSITIONS RELATED TO QUANTITATIVE, ARRAY BASED METHYLATION ANALYSIS - Disclosed are compositions and a method for detection of methylation based on quantitative arrays. | 11-17-2011 |
20110281747 | BIOMARKERS FOR PREDICTING RAPID RESPONSE TO HCV TREATMENT - The present invention is based on the discovery that in patients infected with Genotype 1 of the Hepatitis C virus (HCV-1) or Genotype 4 HCV (HCV-4) that undergo Triple Therapy treatment, certain biomarkers can be predictive of a patient achieving RVR2. | 11-17-2011 |
20110281748 | DRUG SELECTION FOR GASTRIC CANCER THERAPY USING ANTIBODY-BASED ARRAYS - The present invention provides methods for selecting a suitable anticancer therapy, and for identifying and predicting response for the treatment of a gastric cancer. | 11-17-2011 |
20110281749 | HUMAN T2R RECEPTORS FOR ACETAMINOPHEN, RANITIDINE, STRYCHNINE AND DENATONIUM AND RELATED ASSAYS FOR IDENTIFYING HUMAN BITTER TASTE MODULATORS - The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter ligands, i.e., acetaminophen, ranitidine, strychnine and denatonium. The present invention further relates to the use of these receptors in assays for identifying ligands that modulate the activation of these taste receptors and which may be used as additives in foods, beverages and medicinals for modifying (blocking) T2R-associated bitter taste. | 11-17-2011 |
20110281750 | Identifying High Risk Clinically Isolated Syndrome Patients - Disclosed herein are methods and kits for identifying clinically isolated syndrome (CIS) patients at high risk of developing multiple sclerosis (MS). | 11-17-2011 |
20110281751 | CELL SURFACE DISPLAY OF POLYPEPTIDE ISOFORMS BY STOP CODON READTHROUGH - The present invention inter alia pertains to a method for generating or selecting a eukaryotic host cell expressing a desired level of a polypeptide of interest, comprising:
| 11-17-2011 |
20110281752 | BETA-SECRETASE ENZYME COMPOSITIONS AND METHODS - Disclosed are various forms of an active, isolated β-secretase enzyme in purified and recombinant form. This enzyme is implicated in the production of amyloid plaque components which accumulate in the brains of individuals afflicted with Alzheimer's disease. Recombinant cells that produce this enzyme either alone or in combination with some of its natural substrates (β-APPwt and β-APPsw) are also disclosed, as are antibodies directed to such proteins. These compositions are useful for use in methods of selecting compounds that modulate β-secretase. Inhibitors of β-secretase are implicated as therapeutics in the treatment of neurodegenerative diseases, such as Alzheimer's disease. | 11-17-2011 |
20110281753 | RATIONALE, METHODS, AND ASSAYS FOR IDENTIFYING HUMAN AND NON-HUMAN PRIMATE TASTE SPECIFIC GENES AND USE THEREOF IN TASTE MODULATOR AND THERAPEUTIC SCREENING ASSAYS - This invention relates to novel rationale and methods for identifying human and primate taste-specific genes, including genes involved in salty taste perception, especially human salty taste perception, but also genes involved in sweet, bitter, umami, and sour taste perception, and genes involved in other taste cell or taste receptor related activities such as digestive function and digestive related diseases, taste cell turnover, immunoregulation of the oral and digestive tract, and metabolic regulation such as in diabetes and obesity, the genes identified using these methods, and assays for identifying taste modulators (enhancers or blockers) and potential therapeutics using these genes. These compounds have potential application in modulating (enhancing or blocking) taste perception, especially salty taste perception and as potential therapeutics. In addition, this invention relates to novel methods for identifying taste-specific genes that can be used as markers for different taste cell types, including sweet, bitter, umami, sour, salty, and other taste cells in mammals as well as assays that measure the activity of the sweet, bitter, umami, or sour receptor in the presence of these genes to identify modulators of sweet, bitter, umami, and sour taste and to identify therapeutics especially for treating digestive or metabolic disorders, taste loss, and oral infections. Particularly, the genes identified herein and antibodies or oligos thereto can be used as markers to identify and/or purify specific taste cells e.g., from taste cell suspensions by use of FACS or magnetic bead cell selection or other known cell purification and isolation procedures. | 11-17-2011 |
20110281754 | COMPOSITIONS AND METHODS FOR DETECTING, IDENTIFYING AND QUANTITATING MYCOBACTERIAL-SPECIFIC NUCLEIC ACIDS - Disclosed are compositions and methods for isolating, detecting, amplifying, and quantitating | 11-17-2011 |
20110281755 | Karyotyping Assay - This disclosure relates to methods and kits for karyotyping in which chromosomes are interrogated by amplifying loci that are not within copy number variable regions thereof. | 11-17-2011 |
20110281756 | COMPOSITIONS AND METHODS FOR MICRO-RNA EXPRESSION PROFILING OF COLORECTAL CANCER - The present invention relates compositions and methods for microRNA (miRNA) expression profiling of colorectal cancer. In particular, the invention relates to a diagnostic kit of molecular markers for identifying one or more mammalian target cells exhibiting or having a predisposition to develop colorectal cancer, the kit comprising a plurality of nucleic acid molecules, each nucleic acid molecule encoding a miRNA sequence, wherein one or more of the plurality of nucleic acid molecules are differentially expressed in the target cells and in one or more control cells, and wherein the one or more differentially expressed nucleic acid molecules together represent a nucleic acid expression signature that is indicative for the presence of or the predisposition to develop colorectal cancer. The invention further relates to corresponding methods using such nucleic acid expression signatures for identifying one or more mammalian target cells exhibiting or having a predisposition to develop colorectal cancer as well as for preventing or treating such a condition. Finally, the invention is directed to a pharmaceutical composition for the prevention and/or treatment of colorectal cancer. | 11-17-2011 |
20110281757 | Methods and Compositions for Detection of Complement Fixing Antibodies - The invention provides methods for sensitive and specific detection of complement fixing antibodies in a biological sample using complement factor C1q, including autologous complement factor C1q present in the biological sample and a detectably labeled antibody that binds the autologous complement factor C1q, exogenous human complement factor C1q and a detectably labeled antibody that binds the exogenous human complement factor C1q, detectably labeled exogenous human complement factor C1q, or a combination of autologous complement factor C1q and exogenous human complement factor C1q. The invention also features kits, systems, and devices for use in the methods of the invention. | 11-17-2011 |
20110281758 | METHODS OF DIAGNOSING AND PREDICTING RENAL DISEASE - This disclosure relates to methods of diagnosing and predicting renal disease, using one, two, or more biomarkers, including sTNFR1, sTNFR2, sFAS, TNF, and IL-6. | 11-17-2011 |
20110281759 | METHOD FOR DIAGNOSING AUTISM SPECTRUM DISORDER - The present invention provides methods of diagnosing and/or predicting autism spectrum disorder comprising determining the presence of microdeletions and microduplications on chromosomes 15 and 16. | 11-17-2011 |
20110281760 | SUPPORTS FOR ASSAYING ANALYTES AND METHODS OF MAKING AND USING THEREOF - Described herein are supports for assaying an analyte and methods of making and using thereof. | 11-17-2011 |
20110281761 | MULTI-CHAIN EUKARYOTIC DISPLAY VECTORS AND USES THEREOF - A eukaryotic expression vector capable of displaying a multi-chain polypeptide on the surface of a host cell is provided, such that the biological activity of the multi-chain polypeptide is exhibited at the surface of the host cell. Such a vector allows for the display of complex biologically active polypeptides, e.g., biologically active multi-chain polypeptides such as immunoglobulin Fab fragments. The present invention describes and enables the successful display of a multi-chain polypeptide on the surface of a eukaryotic host cell. Preferred vectors are described for expressing the chains of a multi-chain polypeptide in a host cell separately and independently (e.g., under separate vector control elements, and/or on separate expression vectors, thus forming a matched vector set). The use of such matched vector sets provides flexibility and versatility in the generation of eukaryotic display libraries, for example the ability to generate and to display multi-chain polypeptides by combining and recombining vectors that express variegations of the individual chains of a multi-chain polypeptide. Entire repertoires of novel chain combinations can be devised using such vector sets. | 11-17-2011 |
20110287954 | PRIMERS, METHOD AND SET OF TOOLS FOR DETERMINING THE FUNCTIONALITY OF THE HUMAN THYMUS - Determining thymic function in adults has attracted increasing interest in the context of diseases that affect the immunological system and, in particular, diseases that produce lymphopenias. The invention relates to a set of primers for determining the functionality of the human thymus by calculating the quotient between two types of TREC content, as well as to a method based on multiplex nested PCR which uses the aforementioned primers and can be used to determine the TREC quotient measured in samples of human blood or tissue. The invention is advantageous over methods known in the prior art in terms of reducing experimental errors and the time and costs involved. | 11-24-2011 |
20110287955 | POLYPEPTIDE MARKER FOR DIAGNOSIS OF ARTERIOSCLEROSIS, METHOD FOR DETECTION OF ARTERIOSCLEROSIS BY USING THE MAKER OR THE LIKE, AND KIT FOR DIAGNOSIS OF ARTERIOSCLEROSIS - Disclosed are: a polypeptide marker for diagnosing arteriosclerosis; a gene marker for diagnosing arteriosclerosis; an antibody; a probe for detecting an arteriosclerosis marker gene; a DNA microarray or a DNA chip for detecting an arteriosclerosis marker gene; a method for detecting arteriosclerosis; and a kit for diagnosing arteriosclerosis; with which an arteriosclerotic lesion can be detected with much improved accuracy. Specifically disclosed are: a polypeptide marker for diagnosing arteriosclerosis, which comprises a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35 of the Sequence Listing, or a partial amino acid sequence thereof; a gene which encodes the amino acid sequence; a probe for detecting the gene; a DNA microarray or a DNA chip comprising the probe; an antibody bindable to the polypeptide as an antigen; a kit comprising any one of the above-mentioned items; and a method for detecting arteriosclerosis by using any one of the above-mentioned items. | 11-24-2011 |
20110287956 | Nano-Scale Biosensors - Devices, systems, and methods for detecting protein-nucleic acid and cell-nucleic acid hybridization, using surface-tethered aptamer probes, without the use of labeling or target modification and capable of recycling. | 11-24-2011 |
20110287957 | METHODS AND KITS FOR DIAGNOSING COLORECTAL CANCER - The invention pertains to a method for early detection and screening of colorectal cancer in human subjects based on RNA isolated from blood obtained from said subject. According to the invention, the expression of at least 3, 5, 8, 30, 60, 102, 202, 55, 1002 or 1002 RNAs listed in Tables 1-15 are measured. Using the invention, an accurate and noninvasive screening and diagnosis tool for colorectal cancer is provided with a sensitivity of at least 80% and a specificity of 85% that has high clinical utility and the potential for broad adoption. | 11-24-2011 |
20110287958 | Method for Using Gene Expression to Determine Colorectal Tumor Stage - The invention relates to methods of determining a colorectal tumor stage in a patient by gene expression analysis. The method comprises assaying the level of at least one RNA transcript, or its expression product, which is correlated to colorectal tumor stage. The invention may be useful for determining whether a patient has stage II or stage III colorectal cancer. | 11-24-2011 |
20110287959 | PAN-ANTIBODY ASSAYS - PRINCIPLES, METHODS, AND DEVICES - The present invention includes methods, assays, and devices for assaying a sample to detect the presence, absence, or level of at least one analyte in a biological sample using a pan-antibody panel or multiplexed immunoassay, wherein at least one analyte is detected by two or more antibodies. Certain embodiments include the use of a microfluidic device in the immunoassay. Further embodiments of the invention include assays, methods, and devices to detect the presence, absence, or level of at least one analyte which is determined for a diagnostic or a scientific purpose. Still further embodiments of the invention include assays, methods, and devices to detect the presence, absence, or level of at least one analyte which is indicative of a condition or disease. Yet further embodiments of the invention include incorporating additional diagnostic techniques (e.g., PCR, RT-PCR, and DNA hybridization arrays) to the assays, device, and methods. | 11-24-2011 |
20110287960 | Method For Producing Monoclonal Antibodies - The present invention relates to methods for producing monoclonal antibodies. In particular, the invention relates to high throughput methods for producing and screening monoclonal antibodies more rapidly than conventional methods. | 11-24-2011 |
20110287961 | EXPRESSION ANALYSIS OF CORONARY ARTERY ATHEROSCLEROSIS - This invention relates, e.g., to a method for screening a subject for the presence of coronary atherosclerosis, said method comprising measuring the expression level of at least 5 of the genes of Table 2 in a biological sample obtained from said subject, wherein an elevated level of expression of said 5 genes compared to a control level measured in a population of normal subjects is indicative of an increased probability of the subject having significant subclinical coronary atherosclerosis. Methods for deciding on a treatment modality, based on a diagnostic procedure of the invention, are also described, as are kits for carrying out a method of the invention. | 11-24-2011 |
20110287962 | METHOD FOR FAST DETECTION AND IDENTIFICATION OF MICRO-ORGANISMS - The present invention relates to a specific method accomplishing fast and specific detection, identification and characterization of contaminating micro-organisms in various samples. A method has been developed based on the detection of species-specific and/or strain-specific nucleotide sequences that are uniquely identified and amplified and subsequently detected on a microarray using addressable identifier ZIP oligonucleotides. By using a two step screening process, the method of the present invention enables in first instance the fast screening of a multitude of samples for the presence or the absence of specific micro-organisms in such samples, while in a second screening step the positive results of the first step are further processed to identify and characterize the detected micro-organisms. | 11-24-2011 |
20110287963 | SYSTEM USEFUL FOR REPORTING PROTEIN-PROTEIN INTERACTIONS IN THE BACTERIAL PERIPLASM - One aspect of the present invention relates to a reporter system for detection of protein-protein interactions in the periplasm of a prokaryotic host cell. The reporter system includes a first expression system which has a nucleic acid molecule encoding a first fragment of a reporter protein molecule, a nucleic acid molecule encoding a first signal sequence, and a nucleic acid molecule encoding a first member of a putative binding pair, where the nucleic acid molecule encoding the first fragment, the nucleic acid molecule encoding the first signal sequence, and the nucleic acid molecule encoding the first member of the putative binding pair are operatively coupled to permit their expression in a prokaryotic host cell as a first fusion protein. The reporter sys tem also includes a second expression system which has a nucleic acid molecule encoding a second fragment of the reporter protein molecule, a nucleic acid molecule encoding a second signal sequence, and a nucleic acid molecule encoding a second member of the putative binding pair, where the nucleic acid molecule encoding the second fragment, the nucleic acid molecule encoding the second signal sequence, and the nucleic acid molecule encoding the second member of the putative binding pair are operatively coupled to permit their expression in a prokaryotic host cell as a second fusion protein, where, when expressed in a prokaryotic host cell, at least one of the first and the second fusion proteins are co-translationally transported to the periplasm where, when present, the first and second members of the putative binding pair bind together and the first and second fragments of the reporter protein molecule are reconstituted, thereby producing an active reporter protein. The reporter system may be used to carry out methods of identifying candidate compounds which bind to a target protein, identifying a candidate gene which modulates binding between a first protein and second protein, and identifying a candidate compound which modulates binding between a first protein and second protein. | 11-24-2011 |
20110287965 | METHODS AND COMPOSITIONS TO DETECT CLOSTRIDIUM DIFFICILE - Methods for detecting strains of | 11-24-2011 |
20110287966 | MOLECULAR MARKERS FOR RICE BROWN PLANTHOPPER RESISTANCE GENE - Molecular markers for rice planthopper resistance gene Bph14 are provided. The Bph14 gene belongs to the CC-NBS-LRR gene family, and its coded protein is related to plant disease resistance. Bph14 gene has the function of resisting brown planthopper. By determining Bph14 gene molecular markers in rice varieties, breeding is improved. Harm caused by brown planthopper can be alleviated and the aim of increasing and stabilizing production can be achieved. | 11-24-2011 |
20110287967 | Lung Cancer Methylation Markers - The present invention discloses a method of diagnosing lung cancer by using methylation specific markers from a set, having diagnostic power for lung cancer diagnosis and distinguishing lung cancer types in diverse samples; as well as methods to identify sets of prognostic and diagnostic value. | 11-24-2011 |
20110287968 | Methylation Assay - The present invention discloses a method of generating subsets of methylation specific markers from a set, having diagnostic power for various diseases, e.g. cancer of thyroid, breast, colon, or leukemia, in diverse samples; identified subsets of that set, as well as methods for the prognosis and diagnosis of diseases. | 11-24-2011 |
20110287969 | IMMUNOREGULATION IN CANCER, CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES - The present invention primarily relates to a method for analyzing the amount of immunoregulatory integrin binding factors and/or patient endogenous antibodies which are directed against such factors, the factors having the capacity to modulate the immune functions in a. subject suffering from cancer or inflammatory or autoimmune diseases, by utilizing binding reagents to determine these factors and/or the patient endogenous antibodies which are directed against such factors, whereby the prognosis and/or the therapeutic efficacy of any treatment of a subject suffering from cancer or inflammatory or autoimmune diseases can be determined and/or monitored. The invention further relates to the use of therapeutically active compounds for eliminating, inhibiting or enhancing such binding factors for the manufacture of pharmaceuticals to be used in the treatment of cancer, inflammatory conditions or autoimmune diseases. | 11-24-2011 |
20110287970 | MICRORNA FINGERPRINTS DURING HUMAN MEGAKARYOCYTOPOIESIS - The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of cancer and myeloproliferative disorders. The invention also provides methods of identifying anti-cancer agents. | 11-24-2011 |
20110287971 | MULTI-CHAIN EUKARYOTIC DISPLAY VECTORS AND USES THEREOF - A eukaryotic expression vector capable of displaying a multi-chain polypeptide on the surface of a host cell is provided, such that the biological activity of the multi-chain polypeptide is exhibited at the surface of the host cell. Such a vector allows for the display of complex biologically active polypeptides, e.g., biologically active multi-chain polypeptides such as immunoglobulin Fab fragments. The present invention describes and enables the successful display of a multi-chain polypeptide on the surface of a eukaryotic host cell. Preferred vectors are described for expressing the chains of a multi-chain polypeptide in a host cell separately and independently (e.g., under separate vector control elements, and/or on separate expression vectors, thus forming a matched vector set). The use of such matched vector sets provides flexibility and versatility in the generation of eukaryotic display libraries, for example the ability to generate and to display multi-chain polypeptides by combining and recombining vectors that express variegations of the individual chains of a multi-chain polypeptide. Entire repertoires of novel chain combinations can be devised using such vector sets. | 11-24-2011 |
20110287972 | Methods and Systems for Inferring Traits to Breed and Manage Non-Beef Livestock - Methods and systems are provided for managing non-beef livestock subjects in order to maximize their individual potential performance and the value of a product from the non-beef livestock subjects, and to maximize profits obtained in marketing the non-beef livestock subjects. The methods and systems draw an inference of a trait of a non-beef livestock subject by determining the nucleotide occurrence of at least one non-beef livestock SNP that is determined to be associated with the trait. The inference is used in methods of the present invention to establish the economic value of a non-beef livestock subject, to improve profits related to selling beef from a non-beef livestock subject; to manage non-beef livestock subjects, to sort non-beef livestock subjects; to improve the genetics of a non-beef livestock population by selecting and breeding of non-beef livestock subjects, to clone a non-beef livestock subject with a specific trait, to track meat or another commercial product of a non-beef livestock subject; and to diagnose a health condition of a non-beef livestock subject. Certain embodiments of the present invention provide methods, systems, and kits are directed to inferences of a trait related to milk or a dairy product in a livestock subject. | 11-24-2011 |
20110287973 | FRAMELESS MULTIPLEXED MICROARRAYS - The present invention relates to novel methods for the quantitative detection of molecules in an array. In particular, the present invention relates to methods and apparatuses for producing a frameless array. In another embodiment, the present invention relates to a composition comprising nitrocellulose that is useful of producing a frameless array. In another embodiment, the present invention relates to a method for detecting a molecular interaction. In yet another embodiment, the present invention relates to kits useful for practicing the methods and apparatuses of the present invention. The present invention provides improved methods and apparatuses for the high throughput analysis of molecular interactions and quantitative detection. | 11-24-2011 |
20110294678 | CELLS SCREENING METHOD - Provided are a method and means permitting the simultaneous measurement of the reactive properties of more than 10,000 of antigen-stimulated lymphocytes being held on a chip and the separate determination of the states of individual cells. A microwell array comprises multiple wells and a coating layer on one of the principal surfaces of a base member, the wells being of a size permitting the entry of only a single cell into each well. A coating layer of a substance capable of binding to a substance produced by the cells contained in the wells is present on the principal surface around the wells. A method of screening for a target cell, comprises: causing specimen cells and a cell culture broth to be contained in the wells of the above microwell array; immersing the coating layer and the wells in the culture broth and culturing the cells in a state permitting the diffusion of substances in the culture broth from the wells into the coating layer; feeding a label substance binding specifically to a substance produced by a target cell present among the specimen cells onto the coating layer; and detecting the substance produced by the target cell that has bound to the substance in the coating layer by the label substance to specify the target cell. | 12-01-2011 |
20110294679 | METHOD OF FABRICATION OF PHOTONIC BIOSENSOR ARRAYS - This invention relates to a method for the fabrication of photonic biosensor arrays and applications of arrays produced by the method in the biomedical field. A method for the fabrication of a biosensor array for plasmon resonance-based sensing of a plurality of different biological targets simultaneously, the method comprising: (i) providing a transparent substrate; ii) providing seed metallic nanoparticles in the form of a colloid; (iii) depositing said colloid as discrete metallic islands on the transparent substrate, each of said metallic islands comprising a plurality of metallic nanoparticles; (iv) washing the substrate in order to remove unadhered material; (v) developing the substrate in a growth solution, which solution comprises a salt of the same metal which is present in the form of discrete metallic islands on the substrate, a reducing agent, a capping agent and optionally a surfactant; (vi) washing the developed substrate; and (vii) functionalising each of said metallic islands with a different functionalising molecule using a common chemical process to attach said different functionalising molecules to said metallic islands. | 12-01-2011 |
20110294680 | METHODS AND COMPOSITIONS FOR PREDICTING SUCCESS IN ADDICTIVE SUBSTANCE CESSATION AND FOR PREDICTING A RISK OF ADDICTION - The present invention relates to genetic polymorphisms that are associated with dependence on an addictive substance. In particular, the present invention relates to a method for predicting success in addictive substance cessation in a subject, such as predicting success in nicotine cessation. In some embodiments, nicotine cessation is accompanied by a nicotine replacement source and/or an antidepressant. The invention further provides a method for identifying a subject who has an increased risk of becoming dependent on an addictive substance. In some embodiments, the addictive substance is nicotine. Also provided are isolated nucleic acid molecules containing the polymorphisms and reagents for detecting the polymorphic nucleic acid molecules. | 12-01-2011 |
20110294681 | METHODS FOR BREAST CANCER RISK ASSESSMENT - The present invention relates to methods and systems for assessing the overall risk of a human female subject for developing a breast cancer phenotype. In particular, the present invention relates to combining clinical risk assessment and genetic risk assessment to improve risk analysis. | 12-01-2011 |
20110294682 | Polynucleotides Associated With Age-Related Macular Degeneration and Methods for Evaluating Patient Risks - Disclosed are methods for diagnosing AMD or a susceptibility for AMD by identifying one or more markers associated with peripheral retinal phenotypes. | 12-01-2011 |
20110294683 | BIOMARKERS - Provided is a method of identifying myocardially-infarcted patients having an increased risk of developing a heart condition. | 12-01-2011 |
20110294684 | GENE EXPRESSION SIGNATURES FOR LUNG CANCERS - The inventors have found a group of genes whose expression in small bronchoscopic tumor samples gives significant predictions of survival. 10 of the 13 genes are indicators of risk, while the other 3 are indicators of survival. | 12-01-2011 |
20110294685 | SENSING STRATEGIES AND METHODS FOR NUCLEIC ACID DETECTION USING BIOSENSORS - Embodiments of the present invention relate generally to strategies and methods of amplifying short target sequences and removing flanking sequences from target nucleic acids to remove background signal when detecting hybridizations events using sensitive detection biosensors, such as biosensors based on nanowires, carbon nanotubes, nanopores etc, that may be capable of detecting molecules at small molar concentrations (fM and less), or even at the single molecule level. Furthermore, by cropping and therefore standardizing the size of the target sequences to be detected, when detecting many target sequences in an array, the signals across each biosensor can be compared and the hybridization conditions standardized easily. | 12-01-2011 |
20110294686 | EGFR INHIBITOR THERAPY RESPONSIVENESS - Disclosed is the identification, provision and use of biomarkers predictive of sensitivity or resistance to EGFR inhibitors such as gefitinib and products and processes related thereto. Specifically, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for the detection of the copy number or expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described. | 12-01-2011 |
20110294687 | SYSTEM AND METHOD FOR PROPAGATING INFORMATION USING MODIFIED NUCLEIC ACIDS - A method for improving a nucleic acid-based molecular computing system includes (A) identifying a computing system comprised of (i) a nucleic acid structure that includes an incompletely base-paired duplex domain, (ii) at least one polynucleotide displacement molecule that can bind with the nucleic acid structure under hybridizing conditions, such that the nucleic acid structure undergoes a transition in energy state due to a branch migration reaction involving the duplex domain, and (iii) a clashing polynucleotide molecule that competes with the polynucleotide displacement molecule for binding the nucleic acid structure under the hybridizing conditions but that cannot produce a branch migration reaction involving the duplex domain; then (B) reconfiguring at least one of the displacement molecule and the nucleic acid structure, respectively, to incorporate a chemical modification relative to a first reference molecule that comprises natural nucleosides and has the same sequence content as the displacement molecule or the nucleic acid structure, as the case may be, wherein the modification causes binding of the displacement molecule and the nucleic acid structure to have a hybridization free energy, differing from that of a first reference binding between the displacement molecule or the nucleic acid structure and the first reference molecule, such that the branch migration reaction is facilitated relative to the first reference binding; and/or (C) reconfiguring at least one of the clashing molecule and the nucleic acid structure, respectively, to incorporate a chemical modification relative to a second reference molecule that comprises natural nucleosides and has the same sequence content as the clashing molecule or the nucleic acid structure, as the case may be. The modification effected via such reconfiguring causes binding of the clashing molecule and the nucleic acid structure to have a hybridization free energy, differing from that of a second reference binding between the clashing molecule or the nucleic acid structure and the second reference molecule, such that binding of the clashing molecule is impeded relative to the second reference binding. | 12-01-2011 |
20110294688 | QUALITY CONTROL OF AGRICULTURAL PRODUCTS BASED ON GENE EXPRESSION - The invention relates to the field of quality testing of fresh plant-based and mushroom based products. Methods, carriers and kits for determining the quality stage are provided. | 12-01-2011 |
20110294689 | Multiplex Amplification Methods - Compositions and methods for amplifying selected polynucleotides, including DNA and RNA, particularly in multiplex amplification reactions using common primers amplification. Generally, methods of the invention employ multiple steps such as template-specific hybridization, a linear amplification, partial degradation of nucleic acid, and ligation. At the end of the process the sequences of selected polynucleotides are flanked by the common sequences which can be used for exponential amplification using common primers. In some aspects the polynucleotides are associated with a barcode and the presence of the barcode is detected to measure the amount of the polynucleotide. | 12-01-2011 |
20110294690 | DIFFERENTIAL DIAGNOSTIC BIOMARKERS OF STROKE MIMICKING CONDITIONS AND METHODS OF USE THEREOF - The present invention relates to the identification and use of diagnostic markers related with brain damage, particularly, biomarkers independently selected from the group consisting of interleukin-17 (IL-17), Fas ligand (FasL), b nerve growth factor (bNGF), insulin growth factor binding protein 3 (IGFBP3), p55 tumour necrosis factor receptor (TNFR-1), growth-related oncogene alpha (GroA), interleukin-2 soluble receptor gamma (IL2RG) and combinations thereof, that are associated with the diagnosis, prognosis, or differentiation of stroke mimicking conditions and stroke in a subject. | 12-01-2011 |
20110294691 | ENHANCED ON-CHIP SERS BASED BIOMOLECULAR DETECTION USING ELECTROKINETICALLY ACTIVE MICROWELLS - A method for detecting target nucleic acids such as SNPs is provided. The method comprises performing a ligase detection reaction (LDR), performing surface enhanced Raman scattering (SERS) on the LDR, and analyzing the outcome of the LDR using analysis and/or quantification of the SERS by detecting an emitted Raman signature. The LDR-SERS method can be used for sensitive and specific detection of any nucleic acid sequence of interest. A microfluidic SERS detection device is also provided. The device comprises electrokinetically active microwells for mixing and concentrating analytes and in which analytes can be quantified. The device can be used for performing the LDR-SERS method in optofluidic chip format. | 12-01-2011 |
20110294692 | USE OF MIR-126 FOR ENHANCING HEMATOPOIETIC STEM CELL ENGRAFTMENT, FOR ISOLATING HEMATOPOIETIC STEM CELLS, AND FOR TREATING AND MONITORING THE TREATMENT OF ACUTE MYELOID LEUKEMIA - There is disclosed herein composition, methods and uses relating to miR-126 as a measure of engraftment potential of a population of hematopoietic stem cells (HSCs), as a method of purifying HSCs and in the monitoring or treatment of acute myeloid leukemia. | 12-01-2011 |
20110294693 | Compositions and Methods for Identifying Autism Spectrum Disorders - The compositions and methods described are directed to gene chips having a plurality of different oligonucleotides with specificity for genes associated with autism spectrum disorders. The invention further provides methods of identifying gene profiles for neurological and psychiatric conditions including autism spectrum disorders, methods of treating such conditions, and methods of identifying therapeutics for the treatment of such neurological and psychiatric conditions. | 12-01-2011 |
20110294694 | Methods for detecting, diagnosing and treating human renal cell carcinoma - Gene expression profiling and hierarchical clustering analysis readily identify differential gene expressions in normal renal epithelial cells and renal cell carcinomas. Genes identified by this analysis would be useful for diagnosis, prognosis and development of targeted therapy for the prevention and treatment of conventional renal cell carcinoma. | 12-01-2011 |
20110294695 | METHODS, COMPOSITIONS AND KITS FOR DETECTION AND ANALYSIS OF ANTIBIOTIC-RESISTANT BACTERIA - The present invention relates generally to detection of antibiotic-resistant bacteria in a sample. In particular, the invention provides methods, compositions and kits for detecting and analyzing methicillin-resistant | 12-01-2011 |
20110294696 | METHODS FOR CHARACTERIZING AGONISTS AND PARTIAL AGONISTS OF TARGET MOLECULES - In one aspect, the present invention provides methods of determining whether an agent is more like a partial agonist of a target molecule than a full agonist of the same target molecule. In another aspect, the present invention provides methods to select a candidate compound that may reduce blood plasma glucose concentration in a mammal. Populations of genes are provided that are useful in the practice of the present invention. | 12-01-2011 |
20110301049 | Fluid Flow Contour Control Using Flow Resistance - A micro-fluidic device and a method of use are disclosed. The device includes a micro-channel with an inlet port at a first end and an outlet port at a second end. A first fluid, such as air or liquid or both, is disposed in the micro-channel. A focusing structure extends into the micro-channel, whereby when a pulse of a second fluid is introduced to the channel, the pulse advances adjacent sides of the micro-channel at a faster rate than would occur without the focusing structure. | 12-08-2011 |
20110301050 | DNA HYPERMETHYLATION BRAIN CANCER MARKERS - One aspect of the present disclosure relates to a composition comprising a DNA hypermethylation brain cancer marker on acellular DNA of a human subject. DNA hypermethylation brain cancer markers (or DNA hypermethylation markers) are frequently methylated in the DNA of brain cells and acellular DNA of individuals suffering from brain cancer. These DNA hypermethylation markers are not frequently methylated in the DNA of brain cells and acellular DNA of individuals who do not suffer from brain cancer. Another aspect of the present disclosure relates to a method of diagnosing brain cancer in a human subject comprising providing a sample containing acellular DNA from the human subject, determining whether one or more DNA hypermethylation markers on the acellular DNA are hypermethylated, and diagnosing brain cancer when the DNA hypermethylation markers are hypermethylated. | 12-08-2011 |
20110301051 | Biomarkers for Ulcerative Colitis and Crohn's Disease - The present invention provides compositions and their use in diagnosing ulcerative colitis, Crohn's Disease, and inflammatory bowel disease. | 12-08-2011 |
20110301052 | DIAGNOSTIC EVALUATION OF ANTIBODY RESPONSES TO COMMONLY RECOGNIZED PROSTATE CANCER-ASSOCIATED ANTIGENS - The present invention relates to a plurality of antigens that together form a panel of immunoreactive molecules suitable for identifying candidates for prostate cancer examination. Methods for identifying antibodies indicative of a pre-malignant or malignant prostate are disclosed. Further disclosed are kits that can be used to practice the above methods. | 12-08-2011 |
20110301053 | Methods for Diagnosing, Staging, Predicting Risk for Developing and Identifying Treatment Responders for Rheumatoid Arthritis - Disclosed are methods for diagnosing, staging, and predicting risk for developing rheumatoid arthritis and other inflammatory diseases, and methods for identifying treatment responders and non-responders. | 12-08-2011 |
20110301054 | Method of Stratifying Breast Cancer Patients Based on Gene Expression - The present invention assists in prospectively predicting the metastatic likelihood, and thereby, the likely clinical outcome of breast cancer patients, based on the genotype of the patient, in particular, by determining the relative expression level of a set of genes, or subsets thereof. The present invention provides use of an expression level of a gene set for the identification of animals, optionally patients, likely to progress to an invasive phenotype, the gene set comprising at least some of the genes selected from ABCA1, ADD3, ADFP, ADM, ALDH1A3, AQP3, ARIIGAP26, B2M, BAT2D1, BIRC3, BRWD1, C18ORF1, CBLB, CD44, CHKB, CHPT1, CMKOR1, CXCL12, DBN1, EEF1A2, FAS, FLJ11000, FLJ11286, FLRT3, HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DRB1, HLA-DRB4, HLA-DRB5, HLA-F, HLA-G, HNRPD, IFIT-M1, IFITM3, INHBB, ISG20, JAG1, JAG2, KITLG, LAMC1, LAP3, LGALS3BP, MYO1B, NME4, PLCB1, PRLR, PSMB9, PXN, RAB14, SEMA3C, SEPP1, SLC6A8, SP100, SP110, STS, TAP1, TMEPAI, TNFSF10, TRAM1, TRIM14, and WSB1. Methods, arrays and kits for the identification of animals, optionally patients, likely to progress to an invasive phenotype, are also described. | 12-08-2011 |
20110301055 | METHODS FOR DETERMINING A PROGNOSIS IN MULTIPLE MYELOMA - Methods for determining a prognosis in multiple myeloma are disclosed, and in particular to methods that are capable of identifying patients with a poor prognosis and/or for determining the likelihood of a patient responding to a particular treatment. The methods identify myeloma samples having homozygous deletions in cell death genes, with dysregulated expression of 97 cell death genes forming a cell death expression signature, which is associated with poor prognosis in multiple myeloma. In a preferred aspect, three gene pairs, were found to provide a prognostic a “six gene signature” based on BUB1B and HDAC3; CDC2 and FIS1; and RAD21 and ITM2B (high expressors and low expressors respectively). | 12-08-2011 |
20110301056 | NECTIN-4 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS - The present invention features methods for diagnosing cancer or assessing or determining the prognosis of a patient with lung cancer, by detecting the expression level of Nectin-4. The present invention also features double-stranded molecules against the Nectin-4 gene, vectors encoding them, compositions comprising them and methods comprising the step of administering them into a subject, which are useful for treating or preventing cancer. Also, disclosed are methods of identifying candidate compounds for treating and preventing cancer, using the Nectin-4 polypeptide or cells expressing the Nectin-4 gene. | 12-08-2011 |
20110301057 | IN SITU ORIENTED IMMOBILIZATION OF PROTEINS ON A SUPPORT - The present invention relates to a method of directing in situ oriented immobilization of a protein on a support. This method involves providing a support and contacting the support with a solution. The solution comprises (a) a protein comprising a coupling moiety and (b) a molecule comprising a first group reactive with the support and a second group reactive with the coupling moiety. The molecule binds (i) the support at the first group and (ii) the coupling moiety at the second group, thereby immobilizing and orienting, in situ, the protein on the support. Also described are a protein array and a method of screening compounds for protein interaction. | 12-08-2011 |
20110301058 | MICROFLUIDIC DEVICE - A novel approach for fabricating Monolithic Internal micro Pillars (MIPi) made of SU-8 photoresist is described. A microfluidic chip with the internal pillars (a MIPi chip) was used for cell capturing study. The surface of MIPi was coated with specific antibody and then used for capturing cells by affinity binding. An antibody, anti-EGFR, which has high affinity to lung cancer cells, CL1-5, was coated on the micro pillars. The coated MIPi chip specifically captured the cancer cells that were pumped through the MIPi chip. Simulation and experiment was carried out to compare the effect of different geometry of the micro pillars on the cell capturing rate. | 12-08-2011 |
20110301059 | Biomarkers For Human Papilloma Virus-Associated Cancers - Cervical cancer cells and HPV | 12-08-2011 |
20110306507 | METHOD AND TOOLS FOR PROGNOSIS OF CANCER IN HER2+PARTIENTS - A gene or protein set includes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, and possibly 40, 45, 50, 55, 60, 65 genes or proteins, antibodies or hypervariable portion thereof directed against the proteins encoded by these genes. | 12-15-2011 |
20110306508 | Method of Mycotoxin Detection - The presence of mycotoxins in agricultural products necessitates large scale testing of a wide range of sample material to ensure the safety of food and feed. The mycotoxin ochratoxin A represents an enablement for all mycotoxins as the level of sensitivity necessary for regulatory requirements for this compound at the part per billion level are as low or lower than any other mycotoxin. This invention describes the identification of a set of DNA ligands with sufficiently high binding affinity and specificity for ochratoxin A to enable an improvement over existing methods for the separation, concentration and quantitative determination of ochratoxin A in sample material. | 12-15-2011 |
20110306509 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF PROTEIN SYNTHESIS - Compositions and methods for identifying inhibitors of RNA-target molecule interactions are provided as well as identifying inhibitors that block the role of tRNA in protein synthesis. The methods involve forming a mixture comprising a tRNA fragment molecule containing a modified nucleotide, a target molecule capable of binding to the tRNA fragment, and a test compound. The mixture is incubated under conditions that allow binding of the tRNA and the target molecule in the absence of the test compound. Assays can then be performed that detect whether or not the test compound inhibits the binding of the tRNA molecule and the target molecule. High throughput assays are also provided. | 12-15-2011 |
20110306510 | OPTIMIZED PPROBES AND PRIMERS AND METHODS OF USING SAME FOR THE DETECTION, SCREENING, ISOLATING AND SEQUENCING OF MRSA, MSSA STAPHYLOCOCCUS MARKERS, AND THE ANTIBIOTIC RESISTANCE GENE MEC A - Described herein are primers and probes useful for the detection, screening, isolation and sequencing of MRSA, MSSA, | 12-15-2011 |
20110306511 | METHODS FOR MULTIPLEX ANALYTE DETECTION AND QUANTIFICATION - The application refers to a method for detecting and quantifying multiple target analytes in a test sample using a single reaction vessel. The method uses a reaction vessel (a multi-well plate), which comprises a microarray of: (a) calibration spots, each having a predetermined quantity of the target analyte; and (b) capture spots, each having an agent (antibody) that selectively binds the target analyte. The captured analytes and the calibration spots are detected with fluorescently labelled antibodies specific for each different target analyte. The calibration spots are used to generate calibration curves that allow the measurement of the concentration of the different target analytes. The application also refers to a method for detecting and quantifying biomarkers that are useful for diagnosing rheumatoid arthritis. More specifically, the application discloses the use of rheumatoid factor (RF) and cyclic citrullinated peptide (CCP), as capture spots. Finally, based on the above method, it is proposed a method for diagnosing or monitoring rheumatoid arthritis. | 12-15-2011 |
20110306512 | Gene Expression Profiling for Identification, Monitoring, and Treatment of Osteoarthritis - A method is provided in various embodiments for determining a profile data set for a subject with osteoarthritis or conditions related to osteoarthritis based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least one constituent from Tables 1-2, 4-6, and 8. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable. | 12-15-2011 |
20110306513 | NOVEL BIOMARKER FOR LIVER CANCER AND APPLICATIONS FOR SAME - The present invention relates to the elucidation of a gene that can act as a novel marker for liver cancer diagnosis and to diagnostic and prognostic measurements of liver cancer using the same. More specifically, it relates to a diagnosis kit that enables diagnostic and prognostic measurement of a liver cancer using a preparation that measures expression levels of at least one gene selected from a group of liver cancer diagnosis markers consisting of S100P, NK4, CCL20, CSPG2, PLAU, MMP12, ESM-1, ABHD7, HCAPG, CXCL-3, Col5A2, MAGEA, GSN, CDC2, CST1, MELK, ATAD2, FAP and MSN and/or a method for diagnostic and prognostic measurement of liver cancer using the same. These have been discovered using normal liver tissues and liver cancer tissues collected from the same liver cancer patient of the present invention and represent the markers whose accuracy and reliability have been greatly improved as markers of liver cancer. The markers of the present invention can be used for the accurate diagnosis and prognosis of liver cancer. | 12-15-2011 |
20110306514 | RATIO BASED BIOMARKERS AND METHODS OF USE THEREOF - Compositions, methods and kits are described for identifying biomolecules (e.g., proteins and nucleic acids) expressed in a biological sample that are associated with the presence, development, or progression of a disease (such as cancer), or more generally determination of the etiology or risk factors associated with a disease. Sample types analyzed by the disclosed methods include but are not limited to archival tissue blocks that have been preserved in a fixative, tissue biopsy samples, tissue microarrays, and so forth. The methods disclosed herein correlate expression profiles of biomolecules with various disease types, and allow for the determination of relative survival rates; in some embodiments, the methods permit determination of survival rates for a subject with cancer. In other embodiments, the disclosure relates to methods for evaluating therapeutic regimes for the treatment, such as treatment of cancer. | 12-15-2011 |
20110306515 | DEVICE FOR SEROLOGICALLY DETECTING YERSINIA INFECTIONS AND/OR SECONDARY DISEASES THEREOF AND USE OF THE PROTEINS MyfA AND PsaA OF Y. ENTEROCOLITICA AND Y. PSEUDOTUBERCULOSIS AS RECOMBINANT ANTIGENS - Devices are disclosed for serologically detecting an infection with human-pathogenic | 12-15-2011 |
20110306516 | METHODS FOR PRODUCING INDUCED PLURIPOTENT STEM CELLS - The invention provides improved methods for producing induced pluripotent stem cells (iPSC) from adult fibroblasts. The methods include contacting adult fibroblasts with a reprogramming composition suitable for reprogramming the adult fibroblasts to iPSC, under conditions effective for the reprogramming composition to penetrate the adult fibroblasts, followed by culturing the contacted fibroblasts for a time period sufficient for the cells to be reprogrammed. The cultured cells are then sorted to select cells based upon their expression of the cell membrane surface markers CD13 | 12-15-2011 |
20110306517 | REDUCING IRF4, DUSP22, OR FLJ43663 POLYPEPTIDE EXPRESSION - This document relates to the activity of interferon regulatory factor 4 (IRF4) in T-cell lymphomas. For example, methods and materials involved in reducing the expression of an IRF4 polypeptide in T-cell lymphoma cells and identifying agents having the ability to reduce expression of an IRF4 polypeptide in T-cell lymphoma cells are provided. This document also relates to reducing DUSP22 or FLJ43663 polypeptide activity in T-cell lymphomas. For example, methods and materials involved in reducing the expression of DUSP22 polypeptides and/or FLJ43663 polypeptides in T-cell lymphoma cells and identifying agents having the ability to reduce expression of DUSP22 polypeptides and/or FLJ43663 polypeptides in T-cell lymphoma cells are provided. | 12-15-2011 |
20110306518 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION - Methods of diagnosing or monitoring transplant rejection, particularly cardiac transplant rejection, in a patient by detecting the expression level of one or more genes in a patient, are described. Diagnostic oligonucleotides for diagnosing or monitoring transplant rejection, particularly cardiac transplant rejection and kits or systems containing the same are also described. | 12-15-2011 |
20110312511 | Multiplex Detection of Tumour Cells Using a Panel of Agents Binding to Extracellular Markers - The present invention relates to flow cytometry detection of a cancer cell or cancer cell element by binding two or more agents to extracellular markers, wherein at least one agent is cancer specific. | 12-22-2011 |
20110312512 | CULTURE SYSTEM AND METHOD FOR IMMUNOGENICITY AND IMMUNOFUNCTION TESTING IN VITRO - The invention provides a culture device comprising a plurality of culture units, wherein each unit comprises a culture chamber, an inlet port for liquid supply of the culture and an outlet port for discharging liquid from the unit, wherein the inlet port is in fluid communication with the culture chamber and the culture chamber is in fluid communication with the outlet port for allowing a liquid flow through the culture chamber. The culture device is particularly suitable for testing immune cells and immunofunction in vitro. Aspects of the invention include a culture device and associated methods for cultivating immune cells and an in vitro method of analysing the effect of a test compound on immune cells. | 12-22-2011 |
20110312513 | BIOMARKERS FOR PREDICTING SUSTAINED RESPONSE TO HCV TREATMENT - The present invention is based on the discovery that in patients infected with Genotype 1 of the Hepatitis C virus (HCV-1) or Genotype 4 HCV (HCV-4) that undergo Triple Therapy treatment, certain biomarkers can be predictive of a patient achieving sustained virologic response | 12-22-2011 |
20110312514 | Method For Determination And Quantification Of Radiation Or Genotoxin Exposure - The present invention discloses methods for detecting exposure of a living subject to genotoxic agents, testing sensitivity to a genotoxic agent, and determining DNA damage caused by exposure to an agent, comprising detecting the presence of FANCD2-containing foci from a sample collected from said subject. The presence of concentrated foci is indicative of DNA damage, and the degree of foci formation is correlated with degree of exposure. Diagnostic reagents contain a ligand that binds to human FANCD2 associated with a detectable label. Kits for detecting DNA damage in a biological sample contain such diagnostic reagents and signal detection components. The invention further discloses methods for identifying agents which modulate the ability of FANCD2-containing foci to form. Among other things, such agents are potentially useful chemosensitizing agents or may confer protection against damage caused by genotoxic agents. | 12-22-2011 |
20110312515 | IDENTIFICATION OF MARKERS IN LUNG AND BREAST CANCER - Methods for identifying expression of markers indicative of the presence of breast cancer and lung cancer are provided. Also provided are articles of manufacture useful in such methods and compositions containing primers and probes useful in such methods. | 12-22-2011 |
20110312516 | DIAGNOSTIC AND PROGNOSTIC USE OF HUMAN BLADDER CANCER-ASSOCIATED MICRO RNAS - The present invention is based, at least in part, upon discovery of a number of miRNAs having expression that significantly correlates with bladder cancer, including certain stages or types of bladder cancer, as well as with bladder cancer survival and/or responsiveness to bladder cancer therapies. Accordingly, the present invention features the identification and use of miRNAs to detect, diagnose and/or predict the course, progression or therapy responsiveness of bladder cancer. Kits for performing such assessments, and for administering therapeutic agents to subjects diagnosed with bladder cancer or certain forms of bladder cancer using the methods of the invention, are also featured. | 12-22-2011 |
20110312517 | METHOD FOR THE IN VITRO DIAGNOSIS OF STROKE - The present invention relates to a method for the in vitro diagnosis of stroke and transient ischemic attack (TIA) in an individual, comprising the following steps:
| 12-22-2011 |
20110312518 | MICROFLUIDIC DEVICES FOR MEASUREMENT OR DETECTION INVOLVING CELLS OR BIOMOLECULES - Embodiments of the invention are related to microfluidic devices for detecting or determining the concentration of biomolecules in an analyte comprising: a channel, wherein a surface of said channel is fabricated to be functionalized with at least one molecule selected to interact with a biomolecule, said channel being configured to interact with a microsphere, wherein a surface of said microsphere is fabricated to be functionalized with at least one same or different molecule selected to interact with said biomolecule; a second channel in fluid communication with said first channel; a system to move fluid containing said microsphere through said first and second channels; and a system to measure a change in electrical impedance or optical microscopy across said second channel as said microsphere moves through said second channel. Other embodiments concern related devices, and methods of making and using. | 12-22-2011 |
20110312519 | GENETIC FACTORS ASSOCIATED WITH INHIBITOR DEVELOPMENT IN HEMOPHILIA A - The present invention provides methods for predicting the risk of an individual developing antibodies to factor VIII by identifying a single nucleotide polymorphism of an immune response or immune modifier gene. The invention further provides oligonucleotides, diagnostic kits, microarrays, and isolated nucleic acids comprising single nucleotide polymorphisms of immune response or immune modifier genes. | 12-22-2011 |
20110312520 | METHODS AND COMPOSITIONS FOR DIAGNOSING CONDITIONS - The present invention relates to compositions, kits, and methods for molecular profiling for diagnosing disease conditions. In particular, the present invention provides molecular profiles associated with thyroid cancer and other cancers, methods of relating molecular profiles to a diagnosis, and related compositions. | 12-22-2011 |
20110312521 | Genomic Transcriptional Analysis as a Tool for Identification of Pathogenic Diseases - The discovery and validation of a candidate biomarker signature for the diagnosis of sepsis, and more particularly septicemic meliodiosis, based on genomic transcriptional profiling using microarrays is described herein. The microarray technology of the instant invention generates genome-wide transcriptional profiles (>48,000 transcripts) from the whole blood of patients with septicemic melioidosis (n=32), patients with sepsis caused by other pathogens (n=31), and uninfected controls (n=29). Unsupervised analyses demonstrated the existence of a whole blood transcriptional signature distinguishing patients with sepsis from control subjects. | 12-22-2011 |
20110312522 | METHODS OF DETECTION OF CANCER USING PEPTIDE PROFILES - The disclosed methods address the identification and monitoring of cancer in a subject using serum peptide profiles. Such profiles allow the detection of the differential presence of certain serum peptide markers in comparison with controls. The profiles can be determined employing mass spectrometry. | 12-22-2011 |
20110312523 | PROBES, LIQUID PHASE CHIPS AND METHODS FOR DETECTING PIK3CA GENE MUTATIONS - Probes, liquid phase chips and methods for detecting PIK3CA gene mutations are provided, wherein the liquid chips for detecting PIK3CA gene mutations mainly comprise: microspheres coupled with probes; primers used for amplifying target sequences with exon 9 and/or exon 20. The liquid chips and methods for detecting PIK3CA gene mutations are useful for detecting the sites containing mutations of the PIK3CA gene with relatively high frequency simultaneously, and also are useful for detecting the exon 9 and exon 20 separately or simultaneously. The detection methods have identical reaction conditions of detection, good specificity of detection, high sensitivity, above 90% accuracy, and short time of detection. | 12-22-2011 |
20110312524 | METHODS EMPLOYING NON-CODING RNA EXPRESSION ASSAYS - There is disclosed a method comprising the steps of: carrying out a plurality of expression assays, each expression assay comprising the steps of: carrying out an intervention on a biological system, measuring an expression profile of non-coding RNAs in the biological system resulting from the intervention, and storing an expression data set derived from the measured expression profile, the said expression assays concerning either or both a plurality of different interventions and a plurality of different biological systems; and analysing the resulting expression data sets to determine correlations between the effect on the expression profile of non-coding RNAs of the respective intervention in groups of two or more expression assays concerning either or both different interventions or different biological systems. | 12-22-2011 |
20110312525 | SOLUBLE ICAM-1 AS BIOMARKER FOR PREDICTION OF THERAPEUTIC RESPONSE - The present invention relates to the field of immunology and, in particular, to a vaccination procedure for treatment of a patient against diseases caused for example by infection or cancers. More particularly, the invention relates to methods for predicting whether a subject is or is not susceptible to developing a prophylactic or therapeutic response, preferably immune response, after such vaccination. The present invention relates to methods and compositions for selecting patients best able to raise a therapeutic immune response in vivo by an immunogenic composition, in particular a vaccine. | 12-22-2011 |
20110312526 | METHOD OF ANALYSING THE NUCLEIC ACID CONTENT OF A BLOOD SAMPLE - A method of analyzing the nucleic acid content of a blood sample, the method comprising the steps of: providing a test module with an outer casing configured for handheld portability, the outer casing having a receptacle for receiving blood, the test module having a lysis section mounted in the outer casing for lysing cells and organisms in the blood to release the genetic material therein, a hybridization section with an array of probes for hybridization with target nucleic acid sequences in the genetic material, and circuitry for sensing which of the probes have hybridized and generating hybridization data, providing a test module reader for reading the hybridization data from the test module, inserting a blood sample in the receptacle, interfacing the test module with the test module reader, wherein, the test module reader analyses the nucleic acid content from the hybridization data. | 12-22-2011 |
20110312527 | METHOD OF ANALYSING THE NUCLEIC ACID CONTENT OF BIOLOGICAL FLUID - A method of analyzing the nucleic acid content of a biological fluid, the method comprising the steps of: providing a test module with an outer casing configured for handheld portability, the outer casing having a receptacle for receiving the biological fluid, the test module having a hybridization section with an array of probes for hybridization with target nucleic acid sequences in the biological fluid, and circuitry for sensing which of the probes have hybridized and generating hybridization data, providing a test module reader for reading the hybridization data from the test module, inserting the biological fluid in the receptacle, interfacing the test module with the test module reader, wherein, the test module reader analyses the nucleic acid content from the hybridization data. | 12-22-2011 |
20110312528 | Novel synergistic combination of gemcitabine with P276-00 or P1446A in treatment of cancer - Synergistic combinations of gemcitabine with P276-00 or P1446A and their use in the treatment of cancer are disclosed. The invention further describes novel and unique gene signatures comprising gene markers used to monitor the drug response in a subject treated with the said combinations. | 12-22-2011 |
20110312529 | CONFORMATIONAL PROBES AND METHODS FOR SEQUENCING NUCLEIC ACIDS - This disclosure provides a method of determining a sequence of nucleotides for a nucleic acid template. The method can include the steps of contacting the nucleic acid template with a conformationally labeled polymerase and at least four different nucleotide species under conditions wherein the conformationally labeled polymerase catalyzes sequential addition of the nucleotide species to form a nucleic acid complement of the nucleic acid template, wherein the sequential addition of each different nucleotide species produces a conformational signal change from the conformationally labeled polymerase and wherein the rate or time duration for the conformational signal change is distinguishable for each different nucleotide species; detecting a series of changes in the signal from the conformationally labeled polymerase under the conditions; and determining the rates or time durations for the changes in the signal, thereby determining the sequence of nucleotides for the nucleic acid template. | 12-22-2011 |
20110312530 | GENE EXPRESSION SIGNATURE FOR CLASSIFICATION OF TISSUE OF ORIGIN OF TUMOR SAMPLES - The present invention provides a process for classification of cancers and tissues of origin through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA tree-based expression framework allows optimization of treatment, and determination of specific therapy. | 12-22-2011 |
20110312531 | CLINICALLY INTELLIGENT DIAGNOSTIC DEVICES AND METHODS - The invention relates to the clinically intelligent design of diagnostic devices (such as microarrays) and methods of making and using such devices in differential diagnoses of specific clinical symptoms or sets of symptoms. In one aspect, the devices include various probes used to perform parallel screening of a number of analytes. The probes are clustered on the devices based on known clinical presentations of symptoms associated with specific diseases and disorders. | 12-22-2011 |
20110312532 | Gene Expression Markers for Breast Cancer Prognosis - The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer. | 12-22-2011 |
20110319278 | ENCODED SELF-ASSEMBLING CHEMICAL LIBRARIES (ESACHEL) - The invention concerns a chemical compound comprising a chemical moiety (p) capable of performing a binding interaction with a target molecule (e.g. a biological target) and further comprising an oligonucleotide (b) or functional analogue thereof. In a first embodiment according to the invention, the chemical compound is characterized in that the oligonucleotide (b) or functional analogue comprises at least one self-assembly sequence (b1) capable of performing a combination reaction with at least one self-assembly sequence (b1′) of a complementary oligonucleotide or functional analogue bound to another chemical compound comprising a chemical moiety (q). In a second embodiment according to the invention, the chemical compound which comprises a coding sequence (b1) coding for the identification of the chemical moiety (p) is characterized in that the chemical compound further comprises at least one self-assembly moiety (m) capable of performing a combination reaction with at least one self-assembly moiety (m′) of a similar chemical compound comprising a chemical moiety (q). The invention comprises corresponding libraries of chemical compounds as well as methods of biopanning of target molecules and of identifying such targets. | 12-29-2011 |
20110319279 | Assays Based on Liquid Flow Over Arrays | 12-29-2011 |
20110319280 | ECT2 ONCOGENE AS A THERAPEUTIC TARGET AND PROGNOSTIC INDICATOR FOR LUNG AND ESOPHAGEAL CANCER - The invention features methods for detecting lung cancer or esophageal cancer, by detecting over-expression of ECT2 compared the normal organs. Also disclosed are methods of identifying compounds for treating and preventing lung cancer or esophageal cancer, based on the over-expression of ECT2 in the lung cancer or esophageal cancer, the cell proliferation function of ECT2. Also, provided are a method for treating lung cancer or esophageal cancer by administering a double-stranded molecule against the ECT2 gene or an antibody against ECT2 protein. The invention also provides products, including the double-stranded molecules and vectors encoding them, as well as compositions comprising the molecules or vectors, useful in the provided methods. | 12-29-2011 |
20110319281 | Nucleic Acid Analysis by Random Mixtures of Non-Overlapping Fragments - The invention provides methods and kits for ordering sequence information derived from one or more target polynucleotides. In one aspect, one or more tiers or levels of fragmentation and aliquoting are generated, after which sequence information is obtained from fragments in a final level or tier. Each fragment in such final tier is from a particular aliquot, which, in turn, is from a particular aliquot of a prior tier, and so on. For every fragment of an aliquot in the final tier, the aliquots from which it was derived at every prior tier is known, or can be discerned. Thus, identical sequences from overlapping fragments from different aliquots can be distinguished and grouped as being derived from the same or different fragments from prior tiers. When the fragments in the final tier are sequenced, overlapping sequence regions of fragments in different aliquots are used to register the fragments so that non-overlapping regions are ordered. In one aspect, this process is carried out in a hierarchical fashion until the one or more target polynucleotides are characterized, e.g. by their nucleic acid sequences, or by an ordering of sequence segments, or by an ordering of single nucleotide polymorphisms (SNPs), or the like. | 12-29-2011 |
20110319282 | METHODS AND KITS FOR THE DIAGNOSIS AND THE STAGING OF COLORECTAL CANCER - The invention relates to methods for the staging and the diagnosis of colorectal cancer based on the determination of the expression levels of a set of genes, the altered expression of which in relation to a reference sample allows diagnosing said cancer with a high reliability as well as determining the stage in which it is. | 12-29-2011 |
20110319283 | OLIGONUCLEOTIDES CAPABLE OF DISCRIMINATING BETWEEN NUCLEIC ACID SEQUENCES THAT COMPRISE A CONSERVED SEQUENCE - The invention provides inter alia an oligonucleotide (or “probe”) able to discriminate between a nucleic acid target and a nucleic acid variant thereof (for example, mRNA splice variants, or chimeric gene and corresponding parent gene mRNAs) in which the target and variant that share at least one domain of conserved or identical sequence. The oligonucleotide in one aspect has a first portion and a second portion flanking a portion junction, wherein the first portion comprises at least a first discontinuity relative to the first domain of a target sequence and the second portion comprises at least a second discontinuity relative to a second domain of a target sequence, each discontinuity comprising or consisting of a sequence mismatch and/or a non-nucleotide spacer. | 12-29-2011 |
20110319284 | METHOD FOR DETERMINING THE PREDISPOSITION FOR CROHN'S DISEASE - A method is described for determining a predisposition of an organism for Crohn's Disease, especially Crohn's Disease of the small intestine. In this context, in a biological specimen of an organism, the presence or the absence of SNP's in at least one gene is determined, which codes for a protein associated with the Writ signaling pathway in Paneth cells. The gene, in this instance, may be selected from TCF4, LRP5, LRP6, GSK3A, GSK3B and TCF7. The present methods and systems also relate to primers and allele-specific probes to prove the presence or the absence of an SNP, diagnostic kits which have at least one such primer or one such allele-specific probe, as well as the use of certain SNP's for determining a predisposition of an organism for Crohn's Disease. The present method and systems also relate to a method for the differential diagnosis of inflammatory bowel diseases, for distinguishing Crohn's Disease and the other respective inflammatory or infectious intestinal diseases. | 12-29-2011 |
20110319285 | METHODS AND MEANS FOR TYPING A SAMPLE COMPRISING COLORECTAL CANCER CELLS - The invention relates to a method of typing colorectal cancer cells by determining the RNA levels of a set of signature genes. Said typing can be use for predicting a risk for recurrence of said colorectal cancer. The invention further relates to a set of genes that can be used for normalizing the RNA levels of said set of signature genes, and to micro-array comprising said set of signature genes. | 12-29-2011 |
20110319286 | SYSTEM FOR SCREENING AGONISTS/ANTAGONISTS OF CELLULAR SIGNALING PATHWAYS - The present invention identifies a method for investigating the response of a cell membrane-associated protein in a living cell to a drug by labeling the protein with a visual marker, and also selectively labeling the membrane portion of the protein with another visual marker, such that upon exposure of the cell to a stimulus, the translocation of the cell membrane-associated protein may be observed directly. | 12-29-2011 |
20110319287 | MODULATOR ASSAY - The present invention relates inter alia to methods for identifying modulators of tumour necrosis factor (TNF) signalling. In one aspect, the method involves identifying an agent that modulates a signalling pathway mediated by TNF, comprising the steps of providing a host cell comprising TNF receptor 1 (TNFR1)-associated death domain (TRADD) linked to a reporter molecule, and determining at least one cellular characteristic detectable by the reporter molecule in the host cell in the presence of TNF and in the presence and absence of a candidate modulator. The invention is suitable for high-throughput screening (HTS) and high-content screening (HCS), or a combination of HTS and HCS. | 12-29-2011 |
20110319288 | BANK1 RELATED SNPS AND SLE AND/OR MS SUSCEPTIBILITY - The invention relates to a method of genotyping and for predicting the susceptibility for SLE and/or MS by using SNPs related to BANK1 alone or in combination with at least one other SNP. | 12-29-2011 |
20110319289 | MOLECULAR-BASED METHOD OF CANCER DIAGNOSIS AND PROGNOSIS - A gene profiling signature for diagnosis and prognosis of cancer patients is disclosed herein. In one embodiment, the gene signature includes 32 or 79 cancer survival factor-associated genes. Thus, provided herein is a method of determining the prognosis of a subject with a tumor by detecting expression of five of more cancer survival factor-associated genes in a tumor sample and comparing expression of the five or more cancer survival factor-associated genes in the tumor sample to a control. In some examples, an increase in expression of ABCF1, CORO1C, DPP3, PREB, UBE3A, and PTDSS1 in a tumor sample compared to a control sample indicates poor prognosis. Also provided is a method of treating a patient diagnosed with cancer by administering a therapeutically effective amount of an agent that alters expression or activity of one or more of the disclosed cancer survival factor-associated genes. Further provided are arrays including probes or antibodies specific for a plurality of cancer survival factor-associated genes or proteins. | 12-29-2011 |
20110319290 | Methods and Compositions for Multiplex Sequencing - Adapters are joined to target polynucleotides to create adapter-tagged polynucleotides. Adapter-tagged polynucleotides are sequenced simultaneously and sample sources are identified on the basis of barcode sequences. | 12-29-2011 |
20110319291 | TEMPLATE FIXED BETA-HAIRPIN LOOP MIMETICS AND THEIR USE IN PHAGE DISPLAY - Template-fixed β-hairpin mimetics and libraries including a plurality of these mimetics are provided. The template-fixed β-hairpin mimetics are of the following general formula: | 12-29-2011 |
20110319292 | METHODS FOR GENERATING ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND USES - A protein variant of IL-23p19 that has conserved residues in positions 93-102, 93-110, and/or 127-137 of SEQ ID NO:1, can be used to generate anti-IL-23p19 antibodies. | 12-29-2011 |
20120004122 | Diagnostic Marker for Migraine and Use Thereof - The present invention is directed to providing diagnostic markers that enable diagnosis of migraine in a simple and convenient manner and to methods for using them. An α-fodrin (spectrin) gene-related substance or an HPCAL1 gene-related substance are used as a diagnostic marker. As a method for assaying the diagnostic marker, peripheral blood lymphocytes obtained from patients with migraine are immortalized, cell extract is prepared, and the expression level of the diagnostic marker is examined. This assay method enables methods for screening for efficacy and methods for screening for a novel therapeutic agent for migraine. | 01-05-2012 |
20120004123 | SNP-DEPENDENT END LABELING METHOD - Certain embodiments described in this disclosure relate to a method of sample analysis. In certain cases, the method comprises: a) contacting a genomic sample comprising double-stranded genomic DNA with a first restriction endonuclease that recognizes a nucleotide sequence that comprises a SNP site in the double stranded genomic DNA, wherein: i. the restriction endonuclease cleaves the genomic DNA at the sequence regardless of the allele of the SNP present at the SNP site; and ii. cleavage of the sequence by the restriction enzyme creates a 5′ overhang that comprises the SNP site; b) contacting the digested genomic sample with a extension enzyme and a first labeled nucleotide that is used by the extension enzyme to fill in the overhang only if the overhang comprises a first allele of the SNP. | 01-05-2012 |
20120004124 | MARKERS OF REGULATORY T CELL ACTIVATION - Aspects of the present invention include novel marker genes for the identification, isolation, and characterization of activated suppressive and/or regulatory T cells. Use of the isolated activated suppressive and/or regulatory T cells as well as screening assays to identify agents that inhibit or activate suppressive and/or regulatory T cells are also provided. | 01-05-2012 |
20120004125 | PLANT DIACYLGLYCEROL ACYLTRANSFERASES - This invention relates to an isolated nucleic acid fragment encoding a diacylglycerol acyltransferase. The invention also relates to the construction of a chimeric gene encoding all or a portion of the diacylglycerol acyltransferase, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the diacylglycerol acyltransferase in a transformed host cell. | 01-05-2012 |
20120004126 | Efficient Arrays of Amplified Polynucleotides - The present invention is related generally to analysis of polynucleotides, particularly polynucleotides derived from genomic DNA. The invention provides methods, compositions and systems for such analysis. Encompassed by the invention are arrays of polynucleotides in which the polynucleotides have undergone multiple rounds of amplification in order to increase the strength of signals associated with single polynucleotide molecules. | 01-05-2012 |
20120004127 | Gene expression markers for colorectal cancer prognosis - One example embodiment includes a method of preparing a personalized genomics profile for a patient with colorectal cancer. The method includes assaying an expression level of an RNA transcript in a biological sample. The biological sample includes a colorectal cancer cell obtained from a patient. The method also includes determining a normalized expression level of the RNA transcript, wherein the normalized expression level of the RNA transcript correlates with an increased likelihood of colorectal cancer recurrence in the patient. The method further includes creating a report. The report summarizes the data obtained from the normalized expression level and includes an estimate of likelihood of long-term survival without colorectal cancer recurrence in said patient. | 01-05-2012 |
20120004128 | FAST RESULTS HYBRID CAPTURE ASSAY AND ASSOCIATED STRATEGICALLY TRUNCATED PROBES - Strategically truncated probes specific for high-risk HPV nucleic acids, and methods for making and using the same, are disclosed herein. The disclosed probes, and methods of use thereof, permit fast and reliable detection of human papillomavirus in clinical samples without significant cross-reaction. | 01-05-2012 |
20120004129 | BIOMARKERS FOR INHIBITORS WITH ANTI-ANGIOGENIC ACTIVITY - The invention relates to a method for assessing the effect of integrin inhibitors and small molecule ATP site directed multi kinase inhibitors on angiogenesis by the use of certain identified biomarkers. This method is notably beneficial for the determination of the efficacy of integrin inhibitors and small molecule ATP site directed multi-kinase inhibitors mainly used for the treatment of angiogenesis associated diseases such as cancer. Especially, the invention relates to biomarkers linked to angiogenesis that are preferably accessible in body fluids and therefore allow analysis of target modulation in a non-invasive way. The use of said biomarkers for the screening of compounds with integrin-inhibitory activity is also disclosed. | 01-05-2012 |
20120004130 | AUTOIMMUNE DISEASE BIOMARKERS - Provided herein are novel panels of biomarkers for the diagnosis of autoimmune diseases, and methods and kits for detecting these biomarkers in samples of individuals suspected of having an autoimmune disease. Also provided are methods of monitoring the progression of an autoimmune disease and methods of monitoring the efficacy and side effects of a treatment for an autoimmune disease. | 01-05-2012 |
20120004131 | MICROARRAYS AND USES THEREFOR - Methods of using microarrays to simplify analysis and characterization of genes and their function are provided. Such methods can be used to identify and characterize antibodies having binding affinity for a specific target antigen. A method of determining gene expression at the protein level by contacting an array of characterized or uncharacterized antibodies on a solid surface with one or more proteins and identifying the antibodies to which said protein(s) binds also is provided. This method can be used to compare the protein expression in two different populations of cells, such as normal cells and cancer cells or resting cells and stimulated cells. In addition, a method of determining gene expression at the protein level by contacting a microarray of nucleic acid samples derived from a variety of different sources with one or more nucleic acid probes then identifying the sample or samples to which the probe binds is provided. | 01-05-2012 |
20120004132 | Detection of Nucleic Acids and Proteins - Methods of detecting various types of nucleic acids, including methods of detecting two or more nucleic acids in multiplex branched-chain DNA assays, are provided. Detection assays may be conducted at least in vitro, in cellulo, and in situ. Nucleic acids which are optionally captured on a solid support are detected, for example, through cooperative hybridization events that result in specific association of a label probe system with the nucleic acids. Various label probe system embodiments are provided. Embodiments are directed to concurrent detection of one or more nucleic acids and one or more proteins. Embodiments also are directed to determining the methylation state of a target sequence. Other embodiments are directed to detection of one or more proteins using DNA barcodes. Compositions, kits, and systems related to the methods are also described. | 01-05-2012 |
20120004133 | METHOD FOR THE DIAGNOSIS OF AGE-ASSOCIATED VASCULAR DISORDERS - Methods for determining if a subject has or is susceptible to having an age-associated vascular disorder are disclosed. The method includes determining if the subject exhibits altered expression of a product of one or more of the genes listed in Table 1 relative to a control level of expression of the gene product. Altered expression of one or more of the genes listed in Table 1 indicates that the subject has or is susceptible to having an age-associated vascular disorder. In specific examples the gene product is a product of the MFG-E8 and an increase in expression indicates the subject has or is susceptible to having an age-associated vascular disorder. | 01-05-2012 |
20120004134 | Diagnostic Assay For Source of Inflammation - A method of diagnosing the source of local, acute inflammation has been developed based on the discovery that white cells have different patterns of gene expression, and therefore protein markers, depending on the origin of the inflammation. These differences can be readily accessed by analysis of the white cells obtained at a site to be analyzed, for example, in the synovial fluid of a knee. The analysis, by comparison with the analysis of white cells present in known conditions, can be used to differentiate between inflammation due to bacterial infection, arthritis or gout, for example. The examples demonstrate differential gene expression in cells present in synovial fluid biopsies from patients with confirmed bacterial infection as compared to patients with aseptic loosening or patients with inflammation due to gout. | 01-05-2012 |
20120004135 | IDENTIFICATION OF BIOLOGICALLY AND CLINICALLY ESSENTIAL GENES AND GENE PAIRS, AND METHODS EMPLOYING THE IDENTIFIED GENES AND GENE PAIRS - A method of obtaining cut-off expression values should be selected so as to maximise the separation of the respective survival curves of the two groups of patients. Pairs of genes are statistically significant genes are generated by generating a plurality of models, each of which represents a way of partitioning a set of subjects based on the optimal cut-off expression values of the pair of genes. Those gene pairs are identified for which one of the models has a high prognostic significance. Novel survival significant gene sets forming functional modules which could be used to develop specific prognostic and predictive tests are derived. | 01-05-2012 |
20120004136 | MSH2 AND ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN NON-SMALL-CELL LUNG CANCER - The invention is generally directed to a diagnostic method for predicting the benefit of the response of a subject diagnosed with cancer to a platinum compound-based adjuvant chemotherapy, preferably to a cisplatin-based chemotherapy which implements the determination of the MSH2 expression level in the biological sample containing tumor cells, and, optionally, the ERCC1 expression level. | 01-05-2012 |
20120010092 | Methods for Identifying Fragile Histidine Triad (FHIT) Interaction and Uses Thereof - Provided herein are methods and compositions for the diagnosis, prognosis and treatment of a cancer associated disorder using the Fhit gene. | 01-12-2012 |
20120010093 | APPARATUS AND METHODS FOR DETECTING NUCLEIC ACID IN BIOLOGICAL SAMPLES - There are disclosed apparatus and methods for the field-assisted acceleration of biological processes involving charged entities, including in particular the detection of target DNA in a biological sample. A reaction cell is provided with a dielectric surface, and a field is generated by inducing charge-separation in the dielectric material by applying a potential to an electrode in contact with the dielectric material. | 01-12-2012 |
20120010094 | DETECTING AND MONITORING LEFT VENTRICULAR HYPERTROPHY AND CONGESTIVE HEART FAILURE BY PROFILING BIOMARKERS - Disclosed herein are methods of detecting, monitoring, and predicting left ventricular hypertrophy, congestive heart failure and related conditions by profiling biomarkers. | 01-12-2012 |
20120010095 | METHODS FOR DIAGNOSIS AND PROGNOSIS OF PULMONARY HYPERTENSION - The invention relates to diagnostic and prognostic assays and kits for pulmonary hypertension (PH) and types thereof. The invention includes detecting the expression level of markers associated with pulmonary hypertension for diagnosis, prognosis, or treatment of pulmonary hypertension. | 01-12-2012 |
20120010096 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION - Methods of diagnosing or monitoring transplant rejection or cytomegalovirus infection in a patient by detecting the expression level of one or more genes or surrogates derived therefrom in the patient are described. Diagnostic oligonucleotides for diagnosing or monitoring transplant rejection or cytomegalovirus infection and kits or systems containing the same are also described. | 01-12-2012 |
20120010097 | MICROCHANNEL, AND NUCLEIC ACID HYBRIDIZATION MICROCHIP, COLUMN, SYSTEM AND METHOD - A microchannel capable of passing therethrough a solution with target nucleic acid strands contained therein includes: an agarose gel carrier having light transmission properties, supporting capture strands having a base sequence complementary to that of the target nucleic acid strands and immobilized on the agarose gel carrier, and packed in the microchannel; and a filter arranged in the microchannel on a downstream side as viewed in a passing direction of the solution and retaining the agarose gel carrier. | 01-12-2012 |
20120010098 | SELECTION BY COMPARTMENTALISED SCREENING - The invention describes a method for the identification of compounds which bind to a target component of a biochemical system or modulate the activity of the target, by compartmentalizing the compounds into microcapsules together with the target, such that only a subset of the repertoire is represented in multiple copies in any one microcapsules; and identifying the compound which binds to or modulates the activity of the target. The invention enables the screening of large repertoires of molecules which can serve as leads for drug development. | 01-12-2012 |
20120010099 | DIAGNOSTIC MARKERS OF WOUND INFECTION - The present invention relates to a method of determining the microbial bioburden in a wound (in particular a diabetic ulcer) in a test subject, the method comprising the step of measuring the level of a cytokine in a wound sample, wherein a cytokine level lower than a reference level indicates a significant microbial bioburden in the wound (or a cytokine level higher than a reference level indicates an insignificant microbial bioburden in the wound). The invention provides methods of diagnosis, prognosis and treatment of wound infection, and devices and kits for use in such methods. | 01-12-2012 |
20120010100 | PLANT FARNESYLTRANSFERASES - This invention relates to an isolated nucleic acid fragment encoding a farnesyltransferase subunit. The invention also relates to the construction of a chimeric gene encoding all or a portion of the farnesyltransferase subunit, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the farnesyltransferase subunit in a transformed host cell. | 01-12-2012 |
20120010101 | NOVEL TRIPLE TAG SEQUENCES AND METHODS OF USE THEREOF - The present disclosure relates to novel triple tag sequences that may comprise a 6× histidine tag, a c-myc tag and a V5 tag. The present disclosure also provides polynucleotides, proteins, vectors and host cells that comprise the triple tag sequence of the present disclosure, including libraries of such polynucleotides, proteins, vectors and host cells. The novel triple tag sequences of the present disclosure may be used in phage display vectors and phage libraries and in methods for detection, screening, capture, purification, quantitation, and/or recovery of proteins of interest to which they are linked. Proteins of interest include antibodies such as single chain antibodies, single chain antibodies, and Fab fragments of antibodies or peptides such as non-antibody peptides. | 01-12-2012 |
20120010102 | MODULATION OF ABCG2-MEDIATED URATE TRANSPORT TO TREAT HYPERURICEMIA AND GOUT - Genome-wide association studies (GWAS) was recently used to identify SNPs in a genomic region on chromosome 4 that associate with serum urate levels and gout. The present disclosure shows that human ATP-binding cassette, subfamily G, 2 (ABCG2), encoded by the ABCG2 gene contained in this region, is a hitherto unknown urate efflux transporter. The present disclosure further shows that native ABCG2 is located in the brush border membrane of kidney proximal tubule cells, where it mediates renal urate secretion. Introduction of the mutation Q141K encoded by the common SNP rs2231142 by site-directed mutagenesis resulted in reduced urate transport rates compared to wild-type ABCG2. Data from a population-based study of 14,783 individuals support rs2231142 as the causal variant in the region and show highly significant associations with urate levels and gout. | 01-12-2012 |
20120010103 | METHODS OF SCREENING USING AMPHIBIANS - High-throughput methods of screening agents for activities affecting renal, cardiac, blood or lymphatic vascular development and functions in amphibians in multiwell plates are provided. Also provided are novel compounds that modulate blood and lymphatic vascular development. | 01-12-2012 |
20120015835 | Devices and Methods for Enrichment and Alteration of Circulating Tumor Cells and Other Particles - The invention features devices and methods for detecting, enriching, and analyzing circulating tumor cells and other particles. The invention further features methods of diagnosing a condition, e.g., cancer, in a subject by analyzing a cellular sample from the subject. | 01-19-2012 |
20120015836 | KITS FOR MULTIPLEXED NUCLEIC ACID ANALYSIS BY CAPTURE OF SINGLE-STRANDED DNA PRODUCED FROM DOUBLE-STRANDED TARGET FRAGMENTS - A method of fragmentation of double stranded DNA is disclosed for use in nucleic acid analysis, notably in the multiplexed analysis of polymorphisms and mutations. The method produces a multiplicity of labeled sense and anti-sense fragments which are not complementary, and thus do not significantly re-anneal under conditions suitable for hybridization analysis (or capture-mediated elongation analysis) of the polymorphisms and/or mutations. The fragments display a desired or predicted length distribution. Cleavage sites can be selected such that the fragments are short, yet long enough to allow discrimination among fragments in an assay, and as a matter of statistical probability, such that the majority of fragments contain at least one labeled nucleotide to facilitate detection. | 01-19-2012 |
20120015837 | METHOD FOR DIAGNOSING ENDOMETRIAL CANCER - An object of the present invention is to provide a method for diagnosing endometrial cancer by comprehensively analyzing the glycan structures of glycoprotein with the normal endometrium and endometrial cancers (well-differentiated/poorly-differentiated), using the lectin microarray system. The present invention provides a method for diagnosing or determining the state of normal endometrium or endometrial cancer/cancer stages by glycan profiling using a structure of a glycoprotein in a sample as an indicator. | 01-19-2012 |
20120015838 | Method and Kit for Diagnosing Autism Using Gene Expression Profiling - This invention relates to DNA microarray technology, and more specifically to methods and kits for identifying autism and autism spectrum disorders in humans. | 01-19-2012 |
20120015839 | RECURRENT GENE FUSIONS IN CANCER - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusions as diagnostic markers and clinical targets for cancer (e.g., prostate cancer). | 01-19-2012 |
20120015840 | METHODS FOR GENERATION OF RNA AND (POLY)PEPTIDE LIBRARIES AND THEIR USE - The present invention relates to a method for generating an RNA library or a (poly)peptide library comprising the steps of: (a) providing one or more nucleic acid molecules each comprising i) two or more coding elements (A) each giving rise to an RNA molecule upon transcription and/or a (poly)peptide upon transcription and translation; and ii) linking elements (B) arranged according to the general formula of B(AB) | 01-19-2012 |
20120015841 | NOVEL CELL LINES AND METHODS - The invention relates to novel cells and cell lines, and methods for making and using them. | 01-19-2012 |
20120015842 | Enumeration Of Nucleic Acids - Disclosed are methods and systems for enumeration of nucleic acids, including for the detection of rare events in a biological sample. In certain embodiments, the method may comprise arranging polynucleotides obtained from a biological sample to form a plurality of reaction sites, wherein each reaction site contains on average one polynucleotide; amplifying the polynucleotides in the plurality of reaction sites; determining by nucleic acid hybridization (i) a first number of first reaction sites containing a target nucleic acid sequence, or a portion thereof, and (ii) a second number of second reaction sites containing a reference nucleic acid sequence, or a portion thereof; comparing the first number of the first reaction sites to the second number of the second reaction sites to determine the relative amount of the target nucleic acid in the biological sample. | 01-19-2012 |
20120015843 | GENE AND GENE EXPRESSED PROTEIN TARGETS DEPICTING BIOMARKER PATTERNS AND SIGNATURE SETS BY TUMOR TYPE - Provided herein are methods and systems for identifying a therapeutic for an individual, such as a therapeutic not previously identified for treating the individual. The therapeutic can be identified by molecular profiling, such as determining the biomarker patterns or signature sets of a biological sample of an individual. | 01-19-2012 |
20120015844 | DEVICE AND METHOD FOR PRODUCING A REPLICATE OR DERIVATIVE FROM AN ARRAY OF MOLECULES, AND APPLICATIONS THEREOF - A method of producing a replicate or derivative of an array of molecules, the array having a spatial arrangement of separate samples of molecules, includes creating, for each sample, at least one spatially limited effective area which is separate from the effective areas of the other samples, a surface, provided with a binding adapter or binding properties, of a carrier bordering on the effective areas. The molecules are amplified by means of amplifying agents in the effective areas for creating replicates or derivatives of the samples. The replicates or derivatives of the samples are bound to the carrier by means of the binding adapter or the binding properties, so that a spatial arrangement of the replicates or derivatives of the samples on the carrier corresponds to the spatial arrangement of the samples in the array. The carrier having the copies of the samples is removed from the array. | 01-19-2012 |
20120015845 | MARKERS FOR THE DIAGNOSIS OF AML, B-ALL AND T-ALL - Disclosed are diagnostic markers specific for acute myeloid leukemia (AML), B-cell lineage acute lymphoblastic leukemia (B-ALL), and T-cell lineage acute lymphoblastic leukemia (T-ALL). Also disclosed are a composition and a kit, comprising an agent detecting the presence of the markers, and a method of diagnosing AML, B-ALL and T-ALL using the same. | 01-19-2012 |
20120021930 | Multiplex Nucleic Acid Detection - The present invention relates to a novel multiplex detection of nucleic acid targets in a sample. This is accomplished by using novel padlock probes which contain a unique cleavage site for linearization and a first member of a binding pair for isolation of the padlock probe from the sample. Three different designs of the padlock probes are described and examples are shown for ligation, amplification and qualitative and quantitative detection. The combination of these features gives a fast, accurate and specific multiplex detection assay | 01-26-2012 |
20120021931 | DEVICES AND METHODS FOR BATCH PROCESSING MAGNETIC BEAD ASSAYS - A microfluidic device for batch processing magnetic bead assays and having one or more microfluidic sample channels, comprising, one or more micromagnets seated in a fixture; and an actuator; wherein a portion of each micromagnet is in releasable operative association with one or more of the microfluidic sample channels, and another portion of each micromagnet is in releasable operative association with the actuator; and methods for using the same. | 01-26-2012 |
20120021932 | Multiplexed Olfactory Receptor-Based Microsurface Plasmon Polariton Detector - The invention provides a bio-sensing nanodevice comprising: a stabilized G-protein coupled receptor on a support, a real time receptor-ligand binding detection method, a test composition delivery system and a test composition recognition program. The G-protein coupled receptor can be stabilized using surfactant peptide. The nanodevice provides a greater surface area for better precision and sensitivity to odorant detection. The invention further provides a microfluidic chip containing a stabilized G-protein coupled receptor immobilized on a support, and arranged in at least two dimensional microarray system. The invention also provides a method of delivering odorant comprising the step of manipulating the bubbles in complex microfluidic networks wherein the bubbles travel in a microfluidic channel carrying a variety of gas samples to a precise location on a chip. The invention further provides method of fabricating hOR17-4 olfactory receptor. | 01-26-2012 |
20120021933 | SMALL MOLECULE PRINTING - The present invention provides compositions and methods to facilitate the identification of compounds that are capable of interacting with a biological macromolecule of interest. In one aspect, a composition is provided that comprises an array of one or more types of chemical compounds attached to a solid support, wherein the density of the array of compounds is at least 1000 spots per cm | 01-26-2012 |
20120021934 | Methods and Devices for Active Bioassay - The present invention provides an active assay method for detecting a biological analyte. According to the method, a probe molecule is immobilized on a surface. An analyte is then placed in fluidic connection with the probe molecule on the surface. A force is then applied to the analyte to move it toward the surface to facilitate contact and possibly binding of the analyte to the probe. Optionally, another force can be applied or the force can be reversed, to remove unbound or weakly bound analyte from the surface. Analyte that remains bound to the surface is then detected. The detection can include rolling or sliding beads over an analyte and/or probe on a substrate, and detecting bound beads. The present invention furthermore, provides devices, such as electrophoresis apparatuses and biochip assemblies, for carrying out the methods of the invention. | 01-26-2012 |
20120021935 | SIGNATURE FOR THE DIAGNOSIS OF CANCER AGGRESSIVENESS AND GENETIC INSTABILITY - The present invention relates to a method for diagnosing aggressiveness and/or genetic instability of a cancer in a patient from a cancer sample of said patient, comprising: a) measuring in vitro the expression level of the POLQ gene and the expression level of a control gene in said patient cancer sample; b) calculating for said POLQ gene an expression level ratio of the expression level of POLQ to the expression of the said control gene in said patient cancer sample; c) comparing the said POLQ expression level ratio to a corresponding threshold value, and d) diagnosing cancer aggressiveness and genetic instability if the said POLQ expression level ratio is superior to a corresponding threshold values. Dedicated microarrays and kits are also described, as well as a method of selecting a suitable treatment. | 01-26-2012 |
20120021936 | BIOMARKERS FOR DENGUE - The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying dengue status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as infected with dengue or not infected with dengue. The biomarkers can be detected by SELDI mass spectrometry. | 01-26-2012 |
20120021937 | DETECTION OF CARCINOMA IN SITU IN SEMEN SPECIMENS - The present invention provides a method for the detection of testicular cancer and/or precursors hereof by screening a sample for the presence of at least two markers in the same cell, wherein the sample is a semen sample and/or an ejaculate from a male human being. | 01-26-2012 |
20120021938 | Method for detecting transcription factor-protein interactions - A method is provided for identifying complexes between a transcription factor and another protein, the method comprising: isolating from a biological sample transcription factor complexes based on whether the transcription factor complexes comprise a particular type of transcription factor; and identifying which of a plurality of different proteins are present in the isolated transcription factor complexes. | 01-26-2012 |
20120021939 | METHOD FOR PROFILING DRUG COMPOUNDS USING PROTEIN KINASE INHIBITORS - The present invention relates to a method for determining the effect of a drug on the kinase activity in a sample or predicting the response of a patient to a drug, wherein the kinase activity of a sample in the presence of a protein kinase inhibitor is measured, said protein kinase inhibitor mimicking the effect of said drug compound on the kinase activity in said sample. | 01-26-2012 |
20120021940 | Compositions, Methods, and Kits for Identifying Candidate Molecules from Encoded Chemical Libraries - The subject matter relates to relates to a one-bead-one-sequence composition, a library of tagged chemicals comprising a plurality of one-bead-one-sequence compositions, a method for identifying a candidate molecule from a library of tagged chemicals, and a composition produced by a process, all as described herein. | 01-26-2012 |
20120021941 | BLOOD TEST FOR THE DETECTION OF CANCER - Methods of detecting cancers are provided. In certain embodiments, a blood test may utilized to identify the presence of a cancer such as, e.g., a melanoma or glioma (e.g., an astrocytoma, a glioblastoma multiforme) in a human patient. In particular, increased p-STAT3 expression by peripheral blood mononuclear cells is selectively associated with the presence of certain cancers. In various embodiments, fluorescence activated cell sorting (FACS) may be used to measure p-STAT3 expression in the peripheral blood of a human patient. | 01-26-2012 |
20120021942 | USE OF FCCS FOR THE ANALYSIS OF INTERACTION PARAMETERS IN AN IN VIVO-LIKE ENVIRONMENT - The present invention relates to the determination of interaction parameters of at least two analytes in cellular lysates, wherein at least one competitive agent is optionally further present. | 01-26-2012 |
20120021943 | MULTIPLE GENETIC DISEASE DIAGNOSTIC PANELS BY ONE SINGLE TEST USING MICROARRAY TECHNOLOGY - The invention utilizes clinical features of diseases with a genetic background to define logical panels of diseases which have shared signs or symptoms. The invention includes methods for collecting data for use in determining a cause or risk factor for disease and includes micro arrays for use in detecting mutations associated with the diseases set forth in the panel. | 01-26-2012 |
20120021944 | Co-Coupling To Control Reactivity Of Reagents In Immunoassays - Methods and compositions for controlling immunoassay reactivity are provided. In one embodiment, a method for preparing a substrate for an immunoassay is provided in which a composition containing a reagent and a neutral material is applied to a substrate under conditions suitable to couple the reagent and the neutral material to the substrate. | 01-26-2012 |
20120021945 | Hypoxia-Inducible Protein 2 (HIG2), a Diagnostic Marker for Clear Cell Renal Cell Carcinoma - The present invention provides a method for inhibiting growth of a cancer cell, particularly a renal cell carcinoma, by contacting the cell with a composition composed of an HIG2 siRNA or HIG2 antibody. Methods of diagnosing renal cell cancer are also provided within the present invention. | 01-26-2012 |
20120021946 | METHOD OF DIAGNOSING ESOPHAGEAL CANCER - In order to identify the molecules involved in esophageal carcinogenesis and those to be useful for diagnostic markers as well as targets for new drugs and immunotherapy, a cDNA microarray representing 32,256 genes was constructed to analyze the expression profiles of 19 esophageal squamous-cell carcinomas (ESCCS) purified by laser-capture microdissection. A detailed genome-wide database for sets of genes that are significantly up- or down-regulated in esophageal cancer is disclosed herein. These genes find use in the development of therapeutic drugs or immunotherapy as well as tumor markers. Additionally, genes associated with lymph-node metastasis and post-surgery recurrence are disclosed herein. Among the candidate molecular target genes, ECT2, CDC45L and DKK1 are further characterized. Treatment of ESCC cells with small interfering RNAs (siRNAs) of ECT2 or CDC45L suppressed growth of the cancer cells. Thus, the data herein provide valuable information for identifying diagnostic systems and therapeutic target molecules for esophageal cancer. | 01-26-2012 |
20120021947 | System and Method to Obtain Oligo-Peptides with Specific High Affinity to Query Proteins - This application is based on the concept of the Proteomic Code, PC (discovered and described by Biro, 1981-2011, for review see ref 6) and making use of the biological observation, that co-locating amino acids [in interacting proteins] are coded by partially complementary codons. A method is provided to design and produce a special and distinct set of affinity oligopeptides (AffiSeq) using the PC principle. These designed and artificially produced affinity peptides will be used in any biotechnological or pharmacological applications which benefit of the specific and high affinity protein-protein interactions. | 01-26-2012 |
20120021948 | SURFACE DISPLAY OF WHOLE ANTIBODIES IN EUKARYOTES - Methods for display of recombinant whole immunoglobulins or immunoglobulin libraries on the surface of eukaryote host cells, including yeast and filamentous fungi, are described. The methods are useful for screening libraries of recombinant immunoglobulins in eukaryote host cells to identify immunoglobulins that are specific for an antigen of interest. | 01-26-2012 |
20120021949 | Methylation Ligation-Dependent Macroarray (MLM) - A method is disclosed for detecting the presence of a methylated site at a specific location on a single stranded target nucleic acid sequence. Further disclosed are nucleic acid probes for use in the method and a kit for performing the method. | 01-26-2012 |
20120028820 | HYBRID SENSOR ARRAY - The present invention provides devices, methods and systems to selectively detect the binding of a molecular species to a biomolecule. In its olfactory sensing application, the hybrid sensor arrays of the present invention provide a high dimensional signature of odorants present that is also readily reversible, together enabling the identification and localization of a source analyte in the presence of the background odorant landscape inherent in a real-world setting. | 02-02-2012 |
20120028821 | PROGRAMMING AND REPROGRAMMING OF CELLS - The disclosure relates to a method of reprogramming one or more somatic cells, e.g., partially differentiated or fully/terminally differentiated somatic cells, to a less differentiated state, e.g., a pluripotent or multipotent state. In further embodiments the invention also relates to reprogrammed somatic cells produced by methods of the invention, to chimeric animals comprising reprogrammed somatic cells of the invention, to uses of said cells, and to methods for identifying agents useful for reprogramming somatic cells. | 02-02-2012 |
20120028822 | METHODS, FLOW CELLS AND SYSTEMS FOR SINGLE CELL ANALYSIS - A method, flow cell and/or device for increasing the recovery of a limiting analyte in a sample, e.g., for single molecule analysis is disclosed. Methods for preparing a nucleic acid sample from a single cell and capturing nucleic acids on a surface configured for use in or with single molecule analysis are also provided. | 02-02-2012 |
20120028823 | pH MODULATION METHOD TO DETECT LIGAND-RECEPTOR BINDING - The present disclosure relates to detecting receptor-ligand binding by measuring local pH modulation using a pH-sensitive fluorophore. | 02-02-2012 |
20120028824 | METHOD FOR THE IN VITRO DIAGNOSIS OF STROKE - A method for the in vitro diagnosis of stroke and transient ischemic attack (TIA) in an individual, comprising the following steps: (a) measuring the level of proBNP(1-108), or of fragments of proBNP(1-108) comprising a RAPRSP sequence (SEQ ID NO: 1), in a biological sample of the individual; (b) measuring the level of nucleoside diphosphate kinase A (NDKA) in a biological sample of the individual; (c) comparing the level of proBNP(1-108), or of fragments of proBNP(1-108), and the level of NDKA, with one or several cut-off values; and (d) determining therefrom whether a stroke or a TIA has occurred in the individual. | 02-02-2012 |
20120028825 | GALECTIN-1 (GAL1) AS A BIOMARKER FOR DIFFERENTIAL DIAGNOSIS OF OSTEOSARCOMA AND CHONDROSARCOMA - The present invention relates to a method for differential diagnosis of osteosarcoma and chondrosarcoma, especially chondroblastic osteosarcoma and conventional chondrosarcoma, in a patient comprising a step consisting of detecting galectin-1 (GAL1) expression in a bone sample obtained from said patient. | 02-02-2012 |
20120028826 | Methods and Compositions for Analysis of Nucleic Acids - Compositions and methods for analysis of nucleic acids are disclosed. Targets are hybridized to arrays having features that include pairs of co-localized probes within features. The probe pairs may include a first probe type that is oriented so that the 5′ end is free and the 3′ end is attached to the support and a second probe type that is oriented so that the 3′ end is free for extension and the 5′ end is attached to the support. The probes of a feature are complementary to different regions of the same target sequence so they can simultaneously hybridize to a single target with a gap or nick between. The gap may be filled by extension and ligation or ligation. | 02-02-2012 |
20120028827 | METHOD FOR DETERMINING A RISK, FOR A SUBJECT, OF SUFFERING FROM ATOPIC DERMATITIS OR SEVERITY OF ATOPIC DERMATITIS FOR A SUBJECT SUFFERING FROM ATOPIC DERMATITIS AND METHOD FOR USING A SINGLE-NUCLEOTIDE POLYMORPHISM RS12313273 AS A BIOMARKER FOR DETERMINING THE DEVELOPMENT OR SEVERITY OF ATOPIC DERMATITIS - The invention provides a method for determining a risk, for a subject, of suffering from atopic dermatitis, including: obtaining a biosample of the subject; detecting the presence of the single-nucleotide polymorphism rs12313273 (C/T) at position 30881 of the ORAI1 gene (SEQ ID No.: 1) in the biosample; and determining the risk, for the subject, of suffering from atopic dermatitis, wherein the presence of a C allele or genotype CC of the single-nucleotide polymorphism rs12313273 (C/T) indicates that the subject is at increased risk for suffering from atopic dermatitis. | 02-02-2012 |
20120028828 | Fluorescent Methods and Materials for Directed Biomarker Signal Amplification - Methods and compositions are provided that include a multichromophore and/or multichromophore complex for identifying a target biomolecule. A sensor biomolecule, for example, an antibody can be covalently linked to the multichromophore. Additionally, a signaling chromophore can be covalently linked to the multichromophore. The arrangement is such that the signaling chromophore is capable of receiving energy from the multichromophore upon excitation of the multichromophore. Since the sensor biomolecule is capable of interacting with the target biomolecule, the multichromophore and/or multichromophore complex can provide enhanced detection signals for a target biomolecule. | 02-02-2012 |
20120028829 | ANTI-HEDGEHOG ANTIBODIES - The invention relates to anti-hedgehog antibodies, their use in the detection of hedgehog expression in tissue, and to the use of such detection in the treatment of cancer. | 02-02-2012 |
20120028830 | MICROFLUIDIC DEVICE FOR SIMULTANEOUSLY CONDUCTING MULTIPLE ANALYSES - Provided is a rotatable microfluidic device for conducting simultaneously two or more assays. The device includes a platform which can be rotated, a first unit which is disposed at one portion of the platform and detects a target material from a sample using surface on which a capture probe selectively binds to the target material is attached, and a second unit which is disposed at another portion of the platform and detects a target material included in the sample by a different reaction from the reaction conducted in the first unit. | 02-02-2012 |
20120028831 | MiR-29-BASED METHODS FOR THE DIAGNOSIS AND PROGNOSIS OF ACUTE MYELOID LEUKEMIA (AML) - The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (AML). The invention also provides methods of identifying anti-AML agents. | 02-02-2012 |
20120028832 | MiR-182-, miR-191, miR-199a-BASED METHODS FOR THE DIAGNOSIS AND PROGNOSIS OF ACUTE MYELOID LEUKEMIA (AML) - The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (AML). | 02-02-2012 |
20120028833 | MiR-25-BASED METHODS FOR THE DIAGNOSIS AND PROGNOSIS OF ACUTE MYELOID LEUKEMIA (AML) - The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (AML). The invention also provides methods of identifying anti-AML agents. | 02-02-2012 |
20120028834 | COLOR ENCODED MAGNETIC STRUCTURE - Provided is a color encoding method including providing a composition including a liquid medium and magnetic nanoparticles dispersed in the liquid medium; applying a magnetic field to the composition to align the magnetic nanoparticles; and applying a patterned energy source to the composition to solidify the composition, wherein more than one region of the composition are sequentially solidified with varying magnetic field strength to fix a plurality of color codes | 02-02-2012 |
20120028835 | SECERNIN-1 AS A MARKER FOR CANCER - Disclosed is a method aiding in the assessment of cancer. It involves the use of the secernin-1 protein (SCRN1) as a universal marker of different cancer types. More specifically disclosed is a method for assessing cancer from a liquid sample derived from an individual by measuring SCRN1 in the sample. Measurement of SCRN1 can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery. | 02-02-2012 |
20120028836 | USE OF PROTEIN SATB2 AS A MARKER FOR COLORECTAL CANCER - The invention provides new methods, means and uses in connection with detection, characterization and prognosis of colo-rectal cancer, via the identification of the SATB2 protein as a marker for this cancer type. | 02-02-2012 |
20120035065 | Aptamer Regulated Nucleic Acids and Uses Thereof - The invention relates to aptamer-regulated, ligand-responsive nucleic acids, or “ampliSwitches,” and uses thereof. Particular embodiments include a ligand-responsive nucleic acid that comprises a primer sequence domain and an aptamer domain that is responsive to a ligand. | 02-09-2012 |
20120035066 | CONJUGATED POLYMERS FOR USE IN HOMOGENEOUS AND SOLID STATE ASSAYS - The invention further relates to multichromophores, which may be conjugated polymers, and methods, articles and compositions employing them as described herein. In some aspects, the invention relates to methods, articles and compositions for the detection and analysis of biomolecules in a sample. Provided assays include those determining the presence of a target biomolecule in a sample or its relative amount, or the assays may be quantitative or semi-quantitative. The methods can be performed on a substrate. The methods can be performed in an array format on a substrate, which can be a sensor. In some embodiments, detection assays are provided employing sensor biomolecules that do not comprise a fluorophore that can exchange energy with the cationic multichromophore. In some aspects biological assays are provided in which energy is transferred between one or more of the multichromophore, a label on the target biomolecule, a label on the sensor biomolecule, and/or a fluorescent dye specific for a polynucleotide, in all permutations. The multichromophore may interact at least in part electrostatically with the sensor and/or the target, and an increase in energy transfer with the polymer may occur upon binding of the sensor and the target. Other variations of the inventions are described further herein. | 02-09-2012 |
20120035067 | Marker Panels For Idiopathic Pulmonary Fibrosis Diagnosis And Evaluation - The present invention relates to the discovery that of a panel of serum or plasma markers may be used to diagnose Idiopathic Pulmonary Fibrosis (“IPF”) and distinguish this condition from other lung ailments. It further relates to the identification of markers associated with IPF disease progression. | 02-09-2012 |
20120035068 | USE OF MIRCO-RNA AS A BIOMARKER OF IMMUNOMODULATORY DRUG ACTIVITY - Methods of determining the activity of an immunomodulatory compound by measuring the presence of an miRNA in a sample are disclosed. Additionally disclosed are methods of assessing the patient compliance in patients treated with an immunomodulatory compound. | 02-09-2012 |
20120035069 | PROGNOSIS OF BREAST CANCER PATIENTS BY MONITORING THE EXPRESSION OF TWO GENES - The present invention relates to the expression of two genes, CyclinG2 and Sharp1, which correlates with prognosis in individuals having breast cancer. Specifically, this invention provides a method to stratify samples from breast cancer patients in a high or low recurrence risk in the years following primary tumor removal. This classification can be achieved through the analysis of protein or mRNA expression levels for the two identified genes. The invention also illustrates how CyclinG2 and Sharp1 have been identified in mammary cancer cell lines and validated in a large cohort of human patients as powerful metastasis predictors. | 02-09-2012 |
20120035070 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF - There has been a need for coelenterazine analogs that exhibit luminescence properties different from those of known coelenterazine analogs. The present invention provides the compound represented by general formula (1). | 02-09-2012 |
20120035071 | HIGHLY CONSERVED GENES AND THEIR USE TO GENERATE PROBES AND PRIMERS FOR DETECTION OF MICROORGANISMS - Compositions and methods for the detection of vancomycin-resistant pathogens using primers and/or probes to the vanA and vanB genes. | 02-09-2012 |
20120035072 | KASPP (LRRK2) GENE, ITS PRODUCTION AND USE FOR THE DETECTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS - The present invention refers to a newly discovered gene named KASPP for Kinase Associated with Parkinsonism with Pleiomorphic Pathology or alternatively named LRRK2 for Leucine-Rich Repeat Kinase 2, its production, biochemical characterization and use for the detection and treatment of neurodegenerative disorders, such as Parkinson disease (PD) including, without limitation, sporadic PD, Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), and other synucleinopathies and/or tauopathy as well as several polymorphisms and mutations in the KASPP/LRRK2 gene segregated with PD. | 02-09-2012 |
20120035073 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES - The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases. | 02-09-2012 |
20120035074 | METHODS TO DETERMINE ATHEROSCLEROSIS REGRESSION, PLAQUE STABILIZTION AND CARDIOVASCULAR RISK - Provided herein are compositions and methods for examining the progression, regression or risk of individuals at risk for developing coronary artery disease (CAD). | 02-09-2012 |
20120035075 | CARTRIDGE FOR AN AMPLIFICATION PROCESS - The invention relates to real-time array PCR cartridges. The cartridge ( | 02-09-2012 |
20120035076 | IRAK KINASE FAMILY AS NOVEL TARGET AND BIOMARKER FOR ALZHEIMER - The present invention relates to methods and devices for the diagnosis or drug response prediction of neurological disorders by measuring kinase activity and studying the phosphorylation levels and profiles in samples of said patients. Furthermore the present invention relates to methods of identifying drug compounds relevant to neurological disorders by measuring kinase activity and studying phosphorylation levels. Also, the present invention relates to the use of inhibitors of the IRAK protein kinase family or a pharmaceutical composition thereof in the treatment of neurological disorders such as Alzheimer's disease. | 02-09-2012 |
20120040849 | GENE EXPRESSION PROFILE AS AN ENDOMETRIAL RECEPTIVITY MARKER - The present invention relates to determining the receptivity of human endometrium from a gene expression profile. More specifically, the invention consists of developing a specific expression microarray of endometrial receptivity (Endometrial Receptivity Array or ERA) which allows evaluating the receptive state of a human endometrium, as well as assessing said state for diagnostic and therapeutic purposes. | 02-16-2012 |
20120040850 | Methods for Diagnosis and Assessment of Autoimmune Disorders - The present invention relates to methods and compositions for use in the diagnosis, assessment and treatment of patients with suspected autoimmune disorders. In particular, the present invention provides an auto-antibody assessment system that combines a multiplex bead array using purified antigens with human cells. When analysis is performed with the system using means such as flow cytometry, this mixture can provide a more comprehensive auto-antigen profile for assessing disease states in autoimmune disorders. | 02-16-2012 |
20120040851 | miRNA TARGETS - The present invention provides systems for identifying, isolating, and/or characterizing targets of micro RNAs. | 02-16-2012 |
20120040852 | BIOMARKERS - The present invention relates to a method of diagnosing or monitoring schizophrenia or other psychotic disorders | 02-16-2012 |
20120040853 | REAL TIME MULTIPLEX PCR DETECTION ON SOLID SURFACES USING DOUBLE STRANDED NUCLEIC ACID SPECIFIC DYES - The present invention provides method allowing for real time detection of a multitude of target nucleic acids of interest in one reaction (multiplexing) using dyes that are specific for double stranded nucleic acids. | 02-16-2012 |
20120040854 | Method for in vitro diagnosis or prognosis of testicular cancer - The invention relates to a method for in vitro diagnosis or prognosis of testicular cancer which comprises a step of detecting the presence or absence of at least one expression product from at least one nucleic acid sequence selected from the sequences identified in SEQ ID NOS: 1 to 6 or from the sequences which exhibit at least 99% identity with one of the sequences identified in SEQ ID NOS: 1 to 6, to isolated nucleic acid sequences and to the use thereof as a testicular cancer marker. | 02-16-2012 |
20120040855 | TISSUE-SPECIFIC AGING BIOMARKERS - The invention provides methods of developing tissue-specific biomarkers of aging, sets of robust biomarkers identified by those methods, and uses of the biomarkers to identify nutrients and other functional ingredients or agents having anti-aging properties. | 02-16-2012 |
20120040856 | METHOD FOR DETECTING THE PRESENCE OF LIQUIDS IN A MICROFLUIDIC DEVICE, DETECTING APPARATUS AND CORRESPONDING MICROFLUIDIC DEVICE - A method for detecting the presence of liquids includes detecting an initial temperature in a channel accommodating a liquid; heating the channel for a pre-determined test time; detecting a test temperature; determining a temperature variation on the basis of the initial temperature, the test temperature, and the test time; and comparing the temperature variation with at least one threshold. Before detecting an initial temperature, an ambient temperature is read, the channel is heated to the initial temperature, and is kept at the initial temperature for a time period. | 02-16-2012 |
20120040857 | ISOLATION OF FACTORS THAT ASSOCIATE DIRECTLY OR INDIRECTLY WITH CHROMATIN - Methods for isolating non-coding nucleic acids that are associated with chromatin at a target genomic locus are provided. The methods comprise the steps of obtaining a sample that comprises a target genomic DNA sequence and one or more non-coding nucleic acids associated with that DNA sequence; contacting the sample with at least one oligonucleotide probe that comprises a sequence that is complimentary to and capable of hybridising with at least a portion of the target DNA sequence, wherein the oligonucleotide probe comprises at least one modified nucleotide analogue and wherein the oligonucleotide probe further comprises at least one affinity label; allowing the at least one oligonucleotide probe and the target DNA sequence to hybridise with each other so as to form a probe-target hybrid; isolating the probe-target hybrid from the sample by immobilizing the probe-target hybrid through a molecule that binds to the at least one affinity label; and eluting the one or more non-coding nucleic acids that are associated with the target genomic DNA sequence. Also provided are probes suitable for use in the methods of the invention. The methods and probes of the invention are suited to identification of non-coding RNAs including microRNAs and snoRNAs that are associated with chromatin remodelling. | 02-16-2012 |
20120040858 | BIOMARKERS FOR STROKE - Biomarkers for stroke and methods for their detection are disclosed. In one aspect, the present application discloses biomarkers for the diagnosis of stroke in a subject. In another aspect, the application discloses a method for the diagnosis of stroke in a subject. The method comprises detection of stroke biomarkers in cerebrospinal fluid, blood, serum or PMBCs of a subject. Also disclosed is a kit for the detection of biomarkers for the diagnosis of stroke in a subject. | 02-16-2012 |
20120040859 | ASSAY SYSTEMS FOR GENETIC ANALYSIS - The present invention provides assays systems and methods for detection of chromosomal abnormalities and status of single loci associated with monogenic or polygenic traits in a sample containing nucleic acids from a maternal and a fetal source. | 02-16-2012 |
20120040860 | Methods for Determining Protein Binding Specificity Using Peptide Libraries - A method for determining protein binding specificity using a screen of a peptide library is provided. The method can be used to determine binding specificity for human NAD | 02-16-2012 |
20120040861 | Pancreatic Cancer Biomarkers and Uses Thereof - The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of cancer generally and pancreatic cancer specifically. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to diagnose cancer generally or pancreatic cancer specifically. In another aspect, methods are provided for diagnosing pancreatic cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, wherein the individual is classified as having pancreatic cancer, or the likelihood of the individual having pancreatic cancer is determined, based on the at least one biomarker value. In a further aspect, methods are provided for diagnosing cancer generally in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 19, wherein the individual is classified as having cancer generally, or the likelihood of the individual having cancer is determined, based on the at least one biomarker value. | 02-16-2012 |
20120040862 | METHOD FOR DETECTING AND QUANTIFYING ENDOGENOUS WHEAT DNA SEQUENCE - A circular DNA is provided comprising endogenous DNA common to both genetically modified wheat and non-genetically modified wheat along with one or more pieces of DNA each having a sequence present specifically in a strain of genetically modified wheat. Also provided is a method for determining a mix rate of genetically modified wheat in a test sample. | 02-16-2012 |
20120040863 | PROCESS FOR TUMOUR CHARACTERISTIC AND MARKER SET IDENTIFICATION, TUMOUR CLASSIFICATION AND MARKER SETS FOR CANCER - A process to identify tumour characteristics involves obtaining three different marker sets each predictive of a characteristic of interest, obtaining a sample gene expression signals from tumour cells, adding a reporter to affect a change in the sample permitting assessment of a gene expression signal of interest in the tumour, combining the gene expression signals with the reporter, correlating the extracted gene expression signals to the three different marker sets, assigning a designation to the extracted gene expression signals according to the following rankings: if the correlation of all three predictive gene expression signal sets predict it to have characteristics of concern, it is designated a bad tumour; if the correlation of all three predictive gene expression signal sets predict it to lack characteristics of concern it is designated a good tumour; and, if the correlation of all three predictive gene expression signal sets do not provide the same predicted clinical outcome, the tumour is designated as “intermediate”; and, outputting said designation. | 02-16-2012 |
20120040864 | Method for Determining the Cbl-b Expression - The present invention relates to methods of determining intracellular Cbl-b protein in cells of a sample, comprising
| 02-16-2012 |
20120046180 | Releasable nonvolatile mass-label molecules - Releasable tag reagents for use in the detection and analysis of target molecules, particular in mass spectrometric analyses are provided. Also provided are methods of detection that employ releasable tag reagents. | 02-23-2012 |
20120046181 | Biomarkers for the Diagnosis of Renal Allograft and Kidney Status - The present invention relates to the identification and use of protein biomarkers with clinical relevance to kidney status and chronic renal injury or disorder. In particular, the invention provides the identity of marker proteins which are recognized by antibodies present in patients suffering from end-stage renal disorder, stable renal transplant, renal transplant glomerulopathy (TG), and interstitial fibrosis and tubular atrophy (IFTA). Methods and kits are described for using these proteins in the study and diagnosis of chronic renal transplant injury, and in the selection and/or monitoring of treatment regimens. | 02-23-2012 |
20120046182 | NEOEPITOPE DETECTION OF DISEASE USING PROTEIN ARRAYS - A biosensor for use in detecting the presence of diseases, the biosensor comprising a detector for detecting a presence of at least one marker indicative of a specific disease. A method of determining efficacy of a pharmaceutical for treating a disease or staging disease by administering a pharmaceutical to a sample containing markers for a disease, detecting the amount of at least one marker of the disease in the sample, and analyzing the amount of the marker in the sample, whereby the amount of marker correlates to pharmaceutical efficacy or disease stage. Markers for gynecological disease selected from the list in Table 8. An immuno-imaging agent comprising labeled antibodies, whereby the labeled antibodies are isolated and reactive to proteins overexpressed in vivo. Informatics software for analyzing the arrays of claim | 02-23-2012 |
20120046183 | METHOD OF DIAGNOSING A MENTAL STATE - A method of assessing a psychiatric disorder, behavioural problem or mental state following exposure to stress is described. Expression levels of mRNA transcripts for a plurality of genes linked to a stress-related neural state in the peripheral blood of a subject are measured. The expression levels of the genes, relative to a reference set of expression levels for the same genes in a healthy subject, are used to predict or assess a psychiatric disorder following exposure to a stressor. | 02-23-2012 |
20120046184 | METHOD FOR THE SELECTIVE CONCENTRATION OF A SPECIFIC LOW ABUNDANCE BIOMOLECULE - Provided herein is a method for the isolation or removal of a cellular component from a cell that comprises the steps of applying a pulse of nanoparticles to the cell, allowing the nanoparticles to traffic through the cell for a period of time sufficient to allow the nanoparticles locate to and interact with the cellular component to be isolated, and separation of the nanoparticles and isolated cellular component from the cell. | 02-23-2012 |
20120046185 | PANEL OF BIOMARKERS FOR OVARIAN CANCER - The present invention provides a panel of protein-based biomarkers that are useful in diagnosing ovarian cancer in a subject. In particular, the panel of biomarkers of the invention are useful to classify a subject sample as having ovarian cancer or non-ovarian cancer. | 02-23-2012 |
20120046186 | Gene Expression Markers for Prediction of Response to Platinum-Based Chemotherapy Drugs - The present invention provides methods for predicting a likelihood that a patient with cancer will exhibit a positive response to a treatment with a platinum-based chemotherapy drug. The methods generally involve determining an expression level of a gene product that correlates with responsiveness to treatment with a platinum-based chemotherapy drug. In an embodiment of the invention, the platinum-based chemotherapy drug is oxaliplatin, and the cancer is colorectal cancer. | 02-23-2012 |
20120046187 | ANALYSIS CHIP, ANALYSIS METHOD AND METHOD FOR STIRRING SOLUTION - An analysis chip includes a carrier having a surface on which a selective binding substance(s) is(are) immobilized; a vessel holding a solution containing a test substance(s) which react(s) with the selective binding substance(s); and particles for stirring the solution, the particles being sealed within a space formed between the carrier and the vessel wherein a separator which allows passage therethrough of the solution containing the test substance(s), but does not allow passage therethrough of the particles is arranged in the space to separate the surface of the carrier on which the selective binding substance(s) is(are) immobilized and the particles. | 02-23-2012 |
20120046188 | Solid Support for HCV Detection - The present invention relates to a solid support for an immunological test for the detection of HCV, to which the following are attached:
| 02-23-2012 |
20120046189 | MARKERS RELATED TO AGE-RELATED MACULAR DEGENERATION AND USES THEREFOR - Described herein are compositions, kits and methods for diagnosing and tracking the progression of AMD in a subject by detecting the presence or absence of particular lipid metabolism markers associated with AMD. Predictive computer models of disease risk are also disclosed. | 02-23-2012 |
20120046190 | HP1ALPHA AS A PROGNOSTIC MARKER IN HUMAN CANCER - The present invention provides a prognostic marker in human cancer, HP1α, a high expression thereof being associated with a poor prognosis. The present invention further provides a method for diagnosing a cancer in a subject, HP1α a being specifically overexpressed in tumoral cells. The present invention also provides a method for selecting a subject affected with a cancer for an adjuvant therapy and a method for monitoring the response of a subject affected with a cancer to a treatment. | 02-23-2012 |
20120046191 | AUTOMATED DETECTION AND COUNTING OF BIOMOLECULES USING NANOPARTICLE PROBES - An apparatus and method for counting nanoparticle probes is disclosed. In one embodiment, quantum dot-tagged proteins on optically transparent membranes or slides are counted. The transparent membranes or slides are loaded onto a stage (e.g., an X-Y stage or X-Y-Z stage), which can automatically reposition the transparent membrane or slides for image capture at varying locations. A microscope can be used for providing a light source to fluoresce the nanocrystals and for providing the magnification needed for image capture. Once one or more images are captured, the nanoparticles can be automatically counted using post-processing software that maintains a total count across multiple images, if desired. | 02-23-2012 |
20120046192 | METHOD FOR DIAGNOSING ACUTE LYMPHOMIC LEUKEMIA (ALL) USING MIR-221 - Disclosed are compositions and methods for reducing the proliferation of ALL cancer cells through targeted interactions with ALL1 fusion proteins. | 02-23-2012 |
20120046193 | METHOD FOR DIAGNOSING ACUTE LYMPHOMIC LEUKEMIA (ALL) USING MIR-222 - Disclosed are compositions and methods for reducing the proliferation of ALL cancer cells through targeted interactions with ALL1 fusion proteins. | 02-23-2012 |
20120046194 | METHOD FOR DIAGNOSING ACUTE LYMPHOMIC LEUKEMIA (ALL) USING MIR-146a - Disclosed are compositions and methods for reducing the proliferation of ALL cancer cells through targeted interactions with ALL1 fusion proteins. | 02-23-2012 |
20120046195 | DETECTING BCL-B EXPRESSION IN CANCER AND USES THEREOF - Provided herein are compositions and methods of detecting Bcl-B expression in cancer cells to prognose, monitor, or select therapies for cancers such as breast cancer, prostate cancer, lung cancer, or gastric cancer. | 02-23-2012 |
20120046196 | ADRB2 Cancer Markers - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ADRB2 markers for cancer. | 02-23-2012 |
20120046197 | BIOMARKERS OF THERAPEUTIC RESPONSIVENESS - The present invention relates to methods of diagnosing a kidney disorder in a patient, as well as methods of monitoring the progression of a kidney disorder and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein. | 02-23-2012 |
20120058906 | COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF - Methods for making a combinatorial antibody library from human germline segments are provided. Also provided are libraries of nucleic acid molecules compiled from germline segments encoding VL chains and libraries of nucleic acid molecules encoding VH chains, and resulting antibody libraries. The libraries are provided as addressable libraries. Methods for screening antibody libraries against a target protein antigen, and the identified or selected antibodies are provided. | 03-08-2012 |
20120058907 | Mixtures of binding proteins - Described are methods for producing libraries of cells expressing at least two separate single polypeptide chain binding proteins, in which the binding proteins have different target epitopes. Such libraries are made by integration of the nucleic acid sequences encoding the polypeptide chains into the genome of the host cell, and selecting for cells that have successfully integrated these nucleic acids. The selected cells are preferably subjected to a cloning step. Mixtures of binding proteins are produced without having to individually produce each of the components of the mixture. A library of cells wherein essentially each cell encodes at least two single polypeptide chain binding proteins having different target epitopes is also herewith provided, as well as methods for producing a composition comprising at least two separate single polypeptide chain binding proteins having different target epitopes. | 03-08-2012 |
20120058908 | Universal Tags, Probes and Detection Methods For Multiple Targets Detection of Biomolecules - The present invention provides universal tags, probes and detection methods for multiple targets detection of biomolecules. The universal tag in the present invention is a fragment of DNA, RNA, peptide nucleic acid, or LNA, and is 3-20 mer in length. The probe in the present invention contains in order from 3′ terminus to 5′ terminus, a nucleotide sequence which is reverse complementary to a target molecule or a portion of the target molecule, and a nucleotide sequence which is reverse complementary to the universal tag; or said probe contains in order from 3′ terminus to 5′ terminus, a nucleotide sequence which is reverse complementary to the universal tag, and a nucleotide sequence which is reverse complementary to a target molecule or a portion of the target molecule. | 03-08-2012 |
20120058909 | IL-17 HOMOLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF - The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases. | 03-08-2012 |
20120058910 | METHOD FOR DIAGNOSING ACUTE LYMPHOMIC LEUKEMIA (ALL) USING MIR-125b - Disclosed are compositions and methods for reducing the proliferation of ALL cancer cells through targeted interactions with ALL1 fusion proteins. | 03-08-2012 |
20120058911 | METHOD OF DIAGNOSING POOR SURVIVAL PROGNOSIS COLON CANCER USING miR-181b - The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis. | 03-08-2012 |
20120058912 | METHOD OF DIAGNOSING POOR SURVIVAL PROGNOSIS COLON CANCER USING let-7g - The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis. | 03-08-2012 |
20120058913 | METHOD OF DIAGNOSING POOR SURVIVAL PROGNOSIS COLON CANCER USING miR-16b - The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis. | 03-08-2012 |
20120058914 | METHOD OF DIAGNOSING POOR SURVIVAL PROGNOSIS COLON CANCER USING miR-203 - The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis. | 03-08-2012 |
20120058915 | METHOD OF DIAGNOSING POOR SURVIVAL PROGNOSIS COLON CANCER USING miR-10a - The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis. | 03-08-2012 |
20120058916 | DIAGNOSTIC METHODS FOR LIVER DISORDERS - The present invention relates to methods of diagnosing a liver disorder in a patient, as well as methods of monitoring the progression of a liver disorder and/or methods of monitoring a treatment protocol of a therapeutic agent or a chemotherapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein. | 03-08-2012 |
20120065085 | Detection of chromosomal abnormalities associated with endometrial cancer - The methods and compositions described herein address the need for diagnostic method that could be offered to women during yearly checkups to allow for early detection, diagnosis and classification, and treatment of endometrial cancer. In addition, these methods and compositons addresse the current need for improving diagnostic accuracy of biopsy procedures in symptomatic patients. | 03-15-2012 |
20120065086 | Tape stripping methods for analysis of skin desease and pathological skin state - The present invention provides non-invasive methods for detecting, monitoring, and diagnosing skin disease and pathological skin states such as irritated skin and psoriasis. The methods include using tape stripping to analyze expression in epidermal samples, of one or more skin markers. In illustrative examples, the tape stripping is performed using pliable tape that has a rubber adhesive. Furthermore, the present invention provides methods for predicting and monitoring response to therapy for a skin disease, such as psoriasis or dermatitis. Finally, the methods can include the use of a microarray. | 03-15-2012 |
20120065087 | BIOMARKERS FOR DIAGNOSIS OF STROKE AND ITS CAUSES - The present invention provides compositions and methods for the diagnosis of the occurrence and cause of stroke. | 03-15-2012 |
20120065088 | SEQUENCE-SPECIFIC DETECTION OF NUCLEOTIDE SEQUENCES - A method for detecting the presence of a target nucleotide sequence in a sample of DNA is described herein in which a test sample comprising single stranded DNA is exposed to a DNA probe and a nicking endonuclease under conditions that would permit sequence-specific hybridization of the probe to a complementary target sequence. The probe comprises a sequence complementary to the target sequence to be detected and this sequence also includes a recognition sequence for the nicking endonuclease. If the sample contains the target sequence, the probe hybridizes to the target and is cleaved by the nicking endonuclease, which leaves the target intact. Observing the presence of probe cleaved by the nicking endonuclease indicates the presence of the target nucleotide sequence in the sample of DNA. | 03-15-2012 |
20120065089 | Method For Detecting And Distinguishing Intrahepatic Cholangiocarcinoma - Disclosed are a method for early, sensitively and reliably detecting and distinguishing intrahepatic cholangiocarcinoma in a malignant tumor occurring primarily in the liver in a simple way, and a kit therefor. In the method, a glycan biomarker consisting of a lectin WFA (Wisteria floribunda Agglutinin)-binding glycoprotein derived from intrahepatic cholangiocarcinoma is used as a cancer marker to detect intrahepatic cholangiocarcinoma by detecting the cancer marker in a test specimen. The method for detecting intrahepatic cholangiocarcinoma can clearly differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma and enables early detection and determination with a performance clinically acceptable in terms of applicability, sensitivity and precision. | 03-15-2012 |
20120065090 | QUANTUM DOT-ENCODED BEAD SET FOR CALIBRATION AND QUANTIFICATION OF MULTIPLEXED ASSAYS, AND METHODS FOR THEIR USE - Control beads are disclosed that allow for improved quantitation of analytes in multiplexed bead assays. The control beads have a range of concentrations of calibration moieties that provide for the preparation of a titration curve. The titration curve can be used to quantify the concentration of the analytes. The titration curve can be used to correlate the signal obtained from a bead with the concentration (or absolute number of molecules) of the analyte bound to the bead. | 03-15-2012 |
20120065091 | DIRECT MULTIPLEX CHARACTERIZATION OF GENOMIC DNA - The invention is directed to novel methods of multiplexing nucleic acid reactions, including amplification, detection and genotyping. The invention relies on the use of precircle probes that are circularized in the presence of the corresponding target nucleic acids, cleaved, and then amplified. | 03-15-2012 |
20120065092 | FUSION ANALYTE CYTOMETRIC BEAD ASSAY, AND SYSTEMS AND KITS FOR PERFORMING THE SAME - Methods of detecting a fusion analyte in a sample are provided. Aspects of the methods include preparing a reaction mixture that includes a sample and a microparticle comprising a capture ligand for the fusion analyte, as well as first and second fluorescently labeled detector molecules. One of the first and second detector molecules specifically binds to the fusion analyte and the other specifically binds to a parent molecule thereof. Also provided are systems and kits configured for use in practicing methods of the invention. | 03-15-2012 |
20120065093 | Methods and Apparatus for Detecting Molecular Interactions Using FET Arrays - Methods and apparatuses relating to large scale FET arrays for analyte detection and measurement are provided. ChemFET (e.g., ISFET) arrays may be fabricated using conventional CMOS processing techniques based on improved FET pixel and array designs that increase measurement sensitivity and accuracy, and at the same time facilitate significantly small pixel sizes and dense arrays. Improved array control techniques provide for rapid data acquisition from large and dense arrays. Such arrays may be employed to detect a presence and/or concentration changes of various analyte types in a wide variety of chemical and/or biological processes. | 03-15-2012 |
20120065094 | METHODS AND KITS FOR DIAGNOSING OSTEOARTHRITIS AND PREDICTING PROGRESSION - This disclosure relates to methods and kits for diagnosing osteoarthritis and for determining the progression of osteoarthritis in a subject. | 03-15-2012 |
20120065095 | MARKERS OF RENAL TRANSPLANT REJECTION AND RENAL DAMAGE - The present invention relates to methods of detecting renal transplant rejection and other forms of renal damage. Protein markers or renal damage are provided, along with assays for detecting said markers. Also provided are methods for identifying markers of renal damage. | 03-15-2012 |
20120065096 | GENOTYPING TOOL FOR IMPROVING THE PROGNOSTIC AND CLINICAL MANAGEMENT OF MS PATIENTS - The invention relates to methods of evaluating MS severity based on analysis of single nucleotide polymorphisms (SNPs) and to products and kits for use in such methods. The methods include a method of assessing a multiple sclerosis disease severity phenotype in a human subject having multiple sclerosis, by determining the genotype of the subject at one or more positions of single nucleotide polymorphism (SNP) selected from: rs | 03-15-2012 |
20120065097 | METHOD OF DIAGNOSING POOR SURVIVAL PROGNOSIS COLON CANCER USING miR-106a - The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis. | 03-15-2012 |
20120065098 | METHOD OF PREDICTING CHEMOTHERAPY EFFECTIVENESS IN COLON ADENOCARCINOMA PATIENTS, USING MIR-21 - The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis. | 03-15-2012 |
20120065099 | AUTOMATED ANALYSIS OF MULTIPLEXED PROBE-TARGET INTERACTION PATTERNS: PATTERN MATCHING AND ALLELE IDENTIFICATION - Methods and algorithms for automated allele assignments within an integrated software environment are provided. These methods and algorithms offer a multiplicity of functionalities including: data management; system configuration including user authorization, training set analysis and probe masking; pattern analysis including string matching and probe flipping; and interactive redaction of data. The methods and algorithms further include methods of setting thresholds, refining thresholds, and probe masking of signals produced by probes which do not contribute significantly to discriminating among alleles. | 03-15-2012 |
20120065100 | PHOSPHODIESTERASE 9A AS PROSTATE CANCER MARKER - The present invention relates to phosphodiesterase 9A (PDE9A) for use as a marker for prostate cancer, and the use of PDE9A as a marker for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a corresponding method and immunoassay, a method for diagnosing, monitoring or prognosticating hormone-resistant prostate cancer vs. hormone-sensitive prostate cancer, a corresponding immunoassay, a method of data acquisition, an immunoassay for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a method of identifying an individual for eligibility for prostate cancer therapy, an immunoassay for stratifying an individual or cohort of individuals with a prostate cancer disease, an immunoassay for stratifying an individual with prostate cancer. The present invention further envisages pharmaceutical compositions and their use for the treatment of prostate cancer, in particular hormone-resistant prostate cancer. | 03-15-2012 |
20120071334 | Methods And Marker Combinations For Screening For Predisposition To Lung Cancer - The present invention relates to rapid, sensitive methods for determining whether a subject has or is at risk of developing lung cancer based on certain combinations of biomarkers, or biomarkers and biometric parameters. The methods consist of: a) quantifying in a test sample obtained from a subject, the amount of two or more biomarkers in a panel, the panel comprising at least one antibody and at least one antigen: b) comparing the amount of each biomarker quantified in the panel to a predetermined cutoff for said biomarker and assigning a score for each biomarker based on said comparison: c) combining the assigned score for each biomarker quantified in step b to obtain a total score for said subject: d) comparing the total score in step c with a predetermined total score and e) determining whether said subject has a risk of lung cancer based on the comparison in step d. | 03-22-2012 |
20120071335 | Method for Identification, Selection and Analysis of Tumour Cells - The present invention relates to a method for the diagnosis of tumoural conditions and/or of the corresponding state of advance, wherein a specimen of an organic fluid taken from the patient and having a high probability of containing at least one circulating tumour cell (CTC) or a disseminated tumour cell (CTD) is enriched in a population of CTCs or CTDs. According to the invention, at least one type of CTCs or CTDs is isolated by selecting individually single cells in a microfluidic device so to constitute a diagnostic specimen having a purity of at least 90%. On the specimen thus obtained there is subsequently performed a molecular analysis such as to highlight a characteristic thereof suited to enabling diagnosis. | 03-22-2012 |
20120071336 | Antibiotic resistance profile for Neisseria gonorrhoeae and use of same in diagnosis and treatment of gonorrhea - The present invention relates to an antibiotic resistance profile for | 03-22-2012 |
20120071337 | METHODS - The invention provides a method for aiding the diagnosis or prognostic monitoring of Alzheimer's disease in a subject, said method comprising; providing a sample of blood obtained from said patient; assaying the amount of gelsolin present in said sample; comparing the amount of gelsolin present in said sample to a reference amount of gelsolin present in a sample from a healthy subject, wherein detection of a gelsolin level in the sample from said patient which is lower than the gelsolin level in the reference sample indicates an increased likelihood of Alzheimer's disease in said patient. Other markers are C1 protease inhibitor and ceruloplasmin. Both blood samples and tissue samples have been investigated. | 03-22-2012 |
20120071338 | POLYMERIZATION-BASED AMPLIFICATION FOR IMMUNOSTAINING AND BIODETECTION - The invention provides polymerization-based signal amplification methods in which labeling moieties are incorporated into a polymer mass or film formed at a biorecognition site. When the labeling moieties are fluorescent, the invention can be used to provide an immunofluorescent staining method which is non-enzymatic. The invention also provides kits useful for the immunofluorescent staining methods of the invention. | 03-22-2012 |
20120071339 | BIOMARKERS - The invention relates to a method of diagnosing or monitoring multiple sclerosis. | 03-22-2012 |
20120071340 | BIOMARKERS - The invention relates to a method of diagnosing or monitoring major depressive disorder. | 03-22-2012 |
20120071341 | NOVEL METHODS FOR PREDICITING AND TREATING TUMORS RESISTANT TO DRUG, IMMUNOTHERAPY AND RADIATION - The present invention relates to methods for prognosis, diagnosis, and treatment of malignant tumors that were treatment resistant. The present invention provides methods of prognosis and diagnosis of multidrug resistant tumors through detection of the expression levels of nuclear co-repressor 2 (“N-CoR2”), histone deacetylases 3 (“HDAC3”), and their associated gene expression biomarkers. The present invention also provides methods of sensitizing tumors to anti-tumor therapeutics by disrupting HDAC3 activation, abrogating the N-CoR2-HDAC3 interaction, inhibiting the activity of either protein, or by downregulating the expression of either protein. | 03-22-2012 |
20120071342 | SYSTEM AND METHOD FOR DETECTING MULTIPLE MOLECULES IN ONE ASSAY - A rapid diagnostic system that delivers a panel of serologic assay results using a small amount of blood, serum, or plasma is described. The system includes a disposable cartridge and a reader instrument, based on planar waveguide imaging technology. The cartridge incorporates a microarray of recombinant antigens and antibody controls in a fluidic channel, providing multiple parallel fluorescence assay results for a single sample. | 03-22-2012 |
20120071343 | BIOMARKERS FOR DIFFERENTIATING MELANOMA FROM BENIGN NEVUS IN THE SKIN - Disclosed is a method for diagnosing melanoma in a human subject, as well as a method for providing a prognosis to a human subject who is at risk of developing melanoma recurrence, and a method for determining the stage of melanoma in a human subject, comprising the step of determining the level of expression of phosphatase and actin regulator 1 (PHACTR1) gene, or fragments thereof, either alone or in combination with the level of expression of secreted integrin-binding phosphoprotein (SPP1), preferentially expressed antigen in melanoma (PRAME), growth differentiation factor 15 (GDF 15), and chemokine C-X-C motif ligand 10 (CXCL10) genes. Further, the invention relates to a diagnostic kit, comprising at least one substance for detection of the expression of PHACTR1, or fragments thereof, either alone or in combination with the detection of SPP1, PRAME, GDF15, and CXCL10, for the diagnosis or prognosis of melanoma. | 03-22-2012 |
20120071344 | COMPOSITIONS AND METHODS FOR IDENTIFYING ENZYME AND TRANSPORT PROTEIN INHIBITORS - The invention is directed to compositions, e.g., cell-based and multiplexed platforms, to screen for small molecule drugs that inhibit enzymes such as proteases, e.g., viral proteases, e.g., HIV proteases; and methods for making and using these compositions. The invention provides compositions and methods for identifying compositions, e.g., drug molecules, that can inhibit proteases, e.g., viral proteases such as HIV proteases. In alternative embodiments, the invention provides cell-based platforms or assays to screen for compositions, e.g., small molecules or drugs, that inhibit or modify the activity of enzymes such as calcium-dependent protein convertases involved in HIV envelope protein processing, including cleavage of the HIV gp160 envelope precursor, resulting in gp120 and gp41 envelope products. In one embodiment, the invention provides a cell-based or multiplexed platform for monitoring the activity of enzymes, e.g., proteases such as viral proteases. | 03-22-2012 |
20120071345 | SINGLE COLUMN IMMUNOLOGICAL TEST ELEMENTS - A plurality of individual single column test elements are provided for use in a clinical testing apparatus. Each test element is defined by a single test column that includes a quantity of a test material, such as gel material or a bead matrix, including a cover strip used to access the contents of the test column. Individual test elements can be stored, retained and dispensed for testing patient samples. | 03-22-2012 |
20120071346 | GENE-BASED ALGORITHMIC CANCER PROGNOSIS - The present invention is related to the methods and systems for prognosis determination in tumor samples, by measuring gene expression in a tumor sample and applying a gene-expression grade index (GGI) or a relapse score (RS) to yield a number c risk score. | 03-22-2012 |
20120071347 | COMPOSITIONS AND METHODS FOR MONITORING AND DETECTING CANCEROUS CONDITIONS - A method for monitoring or detecting a prostate condition in a subject comprises determining Engrailed-2 (EN2) gene, Paired Box 2 (PAX2) gene, and/or β defensin-1 (DEFB1) gene expression levels in a biological sample from the subject. The expression levels of EN2, PAX2 and/or DEFB1 gene are correlated with cancerous, pre-cancerous, or non-cancerous prostate conditions. | 03-22-2012 |
20120077686 | DIAGNOSIS OF MULTIPLE SCLEROSIS - The present invention relates to methods and kits for diagnosing multiple sclerosis (MS) in a subject. Particularly, the present invention relates to methods and kits for diagnosing a subtype of MS in a subject, the subtype selected from relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS) and a pathologic sub-type of MS lesions selected from Pattern I and Pattern II MS lesion. | 03-29-2012 |
20120077687 | PROGNOSTIC AND PREDICTIVE GENE SIGNATURE FOR NON-SMALL CELL LUNG CANCER AND ADJUVANT CHEMOTHERAPY - The application provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups and for determining the benefit of adjuvant chemotherapy by way of a multigene signature. The application also includes kits and computer products for use in the methods of the application. | 03-29-2012 |
20120077688 | Global Proteomic Screening Of Random Bead Arrays Using Mass Spectrometry Imaging - Methods for proteomic screening on random protein-bead arrays by mass spec is described. Photocleavable mass tags are utilized to code a protein library (bait molecules) displayed on beads randomly arrayed in an array substrate. A library of probes (prey) can be mixed with the protein-bead array to query the array. Because mass spec can detect multiple mass tags, it is possible to rapidly identify all of the interactions resulting from this mixing. | 03-29-2012 |
20120077689 | Compartment-Specific Non-HLA Targets for Diagnosis and Prediction of Graft Outcome - Methods and composition are provided for diagnosing or predicting the status or the outcome of a graft transplant. In some embodiments, the presence or absence of one or more proteins recognizing a non-HLA/non ABO antigen is determined. The obtained result is then employed to diagnose or predict the status or outcome of the graft transplant. Also provided are compositions, systems and kits that find use in practicing the subject methods. | 03-29-2012 |
20120077690 | BIOMARKERS OF RENAL INJURY - This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring hyaluronic acid, death receptor 5, and/or transforming growth factor β1 can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury. | 03-29-2012 |
20120077691 | METHOD OF ANALYZING BINDING INTERACTIONS - The invention is directed to methods for obtaining statistically significant information about how structural elements of proteins, e.g. position and identity of amino acid residues in binding domains, relate to functional properties of interest, such as binding affinity, specificity, and the like. In some embodiments, such information is collected by reacting under binding conditions a focused library of candidate nucleic acid-encoded binding compounds with a ligand, so that complexes form between the ligand and a portion of the candidate binding compounds (“binders”). Samples of binders and non-binders arc then decoded by high throughput nucleic acid sequencing to give statistically significant data about the binding properties of substantially all of the candidate binding compounds, permitting them to be ranked by their respective affinities or dissociation constants. A reference compound, such as a pre-existing antibody, may be included in the reaction to identify candidates with similar or improved binding characteristics that have additional desirable characteristics, such as higher solubility, reduced immunogenicity, higher stability, or the like. | 03-29-2012 |
20120077692 | MULTIPLEX Q-PCR ARRAYS - This invention provides methods and systems for measuring the concentration of multiple nucleic acid sequences in a sample. The nucleic acid sequences in the sample are simultaneously amplified, for example, using polymerase chain reaction (PCR) in the presence of an array of nucleic acid probes. The amount of amplicon corresponding to the multiple nucleic acid sequences can be measured in real-time during or after each cycle using a real-time microarray. The measured amount of amplicon produced can be used to determine the original amount of the nucleic acid sequences in the sample. | 03-29-2012 |
20120077693 | METHOD AND KIT FOR ESTABLISHING AN IN VITRO PROGNOSIS ON A PATIENT EXHIBITING SIRS - A method and a kit for establishing an in vitro prognosis on a patient exhibiting SIRS, the method comprising: (i) measuring the level of expression of the CX3CR1 gene in vitro from the biological material of a patient sample by bringing into contact said sample with a specific reagent of the CX3CR1 gene; and (ii) comparing the expression level of the CX3CR1 gene of the patient to a predetermined expression threshold; wherein (iii) if the expression level of the CX3CR1 gene of the patient is less than the predetermined expression threshold, the survival prognosis of the patient is poor, and if the expression level of the CX3CR1 gene of the patient is greater than the predetermined expression threshold, the survival prognosis of the patient is good. | 03-29-2012 |
20120077694 | TARGETS IN BREAST CANCER FOR PROGNOSIS OR THERAPY - Cancer markers are developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genome wide analyses of genome copy number and gene expression in breast cancer revealed 66 genes in the human chromosomal regions, 8p11, 11q13, 17q12, and 20q13 that were amplified. Diagnosis and assessment of amplification levels of genes shown to be amplified are useful in prediction of patient outcome of a of patient's response and drug resistance in breast cancer. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically breast cancer. Inhibitors of these genes will be useful therapies for treatment of these non-responsive cancers. | 03-29-2012 |
20120077695 | Mesothelioma Biomarkers and Uses Thereof - The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of cancer. In one aspect, methods are provided for diagnosing mesothelioma where the methods include detecting, in a biological sample, at least one biomarker value corresponding to at least one biomarker selected from the biomarkers provided in Table 1, wherein an individual is classified as having mesothelioma, or the likelihood of an individual having mesothelioma is determined, based on the at least one biomarker value. In another aspect, methods are provided for diagnosing cancer generally where the methods include detecting, in a biological sample at least one biomarker value corresponding to at least one biomarker selected from the biomarkers provided in Table 17, wherein an individual is classified as having cancer generally, or the likelihood of an individual having cancer is determined, based on the at least one biomarker value. | 03-29-2012 |
20120077696 | SOLUBLE HLA COMPLEXES FOR USE IN DISEASE DIAGNOSIS - The invention relates to diagnostic kits, methods of diagnosing, prognosing and staging diseases, and immunogenic compositions. The invention is based on the detection of peptides associated with circulating soluble HLA complexes in particular disease states, including malignant diseases. | 03-29-2012 |
20120077697 | Methods for Selecting Oocytes and Competent Embryos with High Potential for Pregnancy Outcome - The present invention relates to a method for selecting a competent oocyte or a competent embryo. | 03-29-2012 |
20120077698 | High Throughput Assay for Cancer Cell Growth Inhibition - A high-throughput, anchorage-independent assay is described, which screens compounds for inhibition of cancer cell growth. The assay utilizes a three-dimensional matrix or semi-solid media transfected with the subject compound, and enables live colony growth determination and imaging. | 03-29-2012 |
20120077699 | METHOD OF DIAGNOSING POOR SURVIVAL PROGNOSIS COLON CANCER USING miR-103-2 - The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis. | 03-29-2012 |
20120077700 | METHOD OF DIAGNOSING POOR SURVIVAL PROGNOSIS COLON CANCER USING miR-29a - The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis. | 03-29-2012 |
20120077701 | Identification of Molecular Sequence Signatures and Methods Involving the Same - Novel means and methods for analyzing hybridization data derived from hybridization assays between a target nucleic acid and differently sequenced polynucleotide probes involve selecting probe sets that define reference sequences for sequence signatures and deriving useful data about the nature of the target nucleic acid molecule based on its hybridization to the probes. The methods are useful for determining whether the target contains a nucleic acid or polypeptide sequence signature, whether the target encodes a member of a gene family, or whether the target is derived from one of any number of genes. | 03-29-2012 |
20120077702 | METHODS AND KITS FOR DETECTING PROSTATE CANCER BIOMARKERS - Provided herein are novel autoantibody biomarkers, and panels for detecting autoantibody biomarkers for prostate cancer, and methods and kits for detecting these biomarkers in the serum of individuals suspected of having prostate cancer. | 03-29-2012 |
20120077703 | Expression of MBNL2 and Other Genes Associated with Bladder Cancer Progression - Disclosed are methods for predicting the risk of bladder cancer progression, including death from bladder cancer by determining gene expression levels of FABP4 and MBNL2 or other markers where increased levels correlate with lack of progression of the subject's bladder cancer, and decreased levels correlate with progression or death from bladder cancer, and/or determining gene expression levels of COL4A1, UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and/or CDC25B or other markers where increased levels correlate with progression of the subject's bladder cancer or death from it, and decreased levels correlate with lack of progression of bladder cancer. | 03-29-2012 |
20120077704 | METHOD FOR SCREENING COMPOUNDS FOR THE TREATMENT OR PREVENTION OF COLON CANCER - The invention is in the field of molecular medicine, more in particular in the field of identifying new compounds for the treatment or prevention of colorectal cancer. The invention provides a method for the screening and/or identification of compounds that are capable of preventing or ameliorating the adverse effects of reactive oxygen species on eukaryotic cells. More in particular, the invention provides a method for the identification of an active therapeutic compound for preventing or ameliorating the adverse effects of reactive oxygen species on eukaryotic cells comprising the steps of: providing an assay wherein the expression of the WNT pathway in Caco cells can be determined under the influence of a reactive oxygen species, providing a candidate therapeutic compound, determining the ability of said therapeutic compound to normalize the expression of said WNT pathway in the presence or absence of said oxidant. | 03-29-2012 |
20120083419 | Method and compositions for inhibiting tumorigenesis - The present invention relates to compounds, small interfering RNAs and compositions and methods of inhibiting tumorigenesis and methods of inhibiting tumor cell growth and proliferation using agents that inhibit the hedgehog and Gli signaling pathway, including agents that inhibit GLI synthesis and/or function. The present invention also relates to particular biomarkers that can be used in the diagnosis and prognosis of prostate cancer. Methods of treating cancer, including prostate cancer are also provided using small organic compounds, siRNAs and blocking antibodies that inhibit or block the SHH/GLI pathway. | 04-05-2012 |
20120083420 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES - The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases. | 04-05-2012 |
20120083422 | Glioblastoma Biomarkers, and Methods and Compositions - Glioblastoma multiforme biomarkers, methods, and compositions are provided. Methods of selecting a treatment for a patient with a brain neoplasm, including Glioblastoma multiforme, are provided. Methods of treating a patient at risk for Glioblastoma multiforme are provided. | 04-05-2012 |
20120083423 | Biomarkers, Methods and Kits for the Diagnosis of Rheumatoid Arthritis - The present invention relates to peptides biomarkers that are specifically recognized by autoantibodies present in the sera of patients with Rheumatoid Arthritis (RA). More specifically, the invention provides epitopes of PAD4, of BRAF, and of calpastatin as well as methods and kits for using these sequences for the diagnosis of RA, in particular for the diagnosis of RA in CCP-negative subjects. | 04-05-2012 |
20120083424 | Expression of UBE2C and Other Genes Associated with Bladder Cancer Progression - Disclosed are methods for predicting the risk of bladder cancer progression, including death from bladder cancer by determining gene expression levels of FABP4 and MBNL2 or other markers where increased levels correlate with lack of progression of the subject's bladder cancer, and decreased levels correlate with progression or death from bladder cancer, and/or determining gene expression levels of COL4A1, UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and/or CDC25B or other markers where increased levels correlate with progression of the subject's bladder cancer or death from it, and decreased levels correlate with lack of progression of bladder cancer. | 04-05-2012 |
20120088680 | REAL-TIME PCR ASSAYS FOR RAPID DETECTION AND DIFFERENTIATION OF THE CLOSTRIDIUM BOTULINUM TOXIN GENES A, B, E, AND F - Provided herein is a method for detecting the presence or absence of at least one of | 04-12-2012 |
20120088681 | METHODS AND KITS USED IN CLASSIFYING ADRENOCORTICAL CARCINOMA - The invention encompasses methods and kits used to detect biomarkers that may be used to predict disease outcome in adrenocortical carcinoma patients. | 04-12-2012 |
20120088682 | Methods and Apparatus for Detecting Molecular Interactions Using FET Arrays - Methods and apparatuses relating to large scale FET arrays for analyte detection and measurement are provided. ChemFET (e.g., ISFET) arrays may be fabricated using conventional CMOS processing techniques based on improved FET pixel and array designs that increase measurement sensitivity and accuracy, and at the same time facilitate significantly small pixel sizes and dense arrays. Improved array control techniques provide for rapid data acquisition from large and dense arrays. Such arrays may be employed to detect a presence and/or concentration changes of various analyte types in a wide variety of chemical and/or biological processes. | 04-12-2012 |
20120088683 | Detection of Cancer Cells in Body Fluids - A method of detecting circulating melanoma or carcinoma cells in a subject. The method comprises obtaining a body fluid from a subject and detecting the expression of a panel of genes in the body fluid, wherein the expression of the panel of genes indicates the presence of circulating melanoma or carcinoma cells in the subject. Genes useful for detecting melanoma cells includes GalNAc-T, MAGE-A3, MART-1, PAX-3, and TRP-2; genes useful for detecting carcinoma cells include C-Met, MAGE-A3, Stanniocalcin-1, Stanniocalcin-2, mammaglobin, HSP27, GalNAc-T, CK20, and β-HCG. Also disclosed are kits containing agents for detecting the expression of these genes. | 04-12-2012 |
20120088684 | MULTIPLEX NUCLEIC ACID DETECTION METHODS AND SYSTEMS - The present invention relates to methods and systems for single molecule based clonal amplification and subsequent detection of nucleic acid molecules, and particularly to the determination of SNPs, mutations, and to the diagnosis of diseases associated with the changes of these nucleic acid molecules. | 04-12-2012 |
20120088685 | DIAGNOSIS OF NEUROPSYCHIATRIC AND BEHAVIOURAL DISORDERS - This invention provides a method of identifying GAS infection as the cause of a neuropsychiatric or behavioural disorder in a patient, or of identifying a patient at risk of developing a neuropsychiatric or behavioural disorder caused by GAS infection. This invention also provides associated protein arrays. | 04-12-2012 |
20120088686 | METHODS OF ARRAY DATA WAVE CORRECTION - The invention relates to methods of correcting auto-correlated wave artifacts of array signal data based on the GC content of the nucleic acids under consideration without affecting signal variations due to copy number variations. | 04-12-2012 |
20120088687 | MicroRNAs (miRNA) as Biomarkers for the Identification of Familial and Non-Familial Colorectal Cancer - A technique for the analysis of global miRNA signatures including a larger panel of miRNAs in various groups of well-characterized colorectal cancers (CRCs) is described in the instant invention. The results presented herein provide a large list of miRNAs that are dysregulated in CRC compared to the normal colonic tissue, and, more importantly, the present invention shows for the first time that Lynch syndrome and sporadic MSI tumors exhibit a different miRNA signature that distinguishes them. | 04-12-2012 |
20120088688 | IN VITRO ASSAY FOR IDENTIFICATION OF ALLERGENIC PROTEINS - In vitro evaluation of a potentially allergenic or tissue irritating substance is conducted by cultivating test cells in the presence of the substance and the presence of up regulated genes chosen from G1P2, OASL, IFIT1, TRIM22, IFI44L, MXI, RSAD2, IFIT3, IFITM1, IFIT2, SPR, GNB2, XK, IFITM3, C 33.28 HERV-H protein mRNA, GPR15, MT1G, MT1B, MT1A, ADFP, IL8, MT1E, MT1F, MT1H, SLC30A1, SERPINB2, CD83, and TncRNA, or expression products from them, are measured. The expression products from one or more of the genes may be used for in vitro analysis of allergy or tissue irritation. A probe comprising at least three nucleic acids, preferably 3-40, especially 5-15, chosen from RNA complementary to the RNA corresponding to any of the genes may be used for in vitro analysis of allergy or tissue irritation. Further, a reagent kit comprising one or more probes that recognize products produced during the expression of any the genes is disclosed. | 04-12-2012 |
20120088689 | METHOD OF DIAGNOSING RENAL DISORDERS - The invention refers to an in vitro method of determining the risk of renal disorders, in a patient, by measuring a VCAN parameter, characterized in that at least one of the isoforms V0 and V1 are specifically determined in a sample of said patient and compared to a reference level. | 04-12-2012 |
20120088690 | METHOD FOR DETECTING A POSITION OF PROBE ON MICROARRAY - A method for detecting hybridization between a probe polynucleotide and a target polynucleotide on a microarray is presented. The method may be used to determine the accuracy of hybridization and possible causes of inaccuracy, such as insufficient washing or deterioration of the microarray. | 04-12-2012 |
20120094852 | MAGNETIC NANOPARTICLE DETECTION ACROSS A MEMBRANE - Magnetic nanoparticles are detected across a thin membrane that separates the nanoparticles from a magnetic sensor. The technique can be used in a medical context, in which an analyte of interest (present in a test fluid, such as blood) is attached to the membrane. Other compounds are in turn bound to the analyte, with one of these compounds including a magnetic nanoparticle that is then detected by the sensor. In this way, the analyte is detected by detecting the magnetic nanoparticle. By counting the number of magnetic nanoparticles, the concentration of the analyte in the test fluid can be determined. | 04-19-2012 |
20120094853 | COMPOSITIONS AND METHODS FOR PREDICTION OF DRUG SENSITIVITY, RESISTANCE, AND DISEASE PROGRESSION - The present invention is based on the discovery that functional stratification and/or signaling profiles can be used for diagnosing disease status, determining drug resistance or sensitivity of cancer cells, monitoring a disease or responsiveness to a therapeutic agent, and/or predicting a therapeutic outcome for a subject. Provided herein are assays for diagnosis and/or prognosis of diseases in patients. Also provided are compositions and methods that evaluate the resistance or sensitivity of diseases to targeted therapeutic agents prior to initiation of the therapeutic regimen and to monitor the therapeutic effects of the therapeutic regimen. Also provided are methods for determining the difference between a basal level or state of a molecule in a sample and the level or state of the molecule after stimulation of a portion of the live sample with a modulator ex vivo, wherein the difference is expressed as a value which is indicative of the presence, absence or risk of having a disease. The methods of the invention may also be used for predicting the effect of an agent on the disease and monitoring the course of a subject's therapy. | 04-19-2012 |
20120094854 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PSYCHOTIC DISORDERS THROUGH THE IDENTIFICATION OF THE OLANZAPINE POOR RESPONSE PREDICTOR GENE SIGNATURE - Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a OPRP genetic signature are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the genetic signature. | 04-19-2012 |
20120094855 | MEANS AND METHODS FOR DIAGNOSING PREDISPOSITION FOR TREATMENT EMERGENT SUICIDAL IDEATION (TESI) - This invention relates to a method of diagnosing a predisposition for or the occurrence of treatment emergent suicidal ideation in an individual, the method comprising determining the presence or absence of one, more or all SNPs selected from the SNPs defined by SEQ ID NOs: 8, 18, 19, 47, 50, 52, 56, 64, 73, 86, 87, 92, 94, 95, 97 and 99. | 04-19-2012 |
20120094856 | METHOD FOR DETECTING AN ANALYTE IN A SAMPLE BY MULTIPLEXING FRET ANALYSIS AND KIT - The invention concerns a method for detecting an analyte in a sample by multiplexing FRET (Förster Resonance Energy Transfer) analysis, the method comprising the following steps: providing a sample containing an energy transfer donor, several spectrally different quantum dot species, and an analyte, wherein the analyte is configured to mediate an energy transfer within a first energy transfer donor-acceptor pair provided by the energy transfer donor and a first quantum dot specie, the energy transfer donor is configured to act as energy transfer donor in the first energy transfer donor-acceptor pair, and the first quantum dot specie is configured to act as energy transfer acceptor in the first energy transfer donor-acceptor pair, irradiating excitation light from an excitation light source to the sample, in the first energy transfer donor-acceptor pair, transferring excitation energy from the energy transfer donor excited by the excitation light to the first quantum dot specie, the energy transfer being mediated by the analyte, and detecting emission light emitted by the first quantum dot specie after receiving the excitation energy. | 04-19-2012 |
20120094857 | Methods of Subclassification of Ductal Carcinoma of the Breast - Provided herein are methods of determining the aggressiveness or indolence of a ductal carcinoma in situ lesion. Also provided are methods of developing treatment plans for subjects with a ductal carcinoma in situ lesion based on the aggressiveness of the lesion. | 04-19-2012 |
20120094858 | BIOMARKERS - The invention relates to a method of diagnosing or monitoring bipolar disorders, in particular bipolar I and bipolar II disorders, such as manic psychosis. | 04-19-2012 |
20120094859 | METHODS FOR DETECTION OF DEPRESSIVE DISORDERS - The present invention relates generally to the detection or diagnosis of depressive disorders, and provides methods and compositions useful for this purpose. In particular, the present invention provides biomarkers for the detection or diagnosis of major depressive disorder, and methods of use thereof. | 04-19-2012 |
20120094860 | Compositions, Antibodies, Asthma Diagnosis Methods, and Methods for Preparing Antibodies - Methods for preparing an antibody are provided with the method including incorporating 3-bromo-4-hydroxy-benzoic acid into a protein to form an antigen, immunizing a mammalian host with the antigen, and recovering an antibody having an affinity for the antigen from the host. Antibodies having a binding affinity for a monohalotyrosine are provided as well as composition comprising an antibody bound with monohalotyrosine. Compositions comprising a protein having a 3-bromo-4-hydroxy-benzoic acid moiety are also provided. Methods for evaluating the severity of asthma are provide with the methods including analyzing sputum of a patient using an antibody having a binding affinity for monohalotyrosine, and measuring the amount of antibody bound to protein. Methods for determining eosinophil activity in bodily fluid are also provided with the methods including exposing bodily fluid to an antibody having a binding affinity for monohalotyrosine, and measuring the amount of bound antibody to determine the eosinophil activity. | 04-19-2012 |
20120094861 | Compositions and Methods for Determining Immune Status - The present invention provides compositions and methods for identifying molecules in samples that bind to molecules associated with pathogenic agents (e.g., infectious agents). In certain aspects, the invention may be used to identify individuals that have been exposed to one or more pathogenic agent or have generated antibodies in response to one or more pathogenic agent. In other aspects, the invention is directed to the identification of molecules of one or more pathogenic agent that may be used to generate immune responses in other individuals. | 04-19-2012 |
20120094862 | CLASS II HUMAN HISTONE DEACETYLASES, AND USES RELATED THERETO - The invention provides histone deacetylase class II nucleic acids and polypeptides, methods and reagents for their use, and related compounds including small molecule libraries containing class II histone deacetylase inhibitors. | 04-19-2012 |
20120094863 | BIOMARKERS AND METHODS FOR DETERMINING EFFICACY OF ANTI-EGFR ANTIBODIES IN CANCER THERAPY - The invention relates to biomarkers based on gene expression products and methods for determining the efficacy of anti-EGFR antibodies in the treatment of EGFR expressing cancer. The invention is further related to the prediction of sensitivity or resistance of a patient suffering from EGFR expressing cancer to the treatment of said patient with a specific anti-EGFR antibody. The invention is preferably related to the identification of respective biomarkers that allow a better prediction of the clinical outcome of the treatment with anti-EGFR antibodies in patients with KRAS wild-type tumors. In this context, the invention especially relates to anti-EFGR antibody c225/cetuximab (Erbitux®) and its use in patients suffering from colorectal Cancer (CRC). | 04-19-2012 |
20120094864 | EXTRACELLULAR ALLOSTERIC INHIBITOR BINDING DOMAIN FROM A TYROSINE KINASE RECEPTOR - The present invention relates to an extracellular binding domain for an allosteric inhibitor, whereby said binding domain is derived from a single membrane span tyrosine kinase receptor. More specifically, the invention relates to an extracellular domain derived from a Fibroblast Growth Factor Receptor (FGFR). It further relates to the use of this domain for the identification of similar domains in the extracellular part of other tyrosine kinase receptors, and to a screening method for identification of a small compound allosteric inhibitor. | 04-19-2012 |
20120101000 | HIGH COMPLEXITY MAMMALIAN DISPLAY LIBRARY AND METHODS OF SCREENING - Provided herein are methods of isolating a polynucleotide encoding a polypeptide such as an antibody with a desired property by way of mammalian display library screening and methods of generating a library of polynucleotides encoding polypeptides such as antibodies, wherein the polynucleotides collectively encode at least 109 different polypeptides. Also provided are kits for carry out the methods described herein, polynucleotides isolated by methods described herein, libraries encoding the antibody reservoir of different species including human, mouse, rabbit, and polypeptides encoded by the polynucleotides. | 04-26-2012 |
20120101001 | METHOD TO ASSESS HUMAN ALLOGRAFT STATUS FROM MICRORNA EXPRESSION LEVELS - The invention relates to, among other things, a method for assessing risk of organ rejection in a patient having a transplanted organ. The method includes measuring an amount of expression of a small non-coding marker RNA in a biological sample from the patient. The method further includes comparing the measured amount of expression of the small non-coding marker RNA in the patient to a reference amount of expression of the small non-coding marker RNA. In another aspect, the invention relates to kits for assessing risk of organ rejection in a patient having a transplanted organ. | 04-26-2012 |
20120101002 | Lung Cancer Biomarkers and Uses Thereof - The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of non-small cell lung cancer and general cancer. In one aspect, methods are provided for diagnosing non-small cell lung cancer, where the methods include detecting, in a sample, at least one biomarker value corresponding to at least one biomarker selected from the biomarkers provided in Table 1, wherein an individual is classified as having lung cancer, or the likelihood of having lung cancer is determined, based on the at least one biomarker value. In another aspect, methods are provided for diagnosing cancer, where the methods include detecting, in a sample, at least one biomarker value corresponding to at least one biomarker selected from the biomarkers provided in Table 19, wherein an individual is classified as having cancer, or the likelihood of having cancer is determined, based on the at least one biomarker value. | 04-26-2012 |
20120101003 | METHODS FOR THE DIAGNOSIS OR PROGNOSIS OF COLORECTAL CANCER - Autoantibodies to different proteins useful as biomarkers for the diagnosis, prognosis or monitoring of the progress of a colorectal cancer (CRC) are described. | 04-26-2012 |
20120101004 | FICOLIN-3 ASSAY - The present invention relates to methods for detecting Ficolin-3 dependent activation of the lectin pathway of complement, methods for identifying abnormalities in Ficolin-3, and methods for screening for deficiencies/and or identifying abnormalities in any downstream components of the Ficolin-3 dependent activation of the lectin pathway of 5 complement using an acetylated Ficolin-3 ligand, said methods generally comprising the steps of: (a) providing a sample of blood, serum, plasma, another body fluid or an extract thereof; (b) (optionally) preventing in the sample activation of the classical pathway and/or the alternative pathway and/or any non-Ficolin-3 mediated activation of the lectin pathway; (c) acetylating a molecule; (d) contacting said acetylated molecule 10 with said sample, in conditions that permit specific binding of Ficolin-3 to said acetylated molecule, and, (e) detecting and quantifying specific binding of the Ficolin-3 to said acetylated molecule, (f) determining in the sample complement activation and/or deposition by the detection of a C2, C3, C4 and/or a C5 cleavage product and/or by detecting any of the terminal complement complex components C6, C7, C8 or C9 or 15 the C5b-9 terminal complement complex as such. The present invention also provides assays and kits comprising the methods of the invention. | 04-26-2012 |
20120101005 | METHODS FOR PREDICTING THE TOXICITY OF A CHEMICAL - The invention relates to methods and kits for predicting the effect of a chemical on a developmental pathway. In particular, the invention relates to methods and kits for predicting the toxicity of a chemical on human developmental pathways. The methods and kits of the invention can be used for predicting changes in a cellular biomap or a developmental pathway during human foetal development. | 04-26-2012 |
20120108450 | Receptors Useful for Gas Phase Chemical Sensing - The invention provides for a receptor, capable of binding to a target molecule, linked to a hygroscopic polymer or hydrogel; and the use of this receptor in a device for detecting the target molecule in a gaseous and/or liquid phase. The invention also provides for a method for detecting the presence of a target molecule in the gas phase using the device. In particular, the receptor can be a peptide capable of binding a 2,4,6-trinitrotoluene (TNT) or 2,4-dinitrotoluene (DNT). | 05-03-2012 |
20120108451 | METHODS AND APPARATUS FOR NANOPARTICLE-ASSISTED NUCLEIC ACID HYBRIDIZATION AND MICROARRAY ANALYSIS - The invention provides nucleic acid hybridization methods for detecting target nucleic acid sequences wherein complexes comprising nanoparticles non-covalently associated with single-stranded tartlet nucleic acid molecules are incubated with immobilized probe nucleic acid molecules. Because the nanoparticles function as competitors in the hybridization reaction between the target nucleic acid molecules and the probe nucleic acid molecules. The methods provide a high degree of discrimination between a perfectly matched target sequence and a sequence having at least a single-base-pair mismatch, even when the hybridization reaction is performed at room temperature. The invention also provides microarray methods and apparatus which incorporate the nanoparticle-assisted hybridization methods. | 05-03-2012 |
20120108452 | Semi-Invasive Method for Characterizing Lung Injury - Described and disclosed are methods for determining, predicting, diagnosing, treating, and monitoring lung diseases, including bronchiolitis obliterans syndrome and acute cellular rejection in a lung transplant recipient by measuring chemokine levels in bronchoalveolar lavage (BAL) samples. The chemokine CXCL10 is measured in combination with at least one analyte selected from the group consisting of IL1RA, CXCL11, MCP-1, CXCL9, RANTES, IL-13, IL-17, IL-22, fractalkine, and eotaxin; and/or biomarkers. The present teachings also relate to methods, treatment decisions and kits for detecting and monitoring onset of lung transplant rejection in advance of clinically recognized symptoms. | 05-03-2012 |
20120108453 | MOLECULAR MARKERS IN PROSTATE CANCER - The present invention relates to methods for diagnosing prostate cancer and especially diagnosing LG, i.e., individuals with good prognosis; HG, i.e., individuals with poor prognosis of primary tumour; PrCa Met, i.e., individuals with poor prognosis and metastasis; and CRPC, i.e., individuals with poor prognosis suffering from aggressive localized disease. Specifically, the present invention relates to method for establishing the presence, or absence, of prostate cancer in a human individual comprising: a) determining the expression of one or more genes chosen from the group consisting of RRM2, HOXC6, TGM4, RORB, HOXDlO, SFRP2, and SNAI2 in a sample originating from said human individual; b) establishing up, or down, regulation of expression of said one or more genes as compared to expression of said respective one or more genes in a sample originating from said human individual not comprising prostate tumour cells or prostate tumour tissue, or from an individual not suffering from prostate cancer; and c) establishing the presence, or absence, of prostate cancer based on the established up- or down regulation of said one or more genes. | 05-03-2012 |
20120108454 | METHOD, MICROREACTOR AND APPARATUS FOR CARRYING OUT REAL-TIME NUCLEIC ACID AMPLIFICATION - A method for carrying out nucleic acid amplification, includes providing a reaction chamber ( | 05-03-2012 |
20120108455 | Methods for assessing and identifying or evolving conditionally active therapeutic proteins - Methods for evolving or selecting or producing therapeutic proteins that exhibit reduced adverse side-effects and the resulting proteins are provided. For example, provided herein is an in vitro assay to identify conditionally active therapeutic proteins that exhibit better activity within one in vivo environment compared to another in vivo environment. The methods include the steps of a) testing the activity of a protein under conditions in which normal or increased activity is desired; b) testing the activity of the protein under conditions in which reduced activity compared to normal is desired; and c) comparing the activity in a) with b) and selecting/identifying a protein that has greater activity in a) compared to b). The selected/identified protein is a conditionally active protein. | 05-03-2012 |
20120108456 | DEVICE SIMILAR TO AN ELECTROMECHANICAL CAMERA AND METHOD FOR THE PRODUCTION AND USE OF THE DEVICE - A device for detecting chemical or biochemical substances in fluids includes a first carrier having a sensor array with a plurality of electrochemical sensors. A second carrier includes a porous layer having at least one functional region, in which specifically binding capturing molecules are immobilized. The at least one functional region is arranged directly adjacent to at least one non-functionalized region. Assigned to the at least one functional region and the at least one non-functionalized region are several sensors of the sensor array, for use as an electrochemical camera. | 05-03-2012 |
20120108457 | MIR-211 EXPRESSION AND RELATED PATHWAYS IN HUMAN MELANOMA - Provided herein are methods for the diagnosis of human melanoma by assessing MITF, miR-211, TRPM1, and/or KCNMA1. Methods for treating melanoma are also provided. | 05-03-2012 |
20120108458 | METHOD OF SYNTHESIZING SINGLE-STRANDED CDNA, METHOD OF PREPARING MICROARRAY SAMPLE, AND METHOD OF DETECTING NUCLEIC ACID - In order to provide a method of amplifying nucleic acid which can produce a nearly constant amount of amplified products despite the amount of RNA to be used as a template, the primer is used at a final concentration of 500 pM to 500 nM in a reaction which synthesizes a single-stranded cDNA using RNA extracted from a biological sample as a template and using a primer with oligo dT and a promoter sequence. | 05-03-2012 |
20120108459 | METHODS AND DEVICES FOR MOLECULAR ASSOCIATION AND IMAGING - The present invention is directed to devices and methods for molecular association, particularly to devices and methods for hybridization of nucleic acids utilizing temperature gradients and imaging thereof. In one aspect, a molecular hybridization system generally includes a substrate having a plurality of molecular probes attached thereto, the plurality of probes being generally present in multiple copies arranged in localized formations on the surface of the substrate. The molecular hybridization system further generally includes a chamber that encloses the plurality of molecular probes such that a fluid containing sample may be applied and kept in contact with the substrate having the probes thereon. The molecular hybridization system also includes a temperature affecting system that generally produces at least one desired temperature on the surface of the substrate and in the adjacent fluid within the chamber. | 05-03-2012 |
20120108460 | NON-INVASIVE FETAL GENETIC SCREENING BY SEQUENCING ANALYSIS - The invention provides a non-invasive technique for the differential detection of multiple genotypes and/or mutations for a plurality of target genes in a biological sample containing genetic material from different genomic sources. Methods are conducted using multiplex amplification of a plurality of target sequences from the biological sample, and sequencing is used to detect and enumerate genetic mutations and chromosomal abnormalities at the single nucleotide level. | 05-03-2012 |
20120108461 | HIGH-THROUGHPUT SLIDE PROCESSING APPARATUS - An assay device and method of use thereof includes a sample tray comprising a plurality of sample wells having a first volume, and a slide tray comprising a slide, and a liquid dispenser. The slide comprises a plurality of reaction sites on a bottom surface of the slide. The liquid dispenser is configured to dispense a plurality of liquid samples into the sample wells. The sample wells are configured to hold the liquid samples. Each of the liquid samples has a second volume such that the second volume exceeds the first volume and each of the liquid sample sits within and above one of the sample wells. The slide tray and the sample tray are configured such that the slide tray can be placed onto the sample tray, at least one of the reaction sites can be positioned directly above at least one of the sample wells containing a liquid sample, and the liquid sample can be drawn onto the reaction site upon the liquid sample contacting the bottom surface of the slide. | 05-03-2012 |
20120108462 | MIRNA FINGERPRINT IN THE DIAGNOSIS OF LUNG CANCER - The present invention provides novel methods for diagnosing diseases based on the determination of specific miRNAs that have altered expression levels in disease states compared to healthy controls. | 05-03-2012 |
20120108463 | COMPOSITIONS AND METHODS FOR MEMBRANE PROTEIN DETERGENT STABILITY SCREEN - The invention provides methods to assess protein stability and to obtain sizing information. In one aspect, the screen comprises a 94 detergent panel and a series of MWCO filtered microplates. A protein of interest is bound to an affinity matrix and aliquoted into a 96-well microplate. Wells containing the immobilized protein are washed in the new detergent and then eluted in the new detergent into a collection plate. Protein not stable in the new detergent is precipitated on the resin and not present in the elutions. Half of the elution is passed through a high (i.e., 300 kDa) MWCO microplate and the other half through a low (i.e., 100 kDa) MWCO microplate. Elutions from the microplates are spotted on a nitrocellulose membrane, visualized by Western analysis (or by some other method), and quantified. The high MWCO provides stability readout and the ratio of low/high kDa provides sizing information. | 05-03-2012 |
20120115738 | Integrated Microfluidic Device and Methods - A microfluidic device for analyzing a sample of interest is provided. The microfluidic device can comprise a microfluidic device body, wherein the microfluidic device body comprises a sample preparation area, a nucleic acid amplification area, a nucleic acid analysis area, and a network of fluid channels. Each of the sample preparation area, the nucleic acid amplification area and the nucleic acid analysis area are fluidly interconnected to at least one of the other two areas by at least one of the fluid channels. Using the microfluidic device, sample preparation can be combined with amplification of a biologically active molecule, and a suitable biological sample can be provided for analysis and/or detection of a molecule of interest. The small-scale apparatus and methods provided are easier, faster, less expensive, and equally efficacious compared to larger scale equipment for the preparation and analysis of a biological sample. | 05-10-2012 |
20120115739 | ASSAY FOR ANTI-EGFRvIII ANTIBODIES - Detection of human antibodies directed against the tumor-specific protein Epidermal Growth Factor Receptor variant Class III (EGFRvIII) provide information on tumor burden and vaccine response. The methods of the invention permit the specific identification of antibodies that are able to bind to EGFRvIII. The methods are useful in determining the presence of an EGFRvIII-expressing tumor and in detecting immune responses following immunization with EGFRvIII-derived peptide as part of a cancer immunotherapy regimen. | 05-10-2012 |
20120115740 | BACTERIAL STRAIN IDENTIFICATION METHOD AND SYSTEM - Methods for identifying bacterial strains by using sets of distributed genes that are present in some but not all strains of a given species, associated methods for treating bacterial infections are disclosed. The methods may include examining a sample of a bacterial species, selecting a strain of interest based on possession of a unique genetic characteristic that is present in only the strain of interest and not in the other strains, examining the distributed genes possessed by the strain of interest, and detecting gene-possession variation in the distributed genes of the sample strains as compared to genes of known strains. | 05-10-2012 |
20120115741 | Reagents For The Atherosclerotic Coronary Plaque And Uses Thereof - The present invention discloses antibodies or fragments thereof able to bind isolated coronary plaque samples and processes for their production using host cells containing DNA sequences encoding for said antibodies of fragments thereof. Methods for screening ligands to said isolated samples are also described, and compositions containing said antibodies are also provided. | 05-10-2012 |
20120115742 | METHODS FOR IDENTIFICATION - The invention relates to methods for the discovery of new chemical entities and pharmaceutical compositions with broad-spectrum chemokine inhibitor (BSCI) activity, together with the use of such agents as anti-inflammatory medicaments. In one aspect, there is provided a method for the identification of a compound or agent with BSCI activity comprising the steps of (a) firstly one or more candidate compounds or agents are screened for binding to a somatostatin receptor such as the type 2 somatostatin receptor (sstr2); then (b) compounds or agents which show binding to the somatostatin receptor are tested for BSCI activity in a functional assay. | 05-10-2012 |
20120115743 | COMPOSITIONS AND METHODS FOR CLASSIFYING THYROID NODULE DISEASE - A system for classifying thyroid nodule tissue as malignant or benign is provided that is based on the identification of sets of gene transcripts, which are characterized in that changes in expression of each gene transcript within a set of gene transcripts can be correlated to with either malignant or benign thyroid nodule disease. The thyroid classification system provides for sets of “thyroid classifying” target sequences and further provides for combinations of polynucleotide probes and primers derived there from. These combinations of polynucleotide probes can be provided in solution or as an array. The combination of probes and the arrays can be used for diagnosis. The invention further provides further methods of classifying thyroid nodule tissue. | 05-10-2012 |
20120115744 | METHODS FOR GENERATING TARGET SPECIFIC PROBES FOR SOLUTION BASED CAPTURE - Provided herein are compositions and kits for single-stranded nucleic acid probes, and methods for making the single-stranded nucleic acid probes, where the single-stranded nucleic acid probes comprise a probe region having a predetermined sequence which is flanked by a 5′ region having a first restriction enzyme recognition sequence and flanked by a 3′ region having a second restriction enzyme recognition sequence, and a region which hybridizes to a capture nucleic acid molecule. The single-stranded nucleic acid probes are useful for solution-based capture methods. | 05-10-2012 |
20120115745 | METHODS FOR PREDICTING SENSITIVITY TO TREATMENT WITH A TARGETED TYROSINE KINASE INHIBITOR - The present disclosure relates generally to the evaluation and/or treatment of a subject having or suspected of having a neoplastic condition, and in particular to the use of biomarkers for identifying patients receptive to a certain drug therapy, and which permit monitoring of patient response to such therapy. | 05-10-2012 |
20120115746 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING IRRITABLE BOWEL SYNDROME - Compositions and methods for diagnosing and treating CVH and CVH-associated disorders are disclosed. Genes differentially expressed in CVH tissues relative to normal tissues are identified. The genes and the gene products (i.e., the polynucleotides transcribed from and polypeptides encoded by the genes) can be used as markers of CVH. The genes and the gene products can also be used to screen agents that modulate the gene expression or the activities of the gene products. | 05-10-2012 |
20120115747 | Methods Of Renal Cancer Detection - Disclosed are methods for detecting, diagnosing or monitoring a renal cancer in a subject. The methods include detecting quantity of one or more polypeptides or fragments thereof comprised by body fluid such as urine, wherein the one or more polypeptides or fragments thereof, can be present at elevated levels in a subject with a kidney cancer, as compared to a subject without a kidney cancer. Non-limiting examples of such polypeptides include aquaporin-1, adipose differentiation-related protein and paired box protein-2. Antibody probes can be used to detect or quantify the polypeptides. In some embodiments, mass spectroscopy can be used to detect or quantify the polypeptides, or to identify a polypeptide in a body fluid sample from a subject with a kidney cancer. | 05-10-2012 |
20120115748 | METHODS FOR MAKING AND USING SPR MICROARRAYS - An article, process, and method for surface plasmon resonance plates are described. A substrate is covered with a thin metal film onto which a second thin metal film is deposited. The surface of the second thin metal film is converted to the metal oxide which is used to covalently bond organosilanes to the surface. Reactive organosilanes containing terminal bonding groups are arranged in a plurality of spots that are surrounded by inert organosilanes. Biomolecule attachment to the binding group is detected or measured from surface plasmon signals from the first thin metal film. | 05-10-2012 |
20120115749 | Tumour Markers - A method of determining the immune response of a mammal to circulating tumour marker proteins is described in which a sample of bodily fluid, for example plasma or serum, is contacted with a panel of two or more distinct tumour marker antigen. The presence of complexes between the tumour marker antigens and any autoantibodies to the antigens present in the sample are detected and provide an indication of an immune response to a circulating tumour marker protein. The method is useful for the diagnosis of cancer, particularly for identifying new or recurrent cancer in an otherwise assymptomatic patient. | 05-10-2012 |
20120115750 | Expression of FABP4 and Other Genes Associated with Bladder Cancer Progression - Disclosed are methods for predicting the risk of bladder cancer progression, including death from bladder cancer by determining gene expression levels of FABP4 and MBNL2 or other markers where increased levels correlate with lack of progression of the subject's bladder cancer, and decreased levels correlate with progression or death from bladder cancer, and/or determining gene expression levels of COL4AI, UBE2C, BIRC5, COLI8A1, KPNA2, MSN, ACTA2, and/or CDC25B or other markers where increased levels correlate with progression of the subject's bladder cancer or death from it, and decreased levels correlate with lack of progression of bladder cancer. | 05-10-2012 |
20120115751 | METHOD OF PREPARING AN ADDUCT - A method for identifying one or several molecular structure(s) having a high-affinity for a target of interest, the molecular structure(s) each including one nucleotide chain onto which is hybridized at least one PNA-encoded molecule. | 05-10-2012 |
20120115752 | Method for Generating Aptamers with Improved Off-Rates - The present disclosure describes the identification and use of aptamers and photoaptamers having slower dissociation rate constants than those obtained using previously described methods. Specifically, the present disclosure describes methods for the identification and use of aptamers to one or more targets within a histological or cytological sample, which have slow rates of dissociation. The aptamers may be used to assess localization, relative density, and presence or absence of one or more targets in cytological and histological samples. Targets may be selected that are specific and diagnostic of a given disease state for which the sample was collected. The aptamers may also be used to introduce target specific signal moieties. In addition to target identification, the aptamers may be used to amplify signal generation through a variety of methods. | 05-10-2012 |
20120122713 | RNA LABELING METHOD - A method of sample analysis is provided. In certain embodiments, the method involves: a) obtaining a fragmented RNA sample comprising fragments of long RNA molecules and short RNA molecules; b) ligating an adaptor to an end of the RNA of the fragmented RNA sample to produce an adaptor-ligated sample; c) hybridizing said adaptor-ligated sample to an array of nucleic acid probes; and d) reading said array to obtain an estimate of the abundance of a long RNA in the RNA sample and an estimate of the abundance a small RNA in the RNA sample. | 05-17-2012 |
20120122714 | SANDWICH ASSAYS IN DROPLETS - The invention generally relates to performing sandwich assays in droplets. In certain embodiments, the invention provides methods for detecting a target analyte that involve forming a compartmentalized portion of fluid including a portion of a sample suspected of containing a target analyte and a sample identifier, a first binding agent having a target identifier, and a second binding agent specific to the target analyte under conditions that produce a complex of the first and second binding agents with the target analyte, separating the complexes, and detecting the complexes, thereby detecting the target analyte. | 05-17-2012 |
20120122715 | ELECTRICAL SENSOR FOR ULTRASENSITIVE NUCLEIC ACID DETECTION - The present invention is direct to a sensor for detecting a nucleic acid molecule comprising an electrode arrangement with two electrodes and nucleic acid probes immobilized at the surface of the electrodes. The present invention also refers to a kit and a method of using the sensor or a sensor array. The present invention is further directed to a process of manufacturing a sensor and sensor array. | 05-17-2012 |
20120122716 | CELL LINE DERIVED FROM THE EPITHELIAL LINING OF THE HUMAN ENDOLYMPHATIC SAC IN THE INNER EAR - In some embodiments, the invention relates to a stable, long-term human ES cell line. In other aspects, the invention relates to methods for establishing a stable long-term ES cell line and methods for screening therapeutic treatments for inner ear diseases, such as Meniere's disease. | 05-17-2012 |
20120122717 | COMPOSITION AND MULTIPLEX ASSAYS FOR MEASURING BIOLOGICAL MEDIATORS OF PHYSIOLOGICAL HEALTH - Multiplex assays are provided including panels of probes for development of multiplex assays capable of simultaneously measuring multiple biologically-relevant proteins using very small quantities of biological samples to rapidly assess the health status of animals, especially companion animals, as well as to formulate nutritional regimens for improving the health status of animals. The probes are provided as are methods for using them to assess the health status of animals, as well as their responses to therapeutic or nutritional interventions therein. | 05-17-2012 |
20120122718 | BRM Expression and Related Diagnostics - The present invention relates to isolated polynucleotides comprising a polymorphism in a promoter region of a BRM gene, and methods and compounds for causing BRM re-expression in cells, such as cancer cells, that have lost BRM expression. The present invention also relates to screening methods for identifying BRM expression-promoting compounds, and to methods of accessing cancer risk through the identification of polymorphisms in the BRM promoter. | 05-17-2012 |
20120122719 | Methods for PCR and HLA typing using unpurified samples - Provided are methods for amplifying a gene or RNA or sets thereof of interest using a tandem PCR process. The primers in the first PCR or set of PCR reactions are locus-specific. The primers in the second PCR or set of PCR reactions are specific for a sub-sequence of the locus-specific primers and completely consumed during the second PCR amplification. For RNA amplification, the first PCR is reverse transcription and the resulting cDNA(s) provide a template for cRNA synthesis, endpoint PCR or real time PCR. Also provided is a tandem PCR method which accepts raw, completely unpurified mouthwash, cheek swabs and ORAGENE™-stabilized saliva as the sample input, the resulting amplicons serving as the substrate for complex, microarray-based genetic testing. Also provided is a method of allelotyping a gene or set thereof by amplifying the gene(s) using tandem PCR on DNA or RNA comprising the sample. | 05-17-2012 |
20120122720 | MEANS AND METHODS FOR RECOGNIZING THE DEVELOPMENT OF CARDIOVASCULAR DISEASE IN AN INDIVIDUAL - A method of recognizing the development of an Acute Myocardial Infarction (AMI) process in an individual, wherein the method comprises steps of: profiling specific antibody reactivities or biomarkers associated with AMI susceptibility, the profiling comprises steps of: attaching a set of defined antigens to a substrate; obtaining a biological fluid derived specimen from an individual, the specimen containing a specific antibody repertoire; and binding said antibodies of the biological fluid specimen to the attached antigens thereby forming bound antibody antigen complexes; and analyzing results obtained, wherein the presence of the complexes is indicative of AMI. | 05-17-2012 |
20120122721 | METHOD FOR NUCLEIC ACID DETECTION USING VOLTAGE ENHANCEMENT - Methods are provided for carrying out nucleic acid analysis, including sequence identification, employing voltage and/or controlled electric charge to enhance operation. A device comprises substrates for nucleic acid analysis, a first electrically conductive layer, a first electrically insulative layer of dielectric material on the first conductive layer, a second electrically conductive layer disposed upon the first insulative layer in a pattern to define discrete attachment sites for macromolecules on the first insulative layer, the second conductive layer provided with means for resisting affinity for the macromolecules to impede their attachment to sites on the second conductive layer, and terminals for the first and second conductive layers for applying a voltage pattern between the first and the second conductive layers to control affinity between the macromolecules and the discrete attachment sites. | 05-17-2012 |
20120122722 | Expression of MBNL2 and Other Genes Associated with Bladder Cancer Progression - Disclosed are methods for predicting the risk of bladder cancer progression, including death from bladder cancer by determining gene expression levels of FABP4 and MBNL2 or other markers where increased levels correlate with lack of progression of the subject's bladder cancer, and decreased levels correlate with progression or death from bladder cancer, and/or determining gene expression levels of COL4A1, UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and/or CDC25B or other markers where increased levels correlate with progression of the subject's bladder cancer or death from it, and decreased levels correlate with lack of progression of bladder cancer. | 05-17-2012 |
20120122723 | METHODS OF DETECTING AUTOANTIBODIES FOR DIAGNOSING AND CHARACTERIZING DISORDERS - Methods for detecting and/or quantitating levels of autoantibodies in subjects are provided. Methods for diagnosing and/or characterizing a disorder associated with autoantibody production are further provided. In some embodiments, the disorder diagnosed and/or characterized can be a cancer or an infertility disorder. | 05-17-2012 |
20120122724 | Agents and Methods Related to Reducing Resistance to Apoptosis-Inducing Death Receptor Agonists - Provided herein is a method of reversing or preventing a target cell's resistance to a death receptor agonist. Also provided are methods of screening for biomarkers resistance of and monitoring resistance to death receptor agonists. Also provided are methods of selectively inducing apoptosis in a target cell, treating a subject with cancer, autoimmune or inflammatory diseases, comprising administering compositions provided herein. Further provided are compositions comprising agents that modulate CARD containing proteins. | 05-17-2012 |
20120122725 | Method of determining risk of a neuropsychiatric disorder - A method of assessing risk of ADHD in a human subject is provided. The method comprises the step of identifying in a nucleic acid-containing sample obtained from the human subject copy number variations associated with one or more genes selected from the group consisting of DCLK1, DCLK2, SORCS3, SORCS1, 16p11.2, ASTN2, MACROD2, CHCHD, CPLX2, ZBBX, PTPRN2 and TRIM32 wherein a determination of copy number variations associated with one or more of said genes is indicative of a risk of ADHD in the human subject. | 05-17-2012 |
20120122726 | MARKERS FOR ENDOMETRIAL CANCER - The invention relates to the surprising finding that biomarkers corresponding to ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1 R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, S0CS2, and DCN are differentially expressed in control samples as compared to samples from patients having endometrial cancer and are therefore useful for detecting endometrial cancer. In particular these biomarkers having excellent sensitivity, specificity, and/or the ability to separate affected from non affected individuals. Furthermore, the inventors found that the differential expression of these biomarkers in primary endometrial cancer tumor tissue is correlated to their expression level in uterine fluid samples as compared to control values. Thus these biomarkers are robust in that they are found to be differentially expressed in several different types of samples from affected individuals. | 05-17-2012 |
20120122727 | IN VITRO METHOD FOR PREDICTING WHETHER A COMPOUND IS GENOTOXIC IN VIVO - The invention is in the field of genomics and it provides an in vitro method for predicting whether a compound is genotoxic in vivo. It provides a method that employs the analysis of expression profiles of primary mouse hepatocytes as an in vitro system to discriminate false GTX compounds from true GTX carcinogens. It was found that differential expression of a number of genes could reliably predict whether a compound was a true genotoxic compound. | 05-17-2012 |
20120129707 | Glycopeptide-Functionalized Nanoparticles Arrays for Capturing and Detecting Biomolecules - A surface-enhanced Raman spectroscopic (SERS) system for detecting a biomolecule. The system includes a substrate, an array of nanoparticles disposed on the substrate, each being partially embedded in the substrate and having a non-embedded surface, and a linking agent disposed on the non-embedded surface of each of the nanoparticles. The array of nanoparticles has a uniform interparticle gap of 1-50 nm and the linking agent is capable of binding to the biomolecule. | 05-24-2012 |
20120129708 | COMPOSITIONS AND METHODS FOR PREDICTING CARDIOVASCULAR EVENTS - The present invention provides methods, systems, devices, panels, and software for determining values for two or more markers in order to characterize a subject's risk of developing cardiovascular disease or experiencing a complication thereof (e.g., within the ensuing one to three years), and for identifying subjects in need of preventative therapy (e.g., statins). In certain embodiments, the markers are selected from: hs-CRP, ACR, Lp-Pla2, MPO, fibrinogen, KIF6, and F2 isoprostanes. | 05-24-2012 |
20120129709 | SENSOR FOR DETECTION OF NUCLEIC ACID - A sensor for detection of target nucleic acid comprising (a) a semiconductor nanostructure; and (b) a nucleic acid detection probe immobilized on the semiconductor nanostructure capable of hybridizing with the target nucleic acid, the detection probe comprising a polymer with a substantially non-ionic backbone. | 05-24-2012 |
20120129710 | METHODS FOR PRODUCING MEMBERS OF SPECIFIC BINDING PAIRS - A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA. Using this method libraries of DNA encoding respective chains of such multimeric sbp members may be combined, thereby obtaining a much greater genetic diversity in the sbp members than could easily be obtained by conventional methods. | 05-24-2012 |
20120129711 | BIOMARKERS FOR THE PROGNOSIS AND HIGH-GRADE GLIOMA CLINICAL OUTCOME - The present invention relates to the identification and use of biomarkers with clinical relevance to high grade gliomas (HGGs). In particular, the invention provides the identity of four genes, CHAF1B, PDLIM4, EDNRB and HJURP, whose expression, at the transcriptome and proteome levels, is correlated with HGG grading and clinical survival outcome. Methods and kits are provided for using these biomarkers in the prognostication of HGGs, and in the selection and/or monitoring of treatment regimens. | 05-24-2012 |
20120129712 | ANTIBODIES DIRECTED TO TRA ANTIGENS, AND METHODS OF PRODUCTION, SCREENING AND ANALYSIS OF SAID ANTIBODIES, AS WELL AS METHODS OF ANALYSIS OF STEM CELLS AND CANCER CELL - A complex of Tra-antibody bound to an isolated glycan comprising type I—N-acetyllactosamine comprising target structure, and methods and uses utilizing said complex. | 05-24-2012 |
20120129713 | Substrates For Isolating, Reacting And Microscopically Analyzing Materials - An immobilizing device for biological material comprises a rigid support ( | 05-24-2012 |
20120129714 | QUANTITATIVE MULTIPLEXED IDENTIFICATION OF NUCLEIC ACID TARGETS - Methods and systems for detecting a target nucleic acid using the quantitative capabilities of real-time nucleic acid amplification systems and the multiplexing capabilities of hybridization systems, comprising: identifying a conservative sequence and a distinctive sequence within each target nucleic acid sequence; simultaneously amplifying the conservative region and the distinctive region; monitoring the amplification of the conservative region in real-time; identifying the distinctive region amplicon via multiplexed identification; and performing quantitative multiplexing analysis of the target by combining the real-time monitoring information with the multiplexed identification of the target nucleic acid. | 05-24-2012 |
20120129715 | GB1 PEPTIDIC LIBRARIES AND METHODS OF SCREENING THE SAME - GB1 peptidic libraries and methods of screening the same for specific binding to a target protein are provided. Libraries of polynucleotides that encode GB1 peptidic compounds are provided. These libraries find use in a variety of applications in which specific binding to target molecules, e.g., target proteins is desired. Also provided are methods of screening the libraries for binding to a target. | 05-24-2012 |
20120129716 | USE OF MICROFLUIDIC SYSTEMS IN THE DETECTION OF TARGET ANALYTES USING MICROSPHERE ARRAYS - The invention relates generally to methods and apparatus for conducting analyses, particularly microfluidic devices for the detection of target analytes. | 05-24-2012 |
20120129717 | Collection and Methods For Its Use - The present disclosure enables collections of variable heavy chain and variable light chain pairs comprising, in part, germline protein sequences that are pre-selected for functional properties relevant to developability, wherein the collections may be used to select against any antigen using, for example, phage display. | 05-24-2012 |
20120129718 | Qualitative/Quantitative Detection of Fungal Species - A method based on species-specific molecular markers applied to a multiplex platform system is provided that permits, in a one-time assay, the qualitative and quantitative screening of multi-species populations in several dozens of environmental samples, tested in parallel, with low cost and rapid turn-around. The method identifies a specific portion of DNA, shared amongst a variety of important mold species, but with sufficient sequence differences that allow for unique identifications. Two pairs of primers, which are capable of amplifying this region across at least 38 different mold species, have been identified. Also short oligonucleotide probes have been designed specifically for each species to detect their presence and concentration in mixed species environmental samples. The method of detection of the invention can be practiced using conventional PCR reactions, followed by nucleotide hybridization assays and quantization of the hybridized biotinylated amplicons in a multiplex liquid array system. | 05-24-2012 |
20120129719 | Mechanically induced trapping of molecular interactions - The invention provides devices and methods for surface patterning the substrate of a microfluidic device, and for detection and analysis of interactions between molecules by mechanically trapping a molecular complex while substantially expelling solvent and unbound solute molecules. Examples of molecular complexes include protein-protein complexes and protein-nucleic acid complexes. | 05-24-2012 |
20120129720 | APTAMER THAT RECOGNIZES PEPTIDE - An aptamer capable of binding to a histidine peptide is provided. A nucleic acid used as the aptamer capable of binding to a histidine peptide is any of the following nucleic acids (a) to (d): (a) a nucleic acid having a base sequence represented by SEQ ID NO: 17: GGUN | 05-24-2012 |
20120129722 | METHOD FOR SCREENING NEW DRUG CANDIDATE INHIBITING TARGET PROTEIN-PROTEIN INTERACTION FOR DEVELOPMENT OF FIRST-IN-CLASS DRUG - The present invention relates to a method for screening a substance inhibiting protein-protein interactions, and more particularly to a method for screening a substance inhibiting protein-protein interactions, the method comprising using a protein chip having immobilized thereon spots comprising a mixture of a sol-gel material and a protein. According to the invention, a protein chip can be easily manufactured in a 96-well plate using a sol-gel material, whereby an inhibitor that inhibits protein-protein interactions can be easily screened from a library of natural substances. | 05-24-2012 |
20120129723 | SYSTEM AND METHOD FOR CARRYING OUT MULTIPLE BINDING REACTIONS IN AN ARRAY FORMAT - Provided is a method for determining one or more kinetic parameters of binding between a first binding member and a second binding member. The method includes adsorbing the first binding member to a surface at a plurality of microspots. The second binding member is then presented to the first binding member at each of the microspots, there being a plurality of combinations of first binding member surface density and second binding member concentration among the plurality of microspots. Data indicative of a binding reaction between the first of microspots are then obtained and analyzed so as to obtain one or more kinetic parameters of the binding between the first and second binding members. Also provided is a system for carrying out the method. A method for localizing a molecular species at microspots on a surface, and a probe array produced by the method are also provided. | 05-24-2012 |
20120129724 | MARKER AND REAGENT FOR DETECTION OF HUMAN IL-17-PRODUCING HELPER T CELLS, AND METHOD FOR DETECTION OF HUMAN IL-17-PRODUCING HELPER T CELLS - The present invention relates to a marker allowing specific detection of human IL-17-producing helper T-cells (human Th17 cells), a method for specifically detecting human Th17 cells and a reagent for detecting human Th17 cells. | 05-24-2012 |
20120129725 | NUCLEIC ACID NANO-BIOSENSORS - There is provided nanobiosensors and more particularly sensors comprising one or more aptamers or other functional nucleic acids adapted for signalling incorporated within a nanoparticle comprising polyacrylamide or other suitable polymer. Moreover, there is provided a novel DNA aptamer, which selectively binds to ATP. There is also provided a novel nanobiosensor for monitoring ATP concentrations in samples, including biological samples; this new approach may be used to monitor kinase activity in a given sample. | 05-24-2012 |
20120135873 | GENOME DETERMINATION ASSAY - The present invention relates to a genome determination assay and method for detecting and cleaving a target non-amplified genomic nucleic acid sequence at two or more genomic nucleic acid sequence sites simultaneously, using a mismatch repair enzyme selected from the group consisting of TDG and Mut Y. The method may be used to detect a species under non-lab conditions and identify a DNA sequence utilizing the specificity of the base excision repair (BER) system enzymes. It may also be used to cleave a specific genomic sequence of choice. Currently, genomic DNA is only cleaved with restriction enzymes at restriction sites. As one example, chicken genome specific sequences are utilized to determine chick gender, without the use of standard assays, such as PCR or Fluorescent In Situ Hybridization (FISH). TDG, a Base Excision Repair (BER) enzyme that restores T/G mismatches to C/G at sites of 5-methylcytosine deamination, is used to detect, bind and function on a primer hybridized to genomic DNA template. The primer sequence may contain a T to mismatch a G in the target genomic DNA sequence or, symmetrically, the mismatch may be reversed so that the primer sequence may contain a G to mismatch a Tin the target genomic DNA sequence, and the T/G is cleaved with high fidelity. | 05-31-2012 |
20120135874 | SINGLE MOLECULE SPECTROSCOPY FOR ANALYSIS OF CELL-FREE NUCLEIC ACID BIOMARKERS - The present invention relates, e.g., to a method for detecting a nucleic acid molecule of interest in a sample comprising cell-free nucleic acids, comprising fluorescently labeling the nucleic acid molecule of interest, by specifically binding a fluorescently labeled nanosensor or probe to the nucleic acid of interest, or by enzymatically incorporating a fluorescent probe or dye into the nucleic acid of interest, illuminating the fluorescently labeled nucleic acid molecule, causing it to emit fluorescent light, and measuring the level of fluorescence by single molecule spectroscopy, wherein the detection of a fluorescent signal is indicative of the presence of the nucleic acid of interest in the sample. | 05-31-2012 |
20120135875 | METHODS FOR DETERMINING SENSITIVITY TO VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 MODULATORS - VEGFR-2 biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an VEGFR-2 modulator, wherein the method comprises (a) exposing the mammal to the VEGFR-2 modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the VEGFR-2 modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a VEGFR-2 modulator indicates that the mammal has responded therapeutically to the method of treating cancer. | 05-31-2012 |
20120135876 | HIGH-THROUGHPUT ASSAY METHODS AND ARTICLES - An assay device and method of use thereof, include a multiwell chip and a microarray slide printed with capture molecules. The chip contains shallow wells for holding liquid samples and, optionally, shoulders for receiving the slide. The slide, when placed on the chip, can contact the top of the liquid sample and draw the liquid sample upwards onto the capture molecules. The microarray slide and multiwell chip are capable of forming a closed incubation chamber preventing outside contamination and liquid evaporation. Patterning of the slide can be carried out by direct write lithography or nanolithography, including DPN printing. Small liquid volumes can be used. | 05-31-2012 |
20120135877 | DNA Methylation Markers For Prostate Cancer Field Defect - A method of detecting the presence of a prostate cancer field defect in a human subject comprising the step of (a) obtaining genomic DNA from the human subject and (b) quantitating methylation in at least one target region selected from the group consisting of CAV1, EVX1, MCF2L, FGF1, NCR2 and WNT2 target, wherein significant methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer. | 05-31-2012 |
20120135878 | Generation of Neural Stem Cells from Human Trophoblast Stem Cells - Provided herein are isolated neural stem cells. Also provided are methods for treatment of neurodegenerative diseases using suitable preparations comprising the isolated neural stem cells. | 05-31-2012 |
20120135879 | Method and Composition for Cancer Diagnosis and Treatment - Methods and compositions for inhibiting the onset of cancer, and cancer diagnosis and treatment are provided. The treatment method comprises inhibiting the level or function of transcriptional positive factor 4 (PC4). Also provided are methods of screening for cancer inhibition agents based on inhibition of PC4 expression or function. | 05-31-2012 |
20120135880 | Crystal of Human Glycoprotein VI Collagen Binding Domain - A crystal comprising the collagen binding domain of human GPVI is provided and defined by structural atomic coordinates. Employing computer modeling based on the crystal structure, including methods for identifying inhibitors of GPVI collagen binding activity, methods for screening libraries of compounds for potential to bind to the GPVI collagen binding domain, and methods of identifying a compound useful for the treatment of a GPVI-mediated disorder, are also provided. | 05-31-2012 |
20120135881 | MARKERS FOR DETECTION OF GASTRIC CANCER - Early detection of tumors is a major determinant of survival of patients suffering from tumors, including gastric tumors. Members of the GTM gene family can be differentially expressed in gastric tumor tissue, and thus can be used as markers for the detection of gastric and other types of cancer. The present invention provides for novel GTMs for the detection of tumors, including gastric tumors, and in particular human zymogen granule protein 16 (ZG16). The GTMs can be used in isolation or together with other known GTMs to provide for novel signatures to be used in the detection of tumors, including gastric tumors. | 05-31-2012 |
20120135882 | METHODS FOR DIAGNOSING CHRONIC KIDNEY DISEASE AND ASSESSING THE RISK OF DISEASE PROGRESSION - Methods and compositions for diagnosing chronic kidney disease and assessing the risk of disease progression, as well as methods of screening for molecular biomarkers useful for diagnosing the likelihood of disease progression, are provided. | 05-31-2012 |
20120135883 | MULTIVALENT OPSONOPHAGOCYTIC ASSAY USING BEAD ARRAY AND IMAGING - Embodiments of the present invention relate to devices and methods for detecting opsonophagocytotic antibodies using detection particles having product-specific detection reagents and having a characteristic spectral feature. Detection substrates, include microwells. Phagocytic cells are grown in the microwells, and a sample of serum or other bodily fluid from a patient is introduced into the wells, along with a set of detection particles, each set having an antigen recognized by opsonophagocytotic antibodies. The detection particles bind to the antibodies present in the sample and the phagocytic cells then take up the detection particles, labeling the phagocytic cells. The cells are then visualized via image analysis, thereby detecting the presence of, and the types of the opsonophagocytotic antibodies in the sample. | 05-31-2012 |
20120135884 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING MACULAR DEGENERATION - The present invention relates generally to biomarkers for macular degeneration. In particular, the present invention provides a plurality of biomarkers for monitoring and diagnosing macular degeneration. The compositions and methods of the present invention find use in diagnostic, therapeutic, research, and drug screening applications. | 05-31-2012 |
20120135885 | Methods and Kits Using Extended Rhodamine Dyes - Extended rhodamine compounds exhibiting favorable fluorescence characteristics having the structure | 05-31-2012 |
20120135886 | METHOD FOR DETECTION OF, OR THE RISK OF, BLADDER CANCER - The present invention provides a method for the detection of or the risk of bladder cancer in a patient, comprising the step of detecting the presence of a combination of at least two biomarkers selected from CEA, VEGF, IL-8, NGAL, NSE, IL-2, EGF, TM, d-Dimer, MMP-9, IL-6, IL-4, MMP-9/NGAL, FAS, CRP, TUP and NMP22 in one or more samples isolated from a patient wherein the presence of a combination of at least two biomarkers in the one or more samples indicates the presence or risk of bladder cancer. | 05-31-2012 |
20120142545 | SOLID PHASE AND CATALYZED ENABLED AUTOMATED ISOTOPE DILUTION AND SPECIATED ISOTOPE DILUTION MASS SPECTROMETRY - A method for the equilibration of enriched isotope species and natural isotope species prior to mass spectrometric analysis using solid phase and/or microwave isotope ratio equilibration and measurement. | 06-07-2012 |
20120142546 | HYPOMETHYLATED GENES IN CANCER - The present invention provides methods and kits for identifying a cell that exhibits or is predisposed to exhibiting unregulated growth by detecting hypomethylation of a gene or a regulatory region in at least one gene in the cell. Also provided are methods for diagnosis or prognosis of a proliferative disorder in a subject. Also provided are methods of ameliorating a cell proliferative disorder in a subject by administering to the subject an agent that methylates a hypomethylated gene or regulatory region thereof. In some aspects, the gene or regulatory region thereof is TKTL1, H19, MAGEA2, MAGEA3, MAGEA4, MAGEA11, GPR1 7, GRTN1, C19ORF28, MAGEA12, MAGEA1, MAGEA5, NY-ESO-1, MAGEA9, MAGEA6, MAGEB2, CT45-2, SBSN, G6PD, ZNF711, CrispL, KRT86, KIPV467, KRT81, CSPG5, PP1R14A, KISS1R, KIAA1937 protein, SOX30, DEAD, or KBGP. | 06-07-2012 |
20120142547 | POLYPEPTIDE IMMOBILIZATION - The present invention provides a method, comprising (a) providing a reactant ligand attached to a substrate; (b) contacting the substrate with a fusion polypeptide, said fusion polypeptide comprising a capture polypeptide fused to a display polypeptide under conditions such that said reactant ligand covalently binds to said capture polypeptide; and (c) analyzing said display polypeptide. | 06-07-2012 |
20120142548 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF ALZHEIMER'S DISEASE - The invention relates to methods of diagnosing Alzheimer's disease (AD) in a subject and methods of determining the prognosis in patients with AD. The adhesion molecules P-selectin and L-selectin are described for the first time for use as biomarkers to aid in the diagnosis of AD. The invention further describes the use of one or more of L-selectin, MCP-1, IL-1α, IL-8 and IFN-γ to aid in the prognosis of either accelerated cognitive decline (ACD) or slow cognitive decline (SCD) in patients with AD. | 06-07-2012 |
20120142549 | RAF GENE FUSIONS - The present disclosure relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure relates to RAF gene fusions as diagnostic markers and clinical targets for cancer. | 06-07-2012 |
20120142550 | Vanin 1 as a Peripheral Blood Oxidative Stress Sensor - Aspects of the subject invention are drawn to methods, compositions, systems and kits for the assessment of oxidative stress in an individual from a blood sample. In certain embodiments, the expression level of VNN1 in blood cells from a subject (or patient) is assessed and used to determine the subject's oxidative stress state, where an increased/high expression level of VNN1 indicates that the subject is in a state of oxidative stress. Expression of VNN1, and optionally other genes, may be done by assessing nucleic acid and/or protein levels in the blood cells obtained from the subject. | 06-07-2012 |
20120142551 | Methods for Genotyping Selected Polymorphism - Methods for genotyping polymorphisms using a locus specific primer that is complementary to a region near a selected polymorphism are described. Methods for synthesizing pools of locus specific primers that incorporate some degenerate positions are also disclosed. A plurality of different sequence capture probes are synthesized simultaneously using degenerate oligonucleotide synthesis. The sequence of the locus specific regions of the capture probes are related in that they have some bases that are identical in each sequence in the plurality of sequences and positions that vary from one locus specific region to another. The sequences are selected based on proximity to a polymorphism of interest and because they conform to a similar sequence pattern. | 06-07-2012 |
20120142552 | HIGH-SENSITIVITY ASSAYS FOR PATHOGEN DETECTION USING METAL-ENHANCED FLUORESCENCE - The present invention relates to an assay including a surface having silver colloids or islands attached thereto. Attached to the surface and/or silver colloids/islands are polynucleotides which are complimentary to a target polynucleotide sequence. The assay is performed by adding the target polynucleotide sequence to the assay surface and allowed to hybridize with the capture polynucleotides. Fluorophore-labeled capture polynucleotides are added and hybridize to the target polynucleotide. Bound target polynucleotides are detected by metal enhanced fluorescence. | 06-07-2012 |
20120142553 | Molecular Markers in Kidney Cancer - The present invention relates to methods for establishing the presence, or absence, of a kidney, or renal, tumour in a human individual suspected of suffering from kidney, or renal, cancer. Specifically, the present invention relates to methods for establishing the presence, or absence, of a kidney tumour in a human individual suspected of suffering from kidney cancer comprising: a) determining the expression of one or more genes chosen from the group consisting of NDUFA4l2, ANGPTL4, EGLN3, PTHLH, and ATP6V1B1 in a sample originating from said human individual; b) establishing up, or down, regulation of expression of said one or more genes as compared to expression of said respective one or more genes in a sample originating from said human individual not comprising kidney tumour cells or tissue, or from an individual, or group of individuals, not suffering from kidney cancer; and c) establishing the presence, or absence, of a kidney tumour based on the established up- or down regulation of said one or more genes. | 06-07-2012 |
20120142554 | HIGH PRECISION QUANTITATIVE ASSAY COMPOSITION AND METHODS OF USE THEREFOR - The invention features compositions and methods that are useful for precisely determining the amount of one or more analytes present in a sample. In one aspect, the invention provides a composition for measuring the abundance of one or more target analytes in a sample, where the composition contains a set of detection units for each analyte fixed to a substrate (e.g.,a membrane, bead, filter, chip, polymer-based film or glass slide, or other printable surface), where each detection unit contains a discrete amount of a capture agent that specifically binds the target analyte, and the amount of capturing agent varies over the set to form a concentration gradient. | 06-07-2012 |
20120142555 | Compositions And Methods For Immunodominant Antigens of Mycobacterium Tuberculosis - Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen | 06-07-2012 |
20120149590 | LACTOBACILLUS ACIDOPHILUS NUCLEIC ACID SEQUENCES ENCODING CELL SURFACE PROTEIN HOMOLOGUES AND USES THEREFORE - Cell wall, cell surface and secreted protein nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, cell wall, cell surface and secreted fusion proteins, antigenic peptides, and anti-cell wall, cell surface and secreted antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and host cells into which the expression vectors have been introduced. Methods for producing the polypeptides of the invention and methods for their use are further disclosed. | 06-14-2012 |
20120149591 | IN VITRO PEPTIDE EXPRESSION LIBRARY - The invention provides a method for making in vitro peptide expression libraries, and for the isolation of nucleotide sequences encoding peptides of interest, wherein the peptides or proteins are specifically associated with the DNA encoding them through non-covalent protein:DNA binding. The method describes ways of making the library itself, DNA molecules encoding the library and uses of the expression library. | 06-14-2012 |
20120149592 | Compositions And Methods For Assessing Cytotoxicity Of Single Cells - The invention provides a method of analyzing interactions between pairs of target and effector cells utilizing high-throughput screenings methods for profiling large numbers of single cells in microarrays. | 06-14-2012 |
20120149593 | METHODS AND ARRAYS FOR PROFILING DNA METHYLATION - This invention provides methods and arrays for determination of the methylation patterns at single-nucleotide resolution by array-based hybrid selection and next-generation sequencing of bisulfite-treated DNA. | 06-14-2012 |
20120149594 | BIOMARKERS FOR PREDICTION OF BREAST CANCER - The invention provides gene expression profiles (GEPs), protein expression profiles (PEPs) as well as gene/protein expression profiles (GPEPs) and methods for using them to identify those patients who are likely to progress to breast cancer after detection of suspicious calcifications and/or fibrocystic disease by standard imaging techniques, e.g., mammography, MRI or ultrasound. The present invention further allows a treatment provider to identify those patients who are most likely to develop breast cancer to initiate and/or adjust treatment options for such patients accordingly. | 06-14-2012 |
20120149595 | MARKERS FOR DIAGNOSIS OF PULMONARY INFLAMMATION AND METHODS RELATED THERETO - The present invention is related to the novel discovery of a number of genes that were identified as systemic markers of pulmonary inflammation. This discovery allows for development of a novel tool for reliable, rapid and efficient assessment of therapeutic responses and enables design of novel therapies targeted against diseases associated with pulmonary inflammation. In one embodiment, the present invention allows quantification of therapeutic response in patients who have a disease associated with pulmonary inflammation. In preferred embodiments, the genes are CD64, ADAM9, CD36, IL32, HPSE, PLXND1, HCA 112, CSPG2, TLR2, and CD163. | 06-14-2012 |
20120149596 | METHODS FOR ASSESSING ATHEROGENESIS BY DETERMINING OXIDIZED PHOSPHOLIPID TO APOLIPOPROTEIN B RATIOS - The present invention relates to the analysis of oxidized phospholipids (OxPL) on apolipoprotein B-100 in patients at high risk or with documented coronary artery disease (CAD) or acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction or suspected of being at risk for ACS. Such methods are useful for diagnostic purposes and for monitoring the effects of dietary interventions or with drugs such as statins. More particularly, the present invention relates to methods for determining OxPL/apoB ratios as indices of atherosclerosis regression and plaque stability. | 06-14-2012 |
20120157328 | Label Free Kinase Assays and Reagents - This disclosure describes methods and compositions for measuring the binding specificity, kinetics and affinity of kinase inhibitors indirectly using mass sensing analytical techniques, such as SPR, through the competitive displacement of detectable signal-inducing kinase binding molecule. Further provided are methods for preparing such molecules. | 06-21-2012 |
20120157329 | Method and Device for the in Vitro Analysis for MRNA of Genes Involved in Haematological Neoplasias - Method and device for the in vitro analysis of mRNA of genes involved in hematological neoplasias. The device, composed of probes which specifically hybridize with genes involved in hematological neoplasias, designed so that its behaviour in the hybridization is similar, permits the evaluation of the mRNA level in biological samples taken from subjects suspected to be suffering from hematological neoplasia and facilitating the comparison between the different samples and their grouping by similarity in the gene expression patterns, especially when the probes are disposed in the form of microarray. The application of the method of the invention to obtain and process data of gene expression differences from the device of the invention permits the identification of genes significant for distinguishing samples associated to hematological neoplasias, facilitates the diagnosis of neoplasias as CLL and permits making a prognosis of the evolution thereof. | 06-21-2012 |
20120157330 | Trenched Sample Assembly for Detection of Analytes with Electromagnetic Read-Write Heads - Described are embodiments of an invention for a sample assembly with trenches for detection of analytes with electromagnetic read heads. The sample assembly includes an outer layer with at least one sample trench. The sample trench includes a first set of antibodies that are bonded on a first surface of a base layer. Target antigens are bonded with the first set of antibodies, and a second set of antibodies are bonded to the target antigens. Further, the sample trench includes nanoparticles that are bonded to the second set of antibodies. A head module includes a write head for magnetizing nanoparticles and a read sensor for detecting the magnetized nanoparticles, and thus, the target antigens. The sample trench constrains the biological sample, and thus the target antigen, during the preparation and subsequent analysis of the biological sample. Accordingly, the target antigen is aligned with read elements of a head module such that the target antigen is reliably and accurately detected. Further, to ensure reliable and accurate detection, the outer layer is formed with a low friction material allowing the read head to remain in contact with the upper surface of the outer layer during the process of detection. | 06-21-2012 |
20120157331 | METHODS OF DETECTING SUSCEPTIBILITY TO LEUKEMIA/ LYMPHOMA AND INDUCTION OF LEUKEMIA AND LYMPHOMAS - A diagnostic test is described using | 06-21-2012 |
20120157332 | Reagent Storage in an Assay Device - The invention relates to methods for conducting binding assays in an assay device that includes one or more storage and use zone. The storage zones of the assay device are configured to house one or more reagents used in an assay conducted in the use zone of the device. | 06-21-2012 |
20120157333 | OLIGONUCLEOTIDES USEFUL FOR DETECTING AND ANALYZING NUCLEIC ACIDS OF INTEREST - The invention features improved nucleic acids and methods for expression profiling of mRNAs, identifying and profiling of particular mRNA splice variants, and detecting mutations, deletions, or duplications of particular exons or other splice variants, e.g., alterations associated with a disease such as cancer, in a nucleic acid sample, e.g., a biological sample or a patient sample. | 06-21-2012 |
20120157334 | MIRNAS AS BIOMARKERS FOR DISTINGUISHING BENIGN FROM MALIGNANT THYROID NEOPLASMS - The present invention concerns methods and compositions for identifying a miRNA profile for a particular condition, such as thyroid nodules or thyroid cancer, and using the profile in the diagnosis of a patient for a condition, such as thyroid nodules or thyroid cancer. | 06-21-2012 |
20120157335 | Flap Endonuclease-1 As A Marker For Cancer - Methods aiding in the assessment of cancer comprising use of the Flap endonuclease-1 protein (=FEN1) as a universal marker of different cancer types are provided. In particular, methods for assessing cancer from a liquid sample derived from an individual, which comprise measuring FEN1 in the sample are disclosed. Measurement of FEN1 is useful for the early detection of cancer or in the monitoring of patients who undergo surgery for tumor removal. | 06-21-2012 |
20120157336 | miRNA FINGERPRINT IN THE DIAGNOSIS OF DISEASES - The present invention provides novel methods for diagnosing a state of health based on the determination of specific miRNAs that have altered expression levels in different conditions, e.g. disease states compared to healthy controls. | 06-21-2012 |
20120157337 | miRNA FINGERPRINT IN THE DIAGNOSIS OF MULTIPLE SCLEROSIS - The present invention provides novel methods for diagnosing diseases based on the determination of specific miR-NAs that have altered expression levels in disease states compared to healthy controls. | 06-21-2012 |
20120157338 | METHOD FOR DETERMINING THE RISK OF DEVELOPING BRAIN METASTASIS, AND A KIT TO CARRY OUT SAID METHOD - The method comprises: (a) isolating a sample from the breast tumour; (b) determining the level of expression of GRP94, FN14 or both in the sample, and (c) comparing said level with the level of said gene(s) in a control sample, wherein if it is detected an overexpression of said gene(s), in respect of the control sample, it is indicative of the risk for developing brain metastasis. | 06-21-2012 |
20120157339 | Molecular Markers and Assay Methods for Characterizing Cells - Disclosed herein are molecular markers and assay methods for characterizing cells. As disclosed, the methods entail determining a methylation state of at least one CpG in a region of a nucleotide molecule of the cell, comparing the methylation state with that of a corresponding CpG of a comparison cell of a known cell type, a known cell line, or a known cell strain, and distinguishing, identifying or designating the cell type, the cell line or the cell strain of the cell based on whether the methylation state is the same or different from that of the corresponding CpG. | 06-21-2012 |
20120157340 | PATHWAYS CHARACTERIZATION OF CELLS - The present invention provides methods, compositions and kits for the characterization of cellular pathways in cells containing genetic alterations. | 06-21-2012 |
20120157341 | DETECTION OF DIGESTIVE ORGAN CANCER, GASTRIC CANCER, COLORECTAL CANCER, PANCREATIC CANCER, AND BILIARY TRACT CANCER BY GENE EXPRESSION PROFILING - The present invention provides a method and a reagent for detecting a digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, or biliary tract cancer patient by analyzing genes with expression levels (in peripheral blood) that vary in association with digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, or biliary tract cancer cases, compared with normal healthy subjects. Specifically, the method for detecting a digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, or biliary tract cancer patient based on expression profiles comprises obtaining the expression profile of at least one gene selected from the group consisting of probes corresponding to genes with expression levels (in peripheral blood) that vary in digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, and biliary tract cancer cases, compared with normal healthy subjects. The reagent for detecting digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, or biliary tract cancer contains nucleotides or partial sequences thereof consisting of the nucleotide sequence of at least one gene selected from the group consisting of probes with expression levels that vary in digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, or biliary tract cancer, or nucleotides containing sequences complementary thereto. | 06-21-2012 |
20120157342 | PREDICTIVE BIOMARKERS USEFUL FOR CANCER THERAPY MEDIATED BY A WEE1 INHIBITOR - The present invention provides the identification of biomarker gene sets whose expression levels are useful for predicting a patient's response to a therapeutically effective dose of a Wee1 inhibitor as well the ability to predict said response prior to dosing with the Wee1 inhibitor. Additional uses are also disclosed in the specification. | 06-21-2012 |
20120157343 | System and Methods to Quantify and Amplify Both Signaling and Probes for cDNA Chips and Gene Expression Microarrays - The invention provides a series of reagent compositions and methods for making and amplifying novel cDNA based probe sets from RNA samples to improve analysis with gene expression arrays. The methods globally produce probe sets with common universal linkers at one or both ends, called WRAP-Probes, wherein the linkers do not bind to the target sequences and they can efficiently bind added reporters to the probes. The universal linkers are also designed as primer binding sites for copying and amplifying the probes, either linearly with one linker, or exponentially with double linkers. The capacity to globally and exponentially amplify the probe set by PCR is a primary advantage. Adding reporters by terminal linkers also improves quantification since each probe gets equivalent signaling. The invention allows expression analysis of small research, clinical and forensic samples to enable improved diagnostics, drug discovery, therapeutic monitoring, and medical, agricultural and general research. | 06-21-2012 |
20120157344 | GENE EXPRESSION SIGNATURE FOR CLASSIFICATION OF KIDNEY TUMORS - The present invention provides a method for classification of kidney tumors through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA expression framework allows optimization of treatment, and determination of specific therapy. | 06-21-2012 |
20120165206 | Method and Assay for Glycosylation Pattern Detection Related to Cell State - A method and assay for characterizing populations of cells according to their glycosylation pattern, particularly for distinguishing between cell populations. In preferred embodiments the present invention is able to determine the state of a stem cell (ie differentiated or undifferentiated) and/or the state of a cancer cell, for example with regard to malignancy. Preferably the present invention is also able to determine whether a patient is likely to respond to a drug according to the glycosylation pattern of a sample of cancer cells taken from the patient (or alternatively examined while in the patient, as described in greater detail below). Also optionally, it may be used to analyze a cell population before and after treatment with a drug for example. | 06-28-2012 |
20120165207 | Methods for Monitoring Allograft Rejection - Methods are provided for monitoring an allograft recipient for a rejection response, e.g., to predict, to diagnose, and/or to characterize a rejection response. In practicing the subject methods, the level of at least one protein in a sample from the allograft recipient, e.g., serum, urine, blood, CSF, tears or saliva, is evaluated, to monitor the subject. Also provided are compositions, systems, and kits that find use in practicing the subject methods. | 06-28-2012 |
20120165208 | METHOD FOR PREDICTING THE RESPONSIVENESS OF A PATIENT TO A TREATMENT WITH AN ANTI-CD20 ANTIBODY AND A METHOD FOR DIAGNOSING RHEUMATOID ARTHRITIS - The present invention relates to a method for predicting the responsiveness of a patient to a treatment with an anti-CD20 antibody, said method comprising measuring the level of miR-125b expression in a biological sample obtained from said patient. The present invention also relates to a method for diagnosing rheumatoid arthritis in a patient, said method comprising measuring the level of miR-125b expression in a biological sample obtained from said patient. | 06-28-2012 |
20120165209 | METHODS AND COMPOSITIONS FOR DIRECTED MICROWAVE CHEMISTRY - The present invention concerns a novel means by which chemical preparations can be made. Reactions can be accelerated on special cartridges using microwave energy. The chips contain materials that efficiently absorb microwave energy causing chemical reaction rate increases. The invention is important in many chemical transformations including those used in protein chemistry, in nucleic acid chemistry, in analytical chemistry, and in the polymerase chain reaction. | 06-28-2012 |
20120165210 | RAPID GENOTYPING ANALYSIS AND THE METHOD THEREOF - The present invention describes methods of performing rapid nucleic acid detection using a flow through process. The methods comprise single-step signal amplification and/or a one-step hybridization protocol. Using the flow through hybridization process, the present invention provides a more efficient, faster and less expensive genotyping method. This invention further provides a Single Nucleotide Polymorphism (SNP)-based DNA fingerprinting method for rapid and accurate genotyping, identification as well as DNA analyses of genetic materials from human beings and other different organisms. In addition this invention also discloses devices for rapid and sensitive analysis of target analysts. | 06-28-2012 |
20120165211 | Human Antibodies Cross-Reacting With A Bacterial And A Self Antigen From Atherosclerotic Plaques - The present invention refers to human antibodies derived from human antibody libraries prepared from atherosclerotic plaques. It further refers to human antibodies able to immunologically recognize both human transgelin or fragments thereof and a protein with at least 50% similarity to OmpK36 (Outer membrane protein, | 06-28-2012 |
20120165212 | Method for the detection of gene transcripts in blood and uses thereof - The present invention relates generally to the identification of biomarkers of conditions including disease and non disease conditions as well as identifying compositions of biomarkers. The invention further provides a method of diagnosing disease, monitoring disease progression, and differentially diagnosing disease. The invention further provides for kits useful in diagnosing, monitoring disease progression and differentially diagnosing disease. | 06-28-2012 |
20120165213 | Methods, Reagents and Kits for Flow Cytometric Immunophenotyping - The invention relates to the field of flow cytometry and more particularly to a panel of antibody reagents conjugated to fluorescent compounds. Provided are reagent compositions, comprising at least eight distinct fluorochrome-conjugated antibodies comprising a set of at least three identification antibodies for the identification of a leukocyte population of interest and at least four characterization antibodies for further characterization and/or classification of said leukocyte population. Also provided are kits and methods related to the reagent compositions. | 06-28-2012 |
20120165214 | METHODS AND COMPOSITIONS FOR ASSESSMENT OF PULMONARY FUNCTION AND DISORDERS - The present invention provides methods for the assessment of risk of developing lung cancer in smokers and non-smokers using analysis of genetic polymorphisms. The present invention also relates to the use of genetic polymorphisms in assessing a subject's risk of developing lung cancer, and the suitability of a subject for an intervention in respect of lung cancer. Nucleotide probes and primers, kits, and microarrays suitable for such assessment are also provided. | 06-28-2012 |
20120165215 | METHODS AND SYSTEMS FOR PHYLOGENETIC ANALYSIS - The present invention discloses methods and systems for designing and using organism-specific and/or operational taxon unit (OTU)-specific probes. The methods and systems allow for detecting, identifying and quantitating a plurality of biomolecules or microrganisms in a sample based on the hybridization or binding of target molecules in the sample with the probes. Some embodiments provide methods of selecting an oligonucleotide probe specific for a node on a clustering tree. Other embodiments provide methods of selecting organism-specific or OTU-specific oligonucleotide probes for use in accurately detecting a plurality of organisms in a sample with high confidence. Some embodiments provide methods and systems to detect the presence of a rare OTU in a sample. | 06-28-2012 |
20120165216 | METHOD FOR IDENTIFYING SENESCENT MESENCHYMAL STEM CELLS - The invention refers to a method for identifying senescent mesenchymal stem cells growing in in vitro culture, comprising: measuring the length of chromosome telomeres, determining the level of ploidy in the cell, detecting the presence of multipolar mitosis and determining the level of expression of the genes SCIN, AKAP9, EDN-1, CXCL1, CXCL12 and/or CD70. This method can be used for performing genetic stability studies in mesenchymal stem cell cultures, enabling identification and selection of the most stable and appropriate cells for use in cell therapy. | 06-28-2012 |
20120165217 | Cancer Biomarkers and Uses Thereof - The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of cancer. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to diagnose cancer. In another aspect, methods are provided for diagnosing cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 24, wherein the individual is classified as having cancer, or the likelihood of the individual having cancer is determined, based on the at least one biomarker value. | 06-28-2012 |
20120165218 | METHOD AND ASSAY FOR DETERMINING FAS EXPRESSION - Methods and immunoassays for the determination of fatty acid synthase (FAS) expression in patients having or suspected of having a proliferative disorder, especially prostate cancer, are disclosed. The sensitive method and assay detect the level of expression of FAS in a biological sample using antibodies that are highly specific for FAS. The method and assay can be used to monitor the progression of cancer, and/or to predict the efficacy of certain treatments or the likelihood of recurrence of the cancer. | 06-28-2012 |
20120165219 | DEVICES AND METHODS FOR MICROARRAY SELECTION - The present invention relates to a device for the specific selection of target molecules, comprising: (a) at least one reaction zone comprising a microarray, wherein the microarray comprises a substrate, on which one or more species of capture molecules are immobilized, comprising one or more temperature control and/or regulating units for controlling and/or regulating the temperature within the zone; (b) at least one non-reaction zone comprising one or more temperature control and/or regulating units for controlling and/or regulating the temperature within the zone, which is in fluid connection with the reaction zone; and (c) at least one transportation means capable of generating and/or regulating a fluid flow between said reaction zone (a) and said non-reaction zone comprising one or more temperature control and/or regulating units (b). The present invention further relates to a device for the specific selection of target molecules wherein the immobilized capture molecules are organized in the microarray in the form of spots, elongated spots and/or lines. In a further aspect the present invention relates to a method of specifically selecting target molecules, comprising the introducing a medium to such a device, performing interaction reactions in a reaction zone, transporting not interacted or not bound target molecules to a zone allowing reactivation of the target molecules and performing additional interaction reactions with the reactivated target molecules at the reaction zone, as well as the use of such a device for specifically selecting target molecules, e.g. for target enrichment also referred to as microarray based genome selection (MGS) in the literature. | 06-28-2012 |
20120165220 | Uses of CD116 Expression Level - The present invention provides methods for using granulocyte macrophage colony-stimulating factor receptor (CD116) expression level for various clinical applications including, but not limited to, diagnosing inflammatory bowel disease in a subject. | 06-28-2012 |
20120165221 | DIAGNOSIS OF CANCERS THROUGH GLYCOME ANALYSIS - Markers and methods of diagnosis and monitoring of cancer through global glycome analysis. | 06-28-2012 |
20120165222 | METHODS AND SYSTEMS FOR ANALYSING HYBRIDISATION - A method is described for the analysis of hybridisation between a target in solution and a probe bound at a surface. The method comprises receiving detection intensity results for hybridisation of the target with a plurality of different probes, the probes being selected so that a range of hybridisation detection intensity results for the hybridisation between the target and the probe is covered. The method further comprises analysing the detection intensity results as function of the hybridisation free energy. According to embodiments of the present invention, the receiving and/or analysing takes into consideration a thermodynamic non-equilibrium state for the target-probe bounding state. | 06-28-2012 |
20120165223 | Human Intestinal Normal Bacterial Flora DNA Chip and Method for Estimating Harmness to Human Body Due to Change of Human Intestinal Normal Bacterial Flora Using DNA Chip - The present invention relates to a DNA chip showing specific responses to a human intestinal normal bacterial flora and a method for estimating harmness to the human bodies due to the change of the human intestinal normal bacterial flora using the DNA chip. | 06-28-2012 |
20120172242 | CANCER SPECIFIC TRANSCRIPT VARIANTS - The present inventors here present a novel strategy for identification of RNA transcript variants and demonstrate that these can be correlated to disease states in mammals such as cancer. In particular, the transcript variants show prevalence and specificity to cancer, and thus also show clinical applicability in e.g. cancer diagnostics and prognostics, treatment and therapeutics. The present inventors have identified RNA transcript variants of VNN1 that can be used as biomarkers. The RNA transcript variant may also be used as biomarkers for diagnosing, prognosing, and/or monitoring a cancer. | 07-05-2012 |
20120172243 | SYSTEMS AND METHODS FOR EXPRESSION-BASED CLASSIFICATION OF THYROID TISSUE - A system for classifying thyroid nodule tissue as malignant or benign is provided that is based on the identification of sets of gene transcripts, which are characterized in that changes in expression of each gene transcript within a set of gene transcripts can be correlated to with either malignant or benign thyroid nodule disease. The thyroid classification system provides for sets of “thyroid classifying” target sequences and further provides for combinations of polynucleotide probes and primers derived there from. These combinations of polynucleotide probes can be provided in solution or as an array. The combination of probes and the arrays can be used for diagnosis. The invention further provides further methods of classifying thyroid nodule tissue. | 07-05-2012 |
20120172244 | BIOMARKERS AND USES THEREOF IN PROGNOSIS AND TREATMENT STRATEGIES FOR RIGHT-SIDE COLON CANCER DISEASE AND LEFT-SIDE COLON CANCER DISEASE - Genetic biomarkers for left side colon cancer (LCC) (such as expression levels of an RNA transcript or expression product of NOX4, MMP3, or a combination) and right side colon cancer (RCC) (such as expression levels of an RNA transcript or expression product of CDCX2, FAM69A, or a combination), are disclosed. Methods for using the biomarkers in providing a prognosis of relapse-free survival probability in patients having LCC or RCC are also presented. Prognostic panels using gene expression values of the biomarkers are also presented. Computer implemented methods employing the biomarkers, and as well as for determining relapse-free survival probability in a patient having RCC or LCC are provided. A genetic method for classifying a colon cancer tissue as a RCC or as a LCC is also disclosed. | 07-05-2012 |
20120172245 | METHODS AND MATERIALS FOR CAPTURE ANTIBODY TARGETED FLOURESCENT IN-SITU HYBRIDIZATION (CAT-FISH) - The subject invention concerns materials and methods for detecting a target cell in a population. Methods of the invention comprise internally labeling cells via fluorescence in situ hybridization (FISH) using probes that target rRNA, followed by binding of capture antibodies targeted (CAT) for specific cell surface epitopes on the target cells. In one embodiment, the target cells are bacterial cells. | 07-05-2012 |
20120172246 | Detection of Nucleic Acids - Methods of detecting various types of nucleic acids, including methods of detecting two or more nucleic acids in multiplex branched-chain DNA assays, are provided. Detection assays may be conducted at least in vitro, in cellulo, and in situ. Nucleic acids which are optionally captured on a solid support are detected, for example, through cooperative hybridization events that result in specific association of a label probe system with the nucleic acids. Various label probe system embodiments are provided. Compositions, kits, and systems related to the methods are also described. | 07-05-2012 |
20120172247 | Method for measuring glycoprotein, method for examining liver disease, reagent for quantitative determination of glycoprotein, and glycan-marker glycoprotein as an index for clinical conditions of liver disease - An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Disclosed is a method for measuring at least one glycoprotein selected from alpha-1-acid glycoprotein (AGP) and Mac-2-binding protein (M2BP) contained in a sample collected from a subject, comprising: measuring AGP binding to a first lectin selected from AOL and MAL, when the glycoprotein is AGP; and measuring M2BP binding to a second lectin selected from WFA, BPL, AAL, RCA120, and TJAII, when the glycoprotein is M2BP. | 07-05-2012 |
20120172248 | METHOD FOR THE DIAGNOSIS AND/OR PROGNOSIS OF ACUTE RENAL DAMAGE - The invention relates to a method for the diagnosis and/or prognosis of acute renal damage by analysing the level of expression of at least one microRNA selected from miR-127, miR-126, miR-210 and miR-101. | 07-05-2012 |
20120172249 | METHOD FOR A HIGHLY SENSITIVE DETECTION AND QUANTIFICATION OF BIOMOLECULES USING SECONDARY ION MASS SPECTROMETRY (SIMS) - The present invention relates to an improved method for detecting and quantifying the presence or absence of a number of biomolecules in a sample using the SIMS technique and arrays for use in said method. | 07-05-2012 |
20120172250 | METHOD AND KIT FOR THE CLASSIFICATION AND PROGNOSIS OF WOUNDS - The invention relates to a method and kit for identifying chronic or acute mammalian wound tissue or for determining the prognosis of mammalian wound tissue based upon the identification of at least one key set of molecular markers or genes whose expression pattern is indicative of a given wound type and so representative of a given prognosis. | 07-05-2012 |
20120172251 | METHODS AND COMPOSITIONS FOR DIAGNOSING HEART FAILURE - The present invention provides diagnostic and prognostic assays and kits for determining whether a heart failure patient will respond to a pharmacotherapy. Methods of the invention include determining the expression level of biomarkers that are differentially expressed in a heart failure patient that responds to a pharmacotherapy compared to a heart failure patient that does not respond to a pharmacotherapy. | 07-05-2012 |
20120172252 | High Density Sequence Detection Methods - A method for performing PCR on a liquid sample comprising a plurality of polynucleotide targets, wherein each polynucleotide target is present at very low concentration within the sample. The method comprises applying PCR reactants to the surface of a substrate to produce a plurality of reaction spots on the surface of the substrate; loading the liquid sample and a PCR reagent mixture onto the reaction spots; forming a sealed reaction chamber, having a volume of less than about 20 nanoliters, over each of the reaction spots; and amplifying the sample. | 07-05-2012 |
20120178637 | BIOMARKERS AND METHODS FOR DETECTING ALZHEIMER'S DISEASE - Methods for classifying a test sample as indicative of Alzheimer's disease use protein and peptide biomarkers that are differentially expressed in the cerebral spinal fluid (CSF) of subjects with Alzheimer's disease relative to age-matched controls. The methods also use protein and peptide signatures indicative of Alzheimer's disease. Microarrays and kits for detecting the protein and peptide biomarkers in CSF samples can be used to classify Alzheimer's disease state from test samples. | 07-12-2012 |
20120178638 | RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS - The present invention is directed to RNA monomers comprising O-acetal levulinyl protecting groups at the 2′ and/or the 5′-hydroxy functionalities of the ribose moiety. Said monomers may be incorporated into oligoribonucleotides or RNA polynucleotides. Furthermore, the invention is directed to methods for the synthesis of said RNA monomers, oligoribonucleotides and RNA polynucleotides, as well as methods for their deprotection and methods for the use of said compounds and compositions comprising said compounds. In particular, such compounds and compositions comprising them are used in methods for light-directed synthesis of RNA microarrays. | 07-12-2012 |
20120178639 | BIONANOSENSOR DETECTION DEVICE - The present invention is directed to a nucleic acid detection device and method that incorporates bio-nanosensor technology to detect duplex DNA. The device is particularly applicable in detecting the presence or absence of duplex DNA and its correlation to the diagnosis of infectious diseases. In one embodiment, the infectious disease is Lyme disease or a bacterial or viral infection. The device comprises a bio-nanosensor element comprising ssDNA primed nanotubes, either single walled or multi-walled. The method comprises contacting the bio-nanosensor element with a test solution potentially containing DNA of interest. DNA of interest that hybridizes to the ssDNA results in a measurable change in the electrical properties of the bio-nanosensor. Correlations between the results provided by the device and the presence of disease states can result in rapid diagnosis of diseases such as Lyme disease or foodborne infections such as salmonellosis. | 07-12-2012 |
20120178640 | Nanotube Array for Optical Detection of Protein-Protein Interactions - A composition can include a nanostructure, and a linker associated with the nanostructure, wherein the linker is configured to interact with a capture protein. The nanostructure can include a single-walled carbon nanotube. A plurality of the compositions can be configured in an array. | 07-12-2012 |
20120178641 | GLOBAL MAPPING OF PROTEIN-DNA INTERACTION BY DIGITAL GENOMIC FOOTPRINTING - The present invention provides a method for globally mapping a genome for its protein-binding pattern. A computer system useful for this purpose is also described. | 07-12-2012 |
20120178642 | GENE EXPRESSION PROFILES ASSOCIATED WITH CHRONIC ALLOGRAFT NEPHROPATHY - By a genome-wide gene analysis of expression profiles of over 50,000 known or putative gene sequences in peripheral blood, the present inventors have identified a consensus set of gene expression-based molecular biomarkers associated with chronic allograft nephropathy and/or interstitial fibrosis and tubular atrophy CAN/IFTA and subtypes thereof. These genes sets are useful for diagnosis, prognosis, monitoring and/or subtyping of CAN/IFTA. | 07-12-2012 |
20120178643 | METHODS AND COMPOSITIONS FOR IDENTIFYING D-PEPTIDIC COMPOUNDS THAT SPECIFICALLY BIND TARGET PROTEINS - Methods and compositions for identifying D-peptidic compounds that specifically bind target proteins are provided. Aspects of the methods include screening libraries of 20 residue or more L-peptidic compounds for specific binding to 40 residue or more D-target proteins. Once a L-peptidic compound has been identified that specifically binds to the D-target protein, the D-enantiomer of that compound may be produced. | 07-12-2012 |
20120178644 | GENE EXPRESSION PROFILING OF EGFR POSITIVE CANCER - The present invention concerns prognostic markers associated with EGFR positive cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed tissue samples of EGFR-expressing cancer, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor. | 07-12-2012 |
20120178645 | IDENTIFYING CIRCULATING TUMOR CELLS (CTCS) USING CD146 IN BREAST CANCER PATIENTS - The present invention relates to a method for diagnosing cancer in a subject said method comprising the steps of providing a biological sample from a subject, and determining the expression of the MCAM gene in a circulating tumor cell (CTC) in said biological sample. | 07-12-2012 |
20120178646 | HIGH THROUGHPUT METHOD AND SYSTEM FOR IN VIVO SCREENING - Provided is a method and system for screening chemical compounds or compositions, wherein replicating entities are introduced into the yolk of an (un)fertilized egg or embryo. The method may be extended to elucidate the mechanism-of-action of functional chemical compounds or compositions in the same method and system. The method and system may also be employed for identifying marker genes, marker proteins or marker metabolites. | 07-12-2012 |
20120178647 | ENGINEERING OF ZINC FINGER ARRAYS BY CONTEXT-DEPENDENT ASSEMBLY - A method of designing a multi-zinc-finger polypeptide predicted to bind to a sequence of interest that has at least three subsites includes the steps of: a) providing a nucleotide sequence of interest having first, second, and third consecutive subsites, wherein each of the first and third subsites are adjacent to the second subsite; b) identifying first and second adjacent zinc finger polypeptide sequences previously shown to bind to the first and second subsites in the context of a multi-zinc finger polypeptide; c) identifying a third zinc finger polypeptide previously shown to bind to a third subsite adjacent to the second subsite when present in the context of a multi-zinc finger polypeptide adjacent to the second zinc finger polypeptide; and d) combining the first, second, and third zinc finger polypeptide sequences in linear order, thereby designing a multi-zinc finger polypeptide predicted to bind to the sequence of interest. | 07-12-2012 |
20120178648 | METHOD FOR DETECTION OF TARGET NUCLEIC ACID - An object of the disclosure of the present specification is to provide a method for detection of a target nucleic acid which allows construction of an effective detection system of a target nucleic acid. For this purpose, in the disclosure of the present specification, a first primer comprising an identification sequence complementary to a target sequence in a target nucleic acid and a tag addition sequence, and a second primer having a label are prepared. The first primer and the second primer are used for the target nucleic acid in a sample to amplify a chimeric DNA having a tag sequence and the label. The chimeric DNA is hybridized with a detection probe on a solid phase to obtain signal intensity information based on the label, and the target nucleic acid is detected based on the signal intensity information. | 07-12-2012 |
20120184451 | LABEL-FREE DETECTION OF RENAL CANCER - Natural and/or synthetic antibodies for specific proteins are adhered to nanoparticles. The nanoparticles are adhered to a substrate and the substrate is exposed to a sample that may contain the specific proteins. The substrates are then tested with surface enhanced Raman scattering techniques and/or localized surface plasmon resonance techniques to quantify the amount of the specific protein in the sample. | 07-19-2012 |
20120184452 | METHODS FOR DIAGNOSING FOLLICULAR THYROID CANCER - Methods for diagnosing follicular thyroid cancer, providing a prognosis for follicular thyroid cancer, and monitoring treatment of follicular thyroid cancer, using biomarkers that are differentially expressed in follicular thyroid cancer are provided. | 07-19-2012 |
20120184453 | BIOMARKERS FOR RECURRENCE PREDICTION OF COLORECTAL CANCER - Methods for determining the likelihood of colorectal cancer (CRC) recurrence in a subject that involve measuring the expression level of two or more micro ribonucleic acids (miRNAs) in a biological sample comprising CRC tumor cells from said subject and using the normalized, measured expression levels to determine the likelihood of colorectal cancer recurrence for said subject. In the methods, the normalized expression levels of specific miRNAs are weighted by their contribution to CRC recurrence to calculate the likelihood of CRC recurrence. Kits for measuring the expression level of specific miRNAs that can be used in determining the likelihood of CRC recurrence are also provided. | 07-19-2012 |
20120184454 | GENE SIGNATURE IS ASSOCIATED WITH EARLY STAGE RECTAL CANCER RECURRENCE - Applicants have identified a 36-gene signature that is associated with recurrence of stage I and II rectal cancers not treated with chemotherapy or radiation. This signature can be used to identify early stage rectal cancer patients that may need additional therapy beyond surgery to treat their cancer as well as identify patients that will not benefit from therapy other than surgery. | 07-19-2012 |
20120184455 | Method and Nucleic Acids for the Improved Treatment of Breast Cell Proliferative Disorders - The present invention relates to modified and genomic sequences, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA, as well as to a method for predicting the response of a subject with a cell proliferative disorder of the breast tissues, to endocrine treatment. | 07-19-2012 |
20120184456 | Methods and systems for analysis of nutraceutical associated components - The present disclosure relates to methods and systems that may be used for analysis of nutraceutical associated components. | 07-19-2012 |
20120184457 | Modulation of miRNA Activity - Provided is a method of identifying a compound which modulates miRNA activity comprising (i) determining the ability of a test compound to alter the polyuridylation activity of a ZCCHC polypeptide wherein a test compound which alters the polyuridylation activity is useful in modulating miRNA activity; or (ii) determining the ability of a test compound to alter the binding of a ZCCHC polypeptide to a LIN28 polypeptide, wherein a test compound which alters said binding may be useful in modulating miRNA activity; or (iii) determining the ability of a test compound to bind to a ZCCHC polypeptide, wherein a test compound which binds to the ZCCHC polypeptide may be useful in modulating miRNA activity. | 07-19-2012 |
20120184458 | METHODS FOR SCREENING AND ARRAYING MICRORGANISMS SUCH AS VIRUSES USING SUBTRACTIVE CONTACT PRINTING BACKGROUND - Methods for screening and arranging microorganisms such as viruses in an array using subtractive contact printing are provided. In one embodiment, a method for forming an array of receptors for microorganisms comprises: patterning an array of structures on a first substrate to form a template on a surface of the first substrate; applying a receptor material to a face of a second substrate; and contacting the face of the second substrate with the template to remove a portion of the receptor material from the second substrate, thereby forming an array of receptors on the second substrate. | 07-19-2012 |
20120184459 | Taste Receptors Of The T1R Family From Domestic Cat - The present invention relates to the discovery of several genes of the domestic cat ( | 07-19-2012 |
20120190562 | METHODS AND COMPOSITIONS FOR DETERMINING SEVERITY OF HEART FAILURE IN A SUBJECT - The application provides a method of determining a severity of heart failure in a human test subject, by determining a level of RNA encoded by one or more heart failure marker genes in blood of the test subject compared to controls. | 07-26-2012 |
20120190563 | METHODS FOR PREDICTING SENSITIVITY TO TREATMENT WITH A TARGETED TYROSINE KINASE INHIBITOR - Methods and kits for predicting the sensitivity of a cancer to treatment with a targeted tyrosine kinase inhibitor are disclosed. | 07-26-2012 |
20120190564 | IDENTIFICATION OF PROTEIN BINDING SITES - The disclosure relates to the field of molecular recognition or detection of discontinuous or conformational binding sites or epitopes corresponding to a binding molecule, in particular, in relation to protein-protein, protein-nucleic acid, nucleic acid-nucleic acid or biomolecule-ligand interactions. Provided is a synthetic molecular library allowing testing for, identification, characterization, or detection of a discontinuous binding site able to interact with a binding molecule, the library having been provided with a plurality of test entities, each test entity comprising at least one first segment spotted next to a second segment, each segment having the capacity of being a potential single part of a discontinuous binding site. | 07-26-2012 |
20120190565 | Method Of Diagnosis Or Prognosis Of A Neoplasm Comprising Determining The Level Of Expression Of A Protein In Stromal Cells Adjacent To The Neoplasm - The invention provides diagnostic and therapeutic methods for neoplastic disease patients with neoplasms of, for example, the breast, skin, kidney, lung, pancreas, rectum and colon, prostate, bladder, epithelial, non-epithelial, lymphomas, sarcomas, melanomas, and the like, wherein the method comprises determining the level of expression o caveolin-1, caveolin-2, vimentin, calponin2, tropomyosin, gelsolin, prolyl 4-hydroxylase alpha, EF-I-delta, or M2-isoform of pyruvate kinase in stromal cells adjacent to the neoplasm. | 07-26-2012 |
20120190566 | COMPOSITIONS AND METHODS FOR INHIBITING BIOFILMS - Using arrays of peptides derived from | 07-26-2012 |
20120190567 | DIAGNOSTIC AND PROGNOSTIC METHODS FOR LUNG DISORDERS USING GENE EXPRESSION PROFILES FROM NOSE EPITHELIAL CELLS - The present invention provides methods for diagnosis and prognosis of lung cancer using expression analysis of one or more groups of genes, and a combination of expression analysis from a nasal epithelial cell sample. The methods of the invention provide far less invasive method with a superior detection accuracy for lung cancer when compared to any other currently available method for lung cancer diagnostic or prognosis. The invention also provides methods of diagnosis and prognosis of other lung diseases, such as lung cancer. | 07-26-2012 |
20120190568 | GENETIC MARKERS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION, METHODS OF DETECTION AND USES THEREOF - Disclosed is a method for identifying an individual who has an altered risk for developing age related macular degeneration comprising detecting a single nucleotide polymorphism (SNP) | 07-26-2012 |
20120190569 | ENDOGENETIC RETROVIRAL SEQUENCES, ASSOCIATED WITH AUTOIMMUNE DISEASES OR WITH PREGNANCY DISORDERS - A genomic retroviral nucleic material, in an isolated or purified state, at least partially functional or non-functional, wherein the genome comprises a reference nucleotide sequence selected from the group including sequences of SEQ ID NOs: 1-15, their complementary sequences, and their equivalent sequences, in particular, nucleotide sequences having, for every series of 100 contiguous monomers, at least 70% and preferably at least 90% homology with the sequences of SEQ ID NOs: 1-15. | 07-26-2012 |
20120190570 | MOLECULAR TARGETS AND COMPOUNDS, AND METHODS TO IDENTIFY THE SAME, USEFUL IN THE TREATMENT OF JOINT DEGENERATIVE AND INFLAMMATORY DISEASES - The application discloses methods for identifying and using compounds that inhibit extra-cellular matrix (ECM) degradation and inflammation, using a polypeptide sequence including SEQ ID NO: 17-127 (hereinafter “TARGETS”) and fragments thereof, expression inhibitory agents such as antisense polynucleotide, a ribozyme, and a small interfering RNA (siRNA), comprising a nucleic acid sequence complementary to, or engineered from, a naturally occurring polynucleotide sequence encoding a polypeptide of SEQ ID NO: 17-127, useful in pharmaceutical compositions comprising said agent, for the treatment, or prevention, of chronic joint degenerative and/or inflammatory diseases such as rheumatoid arthritis. | 07-26-2012 |
20120190571 | METHODS AND APPARATUS FOR DETECTION OF GLUTEN SENSITIVITY, AND ITS DIFFERENTIATION FROM CELIAC DISEASE - Antibodies are used as biomarkers to assist in distinguishing gluten immune reactivity and sensitivity, silent celiac disease, Crohn's disease and other gut-related pathologies from classical celiac disease. In one class of embodiments, sera, saliva or other samples from a human or other animal are tested for antibodies to (a) a wheat antigen; (b) a gliadin antigen; and (c) one or more of a wheat germ agglutinin, a gluteomorphin, a glutenin, a deamidated glutenin, a prodynorphin, and a dynorphin. Test results are considered particularly interesting where the wheat antigen and the gliadin antigen are both selected from the group consisting of an α-gliadin-33-mer, an α-gliadin-17-mer, a γ-gliadin-15-mer, an ω-gliadin-17-mer, and a glutenin-21-mer. Test plates and kits can advantageously test for antigens to at least three, five, seven or all of α-gliadin, γ-gliadin, ω-gliadin, glutenin, wheat germ agglutinin, gluteomorphin, prodynorphins, transglutaminase-2, transglutaminase-3, transglutaminase-6, and gliadin-bound transglutaminase. | 07-26-2012 |
20120190572 | DETECTING GENETIC ABNORMALITIES - The present invention is directed to compositions and methods for detecting genetic abnormalities. The present invention encompasses methods and compositions for comparing alleles in a sample containing both maternal and fetal nucleic acids in order to identify genetic abnormalities. | 07-26-2012 |
20120190573 | BIOMARKER OF LUNG CANCER - The present invention provides methods of providing a prognosis for a lung cancer in a subject and methods of predicting the risk of metastasis of a lung cancer in a subject. The present invention additionally provides kits that find use in the practice of the methods of the invention. | 07-26-2012 |
20120190574 | Compound Arrays for Sample Profiling - The invention provides arrays of compound for use in profiling samples. The arrays include compounds bind to components of the samples at relatively low affinities. The avidity of compounds binding to components of the samples can be increased by forming arrays such that multivalent components of the samples (e.g., antibodies or cells) can bind to more than one molecule of a compound at the same time. When a sample is applied to an array under such conditions, the compounds of the array bind to component(s) of the sample with significantly different avidities generating a profile characteristic of the sample. | 07-26-2012 |
20120190575 | INFLUENZA DETECTION METHOD AND KIT THEREFOR - The invention provides oligonucleotide(s) for simple, specific and/or sensitive test(s) for the presence of Influenza A and/or B virus. Kit(s) comprising the oligonucleotide(s) for use as probe(s) and/or primer(s) useful in the test(s) are also provided. | 07-26-2012 |
20120190576 | Glycan Markers as Measure of Disease State of Hepatic Diseases - The present invention is directed to developing a glycan markers capable of detecting a hepatic disease, and more specifically to developing a glycan marker indicating a hepatic disease-state. Furthermore, the present invention is also directed to developing a glycan marker capable of distinguishing hepatic disease-states with the progress of hepatocarcinoma. The present inventors identified, among the serum glycoproteins, glycopeptides and glycoproteins in which a glycan structure specifically changes due to a hepatic diseases including hepatocarcinoma and provide these as novel glycan markers (glycopeptide and glycoprotein) specific to hepatic disease-states. | 07-26-2012 |
20120190577 | PROCESSES AND METHODS FOR DIAGNOSIS OF ALZHEIMER'S DISEASE - The present application relates to methods and compositions that can be used to diagnose Alzheimer's disease in mammals, most notably humans. Ti describes most notably peripheral blood biomarkers Alzheimer's disease and uses said biomarkers in diagnostic methods. It also relates to tools and/or kits that can be used to implement said methods (reagents, probes, primers, antibodies, arrays or chips, cells, etc.), as well as the preparation and use thereof. The invention can further be used to detect the presence or the advance of Alzheimer's disease in mammals, including during the disease's early phase, as well as to predict the effectiveness of an Alzheimer's disease treatment. | 07-26-2012 |
20120190578 | Plasma Complement Components as Expression Markers for Age-Related Macular Degeneration and Related Phenotypes - The present invention is directed to systems and method for predicting risk of AMD or a susceptibility to AMD in a patient by detecting elevated serum or plasma levels of C3, CFB or CFH and other complement factor polypeptides, wherein devated levels certain complement factors, genetic risk factors, medical risk factors, behavioral and environmental risk factors are associated with are indicative of susceptibility for or an increased risk of developing AMD, or an increased risk of progression of AMD in the patient. | 07-26-2012 |
20120190579 | Functionalisation of Solid Substrates - The present invention relates to a product comprising a solid substrate and a moiety of formula (I) linked thereto: wherein X, X′ and R are as defined herein. The product is useful for immobilising target molecules such as molecules of biochemical interest to solid substrates for numerous applications, such as affinity chromatography, ELISA, biotechnological assay techniques and solid phase peptide synthesis. | 07-26-2012 |
20120190580 | TREATMENT OF PATIENTS AFTER STENT IMPLANTATION OR BALLOON DILATATION AND DRUG ELUTING STENTS - The present invention relates to a nucleic acid molecule for use in the treatment or preventive treatment of a patient after stent implantation or balloon dilatation, wherein the nucleic acid molecule is selected from (a) a single-stranded nucleic acid molecule comprising or consisting of the sequence of SEQ ID NO: 1, 2, 3 or 4 or a sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 1, 2, 3 or 4; (b) a hairpin RNA, wherein one of the regions forming the double-stranded portion of said hairpin RNA comprises or consists of the sequence of SEQ ID NO: 1, 2, 3 or 4 or a sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 1, 2, 3 or 4; (c) an at least partially double-stranded RNA comprising two separate single strands, wherein a region within one of the strands, said region being located within the double-stranded portion of said double-stranded RNA, comprises or consists of the sequence of SEQ ID NO: 1, 2, 3 or 4 or a sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 1, 2, 3 or 4; (d) a nucleic acid molecule encoding the nucleic acid molecule of (a) or the RNA (b); and (e) a nucleic acid molecule or a two nucleic acid molecules encoding the two separate single strands of the RNA of (c). The present invention also relates to a drug eluting stent comprising the nucleic acid molecule according to the invention. | 07-26-2012 |
20120190581 | Detection of Auto-Antibodies to Specific Glycans as Diagnostic Tests for Autoimmune Diseases - The invention provides uses, methods, and kits for diagnosing an autoimmune disease, particularly scleroderma and systemic lupus erythematosus, in a subject by detecting the presence of one or more antibodies that specifically bind to one or more glycans in a subject sample. | 07-26-2012 |
20120190582 | METHOD FOR DESIGNING PROBE IN DNA MICROARRAY, AND DNA MICROARRAY PROVIDED WITH PROBE DESIGNED THEREBY - Provided is a probe to be used in a DNA microarray having an excellent detection rate of a polymorphism such as SNP contained in genomic DNA. A method for designing a probe according to the invention includes the steps of: specifying one or more regions covering at least a part of fragments flanked by restriction enzyme recognition sites recognized by a restriction enzyme, contained in genomic DNA derived from an organism to be tested; and designing a probe for the specified one or more regions for detecting the fragment in the organism to be tested. | 07-26-2012 |
20120196760 | METHODS AND COMPOSITIONS FOR IDENTIFYING MODULATORS OF ANTI-TETHERIN ACTIVITY TO INHIBIT PROPAGATION OF VIRUSES - The present invention provides protein constructs for detection of interaction between Tetherin and ant-Tetherin molecules. The constructs include a Tetherin sequence or a portion of a Tetherin sequence that is sufficient for cell-surface localization, and a sequence providing a detectable signal. The invention further provides methods of using such constructs to screen for substances that modulate the Tetherin-inhibiting properties of anti-Tetherins. Methods of screening for anti-viral agents, including anti-HIV agents, are provided. | 08-02-2012 |
20120196761 | DIAGNOSIS OF IN SITU AND INVASIVE BREAST CANCER - The disclosure includes the use of gene expression profiles, or patterns, with clinical relevance to breast cancer. In particular, the disclosure provides the identities of genes that are expressed in correlation with the presence of breast cancer, the grade of breast cancer, and the type of breast cancer. The disclosed methods assist in the detection and identification of breast cancer in a patient and so helps determine treatment and clinical outcome, and so prognosis, for the patient. The gene expression levels, whether embodied in nucleic acid expression, protein expression, or other expression formats, may be used detect the presence of in situ or invasive breast cancer. | 08-02-2012 |
20120196762 | METHOD AND APPARATUS FOR DISCOVERY, DEVELOPMENT AND CLINICAL APPLICATION OF MULTIPLEX ASSAYS BASED ON PATTERNS OF CELLULAR RESPONSE - A method for deriving a multiplex cell response assay (MCRA), the method comprising:
| 08-02-2012 |
20120196763 | ANTIFUNGAL TARGET - A method of identifying an antifungal agent which targets a PPTB protein of a fungus comprising determining whether a candidate compound binds to or inhibits a PPTB protein, wherein binding or inhibition indicates that the candidate sub-stance is an antifungal agent. | 08-02-2012 |
20120196764 | SALIVARY TRANSCRIPTOMIC AND MICROBIAL BIOMARKERS FOR PANCREATIC CANCER - The present invention relates to the identification of pancreatic cancer biomarkers for the detection of early pancreatic cancer. The present invention also provides methods of diagnosing pancreatic cancer and distinguishing between pancreatic cancer and chronic pancreatitis. The present invention additionally provides kits that find use in the practice of the methods of the invention. | 08-02-2012 |
20120196765 | METHOD FOR DETECTION OR ANALYSIS OF TARGET SEQUENCE IN GENOMIC DNA - A method of detecting or analyzing a target sequence in a genomic DNA by using a capture probe immobilized on a solid carrier includes: bringing the target nucleic acid into contact with a first query probe that has a sequence complementary to a portion of the target sequence or to a sequence adjacent to the portion and a second query probe that has a sequence complementary to another portion of the target sequence or to a sequence adjacent to the another portion and that has a recognition sequence complementary to a portion of the capture probe; acquiring a ligated molecule by ligating the first query probe and the second query probe that are hybridized to the target nucleic acid; bringing the ligated molecule into contact with the capture probe on the solid carrier and then capturing the ligated molecule on the solid carrier by hybridizing the capture probe with the recognition sequence in the ligated molecule; and detecting the captured ligated molecule. | 08-02-2012 |
20120196766 | Therapeutic Use of Farnesyltransferase Inhibitors and Methods of Monitoring the Efficacy Thereof - The therapeutic use of farnesyltransferase inhibitors (e.g., tipifarnib) for the treatment of sepsis is described. Methods useful to monitor the effectiveness of such treatment are also described. | 08-02-2012 |
20120196767 | MICROARRAY BASED SAMPLE DETECTION SYSTEM - A microarray assembly for detection of a target molecule is disclosed. The microarray assemblies comprise an array chamber having a microarray located therein and features that facilitate liquid movement within the array chamber. Also disclosed are methods for making the microarray assembly using rollable films and methods for detecting microarray spots using an internal control fluorophore in the array spot. | 08-02-2012 |
20120196768 | METHOD FOR PREPARING aRNA AND METHOD FOR ANALYSIS OF GENE EXPRESSION - A method for preparing aRNA to be used for gene expression analysis from an RNA sample extracted from a tissue or cell(s) fixed with a fixative includes an amplification step of the RNA sample by reverse transcription and in vitro transcription, the ratio of aminoallyl uridine 5′-triphosphate (AA-UTP) in a nucleotide reagent used in the in vitro transcription is not less than 5 mol % and less than 25 mol % with respect to the total of uridine 5′-triphosphate (UTP) and AA-UTP. | 08-02-2012 |
20120202700 | Sample preparation and detection method - A method for detecting a biological agent in a liquid sample is disclosed. The method comprises: passing a liquid sample through a filter in the presence of a surfactant; and subjecting the filtered sample to direct polymerase chain reaction (PCR) analysis for the presence of a biological agent, wherein the filter has a porosity that allows the biological agent to pass through the filter in its intact form. | 08-09-2012 |
20120202701 | AN ANTIBODY-GLYCAN COMPLEX TARGETING THE DISIALYL CORE II AND SIALYL LEWIS X STRUCTURES, AND USES THEREOF INVOLVING ANALYSIS OF STEM CELLS OR CANCER CELLS - Antibody-saccharide-complexes and methods and uses related to analysis of cells. Also disclosed is a method of selection of new antibody with CHO-specificity and to a use of antibodies produced for the analysis of stem cells or cancer cells or other cells or tissues known to bind to CHO-antibodies. | 08-09-2012 |
20120202702 | DETECTION OF LOW CONCENTRATION BIOLOGICAL AGENTS - Provided are methods of preparing a sample for detection by placing the sample on a shrinkable scaffold and then shrinking the scaffold. An exemplary shrinkable scaffold is a thermoplastic substrate. | 08-09-2012 |
20120202703 | METHOD FOR DETECTING AND QUANTIFYING A TARGET SUBSTANCE USING A BIOCHIP - The present invention relates to a method for detecting and quantifying a target substance using a biochip having a substrate onto which probe molecules are fixed, and more particularly, to a method for detecting and quantifying a target substance with the naked eye by using a biochip, comprising the steps of preparing a biochip having a substrate onto which probe molecules are fixed, contacting the biochip with a sample containing a target substance having electric charges, reacting the target substance with nanoparticles having electric charges that are opposite to those of the target substance, and then reacting with a metal enhancing solution so as to amplify the size of the nanoparticles. | 08-09-2012 |
20120202704 | MULTI-SAMPLE INDEXING FOR MULTIPLEX GENOTYPING - A method for determining the presence of multiple nucleotide sequences of interest in multiple samples while preserving the identity of each sample, by contacting the samples with a plurality of probe sets. The probes are designed to indicate the presence of the sequences of interest and the identity of the sample containing the sequence of interest in complex mixtures. Applications of the method include genotyping, expression analysis, and identification of individual species in complex samples. Kits of probe sets for use in the methods are also provided. | 08-09-2012 |
20120202705 | ACUTE KIDNEY INJURY RISK TESTING - The present invention relates to the method of determining the risk of acute kidney injury comprising determining the amount of one or more marker(s) selected from REN, SLC38A4, IL17RB, TMEM149, FLRT3, and CATSPERG or any combination thereof in a sample. | 08-09-2012 |
20120208712 | SIRTUIN 5 POLYMORPHISMS AND NEUROLOGICAL DISEASES - A method for determining a subject's risk of developing a neurological disease or disorder such as Huntington's or Parkinson's disease, based on the presence of SIRT5 | 08-16-2012 |
20120208713 | METHODS AND COMPOSITIONS RELATING TO FUSIONS OF ALK FOR DIAGNOSING AND TREATING CANCER - Disclosed are methods and compositions for detecting the presence of a cancer in a subject and assessing the efficacy of treatments for the same. The disclosed method use reverse transcription polymerase chain reaction (RT-PCR) and multiplex polymerase chain reaction techniques as well as Template Exchange Extension Reaction (TEER) to detect the presence of point mutations, truncations, or fusions of anaplastic lymphoma kinase. | 08-16-2012 |
20120208714 | DNA-BASED METHODS FOR CLONE-SPECIFIC IDENTIFICATION OF STAPHYLOCOCCUS AUREUS - MRSA CC398 is a clone of | 08-16-2012 |
20120208715 | METHODS AND COMPOSITIONS FOR DIAGNOSIS OF ACUTE MYOCARDIAL INFARCTION (AMI) - Embodiments of the invention utilizes advanced detection methodologies, such as the lab-on-a-chip (LOC) technology, as a cost-effective, efficient, ultra-sensitive rapid method for diagnosing Acute Myocardial Infarction (AMI) in human subjects. In certain aspects, multiple biomarkers of AMI are concurrently detected and measured in serum and saliva to provide a more efficient, sensitive and accurate diagnosis of AMI. | 08-16-2012 |
20120208716 | DEVICE AND METHOD FOR PARTICLE COMPLEX HANDLING - An embodiment of the invention relates to a device for detecting an analyte in a sample. The device comprises a fluidic network and an integrated circuitry component. The fluidic network comprises a sample zone, a cleaning zone and a detection zone. The fluidic network contains a magnetic particle and/or a signal particle. A sample containing an analyte is introduced, and the analyte interacts with the magnetic particle and/or the signal particle through affinity agents. A microcoil array or a mechanically movable permanent magnet is functionally coupled to the fluidic network, which are activatable to generate a magnetic field within a portion of the fluidic network, and move the magnetic particle from the sample zone to the detection zone. A detection element is present which detects optical or electrical signals from the signal particle, thus indicating the presence of the analyte. | 08-16-2012 |
20120208717 | Systems and methods for characterizing kidney diseases - The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of kidney disorders by detection of cytokines, cytokine-related compounds and chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat kidney disorders. | 08-16-2012 |
20120208718 | SCHIZOPHRENIA TREATMENT RESPONSE BIOMARKERS - The present invention provides biomarker of antipsychotic treatment response in patients with schizophrenia and other disorders involving DRD2 and methods for using the same. | 08-16-2012 |
20120208719 | ASSESSING RHEUMATOID ARTHRITIS - This document provides methods and materials related to assessing mammals (e.g., humans) with arthritis (e.g., RA). For example, methods and materials for using cytokine response profiles to assist clinicians in assessing RA disease activity, assessing the likelihood of response and outcomes of RA therapy, predicting long-term RA disease outcomes, and assessing the risk of developing heart conditions are provided. Methods and materials for using cytokine response profiles to assist clinicians in diagnosing arthritis (e.g., RA) also are provided. | 08-16-2012 |
20120208720 | RAPID DISPLAY METHOD IN TRANSLATIONAL SYNTHESIS OF PEPTIDE - Provided are linkers suitable for preparing a conjugate of a nucleic acid and a peptide as a translation product thereof in a reconstituted cell-free translation system in genotype-phenotype mapping (display methods), said linkers comprising a single-stranded structure region having a side chain base pairing with the base at the 3′-end of an mRNA at one end and a peptidyl acceptor region containing an amino acid attached to an oligo RNA consisting of a nucleotide sequence of ACCA via an ester bond at the other end, characterized in that the ester bond is formed by using an artificial RNA catalyst. Also provided are display methods using [mRNA]-[linker]-[peptide] conjugates assembled via such linkers. | 08-16-2012 |
20120214679 | METHODS AND SYSTEMS FOR EVALUATING THE SENSITIVITY OR RESISTANCE OF TUMOR SPECIMENS TO CHEMOTHERAPEUTIC AGENTS - The present invention provides methods, systems, and kits for evaluating the sensitivity and/or resistance of tumor specimens to one or a combination of chemotherapeutic agents. Particularly, the invention provides malignant cell gene signatures that are predictive of a tumor's response to candidate chemotherapeutic regimens. | 08-23-2012 |
20120214680 | NUCLEIC ACID-BASED TESTS FOR RHD TYPING, GENDER DETERMINATION AND NUCLEIC ACID QUANTIFICATION - The invention in part provides nucleic acid-based assays, which are particularly useful for non-invasive prenatal testing. The invention in part provides compositions and methods for RhD typing, detecting the presence of fetal nucleic in a sample, determining the relative amount of fetal nucleic acid in a sample and determining the sex of a fetus, wherein each of the assays may be performed alone or in combination. | 08-23-2012 |
20120214681 | Multiplexed Analysis Of Polymorphic Loci By Concurrent Interrogation And Enzyme-Medicated Detection - The invention provides methods and processes for the identification of polymorphisms at one or more designated sites, without interference from non-designated sites located within proximity of such designated sites. Probes are provided capable of interrogation of such designated sites in order to determine the composition of each such designated site. By the methods of this invention, one or more mutations within the CFTR gene and the HLA gene complex can be identified. | 08-23-2012 |
20120214682 | MICRORNA SIGNATURES INDICATIVE OF IMMUNOMODULATING THERAPY FOR MULTIPLE SCLEROSIS - The present invention provides methods, systems, and kits for evaluating multiple sclerosis (MS) in a patient. Particularly, the invention provides convenient miRNA-based tests for evaluating a patient for MS, including for diagnosing MS, for excluding MS as a diagnosis, and for monitoring the course of disease or efficacy of treatment, including evaluation of immunomodulating therapy. | 08-23-2012 |
20120214683 | METHODS OF TARGETING BAFF - The present disclosure provides compositions and methods relating to the structure of BAFF in solution. The disclosure includes BAFF 60-mers, BAFF trimers, methods of making BAFF 60-mers and BAFF trimers, antibodies that preferentially bind one form or the other, and methods of identifying or evaluating a compound on the basis of its relative binding to or activity towards a BAFF 60-mer and a BAFF trimer. The disclosure also provides computer-based systems and methods relating to BAFF structures. | 08-23-2012 |
20120214684 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING PROSTATE CARCINOMA - Compositions and methods for the diagnosis, treatment and prevention of prostate cancer, as well as for treatment selection. | 08-23-2012 |
20120214685 | METHODS AND COMPOSITIONS FOR DIAGNOSIS OF ECTOPIC PREGNANCY - Methods and compositions are provided for diagnosing ectopic pregnancy in a mammalian subject by detecting changes in expression of ISM2, ADAM12, PST1, PSG7, PST11, PSG9, PSG2 and other genes identified therein, including combinations thereof. A selected gene, gene transcript or protein/peptide expression product, or profiles or signatures formed by combinations of same, detected in a biological fluid of a subject, enables comparison of the corresponding genes, proteins or profiles from that of a reference or control having a normal intrauterine pregnancy. Detection of characteristic changes in the gene profile or protein expression signature of the subject is correlated with a diagnosis of ectopic pregnancy. Various compositions for use in such diagnosis include PCR primer-probe sets or ligands, labeled or immobilized, which are capable of detecting the changes in expression or translation of these targets. | 08-23-2012 |
20120214686 | Quantitative, Highly Multiplexed Detection of Nucleic Acids - This invention provides methods of detecting and quantifying target nucleic acids in samples in multiplexed single chamber reactions. Consumables incorporating chambers optimized to reduce signal background proximal to high efficiency arrays are provided, as well as methods of use. Devices and systems configured to use the consumables to practice the methods are a feature of the invention. | 08-23-2012 |
20120214687 | BAFF RECEPTOR (BCMA), AN IMMUNOREGULATORY AGENT - A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided. | 08-23-2012 |
20120214688 | Methods for Diagnosing Breast, Colon, Lung, Pancreatic and Prostate Cancer Using miR-21 and miR-17-5p - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 08-23-2012 |
20120214689 | Methods for Diagnosing Breast and Lung Cancer Using miR-210 and miR-213 - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 08-23-2012 |
20120214690 | Methods for Diagnosing Colon, Stomach, Prostate and Pancreas Cancer Using miR-223 - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 08-23-2012 |
20120214691 | Methods for Diagnosing Breast Cancer Using miR-21, miR-125-1, miR-125b-2 and miR-145 - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 08-23-2012 |
20120214692 | Methods for Diagnosing Pancreatic Cancer Using miR-103-1, miR-103-2, miR-24-2 and miR-107 - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 08-23-2012 |
20120214693 | Methods for Diagnosing Breast Cancer Using MicroRNAs - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 08-23-2012 |
20120214694 | Methods for Diagnosing Colon Cancer Using MicroRNAs - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 08-23-2012 |
20120214695 | Methods for Diagnosing Lung Cancer Using MicroRNAs - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 08-23-2012 |
20120214696 | Methods for Diagnosing Pancreatic Cancer Using MicroRNAs - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 08-23-2012 |
20120214697 | Methods for Diagnosing Prostate Cancer Using MicroRNAs - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 08-23-2012 |
20120214698 | Methods for Diagnosing Stomach Cancer Using MicroRNAs - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 08-23-2012 |
20120214699 | Methods for Diagnosing Breast Cancer Using MicroRNA Signatures - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 08-23-2012 |
20120214700 | Methods for Diagnosing Colon Cancer Using MicroRNA Signatures - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 08-23-2012 |
20120214701 | Methods for Diagnosing Lung Cancer Using MicroRNA Signatures - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 08-23-2012 |
20120214702 | Methods for Diagnosing Prostate Cancer Using MicroRNA Signatures - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 08-23-2012 |
20120214703 | Methods for Diagnosing Stomach Cancer Using MicroRNA Signatures - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 08-23-2012 |
20120214704 | Methods for Identifying DNA Copy Number Changes - Methods of identifying allele-specific changes in genomic DNA copy number are disclosed. Methods for identifying homozygous deletions and genetic amplifications are disclosed. An array of probes designed to detect presence or absence of a plurality of different sequences is also disclosed. The probes are designed to hybridize to sequences that are predicted to be present in a reduced complexity sample. The methods may be used to detect copy number changes in cancerous tissue compared to normal tissue. The methods may be used to diagnose cancer and other diseases associated with chromosomal anomalies. | 08-23-2012 |
20120214705 | BETA-DEFENSIN 2 GENETIC VARIATION PREDICTS H. PYLORI SUSCEPTIBILITY - The present invention relates to correlating high gene copy number and/or the overexpression of β-defensin 2 (“BD2”) with susceptibility to disease conditions resulting from, associated with or mediated by | 08-23-2012 |
20120214706 | RAPID DETECTION OF SNP CLUSTERS - The present invention relates to the rapid detection of clusters of single nucleotide polymorphisms (SNPs) using an array technology. It further relates to the use of these clusters as markers in strain improvement and breeding, and in strain identification. | 08-23-2012 |
20120214707 | METHOD FOR DETECTION OF AN ANALYTE IN A FLUID SAMPLE - A method for detecting an analyte in a fluid sample is disclosed. The method comprises: a) providing a measurement region and a reference region, the measurement region being provided with a receptor for binding the analyte; b) providing at least one light beam so as to travel along the measurement region and along the reference region; c) providing the fluid sample into at least the measurement region; d) detecting by means of a detector an optical pattern provided by the at least one light beam after having travelled along the measurement region and the reference region; and e) deriving a presence of the analyte in the fluid sample from the detected optical pattern, wherein prior to c) a blocking fluid is provided along the measurement region and along the reference region. | 08-23-2012 |
20120220473 | METHOD OF IDENTIFYING TARGET BIOMOLECULE BY USING PROBE-BINDING FREQUENCY - An efficient and accurate method of identifying a target biomolecule in a sample by using target molecule-probe binding frequencies is disclosed. | 08-30-2012 |
20120220474 | METHODS AND COMPOSITIONS FOR DIAGNOSIS OF THYROID CONDITIONS - The present invention relates to compositions, kits, and methods for molecular profiling and cancer diagnostics, including but not limited to genomic DNA markers associated with cancer. In particular, the present invention provides molecular profiles associated with thyroid cancer, methods of determining molecular profiles, and methods of analyzing results to provide a diagnosis. | 08-30-2012 |
20120220475 | DNA Methylation Changes Associated with Major Psychosis - The present invention provides a method of identifying one or more epigenetic markers associated with psychosis-associated diseases such as bipolar disease or schizophrenia, the method comprising a) obtaining a first group of samples comprising genomic DNA from a plurality of bipolar or schizophrenic subjects and a second group of samples comprising genomic DNA from a plurality of control subjects; b) performing DNA methylation analysis to determine methylation differences in one or more DNA regions between the first group and second group of samples, wherein a methylation difference in a DNA region is indicative of an epigenetic marker associated with bipolar disease or schizophrenia. The invention also provides one or more epigenetic markers associated with psychosis-associated diseases such as bipolar disease or schizophrenia. | 08-30-2012 |
20120220476 | BIOMARKERS FOR OVARIAN CANCER - The present invention relates to a method of qualifying ovarian cancer status in a subject comprising: (a) measuring at least one biomarker in a sample from the subject and (b) correlating the measurement with ovarian cancer status. The invention further relates to kits for qualifying ovarian cancer status in a subject. | 08-30-2012 |
20120220477 | GENETIC MARKERS ASSOCIATED WITH RISK OF DIABETES MELLITUS - The invention relates to variants that predispose to risk of type 2 diabetes, basal cell carcinoma and breast cancer. It has been discovered that certain genetic variants confer risk of these diseases when inherited from one parent, but not the other. The invention provides methods of disease management, including diagnostic methods, utilizing such parental origin effects. | 08-30-2012 |
20120220478 | METHODS FOR ASSESSING DISEASE RISK - The invention relates to methods and biomarkers for assessing a subject's risk for a disease, such as cancer, an autoimmune disease or a neurological disease. In particular, the invention provides methods and biomarkers for creating exon copy number variation (ECNV) profiles, and determining disease risk according to the subject's ECNV profiles. | 08-30-2012 |
20120220479 | PROBES FOR SPECIFIC ANALYSIS OF NUCLEIC ACIDS - The present invention provides a method for detecting or enriching for a target deoxyribonucleic acid (DNA) present in a nucleic acid sample, said method comprising: (a) fragmenting a nucleic acid sample to generate nucleic acid fragments including a target fragment containing said target DNA; (b) rendering said fragments, including said target fragment, at least partially single-stranded, wherein the single-stranded portion includes an end portion and wherein the length of said single-stranded portion is sufficient to allow hybridisation of at least part of the single-stranded portion of said target fragment to the probe of step (c); (c) contacting the at least partially single-stranded fragments of step (b) with oligonucleotides A and B of a single target-specific nucleic acid probe, wherein: (i) oligonucleotide A is a single-stranded oligonucleotide comprising at one end a first target-specific part comprising at least 10 nucleotides complementary in sequence to at least part of said single-stranded portion of said target fragment, and comprising at the other end a second non-target-specific part which comprises a nucleotide sequence complementary to at least a portion, including one end, of oligonucleotide B of the probe, and (ii) oligonucleotide B is a single-stranded oligonucleotide which may contain or carry at least one element for detection and/or enrichment of said target fragment, and of which at least a portion, including one end, is complementary in sequence to the second non-target-specific part of oligonucleotide A, such that said target fragment becomes annealed to said probe through hybridisation to the first target-specific part of oligonucleotide A resulting in only one target-specific probe-binding event per target fragment; (d) ligating oligonucleotide B of said probe to the part of the single-stranded portion of said target fragment which is hybridised to oligonucleotide A of said probe to produce a probe-target fragment hybrid; and (e) detecting or enriching for said probe-target fragment hybrid. Kits for use in the method of the invention are also provided. | 08-30-2012 |
20120220480 | METHOD FOR THE DETECTION OF RENAL DAMAGE - The invention relates to a method for determining the presence of renal damage in an individual and also to a method for detecting one or several proteins selected from the list comprising Reg3B, fetuin B, Ras-related GTP-binding protein A serine protease inhibitor A3L, subunit 1 of COP9, gamma subunit of ATP synthase, gelsolin, ribonuclease UK114, aminoacylase 1A, alpha-enolase, keratin 5, parvalbumin alpha, ribonuclease 4 or serine protease inhibitor A3K. The renal damage may be acute renal failure. Said renal pathologies may be caused by the administration of a nephrotoxic agent, wherein the nephrotoxic agent may be an aminoglycoside antibiotic such as gentamicin, or cisplatin. The invention also provides means to differentiate the renal damage or renal failure induced by gentamicin from that induced by cisplatin, through the biochemical analysis of the urinary level of Reg3B and/or gelsolin, or fragments thereof. | 08-30-2012 |
20120220481 | BILAYERS - A method for producing a bilayer, the method comprising: (a) providing a hydrated support and a hydrophilic body immersed in a hydrophobic medium; wherein a first monolayer of amphipathic molecules is formed on an interface between the hydrophobic medium and the hydrophilic body and a second monolayer of amphipathic molecules is formed on an interface between the hydrophobic medium and the hydrated support; and (b) bringing the first monolayer into contact with the second monolayer to form a bilayer of amphipathic molecules, wherein at least part of a cell membrane, comprising cell membrane constituents, is provided in or on the hydrated support and/or in the hydrophilic body, and such that constituents of the cell membrane incorporate into the bilayer during or after the bilayer formation. A bilayer produced by the method of the invention, and uses of the bilayer. | 08-30-2012 |
20120220482 | COMPOSITIONS AND METHODS FOR SCREENING PEPTOID LIBRARIES - Certain embodiments are directed to methods for screening synthetic libraries and characterizing the resultant hits that combines many of the attractive features of bead library screening and microarray-based analysis in a seamless fashion. | 08-30-2012 |
20120220483 | METHODS FOR FRAGMENTATION AND LABELING OF NUCLEIC ACIDS - The invention provides methods, compositions, and kits for fragmentation and labeling of nucleic acids. More particularly, the invention relates to methods for fragmentation of nucleic acids to produce fragments with 3′ end hydroxyl groups within a desired size range. In methods of the invention, nucleic acids are fragmented at abasic sites to produce fragments with blocked 3′ ends. The 3′ ends are unblocked to produce polynucleotide fragments with hydroxyl groups at their 3′ ends. Methods, kits, and compositions for carrying out fragmentation of a polynucleotide template in a single reaction mixture to yield fragments with 3′-hydroxyl ends within the desired size range are disclosed. | 08-30-2012 |
20120220484 | TISSUE REJECTION - This document relates to methods and materials involved in detecting tissue rejection (e.g., organ rejection). For example, this document relates to methods and materials involved in the early detection of kidney tissue rejection. | 08-30-2012 |
20120220485 | PROBE SET AND METHOD FOR IDENTIFYING HLA ALLELE - Provided is a probe set that is useful for identifying each allele of HLA individually, and a method of identification of an allele of HLA by the use thereof for each type. | 08-30-2012 |
20120220486 | METHODS AND APPARATUS FOR BINDING ASSAYS - The present teachings relate to methods, systems, and apparatus for low cost label-free assay detection. The present teachings, in a variety of embodiments, employ opposing forces to detect signals which depend on the number of charges on and/or the size of a particle. The particle, which can be subjected to opposing forces, can have specific capture probes at its surface. As analytes of interest are captured by the particle, the number of charges on the particle surface and/or the size of the particle is changed. A particle parameter or kinematic property such as the position, velocity, acceleration or force of/on the particle can be measured, and results obtained relating, for example, to the present, absence, quantity, and such, of one or more analytes of interest. Various embodiments are described for efficient, high throughput assays of samples potentially including one or more analytes of interest, such as bioanalytes. As well, various embodiments are described wherein binding assays can be carried out without the need or use of extrinsic labels. A number of embodiments provide, for example, methods, systems, and apparatus for detecting analytes (such as nucleic acids, proteins, cells and other entities, particulates, and the like) in one or more samples. Also described are: detection of a single copy of a target biomolecule, such as DNA, captured onto a trapped (e.g., tethered) bead; protocols for fabricating encoded bead arrays for multiplex assays; and methods, systems and apparatus for efficient and specific capture of pathogen biomolecular markers onto bead-bound capture probes, as well as detection and measurement of such capture events. | 08-30-2012 |
20120220487 | Determination of 17q Gain in Neuroblastoma Patients by Analysis of Circulating DNA - Methods for diagnosis of neuroblastoma comprising determining whether there is a gain of genetic material from chromosome arm segment 17q21-qter in the circulating DNA of a human subject. | 08-30-2012 |
20120220488 | HEART AGING BIOMARKERS AND METHODS OF USE - The invention provides a set of robust biomarkers of aging in the heart comprising several genes involved in the Wnt signaling pathway. These genes have been found to be down-regulated in aged versus young heart tissue. Methods of using those biomarkers to monitor heart aging and to identify nutrients and dietary regimens for retarding heart aging are disclosed. Methods for the modulation of the genes themselves to retard heart aging are also disclosed. | 08-30-2012 |
20120220489 | CALIBRATION REAGENT AND USES THEREOF - The present invention provides a calibration reagent comprising a peptide conjugated to a protein carrier via a linker, wherein said peptide comprises an epitope of interest and the use thereof. | 08-30-2012 |
20120225788 | Topoisomerase Binding Probe and Method of Use - An aminocoumarin conjugated to a fluorescent label through a secondary amine, is operative as a fluorescent polarization probe of the DNA gyrase B or topoisomerase IV E subunit. The probe is used for detecting topoisomerase inhibitor binding by fluorescence polarization, particularly in a high-through put topoisomerase inhibitor assay. | 09-06-2012 |
20120225789 | DNA REPAIR OR BRCA1-LIKE GENE SIGNATURE - The present invention concerns the identification of individuals that have triple negative breast cancer and/or identification of an appropriate treatment therefor. In certain cases, the identification includes determining the expression levels of a multitude of genes. | 09-06-2012 |
20120225790 | VITRO METHOD FOR THE PROGNOSIS OR PREDICTION OF THE RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH AGENTS THAT RECOGNIZE THE CD20 MEMBRANE RECEPTOR IN B LYMPHOCYTES - An in vitro method for the prognosis or prediction of response in patients with rheumatoid arthritis to treatment with agents recognising the B-lymphocyte CD20 membrane receptor. The method of the invention comprises an assay in a blood sample from these patients and measuring, before starting the treatment, the transcriptional expression level (mRNA) of at least one of the genes selected from the group: ARG1, CPD, TRAF1, C1QA, LRRN3, HLA-DQA1, NLK, TLR4, LOC89944, TOM1L1, BACH, NCALD, EIF2C2, NFIC, PCDHB7, FLJ32770, ARID3A, C14ORF9, CSNK1E, BCAS1, TEAD2, C6orfl45 and SNTA1; and the comparison of this expression level to the expression values previously obtained in patients who responded and who did not respond to the treatment. | 09-06-2012 |
20120225791 | ARRAY-BASED METHOD FOR DETECTION OF COPY NUMBER VARIATIONS IN THE HLA LOCUS FOR THE GENETIC DETERMINATION OF SUSCEPTIBILITY OF DEVELOPMENT OF VENOUS MALFORMATIONS IN THE EXTRACRANIAL SEGMENTS OF THE CEREBROSPINAL VEINS AND KIT THEREOF - Method for in vitro diagnosis of susceptiblility of developing venous malformations i the extracranial segment of the cerebrospinal veins in a patient comprising the detection of copy number variations (CNVs) in chromosome 6p21 in a sample of genomic DNA of the patient, wherein the venous malformations are associated with the development of multiple sclerosis. | 09-06-2012 |
20120225792 | Gene Expression Biomarkers in PAP Test Material for Assessing HPV Presence and Persistence - In accordance with certain embodiments of the present disclosure, a method for the diagnosis of persistent HR-HPV in an individual is provided. An expression level of at least one biomarker in a biological sample is determined. The expression level of the at least one biomarker is compared to an expression level of corresponding biomarker(s) in a comparative sample, wherein the comparative sample contains the at least one biomarker in a level indicative of persistent HR-HPV. Persistent HR-HPV infection is predicted in the individual based upon the comparison of the expression level of the at least one biomarker between the comparative sample and the biological sample. | 09-06-2012 |
20120225793 | METHODS FOR IDENTIFYING, DIAGNOSING, AND PREDICTING SURVIVAL OF LYMPHOMAS - Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject. | 09-06-2012 |
20120225794 | Antibodies Specific to Heterodimers of Bcl-2 Family and Uses Thereof - Isolated antibodies specifically binding to heterodimers of the Bcl-2 family and uses thereof for detecting presence of Bcl-2 heterodimers in a patient. | 09-06-2012 |
20120225795 | PROTEIN MARKERS FOR DETECTING LIVER CANCER AND METHOD FOR IDENTIFYING THE MARKERS THEREOF - The present invention relates to the diagnosis of liver cancer. It discloses the use of protein ERBB3 and protein IGFBP2 in the diagnosis of liver cancer. It relates to a method for diagnosis of liver cancer from a liquid sample, derived from an individual by measuring ERBB3 protein and IGFBP2 protein in the sample. Measurement of ERBB3 protein and IGFBP2 protein can, e.g., be used in the early detection or diagnosis of liver cancer. | 09-06-2012 |
20120225796 | TOOL FOR DIAGNOSIS AND PROGNOSIS OF MATURE B-CELL NEOPLASMS - The present invention provides a microarray useful as a tool in the diagnosis and/or prognosis of certain types of cancers, particularly mature B-cell neoplasms. The microarray can include a plurality of genomic regions represented thereon, the genomic regions corresponding to regions wherein alterations, such as copy number alterations, at such locations correlate to specific, identifiable cancers, particularly mature B-cell neoplasms. The invention further provides methods of diagnosing and providing prognosis certain types of cancer, particularly mature B-cell neoplasms. The methods can comprise contacting a sample to a microarray according to the invention, allowing any genetic material in the sample to hybridize to the genomic regions on the microarray, analyzing the hybridizations, and correlating the hybridizations to certain cancer types, particularly mature B-cell neoplasms. | 09-06-2012 |
20120231962 | REAL-TIME PCR OF TARGETS ON A MICRO-ARRAY - The present invention relates to a method and apparatus for monitoring on a micro-array a PCR amplification of a nucleotide molecule being present in a solution. The method includes the steps of: providing a support having fixed upon its surface a microarray having at least a capture molecule being immobilized in specifically localized areas of the support and a reaction chamber; introducing a solution containing the nucleotide molecule into the reaction chamber and reagents for nucleotide molecule amplification and labelling; submitting the solution to at least 2 thermal cycles having at least 2 and preferably 3 different temperature steps in order to obtain labelled target nucleotide molecule by PCR amplification; performing at least a measurement of the labelled target nucleotide molecule in at least one thermal cycle by incubating the labelled target nucleotide molecule under conditions allowing a specific binding between the target nucleotide molecule and its corresponding capture molecule and measuring the light emission from the bound labelled target nucleotide molecule in response to excitation light with the solution being present in the chamber and containing the labelled target nucleotide molecule. The surface of emission for a localized area is between about 0.1 μm | 09-13-2012 |
20120231963 | BIOTIN-LABEL-BASED ANTIBODY ARRAY FOR HIGH-CONTENT PROFILING OF PROTEIN EXPRESSION - The biotin-label-based array methods of the present disclosure have several advantages over fluorescence label. Biotin-label can be used as signal amplification. Biotin is the most common method for labeling protein and the label process can be highly efficient. Furthermore, biotin can be detected using fluorescence-streptavidin and, therefore, visualized using laser scanner, or by using HRP-streptavidin imaged using chemiluminescence. The results of the present disclosure show that using biotin-label-based antibody arrays, most targeted proteins can be detected at pg/ml levels. Systems for identifying at least one biomarker characteristic of a cancer or a cancer cell comprise: an antibody array comprising at least one antibody species capable of capturing a biomarker characteristic of a cancer or a cancer cell; a system for biotinylating at least one biomarker of a biosample obtained from a subject human or animal; and a detectable biotin-binding polypeptide. | 09-13-2012 |
20120231964 | METHOD FOR SELECTING NUCLEIC ACIDS THAT BOND WITH HIGH-AFFINITY TO A TARGET - The invention relates to a method for selecting nucleic acids that bond with high affinity to a target molecule from a mixture of nucleic acids, comprising: a) loading a column with the target molecules, b) feeding the nucleic acids into a first end of the column, to create a defined volumetric flow of medium through the column, c) immobilizing the nucleic acids to the target molecule wherein an affinity of the nucleic acids to the target molecule decreases as the distance from the first end of the column increases, d) stopping the volumetric flow after a defined period of time, e) cutting the column into segments, and allocating a routing co-ordinate to each segment, and f) identifying and collecting nucleic acids that bond with a high affinity to the target molecule by desorbing the immobilized nucleic acids from at least one segment. | 09-13-2012 |
20120231965 | DRUG SELECTION FOR COLORECTAL CANCER THERAPY USING ANTIBODY-BASED ARRAYS - The present invention provides methods for selecting a suitable anticancer drug therapy, and for identifying and predicting response, for the treatment of colorectal cancer. The present invention also provides methods for monitoring the status of colorectal cancer and monitoring how a patient with colorectal cancer is responding to anticancer drug therapy. | 09-13-2012 |
20120231966 | LUNG CANCER DIAGNOSTIC ASSAY - A method for selecting a person at risk for lung cancer to undergo radiographic testing is provided. The method provides for the identification of markers for lung cancer in a population of patients that have not previously diagnosed with the disease. The markers identify autoantibodies present in a fluid sample of a patient who may not show other symptoms of lung cancer. | 09-13-2012 |
20120231967 | SEQUENTIAL ANALYSIS OF BIOLOGICAL SAMPLES - Methods for detecting multiple targets in a biological sample are provided. The methods includes contacting the sample with a first probe; physically binding the first probe to a first target; observing a first signal from the first probe; applying a chemical agent to modify the first signal; contacting the sample with a second probe; physically binding the second probe to a second target; and observing a second signal from the second probe. The methods disclosed herein also provide for multiple iterations of binding, observing, signal modification for deriving information about multiple targets in a single sample. An associated kit and device are also provided. | 09-13-2012 |
20120231968 | Comparative Genomic Hybridization Assays Using Immobilized Oligonucleotide Features and Compositions for Practicing the Same - Comparative genomic hybridization assays and compositions for use in practicing the same are provided. A characteristic of the subject comparative genomic hybridization assays is that solid support immobilized oligonucleotide feature elements, e.g., in the form of an array, are employed. Specifically, at least first and second nucleic acid populations prepared from genomic templates are contacted with a plurality of distinct oligonucleotide feature elements immobilized on a solid support surface and the binding of the at least first and second populations is then evaluated. Also provided are kits for use in practicing the subject methods. | 09-13-2012 |
20120231969 | PROTEIN ARRAYS AND USES THEREOF - Illustrative embodiments herein disclosed relate to protein arrays, methods for making the arrays and methods for using them, among others. In some embodiments known proteins representing at least 50% of the loci in the human genome are arrayed in known positions on a support. In some embodiments arrays are made of proteins purified from cell lysates by affinity binding to the support. In some embodiments protein arrays are used to decode the binding specificity of antibodies. In some embodiments protein arrays are used to diagnose auto-immune disorders. Many other embodiments and general features are disclosed. | 09-13-2012 |
20120231970 | COLON CANCER MARKER AND METHOD FOR TESTING FOR COLON CANCER - Provided are a micro RNA which can be used as a colon cancer marker, a method for testing for colon cancer which uses the micro RNA which can be used as a colon cancer marker, and a test kit which can be used for the testing method. The colon cancer marker includes micro RNA molecules which are represented by any of the sequences 1 through 25. The method for testing for colon cancer in a subject involves preparing a sample, which contains a micro RNA molecule derived from the subject's colon tissue or colon cell, and detecting a micro RNA molecule represented by any of the sequences 1 through 25 present in the obtained sample. | 09-13-2012 |
20120231971 | METHOD AND APPARATUS FOR DETECTING ANALYTES - Provided is a method and apparatus for detecting analytes, in which an analyte-receptor complex that is formed by a coupling of an analyte and a receptor is separated from a free receptor that has not been coupled with the analyte, to then detect the analyte-receptor complex. The method and apparatus for detecting analytes does not only provide an effect of detecting various substances with a single sensor chip, but also provides advantages of detecting a particular object substance from a sample containing a number of substances and easily amplifying a signal. | 09-13-2012 |
20120238460 | RANTES LEVELS AS A DIAGNOSTIC AND THERAPEUTIC FOR ACUTE GRAFT VERSUS HOST DISEASE - Disclosed herein are methods for determining the likelihood of a subject to develop Acute graft versus host disease (aGVHD) upon receiving myeloablative allogeneic hematopoietic stem cell transplantation (HSCT). One such method comprises assaying for baseline plasma concentration of RANTES in a sample obtained from the subject, and comparing the baseline plasma concentration of RANTES to a predetermined level. The method may further comprise assaying for day 7 plasma concentration of RANTES in sample obtained from the subject, and comparing the day 7 plasma concentration of RANTES to a predetermined level. Another such method comprises assaying for day 7 plasma concentration of RANTES in a sample obtained from the subject, and comparing the day 7 plasma concentration of RANTES to a predetermined level. Another such method comprises assaying for donor plasma concentration of RANTES in a sample obtained from a donor of the hemtopoietic stem cells, and comparing the donor plasma concentration of RANTES to a predetermined level, wherein a donor plasma concentration of RANTES less than the predetermined level indicates a likelihood of the subject to develop aGVHD upon receiving myeloablative allogeneic HSCT from that donor. Other methods include assaying for day 0, or for day 7, plasma concentration of MCP-1 in a sample obtained from the subject, and comparing the day 0 or day 7, plasma concentration of MCP-1 to a predetermined level. | 09-20-2012 |
20120238461 | METHOD FOR DETERMINING THE RISK OF OCCURRENCE OF ALZHEIMER'S DISEASE - The present invention relates to an in vitro method for determining that an individual is at risk of developing Alzheimer's disease, which comprises: —determining whether the individual harbours at least one variant allele of a susceptibility gene selected from the apolipoprotein J gene (APOJ) and the complement component receptor 1 gene (CR 1); —deducing that if the individual harbours at least one variant allele of the APOJ and/or CR1 gene, then the individual is at risk of developing Alzheimer's disease. | 09-20-2012 |
20120238462 | METHODS FOR REGULATING THE GROWTH AND/OR SURVIVAL OF TUMOR CELLS AND STEM CELLS BY MODULATING THE EXPRESSION OR FUNCTION OF THE TRANSCRIPTION FACTORS ATF5 - The present invention provides methods for regulating the growth and/or survival of tumor cells and stem cells by modulating the expression or function of ATF5. | 09-20-2012 |
20120238463 | LINE-1 Hypomethylation as a Biomarker for Early-Onset Colorectal Cancer - A method for detecting an early-onset of colorectal cancer in a human subject is disclosed herein. The method comprises the steps of: (i) identifying the human subject suspected of suffering from a colorectal cancer, (ii) obtaining one or more biological samples from the human subject; (iii) determining a LINE-1 methylation level for the one or more biological samples; and (iv) comparing the LINE-1 methylation level to a LINE-1 methylation control level, wherein a higher degree of the LINE-1 methylation level is indicative of an early-onset colorectal cancer. | 09-20-2012 |
20120238464 | Biomarkers for Predicting the Recurrence of Colorectal Cancer Metastasis - The present invention includes biomarkers and methods for predicting recurrence-free survival and determination of risk for colorectal liver metastasis (LM) by determining a level of microsatellite instability at tetranucleotide repeats (EMAST) and at mono- and a dinucleotide repeat loci (MSI-L) or a SMARCA | 09-20-2012 |
20120238465 | DRUG SCREENING TARGET FOR ALZHEIMER'S DISEASE AND METHOD OF SCREENING POTENTIAL DRUGS - Drug screening targets and method of screening for potential drugs for treatment or amelioration of Alzheimer's Disease are provided. | 09-20-2012 |
20120238466 | Multiplexed Assay Using Encoded Solid Support Matrices - In a multiplexed assay, each molecule of a plurality of molecules is attached to a support matrix with a substrate adapted for attachment and/or synthesis of molecules and an integrally-formed memory device with an optically-encoded identifier to uniquely identify the molecule attached to the substrate. The molecules are exposed to one or more processing conditions then placed within the path of an optical detector adapted to read the optically-encoded identifier and measure biochemical processes on each support matrix. The support matrices may be singulated to be read by the optical detector one at a time. | 09-20-2012 |
20120238467 | EXOSOME-ASSOCIATED MICRORNA AS A DIAGNOSTIC MARKER - The presently disclosed subject matter provides methods of diagnosis of cancer or adverse pregnancy outcomes in a subject by measuring amounts of one or more microRNAs present in cancer-derived exosomes isolated from a biological sample from the subject. | 09-20-2012 |
20120238468 | METHODS FOR DIAGNOSING IRRITABLE BOWEL SYNDROME - The present invention discloses a method for diagnosing Irritable Bowel Syndrome (IBS) in a test sample by determining the level of several bacterial taxa in the test sample, comparing this level with the levels of those bacterial taxa in a control sample, and relating the level to a diagnosis of IBS. Additionally, the present invention provides a method for treatment of IBS based on said diagnosis. Also, the invention provides a method for subtyping IBS in a test sample. | 09-20-2012 |
20120238469 | DIAGNOSTIC BIOMARKER TO IDENTIFY WOMEN AT RISK FOR PRETERM DELIVERY - The invention relates to biomarkers associated with preterm delivery. More specifically, the invention provides methods of measuring biomarkers found in women that are at risk for preterm delivery. | 09-20-2012 |
20120245045 | METHODS AND KITS TO IDENTIFY INVASIVE GLIOBLASTOMA - The invention encompasses methods and kits used in the detection of invasive glioblastoma based upon the expression of NHERF-1. The methods and kits also allow prediction of disease outcome as well as therapeutic outcome. | 09-27-2012 |
20120245046 | GENE EXPRESSION PROFILING FROM FFPE SAMPLES - Methods and compositions relating to the generation and use of gene expression data from tissue samples that have been fixed and embedded are provided. The data can electronically stored and implemented as well as used to augment diagnosis and treatment of diseases. | 09-27-2012 |
20120245047 | DEVICE AND METHODS FOR MOLECULAR ANALYSIS - Systems and methods are provided for high speed sorting of objects in a continuous body of fluid. The object can be analyzed within one or more interrogation volumes that allow for simultaneous or time-correlated measurement of the object's properties. A processor can interpret the properties of the object and then measured and then direct the object to one of a plurality of downstream flow paths. In some embodiments, the sorting of the object is based on two or more properties of the object. The sorting process can be repeated to create a network of sorting events. | 09-27-2012 |
20120245048 | CELLULAR RESPONSE ASSAY FOR BIOFLUID BIOMARKER DISCOVERY AND DETECTION - The invention provides a method to detect an abnormal condition or disease state by assessing a characteristic response pattern of responder cells to indicators contained in a biological fluid of a subject. A characteristic disease-associated pattern can be obtained by determining the response pattern of responder cells to that of bodily fluids or fractions thereof from subjects known to exhibit a particular abnormal condition optionally comparing said pattern to such pattern elicited by fluids or fractions from normal subjects and identifying elements that differ. The identified elements constitute a characteristic or differential pattern which can then be used to identify the presence or stage of a disease in a test subject. | 09-27-2012 |
20120245049 | System and Method for Pixelated Fluid Assay - A method of performing a fluid-material assay employing a device including at least one active pixel having a sensor with an assay site functionalized for selected fluid-assay material. The method includes exposing the pixel's sensor assay site to such material, and in conjunction with such exposing, and employing the active nature of the pixel, remotely requesting from the pixel's sensor assay site an assay-result output report. The method further includes, in relation to the employing step, creating, relative to the sensor's assay site in the at least one pixel, a predetermined, pixel-specific electromagnetic field environment. | 09-27-2012 |
20120245050 | BIOMARKER FOR PREDICTING THERAPEUTIC EFFICACY OF ALLERGEN IMMUNOTHERAPY - [Problem] To provide a biomarker for predicting the therapeutic efficacy of allergen immunotherapy. | 09-27-2012 |
20120245051 | OBJECTIVE, QUANTITATIVE METHOD TO PREDICT HISTOLOGICAL SUBTYPE IN NON-SMALL CELL LUNG CANCER - The invention provides a method for determining the histotype of a non-small cell lung cancer tumor which comprises: (a) determining the levels of expression of each of thyroid transcription factor-1, cytokeratin-5, cytokeratin-13 and epidermal growth factor receptor in a sample from the non-small cell lung cancer tumor; (b) calculating a score based on the levels of expression determined in step (a); and (c) comparing the score obtained in step (b) with a predetermined reference score associated with histotypes of non-small cell lung cancer; wherein the tumor is determined to be an adenocarcinoma if the score obtained in (b) is greater than the predetermined reference score and wherein the tumor is determined to be a squamous cell carcinoma if the score obtained in (b) is less than the predetermined reference score. | 09-27-2012 |
20120245052 | SYSTEM AND METHOD FOR ANALYZING DNA MIXTURES - Provided is a method for determining the presence or absence of an individual's DNA in a sample containing DNA from two or more contributors. A panel of a plurality of single nucleotide polymorphisms (SNPs) is used. For each SNP in the panel, it is determined whether the minor allele of the SNP is present in the sample, and whether the minor allele is present in the individual's DNA. If the number of minor alleles that are present in the individual's DNA that are also present in the DNA sample is above a predetermined threshold, the individual's DNA is concluded to be present in the sample. Also provided is an array of DNA molecules for use in the method, as well as a method for estimating the number of individuals contributing to a DNA containing sample. | 09-27-2012 |
20120245053 | GENE EXPRESSION ANALYSIS METHOD USING TWO DIMENSIONAL cDNA LIBRARY - The present invention provides a method and/or means for collecting and analyzing an individual cell in a tissue, and at the same time, quantitatively monitoring the expression levels of various genes while keeping two-dimensional information in the tissue. Specifically, the present invention provides a method comprising preparing a cDNA library from mRNA while keeping two-dimensional cellular distribution information and obtaining the gene expression levels at any site or all sites at a level of single cell. More specifically, the present invention provides a method comprising preparing a cDNA library in a sheet-form from mRNA while keeping two-dimensional cellular distribution information and repeatedly using the cDNA library in the detection of the gene expression, thereby allowing measurement of the expression distribution for a number of genes at a high accuracy. | 09-27-2012 |
20120252685 | SEQUENTIAL ANALYSIS OF BIOLOGICAL SAMPLES - Methods for probing multiple targets in a biological sample are provided. The methods include the steps of providing a sample containing multiple targets, binding at least one probe having a binder coupled to an enzyme to one or more target present in the sample, and reacting the bound probe with an enzyme substrate coupled to a fluorescent signal generator. The methods include the steps of observing a signal from the fluorescent signal generator and applying to the sample a solution containing an oxidizing agent that substantially inactivates both the fluorescent signal generator and the enzyme. The methods further include the steps of binding at least one probe having a binder coupled to an enzyme to one or more target present in the sample of step, reacting the bound probe with an enzyme substrate coupled to a fluorescent signal generator; and observing a signal from the fluorescent signal generator. The methods disclosed herein also provide for multiple iterations of binding, observing, and oxidizing for deriving information about multiple targets in a single sample. An associated kit is also provided. | 10-04-2012 |
20120252686 | METHODS FOR MAINTAINING THE INTEGRITY AND IDENTIFICATION OF A NUCLEIC ACID TEMPLATE IN A MULTIPLEX SEQUENCING REACTION - The invention generally relates to methods for maintaining the integrity and identification of a nucleic acid template in a multiplex sequencing reaction. In certain embodiments, methods of the invention involve obtaining a solution including a template nucleic acid, introducing an identifier nucleic acid to the solution, incorporating the same barcode sequence into the template and the identifier nucleic acids, and sequencing the template and the identifier nucleic acids. | 10-04-2012 |
20120252687 | Scoring Function Penalizing Compounds Which Desolvate Charged Protein Side Chains Structure - A method of scoring binding affinity of a proposed ligand molecule for a receptor molecule using a computer and computer data bases, which accounts for the increase in energy required where docking disrupts water molecules that are localized or localized. The method uses computer-stored data representing a predicted ligand-receptor structure (preferably one that is validated) as well as computer-stored data representing a library of compounds to be tested. Data representing members of the compound library is analyzed by computerized operations which determine whether the receptor in the predicted ligand-receptor structure includes a) determining whether the receptor in the predicted ligand-receptor structure includes solvating water molecule(s) whose desolvation into the surrounding environment requires substantial energy, b) determining whether a docking configuration for a member of the compound library with the receptor requires desolvation of one or more of the desolvating water molecule(s), and, if so, assigning a desolvation penalty to the member of the compound library. | 10-04-2012 |
20120252688 | NOVEL BIOMARKERS OF DISEASE HISTOPATHOLOGY - Use of FGF-2 and Anosmin-1 proteins to predict the histopathology of the lesions of a subject with a demyelinating disease of the central nervous system (CNS) by detecting the amount of such proteins in a sample of isolated biological fluid. Furthermore, the present invention relates to a method for the understanding of the histopathological features of the lesions of a subject with a CNS demyelinating disease a kit to carry out this method. Preferably, the CNS demyelinating disease is multiple sclerosis, and the biological fluid is cerebrospinal fluid (CSF). | 10-04-2012 |
20120252689 | GENE EXPRESSION SIGNATURE FOR WNT/B-CATENIN SIGNALING PATHWAY AND USE THEREOF - The present invention relates to a novel set of 16 biomarkers, microarrays that provide for the detection thereof, an expression signature comprising 16 genes or a subset thereof, and the use thereof in determining the regulation status of Wnt/β-catenin signaling pathway. The regulation status of Wnt/β-catenin signaling pathway may be assayed based on the level of expression of one or more of these genes. The expression of these biomarkers may be used to evaluate Wnt/β-catenin pathway deregulation status; classify a cell sample as having a deregulated or regulated Wnt/β-catenin signaling pathway; determine whether an agent modulates the Wnt/β-catenin signaling pathway; predict response of a subject to an agent that modulates the Wnt/β-catenin signaling pathway; assign treatment to a subject; or evaluate the pharmacodynamic effects of therapies designed to regulate Wnt/β-catenin pathway signaling. | 10-04-2012 |
20120252690 | METHOD FOR DETECTING BALANCED CHROMOSOMAL ABERRATIONS IN A GENOME - The present disclosure provides methods and systems for the capture and enrichment of target nucleic acids and analysis of the enriched target nucleic acids for detecting balanced chromosomal aberrations including translocations and inversions. The present disclosure provides for the enrichment of targeted sequences in a format whereby one fusion partner gene on a capturing platform is represented to allow subsequent sequencing of chimeric nucleic acids (i.e., nucleic acid strands that carry information on different DNA regions of a genome). Such a design enables identification of novel fusion partner genes occurring as a result of a chromosomal translocation or inversion. | 10-04-2012 |
20120252691 | MODIFIED NUCLEOTIDES METHODS AND KITS - Modified nucleotides, and methods to modify nucleotides with a moiety or label, such as biotin, that permits their detection and results in a modified nucleotide, and methods of use of the modified nucleotide in quantitative and qualitative assays. | 10-04-2012 |
20120252692 | METHODS AND COMPOSITIONS FOR DETECTION OF NUCLEIC ACIDS BASED ON STABILIZED OLIGONUCLEOTIDE PROBE COMPLEXES - Provided are nucleic acid detection methods wherein targeted primer extension or products or amplification products incorporate a probe-anchoring modification introduced using a primer incorporating a probe-anchoring primer modification, wherein oligonucleotide detection probes incorporate a probe-anchoring probe modification, the primers and probes designed to place the binding site of the oligonucleotide probe proximate to the probe-anchoring primer modification in the detected target sequence. The probe-anchoring modifications of the probe and the primer-extension product form a stabilized complex comprising a detectible duplex of the probe with the detected target sequence. In certain aspects, the probe-anchoring modified primer also incorporates a probe-directing sequence. The methods allow use of exceptionally short oligonucleotide probes (e.g., 10-mer and shorter) enabling establishment of a complete probe inventory or universal library containing a probe complementary to any target nucleic acid sequence. Real-time and post-amplification detection methods are provided, along with detection kits. | 10-04-2012 |
20120252693 | METHODS OF USING SMALL RNA FROM BODILY FLUIDS FOR DIAGNOSIS AND MONITORING OF NEURODEGENERATIVE DISEASES - Described are methods for detection of neuronal pathologies using quantitative analysis in bodily fluids of synapse and/or neurite small RNAs and application of these methods to early diagnosis and monitoring of neurodegenerative diseases and other neurological disorders. | 10-04-2012 |
20120252694 | MARKERS, METHODS, BIOCHIPS AND KITS FOR MILK QUALITY DETECTION - This invention provides markers, methods, biochips and kits for milk quality detection. The present invention particularly provides a method for milk quality detection by means of detecting the particular microRNAs in milk, so as to establish the standard of raw milk content. | 10-04-2012 |
20120252695 | Predictive Value of IL28B Gene Polymorphism Combined with Pretreatment Serum IP-10 Quantification for Response to Peginterferon and Ribavirin Is Enhanced in Comparison with any of these Biomarkers alone - The current invention relates to a method of combining IL28B genotype determination with pre-treatment serum level measurement of IP-10 to predict the outcome of a sustained virological response (SVR) or non-response to peginterferon and ribavirin for individual patients infected with HCV. | 10-04-2012 |
20120252696 | DETECTION OF NUCLEIC ACID SEQUENCE DIFFERENCES USING COUPLED LIGASE DETECTION AND POLYMERASE CHAIN REACTIONS - The present invention relates to a method for identifying a target nucleotide sequence. This method involves forming a ligation product on a target nucleotide sequence in a ligation detection reaction mixture, amplifying the ligation product to form an amplified ligation product in a polymerase chain reaction (PCR) mixture, detecting the amplified ligation product, and identifying the target nucleotide sequence. Such coupling of the ligase detection reaction and the polymerase chain reaction permits multiplex detection of nucleic acid sequence difference. | 10-04-2012 |
20120258876 | NUCLEIC ACID BEACONS FOR FLUORESCENT IN-SITU HYBRIDISATION AND CHIP TECHNOLOGY - The present invention relates to beacons for fluorescent in-situ hybridisation and chip technology. | 10-11-2012 |
20120258877 | IDENTIFICATION OF CANCER BIOMARKERS AND PHOSPHORYLATED PROTEINS - Methods are provided for identifying proteins that are differentially expressed in disease state and normal cells. Stable isotope labeling of cells in culture allows for the identification of a multiplicity of proteins whose differential abundance in normal and disease state cells can be indicative of the disease state. Biomarkers are identified for breast cancer, in which the biomarkers are proteins having a two-fold or greater difference in abundance between breast cancer and normal cells. Identified biomarkers can be used detection methods that can provide diagnosis, typing, staging, or prognosis of cancer, such as breast cancer, or can be used to predict the response of cancer, such as breast cancer, to one or more anti-cancer agents. | 10-11-2012 |
20120258878 | PROGNOSTIC GENE SIGNATURES FOR NON-SMALL CELL LUNG CANCER - The application provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups by way of a multigene signature, comprising at least 5 genes from Table 3. The application also includes kits and computer products for use in the methods of the application. | 10-11-2012 |
20120258879 | Polymorphism Detection - The present invention generally provides a rapid efficient method for analyzing polymorphic or biallelic markers, and arrays for carrying out these analyses. In general, the methods of the present invention employ arrays of oligonucleotide probes that are complementary to target nucleic acids which correspond to the marker sequences of an individual. The probes are typically arranged in detection blocks, each block being capable of discriminating the three genotypes for a given marker, i.e., the heterozygote or either of the two homozygotes. The method allows for rapid, automatable analysis of genetic linkage to even complex polygenic traits | 10-11-2012 |
20120258880 | Methods and/or Use of Oligonucleotide Conjugates for Assays and Flow Cytometry Detections - The present disclosure is directed to methods and/or uses of oligonucleotide conjugates for assays and flow cytometry detections and related systems and/or kits. Certain methods are directed to a method for detecting one or more biological targets of a sample in a detection assay, comprising: providing a molecular probe, comprising a binding moiety and an oligonucleotide sequence, to a sample comprising one or more biological targets; binding the one or more biological targets with the binding moiety; providing a detectable component to the sample, wherein the detectable component comprises a signal generating moiety conjugated to an oligonucleotide sequence complementary to the oligonucleotide sequence of the molecular probe; hydridizing the oligonucleotide sequence of the target-bound molecular probe to the detectable component; and detecting a signal generated from the hydridized detectable component. Various other embodiments, applications etc. are disclosed herein. | 10-11-2012 |
20120258881 | Methods and/or Use of Oligonucleotide Conjugates for Assays and Microscopy/Imaging Detections - The present disclosure is directed to methods and/or uses of oligonucleotide conjugates for assays and microscopy/imaging detections and related systems and/or kits. Certain methods are directed to a method for detecting one or more biological targets of a sample in a detection assay, comprising: providing a molecular probe, comprising a binding moiety and an oligonucleotide sequence, to a sample comprising one or more biological targets; binding the one or more biological targets with the binding moiety; providing a detectable component to the sample, wherein the detectable component comprises a signal generating moiety conjugated to an oligonucleotide sequence complementary to the oligonucleotide sequence of the molecular probe; hydridizing the oligonucleotide sequence of the target-bound molecular probe to the detectable component; and detecting a signal generated from the hydridized detectable component. Various other embodiments, applications etc. are disclosed herein. | 10-11-2012 |
20120258882 | METHOD FOR QUANTITATIVELY DETECTING BIOMOLECULES - Provided is a method for quantitatively detecting biomolecules with high sensitivity for a short time by using nanoparticles and a metal deposition method in an immuno-detection using a well-type plastic substrate. | 10-11-2012 |
20120258883 | METHOD OF USING CYTOKINE ASSAYS TO DIAGNOSE, TREAT, AND EVALUATE INFLAMMATORY AND AUTOIMMUNE DISEASES - The invention provides methods for diagnosing, treating, or evaluating inflammatory and autoimmune diseases by sampling peripheral blood, serum, plasma, tissue, cerebrospinal fluid, or other bodily fluids from a human subject having a suspected diagnosis. The sample is analyzed for the presence and amount of certain cytokines, which provides the diagnosis, prognosis or evaluation of therapeutic response. | 10-11-2012 |
20120258884 | Method of Determining Predisposition to Scoliosis - The present invention relates to novel genetic markers associated with scoliosis, risk of developing scoliosis and risk of scoliosis curve progression, and simplified methods and materials for determining whether a human subject has scoliosis, is at risk of developing scoliosis or is at risk of scoliosis curve progression. | 10-11-2012 |
20120264625 | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF CERVICAL CANCER - The invention relates to nucleic acid molecules and proteins associated with cervical cancer including pre-malignant conditions such as dysplasia. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human cervical cancers are also provided. | 10-18-2012 |
20120264626 | MicroRNA Expression Profiling and Targeting in Chronic Obstructive Pulmonary Disease (COPD) Lung Tissue and Methods of Use Thereof - A method for diagnosing and staging of chronic obstructive pulmonary disease (COPD) includes measuring expression of one or more miRNAs levels in a subject suspected of suffering from COPD. | 10-18-2012 |
20120264627 | Oligonucleotide Array For Tissue Typing - Oligonucleotide-based microarrays for tissue typing (e.g., HLA tissue typing) are provided. More particularly, the microarrays are high resolution arrays useful for diagnostic evaluations and determining donor/recipient transplant compatibility. | 10-18-2012 |
20120264628 | Methods for Enriching Microparticles or Nucleic Acids in a Complex Mixture Using Size Exclusion Filtration - Embodiments of the present invention provide methods for the enrichment of rare microparticles, cells, or nucleic acids from a complex mixture using serial size exclusion filtration. Also provided are less invasive methods for detecting chromosomal or genetic abnormalities in a fetus, by enriching fetal microparticles in maternal plasma using serial size exclusion filtration, and isolating and analyzing the fetal nucleic acids from the fetal microparticles. Methods for diagnosis of diseases such as cancer are also provided, including enriching disease specific microparticles in the patient's plasma using serial size exclusion filtration, and isolating and analyzing the nucleic acids from the disease specific microparticles. | 10-18-2012 |
20120264629 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Beta-2-glycoprotein 1 as a diagnostic and prognostic biomarker in renal injuries. | 10-18-2012 |
20120264630 | METHOD FOR DETECTING A CIRCULARIZED DNA, AND USE OF SAID METHOD FOR DETECTING MUTATIONS - The present invention relates to a method for detecting a circularized single-stranded DNA by means of the isothermal hyperbranched rolling circle amplification technique, in which the primers used comprise a detectable barcode sequence and, optionally, a spacer which blocks polymerization by DNA polymerase. The present invention also relates to the use of said method for detecting a genetic polymorphism of one or more base pair(s). | 10-18-2012 |
20120264631 | Targets For Use In Diagnosis, Prognosis And Therapy Of Cancer - Provided herein are targets that can be used for the diagnosis, prognosis and therapy of a variety of cancers. | 10-18-2012 |
20120264632 | Methods for Determining Sequence Variants Using Ultra-Deep Sequencing - The claimed invention provides for new sample preparation methods enabling direct sequencing of PCR products using pyrophosphate sequencing techniques. The PCR products may be specific regions of a genome. The techniques provided in this disclosure allows for SNP (single nucleotide polymorphism) detection, classification, and assessment of individual allelic polymorphisms in one individual or a population of individuals. The results may be used for diagnostic and treatment of patients as well as assessment of viral and bacterial population identification. | 10-18-2012 |
20120264633 | METHODS FOR DETECTING THROMBOCYTOSIS USING BIOMARKERS - The present invention relates to a method to determine the gene expression profile of thrombocytotic sensitive genes. The method comprises the following steps; obtaining hematologic samples from subjects in a training set, analyzing the obtained hematologic samples with a microarray, measuring the expression values of each gene on the microarray, performing analysis to identify differentially expressed genes in the training set among three cohorts of thrombocytosis, obtaining hematologic samples from subjects in an independent testing set, and validating the identity of the differentially expressed genes in the independent testing set among the three cohorts of thrombocytosis. The invention also relates to a method to distinguish thrombocytosis cohorts. The method includes the following steps; obtaining a hematologic sample from a subject, determining gene expression of a biomarker subset, analyzing gene expression of the biomarker subset, and classifying the subject into one of three cohorts. | 10-18-2012 |
20120264634 | Marker Sequences for Pancreatic Cancer Diseases, Pancreatic Carcinoma and Use Thereof - The present invention relates to novel marker sequences for pancreatic cancer diseases, pancreatic carcinoma and the diagnostic use thereof together with a method for screening of potential active substances for pancreatic cancer diseases, pancreatic carcinoma by means of these marker sequences. Furthermore, the invention relates to a diagnostic device containing such marker sequences for pancreatic cancer diseases, pancreatic carcinoma, in particular a protein biochip and the use thereof. | 10-18-2012 |
20120264635 | DETECTION OF CHROMOSOMAL ABNORMALITIES ASSOCIATED WITH PROGNOSIS OF NON SMALL CELL LUNG CANCER - The methods and compositions described herein address the need for a diagnostic method that can be provided to patients with early stage lung cancer, especially non-small cell lung cancer (NSCLC), to determine whether the patient is at increased risk of poor disease outcome. The methods and compositions thus allow for more informed treatment decisions for the early stage lung cancer patient. | 10-18-2012 |
20120264636 | GENETIC VARIANTS INDICATIVE OF VASCULAR CONDITIONS - The invention relates to procedures and methods of determining a susceptibility to certain vascular conditions, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with these conditions. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic methods, uses and procedures for utilizing such markers. | 10-18-2012 |
20120264637 | METHODS AND SYSTEMS FOR PHYLOGENETIC ANALYSIS - Methods and systems for designing and using organism specific and/or operational taxon unit (OTU)-specific probes. The methods and systems allow for detecting, identifying and quantitating a plurality of biomolecules or microorganisms in a sample based on the hybridization or binding of target molecules in the sample with the probes, including the detection of rare OTU's in a sample. In some cases, methods are provided for selecting an oligonucleotide probe specific for a node on a clustering tree. | 10-18-2012 |
20120264638 | CIRCULATING miRNAs AS NON-INVASIVE MARKERS FOR DIAGNOSIS AND STAGING IN PROSTATE CANCER - The present invention relates to a method for staging prostate cancer in a subject suffering from prostate cancer, said method comprises (a) determining the amount of at least one miRNA selected from the group consisting of miRNA-375, miRNA-141, miRNA-200b, miRNA-516a-3p and miRNA9*, or the amount of a precursor molecule in a sample from said patient and (b) comparing the, thus, determined amount with a reference amount. Moreover, the present invention is concerned with a method for identifying a subject susceptible to prostate cancer therapy and to a method for diagnosing prostate cancer. Further envisaged by the present invention are a kit and a device adapted to carry out the method of the present invention. | 10-18-2012 |
20120264639 | METHODS AND COMPOSITIONS FOR PREDICTING SURVIVAL IN SUBJECTS WITH CANCER - Methods for generating a prognostic signature for a subject with pancreatic ductal adenocarcinoma (PDAC) are disclosed. In some embodiments, the methods include determining expression levels for one or more genes selected from among Fos B, KLF6, NFKBIZ, ATP4A, GSG1, and SIGLEC11 in PDAC cells obtained from the subject, wherein the determining provides a prognostic signature for the subject. Also disclosed are methods for assessing risk of an adverse outcome of a subject with pancreatic ductal adenocarcinoma (PDAC), methods for predicting a clinical outcome of a treatment in a subject diagnosed with pancreatic ductal adenocarcinoma (PDAC), methods for predicting a positive or a negative clinical response of a subject with pancreatic ductal adenocarcinoma (PDAC) to a treatment, and arrays for use in the disclosed methods. | 10-18-2012 |
20120264640 | METHOD FOR DETECTING THE METHYLATION OF COLORECTAL-CANCER-SPECIFIC METHYLATION MARKER GENES FOR COLORECTAL CANCER DIAGNOSIS - The present invention relates to a method for detecting the methylation of colorectal cancer-specific marker genes for colorectal cancer diagnosis, and more particularly to a method of detecting colorectal cancer-specific marker genes, which are methylated specifically in colorectal cancer cells, to provide information for diagnosing colorectal cancer. The use of the inventive method for detecting methylation and the inventive composition, kit and nucleic chip for diagnosing colorectal cancer makes it possible to diagnose colorectal cancer at an early transformation stage, thus enabling the early diagnosis of colorectal cancer. In addition, the inventive method enables colorectal cancer to be effectively diagnosed in an accurate and rapid manner compared to conventional methods. | 10-18-2012 |
20120264641 | METHODS AND KITS FOR IDENTIFYING HUMAN ADENOVIRUS SEROTYPES - Methods, kits, primers and oligonucleotide probes for conveniently and rapidly detecting and identifying four or more human adenovirus (HAdV) serotypes in a sample are provided. Following a nucleic acid amplification reaction with specific primers, serotype specific oligonucleotide probes are used not only to detect HAdV present in a sample but also to discriminate between the HAdV serotypes present in the sample, and in particular to discriminate between the clinically relevant serotypes HAdV-3, HAdV-4, HAdV-7, HAdV-14, and HAdV-21 and/or HAdV-I, HAdV-2, HAdV-5, and HAdV-6. The combination of these primers and oligonucleotide probes permit the rapid and convenient serotyping of HAdV. | 10-18-2012 |
20120264642 | METHODS AND REAGENTS FOR IMPROVED DETECTION OF AMYLOID BETA PEPTIDES - The invention relates to methods for the diagnostic of a neurodegenerative disease, for the detection of a stage prior to a neurodegenerative disease or for distinguishing neurodegenerative disease from a stage prior to a neurodegenerative disease based on the level of certain pools of amyloid beta peptides which are either bound to plasma components or bound to blood cells as well as on certain calculated parameters which are obtained by an arithmetic combination of one or more of the amyloid peptide levels. The invention relates as well to kits for carrying out the above method. | 10-18-2012 |
20120264643 | TSG PRIMER TARGET DETECTION - The present invention relates to the detection of a target nucleic acid sequence in a real-time manner using a target signal generating primer (TSG primer) having dual interactive labels. The present invention allows for both target amplification and signal amplification by introducing dual interactive labels into a primer used in PCR reactions, ensuring real-time target detection by PCR reactions without the use of complicated oligonucleotides. The present invention could be free from the troublesome matters and shortcomings associated with conventional real-time PCR methods. The present invention allows for successful real-time target detection by using only a labeled primer. Also, the present invention can obtain strong signals indicative of the presence of target nucleic acid sequences in both a liquid phase and solid phase. | 10-18-2012 |
20120264644 | Oxide Layers on Silicone Substrates for Effective Confocal Laser Microscopy - Methods of performing confocal laser microscopy on a polymer array disposed on a silicon wafer substrate, the method comprising the steps of providing a silicon wafer substrate having a top side and a bottom side, coating the top side of the silicon wafer with an oxide coating to provide an oxide coated wafer, covalently coupling a plurality of probes to the top side of the coated wafer to provide a fixed polymer array, hybridizing the fixed polymer array with a plurality of labeled ligands, and assaying for one or more hybridized ligands using confocal laser fluorescence microscopy to detect hybridization are provided. | 10-18-2012 |
20120264645 | ANTI-CXCL9, ANTI-CXCL10, ANTI-CXCL11, ANTI-CXCL13, ANTI-CXCR3 AND ANTI-CXCR5 AGENTS FOR INFLAMMATORY DISORDERS - A method for detecting an inflammatory disease in a subject is disclosed. The method comprises the steps of (a) detecting a level of expression of one or more inflammatory disease markers in a biological sample obtained from the subject; and (b) comparing the level of expression of said one or more inflammatory disease markers in the biological sample to a normal level of expression of the one or more inflammatory disease markers, wherein the one or more inflammatory disease markers comprise one or more markers selected from the group consisting of CXCL9, CXCL10, CXCL11, CXCL13, CXCR3 and CXCR5. Also disclosed are a method for monitoring the course of treatment for an inflammatory disease in a subject and a kit for detecting an inflammatory disease in a subject. | 10-18-2012 |
20120270743 | Genetic Signatures and Gene Chips Associated With Administration of Electrically Conducted Radio Frequency Current to Skin and Methods and Treatments Relating Thereto - A gene panel comprising genes regulated in mammalian skin in response to generation of a radio frequency current in a tissue volume of the mammalian skin sufficient to heat the tissue volume to a treatment temperature, wherein at least one gene is selected from Table 1 or Table 2 and at least one gene is selected from Table 3. Further there is a method for providing a benefit to mammalian skin, the benefit comprising inducing collagen formation and/or dermal remodeling in a dermal layer of the mammalian skin in the absence of a skin-damaging inflammatory cytokine response, the method comprising generating a radio frequency current in a tissue volume of the mammalian skin for a treatment cycle sufficient to heat the tissue volume to a treatment temperature while avoiding an upregulation in expression of genes listed in Table 3. | 10-25-2012 |
20120270744 | METHODS TO DETERMINE IF A SUBJECT WILL RESPOND TO A BCR-ABL INHIBITOR - Methods are provided for determining if a subject of interest will respond to treatment with BCR-ABL inhibitor, comprising. The method includes quantitating expression of a plurality of genes in CD34+ cells isolated from the subject. Expression of the plurality of genes in the subject of interest is compared to a control. Altered expression of the plurality of genes in as compared to the control indicates that the subject of interest will respond to treatment with the BCR-ABL inhibitor. Arrays are also provided. | 10-25-2012 |
20120270745 | DRUG SELECTION FOR CANCER THERAPY BY PROFILING SIGNAL TRANSDUCTION PROTEINS IN ASCITES OR PLEURAL EFFLUX SAMPLES - The present invention provides methods for selecting a suitable anticancer therapy and for identifying and predicting response for the treatment of a gastric cancer by determining the expression level and/or activation level of one or more analytes in a cell such as a cancer cell from an ascites sample. The present invention also provides methods for selecting a suitable anticancer therapy and for identifying and predicting response for the treatment of a lung cancer such as a non-small cell lung cancer by determining the expression level and/or activation level of one or more analytes in a cell such as a cancer cell from a pleural efflux sample. | 10-25-2012 |
20120270746 | CANCER MARKER, METHOD FOR EVALUATION OF CANCER BY USING THE CANCER MARKER, AND EVALUATION REAGENT - The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494. | 10-25-2012 |
20120270747 | METHOD OF PREDICTING RISK OF PRE-TERM BIRTH - A method for diagnosing, or differentially diagnosing, an increased risk of pre-term birth (PTB) involves detecting or measuring increased expression of a biomarker Soluble E-cadherin (SE-CAD) in a biological sample from a mammalian subject, particularly in the urine, cervicovaginal fluid or blood. An increased level of expression of SE-CAD above the level of expression in the same sample of a healthy mammalian subject is an indication of a diagnosis of increased risk of PTB. Such diagnosis may further involve identify other clinical symptoms of PTB or PTL. Additionally the method may use additional biomarkers, such as fetal fibronectin. | 10-25-2012 |
20120270748 | PEPTIDE DISPLAY ARRAYS - The present invention provides arrays, methods of constructing arrays, and methods of use of such arrays. The arrays of the invention comprise a substrate with two or more discrete constructs or discrete sets of constructs associated on the surface of the substrate, optionally via a linker molecule. The constructs include an oligonucleotide comprising a region encoding a peptide of interest and an affinity tag and an untranslated region, a fusion peptide comprising both the peptide of interest and the affinity tag and a capture agent that forms a binding pair with the affinity tag. | 10-25-2012 |
20120277108 | SOL-GEL KIT FOR PREPARING BIOCHIP AND METHOD FOR PREPARING BIOCHIP USING THE SAME - A method of preparing a protein chip by gelation of a sol composition. In the method, a mixture of specific silicate monomers, such as SolB1, SolB2 and SolB3, SolBH, and a mixture of SolBS, distilled water and a detector protein are mixed sequentially, so that the gelation rate of the sol composition can be delayed, thus inducing the stable gelation of the composition. Also, the biochip can be fabricated in a simple and easy manner by dispensing the sol composition by hand using an arrayer or a tool such as a pipette. In addition, a uniform biochip can be prepared by dispensing the sol composition, solution I (SolBH) and solution II (a mixture of buffer, SolBS, distilled water and a detector protein) sequentially onto a substrate without needing a conventional pretreatment process such as mixing. | 11-01-2012 |
20120277109 | PROXIMITY-MEDIATED ASSAYS FOR DETECTING ONCOGENIC FUSION PROTEINS - The present invention provides antibody-based arrays for detecting the activation state and/or total amount of one or a plurality of oncogenic fusion proteins in a biological sample such as whole blood or tumor tissue and methods of use thereof. In certain instances, the activation state and/or total amount of oncogenic fusion protein(s) present in a sample can be measured in combination with one or a plurality of signal transduction molecules. The compositions and methods of the present invention have the advantages of specificity associated with enzyme-linked immunosorbent assays, sensitivity associated with signal amplification, and high-throughput multiplexing associated with microarrays. | 11-01-2012 |
20120277110 | PARP AND ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN NON-SMALL-CELL LUNG CANCER - The invention is generally directed to a diagnostic method for predicting the benefit of the response of a subject diagnosed with cancer to a platinum compound-based adjuvant chemotherapy, preferably to a cisplatin-based chemotherapy which implements the determination of the PARP expression level in the biological sample containing tumor cells, and, preferably, together with the MSH2 and/or ERCC1 expression level, more preferably together with the MSH2 and ERCC1 expression levels. | 11-01-2012 |
20120277111 | MicroRNA Mediated Neuronal Cell Induction - Methods of converting non-neuronal somatic cells into induced neuronal cells are provided. Aspects of the methods include contacting a non-neuronal somatic cell with a microRNA mediated neuronal cell induction agent. Aspects of the invention further include compositions produced by methods of the invention as well as compositions that find use in practicing embodiments of methods of invention. The methods and compositions find use in a variety of different applications. | 11-01-2012 |
20120277112 | PREDICTING RESPONSE TO ANTI-CANCER THERAPY VIA ARRAY COMPARATIVE GENOMIC HYBRIDIZATION - Array comparative genomic hybridization classifiers, arrays comprising the classifiers, and related methods of using the same for predicting the therapeutic efficacy of anti-cancer therapy by detecting phenotypic genetic traits using comparative genomic hybridization are disclosed. | 11-01-2012 |
20120277113 | ARRAY-BASED PROXIMITY LIGATION ASSOCIATION ASSAYS - Embodiments of this disclosure encompass methods, systems and probes for the detection of a target analyte in a sample. The method uses of the detection of at least two distinct sites on an analyte molecule, or the pairing of two distinct sites on two adjacent and contacting molecules, the sites being integral to the structure of a single molecule or positioned near one another due to the three-dimensional structure of the polypeptide. At least one of the detectable sites may be formed by a modification of a larger molecule. The methods of detecting a target analyte comprise contacting a sample with a pair of probes, each probe comprising a binding moiety capable of specifically binding to a target analyte or a tag thereon, and an oligonucleotide tail that comprises a PCR initiator region proximal to the target analyte binding moiety, a barcoding region uniquely associated with the target analyte binding moiety, and a connector-hybridizing region complementary to a region of a connector oligonucleotide; hybridizing a connector oligonucleotide to the connector-hybridizing regions of the probes and ligating the connector-hybridizing regions of the probes; PCR amplifying the the ligated oligonucleotide tails; hybridizing the amplification product with a substrate-immobilized oligonucleotide that as regions complementary to the barcoding regions of the probes; digesting any single-strand DNA molecule; hybridizing a signaling oligonucleotide to the product of the previous step; and detecting the signal, thereby detecting the presence of the analyte in the sample. | 11-01-2012 |
20120277114 | ULTRA-SENSITIVE DETECTION OF MOLECULES OR PARTICLES USING BEADS OR OTHER CAPTURE OBJECTS - The present invention relates to systems and methods for detecting analyte molecules or particles in a fluid sample and in some cases, determining a measure of the concentration of the molecules or particles in the fluid sample. Methods of the present invention may comprise immobilizing a plurality of analyte molecules or particles with respect to a plurality of capture objects. At least a portion of the plurality of capture objects may be spatially separated into a plurality of locations. A measure of the concentration of analyte molecules in a fluid sample may be determined, at least in part, on the number of reaction vessels comprising an analyte molecule immobilized with respect to a capture object. In some cases, the assay may additionally comprise steps including binding ligands, precursor labeling agents, and/or enzymatic components. | 11-01-2012 |
20120277115 | BIOMARKER FOR SUCCESSFUL AGING WITHOUT COGNITIVE DECLINE - Methods and compositions for determining whether a subject will age without developing cognitive decline are provided. An exemplary method includes detecting one or more allelic variants in a gene encoding low density lipoprotein-related protein 1B. In a preferred embodiment, the detecting step is accomplished by contacting a sample obtained from the subject with a probe that forms a detectable complex with a nucleic acid in the sample containing an allelic variant indicative of aging without developing cognitive decline, wherein detection of the allelic variant in the sample indicates that the subject will age without developing cognitive decline. | 11-01-2012 |
20120277116 | Disease diagnosis according to saccharide binding - Disclosed is a method for characterizing carbohydrate polymer by identifying at least two binding agents that bind to the carbohydrate polymer. Binding is preferably determined by contacting the carbohydrate polymer with substrate that contains a plurality of first saccharide-binding agents affixed at predetermined locations on the substrate. The carbohydrate polymer is allowed to contact the substrate under conditions that allow for formation of a first complex between the first saccharide-binding agent and the carbohydrate polymer. In one aspect, the method is used in the diagnosis of a disease, including a viral disease, an autoimmune disease, a bacterial infection, or cancer. | 11-01-2012 |
20120283113 | Compositions and methods for antibody and ligand identification - Embodiments disclosed herein relate to methodology, and kits thereof for identifying particular disease-associated antibodies partially based on comparative binding to a mimotope array. Isolation of identified disease-associated antibodies and uses thereof are also described. | 11-08-2012 |
20120283114 | NEW DIAGNOSTIC TOOLS FOR ALZHEIMER DISEASE - The present invention relates to development, validation and application of new sets of biomarkers for diagnosis of Alzheimer's disease (AD) and related disorders including early diagnosis of MCI and early prodrome of AD, identification of disease sub types, prediction of their response to disease management procedures, drugs and their combinations and for monitoring response for these treatment, including validation of biomarkers for clinical trials. | 11-08-2012 |
20120283115 | SEROMIC ANALYSIS OF OVARIAN CANCER - The invention relates to the discovery of cancer antigens associated with ovarian cancer. In further aspects, the invention relates to methods, compositions and kits for the diagnosis and treatment of cancer, particularly ovarian and pancreatic cancers. | 11-08-2012 |
20120283116 | Mutant Sodium Channel Nav1.7 and Methods Related Thereto - Described are mutant Na | 11-08-2012 |
20120283117 | DETERMINATION OF EOSINOPHILIC ESOPHAGITIS - Eosinophilic esophagitis (EE), an emerging disorder with poorly understood pathogenesis, was examined. Esophageal tissue was analyzed by a genome wide microarray expression analysis. EE patients had a transcript signature involving 1% of the genome that was conserved across gender, age, and atopic status, and was distinct from that associated with chronic esophagitis (CE). The eosinophil specific chemokine eotaxin-3 was the top induced gene compared with normal controls. Levels C of eotaxin-3 mRNA and protein correlated with disease severity. A single nucleotide polymorphism in the human eotaxin-3 gene conferred susceptibility to disease. Mice deficient in the eotaxin-3 receptor (CCR-3) were protected from experimental EE. Eotaxin-3 was identified as a specific effector molecule, biomarker, and genetic risk factor for EE, and distinguished EE from CE. | 11-08-2012 |
20120283118 | METHODS FOR DETECTING MYCOBACTERIUM TUBERCULOSIS ANTIGENS - Method for detecting | 11-08-2012 |
20120283119 | POTENTIOMETRIC DNA MICROARRAY, PROCESS FOR PRODUCING THE SAME AND METHOD OF ANALYZING NUCLEIC ACID - A DNA microarray system whereby measurement can be performed at a low running cost, a low price and yet a high accuracy. A nucleic acid probe ( | 11-08-2012 |
20120283120 | SCREENING METHOD - The present invention provides a novel variant androgen receptor (ARaiv) lacking ligand binding domain, a nucleic acid encoding the same and use thereof. That is, the present invention provides a method of screening for a substance for the prophylaxis or treatment of cancer, which includes contacting an ARaiv protein or ARaiv-producing cell with a test compound, measuring the activity of ARaiv (e.g., transcription regulating action of androgen responsive gene) or expression level thereof, and selecting a compound that suppresses the activity or expression level. | 11-08-2012 |
20120283121 | Quantification of IR-A and IR-B for Tumor Classification - Without limitation, this disclosure relates to compositions and methods for detecting and quantifying the expression of insulin receptor isoform A (IR-A) and/or insulin receptor isoform B (IR-B) in a tissue sample. The disclosure also relates to methods of diagnosis and classification based at least in part upon detecting and quantifying the expression of insulin receptor isoform A (IR-A) and/or insulin B (IR-B) in a tissue sample. Methods of treating a subject based upon such a classification are among additional aspects of the disclosure presented herein. | 11-08-2012 |
20120283122 | ANALYTE QUANTIFICATION MULTIPLEX MICROARRAYS COMBINING INTERNAL AND EXTERNAL CALIBRATION - The present invention relates to multiplex microarrays and methods for the quantification of analytes. In particular, the invention relates to improved methods which standardize a target analyte concentration in a test sample against a reference standardization curve derived from validated, approved and recognized reference standards for the target analyte of known concentrations. The present invention also relates to methods and checks for simultaneous measurement of confidence confirming normalization standards and controls. | 11-08-2012 |
20120283123 | Biomarkers for the Diagnosis of Kidney Graft Rejection - Methods are provided for determining a transplant category of a subject having a kidney graft. In practicing one aspect of the subject methods, the peptide signature of a non-invasive sample derived from the transplant subject (e.g., a urine sample) is used to determine the subject's transplant category (e.g., acute allograft rejection (AR), stable allograft (STA), BK virus nephropathy (BK), and the like). In other embodiments, a gene expression signature from a biopsy sample from the subject (e.g., mRNA level) is used to determine the subject's transplant category. In certain embodiments both a peptide signature and a gene expression signature are used. Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods. | 11-08-2012 |
20120283124 | Cell Surface Marker Expression in Hematopoietic Stem Cells and Progenitors for the Diagnosis, Prognosis, and Treatment of Myelodysplastic Syndromes - Myelodysplastic syndromes are staged by analysis of the presence of hematopoietic stem and/or progenitor cells, particularly progenitor cells dedicated to the myeloid lineage and hematopoietic stem cells. | 11-08-2012 |
20120283125 | Ovarian Markers of Oocyte Competency and Uses Thereof - The present invention relates to the competence of oocytes to fertilization, uterine implantation and development into a living being. The invention describes ovarian markers whose expression is predicative of oocyte competency that are detected and/or measured in follicular fluid, cumulus cells and/or follicular cells of a mammal. Also described are methods for evaluating competence of mammalian oocytes, methods for selecting a mammalian oocyte for assisted reproduction (AR), and screening methods for identifying stimulatory or inhibitory compounds to mammalian oocyte competence. | 11-08-2012 |
20120283126 | HUMAN FERTILITY TEST USING DPY19L2 - The present patent application concerns a method for diagnosing infertility related to the DPY19L2 protein, in a male human subject, and a method for treating said subject with a view to restoring fertility. The present invention also concerns the use of molecules inhibiting the action of the DPY19L2 polypeptide in a wild-type carrier male subject, for example of anti-DPY19L2 interfering nucleic acid type selectively inhibiting the expression of the DPY19L2 polypeptide. | 11-08-2012 |
20120283127 | DIAGNOSTIC METHOD FOR ALZHEIMER'S DISEASE - The present invention provides an ex vivo method for aiding the diagnosis of Alzheimer's disease in a patient, the method comprising the steps of determining the level of expression of at least four platelet proteins in a platelet sample from the patient selected from monoamine oxidase-B, coagulation factor Xllla, total tropomyosin (a and 13), WD-repeat protein 1 and apolipoprotein E4; and comparing the result of (i) to a control value, wherein a result higher than the control value is indicative of Alzheimer's disease. Preferably, the method of the invention further comprises determining the level of expression of wild-type GSTO-1 or mutant GSTO-1. | 11-08-2012 |
20120283128 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays, one or more of which is configured to detect a kidney injury marker selected from the group consisting of Hyaluronic acid, Immunoglobulin A, Immunoglobulin G1, Immunoglobulin G2, Insulin-like growth factor-binding protein 7, Alpha-1 antitrypsin, Serum amyloid P component, Metalloproteinase inhibitor 2, Hepatocyte growth factor, Intercellular adhesion molecule 1, Beta-2-glycoprotein 1, Interleukin-1 beta, Neutrophil Elastase, Tumor necrosis factor receptor superfamily member 11B, Interleukin-11, Cathepsin D, C—C motif chemokine 24, C—X—C motif chemokine 6, C—C motif chemokine 13, C—X—C motif chemokines -1, -2, and -3, Matrilysin, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, and Macrophage colony-stimulating factor 1 as diagnostic and prognostic biomarkers in renal injuries. | 11-08-2012 |
20120283129 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING KIDNEY DISORDERS IN A CANINE - The present invention provides methods for: diagnosing of, devising and monitoring a treatment plan for, and monitoring the status of a kidney disorder characterized by an abnormal loss of renal function, renal failure, reduced glomerular filtration rate or glomerulonephritis, in a canine, wherein the kidney disorder is detectable by utilizing at least one relevant biomarker isolated and measured from a biological test sample taken from such canine. The invention additionally relates to compositions, reagents and kits for carrying out the specified methods. | 11-08-2012 |
20120283130 | METHOD FOR SCREENING INDUCED PLURIPOTENT STEM CELLS - The present invention relates to miRNA or genes expressed in induced pluripotent stem cells, and a method for screening for induced pluripotent stem cells having functions equivalent to those of embryonic stem cells by confirming methylation of specific gene regions of induced pluripotent stem cells. | 11-08-2012 |
20120283131 | HIV TYPE AND SUBTYPE DETECTION - The present invention relates to the detection of HIV by amplification and PCR-based methods. | 11-08-2012 |
20120283132 | MOLECULAR IN VITRO DIAGNOSIS OF BREAST CANCER - A method for determining the benign or malignant state of a breast tumor in a biological sample is presented. The benign or malignant state is determined by measuring the variation of expression of twelve genes and at least one variant of each of the twelve genes when the variants exist, using a combination of 50 polynucleotide probe sets. An expression profile of the sample is then compared with reference expression profiles of control benign and malignant breast tissues. The probe sets can be arranged in a microarray. | 11-08-2012 |
20120283133 | MICROFLUIDIC SELECTION OF LIBRARY ELEMENTS - A microfluidic device includes a chip; a flow channel being disposed in the chip; the flow channel being in communication with an entry port and an exit port; the flow channel being operative to permit the flow of a library from the entry port to the exit port; a substrate; the substrate being disposed upon the chip; the substrate being operative to act as an upper wall for the flow channels; and a plurality of receptors; the plurality of receptors being disposed on the substrate; the plurality of receptors being operative to interact with an element from the library. | 11-08-2012 |
20120283134 | Method for Identifying Lineage-Related Antibodies - In certain embodiments, the method may comprise: a) obtaining the antibody sequences from a population of B cells; b) grouping the antibody sequences to provide a plurality of groups of lineage-related antibodies; c) testing a single antibody from each of the groups in a bioassay and, after the first antibody has been identified, d) testing further antibodies that are in the same group as the first antibody in a second bioassay. In another embodiment, the method may comprise: a) testing a plurality of antibodies obtained from a first portion of an antibody producing organ of an animal; b) obtaining the sequence of a first identified antibody; c) obtaining from a second portion of said antibody producing organ the sequences of further antibodies that are related by lineage to said first antibody; and, c) testing the further antibodies in a second bioassay. | 11-08-2012 |
20120283135 | PRIMERS AND PROBES FOR DETECTION AND DISCRIMINATION OF TYPES AND SUBTYPES OF INFLUENZA VIRUSES - Methods of detecting influenza, including differentiating between type and subtype are disclosed, for example to detect, type, and/or subtype an influenza infection. A sample suspected of containing a nucleic acid of an influenza virus, is screened for the presence or absence of that nucleic acid. The presence of the influenza virus nucleic acid indicates the presence of influenza virus. Determining whether the influenza virus nucleic acid is present in the sample can be accomplished by detecting hybridization between an influenza specific probe, influenza type specific probe, and/or subtype specific probe and an influenza nucleic acid. Probes and primers for the detection, typing and/or subtyping of influenza virus are also disclosed. Kits and arrays that contain the disclosed probes and/or primers also are disclosed. | 11-08-2012 |
20120289418 | DIAGNOSTIC METHOD AND KIT FOR THE DETECTION OF A LYMPHOCYTIC VARIANT OF HYPEREOSINOPHILIC SYNDROME - The present invention is related to a gene set, a kit and a method for diagnosis of lymphocytic variant hypereosinophilic syndrome. | 11-15-2012 |
20120289419 | Methods and Compositions for the Target-localized Anchoring of Detectable Label - Highly reactive functionalized substrates and linker molecules for use in the detection of molecular targets and other analytes of interest are provided as are kits, reaction mixtures and methods utilizing the same. | 11-15-2012 |
20120289420 | MICRORNA BIOMARKERS FOR AIRWAY DISEASES - The present invention provides miRNA biomarkers useful for diagnosis, prognosis, and/or treatment of airway diseases such as asthma, asthma exacerbation and nasal polyps. | 11-15-2012 |
20120289421 | Method and Apparatus for High Accuracy Genomic Analysis Platform Utilizing Hybridization and Enhanced Dissociation - Methods and an apparatus according to the present invention, can be used in capture/enrichment, gene expression profiling and targeted sequencing. Provided are methods for improving accuracy and stringency of microarrays and/or other genomic analysis methods relying on nucleic acid hybridization and melting curve analysis by controlling surface chemistry. This method comprises producing a positively charged surface or surface coating, on the surface of microarray slides or other types of surfaces similarly purposed, such as micro beads, which enhances melting curve analysis to the point of allowing detection or differentiation of small changes in sequences between nucleic acid binding partners. Also provided is an improved microarray reader machine, to collect melting curve data on microarray slides. The accuracy or resolution of melting curve analysis was to be sufficient to distinguish between the melting of perfect matched dsDNA and dsDNA with the smallest possible change in sequence, a one base pair mismatch. | 11-15-2012 |
20120289422 | QUANTITATIVE DIAGNOSTIC METHODS USING MULTIPLE PARAMETERS - Materials and Methods related to diagnosing a clinical condition in a subject, or determining the subject's predisposition to develop the clinical condition, using a multi-parameter system to measure a plurality of parameters and an algorithm to determine a disease score. | 11-15-2012 |
20120289423 | ONLINE REAL-TIME WATER QUALITY MONITORING AND CONTROL SYSTEM INCORPORATING SYSTEMS FOR AUTOMATED MICROBIOLOGICAL TESTING AND ONE-STEP DNA DETECTION - A system for detecting deoxyribonucleic acid (DNA) biomarkers. The system is configured to monitor and control standard parameters (temperature, pH, free chlorine, redox potential, TDS, turbidity), via an array of sensors. The system is configured to perform automated microbiological testing using a DNA hybridization based optical detection sensor, wherein the sensor is configured to provide automated sample collection, primer and buffer addition, thermocycling and fluorescence detection via laser excitation and a linear CCD. | 11-15-2012 |
20120289424 | IGF1R POLYMORPHISM PREDICTS TUMOR RECURRENCE IN BREAST CANCER PATIENTS - The disclosure provides compositions and methods for determining the likely tumor recurrence in breast cancer patients by screening IGFR1 polymorphism in samples isolated from the patient. | 11-15-2012 |
20120289425 | Techniques for Identifying, Confirming, Mapping and Categorizing Polymers - Systems and methods for identifying, confirming, mapping, and categorizing sample polymers, such as nucleic acid sequences, are provided. An estimation of the fraction of first and second polymers in a sample of polymers can be calculated by inputting a first hybridization value indicative of hybridization affinity of the sample of polymers to polymers probes that are complementary to the first polymer and inputting a second hybridization value indicative of hybridization affinity of the sample of polymers to polymers probes that are complementary to the second polymer. The estimation of the fraction of the first and second polymers in the sample of polymers can then be calculated by dividing the first hybridization value by a sum of the first and second hybridization values. Estimations of the fractions of alleles in a sample can be clustered to form a fraction pattern usable for identifying, confirming, mapping, and genotyping sample nucleic acids. | 11-15-2012 |
20120289426 | METHOD FOR AMPLIFICATION OF TARGET NUCLEIC ACID - A method for amplifying a target nucleic acid is disclosed, which includes: (a) fragmenting a nucleic acid sample to create a target fragment comprising a target nucleic acid and two probe-complementary portions; (b) contacting said fragmented nucleic acid sample with a probe comprising two target fragment-complementary portions complementary to the probe-complementary portions of the target fragment; (c) rendering the fragmented nucleic acid sample single-stranded; (d) allowing the probe-complementary portions to hybridise with the target-fragment complementary portions; (e) if the probe in step (b) is not immobilised, immobilising the probe-target fragment hybrid on a solid phase via immobilisation moiety; (f) separating non-immobilised nucleic acid fragments from the solid phase; (g) contacting the solid phase with a ligase to ligate ligatable 5′ and 3′ ends of the target fragment whereby the target fragment is circularized; and (h) amplifying said circularized target fragment. | 11-15-2012 |
20120289427 | DETECTION METHOD FOR MICROARRAY - Described is a means for objectively determining hybridization failure in addition to performance degradation, insufficient washing and the like in a microarray. In particular a method for detecting the hybridization between a probe polynucleotide and a target polynucleotide by using a microarray is presented. | 11-15-2012 |
20120289428 | ULTRA-SENSITIVE DETECTION OF MOLECULES OR PARTICLES USING BEADS OR OTHER CAPTURE OBJECTS - The present invention relates to systems and methods for detecting analyte molecules or particles in a fluid sample and in some cases, determining a measure of the concentration of the molecules or particles in the fluid sample. Methods of the present invention may comprise immobilizing a plurality of analyte molecules or particles with respect to a plurality of capture objects. At least a portion of the plurality of capture objects may be spatially separated into a plurality of locations. A measure of the concentration of analyte molecules in a fluid sample may be determined, at least in part, on the number of reaction vessels comprising an analyte molecule immobilized with respect to a capture object. In some cases, the assay may additionally comprise steps including binding ligands, precursor labeling agents, and/or enzymatic components. | 11-15-2012 |
20120289429 | BIOCHIP COMPRISING MULTIPLE MICROCHANNELS - A biochip includes a plurality of microchannels; and a plurality of probes disposed in an inner wall of each of the plurality of microchannels forming a one-dimensional array. The one-dimensional array of probes are configured to react with a sample in the microchannel. The plurality of microchannels are arranged such that the plurality of probes of the plurality of microchannels form a two-dimensional or three-dimensional array. | 11-15-2012 |
20120289430 | METHODS FOR MEASURING ENHANCEMENT IN THE QUALITY OF LIFE OF AN ANIMAL - A method to measure enhancement in the quality of life of an animal fed a super senior pet food composition comprising quantitating the gene expression levels of one or more genes in said animal and comparing said levels in the animal to levels in the animal prior to administration of said super senior pet food composition. A method to enhance the quality of life of an animal by modulating the expression level of one or more genes in said animal in order to mimic the pattern of expression seen in vivo after administration of a super senior pet food composition. | 11-15-2012 |
20120289431 | DIAGNOSIS OF BREAST CANCER BASED ON EXPRESSION LEVEL OF THIOREDOXIN-1 - The present disclosure relates to a diagnostic marker for breast cancer, having thioredoxin-1 as an active ingredient, and to a diagnostic kit for breast cancer using the same. The thioredoxin-1 is overexpressed in human breast cancer tissue so as to enable the early diagnosis of breast cancer or the early prediction prognosis of breast cancer, and therefore has a valuable use as a diagnostic marker for breast cancer. The present disclosure further relates to a method for the diagnosis of breast cancer comprising measuring serum thioredoxin 1 level. In addition, the method is useful in the early diagnosis of breast cancer thanks to its high diagnostic sensitivity and selectivity. | 11-15-2012 |
20120295797 | METHODS FOR DIAGNOSIS AND PROGNOSIS OF PULMONARY HYPERTENSION - The invention relates to diagnostic and prognostic assays and kits for pulmonary hypertension (PH) and types thereof. The invention includes detecting the expression level of markers associated with pulmonary hypertension for diagnosis, progosis, or treatment of pulmonary hypertension. | 11-22-2012 |
20120295798 | SORTING OF ADHERENT CELLS BY SELECTIVE TRANSFORMATION OF LABELS - Adherent cells bearing characteristics that are detectable only in the adherent state can be sorted on the basis of these characteristics independently of their adherent state, by applying a transformable label to the entire population of cells, both those bearing the characteristics of interest and those not, in their adherent state and identifying the locations of the cells of interest on the adherent surface. The cells of interest, or all cells other than those of interest, are then selectively treated to transform the labels and achieve differentiation between the cells of interest and the remaining cells. All cells are then released from the adherent state and sorted in the same manner as non-adherent cells but on the basis of whether the labels are transformed or not transformed. | 11-22-2012 |
20120295799 | Methods and compositions for detecting autoimmune disorders - The invention provides methods and compositions useful for detecting autoimmune disorders. | 11-22-2012 |
20120295800 | OLIGONUCLEOTIDES FOR CANCER DIAGNOSIS - The present invention provides sets of oligonucleotides corresponding to genes encoding proteins involved in protein synthesis and/or stability or genes encoding proteins involved in the regulation of defense and/or chromatin remodeling for use in preparing transcript patterns particularly for cancer diagnosis. The invention also extends to such sets and kits containing such sets as well as related method reliant on analysis of marker polypeptides encoded by the genes to develop characteristic expression profiles. | 11-22-2012 |
20120295801 | High-Throughput In Situ Hybridization - Novel methods and compositions for providing high-throughput fluorescence in situ hybridization (FISH) are provided. | 11-22-2012 |
20120295802 | METHODS AND COMPOSITIONS FOR CANCER TREATMENT RELATING TO BRCA1 BRCT DOMAIN RECOGNITION OF PHOSPHORYLATED BACH1 - The present invention relates to compounds (e.g., peptidomimetics and non-peptides) that treat, prevent, or stabilize cellular proliferative disorders and methods of treating, preventing, or stabilizing such disorders. The invention also provides three-dimensional structures of a human BRCT domain-BACH1 phosphopeptide complex. | 11-22-2012 |
20120295803 | LUNG CANCER SIGNATURE - The present disclosure relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure relates to cancer markers as diagnostic markers and clinical targets for lung cancer. | 11-22-2012 |
20120295804 | Compositions and Methods for Diagnosis and Treatment of Breast Cancer - The present invention is a population of breast cancer cells with preference for establishing dormancy in bone marrow. The breast cancer cells have characteristics of stem cells and express high levels of Oct4, designated Oct4 | 11-22-2012 |
20120295805 | SOLID PHASE METHODS FOR THERMODYNAMIC AND KINETIC QUANTIFICATION OF INTERACTIONS BETWEEN NUCLEIC ACIDS AND SMALL MOLECULES - Methods for analysis of interactions between nucleic acid-binding agents (BAs) and nucleic acids (NAs) by performance of nucleic acid denaturation assays on solid supports. Typically, BA is a small molecule less than 1000 g/gmol in molecular weight. The methods provide quantitative thermodynamic and kinetic analysis of BA-NA interaction; for example, in the form of free energies, enthalpies, and entropies of BA-NA binding in case of thermodynamic analysis, or in the form of rate constants and activation energies of BA-NA binding in the case of kinetic analysis. Examples of BAs of interest include transcription regulators and other NA-recognition molecules such as dyes and drug potentiators, DNA-targeted therapeutic agents including anticancer, antibiotic, antiviral, and antitrypanosomal compounds, carcinogens, and any other molecules whose interaction with DNA may, or is suspected to, lead to a biologically-relevant consequence. BA may bind to NA either through physical interactions or through formation of covalent adducts. | 11-22-2012 |
20120295806 | METHODS, SYSTEMS, AND COMPOSITIONS FOR DETECTION OF MICROBIAL DNA BY PCR - This invention provides methods, systems, and compositions for detecting low abundance microbial DNA in a sample by broad-range PCR. Methods of the present invention are based on a novel strategy that tags the 5′-end of the target DNA templates with a non-bacterial tagging sequence so as to set the templates apart from the endogenous contaminants present in the PCR reagents. There is also provided fusion probes for tagging the templates and primer sets to amplify the tagged templates. Systems and kits for facilitating and automating methods of the present invention are also provided. | 11-22-2012 |
20120295807 | CHROMOSOME COPY NUMBER GAIN AS A BIOMARKER OF UROTHELIAL CARCINOMA LETHALITY - Diagnostic assays for medically classifying cancer patients are provided. The method comprises assessing a tissue sample of the patient for the presence of a copy number gain of chromosome regions 1q23.3 and/or 1q21.2. Copy number gain of chromosome regions 1q23.3 and/or 1q21.2 is indicative of a less favorable prognosis as compared to the prognosis if there was no copy number gain in the same regions. | 11-22-2012 |
20120295808 | Solid Support Assay Systems and Methods Utilizing Non-Standard Bases - Solid support assays using non-standard bases are described. A capture oligonucleotide comprising a molecular recognition sequence is attached to a solid support and hybridized with a target. In some instances, the molecular recognition sequence includes one or more non-standard bases and hybridizes to a complementary tagging sequence of the target oligonucleotide. In other instances, incorporation of a non-standard base (e.g., via PCR or ligation) is used in the assay. | 11-22-2012 |
20120295809 | RECURRENT GENE FUSIONS IN PROSTATE CANCER - Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided. | 11-22-2012 |
20120295810 | Non-Invasive Diagnosis of Graft Rejection in Organ Transplant Patients - The disclosure provides methods, devices, compositions and kits for diagnosing or predicting transplant status or outcome in a subject who has received a transplant. The methods comprise determining the presence or absence of one or more nucleic acids from a donor transplant, wherein said one or more nucleic acids from said donor are identified based on a predetermined marker profile, and diagnosing or predicting transplant status or outcome based on the presence or absence of said one or more nucleic acids. | 11-22-2012 |
20120295811 | APTAMERS DIRECTED AGAINST THE MATRIX PROTEIN-1 OF TYPE A INFLUENZA VIRUSES AND USES THEREOF - The present invention relates to nucleic acids that bind specifically to the matrix protein-1 of type A influenza viruses and uses thereof for detecting such viruses in a sample of interest. More particularly, the present invention relates to a nucleic acid that binds specifically to matrix protein-1 of type A influenza viruses characterized in that said nucleic acid comprises the following nucleotide sequence: 5′-N1-NS1-U-N3-A-NS3-NS5-NS7-NS6-CGCAU-NS4-C-N4-NS2-N2-3′ wherein: -N1 consists of a nucleotide -NS1 and NS2 consist of polynucleotides having 3 or 4 nucleotides in length, and NS1 and NS2 have complementary sequences; -N3 and N4 consists of a nucleotide, and N4 is complementary to N3; -NS3 and NS4 consist of polynucleotides having 3 nucleotides in length, and -NS3 and NS4 have complementary sequences -NS5 and NS6 consist of polynucleotides having 3 nucleotides in length, and -NS5 and NS6 have complementary sequences; -NS7 consists of a polynucleotide selected from the group consisting of AGAAUC (SEQ ID NO:12), UGAG (SEQ ID NO: 13), UAUUCC (SEQ ID NO:14), AGAU (SEQ ID NO:15), AGAATC (SEQ ID NO:16) or TGAG (SEQ ID NO:17) -N2 consists of a nucleotide that is complementary or not complementary to nucleotide N1. | 11-22-2012 |
20120295812 | METHOD FOR EXTRACTING STAPHYLOCOCCUS AUREUS ANTIGEN, REAGENT FOR EXTRACTING STAPHYLOCOCCUS AUREUS ANTIGEN, AND METHOD FOR ASSESSING STAPHYLOCCOCCUS AUREUS - The invention provides a method for extracting a | 11-22-2012 |
20120295813 | PLASMIDS AND METHODS FOR PEPTIDE DISPLAY AND AFFINITY-SELECTION ON VIRUS-LIKE PARTICLES OF RNA BACTERIOPHAGES - The present invention relates to a system and method for controlling peptide display valency on virus-like particles (VLPs), especially including MS2 VLPs. In this method, large amounts of wild-type and low quantities of single-chain dimer coat proteins may be produced from a single RNA. Valency is controlled in immunogen (vaccine) production by providing a system that allows the production of large amounts of wild-type and low quantities of single-chain dimer coating proteins from a single RNA, allowing facile adjustment of display valency levels on VLPs, especially MS2 VLPS over a wide range, from few than one-on average—to as many as ninety per particle. This facilitates the production of immunogens and vaccines, including VLPs exhibiting low valency. Nucleic acid constructs useful in the expression of virus-like particles are disclosed, comprised of a coat polypeptide of MS2 modified by insertion of a heterologous peptide, wherein the heterologous peptide is displayed on the virus-like particle and encapsidates MS2 niRNA. Nucleic acid constructs are also disclosed which are useful in the expression of virus-like particles comprised of a coat polypeptide of PP7 modified by insertion of a heterologous peptide, wherein the heterologous peptide is displayed on the virus-like particle and encapsidates PP7 mRNA. | 11-22-2012 |
20120295814 | CA-125 Immune Complexes as Biomarkers of Ovarian Cancer - The invention is directed to assays of CA-125 immune complexes that can be used diagnostically. It also includes glass or plastic plates or slides on which the monoclonal antibodies against CA-125 have been immobilized and kits containing these plates or slides. | 11-22-2012 |
20120295815 | DIAGNOSTIC GENE EXPRESSION PLATFORM - The invention provides a set of oligonucleotide probes specific to cancer, preferably breast cancer, kits containing them and their use in preparing standard and test patterns and methods of diagnosis of cancer, preferably breast cancer. | 11-22-2012 |
20120295816 | SINGLE TUBE MULTIPLEX ASSAY FOR DETECTION AND QUANTIFICATION OF ADULTERANTS IN BASMATI RICE SAMPLES - The present invention provides a single tube multiplex assay for distinguishing basmati from non-basmati rice varieties, and thereby identifying the adulteration of basmati rice varieties. The present invention further provides a method for quantifying adulteration in basmati rice varieties. The present invention also provides a kit for performing a multiplex assay for distinguishing basmati from non-basmati rice varieties. The kit may comprise a primer directed to an SSR loci, appropriate reagents for PCR, and optionally, a package insert for conducting the assay. | 11-22-2012 |
20120295817 | Aza-benzazolium Containing Cyanine Dyes - Unsymmetrical cyanine dyes that incorporate an aza-benzazolium ring moiety are described, including cyanine dyes substituted by a cationic side chain, monomeric and dimeric cyanine dyes, chemically reactive cyanine dyes, and conjugates of cyanine dyes. The subject dyes are virtually non-fluorescent when diluted in aqueous solution, but exhibit bright fluorescence when associated with nucleic acid polymers such as DNA or RNA, or when associated with detergent-complexed proteins. A variety of applications are described for detection and quantitation of nucleic acids and detergent-complexed proteins in a variety of samples, including solutions, electrophoretic gels, cells, and microorganisms. | 11-22-2012 |
20120295818 | METHOD OF MULTI PATHOGEN DETECTION - A culturing method includes culturing a sample having one or more species of target pathogens of a detection assay and competing microorganisms under oxygen-poor condition in a growth medium. The growth medium can be a non-selective medium. The oxygen-poor condition is effective to prevent competing microorganisms from suppressing growth of the target pathogens. This method can be used in combination with a sample preparation method for large volume particulate samples using highly porous filter material and porous spherical filter aid. | 11-22-2012 |
20120302453 | OXOCARBONAMIDE PEPTIDE NUCLEIC ACIDS AND METHODS OF USING SAME - The present invention concerns oxocarbonamide peptide nucleic acids (OxoPNAs). OxoPNAs provide increased stability, sensitivity, and specificity as compared to their natural DNA and RNA counterparts. The OxoPNA molecules of the present invention may be employed in a wide range of applications, particularly in applications involving hybridization. For example, OxoPNA probes may be employed for the detection and functional analysis of nucleic acid molecules, including miRNAs and other non-coding RNAs. | 11-29-2012 |
20120302454 | NANO-SENSOR ARRAY - In one embodiment, a method is provided for the manufacture of a nano-sensor array. A base having a sensing region is provided along with a plurality of nano-sensors. Each of the plurality of nano-sensors is formed by: forming a first nanoneedle along a surface of the base, forming a dielectric on the first nanoneedle, and forming a second nanoneedle on the dielectric layer. The first nanoneedle of each sensor has a first end adjacent to the sensing region of the base. The second nanoneedle is separated from the first nanoneedle by the dielectric and has a first end adjacent the first end of the first nanoneedle. The base is provided with a fluidic channel. The plurality of nano-sensors and the fluidic channel are configured and arranged with the first ends proximate the fluidic channel to facilitate sensing of targeted matter in the fluidic channel. | 11-29-2012 |
20120302455 | METHODS OF IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF LUNG DISEASES AND KITS THEREOF - The invention provides biomarkers and combinations of biomarkers useful in diagnosing lung diseases such as non-small cell lung cancer or reactive airway disease. The invention also provides methods of differentiating lung disease, methods of monitoring therapy, and methods of predicting a subjects response to therapeutic intervention based on the extent of expression of the biomarkers and combinations of biomarkers. Kits comprising agents for detecting the biomarkers and combination of biomarkers are also provided. | 11-29-2012 |
20120302456 | VERTICAL FLOW-THROUGH DEVICES FOR MULTIPLEXED ELISA DRIVEN BY WICKING - The invention provides kits, methods and devices for detection of analytes in a biological sample. Capillary action is employed to carry out single or multiplexed immunoassays in a vertical flow-through format. | 11-29-2012 |
20120302457 | Population Scale HLA-Typing and Uses Therof - The present invention provides a portable system for real-time population-scale HLA genotyping and/or allelotyping in a field environment and methods of such population-scale HLA genotyping. The individual components of the system are portable to and operable within a field environment thereby providing high throughput with real-time geno- or allelotyping. Also provided are HLA gene-specific primers and HLA allele-specific or single nucleotide polymorphism-specific hybridization probes. In addition the present invention provides a microarray comprising the hybridization probes. Further provided is a kit comprising the HLA gene-specific primers and the microarray. | 11-29-2012 |
20120302458 | CARDIOVASCULAR AUTOIMMUNE DISEASE PANEL AND METHODS OF USING SAME - Provided herein are diagnostic tests, methods of use, and kits for the assessment and management of cardiovascular autoimmune disease and risk of cardiovascular autoimmune disease. Assay methods of the invention can be employed to identify cardiovascular autoimmune disease, or risk thereof, in subjects who have cardiovascular disease, an autoimmune disease, or who are related to an individual with an autoimmune disease; for testing of a subject that exhibits symptoms of cardiovascular disease, as well as of a subject that is apparently healthy and does not yet exhibit symptoms of cardiovascular disease; and for determining whether a subject having, or at risk for, a cardiovascular disease is a candidate for immunosuppressive therapy or immunoabsorption therapy. The invention also provides kits and kit components useful for performing the methods. | 11-29-2012 |
20120302459 | Articles Having Localized Molecules Disposed Thereon and Methods of Producing Same - Methods of producing substrates having selected active chemical regions by employing elements of the substrates in assisting the localization of active chemical groups in desired regions of the substrate. The methods may include optical, chemical and/or mechanical processes for the deposition, removal, activation and/or deactivation of chemical groups in selected regions of the substrate to provide selective active regions of the substrate. | 11-29-2012 |
20120302460 | Use of Low Affinity Neurotrophin Receptor P75 As Marker for High Differentiation Potential Muscle Stem Cells, Muscle Satellite Cells, And Degenerative Skeletal Muscle Diseases - The marker for highly differentiating power muscle stem cells, muscle satellite cells and degenerative skeletal muscle diseases consists in the receptor recorded as PG8138, TNR16_HUMAN in the UniProtKB database, expressed in the skeletal muscle cells. The cellular expression of said receptor is also determined by the identification of highly differentiating power muscle stem cells and satellite cells. | 11-29-2012 |
20120309636 | SYSTEMS AND METHODS FOR SAMPLE USE MAXIMIZATION - The present invention provides systems, devices, and methods for point-of-care and/or distributed testing services. The methods and devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device can be modified to allow for more flexible and robust use with the disclosed methods for a variety of medical, laboratory, and other applications. The systems, devices, and methods of the present invention can allow for effective use of samples by improved sample preparation and analysis. | 12-06-2012 |
20120309637 | METHODS AND COMPOSITIONS FOR RAPID MULTIPLEX AMPLIFICATION OF STR LOCI - Provided are methods for multiplex polymerase chain reaction (PCR) amplification of short tandem repeat (STR) loci that can be used to rapidly generate a highly specific STR profile from target nucleic acids. The resulting STR profiles are useful for human identification purposes in law enforcement, homeland security, military, intelligence, and paternity testing applications. | 12-06-2012 |
20120309638 | MARKERS AND METHODS FOR DETERMINING RISK OF DISTANT RECURRENCE OF NON-SMALL CELL LUNG CANCER IN STAGE I-IIIA PATIENTS - New markers for determination of the high risk of NSCLC distant recurrence (distant metastases), where the markers are selected from the group of hsa.miR-192, hsa.miR-194, hsa.miR-662, hsa.miR-502.3p, hsa.miR-128 and hsa.miR-362.5p. A method for determination of the risk of distant recurrence (distant metastases) of NSCLC in surgically treated patients in stage I-IIIA after pulmonary resection, where: total RNA is isolated from a fragment of NSCLC tumor, the amount and quality of RNA in the examined sample are determined, with biotechnology methods of measuring the amount of microRNAs, preferably quantitative RT-PCR, the expression (amount) of microRNA in tumor tissue is determined; and, subsequently, the microRNA expression is analyzed according to the model of prediction of the occurrence of distant metastases, where the high expression of microRNAs: hsa.miR-192, hsa.miR-194, hsa.miR-662 and low expression of microRNAs: has.miR-502.3p, hsa.miR-128 and hsa.miR-362.5p indicate the high risk of distant metastases. | 12-06-2012 |
20120309639 | Compositions and Methods for Diagnosing Genome Related Diseases and Disorders - Compositions, methods, and kits for diagnosing genetic disorders such as type I diabetes are disclosed. | 12-06-2012 |
20120309640 | Diagnostic and Prognostic Markers for Cancer - Compositions and methods useful for diagnosis and prognosis of cancer are provided. | 12-06-2012 |
20120309641 | DIAGNOSTIC KITS, GENETIC MARKERS, AND METHODS FOR SCD OR SCA THERAPY SELECTION - Variations in certain genomic sequences useful as genetic markers of Sudden Cardiac Death (“SCD”), or Sudden Cardiac Arrest (“SCA”) risk, are described. Novel diagnostic kits and methods employing these genetic markers are used in assessing the risk of SCD, or SCA. Methods of distinguishing patients having an increased susceptibility to SCD, or SCA, through use of these markers, alone or in combination with other markers, are also provided. Further, methods for assessing the need for an Implantable Cardio Defibrillator (“ICD”) in a patient with computer programmable processors and genetic databases are described. | 12-06-2012 |
20120309642 | SNP MARKERS ASSOCIATED WITH POLYCYSTIC OVARY SYNDROME - The present invention discloses SNP markers associated with PCOS and provides probes, chips, primers, kits and methods for detecting the SNP markers. Furthermore, the present invention relates to the use of SNPs in predicting or diagnosing the risk of PCOS. | 12-06-2012 |
20120309643 | METHOD AND/OR APPARATUS OF OLIGONUCLEOTIDE DESIGN AND/OR NUCLEIC ACID DETECTION - A method of designing at least one oligonucleotide for nucleic acid detection including: (I) identifying and/of selecting region(s) of at least one target nucleic acid to be amplified, the region(s) having an efficiency of amplification (AE) higher than the average AE; and (II) designing at least one oligonucleotide capable of hybridizing to the selected region(s). Also, a method of detecting at least one target nucleic acid including: (i) providing at least one biological sample; (ii) amplifying nucleic acid(s) in the biological sample; (iii) providing at least one oligonucleotide capable of hybridizing to at least one target nucleic acid, if present in the biological sample; and (iv) contacting the oligonucleotide(s) with the amplified nucleic acids and detecting the oligonucleotide(s) hybridized to the target nucleic acid(s). The method is useful for detecting the presence of at least one pathogen, such as a virus, in a human biological sample. | 12-06-2012 |
20120309644 | FLUIDICS DEVICE - The present invention contemplates various devices that are configured to separate a sample, which contains more than one unique species, into any desired number of sub-samples by passing the sample across a like number of separation media configured for a first separation protocol. Each of the sub-samples may be further separated by an additional separation protocol, thereby creating a plurality of mini-samples, each of which may be further separated and/or analyzed. The invention also contemplates using a simple method of using conduits to form a fluid path that passes through a plurality of separation media, each of which media is configured to isolate a particular sub-sample. After various sub-samples of the sample are isolated by the various separation media, the conduits may be removed, thereby enabling each of the isolated sub-samples to be further separated and/or analyzed independent of any other sub-sample. | 12-06-2012 |
20120309645 | miRNA IN THE DIAGNOSIS OF OVARIAN CANCER - The present invention provides novel methods for diagnosing a state of health based on the determination of specific miRNAs that have altered expression levels in different conditions, e.g. disease states compared to healthy controls. | 12-06-2012 |
20120309646 | RNA COMPLEXES, METHODS OF THEIR PRODUCTION AND SENSORS AND ANALYTICAL METHODS INVOLVING SAME - The invention includes RNA complexes comprising at least three monomeric units of an RNA molecule, each monomeric unit comprising an RNA polymer having first and second helical domains that have respective first and second binding sites, wherein the first binding sites are adapted to binding to one another and are not adapted to bind to the second binding sites, and the second binding sites are adapted to binding to one another and are not adapted to bind to the first binding sites; such that the at least three monomeric units are adapted to self-assemble by forming pairs of cognate interactions and so as to form the RNA complex in a circular closed complex. The invention also includes derivatives of these complexes including aptamers, and analytical methods and devices using same. | 12-06-2012 |
20120316076 | BIOMARKERS FOR THE DIAGNOSIS OF LACUNAR STROKE - This invention provides gene expression profiles useful for diagnosing lacunar stroke and for distinguishing lacunar stroke from non-lacunar stroke. | 12-13-2012 |
20120316077 | System And Method For Detection And Analysis Of A Molecule In A Sample - Disclosed here is a system and method for analyzing and/or detecting one or more target analytes in a sample by using a competitive assay. A standard curve may be constructed using known amounts of a molecule that is identical or substantially identical to the target analyte. Signals obtained from the target analyte can be compared against the standard curve in order to determine the level of the target analyte in the sample. The disclosed methods may be used in a multiplexed analyte detection and quantitation system. | 12-13-2012 |
20120316078 | METHODS AND MATERIALS FOR PRODUCING POLYPEPTIDES IN VITRO - Methods for producing polypeptides in vitro are described that use free template nucleic acids that are not immobilized on a substrate. Polypeptides that are produced can be captured on particles without the use of capture agents and can be used to produce polypeptide arrays. | 12-13-2012 |
20120316079 | Low Density Microarrays for Vaccine Related Protein Quanitification, Potency Determination and Efficacy Evaluation - Methods for the quantification of influenza HA proteins and anti-influenza antibodies for the fields of vaccine-related protein quantification, potency determination, and efficacy evaluation are provided. According to the technology, quantification is achieved by providing capture agents attached to an array in a series of decreasing concentrations. Serial dilutions of a reference material also may be introduced. The reference material within each solution binds to the capture agents on the array and is labeled with a label agent capable of producing a detectable signal used to construct a calibration curve. A target material of unknown concentration is introduced to a separate identical array, and the target material binds to the capture agents and also is labeled by a label agent to produce a detectable signal. The calibration curve based on the reference material is then utilized to determine the concentration of the target material without the need to perform replicate experiments. | 12-13-2012 |
20120316080 | DIFFERENTIATION BETWEEN BRCA2-ASSOCIATED TUMOURS AND SPORADIC TUMOURS VIA ARRAY COMPARATIVE GENOMIC HYBRIDIZATION - Array comparative genomic hybridization classifiers, arrays comprising the classifiers and methods of using the same for differentiating between BRCA2-associated tumors and sporadic tumors by detecting phenotypic genetic traits using comparative genomic hybridization are disclosed. | 12-13-2012 |
20120316081 | Method of Identifying Myelodysplastic Syndromes - Myelodysplastic syndromes display both hematological and biological heterogeneity with variable leukemia potential. To determine whether microRNAs expression offers diagnostic discrimination or influences malignant potential in MDS, bone marrow miRNA expression was investigated from prognostically distinct MDS subsets using a microarray platform. After background subtraction and normalization, data were analyzed indicating thirteen miRNA signature with statistically significant differential expression, including down-regulation of members of a leukemia associated miRNA family. A unique signature consisting of 10 miRNAs was closely associated with International Prognostic Scoring System risk category permitting discrimination between lower and higher risk disease. Selective overexpression of miRNA-181 family members was detected in higher risk MDS, indicating pathogenetic overlap with acute myeloid leukemia. Analysis of miRNA expression profile offers diagnostic utility, and provides pathogenetic and prognostic discimination in MDS. | 12-13-2012 |
20120316082 | NUCLEIC ACID DETECTION AND QUANTIFICATION BY POST-HYBRIDIZATION LABELING AND UNIVERSAL ENCODING - The present invention provides, among other things, methods and compositions for detecting and quantifying target nucleic acids via post-hybridization labeling. | 12-13-2012 |
20120316083 | Methods of Detecting Target Nucleic Acids - The present disclosure relates to methods of identifying target nucleic acids by using coded molecules and its analysis by translocation through a nanopore. Generally, coded molecules are subject to a target polynucleotide dependent modification. The modified coded molecule is detected by isolating the modified coded molecules from the unmodified coded molecules prior to analysis through the nanopore or by detecting a change in the signal pattern of the coded molecule when analyzed through the nanopore. | 12-13-2012 |
20120316084 | GENE EXPRESSION PROFILING FROM FFPE SAMPLES - Methods and compositions relating to the generation and use of gene expression data from tissue samples that have been fixed and embedded are provided. The data can electronically stored and implemented as well as used to augment diagnosis and treatment of diseases. | 12-13-2012 |
20120322672 | METHOD FOR GENERATING AND SELECTING ANTIBODIES AGAINST TARGET PROTEIN - Compositions are provided that comprise antibody against membrane proteins such as chemokine receptors. In particular, monoclonal human antibodies against human CXCR4 are provided that are capable of inhibiting HIV infection and chemotaxis in human breast cancer cells. The antibodies can be used as prophylactics or therapeutics to prevent and treat HIV infection and cancer, for screening drugs, and for diagnosing diseases or conditions associated with interactions with chemokine receptors. | 12-20-2012 |
20120322673 | ISOLATION OF NUCLEIC ACID FROM MOUTH EPITHELIAL CELLS - The present invention is directed to a scraping instrument for collection of a biological sample, and a non-invasive method for obtaining nucleic acid from buccal mucosa epithelial cells using the scraping instrument. Such nucleic acid can be used for example for gene expression profiling, including to assess lung disease risk associated with airway pollutants. | 12-20-2012 |
20120322674 | DETECTING CYP24 EXPRESSION LEVEL AS A MARKER FOR PREDISPOSITION TO CANCER - This invention pertains to the discovery that an amplification of the CYP24 gene or an increase in CYP24 activity is a marker for the presence of, progression of, or predisposition to, a cancer (e.g., breast cancer). Using this information, this invention provides methods of detecting a predisposition to cancer in an animal. The methods involve (i) providing a biological sample from an animal (e.g. a human patient); (ii) detecting the level of CYP24 within the biological sample; and (iii) comparing the level of CYP24 with a level of CYP24 in a control sample taken from a normal, cancer-free tissue where an increased level of CYP24 in the biological sample compared to the level of CYP24 in the control sample indicates the presence of said cancer in said animal. | 12-20-2012 |
20120322675 | GENOME-SCALE ANALYSIS OF REPLICATION TIMING - Methods for identifying and/or distinguishing a homogeneous population of cells based on their replication domain timing profile using high resolution genomic arrays or sequencing procedures are provided. These methods may be used to compare the replication timing profile for a population of cells to another replication timing profile(s), a replication timing fingerprint, and/or one or more informative segments of a replication timing fingerprint, which may be simultaneously or previously determined and/or contained in a database, to determine whether there is a match between them. Based on such information, the identity of the population of cells may be determined, or the identity of the population of cells may be distinguished from other populations of cells or cell types. Methods for determining a replication timing fingerprint for particular cell types are also provided. | 12-20-2012 |
20120322676 | COMPOSITIONS AND METHODS FOR DETECTION OF CRONOBACTER SPP. AND CRONOBACTER SPECIES AND STRAINS - Disclosed are genomic sequences for nine strains of | 12-20-2012 |
20120322677 | PREDICTING BENEFIT OF ANTI-CANCER THERAPY VIA ARRAY COMPARATIVE GENOMIC HYBRIDIZATION - Array comparative genomic hybridization classifiers, arrays comprising the classifiers, and related methods of using the same for predicting the therapeutic efficacy of anti-cancer therapy by detecting phenotypic genetic traits using comparative genomic hybridization are disclosed. | 12-20-2012 |
20120322678 | NOVEL PHAGE DISPLAY VECTOR - The invention relates to a minimized phage display vector comprising at least a cloning cassette, a phage display cassette and a bacterial cassette, said cloning cassette comprising a nucleic acid sequence encoding a polypeptide corresponding at least to the intra-domain loop of a constant domain of an antibody. It also relates to their uses for the production of libraries of phages, each phage expressing on its surface a binding protein to be screened for its capacity to bind a binding partner. | 12-20-2012 |
20120322679 | BIOCHEMICAL ANALYSIS INSTRUMENT - An analysis instrument comprises plural modules connected together over a data network, each module comprising an analysis apparatus operable to perform biochemical analysis of a sample. Each module comprises a control unit that controls the operation of the analysis apparatus. The control units are addressable to select an arbitrary number of modules to operate as a cluster for performing a common biochemical analysis. The control units communicate over the data network, repeatedly during the performance of the common biochemical analysis, to determine the operation of the analysis apparatus of each module required to meet the global performance targets, on the basis of measures of performance derived from the output data produced by the modules. The arrangement of the instrument as modules interacting in this manner provides a scalable analysis instrument. | 12-20-2012 |
20120322680 | USE OF MIRNAS AS BIOMARKERS IN GLIOMA DIAGNOSIS - The present application relates to the use of miRNAs as biomarkers in glioma diagnosis. It also relates to the use of miRNAs as biomarkers in glioblastoma and oligodendroglioma diagnosis. | 12-20-2012 |
20120322681 | Methods for Preparative In Vitro Cloning - Methods and devices relate to the isolation of nucleic acids of interest from within a population of nucleic acids such as libraries of nucleic acid sequences. | 12-20-2012 |
20120322682 | BRAIN INJURY BIOMARKER PANEL - A panel of biomarkers for diagnosis, monitoring of progression and prognosis of various brain injuries and PTSD. | 12-20-2012 |
20120322683 | ENZYMATIC SIGNAL GENERATION AND DETECTION OF BINDING COMPLEXES IN STATIONARY FLUIDIC CHIP - An embodiment of the invention relates to a device for detecting an analyte in a sample. The device comprises a fluidic network and an integrated circuitry component. The fluidic network comprises a sample zone, a cleaning zone and a detection zone. The fluidic network contains a magnetic particle and/or a signal particle. A sample containing an analyte is introduced, and the analyte interacts with the magnetic particle and/or the signal particle through affinity agents. A microcoil array or a mechanically movable permanent magnet is functionally coupled to the fluidic network, which are activatable to generate a magnetic field within a portion of the fluidic network, and move the magnetic particle from the sample zone to the detection zone. A detection element is present which detects optical or electrical signals from the signal particle, thus indicating the presence of the analyte. | 12-20-2012 |
20120322684 | G-CSF PROTEIN HAVING A DELETION OF AN AMINO ACID SEQUENCE CORRESPONDING TO EXON 3 FOR USE AS A DIAGNOSTIC CANCER MARKER - Disclosed are a method, a composition, a microarray, an antibody and a kit for diagnosis and prognosis of cancer, based on detection of deletion of the exon 3 region of G-CSF gene or levels of a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to the exon 3 region, wherein the deletion of the exon 3 region of the G-CSF gene is used as a cancer biomarker. | 12-20-2012 |
20120322685 | DEVICE FOR COLLECTING AND ANALYZING MIGRATORY TUMOR CELLS - The present invention provides a method of isolating motile cells from an animal tissue, the method comprising implanting in the animal tissue a cell trap comprising a chamber with an inlet for ingress of motile cells and a porous matrix located in the chamber comprising a chemotactic factor, for a time sufficient for the motile cells to migrate into the cell trap; removing the implanted cell trap; and retrieving the motile cells from the cell trap. | 12-20-2012 |
20120322686 | METHODS FOR SCREENING ANTIBODIES - The invention provides methods for making antibody conjugates for use in antibody screening assays and antibody conjugates produced by the claimed methods. | 12-20-2012 |
20120322687 | METHODS OF PREDICTING HIGH GRADE GLIOMAS USING SENESCENCE ASSOCIATED GENES - The present invention relates to biomarkers for neoplasias such as high grade gliomas. The inventors have discovered that the overexpression of senescence associated genes (SAG) is associated with a poor prognosis in subjects with high grade gliomas. The present invention provides SAG biomarkers for predicting response to therapy for subjects having high grade glioma based on dividing the samples into high and low risk groups; diagnosing high grade glioma; monitoring progression of high grade glioma from one biological state to another; and determining efficacy of treatment for high grade gliomas. | 12-20-2012 |
20120322688 | TESTING LUMENECTOMY SAMPLES FOR MARKERS OF NON-VASCULAR DISEASES - Lumenectomy material is tested to determine the presence or likelihood of a condition of a patient. The lumenectomy material is in the form of at least one continuous tissue strand collected in vivo from an inner surface of a body lumen of the patient. The presence of at least one marker of a disease is determined. The disease may be hypertension, hyperlipidemia, depression, obesity, metabolic syndrome, insulin resistance, kidney damage, or diabetes. The patient is identified as having or as likely to develop the disease if a marker of the disease is identified in the lumenectomy material of the patient. | 12-20-2012 |
20120329663 | 14-3-3 sigma as a Biomarker of Basal Cancer - Methods and compositions for using 14-3-3sigma gene and protein as a highly sensitive and specific basal breast cancer biomarker, which when present, correlates with metastasis and poor outcome in independent patient cohorts. Methods and compositions for targeting 14-3-3sigma-regulated actin cytoskeletal interactions, activity and function may benefit patients having the basal-like breast cancer subtype. | 12-27-2012 |
20120329664 | MULTIPLEXED DIGITAL ASSAYS WITH COMBINATORIAL USE OF SIGNALS - System, including methods, apparatus, and compositions, for performing a multiplexed digital assay on a greater number of targets through combinatorial use of signals. | 12-27-2012 |
20120329665 | SYSTEMS AND METHODS FOR AUTOMATED ANALYSIS OF CELLS AND TISSUES - Systems and methods for rapidly analyzing cell containing samples, for example to identify morphology or to localize and quantitate biomarkers are disclosed. | 12-27-2012 |
20120329666 | Peripheral Blood Biomarkers for Idiopathic Interstitial Pneumonia and Methods of Use - The present invention provides methods for diagnosing several types of diseases. Specifically, the present disclosure provides a panel of diagnostic genes, the differential expression of whose mRNAs or proteins in the sample of a subject indicates the presence of the disease in the subject. The methods involve extracting mRNAs or proteins from the sample and performing gene expression profiling assays such as microarray assay, RT-PCR oligonucleotide binding array, quantitative RT-PCR assay, proteomics assay, and/or ELISA assay. | 12-27-2012 |
20120329667 | EPIGENETIC DNA ENRICHMENT - This application relates to methods for enriching DNA from a first cell type from a sample comprising DNA from the first cell type and DNA from a second cell type, wherein the first cell type methylates DNA to a lesser extent than the second cell type. DNA is enriched by, selecting for fragments by size after digestion of the sample with a methylation-sensitive restriction enzyme. Cell types of interest include fetal cells and cancerous cells. The enriched DNA can be used for a variety of procedures including, detection of a trait of interest such as a disease trait, or a genetic predisposition thereto, gender typing and parentage testing. | 12-27-2012 |
20120329668 | Biomarkers for Determining an Allograft Tolerant Phenotype - Methods are provided for determining whether a subject has a graft tolerant phenotype. In practicing the subject methods, the expression level of one or more gene in a sample from the subject, e.g., a blood sample, is assayed to obtain a gene expression result, where the gene expression result includes a result for a biomarker of graft tolerance. The obtained gene expression result is then employed to determine whether the subject has a graft tolerant phenotype. Also provided are compositions, systems and kits that find use in practicing the subject methods. The methods and compositions find use in a variety of applications, including the determination of an immunosuppressive therapy regimen. | 12-27-2012 |
20120329669 | USE OF DKK-1 PROTEIN IN THE CANCER DIAGNOSIS - Use of DKK-1 protein or the nucleic acid sequence in preparation of cancer diagnostic agents or kits, method to detect liver cancer with the monoclonal antibody thereof, the kit comprising anti-DKK-1 antibody or protein specific nucleic acid probes, together with a label, and method to detecting specific DKK-1 protein expression are disclosed. | 12-27-2012 |
20120329670 | EPITOPE TESTING USING SOLUBLE HLA - A methodology is provided for assaying the ability of a peptide of interest to displace an endogenously loaded peptide in a recombinantly produced, secreted, individual, soluble HLA trimolecular complex. | 12-27-2012 |
20120329671 | METHODS OF IDENTIFYING OBM MODULATORS - Novel proteins and polypeptides binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecules, OBMs) and nucleic acids encoding these proteins and polypeptides are provided. Processes for producing these proteins, polypeptides, and nucleic acid molecules by genetic engineering are provided. Medicinal compounds are provided which comprise proteins and nucleic acids according to the invention, as well as proteins which bind to OBM, including anti-OBM antibodies. These compounds may be used for the treatment of bone disease. | 12-27-2012 |
20120329672 | MicroRNA Expression Signature for Predicting Survival and Metastases in Hepatocellular Carcinoma - Provided herein are microarrays, kits, methods and compositions for the diagnosis, prognosis and treatment of Hepatocellular carcinoma (HCC). Also provided are methods of identifying anti-HCC agents. | 12-27-2012 |
20130005591 | METHOD FOR PARALLEL AMPLIFICATION OF NUCLEIC ACIDS - A new method that enables parallel amplification of nucleic sequences from a complex source is disclosed. The amplification is compartmentized into microdroplets by porous-walled hollow glass microspheres and subjected to PCR thermal cycling or isothermal amplification. The rigid wall of the glass microspheres allows very simple and conventional manipulation of the amplification products for downstream application such as sequencing or detection of copy number of specific sequences in a complex sample. | 01-03-2013 |
20130005592 | METHODS AND COMPOSITIONS FOR PREDICTING CANCER THERAPY RESPONSE - The invention generally relates to molecular diagnostics, and particularly to molecular markers for cancer therapy response and methods of use thereof. | 01-03-2013 |
20130005593 | RNA-Oligonucleotide Quantification Technique for the Enumeration of Uncultivated Bacterial Species - Methods for RNA-Oligonucleotide Quantification Technique for the Enumeration of Uncultivated Bacterial Species are disclosed. | 01-03-2013 |
20130005594 | METHODS AND COMPOSITIONS FOR DETECTING TARGET NUCLEIC ACIDS - The present invention provides compositions, apparatuses and methods for detecting one or more nucleic acid targets present in a sample. Methods of the invention include utilizing two or more ligation probes that reversibly bind a target nucleic acid in close proximity to each other and possess complementary reactive ligation moieties. When such probes have bound to the target in the proper orientation, they are able to undergo a spontaneous chemical ligation reaction that yields a ligation product that is directly detected or that is amplified to produce amplicons that are then detected. The present invention also provides methods to stabilize sample RNA so that degradation does not significantly affect the results of the analysis. | 01-03-2013 |
20130005595 | Primer And Probe For Detection Of Mycobacterium Intracellulare, And Method For Detection Of Mycobacterium Intracellulare Using The Same - The present invention discloses an oligonucleotide which comprises a part or the entire sequence of the nucleotide sequence shown in SEQ ID NOS: 1-8, or a part or the entire sequence of a sequence complementary to the nucleotide sequence shown in SEQ ID NOS: 1-8, wherein the oligonucleotide is capable of hybridizing with a nucleotide sequence of | 01-03-2013 |
20130005596 | NOVEL GENOMIC BIOMARKERS FOR IRRITABLE BOWEL SYNDROME DIAGNOSIS - The invention provides novel biomarkers, kits, and methods of diagnosing, prognosing, and subtyping IBS. In one aspect, the invention provides novel genomic biomarkers for diagnosing, classifying, providing a prognosis for, and assigning therapy for IBS in a subject in need thereof. In another aspect, the present invention provides novel algorithms for the diagnosis and prognosis of IBS. | 01-03-2013 |
20130005597 | METHODS AND COMPOSITIONS FOR ANALYSIS OF CLEAR CELL RENAL CELL CARCINOMA (CCRCC) - Methods for generating a prognostic signature for a subject with clear cell renal cell carcinoma (ccRCC) are disclosed. The methods include determining expression levels for three or more genes disclosed in ccRCC cells obtained from the subject, wherein the determining provides a prognostic signature for the subject. Also provided are methods for assessing risk of an adverse outcome of a subject clear cell renal cell carcinoma (ccRCC), method for predicting a clinical outcome of a treatment in a subject diagnosed with clear cell renal cell carcinoma (ccRCC), and arrays that include polynucleotides that hybridize to at least three genes disclosed or that include specific peptide or polypeptide gene products of at least three of the genes disclosed. | 01-03-2013 |
20130005598 | Methods for Diagnosing The Malignant Potential of Pancreatic Cystic Lesions - A method of diagnosing the malignant potential of a pancreatic cystic lesion in a subject including: detecting a glycan alteration in MUC5AC in a sample of pancreatic cystic lesion fluid from a subject, determining whether the glycan alteration is differentially present in the sample, and diagnosing the malignant potential of the pancreatic cystic lesion. A method of diagnosing the malignant potential of a pancreatic cystic lesion in a subject including: (a) detecting a glycan alteration in MUC5AC in a sample of pancreatic cystic lesion fluid from a subject, (b) detecting CA 19-9 in the sample, (c) determining whether the glycan alteration and CA 19-9 are differentially present in the sample, and (d) diagnosing the malignant potential of the pancreatic cystic lesion. Related methods of treatment and kits also are included. | 01-03-2013 |
20130005599 | METHODS AND SYSTEMS OF USING EXOSOMES FOR DETERMINING PHENOTYPES - Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin. | 01-03-2013 |
20130005600 | Assay for Determining the Type and/or Status of a Cell Based on the Epigenetic Pattern and the Chromatin Structure - The present invention relates to a method for identifying a specific type and/or state of a mammalian cell in a sample obtained from a mammal, comprising a) analyzing the relative amount of accessible chromatin in regions that are specific for a cell-type and/or cellular state in the genome of said cell, b) comparing said relative amount of accessible chromatin said in regions with the relative amount of accessible chromatin in regions in the genome of said cell that are unspecific for a cell-type and/or cellular state, and c) deducing the specific type and/or state of said mammalian cell in said sample based on said comparison. Preferably, said identifying further comprises a relative quantification of said specific cell type and/or state based on said comparison. The method can further comprise a diagnosis of a predisposition to a disease or a disease based on said identification. Kits and certain markers in regions of accessible chromatin in the genome are described, too. | 01-03-2013 |
20130005601 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Endothelin-1, Somatotropin, and Interleukin-13 as diagnostic and prognostic biomarkers in renal injuries. | 01-03-2013 |
20130005602 | METHOD FOR EVALUATING THE SENSITIZING POTENTIAL OF A TEST COMPOUND - The invention relates to a method for evaluating the sensitizing potential of a test compound, and to a kit for implementing said method. | 01-03-2013 |
20130005603 | DETECTING NUCLEIC ACID - This document provides methods and materials for detecting target nucleic acid. For example, methods and materials for detecting the presence or absence of target nucleic acid, methods and materials for detecting the amount of target nucleic acid present within a sample, kits for detecting the presence or absence of target nucleic acid, kits for detecting the amount of target nucleic acid present within a sample, and methods for making such kits are provided. | 01-03-2013 |
20130005604 | Method for Label-Free Multiple Analyte Sensing, Biosensing and Diagnostic Assay - Methods and systems for label-free multiple analyte sensing, biosensing and diagnostic assay chips consisting of an array of photonic crystal microcavities along a single photonic crystal waveguide are disclosed. The invention comprises an on-chip integrated microarray device that enables detection and identification of multiple species to be performed simultaneously using optical techniques leading to a high throughput device for chemical sensing, biosensing and medical diagnostics. Other embodiments are described and claimed. | 01-03-2013 |
20130005605 | Photonic Crystal MicroArray Layouts for Enhanced Sensitivity and Specificity of Label-Free Multiple Analyte Sensing, Biosensing and Diagnostic Assay - Methods and systems for label-free multiple analyte sensing, biosensing and diagnostic assay chips consisting of an array of photonic crystal microcavities along a single photonic crystal waveguide are disclosed. The invention comprises an on-chip integrated microarray device that enables detection and identification of multiple species to be performed simultaneously using optical techniques leading to a high throughput device for chemical sensing, biosensing and medical diagnostics. Other embodiments are described and claimed. | 01-03-2013 |
20130005606 | Packaged chip for multiplexing photonic crystal waveguide and photonic crystal slot waveguide devices for chip-integrated label-free detection and absorption spectroscopy with high throughput, sensitivity, and specificity - Systems and methods for chip-integrated label-free detection and absorption spectroscopy with high throughput, sensitivity, and specificity are disclosed. The invention comprises packaged chips for multiplexing photonic crystal waveguide and photonic crystal slot waveguide devices. Other embodiments are described and claimed. | 01-03-2013 |
20130005607 | QUALITY CONTROL OF AGRICULTURAL PRODUCTS BASED ON GENE EXPRESSION - The invention relates to the field of quality testing of fresh plant-based and mushroom based products. Methods, carriers and kits for determining the quality stage are provided. | 01-03-2013 |
20130012401 | SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH DIETARY WEIGHT LOSS - The present invention relates to genetic polymorphisms associated with obesity and obesity-related phenotypes and their use in predicting if an individual successfully completes a dietary weight loss intervention program. | 01-10-2013 |
20130012402 | BIOMARKERS - The invention relates to a method of diagnosing or monitoring schizophrenia or other psychotic disorder. | 01-10-2013 |
20130012403 | Compositions and Methods for Identifying Autism Spectrum Disorders - The compositions and methods described are directed to microRNA chips having a plurality of different oligonucleotides with specificity for genes associated with autism spectrum disorders. The invention further provides methods of identifying microRNA profiles for neurological and psychiatric conditions including autism spectrum disorders, methods of treating such conditions, and methods of identifying therapeutics for the treatment of such neurological and psychiatric conditions. | 01-10-2013 |
20130012404 | CULTURE METHOD, EVALUATION METHOD AND STORAGE METHOD FOR CANCER-TISSUE-DERIVED CELL MASS OR AGGREGATED CANCER CELL MASS - It is intended to provide a method for culturing a novel cancer tissue-derived cell mass or a novel aggregated cancer cell mass that can reflect the behavior of cancer cells accurately in vivo. First, a cancer tissue-derived cell mass or an aggregated cancer cell mass is prepared from an individual. The novel cancer tissue-derived cell mass or the novel aggregated cancer cell mass is cultured, and the properties are evaluated using the cultured cell mass. Examples of the evaluation of properties include the evaluation of genes and the evaluation of culture conditions. In addition, the cancer tissue-derived cell mass or the aggregated cancer cell mass can be stored. It is possible to establish an optimal therapeutic method for an individual efficiently by linking the clinical information or the genetic information on the individual to the stored cancer tissue-derived cell mass or the stored aggregated cancer cell mass. | 01-10-2013 |
20130012405 | Circulating miRNA Biomaker Signatures - Methods for diagnosis and surveillance of complex multi-factorial disorders such as cancer by screening of easily accessible biomarkers are disclosed. Highly stable cell free Circulating Nucleic Acids (CNA) present as both RNA and DNA species have been discovered in the blood and plasma of humans. Correlations between tumor-associated genomic/epigenetic/transcriptional changes and alterations in CNA levels are strong predictors of the utility of this biomarker class as clinical indicators. Methods for using microRNAs (miRNAs) representing a class of naturally occurring small non-coding RNAs of 19-25 nt as markers that can associate their specific expression profiles with cancer development are disclosed. Methods for isolating plasma fractions for the study of miRNA biomarkers and for measurement of circulating miRNA levels are disclosed. | 01-10-2013 |
20130012406 | METHODS AND KITS FOR MULTIPLEX AMPLIFICATION OF SHORT TANDEM REPEAT LOCI - Methods and materials are disclosed for use in simultaneously amplifying at least 11 specific STR loci of genomic DNA in a single multiplex reaction, as are methods and materials for use in the analysis of the products of such reactions. Included in the present invention are materials and methods for the simultaneous amplification of 16 specific loci in a single multiplex reaction, comprising the 10 AmpFlSTR® SGMplus® STR loci, the Amelogenin locus, and 5 new STR loci, including methods and materials for the analysis of these loci. | 01-10-2013 |
20130012407 | METHODS FOR PREDICTING RESPONSE OF TRIPLE-NEGATIVE BREAST CANCER TO THERAPY - The present invention provides compositions and methods for detecting the expression and/or activation levels of components of signal transduction pathways in tumor cells such as triple-negative metastatic breast tumor cells. Information on the expression and/or activation levels of components of signal transduction pathways derived from use of the present invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments. | 01-10-2013 |
20130012408 | METHOD FOR DETERMINATION OF ONSET RISK OF GLAUCOMA - A method of determining the presence or the absence of a glaucoma risk by detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism, comparing the allele and/or the genotype detected with at least one of an allele and/or a genotype with a high-risk allele, wherein the presence of a glaucoma risk is determined in a case where the allele detected is the high-risk allele, or the presence of a glaucoma risk is determined in a case where the genotype detected is a homozygote of the genotype comprising the high-risk allele or a heterozygote when the high-risk allele complies with a dominant genetic model, or the presence of a glaucoma risk is determined in a case where the genotype detected is a homozygote of the genotype comprising the high-risk allele when the high-risk allele complies with a recessive genetic model. | 01-10-2013 |
20130012409 | Diagnostic and Prognostic Markers for Cancer - Compositions and methods useful for diagnosis and prognosis of cancer are provided. | 01-10-2013 |
20130012410 | METHODS AND MATERIALS FOR DETECTING COLORECTAL CANCER AND ADENOMA - The present invention provides methods and materials related to the detection of colorectal neoplasm-specific markers (e.g., markers associated with colorectal cancer, markers associated with adenoma) in or associated with a subject's stool sample. In particular, the present invention provides methods and materials for identifying mammals (e.g., humans) having a colorectal neoplasm by detecting the presence and level of indicators of colorectal neoplasia such as, for example, long DNA (e.g., quantified by Alu PCR) and the presence and level of tumor-associated gene alterations (e.g., mutations in KRAS, APC, melanoma antigen gene, p53, BRAF, BAT26, PIK3CA) or epigenetic alterations (e.g., DNA methylation) (e.g., CpG methylation) (e.g., CpG methylation in coding or regulatory regions of bmp-3, bmp-4, SFRP2, vimentin, septin9, ALX4, EYA4, TFPI2, NDRG4, FOXE1) in DNA from a stool sample obtained from the mammal. | 01-10-2013 |
20130012411 | TESTING A PATIENT POPULATION HAVING A CARDIOVASCULAR CONDITION FOR DRUG EFFICACY - Lumenectomy material is tested to determine the efficacy of a test drug in a patient population having a cardiovascular condition. The material is removed from at least a first and a second patient and tested for one or more markers of a cardiovascular condition. The first patient is administered the test drug, and the second patient is administered a placebo. At a later date, more lumenectomy material is removed and tested for the same marker or markers. The presence, absence or amount of the markers is compared in the first patient receiving the drug and the second patient receiving the placebo to determine whether the drug is effective in the patient population. The drugs tested include drugs believed to be effective in treating a cardiovascular condition. The markers used can include any marker that can indicate the effectiveness of the drug being tested. | 01-10-2013 |
20130012412 | MARKER FOR DIAGNOSIS OF BREAST CANCER, TEST METHOD, AND TEST KIT - An embodiment of the present invention provides a marker, a test method, and a test kit which can detect the onset of breast cancer that cannot be detected by palpation or mammography examination or breast cancer in an early stage (clinical stage 0), which are simple, and which have high reliability. | 01-10-2013 |
20130017962 | METHODS AND COMPOSITIONS FOR CORRELATING GENETIC MARKERS WITH CARDIOVASCULAR DISEASE - The present invention provides methods of identifying a subject having an increased or decreased risk of developing cardiovascular disease, comprising: a) correlating the presence of one or more genetic markers in chromosome 3q13.31 with an increased or decreased risk of developing cardiovascular disease; and b) detecting the one or more genetic markers of step (a) in the subject, thereby identifying the subject as having an increased or decreased risk of developing cardiovascular disease. Also provided are methods of identifying subjects with cardiovascular disease as having a good or poor prognosis, as well as methods of identifying effective treatment regimens for cardiovascular disease, based on correlation with genetic markers in chromosome 3q13.31. | 01-17-2013 |
20130017963 | METHOD FOR DETERMINING SURIVIVAL PROGNOSIS OF PATIENTS SUFFERING FROM NON-SMALL CELL LUNG CANCER (NSCLC)AANM De Wijn; RichardAACI NijmegenAACO NLAAGP De Wijn; Richard Nijmegen NLAANM Ruijtenbeek; RobbyAACI UtrechtAACO NLAAGP Ruijtenbeek; Robby Utrecht NLAANM Hilhorst; Maria HelenaAACI WageningenAACO NLAAGP Hilhorst; Maria Helena Wageningen NL - The present invention relates to a method for determining the survival prognosis of patients suffering from non-small cell lung cancer. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels in response to a kinase inhibitor and profiles in samples obtained from patients diagnosed with non-small cell lung cancer. The present invention also provides methods for predicting the response of a patient diagnosed with non-small cell lung cancer to a medicament. | 01-17-2013 |
20130017964 | Methods to Identify Chronic Lymphocytic Leukemia Disease Progression - The present invention provides materials and methods related to CLL disease progression. The invention provides methods related to differential expression signatures, including distinguishing histological subtypes, progression patterns, poor survival patterns, and disease-free survival patterns. Antisense and sense miRNAs, kits, and other compositions, such as pharmaceutical formulations and combination therapies are also provided. | 01-17-2013 |
20130017965 | OSTEOARTHRITIS BIOMARKERS AND USES THEREOF - The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in osteoarthritis and/or in a particular stage of osteoarthritis, as well as a means of selecting the novel biomarker combinations. The measurement of expression of the products of the biomarkers and combinations of biomarkers demonstrates particular advantage in one or more of the following: (a) diagnosing individuals as having arthritis, (b) differentiating between two stages of osteoarthritis (OA) and (c) diagnosing individuals as having a particular stage of OA. Polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers are within the scope of the invention as are kits containing said polynucleotides and proteins and the use of said polynucleotides and proteins. The biomarker products can be used to identify therapeutic targets for osteoarthritis, and compounds that bind and/or modulate the gene activity. | 01-17-2013 |
20130017966 | Methods for Genotyping with Selective Adaptor Ligation - The present invention provides methods for reducing the complexity of a nucleic acid sample to interrogate a collection of target sequences. Complexity reduction can be accomplished by fragmenting the nucleic acid sample with a restriction enzyme that has at least one variable position in the recognition sequence. In some aspects adaptors that ligate to some but not all possible overhangs generated by digestion are ligated to the fragments. This selective adaptor ligation allows for selective amplification of a subset of the fragments using primers complementary to the adaptor sequence. In another aspect primers that are complementary to a subset of the fragments after adaptor ligation are used for amplification. Amplified fragments may be analyzed to genotype polymorphisms by hybridization to an array of probes that are complementary to target sequences that will be amplified. | 01-17-2013 |
20130017967 | NANOFLUIDIC BIOSENSOR AND ITS USE FOR RAPID MEASUREMENT OF BIOMOLECULAR INTERACTIONS IN SOLUTION AND METHODSAANM Durand; NicolasAACI BlonayAACO CHAAGP Durand; Nicolas Blonay CHAANM Fournier; YannickAACI EcublensAACO CHAAGP Fournier; Yannick Ecublens CHAANM Lasser; TheoAACI DengesAACO CHAAGP Lasser; Theo Denges CHAANM Marki; IwanAACI YverdonAACO CHAAGP Marki; Iwan Yverdon CH - A method and device for the rapid detection of biomolecules ( | 01-17-2013 |
20130017968 | PROFILING OF CELL POPULATIONS - Understanding the heterogeneity within a stem cell population remains a major impediment to the development of clinically effective cell-based therapies. Gene expression patterns exhibited by individual cells are a crucial component of this heterogeneity, yet transcriptional events within a single cell are inherently stochastic and can produce tremendous variability, even among genetically identical cells. It remains unclear how mammalian cellular systems overcome this intrinsic noisiness of gene expression to produce consequential variations in function. To address these questions, we utilized a novel single cell analysis method to characterize transcriptional programs across hundreds of individual murine long-term hematopoietic stem cells (LT-SCs). We demonstrate that multiple subpopulations exist within this putatively homogeneous stem cell population, defined by nonrandom patterns that are distinguishable from noise and can predict functional properties of these cells. This represents a powerful new tool to elucidate the relationship between transcriptional and phenotypic variation within a cell population. | 01-17-2013 |
20130017969 | MARKERS AND METHOD FOR THE DIAGNOSIS OF ROSACEA - Markers for rosacea among the chemokines and cytokines and their receptors, selected from interleukin 8 (IL-8), CXCL1, CXCL2, CXCL3 and CXCL5, the CXCR1 receptor and the CXCR2 receptor are described. Also described, is a method for the diagnosis of rosacea. | 01-17-2013 |
20130017970 | BIOMARKERSAANM Bahn; SabineAACI CambridgeAACO GBAAGP Bahn; Sabine Cambridge GBAANM Levin; YishaiAACI CambridgeAACO GBAAGP Levin; Yishai Cambridge GBAANM Schwarz; EmanuelAACI CambridgeAACO GBAAGP Schwarz; Emanuel Cambridge GB - The invention relates to a method of diagnosing or monitoring schizophrenia or other psychotic disorder. | 01-17-2013 |
20130017971 | Multivariate Diagnostic Assays and Methods for Using Same - The application describes compositions and methods for detecting the relative expressions of a plurality of target nucleic acid molecules in one assay. The compositions comprise a plurality of probe molecules which specifically bind to one target nucleic acid molecule of a plurality of target nucleic acids in a sample, and a plurality of reference molecules that represent each of the plurality of target nucleic acid molecules, where the probe molecules specifically bind to the plurality of reference molecules, and each of the plurality of reference molecules is present in known amounts in the composition. | 01-17-2013 |
20130017972 | METHOD AND COMPOSITIONS INVOLVING MICRORNA - The present invention concerns methods and compositions for isolating, enriching, and/or labeling miRNA molecules and for preparing and using arrays or other detection techniques for miRNA analysis. Moreover, the present invention concerns methods and compositions for generating miRNA profiles and employing such profiles for therapeutic, diagnostic, and prognostic applications. | 01-17-2013 |
20130017973 | FUNCTIONAL MOLECULE, FUNCTIONAL MOLECULE SYNTHESIZING AMIDITE AND TARGET SUBSTANCE ANALYSIS METHOD - To provide a functional molecule including a modified nucleotide unit having a substituent introduced to a base thereof, wherein the substituent is removably introduced to the base; a functional molecule synthesizing amidite that has a substituent removably introduced to its base and that is used for the manufacture of the functional molecule; and a target substance analysis method including: preparing a random pool of functional molecules using a functional molecule synthesizing amidite; screening a functional molecule having affinity for a target substance from the random pool; amplifying the functional molecules having affinity for the target substance, wherein the method further comprises, prior to the amplification step, removing a substituent from the functional molecule having affinity for the target substance. | 01-17-2013 |
20130017974 | METHODS AND COMPOSITIONS RELATING TO MULTIPLEX GENOMIC GAIN AND LOSS ASSAYS - Compositions and methods are provided for detecting genomic DNA gain and loss. Embodiments of inventive compositions and methods include composite nucleic acid probes which specifically hybridize to two or more genomic loci in a genomic region of a reference genome for detection of genomic gain and/or loss in a subject genome. In some embodiments, a substrate-attached composite nucleic acid probe is provided which includes a mixture of separate populations of beads having attached DNA probes wherein all of the beads are identically encoded and wherein each individual bead has exclusively DNA derived from one source, such as a particular large insert vector containing chromosomal DNA, or amplicons generated by amplification of DNA derived from a large insert vector containing chromosomal DNA. | 01-17-2013 |
20130017975 | SINGLE NUCLEOTIDE POLYMORPHISM FOR PREDICTING PROGNOSIS OF HEPATOCELLULAR CARCINOMAAANM Chung; Young HwaAACI SeoulAACO KRAAGP Chung; Young Hwa Seoul KRAANM Park; Neung HwaAACI UlsanAACO KRAAGP Park; Neung Hwa Ulsan KRAANM Yu; Eun SilAACI SeoulAACO KRAAGP Yu; Eun Sil Seoul KRAANM Lee; Young-JooAACI SeoulAACO KRAAGP Lee; Young-Joo Seoul KRAANM Kim; Jeong AAACI SeoulAACO KRAAGP Kim; Jeong A Seoul KRAANM Lee; Dan-BiAACI SeoulAACO KRAAGP Lee; Dan-Bi Seoul KRAANM Lee; Sae-HwanAACI Cheonan-shiAACO KRAAGP Lee; Sae-Hwan Cheonan-shi KRAANM Lee; Jong-EunAACI SeoulAACO KRAAGP Lee; Jong-Eun Seoul KR - Single nucleotide polymorphisms (SNP) for predicting prognosis of hepatocellular carcinoma after curative surgical resection are provided. The SNPs have a significant correlation with an over-expression of MTA1 which is useful prognostic factor for prediction of prognosis or poor survival after curative surgical resection of hepatocellular carcinoma. Therefore, the SNPs can be used in developing micro-arrays or test kits for prediction of the prognosis of hepatocellular carcinoma, and in screening drugs to improve poor prognosis of hepatocellular carcinoma after curative surgical resection. | 01-17-2013 |
20130023426 | Methods of Detecting Signatures of Disease or Conditions in Bodily Fluids - Methods and compositions for diagnosing the presence of a cancer cell in an individual are provided. Methods and compositions for identifying a tumor-specific signature in an individual having cancer are also provided. Methods and compositions for diagnosing the presence of an infectious agent in an individual and/or for identifying an infectious agent-specific signature in an infected individual are provided. Methods and compositions for diagnosing the presence of a disease in an individual are also provided. Methods and compositions for identifying a disease-specific signature in an individual having the disease are also provided. | 01-24-2013 |
20130023427 | METHODS FOR ASSESSING GENOMIC INSTABILITIES IN TUMORS - The invention generally relates to methods for assessing genomic instabilities in a tumor sample. The invention may further be used to predict grade, stage, and prognosis of cancer in a patient. The invention further relates to cataloging the efficacy of therapeutics on specific genomic instabilities and generating a personalized therapeutic regimen for a cancer patient based upon their genomic instabilities. | 01-24-2013 |
20130023428 | BIOMARKERS FOR NEUROLOGICAL CONDITIONS - Methods and kits for identifying and/or monitoring neurological conditions in a patient using ratios of biomarkers are disclosed. The neurological conditions may include, for example, Alzheimer's disease or mild cognitive impairment. The particular biomarkers that may be useful in identifying and/or monitoring neurological conditions may include, for example, biliverdin reductase, biliverdin reductase, estrogen receptor alpha, superoxide dismutase, S100A7, hemeoxygenase 1, matrix metalloproteinase 9 and platelet derived growth factor receptor. In particular, ratios of these biomarkers are useful. | 01-24-2013 |
20130023429 | TRANSCRIPTION CHIP - A transcription chip comprising a substrate and, immobilized thereon, at least one polynucleotide including an element sequence to which a transcription factor can be bound. | 01-24-2013 |
20130023430 | CANCER STEM CELL GENE VARIANTS ARE ASSOCIATED WITH TUMOR RECURRENCE - The disclosure provides compositions and methods for determining the likely tumor recurrence in cancer patients by screening CD44, CD166 and/or LGR5 polymorphism in samples isolated from the patient. | 01-24-2013 |
20130023431 | Methods of Assessing Chromosomal Instabilities - Method of assessing or quantifying chromosomal instability in a subject, wherein the sample is obtained from an effluent, lavage, or organ wash. Methods of obtaining a whole genome sequence from an effluent, lavage, or organ wash. | 01-24-2013 |
20130023432 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF IMMUNOTHERAPY ON CANCER PATIENT AND/OR PROGNOSIS AFTER IMMUNOTHERAPY, AND GENE SET AND KIT TO BE USED THERIN - The present invention provides a method for predicting effect of immunotherapy on a cancer patient and/or prognosis of the cancer patient after the immunotherapy, and a gene set and a kit for use in the method. | 01-24-2013 |
20130023433 | METHODS OF DETECTING NUCLEIC ACID SEQUENCES WITH HIGH SPECIFICITY - The invention relates to methods of detecting nucleic acids, including methods of detecting one or more target nucleic acid sequences in multiplex branched-chain DNA assays, are provided. Nucleic acids captured on a solid support or suspending cells are detected, for example, through cooperative hybridization events that result in specific association of a label with the nucleic acids. The invention further relates to methods to improve probe hybridization specificity and their application in genotyping. The invention also relates to in situ detection of mis-joined nucleic acid sequences. The invention relates to reducing false positive signals and improve signal-to-background ratio in hybridization-based nucleic acid detection assay. The invention further relates to method to improve specificity in hybridization based nucleic acid using co-location probes. Compositions, tissue slides, sample of suspended cells, kits, and systems related to the methods are also described. | 01-24-2013 |
20130023434 | System and Method for Classification of Patients | 01-24-2013 |
20130023435 | SERS-BASED ANALYTE DETECTION - The present invention relates to method detecting analytes by surface enhanced Raman spectroscopy (SERS), comprising contacting the analytes with at least one analyte binding molecule attached to a metal substrate surface that enhances Raman scattering via a Raman-active molecular linker; and detecting a surface enhanced Raman signal from said compound. In a further aspect, this invention relates to a conjugate and a biosensor suitable for the invented SERS-based analyte detection method. | 01-24-2013 |
20130023436 | DISEASE DIAGNOSIS AND TREATMENT USING COMPUTATIONAL MOLECULAR PHENOTYPING - Disclosed are methods for detecting the presence or absence of disease in subjects based, at least in part, on results of analysis of a sample using computational molecular phenotyping. Further disclosed herein are methods for monitoring the status of subjects diagnosed with disease based at least partially on results of computational molecular phenotyping. The test samples disclosed herein are represented by, but not limited in anyway to, biopsy samples of body tissue. | 01-24-2013 |
20130023437 | DIAGNOSTIC FOR LUNG DISORDERS USING CLASS PREDICTION - The present invention provides methods for diagnosis and prognosis of lung cancer using expression analysis of one or more groups of genes, and a combination of expression analysis with bronchoscopy. The methods of the invention provide far superior detection accuracy for lung cancer when compared to any other currently available method for lung cancer diagnostic or prognosis. The invention also provides methods of diagnosis and prognosis of other lung diseases, particularly in individuals who are exposed to air pollutants, such as cigarette or cigar smoke, smog, asbestos and the like air contaminants or pollutants. | 01-24-2013 |
20130023438 | MAGNETIC RECOVERY METHOD OF MAGNETICALLY RESPONSIVE HIGH-ASPECT RATIO PHOTORESIST MICROSTRUCTURES - Systems and methods that facilitate magnetic collection and/or manipulation of individual micropallets are provided. The embodiments provided herein are directed to a new method for collecting micropallets once released from a substrate. It is accomplished by endowing the micropallets with magnetic properties by incorporating ferromagnetic or superparamagnetic nanoparticles into the photoresist material or otherwise incorporating magnetically responsive material into the micropallet structure. The magnetic particles, which posses magnetic qualities, e.g., ferromagnetism, ferrimagnetism, paramagnetism, and are composed of iron, nickel, and/or other magnetic materials, are mixed into the bulk photoresist prior to its use in the fabrication of microstructures. Also covered are other methods of incorporating magnetically-attractable material into the micropallet structure, such as plating of the micropallets with a material that is magnetically responsive, such as nickel. Additionally, the embodiments provided include a “collection probe” that is used to collect the released magnetic micropallets. | 01-24-2013 |
20130023439 | Method and Kit for Determining Sensitivity to Decitabine Treatment - The present invention is a gene expression panel of chemotherapeutic drug-resistant cancer stem cells comprising RIN1, SOX15 and TLR4. In one embodiment the cancer stem cells are testicular cancer germ cells. The present invention provides for a kit and method for determining response to treatment with decitabine at low doses. | 01-24-2013 |
20130023440 | Polynucleotides Associated With Age-Related Macular Degeneration and Methods for Evaluating Patient Risk - The present invention provides for certain polynucleotide sequences that have been correlated to AMD. These polynucleotides are useful as diagnostics, and are preferably used to fabricate an array, useful for screening patient samples. The array is used as part of a laboratory information management system, to store and process additional patient information in addition to the patient's genomic profile. As described herein, the system provides an assessment of the patient's risk for developing AMD, risk for disease progression, and the likelihood of disease prevention based on patient controllable factors. | 01-24-2013 |
20130023441 | Identification of Tumors - The invention provides methods for the use of gene expression measurements to classify or identify tumors in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples. | 01-24-2013 |
20130023442 | SINGLE NUCLEOTIDE POLYMORPHISM FOR PREDICTING RECURRENCE OF HEPATOCELLULAR CARCINOMA - Single nucleotide polymorphisms (SNP) for predicting recurrence of hepatocellular carcinoma after curative surgical resection are provided. The SNPs have a significant correlation with higher risk of hepatocellular carcinoma recurrence after curative surgical resection. Therefore, the SNPs can be used in developing micro-arrays or test kits for predicting recurrence of hepatocellular carcinoma, and in screening drugs to prevent recurrence of hepatocellular carcinoma after curative surgical resection. | 01-24-2013 |
20130023443 | METHOD FOR DETECTING PNEUMONIA CAUSATIVE BACTERIA USING NUCLEIC ACID CHROMATOGRAPHY - Provided are a method and a kit for accurately and rapidly detecting ten types of targeting pneumonia bacteria: | 01-24-2013 |
20130029857 | METHOD FOR DETERMINING AN ALLELE PROFILE OF NUCLEIC ACID - A method of identifying alleles of polymorphic sites in a plurality of nucleic acid samples including the steps of determining a source tag sharing number “d” for each of the alleles; performing a first reaction in a plurality of pools of the alleles to be identified to produce reaction products including a source tag identifying said each pool; pooling the pools to provide pooled pools; for each of the alleles to be identified, performing a second reaction using said reaction products to produce allele-specific second reaction products comprising a marker tag and a derived source tag; identifying said allele-specific second reaction products to identify the alleles. If “d” is equal to or larger than a maximum pool size, the first reaction may not be performed. Alleles may be binned together. A microparticle comprising one or more capture probes each comprising an oligonucleotide complementary to a subsequence of a target polynucleotide. | 01-31-2013 |
20130029858 | Method of Drug Screening through Quantitative Detection by Atomic Force Microscopy and Effective Protein Chips Development through Method Thereof - A method for drug screening is provided. An atomic force microscopy (AFM) is used to obtain quantitative difference. At least one receptor is immobilized on a probe of the AFM and at least one ligand is immobilized on chips. By flowing a candidate drug on the chips or even applying different candidate drugs to different areas of each chip, drug screening is processed through measuring the binding force between the receptor and the ligand. Multiple drugs can be screened without weakening activity of the proteins during repeated drug screening processes. The drug screening process is cost saved and has high quality. Highly effective protein chips can be developed based on the present disclosure. | 01-31-2013 |
20130029859 | BIOMARKER ASSAY OF NEUROLOGICAL CONDITION - A process and assay for determining the neurological condition in a subject is provided whereby the level of one or more neuroactive biomarkers is measured in a sample obtained from the subject. The processes and assay include measurement of multiple neuroactive biomarkers for synergistic determination of a neurological condition such as neurological damage due to injury, disease, contact with a compound, or other source. | 01-31-2013 |
20130029860 | Methods Of Diagnosing Or Treating Prostate Cancer Using The ERG Gene, Alone Or In Combination With Other Over Or Under Expressed Genes In Prostate Cancer - The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and/or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene. | 01-31-2013 |
20130029861 | Method for Detecting a Plurality of Nucleotide Polymorphisms at a Single Wavelength Using a Plurality of Oligonucleotides Modified With Fluorescent Dye Having the Same or Close Detection Wavelength - The present disclosure includes a method for simultaneously detecting a plurality of nucleotide polymorphisms, comprising detecting a plurality of nucleotide polymorphisms at a single wavelength by using a plurality of oligonucleotides labeled with a dye, each of which hybridizes to a region containing each of the plurality of nucleotide polymorphisms. | 01-31-2013 |
20130029862 | Clinical application utilizing genetic data for effective medication management - The present disclosure relates a predictive method, based on a subject's genetic profile, which defines variability in a specific disease or condition to determine medication response, including determining select VNTR and SNP occurrence combinations which are associated with specific responses to medications, kits and DNA chips/arrays containing such combinations so as to effectuate better medication management. | 01-31-2013 |
20130029863 | METHOD FOR DETECTING MICROORGANISMS - The invention relates to the diagnostic field and to the characterization of antibiotic-resistant bacteria in a sample by detecting specific nucleotides in the CMY-2 gene. | 01-31-2013 |
20130029864 | BIOMARKERS FOR ALZHEIMER'S DISEASE - The invention relates to novel marker sequences for Alzheimer's disease, in particular Alzheimer's dementia, and their diagnostic use including a screening method in order to identify potential drugs for the treatment/prophylaxis of Alzheimer's disease by means of the said novel marker sequences. Moreover, the invention relates to a diagnostic device comprising said novel marker sequences for diagnosing Alzheimer's disease, particularly a protein array (chip) and its use hereto. | 01-31-2013 |
20130029865 | Stromal Antigen 2 (STAG2) Compositions and Methods - Compositions and methods related to stromal antigen 2 (STAG2) and its role in diverse human cancers, including nucleic acids, polypeptides, vectors, cells and cell lines. | 01-31-2013 |
20130029866 | CARDIOMYOCYTES FROM INDUCED PLURIPOTENT STEM CELLS FROM PATIENTS AND METHODS OF USE THEREOF - Human somatic cells obtained from individuals with a genetic heart condition are reprogrammed to become induced pluripotent stem cells (iPS cells), and differentiated into cardiomyocytes for use in analysis, screening programs, and the like. | 01-31-2013 |
20130029867 | CONCENTRATION MEASUREMENT METHOD AND CONCENTRATION MEASUREMENT SYSTEM - A concentration measurement method for measuring the concentration of a target molecule, capable of carrying out a quantitative measurement of the concentration by use of a chip. A relationship between concentration of a target molecule of a calibration liquid, found with respect to a calibration chip identical in performance to the measurement chip and a measured quantity of light is found when the probe molecule and the target molecule undergo bonding reaction in a condition where the specific probe molecule and the target molecule undergo bonding reaction using the calibration chip. The concentration of a target molecule in the measured target liquid is worked out on the basis of the measured quantity of light, found in the step of finding the measured quantity of light by use of a relationship found with respect to a calibration chip | 01-31-2013 |
20130029868 | METHODS AND KITS FOR THE DETECTION OF CANCER INFILTRATION OF THE CENTRAL NERVOUS SYSTEM - This invention relates to methods to detect the presence of cancer infiltration of the Central Nervous System (CNS) based on the detection of soluble proteins, preferably, in cerebrospinal fluid samples and vitreous fluid. The invention also relates to kits to perform the methods of the invention. | 01-31-2013 |
20130029869 | Molecular Profile For the Diagnosis of Metabolic Myopathies - Provided is a method for determining whether an individual is at risk for, or has a metabolic muscle disease. The method involves testing a biological sample obtained or derived from an indivdival for the presence or absence of at least one mutation from a plurality of mutations in genes related to muscle metabolism and identifying the individual as having or at risk for developing a metabolic muscle disease based on the presence or absence of the mutation. | 01-31-2013 |
20130029870 | MATERIALS AND METHODS FOR DIAGNOSIS OF ASTHMA - The present invention pertains to materials and methods for diagnosing and/or determining the prognosis and likelihood of developing asthma. In one embodiment, methods of the invention comprise the use of single nucleotide polymorphic markers of asthma. Markers of the invention are present in the atria natriuretic peptide (NPPA) gene, and serve as a marker for genetic susceptibility of a person or animal in developing asthma. | 01-31-2013 |
20130029871 | METHODS OF STRATIFYING ADOLESCENT IDIOPATHIC SCOLIOSIS, ISOLATED NUCLEIC ACID MOLECULES FOR USE IN SAME AND KITS USING SAME - A method of stratifying a subject having adolescent idiopathic scoliosis (AIS) comprising: providing a cell sample isolated from the subject; detecting Paired-like homeodomain transcription factor 1 (Pitx1) expression in the cell sample; whereby the results of the detecting step enables the stratification of the subject having AIS as belonging to an AIS subclass. | 01-31-2013 |
20130029872 | ARRAY FOR DETECTING BIOLOGICAL SUBSTANCE, ASSAY SYSTEM AND ASSAY METHOD - Provided are a device, whereby cells, a bacterium or a virus can be quantified in a single unit, an assay system and an assay method. A subject to be assayed such as cells, a bacterium or a virus, which are present on a sensor, can be quantified by using a sensor equipped with multiple electrodes, said electrodes being similar in size to the subject to be assayed, detecting, concerning each electrode, the presence or absence of the subject in the vicinity of the electrode, and adding up the electrodes in which the subject is detected. | 01-31-2013 |
20130029873 | METHODS AND COMPOSITIONS FOR DIAGNOSING PULMONARY FIBROSIS SUBTYPES AND ASSESSING THE RISK OF PRIMARY GRAFT DYSFUNCTION AFTER LUNG TRANSPLANTATION - A method for determining pulmonary fibrosis subtype and/or prognosis in a subject having pulmonary fibrosis comprising: a. determining an expression profile by measuring the gene expression levels of a plurality of genes selected from genes listed in Table 1, 2, 3, 4 7, 8, 9, and/or 10, in a sample from the subject; and b. classifying the subject as having a good prognosis or a poor prognosis based on the expression profile; wherein a good prognosis predicts decreased risk of post lung transplant primary graft dysfunction, and wherein a poor prognosis predicts an increased risk of post lung transplant primary graft dysfunction. | 01-31-2013 |
20130029874 | MICRORNA MARKERS FOR RECURRENCE OF COLORECTAL CANCER - The present invention concerns methods and compositions for identifying a miRNA profile for a particular condition, such as colorectal cancer, and using the profile in the diagnosis and/or prognosis of a patient for a condition, such as colorectal cancer and colorectal cancer recurrence or response to therapy. | 01-31-2013 |
20130035245 | INORGANIC-BINDING PEPTIDES AND QUALITY CONTROL METHODS USING THEM - The present invention relates to quality control methods using inorganic binding peptides, wherein inorganic entities are identified using inorganic-binding peptides specifically binding to the inorganic entity of interest. In particular, the invention includes a method for the identification of defects or inhomogeneities on a surface by detecting an inorganic entity of interest. It further includes a method for the isolation of powder particles comprising an inorganic entity of interest from a mixture of powder particles. In addition, the present invention relates to inorganic-binding peptides comprising the amino acid sequence MTWDPSLASPRS (SEQ ID NO: 31) and the amino acid sequence LNAAVPFTMAGS (SEQ ID NO: 32), respectively. | 02-07-2013 |
20130035246 | Method and Apparatus for Determining a Mammal's Exposure to Chemical or Biological Agents - Cellular immunologic methods are disclosed for determining human health effects of exposures to environmental molds and toxins. In one embodiment, a method for assessing a patient's exposure to a mold strain is provided. The method comprises measuring cytokine production in at least the peripheral blood mononuclear cells of a mammal suspected of being exposed to mold or other toxin and determining if there is a decreased production of cytokines in the mammal suspected of being exposed to mold or other toxin when compared to the production of cytokines produced in a mammal not suspected of being exposed to mold or other toxin. Other methods, including methods of diagnosing respiratory disorders, including asthma, are also disclosed. | 02-07-2013 |
20130035247 | GLOBAL DNA HYPOMETHYLATION AND BIOMARKERS FOR CLINICAL INDICATIONS IN CANCER - The present invention provides methods of determination of a global DNA methylation index (GDMI) in a sample from a subject, using a variety of methods which can detect global, genome-wide, and gene-specific DNA methylation to create methylation portraits that can be used for early detection, diagnosis, and clinical management in the personalized medicine space. Further, the invention provides methods of diagnosis of cancer, including gastric cancer and hepatocellular cancer in a subject, by comparing the GDMI in a sample obtained from a subject to the methylation index of standard controls. These methods allow diagnosis of gastric carcinoma and liver cancer in patients who may be asymptomatic or have inconclusive pathology, and allowing earlier treatment of the subject. | 02-07-2013 |
20130035248 | Microsporidia Detection System and Method - In various aspects, a multiplex primer set, a kit for performing an assay to detect microsporidia, and a method of identifying a microsporidia in a sample is provided. The multiplex PCR primer set including SEQ ID NOS 1-4. The kit includes a multiplex PCR primer set having SEQ ID NOS 1-4 and a set of probes having SEQ ID NOS 5-8. In the method a sample is obtained and a multiplex PCR assay is performed on the sample. A multiplex PCR primer set including SEQ ID NOS 1-4 is included in the multiplex PCR assay. The sample is determined to have the microsporidia in response to the multiplex PCR assay amplifying a target sequence associated with microsporidia. | 02-07-2013 |
20130035249 | METHODS AND COMPOSITIONS FOR DETECTING AND TREATING CEA-EXPRESSING CANCERS - Provided are improved methods and compositions for detecting, monitoring and/or treating a CEA-expressing cancer. | 02-07-2013 |
20130035250 | NON-INVASIVE METHOD FOR DIAGNOSIS OF PROSTATE CANCER - The present invention relates on a non-invasive method for diagnosing prostate cancer and/or assessing the risk of a subject acquiring prostate cancer comprising the analysis of the expression of the marker gene hepsin in an urine sample. It further relates on a non-invasive method for diagnosing prostate cancer and/or assessing the risk of a subject acquiring prostate cancer by determining the expression levels of the marker genes hepsin, EZH2, prostein and PCA3. | 02-07-2013 |
20130035251 | miRNA FINGERPRINT IN THE DIAGNOSIS OF WILMS' TUMOUR - MicroRNAs (miRNA) are a recently discovered class of small non-coding RNAs (17-14 nucleotides). Due to their function as regulators of gene expression they play a critical role both in physiological and in pathological processes, such as cancer. The present invention provides novel methods for diagnosing a state of health based on the determination of specific miRNAs that have altered expression levels in different conditions, e.g. disease states compared to healthy controls. | 02-07-2013 |
20130035252 | METHODS FOR DETERMINING A GENE EXPRESSION PROFILE AND FOR DISEASE DIAGNOSIS - The invention generally relates to methods for determining a gene expression profile and for disease diagnosis. In certain aspects, methods of the invention involve obtaining a sample including somatic cells, transforming the somatic cells into target cells, and determining an expression profile from the target cells. | 02-07-2013 |
20130035253 | METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT - The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations. | 02-07-2013 |
20130035254 | DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) - The present invention relates to methods and kits for diagnosing systemic lupus erythematosus (SLE) in a subject. Particularly, the present invention relates to a specific antibody profile useful in diagnosing SLE in a subject. | 02-07-2013 |
20130035255 | CONTROLLED RELEASE HYBRID SYSTEMS - Described herein are controlled release hybrid systems and methods of use thereof. In certain embodiments, the controlled release hybrid systems can be used to screen for interactions between candidate molecules. In addition, these controlled release hybrid systems can be modified to screen for chemical inhibitors of interacting candidate molecules. In another embodiment, the controlled release hybrid systems described herein can be modified to screen for mutant molecules (e.g., peptides, proteins, polypeptides, portions of proteins, portions of polypeptides, or any combination thereof) when compared to candidate molecules that were previously shown to interact. Upon identifying these mutant molecules, the controlled release hybrid systems can be further utilized to identify peptide, chemicals, or a combination thereof that potentially act as inhibitors of these mutant molecules. In this embodiment, the controlled release systems can be readily modified for personalized medication applications. | 02-07-2013 |
20130035256 | Chimeric Polypeptides Useful in Proximal and Dynamic High-Throughput Screening Methods - The present invention provides a method of high-throughput screening (HTS) of active agents of a cell-surface G-Protein coupled receptor (GPCR) or another target receptor of interest. The method uses a non-invasive, sensitive reporting system that is proximal to the target of interest, combined with a dynamic, automated screening procedure so as to detect orthosteric ligands, such as agonists and antagonists, but is also suitable to detect allosteric or low affinity active agents of a GPCR and possibly other disease-related receptors. | 02-07-2013 |
20130040831 | Predicting Response to Anti-CD40 Therapy in DLBCL Patients - This invention provides methods, compositions, and kits relating to biomarkers whose expression levels are correlated with diffuse large B-cell lymphoma (DLCBL) patients' response to treatment with a CD20 antagonist, such as a CD20 antibody, exemplified by rituximab. The methods, compositions, and kits of the invention can be used to identify DLBCL patients who are likely or not likely, to respond to anti-CD20 treatments. | 02-14-2013 |
20130040832 | IDENTIFYING VIRAL CELL TROPISM - The invention relates to an in vitro method for identifying microRNAs or the target mRNAs thereof, the expression of which during the infection of cells by a virus using a cell receptor and at least one cell co-receptor for entering the cell, is specifically modified on the basis of the cell co-receptor used by the virus for its entering the cells, comprising:
| 02-14-2013 |
20130040833 | USE OF MICROVESICLES IN ANALYZING NUCLEIC ACID PROFILES - The invention concerns gene signatures obtained from microvesicles and a method of applying these gene signatures in helping to determine a biological condition. The determination of a biological condition may aid, for example, the diagnosis, prognosis, and therapy treatment selection for a disease in a subject. | 02-14-2013 |
20130040834 | SAMPLE PLATE SYSTEMS AND METHODS - A sample plate comprising a sample well is disclosed. The sample well can comprise one or more bead retaining chambers. Also provided herein is a method of using the sample plate and kits comprising the sample plate. | 02-14-2013 |
20130040835 | Genes predictive of anti-TNF response in inflammatory diseases - The present invention provides compositions and their use in predicting anti-tumor necrosis factor therapy response in a patient with an inflammatory disease. | 02-14-2013 |
20130040836 | METHODS FOR ENGINEERING T-CELL RECEPTORS - The present invention provides a method for engineering a T-cell receptor domain polypeptide comprising at least one modification in a structural loop region of the T-cell receptor domain polypeptide and determining the binding of the T-cell receptor domain polypeptide to an epitope of an antigen, wherein the unmodified T-cell receptor domain polypeptide does not significantly bind to said epitope. The present invention also covers modified T cell receptor domain polypeptides, their use and libraries containing the modified T cell receptor domain polypeptides. | 02-14-2013 |
20130040837 | APTAMER CELL COMPOSITIONS - A composition includes an isolated cell, wherein a surface of the cell is attached to a nucleic acid that specifically binds to a non-nucleic target. | 02-14-2013 |
20130040838 | METHODS FOR IDENTIFYING THE PRESENCE OF A BICUSPID AORTIC VALVE - The present invention features a method for identifying a subject with a bicuspid aortic valve (BAV) by detecting one or more single nucleotide polymorphisms (SNPs) present in one or more BAV-associated chromosomal regions (e.g., chromosomal regions containing the AXIN1-PDIA2, ENG, BAT2/3, or ZNF385D gene(s)). | 02-14-2013 |
20130040839 | Method for Diagnosing or Determining the Prognosis of Colorectal Cancer (CRC) Using Novel Autoantigens: Gene Expression Guided Autoantigen Discovery - The invention relates to the discovery and use of novel antigens/autoantigens, polyclonal and monoclonal antibodies/autoantibodies thereto, and in particular methods of using the antigens/autoantigens and antibodies/autoantibodies in the diagnostic, prognostic, staging and therapeutic regimens for the control of colorectal cancer. | 02-14-2013 |
20130040840 | NUCLEIC ACID AMPLIFICATION WITH INTEGRATED MULTIPLEX DETECTION - Compositions and methods of detecting multiple proteins of interest in a sample using arrays are provided herein. | 02-14-2013 |
20130040841 | DIGITAL ASSAYS WITH MULTIPLEXED DETECTION OF TWO OR MORE TARGETS IN THE SAME OPTICAL CHANNEL - System, including methods and apparatus, for performing a digital assay with multiplexed detection of two or more distinct targets in the same optical channel. | 02-14-2013 |
20130040842 | Methods And Compositions For Phototransfer - Methods are described for phototransferring a compound from a first surface to a second surface. Compounds are described with photocleavable linkers. Compounds attached to a first surface through a photocleavable linker are put in proximity (or contact) with a second surface, and then phototransferred to the second surface upon exposure to electromagnetic radiation. Illuminating the compound with radiation photocleaves the compound from the first surface and transfers the compound to the second surface. | 02-14-2013 |
20130040843 | Increasing Multiplex Level by Externalization of Passive Reference in PCR Reactions - Methods for increasing multiplex level by externalization of a passive reference in polymerase chain reactions (PCR) are provided. An exemplary method comprises providing a first mastermix including a passive fluorescence dye in at least a first well of a plate; providing a second mastermix including an active fluorescence dye in at least a second well of the plate; wherein the passive fluorescence dye and the active fluorescence dye emit a same spectrum and an intensity of the spectrum is adapted to be measured; and wherein the first mastermix is devoid of an active fluorescence dye emitting the same spectrum and the second mastermix is devoid of the passive fluorescence dye emitting the same spectrum. Numerous other aspects are provided. | 02-14-2013 |
20130040844 | BIOMARKERS OF AGING FOR DETECTION AND TREATMENT OF DISORDERS - Provided are methods of diagnosis, prognosis, and monitoring of aging using biomarkers that have been discovered to be linked to biological aging process. Methods for increasing neural cell regeneration and cognitive function are also provided. The methods are, at least in part, based on a discovery that altered expression patterns of certain biological markers are associated with biological aging processes. These markers comprise at least Eotaxin/CCL11, 2-microglobulin, MCP-1 and Hap-toglobulin, increased expression of which has been shown to be associated with increase in biological aging process. | 02-14-2013 |
20130040845 | METHOD FOR SCREENING RECEPTORS/LIGANDS INTERACTIONS - Embodiments of the invention herein relate to methods of studying binding interactions between two entities and methods for screening of modulators of such binding interactions, in particular, the protein-protein interaction observed in receptor-ligand interactions. | 02-14-2013 |
20130040846 | Signatures for Kidney Aging - Sets of genes associated with aging in the kidney are identified herein, and methods of assessing the health and longevity of the kidney in a human subject are disclosed. Methods include obtaining a DNA sample from the subject and analyzing the sample for the occurrence of at least one single nucleotide polymorphism (SNP) in at least one gene that is identified herein as correlating with physiological aging of the kidney. Also disclosed are potential drug targets for improving the physiological health and lifespan of the kidney. | 02-14-2013 |
20130040847 | ENHANCED MULTIPLEX FISH - Subject of the present invention is a combination of nucleic acid molecules capable of hybridising with a target nucleic acid sequence. In order to overcome problems with the reproducibility of FISH assays and to decrease assay time, hairpin probes are used in combination with helper probes annealing adjacent to the target site of the hairpin probe. | 02-14-2013 |
20130040848 | Methods and Devices for Detecting Structural Changes in a Molecule Measuring Electrochemical Impedance - The invention relates to a method of detecting a structural change in a molecule, said molecule being attached to a surface, said surface being electrically conductive, wherein the phase of the electrochemical impedance at said surface is monitored, and wherein a change in the phase in the electrochemical impedance at said surface indicates a change in the structure of said molecule. The invention further relates to methods for making arrays having molecules such as, polypeptides attached to electrically conductive surfaces such as electrodes, and to arrays. | 02-14-2013 |
20130040849 | METHOD AND KIT FOR CANCER DIAGNOSIS - A method for diagnosing or providing a prognosis of a subject suspected of suffering from prostate cancer, comprising in vitro detection of prostasomes and quantification of prostasomal expression of at least one antigen chosen from the group consisting of CD13, CD59, CD10, CD26 CD142, CD143 and MHC I, and comparing said quantified expression value with a reference value for the respective antigen derived from healthy subject(s). Quotients between said antigens may moreover be made use of. Detection may be by way of flow cytometry or ELISA. A kit for use in diagnosis or providing a prognosis of a subject suspected of suffering from prostate cancer is furthermore provided. | 02-14-2013 |
20130040850 | SEROLOGY ASSAYS - The invention provides methods and kits for measuring the ability of a test sample to inhibit the binding of a receptor expressed by a pathogen to a host cell ligand of the pathogen. | 02-14-2013 |
20130040851 | Evaluation Method for Arteriosclerosis - Arteriosclerosis induces cerebral infarction and myocardial infarction. A multi-marker (a group of protein markers) that assesses the accurate pathogenesis of arteriosclerosis and enables the selection of an adequate treatment method for arteriosclerosis and prediction of the progression of arteriosclerosis, and an evaluation method for the diagnosis, prevention, and treatment of arteriosclerosis that uses said marker group as an indicator have been sought. The present invention relates to A method for evaluation of arteriosclerosis comprising the steps of (a) measuring the expression of von Willebrand factor and/or complement factor D in a sample derived from a subject, (b) measuring the expression of complement component C8 and/or vitamin K-dependent protein Z in the sample derived from the subject, and (c) evaluating arteriosclerosis in the subject on the basis of the results from (a) and (b). | 02-14-2013 |
20130040852 | BIOMARKERS BASED ON A MULTI-CANCER INVASION-ASSOCIATED MECHANISM - The present invention relates to biomarkers which constitute a metastasis associated fibroblast (“MAF”) signature and their use in diagnosing and staging a variety of cancers. It is based, at least in part, on the discovery that identifying the differential expression of certain genes indicates a diagnosis and/or stage of a variety of cancers with a high degree of specificity. In particular, the presence of the signature implies that the cancer has already become invasive. Accordingly, in various embodiments, the present invention provides for methods of diagnosis, diagnostic kits, as well as methods of treatment that include an assessment of biomarker status in a subject. Further, because the differential expression of certain genes can function as marker for the acquisition of metastatic potential, such expression profiles can be used to predict the appropriateness of certain therapeutic interventions, such as the appropriateness of neoadjuvant therapies. Such profiles can also be used to screen for therapeutics capable of inhibiting acquisition of metastatic potential. Accordingly, in various embodiments, the present invention provides for methods of screening therapeutics for their anti-metastatic properties as well as screening kits. | 02-14-2013 |
20130045879 | METHODS, COMPUTER-ACCESSIBLE MEDIUM, AND SYSTEMS FOR GENERATING A GENOME WIDE HAPLOTYPE SEQUENCE - Methods, computer-accessible medium, and systems for generating a genome wide probe map and/or a genome wide haplotype sequence are provided. In particular, a genome wide probe map can be generated by obtaining a plurality of detectable oligonucleotide probes hybridized to at least one double stranded nucleic acid molecule cleaved with at least one restriction enzyme, and detecting the location of the detectable oligonucleotide probes. For example, genome wide haplotype sequence can be generated by analyzing at least one genome wide restriction map in conjunction with at least one genome wide probe map to determine distances between restriction sites of the genome wide restriction map(s) and locations of detectable oligonucleotide probes of the genome wide probe map(s) and defining a consensus map indicating restriction sites based on the genome wide restriction map(s) and/or locations of detectable oligonucleotide probes based on each of the genome wide probe map(s). | 02-21-2013 |
20130045880 | DRUG SELECTION FOR BREAST CANCER THERAPY USING ANTIBODY-BASED ARRAYS - The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments. | 02-21-2013 |
20130045881 | Probe Based Nucleic Acid Detection - The invention provides a method for detecting a target nucleotide sequence by tagging the nucleotide sequence with a nucleotide tag, providing a probe oligonucleotide with a melting temperature Tm | 02-21-2013 |
20130045882 | METHODS FOR ASSESSING RNA PATTERNS - Methods and compositions for the characterizing of cancers by assessing RNA levels, such as determining an RNA pattern, are provided herein. The diagnosis, prognosis, monitoring and treatment or a cancer can be determined by detecting one or more RNAs, such as microRNAs. | 02-21-2013 |
20130045883 | Sample Block Apparatus and Method for Maintaining a Microcard on a Sample Block - A sample block apparatus for a thermal cycler is provided, which can be configured for use with a microcard containing a plurality of samples of biological material. The apparatus can comprise a sample block comprising an upper surface configured for resting a microcard thereon. The upper surface can include surface irregularities for defining spaces between the surface irregularities and a microcard that may be positioned thereon. The apparatus can include a vacuum source in fluid communication with the space between the surface irregularity and the microcard positioned thereon. The vacuum source can be configured to create a substantial vacuum in the spaces thereby imparting a force on the microcard to retain the microcard on the sample block upper surface. The sample block apparatus can also include a temperature control system operatively connected with the sample block to cycle the sample block according to a user-defined profile. | 02-21-2013 |
20130045884 | MEANS AND METHODS FOR DIAGNOSING PANCREATIC CANCER - The present invention pertains to the field of cancer diagnosis. Specifically, it relates to a method for diagnosing pancreas cancer in a subject comprising the steps of determining in a sample of a subject suspected to suffer from pancreas cancer the amount of at least one biomarker selected from the biomarkers shown in Table 1 and comparing the said amount of the at least one biomarker with a reference, whereby pancreas cancer is to be diagnosed. The present invention also contemplates a method for identifying whether a subject is in need of a pancreas cancer therapy comprising the steps of the aforementioned methods and the further step of identifying a subject in need of a pancreas cancer therapy if said subject is to be diagnosed to suffer from pancreas cancer. Contemplated are, furthermore, diagnostic devices and kits for carrying out said methods. | 02-21-2013 |
20130045885 | MATERIALS AND METHODS FOR PROFILING MICRORNAS - The present invention provides materials and methods for detecting, quantifying, and/or profiling microRNAs. Advantageously, the present invention is sensitive, specific, convenient, and cost-effective. In one embodiment, the present invention provides a universal primer for reverse transcription of miRNAs, a universal reverse primer for PCR amplification reaction, and a universal probe. In another embodiment, the present invention provides assays that allow the detection and/or quantification of a plurality of target miRNAs using a single reverse transcription reaction and a single qPCR reaction. | 02-21-2013 |
20130045886 | Methods For Diagnosing Feline Coronavirus Infections - Provided is a method for determining whether a feline is infected with pathogenic Feline Infectious Peritonitis Virus (FIPV) or Feline Enteric Infection Virus (FECV). The method involves determining the presence or absence of intact or mutated S1/S2 and S2′ cleavage sites in the spike protein of serotype 1 feline coronaviruses (FCoV1). The presence of both intact cleavage sites is indicative of FECV. The presence of a mutation in one or both cleavage sites is indicative of FIPV. The absence of both sites is indicative of an absence of FCoV1 infection. Compositions for use in determining infection and kits are also provided. | 02-21-2013 |
20130045887 | PEPTIDE AND PROTEIN BIOMARKERS FOR TYPE 1 DIABETES MELLITUS - A method for identifying persons with increased risk of developing type 1 diabetes mellitus, or having type I diabetes mellitus, utilizing selected biomarkers described herein either alone or in combination. The present disclosure allows for broad based, reliable, screening of large population bases. Also provided are arrays and kits that can be used to perform such methods. | 02-21-2013 |
20130045888 | MULTI-COPY STRATEGY FOR HIGH-TITER AND HIGH-PURITY PRODUCTION OF MULTI-SUBUNIT PROTEINS SUCH AS ANTIBODIES IN TRANSFORMED MICROBES SUCH AS PICHIA PASTORIS - Methods for producing heterologous multi-subunit proteins in transformed cells are disclosed. In particular, the present disclosure provides improved methods of producing multi-subunit proteins, including antibodies and other multi-subunit proteins, which may or may not be secreted, with a higher yield and decreased production of undesired side-products. In exemplary embodiments, the transformed cells are a yeast, e.g., methylotrophic yeast such as | 02-21-2013 |
20130045889 | BIOMARKERS FOR HYPERTENSIVE DISORDERS OF PREGNANCY - The application discloses new biomarkers for hypertensive disorders of pregnancy and particularly preeclampsia; methods for the diagnosis, prediction, prognosis and/or monitoring said disorders based on measuring said biomarkers; and kits and devices for measuring said biomarker and/or performing said methods. | 02-21-2013 |
20130045890 | TEST FOR MALE FERTILITY - The present invention relates generally to a method for predicting the fertility potential in a male mammal. In particular it relates to a method for predicting the fertility potential in a male mammal by determining the expression of at least one protein of the vitamin D metabolising machinery in a semen sample. The expression level of the at least one protein of the vitamin D metabolising machinery is then indicative of the fertility potential of the subject. An object of the present invention relates to a method, which can predict whether the semen quality is sufficient to achieve pregnancy spontaneously or if the couple should proceed to assisted reproduction or further investigation. | 02-21-2013 |
20130053260 | CHIP FOR PROTEIN DETECTION, METHOD FOR MANUFACTURING THE SAME, AND METHOD FOR DETECTING PROTEIN BY USING THE SAME - A chip for protein detection, a method for manufacturing the same, and a method for detecting protein by using the chip are provided in the present invention. The chip for protein detection of the present invention comprises: a substrate; a covalent modification layer disposed on the substrate; a fluorinated layer disposed on the covalent modification layer, wherein the fluorinated layer comprises fluorinated functional groups and bio-molecular binding groups; and antibody-binding molecules connecting to the bio-molecular binding groups. | 02-28-2013 |
20130053267 | CELL FREE TRANSLATION SYSTEM FOR COMPOUND SCREENING AND RELATED USES - The invention provides a cell-free system comprising not more than about 5% wheat germ extract for expressing proteins such as viral proteins and proteins required for viral capsid assembly, and proteins that assemble into multiprotein complexes in a manner analogous to viral capsids, are provided. Further provided are methods for expressing proteins such as viral proteins, proteins required for capsid assembly, and proteins that assemble into multiprotein complexes in a manner analogous to viral capsids using a cell-free system comprising not more than about 5% wheat germ extract. Further provided are methods to assay for compounds that modulate viral protein, viral capsid assembly, and assembly of proteins into multiprotein complexes whose disruption can ameliorate bacterial, parasitic, metabolic, oncologic, immunologic, or CNS disease in a cell-free system comprising not more than about 5% wheat germ extract. | 02-28-2013 |
20130053268 | ANALYTE DETECTION METHOD AND ANALYTE DETECTION INTEGRATED CIRCUIT - A method for providing an integrated circuit such that first and second sensing electrodes respectively have at their surfaces first and second receptor molecules for selectively binding to first and second analytes of interest; exposing the integrated circuit to a sample potentially comprising at least one of the first and second analytes, providing a first bead having a first electrical signature attached to a first molecule having a conformation/affinity for binding to the first sensing electrode dependent on the presence of the first analyte; providing a second bead having a second electrical signature attached to a second molecule having a conformation/affinity for binding to the second sensing electrode dependent on the presence of the second analyte; and determining the presence of the electrical signature of the first and/or second bead(s) on the first and second sensing electrodes respectively. An IC for implementing this method. | 02-28-2013 |
20130053269 | Primer Sequences for Amplification of Sea Otter Genes, and Methods of Use Thereof - Gene expression technologies have the exciting potential of providing methods for monitoring long-term effects of contaminants and disease on free-ranging marine wildlife species. An added benefit is that these methods may elucidate the mechanisms by which these stressors can deleteriously affect an individual over a long period, and thereby aid in the design of therapeutic and preventative strategies to treat and protect susceptible individuals and populations at risk from oil exposure. Our presentation will assess specific quantifiable genetic markers that can signify persistent pathological and physiological injury associated primarily with chronic hydrocarbon exposure. Using empirical evidence from captive animals and recent captures, we will discuss how we are developing an understanding of gene expression as it relates to the immune system of the sea otter and other marine megafauna, and the potential effects of contaminants or disease. | 02-28-2013 |
20130053270 | METHODS FOR DETERMINING GENE-NUTRIENT INTERACTIONS - The present invention provides methods and tests that allow for the establishment of personalized weight-management programs for an individual based upon the individual's genotype in the glutathione S-transferase pi gene and/or the interleukin-6 gene. Methods are disclosed for determining the individual's genotype, which may be used to select an appropriate therapeutic/dietary program or lifestyle recommendation. Such a personalized weight-management program will have obvious benefits (e.g., yield better results in terms of weight loss and weight maintenance) over traditional weight-management programs that do not take into account genetic information. | 02-28-2013 |
20130053273 | METHODS AND DEVICES FOR MULTIPLEXED MICROARRAY MICROFLUIDIC ANALYSIS OF BIOMOLECULES - Rapid and specific detection of biological cells and biomolecules is important to biological assays across diverse fields including genomics, proteomics, diagnoses, and pathological studies. Microarrays and microfluidics increasingly dominate such detection techniques due to the ability to perform significant numbers of tests with limited sample volumes. A snap chip assembly is provided for the transfer of a microarray of reagents within semi-spherical liquid droplets on a transfer chip to a target assay microarray on an assay chip following assembly of the two chips and physical contact of the droplets with the target array. Reagents in nanolitre quantities are spotted on both chips and selectively transferred as liquid droplets between transfer chip and assay chip within the contact areas. Using the snap chip structure the inventors performed immunoassays with colocalization of capture and detection antibodies with 10 targets and bead-in-gel droplet microarrays with 9 targets in the low pg/ml regime. | 02-28-2013 |
20130053274 | QUANTIFICATION OF NUCLEIC ACID MOLECULES USING MULTIPLEX PCR - Described are novel quantification methods and systems that permit, within the context of multiplex PCR, the quantification of all targets within a single reaction tube. The methods employ quantitation algorithms applied to the amplification profiles of internal calibration controls or standards utilizing a plurality of nucleic acid templates that are amplified within the same reaction tube as the nucleic acid target(s) interrogated. | 02-28-2013 |
20130059742 | GLOBAL ANALYSIS OF SERUM MICRO RNAS AS POTENTIAL BIOMARKERS FOR LUNG ADENOCARCINOMA - A diagnostic kit to detect lung adenocarcinoma, or to stratify patients according to expected prognosis comprising at least one oligonucleotide probe capable of binding to at least a portion of a circulating miRNA selected from the group comprising miR-556, -550, -939, -616*, 146b-3p and -30c-1* biomarkers. | 03-07-2013 |
20130059743 | METHODS AND MICROARRAYS COMPATIBLE WITH DUAL FUNCTIONALITY OPTICAL DRIVES - A microarray with optically recorded information and a sample capable of producing a signal as a response to external influence, or a precursor which, when activated or combined with a reagent, produces a sample capable of generating a signal. The microarray is compatible with a dual functionality optical drive. A method for acquiring information about a sample comprises directing a probe to a sample at a microarray to produce a signal from the sample, wherein the microarray is compatible with a dual functionality optical drive, and detecting the signal. The information optically recorded on the microarray can be in the CD, DVD or HD DVD or Blue Ray format. | 03-07-2013 |
20130059744 | METHOD FOR EARLY DETECTION OF CANCER - The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilising a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. Detected antibodies were demonstrated as glycopeptide specific, and it could be discriminated between e.g. colorectal cancer patients and healthy individuals. The inventors have also developed monoclonal antibodies based on the identified glycopeptides epitope baits, and demonstrated differential expression of the relevant target antigens. The invention thus, in a lock and key-based manner includes both glycopeptides and antibody tools for early detection of cancer, as well as methods of using the same for in situ visualisation and treatment of specific cancer types. | 03-07-2013 |
20130059745 | METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND INVOLVED IN PAIN AS WELL AS METHODS OF DIAGNOSING ALGESIA - The present invention relates to a method of identifying a compound involved in pain, the use of Il2rg nucleic acid or Il2rg protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same. | 03-07-2013 |
20130059746 | GENE EXPRESSION PROFILING OF CYTOGENETIC ABNORMALITIES - Provided herein are methods of predicting cytogenetic abnormalities associated with a cancer in a subject, for example, multiple myeloma. A cytogenetic abnormalities model of a set of reference values obtained from an average of gene expression profile values based on copy number-sensitive genes that correlate to cytogenetic abnormalities associated with the cancer is utilized as a predictive tool. The cytogenetic abnormalities model, as a virtual model (i.e. a “virtual karyotype”), may be tangibly stored with program instructions to implement the model in a computer system. In particular embodiments, the methods and systems provided by the invention operate without FISH (fluorescent in situ hybridization). | 03-07-2013 |
20130059747 | MULTIGENE PROGNOSTIC ASSAY FOR LUNG CANCER - The present invention provides methods for providing a prognosis for lung cancer using a panel of eleven molecular markers that includes BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, and WNT3A, which are differentially expressed in lung cancer. The eleven markers are related to patient prognosis to 5-year overall survival outcomes, and are particularly useful in providing a prognosis for non-squamous NSCLC. | 03-07-2013 |
20130059748 | OPTIMIZED PROBES AND PRIMERS AND METHODS OF USING SAME FOR THE BINDING, DETECTION, DIFFERENTIATION, ISOLATION AND SEQUENCING OF INFLUENZA A; INFLUENZA B AND RESPIRATORY SYNCYTIAL VIRUS - Described herein are primers and probes useful for the binding, detecting, differentiating, isolating, and sequencing of influenza A, influenza B and RSV viruses. | 03-07-2013 |
20130059749 | METHOD FOR PREDICTING THE RESPONSE OF A SUBJECT SUFFERING FROM A VIRAL INFECTION OF THE LIVER TO AN ANTIVIRAL THERAPY - The application relates to treatments for improving antiviral therapies and to method for determining whether or not antiviral therapies will be effective. In particular, the present application provides a method for determining the likelihood that a subject having a viral infection of the liver will be responsive to antiviral therapy that includes stimulation of Interferon (IFN) activity, and kits for the performance of said determination. | 03-07-2013 |
20130059750 | BIOMARKERS - The invention relates to a method of diagnosing or monitoring schizophrenia or other psychotic disorder. | 03-07-2013 |
20130059751 | GENE FAMILY (LBFL313) ASSOCIATED WITH PANCREATIC CANCER - The invention relates generally to the changes in gene expression in human pancreatic adenocarcinoma. The invention relates specifically to a human gene family which is differentially expressed in cancerous pancreatic tissues compared to corresponding non-cancerous pancreatic tissues. | 03-07-2013 |
20130059752 | Compositions and methods for the treatment of immune related diseases - The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases. | 03-07-2013 |
20130059753 | Global Analysis of Serum microRNAs as Potential Biomarkers for Lung Adenocarcinoma - A diagnostic kit to detect lung adenocarcinoma, or to stratify patients according to expected prognosis comprising at least one oligonucleotide probe capable of binding to at least a portion of a circulating miRNA selected from the group comprising miR-556, -550, -939, -616*, -146b-3p, -30c-1*, -339-5p and -656. | 03-07-2013 |
20130059754 | DIGITAL ASSAYS WITH REDUCED MEASUREMENT UNCERTAINTY - The present disclosure provides a digital assay system, includes methods and apparatus, with reduced measurement uncertainty. In an exemplary method, an expected value for a measure that is a function of a level of a first target and a level of a second target in a sample may be provided. An optimal concentration for the first target may be obtained based on the expected value. An experimental value for the measure may be determined from a digital assay with partitions formed according to the optimal concentration. | 03-07-2013 |
20130059755 | Gene Based Prediction of PSA Recurrence for Clinically Localized Prostate Cancer Patients - Disclosed are methods, devices and kits for determining the likelihood of recurrence of prostate cancer using the expression levels of preferably three-gene classifier. The methods, devices and kits can be used independent of many nomograms currently in use or to improve the overall performance of such nomograms. | 03-07-2013 |
20130059756 | PRIMER SET FOR PCR, PEACTION LIQUID FOR PCR, AND METHOD FOR DETECTING FOOD POISONING BACTERIA - Nucleic acid of two or more types of food poisoning bacteria among | 03-07-2013 |
20130065771 | Apparatus and method for parallel collection and analysis of the proteome and complex compositions - This invention relates to a kit and a method for the collection and analysis of complex protein mixtures. More particularly, the invention relates to a kit comprising a single barrel filtration well or a multi-well filtration plate wherein each well comprises an upper filtration zone; a lower filtration zone; a conical flow director zone; and, an elution tip, wherein the upper filtration zone and the lower filtration zone are separated by a retainer ring disposed within the lower filtration zone. The upper filtration zone comprises an upper collection zone, a sponge zone, and a deep bed filtration zone; and, the lower filtration zone comprises the retainer ring, a supported hydrophilic membrane and a lower bed filtration media. When used with an array of selected buffer solutions, the multi-well filtration plate can provide accurate, automated, high-throughput protein analysis by affinity chromatography. | 03-14-2013 |
20130065772 | PROGNOSTIC MOLECULAR SIGNATURE OF SARCOMAS, AND USES THEREOF - Described herein are methods and compositions that can be used for diagnosis and treatment of soft tissue sarcoma cancer phenotypes and soft tissue sarcoma cancer-associated diseases. Also described herein are methods that can be used to identify modulators of soft tissue sarcoma cancer. | 03-14-2013 |
20130065773 | Microfluidic Device and Methods of Using Same - A variety of elastomeric-based microfluidic devices and methods for using and manufacturing such devices are provided. Certain of the devices have arrays of reaction sites to facilitate high throughput analyses. Some devices also include reaction sites located at the end of blind channels at which reagents have been previously deposited during manufacture. The reagents become suspended once sample is introduced into the reaction site. The devices can be utilized with a variety of heating devices and thus can be used in a variety of analyses requiring temperature control, including thermocycling applications such as nucleic acid amplification reactions, genotyping and gene expression analyses. | 03-14-2013 |
20130065774 | DNA RECOMBINATION JUNCTION DETECTION - The present invention provides methods, compositions and kits for detecting the presence or absence of an integrated insertion polynucleotide. | 03-14-2013 |
20130065775 | Methods for diagnosing skin diseases - The present invention relates to methods for diagnosing cornification disorders and metabolic diseases. More specifically, the present invention relates to an in vitro method for diagnosing and/or predicting a cornification disorder in a subject, comprising determining the presence or the absence of a genetic variation in the Patatin-like phospholipase domain-containing protein 1 (PNPLA1) gene sequence in a biological sample from said subject, as compared with the PNPLA1 gene sequence of a healthy non-carrier subject, wherein the presence of said genetic variation indicates that said subject suffers from or is at risk of suffering from said cornification disorder. The method according to the invention allows for example diagnosing ichthyosis in dogs of the Golden Retriever breed. | 03-14-2013 |
20130065776 | SELECTIVE ENRICHMENT OF NON-METHYLATED NUCLEIC ACIDS - The present invention relates to a method for selectively amplifying non-methylated sequences of a DNA comprising the steps of (i) providing a sample comprising a DNA which is methylated at least one site, (ii) treating the DNA in the sample with a methylation-dependent nuclease, and (iii) amplifying the DNA cut using the methylation-dependent nuclease. In addition, the invention relates to kits for use in the method according to the invention. The method according to the invention can be used for selectively preparing to (selectively accumulating) non-methylated sequence segments of genomic DNA and for analysing the global methylation pattern in genomic DNA. | 03-14-2013 |
20130065777 | NANOSTRUCTURE BIOSENSORS AND SYSTEMS AND METHODS OF USE THEREOF - A sensor scheme combining nano-photonics and nano-fluidics on a single platform through the use of free-standing photonic crystals is described. By harnessing nano-scale openings, both fluidics and light can be manipulated at sub-wavelength scales. The convective flow is actively steered through the nanohole openings for effective delivery of the analytes to the sensor surface, and refractive index changes are detected in aqueous solutions. Systems and methods using cross-polarization measurements to further improve the detection limit by increasing the signal-to-noise ratio are also described. | 03-14-2013 |
20130065778 | MicroRNA Signatures Predicting Responsiveness To Anti-HER2 Therapy - The invention provides miRNA signatures and methods of making and using thereof. MiRNA signatures determine the responsiveness of HER2 expressing breast tumors to anti-HER2 treatment, such as the targeted drug therapy trastuzumab. | 03-14-2013 |
20130065779 | METHOD AND REAGENT FOR DIAGNOSIS AND/OR EVALUATION OF PROGRESSION OF GRAFT-VERSUS-HOST DISEASE - Disclosed is a method of diagnosing graft-versus-host disease, comprising measuring the level of CCL8 protein in a sample obtained from a subject as an indicator for the diagnosis or course of graft-versus-host disease. Also a diagnostic reagent for graft-versus-host disease comprising an anti-CCL8 antibody is disclosed. The method of the present invention enables diagnosis of the onset of graft-versus-host disease and monitoring of the progress, in particular, differential diagnosis between graft-versus-host disease and an infectious disease. The present invention also provides a method for treating graft-versus-host disease utilizing the anti-CCL8 antibody. | 03-14-2013 |
20130065780 | Label-Free Multiplexing Bioassays Using Fluorescent Conjugated Polymers and Barcoded Nanoparticles - Label-free, multiplexed DNA assay using fluorescent conjugated polymers as a detection probe to illustrate hybridization on metallic striped nanorods are disclosed. Different DNA capture probes are encoded by the different reflectivity of Au and Ag stripe patterns. The integration of fluorescent conjugated polymers as detection moieties with metallic striped nanorods for multiplexed detection of clinically important cancer marker proteins in an immunoassay format is also provided. | 03-14-2013 |
20130065781 | GENE SETS FOR DETECTION OF ULTRAVIOLET A EXPOSURE AND METHODS OF USE THEREOF - Ultraviolet radiation (UVR) has profound effects on human skin. However, its effects on the global transcriptome in vivo have not been well characterized. In addition, the contribution of the UVA component of UVR has not been previously assessed in vivo. Disclosed herein is the identification of sets of genes that are either up-regulated or down-regulated in response to UVA exposure. The gene sets described herein can be used to accurately identify skin samples that have been exposed to UVA and to assess the ability of a sun protection product to block the effects of UVA. | 03-14-2013 |
20130065782 | Renal Cell Carcinoma Biomarkers and Uses Thereof - The subject disclosure concerns methods for evaluation of renal cell carcinoma (RCC). Such methods include a method of determining of a diagnosis of the individual as having or not having RCC; determination of a prognosis of a future course of RCC; determination of disease burden; or determination of recurrence of RCC in an individual who had been apparently cured of RCC. The methods each involve the detection of the value of at least one biomarker of Table 1. The biomarker value is used, in some of the methods, to determine whether the individual does or does not demonstrate evidence of disease, and in another method, to determine the degree or a score indicative of the individual's extent of disease. | 03-14-2013 |
20130065783 | MICROARRAYS BASED ON ENZYME-MEDIATED SELF-ASSEMBLY - Provided herein are systems and related methods comprising (i) short stretches (e.g., 9 to 24 bases) of single-stranded nucleic acid (e.g., DNA) capture probes coated with RecA and, in some instances, bound to a solid substrate, and (ii) double-stranded nucleic acid (e.g., DNA or RNA) target(s). | 03-14-2013 |
20130065784 | MULTIPHASE MICROARRAYS AND USES THEREOF - The present invention relates to solution microarrays. In particular, the present invention relates to an aqueous 2-phase system for solution microarrays and uses thereof. Additional embodiments are described herein. | 03-14-2013 |
20130065785 | PROGNOSIS OF OESOPHAGEAL AND GASTRO-OESOPHAGEAL JUNCTIONAL CANCER - The present invention relates to a method of aiding in the prognosis of a subject with oesophageal and/or gastro-oesophageal junctional (GOJ) adenocarcinoma, the method comprising the steps of: (a) providing a sample from the subject, (b) determining the expression level of biomarkers TRIM44 and SIRT2 in said sample, and either (i) determining the expression level of biomarker PAPPS2 in said sample; or (ii) determining the expression level of biomarkers WT1 and EGFR in said sample; (c) comparing the expression level of each of said biomarkers to a corresponding reference standard, (d) determining the biomarkers of (b) whose expression is dysregulated compared to the reference standard, (e) inferring from the dysregulated biomarkers identified in (d) the prognosis of 5-year survival, wherein the greater the number of said biomarkers which are dysregulated, the greater the reduction in prognosis of 5-year survival. The invention also relates to kits, uses and devices. | 03-14-2013 |
20130065786 | METHOD FOR BREAST CANCER RECURRENCE PREDICTION UNDER ENDOCRINE TREATMENT - The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising:
| 03-14-2013 |
20130065787 | REAL TIME PCR ASSAY FOR DETECTION OF BACTERIAL RESPIRATORY PATHOGENS - Methods for detecting | 03-14-2013 |
20130065788 | ASSAY MODULES HAVING ASSAY REAGENTS AND METHODS OF MAKING AND USING SAME - We describe assay modules (e.g., assay plates, cartridges, multi-well assay plates, reaction vessels, etc.), processes for their preparation, and method of their use for conducting assays. Reagents may be present in free form or supported on solid phases including the surfaces of compartments (e.g., chambers, channels, flow cells, wells, etc.) in the assay modules or the surface of colloids, beads, or other particulate supports. In particular, dry reagents can be incorporated into the compartments of these assay modules and reconstituted prior to their use in accordance with the assay methods. A desiccant material may be used to maintain and stabilize these reagents in a dry state. | 03-14-2013 |
20130065789 | COMPOSITIONS AND METHODS FOR CLASSIFYING LUNG CANCER AND PROGNOSING LUNG CANCER SURVIVAL - The application provides methods of prognosmg, diagnosing, screening and classifying lung cancer patients into poor survival groups or good survival groups. A number of altered genomic regions have been identified that distinguish subtype of lung adenocarcinoma (ADC), specifically between bronchioloalveolar carcinoma (BAC) and invasive ADC with BAC features (AWBF), and genes and biomarkers whose expression are altered in individuals with pulmonary ADC according to different survival outcomes. The amplification and/or deletion of these genomic regions, and/or the biomarker expression profiles can be used to classify patients with ADC into a BAC group with excellent survival outcome, or an invasive ADC with BAC features group with higher risk of developing metastatic recurrence and poorer survival outcome. The application also includes kits for use in the methods of the application. | 03-14-2013 |
20130065790 | ASSAYS, COMPOSITIONS AND METHODS FOR DETECTING DRUG RESISTANT MICRO-ORGANISMS - The present invention relates to assays, compositions and methods for the detection and discrimination of specific gene sequences encoding antibiotic resistance in a sample. The nucleotide sequences encoding antibiotic resistance genes are uniquely identified. In particular, these sequences are hybridized to capture probes, enabling real-time PCR. For this purpose, the capture probes may also be covalently linked to amplification primers. Alternatively, detection of amplified products with hybridization to capture probes may be performed after amplification by hybridization to capture probes bound to a solid support such as microarrays and microspheres (beads). Finally, detection of amplification products during amplification in real-time using capture probes may be combined with detection of such amplification products after amplification using the same and/or different capture probes. | 03-14-2013 |
20130065791 | METHODS AND KITS FOR DIAGNOSING COLORECTAL CANCER - The invention pertains to a method for early detection and screening of colorectal cancer in human subjects based on RNA isolated from blood obtained from said subject. According to the invention, the abundance of at least 3, 5, 8, 30, 60, 102, 202, 55, 1002 or 1002 RNAs listed in tables 1 to 13 is measured. Using the invention, an accurate and noninvasive screening and diagnosis tool for colorectal cancer is provided with a sensitivity of at least 80% and a specificity of 85% that has high clinical utility and the potential for broad adoption. | 03-14-2013 |
20130072389 | THERANOSTIC AND DIAGNOSTIC METHODS USING SPARC AND HSP90 - Provided herein are methods and systems of molecular profiling of diseases, such as cancer. The molecular profiling can be used to provide a diagnosis, prognosis, or theranosis for the disease, such as identifying a candidate treatment. The methods can detect overexpression of SPARC and HSP90. The cancer can be, e.g., a renal cell carcinoma or an interdigitating dendritic cell sarcoma. | 03-21-2013 |
20130072390 | Methods for Synthesizing Pools of Probes - Compositions, methods and kits are disclosed for synthesizing and amplifying pools of probes using precursor oligonucleotides. In some aspects the precursor is amplified and nicking enzymes are used to separate the full length probes from the amplification products. The methods enable the preparation of single stranded DNA probes of defined sequence and length that are suitable for use in target detection assays. | 03-21-2013 |
20130072391 | COMPOSITION, KIT, AND METHOD FOR DIAGNOSING ADHD RISK - The following disclosure relates to a technology of genotyping a particular single nucleotide polymorphism (SNP) having significant association with attention deficit hyperactivity disorder (ADHD) and using the SNP genotypes for predicting the risk of ADHD. The present invention relates to providing a method of predicting ADHD risk by identifying the nucleotide of rs5508181 SNP in GIT1, which is C or T at the 24926101st residue on human chromosome 17, and a linkage disequilibrium block harboring rs5508181. Further, the present invention relates to a composition for diagnosing ADHD risk, including a probe for detecting the SNP or a primer for amplifying the chromosomal region, and a diagnosing kit having the probe immobilized on a surface thereof. Therefore, the method, the composition and the kit for diagnosing ADHD risk according to the following disclosure are useful technologies that can conveniently classify risk groups for ADHD at high sensitivity. | 03-21-2013 |
20130072392 | Compositions, Kits, and Methods for Identification, Assessment, Prevention, and Therapy of Cancer - The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human cancer. A variety of chromosomal regions (MCRs) and markers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the MCRs and/or alterations in the amount, structure, and/or activity of one or more of the markers is correlated with the presence of cancer. | 03-21-2013 |
20130072393 | PANCREATIC CANCER MARKERS, AND DETECTING METHODS, KITS, BIOCHIPS THEREOF - The present invention provides microRNAs for assessing the status of pancreatic cancer in a subject, and provides methods, kits, and biochips for detecting said microRNAs. | 03-21-2013 |
20130072394 | KETOL-ACID REDUCTOISOMERASE USING NADH - Methods for the evolution of NADPH binding ketol-acid reductoisomerase enzymes to acquire NADH binding functionality are provided. Specific mutant ketol-acid reductoisomerase enzymes isolated from | 03-21-2013 |
20130072395 | METHOD FOR EARLY DETECTION OF CANCERS - The invention includes methods for detecting the presence of a neoplastic condition by comparing a sample level of a BIF-1 to a reference, wherein a low level of BIF-1 in the sample correlates with the presence of a neoplastic condition. Another method involves determining the risk of relapse, tumor recurrence and/or metastasis by determining a sample level of a Bif-1 to a reference level of Bif-1, wherein low sample levels correlate with a likelihood of relapse, recurrence and/or metastasis. Yet another method includes detecting the presence of a pre-neoplastic condition, such as prostatic intraepithelial neoplasia. The method involves measuring a level of a Bif-1 in a sample and comparing the level of Bif-1 in the sample to a reference level of Bif-1. High levels of Bif-1 in the sample correlate with the presence of the pre-neoplastic condition. | 03-21-2013 |
20130072396 | Transplant Rejection Markers - The invention relates to the analysis and identification of genes that are regulated simultaneously in chronic kidney transplant rejection. This simultaneous regulation of genes provides a molecular signature to accurately detect, and optionally classify, chronic kidney transplant rejection. | 03-21-2013 |
20130072397 | METHODS FOR THE DIAGNOSIS AND PROGNOSIS OF A TUMOR USING BCAT1 PROTEIN - The present invention relates to methods for the diagnosis of a tumor, in particular a brain tumor, and for the estimation of a prognosis for patients afflicted with such tumor based on the determination of expression of BCAT1 in a patient sample. | 03-21-2013 |
20130072398 | Compositions And Methods For Immunodominant Antigens of Mycobacterium Tuberculosis - Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen | 03-21-2013 |
20130072399 | METHOD AND KIT FOR DISCRIMINATING BETWEEN BREAST CANCER AND BENIGN BREAST DISEASE - A method and kit are related to discriminating between breast cancer and benign breast disease by the determination of the expression level of at least one target gene including a nucleic acid sequence selected from the nucleic acid sequences set forth in SEQ ID NOs: 1, 2 or 3, 4 and 5 or 6 to obtain an expression profile for the patient, and the comparison of the expression profile of the patient with expression profiles of target genes from patients previously clinically classified as breast cancer and expression profiles of target genes from patients previously clinically classified as benign breast disease. | 03-21-2013 |
20130072400 | METHOD FOR THE DIAGNOSIS/PROGNOSIS OF COLORECTAL CANCER - The present invention relates to a method for obtaining useful data for the diagnosis, prognosis or monitoring of colorectal cancer (CRC) progression, to a method for the diagnosis of CRC, to a method for the prognosis of CRC and to a kit for carrying out said methods. | 03-21-2013 |
20130072401 | METHOD AND KIT FOR THE PROGNOSIS OF COLORECTAL CANCER - A method and kit for the prognosis of colorectal cancer where the method includes the steps of: a) obtaining a peripheral blood sample and extracting total RNA from the sample, b) contacting the total RNA with at least one reagent specific for at least one NK cell gene and no more than 25 specific reagents for 25 NK cell genes, c) determining the expression level of at least one and at most 25 NK cell genes to obtain an expression profile for the patient, d) analyzing the expression profile with expression profiles previously clinically classified as a good prognosis and as a poor prognosis, wherein if the expression profile is clustered with the poor prognosis profiles, then the patient is determined to have a poor prognosis, and if the expression profile is clustered with the good prognosis profiles, then the patient is determined to have a good prognosis. | 03-21-2013 |
20130072402 | METHOD FOR COLLECTING NUCLEATED RED BLOOD CELLS VIA DENSITY-GRADIENT CENTRIFUGATION UTILIZING CHANGES IN BLOOD CELL DENSITY - This invention provides a method for concentrating and collecting small quantities of fetal nucleated red blood cells contained in the maternal blood. The method for concentrating and collecting nucleated red blood cells from the maternal blood comprises: (i) subjecting the maternal blood to a first density-gradient centrifugation and collecting a cell fraction containing nucleated red blood cells; (ii) treating the cell fraction containing nucleated red blood cells so as to selectively changes the density of the nucleated red blood cells from that of the white blood cells; and (iii) subjecting the treated cell fraction containing the nucleated red blood cells to a second density-gradient centrifugation so as to collect a fraction containing nucleated red blood cells. | 03-21-2013 |
20130079234 | GENE EXPRESSION PROFILING OF PRIMARY BREAST CARCINOMAS USING ARRAYS OF CANDIDATE GENES - A method for predicting the sensitivity of tumor cells to an anthracycline-based chemotherapy includes determining the differential expression level of a MYBL2 gene in tumors cells. A polynucleotide library is useful to predict the sensitivity of tumor cells to an anthracycline-based chemotherapy and includes a pool of polynucleotide sequences or subsequences thereof wherein the sequences or subsequences correspond substantially to any of the polynucleotide sequences SEQ ID No: 308, SEQ ID No: 309 and/or SEQ ID No: 310 or the complements thereof. | 03-28-2013 |
20130079235 | SPLICE VARIANT SPECIFIC MESSENGER RNA TRANSCRIPTS AS BIOMARKERS OF PARKINSON'S DISEASE - The present invention provides a method and a diagnostic kit for diagnosing the presence of Parkinson's disease in a human subject. The method includes the steps of: (1) extracting RNA molecules from a blood sample of the human subject to define a test sample; (2) measuring the amount of each RNA molecule having Sequence ID Nos. 1-14 in the test sample; (3) comparing the amount of each of the RNA molecules having Sequence ID Nos. 1-14 to the amount of RNA molecules having Sequence ID Nos. 1-14 present in a control sample to determine how many of the RNA molecules of Sequence ID Nos. 1-14 are present in a significant amount in the test sample greater or less than in the control sample to define a number of biomarkers; and (4) diagnosing the presence of Parkinson's disease in the human subject if the number of biomarkers is equal to or greater than five. | 03-28-2013 |
20130079236 | SYSTEMS AND METHODS FOR MULTI-ANALYSIS - Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample. | 03-28-2013 |
20130079237 | ALLERGEN MICROARRAY - The present invention relates to a method of assessing if a subject is at risk of developing or has already developed asthma, conjunctivitis or rhinitis. The invention further relates to antigen sets for use in such methods including identifying other suitable antigens correlated with asthma, conjunctivitis or rhinitis. | 03-28-2013 |
20130079238 | METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND INVOLVED IN PAIN AS WELL AS METHODS OF DIAGNOSING ALGESIA - The present invention relates to a method of identifying a compound involved in pain, the use of Irf8 nucleic acid or Irf8 protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same. | 03-28-2013 |
20130079239 | METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND INVOLVED IN PAIN AS WELL AS METHODS OF DIAGNOSING ALGESIA - The present invention relates to a method of identifying a compound involved in pain, the use of Ifi205 nucleic acid or Ifi205 protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same. | 03-28-2013 |
20130079240 | PARTICLE QUANTIFYING SYSTEMS AND METHODS USING ACOUSTIC RADIATION PRESSURE - The present invention comprises methods and systems that use acoustic radiation pressure. | 03-28-2013 |
20130079241 | Methods for Diagnosing Prostate Cancer and Predicting Prostate Cancer Relapse - The present invention relates to methods and compositions for diagnosing prostate cancer and/or determining whether a prostate cancer patient is at increased risk of suffering a relapse, or a rapid relapse, of his cancer. It is based, at least in part, on the results of a comprehensive genome analysis on 241 prostate cancer samples (104 prostate cancer, 85 matched bloods, 49 matched benign prostate tissues adjacent to cancer, and 3 cell lines) which indicate that (i) genome copy number variation (CNV) occurred in both cancer and non-cancer tissues, and (ii) CNV predicts prostate cancer progression. | 03-28-2013 |
20130079242 | Compound Arrays for Sample Profiling - The invention provides arrays of compound for use in profiling samples. The arrays include compounds bind to components of the samples at relatively low affinities. The avidity of compounds binding to components of the samples can be increased by forming arrays such that multivalent components of the samples (e.g., antibodies or cells) can bind to more than one molecule of a compound at the same time. When a sample is applied to an array under such conditions, the compounds of the array bind to component(s) of the sample with significantly different avidities generating a profile characteristic of the sample. | 03-28-2013 |
20130079243 | Fibronectin Type III Repeat Based Protein Scaffolds with Alternative Binding Surfaces - Protein scaffolds and scaffold libraries based on a fibronectin type III (FN3) repeat with an alternative binding surface design, isolated nucleic acids encoding the protein scaffolds, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders. | 03-28-2013 |
20130079244 | METHODS OF PREDICTING PREDISPOSITION TO OR RISK OF KIDNEY DISEASE - Methods are disclosed herein for detecting a genetic predisposition to focal segmental glomerulosclerosis (FSGS) or hypertensive end-stage kidney disease (ESKD) or both in a human subject, e.g., by detecting the presence of at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. In a further embodiment, methods are disclosed for detecting resistance of a subject to a disease associated with | 03-28-2013 |
20130079245 | Biomarkers for Ulcerative Colitis and Crohn's Disease - The present invention provides compositions and their use in diagnosing ulcerative colitis, Crohn's Disease, and inflammatory bowel disease. | 03-28-2013 |
20130085074 | Antibody Categorization Based on Binding Characteristics - Methods for categorizing antibodies based on their epitope binding characteristics are described. Methods and systems for determining the epitope recognition properties of different antibodies are provided. Also provided are data analysis processes for clustering antibodies on the basis of their epitope recognition properties and for identifying antibodies having distinct epitope binding characteristics. | 04-04-2013 |
20130085075 | DIAGNOSTIC METHODS FOR LIVER DISORDERS - The present invention relates to methods of diagnosing a liver disorder in a patient, as well as methods of monitoring the progression of a liver disorder and/or methods of monitoring a treatment protocol of a therapeutic agent or regimen. The invention also relates to assay kits used in connection with the diagnostic methods described herein. | 04-04-2013 |
20130085076 | BORRELIA BURGDORFERI BACTERIAL ANTIGEN DIAGNOSIC TEST USING POLYMERIC BAIT CONTAINING CAPTURE PARTICLES - The invention relates to both a sensitive method for the capture and detection of low-abundance | 04-04-2013 |
20130085077 | MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Prostate Related Disorders - Methods and compositions for the diagnosis, prognosis and/or treatment of prostate associated disorders are disclosed. | 04-04-2013 |
20130085078 | Hydrolysis Probes - Methods and compositions for the detection and quantification of nucleic acids are provided. In one embodiment, a sample is contacted with a primer complementary to a first region of a target nucleic acid and a probe complementary to a second region of the target nucleic acid downstream of the first region under conditions suitable for hybridization of the target nucleic acid with the primer and the probe. The probe in this embodiment comprises a fluorophore and is attached to a solid support. The hybridized probe is cleaved with a nucleic acid polymerase having exonuclease activity to release the reporter from the solid support. The presence of the target nucleic acid is then detected and optionally quantified by detecting a decrease in signal from the reporter on the solid support. | 04-04-2013 |
20130085079 | Cardiovascular Risk Event Prediction and Uses Thereof - The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the evaluation of risk of a caradiovascular (CV) Event within 5 years. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to evaluate risk of a CV event within 5 years. In another aspect, methods are provided for evaluating risk of a CV event within 5 years in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1. In a further aspect, methods are provided for evaluating the risk of a CV, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 2. In a further aspect, methods are provided for evaluating the risk of a CV event in an individual, generally within 5 years, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 3. | 04-04-2013 |
20130085080 | PREDICTING CANCER OUTCOME - This document provides methods and materials related to assessing prostate cancer in mammals. For example, this document provides nucleic acids and polypeptides that can be analyzed to determine whether a male mammal having prostate cancer is susceptible to a good or poor outcome. | 04-04-2013 |
20130085081 | RISK PREDICTION OF DEVELOPING DRUG-INDUCED LUNG INJURY AND DETECTION METHOD AND KIT OF GENE FOR RISK PREDICTION - Disclosed are a method of detecting the presence or absence of a single nucleotide polymorphism of a gene, for prediction of the risk of developing drug-induced lung injury, or for improving a therapeutic method, and a kit for carrying out the detection method. The detection method is characterized by comparing an ABCB1 gene in a biological sample with a wild-type ABCB1 gene to detect the presence or absence of a single nucleotide polymorphism in the ABCB1 gene in the biological sample, in particular, by determining the nucleotide at position 3751 of the CDS of the ABCB1 gene. The kit comprises an oligonucleotide probe which specifically binds to a single nucleotide polymorphism in an ABCB1 gene under selective binding conditions, or an oligonucleotide primer which amplifies a nucleic acid sequence comprising a single nucleotide polymorphism in an ABCB1 gene. | 04-04-2013 |
20130085082 | METHODS FOR HAPLOTYPING SINGLE CELLS - We developed a generic approach to type genome-wide single nucleotide polymorphisms in single human cells and to reconstruct for the first time genome-wide haplotypes of single- or dual-cell derived genotypes. Proof-of-principle is delivered for EBV-transformed lymphoblastoid cells as well as human blastomeres. To this end, multiple displacement amplified DNA samples of single cells were hybridized to Affymetrix 250K SNP-arrays. Different algorithmic designs were subsequently developed to assess from the single-cell derived SNP-probe intensities the sequence of syntenic alleles and to pinpoint accurately the majority of parental homologous recombination sites across the entire genome using a linkage-based approach. This included the development of algorithms that rectify a large part of the discrepant allelic assignments in raw single or dual-cell derived haplotypes. This method to infer genome-wide haplotypes from the analysis of only one or two cells has tremendous applicative value. It has the capacity to revolutionize not only genetic diagnosis of preimplantation in vitro fertilized human embryos in the clinic, but also animal breeding programs by enabling genome-wide quantitative trait loci selection at the embryonic level. In addition, it allows to further scrutinize drivers of haplotype diversity, mainly meiotic homologous recombination as well as somatic (homologous) recombination processes that occur often during (human) tumorigenesis. | 04-04-2013 |
20130090251 | Tumour Markers - A method of determining the immune response of a mammal to circulating tumour marker proteins is described in which a sample of bodily fluid, for example plasma or serum, is contacted with a panel of two or more distinct tumour marker antigen. The presence of complexes between the tumour marker antigens and any autoantibodies to the antigens present in the sample are detected and provide an indication of an immune response to a circulating tumour marker protein. The method is useful for the diagnosis of cancer, particularly for identifying new or recurrent cancer in an otherwise assymptomatic patient. | 04-11-2013 |
20130090252 | Quantitative, Highly Multiplexed Detection of Nucleic Acids - This invention provides methods of detecting and quantifying target nucleic acids in samples in multiplexed single chamber reactions. Consumables incorporating chambers optimized to reduce signal background proximal to high efficiency arrays are provided, as well as methods of use. Devices and systems configured to use the consumables to practice the methods are a feature of the invention. | 04-11-2013 |
20130090253 | ACCURATE QUANTITATION OF BIOMARKERS IN SAMPLES - Methods and apparatus for the accurate quantitation of biomarkers in dried blood spots (DBS), including providing a substrate comprising at least one DBS, wherein the DBS comprises at least one biomolecule distributed on the substrate in a gradient pattern; excising at least one sector-shaped sample from the DBS; and assaying the biomolecule in the sector-shaped sample. | 04-11-2013 |
20130090254 | GENE-EXPRESSION PROFILING WITH REDUCED NUMBERS OF TRANSCRIPT MEASUREMENTS - The present invention provides compositions and methods for making and using a transcriptome-wide gene-expression profiling platform that measures the expression levels of only a select subset of the total number of transcripts. Because gene expression is believed to be highly correlated, direct measurement of a small number (for example, 1,000) of appropriately-selected transcripts allows the expression levels of the remainder to be inferred. The present invention, therefore, has the potential to reduce the cost and increase the throughput of full-transcriptome gene-expression profiling relative to the well-known conventional approaches that require all transcripts to be measured. | 04-11-2013 |
20130090255 | Biological Markers of Chronic Wound Tissue and Methods of Using for Criteria in Surgical Debridement - The present invention relates to methods for identifying tissue sites in a chronic wound that are suitable for debridement and whether debridement procedure has been successful using particular biological markers of the cells within the tissue sites of the chronic wounds. | 04-11-2013 |
20130090256 | BIOMARKERS FOR EARLY DETECTION OF OVARIAN CANCER - Biomarker proteins that can be used in the diagnosis of early-stage ovarian cancer (OC) are described. The biomarker panels not only permit the distinction of patients with ovarian neoplasia (benign or malignant) from normal subjects, but they also allow the identification of patients with early-stage (stage I/II) ovarian cancer from those patients with benign ovarian tumors or normal individuals. The invention additionally provides methods for detecting and treating various cancers, including cancer of the ovary using OC-related molecules. | 04-11-2013 |
20130090257 | PATHWAY ANALYSIS FOR PROVIDING PREDICTIVE INFORMATION - A method for assigning ranking scores to pathways in a set of pathways for classifying patients is disclosed. The method comprises the steps of comparing biomolecular datasets from different groups of patients and performing an analysis in order to assign ranking scores to pathways in a set of pathways. Furthermore, a method for using cancer pathway evaluation to support clinical decision making is disclosed. This assessment is further used for stratifying ovarian cancer patients based on chemosensitivity to platinum based drugs, the standard chemotherapy. We present the method for evaluation and ranking of the most relevant pathways responsible for platinum sensitivity. Clinical decision support software system should be able to then visualize this information for a clinician, contextualize it within a patient data set and help make a final decision on the potential responsiveness. | 04-11-2013 |
20130090258 | METHOD FOR DETECTING COLORECTAL TUMOR - An object of the present invention is to provide a method for detecting a colorectal tumor, and particularly advanced adenoma and early cancer, by using a component contained in stool as an indicator. | 04-11-2013 |
20130090259 | IMPROVED METHOD FOR SELECTING HIGH PRODUCING CELL LINES - The invention provides methods for the rapid identification and selection of cell lines suitable for biopharmaceuticals production, which do no utilize animal derived components. | 04-11-2013 |
20130090260 | Multiplexed Assay Using Spectrally-Encoded Solid Support Matrices - In a multiplexed assay, each molecule of a plurality of molecules is attached to a support matrix particle with a substrate adapted for attachment and/or synthesis of molecules. A spectrally-encoded identifier embodied in a photochemical medium is embedded or encased within the substrate to uniquely identify the molecule attached to the substrate. The molecules are exposed to one or more processing conditions, and then placed within the path of an optical detector adapted to read the spectrally-encoded identifier and measure biochemical activity on each support matrix particle. The measured biochemical activity is associated with the unique identity of the support matrix particle and, hence, with the molecule attached to the particle. | 04-11-2013 |
20130090261 | Device for Determining or Studying the State of Stimulation of the Natural Defences of Plants or Portions of Plants - The present invention relates to a device for determining or studying the state of stimulation of the natural defenses of plants or plant portions, which plants advantageously belong to the Rosaceae family. The corresponding device includes means for determining the expression level, in a sample of plants or plant portions, of at least one target gene in each of the following groups (a) to (i): | 04-11-2013 |
20130096018 | METHOD FOR PREDICTING THE SURVIVAL STATUS AND PROGNOSIS OF ESOPHAGEAL CANCER AND A KIT THEREOF - The present invention provides a method for predicting the survival rate and prognosis of esophageal carcinoma patients, which is characterized in examining the expression level of a specific gene, peptidase inhibitor 3 (PI3) or CD14 antigen (CD14) in a sample, and comparing to the average expression level of said specific gene from patients to determine the survival and prognosis status for esophageal cancer. The present invention further provides a kit for predicting the survival rate and prognosis of esophageal carcinoma patients. | 04-18-2013 |
20130096019 | Fibronectin Type III Domain Based Scaffold Compositions, Methods and Uses - A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG have been identified as useful for diagnostic and/or therapeutic applications. | 04-18-2013 |
20130096020 | GENERATION OF BINDING MOLECULES - Provided are methods for efficiently and comprehensively screening antibody repertoires from B cells to obtain and produce molecules with binding characteristics and functional activities for use in human therapy. | 04-18-2013 |
20130096021 | RECURRENT GENE FUSIONS IN BREAST CANCER - The present disclosure relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure relates to gene fusions as diagnostic markers and clinical targets for breast cancer. | 04-18-2013 |
20130096022 | Methods and Materials Related to Ovarian Cancer - Described herein are methods for diagnosing ovarian cancer. In particular, certain microRNAs are useful to the response to chemotherapy of ovarian cancer patients. | 04-18-2013 |
20130096023 | Hepcidins as Biomarkers for Impending Lupus Nephritis Flare - Biomarkers for determining a kidney flare episode in systemic lupus erythematosus are described. | 04-18-2013 |
20130096024 | METHOD FOR DETECTING THE SUSCEPTIBILITY TO DEVELOP ADVERSE SIDE EFFECTS RELATED TO BIOIMPLANTS - An in vitro method for the analysis of the genetic predisposition of an individual to develop adverse effects related to non-metallic materials implanted into the body. The method comprises determining if in a biological sample from an individual there is/are present the antigen/s HLA-B*08 and/or HLA-DRB1*03 of the major histocompatibility complex. The use of a kit for carrying out the determination and the use of the antigens as genetic markers is also disclosed. | 04-18-2013 |
20130096025 | MOLECULAR CLASSIFICATION OF MULTIPLE MYELOMA - The present invention is in the field of molecular diagnostics and relates to a method for classifying samples obtained from patients diagnosed with multiple myeloma into three newly defined clusters. The invention also relates to a method for determining the prognosis of an individual diagnosed with multiple myeloma as well as a method for the prediction of the response to treatment of an individual diagnosed with multiple myeloma. | 04-18-2013 |
20130096026 | METHODS AND COMPOSITIONS FOR THE ASSESSMENT OF DRUG RESPONSE - The present invention provides methods for predicting or determining a subject's response to an antiplatelet agent, and methods for determining a subject's suitability to a treatment regime or intervention for a disease associated with platelet aggregation, using analysis of genetic polymorphisms. The present invention also relates to the use of genetic polymorphisms in assessing a subject's response to an antiplatelet agent. Nucleotide probes and primers, kits, and microarrays suitable for such assessment are also provided | 04-18-2013 |
20130096027 | RIBONUCLEOTIDE TAG NUCLEIC ACID DETECTION - The present application provides polynucleotides comprising 5′-tails with sequence segments useful for the detection of target nucleic acid sequences, and methods for their use in detecting target nucleic acids. The polynucleotides are used to amplify a subsequence of a target nucleic acid in the presence of one or more ribonucleotides. The ribonucleotides are incorporated into amplification products at regular intervals complementary to the 5′-tail sequence segments. Cleavage of amplification products at the bond immediately 3′ to incorporated ribonucleotides produces detectably distinct fragments indicative of the presence or absence of a target nucleic acid. | 04-18-2013 |
20130096028 | CELL CAPABLE OF EXPRESSING TSLP CONSTANTLY AND AT HIGH LEVEL, AND METHOD FOR SCREENING FOR TSLP MODULATOR UTILIZING THE CELL - The present invention relates to a mouse epithelial cell line constantly producing TSLP and use thereof. More specifically, the present invention relates to a method for screening for a TSLP modulator using a mouse epithelial cell line (KCHM-1) constantly producing TSLP, and a method for producing wild-type TSLP using the cell line. | 04-18-2013 |
20130102481 | Fluorescence Scanning Head With Multiband Detection - In a scanning system for the detection and discrimination of a plurality of targets in each of a plurality of samples, one or more multiband fluorescence detection channels each of which contains a single multiband emission filter and a single detector replaces multiple detection components in scanning heads of the prior art. In certain embodiments, a single multi-emitter light source is used as well, to illuminate each sample with excitation light at a variety of distinct wavelengths in succession. | 04-25-2013 |
20130102482 | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF BREAST AND OVARIAN CANCER - The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided. | 04-25-2013 |
20130102483 | METHODS FOR THE ANALYSIS OF BREAST CANCER DISORDERS - The present invention relates to methods, arrays and computer programs for assisting in classifying breast cancer diseases. In particular the invention relates to classifying breast cancer disorders by determining the methylation status of one or more sequences according to SEQ ID NO: 1-111. The classification may be further strengthened by also taking the expression levels of one or more proteins into account. | 04-25-2013 |
20130102484 | METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF - The present invention relates generally to the identification of biomarkers of conditions including disease and non disease conditions as well as identifying compositions of biomarkers. The invention further provides a method of diagnosing disease, monitoring disease progression, and differentially diagnosing disease. The invention further provides for kits useful in diagnosing, monitoring disease progression and differentially diagnosing disease. | 04-25-2013 |
20130102485 | Method of Determining a Diseased State in a Subject - A method includes a step of identifying candidate miRNA-mRNA complexes where an mRNA sequence from a set of mRNA sequences stably hybridizes to a miRNA from a set of miRNA sequences. The candidate miRNA-mRNA complexes have stably hybridizing sub-regions of a downstream region to portions of a 5′ miRNA section and stably hybridizing sub-regions of an upstream region to portions of a 3′ miRNA section. Candidate mRNA and/or miRNA sequences are identified as sequences that form candidate microRNA-mRNA complexes. Differences between expression levels between candidate mRNA and/or miRNA sequences in subjects having a disease and subjects not having the disease are determined for each candidate mRNA and/or miRNA sequence to identify candidate mRNA sequences and/or miRNA sequences. The expression levels of each candidate RNA disease markers are compared to controls such that deviation of expression levels of the candidate RNA disease markers from the controls indicates presence of the disease. | 04-25-2013 |
20130102486 | PERP AS A PROGNOSTIC AND DIAGNOSTIC MARKER FOR DYSPLASIA AND CANCER - Methods for prognosis and diagnosis of dysplasia and cancer are disclosed. In particular, the invention relates to the use of the biomarker PERP, a desmosome protein involved in cell adhesion and apoptosis, for aiding diagnosis, prognosis, and treatment of dysplasia and cancer. | 04-25-2013 |
20130102487 | PLASMA MICRORNAS FOR THE DETECTION OF EARLY COLORECTAL CANCER - The present invention relates in general to the field of colorectal cancer detection, and more particularly, to plasma microRNAs for the detection of early colorectal cancer. Specifically, the present invention includes methods, kits and biomarkers for diagnosing or detecting colorectal neoplasia in a human subject comprising the steps of: A method for diagnosing or detecting colorectal neoplasia in a human subject comprising the steps of: obtaining one or more biological samples from the subject suspected of suffering from colorectal neoplasia; measuring an overall expression pattern or level of one or more microRNAs obtained from the one or more biological samples of the subject; and comparing the overall expression pattern of the one or more microRNAs from the biological sample of the subject suspected of suffering from colorectal neoplasia with the overall expression pattern of the one or more microRNAs from a biological sample of a normal subject, wherein the normal subject is a healthy subject not suffering from colorectal neoplasia, wherein overexpression of a combination of miR19a and miR19b, or miR19a and miR19b and miR15b is indicative of colorectal cancer. | 04-25-2013 |
20130102488 | Methods of Detecting Cervical Cancer - Methods of detecting cervical dysplasia, such as cervical dysplasia likely to progress to carcinoma in a sample of human cervical cells, are provided. Methods of detecting changes in expression of one or more microRNAs or mRNAs associated with cervical dysplasia or cervical cancer are also provided. Compositions and kits are also provided. | 04-25-2013 |
20130102489 | SYSTEMS AND METHODS FOR HIGH-THROUGHPUT DETECTION OF AN ANALYTE IN A SAMPLE - Provided are high-throughput detection systems. The systems include a magnetic sensor device, a magnetic field source and a reservoir plate that includes a plurality of fluid reservoirs. The magnetic sensor device includes a support with two or more elongated regions each having a magnetic sensor array disposed at a distal end. Also provided are methods in which the subject high-throughput detection systems find use. | 04-25-2013 |
20130102490 | METHOD FOR COUNTING CHROMATID COPY NUMBERS IN A SINGLE CELL - The present invention provides a method for counting the absolute copy number of a nucleic acid sequence in a cell, which comprises the following steps: (i) dividing a lysate of the cell or a lysate of a sample of the cell into a plurality aliquots: (ii) providing conditions suitable for the amplification of the nucleic acid sequence in each aliquot: (iii) counting the number of aliquots in which the nucleic acid was amplified in step (ii) and directly deducing the copy number of the nucleic acid sequence in a cell. The method may be used to count chromatid copy number, for example to investigate the ploidy of a cell such as an oocyte or an embryo-derived cell. | 04-25-2013 |
20130102491 | METHOD FOR THE DIAGNOSIS OF TUBERCULOSIS - A method for the diagnosis of a tuberculosis infection caused by Mycobacteria belonging to the Mycobacteria tuberculosis complex group (MTC) in an animal including a human being, which comprises in vitro-detection of cell-mediated immune response to OmpAtb and/or antibodies against OmpAtb in a sample taken from that animal. | 04-25-2013 |
20130102492 | GENE EXPRESSION MARKERS FOR COLORECTAL CANCER PROGNOSIS - A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject. | 04-25-2013 |
20130102493 | GENE EXPRESSION ANALYSES FOR CHARACTERIZING AND IDENTIFYING GENOTOXIC COMPOUNDS - The invention relates to a method for screening compounds with (pro-)genotoxic activity by providing a cellular system being capable of expressing at least a panel of 11 defined genes, incubating at least a portion of the system with compounds to be screened, and comparing the expression of the genes in the system with the gene expression in a control cellular system, thereby detecting the (pro-)genotoxic activity. Another object of the invention concerns a method for monitoring physiological and/or pathological conditions, which are caused, mediated and/or propagated by the genetic deregulation of proliferation, differentiation and/or damage repair, by administering an effective amount of at least a single (pro-)genotoxic compound to a mammal in need of such treatment and determining an expression of 11 defined genes in a biological sample withdrawn from the mammal. The invention also relates to arrays for screening compounds with (pro-)genotoxic activity comprising nucleic acid probes that specifically hybridize under stringent conditions with the marker genes of Table 1, FIG. | 04-25-2013 |
20130102494 | NOVEL ANTIBODY FOR THE DIAGNOSIS AND/OR PROGNOSIS OF CANCER - The present invention relates to the field of prognosis and/or diagnosis of a proliferative disease in a patient. More particularly, the invention relates to novel antibodies capable of binding specifically to the human cMet receptor, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of said antibodies, and corresponding process, for detecting and diagnosing pathological hyperproliferative oncogenic disorders associated with expression of cMet. In certain embodiments, the disorders are oncogenic disorders associated with increased expression of cMet polypeptide relative to normal or any other pathology connected with the over expression of c Met. The invention finally comprises products and/or compositions or kits comprising at least such antibodies for the prognosis or diagnostic of certain cancers. | 04-25-2013 |
20130109580 | High-Affinity Peptide Probes for Tumor Biomarker, GRP-78, and Screening Method Thereof | 05-02-2013 |
20130109581 | POSITIVELY CHARGED SPECIES AS BINDING REAGENTS IN THE SEPARATION OF PROTEIN AGGREGATES FROM MONOMERS | 05-02-2013 |
20130109582 | METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND INVOLVED IN PAIN AS WELL AS METHODS OF DIAGNOSING ALGESIA | 05-02-2013 |
20130109583 | METHODS AND DEVICES FOR ASSESSING RISK TO A PUTATIVE OFFSPRING OF DEVELOPING A CONDITION | 05-02-2013 |
20130109584 | Hypermethylation Biomarkers for Detection of Cervical Cancer | 05-02-2013 |
20130109585 | MICROARRAYS | 05-02-2013 |
20130109586 | GENERATION OF ANTIBODIES TO AN EPITOPE OF INTEREST THAT CONTAINS A PHOSPHOMIMETIC AMINO ACID | 05-02-2013 |
20130109587 | USP2A PEPTIDES AND ANTIBODIES | 05-02-2013 |
20130109588 | DETECTION OF TARGET NUCLEIC ACID SEQUENCES BY PTO CLEAVAGE AND EXTENSION ASSAY | 05-02-2013 |
20130109589 | SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH AMYOTROPHIC LATERAL SCLEROSIS | 05-02-2013 |
20130109590 | ISOLATING A TARGET ANALYTE FROM A BODY FLUID | 05-02-2013 |
20130109591 | PLANAR SUPPORT HAVING AN ULTRAFLAT SURFACE AND A DEVICE FOR DETECTING ANTIGENS COMPRISING SAID PLANAR SUPPORT | 05-02-2013 |
20130116131 | METHODS AND MATERIALS FOR THE DIAGNOSIS OF PROSTATE CANCERS - Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in a biological sample obtained from the subject and comparing the levels of expression with predetermined threshold levels. Levels of expression of at least two of the polypeptide markers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Determination of the expression levels of specific combinations of biomarkers can also be used to determine the type and/or stage of prostate cancer. | 05-09-2013 |
20130116132 | ALZHEIMER'S PROBE KIT - Oligonucleotide probes for use in assessing gene transcript levels in a sample, which may be used in analytical techniques, particularly diagnostic techniques, are disclosed. Conveniently the probes are provided in kit form. Different sets of probes may be used in techniques to prepare gene expression patterns and identify, diagnose or monitor neurodegenerative diseases or conditions and their progression. | 05-09-2013 |
20130116133 | METHODS AND MATERIALS FOR THE DIAGNOSIS OF PROSTATE CANCERS - Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in a biological sample obtained from the subject and comparing the levels of expression with predetermined threshold levels. Levels of expression of at least two of the polypeptide markers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Determination of the expression levels of specific combinations of biomarkers can also be used to determine the type and/or stage of prostate cancer. | 05-09-2013 |
20130116134 | METHOD AND KIT FOR THE CLASSIFICATION AND PROGNOSIS OF WOUNDS - The invention relates to a method and kit for identifying chronic or acute mammalian wound tissue or for determining the prognosis of mammalian wound tissue based upon the identification of at least one key set of molecular markers or genes whose expression pattern is indicative of a given wound type and so representative of a given prognosis. | 05-09-2013 |
20130116135 | Methods, Kits and Reagents for Diagnosing, Alding Diagnosis and/or Monitoring Progression of a Neurological Disorder - The present inventors have identified a panel of biomarkers present in a biological sample of an individual (e.g. blood, including serum or plasma) whose concentrations or levels are altered in individuals with a neurological disorder. Accordingly, changes in the level of any one or more of these biomarkers can be used to assess cognitive function, to diagnose or aid in the diagnosis of a neurological disorder and/or to monitor a neurological disorder in a patient (e.g., tracking disease progression in a patient and/or tracking the effect of medical or surgical therapy in the patient). Changes in the level of any one or more of these biomarkers can also be used to stratify a patient (i.e., sorting an individual with a probable diagnosis of a neurological disorder or diagnosed with a neurological disorder into different classes of the disorder) and diagnosing or aiding in the diagnosis of mild cognitive impairment (MCI) as well as diagnosing or aiding in the diagnosis of cognitive impairment. | 05-09-2013 |
20130116136 | PROBES FOR GENOTYPING LOW-RISK-HPV - The current invention is concerned with a composition comprising at least one probe oligonucleotide each for the nucleotide sequences of the invention, said probe oligonucleotides specifically hybridizing to the sense strand or the antisense strand of said nucleotide sequences. Moreover, the present invention relates to a method for the identification of low-risk HPV types in a sample comprising the steps of a) contacting a sample with an amplification composition allowing amplification of at least one region of the HPV genome specifically hybridizing to at least one of the probe oligonucleotides of the current invention under conditions which allow for the amplification of polynucleotides and b) identifying low-risk HPV genotypes in said sample based on the amplified polynucleotides obtained in step a) by hybridizing the amplified polynucleotides with at least one labelled probe oligonucleotide of the current invention while said amplified polynucleotides are present in the same reaction container. The invention also relates to the use of a composition of the current invention for identifying low-risk HPV hi a sample and to a kit comprising the composition of the invention and/or adopted for carrying out the method of the invention and an instruction manual. | 05-09-2013 |
20130116137 | CANTILEVERED PROBE DETECTOR WITH PIEZOELECTRIC ELEMENT - A disclosed chemical detection system for detecting a target material, such as an explosive material, can include a cantilevered probe, a probe heater coupled to the cantilevered probe, and a piezoelectric element disposed on the cantilevered probe. The piezoelectric element can be configured as a detector and/or an actuator. Detection can include, for example, detecting a movement of the cantilevered probe or a property of the cantilevered probe. The movement or a change in the property of the cantilevered probe can occur, for example, by adsorption of the target material, desorption of the target material, reaction of the target material and/or phase change of the target material. Examples of detectable movements and properties include temperature shifts, impedance shifts, and resonant frequency shifts of the cantilevered probe. The overall chemical detection system can be incorporated, for example, into a handheld explosive material detection system. | 05-09-2013 |
20130116138 | PEPTIDE DOMAINS THAT BIND SMALL MOLECULES OF INDUSTRIAL SIGNIFICANCE - Described herein are small peptide domains and consensus sequences that bind small target molecules of industrial importance, e.g., metals such as nickel, β carotene, and isoflavones such as genistein. Also described are fusion proteins containing such binding domains fused to proteins or to peptide domains like GST or GBD that bind other ligands and can be used to immobilize the target binding domain on a support. One class of fusion proteins that is useful in industrial settings are fusions that contain concatemers of target binding domains, which increases the binding equivalents per molecule. | 05-09-2013 |
20130116139 | INNATE IMMUNITY MARKERS OF CANCER - This invention relates generally to methods of determing if a subject has a genetic predisposition to cancer, e.g., prostate cancer and breast cancer. | 05-09-2013 |
20130116140 | METHODS AND MATERIALS FOR DETERMINING THE EFFICACY OF PROSTATE CANCER THERAPIES - Methods for monitoring, and determining the efficacy of, a treatment for prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in biological samples obtained from the subject prior to, and during, a course of treatment. Specific patterns of changes in the expression of the polypeptide biomarkers are indicative of the effectiveness of the treatment in the subject. | 05-09-2013 |
20130116141 | Systems and Methods for Multiplex Analysis of PCR in Real Time - The present invention provides methods and systems for real-time measurements of PCR with multiplexing capability. Certain embodiments relate to methods and systems that use fluorescently encoded superparamagnetic microspheres for the immobilization of amplification products during the PCR process, and an imaging chamber of a measurement device that is also capable of controllable thermal cycling for assisting the PCR process. | 05-09-2013 |
20130116142 | METHODS AND MATERIALS FOR THE DIAGNOSIS OF PROSTATE CANCERS - Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in a biological sample obtained from the subject and comparing the levels of expression with predetermined threshold levels. Levels of expression of at least two of the polypeptide markers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Determination of the expression levels of specific combinations of biomarkers can also be used to determine the type and/or stage of prostate cancer. | 05-09-2013 |
20130116143 | DETECTION AND ANALYSIS OF EPIGENETIC AND GENETIC CHANGES IN TUMOR TISSUE - The invention generally relates to a novel method and related compositions for detecting and analyzing cancer. More particularly, the invention relates to unique methods, compositions and assays useful for diagnosing and measuring the presence and/or risk of ovarian cancer involving the utilization of various generic and epigenetic biomarkers. | 05-09-2013 |
20130116144 | METHYLATION MARKER FOR DIAGNOSIS OF CERVICAL CANCER - The present invention relates to a cervical cancer-specific methylation marker for diagnosis of cervical cancer, and more particularly, to a cervical cancer-specific methylation marker, the CpG island region of which is methylated specifically in cervical cancer cells. The use of the kit and nucleic acid chip for diagnosis of cervical cancer of the present invention enables diagnosis of cervical cancer at an initial transformation stage, thus making it possible to diagnose cervical cancer at an early stage. In addition, the invention makes it possible to predict progression for high-risk groups and screen cervical cancer in a more accurate and rapid manner compared to conventional methods. | 05-09-2013 |
20130116145 | DIAGNOSIS AND PROGNOSIS OF BREAST CANCER PATIENTS - The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein. | 05-09-2013 |
20130116146 | Peptide Microarray and Method of Use - A peptide microarray comprising a plurality of predicted unique binding peptides being selected by computational prediction of interaction with a protein of interest or a domain thereof. The selected unique binding peptides are pre-synthesized and then printed and/or immobilized onto a solid support surface via N-terminus with a linker. Methods of using the invention peptide microarray for quantitative determination of protein-peptide interaction, epitope mapping, and drug screening are also provided. | 05-09-2013 |
20130116147 | DNA METHYLATION BIOMARKERS FOR LUNG CANCER - The present invention relates to the identification of novel DNA biomarkers and the use of the aberrant methylation patterns of the biomarkers to diagnose a disease or a condition (e.g., a cancer) associated therewith. In particular, the present invention relates to the use of the novel DNA biomarkers to diagnose lung cancers, e.g., squamous cell carcinomas and adenocarcinomas. | 05-09-2013 |
20130116148 | LIVER DISEASE MARKER, METHOD AND APPARATUS FOR MEASURING THE SAME, AND METHOD FOR ASSAYING PHARMACEUTICAL PREPARATION - Disclosed is a method for promptly identifying a liver disease. A normal person or a liver disease such as drug-induced liver injury, asymptomatic hepatitis B carrier, chronic hepatitis B, hepatitis C with persistently normal ALT, chronic hepatitis C, cirrhosis type C, hepatocellular carcinoma, simple steatosis, or non-alcoholic steatohepatitis is identified by measuring the concentration of a γ-Glu-X (wherein X represents an amino acid or an amine) peptide or the level of AST or ALT in blood and carrying out, for example, a multiple logistic regression based on the measured value. | 05-09-2013 |
20130116149 | Genetic Markers Associated with Intellectual Disability - Genetic markers associated with intellectual disability as well as compositions, methods and kits for screening for genetic markers intellectual disability, diagnosing intellectual disability and identifying individuals with a predisposition for offspring suffering from intellectual disability are provided. | 05-09-2013 |
20130116150 | Lung Cancer Biomarkers and Uses Thereof - The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of lung cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose lung cancer or permit the differential diagnosis of pulmonary nodules as benign or malignant. In another aspect, methods are provided for diagnosing lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 18, Table 20, or Table 21, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value. | 05-09-2013 |
20130116151 | BIOMARKER FOR HYPERTENSIVE DISORDERS OF PREGNANCY - The application discloses a new tool for predicting, diagnosing and prognosing hypertensive disorders of pregnancy and particularly preeclampsia; methods for the diagnosis, prediction, prognosis and/or monitoring said disorders; and kits and devices for measuring said biomarker and/or performing said methods. | 05-09-2013 |
20130123121 | Methods and/or Use of Oligonucleotide-Bead Conjugates for Assays and Detections - The present disclosure is directed to methods and/or uses of oligonucleotide-bead conjugates for assays and detections and related systems and/or kits. Certain methods are directed to a method for detecting one or more biological targets of a sample in a detection assay, comprising: providing a molecular probe, comprising a binding moiety and an oligonucleotide sequence, to a sample comprising one or more biological targets; binding the one or more biological targets with the binding moiety; providing a detectable component to the sample, wherein the detectable component comprises a signal generating moiety conjugated to an oligonucleotide sequence complementary to the oligonucleotide sequence of the molecular probe; hydridizing the oligonucleotide sequence of the target-bound molecular probe to the detectable component; and detecting a signal generated from the hydridized detectable component. Various other embodiments, applications etc. are disclosed herein. | 05-16-2013 |
20130123122 | SECRETED PROTEINS AND USES THEREOF - The invention provides isolated nucleic acid molecules, designated TANGO 228 nucleic acid molecules, which encode secreted proteins with homology to the rat MCA-32 protein, isolated nucleic acid molecules, designated TANGO 240 nucleic acid molecules, which encode secreted proteins with homology to the | 05-16-2013 |
20130123123 | RNA Interactome Analysis - A method of sample analysis is provided. In certain cases, the method comprises: a) cross-linking the contents of a cell using a heat stable crosslinking agent to produce cross-linked ribonucleotide complexes; b) fragmenting the cross-linked ribonucleotide complexes to produce complexes comprising protein, RNA fragments and, optionally, genomic DNA fragments; c) contacting the complexes with a plurality of non-overlapping oligonucleotides comprise an affinity tag and that are complementary to a specific target RNA of the cell under high stringency conditions that include high temperature; d) isolating complexes that contain the oligonucleotides using the affinity tag to produce isolated complexes; e) enzymatically releasing the protein, RNA fragments and/or the genomic DNA fragments from the isolated complexes to produce a released component, without reversing the crosslinking; and f) analyzing the released component. | 05-16-2013 |
20130123124 | METHODS AND COMPOSITIONS FOR CHARACTERIZING AUTISM SPECTRUM DISORDER BASED ON GENE EXPRESSION PATTERNS - The invention relates to methods and kits for characterizing and diagnosing autism spectrum disorder in an individual based on gene expression levels. | 05-16-2013 |
20130123125 | Identification Method of Species of Diatoms in Coast of Korea, and Polynucleotide Probe, DNA Chip and Kit for Identification of Species of Diatoms According to Same - Disclosed is a method for identifying the species of diatoms found in the coastal area of Korea, a polynucleotide probe, a DNA chip and a kit used for identifying the diatom species. The method includes obtaining a PCR product by performing a PCR reaction using the DNA extracted from diatoms, binding the PCR product respectively to a probe which is the same as or complementary to one or more of the nucleotide sequences selected from SEQ. ID. NOs: 3˜51, and identifying the species of a given diatom based on the result of the above binding. More importantly, the present invention enables to identify a given diatom species by analyzing the genotypes of various diatom species found in the coastal area of Korea based on their SNPs in a convenient, fast and accurate way. | 05-16-2013 |
20130123126 | SELECTION AND USE OF HOST CELLS FOR PRODUCTION OF GLYCOPROTEINS - A method of making a glycoprotein having a selected glycostructure. | 05-16-2013 |
20130123127 | MICROARRAYS AND USES THEREOF - Methods of using microarrays to simplify analysis and characterization of genes and their function are provided. Such methods can be used to identify and characterize antibodies having binding affinity for a specific target antigen. A method of determining gene expression at the protein level by contacting an array of characterized or uncharacterized antibodies on a solid surface with one or more proteins and identifying the antibodies to which said protein(s) binds also is provided. This method can be used to compare the protein expression in two different populations of cells, such as normal cells and cancer cells or resting cells and stimulated cells. In addition, a method of determining gene expression at the protein level by contacting a microarray of nucleic acid samples derived from a variety of different sources with one or more nucleic acid probes then identifying the sample or samples to which the probe binds is provided. | 05-16-2013 |
20130123128 | METHOD FOR THE DETECTION OF SCHIZOPHRENIA RELATED GENE TRANSCRIPTS IN BLOOD - The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using gene-specific and/or tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 05-16-2013 |
20130123129 | USE OF DNAZYMES FOR ANALYSIS OF AN RNA SAMPLE - Provided herein is method comprising: contacting an initial RNA sample containing a population of different RNA molecules with a divalent cation and a set of DNAzymes that are designed to cleave multiple target RNAs in the initial sample, thereby producing a product RNA sample that comprises: a) uncleaved RNA molecules and b) cleaved RNA fragments that contain a 2′,3′-cyclic-phosphate and a 5′ hydroxyl as the result of DNAzyme cleavage. | 05-16-2013 |
20130123130 | MULTIGENE PROGNOSTIC ASSAY FOR LUNG CANCER - The present invention provides methods for providing a prognosis for lung adenocarcinoma, using a panel of eight molecular markers that are differentially expressed in lung adenocarcinoma. | 05-16-2013 |
20130123131 | Process for Ensuring Consistency and Reproducibility of a Diagnostic or Research Method - A method is disclosed in which control processes are used to maintain consistency across a research or diagnostic series of steps. Some embodiments of the processes include the use of fresh or lyophilized cell lines, beads, surface or other markers. The use of quality control processes is intended to monitor data from the underlying methods in order to detect unacceptable variations and to allow for exclusion or normalization. Overlapping control processes allows for tighter control and for redundancy in the monitoring. | 05-16-2013 |
20130123132 | Method for Diagnosing Propionibacterium Bacterial Infections - The invention concerns an in vitro method for determining if an individual is infected by a bacterium of the | 05-16-2013 |
20130123133 | SCREENING METHODS - The present invention provides materials and methods relating to screening for compounds useful in the treatment of Alzheimer's disease and related conditions. In particular, screening methods using tyrosine kinases are provided, as are methods relating to the role of tyrosine kinases as therapeutic targets. | 05-16-2013 |
20130123134 | SMALL MOLECULE PRINTING - The present invention provides compositions and methods to facilitate the identification of compounds that are capable of interacting with a biological macromolecule of interest. In one aspect, a composition is provided that comprises an array of one or more types of chemical compounds attached to a solid support, wherein the density of the array of compounds is at least 1000 spots per cm | 05-16-2013 |
20130123135 | Methods To Identify Modulators of TAS2R48 Receptors - Disclosed are compounds that activate the human G-protein coupled receptor TAS2R48, and methods of using these compounds for identifying compounds that modulate the response of the TAS2R48 receptor. Compounds identified as modulators of the response of the receptor TAS2R48 may be used to decrease or mask the bitter taste of foods or drugs. | 05-16-2013 |
20130123136 | REAL-TIME ELECTRONIC CELL SENSING SYSTEM AND APPLICATIONS FOR CYTOTOXICITY PROFILING AND COMPOUND ASSAYS - A method of performing an assay of a response of two or more cell types to a test compound, including: providing a device for monitoring cell-substrate impedance, adding at least two different cell types to the device; adding at least one test compound to form at least two test compound wells; providing at least two control wells; monitoring impedance of the at least two test compound wells and of the at least two control wells at three or more time points after adding the at least one test compound; and analyzing measured impedance from the at least two test compound wells and from the at least two control wells at the three or more time points to obtain information on the response of the different cell types to the at least one test compound. | 05-16-2013 |
20130123137 | METHOD FOR THE CHARACTERIZATION OF INTERMOLECULAR INTERACTIONS - The invention relates to a method for identifying in a sample molecules with the capacity to bind to the different members of a molecule library, wherein the molecules which are in the sample are fractionated based on a physicochemical property of the sample and subsequently transferred from the support in which said molecules have been separated to a second support in which the different members of the molecule library are grouped into microarrays such that they uniformly coat the surface of the support. This technique is especially interesting for the identification in a sample of glycoproteins with affinity for a lectin library as well as for the identification of compounds capable of modulating the glycosylation of proteins and for the rapid characterization of alterations in the glycosylation pattern of a sample of proteins, which can be useful in the diagnosis of diseases in which there are alterations in cell glycosylation. | 05-16-2013 |
20130123138 | COMPOSITIONS AND METHODS FOR PROGNOSIS OF MESOTHELIOMA - Disclosed are compositions and methods for the prognosis of mesothelioma patients after surgical operation. Specifically the disclosure provides microRNA (miRNA) molecules associated with prognosis of mesothelioma, as well as various nucleic acid molecules relating thereto or derived therefrom. The disclosure further provides altered expression of miRNAs that are associated with good or poor prognosis of mesothelioma. | 05-16-2013 |
20130123139 | APPARATUS AND METHOD FOR MULTIPLE REACTIONS IN SMALL VOLUMES - In some embodiments, the invention relates to a removable grid insertable into an apparatus comprising a plate comprising a number of elements having a first surface energy arranged in an array with an overlay having a second surface energy and a wall circumferential to the plate, said grid comprising dividers enclosing a number of through-holes, said through-holes spaced in the grid to allow alignment of the through- holes of the grid over the elements in the plate when said grid is inserted into the apparatus, wherein said dividers of the grid inserted into the apparatus form sides of wells bottomed by the plate and at least one element on said plate. In other embodiments, the invention also relates to an apparatus comprising: a plate comprising a number of elements, said elements each having an identical diameter and having a first surface energy, said elements arranged in an array in an overlay having a second surface energy, and a wall circumferential to the plate, wherein said overlay is a height over the elements of between about | 05-16-2013 |
20130130924 | METHOD FOR ANALYZING D4Z4 TANDEM REPEAT ARRAYS OF NUCLEIC ACID AND KIT THEREFORE - The present invention relates to a method for analysing in vitro D4Z4 tandem repeat arrays of nucleic acid contained on nucleic acid representative of chromosomes, in particular on nucleic acid representative of Human chromosomes 4 and 10, and to a kit therefore. Said method is in particular suitable for determining the number of D4Z4 repeat units in said D4Z4 repeat arrays. Said method is based on stretching of nucleic acid and in particular on Molecular Combing and relies on the use of probes, especially nucleic acid probes, with a particular design. The invention also relates to a method for providing tools for the diagnosis of facioscapulohumeral muscular dystrophy (FSHD) and to a diagnostic kit therefore. The invention further relates to a method for identifying biochemical events and/or genetic in regions containing such tandem repeat arrays. | 05-23-2013 |
20130130925 | TOOL FOR DIAGNOSIS AND PROGNOSIS OF MATURE B-CELL NEOPLASMS - The present invention provides a microarray useful as a tool in the diagnosis and/or prognosis of certain types of cancers, particularly mature B-cell neoplasms. The microarray can include a plurality of genomic regions represented thereon, the genomic regions corresponding to regions wherein alterations, such as copy number alterations, at such locations correlate to specific, identifiable cancers, particularly mature B-cell neoplasms. The invention further provides methods of diagnosing and providing prognosis certain types of cancer, particularly mature B-cell neoplasms. The methods can comprise contacting a sample to a microarray according to the invention, allowing any genetic material in the sample to hybridize to the genomic regions on the microarray, analyzing the hybridizations, and correlating the hybridizations to certain cancer types, particularly mature B-cell neoplasms. | 05-23-2013 |
20130130926 | Methods for Screening Cells and Antibodies - The invention provides methods of detecting a change in cell growth patterns, methods of screening many different antibodies in one receptacle, and methods of detecting specific binding of an antibody to a protein or cell, wherein the antibody is in a mixture of many different antibodies. | 05-23-2013 |
20130130927 | DETECTION AND QUANTIFICATION OF MICRORNAS IN THE CIRCULATION AND THE USE OF CIRCULATING MICRORNAS AS BIOMARKERS FOR CANCER - The present invention relates to the identification of circulating miRNAs as biomarkers suitable for use in the diagnosis and prognosis of a number of cancers, in particular breast cancer. In addition, the invention relates to improved methods for the identification and quantification of such biomarkers in samples taken from patients. | 05-23-2013 |
20130130928 | METHODS FOR PREDICTING OR MONITORING WHETHER A PATIENT AFFECTED BY A CANCER IS RESPONSIVE TO A TREATMENT WITH A MOLECULE OF THE TAXOID FAMILY - The present invention concerns in vitro methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family based on a resistance expression signature, kits for performing the methods, and methods for screening or identifying a compound suitable for improving the treatment of a cancer with a molecule of the taxoid family or for reducing the resistance development during the treatment of a cancer with the molecule of the taxoid family. | 05-23-2013 |
20130130929 | METHODS, DEVICES, AND KITS FOR OBTAINING AND ANALYZING CELLS - A method for concentrating and isolating nucleated cells, such as maternal and fetal nucleated red blood cells (nRBCs), in a maternal whole blood sample. The invention also provides methods and apparatus for preparing to analyze and analyzing the sample for identification of fetal genetic material as part of prenatal genetic testing. The invention also pertains to methods and apparatus for discriminating fetal nucleated red blood cells from maternal nucleated red blood cells obtained from a blood sample taken from a pregnant woman. | 05-23-2013 |
20130130930 | METHODS AND DEVICES FOR OBTAINING AND ANALYZING CELLS - A method for concentrating and isolating nucleated cells, such as maternal and fetal nucleated red blood cells (nRBCs), in a maternal whole blood sample. The invention also provides methods and apparatus for preparing to analyze and analyzing the sample for identification of fetal genetic material as part of prenatal genetic testing. The invention also pertains to methods and apparatus for discriminating fetal nucleated red blood cells from maternal nucleated red blood cells obtained from a blood sample taken from a pregnant woman. | 05-23-2013 |
20130130931 | BIOMARKER FOR THE DIAGNOSIS, PROGNOSIS AND MONITORING OF CANCER - The present invention provides a new biomarker for the diagnosis, prognosis and monitoring of cancer, preferably breast and colon cancer, the PIK3R2 gene or any of its expression products; since high levels of PIK3R2 correlate with advanced tumor stages, and in the case of breast cancer, with invasive or metastatic capacity. Thus, the invention is also related to a method for the diagnosis, prognosis and monitoring of cancer, preferably breast or colon cancer, in which the quantification of said biomarker in a biological sample comprising tumor cells is necessary. | 05-23-2013 |
20130130932 | Method for Identifying Lineage-Related Antibodies - In certain embodiments, the method may comprise: a) obtaining the antibody sequences from a population of B cells; b) grouping the antibody sequences to provide a plurality of groups of lineage-related antibodies; c) testing a single antibody from each of the groups in a bioassay and, after the first antibody has been identified, d) testing further antibodies that are in the same group as the first antibody in a second bioassay. In another embodiment, the method may comprise: a) testing a plurality of antibodies obtained from a first portion of an antibody producing organ of an animal; b) obtaining the sequence of a first identified antibody; c) obtaining from a second portion of said antibody producing organ the sequences of further antibodies that are related by lineage to said first antibody; and, c) testing the further antibodies in a second bioassay. | 05-23-2013 |
20130130933 | BIOMARKER SIGNATURES FOR WELLNESS TESTING - This invention generally relates to the use of devices to measure and assess the level of biomarkers that are indicative of the general wellness of an individual and methods of correlating such information into a wellness index. | 05-23-2013 |
20130137590 | Assessment of Oocyte Competence - Methods are provided for evaluating an oocyte for fertilization and implantation. For example, methods are provided for determining whether an oocyte expresses, or does not express, one or more of a group of markers identified as differently expressed between chromosomally normal and chromosomally abnormal oocytes. Also provided, for example, are methods for determining whether a cumulus cell expresses, or does not express, one or more of a group of markers identified as differently expressed between cumulus cells associated with chromosomally normal oocytes and cumulus cells associated with chromosomally abnormal oocytes. Methods are provided for the detection of marker expression of differentially expressed genes at the RNA level, as well as at the protein level. | 05-30-2013 |
20130137591 | FLUIDICS DEVICES - The invention relates to fluidics as used in medical and diagnostic equipment and relates further to means for purifying, abstracting, filtering, detecting and/or measuring analytes in liquid samples. | 05-30-2013 |
20130137592 | BIOMARKERS - An object of the present invention is to provide biomarkers for predicting response to chemoradiotherapy for cancer and predicting prognosis of a patient with cancer, as well as methods of measuring such biomarkers. The response to chemoradiotherapy for cancer in a vertebrate animal can be predicted by measuring concentrations of a soluble interleukin-6 receptor, MIP-1β, and an activated plasminogen activator inhibitor in the blood obtained from that individual with cancer before treatment with chemoradiotherapy, and prognosis of the same vertebrate animal can be determined by measuring a concentration of soluble interleukin-6 receptor. | 05-30-2013 |
20130137593 | EARLY DETECTION AND STAGING OF COLORECTAL CANCER USING A PANEL OF MICRO RNAS - The present invention provides compositions, methods and kits for diagnosing cancer, specifically the diagnosis of colorectal cancer (CRC). More specifically, the invention provides simple assays, with high sensitivity and specificity for CRC, wherein a panel of microRNA (miRNA) are used as biomarkers. | 05-30-2013 |
20130137594 | SYSTEMS AND METHODS FOR PERFORMING AMPLICON RESCUE MULTIPLEX POLYMERASE CHAIN REACTION (PCR) - Embodiments of the present disclosure generally pertain to systems and methods for performing amplicon rescue multiplex polymerase chain reaction (arm-PCR). In one embodiment, the system comprises a processor and a reader coupled to a control element. The control element is configured to control the operation of the processor and the reader based on a variety of settings. The processor is configured to receive a self-contained cassette for performing PCR amplification of DNA and/or RNA obtained from an organic specimen. The processor engages with the cassette and manipulates reagents within the cassette in order to amplify and detect the DNA from the specimen. The processor also causes the cassette to deposit the DNA on a microarray within the cassette. The reader is configured to receive the cassette after it has been processed by the processor and to capture an image of the microarray for transmission to the control element as test data. The control element is further configured to analyze the test data received from the reader and to produce an output indicative of a comparison of the test data to predefined data. | 05-30-2013 |
20130137595 | BIOMARKERS FOR LYMPHOMA - A biomarker, method, test kit, and diagnostic system for detecting the presence of lymphoma in a person are disclosed. The lymphoma may be Hodgkin's lymphoma or non-Hodgkin's lymphoma. The person may be a high-risk subject. In one embodiment, a plasma sample from a person is obtained. The level of at least one protein listed in Table S3 in the plasma sample is measured. The level of at least one protein in the plasma sample is compared with the level in a normal or healthy subject. The lymphoma is diagnosed based upon the level of the at least one protein in the plasma sample in comparison to the normal or healthy level. | 05-30-2013 |
20130137596 | MicroRNA Expression Abnormalities in Pancreatic Endocrine and Acinar Tumors - The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of pancreatic cancer. The invention also provides methods of identifying anti-pancreatic cancer agent. | 05-30-2013 |
20130137597 | Microrna-based method for anti-colorectal cancer effects and prognosis of colorectal cancer - The present invention discloses a method of providing anti-oncogenic effects in a subject suffered from colorectal cancer. The present invention also discloses a method for screening an anti-colorectal cancer agent. The present invention further discloses a method of determining the prognosis of a subject with colorectal cancer. | 05-30-2013 |
20130137598 | METHOD OF DETECTING SURROGATE MARKERS IN A SERUM SAMPLE - The invention provides a method of detecting surrogate markers for active tuberculosis in a serum sample. The surrogate markers are selected from serum mycolic acid antigen, serum anti-mycolic acid antibodies or both. The method includes the steps of combining the serum sample with a labelled monoclonal immunoglobulin antibody or fragment thereof to mycolic acids to produce a combined serum sample, the antibody or fragment thereof not substantially cross-reacting with cholesterol and the label being selected so that binding of the labelled antibody to immobilized mycolic acid antigen of mycobacterial origin produces a detectable signal and combining a blank sample with the labelled monoclonal immunoglobulin antibody or fragment thereof to mycolic acid to produce a combined blank sample. The method includes exposing both samples to immobilised mycolic acid antigen of mycobacterial origin or a synthetic analogue or analogues thereof so that the labelled immunoglobulin antibodies or fragments thereof in each sample bind to the immobilised antigen to produce detectable signals. If the surrogate markers are present, the signal produced by the blank sample will be stronger than that produced by the serum sample because of inhibition of binding of the labelled antibody in the serum sample arising from prior binding of the labelled antibody with the mycolic acid antigen in the serum sample or by competitive binding of serum anti-mycolic acid antibodies in the serum sample to the immobilised mycolic acid antigen or both. | 05-30-2013 |
20130143749 | METHODS OF IDENTIFYING A PAIR OF BINDING PARTNERS - The present invention relates to methods of identifying a binding partner of a target molecule within a plurality of analyte molecules, including a plurality of peptides and/or proteins. The target molecule is physically combined with a target labeling nucleic acid molecule, which includes a specific nucleotide sequence. Where the target molecule is a peptide/protein this specific nucleotide sequence may include a sequence encoding the target molecule. Each member of the plurality of analyte molecules is physically linked to an analyte labeling nucleic acid molecule, each analyte labeling nucleic acid molecule comprising a selected nucleotide sequence. This specific nucleotide sequence may include a sequence encoding a peptide/protein combined therewith. The target molecule is contacted with the analyte molecules and a complex between the target molecule and an analyte molecule forms. The mixture is subdivided into compartments, with each compartment comprising at most one target molecule or one complex between the target and an analyte molecule. The target labeling nucleic acid molecule and the analyte labeling nucleic acid molecule are linked and the plurality of compartments allowed to disintegrate. The linked nucleic acid molecule is retrieved and the sequence determined. | 06-06-2013 |
20130143750 | Phoshorylation of Estrogen Receptor Alpha - The present invention provides use and methods markers based on the phosphorylation state of certain amino acid residues of estrogen receptor α. | 06-06-2013 |
20130143751 | Set of Probes for the Detection and Typing of 46 Human Papillomavirus Mucosal Types - We have developed a set of probes to detect and identify 46 types of mucosal human papillomaviruses (HPV). These probes recognize the variable region comprised between the 2 conserved regions of the published GP5+/GP6+ set of PCR primers. The example described in this application, called NML Luminex genotyping method, uses a multiplex assay based on nested PCR amplification and the Luminex xMAP technology. The 46 probes have been shown to hybridize, as intended, to the DNA derived from the following HPV types: 6, 11, 13, 16, 18, 26, 30, 31, 32, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 71, 72, 73, 74, 81, 82, 83, 84, 85, 86, 87, 89, 90, 91 and 97. The hybridization of each probe is specific for each type without any cross hybridization among types and it is sensitive enough to allow detection of PCR products for genotyping of HPV DNA contained in clinical samples. We also present a validation of the NML Luminex method against direct sequencing of HPV types and against the Roche Linear Array, a leading commercial method for HPV genotyping. The probes described here are suitable for use in other assays based on hybridization with labelled target HPV DNA, including, but not limited to, Southern and Northern blots, reverse line blot hybridization, DNA microarray, or ELISA. | 06-06-2013 |
20130143752 | GENE BIOMARKERS OF LUNG FUNCTION - Described herein are a group of 1,013 genes and 1 phenotypic variable are identified as candidate predictors that differentiated smokers (current or former) with or without COPD. The full predictor set can be reduced to a nine-gene classifier (IL6R, CCR2, PPP2CB, RASSF2, WTAP, DNTTIP2, GDAP1, LIPE, and RPL14) with similar performance. Also described herein is the use of the full predictor set and the reduced nine gene set in methods of diagnosing lung disease or an increased risk of developing lung disease, such as COPD, in a subject. Also described herein is the use of the full predictor set and the reduced nine gene set in methods of providing a prognosis for a subject with lung disease, such as COPD. | 06-06-2013 |
20130143753 | METHODS FOR PREDICTING OUTCOME OF BREAST CANCER, AND/OR RISK OF RELAPSE, RESPONSE OR SURVIVAL OF A PATIENT SUFFERING THEREFROM - The present invention relates to biomarkers allowing predicting breast tumor and solid tumor outcome using hypoxia related genes. More specifically, the present invention relates to a method for predicting the survival of a patient suffering from cancer, said method comprising the steps of (a) measuring the expression of at least five genes selected from the group consisting of GLUT1, PGK1, LDHA, ENO1, CAIX, NHERF1, TPI, AMF/GPI, VEGFA, TGFB3, ENG, LEP, EDN1, MDR1, AK3, MXR1, TGM2, CDH1, MMP2, CK1 9, VIM, CXCR4, UPAR, CATHD, CTGF, C0X2, MET, IGF-2, CCND1, EPO, NDRG1, BNIP3, NIX, ETS1, PHD2, TWIST1, DEC1, SNAH, CEBPA, CITED2, F0X03A, NUR77, BRCA1, PTEN, VHL and ERBB2 in a biological sample of said patient, and (b) analyzing the expression values to generate a risk score of relapse, wherein a risk score superior or equal to three is indicative of high risk of relapse and a risk score inferior or equal to two is indicative of a low risk of relapse. In particular the following genes: EPO, ETS1, ENO1, PGK1, LDHA, TPI and optionally VEGFA were significantly over-expressed in patients with relapse. | 06-06-2013 |
20130143754 | METHODS FOR MULTIPLEXING AMPLIFICATION REACTIONS - A two-step multiplex amplification reaction includes a first step which truncates the standard initial multiplex amplification round to “boost” the sample copy number by only a 100-1000 fold increase in the target. Following the first step the product is divided into optimized secondary single amplification reactions, each containing one of the primer sets that were used previously in the first or multiplexed booster step. The booster step can occur using an aqueous target nucleic acid or using a solid phase archived nucleic acid. In particular, nucleic acid sequences that uniquely identify | 06-06-2013 |
20130143755 | Protein and Gene Biomarkers for Rejection of Organ Transplants - Aspects of the present invention include methods for determining a transplant category of a subject having a transplant. Common mechanisms of rejection injury are uncovered across different tissue transplants, and provide a means to understand rational drug design. Various sources of tissues are examined form the patient for understanding AR mechanism (graft biopsy), as well as monitoring by minimal invasive means (blood) or non-invasive means (urine for the kidney allograft). For biomarker discovery different categories of markers are examined such as genes, proteins, peptides and antibodies. These biomarkers can help determine the subject's transplant category (e.g., acute allograft rejection (AR), stable allograft (STA), BK viremia, BK nephritis, drug toxicity or chronic allograft injury (CAI), and the like). Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods. The methods and compositions find use in a variety of applications. | 06-06-2013 |
20130143756 | COMPOUND ARRAYS FOR SAMPLE PROFILING - The invention provides arrays of compound for use in profiling samples. The arrays include compounds bind to components of the samples at relatively low affinities. The avidity of compounds binding to components of the samples can be increased by forming arrays such that multivalent components of the samples (e.g., antibodies or cells) can bind to more than one molecule of a compound at the same time. When a sample is applied to an array under such conditions, the compounds of the array bind to component(s) of the sample with significantly different avidities generating a profile characteristic of the sample. | 06-06-2013 |
20130143757 | Methods and Compositions for Chlamydial Antigens as Reagents for Diagnosis of Tubal Factor Infertility and Chlamydial Infection - The present invention provides | 06-06-2013 |
20130143758 | METHODS AND COMPOSITIONS FOR IMPROVED CATTLE LONGEVITY AND MILK PRODUCTION - A single nucleotide polymorphic site at position 10793 of the bovine POU1F1 gene is associated with improved longevity and milk product traits. Disclosed are nucleic acid molecules, kits, methods of genotyping and marker assisted bovine breeding methods. | 06-06-2013 |
20130143759 | FOOD-POISONING BACTERIA DETECTION CARRIER, AND METHOD FOR DETECTING FOOD-POISONING BACTERIA - A plurality of probes are immobilized on a carrier for detecting food poisoning bacteria, the plurality of probes being selected, either alone or in combination, respectively from two or more groups among a first probe group for detecting | 06-06-2013 |
20130143760 | Method, Array and Use Thereof - The present invention provides a method for the prognosis of breast cancer in a subject comprising the steps of: (a) providing a first proteome sample from the subject; (b) measuring in the first proteome sample the amount of one or more biomarkers selected from the group of biomarkers listed in Table 1; (c) providing an additional (e.g. a second) proteome sample from the subject; (d) measuring in the additional proteome sample the amount of the one or more biomarkers selected from the group of biomarkers listed in Table 1 measured in step (b); and (e) determining the difference between the amount of the one or more biomarkers in the first and additional proteome samples; wherein the first proteome sample and additional proteome sample are representative of the proteome composition of the subject on different days, and wherein the difference between the amount of the one or more biomarkers in the first and additional (e.g. second) proteome samples is indicative of the risk of recurrence and/or metastasis of the breast cancer in the subject. In further embodiments, step (b) comprises measuring the amount of each the biomarkers listed in Table 1(A) or all of the biomarkers listed in Table 1. The present invention additionally provides an array for performing the method of the invention, the use in vitro of a biomarker selected from the group of biomarkers in Table 1 as a prognostic marker for determining risk of recurrence and/or metastasis of breast cancer in a subject, and a kit for performing the method of the invention comprising one or more binding agents capable of binding to a biomarker listed in Table 1. | 06-06-2013 |
20130143761 | PRODUCT AND METHOD - The present invention relates to oligonucleotide probes, for use in assessing gene transcript levels in a cell, which may be used in analytical techniques, particularly diagnosis techniques and kits containing the same. | 06-06-2013 |
20130143762 | Gene expression profiles and methods of use - The present invention relates to gene expression profiles, microarrays comprising nucleic acid sequences representing gene expression profiles, and methods of using expression profiles and microarrays. The invention also provides methods and compositions for diagnostic assays for detecting cancer and therapeutic methods and compositions for treating cancer. The invention also provides methods for designing, identifying, and optimizing therapeutics for cancer. | 06-06-2013 |
20130143763 | METHODS FOR DETERMINING SIGNAL TRANSDUCTION ACTIVITY IN TUMORS - The method of the invention pertains to determining signal transduction activity in a tissue section by immunohistochemistry techniques. The expression level of the receptor of interest is determined as well as the expression levels of one or more effector molecules of the receptor signal transduction pathway. Furthermore a combined ratio of expression levels of effector molecules in subcellular compartments with the receptor expression was found to have prognostic significance. | 06-06-2013 |
20130143764 | METHOD FOR CLASSIFYING AN INFLAMMATORY BOWEL DISEASE AS A CROHN'S DISEASE OR AS AN ULCERATIVE COLITIS - The present invention relates to a method for classifying an inflammatory bowel disease in a patient as a Crohn's disease or as an ulcerative colitis, said method comprising a step of measuring an expression profile of miRNA in a sample from the patient, wherein said miRNA are miR15a, miR26a, miR29a, miR29b, miR30c, miR126*, miR127-3p, miR-142-3p, miR-142-5p, miR-146a, miR-146b-5p, miR150, miR-181d, miR-182, miR185, miR196a, miR199a-3p, miR199a-5p, miR199b-5p, miR-203, miR223, miR-299-5p, miR320a, miR324-3p, miR-328. | 06-06-2013 |
20130150254 | Reagents and methods for direct labeling of nucleotides - The present invention provides systems and methods for production of activatable diazo-derivatives for use in labeling nucleotides. Labeling nucleotides is accomplished by contacting a stable hydrazide derivative of a detectable moiety with an activating polymer reagent which is used to directly label the nucleotide sample. Labeling occurs on the phosphate backbone of the nucleotide which does not perturb hybridization of the labeled nucleotide with its anti-sense strand. Since the method involves direct labeling, all types of nucleotides can be labeled without prior amplification or alteration. | 06-13-2013 |
20130150255 | DNA METHYLATION BIOMARKERS OF LUNG FUNCTION - Biomarkers of lung disease are provided. The biomarkers comprise target genomic DNA sequences having one or more CpG dinucleotides that are differentially methylated in genomic DNA of subjects having lung disease as compared to normal subjects or subjects not having lung disease. In one exemplary embodiment, methylation status profiles of 71 CpG sites mapping to 67 unique genes are significantly associated with at least one of three lung function decline measures associated with lung disease. Other biomarkers significantly associated with cigarette smoking-related lung function decline, with age-related lung function decline, and with the intensifying effects of cigarette smoking on lung function decline with age are also provided. | 06-13-2013 |
20130150256 | NOVEL MICRORNAS FOR THE DETECTION AND ISOLATION OF HUMAN EMBRYONIC STEM CELL-DERIVED CARDIAC CELL TYPES - The present invention relates to the use of human-derived microRNAs (miRNAs) as targets for the identification of cardiac and cardiac-like cell types. In particular, it relates to a specific set of miRNAs which have been found to be correlated to cardiac differentiation and can act to up or downregulate a number of putative mRNA targets to guide differentiation and also act as markers for a cardiac phenotype. In addition, it also relates to the use of these miRNAs as tools for the isolation, selection, purification and characterisation of cardiac and cardiac-like cells and tissues. The invention also encompasses the possible use of these miRNAs in the differentiation and maturation of cardiac or cardiac-like cell types. | 06-13-2013 |
20130150257 | METHODS AND COMPOSITIONS FOR SAMPLE IDENTIFICATION - Compositions and methods are provided to provide an expression signature for a sample, where an alternative splicing index and profile are determined for the sample based on variations in the splicing of messenger RNA for at least one gene in the sample. | 06-13-2013 |
20130150258 | PROGNOSIS AND THERAPY PREDICTIVE MARKERS AND METHODS OF USE - Disclosed is a set of genes differentially expressed in chemotherapy and radiation resistant tumors useful in predicting response to therapy and assessing risk of local-regional failure, survival and metastasis in cancer patients. Also disclosed are methods for characterizing tumors according to gene expression and kits for use in the methods of the invention. | 06-13-2013 |
20130150259 | BIOMARKERS FOR THE EARLY DETECTION OF BREAST CANCER - The present invention provides reagents and methods for breast cancer detection. | 06-13-2013 |
20130157878 | METHOD FOR IDENTIFYING HETERO-MULTIMERIC MODIFIED UBIQUITIN PROTEINS WITH BINDING CAPABILITY TO LIGANDS - The present invention refers to a method for identifying hetero-multimeric ubiquitins with binding capability to a ligand. Furthermore, the invention provides DNA libraries encoding for a population of said hetero-multimeric ubiquitins as well as protein libraries obtained by expression of said DNA libraries, cells and phages containing said DNA or proteins, polynucleotides encoding for said fusion proteins and vectors comprising said polynucleotides. Further new binding proteins based on hetero-multimeric ubiquitin being able to bind specifically with high affinity to selected ligands are provided. | 06-20-2013 |
20130157879 | BIOMARKER DACT1 FOR GASTRIC CANCER - The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the DACT1 gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating gastric cancer by increasing DACT1 gene expression or activity. | 06-20-2013 |
20130157880 | METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND INVOLVED IN PAIN AS WELL AS METHODS OF DIAGNOSING ALGESIA - The present invention relates to a method of identifying a compound involved in pain, the use of Car3 nucleic acid or Car3 protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same. | 06-20-2013 |
20130157881 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor VII, CA19-9, Insulin-like growth factor-binding protein 7, C—X—C motif chemokine 6, and C—C motif chemokine 13 as diagnostic and prognostic biomarkers in renal injuries. | 06-20-2013 |
20130157882 | Biomedical and Chemical Sensing with Nanobeam Photonic Crystal Cavities Using Optical Bistability - A miniature optical biosensor and biosensor array where high sensitivity for detection of biomolecular interaction does not require a fluorescent label. Non-linear frequency-shifts of optical resonators (‘nanobeams’) provide a digital all-or-nothing response to equilibrium binding of a biomarker to surface-immobilized bio-recognition elements, a signal suitable to identify active components in genetic and proteomic circuits, as well as toxic substances. The threshold level for the digital response is adjustable to accommodate for varying receptor affinities. A bistable cavity sensing (BCS) method can be used to track the shift of the resonance induced by the analyte more precisely than the conventional cavity sensing method, where the resolution is limited by the cavity linewidth. BCS method can be used to quantitate the concentration of the analyte, and their binding kinetics, affinities and etc. | 06-20-2013 |
20130157883 | Complex miRNA Sets as Novel Biomarkers for an Acute Coronary Syndrome - The present invention relates to single polynucleotides or sets of polynucleotides for detecting single miRNAs or sets of miRNAs for diagnosing and/or prognosing of an acute coronary syndrome in a blood sample from a human. Further, the present invention relates to means for diagnosing and/or prognosing of an acute coronary syndrome comprising said polynucleotides or sets of polynucleotides. Furthermore, the present invention relates to a method for diagnosing and/or prognosing of an acute coronary syndrome based on the determination of expression profiles of single miRNAs or sets of miRNAs representative for an acute coronary syndrome compared to a reference. In addition, the present invention relates to a kit for diagnosing and/or prognosing of an acute coronary syndrome comprising means for determining expression profiles of single miRNAs or sets of miRNAs representative for an acute coronary syndrome and at least one reference. | 06-20-2013 |
20130157884 | METHODS AND COMPOSITIONS INVOLVING MIRNA EXPRESSION LEVELS FOR DISTINGUISHING PANCREATIC CYSTS - Embodiments concern methods and compositions for evaluating a pancreatic cyst in a patient based on the expression levels of one or more miRNAs to determine whether the pancreatic cyst is a low or high risk lesion and in further need of treatment such as resection. | 06-20-2013 |
20130157885 | SYSTEM AND METHODS FOR SELECTIVE MOLECULAR ANALYSIS - Methods and systems for selectively amplifying a target DNA sequence in the presence of non-target DNA sequence in a sample, comprising: contacting the sample with an oligonucleotide system under hybridization conditions to form a reaction mixture including a forward primer and a reverse primer, wherein either the forward or reverse primer is modified to preferentially increase hybridization between the primer and the target sequence; cycling the hybridization of the oligonucleotide system so that, if the target DNA sequence is present in the sample, the primers hybridize to the target DNA sequence and the reaction mixture results in a first amplified product; and detecting the first amplified product. | 06-20-2013 |
20130157886 | METHODS OF DETECTING LUNG CANCER - Methods of lung cancer in a sample from a patient are provided. Methods of detecting changes in expression of one or more target RNAs associated with lung cancer are also provided. Compositions and kits are also provided. | 06-20-2013 |
20130157887 | DISCRETE STATES FOR USE AS BIOMARKERS - The present invention describes the use of discrete states and signatures for classifying samples. | 06-20-2013 |
20130157888 | DIAGNOSTIC AUTOANTIBODY PROFILES FOR THE DETECTION AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES - The present invention provides methods, compositions, and kits for the detection of neurodegenerative disease specific autoantibodies for the diagnosis of neurodegenerative diseases and risk for developing neurodegenerative diseases, and for the generation of patient-specific neurodegenerative disease diagnostic autoantibody profiles. | 06-20-2013 |
20130157889 | DETECTION DEVICES AND RELATED METHODS OF USE - Disclosed are devices and methods for detecting analytes from a sample. | 06-20-2013 |
20130157890 | METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND INVOLVED IN PAIN AS WELL AS METHODS OF DIAGNOSING ALGESIA - The present invention relates to a method of identifying a compound involved in pain, the use of Ctla2b nucleic acid or Ctla2b protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same. | 06-20-2013 |
20130157891 | ORGAN SPECIFIC DIAGNOSTIC PANELS AND METHODS FOR IDENTIFICATION OF ORGAN SPECIFIC PANEL PROTEINS - The present application provides novel compositions, methods, and assays for use in identification of appropriate diagnostic markers in blood. These compositions, methods, and assays are capable of distinguishing normal levels of detectable markers from changes in marker levels that are indicative of changes in health status. | 06-20-2013 |
20130157892 | ASSAY FOR MEASUREMENT OF ANTIBODIES BINDING TO A THERAPEUTIC MONOCLONAL ANTIBODY - Methods and system for determination of an anti- antibody (anti-AB) in vitro in a sample from a patient treated with a therapeutic monoclonal antibody (TmAB). Also, methods and systems for the determination of antigen specific antibodies of a particular immunoglobulin class and for the identification of a patient who is at risk of developing an adverse drug reaction (ADR) during treatment with a TmAB. | 06-20-2013 |
20130157893 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF IMMUNOTHERAPY ON CANCER PATIENT, AND GENE SET AND KIT TO BE USED IN THE METHOD - Provided is a gene set which is useful for predicting the therapeutic effect of an immunotherapy on a cancer patient. Also provided is a method for examining whether an immunotherapy is efficacious or not, said method comprising quantifying the expression amount of each of the genes constituting the aforesaid gene set. This examination method is useful for determining a therapeutic strategy for the cancer patient. | 06-20-2013 |
20130157894 | METHODS TO IDENTIFY COMBINATIONS OF NS5A TARGETING COMPOUND THAT ACT SYNERGISTICALLY TO INHIBIT HEPATITIS C VIRUS REPLICATION - The present invention is based on the surprising finding that pairs of HCV NS5A-targeting inhibitors can be identified which display similar resistance profiles yet, when combined, exhibit synergistic inhibition of wild type replicons and/or replicons carrying mutations conferring resistance to the HCV NS5A-targeting inhibitor. In addition, combinations of these molecules result in a higher genetic barrier to resistance, demonstrating their potential utility as novel combination therapies for treatment of HCV. | 06-20-2013 |
20130157895 | TISSUE STAINING METHOD, TISSUE EVALUATION METHOD AND BIOSUBSTANCE DETECTION METHOD - A tissue staining method which comprises: staining a tissue with a staining reagent wherein a biosubstance recognition site is bonded to particles carrying multiple fluorescent substances accumulated therein; in the stained tissue, counting fluorescent points or measuring fluorescent brightness; and evaluating the expression level of a biosubstance, which matches the biosubstance recognition site, in the aforesaid tissue on the basis of the number of the fluorescent points or fluorescent brightness that was measured. | 06-20-2013 |
20130165329 | MULTIMODE SYSTEMS AND METHODS FOR DETECTING A SAMPLE - A multimode detection system for detecting one or more samples is provided. The detection system comprises an electromagnetic radiation source, a reference arm, and a sample arm comprising a sensing substrate having a plurality of sample fields, wherein the sample fields are configured to receive the one or more samples. The system further comprises a phase difference generator configured to introduce pathlength differences in the reference arm, sample arm, or both, a spatial light modulator operatively coupled to the reference arm, sample arm, or both, wherein the spatial light modulator is configured to modulate incident radiation, resultant radiation, or both in the reference arm, sample arm, or both, and an imaging spectrometer configured to discriminate between two or more spatially separated sample en two or more spatially separated sample fields. | 06-27-2013 |
20130165330 | PHOTOACTIVATED CHEMICAL BLEACHING OF DYES - Methods comprising the use of photoactivated chemical bleaching for detecting multiple targets in a biological sample are provided. The methods include the steps of providing a biological sample containing multiple targets, binding at least one probe to one or more target present in the sample, and observing a signal from the probe. The method further includes the steps of contacting the sample comprising the bound probe with an electron transfer reagent and irradiating the sample, thereby initiating a photoreaction that substantially inactivates the probe by photoactivated chemical bleaching. The method further includes the steps of binding at least one probe to one or more target present in the sample, and observing a signal from the probe. The process of binding, observing and bleaching may be iteratively repeated. | 06-27-2013 |
20130165331 | CHROMOSOME COPY NUMBER GAIN AS A BIOMARKER OF UROTHELIAL CARCINOMA LETHALITY - Diagnostic assays for medically classifying cancer patients are provided. The method comprises assessing a tissue sample of the patient for the presence of a copy number gain of chromosome regions 1q23.3 and/or 1q21.2. Copy number gain of chromosome regions 1q23.3 and/or 1q21.2 is indicative of a less favorable prognosis as compared to the prognosis if there was no copy number gain in the same regions. | 06-27-2013 |
20130165332 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES - The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases. | 06-27-2013 |
20130165333 | Methods and Systems for Preparing Irreversible Inhibitors of Protein Tyrosine Phosphatases - Described herein are the preparation and use of novel bromo-phosphonomethylphenylalanine amino acid derivatives (BrPmp) and BrPmp-containing peptides as specific, irreversible protein tyrosine phosphatase inhibitors, which are suitable for application in peptide synthesis. These derivatives are particularly advantageous since their synthesis is both easy and scalable, and they are suitable for peptide synthesis. The BrPmp derivatives described herein can be appropriately protected to allow for solid phase peptide synthesis (SPPS) and incorporation into peptides for preparation of protein tyrosine phosphatase inhibitors and inhibitor libraries. The peptides and peptide libraries can be used to identify new protein tyrosine phosphatase specific sequences and profile protein tyrosine phosphatase activity in cell lysates, diagnostic samples and biopsy samples. | 06-27-2013 |
20130165334 | INTEGRATED ASSAY THAT COMBINES FLOW-CYTOMETRY AND MULTIPLEXED HPV GENOTYPE IDENTIFICATION - A two part assay is disclosed that enables collection of both protein biomarker phenotype and specific HPV genotype data from within a clinically derived population of cervical epithelial cells. Presence of multiple transformation-associated protein biomarkers acts as a gating criterion for cell sorting, followed by application of a PCR protocol sensitive enough to detect and identify individual HPV types from within the cells captured during sorting. The workflow has been optimized to work with cells conventionally fixed in PreservCyt (Cytyc), and it can be performed on residual cells remaining in a stored sample after a Pap test has been performed. | 06-27-2013 |
20130165335 | MULTIPLEX MEASURE OF ISOTYPE ANTIGEN RESPONSE - The application discloses methods for simultaneous detection and quantifying multiple target analytes, including immunoglobulin isotypes and sub-classes, single and multiple protein antibodies within a test sample in a single reaction vessel. The method uses reaction wells as on a multi-well plate, each single well comprising microarrays of: calibration spots, having a predetermined quantity of a target analyte; and capture spots, having multiple agent antibodies, including isotypes and subclasses that specifically bind the target analytes. The captured analytes and the calibration spots are detected with fluorescently labeled antibodies specific for each analyte. The application also discloses methods for detecting and quantifying biomarkers, therapeutic proteins and patient derived antibodies; the use of secondary reagents to determine immunoglobulin classes Ig G, A, M, E and sub-classes including IgG1, IgG2, IgG3, IgG4 and IgA. The intensity of each fluorescent signal allows measurement of a specific immune response to a therapeutic protein and associated analytes. | 06-27-2013 |
20130165336 | Biomarkers for Diagnosing Schizophrenia and Bipolar Disorder - The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in blood and useful in diagnosing schizophrenia and/or bipolar disorder as well as monitoring therapeutic efficacy of treatment for schizophrenia or bipolar disorder. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention can be used to diagnose schizophrenia and/or bipolar disorder. Measurement of the expression level of products of biomarkers of the invention using polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are compositions and kits containing said polynucleotides and proteins. Further encompassed by the invention is the use of the polynucleotides and proteins to monitor the efficacy of therapeutic regimens. | 06-27-2013 |
20130165337 | IDENTIFICATION OF MULTIGENE BIOMARKERS - Methods for identifying multigene biomarkers for predicting sensitivity or resistance to an anti-cancer drug of interest, or multigene cancer prognostic biomarkers are disclosed. The disclosed methods are based on the classification of the mammalian genome into 51 transcription clusters, i.e., non-overlapping, functionally relevant groups of genes whose intra-group transcript levels are highly correlated. Also disclosed are specific multigene biomarkers for predicting sensitivity or resistance to tivozanib, or rapamycin, and a specific multigene biomarker for determining breast cancer prognosis, all of which were identified using the methods disclosed herein. | 06-27-2013 |
20130165338 | BIOMARKERS FOR DETERMINATION OF TEMPORAL PHASE OF ACUTE KIDNEY INJURY - The invention relates to a method for determining the temporal phase of acute kidney injury, comprising obtaining a test sample from a subject and measuring the expression level of at least one biomarker selected from the group comprising Chac1, Birc5 and Angpt17. The invention also relates to a method for determining the early early phase, the late early phase, the severity and/or timing of acute kidney injury via analysis of the biomarkers Chac1, Birc5 and/or Angptl7, in addition to a test kit for carrying out said methods and antibodies directed against Chac1, Birc5 or Angptl7. | 06-27-2013 |
20130165339 | SAPP-ALPHA AS A BIOMARKER FOR PREDICTION OF INFLAMMATORY AND AUTOIMMUNE-RELATED DISORDERS - The subject invention pertains to the use of amyloid precursor protein-alpha (sAPP-α) as a biomarker for prediction of a subject's risk of developing inflammatory and/or autoimmune-related disorders. In addition, the present invention provides methods for optimizing vaccine schedules and compositions, thereby preventing or reducing the risks of vaccine-induced inflammatory and/or autoimmune-related disorders. | 06-27-2013 |
20130165340 | MULTIPLEX COLON CANCER MARKER PANEL - The present invention provides a specific combination of colon cancer markers based on statistical knowledge, which is capable of detecting a larger number of colon cancer patients in an earlier stage while maintaining high specificity. A multiplex colon cancer marker panel comprising a combination of five colon cancer markers of Carcinoembryonic antigen-related cell adhesion molecule 5, Carbohydrate antigen 19-9, Galectin-4, APEX nuclease and Actin-related protein 2. | 06-27-2013 |
20130165341 | STRUCTURE-ACTIVITY RELATIONSHIPS - The present disclosure relates to compositions and methods for screening a plurality of polypeptide variants. | 06-27-2013 |
20130165342 | METHODS AND SYSTEMS FOR EXTENDING DYNAMIC RANGE IN ASSAYS FOR THE DETECTION OF MOLECULES OR PARTICLES - Described herein are systems and methods for extending the dynamic range of assay methods and systems used for determining the concentration of analyte molecules or particles in a fluid sample. In some embodiments, a method comprises spatially segregating a plurality of analyte molecules in a fluid sample into a plurality of locations. At least a portion of the locations may be addressed to determine the percentage of said locations containing at least one analyte molecule. Based at least in part on the percentage, a measure of the concentration of analyte molecules in the fluid sample may be determined using an analog, intensity-based detection/analysis method/system and/or a digital detection/analysis method/system. In some cases, the assay may comprise the use of a plurality of capture objects. | 06-27-2013 |
20130165343 | IDENTIFICATION OF MULTIGENE BIOMARKERS - Methods for identifying multigene biomarkers for predicting sensitivity or resistance to an anti-cancer drug of interest, or multigene cancer prognostic biomarkers are disclosed. The disclosed methods are based on the classification of the mammalian genome into 51 transcription clusters, i.e., non-overlapping, functionally relevant groups of genes whose intra-group transcript levels are highly correlated. Also disclosed are specific multigene biomarkers for predicting sensitivity or resistance to tivozanib, or rapamycin, and a specific multigene biomarker for determining breast cancer prognosis, all of which were identified using the methods disclosed herein. | 06-27-2013 |
20130165344 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Cancer antigen CA 15-3, C-C Motif chemokine 18, C-C Motif chemokine 24, Cathepsin D, C-X-C Motif chemokine 13, C-C motif chemokine 8, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, Interleukin-11, Matrix Metalloproteinase-8, Transforming growth factor alpha, IgG1, and IgG2 as diagnostic and prognostic biomarkers in renal injuries. | 06-27-2013 |
20130165345 | METHOD FOR ASSAYING PERITONITIS IN HUMANS - The present invention relates to a reliable method of prediction of infectious peritonitis in humans, wherein the level of pancreatic stone protein/regenerating protein (PSP/reg) is determined in serum or plasma, and a high level is indicative of the development and the severity of peritonitis, allowing the classification of patients according to risk. | 06-27-2013 |
20130172202 | SENSOR AND METHOD FOR DETECTION OF A TARGET SUBSTANCE - A sensor, in one configuration, includes a plurality of beads located in a channel. The beads are attached to a surface of the channel by a biological binding mechanism that can be selectively unbound in the presence of a target substance. A measurement system is configured and arranged to determine the population of beads in the channel after the introduction of an analyte solution into the channel. | 07-04-2013 |
20130172203 | HYBRID MODEL FOR THE CLASSIFICATION OF CARCINOMA SUBTYPES - A two-tiered classification system that can be integrated with the current algorithm used by pathologists for identification of the site of origin for ‘malignancy with unknown primary ’ is presented. In use, morphology, immunohistochemical (IHC) studies, and microarry-based top tier gene expression classifiers first subclassify cytokeratin positive carcinomas into adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma and urothelial carcinoma. Subsequently, organ-specific IHC-markers, if available, are used in conjunction with microarray-based second tier gene expression classifiers to assign the primary site of origin to the sample. This new hybrid approach combines IHC with a hierarchy of quantitative gene expression based classifiers into an algorithmic method that can assist pathologists to further refine and support their decision making process. | 07-04-2013 |
20130172204 | Diagnostic Methods for Glaucoma - The invention concerns a first diagnostic method for glaucoma based on an analysis of autoimmune reactivity in body fluids against at least one sample of at least partially purified ocular antigens, wherein the autoimmune reactivity against individual antigens is measured and transformed into a glaucoma score to determine the diagnostic result. Further aspects of the invention include antigen carrying elements carrying at least one sample of the at least partially purified ocular antigens and kits for diagnosis of glaucoma. Further aspects include methods of collecting a body fluid such as tears for the use in the diagnostic method for glaucoma. Yet further aspects include ocular antigens serving as diagnostic markers and/or for preparing pharmaceutical compositions for treatment of glaucoma. The invention further concerns a second diagnostic method for glaucoma comprising the steps of a) providing an in vitro culture of cells; b) incubating a body fluid from a test individual with the in vitro culture of cells or incubating components, which are fractionated from the body fluid or from a body specimen of the test individual with the in vitro culture of cells; c) analyzing protein expression of the cells and/or analyzing the viability of the cells after treatment according to step b); and d) comparing the results of the analysis in step c) with standard data to determine a diagnostic result. | 07-04-2013 |
20130172205 | MARKERS OF ACUTE KIDNEY FAILURE - The present invention relates to the method of determining the risk of acute kidney injury comprising determining the amount of a marker selected from VCAN, NRP1, CCL2, CCL19, COL3A1, GZMM or any combination thereof in a sample. | 07-04-2013 |
20130172206 | GENOME-WIDE DETECTION OF GENOMIC REARRANGEMENTS AND USE OF GENOMIC REARRANGEMENTS TO DIAGNOSE GENETIC DISEASE - The disclosure relates to the genome-wide identification of “rearrangement hotspots”. The disclosure also relates to a microarray chip system for use in detecting genomic rearrangements and a method of manufacturing a microarray chip system useful for detecting genomic rearrangements. The disclosure also relates to methods for detecting genomic rearrangements associated with genetic diseases. The disclosure further relates to methods for using copy number variants in chromosome 2 for detecting Tourette Syndrome. | 07-04-2013 |
20130172207 | FLUORESCENCE ENHANCING PLASMONIC NANOSCOPIC GOLD FILMS AND ASSAYS BASED THEREON - Disclosed are nanostructured gold films which may be produced by solution-phase depositions of gold ions onto a variety of surfaces. The resulting plasmonic gold films are used for enhanced spectroscopic-based immunoassays in multiplexed microarray format with detection mechanisms based on either surface-enhanced Raman scattering or near-infrared fluorescence enhancement. The preparation of the films and subsequent modifications of the gold film surfaces afford increased sensitivity for various microarrays. The films are discontinuous, forming gold “islands.” Sensitivity, size, shape, and density of the nanoscopic gold islands comprising the discontinuous nanostructured gold film are controlled to enhance the intensity of Raman scattering and fluorescence in the near-infrared, allowing for improved measurements in clinical diagnostic or biomedical research applications. | 07-04-2013 |
20130172208 | ASSESSMENT OF BONE MARROW RECOVERY BY MEASURING PLASMA EXOSOME mRNAS - The present disclosure relates to the characterization of bone marrow conditions through the quantification of bone marrow-associated markers. In several embodiments, the bone marrow-associated markers are expressed in exosomes, which can be obtained from biological fluid samples, such as plasma or whole blood. In several embodiments, quantification of such markers allows for the assessment of bone marrow recovery following bone marrow transplantation. | 07-04-2013 |
20130172209 | METHOD FOR IN VITRO DIAGNOSIS OR PROGNOSIS OF TESTICULAR CANCER - The invention relates to a method for in vitro diagnosis or prognosis of testicular cancer which comprises a step of detecting the presence or absence of at least one expression product from at least one nucleic acid sequence selected from the sequences identified in SEQ ID NOS: 1 to 6 or from the sequences which exhibit at least 99% identity with one of the sequences identified in SEQ ID NOS: 1 to 6, to isolated nucleic acid sequences and to the use thereof as a testicular cancer marker. | 07-04-2013 |
20130172210 | METHOD OF DRUG DESIGN - The invention provides a method of identifying biologically active compounds comprising: (a) designing a first library of compounds of formula (1) to scan molecular diversity wherein each compound of the library has at least two pharmacophoric groups R1 to R5 as defined below and wherein compound of the library has same number of pharmacophoric groups; (b) assaying the first library of compounds in one or more biological assay(s); and (c) designing a second library wherein each compound of the second library contains one or more additional pharmacophoric group with respect to the first library; such that the/each component of the first and second library is a compound of formula (1). | 07-04-2013 |
20130172211 | LIGATION-BASED DETECTION OF GENETIC VARIANTS - The present invention provides assays systems and methods for detection of genetic variants in a sample, including copy number variation and single nucleotide polymorphisms. The invention preferably employs the technique of tandem ligation, i.e. the ligation of two or more fixed sequence oligonucleotides and one or more bridging oligonucleotides complementary to a region between the fixed sequence oligonucleotides. | 07-04-2013 |
20130172212 | LIGATION-BASED DETECTION OF GENETIC VARIANTS - The present invention provides assays systems and methods for detection of genetic variants in a sample, including copy number variation and single nucleotide polymorphisms. The invention preferably employs the technique of tandem ligation, i.e. the ligation of two or more fixed sequence oligonucleotides and one or more bridging oligonucleotides complementary to a region between the fixed sequence oligonucleotides. | 07-04-2013 |
20130172213 | LIGATION-BASED DETECTION OF GENETIC VARIANTS - The present invention provides assays systems and methods for detection of genetic variants in a sample, including copy number variation and single nucleotide polymorphisms. The invention preferably employs the technique of tandem ligation, i.e. the ligation of two or more fixed sequence oligonucleotides and one or more bridging oligonucleotides complementary to a region between the fixed sequence oligonucleotides. | 07-04-2013 |
20130172214 | METHODS FOR DETECTING PLASTICIZERS - Nanoparticles having one or more attached sensing moieties including uridine 5′-triphosphate (UTP) and deoxythymidine 5′-triphosphate (dTTP), are disclosed herein. These nanoparticles can, for example, be used for detection of plasticizers, such as phthalates, in the sample. Methods, kits and apparatuses using these nanoparticles for detecting plasticizers in a sample are also disclosed herein. | 07-04-2013 |
20130178378 | MULTIPLEX DIGITAL PCR - Embodiments of the claimed subject matter are directed to the ability to further multiplex in the digital regime using combinatorial color, temporal, and intensity encoding of probe sequences for a greater number of total signal readouts. A digital PCR solution is provide which enables the unique ability to identify a greater number of fluorescent probe sequences by using multiple color, temporal, and intensity combinations to encode each unique probe sequence. Furthermore, less expensive real-time PCR amplification indicators such as PicoGreen can be used to achieve multiplexed digital PCR based on temporal cues, intensity cues, or intensity and temporal cues combined, thus distinguishing primer pairs at greater degrees with significant cost reductions. These can also be used to enhance controls and normalize results for greater accuracy. | 07-11-2013 |
20130178379 | Identifying Markers of Caloric Restriction and Caloric Restriction Mimetics - Markers of caloric restriction (CR) can be identified in a selected tissue by exposing an animal to CR conditions and selecting one or more genes differentially expressed in response to CR conditions in multiple subject groups. A candidate compound can be screened for likely ability to mimic the effects of CR when administered to an animal by comparing the tissue levels of expression products of the genes in animals treated with the candidate compound to those of animals subjected to CR. | 07-11-2013 |
20130178380 | O-RING SYSTEMS AND METHODS FOR QUANTIFICATION OF MULTIPLEX BIOMARKERS IN MULTIPLE SAMPLES - Kits and methods of using O-rings having apertures are provided herein. O-rings are useful for incubating with a sample fluid potentially having one or more biomarkers, in order to detect the presence of the biomarkers. O-rings can be readily organized in a trackable manner prior to and during incubation with the sample fluid. O-rings can also be readily transferred and organized into one or more trackable arrays for detecting the presence of bound biomarkers and measuring the signaling product generated by bound detect molecule-linked enzymes present in a homogeneous solution with a spectrophotometer. | 07-11-2013 |
20130178381 | MEANS AND METHODS FOR MOLECULAR CLASSIFICATION OF BREAST CANCER - The invention relates to a method of typing a sample from a breast cancer patient. More specifically, the invention relates to a method for classification of breast cancer according to the presence or absence of Estrogen Receptor (ER), Progesterone Receptor (PR) and Human Epidermal growth factor Receptor 2 (ERBB2; HER2). More specifically, the invention provides methods and means to classify breast cancer as ER positive, triple negative (ER | 07-11-2013 |
20130178382 | Identification of Modulators of Autophagy - Methods for identifying compounds that inhibit or stimulate the autophagy pathway are described. Devices for detecting the expression of autophagy-related genes and kits for assaying the expression of autophagy-related genes are also described. Also described are methods for identifying individuals susceptible to or afflicted with a disease state associated with an autophagy pathway defect. | 07-11-2013 |
20130178383 | VESICLE ISOLATION METHODS - Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease. Circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles. Biomarkers can be used for theranostic purposes to select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. The biomarkers can be circulating biomarkers, including vesicles and microRNA. | 07-11-2013 |
20130178384 | Process For Measuring Antigen Content - A process for measuring the amount of an antigen in a sample comprising the steps of binding the antigen to a solid phase, forming an antigen-antibody immunocomplex on the solid phase by applying a detection antibody that is specific for the antigen, liberating the detection antibody from the immunocomplex by applying a polypeptide that disrupts the immunocomplex by competing against the antigen for binding to the detection antibody, collecting the liberated detection antibody; and quantifying the liberated detection antibody to measure the amount of the antigen in the sample. | 07-11-2013 |
20130178385 | BIOMARKERS - The invention relates to a method of diagnosing or monitoring schizophrenia or other psychotic disorder. | 07-11-2013 |
20130178386 | PLATELET BIOMARKERS FOR THE DETECTION OF DISEASE - The present inventors have surprisingly discovered that platelets sequester angiogenic regulators and prevent their degradation. Thus, by analyzing levels of angiogenic regulators in platelets, it is now possible to detect angiogenic activity, even at an early stage. By monitoring for changes in angiogenic activity, the presence of cancer or other angiogenic diseases or disorders can be predicted. | 07-11-2013 |
20130178387 | NUCLEIC ACID MOLECULES AND COLLECTIONS THEREOF, THEIR APPLICATION AND MODIFICATION - The invention provides a method for characterising a sample comprising nucleic acid derived from a cell. The method comprises determining whether a sample comprises at least a minimal sequence of at least one new microRNA (miRNA) according to the invention or a mammalian ortholog thereof and characterizing the sample on the basis of the presence or absence of the miRNA. The invention further provides nucleic acid molecules and collections thereof and their use in therapeutic and diagnostic applications. The invention furthermore provides a method for identifying a miRNA molecule or a precursor molecule thereof. | 07-11-2013 |
20130178388 | Methods and Kits for the Diagnosis of Rheumatoid Arthritis - The present invention relates to the identification and use of proteins with clinical relevance to rheumatoid arthritis (RA). In particular, the invention provides the identity of marker proteins that specifically react with RA-associated autoantibodies. Also provided are methods, arrays and kits for using these proteins in the diagnosis of RA, and in the selection and/or monitoring of treatment regimens. | 07-11-2013 |
20130178389 | COMPOSITE ASSAY FOR DEVELOPMENTAL DISORDERS - This invention relates generally to diagnosing developmental disorders by detecting two or more genetic characteristics from a nucleic acid extracted from a sample taken from a patient. The genetic characteristics detected include nucleic acid expression profiles, nucleic acid sequences, and nucleic acid copy numbers. The genetic characteristics may be detected using sequencing technology, array based technology, or both. At least two genetic characteristics are compared to respective controls. From the comparison a diagnostic profile of a developmental disorder for the patient is formed. | 07-11-2013 |
20130178390 | SYSTEM COMPRISING BACTERIOPHAGES AND PARTICLES THAT CONTAIN ACTIVE SUBSTANCES - The present invention concerns a system, comprising bacteriophages and particles comprising active agents, in which a first additional peptide is fused to proteins of the bacteriophage, the first additional peptide adheres to the surface of the particle and furthermore a second additional peptide is fused to proteins of the bacteriophage. The second additional peptide can adhere on substrate surfaces. The present invention furthermore concerns the use of the system for delayed release of active agents and also a method for production of the system. The present invention furthermore concerns a method for the selection of phage species from a combinatorial phage population. | 07-11-2013 |
20130178391 | METHODS FOR PREDICTING TREATMENT RESPONSE BASED ON THE EXPRESSION PROFILES OF BIOMARKER GENES IN NOTCH MEDIATED CANCERS - The invention relates to the identification and use of gene expression profiles, or patterns, with clinical relevance to the treatment of cellular proliferative disorders, especially those mediated by aberrant Notch signaling using a Notch signaling inhibitor. In particular, the invention provides the identities of genes, whose individual or cumulative expression patterns may be useful in various assays. The gene expression profiles, whether embodied in nucleic acid expression, protein expression, or other expression formats, may be used to select subjects afflicted with a Notch mediated cancer who will likely respond to treatment with a gamma-secretase inhibitor or another Notch inhibiting agent. It is to be understood and will be appreciated that the same markers may be used in the classification of patients being treated with other Notch inhibitors. The methods may further comprise providing diagnostic, prognostic, or predictive information based on the classifying step. Classifying may include stratifying the tumor (and thus stratifying a subject having the tumor), e.g., for a clinical trial. The methods may further comprise selecting a treatment based on the classifying step. The gene expression profiles may also aid in the early identification of patients who may be failing a therapeutic protocol with a gamma secretase inhibitor and thus provide the basis for early intervention. | 07-11-2013 |
20130178392 | METHODS OF ANALYZING AN H&E STAINED BIOLOGICAL SAMPLE - Methods comprising the use probing multiple targets in a H&E stained biological sample are provided. The methods include the steps of providing a hematoxylin and eosin stained biological sample containing multiple targets, observing the sample, removing the hematoxylin and partially removing the eosin by washing the sample, contacting the sample with a borate salt, and irradiating the sample to remove the residual eosin fluorescence. The method further includes the optionally performing the additional steps of binding at least one probe to one or more targets to the sample ,observing a signal from the probe and contacting the sample with a bleaching agent. The process of binding, observing and bleaching may be iteratively repeated. | 07-11-2013 |
20130178393 | METHODS AND KITS FOR THE DIAGNOSIS OF PROSTATE CANCER - The invention relates to methods and kits for the diagnosis of prostate cancer (PCa) in a subject, for assessing or monitoring the response to a therapy in a subject having PCa or for monitoring the progression of prostate cancer PCa based on the detection of alteration in the expression levels of at least one gene selected from the group of PC A3, PSMA and PSGR. The invention relates as well to methods for assessing whether a subject has to be subjected to a prostate biopsy, said subject having a serum PSA range within 4-10 ng/mL. | 07-11-2013 |
20130178394 | METHOD FOR CONSTRUCTING LIBRARIES OF NON-STANDARD PEPTIDE COMPOUNDS COMPRISING N-METHYL AMINO ACIDS AND OTHER SPECIAL (NON-STANDARD) AMINO ACIDS AND METHOD FOR SEARCHING AND IDENTIFYING ACTIVE SPECIES - A method for screening a non-standard peptide compound in the peptide library that binds to the target substance, comprising the steps: (i) preparing a non-standard peptide library wherein a special (non-standard) amino acid is randomly incorporated into the peptide sequence by a cell-free (in vitro) translation system comprising a tRNA acylated by a special (non-standard) amino acid; (ii) bringing the obtained peptide library in contact with a target substance; and (iii) selecting a non-standard peptide that binds to the target substance as an active peptide. | 07-11-2013 |
20130184167 | GENETIC MARKERS FOR THE PROGNOSIS OF MULTIPLE SCLEROSIS - The present invention relates to a series of genes the expression of which is altered in subjects suffering multiple sclerosis with respect to healthy subjects or in subjects suffering multiple sclerosis with a good prognosis with respect to subjects suffering multiple sclerosis with a bad prognosis. A subset formed by 13 genes and two clinical variables which allows predicting the progress of a patient with a high reliability has been validated from an initial set of genes which showed said differential expression. From said expression values, the invention provides methods for predicting the progress of a patient diagnosed with multiple sclerosis from tables of conditional probability between the expression levels of a determined gene or group of genes and the probability that the patient has a good or bad prognosis of the disease. | 07-18-2013 |
20130184168 | IMMUNOREACTIVE FRANCISELLA TULARENSIS ANTIGENS - The present invention relates to immunoreactive | 07-18-2013 |
20130184169 | METHODS FOR ASSESSING RNA PATTERNS - Methods and compositions for the characterizing of cancers by assessing RNA levels, such as determining an RNA pattern, are provided herein. The diagnosis, prognosis, monitoring and treatment or a cancer can be determined by detecting one or more RNAs, such as microRNAs. | 07-18-2013 |
20130184170 | OLIGONUCLEOTIDE AMPLIFICATION PRIMERS FOR TARGETING ONCOGENIC HPV - The present invention relates generally to the field of diagnostic and detection assays. More particularly, the present invention provides methods and reagents including biochips for detecting the presence of, or distinguishing between, one or more analytes in a sample. | 07-18-2013 |
20130184171 | MULTIPLEXED AMPLIFICATION OF SHORT NUCLEIC ACIDS - The present teachings provide methods, compositions, and kits for reverse transcribing and amplifying small nucleic acids such as micro RNAs. High levels of multiplexing are provided by the use of a zip-coded stem-loop reverse transcription primer, along with a PCR-based pre-amplification reaction that comprises a zip-coded forward primer. Detector probes in downstream decoding PCRs can take advantage of the zip-code introduced by the stem-loop reverse transcription primer. In some embodiments, further amplification is achieved by cycling the reverse transcription reaction. The present teachings also provide compositions and kits useful for performing the reverse transcription and amplification reactions described herein. | 07-18-2013 |
20130184172 | Bladder Cancer Detection Composition, Kit and Associated Methods - Compositions, kits, and methods for the diagnosis, prognosis, and monitoring of bladder cancer in a subject are provided by detecting in a urine sample a combination of biomarkers. In one embodiment of the invention, a nine-biomarker panel consisting of IL-8, MMP9, SDC1, CCL18, SERPINE1, CD44, VEGF-A, CA9, and ANG may be detected. In another embodiment of the invention, a three-biomarker panel consisting of CCL18, CD44, and VEGF-A may be detected. In yet another embodiment of the invention, a nine-biomarker panel consisting of CA9, CCL18, MMP12, TMEM45A, MMP9, SEMA3D, ERBB2, CRH, and MXRA8 may be detected. | 07-18-2013 |
20130184173 | BIOMARKERS FOR MULTIPLE SCLEROSIS - Biomarkers that can be used for the diagnosis and prognosis of multiple sclerosis in pediatric patients presenting with clinically isolated syndrome or acquired demyelination syndrome are described. | 07-18-2013 |
20130184175 | MICRORNAS DIFFERENTIALLY EXPRESSED IN CERVICAL CANCER AND USES THEREOF - The present invention concerns methods and compositions for identifying a miRNA profile for a particular condition, such as cervical disease, and using the profile in assessing the condition of a patient. | 07-18-2013 |
20130184176 | Methods and Compositions for Rapid Multiplex Amplification of STR Loci - Provided are methods for multiplex polymerase chain reaction (PCR) amplification of short tandem repeat (STR) loci that can be used to rapidly generate a highly specific STR profile from target nucleic acids. The resulting STR profiles are useful for human identification purposes in law enforcement, homeland security, military, intelligence, and paternity testing applications. | 07-18-2013 |
20130184177 | BACTERIAL SURFACE DISPLAY AND SCREENING OF THIOETHER-BRIDGE-CONTAINING PEPTIDES - The invention relates to bacterial cell surface display of post-translationally modified heterologous proteins. Provided is an isolated nucleic acid construct encoding a proteinaceous substance comprising, from the N-terminus to the C-terminus, at least (a) an N-terminal a lantibiotic leader sequence; (b) an amino acid sequence of interest to be post-translationally modified to a dehydroresidue- or thioether-bridge containing polypeptide; (c) a hydrophilic cell-wall spanning domain; (d) a sortase recognition motif; (e) a hydrophobic membrane spanning domain and (f) a C-terminal charged membrane anchoring domain. Also provided is a Gram-positive host cell expressing the construct, as well as a library of host cells. | 07-18-2013 |
20130184178 | Methods of Detecting Autoimmune or Immune-Related Diseases or Conditions - The disclosure provides methods of using phagocytic cells alone or in combination with non-phagocytic cells in the diagnosis, prognosis, or monitoring of autoimmune or immune-related diseases or conditions. The disclosure also provides methods of using phagocytic cells alone or in combination with nonphagocytic cells to identify markers of autoimmune or immune-related diseases or conditions. | 07-18-2013 |
20130190193 | COMPOSITIONS FOR DETECTION AND ANALYSIS OF POLYNUCLEOTIDES USING LIGHT HARVESTING MULTICHROMOPHORES - Methods, compositions and articles of manufacture for assaying a sample for a target polynucleotide are provided. A sample suspected of containing the target polynucleotide is contacted with a polycationic multichromophore and a sensor PNA complementary to the target polynucleotide. The sensor PNA comprises a signaling chromophore to absorb energy from the excited multichromophore and emit light in the presence of the target polynucleotide. The methods can be used in multiplex form. Kits comprising reagents for performing such methods are also provided. | 07-25-2013 |
20130190194 | DETERMINATION OF GENE EXPRESSION LEVELS OF A CELL TYPE - Methods, systems, and compositions can determine gene expression level of a specified cell-type subpopulation by direct analysis of a cell mixture sample composed of multiple subpopulations of various cell-types without the need of prior separation of the component cell-type subpopulations. A target gene and a reference gene can be identified as being informative for a specific cell-type subpopulation when at least 50% of the gene's transcripts in the cell mixture are from the subpopulation. This relative expression level in the cell mixture of the informative target and reference genes can correlate to the relative expression when measured in the isolated subpopulation. Thus, a similar biomarker can be obtained without the difficult step of isolating the cells of the subpopulation. | 07-25-2013 |
20130190195 | NUCLEIC ACID DETECTION BY BRIDGE AMPLIFICATION ON CODED PARTICLES - Particles that generate electromagnetic spectra upon appropriate illumination and in which the spectra can be converted to codes that reflect differences in the spectra are functionalized with a plurality of identical primer pairs on which bridge amplification can be performed. Using these particles, nucleic acids in a biological sample are amplified and exposed to a label that sends a signal only when bound to double-stranded DNA. The code for each particle is correlated with the primer pairs, and the captured nucleic acids are thus detected and identified. The procedure is useful for multiplex DNA or RNA detection as well as counting of target DNA and RNA molecules in the sample. | 07-25-2013 |
20130190196 | RAPID PHENOTYPIC DIAGNOSIS OF PATHOGENS AND DRUG RESISTANCE USING TRANSCRIPTIONAL EXPRESSION SIGNATURES - The specification relates generally to methods of detecting, diagnosing, and/or identifying pathogens, e.g., infectious disease pathogens and determining their drug sensitivity and appropriate methods of treatment. This invention also relates generally to methods of monitoring pathogen infection in individual subjects as well as larger populations of subjects. | 07-25-2013 |
20130190197 | METHOD OF PROFILING GENE EXPRESSION IN A SUBJECT HAVING COLORECTAL CANCER - The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 07-25-2013 |
20130190198 | METHOD FOR AUTOMATED TISSUE ANALYSIS - The invention provides an improved method for identifying and interpreting tissue specimens and/or cells derived from tissue specimens. A panel of cell-based reagents provides a number of readouts of cellular states or biomarkers that together define a profile of a diversity of cellular states or biomarkers in a tissue specimen representing the ‘systems” nature of biology. This cellular profile is interpreted using informatics tools, to identify similarities between specimens, in vivo medical conditions, and suggest options for treating medical conditions. | 07-25-2013 |
20130190199 | Methods of Analysis of Allelic Imbalance - Methods are provided for identification of genes that are imprinted. In another embodiment methods are provided for identification and analysis of genes whose expression shows allelic imbalance. The expression products transcribed from genes that are present in the genome as two or more alleles may be distinguished by hybridization to an array designed to interrogate individual alleles. Genes whose transcription products are present in amounts that vary from expected are candidates for allelic imbalance, imprinting and imprinting errors. | 07-25-2013 |
20130190200 | SNP FOR PREDICTING THE SENSITIVITY TO ANTICANCER TARGETED THERAPEUTIC FORMULATION - The present invention relates to a single nucleotide polymorphism (SNP) for predicting the sensitivity to an anticancer targeted therapeutic formulation, a polynucleotide containing the same, and a method for predicting the sensitivity to an anticancer targeted therapeutic formulation. According to the present invention, it is possible to predict the sensitivity of each individual to a certain anticancer targeted therapeutic formulation, using a small amount of a sample taken from a patient and thus to select a most suitable targeted therapeutic formulation over the entire duration of treatment for the patient. | 07-25-2013 |
20130190201 | DETECTION OF HUMAN UMBILICAL CORD TISSUE DERIVED CELLS - The invention relates to methods for detecting allogeneic therapeutic cells (such as human umbilical cord tissue-derived cells (hUTC)) in blood. The methods includes the steps of identifying one or more one or more markers positive for allogeneic therapeutic cells (e.g. hUTC) and one or more markers positive for human peripheral blood mononuclear cells (PBMC); providing a blood sample from a patient that has been treated with allogeneic therapeutic cells (e.g. hUTC), analyzing the sample using an assay method to detect one or more markers positive for PBMC and one or more markers positive for allogeneic therapeutic cells (e.g. hUTC); and distinguishing between the PBMC and one or more markers positive for allogeneic therapeutic cells (e.g. hUTC). In one embodiment, the cells are hUTC and the markers positive of hUTC include CD10 and/or CD13 and the one or more markers positive for PBMC includes CD45. | 07-25-2013 |
20130190202 | DEVICES AND PROCESSES FOR ANALYSING INDIVIDUAL CELLS - A device for individually analysing cells of interest, comprising (a) a channel for receiving the contents of a cell of interest, wherein the channel has an input end and an output end, and (b) a cell trapping site in proximity to the input end of the channel, wherein (i) the input end of the channel is adapted such that an intact cell of interest cannot enter the channel; and (ii) the channel contains one or more analytical components for analysing the contents of the cell of interest. In use, a cell is applied to the device, where it is trapped by the cell trapping means. The cell cannot enter the channel intact, but its contents can be released in situ to enter the channel's input end. The contents can then move down the channel, towards the output end, and they encounter the immobilised reagents, thereby permitting analysis of the cell contents. | 07-25-2013 |
20130190203 | Reporting And Self-Decontaminating Articles For Individual Hazard Detection And Protection - Methods, systems, and devices for the self-detection and/or self-decontamination of chemical, biological, radiological, and/or nuclear hazards, threats, and contaminants. The self-detection system preferably uses aptamers functionalized to an electronic system to sense CBRN threats. The aptamers are functionalized directly to a conductive surface such as a noble metal coated fiber or other conductive fiber strand. The self-decontamination system is preferably in communication with the self-detection system and responds to the detection of a CBRN agent by switching to a decontamination state, such as becoming absorbent or releasing an anti-CBRN agent such that it can neutralize the threat. In a preferred embodiment, the system is worn by a user. | 07-25-2013 |
20130190204 | MONOCLONAL ANTIBODIES AGAINST PCBP-1 ANTIGENS, AND USES THEREFOR - The present invention provides and includes monoclonal antibodies (MoAbs or mAbs) specific or preferentially selective for PCBP-1 antigens, hybridoma lines that secrete these PCBP-1 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect PCBP-1 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble form of PCBP-1. The present invention further includes chimeric and humanized antibodies, processes for producing monoclonal, chimeric, and humanized antibodies using recombinant DNA technology, and their therapeutic uses, particularly in the treatment of cancer. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express PCBP-1 antigens. | 07-25-2013 |
20130190205 | METHOD FOR DETECTING CYTOSINE METHYLATION IN DNA SAMPLES - Described is a method for detecting 5-methylcytosine in genomic DNA samples. First, a genomic DNA from a DNA sample is chemically converted with a reagent, 5-methylcytosine and cytosine reacting differently, and the pretreated DNA is subsequently amplified using a polymerase and at least one primer. In the next step, the amplified genomic DNA is hybridized to at least one oligonucleotide, forming a duplex, and said oligonucleotide is elongated by at least one nucleotide, the nucleotide carrying a detectable label, and the elongation depending on the methylation status of the specific cytosine in the genomic DNA sample. In the next step, the elongated oligonucleotides are analyzed for the presence of the label. | 07-25-2013 |
20130190206 | Direct Clone Analysis and Selection Technology - The present invention describes a spatial addressing technique that uses a very high-density micro-pore array for high-throughput screening of biological interactions. The therapeutic, diagnostic and drug-discovery implications of being able to identify, select and characterize specific protein-protein, protein-DNA and/or protein-carbohydrate interactions from heterogeneous populations of millions (to billions) of cells is discussed. Importantly, this technique possesses the screening and selection capacity of current display-based screening systems (i.e., millions-billions) but with greater efficiency and shorter time. | 07-25-2013 |
20130190207 | PRIORITISED GENETIC POLYMORPHISMS AND MIGRAINE SUSCEPTIBILITY - The invention provides identification of an increased risk of or a predisposition to migraine according to the presence of one or more polymorphisms in the adenosine deaminase, RNA-specific, B2 (ADARB2) gene in the nucleic acid complement of a subject. | 07-25-2013 |
20130190208 | DETECTION OF TARGET NUCLEIC ACID SEQUENCES BY EXONUCLEOLYTIC ACTIVITY USING SINGLE-LABELED IMMOBILIZED PROBES ON SOLID PHASE - The present invention relates to a novel method for detection of target nucleic acid sequences by cyclic exonucleolytic reactions (CER) or exonucleolytic reactions (ER) using single-labeled immobilized probes on a solid phase. The present invention enables to detect target nucleic acid sequences on a solid phase using single-labeled systems. Comparing with multiple-labeled systems such as dual labeling, the present invention using single-labeled probes has excellent advantages in light of convenience and cost effectiveness in probe design and preparation. Furthermore, the measurement of changes of the signal decrease during reactions is responsible for more accurate qualitative and quantitative analysis of target nucleic acid sequences. | 07-25-2013 |
20130196865 | METHOD FOR SELECTING AN IPS CELL - This application relates to a method for selecting an induced pluripotent stem cell (iPS), the method comprising: selecting an iPS cell that expresses a gene in the Dlk1-Dio3 cluster from a population of iPS cells. The method further comprises: comparing the gene expression profile determined for an iPS cell with the gene expression profile determined for an embryonic stem cell; identifying a gene that is differentially expressed in the embryonic stem cell as compared to the iPS cell; and selecting the desired iPS cell from a population of iPS cells. | 08-01-2013 |
20130196866 | EXPRESSION OF ETS RELATED GENE (ERG) AND PHOSPHATASE AND TENSIN HOMOLOG (PTEN) CORRELATES WITH PROSTATE CANCER CAPSULAR PENETRATION - The disclosure provides methods for characterizing a prostate cancer sample by detecting expression of ERG, PTEN or both, changes in which relative to a normal control are shown herein to be correlated with prostate cancer capsular penetration and more aggressive forms of prostate cancer. Such methods are useful for the prognosis of prostate cancer capsular penetration and for making treatment decisions in patients with prostate cancer that has penetrated the capsule. Also provided are kits that can be used with such methods. | 08-01-2013 |
20130196867 | COMBINATORIAL POST-TRANSLATIONALLY-MODIFIED HISTONE PEPTIDES, ARRAYS THEREOF, AND METHODS OF USING THE SAME - The present invention generally relates to combinatorial post-translationally-modified histone peptides and arrays thereof. The invention further relates to methods of using the same. | 08-01-2013 |
20130196868 | METHODS AND ALGORITHMS FOR AIDING IN THE DETECTION OF CANCER - A method of data interpretation from a multiplex cancer assay is described. The aggregate normalized score from the assay is transformed to a quantitative risk score quantifying a human subject's increased risk for the presence of cancer as compared to the known prevalence of the cancer in the population before testing the subject. | 08-01-2013 |
20130196869 | MICRORNA PROFILING FOR DIAGNOSIS OF DYSPLASTIC NEVI AND MELANOMA - Provided herein are methods for miRNA profiling for the diagnosis, prognosis, and management of melanoma and differentiation of melanoma from nevi. | 08-01-2013 |
20130196870 | SYSTEMS AND METHODS USING BIOMARKER PANEL DATA - Embodiments of the disclosure are related to systems and methods for utilizing biomarker panel data and related medical devices and methods, amongst other things. An embodiment can include a method of screening patients. The method can include quantifying levels of one or more of a panel of biomarkers in a biological sample of a patient. The method can further include analyzing the quantified levels. In some embodiments, the panel of biomarkers includes at least two selected from the group consisting of CRP, SGP-130, sIL-2R, sTNFR-II, IFNg, BNP, sST2, MMP-2, MMP-9, TIMP-1, TIMP-2, TIMP-4. In an embodiment, the disclosure can include a method of diagnosing a patient. The method can include quantifying levels of one or more of a panel of biomarkers in a biological sample of a patient. The method can further include diagnosing the patient based at least in part on the quantified levels. In some embodiments, the panel of biomarkers includes at least two selected from the group consisting of CRP, SGP-130, sIL-2R, sTNFR-II, IFNg, BNP, sST2, MMP-2, MMP-9, TIMP-1, TIMP-2, TIMP-4. Other embodiments are also included herein. | 08-01-2013 |
20130196871 | Fibronectin Binding Domains with Reduced Immunogenicity - Fibronectin type III ( | 08-01-2013 |
20130196872 | PATHOGEN DETECTION - Pathogens are detected through the use of mutation-resistant ligands. | 08-01-2013 |
20130196873 | METHOD OF ANALYSING A BLOOD SAMPLE OF A SUBJECT FOR THE PRESENCE OF A DISEASE MARKER - The present invention relates to a method of analyzing a blood sample of a subject for the presence of a disease marker, said method comprising the steps of a) extracting nucleic acid from anucleated blood cells in said blood sample to provide an anucleated blood cells-extracted nucleic acid fraction, and b) analysing said anucleated blood cells-extracted nucleic acid fraction for the presence of a disease marker, wherein said disease marker is a disease-specific mutation in a gene of a cell of said subject, or wherein said disease marker is a disease-specific expression profile of genes of a cell of said subject. | 08-01-2013 |
20130196874 | SENSOR FOR DETECTION AND IDENTIFICATION OF ANALYTES AND A METHOD THEREOF - The present invention discloses a method and sensor for detection and identification of analytes such as foreign material or DNA and RNA in particular in low concentration. The sensitivity of the method allows the detection of few molecules (down to a single one) independent on the concentration of the sample. There is provided a sensor for analyte(s) detection in a fluid sample. The sensor comprises at least one tube-like member carrying an arrangement of probes patterned thereinside. | 08-01-2013 |
20130196875 | CELL CHARACTERISATION - The present invention concerns the finding that non-coding RNA profiles can be exploited as a means of monitoring, assessing, comparing, establishing and/or determining certain cell characteristics and/or profiles. Accordingly, the invention provides the use of non-coding RNA molecules for characterising and/or profiling cells. | 08-01-2013 |
20130196876 | DIFFERENTIAL DIAGNOSIS OF PANCREATIC ADENOMAS - The invention relates to a method for the diagnosis of pancreatic adenomas, to biomarkers for use in said method, to kits for carrying out the method, and to the use of said method for detecting pancreatic adenomas. The following markets are used: KCNABT, CIORF77, SPSB2, MED9, STK40, ITGB3BP, SCEL, PDPK1, DUSP15, MED19, NAP1L3, TMOD3, CSPP1, TMOD2, INPP5A and IGHG. | 08-01-2013 |
20130196877 | IDENTIFICATION OF MULTI-MODAL ASSOCIATIONS BETWEEN BIOMEDICAL MARKERS - The present invention relates to a method for identifying multi-modal associations between biomedical markers which allows for the determination of network nodes and/or high ranking network members or combinations thereof, indicative of having a diagnostic, prognostic or predictive value for a medical condition, in particular ovarian cancer. The present invention further relates to a biomedical marker or group of biomedical markers associated with a high likelihood of responsiveness of a subject to a cancer therapy, preferably a platinum based cancer therapy, wherein said bio-medical marker or group of biomedical markers comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 8, 19, 20 or all markers selected from PKMYT1, SKIL, RAB8A, HIRIP3, CTNNB1, NGFR, ZCCHC11, LSP1, CD200, PAX8, CYBRD1, HOXC11, TCEAL1, FZD10,FZD1, BBS4, IRS2, TLX3, TSPAN2, TXN, and CFLAR. Furthermore, an assay for detecting, diagnosing, graduating, monitoring or prognosticating a medical condition, or for detecting, 1 diagnosing, monitoring or prognosticating the responsiveness of a subject to a therapy against said medical condition, in particular ovarian cancer, is provided, as well as a corresponding method for classifying a subject comprising and a medical decision support system. | 08-01-2013 |
20130196878 | APPARATUS AND METHOD FOR DETECTING MULTIPLEX TARGET NUCLEIC ACIDS IN REAL TIME - The present invention relates to an apparatus and method for simultaneously detecting various types of target nucleic acids in real time, whereby various types of target nucleic acids can be simultaneously detected in real time to allow manufacturing an apparatus in the shape of a chip, and to efficiently detect a plurality of species of nucleic acids in a small space. | 08-01-2013 |
20130203613 | DEVICE AND METHOD FOR THE VERIFICATION AND QUANTITATIVE ANALYSIS OF ANALYTES, PARTICULARLY MYCOTOXINS - The present invention relates to a device and a method for the verification and quantitative analysis of analytes and their application for the verification and quantitative analysis of mycotoxins. | 08-08-2013 |
20130203614 | METHODS FOR PREDICTING THE SURVIVAL TIME OF A PATIENT SUFFERING FROM A SOLID CANCER - The present invention provides methods and kits for the prognosis of survival time of a patient suffering from a cancerous tumor. The method involves quantitating the density of Th17 cells at the center of the tumor and at the invasive margin of the tumor, where low density values at each location indicate a favourable prognosis, high values at each location indicate an unfavourable prognosis, and heterogeneous values at the two locations (one high, one low) indicate an intermediate prognosis. | 08-08-2013 |
20130203615 | ANTIANDROGEN THERAPY MONITORING METHODS AND COMPOSITIONS - The present invention provides methods of evaluating the effectiveness of an antiandrogen therapy in a human by comparing the pre- and post antiandrogen treatment levels of an androgen modulated diagnostic marker and a prostate-specific, androgen independent, diagnostic marker in the human. Methods utilizing these markers are also provided that are useful for identifying antiandrogen compounds capable of killing prostate cancer cells, and identifying a human suspected of responding more, or less, favorably to treatment with an antiandrogen compound and monitoring the treatment thereof. Kits and compositions related to these methods are also provided. | 08-08-2013 |
20130203616 | ASSAYS FOR ANTI-DRUG ANTIBODIES IN THE PRESENCE OF ABUNDANT ENDOGENOUS PROTEIN COUNTERPART OF THE DRUG - Methods and kits for detecting antibodies (e.g., anti-drug antibodies) specific for abundant body fluid components are provided. Such methods and kits permit the detection of, for example, human serum albumin in human body fluids, such as blood, plasma and serum. | 08-08-2013 |
20130203617 | Glycoprotein Analysis Kit and Use Thereof - Disclosed are a glycoprotein analysis kit and use thereof. The glycoprotein analysis kit comprises a fluorescently labeled antibody, a fluorescently labeled biomaterial, and a support, and is used in a dual probing method for analyzing the content of a glycoprotein and profiling the oligosaccharide chain, simultaneously, and a method for selecting a single cell producing the glycoprotein having a desired glycosylation pattern. Also, a single cell producing the glycoprotein having a desired glycosylation pattern is provided. | 08-08-2013 |
20130203618 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS - The present invention features methods and compositions for the diagnosis, prognosis, treatment, and/or amelioration of cellular proliferative disorders utilizing enzymes of the serine biosynthetic pathway (e.g., phosphoglycerate dehydrogenase (PHGDH), phosphoserine aminotransferase (PSAT), or phosphoserine phosphatase (PSPH)). | 08-08-2013 |
20130203619 | Methods for Detecting, Diagnosing and Treating Human Renal Cell Carcinoma - Gene expression profiling and hierarchical clustering analysis readily identify differential gene expressions in normal renal epithelial cells and renal cell carcinomas. Genes identified by this analysis would be useful for diagnosis, prognosis and development of targeted therapy for the prevention and treatment of conventional renal cell carcinoma. | 08-08-2013 |
20130203620 | MODULAR ASSAY PLATES, READER SYSTEMS AND METHODS FOR TEST MEASUREMENTS - Luminescence test measurements are conducted using an assay module having integrated electrodes with a reader apparatus adapted to receive assay modules, induce luminescence, preferably electrode induced luminescence, in the wells or assay regions of the assay modules and measure the induced luminescence. | 08-08-2013 |
20130203621 | GENE RELATING TO ESTIMATION OF POSTOPERATIVE PROGNOSIS FOR BREAST CANCER - It is intended to provide a system of predicting the postoperative prognosis in a patient with breast cancer from the viewpoint of gene expression based on the data obtained by genome-wide and comprehensive analysis on gene expression in breast cancer. Expression of human genes is comprehensively analyzed by using a DNA microarray and gene expression functions in various breast cancer conditions are compared, thereby establishing a system of predicting the postoperative prognosis of breast cancer. | 08-08-2013 |
20130203622 | TRANSCRIPTOMIC BIOMARKER OF MYOCARDITIS - Molecular signatures that function as very sensitive diagnostic biomarker for myocarditis, heart disease and disorders thereof, are identified. | 08-08-2013 |
20130203623 | METHOD AND KIT FOR CLASSIFYING A PATIENT - Provided is a Suppressive Subtractive Hybridization-Oligonucleotide Microarray (SSH-OM) method for the prediction of treatment response for personalized medicine applications and for the prediction of cancer classes and subclasses. | 08-08-2013 |
20130203624 | Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions - This invention provides methods of using phagocytic cells alone or in combination with non-phagocytic cells in the diagnosis, prognosis, or monitoring of prenatal or pregnancy-related diseases or conditions. The invention also provides methods of using phagocytic cells alone or in combination with non-phagocytic cells to identify markers of prenatal or pregnancy-related diseases or conditions. | 08-08-2013 |
20130203625 | SUV420H1 AND SUV420H2 AS TARGET GENES FOR CANCER THERAPY AND DIAGNOSIS - The present invention relates to the roles played by the SUV420H1 and SUV420H2 genes in carcinogenesis and features a method for treating or preventing cancer by administering a double-stranded molecule against the SUV420H1 or SUV420H2 gene or a composition or vector containing such a double-stranded molecule. The present invention also features methods and kits for detecting or diagnosing cancer in a subject, including detecting an expression level of the SUV420H1 or SUV420H2 gene. The present invention further features methods and kits for assessing or determining the prognosis of a subject with cancer, including detecting the expression level of an SUV420H2 gene. Also, disclosed are methods of screening for candidate substances for treating or preventing cancer or inhibiting cancer cell growth, using as an index their effect on the expression or activity of SUV420H1 or SUV420H2. | 08-08-2013 |
20130203626 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID BASED DIAGNOSTIC ASSAYS FOR VARIABLE SEQUENCE TARGETS - The present invention relates to compositions and methods for nucleic acid based diagnostic assays. In particular, the present invention provides primers for asymmetric PCR and other amplification modalities. In some embodiments, the present invention provides multiple primers for amplification of related nucleic acid targets in a single reaction. | 08-08-2013 |
20130203627 | System and Method For Detecting Multiple Molecules in One Assay - A rapid diagnostic system that delivers a panel of serologic assay results using a small amount of blood, serum, or plasma is described. The system includes a disposable cartridge, including an integral lens portion coupled to a planar waveguide, and a reader instrument, based on planar waveguide imaging technology. The cartridge incorporates a microarray of recombinant antigens and antibody controls in a fluidic channel, providing multiple parallel fluorescence assay results for a single sample. | 08-08-2013 |
20130203628 | SET OF OLIGONUCLEOTIDE PROBES AS WELL AS METHODS AND USES THERETO - The present disclosure relates to a set of at least 100 single-stranded oligonucleotide probes directed against (or complementary to) portions of a genomic target sequence of interest. The present disclosure also relates to a method of detecting a genomic target sequence of interest using the set of oligonucleotide probes and a method of generating the set of oligonucleotide probes. Further, the present disclosure relates to a kit comprising the set of oligonucleotide probes and at least one further component. | 08-08-2013 |
20130203629 | METHOD FOR FUNCTIONALIZING SURFACES FOR ANALYTE DETECTION - The invention relates to a device for detecting analytes, including a plastic substrate at least partially covered by bonding polymers attached to the substrate in a non-covalent manner, said bonding polymers comprising a polysaccharide backbone provided with aromatic groupings and carboxylic acid groupings. | 08-08-2013 |
20130210649 | PLATFORM FOR IMMOBILIZATION AND OBSERVATION OF SUBCELLULAR PROCESSES - A method of immobilizing matter for imaging that includes providing an array of nanofibers and directing matter to the array of the nanofibers. The matter is immobilized when contacting at least three nanofibers of the array of nanofibers simultaneously. Adjacent nanofibers in the array of nanofibers may be separated by a pitch as great as 100 microns. The immobilized matter on the array of nanofibers may then be imaged. In some examples, the matter may be cell matter, such as protoplasts. | 08-15-2013 |
20130210650 | PERIPHERAL GENE EXPRESSION BIOMARKERS FOR AUTISM - The disclosed invention comprises methods and materials for screening cells for genetic profiles associated with autism spectrum disorders. The methods typically involve isolating a cell from an individual and then observing the expression profile of one or more genes in the cell, wherein certain expression patterns of the genes observed are associated with autism spectrum disorders. | 08-15-2013 |
20130210651 | Borrelia Diagnostics and Screening Methods - The present invention provides methods of detecting | 08-15-2013 |
20130210652 | NANOTECHNOLOGY ENABLED POINT OF CARE TESTING DEVICE - The present invention relates to an apparatus to detect biological parameters in the analysis of a sample, specimen, or assay. The system includes a device for determining one or more values for one or more measurable characteristics of a sample. In an aspect, the device can be configured to operate on any of a mobile device, tablet computer, laptop computer, desktop computer, digital pen, medical testing tool or electronic device. In another aspect, the device can comprise a synchronization component that synchronizes the device to a network system. | 08-15-2013 |
20130210653 | SCANNING MULTIFUNCTIONAL PARTICLES - The present invention provides, among other things, methods and systems for characterizing multifunctional objects using a flow-through device, such as, a flow cytometer. In some embodiments, an inventive method according to the present invention includes one more steps of (a) interrogating a plurality of objects (e.g., particles), wherein each individual object (e.g., particle) comprises one or more interrogation regions detectable as a sequence of events; (b) recording multiple events, wherein each individual event corresponds to each individual interrogation region detectable above a pre-determined triggering threshold; (c) grouping the recorded multiple events, and (d) characterizing the plurality of objects based on the grouped events. | 08-15-2013 |
20130210654 | Multiplex Immune Effector Molecule Assay - Methods for detecting at least seven cytokines in a porcine biological sample are provided. Also provided are multiplex assay kits that allow for the detection and quantification of the cytokines in a single reaction mixture. Use of the methods and kits for diagnosis, prognosis, and monitoring of immunity is also contemplated. | 08-15-2013 |
20130210655 | MICROARRAY WITH ENHANCED SPECIFICITY - Provided is an array including a plurality of target specific array nucleic acid molecules wherein each target specific array nucleic acid molecule contains: (i) a 5′-end DNA segment, (ii) a 3′-end DNA segment, and (iii) an RNA sequence of 1-6 bases within the molecule; and wherein each of the 5-end of the target specific array nucleic acid molecules is coupled to a detectable label. A method for detecting a target nucleic acid and a method for detecting polymorphism in a target nucleic using the array are also provided. | 08-15-2013 |
20130210656 | LATE-PCR - A non-symmetric polymerise chain reaction (PCR) amplification method employing a limiting primer in low concentration whose concentration-adjusted melting point at least equals, and preferably exceeds, that of the excess primer, the latter in turn not being more than 25° C. below the melting temperature of the amplicon. Assays employing such amplification and labeled hybridization probes, including assays that include a detection step following primer extension or a low-temperature probe, or both. Kits for performing such assays and primer or primer-and-probe sets for performing the foregoing amplifications and assays. | 08-15-2013 |
20130210657 | Method of Determining Risk of Autism Spectrum Disorder - A method of assessing risk in a human subject of ASD is provided comprising the step of identifying in a nucleic acid-containing sample obtained from the human subject copy number variations associated with SHANK1. Determination of copy number variations associated with SHANK1 is indicative of a risk of ASD in the human subject. | 08-15-2013 |
20130210658 | Polynucleotide Marker Genes and their Expression, for Diagnosis of Endotoxemia - The invention discloses isolated endotoxemia marker polynucleotides selected from any one of 163 different polynucleotide sequences, or variants thereof. Endotoxemia related conditions are diagnosed in a test subject by aberrant expression of at least one of the endotoxemia markers or variants thereof. Of practical use, is the early diagnosis of disease, determining those animals at risk of developing endotoxemia, monitoring of an animals immune response to the disease and the enablement of better treatments. Of particular interest is the diagnosis of laminitis in hoofed animals, including horses. | 08-15-2013 |
20130210659 | MOLECULAR DIAGNOSTIC SCREENING ASSAY - The invention generally relates to method for screening for a condition in a subject. In certain embodiments, methods of the invention involve obtaining a pool of nucleic acids from a sample, incubating the nucleic acids with first and second sets of binders, in which the first set binds uniquely to different regions of a target nucleic acid in the pool, the second set binds uniquely to different regions of a reference nucleic acid in the pool, and the first and second sets include different detectable labels, removing unbound binders, detecting the labels, and screening for a condition based upon results of the detecting step. | 08-15-2013 |
20130210660 | Method for Active Hybridization in Microarrays with Denaturing Function - A method for active hybridization in microarrays includes pumping an already prepared sample through a denaturing unit with a microarray and then through a reaction region which is spatially separate from the denaturing unit. The denatured reactive sample components are hybridized in the reaction region. | 08-15-2013 |
20130210661 | MARKERS OF VULNERABILITY OF THE ATHEROSCLEROSIS PLAQUE - The present invention relates to methods for determining the presence of an unstable atherosclerotic plaque in an individual, comprising the steps of measuring the presence and/or level of at least one biochemical marker in a biological sample obtained from said individual, and, based on the result of this measurement, determining the presence of an unstable atherosclerotic plaque in the individual. The present invention also relates to a method for diagnosing a vascular or metabolic disease or an increased predisposition to an adverse outcome in an individual comprising determining the presence of an unstable atherosclerotic plaque in the individual. The present invention also relates to an in vitro method for identifying markers of the presence of an unstable atherosclerotic plaque in a subject, using depleted protein extracts obtained from proteins extracts from biological samples representative of stable and unstable atherosclerotic plaques. | 08-15-2013 |
20130210662 | DETECTION OF TARGET METABOLITES - The present invention provides methods and compositions for highly sensitive detection of a metabolite of interest comprising use of a nanodetection device that comprises an anchoring part, a bridging part and a signal producing part wherein the anchoring part is a molecular motor, the signal producing part is a nanorod and the bridging part is a protein that specifically binds to the metabolite of interest. | 08-15-2013 |
20130210663 | METHODS AND COMPOUNDS FOR THE DIAGNOSIS AND TREATMENT OF CANCER - The present invention provides for methods for use in the diagnosis and prognosis of cancer. The invention further provides to binding agents and kits for us e.g., in such methods. The present invention further relates to compositions, methods of making said compositions and methods of using the same, including use in the treatment and diagnosis of cancer, including lung, lymphoma, liver, thyroid and bladder cancer. Compositions of the present invention useful in the treatment of cancer include anti-sense and small inhibitory RNAs (siRNA). | 08-15-2013 |
20130210664 | Methods for the Identification of Methyltransferase Interacting Molecules and for the Purification of Methyltransferase Proteins - The present invention relates to immobilization compounds, immobilization products and preparations thereof as well as methods and uses for the identification of methyltransferase interacting compounds or for the purification or identification of methyltransferase proteins. | 08-15-2013 |
20130210665 | METHOD AND KIT FOR THE DIAGNOSIS AND/OR PROGNOSIS OF TOLERANCE IN LIVER TRANSPLANTATION - The invention refers to a method and kit for the in vitro diagnosis and/or prognosis of the tolerant state of a patient to be submitted to liver transplantation, which comprises assessing the level of systemic and/or intra-hepatic iron stores in a biological sample obtained from the patient under investigation, and comparing it either with the level of iron stores of a reference sample, or with a pre-determined threshold. | 08-15-2013 |
20130210666 | Markers of the Male Urogenital Tract - Methods for detecting urogenital conditions or urogenital status in a subject are described comprising measuring urogenital markers or polynucleotides encoding the markers in a sample from the subject. The invention also provides localization or imaging methods for urogenital conditions, and kits for carrying out the methods of the invention. The invention also contemplates therapeutic applications for urogenital conditions employing urogenital markers, polynucleotides encoding the markers, and/or binding agents for the markers. | 08-15-2013 |
20130210667 | Biomarkers for Predicting Kidney and Glomerular Pathologies - Biomarkers for determining a kidney and glomerular pathologies and methods of using the same are described. | 08-15-2013 |
20130210668 | METHOD FOR DETERMINATION OF PROGRESSION RISK OF GLAUCOMA - A method of determining the presence or the absence of a glaucoma risk, including the steps of detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism which is located on a 31st base of a base sequence, in a sample from a subject, wherein the base sequence is at least one base sequence selected from the group consisting of base sequences shown in SEQ ID NOs: 203 to 752 or a complementary sequence thereto (step A), and comparing the allele and/or the genotype detected in the step A with at least one of an allele and/or a genotype, containing a high-risk allele, in the base sequences shown in SEQ ID NOs: 203 to 752 (step B). According to the method of the present invention, the level of a progressive risk of glaucoma in a sample donor can be determined by analyzing an allele or a genotype of a single nucleotide polymorphism in the present invention in the sample, so that the sample donor can take a preventive measure of glaucoma, or can receive appropriate treatments, on the basis of this risk. | 08-15-2013 |
20130210669 | DEVICE AND METHODS FOR THE IMMUNOLOGICAL IDENTIFICATION OF CEREBROSPINAL FLUID - The present disclosure relates to detection of the presence or absence of cerebrospinal fluid (CSF) in a sample by the detection of one or more antigens that are enriched in CSF compared to their levels in other bodily fluids. The devices and methods are suitable for the detection of the presence or absence of cerebrospinal fluid in samples of mixed bodily fluids from a wide variety of human populations crossing ethnicity, age, gender, health status and genetic variability. | 08-15-2013 |
20130210670 | METHOD FOR DETERMINING A BIOLOGICAL PATHWAY ACTIVITY - Method for determining a level of activity of a biological pathway from a biological sample of a patient suffering from a pathology, the method comprising the steps of:
| 08-15-2013 |
20130210671 | IMMUNOREACTIVE ANTIGENS OF MYCOPLASMA HEAMOFELIS AND DIAGNOSTIC IMMUNOASSAY - Compositions for use in diagnostic screens for | 08-15-2013 |
20130217588 | Methods for Identifying Eubacteria - This invention relates, e.g., to methods for detecting a aubacterium, determining if the eubacterium is Gram-positive or Gram-negative, and determining the species of the eubacterium in a sample. | 08-22-2013 |
20130217589 | METHODS FOR IDENTIFYING AGENTS WITH DESIRED BIOLOGICAL ACTIVITY - Provided are methods, systems and apparatus for identifying agents with desired biological activity. Specifically, the methods, systems, and apparatus identify functional relationships between multiple agents and/or between one or more agents and a condition of interest. Data of multiple experimental batches are normalized, batch effects accounted for, and the adjusted data used to create a projection matrix or function. The projection matrix is used to project the data into a projection space, in which the distance between a query agent or a query condition and various candidate agents may be determined. | 08-22-2013 |
20130217590 | METHODS FOR DETERMINING A PROGNOSIS FOR SURVIVAL FOR A PATIENT WITH LEUKAEMIA - A method for determining a prognosis for survival for a patient with leukaemia is described. Also described is a method for monitoring the effectiveness of a course of treatment for a patient with leukaemia, and the use of such a method in a kit. A kit determining the level of RINF is also described. | 08-22-2013 |
20130217591 | Marker Sequences for Inflammatory Prostate Diseases, Prostate Carconoma and Their Use - The present invention relates to novel marker sequences for inflammatory prostate diseases, prostate carcinoma and the diagnostic use thereof together with a method for screening of potential active substances for inflammatory prostate diseases, prostate carcinoma by means of these marker sequences. Furthermore, the invention relates to a diagnostic device containing such marker sequences for inflammatory prostate diseases, prostate carcinoma, in particular a protein biochip and the use thereof. | 08-22-2013 |
20130225426 | REACTIVITY-DEPENDENT AND INTERACTION-DEPENDENT PCR - Methods, reagents, compositions, and kits for reactivity-dependent polymerase chain reaction (RD-PCR) and interaction-dependent polymerase chain reaction (ID-PCR) are provided herein. RD-PCR is a technique useful for determining whether a reactive moiety can form a covalent bond to a target reactive moiety, for example, in screening a library of candidate reactive moieties for reactivity with a target reactive moiety, and in identifying an enzyme substrate, for example, in protease substrate profiling. ID-PCR is a technique useful for determining whether a ligand can non-covalently bind to a target molecule, for example, in screening a library of candidate ligands for non-covalent interaction with a target molecule. RD-PCR and ID-PCR are also useful in detecting the presence of an analyte or an environmental condition. | 08-29-2013 |
20130225427 | METHOD FOR PREDICTION OF RESPONSE TO IMMUNE MEDIATED DISEASE THERAPEUTICS - The present invention is based in part on the identification of a signature marker profile of immune variables to diagnose an immune mediated disease or for prediction of response to an immune mediated disease therapeutic agent. Additionally, the present invention provides methods for the prediction of response to an immune mediated disease therapeutic agent. | 08-29-2013 |
20130225428 | LIVER DISEASE MARKERS - New markers for diseased liver conditions have been identified. A combination of protein C (PROC) and retinol binding protein 4 (RBP4) in blood are biomarkers to distinguish patients at different stages of hepatic fibrosis due, for example, to chronic infection with hepatitis C virus (HCV). Also, alpha-1-B glycoprotein (A1BG), complement factor H (CFH) and insulin-like growth factor binding protein acid labile subunit (IGFALS) distinguish subjects with chronic or acute liver conditions such as hepatitis infection or liver fibrosis from healthy controls. | 08-29-2013 |
20130225429 | Method of Determining Thermodynamic and Kinetic Parameters from Measured Off Rates - A method for measuring a property of a binding interaction between a capture agent and a binding partner for the capture agent is provided. In certain embodiments, this method comprises: a) contacting a population of particles that are linked to a capture agent with a substrate comprising a binding partner to produce capture agent/binding partner complexes, wherein the population of particles comprises first particles that are bound to a single molecule of the capture agent and second particles that are bound to two molecules of the capture agent; b) applying a force to the bound support, wherein the force is in a direction that separates the particles from the support; and c) separately measuring the forces required to disassociate the first particles and the second particles from their respective complexes. | 08-29-2013 |
20130225430 | METHODS AND COMPOSITIONS FOR TREATMENT OF TOX-3 AND TFF-1 MEDIATED CANCER PATHOGENESIS - The present invention relates to biomarkers useful for the diagnosis, prognosis and treatment of cancer. In different embodiments, the invention relates to TOX3 and related biomarkers, such as TFF1, TFF3, AGR2, SCUBE2, CEACAM6, TSPAN1 or CXCR4. TOX3 and these related biomarkers are also useful for the characterization of different breast cancer disease subtypes. Also described herein are inventive compositions and methods drawn to the use of anti-TOX3 antibodies, inducible TOX3 transgenic animal models, TOX3 nucleic acids, peptides, and small molecules for detection and modulation of TOX3 function and/or expression. | 08-29-2013 |
20130225431 | ASSESSMENT OF CELLULAR FRAGMENTATION DYNAMICS FOR DETECTION OF HUMAN EMBRYONIC ANEUPLOIDY - Methods of evaluating the developmental potential of human embryos are disclosed. In particular, the invention relates to methods of detecting embryonic aneuploidy by assessment of cellular fragmentation dynamics in individual blastomeres of embryos up to the 4-cell stage. The methods of the invention should improve in vitro fertilization (IVF) outcomes by reducing inadvertent transfer of non-viable embryos likely to result in spontaneous miscarriage. | 08-29-2013 |
20130225432 | SOLUTION-BASED METHODS FOR RNA EXPRESSION PROFILING - The present invention is directed to novel high-throughput, low-cost, and flexible solution-based methods for RNA expression profiling, including expression of microRNAs and mRNAs. | 08-29-2013 |
20130225433 | PROSTATE CANCER MARKERS AND USES THEREOF - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to mutations in cancer markers as diagnostic markers and clinical targets for prostate cancer. | 08-29-2013 |
20130225434 | COMPOSITIONS COMPRISING ENGINEERED PHOSPHOTHREONINE AFFINITY REAGENTS, METHODS OF MAKING, AND METHODS OF USE - This invention relates to the use of protein scaffolds for producing affinity reagents that are polypeptides that specifically bind to phosphopeptides. | 08-29-2013 |
20130225435 | METHODS AND SYSTEMS FOR ANALYSIS OF SINGLE CELLS - Methods are provided for diagnosis and prognosis of disease by analyzing expression of a set of genes obtained from single cell analysis. Classification allows optimization of treatment, and determination of whether on whether to proceed with a specific therapy, and how to optimize dose, choice of treatment, and the like. Single cell analysis also provides for the identification and development of therapies which target mutations and/or pathways in disease-state cells. | 08-29-2013 |
20130225436 | SPECIFIC ACTIVE SITE INHIBITORS OF ENZYMES AND METHODS OF PRODUCING SAME - The present disclosure provides a method of producing enzyme-specific inhibitors or substrate binding partners comprising: identifying active site residues of the substrate in the enzyme substrate complex or in substrate binding partner-substrate complex; randomizing the active site residues to produce a combinatorial library of substrate variants; and selecting substrate variants that inhibit enzyme activity or bind substrate as substrate-specific binding partners. The present disclosure also provides ubiquitin enzyme specific inhibitors and ubiquitin variants that bind ubiquitin interaction motifs. | 08-29-2013 |
20130225437 | BIOMARKERS OF CANCER - Disclosed is an IL-37 biomarker of cancer and methods of using the biomarker, including methods for diagnosis of cancer, methods of determining predisposition to cancer, methods of monitoring progression/regression of cancer, methods of assessing efficacy of compositions for treating cancer, as well as other methods based on the use of this cancer biomarker. | 08-29-2013 |
20130225438 | SOLUTION MICROARRAYS AND USES THEREOF - The present invention relates to solution microarrays. In particular, the present invention relates to an aqueous 2-phase system for solution microarrays and uses thereof. The present invention further relates to systems and methods for performing assays within the solution microarrays (e.g., diagnostic assays). | 08-29-2013 |
20130225439 | METHODS FOR IMPROVING INFLAMMATORY BOWEL DISEASE DIAGNOSIS - The present invention provides methods and systems to predict and diagnose inflammatory bowel disease (IBD) and subtypes such as ulcerative colitis (UC) and Crohn's disease (CD) by detecting the presence, absence, level, and/or genotype of one or more sero-genetic-inflammation markers. Advantageously, with the present invention, it is possible to provide a diagnosis of IBD versus non-IBD, to rule out IBD that is inconclusive for CD and UC, and to differentiate between CD and UC with increased accuracy. | 08-29-2013 |
20130225440 | Compositions and Methods Useful for the Treatment and Diagnosis of Inflammatory Bowel Disease - Compositions and methods useful for the diagnosis and treatment of IBD including Crohn's disease are disclosed. | 08-29-2013 |
20130225441 | INTEGRATED SEMICONDUCTOR BIOARRAY - A biosensor array, system and method for affinity based assays that are able to simultaneously obtain high quality measurements of the binding characteristics of multiple analytes, and that are able to determine the amounts of those analytes in solution. The invention also provides a fully integrated bioarray for detecting real-time characteristics of affinity based assays. | 08-29-2013 |
20130225442 | Lung Cancer Tests - Methods for the diagnosis of lung cancer and more specifically, non-small cell lung cancer are described. An assortment of biomarkers with diagnostic or prognostic value for non-small cell lung cancer (NSCLC) are used to establish a multi-analyte serum test capable of diagnosing patients with lung cancer. A first method assesses an elevated level of expression of one or more nucleic acids, a polypeptide encoded by the nucleic acid or an autoantibody to said polypeptide. An alternative method includes (a) determining whether or not a patient has NSCLC versus a non-NSCLC lung cancer, and (b) classifying the patient as susceptible to specific treatments if the patient has a NSCLC profile and classifying the patient as not susceptible to a specific treatment if the patient does not have a NSCLC profile. | 08-29-2013 |
20130225443 | METHOD OF EXAMINING POLYCYSTIC KIDNEY DISEASE AND METHOD OF SCREENING FOR THERAPEUTIC AGENT OF THE DISEASE - The present invention provides a method of examining polycystic kidney disease or a complication of polycystic kidney disease using a gene(s) selected from the group consisting of NTNG1, POSTN, TNC, KAL1, BST1, ACAT2, INSIG1, SCD, HSD3B1, KRT7, USP40, SULT1E1, BMP6, CD274, CTGF, E2F7, EDN1, FAM43A, FRMD3, MMP10, MYEOV, NR2F1, NRCAM, PDCK1, PLXNA2, SLC30A3, SNAI1, SPOCD1, MMP1, TFPI2, HMGA2, KRTAP4-7, KRTAP4-8, KRTAP4-9, MYPN, RPPH1, and SIAE, and a method of screening for a therapeutic agent or a preventive agent therefore, and further vascular endothelial cells or vascular mural cells obtained via differentiation induction from iPS cells formed from a somatic cell of a subject suffered from polycystic kidney disease and having cerebral aneurysm as a complication. | 08-29-2013 |
20130231256 | MULTIPLEXED KRAS MUTATION DETECTION ASSAY - Provided herein is reagent mixture comprising multiplexed amplification reagents and flap assay reagents for detecting, in a single reaction, mutant copies of the KRAS gene that contain any of the 34A, 34C, 34T, 35A, 35C, 35T or 38A point mutations. Methods that employ the reagent mix and kits for performing the same are also provided. | 09-05-2013 |
20130231257 | BIOMARKER - A method of diagnosing or determining the degree of an arterial aneurysm, especially an abdominal aortic aneurysm, which comprises determining the presence or level of interleukin-1α (IL-1aα) in a serum or plasma sample. | 09-05-2013 |
20130231258 | Methods and Compositions for Classification of Samples - Disclosed herein are kits, compositions, and methods relating to the classification of samples. Methods disclosed herein can be used to identify sample mix-ups. Methods disclosed herein can also be used to diagnose conditions or to support treatment-related decisions. | 09-05-2013 |
20130231259 | Detection of Micro Metastasis of Melanoma and Breast Cancer in Paraffin-Embedded Tumor Draining Lymph Nodes by Multimarker Quantitative RT-PCR - The invention provides a quantitative realtime RT-PCR assay for detection of metastatic breast, gastric, pancreas or colon cancer cells or metastatic melanoma. The assay allows to predict disease recurrence and survival in patients with AJCC stage I and II, and III disease using multimarker panels. The method for detecting metastatic melanoma cells utilizes panels of markers selected from a group consisting of MAGE-A3, GaINAcT, MART-1, PAX3, Mitf, TRP-2, and Tyrosinase. The method for detecting metastatic breast, gastric, pancreas or colon cancer cells in paraffin-embedded samples utilizes panels of markers selected from a group consisting of C-Met, MAGE-A3, Stanniocalcin-1, mammoglobin, HSP27, GaINAcT, CK20, and β-HCG. | 09-05-2013 |
20130231260 | POLYMER SCAFFOLDS FOR ASSAY APPLICATIONS - Reactive polymers bound to a solid support, modified solid supports and reactive polymers are provided. Solid supports comprising the same for use as analytical devices for the detection and/or characterization of analytes, such as biomolecules, are also provided. | 09-05-2013 |
20130231261 | RNASE H-BASED RNA PROFILING - Methods for determining the presence, absence and/or amount and/or identity of RNA in a biological or other sample employs capturing and separating a DNA:RNA hybrid formed by a DNA probe and the RNA of interest from unhybridized DNA and RNA with an RNase H under conditions wherein the nuclease activity of the RNase H is inhibited, releasing the DNA probe by altering the conditions so that the nuclease activity is restored, and determining the presence or amount, and, for multiplex samples, nature of the DNA released. The method can be used to determine RNA of various types, including RNA comprising transcriptomes. | 09-05-2013 |
20130231262 | ENGINEERED PROTEIN: "2-COLOR SERCA", AN ION-MOTIVE ATPase FUSED TO CERULEAN AND YELLOW FLUORESCENT PROTEIN - A method and engineered proteins for use therewith suitable for studying SERCA that are capable of being used in vivo and do not require protein purification or chemical labeling of SERCA, or reconstitution into artificial membranes. The engineered protein for calcium handling within human cells includes a two-color SERCA construct having three component proteins fused together. The three component proteins include a blue fluorescent protein (cerulean), SERCA2a and a yellow fluorescent protein (YFP), or a red fluorescent protein (tagRFP acceptor), SERCA and a green fluorescent protein (GFP). The method of determining SERCA activity for optimization of cardiac function includes resolving structure changes of the two-color SERCA construct. The two-color SERCA constructs are catalytically active and able to pump calcium following the step of resolving structure changes. | 09-05-2013 |
20130231263 | METHODS FOR SELECTING COMPETENT OOCYTES AND COMPETENT EMBRYOS WITH HIGH POTENTIAL FOR PREGNANCY OUTCOME - The present invention relates to a method for selecting a competent oocyte or a competent embryo. | 09-05-2013 |
20130231264 | Ultra-High Throughput Screening Methods to Detect Synergistic Drug Interactions - Synergy occurs when combined agents induce a response greater than the sum of their individual effects. The present invention provides new high throughput screening methods to detect agents acting synergistically in orthogonally pooled mixtures. Computational de-convolution of the pooled data with software reveals single-actives in the pools with twice the statistical power and with much greater efficiency than common high throughput screening approaches. Cross-correlating the orthogonal data reveals pools with activity that cannot be ascribed to any single compound. The components of such ‘Orphan’ activity pools are then tested individually and in all possible combination-pairs to identify and confirm synergy. The high throughput screening invention disclosed, which we name “Ultra-High Throughput Screening for Synergy (uHTSS)”, is applicable for more efficiently discovering nucleic acids, proteins and small molecules that act synergistically without having to systematically test each possible pair, as is required by known screening practices. | 09-05-2013 |
20130237436 | DRUG SELECTION FOR GASTRIC CANCER THERAPY USING ANTIBODY-BASED ARRAYS - The present invention provides methods for selecting a suitable anticancer therapy, and for identifying and predicting response for the treatment of a gastric cancer. | 09-12-2013 |
20130237437 | NUCLEIC ACID HYBRIDIZATION PROBES - Compositions of nucleic acid hybridization probes for detecting a nucleic acid target sequence and methods for their production are described. In one preferred embodiment, the nucleic acid hybridization probe includes a hybridization domain, an adaptor, a linker, and a signaling domain. The hybridization domain includes a nucleic acid sequence having complementarity to the nucleic acid target sequence. The adaptor is a nucleic acid sequence. The linker includes a moiety having at least one abasic site, such that the moiety blocks extension by an elongating polymerase on a nucleic acid template containing the moiety. The signaling domain comprises a nucleic acid having at least one label or a nucleic acid having at least one nucleic acid domain for binding at least one additional nucleic acid. | 09-12-2013 |
20130237438 | PHYSIOGENOMIC METHOD FOR PREDICTING STATIN INJURY TO MUSCLE AND MUSCLE SIDE EFFECTS - The present invention relates to the use of genetic variants of associated marker genes to predict an individual's susceptibility to muscular injury and muscular side effects in response to statin therapy. The present invention further relates to analytical assays and computational methods using the novel marker gene set. The present invention has utility for personalized medical treatment, drug safety, statin compliance, and prophylaxis of muscle side effect. | 09-12-2013 |
20130237439 | SYSTEMS AND METHODS USING BIOMARKER PANEL DATA - Embodiments of the disclosure are related to systems and methods for utilizing biomarker panel data with respect to medical devices and methods, amongst other things. In an embodiment, the disclosure can include a method of predicting the likelihood of response to CRT therapy. The method can include quantifying levels of one or more biomarkers in a biological sample of a patient, analyzing the quantified levels to determine response to CRT therapy, wherein a panel of biomarkers includes at least two selected from the group consisting of CRP, SGP-130, sIL-2R, sTNFR-II, IFNg, BNP, sST2, MMP-2, MMP-9, TIMP-1, TIMP-2, TIMP-4. Other embodiments are also included herein. | 09-12-2013 |
20130237440 | METHOD AND MEANS FOR IDENTIFICATION OF ANIMAL SPECIES - There is provided a method of rapid identification of a mammalian species origin or mammalian species origins of a sample. The method includes but not limited to the steps of 1) gathering a sample to be tested, 2) processing the sample for use for identification purpose, 3) dividing the sample into a number of portions for situation in a multi-well container or containers, 4) providing a plurality of DNA probes, at least some of the DNA probes having DNA sequences with SEQ ID NOs. 1-241, wherein the number of the sample portions is greater than the number of mammalian species types from which the DNA probes derives. | 09-12-2013 |
20130237441 | Mig-6 Knockout Mice and Elucidation of Association of Mig-6 With Early Onset Degenerative Joint Disease and Role As A Tumor Suppressor - The molecular mechanism underlying degenerative joint disease, also known as osteoarthritis (OA), is not fully understood. Disruption of mitogen inducible gene 6 (Mig-6) in mice by homologous recombination (KO mice) led to early onset OA as revealed by simultaneous enlargement and deformity of multiple joints, degradation of articular cartilage and the development of bony outgrowths or osteophytes within the joint space. The latter appeared to be derived from proliferation of mesenchymal progenitor cells followed by differentiation into chondrocytes. Because of the striking similarity to human OA, Mig-6 KO mice arc a useful animal model for studying the mechanism of this disease and for testing new drugs or therapies for treating OA. These KO mice also developed epithelial hyperplasia, adenoma, and adenocarcinoma in organs such as lung, gallbladder, and bile duct. Mig-6 is therefore a tumor suppressor gene and is a candidate gene for the frequent Ip36 genetic alterations found in lung cancer. It can be used as a tumor biomarker as well as a target for cancer therapy. Mig-6 is located in human chromosome Ip36, a locus frequently associated with human lung cancer. Mig-6 is a negative regulator of EGF signaling, and like EGF, was induced by HGF/SF in human lung cancer cell lines. Frequently the receptors EGFR and Met were co-expressed, and Mig-6 was induced by both EGF and HGF/SF in a MAPK-dependent fashion. Not all tumor lines express Mig-6 in response to either EGF or HGF/SF. In these cases, missense and nonsense mutations in the Mig-6 coding region were found, as was evidence for Mig-6 transcriptional silencing. | 09-12-2013 |
20130237442 | Methods and Compositions for Diagnosis of Non-Viable Early Pregnancy - Methods and compositions are provided for diagnosing an abnormal early pregnancy in a mammalian subject by contacting a biological sample of the subject with a reagent that enables measurement of certain biomarker targets, e.g., human placental lactogen (hPL) and/or human chorionic gonadotropin (hCG). In one embodiment, the mRNA of these biomarkers is measured in a biological sample, e.g., serum. The absolute levels of mRNA or protein levels, a ratio of mRNA to protein levels, or a pattern of multiple biomarker mRNA and/or protein levels or ratios are measured and a relation to the ratio or pattern of expression levels of the same biomarkers in the same biological fluid of a reference or control female mammalian subject having a normal intrauterine pregnancy (IUP) is determined. The presence of, absence of, or changes in expression levels, ratios or patterns of the biomarker(s) in relation to those of the reference or control correlates with a diagnosis of abnormal pregnancy, i.e., miscarriage or ectopic pregnancy. Various reagents for use in kits and panels for such diagnosis include PCR primer-probe sets or ligands, labeled or immobilized, which are capable of detecting the changes in expression or translation of these biomarker targets. | 09-12-2013 |
20130237443 | SPOTTING PLATE AND PROCESS FOR ITS PRODUCTION - A process for the production of a reaction chamber assembly, wherein a flat substrate and bottomless reaction chambers are provided, the substrate is first loaded with a biological agent and then the bottomless reaction chambers are bonded glue-free to the substrate, in particular through laser bonding, and liquid-tight reaction chambers, for instance individual wells, individually connected wells, such as strips, or wells in the form of a microtiter plate, are obtained. The present invention further provides a kit comprising a substrate suitable for being loaded with at least one biological agent and at least one bottomless reaction chamber, wherein the kit is suitable for glue-free bonding of the bottomless reaction chamber to the substrate. | 09-12-2013 |
20130237444 | GBM MOLECULAR CONTEXTS ASSOCIATED WITH PATIENT SURVIVAL - This disclosure provides a glioblastoma biomarker profile comprising glioblastoma associated genetic aberrations. The profile is indicative of a cellular and physiological characteristic of a sample from a subject. The disclosure further provides methods for profiling glioblastoma cellular and physiological characteristics including subtype, survival and drug response. | 09-12-2013 |
20130237445 | METHODS AND KITS FOR DETECTING MELANOMA - This invention is directed to a method for detecting melanoma in a tissue sample by measuring a level of methylation of one or more regulatory elements differentially methylated in melanoma and benign nevi. The invention provides methods for detecting melanoma, related kits, and methods of screening for compounds to prevent or treat melanoma. | 09-12-2013 |
20130237446 | Use of the Genes in the Hog, Ras and cAMP Pathway for Treatment Of Fungal Infection - Provided herein are uses of genes for HOG, Ras and cAMP signal transduction pathways to treat fungal infection. To regulate the HOG pathway of | 09-12-2013 |
20130237447 | GENETIC MARKERS ASSOCIATED WITH SCOLIOSIS AND USES THEREOF - The present invention relates to novel genetic markers associated with scoliosis, risk of developing scoliosis and risk of scoliosis curve progression, and methods and materials for determining whether a human subject has scoliosis, is at risk of developing scoliosis or is at risk of scoliosis curve progression. | 09-12-2013 |
20130237448 | SUGARCANE-SUGAR-YIELD-RELATED MARKER AND THE USE THEREOF - According to the present invention, a sugarcane-sugar-yield-related marker linked to a sugarcane quantitative trait is provided. Such marker is a sugarcane-sugar-yield-related marker, which comprises a continuous nucleic acid region existing in a region sandwiched between the nucleotide sequence shown in SEQ ID NO: 1 and the nucleotide sequence shown in SEQ ID NO: 5, a region sandwiched between the nucleotide sequence shown in SEQ ID NO: 6 and the nucleotide sequence shown in SEQ ID NO: 24, or a region sandwiched between the nucleotide sequence shown in SEQ ID NO: 25 and the nucleotide sequence shown in SEQ ID NO: 47 of a sugarcane chromosome. | 09-12-2013 |
20130237449 | USP2A PEPTIDES AND ANTIBODIES - The invention relates to novel USP2a peptides and antibodies, as well as nucleic acids related to them. The peptides, antibodies and the nucleic acids are useful for the detection, staging and monitoring of the progression of cancer, as well as for determining or monitoring the efficacy of treatment. | 09-12-2013 |
20130237450 | Method for Detecting Nucleic Acids - A method for simultaneously detecting at least one specific DNA target molecule in a plurality of samples by means of nucleic acid amplification is provided. The method comprising: bringing at least two DNA samples comprising DNA in contact with forward and reverse primers, which in the 3′ portion contain a nucleotide sequence that is complementary to the amplifying DNA target molecule, and which in the 5′ portion comprises an oligonucleotide having an artificial DNA sequence that is associated with the individual samples; amplifying the samples; contacting the amplified samples with a solid substrate on which oligonucleotides are immobilized at a preselected site, said oligonucleotides comprising at the 3′ ends the artificial DNA sequence associated with the individual samples; and ascertaining binding of the amplification products at the oligonucleotides immobilized on the solid substrate. | 09-12-2013 |
20130244890 | EVALUATING MMP EXPRESSION IN PATIENT STRATIFICATION AND OTHER THERAPEUTIC, DIAGNOSTIC AND PROGNOSTIC METHODS FOR CANCER - Provided are compositions, methods and kits for quantifying the expression and/or activity of MMP-14 and other biomarkers of cancer, which may be used diagnostically and prognostically, e.g., in patient stratification and evaluation of appropriate therapeutic regimens. | 09-19-2013 |
20130244891 | TARGETED PROBES OF CELLULAR PHYSIOLOGY - Biosensor comprising an activatable acceptor fluorogen linked via a linker to a donor which transfers energy to the fluorogen on detecting an analyte wherein the fluorogen component reacts and a 100 fold increase in intensity results when the fluorogen interacts non-covalently with an activator e.g. fluorogen activator peptide. | 09-19-2013 |
20130244892 | Risk Factors and Prediction of Adverse Events - Biomarkers, methods, systems, and related teachings are disclosed for diagnosing the risk of an adverse event in a human, where the adverse event can be unstable angina, ischemic stroke, non-ischemic stroke, all-cause stroke, heart failure, all-cause death, and being a candidate for coronary revascularization surgery. | 09-19-2013 |
20130244893 | Methods And Compositions For The Diagnosis And Treatment Of Cancer Resistant To Anaplastic Lymphoma Kinase (ALK) Kinase Inhibitors - Compositions and methods for the diagnosis and treatment of a cancer that is resistant to at least one anaplastic lymphoma kinase (ALK) kinase inhibitor are provided herein. The present invention is based on the discovery of mutations within ALK that confer resistance to at least one ALK kinase inhibitor. Polynucleotides and polypeptides having at least one ALK inhibitor resistance mutation are provided and find use in methods and compositions useful in the diagnosis, prognosis, and/or treatment of diseases associated with aberrant ALK activity, more particularly, those that are resistant to at least one ALK kinase inhibitors. Methods and compositions are also provided for the identification of agents that can inhibit the kinase activity and/or reduce the expression level of the ALK resistance mutants. | 09-19-2013 |
20130244894 | NUCLEIC ACID-BASED AUTHENTICATION CODES - This invention relates to a nucleic-acid based product authentication by determining authentication codes comprising target nucleic acids using oligonucleotide probes immobilized on particulate and non-particulate substrates. The presence of the authentication code is determined using detection methods, such as flow cytometric methods, capable of particle discrimination based on the light scattering or fluorescence properties of the particle, or by spatial resolution of oligonucleotides immobilized at specific loci on a substrate. Target-correlated fluorescence signal, originating from a target nucleic acid hybridized to substrate-immobilized oligonucleotide is determined as an indicator of the presence of the authentication code. | 09-19-2013 |
20130244895 | Microwell Arrays for Direct Quantification of Analytes on a Flat Sample - The present invention relates to a bioanalytical device consisting of a microwell array with microwell ( | 09-19-2013 |
20130244896 | IN VITRO METHOD FOR PREDICTING WHETHER A COMPOUND IS GENOTOXIC IN VIVO - The invention is in the field of genomics and it provides an in vitro method for predicting whether a compound is genotoxic in vivo. It provides a method that employs the analysis of expression profiles of microRNAs in cells exposed to a potentially genotoxic compound. It was found that differential expression of a number of microRNAs could reliably predict whether a compound was a genotoxic or a non-genotoxic compound. | 09-19-2013 |
20130244897 | Marker Sequences for Multiple Sclerosis and Use Thereof - The invention relates to novel marker sequences for multiple sclerosis and to the use thereof in diagnosis as well as to a method for screening potential active ingredients for multiple sclerosis diseases the marker sequences. The invention further relates to a diagnostic device containing such marker sequences for multiple sclerosis, especially to a protein biochip and the use thereof. | 09-19-2013 |
20130244898 | MODULAR POINT-OF-CARE DEVICES, SYSTEMS, AND USES THEREOF - The present invention provides devices and systems for use at the point of care. The methods devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device are modular to allow for flexibility and robustness of use with the disclosed methods for a variety of medical applications. | 09-19-2013 |
20130244899 | DETECTING INFECTION IN REDUCED PRESSURE WOUND TREATMENT - Provided is a method of detecting infection in a wound caused by an infecting organism at a wound site. Also provided is a system for detecting an infection in a wound at a wound site. Additionally, a porous pad comprising luciferase is provided. | 09-19-2013 |
20130244900 | Gene Expression Profiling in Primary Ovarian Serous Papiliary Tumors and Normal Ovarian Epithelum - Provided herein are methods for detecting ovarian serous papillary carcinoma in an individual. A tumor sample from the individual is examined for gene product expression levels of a group of genes consisting of transforming growth factor beta receptor III, platelet-derived growth factor receptor alpha, SEMACAP3, ras homolog gene family member I (ARHI), thrombospondin 2, and disabled-2/differentially expressed in ovarian carcinoma 2 (Dab2/DOC2) Gene products which are down-regulated compared to those in a control individual indicate the presence of ovarian serous papillary carcinoma | 09-19-2013 |
20130244901 | METHOD AND SYSTEM FOR PROGNOSIS AND TREATMENT OF DISEASES USING PORTFOLIO OF GENES - This disclosure generally relates to a method, a system and a kit for diagnosing and treating various disease conditions using the gene expression value in a given sample obtained from a subject. This disclosure further relates to selecting the right set of genes as a portfolio of genes for a particular disease. Providing a set of appropriate portfolio of gene for studying the gene expression values and using the values as a diagnostic tool is also disclosed. The gene expression value is further used for intervention by pharmaceuticals as a prediction model for the treatment of the disease. An individual may have a personalized health card that may store the gene expression value for that particular individual. A system may store the data for portability and integrated view of the individual's medical data for effective diagnosis and treatment. | 09-19-2013 |
20130244902 | EARLY DETECTION OF PANCREATIC CANCER - This document provides methods and materials involved in the early detection of pancreatic cancer. For example, this document provides methods and materials for assessing nucleic acid obtained from a blood sample of a human for a CpG methylation site profile that, at least in part, indicates that the human has pancreatic cancer. | 09-19-2013 |
20130252832 | KRAS Variant and Tumor Biology - The disclosure provides methods for identifying a subject at risk of developing cancer, predicting the onset of cancer, and predicting a subject's response to chemotherapy/treatment by determining the presence or absence of a SNP in the KRAS oncogene, known as the KRAS variant. | 09-26-2013 |
20130252833 | DRG11-RESPONSIVE (DRAGON) GENE AND USES THEREOF - This invention features methods and compositions useful for treating and diseases caused by a dysregulation of the BMP/GDF branch of the TGF-β signaling pathway. Also disclosed are methods for identifying compounds useful for such therapy. | 09-26-2013 |
20130252834 | Diagnostic Methods - The invention relates to a method of aiding the diagnosis of acute brain damage in a subject, said method comprising (i) assaying the concentration of at least one oxidative stress polypeptide selected from the group consisting of: PRDX1, PRDX6 and GSTP1 in a sample from said subject; and (ii) assaying the concentration of at least one further polypeptide selected from Panel A; (Hi) comparing the concentrations of (i) and (ii) to the concentrations of the polypeptides in a reference standard and determining quantitative ratios for said polypeptides; (iv) wherein a finding of a quantitative ratio of each of the assayed polypeptides in the sample to the polypeptides in the reference standard of greater than 1.3 indicates an increased likelihood of acute brain damage having occurred in said subject. | 09-26-2013 |
20130252835 | METHODS FOR PROFILING AND QUANTITATING CELL-FREE RNA - The invention generally relates to methods for assessing the health of a tissue by characterizing circulating nucleic acids in a biological sample. According to certain embodiments, methods for assessing the health of a tissue include the steps of detecting a sample level of RNA in a biological sample, comparing the sample level of RNA to a reference level of RNA specific to the tissue, determining whether a difference exists between the sample level and the reference level, and characterizing the tissue as abnormal if a difference is detected. | 09-26-2013 |
20130252836 | DIAGNOSTIC TEST FOR CARDIOMYOPATHY - Methods and compositions relating to diagnosing and treating cardiomyopathy and particularly relating to methods and compositions for diagnosing and treating arrhythmogenic right ventricular dysplasia/cardiomyophathy (ARVD/C) are described. Provided are methods for screening for, diagnosing or detecting a risk of developing arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) comprising detecting the presence of a transmembrane protein 43 (TMEM43) disease associated variant in a sample of a subject, wherein the presence of a TMEM43 disease variant is indicative that the subject has ARVD/C or an increased risk of developing ARVD/C compared to an individual having wild type TMEM43. | 09-26-2013 |
20130252837 | METHOD FOR MEASURING RESISTANCE OR SENSITIVITY TO DOCETAXEL - The present invention relates to novel and useful methods that predict or monitor a patient's response to a molecule of the taxoid family by measuring the increase or decrease of specific genetic markers as compared to controls. The present invention also provides kits that predict of monitor patient's response to a molecule of the taxoid family by measuring nucleic acid or protein levels of particular genetic markers and comparing their levels to controls or reference markers. | 09-26-2013 |
20130252838 | TARGET FOR BREAST CANCER THEREAPY AND/OR DIAGNOSIS - The present invention relates to breast cancer and methods for identifying therapeutics and diagnosis. In general, methods for identifying therapeutic agents directed to calcium flow are disclosed. Also provided are methods for diagnosis of breast cancer and/or a predisposition to breast cancer and methods of treatment of breast cancer. The methods include identifying therapeutic agents which modulate a CRAC channel and/or a glycoprotein activator of a CRAC channel. Also provided are diagnostic methods that utilise a CRAC channel and/or a glycoprotein activator of a CRAC channel. | 09-26-2013 |
20130252839 | MARKERS OF PRIMARY GRAFT DYSFUNCTION - The present invention relates to methods for diagnosing transplant rejection, or a condition associated with transplant rejection, such as, primary graft dysfunction in a subject, to antigen probe arrays for performing such a diagnosis, and to antigen probe sets for generating such arrays. | 09-26-2013 |
20130252840 | LIQUID TISSUE PREPARATION FROM HISTOPATHOLOGICALLY PROCESSED BIOLOGICALLY SAMPLES, TISSUES AND CELLS - The current invention provides a method for directly converting histopathologically processed biological samples, tissues, and cells into a multi-use biomolecule lysate. This method allows for simultaneous extraction, isolation, solublization, and storage of all biomolecules contained within the histopathologically processed biological sample, thereby forming a representative library of said sample. This multi-use biomolecule lysate is dilutable, soluble, capable of being fractionated, and used in any number of subsequent experiments. | 09-26-2013 |
20130252841 | ARRAYED DETECTOR SYSTEM FOR MEASUREMENT OF ANTI-VIRAL IMMUNE RESPONSE - A sensor chip for detecting an immune response against a virus, the sensor chip including a substrate having a surface and a plurality of virus-like particles or capsid fragments bound to discrete locations on the surface of the substrate. Detection devices containing the sensor chip and methods of detecting anti-viral immune responses are also described herein. | 09-26-2013 |
20130252842 | Methine-Substituted Cyanine Dye Compounds - Cyanine dye compounds having a substituted methine moiety that are nucleic acid stains, particularly for fluorescent staining of RNA, including compounds having the formula | 09-26-2013 |
20130252843 | METHOD OF MAKING AND USING FLUORESCENT-TAGGED NANOPARTICLES AND MICROARRAYS - Disclosed embodiments concern differentiating and classifying one or more targets using a perhalophenylazide-derived nanoparticle probe, or multiple such probes. Particular embodiments concern using statistical analysis to produce score plots illustrating the level of differentiation and/or classification. Also disclosed are methods for making perhalophenylazide-derived nanoparticle probes, individually or by using a microarray technique. Particular embodiments concern methods for using the per halophenylazide-derived nanoparticle probes to diagnose, detect, and/or treat a disease. Kits comprising the perhalophenylazide-derived nanoparticle probes are also disclosed. | 09-26-2013 |
20130252844 | SUGARCANE-STALK-SUGAR-CONTENT-RELATED MARKER AND THE USE THEREOF - According to the present invention, a sugarcane-stalk-sugar-content-related marker linked to a sugarcane quantitative trait is provided. Such marker is a sugarcane-stalk-sugar-content-related marker, which comprises a continuous nucleic acid region existing in a region sandwiched between the nucleotide sequence shown in SEQ ID NO: 1 and the nucleotide sequence shown in SEQ ID NO: 8 or a region sandwiched between the nucleotide sequence shown in SEQ ID NO: 9 and the nucleotide sequence shown in SEQ ID NO: 16. | 09-26-2013 |
20130252845 | METHOD FOR SCREENING SKIN AGING-RELATED GENES AND MATERIALS FOR PREVENTING SKIN AGING - The present invention relates to a method for screening skin aging-specific genes and a method for screening anti-aging materials by controlling the expression of the genes. The invention can provide a new material having an effect on the prevention of skin aging and the treatment of skin diseases by obtaining new target genes related to skin aging and controlling the expression of the genes. | 09-26-2013 |
20130252846 | SCREENING METHOD - A method of screening a plurality of fluid samples for the presence of species capable of specifically binding to a binding partner immobilized on a sensing surface of a sensor is disclosed. The method comprises contacting each sample with the sensing surface and a reference surface, and subjecting the sensing surface responses obtained for all samples to a computational process which comprises fitting al responses to a model equation for the relationship between a response at the sensing surface and the corresponding response at the reference surface. In an iterative process residuals above a pre-determined threshold value are removed, the model equation is adjusted, and all remaining samples are refitted to the adjusted model equation until the model equation at least substantially converges. Residuals above the predetermined threshold value are considered as species specifically binding to the binding partner. The method may be computer-implemented, and a computer program product therefore comprises instructions for causing a computer to perform the computational process. | 09-26-2013 |
20130252847 | ASSAY ASSEMBLY AND METHOD - The present invention relates to assay assemblies, components of assay assemblies, methods of determining one or more properties of a sample liquid, and methods of making components of assay assemblies. The present invention allows the properties of very small volumes of sample liquid to be probed, by providing a first surface having at least one sample liquid wettable surface region defined by a sample liquid repelling boundary, and a second surface, opposed to the first surface, having analyte binding agent immobilised thereon. | 09-26-2013 |
20130261008 | METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF - The present invention is directed to detection and measurement of gene transcripts ad their equivalent nucleic acid products in blood. Specifically provided is analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using gene-specific and/or tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 10-03-2013 |
20130261009 | Highly Sensitive Biomarker Panels - Cardiovascular disease, e.g., congestive heart failure, is often first diagnosed after the onset of clinical symptoms, eliminating potential for early intervention. The invention provides a multi-marker immunoassay, including cardiac pathology and vascular inflammation biomarkers, yielding a more sensitive assay for early detection of CHF in plasma. A panel consisting of cardiac pathology (cTnI, BNP) and vascular inflammation (IL-6, TNFα, IL-17a) biomarkers provided a sensitivity of 94% for association with CHF. | 10-03-2013 |
20130261010 | OPTICAL ANALYTE DETECTION SYSTEMS WITH MAGNETIC ENHANCEMENT AND METHODS OF USE - Various embodiments are drawn to systems and methods for detecting an analyte of interest in a solution that also contains a plurality of magnetic particles. The system may include a first magnet configured to generate a first magnetic field that forces the magnetic particles in the solution toward an optical sensor with a capture probe. A detector may be included to detect a change in an optical property of the optical sensor, the change in the optical property resulting from the binding of at least the analyte, a magnetic particle, and the capture probe at the optical sensor. | 10-03-2013 |
20130261011 | ANALYZING NEONATAL SALIVA AND READINESS TO FEED - The present invention provides systems for assessing neonatal development and/or conditions by analyzing neonatal saliva RNA. Methods of identifying genes involved in neonatal development and/or conditions affecting neonates, are provided. Methods of determining a diagnosis of a neonate comprising detection of one or more differentially expressed genes are also provided. | 10-03-2013 |
20130261012 | COMPOSITION AND METHOD FOR DIVERSIFICATION OF TARGET SEQUENCES - The disclosure relates generally to the targeting of genes to, and their integration into, an immunoglobulin (antibody) heavy chain locus. In particular, the methods described herein contemplate replacing the single rearranged heavy chain V, D, and J genes of a B cell lymphoma such as DT40 with independently rearranged V | 10-03-2013 |
20130261013 | Compounds and Methods - A molecular tool for use in a method of providing a molecule that is capable of binding a target molecule based on a set of polypeptides. A polypeptide having a sequence selected from SEQ ID NOs 1-32. The polypeptide may be used in a method of screening for a ligand-polypeptide conjugate capable of binding a target molecule for the ligand. A ligand-polypeptide conjugate, useful e.g. in therapy. | 10-03-2013 |
20130261014 | FUNCTIONALIZED 3-ALKYNYL PYRAZOLOPYRIMIDINE ANALOGUES AS UNIVERSAL BASES AND METHODS OF USE - 3-alkynyl inosine analogs and their uses as universal bases are provided. The inosine analogues can be incorporated into nucleic acid primers and probes. They do not significantly destabilize nucleic acid duplexes. As a result, the novel nucleic acid primers and probes incorporating the inosine analogues can be used in a variety of methods. The analogs function unexpectedly well as universal bases. Not only do they stabilize duplexes substantially more than hypoxanthine opposite A, C, T, and G but they are also recognized in primers by polymerases, allowing efficient amplification. | 10-03-2013 |
20130261015 | POLYPEPTIDE MARKERS FOR THE DIAGNOSIS OF CANCERS, AND METHODS FOR THE DIAGNOSIS OF CANCERS USING THE SAME - A method for diagnosing cancer using information on aberrant glycosylation of glycoproteins, which is related with cancer progression. More particularly, the present invention relates to a peptide marker for cancer diagnosis and a method for diagnosing cancer using the peptide marker, wherein glycoproteins aberrantly glycosylated due to cancer incidence and progression is isolated using lectin; and marker peptides generated by hydrolysis or the glycoproteins isolated by the lectin is selected and quantified. | 10-03-2013 |
20130261016 | DIAGNOSTIC METHODS FOR INFLAMMATORY DISORDERS - The present invention relates to methods of diagnosing an inflammatory disorder in a patient, as well as methods of monitoring the progression of an inflammatory disorder and/or methods of monitoring a treatment protocol of a therapeutic agent or regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein. | 10-03-2013 |
20130261017 | DDR2 Mutations in Squamous Cell Lung Cancer - Methods for treating patients with squamous cell lung cancer, including detecting the presence of mutations in the discoidin domain receptor 2 (DDR2) gene. | 10-03-2013 |
20130261018 | INTERFERON GENE SIGNATURE AND METHODS OF USE THEREOF - The present invention is a method and kit for determining responsiveness of a subject to treatment with a Type I interferon based upon the expression of gene signatures shown to be stimulated by interferon. A method for testing the propensity of a test compound to induce a Type I interferon response is also provided. | 10-03-2013 |
20130261019 | NUCLEIC ACID NANOSTRUCTURE BARCODE PROBES - Provided herein are, inter alia, barcode probes comprised of transiently or stably fhiorescently labeled nucleic acid nanostructures that are fully addressable and able to be read using standard fluorescent microscope and methods of use thereof including methods of use as detectable labels for probes. | 10-03-2013 |
20130261020 | Method of Diagnosing Down's Syndrome - A method of diagnosing Down's syndrome, the method comprising identifying a different expression pattern of at least one diagnostic marker in a blood, plasma or serum sample from a patient compared to the normal expression pattern of the marker. | 10-03-2013 |
20130261021 | MICROANALYSIS OF CELLULAR FUNCTION - An inverted microwell ( | 10-03-2013 |
20130267430 | METHOD AND REAGENT FOR DIAGNOSIS AND/OR EVALUATION OF PROGRESSION OF GRAFT-VERSUS-HOST DISEASE - Disclosed is a method of diagnosing graft-versus-host disease, comprising measuring the level of CCL8 protein in a sample obtained from a subject as an indicator for the diagnosis or course of graft-versus-host disease. Also a diagnostic reagent for graft-versus-host disease comprising an anti-CCL8 antibody is disclosed. The method of the present invention enables diagnosis of the onset of graft-versus-host disease and monitoring of the progress, in particular, differential diagnosis between graft-versus-host disease and an infectious disease. The present invention also provides a method for treating graft-versus-host disease utilizing the anti-CCL8 antibody. | 10-10-2013 |
20130267431 | ADDRESSABLE ANTIBODY ARRAYS AND METHODS OF USE - Systems and assay methods are disclosed for detecting an autoantibody in a sample. In certain instances, the systems and methods employ a mass tag releasably connected to an antigen. The tag is thereafter released for detection. A tag can be detected by mass spectrometry or in certain instances the tag is fluorescent. Methods for diagnosing a disease or disorder in a subject are also disclosed. | 10-10-2013 |
20130267432 | IN VITRO DIAGNOSTIC METHOD FOR PATIENTS WITH SPLENIC MARGINAL ZONE LYMPHOMA - The present invention refers to an in vitro SMZL diagnostic method based on analysis of the expression of a series of genes located in a very specific deleted region of human chromosome 7. The deleted region in SMZL patients has been defined by means of high-resolution array CGH and is located at 7q22.1 between bases 99925039-101754718, preferably between 99925039-101348479, and more preferably between 100260234-100596921 and/or 101244026-101754718, which is the location for the following genes: CUX1, SH2B2, EPHB4, SLC12A9, TRIP6, SRRT, ACHE, UFSP1, TRIM56, SERPINE1, APIS1, VGF, TSC22D4, HRBL, LRCH4, MUC3, MUC12 and MUC17. The present invention further describes in vitro SMZL diagnostic kits that comprise at least one probe that recognizes the deleted region at 7q22.1 or hybridizes with at least one of the nucleotide sequences of the genes mentioned above. | 10-10-2013 |
20130267433 | Carbohydrate Chip for Detection of Pathogen Vibrio Cholerae and Method of Preparing the Same - The present invention related to a saccharide-based cholera toxin detection sensor for detection of | 10-10-2013 |
20130267434 | MULTIPLEX AMPLIFICATION AND DETECTION - The invention relates to the field of multiplex amplification. In particular, the invention relates to methods for assaying a sample for one or more nucleic acid targets in a single reaction based on the distinct melting temperatures or melting profiles of primers and/or probes. The invention also provides probes and kits for use in such methods. | 10-10-2013 |
20130267435 | MARKER AND REAGENT FOR DETECTION OF HUMAN IL-17-PRODUCING HELPER T CELLS, AND METHOD FOR DETECTION OF HUMAN IL-17-PRODUCING HELPER T CELLS - The present invention relates to a marker allowing specific detection of human IL-17-producing helper T-cells (human Th17 cells), a method for specifically detecting human Th17 cells and a reagent for detecting human Th17 cells. | 10-10-2013 |
20130267436 | LUMINOPHORE-LABELED MOLECULES COUPLED WITH PARTICLES FOR MICROARRAY-BASED ASSAYS - A microarray-based assay is provided, which is used for analyzing molecular interactions, including polynucleotides, polypeptides, antibodies, small molecule compounds, peptides and carbohydrates. Such method comprises labeling a target molecule with a luminophore, coupling the target molecule to a particle, and binding to a probe molecule on microarray. In particular, multiplexed genetic analysis of nucleic acid fragments can be implemented. Specific genes, single nucleotide polymorphisms or gene mutations, such as deletions, insertions, and indels, can be identified. This technology, with high sensitivity, enables the detection and interpretation of molecular interactions in an efficient way. | 10-10-2013 |
20130267437 | USE OF SPECIFIC GENES OR THEIR ENCODED PROTEINS FOR A PROGNOSIS METHOD OF CLASSIFIED LUNG CANCER - At least one element for the implementation of a prognosis method, preferably in vitro, of the survival rate of a patient afflicted by a lung cancer, the lung cancer being previously classified as a lung tumour selected from squamous cell carcinoma (SQC), adenocarcinoma (ADK), large cell neuro-endocrine tumours (LCNE) and basaloid tumours (BAS). | 10-10-2013 |
20130267438 | USE OF SPECIFIC GENES FOR THE PROGNOSIS OF LUNG CANCER AND THE CORRESPONDING PROGNOSIS METHOD - At least 13 genes chosen among a set of 28 genes for carrying out a method for identifying at least 66% of patients of those having a survival rate of at most about 20% at 30 months, among a population of patients afflicted by lung cancer having an estimated survival rate of at least 30% at 30 months based on the diagnosis of the lung cancer according to histopathological criteria. | 10-10-2013 |
20130267439 | PREDICTIVE MARKERS AND BIOMARKER PANELS FOR OVARIAN CANCER - Methods are provided for predicting the presence, subtype and stage of ovarian cancer, as well as for assessing the therapeutic efficacy of a cancer treatment and determining whether a subject potentially is developing cancer. Associated test kits, computer and analytical systems as well as software and diagnostic models are also provided. | 10-10-2013 |
20130267440 | MARKER FOR CARCINOMA - The present invention relates to a method for diagnosis of different stages of endometrial cancer in an individual. Further, the present invention relates to a method for evaluating the probability of survival for an individual suffering from endometrial carcinoma. In another aspect, the present invention relates to the stratification of therapy regimen of endometrial tumor, ovarian cancer, breast cancer, non-small lung cancer or hormone refractory prostate cancer therapy in an individual or monitoring therapeutic efficacy in an individual suffering from the same based on the expression status of STMN1 gene or protein. Moreover, the present invention relates to a kit for use in any of the above referenced methods comprising a means for determining amplifications and deletions of chromosomal regions 3q26.32 and 12p12.1, determining alterations of the gene expression profile of the genes (gene signature): upregulation of the genes PLEKHK1, ATP10B, NMU, MMP1, ATAD2, NETO2, TNNI3, PHLDA2, OVOL1 and down-regulation of the genes: NDP, KIAA1434, MME, CFH, MOXD1, SLC47A1, RBP1, PDE8B, ASRGL1, ADAMTS19, EFHD1, ABCA5, NPAS3, SCML1, TNXB, ENTPD3, AMY1A, ENPP, RASL11B, PDZK3, or the expression status of the STMN1 gene or protein, respectively. Finally, the present invention provides a method for predicting the response to taxanes in an individual suffering from a disease treated with the taxanes based on the expression status of the STMN1 gene or protein. | 10-10-2013 |
20130274118 | COMBINATORIAL PROBE LIBRARIES - Provided herein is a set of reagents comprising: a plurality of at least three probe libraries, wherein each library of the plurality comprises one or more probe sets that are each specific for a target; and at least one of the libraries comprises a probe set that is present in another of the libraries. The plurality of libraries can be hybridized to spatially separated targets, simultaneously or sequentially. The identity of a spatially separated target can be determined by identifying which combination of the multiple libraries hybridize thereto. | 10-17-2013 |
20130274119 | METHODS AND APPARATUSES FOR DETECTION OF POSITIONAL FREEDOM OF PARTICLES IN BIOLOGICAL AND CHEMICAL ANALYSES AND APPLICATIONS IN IMMUNODIAGNOSTICS - The present invention relates to methods and apparatuses for the detection of positional freedom of particles used in biological, biochemical, physical, biophysical, and chemical analyses. In particular, the present invention relates to methods and apparatuses which can detect and characterize a population of particles/cells based upon their detected mobility. In one embodiment consistent with the invention, detection of certain cells is based on differences detected in populations of cells that bind to a substrate and those that exhibit weaker binding forces. Initially, cells are settled on the substrate, and in the presence of gravitational, natural thermodynamic pressure fluctuations, and other random or applied forces, some of the particles may exhibit translational movement. Particle movement is detected, and measurements are computed, according to the methods and apparatuses of the present invention, to determine the binding of specific analytes. | 10-17-2013 |
20130274120 | METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND INVOLVED IN PAIN AS WELL AS METHODS OF DIAGNOSING ALGESIA - The present invention relates to a method of identifying a compound involved in pain, the use of Ms4a6d nucleic acid or Ms4a6d protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same. | 10-17-2013 |
20130274121 | Diagnostic Method - The present invention relates to a multiplex in vitro nucleic acid amplification method for identifying a species of the | 10-17-2013 |
20130274122 | ASSAY FOR CHLAMYDIA TRACHOMATIS BY AMPLIFICATION AND DETECTION OF CHLAMYDIA TRACHOMATIS PMPA GENE - A region of the | 10-17-2013 |
20130274123 | MATERNAL BIOMARKERS FOR GESTATIONAL DIABETES - Embodiments herein relate to the field of screening tools for fetal/maternal wellness, and, more specifically, to biomarkers for gestational diabetes. In various embodiments, the methods may provide non-invasive and minimally-invasive screening tools for gestational diabetes that involve detection of changes in a proteomic profile of a test sample relative to a reference sample. In particular embodiments, the method may include determining whether a proteomic profile of a test sample from the subject includes at least one expression signature characteristic of gestational diabetes, wherein the proteomic profile comprises information on the expression of glycosylated fibronectin and glycosylated PSG, for example information on levels of fibronectin-SNA or a fibronectin-antibody complex, and PSG-AAL or a PSG-antibody complex. In some embodiments, the proteomic profile may also include information on the expression of adiponectin, sex hormone binding globulin (SHBG), C-reactive protein (CRP), a ratio of human chorionic gonadotropin (hCG) to placental lactogen, or a combination thereof. | 10-17-2013 |
20130274124 | ADHESION SIGNATURES - The present invention provides arrays comprising polypeptides associated with extracellular matrix that can be used to isolate, differentiate, or culture certain cell types including stem cells, cancer cells, and/or primary hepatocytes. The array comprises at least a pair of polypeptides that comprise a polypeptide associated with extracellular matrix or functional fragments thereof. The invention also provides for methods of diagnosing and/or prognosing a certain disease or disorder through contacting a cell sample from a patient with an array comprising at least a pair of polypeptides that comprise a polypeptide sequence associated with extracellular matrix or functional fragments thereof. | 10-17-2013 |
20130274125 | MULTIPLEX IMMUNOASSAY FOR RHEUMATOID ARTHRITIS AND OTHER AUTOIMMUNE DISEASES - Rheumatoid arthritis and other autoimmune diseases are diagnosed by multiplex assays for antibodies to a panel of antigens that includes cyclic citrullinated peptide and at least five members of a list that includes BRAF1 506-525, BRAF2 656-675, Vimentin (protein) citrullinated, Vimentin 415-433 cit cyclic, Vimentin 58-77 cit3 cyclic, Clusterin 231-250 cit sm1 cyclic, Fibrinogen A 556-575 cit sm cyclic, Fibrinogen A 616-635 cit sm cyclic, Histones2A H2A/a 1-20 cit sm2 cyclic, Filaggrin 48-65 cit2v1 cyclic, BRAF (catalytic domain from v raf murine sarcoma viral oncogene homologue B1, amino acids 416-766). | 10-17-2013 |
20130274126 | SENSOR CHIP AND MEASUREMENT METHOD USING THE SAME - Provided is a device that can detect cells or bacteria in units of a single cell or bacterium, and can further measure the amounts of activity of cells or bacteria or responses of the cells or bacteria to drugs in units of a single cell or bacterium. A plurality of partitioned regions each having about the same size as a cell or a bacterium is provided, and a plurality of types of electrical sensors | 10-17-2013 |
20130274127 | GENE EXPRESSION MARKERS FOR PREDICTION OF RESPONSE TO PHOSPHOINOSITIDE 3-KINASE INHIBITORS - The present invention provides methods for predicting a likelihood that a tumor cell will be sensitive or resistant to a phosphoinositide 3-kinase (PI3K) inhibitor. The methods generally involve determining an expression level of a gene product that correlates with sensitivity or resistance to a PI3K inhibitor. The present invention also provides methods for increasing sensitivity of a tumor cell to a PI3K inhibitor by contacting the tumor cell with an activator or inhibitor of a gene product that correlates with sensitivity or resistance to a PI3K inhibitor. | 10-17-2013 |
20130274128 | GENE EXPRESSION IN N-CADHERIN OVEREXPRESSING PROSTATE CANCERS AND THEIR CONTROLS - The present invention provides methods of diagnosing a cancer or providing a prognosis for a cancer by analyzing the level of expression of a marker that is a downstream target of N-cadherin. | 10-17-2013 |
20130274129 | TAL-EFFECTOR ASSEMBLY PLATFORM, CUSTOMIZED SERVICES, KITS AND ASSAYS - The invention generally relates to compositions and methods for designing and producing functional DNA binding effector molecules and associated customized services, tool kits and functional assays. In some aspects, the invention provides methods and tools for efficient assembly of customized TAL effector molecules. Furthermore, the invention relates to uses of TAL effector molecules and functional evaluation of such TAL by, for example, customized assays. | 10-17-2013 |
20130274130 | SENSITIVE HIGH THROUGHPUT METHOD FOR DNA DAMAGE AND REPAIR - A high throughput method and apparatus for rapidly screening a plurality of genotoxicants to determine the degree and type of genotoxicity are provided. | 10-17-2013 |
20130274131 | Advanced Reverse-phase Magnetic Immunoassay - A magnetic assay is provided where capture probes are disposed on the sensor array as capture probe spots that overlap with the sensor elements. The capture probes on the sensor elements can be the same or they can be different. Two or more sample solutions are also disposed on the sensor array as sample spots that overlap with the sensor elements. Targets in the sample solutions can bind to the capture probes to provide immobilized targets. Magnetically labeled probes capable of binding to targets are provided to the assay, and the resulting assay signal is from immobilized magnetically labeled probes at the sensor elements. | 10-17-2013 |
20130274132 | Genetic Modifiers of Cystic Fibrosis - Disclosed herein are compositions and methods for and treating Cystic Fibrosis lung disease severity and/or secondary manifestations, including meconium ileus and CF related liver disease. | 10-17-2013 |
20130274133 | GENETIC VARIATIONS IN THE INTERLEUKIN-6 RECEPTOR GENE AS PREDICTORS OF THE RESPONSE OF PATIENTS TO TREATMENT WITH INTERLEUKIN-6 RECEPTOR INHIBITORS - The present invention relates to a method for predicting the response of patients to treatment with Interleukin-6 Receptor (IL6R) inhibitors, such as antibodies directed against the IL6R. The method comprises the analysis of one or more genetic variations, in particular single nucleotide polymorphisms, in or associated with the Interleukin-6 Receptor gene. The present invention further relates to a kit for use in predicting the response of patients to treatment with IL6R inhibitors, such as Tocilizumab. The patients suffers from rheumatoid arthritis. | 10-17-2013 |
20130274134 | Analytical Methods and Arrays for Use in the Same - The present invention relates to an in vitro method for identifying agents capable of inducing sensitization of human skin and arrays and diagnostic kits for use in such methods. In particular, the methods include measurement of the expression of the biomarkers listed in Table 3A and/or 3B in MUTZ-3 cells exposed to a test agent. | 10-17-2013 |
20130274135 | COMPOSITIONS OF TOEHOLD PRIMER DUPLEXES AND METHODS OF USE - Provided herein are primers and primer systems having improved specificity and kinetics over existing primers, and methods of use thereof. | 10-17-2013 |
20130274136 | PROSTATE CANCER POINT OF CARE DIAGNOSTICS - The invention relates to point of care diagnostic disposables, devices, methods, and systems for diagnosing or predicting prostate cancer. The present invention employs biomarker specific reagents in disposable cassettes or lab cards for use as analyzers, as well as software to evaluate and report test results. The system promises to improve point of care in vitro diagnostics. | 10-17-2013 |
20130274137 | METHOD AND SYSTEM FOR DETECTING A TARGET WITHIN A POPULATION OF MOLECULES - A method of detecting a target within a population of molecules comprising: contacting a plurality of labeled probe molecules with the population of molecules potentially containing a target of the probe molecules; acquiring a probe specific signal emitted by said labeled probe molecules that bound to said target together with a background signal; preferentially modulating said probe specific signal by at least one of modulating said acquisition and modulating an emission of said probe specific signal; and detecting said probe specific signal over said background signal using said preferential modulation. | 10-17-2013 |
20130274138 | GENE SIGNATURES FOR PREDICTION OF THERAPY-RELATED MYELODYSPLASIA AND METHODS FOR IDENTIFICATION OF PATIENTS AT RISK FOR DEVELOPMENT OF THE SAME - In one embodiment, a gene expression signature for predicting risk of developing therapy-related myelodysplasia or acute myeloid leukemia (t-MDS/AML) after autologous hematopoietic cell transplantation (aHCT) is provided. In another embodiment, a method for predicting a risk for development of t-MDS/AML after aHCT is provided. Such a method may include providing a biological sample that contains CD34 cells from a subject; detecting a test expression level of a set of two or more genes of a gene expression signature; comparing the test expression level of a set of corresponding training expression levels that include a training case expression level and a training control expression level; and predicting a high risk of developing t-MDS/AML when the test expression level is at or about the training case expression level or predicting a low risk of developing t-MDS/AML when the test expression level is at or about the training control expression level. | 10-17-2013 |
20130274139 | MODULAR POINT-OF-CARE DEVICES, SYSTEMS, AND USES THEREOF - The present invention provides devices and systems for use at the point of care. The methods devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device are modular to allow for flexibility and robustness of use with the disclosed methods for a variety of medical applications. | 10-17-2013 |
20130274140 | MicroRNA Fingerprints During Human Megakaryocytopoiesis - Described herein are methods of diagnosing a cancer and/or myeloproliferative disorder using microRNAs. Also described are compositions and methods related to cancers and myeloproliferative disorders. | 10-17-2013 |
20130281309 | Novel biomarker for non-alcoholic fatty liver disease, and method for detecting non-alcoholic fatty liver disease by using the biomarker - The present invention aims to present methods to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis by using a protein or its partial peptide that differs in presence or absence, or in quantity between healthy human subjects and patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis or between patients with fatty liver and nonalcoholic steatohepatitis and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis. Specifically, 35 kDa protein fragment consisting of amino acid sequence expressed by Sequence No. 2 and its partial peptide consisting of amino acid sequence expressed by Sequence No. 3 (including its glycated form) of inter-alpha-trypsin inhibitor heavy chain H4 precursor consisting of amino acid sequence expressed by Sequence No. 1 could be used as biomarkers to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis. | 10-24-2013 |
20130281310 | SENSITIVE IMMUNOASSAYS USING COATED NANOPARTICLES - Coated nanoparticles comprising a core surrounded by a shell that increases the reflectance of the nanoparticle, wherein the coated nanoparticle does not include a Raman-active molecule, are provided. Test devices and immunoassay methods utilizing the coated nanoparticles are provided. | 10-24-2013 |
20130281311 | SPECIFIC BIOMARKER FOR IDENTIFICATON OF EXPOSURE TO PROPIONALDEHYDE AND THE METHOD OF IDENTIFICATION USING THE SAME - The present invention relates to a biomarker for the identification of specific exposure to propionaldehyde which is one of volatile organic compounds exposed in the environment, and a method for the identification of specific exposure to propionaldehyde using the same, precisely a biomarker which is up-regulated or down-regulated specifically by propionaldehyde and a method for the identification of specific exposure to propionaldehyde using the biomarker. The biomarker of the present invention is the reacted genes selected by using DNA microarray chip, which can be effectively used for the monitoring and evaluation of propionaldehyde contamination in the environment samples and at the same time as a tool for the investigation of the toxic mechanism induced specifically by propionaldehyde. | 10-24-2013 |
20130281312 | METHODS FOR PREDICTING ANTI-CANCER RESPONSE - The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs. | 10-24-2013 |
20130281313 | PROGNOSTIC AND/OR PREDICTIVE BIOMARKERS AND BIOLOGICAL APPLICATIONS THEREOF - The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to the identification of human genes and expression products thereof which can be used to assess the prognosis of a cancer in a subject, to assess the sensitivity of a subject to a treatment of cancer, or monitor, in particular determine the efficacy, of such a treatment of cancer after a given period of time. Said human genes and expression products can further be used (i) in the prevention or treatment of cancer, in particular to determine or select the appropriate cancer treatment for a given subject and/or for a particular tumor, as well as (ii) for the screening of therapeutically active drugs. Particular compounds capable to compensate, in a subject, an abnormal expression of one of the herein described products, in particular when the subject is exposed to a therapeutic treatment of cancer, thereby allowing or improving its efficiency in the subject, are also herein disclosed. Inventors, in addition, provide kits and DNA chips usable in the context of the present invention. | 10-24-2013 |
20130281314 | ENGINEERED CONFORMATIONALLY-STABILIZED PROTEINS - Provided herein are conformationally stabilized ubiquitin proteins and methods for using the same to identify agents that bind to the stabilized ubiquitin protein or that bind to a protein that interacts with or processes the stabilized form of the ubiquitin protein. Also provided herein are methods for screening for conformationally stabilized proteins having increased binding affinity to a binding partner in comparison to the binding affinity of the wildtype form of the protein to the binding partner. | 10-24-2013 |
20130281315 | ENHANCING SURFACE PLASMON RESONANCE IMAGING SIGNAL - Described is a biointerface using near-infrared quantum dots for surface plasmon resonance imaging biosensors. | 10-24-2013 |
20130281316 | SLIP-INDUCED COMPARTMENTALIZATION - The present invention relates to fluidic devices for compartmentalizing samples. In particular, the devices and related systems and methods allow for compartmentalization by using one or more first chambers connect by a first channel (e.g., where the cross-sectional dimension of the first channel is less than the cross-sectional dimension of at least one first chamber). | 10-24-2013 |
20130281317 | CONSTRUCTS AND METHODS TO IDENTIFY ANTIBODIES THAT TARGET GLYCANS - Nucleic acid constructs for expressing an antibody on the surface of bacteriophage are disclosed, as are methods for using the constructs to identify antibodies that target glycans. | 10-24-2013 |
20130281318 | DESIGN AND SELECTION OF MEDICAMENTS THAT MODULATE THE FUNCTION AND ACTIVITY OF INTERLEUKIN 13 - The present invention relates generally to the field of medicaments in the form of therapeutic molecules including inflammatory modulators and their design and selection. More specifically, the present invention relates to a target site on Interleukin 13 (IL-13) by which a GAG molecule or polyanionic glycoconjugate or anionic polysaccharide modulates IL-13 activity or function, said target site selected from the list consisting of amino acids located in the AB loops and/or helix D of human IL-13 or its homolog or derivative, and the use of said IL-13 target site to design a medicament for modulating physiological processes. Therapeutic and prophylactic compositions comprising the designed medicaments are also contemplated. | 10-24-2013 |
20130288910 | METHODS AND SYSTEMS FOR GENERATING, VALIDATING AND USING MONOCLONAL ANTIBODIES - Provided herein is a library of antibodies, wherein the library of antibodies can comprise a plurality of monoclonal, monospecific, or immunoprecipitating antibodies. Also provided herein is a method for producing and using the library of antibodies. | 10-31-2013 |
20130288911 | FLUOROGENIC HYDRAZINE-SUBSTITUTED COMPOUNDS - The present disclosure is directed to fluorogenic schiff base-forming dyes capable of detecting analytes containing aldehyde and ketone groups. The dyes contain nucleophilic hydrazinyl appendages and are capable of binding and detecting analytes in situ. | 10-31-2013 |
20130288912 | BIOMARKER SIGNATURES AND USES THEREOF - The invention provides a method for determining a Systemic Lupus Erythematosus-associated disease state in a subject comprising the steps of (a) providing a sample to be tested; and (b) measuring the presence and/or amount in the test sample of one or more biomarker(s) selected from the group defined in Table 1, wherein the presence and/or amount in the test sample of the one or more biomarker(s) selected from the group defined in Table 1 is indicative of a Systemic Lupus. The invention also provides an array and a kit suitable for use in the methods of the invention. | 10-31-2013 |
20130288913 | METHOD OF DETERMINING PREDISPOSITION TO SCOLIOSIS - The present invention relates to novel genetic markers associated with scoliosis, risk of developing scoliosis and risk of scoliosis curve progression, and simplified methods and materials for determining whether a human subject has scoliosis, is at risk of developing scoliosis or is at risk of scoliosis curve progression. | 10-31-2013 |
20130288914 | Method Of Determining Administration Effect In Cancer Chemotherapy With S-1 - Provided is a method of determining a therapeutic effect of cancer chemotherapy with an anticancer drug obtained by blending three ingredients, i.e., tegafur, gimeracil, and oteracil potassium as active ingredients (hereinafter abbreviated as S-1) quickly, simply, and accurately before carrying out the cancer chemotherapy. Specifically, provided is a method of determining an administration effect in chemotherapy with S-1, the method comprising: a step (a) of measuring expression level of a decorin gene in a biological sample collected from a subject to be diagnosed; and a step (b) of determining an administration effect of S-1 based on the expression level of the gene obtained from the measurement. | 10-31-2013 |
20130288915 | COMPOSITIONS AND METHODS FOR ALK MOLECULAR TESTING - Disclosed herein are methods of predicting response of a tumor to an ALK inhibitor and methods of determining diagnosis or prognosis of a subject with a tumor. The methods can include detecting presence of an ALK gene fusion (such as EML4-ALK, TFG-ALK, or KIF5B-ALK) in a sample from a subject. Also disclosed herein are arrays for detecting the presence of ALK and/or ROS1 gene fusions in a sample. In some embodiments, the array includes one or more oligonucleotides complementary to an ALK or ROS1 gene fusion. | 10-31-2013 |
20130288916 | REAL-TIME AMPLIFICATION AND MICRO-ARRAY BASED DETECTION OF NUCLEIC ACID TARGETS IN A FLOW CHIP ASSAY - The present method is related to a method for identification and/or quantification of at least one polynucleotide target compound present in a biological sample among possible other ones by its amplification in a cycling flow chip solution passing through different temperatures required for the amplification and its detection in real-time onto a micro-array of specific capture molecules. | 10-31-2013 |
20130288917 | Rapid High Resolution, High Throughput RNA Structure, RNA-Macromolecular Interaction, and RNA-Small Molecule Interaction Mapping - Compositions and methods are provided for a rapid, high-resolution, high-throughput method for determining the intramolecular interactions between the nucleotides present in an polynucleotide, such that single-stranded nucleotides, and nucleotides in a double-stranded configuration are distinguished and identified. Tertiary contacts and solvent accessible regions may also be determined, where such contacts and regions may result from a single stranded configuration, intermolecular interactions with other macromolecules including, without limitation, DNA, protein, RNA, etc.; intermolecular interactions with small molecules which may include drug candidates; or a combination of macromolecules and small molecules. | 10-31-2013 |
20130288918 | Colorectal Cancer Screening Method - The invention relates to a method of screening for colorectal cancer in a subject, comprising a step of measuring the degree of methylation of at least one of the genes selected from NPY, PENK and fragments or variants thereof in a biological sample obtained from said subject. | 10-31-2013 |
20130288919 | LABEL-FREE MOLECULE DETECTION AND MEASUREMENT - A system and method for electrically detecting a target material in a sample without the need for labeling is described. A probe supporting member defining at least one hole is functionalized with target specific probe material and a change in the hole area on binding of target material is detected as a change in an ionic current through the hole. In some embodiments, an electro-chemical cell comprising an electrode having a conducting layer and a porous insulating layer is provided. In some embodiments, an electrically addressable array is provided for detection of a potentially large number of target materials in a sample. | 10-31-2013 |
20130288920 | MULTIANALYTE MOLECULAR ANALYSIS USING APPLICATION-SPECIFIC RANDOM PARTICLE ARRAYS - The present invention provides a method for the generation of novel libraries of encoded magnetic particles from sub-libraries of by the generation of novel sub-libraries of magnetic nanoparticles and encoded particles. The sub-libraries are functionalized on demand are useful in the formation of arrays. The present invention is especially useful for performing multiplexed (parallel) assays for qualitative and/or quantitative analysis of binding interations of a number of analyte molecules in a sample. | 10-31-2013 |
20130288921 | MUTATED PARVOVIRUS STRUCTURAL PROTEINS AS VACCINES - The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use. | 10-31-2013 |
20130288922 | ARRAYED DETECTOR SYSTEM FOR MEASUREMENT OF INFLUENZA IMMUNE RESPONSE - A sensor chip for detecting an immune response against an influenza virus, the sensor chip including a substrate having a surface and a plurality of hemagglutinin polypeptides bound to discrete locations on the surface of the substrate, each hemagglutinin polypeptide having a hemagglutinin epitope. Detection devices containing the sensor chip and methods of detecting influenza immune responses are also described herein. | 10-31-2013 |
20130288923 | Nucleotide-Based Probes and Methods for the Detection and Quantification of Macromolecules and Other Analytes - Provided are unimolecular oligonucleotide probes for detecting a target in a sample. The probes use target binding-induced structural changes to detect the presence of the target in the sample. Also provided are methods of using the probes to detect a target in a sample. | 10-31-2013 |
20130288924 | METHOD FOR DIAGNOSING HEMATOLOGICAL DISORDERS - Disclosed is a method for the diagnosis, and/or the classification, of a hematological disorder, including the steps of: a). measuring, the expression level of at least the genes of a sub-group of 6 genes, b). comparing the expression level of each genes measured in step a)., with the expression level of the same genes in healthy control sample, and c). determining the status of the biological sample. | 10-31-2013 |
20130296177 | CHEMICALLY-DEFINED ARRAYS FOR SCREENING CELL-SUBSTRATE INTERACTIONS - Patterned SAM arrays and methods of preparing patterned SAM arrays are disclosed. Advantageously, the methods used to prepare the patterned SAM arrays allow for controlling SAM spot-to-spot conditions such as ligand identity and ligand density, which allows for preparing a wide range of SAM spots in a single array format. Additionally, the patterned SAM arrays of the present disclosure support the culture of a range of cell types. The patterned SAM arrays offer the ability to rapidly screen substrate components for influencing cell attachment, spreading, proliferation, migration, and differentiation. | 11-07-2013 |
20130296178 | METHODS FOR GENETIC ANALYSIS - Methods of treating an individual exhibiting a medical condition are disclosed. The methods involve determining a score of an individual based on the individual's genotypic information, comparing the score to at least one threshold value, wherein the result of the comparison is indicative of a beneficial response to a treatment, and providing a suitable treatment to the individual. | 11-07-2013 |
20130296179 | NUCLEIC ACID PROBE-BASED DIAGNOSTIC ASSAYS FOR PROKARYOTIC AND EUKARYOTIC ORGANISMS - Use of the ssrA gene or tmRNA, an RNA transcript of the ssrA gene, or fragments thereof as target regions in a nucleic acid probe assay for the detection and identification of prokaryotic and/or eukaryotic organisms is described. Nucleotide sequence alignment of tmRNA sequences from various organisms can be used to identify regions of homology and non-homology within the sequences which in turn can be used to design both genus specific and species specific oligonucleotide probes. These newly identified regions of homology and non-homology provide the basis of identifying and detecting organisms at the molecular level. Oligonucleotide probes identified in this way can be used to detect tmRNA in samples thereby giving an indication of the viability of non-viral organisms present in various sample types. | 11-07-2013 |
20130296180 | PROCESSES AND COMPOSITIONS FOR METHYLATION-BASED ENRICHMENT OF FETAL NUCLEIC ACID FROM A MATERNAL SAMPLE USEFUL FOR NON-INVASIVE PRENATAL DIAGNOSES - Provided are compositions and processes that utilize genomic regions differentially methylated between a mother and her fetus to separate, isolate or enrich fetal nucleic acid from a maternal sample. The compositions and processes described herein are useful for non-invasive prenatal diagnostics, including the detection of chromosomal aneuploidies. | 11-07-2013 |
20130296181 | COMPOSITIONS AND ASSAYS TO DETECT SWINE H1N1 INFLUENZA A VIRUS, SEASONAL H1 INFLUENZA A VIRUS AND SEASONAL H3 INFLUENZA A VIRUS NUCLEIC ACIDS - Methods for detecting the presence or absence of the swine H1N1 influenza A virus, seasonal H1 influenza A virus and/or seasonal H3 influenza A virus nucleic acids in biological samples are disclosed. Compositions that are target-specific nucleic acid sequences and kits comprising target-specific nucleic acid oligomers for amplifying in vitro the swine H1N1 influenza A virus, seasonal H1 influenza A virus and/or seasonal H3 influenza A virus nucleic acid and detecting amplified nucleic acid sequences are disclosed. | 11-07-2013 |
20130296182 | VARIABILITY SINGLE NUCLEOTIDE POLYMORPHISMS LINKING STOCHASTIC EPIGENETIC VARIATION AND COMMON DISEASE - Provided are methods and models for an alternative source of disease risk, which identifies not genetic variants for a phenotype per se, but variants for variability itself. Also provided are methods and models for a genome-scale, gene-specific analysis of DNA methylation in the same individuals over time, in order to identify a personalized epigenomic signature that may correlate with common genetic disease. Also provided are methods and models for simulating stochastic epigenetic variation as a driving force of development, evolutionary adaptation, and disease. | 11-07-2013 |
20130296183 | FUNCTIONAL GENOMICS ASSAY FOR CHARACTERIZING PLURIPOTENT STEM CELL UTILITY AND SAFETY - The present invention generally relates set of reference data or “scorecard” for a pluripotent stem cell, and methods, systems and kits to generate a scorecard for predicting the functionality and suitability of a pluripotent stem cell line for a desired use. In some aspects, a method for generating a scorecard comprises using at least 2 stem cell assays selected from: epigenetic profiling, differentiation assay and gene expression assay to predict the functionality and suitability of a pluripotent stem cell line for a desired use. In some embodiments, the scorecard reference data can be compared with the pluripotent stem cells data to effectively and accurately predict the utility of the pluripotent stem cell for a given application, as well as any to identify specific characteristics of the pluripotent stem cell line to determine their suitability for downstream applications, such as for example, their suitability for therapeutic use, drug screening and toxicity assays, differentiation into a desired cell lineage, and the like. | 11-07-2013 |
20130296184 | Novel Method for Diagnosing Lyme Disease Using a Cellular Immunological Test - The present invention relates to a method for diagnosing Lyme disease in a subject, the method comprising the steps of: (a) obtaining a sample from said subject, (b) contacting said sample with a source of | 11-07-2013 |
20130296185 | TAPE STRIPPING METHODS FOR ANALYSIS OF SKIN DISEASE AND PATHOLOGICAL SKIN STATE - The present invention provides non-invasive methods for detecting, monitoring, and diagnosing skin disease and pathological skin states such as irritated skin and psoriasis. The methods include using tape stripping to analyze expression in epidermal samples, of one or more skin markers. In illustrative examples, the tape stripping is performed using pliable tape that has a rubber adhesive. Furthermore, the present invention provides methods for predicting and monitoring response to therapy for a skin disease, such as psoriasis or dermatitis. Finally, the methods can include the use of a microarray. | 11-07-2013 |
20130296186 | SELF-ENCODING SENSOR WITH MICROSPHERES - Disclosed herein are compositions and methods for combining the output obtained from redundant sensor elements in a sensor array. | 11-07-2013 |
20130296187 | Microfluidics System for Sequencing - A sensor chip ( | 11-07-2013 |
20130296188 | TARGETING METABOLIC ENZYMES IN HUMAN CANCER - Targeting metabolic enzymes in human cancer Abstract Lung cancer is a devastating disease and a major therapeutic burden with poor prognosis. The functional heterogeneity of lung cancer (different tumor formation ability in bulk of tumor) is highly related with clinical chemoresistance and relapse. Here we find that, glycine dehydrogenase (GLDC), one of the metabolic enzyme involved in glycine metabolism, is overexpressed in various subtypes of human lung cancer and possibly several other types of cancers. GLDC was found to be highly expressed in tumor-initiating subpopulation of human lung cancer cells compared with non-tumorigenic subpopulation. By array studies we showed that normal lung cells express low levels of GLDC compared to xenograft and primary tumor. Functional studies showed that RNAi inhibition of GLDC inhibits significantly the clonal growth of tumor-initiating cells in vitro and tumor formation in immunodeficient mice. Overexpression of GLDC in non-tumorigenic subpopulation convert the cells to become tumorigenic. Furthermore, over-expression of GLDC in NIH/3T3 cells and human primary lung fibroblasts can transform these cells, displaying anchorage-independent growth in soft agar and tumor-forming in mice. Not only is GLDC is expressed human lung cancer, it is also up-regulated in other types of cancer, such as colon cancer. RNAi knockdown of GLDC in colon cancer cell line, CACO-2 cells, can also inhibit the tumor formation in mice. Thus GLDC maybe a new metabolic target for treatment of lung cancer, and other cancers. | 11-07-2013 |
20130296189 | PROBES UTILIZING UNIVERSAL TAGS, A KIT COMPRISING THE SAME AND DETECTION METHODS - The present invention provides a kit and a detection method for multiple targets detection of biomolecules. The kit comprises a universal tag, a probe and an optional instruction for using the same. The universal tag in the present invention is a fragment of DNA, RNA, peptide nucleic acid, or LNA, and is 3-20 mer in length. The probe in the present invention contains in order from 3′ terminus to 5′ terminus, a nucleotide sequence which is reverse complementary to a target molecule or a portion of the target molecule, and a nucleotide sequence which is reverse complementary to the universal tag; or said probe contains in order from 3′ terminus to 5′ terminus, a nucleotide sequence which is reverse complementary to the universal tag, and a nucleotide sequence which is reverse complementary to a target molecule or a portion of the target molecule. | 11-07-2013 |
20130296190 | PREDICTION OF SPONTANEOUS PRETERM BIRTH BY MEASURING CELL FREE NUCLEIC ACIDS IN MATERNAL BLOOD - A nucleic acid normalization kit can include a nucleic acid having a normalization sequence including or complementary to one or more of SEQ ID NOs: 1-4 and 301-303 or unique segment thereof, the nucleic acid being present in an amount sufficient for use in a nucleic acid normalization protocol. The normalization kit can be used in a method of identifying a pregnancy normalization nucleic acid sequence. A nucleic acid diagnostic kit for diagnosing susceptibility to preterm birth (PTB) can include a nucleic acid having a CFP RNA PTB biomarker sequence including or complementary to one or more of SEQ ID NOs: 5-300 or unique segment thereof, the nucleic acid being present in an amount sufficient for use in a nucleic acid diagnostic protocol for diagnosing susceptibility to PTB. The diagnostic kit can be used in a method for predicting susceptibility of a pregnant woman to preterm birth (PTB). | 11-07-2013 |
20130296191 | Methods and Means for Molecular Classification of Colorectal Cancers - The invention relates to methods of typing a sample from a colorectal cancer patient based on the levels of RNA expression products in a cancer cell of the patient. The invention further relates to methods for determining a strategy for treatment of a patient suffering from colorectal cancer, and to methods for assigning treatment to a patient suffering from colorectal cancer. | 11-07-2013 |
20130303388 | COMPOSITIONS FOR DETECTION AND ANALYSIS OF POLYNUCLEOTIDES USING LIGHT HARVESTING MULTICHROMOPHORES - Methods, compositions and articles of manufacture for assaying a sample for a target polynucleotide are provided. A sample suspected of containing the target polynucleotide is contacted with a polycationic multichromophore and a sensor PNA complementary to the target polynucleotide. The sensor PNA comprises a signaling chromophore to absorb energy from the excited multichromophore and emit light in the presence of the target polynucleotide. The methods can be used in multiplex form. Kits comprising reagents for performing such methods are also provided. | 11-14-2013 |
20130303389 | METHOD OF CLASSIFYING GENE EXPRESSION STRENGTH IN LUNG CANCER TISSUES - The present invention provides a method of confirming the gene expression, useful in the decision of a five year survival rate of a patient with lung cancer and the use of a DNA probe kit in the method. A method useful in the decision of a survival rate of a patient with non-small cell lung cancer comprising confirming the expression strength of at least one gene in lung cancer tissues isolated from the patient. | 11-14-2013 |
20130303390 | SYSTEM FOR INTEGRATED ANALYSIS OF REAL-TIME POLYMERASE CHAIN REACTION AND DNA CHIP AND METHOD FOR INTEGRATED ANALYSIS USING THE SAME - Provided are a system for integrated analysis of a real-time polymerase chain reaction and a DNA chip and a method for integrated analysis using the same, and more particularly to an apparatus for integrated analysis of a real-time polymerase chain reaction and a DNA chip and a method for integrated analysis using the same. According to the method for integrated analysis of a biomaterial of the present invention, gene amplification proceeds and subsequently hybridization proceeds in a single reactor, thereby preventing contamination of the sample due to external factors, which may be caused while the sample is transferred for reaction, and automating a series of procedures such as injection of the sample, reaction of the biomaterial, and detection and analysis of results. | 11-14-2013 |
20130303391 | METHODS FOR DIAGNOSIS AND PROGNOSIS OF INFLAMMATORY BOWEL DISEASE USING CYTOKINE PROFILES - The present invention relates to the field of inflammatory bowel disease. More specifically, the present invention relates to the use of cytokines to detect, diagnose, and assess inflammatory bowel disease. In one embodiment, a method for diagnosing Crohn's Disease (CD) in a patient comprises the steps of (a) collecting a sample from the patient; (b) measuring the levels of at least one cytokine in the sample collected from the patient; and (c) comparing the levels of the at least one cytokine with predefined cytokine levels, wherein a correlation between the cytokine levels in the patient sample and predefined cytokine levels indicates that the patient has CD. In a specific embodiment, the at least one cytokine comprises Interferon (IFN)-gamma, Interleukin (IL)-1beta, IL-6, IL-8, IL-12, IL-17 and CXCL10. | 11-14-2013 |
20130303392 | Multiplex branched-chain DNA assays - Methods of detecting two or more nucleic acids in a multiplex branched-chain DNA assay are provided. Different nucleic acids are captured through cooperative hybridization events on different, identifiable subsets of particles or at different selected positions on a spatially addressable solid support. Compositions, kits, and systems related to the methods are also described. | 11-14-2013 |
20130303393 | IMMUNOGLOBULIN LIBRARIES - Methods and compositions for the screening and isolation of ligand-binding polypeptides, such as antibodies. In some aspects, methods of the invention enable the isolation of intact soluble antibodies comprising a constant domain. Screening methods that employ genetic packages such as bacteria and bacteriophages enable high through-put identification of ligand binding molecules. | 11-14-2013 |
20130303394 | FLUIDIC CHIPS HAVING SURFACE ENERGY TRAPS - A method of using a fluidic device includes providing a fluidic chip having a plurality of surface energy traps; depositing at least one fluid droplet on the fluidic chip, the fluid droplet including magnetic particles suspended therein; and moving at least a portion of the at least one fluid droplet across a surface of the fluidic chip by altering a magnetic interaction applied to the magnetic particles such that the at least one fluid droplet interacts with at least one of the plurality of surface energy traps. | 11-14-2013 |
20130303395 | MARKER SEQUENCES FOR SYSTEMIC LUPUS ERYTHEMATOSUS AND THE USE THEREOF - The invention relates to novel marker sequences for systemic lupus erythematosus and to the use thereof in diagnosis as well as to a method for screening potential active ingredients for systemic lupus erythematosus diseases using said marker sequences. The invention further relates to a diagnostic device containing such marker sequences for systemic lupus erythematosus, especially to a protein biochip and the use thereof. | 11-14-2013 |
20130303396 | ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO TWO OR MORE ANTIGEN MOLECULES REPEATEDLY - The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen. | 11-14-2013 |
20130303397 | OLIGONUCLEOTIDE PROBE SET AND METHODS OF MICROBIOTA PROFILING - Described herein is a set of oligonucleotide probes. Also included are methods of using the oligonucleotide probes in profiling the microbiota of the GI tract of a subject and methods of diagnosing or monitoring a disease or condition in a subject or predicting or assessing the risk of a subject developing a disease or condition. Kits comprising the oligonucleotide probe set described herein are also provided | 11-14-2013 |
20130303398 | USE AND IDENTIFICATION OF BIOMARKERS FOR GASTROINTESTINAL DISEASES - The described invention relates to the identification of biomarkers for gastrointestinal diseases and provides methods utilizing the biomarkers for in drug discovery, monitoring of treatment efficacy, and diagnostics. The invention further provides methods for identifying a therapeutic target to treat ulcerative colitis, colorectal cancer, and Crohn's disease. | 11-14-2013 |
20130303399 | EXPRESS HUMANIZATION OF ANTIBODIES - The disclosure provides a method for generation of humanized full length antibodies in mammalian cells. A library of humanized variants is provided with high, validated human framework diversity without requiring back-mutations to retain original affinity. Synthetic CDR encoding fragment libraries derived from a template antibody are ligated to human framework region encoding fragments from a human framework pool limited only to germline sequences from a functionally expressed anti-Combine bodies. The vector comprises a nucleic acid sequence encoding HC framework region 4. No CDR grafting or phage display is required. | 11-14-2013 |
20130303400 | MULTIMARKER PANEL - The invention is directed to a method of diagnosing a malignant ovarian tumor disease in a subject, which comprises —providing a sample of peripheral blood cells (PBC) of the subject, —measuring the expression of a multimarker gene panel comprising at least NEAT1, BC037918, C1 orf63, PRIC285, OSM, and optionally further genes or protein markers, and —comparing to a reference value, the differential expression being indicative of a malignant ovarian tumor, and a set of reagents to determine the expression of such a multimarker panel, as well as the use of a PBC-expression based test to improve the diagnosis of ovarian cancer. The invention further relates to a method of determining the expression of at least one of the RPL21, RPL9 and/or SH3BGRL3 genes in a PBC sample of a subject as internal control. | 11-14-2013 |
20130310266 | Methods and Compositions For The Diagnosis And Treatment Of Cancer and Autoimmune Disorders - Compositions, devices, and methods are contemplated for predicting a patient's likelihood of having a disease. An antigen composition can have a plurality of autoantibody reactive antigens associated with a carrier, where at least two of the antigens have quantified and known relative autoantibody reactivities with respect to sera of a population affected by a disease. The at least two antigens can also have a known association with a disease parameter. A method can include determining autoantibody reactivity against one or more antigens or their variants in a serum sample obtained from a patient, where the autoantibody reactivity against one or more of the antigens indicates an increased likelihood of the patient having a disease. | 11-21-2013 |
20130310267 | QUANTITATIVE METHODS AND KITS FOR PROVIDING REPRODUCIBLE IHC4 SCORES - The present technology relates generally to determining a risk of recurrence of disease in a cancer patient. In particular, this approach to determining a risk of recurrence involves utilizing standardized quantitative assessments of the level of biomarker expression selected from estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67 (Ki67) in a patient's tumor to determine the risk of recurrence, thereby allowing a caretaker to determine the best course of treatment for the patient. | 11-21-2013 |
20130310268 | METHOD AND SYSTEM FOR STANDARIZING MICROSCOPE INSTRUMENTS - Methods and apparatus for standardizing quantitative measurements from a microscope system. The process includes a calibration procedure whereby an image of a calibration slide is obtained through the optics of the microscope system. The calibration slide produces a standard response, which can be used to determine a machine intrinsic factor for the particular system. The machine intrinsic factor can be stored for later reference. In use, images are acquired of a target sample and of the excitation light source. The excitation light source sample is obtained using a calibration instrument configured to sample intensity. The calibration instrument has an associated correction factor to compensate its performance to a universally standardized calibration instrument. The machine intrinsic factor, sampled intensity, and calibration instrument correction factor are usable to compensate a quantitative measurement of the target sample in order to normalize the results for comparison with other microscope systems. | 11-21-2013 |
20130310269 | HOT-START DIGITAL PCR - The present disclosure provides methods and compositions for performing nucleic acid reactions, such as hot-start digital polymerase chain reaction (dPCR). | 11-21-2013 |
20130310270 | Holographic Imaging for Analyzing Molecules - The present disclosure provides a device for analyzing target molecules. The device comprises a substrate retention device for holding a substrate having a functionalized surface provided thereon. This functionalized surface is adapted for capturing a plurality of target molecules. The device also comprises a light source for illuminating the functionalized surface and an image sensor for recording interference patterns of magnetic particles present on the functionalized surface. The device further comprises a first magnetic field generator configured to generate a magnetic field to attract magnetic particles linked to the target molecules to the functionalized surface. The disclosure further relates to a method for analyzing target molecules. | 11-21-2013 |
20130310271 | TUBERCULOSIS DIAGNOSTIC TEST - A method of diagnosing in a host infection by or exposure to a mycobacterium which expresses ESAT-6 comprising (i) contacting a population of T cells from the host with one or more peptides or analogues selected from the peptides represented by SEQ ID NO:1 to 11 and analogues thereof which can bind a T cell receptor which recognises any of the said peptides, and (ii) determining whether the T cells of said T cell population recognise the peptide(s) and/or analogue(s). The method may performed in vivo. Peptides and a kit which enable the method to be carried out are provided. | 11-21-2013 |
20130310272 | METHOD FOR EVALUATING THE PRESENCE OF RHEUMATOID ARTHRITIS AND BIOMARKER SET USED IN THE SAME - An object is to provide a method for evaluating presence of rheumatoid arthritis by using a new biomarker set. The object is achieved by a method for evaluating presence of rheumatoid arthritis, in which the method includes the steps of: acquiring, from a biological specimen obtained from a subject, information regarding expression level of a first biomarker which is SLC16A4, and information regarding expression level of at least one second biomarker selected from the group consisting of SLCO2B1, PTPRM, SHB, and ATP9A; and evaluating presence of rheumatoid arthritis in the subject based on the information regarding expression levels of the acquired first and second biomarkers. | 11-21-2013 |
20130310273 | Methods and Means for Diagnosing Vasculitis - The present inventions relates generally to methods for diagnosing the presence or the risk of development or the therapy control of vasculitis, in particular, of large vessel vasculitis, like giant-cell arteritis (GCA), polymyalgia rheumatica (PMR) and Takayasu's arteritis in a subject, in particular, in mammals. In addition, the present invention relates to test kits for use in the diagnosis of the presence or the risk of development, or for the therapy control of vasculitis, in particular of large vessel vasculitis, like GCA, PMR and Takayasu's arteritis, in a subject. In particular, the present invention relates to a method for diagnosing the presence or the risk of development, or for the therapy control of vasculitis, in particular of large vessel vasculitis, like GCA, PMR and Takayasu's arteritis, in a subject analyzing for the presence of antibodies against ferritin, in particular heavy chain ferritin or immunoreactive peptides thereof or ferritin analog protein, preferably bacterial ferritin analog protein, or immunoreactive peptides thereof, in a subject. The presence of antibodies against ferritin or immunoreactive peptides thereof is indicative for the presence or the risk of development, or for the therapy control of vasculitis, in particular of large vessel vasculitis, like GCA, PMR and Takayasu's arteritis. In particular, detection of the presence of antibodies against ferritin or immunoreactive peptides thereof, allows early diagnosis of vasculitis, in particular of large vessel vasculitis, like GCA, PMR and Takayasu's arteritis. | 11-21-2013 |
20130310274 | ANTIBODY PREPARATION METHOD, AND ANTIBODY AND ANTIBODY LIBRARY THUS PREPARED - Provided is a method for preparing antibodies against a protein of interest, through which highly specific antibodies against all proteins can be effectively and rapidly prepared with low cost, and the epitope to which the antibody is directed can be determined, so that a library covering epitopes on the surface of the proteins of interest and a library of antibodies against all the epitopes can be established. The antibodies are proved to be useful in detection, protein function investigation and antibody pharmaceuticals. | 11-21-2013 |
20130310275 | DIAGNOSIS OF ASYMPTOMATIC LEFT VENTRICULAR SYSTOLIC DYSFUNCTION - The invention relates a method for diagnosing asymptomatic left ventricular systolic dysfunction in a subject comprising the step a) of: —measuring the level of expression of the genes FECH, TMEM79, FBXW7, NGFB, ALK, UBN1 and SLC43A2 in a biological sample of said subject; or—measuring the level of expression of at least one gene selected from the group consisting of FECH, TMEM79, FBXW7, NGFB, ALK, UBN1 and SLC43A2 in a biological sample of said subject. | 11-21-2013 |
20130310276 | MICRORNA FOR DIAGNOSIS OF PANCREATIC CANCER - The present invention relates to methods for improving the diagnosis of pancreatic and ampullary adenocarcinomas by making use of specific mi RNA biomarkers and/or mi RNA classifiers. | 11-21-2013 |
20130310277 | MULTI-ANALYTE MICROARRAYS USING TAG-SPECIFIC ANTIBODIES AND TAG-ANCHORED ANTIBODIES - The invention describes accurate and flexible methods and kits for conducting multi-analyte microarrays through the use of Tag-specific antibodies and analyte-specific Tag-anchored antibodies. | 11-21-2013 |
20130316922 | QUANTITATION AND PROFILING OF VAGINAL MICROFLORA - Disclosed are methods of quantifying microflora in vaginal samples. Quantitative assessment of vaginal microflora by real-time PCR to create a profiling of | 11-28-2013 |
20130316923 | METHODS FOR PREDICTING ANTI-INTEGRIN ANTIBODY RESPONSE - The present invention relates to methods and procedures for predicting responsiveness to anti-integrin αv monoclonal antibody. | 11-28-2013 |
20130316924 | METHOD FOR DETERMINING THE NEURODEVELOPMENTAL TOXICITY OF A COMPOUND IN VITRO - This invention is in the field of medical molecular diagnostics. It provides methods and means for the in vitro detection of the neurodevelopmental toxicity of a compound by determining the gene expression of a limited number of genes. More in particular, it relates to a method for determining the likelihood that a compound is neurodevelopmental toxic, comprising the steps of: providing embryonic stem cells, allowing the stem cells to form embryoid bodies, allowing the embryoid bodies to differentiate into neural cells, in the presence of said compound, thereby creating a neural differentiation culture, extracting total RNA from the cells in said neural differentiation culture, determining the expression levels of genes Hoxb6, Nrk, 1700011H14Rik and Tph1, comparing the expression levels with a predetermined reference value and determining the increase or decrease of the expression level relative to the reference value, wherein a relative increase or decrease in expression value of more than 20% indicates that a compound is neurodevelopmental toxic. | 11-28-2013 |
20130316925 | MicroRNA Expression in Human Peripheral Blood Microvesicles and Uses Thereof - The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of disorders by examining samples containing microvesicles and miRs therein. | 11-28-2013 |
20130316926 | METHOD FOR THE MONITORING OF SMOKING CESSATION COMPLIANCE AND RECOVERY, THERAPEUTIC INTERVENTION, AND RISK MANAGEMENT - The invention provides compositions and methods for determining patient compliance with a smoking cessation program, and monitoring the patient for physiological recovery from the deleterious effects of smoking, with particular emphasis on those effects that impact risk of cardiovascular disease and development of cancer. The invention also provides compositions and methods for treating a subject according to the patient compliance with the smoking cessation program. | 11-28-2013 |
20130316927 | MICROARRAY SYSTEM WITH IMPROVED SEQUENCE SPECIFICITY - The invention provides a novel array method for nucleic acid sequence detection with improved specificity which allows for detection of genetic variation, from simple SNPs (where the variation occurs at a fixed position and is of limited allelic number) to more complex sequence variation patterns (such as with multigene families or multiple genetic strains of an organism where the sequence variation between the individual members is neither fixed nor consistent). The array is comprised of short, synthetic oligonucleotide probes attached to a solid surface which are hybridized to single-stranded targets. Single stranded targets can be produced using a method that employs primers modified on the 5′ end to prohibit degradation by a 5′-exonuclease that is introduced to degrade the unprotected strand. The invention further provides for printing buffers/solutions for the immobilization of oligonucleotide probes to an array surface. The invention also provides hybridization and wash buffers and conditions to maximize hybridization specificity and signal intensity, and reduce hybridization times. | 11-28-2013 |
20130316928 | REAGENT STORAGE IN AN ASSAY DEVICE - The invention relates to methods for conducting binding assays in an assay device that includes one or more storage and use zone. The storage zones of the assay device are configured to house one or more reagents used in an assay conducted in the use zone of the device. | 11-28-2013 |
20130316929 | PEPTIDE LIBRARY - The present invention provides a peptide selected from the following (i) and (ii): (i) a peptide having the amino acid sequence represented by SEQ ID NO: 1 in the Sequence Listing; and (ii) a peptide having an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 1 in the Sequence Listing by the conservative amino acid substitution, deletion, addition, or insertion of 1 to (inclusive) amino acids except at the 1st Xaa to the 11th Xaa counting from the amino terminus. | 11-28-2013 |
20130316930 | PROCESS AND KIT FOR DETERMINING IN VITRO THE IMMUNE STATUS OF AN INDIVIDUAL - The present invention relates to a process for determining in vitro the immune status of an individual according to which: (a) a blood sample from the individual is provided, (b) at least two reagents specific to at least two products of expression of at least two target genes are provided; (c) the expression of said at least two target genes is determined, and (d) the expression of said at least two target genes respectively is compared with a reference expression, with a change in the expression of said at least two target genes relative to their reference expression indicating that the individual's immune status has changed, and a correlation between the expression of said at least two target genes with their reference expression indicating that the individual's immune status is normal; as well as a kit for determining said immune status of the individual. | 11-28-2013 |
20130316931 | MARKERS OF MELANOMA AND USES THEREOF - The invention relates to a method for determining prognosis, predicting or monitoring response to therapy of patients affected by melanoma through the evaluation of the methylation of different genomic DNA sequences, including the Long Interspersed Nucleotide Element-1 (LINE-1) repetitive DNA sequences and/or the concomitant methylation profile of specific groups of genes defined as methylation signature. | 11-28-2013 |
20130316932 | GLYCOPEPTIDE ARRAY - The present invention provides: a glycopeptide array which is useful for the detection of the binding between a substance to be detected and a glycopeptide; and an array which can inhibit the non-specific adsorption or binding of a substance to be detected without the need of coating any adsorption-inhibiting agent and which has the glycopeptide immobilized thereon. In the present invention, it was found that a glycopeptide that has a molecule having a carbonyl group bound to a peptide moiety thereof can be immobilized on a substrate that is coated with a polymer compound containing a unit having a primary amino group with high efficiency through the carbonyl group. Particularly, it was found by the present inventors that a glycopeptide can be immobilized on a substrate with high efficiency and the non-specific adsorption or binding of a substance to be detected can be inhibited effectively when a substrate that is coated with a polymer compound containing a unit having a primary amino group, a unit for retaining hydrophilicity and a unit having a hydrophobic group is used as the substrate for the glycopeptide. | 11-28-2013 |
20130316933 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND MONITORING OF MUSCULAR DEGENERATION - The invention relates to methods based on the quantification of a set of biomarkers, preferably in biological samples isolated from skeletal muscle, for performing the diagnosis, prognosis and/or monitoring of muscular degeneration, preferably muscular degeneration caused by motor neuron diseases, more preferably amyotrophic lateral sclerosis (ALS); and to a kit for the diagnosis, prognosis and monitoring of said type of diseases. The method in the invention for the prognosis and/or monitoring of muscular degeneration makes it possible to determine the rate of progression of said degeneration (fast or slow rate of progression in relation to the normal rate of progression). | 11-28-2013 |
20130324427 | ASSESSMENT AND REDUCTION OF RISK OF GRAFT-VERSUS-HOST DISEASE - Methods of assessing and reducing risk of graft versus host disease (GVHD) based on gene expression profiling are described, as well as methods of selecting a suitable transplant donor. Corresponding reagents and kits are also described. | 12-05-2013 |
20130324428 | SPECIFIC BIOMARKER FOR IDENTIFICATION OF EXPOSURE TO LOWER ALIPHATIC SATURATED ALDEHYDES AND THE METHOD OF IDENTIFICATION USING THE SAME - The present invention relates to a biomarker for the identification of specific exposure to lower aliphatic saturated aldehydes which are volatile organic compounds exposed in the environment, and a method for the identification of specific exposure to lower aliphatic saturated aldehydes using the same, precisely a biomarker which is up- or down-regulated specifically by lower aliphatic saturated aldehyde exposure and a method for the identification of specific exposure to lower aliphatic saturated aldehydes using the biomarker. The biomarker of the present invention is the reacted genes selected by using DNA microarray chip, which can be effectively used for the monitoring and evaluation of lower aliphatic saturated aldehyde contamination in the environment samples and at the same time as a tool for the investigation of the toxic mechanism induced specifically by lower aliphatic saturated aldehydes. | 12-05-2013 |
20130324429 | MicroRNAs For Identification Of Exposure To Lower Aliphatic Saturated Aldehydes And The Method Of Identification Using Thereof - The present invention relates to a biomarker for the identification of exposure to lower aliphatic saturated aldehydes by using micro RNA and a method for the identification of exposure to lower aliphatic saturated aldehydes using the same. In this invention, the micro RNA at least 1.5 fold up-regulated by exposure to lower aliphatic saturated aldehydes and the micro RNA up to 0.66 fold down-regulated by the same were selected. These two micro RNAs can be effectively used as the biomarker for the monitoring of lower aliphatic saturated aldehydes and for the risk assessment thereby and at the same time as a tool to investigate the mechanism of toxicity caused by such lower aliphatic saturated aldehydes. | 12-05-2013 |
20130324430 | DRUG SELECTION FOR COLORECTAL CANCER THERAPY USING RECEPTOR TYROSINE KINASE PROFILING - The present invention provides methods for selecting a suitable anticancer drug therapy, and for identifying and predicting response, for the treatment of colorectal cancer. The present invention also provides methods for monitoring the status of colorectal cancer and monitoring how a patient with colorectal cancer is responding to anticancer drug therapy. The present invention further provides methods for the rational selection of therapy with one or more anticancer drugs tailored to target signal transduction pathway components with dysregulated expression and/or activation levels in patients with somatic mutations in an oncogene. | 12-05-2013 |
20130324431 | OLFACTORY RECEPTOR COPY NUMBER ASSOCIATION WITH AGE AT ONSET OF ALZHEIMER'S DISEASE - The present invention concerns determination of risk for an early age of onset for Alzheimer's Disease in an individual. In specific embodiments, it concerns identification of copy number at chromosome 14q11.2 or a region thereof and associating a high copy number with an earlier age of onset of Alzheimer's Disease. | 12-05-2013 |
20130324432 | BIN1 EXPRESSION AS A MARKER OF SKELETAL MUSCLE MASS AND NEUROLOGICAL CONDITIONS - Provided are methods for determining skeletal muscle mass in subject. Also provided are methods for diagnosing a neurological condition or disease or a condition or disease associated with reduced skeletal muscle mass in a subject. Further provided are purified antibodies that bind specifically to a BIN1 polypeptide that is expressed specifically in skeletal muscle. | 12-05-2013 |
20130324433 | Agents and Methods Related to Reducing Resistance to Apoptosis-Inducing Death Receptor Agonists - Provided herein is a method of reversing or preventing a target cell's resistance to a death receptor agonist. Also provided are methods of screening for biomarkers resistance of and monitoring resistance to death receptor agonists. Also provided are methods of selectively inducing apoptosis in a target cell, treating a subject with cancer, autoimmune or inflammatory diseases, comprising administering compositions provided herein. Further provided are compositions comprising agents that modulate CARD containing proteins. | 12-05-2013 |
20130324434 | METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF - The present invention relates generally to the identification of biomarkers of conditions including disease and non-disease conditions as well as identifying compositions of biomarkers. The invention further provides a method of diagnosing disease, monitoring disease progression, and differentially diagnosing disease. The invention further provides for kits useful in diagnosing, monitoring disease progression and differentially diagnosing disease. | 12-05-2013 |
20130324435 | ESOPHAGEAL CYTOKINE EXPRESSION PROFILES IN EOSINOPHILIC ESOPHAGITIS - Methods and compositions disclosed herein generally relate to methods of providing or enhancing a diagnosis of eosinophilic esophagitis (EE). In particular, the invention relates to obtaining a sample from a patient having at least one indication of EE, then quantifying from the sample an amount of one or more cytokines associated with EE or an mRNA corresponding to the cytokine or its receptor, wherein an altered level of the cytokine or mRNA correlates with a positive diagnosis of EE. An EE diagnosis can then be provided or enhanced, based upon the quantifying step. The invention further relates to diagnostic kits, tests, and/or arrays that can be used to quantify the one or more cytokines associated with EE or an mRNA corresponding to the cytokine or its receptor. | 12-05-2013 |
20130324436 | PROCEDURE FOR NUCLEIC ACID-BASED DIAGNOSTIC DETERMINATION OF BACTERIAL GERM COUNTS AND KIT FOR THIS PURPOSE - Disclosed are procedures and kits for nucleic acid-based molecular diagnostic determination of bacterial germ counts during which procedure evolutionarily conserved genes and genes coding for characteristic pathogenicity markers, favourably microbial enzyme, toxin, special resistance, are detected using real-time PCR amplification method with the application of fluorescent hydrolysis probes. The multiplication of nucleotide chains takes place with oligonucleotides annealing to the structural gene 5′ end region and to the adjacent upstream regulatory promoter-operator region so that the presence of the structural gene is shown along with the adjacent upstream regulatory promoter-operator sequences; the functional nature of the structural gene is simultaneously checked. The result is measured with a genome unit equivalent DNA amount calibrated to the germ number of sample units equivalent to standard procedures. The calibrated determination of bacterial germ counts is favourably based on single copy gene sequences in the genome, like those coding for characteristic pathogenicity markers. | 12-05-2013 |
20130331281 | MOLECULAR MARKERS FOR PROGNOSTICALLY PREDICTING PROSTATE CANCER, METHOD AND KIT THEREOF - The present application provides a method for predicting clinical prognosis for a human subject diagnosed with prostate cancer, comprising: detecting an expression level of a marker gene selected from a group consisting of ABCG1, PDCD4, KLF6, ST6, BTD, BANF1, IRS1, ZNF185, ANXA11, DUSP2, KLF4 and DSC2, in a biological sample containing prostate cancer cells obtained from the human subject; and predicting a likehood of the clinical prognosis by comparing the expression level of the marker gene with a reference level. The present application also provides a combination of molecular markers and a kit containing thereof. | 12-12-2013 |
20130331282 | MARKER COMPOSITION COMPRISING S1P PROTEIN FOR PREDICTION OF RISK IN OSTEOPOROTIC FRACTURE AND OSTEOPOROSIS - Disclosed herein is a marker composition that includes sphingosine 1-phosphate (S1P) protein and that may be used to predict the risk of fracture or osteoporosis; a kit that includes an antibody that specifically binds to the S1P protein and that can be used to predict the risk of fracture or osteoporosis; and a method that can be used to obtain information that allows prediction of the risk of fracture or osteoporosis and includes measurements of S1P protein concentrations by measuring the binding of a S1P-specific antibody to S1P protein. The S1P protein disclosed herein is highly expressed in individuals with fracture, regardless of their bone mineral density. Accordingly, it may be useful as a biomarker of the risk of fracture or osteoporosis. | 12-12-2013 |
20130331283 | AUTO-ANTIGEN BIOMARKERS FOR LUPUS - The presence of certain auto-antibodies indicates that a subject has lupus. The auto-antibodies recognise antigens listed in Table 1 herein. These auto-antibodies and/or the antigens themselves can be used as biomarkers for assessing lupus in a subject. | 12-12-2013 |
20130331284 | ENRICHMENT AND IDENTIFICATION OF FETAL CELLS IN MATERNAL BLOOD AND LIGANDS FOR SUCH USE - The present invention relates to enrichment and/or identification of fetal cells of a maternal blood sample using fetal cell specific ligands and/or fetal cell specific hybridization probes wherein the ligand or probes are directed to an endothelial/mesenchymal marker, e.g. CD105, CD146 or CD141, in a first round of enrichment and the ligand or probes, in a second round of enrichment, are directed to an epithelial marker, e.g. a cytokeratin, such as CK7, CK8, CK18 or CK19. Enriched or identified fetal cells may be subjected to steps of detection or diagnosis, wherefore the present invention enables non-invasive 5 prenatal diagnostics. | 12-12-2013 |
20130331285 | METHODS AND COMPOSITIONS FOR DETECTION OF LEGIONELLA - Methods for detecting | 12-12-2013 |
20130331286 | UNIVERSAL RANDOM ACCESS DETECTION OF NUCLEIC ACIDS - Provided herein is technology relating to detecting nucleic acids in a sample and particularly, but not exclusively, to systems and methods related to random access primer pair libraries that are used to configure or customize assays for nucleic acid detection. | 12-12-2013 |
20130331287 | Autoimmune Antibodies - The invention generally relates to biomarkers associated with NSCLC, and methods and compositions for the detection and diagnosis of non-small cell lung cancer in a human subject. | 12-12-2013 |
20130331288 | DETECTION OF NUCLEIC ACID REACTIONS ON BEAD ARRAYS - The present invention is directed to methods and compositions for the use of micro sphere arrays to detect and quantify a number of nucleic acid reactions. The invention finds use in genotyping, i.e. the determination of the sequence of nucleic acids, particularly alterations such as nucleotide substitutions (mismatches) and single nucleotide polymorphisms (SNPs). Similarly, the invention finds use in the detection and quantification of a nucleic acid target using a variety of amplification techniques, including both signal amplification and target amplification. The methods and compositions of the invention can be used in nucleic acid sequencing reactions as well. All applications can include the use of adapter sequences to allow for universal arrays. | 12-12-2013 |
20130331289 | MULTI-CHAIN EUKARYOTIC DISPLAY VECTORS AND USES THEREOF - A eukaryotic expression vector capable of displaying a multi-chain polypeptide on the surface of a host cell is provided, such that the biological activity of the multi-chain polypeptide is exhibited at the surface of the host cell. Such a vector allows for the display of complex biologically active polypeptides, e.g., biologically active multi-chain polypeptides such as immunoglobulin Fab fragments. The present invention describes and enables the successful display of a multi-chain polypeptide on the surface of a eukaryotic host cell. Preferred vectors are described for expressing the chains of a multi-chain polypeptide in a host cell separately and independently (e.g., under separate vector control elements, and/or on separate expression vectors, thus forming a matched vector set). The use of such matched vector sets provides flexibility and versatility in the generation of eukaryotic display libraries, for example the ability to generate and to display multi-chain polypeptides by combining and recombining vectors that express variegations of the individual chains of a multi-chain polypeptide. Entire repertoires of novel chain combinations can be devised using such vector sets. | 12-12-2013 |
20130331290 | COMPLEX MIRNA SETS AS NOVEL BIOMARKERS FOR LUNG DISEASES - The present invention relates to single polynucleotides or sets of polynucleotides for detecting single miRNAs or sets of miRNAs for diagnosing and/or prognosing of a lung disease in a biological sample from a patient. Further, the present invention relates to means for diagnosing and/or prognosing of a lung disease comprising said polynucleotides or sets of polynucleotides. Furthermore, the present invention relates to a method for diagnosing and/or prognosing of a lung disease based on the determination of expression profiles of single miRNAs or sets of miRNAs representative for a lung disease. In addition, the present invention relates to a kit for diagnosing and/or prognosing of a lung disease comprising means for determining expression profiles of single miRNAs or sets of miRNAs representative for a lung disease and optionally at least one reference and/or algorithm or mathematical function comprised on at least one data carrier. | 12-12-2013 |
20130331291 | METHOD FOR PREDICTING THE OUTCOME OF COLON CANCER BY ANALYSING MIRNA EXPRESSION - The present invention relates to a method for predicting the outcome of a cancer. More particularly, the present invention relates to a method for predicting the outcome of a cancer in a patient comprising a step consisting of determining the expression level of a miRNA cluster in a sample obtained from said patient, wherein said miRNA cluster comprises: -miR.609 or, -miR.518c or, -miR.520f or, -miR.220a or, -miR.362 or, -miR.29a or, -miR.660 or, -miR.603 or, -miR.558 or, -miR519b or, -miR.494 or, -miR.130a or, -miR.639. | 12-12-2013 |
20130331292 | SCREENING METHOD - A method of screening a plurality of fluid samples for the presence of analytes capable of specifically binding to a ligand immobilized on a sensing surface of a sensor, wherein respective response curves representing the progress of each interaction with time are produced, comprises subjecting a set of resulting response curves to an evaluation procedure comprising determining for each response curve a binder classification based on at least two binding-related features of the response curve, identifying response curves for which the binder classification deviates significantly from that of the remaining response curves as a group, and classifying these deviating response curves as representing sample analytes which are binding partners to the ligand. | 12-12-2013 |
20130338017 | METHODS OF SCREENING COMPLEX PROTEIN LIBRARIES TO IDENTIFY ALTERED PROPERTIES - The invention provides methods of making designed and constructed protein (e.g., antibody) libraries and libraries resulting from the same. | 12-19-2013 |
20130338018 | PRIMERS, SEQUENCES AND RECOMBINANT PROBES FOR IDENTIFICATION OF MYCOBACTERIUM SPECIES - The subject invention pertains to an assay and a method for diagnosing, identifying and/or differentiating microorganisms, and in particular bacteria such as | 12-19-2013 |
20130338019 | METHODS AND COMPOSITIONS FOR DETECTING AUTOIMMUNE DISORDERS - This invention provides methods and compositions useful for detecting autoimmune disorders. | 12-19-2013 |
20130338020 | EPIGENETIC MARKERS OF COLORECTAL CANCERS AND DIAGNOSTIC METHODS USING THE SAME - The present invention relates generally to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset or predisposition to the onset of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or adenocarcinoma. The DNA methylation status of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in DNA methylation of one or more nucleic acid molecules. | 12-19-2013 |
20130338021 | METHODS AND COMPOSITIONS FOR THE DETECTION OF COMPLICATIONS OF DIABETES - The present disclosure provides methods and compositions for determining the presence of or predisposition to insulin resistance, diabetes, and complications of diabetes in a subject. The methods relate to measuring the capacity of a subject's peripheral blood mononuclear cells (PBMCs) to induce physiological and/or morphological changes characteristic of fibrosis in cultured. | 12-19-2013 |
20130338022 | Chimeric Oligonucleotides for Ligation-Enhanced Nucleic Acid Detection, Methods and Compositions Therefor - Ligation-enhanced nucleic acid detection assay embodiments for detection of RNA or DNA are described. The assay embodiments rely on ligation of chimeric oligonucleotide probes to generate a template for amplification and detection. The assay embodiments are substantially independent of the fidelity of a polymerase for copying compromised nucleic acid. Very little background amplification is observed and as few as 1000 copies of target nucleic acid can be detected. Method embodiments are particularly adept for detection of RNA from compromised samples such as formalin-fixed and paraffin-embedded samples. Heavily degraded and cross-linked nucleic acids of compromised samples, in which classic quantitative real time PCR assays typically fail to adequately amplify signal, can be reliably detected and quantified. | 12-19-2013 |
20130338023 | BACH2 REPRESSION IN CELLS - A method for measuring the proliferation status of a cell present in a biological sample, comprising the step of measuring in the said cell the loss of BACH2 by Fluorescence after In Situ Hybridization (FISH) analysis and mRNA quantification or by Comparative Genomic Hybridization (CGH) and corresponding kit and applications. | 12-19-2013 |
20130338024 | CLASS II HUMAN HISTONE DEACETYLASES, AND USES RELATED THERETO - The invention provides histone deacetylase class II nucleic acids and polypeptides, methods and reagents for their use, and related compounds including small molecule libraries containing class II histone deacetylase inhibitors. | 12-19-2013 |
20130338025 | USE OF GENE EXPRESSION PROFILING TO PREDICT SURVIVAL IN CANCER PATIENT - Gene expression profiling in multiple myeloma patients identifies genes that distinguish between patients with subsequent early death or long survival after treatment. Poor survival is linked to over-expression of genes such as ASPM, OPN3 and CKS1B which are located in chromosome 1q. Given the frequent amplification of 1q in many cancers, it is possible that these genes can be used as powerful prognostic markers and therapeutic targets for multiple myeloma and other cancer. | 12-19-2013 |
20130338026 | Prognostic Marker for Endometrial Carcinoma - A method for diagnosis of different stages of endometrial cancer and for evaluating the probability of survival for an individual suffering from endometrial carcinoma, and for stratification of a therapy regimen for an endometrial tumor or monitoring therapeutic efficacy in an individual suffering considers the expression status of STMN1 gene or protein. A kit for use in the methods allows for determining amplifications and deletions of chromosomal regions 3q26.32 and 12p12.1, determining alterations of the gene expression profile of the genes (gene signature): upregulation of the genes PLEKHK1, ATP10B, NMU, MMP1, ATAD2, NETO2, TNNI3, PHLDA2, OVOL1 and down-regulation of the genes: NDP, KIAA1434, MME, CFH, MOXD1, SLC47A1, RBP1, PDE8B, ASRGL1, ADAMTS19, EFHD1, ABCA5, NPAS3, SCML1, TNXB, ENTPD3, AMY1A, ENPP, RASL11B, PDZK3, or the expression status of the STMN1 gene or protein. | 12-19-2013 |
20130338027 | Predictive Markers For Cancer and Metabolic Syndrome - Disclosed are predictive biomarkers and methods of use for the determination of insulin resistance and sensitivity, in addition to cardiovascular disease and risk associated with obesity. Methods for the stratification of patients along continuum of susceptibility to cardiometabolic risk, including prediction and progression to metabolic syndrome are also provided. | 12-19-2013 |
20130338028 | TAZ/WWTR1 FOR DIAGNOSIS AND TREATMENT OF CANCER - We provide an anti-TAZ agent for the treatment, prophylaxis or alleviation of cancer. We further provide a kit for detecting breast cancer in an individual or susceptibility of the individual to breast cancer comprising means for detection of TAZ expression in the individual or a sample taken from him or her as well as a method of detecting a cancer cell, the method comprising detecting modulation of expression, amount or activity of TAZ in the cell. | 12-19-2013 |
20130338029 | METHOD FOR A HIGHLY SENSITIVE DETECTION AND QUANTIFICATION OF BIOMOLECULES USING SECONDARY ION MASS SPECTROMETRY (SIMS) AND RELATED TECHNOLOGIES - The present invention relates to a method for detecting and quantifying the presence or absence of a number of biomolecules in a sample using the SIMS technique and arrays for use in said method. | 12-19-2013 |
20130338030 | SCREENING ASSAYS AND METHODS - Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody. | 12-19-2013 |
20130338031 | Biomarkers for Pre-Diabetes, Cardiovascular Diseases, and Other Metabolic-Syndrome Related Disorders and Methods Using the Same - Biomarkers relating to insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy are provided, as well as methods for using such biomarkers as biomarkers for insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy. In addition, methods for modulating the respective disorders or conditions of a subject are also provided. Also provided are suites of small molecule entities as biomarkers for insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy. | 12-19-2013 |
20130338032 | ASSAY FOR DETERMINING EPIGENETIC PROFILES OF MARKERS OF FRAGILE X ALLELES - The present invention relates generally to an assay for the determination of epigenetic profiles, particularly epigenetic profiles associated with a pathological condition. Even more particularly, the present invention provides an assay to detect epigenetic profiles within the Fragile X Mental Retardation (FMR) genetic locus indicative of a pathoneurological condition such as pathoneurodevelopmental and pathoneurodegenerative conditions. The epigenetic profiles can also identify potential non-neurological conditions. Kits and assays for medicaments also form part of the present invention as do computer programs to monitor changes in epigenetic patterns and methods for screening for agents which modulate epigenetic modification. | 12-19-2013 |
20130338033 | Diagnostic and Prognostic Markers for Metastasis - Methods for monitoring cancer metastasis and/or monitoring the response of a patient to cancer therapy directed against metastatic cancer are provided. The methods involve measuring Insulin Growth Factor Binding Protein-2 (IGFBP-2) and/or other biomarkers in biological (e.g., blood, plasma, serum) samples from the patient. | 12-19-2013 |
20130338034 | METABOLIC DISEASES-RELATED ODORANT RECEPTOR GENES AND USE THEREOF - The present invention relates to a diagnostic kit for metabolic diseases selected from the group consisting of obesity, dyslipidemia, fatty liver, and insulin resistance syndrome, and a method for screening a therapeutic composition for said diseases. The invention provides a large number of new gene targets for metabolic diseases such as obesity and the like, thereby enabling a more reliable diagnosis of genes such as obesity and the like and the use in the screening of a therapeutic candidate material based on the new gene targets. | 12-19-2013 |
20130338035 | MHC Genes and Risk of Graft Versus Host Disease - The invention relates to the novel use of gene markers in a method of predicting the risk of or diagnosing a subject to develop graft versus host reaction (GvHR) or graft versus host disease (GvHD). In other aspects the invention also relates to methods of monitoring the efficacy of treatment of GvHR or GvHD, and methods of screening a candidate substance for the treatment of GvHR or GvHD. | 12-19-2013 |
20130338036 | DETECTION OF STAPHYLOCOCCUS AUREUS AND IDENTIFICATION OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS - Aspects of the present invention relate to methods and compositions for the detection and/or quantification of | 12-19-2013 |
20130338037 | DETECTION OF STAPHYLOCOCCUS AUREUS AND IDENTIFICATION OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS - Aspects of the present invention relate to methods and compositions for the detection and/or quantification of | 12-19-2013 |
20130345073 | USE OF ALPHA-2-MACROGLOBULIN FOR DETERMINING OSTEONECROSIS DISEASE STATUS AND FOR SCREENING THERAPEUTIC AGENTS FOR PREVENTING OR TREATING OSTEONECROSIS - The present application presents a method of assessing a predisposition to osteonecrosis in an individual based on the level of expression/activity of alpha-2-macroglubulin, a biomarker whose expression is positively correlated with osteonecrosis. Also provided herein are a diagnostic/prognostic system as well as a software product based on the determination of the level of expression/activity of alpha-2-macroglobulin. Screening methods for the determination of usefulness of an agent in the prevention and/or treatment of osteonecrosis are also provided. | 12-26-2013 |
20130345074 | Biomarker and method for evaluating risk for Parkinson's disease - A biomarker and a method for evaluating a risk for Parkinson's disease are disclosed. The method comprises: obtaining a sample from a tester, analyzing the polymorphic biomarker of the sample, wherein the biomarker is substrate-specifying subunit of SCF E3 ubiquitin ligase complex-FBXO7 gene; and when the cDNA sequence in position 155 of the biomarker is G or the amino acid sequence in position 52 of the biomarker is cysteine, it represents that the tester has a lower risk for Parkinson's disease. | 12-26-2013 |
20130345075 | Tissue Preservation and Fixation Method - This invention relates, e.g., to a composition that, at room temperature, when contacted with a sample comprising phosphoproteins, can fix and stabilize cellular phosphoproteins, preserve cellular morphology, and allow the sample to be frozen to generate a cryostat frozen section suitable for molecular analysis. The composition comprises (1) a fixative that stabilizes the proteins in the sample and that has a sufficient water content for a stabilizer and/or a permeability enhancing agent to be soluble therein; (2) a stabilizer, comprising (a) a kinase inhibitor and (b) a phosphatase inhibitor and, optionally, (c) a protease (e.g., proteinase) inhibitor; (3) a permeability enhancing agent; and (4) lactic acid. Methods and kits are described for preserving phosphoproteins, using such a composition. Also described are endogenous surrogate markers for monitoring protein degradation, including the loss of posttranslational modifications (such as phosphorylation), e.g. following removal of a cell or tissue from a subject; and exogenous molecular sentinels (e.g. phosphoproteins attached to magnetic nanoparticles) that allow one to evaluate the processing history of a cellular or tissue population sample. | 12-26-2013 |
20130345076 | PROBE, CHIP, KIT AND METHOD FOR DETECTION OF MYCOBACTERIUM TUBERCULOSIS, NON-TUBERCULOUS MYCOBACTERIA AND DRUG RESISTANT OF MYCOBACTERIUM TUBERCULOSIS - This invention provides probes, chip, kit and method for detection the species of | 12-26-2013 |
20130345077 | DIAGNOSIS OF LYMPH NODE INVOLVEMENT IN RECTAL CANCER - A method of determining the risk that a subject that has been diagnosed with rectal cancer has stage III rectal cancer is described. The method includes determining the expression levels of a plurality of differentially expressed genes in a rectal cancer sample from the subject, comparing the expression levels of the plurality of genes with the corresponding controls, and characterizing the subject as having an increased risk of having stage III rectal cancer if the expression levels of the genes are increased or decreased compared to the corresponding control values. The inventor has determined which genes are expressed at higher or lower levels by a subject who has stage III rectal cancer. Microarrays and kits for staging subjects are also provided. | 12-26-2013 |
20130345078 | METHODS AND ARRAYS FOR TARGET ANALYTE DETECTION AND DETERMINATION OF TARGET ANALYTE CONCENTRATION IN SOLUTION - Arrays of single molecules and methods of producing an array of single molecules are described. Arrays with defined volumes between 10 attoliters and 50 picoliters enable single molecule detection and quantitation. | 12-26-2013 |
20130345079 | MYCOBACTERIUM TUBERCULOSIS ANTIGENS AND COMBINATIONS THEREOF HAVING HIGH SEROREACTIVITY - The present invention relates to compositions and fusion proteins containing comprising | 12-26-2013 |
20130345080 | Diagnosis, Prognosis and Identification of Potential Therapeutic Targets of Multiple Myeloma Based on Gene Expression Profiling - Gene expression profiling is a powerful tool that has varied utility. It enables classification of multiple myeloma into subtypes and identifying genes directly involved in disease pathogensis and clinical manifestation. The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myeloma. It is further contemplated that therapeutic strategies that directly target CKS1B or related pathways may represent novel, and more specific means of treating high risk myeloma and may prevent its secondary evolution. | 12-26-2013 |
20130345081 | HUMAN FACTOR XIII AS A NORMALIZATION CONTROL FOR IMMUNOASSAYS - The present disclosure provides compositions and methods that are useful for normalizing the amount of signal detected in an assay, such as an immunoassay. The compositions and methods are useful for improving the accuracy of immunoassays, such as immunoassays that detect whether a subject is infected with a retrovirus such as HIV. | 12-26-2013 |
20130345082 | PEPTIDE NUCLEIC ACID PROBES FOR ANALYSIS OF CERTAIN STAPHYLOCOCCUS SPECIES - The present invention relates to peptide nucleic acid (PNA) probes, PNA probe sets and methods for the analysis of certain | 12-26-2013 |
20130345083 | REGULATING STEM CELLS - Provided are methods for producing progenitor/precursor cells from a population of initiating cells (ICP) that have a density of less than 1.072 g/ml and at least 25% of which are CD31Bright by in vitro stimulating the ICP with different factors. | 12-26-2013 |
20130345084 | METHODS AND DEVICES FOR OBTAINING AND ANALYZING CELLS - A method for concentrating and isolating nucleated cells, such as maternal and fetal nucleated red blood cells (nRBCs), in a maternal whole blood sample. The invention also provides methods and apparatus for preparing to analyze and analyzing the sample for identification of fetal genetic material as part of prenatal genetic testing. The invention also pertains to methods and apparatus for discriminating fetal nucleated red blood cells from maternal nucleated red blood cells obtained from a blood sample taken from a pregnant woman. | 12-26-2013 |
20130345085 | METHOD FOR DETECTING NUCLEIC ACID - The present invention provides: a method for detecting a nucleic acid, which efficiently eliminates non-specific detection of nucleic acids other than the nucleic acid as a detection target, so that detection specificity of the nucleic acid as a detection target can be further improved; or the like. This method for detecting a nucleic acid comprises: (a) a step wherein a gel, on which a probe is immobilized, is brought into contact with a reaction solution which contains a nucleic acid that serves as a template for nucleic acid amplification, a primer set for nucleic acid amplification, a nucleotide unit and a DNA extension enzyme; (b) a step wherein the gel and the reaction solution are subjected to a heat cycle for performing a nucleic acid amplification reaction; (c) a step wherein nucleic acid fragments having a specific base length are selected from among the amplified nucleic acid fragments; and (d) a step wherein the selected nucleic acid fragments are detected. | 12-26-2013 |
20130345086 | CD4+ T-CELL GENE SIGNATURE FOR RHEUMATOID ARTHRITIS (RA) - The present invention relates to methods and products for the identification and diagnosis of Rheumatoid arthritis (RA), in particular for the diagnosis of anti-citrullinated peptide antibody (ACPA)-negative RA. Most particularly the invention relates to a gene expression signature comprising at least 12 biomarkers for use in the prognosis or diagnosis of RA. | 12-26-2013 |
20130345087 | PROBE FOR ANALYZING BIOLOGICAL TISSUE AND METHOD FOR UTILIZING SAME - The present invention relates to a method for obtaining cells or cell populations having a high biological activity from a biological tissue by enzymatic isolation, and probes for use in the method; more specifically to a method for analyzing a biological tissue, comprising applying two or more probes respectively containing biological-component binding domains through which two or more proteins bind to a predetermined biological component, to an isolated biological tissue, and analyzing binding amounts of the probes to the biological tissue. | 12-26-2013 |
20130345088 | BEAD SEALING METHOD, METHOD FOR DETECTING TARGET MOLECULE, ARRAY, KIT, AND TARGET MOLECULE DETECTION DEVICE - This invention provides a technique enabling to detect target molecules of low concentration with high sensitivity. This invention includes (i) a step of introducing a hydrophilic solvent ( | 12-26-2013 |
20130345089 | PHOTOACTIVATED CHEMICAL BLEACHING OF DYES - Methods comprising the use of photoactivated chemical bleaching for detecting multiple targets in a biological sample are provided. The methods include the steps of providing a biological sample containing multiple targets, binding at least one probe to one or more target present in the sample, and observing a signal from the probe. The method further includes the steps of contacting the sample comprising the bound probe with an electron transfer reagent and irradiating the sample, thereby initiating a photoreaction that substantially inactivates the probe by photoactivated chemical bleaching. The method further includes the steps of binding at least one probe to one or more target present in the sample, and observing a signal from the probe. The process of binding, observing and bleaching may be iteratively repeated. | 12-26-2013 |
20130345090 | NOVEL METHOD FOR THE SELECTION OF SPECIFIC AFFINITY BINDERS BY HOMOGENEOUS NONCOMPETITIVE ASSAY - The invention generally relates to the field of immunochemistry including antibody therapy, diagnostics, and basic research and specifically relates to the area of selecting affinity molecules such as natural antibodies, including artificial antibodies, antibody mimics, and aptamers. The invention relates particularly to a method of selecting affinity molecules using a homogeneous noncompetitive assay in a high throughput process. | 12-26-2013 |
20130345091 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC MYELOID LEUKEMIA AND ACUTE LYMPHOBLASTIC LEUKEMIA - Compositions and methods for the identification, prognosis, classification, treatment, and diagnosis of leukemia or a genetic predisposition to leukemia are provided. The present invention is based on the discovery of various genomic abnormalities of the IKZF1 gene which are shown herein to be associated with acute lymphoblastic leukemia (ALL), more particularly, associated with BCR-ABL1 positive ALL and/or shown to be associated with chronic myeloid leukemia (CML), more particularly, associated with blast crisis chronic myeloid leukemia (BC-CML) and/or the likelihood of progression into blastic transformation of CML. These various genomic abnormalities of the IKZF1 gene can further be used as prognostic markers to identify a subgroup of ALL having very poor outcomes. Such genomic abnormalities of IKZF1 find use in methods and compositions useful in the identification and/or prognosis and/or predisposition and/or treatment of ALL, more particularly, BCR-ABL1 positive ALL and/or in the identification and/or prognosis and/or predisposition and/or treatment of CML, more particularly, of BC-CML and/or the likelihood of progression into blastic transformation of CML and/or as prognostic markers to identify a subgroup of ALL having very poor outcomes. | 12-26-2013 |
20140005059 | BIOMARKERS FOR CANCER | 01-02-2014 |
20140005060 | METHOD AND SYSTEM FOR THE ANALYSIS OF HIGH DENSITY CELLS SAMPLES | 01-02-2014 |
20140005061 | COMPOSITIONS AND METHODS FOR DETECTION OF MULTIPLE MICROORGANISMS | 01-02-2014 |
20140005062 | Method to Assess Patterns of Molecular Expression | 01-02-2014 |
20140005063 | METHOD FOR DETECTING RISK OF PROGRESSION OF LOW GRADE CERVICAL DYSPLASIA | 01-02-2014 |
20140005064 | POLYMORPHISMS IN ANGIOGENESIS PATHWAY GENES ASSOCIATED WITH TUMOR RECURRENCE IN SURGERY TREATED CANCER PATIENTS | 01-02-2014 |
20140005065 | METHOD FOR DIAGNOSING LUNG CANCERS USING GENE EXPRESSION PROFILES IN PERIPHERAL BLOOD MONONUCLEAR CELLS | 01-02-2014 |
20140005066 | Multiplexed PCR and Fluorescence Detection on a Droplet Actuator | 01-02-2014 |
20140005067 | Stable Nanoreporters | 01-02-2014 |
20140005068 | PROTEIN DETECTION METHOD | 01-02-2014 |
20140005069 | GLYCOPROFILING WITH MULTIPLEXED SUSPENSION ARRAYS | 01-02-2014 |
20140005070 | MARKERS ASSOCIATED WITH CYCLIN-DEPENDENT KINASE INHIBITORS | 01-02-2014 |
20140005071 | Method of Using Cytokine Assays to Diagnose, Treat, and Evaluate Inflammatory Disease | 01-02-2014 |
20140011689 | METHODS AND COMPOSITIONS FOR DIAGNOSIS, STRATIFICATION, AND MONITORING OF ALZHEIMER'S DISEASE AND OTHER NEUROLOGICAL DISORDERS IN BODY FLUIDS - The inventors have discovered a collection of proteinaceous biomarkers (“AD biomarkers) which can be measured in peripheral biological fluid samples to aid in the diagnosis of neurodegenerative disorders, particularly Alzheimer's disease and mild cognitive impairment (MCI). The invention further provides methods of identifying candidate agents for the treatment of Alzheimer's disease by testing prospective agents for activity in modulating AD biomarker levels. | 01-09-2014 |
20140011696 | BAP1 MUTATIONAL ANALYSIS IN DETERMINING SUSCEPTIBILITY TO, PROGNOSIS OF, AND TREATMENT OF MELANOCYTIC NEOPLASIA - Methods and compositions for diagnosing and prognosing neoplasms, particularly malignant melanomas, and for identifying patients at high risk for melanocytic nevi and/or melanomas or other cancers are provided. Methods for distinguishing between nevi at high and low risk for malignant transformation and for characterizing or classifying lesions or nevi are also disclosed. Assays and kits for prognosis of melanoma in a human subject comprising assessment of BAP1 protein and/or BAP1 nucleic acid are provided. | 01-09-2014 |
20140011697 | 3D RF MEMS biosensor for multiplexed label free detection - A label-free RF MEMS-based biosensor is described for detecting biomarkers in a given environment. The biosensor is capable of sensing the presence of biomarkers by exploiting both its mechanical and electrical characteristics. In addition, the method employed for detecting mechanical deflections due to antigen-antibody binding uses a simple electrical circuitry which allows the sensor to be used at any location and time. Such a sensor, when placed in a matrix like structure allows for the detection of multiple biomarkers simultaneously. | 01-09-2014 |
20140011700 | THREE-DIMENSIONAL STRUCTURE OF H1N1 NUCLEOPROTEIN IN COMPLEX WITH ANTIVIRAL COMPOUNDS - The binding mode of the antiviral compounds have been characterized through a variety of biophysical and structural studies, elaborating on the proposed aggregation mechanism of action. We demonstrate the direct binding of these antiviral compounds to NP using thermal shift enhancement assay (TSE) and NMR. In addition, we have completed a detailed analysis of the oligomerization mechanism of action using dynamic light scattering, analytical ultracentrifugation, and surface plasmon resonance (SPR). Structure determination using x-ray crystallography confirmed the proposed compound-induced oligomerization mechanism of action. The co-crystal structure revealed that two compounds bound in an anti-parallel fashion bridging two NP monomers, inducing a novel non-native NP oligomer. Taken together, our data suggest a complex binding mode in which the compounds bind NP specifically in stoichiometric fashion inducing the formation of an NP oligomer without obstructing the RNA binding pocket or interfering with the native NP homo-oligomerization. | 01-09-2014 |
20140011701 | Prognostic Marker Sets For Prostate Cancer - Prostate cancer marker sets consisting of particular genes differentially expressed in prostate tumours provide improved accuracy of prostate cancer prognosis. The prostate cancer marker sets of the present invention, one of which consists of 30 genes related to apoptosis, one of which consists of 22 genes related to cell cycle and one of which consists of 30 genes related to response to external stimulus, may be used in a clinical setting to provide information about the likelihood of a prostate cancer patient to survive without treatment (i.e. whether the prostate tumour is “good” or “bad”). | 01-09-2014 |
20140011704 | Markers and Methods for Assessing and Treating Crohn's Disease and Related Disorders - A method for assessment of the suitability of and/or effectiveness of a target therapy for a gastrointestinal-related disorder, such as Crohn's disease, in a subject evaluates the presence, absence, and/or magnitude of expression of one or more genes in a 10-member gene panel in a sample. The method enables identification of the effectiveness of target therapies prior to or after starting a patient on such therapies. | 01-09-2014 |
20140018248 | METHOD FOR DETECTING ESOPHAGEAL CARCINOMA AND AGENT FOR SUPPRESSING ESOPHAGEAL CARCINOMA - An object of the present invention is to provide a method for detecting cancer and an agent for suppressing cell growth by identification of genes showing behaviors characteristic in cancer such as esophageal carcinoma. The present invention provides a method for detecting cancer, which comprises detecting canceration through detection of amplification of at least one gene existing in an 1q32-1q41 chromosomal region in a specimen. | 01-16-2014 |
20140018249 | BIOMARKERS FOR SCREENING, PREDICTING, AND MONITORING BENIGN PROSTATE HYPERPLASIA - Gene expression data are analyzed using learning machines such as support vector machines (SVM) and ridge regression classifiers to rank genes according to their ability to distinguish between BPH (benign prostatic hyperplasia) and all other conditions. Results are provided showing the correlation of results obtained using data from two independent studies that took place at different times using different microarrays. Genes are ranked according to area-under-the-curve, false discovery rate and fold change. | 01-16-2014 |
20140018250 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES - The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases. | 01-16-2014 |
20140018251 | Methods for Predicting Response to Anti-Cancer Therapy in Cancer Patients - Methods for optimizing the therapeutic efficacy of anti-cancer therapy by detecting phenotypic genetic traits using comparative genomic hybridization are disclosed. | 01-16-2014 |
20140018252 | GENE ARRAY TECHNIQUE FOR PREDICTING RESPONSE IN INFLAMMATORY BOWEL DISEASES - Disclosed are methods for classifying individuals having or suspected of having an inflammatory bowel disease, such as Crohn's Disease or Ulcerative Colitis, as ‘responders’ or ‘non-responders’ to first-line treatment, generally comprising the steps of a) obtaining a biological sample from the individual, b) isolating mRNA from the biological sample c) determining a gene expression profile from the biological sample; and d) comparing the gene expression profile of the individual to a reference gene expression profile or other suitable control such that changes in expression can be used to stratify individuals and predict efficacy of first-line therapy. A gene expression system is further provided for carrying out these methods. | 01-16-2014 |
20140018253 | GENE EXPRESSION PANEL FOR BREAST CANCER PROGNOSIS - The invention described in the application relates to a panel of gene expression markers for node-negative, ER-positive, HER2-negative breast cancer patients. The invention thus provides methods and compositions, e.g., kits and/or microarrays, for evaluating gene expression levels of the markers and methods of using such gene expression levels to evaluate the likelihood of relapse of a node-negative, ER-positive, HER2-negative breast cancer patient. Such information can be used in determining treatment options for patients. | 01-16-2014 |
20140018254 | THERANOSTIC AND DIAGNOSTIC METHODS USING SPARC AND HSP90 - Provided herein are methods and systems of molecular profiling of diseases, such as cancer. The molecular profiling can be used to provide a diagnosis, prognosis, or theranosis for the disease, such as identifying a candidate treatment. The methods can detect expression levels of SPARC and HSP90. The cancer can be, e.g., a renal cell carcinoma or an interdigitating dendritic cell sarcoma. | 01-16-2014 |
20140018255 | METHODS FOR PREDICTING THE OUTCOME OF A CANCER IN A PATIENT BY ANALYSING GENE EXPRESSION - The present invention relates to a method for predicting the outcome of a cancer in a patient by analysing gene expression in a sample obtained from said patient. More particularly the present invention relates to a method for predicting the outcome of a cancer comprising a step consisting of determining the expression level of a gene cluster consisting of at least 3 genes in a sample obtained from said patient. | 01-16-2014 |
20140018256 | METHOD OF DIAGNOSING AUTISM SPECTRUM DISORDER - The present invention provides a method for diagnosing an autism spectrum disorder (ASD), or predisposition to develop an ASD, in a subject, which comprises the step of investigating a set of single nucleotide polymorphisms (SNPs) in a sample from the subject, wherein the number of SNPs in the set is such that the method can diagnose ASD with at least 70% accuracy. The invention also provides a kit for diagnosing an ASD, or predisposition to develop an ASD, in a subject, which comprises a plurality of primer pairs or probes capable of investigating such a set of SNPs in a sample from a subject, and a method for making such a kit. | 01-16-2014 |
20140018257 | Peptide Library Production Method, Peptide Library, and Screening Method - Object is to provide a method of constructing a library of peptides having, at a desired position in the random sequence of each peptide, an amino acid having a portion capable of binding to a target. The invention provides a method of producing a library of peptides having, at a designated position in the random sequence of each peptide, a special amino acid having a portion capable of binding to a target, including (i) preparing a library of mRNAs having, in the mRNA sequence coding for a random amino acid sequence, a base sequence having an altered codon encoding the special amino acid, (ii) preparing an aminoacyl tRNA with the special amino acid linked to a tRNA encoded by the altered codon, and (iii) translating the mRNAs by using a cell-free translation system containing the aminoacyl tRNA to obtain a library of peptides having, in the random sequence thereof, a predetermined special amino acid. | 01-16-2014 |
20140018258 | METHODS FOR GENETIC ANALYSIS - Methods of treating an individual exhibiting a medical condition are disclosed. The methods involve determining a score of an individual based on the individual's genotypic information, comparing the score to at least one threshold value, wherein the result of the comparison is indicative of a beneficial response to a treatment, and providing a suitable treatment to the individual. | 01-16-2014 |
20140018259 | Novel tumor marker determination - A method of determining CCNE2 in a body fluid sample of patients at risk for solid tumor disease. A multi-marker panel is preferably used for detecting circulating tumor cells, comprising CCNE2, DKFZp762E1312, EMP2, MAL2, PPIC, SLC6A8 and GTF2IRD1, and optionally further comprising one or more markers from the group consisting of AGR2, FXYD3, S100A16, TFF1, mammaglobin A, FN, Epcam, tm4sf and rbpms. | 01-16-2014 |
20140024541 | METHODS AND COMPOSITIONS FOR HIGH-THROUGHPUT SEQUENCING - The invention provides methods, apparatuses, and compositions for high-throughput amplification sequencing of specific target sequences in one or more samples. In some aspects, barcode-tagged polynucleotides are sequenced simultaneously and sample sources are identified on the basis of barcode sequences. In some aspects, sequencing data are used to determine one or more genotypes at one or more loci comprising a causal genetic variant. | 01-23-2014 |
20140024542 | METHODS AND COMPOSITIONS FOR ENRICHMENT OF TARGET POLYNUCLEOTIDES - The invention provides methods, apparatuses, and compositions for high-throughput amplification sequencing of specific target sequences in one or more samples. In some aspects, barcode-tagged polynucleotides are sequenced simultaneously and sample sources are identified on the basis of barcode sequences. In some aspects, sequencing data are used to determine one or more genotypes at one or more loci comprising a causal genetic variant. | 01-23-2014 |
20140024543 | COMPOSITIONS FOR DETECTING FOODSTUFF SPOILAGE MICROORGANISMS - The invention provides nucleic acids, collections of nucleic acids, assay kits, and methods for the sensitive and specific detection of microorganisms in a foodstuff. The nucleic acid consists of a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-45. | 01-23-2014 |
20140024544 | RANDOM ARRAY DNA ANALYSIS BY HYBRIDIZATION - The invention relates to methods and devices for analyzing single molecules, i.e., nucleic acids. Such single molecules may be derived from natural samples, such as cells, tissues, soil, air, and water without separating or enriching individual components. In certain aspects of the invention, the methods and devices are useful in performing nucleic acid sequence analysis by probe hybridization. | 01-23-2014 |
20140024545 | BIOMARKER FOR DIAGNOSING TOXICITY OF NANOPARTICLES AND METHOD FOR EVALUATING TOXICITY OF NANOPARTICLES USING THE SAME - The present invention relates to a biomarker composition for diagnosing the toxicity of nanoparticles, which shows a change in expression by exposure to the nanoparticles, the biomarker composition comprising at least one gene selected from the group consisting of aldehyde dehydrogenase, glutamic-pyruvate transaminase, glutamate dehydrogenase, glutamicoxaloacetic transaminase, glutamic acid decarboxylase and glutamate-ammonia ligase, and to a method for evaluating the toxicity of nanoparticles using the same. The biomarker is a gene marker having a high correlation with the toxicity of nanoparticles, and the use of the biomarker can determine whether nanoparticles have toxicity, with high detection sensitivity. Also, the method is useful in monitoring or evaluating the toxicity of nanoparticles by analyzing factors having a high correlation with toxicity of nanoparticles. Furthermore, the method can be effectively used as a tool for studying various diseases caused by exposure to nanoparticles or evaluating the effects of nanoparticles on health. | 01-23-2014 |
20140024546 | SYSTEMS AND METHODS FOR NORMALIZING GENE EXPRESSION PROFILES OF BIOLOGICAL SAMPLES HAVING A MIXED CELL POPULATION - The present disclosure generally provides methods for normalizing gene expression profiles against a cellular repertoire, i.e., the different proportions of various cell types in a sample containing multiple cell types. More specifically, the present disclosure encompasses a method for normalizing the gene expression profile against a mixed cell population. | 01-23-2014 |
20140024547 | Gene Expression Profiling For Identification, Monitoring And Treatment Of Colorectal Cancer - A method is provided in various embodiments for determining a profile data set for a subject with colorectal cancer or conditions related to colorectal cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Tables 1-5. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable. | 01-23-2014 |
20140024548 | DRUG SELECTION FOR MALIGNANT CANCER THERAPY USING ANTIBODY-BASED ARRAYS - The present invention provides methods for selecting a suitable anticancer drug therapy, and for identifying and predicting response, for the treatment of a malignant cancer involving aberrant c-Met signaling. The present invention also provides methods for monitoring the status of a malignant cancer involving aberrant cMet signaling and monitoring how a patient with the malignant cancer is responding to anticancer drug therapy. | 01-23-2014 |
20140024549 | Devices and methods for detecting human metapneumovirus - The present invention discloses specific human metapneumovirus monoclonal antibodies. The antibody is at least two-fold less reactive with non-human metapneumoviruses including, but not limited to, respiratory viruses or avian metapneumoviruses. Further, the antibody is at least two-fold more reactive with a human metapneumovirus (i.e., for example, Type A or Type B) than with non-human metapneumoviruses including, but not limited to, respiratory viruses or avian metapneumoviruses. Consequently, these novel antibodies are useful as a clinical diagnostic agent, especially when using fresh nasopharengeal aspirates. The invention also contemplates numerous diagnostic platforms that together with the novel antibodies can support economical, fast, and highly selective detection and identification of clinical inoculum samples. | 01-23-2014 |
20140024550 | Solid Support Assay Systems and Methods Utilizing Non-Standard Bases - Solid support assays using non-standard bases are described. A capture oligonucleotide comprising a molecular recognition sequence is attached to a solid support and hybridized with a target. In some instances, the molecular recognition sequence includes one or more non-standard bases and hybridizes to a complementary tagging sequence of the target oligonucleotide. In other instances, incorporation of a non-standard base (e.g., via PCR or ligation) is used in the assay. | 01-23-2014 |
20140024551 | MIRNA-Based Detection Methods - The present invention relates to a method of detecting diabetes and associated complications. The present invention also relates to a method of predicting diabetes. The present invention also relates to a method of detecting and/or predicting vascular disorders and cardiovascular disorders. The present invention also relates to kits for performing the methods of the present invention. | 01-23-2014 |
20140024552 | COMPOSITIONS AND METHODS FOR DIAGNOSING OVARIAN CANCER - The invention provides methods and compositions for distinguishing ovarian cancer from a benign pelvic mass using two or more of the following biomarkers: IL-6, MMP9, tPA, IGFBP2, MMP7, Tenascin, NAP2, glycodelin, MCSF, MMP2, Inhibin A, uPAR, and EGFR. The methods are useful in distinguishing a benign pelvic mass from ovarian cancer in subjects, particularly in subjects identified as having increased CA125 levels. | 01-23-2014 |
20140024553 | METHODS OF IDENTIFICATION AND DIAGNOSIS OF LUNG DISEASES USING CLASSIFICATION SYSTEMS AND KITS THEREOF - The invention provides biomarkers and combinations of biomarkers useful in diagnosing lung diseases such as non-smail cell lung cancer or reactive airway disease. Measurements of these biomarkers are inputted into a classification system such as a support vector machine or AdaBoost to assist in determining the likelihood that an individual has a lung disease. Kits comprising agents for detecting the biomarkers and combination of biomarkers, as well as systems that assist in diagnosing lung diseases are also provided. | 01-23-2014 |
20140024554 | COMPLEX SETS OF MIRNAS AS NON-INVASIVE BIOMARKERS FOR GLIOBLASTOMA - The present invention relates to non-invasive methods, kits and means for diagnosing and/or prognosing of glioblastoma in a body fluid sample from a subject. Further, the present invention relates to set of polynucleotides or sets of primer pairs for detecting sets of miRNAs for diagnosing and/or prognosing of glioblastoma in a body fluid sample from a subject. In addition, the present invention relates to sets of miRNAs for diagnosing and/or prognosing of glioblastoma in a body fluid sample from a subject. | 01-23-2014 |
20140024555 | METHOD OF IDENTIFYING SOLUBLE PROTEINS AND SOLUBLE PROTEIN COMPLEXES - Provided herein are methods of identifying a protein as soluble, as well as methods of identifying a soluble protein complex of at least two proteins. The methods allow for the determination of in vitro solubility, or both in vitro and in vivo solubility, of a protein or protein complex. | 01-23-2014 |
20140024556 | CO-COUPLING TO CONTROL REACTIVITY OF REAGENTS IN IMMUNOASSAYS - Methods and compositions for controlling immunoassay reactivity are provided. In one embodiment, a method for preparing a substrate for an immunoassay is provided in which a composition containing a reagent and a neutral material is applied to a substrate under conditions suitable to couple the reagent and the neutral material to the substrate. | 01-23-2014 |
20140024557 | METHODS OF DIAGNOSING ENDOMETRIOSIS - The present invention provides biomarkers for the diagnosis and prognosis of endometriosis. Generally, the methods of this invention find use in diagnosing or for providing a prognosis for endometriosis by detecting the expression levels of biomarkers, which are differentially expressed (up- or down-regulated) in endometrial cells from a patient with endometriosis. Similarly, these markers can be used to diagnose reduced fertility in a patient with endometriosis or to provide a prognosis for a fertility trial in a patient suffering from endometriosis. The present invention also provides methods of identifying a compound for treating or preventing endometriosis. Finally, the present invention provides kits for the diagnosis or prognosis of endometriosis. | 01-23-2014 |
20140031243 | MULTIPLEX DETECTION OF MOLECULAR SPECIES IN CELLS BY SUPER-RESOLUTION IMAGING AND COMBINATORIAL LABELING - Methods and systems are provided for creating molecular barcodes or indicia for cellular constituents within single cells and for resolving such barcodes or indicia with super-resolution technologies such as super-resolution microscopy. By this approach, numerous molecular species that can be measured simultaneously in single cells. It has been demonstrated that multiple mRNA transcripts can be labeled with a spatially ordered sequence of fluorophores, and that barcodes can be resolved. In addition, alternative splicing events can be characterized by identifying and quantifying mRNA isoforms in an individual cell. | 01-30-2014 |
20140031244 | OPTIMIZED PROBE SELECTION METHOD - The present invention provides methods for optimizing oligonucleotide hybridization probes for use in basic and clinical research. Specifically, the invention involves hybridizing serially diluted genomic sample to the oligonucleotide probes on the array, such that a signal intensity is produced for each of the probes; computationally identifying optimized probes which exhibit signal intensities that correspond to the serial dilutions of genomic sample and are reproducibly strong relative to non-optimized probes. | 01-30-2014 |
20140031245 | ALZHEIMER'S DISEASE-SPECIFIC ALTERATIONS OF THE ERK1/ERK2 PHOSPHORYLATION RATIO-ALZHEIMER'S DISEASE-SPECIFIC MOLECULAR BIOMARKERS (ADSMB) - The present invention relates to methods of diagnosing Alzheimer's Disease as well as to methods of confirming the presence or absence of Alzheimer's Disease in a subject. The present invention is also directed to methods of identifying a lead compound useful for the treatment of Alzheimer's Disease by contacting non-Alzheimers cells with an amyloid beta peptide, stimulating the cells with a protein kinase C activator, contacting the cells with a test compound, and determining the value of an Alzheimer's Disease-specific molecular biomarker. The present invention is also directed to methods of diagnosing Alzheimer's Disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator. The Alzheimer's Disease-specific molecular biomarkers disclosed herein are useful for the diagnosis of Alzheimer's Disease, monitoring the progression of Alzheimer's Disease in a subject and in screening methods for the identification of compounds for treating or preventing Alzheimer's Disease. The invention is also directed to kits containing reagents for the detection and diagnosis of the presence or absence of Alzheimer's Disease using the Alzheimer's Disease-specific molecular biomarkers disclosed herein. | 01-30-2014 |
20140031246 | CIRCULATING MICRORNAS ARE BIOMARKERS OF VARIOUS DISEASES - The present invention relates to the field of biomarkers. More specifically, the present invention relates to the use of biomarkers to diagnose and monitor various diseases such as cancer. | 01-30-2014 |
20140031247 | METHODS AND COMPOSITIONS FOR GAMMA-SECRETASE ASSAY - Presented herein are polypeptide substrates based on Notch polypeptides, assay methods based on the use of these substrates, and screening methods directed toward identifying inhibitors of γ-secretase activity. The assay methods and the screening methods are adapted for use in high throughput multi-well plate assay apparatuses. In many embodiments the substrate polypeptides are labeled for ease of detection, and/or may bind specific ligands that themselves are labeled. Generally the labels promote high specificity as well as high sensitivity of detection. These features render the assay and screening methods that employ the labeled substrates especially suited for use in high throughput assay formats. | 01-30-2014 |
20140031248 | Detection of Amplification Products - Compositions and methods are provided for quantitative detection of amplification products, the methods being suitable for multiplexing. A first oligonucleotide that includes a primer sequence for priming an amplification reaction and also is labeled with a fluorescent label or quencher is mixed with a second oligonucleotide which has a sequence suitable for hybridizing to a portion of the first oligonucleotide and has a fluorescent label if the first oligonucleotide has a quencher or a quencher if the first oligonucleotide has a fluorescent label; and a third nucleotide which includes some or all the primer sequence contained in the first oligonucleotide but is not labeled, the first and third oligonucleotide being combined in a molar ratio of 2.8 to 8.2. | 01-30-2014 |
20140031249 | MULTIPLEX MEASURE OF ISOTYPE ANTIGEN RESPONSE - Described are methods for simultaneous detection and quantifying multiple target analytes, including immunoglobulin isotypes and sub-classes, single and multiple protein antibodies within a test sample contained in a single reaction vessel. Such methods use reaction wells as on a multi-well plate, each single well comprising microarrays of calibration spots, each having a predetermined quantity of a target analyte; and capture spots, each having multiple agent antibodies, including isotypes and subclasses that specifically bind the target analytes. The captured analytes and the calibration spots are detected with fluorescently labeled antibodies specific for each different target analyte. Calibration spots generate calibration curves for quantitative determinations of different target analytes. Also described are methods for detecting and quantifying biomarkers, therapeutic proteins and patient derived antibodies; the use of secondary reagents to determine immunoglobulin classes Ig G, A, M, E and sub-classes including IgG1, IgG2, IgG3, IgG4 and IgA. The intensity of each fluorescent signal allows measurement of a specific immune response to a therapeutic protein and associated analytes; interrogates neutralizing effects of patient antibodies on therapeutic proteins, e.g., insulin therapy. | 01-30-2014 |
20140031250 | Biomarkers of Cancer - Methods for diagnosing cancer based on detecting the presence of increased levels of expression of satellite repeats and/or Line-1. | 01-30-2014 |
20140031251 | METHODS OF CLASSIFYING HUMAN SUBJECTS WITH REGARD TO CANCER PROGNOSIS - In one aspect, methods, markers, and expression signatures are disclosed for assessing the degree to which a cell sample has epithelial cell-like properties or mesenchymal cell-like properties. In another aspect, methods are provided for predicting cancer patient prognosis based on whether the cancer is classified as having a high or low EMT Signature Score. | 01-30-2014 |
20140031252 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF INLAMMATORY DISORDERS AND FIBROTIC DISEASE - Compositions and methods are disclosed for the treatment and diagnosis of inflammatory diseases and disorders, including pulmonary diseases and fibrotic disorders, including COPD. The invention also provides means for predicting an increased risk of progression of COPD symptoms. | 01-30-2014 |
20140031253 | Protein Detection Using Three-Dimensional Carbon Microarrays - The potential of aptamers as ligand binding molecule have opened new avenues in the development of biosensors for proteins, such as cancer oncoproteins. Disclosed herein is a label-free detection strategy using signaling aptamer/protein binding complex for proteins, such as platelet-derived growth factor (PDGF-BB) oncoprotein. The detection mechanism is based on the release of a fluorophore (e.g., TOTO intercalating dye) from the target binding aptamer's stem structure when it captures the protein, e.g., PDGF. Amino-terminated three-dimensional carbon microarrays fabricated by pyrolyzing patterned photoresist are used as a detection platform. The sensor showed near linear relationship between the relative fluorescence difference and protein concentration even in the sub-nanomolar range with an excellent detection limit of 5 pmol. This detection strategy is promising in a wide range of applications in the detection of cancer biomarkers and other proteins. | 01-30-2014 |
20140031254 | DETECTION OF CHROMOSOMAL ABNORMALITIES ASSOCIATED WITH ENDOMETRIAL CANCER - The methods and compositions described herein address the need for diagnostic method that could be offered to women during yearly checkups to allow for early detection, diagnosis and classification, and treatment of endometrial cancer. In addition, these methods and compositions address the current need for improving diagnostic accuracy of biopsy procedures in symptomatic patients. | 01-30-2014 |
20140031255 | METHOD FOR IDENTIFYING NEONATES AT RISK FOR NECROTIZING ENTEROCOLITIS - The invention provides a method for identifying a neonatal subject at risk for NEC, said method comprising (a) profiling the microbiota in a sample from the GI tract of said subject prior to a conclusive diagnosis of NEC and/or prior to full onset of NEC, (b1) comparing said profile to a standard microbiota profile obtained from corresponding samples from neonatal subjects with NEC or subjects which later developed NEC and determining the degree of correlation between said profile and the standard profile(s), and/or (b2) comparing said profile to a standard microbiota profile obtained from corresponding samples from neonatal subjects which did not develop NEC and determining the degree of correlation between said profile and the standard profile, and (c) identifying the subject as being at risk of NEC if significant correlation is observed in (b1) and/or significant correlation is not seen in (b2). An oligonucleotide probe set for use in the method of the invention, and kits containing the same, are also provided. | 01-30-2014 |
20140031256 | METHODS OF DETECTING THERAPEUTIC EXOSOMES - We describe a method of detecting a therapeutic exosome, the method comprising detecting an activity of an exosome. The activity may be selected from the group consisting of: (a) immunodulatory activity; (b) complement inhibition activity; (c) proteasome activity; (d) glycolytic enzyme activity; (e) anti-oxidative activity; (f) extracellular matrix (ECM) modifying activity; (g) NT5E (CD73) ecto-5′-ectonucleotidase activity; (h) ion homeostasis activity; and (i) chaperone activity. If the exosome is detected as having one or more such activities, the exosome is likely to comprise a therapeutic exosome having therapeutic activity. | 01-30-2014 |
20140031257 | METHODS AND BIOMARKERS FOR DETECTION OF GASTROINTESTINAL CANCERS - The present invention relates to methods and biomarkers (e.g., epigenetic biomarkers) for detection of gastrointestinal cancers (e.g., colorectal cancer, gastric cancer, pancreatic cancer, liver cancer, cancer of the gall bladder and/or bile ducts (e.g., cholangiocarcinoma)) in biological samples (e.g., tissue samples, stool samples, blood samples, plasma samples, cell samples, gall samples, bile samples, serum samples). | 01-30-2014 |
20140031258 | SERUM-BASED MIRNA MICROARRAY AND ITS USE IN DIAGNOSIS AND TREATMENT OF BARRETT'S ESOPHAGUS (BE) AND ESOPHAGEAL ADENOCARCINOMA (EAC) - Robust and reliable molecular diagnostic screening tools for early detection of esophageal and gastrointestinal tract cancers and pre-cancerous lesions, such as Barrett's Esophagus, and esophageal adenocarcinoma are provided. Included in the invention is an array of miRNA probes specific for identifying, diagnosing and prognosticating esophageal and gastrointestinal tract cancers and pre-cancerous lesions in subjects from blood or serum samples. A biochip comprising the array as well as methods for its use are also provided. | 01-30-2014 |
20140031259 | BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS - Methods for predicting sensitivity to cancer treatments by assessing biomarkers and combinations of biomarkers include evaluating the presence of mutations to Akt, wherein the presence of said mutations correlates with the sensitivity of Akt inhibitors. | 01-30-2014 |
20140031260 | Molecular Diagnostic Test for Cancer - Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. | 01-30-2014 |
20140038834 | NOVEL BIOMARKERS FOR DETECTING NEURONAL LOSS - The present invention relates to a biomarker for the detection of brain damage or a disease associated with loss of neurons, said biomarker comprising a protein fragment of the neurofilament heavy chain (NfH) protein in a biological sample, wherein said protein fragment is a polypeptide selected from the group consisting of i) a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and polypeptides composed of amino acids 476-1026 and 476-986 of SEQ ID NO 6; ii) a protein fragment of the NfH protein having an amino acid sequence that is at least 60% identical to SEQ ID NO:1, at least 60% identical to SEQ ID NO:2, at least 60% identical to SEQ ID NO:3, at least 60% identical to SEQ ID NO:4, at least 60% identical to SEQ ID NO:5; or at least 60% identical to a polypeptide composed of amino acids 476-1026 and.or 476-986 of SEQ ID NO 6; iii) an Enterokinase cleavage product of the NfH protein; and iv) a polypeptide that is derived from a naturally occurring allelic variant of the nucleic acid coding for NfH protein. | 02-06-2014 |
20140038835 | METHODS FOR DIAGNOSING HYPERTROPHIC CARDIOMYOPATHY - The present invention features a method for diagnosing hypertrophic cardiomyopathy by detecting one or more single nucleotide polymorphisms (SNPs) of the formin homology 2 domain containing 3 gene (FHOD3). | 02-06-2014 |
20140038836 | Novel Pharmacogene Single Nucleotide Polymorphisms and Methods of Detecting Same - The present invention provides pharmacogene polymorphisms and their use in predicting therapeutic effectiveness. The present invention also provides methods comprising targeted analysis of selected pharmacogenes in thousands of compiled whole human genome sequences for identifying polymorphic sequences associated with drug response are described. The methods also provide confirmation and validation of these pharmacogene polymorphisms, based on concordance between different sequencing technologies, and statistical error-checking. Imputation of the deleterious consequences of novel variants is predicted by bioinformatics analysis. | 02-06-2014 |
20140038837 | BIOMARKERS FOR THE DETECTION OF EARLY STAGE OVARIAN CANCER - The present invention provides methods and compositions for detecting early stage ovarian cancer in a patient. Also, methods for evaluating the ovarian cancer state of a patient are described herein. These methods involve the detection, analysis, and classification of biomarkers in biological samples. | 02-06-2014 |
20140038838 | USE OF MARKERS IN THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER - The invention provides method for diagnosis, monitoring, and prognosis of prostate cancer using one or more of keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, and LY9, and PSA. The invention provides kits for practicing the methods of the invention. | 02-06-2014 |
20140038839 | HUMAN IL-17 PRODUCING HELPER T CELL DETECTION METHOD - An object is to provide a method for specific detection of human IL-17-producing helper T-cells (human Th17 cells). | 02-06-2014 |
20140038840 | DNA Methylation Changes Associated with Major Psychosis - The present invention provides a method of identifying one or more epigenetic markers associated with psychosis-associated diseases such as bipolar disease or schizophrenia, the method comprising a) obtaining a first group of samples comprising genomic DNA from a plurality of bipolar or schizophrenic subjects and a second group of samples comprising genomic DNA from a plurality of control subjects; b) performing DNA methylation analysis to determine methylation differences in one or more DNA regions between the first group and second group of samples, wherein a methylation difference in a DNA region is indicative of an epigenetic marker associated with bipolar disease or schizophrenia. The invention also provides one or more epigenetic markers associated with psychosis-associated diseases such as bipolar disease or schizophrenia. | 02-06-2014 |
20140038841 | BIOMARKERS FOR OSTEOARTHRITIS - The invention relates to biomarkers which may be used individually or in combination to diagnose osteoarthritis. In particular, it relates to the use of one or more of V65 vitronectin fragment or fragments, variants or degradation products thereof; complement fragment C3f or fragments, variants or degradation products thereof; or a decreased concentration of CTAPIII protein or fragments, variants or degradation products thereof, as a marker of osteoarthritis. | 02-06-2014 |
20140038842 | CELL SURFACE DISPLAY USING PDZ DOMAINS - Novel materials and methods useful for displaying polypeptides on the surface of a cell are provided, including cell surface proteins fused to a PDZ domain peptide and antibodies fused to PDZ-binding peptides. | 02-06-2014 |
20140038843 | NOVEL TUMOR MARKER DETERMINATION - A method of determining ovarian cancer disease in a subject, which comprises—measuring the PPIC expression of cells in a sample of peripheral blood of said subject, and—comparing to a reference value, the PPIC overexpression being indicative of a ovarian cancer disease and/or disease progression, and the use of such a method for the diagnosis of ovarian cancer or a method for the determination of the metastatic potential in an ovarian cancer patient at risk of disease progression. | 02-06-2014 |
20140038844 | Method, Array and Use for Determining the Presence of Pancreatic Cancer - The present invention relates to a method for determining the presence of pancreatic cancer in an individual comprising or consisting of the steps of: (a) providing a sample to be tested from the individual, and (b) determining a biomarker signature of the test sample by measuring the expression in the test sample of one or more biomarkers selected from the group defined in Table III, wherein the expression in the test sample of one or more biomarkers selected from the group defined in Table III is indicative of the individual having pancreatic cancer. The invention also comprises arrays and kits of parts for use in the method of the invention. | 02-06-2014 |
20140038845 | Corn Polymorphisms and Methods of Genotyping - Polymorphic corn DNA loci useful for genotyping between at least two varieties of corn. Sequences of the loci are useful for providing the basis for designing primers and probe oligonucleotides for detecting polymorphisms in maize DNA. Polymorphisms are useful for genotyping applications in corn. The polymorphic markers are useful to establish marker/trait associations, e.g. in linkage disequilibrium mapping and association studies, positional cloning and transgenic applications, marker-aided breeding and marker-assisted selection, hybrid prediction and identity by descent studies. The polymorphic markers are also useful in mapping libraries of DNA clones, e.g. for corn QTLs and genes linked to polymorphisms. | 02-06-2014 |
20140038846 | SYSTEM AND METHOD FOR DETERMINING INDIVIDUALIZED MEDICAL INTERVENTION FOR A DISEASE STATE - A system and method for determining individualized medical intervention for a particular disease state, and especially for cancers, that includes the molecular profiling of a biological sample from the patient, determining whether any molecular findings including one or more genes, one or more gene expressed proteins, one or more molecular mechanisms, and/or combinations of such exhibit a change in expression compared to a reference, and identifying a non-specific disease therapy or agent capable of interacting with the genes, gene expressed proteins, molecular mechanisms, or combinations of such molecular findings that exhibited a change in expression. | 02-06-2014 |
20140045709 | MicroRNA Expression Abnormalities in Pancreatic Endocrine and Acinar Tumors - The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of pancreatic cancer. The invention also provides methods of identifying anti-pancreatic cancer agent. | 02-13-2014 |
20140045710 | SINGLE NUCLEOTIDE POLYMORPHISMS AND USE OF SAME IN PREDICTING MALE-SPECIFIC PRENATAL LOSS - The present invention is directed to a panel of single nucleotide polymorphisms (SNPs) in specific genes that serve as biomarkers for sex-specific prenatal loss of a conceptus or embryo. There is provided herein methods and reagents for assessing the specific SNPs in those genes. The method useful in applying these SNPs in predicting an increased risk of prenatal loss is also disclosed. | 02-13-2014 |
20140045711 | SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH BULL FERTILITY - Single nucleotide polymorphic sites of the bovine MAP1B, PPP1R11, and DDX4 genes are associated with improved bull fertility as measured by e.g. sire conception rates. Nucleic acid molecules, arrays, kits, methods of genotyping and marker-assisted bovine breeding methods based on these SNPs are disclosed. | 02-13-2014 |
20140045712 | DIGITAL ANALYTE ANALYSIS - The invention generally relates to detecting target molecules. | 02-13-2014 |
20140045713 | BIOMARKERS OF BRAIN INJURY - The present invention relates to the field of biomarkers. More specifically, the present invention relates to biomarkers useful in diagnosing brain injuries. Brain injury can include overt or traumatic brain injury, as well as subclinical brain injury (SCI). In one embodiment, a method for diagnosing SCI in a patient comprises (a) collecting a sample from the patient; (b) measuring the levels of a panel of biomarkers in the sample collected from the patient, wherein the panel of biomarkers comprises ASTN1, BAI3, CNDP1, ERMIN, GFAP, GRM3, KLH32, MAGE2, NRG3, NRGN, OMG, SLC39A12, RTN1, and MT3; and (c) comparing the levels of the panel of biomarkers with predefined levels of the same panel of biomarkers that correlate to a patient having SCI and predefined levels of the same panel of biomarkers that correlate to a patient not having SCI, wherein a correlation to one of the predefined levels provides the diagnosis. | 02-13-2014 |
20140045714 | Novel Biomarkers For Cardiovascular Injury - The invention provides methods for the early detection of cardiovascular injury using one or more cardiac injury biomarkers identified herein. | 02-13-2014 |
20140045715 | TIVOZANIB RESPONSE PREDICTION - A diagnostic method for predicting whether a human tumor will be sensitive or resistant to treatment with tivozanib (AV-951) is disclosed. The method is based on measurement of macrophage content in a tissue sample from a tumor. Measurement of macrophage content can be based on analysis of macrophage marker gene expression, e.g., by RNA analysis or immunohistochemistry. | 02-13-2014 |
20140045716 | Methods and Systems for Detecting Nucleic Acids - Methods and kits for detecting a target nucleic acid in a sample are described. In some embodiments, the sample to be analyzed includes a primer which hybridizes to at least a portion of the target nucleic acid, a probe having a first region which hybridizes to at least a portion of the target nucleic acid and a second region having a detectable label, a polymerase which extends the hybridized primer and an enzyme comprising nuclease activity that can cleave the hybridized hybridization probe to thereby release a labeled probe fragment. In some embodiments, the sample can then be contacted with a solid support comprising surface bound capture probes which can hybridize to the labeled probe fragment(s). These capture probes more readily bind to the probe fragment(s) than to the intact hybridization probe. The label can then be detected on the support surface. In this manner, improved discrimination between the probe fragments and the intact hybridization probes can be achieved. | 02-13-2014 |
20140045717 | Single Nucleotide Polymorphism Biomarkers for Diagnosing Autism - The invention provides methods of identifying biomarkers associated with autism or autism spectrum disorder based upon quantitative trait association analyses using genome-wide genotype data combined with case-control association analyses using distinct ASD phenotypes identified on the basis of symptomatic profiles, including deficits in language usage, non-verbal communication, social development, play skills, and insistence on sameness and rituals. Also provided are compositions identified using the methods of the invention and use thereof. | 02-13-2014 |
20140045718 | BIOMARKERS FOR INFLAMMATION OF THE LIVER - The invention relates to a method for the diagnostic investigation of biological samples from a person for inflammation of the liver, in particular hepatic fibrosis and/or cirrhosis of the liver, where the sample is investigated for one or more proteins as markers of inflammation of the liver, in particular hepatic fibrosis and/or cirrhosis of the liver, where a concentration of the proteins which is elevated or decreased by comparison with the healthy state indicates the presence of an inflammation of the liver, in particular a hepatic fibrosis and/or cirrhosis of the liver.; The proteins are selected from the group of ER6Q, vimentin, actin alpha 1 skeletal muscle protein, hMFAP 4, tropomyosin, PTGES 2, amyloid P component, transgelin, calponin 1, homo sapiens p20 protein, 17 kDa myosin light chain, H chain H Igg B12, prolyl 4-hydroxylase, beta subunit methylenetetrahydrofolate dehydrogenase 1, PRO2619, aldehyde dehydrogenase 1, fibrinogen alpha chain preproprotein, fructose-bisphosphate aldolase B, argininosuccinate synthetase, Eefla2, AT P 5 Al, alpha-2 actin, regucalcin, serum albumin, mitochondrial malate dehydrogenase, mitochondrial acetoacetyl-CoA thiolase or in each case a partial sequence thereof. | 02-13-2014 |
20140045719 | DIRECTED SYNTHESIS OF OLIGOPHOSPHORAMIDATE STEREOISOMERS - The trivalent phosphorous atom of a compound is reacted with a reagent in such a manner that a stable phosphate mimetic or a specifier is formed. Phosphoramidites with a phosphorous atom containing at least one hydroxyl residue which is provided with a protective group are reacted for this purpose with a free hydroxyl group: In the first synthesis cycle the hydroxyl group is linked to a solid support via a cleavable or non-cleavable linker. In further synthesis cycles the hydroxyl group is created by cleavage of the protective group from the growing oligomer. This results in formation of a phosphorous acid triester which is reacted with azides. By selecting suitable monomers for the synthesis which have a defined stereoconformation compounds of Formula 1 are produced in a stereocontrolled manner. | 02-13-2014 |
20140045720 | COMPOSITIONS AND METHODS FOR REPRESENTATIONAL SELECTION OF NUCLEIC ACIDS FROM COMPLEX MIXTURES USING HYBRIDIZATION - The invention provides a method of selecting a representational sample of nucleic acid sequences from a complex mixture. The method includes: (a) contacting a complex mixture of nucleic acids under conditions sufficient for hybridization with a population of capture probes complementary to one or more nucleic acids comprising a predetermined portion of the sequence collectively present in the complex mixture to form hybridization complexes of the one or more nucleic acids with the population of probes, the population of capture probes being attached to a solid support, and (b) removing unhybridized nucleic acids to select a representational sample of nucleic acids having a complexity of less than 10% but more than 0.001% of the complex mixture, wherein the representational sample comprises a nucleic acid copy having a proportion of each sequence in the copy relative to all other sequences in the copy substantially the same as the proportions of the sequences in the predetermined portion of one or more nucleic acids within the complex mixture. A method of selecting a representational sample of genomic sequences from a complete genome also is provided. The invention further provides a nucleic acid population that includes a representational sample having a complexity of less than 10% but more than 0.001% of a complex mixture, the representational sample comprising a nucleic acid copy having a proportion of each sequence in the copy relative to all other sequences in the copy substantially the same as the proportions of sequences in a predetermined portion of a sequence collectively present in one or more nucleic acids within the complex mixture. | 02-13-2014 |
20140045721 | Microarray System and a Process for Producing Microarrays - A process for making a micro-array. The process comprises the step of depositing a population of microbeads on a substrate having at least one fiducial. The population being comprised of at least two sub-populations, preferably multiple sub-populations, each comprising a known active agent capable of specific binding with at least one target analyte. The said subpopulations are deposited sequentially and at discrete periods of each other. The process also comprises the step of making images of the substrate after deposition of each subpopulation. The images are then compared using the fiducial as a reference to thereby determine the location of each microbead and to identify the subpopulation, and its known active agent, based on differences between each image. Also disclosed in a system for using the microarray. | 02-13-2014 |
20140045722 | SYSTEMS AND METHODS FOR DETECTING AND QUANTIFYING A SEQUENCE OF NUCLEOTIDES - Methods and systems of quantifying a target material in solution include detection of a size change of a hybridized nanoparticle. In particular, the examples include functionalizing a plurality of nanoparticles to adapt the nanoparticles to hybridize with a species-specific target material, measuring the size of the functionalized nanoparticles to predetermine a standard distribution of non-hybridized nanoparticles, introducing the functionalized nanoparticles in a solution containing species-specific target materials and/or non-target materials, and hybridizing the functionalized nanoparticles with the species-specific target material if present in the solution. The size of the nanoparticles in solution are then measured after hybridization, and the presence or non-presence of the species-specific target material is detected and/or quantified by comparing the measured size of the nanoparticles after hybridization to the standard distribution of non-hybridized nanoparticles. | 02-13-2014 |
20140051590 | Compositions and Methods for Detection of Herpes Simplex Virus 1 and 2 - Methods for the rapid detection of the presence or absence of Herpes simplex virus 1 and 2 (HSV-1 and HSV-2) in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers, probes targeting the genes for HSV-1 viral DNA polymerase B (HSV-1 Pol) and HSV-1 thymidine kinase C(HSV-1 TK), and also target the genes for HSV-2 thymidine kinase C(HSV-2 TK) and HSV-2 glycoprotein B (HSV-2 gB), along with kits are provided that are designed for the detection of HSV-1 and/or HSV-2. | 02-20-2014 |
20140051591 | MOLECULAR DIAGNOSTIC TEST FOR CANCER - Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. | 02-20-2014 |
20140051592 | PROTEIN SYNTHESIS MODULATORS - The invention provides a high resolution three-dimensional structure of a deacylated transfer RNA protein synthesis modulator in association with a large ribosomal subunit. The protein synthesis modulator binds at least a portion of the E-site of a large ribosomal subunit. The invention provides methods for designing and/or identifying analogs of candidate molecules, for example, analogs or derivatives of the protein synthesis modulator, that bind and/or modulate the protein biosynthetic activity of the ribosome. | 02-20-2014 |
20140051593 | Assay Methods and Systems - Assay methods and systems that detect and quantify target nucleic acid sequences in samples, employing amplification processes and real time amplification processes in the presence of target specific probe sequences and capture probe sequences for indication of the amplification of, and therefor the presence of the target sequence in the sample. | 02-20-2014 |
20140051594 | METHODS FOR DIAGNOSING IRRITABLE BOWEL SYNDROME - The present invention provides methods, systems, and code for accurately classifying whether a sample from an individual is associated with irritable bowel syndrome (IBS). In particular, the present invention is useful for classifying a sample from an individual as an IBS sample using a statistical algorithm and/or empirical data. The present invention is also useful for ruling out one or more diseases or disorders that present with IBS-like symptoms and ruling in IBS using a combination of statistical algorithms and/or empirical data. Thus, the present invention provides an accurate diagnostic prediction of IBS and prognostic information useful for guiding treatment decisions. | 02-20-2014 |
20140051595 | Methods and Compositions for Determining Nucleic Acid Degradation - Described herein are methods, systems, compositions and kits to enable determination of a level of degradation of nucleic acids in a sample. For example, the determination of the amount of degradation of RNA in a sample can be accomplished by labeling one or both of the intact 5′- and/or 3′-ends of an mRNA molecule by taking advantage of the unique diol moiety present at these structures. Labeled nucleotides can then be partitioned into droplets and the amount of degradation can be determined by detecting label present in the partitions and making quantitative or qualitative comparisons with a reference sample. In some cases, the degree of degradation is also determined by factoring in the total concentration or quantity of RNA in the sample. | 02-20-2014 |
20140051596 | NUCLEIC ACID CLASSIFICATION - A method and system for classifying a target nucleic acid includes exposing, in a test system, one or more capture probes to the target nucleic acid. The one or more capture probes is attached to a surface. A first hybridization condition is established in the test system. A first degree of hybridization of the one or more capture probes with the target nucleic acid under the first hybridization condition is determined. A second hybridization condition in the test system is established. A second degree of hybridization of the one or more capture probes with the target nucleic acid under the second hybridization condition is determined and the target nucleic acid is classified by comparing the first and the second degrees of hybridization. | 02-20-2014 |
20140051597 | Antibody Biomarkers for Diabetes - Methods are provided for determining whether a subject has a diabetes phenotype. In practicing the subject methods, a sample, e.g., a blood sample, from a subject is analyzed for the presence of one or more autoantibodies to obtain an antibody signature. The obtained antibody signature is then employed to determine whether the subject has a diabetes phenotype. The subject methods may be used in diagnostic or prognostic applications, e.g., determining whether the subject has diabetes (e.g., T1D or T2D), or monitoring a subject with diabetes to determine whether the subject has or will develop ESRD. Also provided are compositions, systems and kits that find use in practicing the subject methods. The subject methods and compositions find use in a variety of applications, including the diagnosis and monitoring of diabetes in a subject. | 02-20-2014 |
20140051598 | DIAGNOSTIC BIOMARKER TO PREDICT WOMEN AT RISK FOR PRETERM DELIVERY - The invention relates to biomarkers associated with preterm delivery. More specifically, the invention provides methods of measuring biomarkers including but not limited to cytokines, cytokine receptors, cytokine receptor antagonists, chemokines, chemokine receptors, and/or chemokine receptor antagonists found in women that are at risk for preterm delivery. The diagnostic methods may be performed on whole blood. | 02-20-2014 |
20140051599 | METHOD FOR DETERMINING EXPOSURE TO MYCOBACTERIA - A method of determining the presence or absence in a sample of a biomarker indicative of exposure to mycobacteria, the method comprising: (a) providing a substrate carrying a mycolic acid derived antigen; (b) contacting the substrate with the sample; (c) contacting the substrate with a fluorophore species; (d) creating an evanescent wave at the boundary of the substrate and the sample; (e) detecting the presence or absence of fluorescence. | 02-20-2014 |
20140057795 | Methods and Compositions for Correlating Genetic Markers with Prostate Cancer Risk - The present invention provides methods of assessing an individual subject's risk of developing prostate cancer, comprising: a) analyzing a nucleic acid sample obtained from the subject and determining a genotype for the subject at a plurality of biallelic polymorphic loci, wherein each of said plurality has an associated allele and an unassociated allele, wherein the genotype is selected from the group consisting of homozygous for the associated allele, heterozygous, and homozygous for the unassociated allele; and b) calculating a cumulative relative risk (CRR) for the subject based on the genotype determined in step (a). A CRR of greater than 1.00 identifies a subject as having an increased risk of developing prostate cancer and also can identify a subject who is a candidate for early PSA screening, prostate biopsy and/or chemoprevention. | 02-27-2014 |
20140057796 | Method for the Diagnosis, Prognosis and Treatment of Breast Cancer Metastasis - The present invention relates to a method for the diagnosis or the prognosis of metastasis in breast cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in ER− breast cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the ER− breast cancer metastasis. | 02-27-2014 |
20140057797 | Methods for Detecting an increased risk for coronary heart disease - The invention relates generally to an allele on human chromosome 9 associated with increased risk for coronary heart disease and the use or detection of such an allele in determining whether a human has an increased risk for coronary heart disease. In one aspect, the invention relates to methods for detecting a predisposition or propensity or susceptibility for coronary heart disease in a human, comprising detecting the presence of an allele on human chromosome 9 that is associated with an increased risk for coronary heart disease in a human. Disclosed are methods and compositions for determining whether a person carries an allele associated with increased risk for coronary atherosclerosis by determining whether the person has an RA-CHR9 allele, such as by determining whether the person has an RA-CHR9 allele-associated single nucleotide polymorphism (SNP). The invention also relates to kits for detecting the presence of an allele on chromosome 9 associated with an increased risk for coronary heart disease. | 02-27-2014 |
20140057798 | PREDICTION OF DRUG SENSITIVITY OF LUNG TUMORS BASED ON MOLECULAR GENETIC SIGNATURES - The present invention provides a method for predicting therapeutic efficacy or response to an anticancer drug or a combination of anticancer drugs in a subject having lung cancer comprising analyzing a sample obtained from the subject to determine the presence, expression level, activation level, or genotype of one or more markers to obtain a marker profile, and comparing the marker profile with known marker profiles obtained from one or more lung cancer cell lines. As such, the present invention is particularly useful in predicting therapeutic efficacy or response to one or more anticancer drugs by analyzing one or a panel of pathway biomarkers and/or mutated genes in tumor tissue obtained from a subject with lung cancer to guide treatment options for the subject based upon similarities in marker profiles obtained from the tumor tissue and lung cancer cell lines and the drug sensitivity of those lung cancer cell lines. | 02-27-2014 |
20140057799 | System and Methods for Massively Parallel Analysis of Nucleic Acids in Single Cells - Methods and systems are provided for massively parallel genetic analysis of single cells in emulsion droplets or reaction containers. Genetic loci of interest are targeted in a single cell using a set of probes, and a fusion complex is formed by molecular linkage and amplification techniques. Methods are provided for high-throughput, massively parallel analysis of the fusion complex in a single cell in a population of at least 10,000 cells. Also provided are methods for tracing genetic information back to a cell using barcode sequences. | 02-27-2014 |
20140057800 | SINGLE NUCLEOTIDE POLYMORPHISM ASSOCIATED WITH RISK OF INSULIN RESISTANCE DEVELOPMENT - The present invention is directed to methods of identifying quantitative trait loci (QTL) markers associated with insulin resistance, and use of these markers to explain individual physiological responses to dietary glycemic load. In addition, expressional QTLs (eQTLs) have been identified to characterize the contribution of the genotype to variations in gene expression. | 02-27-2014 |
20140057801 | MAMMALIAN HAPLOID EMBRYONIC STEM CELLS - The invention relates to mammalian haploid embryonic stem cells and methods for the production of such stem cells. The inventions also relates to a cell culture and a cell line of mammalian haploid embryonic stem cells. | 02-27-2014 |
20140057802 | METHOD AND KIT FOR DETERMINING IN VITRO THE PROBABILITY FOR AN INDIVIDUAL TO SUFFER FROM COLORECTAL CANCER - The present invention provides a method for determining in vitro, in a peripheral blood sample, the probability for an individual to suffer from a colorectal cancer, using the comparison of the amount of expression products of nucleic acids of genes of the individual to be tested with the amount of expression products of nucleic acids of the same genes obtained from a CRC group of patients constituting the positive control and with the amount of expression products of nucleic acids of the same genes obtained from a CNC group of individuals constituting the negative control; and a kit comprising specific binding partners for said expression products. | 02-27-2014 |
20140057803 | IMMUNOASSAY REAGENTS AND METHODS OF USE THEREOF - The present invention provide reagents and methods of using the reagents, for example, on automated staining devices, that facilitate detection of two or more antigens in a sample simply and efficiently. | 02-27-2014 |
20140066322 | MOUSE CELL LINE AUTHENTICATION - A multiplex polymerase chain reaction assay that targets nine tetranucleotide short tandem repeat (STR) markers in the mouse genome. Unique profiles were obtained from seventy-two mouse samples that were used to determine the allele distribution for each STR marker. Correlations between allele fragment length and repeat number were determined with DNA Sanger sequencing. Genotypes for L929 and NIH3T3 cell lines were shown to be stable with increasing passage numbers as there were no significant differences in fragment length with samples of low passage when compared to high passage samples. In order to detect cell line contaminants, primers for two human STR markers were incorporated into the multiplex assay to facilitate detection of human and African green monkey DNA. This multiplex assay is the first of its kind to provide a unique STR profile for each individual mouse sample and can be used to authenticate mouse cell lines. | 03-06-2014 |
20140066323 | CANCER DIAGNOSTICS USING BIOMARKERS - Disclosed herein, in certain instances, are methods, systems and kits for the diagnosis, prognosis and determination of cancer progression of a cancer in a subject. Further disclosed herein, in certain instances, are methods, systems and kits for determining the treatment modality of a cancer in a subject. The methods, systems and kits comprise expression-based analysis of biomarkers. Further disclosed herein, in certain instances, are probe sets for use in assessing a cancer status in a subject. | 03-06-2014 |
20140066324 | GENE EXPRESSION SIGNATURE IN SKIN PREDICTS RESPONSE TO MYCOPHENOLATE MOFETIL - Described herein are methods and compositions for identifying patients with SSc or scleroderma who are responders to MMF treatment. | 03-06-2014 |
20140066325 | Protein Biomarkers for the Diagnosis of Prostate Cancer - The invention is directed to tumor associated markers (TAMs) and autoantibody biomarkers that can be used diagnostically. It also includes methods for detection of the markers and compositions that can be used in carrying out assays | 03-06-2014 |
20140066326 | MULTIPHASE NUCLEIC ACID AMPLIFICATION - Improved methods for use in nucleic acid amplification, including multiplex amplification, where the amplification is carried out in two or more distinct phases are disclosed. The first phase amplification reaction preferably lacks one or more components required for exponential amplification. The lacking component is subsequently provided in a second, third or further phase(s) of amplification, resulting in a rapid exponential amplification reaction. The multiphase protocol results in faster and more sensitive detection and lower variability at low analyte concentrations. Compositions for carrying out the claimed methods are also disclosed. | 03-06-2014 |
20140066327 | Kits and Methods for Assessing Oxidative Stress - The invention relates to kits and methods for assessing the susceptibility of a human to oxidative stress or damage. The methods involve assessing occurrence in the human's genome of one or more polymorphisms (e.g., single nucleotide polymorphisms) that occur in one or more genes associated with oxidative stress and that are associated with a disorder in humans. Preferred assessment and scoring methods are disclosed, as are kit for performing the methods. | 03-06-2014 |
20140066328 | PREDICTING GASTROENTEROPANCREATIC NEUROENDOCRINE NEOPLASMS (GEP-NENs) - Described are embodiments related to gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) biomarkers and agents, systems, and kits for detecting the same, and associated GEP-NEN diagnostic, prognostic, and predictive methods and uses thereof, such as detection, prediction, staging, profiling, classification, and monitoring treatment efficacy and other outcomes. | 03-06-2014 |
20140066329 | LUNG CANCER DIAGNOSTIC ASSAY - A method for selecting a person at risk for lung cancer to undergo radiographic testing is provided. The method provides for the identification of markers for lung cancer in a population of patients that have not previously diagnosed with the disease. The markers identify autoantibodies present in a fluid sample of a patient who may not show other symptoms of lung cancer. | 03-06-2014 |
20140066330 | TAGGED OLIGONUCLEOTIDES AND THEIR USE IN NUCLEIC ACID AMPLIFICATION METHODS - The present invention provides nucleic acid amplification systems and methods that desirably reduce or eliminate false positive amplification signals resulting from contaminating biological material, e.g., nucleic acid, that may be present in one or more reagents used in an amplification reaction and/or that may be present in the environment in which an amplification reaction is performed. The invention offers the further advantage of requiring less stringent purification and/or sterility efforts than conventionally needed in order to ensure that enzymes and other reagents used in amplification reactions, and the environment in which an amplification reaction is performed, are free of bacterial or other nucleic acid contamination that may yield false positive results. | 03-06-2014 |
20140066331 | PS-SPCL SEARCHING APPARATUS AND METHOD USING SURFACE PLASMON RESONANCE - A Positional Scanning-Synthetic Peptide Combinatorial Library (PS-SPC) searching apparatus and method using Surface Plasmon Resonance (SPR) are provided. The method includes spotting and fixing each of a plurality of peptide pools to a top of one thin metal film, inputting specific materials to the top of the thin metal film, applying a TM-mode light to a bottom of the thin metal film and exciting SPR for the thin metal film, and detecting a TM mode reflected light reflected from the thin metal film and displaying the detected light as a two-dimensional image. | 03-06-2014 |
20140066332 | METHODS FOR THE DIAGNOSIS OF FETAL DISEASE - Methods are provided for detecting an aneuploidy in a fetus. These methods can be used to detect trisomy 13, 8 or 21, amongst other aneupoloidies. In some embodiments, the methods include selectively purifying fetal DNA from a maternal biological sample using the methylation status of a CpG containing genomic sequence and genotyping the fetus using the purified fetal DNA, thereby detecting aneuploidy in the fetus. | 03-06-2014 |
20140066333 | ARRAY PRINTING - The invention provides a method of printing, onto a substrate ( | 03-06-2014 |
20140073515 | Microorganism detection and analysis using carbohydrate and lectin recognition - Methods of binding and detecting a microorganism on a solid substrate. The microorganism is bound on a solid substrate covalently bound to a capture agent having a saccharide moiety. A lectin capable of binding to the microorganism and the saccharide moiety of the capture agent is added to the sample to bind the microorganism on the solid substrate. Further provided are biosensor devices, such as a quartz crystal microbalance (QCM) device or a surface plasmon resonance (SPR) device, that incorporate the solid substrate for the detection of microorganisms. | 03-13-2014 |
20140073516 | MARKERS AND METHODS FOR DETECTING POSTTRAUMATIC STRESS DISORDER (PTSD) - Concentrations of certain miRNA, mRNA and/or protein markers in the biological fluids and/or tissues of a subject are used to determine the probability that the subject does or does not have Posttraumatic Stress Disorder (PTSD). The concentrations of these markers in fluids and/or tissues are different in subjects with PTSD as compared to subjects who do not suffer from this disorder. | 03-13-2014 |
20140073517 | SELF-CONTAINED BIOLOGICAL ASSAY APPARATUS, METHODS, AND APPLICATIONS - A self-contained, fully automated, biological assay-performing apparatus includes a housing; a dispensing platform including a controllably-movable reagent dispensing system, disposed in the housing; a reagent supply component disposed in the housing; a pneumatic manifold removably disposed in the housing in a space shared by the dispensing platform, removably coupled to a fluidic transport layer and a plurality of reservoirs, wherein the fluidic transport layer, the reservoirs, and a test sample to be introduced therein are disposed in the housing in the space separate from the dispensing platform; a pneumatic supply system removably coupled to the pneumatic manifold in the housing in a space separate from the dispensing platform; and a control system coupled to at least one of the dispensing platform and the pneumatic supply system, disposed in the housing. | 03-13-2014 |
20140073518 | FUSION PROTEINS COMPRISING AN ENGINEERED KNOTTIN PEPTIDE AND USES THEREOF - The present disclosure presents a general approach to engineering existing protein-protein interactions through domain addition and evolution. The disclosure teaches the creation of novel fusion proteins that include knottin peptides where a portion of the knottin peptide is replaced with a sequence that has been created for binding to a particular target. Such fusion proteins can also be bispecific or multi specific in that they can bind to and/or inhibit two or more receptors or receptor ligands. Knottins may be fused with an existing ligand (or receptor) as a general platform for increasing the affinity of a ligand-receptor interaction or for creating a multi specific protein. In addition, the fusion proteins may comprise a knottin peptide fused to another protein where the other protein facilitates proper expression and folding of the knottin. | 03-13-2014 |
20140073519 | LUNG CANCER-RELEVANT HUMAN EMBRYONIC STEM CELL SIGNATURE - The invention provides a method of detecting cancer, a progression of cancer, or a predisposition to cancer in a human, comprising (a) obtaining a sample of airway basal cells from the human, and (b) analyzing the sample to determine expression of one or more hESC-signature genes, wherein the expression or lack of expression of the one or more hESC-signature genes is indicative of a presence or absence of cancer, a progression of cancer, or a predisposition to cancer in the human. The invention also provides an in vitro model for lung cancer, comprising airway basal cells that express one or more hESC-signature genes. | 03-13-2014 |
20140073520 | IMAGING CHROMOSOME STRUCTURES BY SUPER-RESOLUTION FISH WITH SINGLE-DYE LABELED OLIGONUCLEOTIDES - Methods and systems are provided for creating molecular barcodes for DNA sequences of interest in chromosomes within single cells and for resolving such barcodes using super-resolution technologies. The invention additionally teaches creating molecular barcodes for mRNA sequences that can be visualized at the same time as the aforementioned DNA sequences. The inventive approach allows for the detection of multiple loci on the chromosomes of tumor biopsy sample cells, and can accomplish all of the current applications of DNA FISH in cancer diagnostics, with the additional benefit of being highly multiplexable. | 03-13-2014 |
20140073521 | Mesothelioma Biomarkers and Uses Thereof - The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of cancer. In one aspect, methods are provided for diagnosing mesothelioma where the methods include detecting, in a biological sample, at least one biomarker value corresponding to at least one biomarker selected from the biomarkers provided in Table 1, wherein an individual is classified as having mesothelioma, or the likelihood of an individual having mesothelioma is determined, based on the at least one biomarker value. In another aspect, methods are provided for diagnosing cancer generally where the methods include detecting, in a biological sample at least one biomarker value corresponding to at least one biomarker selected from the biomarkers provided in Table 17, wherein an individual is classified as having cancer generally, or the likelihood of an individual having cancer is determined, based on the at least one biomarker value. | 03-13-2014 |
20140073522 | Pancreatic Cancer Biomarkers and Uses Thereof - The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of cancer generally and pancreatic cancer specifically. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to diagnose cancer generally or pancreatic cancer specifically. In another aspect, methods are provided for diagnosing pancreatic cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, wherein the individual is classified as having pancreatic cancer, or the likelihood of the individual having pancreatic cancer is determined, based on the at least one biomarker value. In a further aspect, methods are provided for diagnosing cancer generally in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 19, wherein the individual is classified as having cancer generally, or the likelihood of the individual having cancer is determined, based on the at least one biomarker value. | 03-13-2014 |
20140073523 | USE OF GLYCOLYTIC PATHWAYS FOR INHIBITING OR MEASURING ONCOGENIC SIGNALING - Disclosed are methods in which glucose metabolism is correlated to oncogenesis through certain specific pathways; inhibition of certain enzymes is shown to interfere with oncogenic signaling, and measurement of certain enzyme levels is correlated with patient survival. The present methods comprise measuring level of expression of at least one of the enzymes involved in glucose uptake or metabolism, wherein increased expression of the at least one of the enzymes relative to expression in a normal cell correlates with poor prognosis of disease in a patient. Preferably the genes whose expression level is measured include GLUT3, PFKP, GAPDH, ALDOC, LDHA and GFPT2. Also disclosed are embodiments directed towards down-regulating the expression of some genes in glucose uptake and metabolism. | 03-13-2014 |
20140073524 | MARKERS AND METHODS FOR DETECTING POSTTRAUMATIC STRESS DISORDER (PTSD) - Concentrations of certain miRNA, mRNA and/or protein markers in the biological fluids and/or tissues of a subject are used to determine the probability that the subject does or does not have Posttraumatic Stress Disorder (PTSD). The concentrations of these markers in fluids and/or tissues are different in subjects with PTSD as compared to subjects who do not suffer from this disorder. | 03-13-2014 |
20140073525 | DIAGNOSTIC, PROGNOSTIC AND THERAPEUTIC USES OF LONG NON-CODING RNAS FOR CANCER AND REGENERATIVE MEDICINE - Long non-coding RNAs (lncRNAs) and methods of using them diagnostically and therapeutically for treatment of cancer, stem cell therapy, or regenerative medicine are disclosed. In particular, the invention relates to lncRNAs that that play roles in regulation of genes involved in cell proliferation, differentiation, and apoptosis. Such lncRNAs can be used as biomarkers to monitor cell proliferation and differentiation during cancer progression or tissue regeneration. One of the identified lncRNAs, referred to as PANDA (a P21-Associated NcRNA, DNA damage Activated), inhibits the expression of apoptotic genes normally activated by the transcription factor NF-YA. Inhibitors of PANDA sensitize cancerous cells to chemotherapy and can be used in combination with chemotherapeutic agents for treatment of cancer. | 03-13-2014 |
20140073526 | IMMUNE FUNCTION BIOMARKERS - The invention provides biomarkers associated with age related immune function and the use of the biomarkers to identify compositions useful for strengthening immune function in animals and to determine if an animal is responding to treatment targeted to strengthen the immune system. | 03-13-2014 |
20140073527 | METHODS FOR DIAGNOSIS AND PROGNOSIS OF CANCER - The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for assessing prostate cancer in a patient. In a specific embodiment, a method for determining a likelihood of prostate cancer recurrence in a patient following prostectomy comprises the steps of (a) obtaining a biological sample from the patient; (b) subjecting the sample to an assay for detecting SPARCL1 expression; and (c) determining that prostate cancer is likely to recur if SPARCL1 expression is decreased relative to a reference non-prostate cancer sample. | 03-13-2014 |
20140073528 | METHODS OF DEPLETING A TARGET MOLECULE IN A SAMPLE AND KITS FOR PRACTICING THE SAME - Provided are methods of depleting a target molecule in a sample. The methods include contacting a target molecule with a free radical-generating system and generating free radicals from the free radical-generating system to deplete the target molecule in the sample. Kits for practicing the subject methods are also provided. | 03-13-2014 |
20140073529 | SINGLE DONOR VERSUS ELITE PANEL METHODOLOGY FOR IDENTIFICATION OF MARKER-ASSISTED BREEDING FRIENDLY MARKERS - Provided herein is a method of identifying at least one marker-assisted breeding friendly marker that is located under the QTL peak, which might or might not represent a causative allele of a phenotype. In an embodiment, a single donor versus elite panel (SDvEP) method is implemented to determine the MAB-friendly marker that is highly associated with trait and might/not discriminate a causative allele for a phenotype. SDvEP method compares the genotype from at least one locus of a donor line with a particular phenotype against a large panel of unrelated lines that all lack the phenotype. | 03-13-2014 |
20140073530 | Rapid Genotyping Analysis and the Method Thereof - The present invention describes methods of performing rapid nucleic acid detection using a flow through process. The methods comprise single-step signal amplification and/or a one-step hybridization protocol. Using the flow through hybridization process, the present invention provides a more efficient, faster and less expensive genotyping method. This invention further provides a Single Nucleotide Polymorphism (SNP)-based DNA fingerprinting method for rapid and accurate genotyping, identification as well as DNA analyses of genetic materials from human beings and other different organisms. In addition this invention also discloses devices for rapid and sensitive analysis of target analysts. | 03-13-2014 |
20140073531 | NANO-SENSOR ARRAY - In one embodiment, a method is provided for the manufacture of a nano-sensor array. A base having a sensing region is provided along with a plurality of nano-sensors. Each of the plurality of nano-sensors is formed by: forming a first nanoneedle along a surface of the base, forming a dielectric on the first nanoneedle, and forming a second nanoneedle on the dielectric layer. The first nanoneedle of each sensor has a first end adjacent to the sensing region of the base. The second nanoneedle is separated from the first nanoneedle by the dielectric and has a first end adjacent the first end of the first nanoneedle. The base is provided with a fluidic channel. The plurality of nano-sensors and the fluidic channel are configured and arranged with the first ends proximate the fluidic channel to facilitate sensing of targeted matter in the fluidic channel. | 03-13-2014 |
20140073532 | MULTIPLEX IMMUNOASSAYS FOR HEMOGLOBIN, HEMOGLOBIN VARIANTS, AND GLYCATED FORMS - Hemoglobin, its variants, and glycated forms of each are determined individually in a multiplex assay that permits correction of the measured level of HbA1c to account for glycated variants and other factors related to the inclusion of the variants in the sample. New antibodies that are particularly well adapted to the multiplex assay are also provided. | 03-13-2014 |
20140073533 | COMPOSITION AND METHOD FOR PREDICTING RESPONSE TO TRASTUZUMAB THERAPY IN BREAST CANCER PATIENTS - This invention relates to a composition and a method for prediction of a response to Trastuzumab therapy in a breast cancer patient, and more specifically, a composition, a kit, a DNA chip, and a method for predicting a response to Trastuzumab therapy by using polynucleotides each comprising a nucleotide sequence represented by any of SEQ ID NOs: 1 to 9, 11 to 19, and 21 to 23 in the Sequence Listing or a nucleotide sequence derived therefrom by substitution of u with t, mutants thereof, derivatives thereof, or fragments thereof comprising at least 16 continuous nucleotides, or a polynucleotide comprising a complementary sequence thereof, and using an increase or decrease in Her2 protein expression level as an indicator. | 03-13-2014 |
20140073534 | DETECTION OF TARGET NUCLEIC ACID SEQUENCES BY PO CLEAVAGE AND HYBRIDIZATION - The present invention relates to the detection of a target nucleic acid sequence by a POCH (PO Cleavage and Hybridization) assay on a solid substrate. The present invention detects the target nucleic acid sequence by use of in which the PO (Probing Oligonucleotide) hybridized with the target nucleic acid sequence is cleaved and the cleavage of the PO is detected by hybridization with the CO (Capturing Oligonucleotide). In the present invention, an uncleaved PO is hybridized with the CO immobilized onto the solid substrate. The designs of the PO and the CO are convenient and the optimization of reaction conditions is routinely easy in the present invention. Where the detection of signal on the solid substrate is continuously performed along with repetition of cleavage of the POs in the present invention, the number of the POs cleaved is increased upon the repetition number of the cleavage reaction and the signal is changed in parallel with the number of the POs cleaved. Then, the target nucleic acid sequence can be detected in a real-time manner. In contrast, the change of the signal is not observed in the absence of the target nucleic acid sequence. | 03-13-2014 |
20140073535 | MOLECULAR MARKERS IN PROSTATE CANCER - The present invention relates to methods for diagnosing prostate cancer and especially diagnosing LG, HG, PrCa Met and CRPC. Specifically, the present invention relates to methods for in vitro diagnosing prostate cancer in a human individual comprising: 1) determining the expression of one or more genes chosen from the group consisting of ACSM1, ALDH3B2, CGREF1, COMP, C19orf48, DLX1, GLYATL1, MS4A8B, NKAIN1, PPFIA2, PTPRT, TDRD1 and/or UGT2B15; | 03-13-2014 |
20140080722 | METHOD OF SNP DETECTION BY USING DASH TECHNIQUE IN BEAD-BASED MICROFLUIDICS - The present invention provides a method of SNP detection by using DASH technique in bead-based microfluidics comprising following steps: (a) immobilizing a target single-strand DNA onto a microbead; (b) hybridizing the target single-strand DNA with an allele-specific probe; (c) intercalating a dye into a target-probe duplex region; (d) delivering the microbead into a microchannel; (e) heating the microbead to denature a hybridized DNA obtained from the step (c); (f) monitoring a fluorescence intensity of the hybridized DNA during the step (e) to obtain a melting curve; and (g) determining the SNP by a melting curve analysis method. Also, the present invention offers a rapid genotyping detection scheme with minimal amount of the reagents by confining the microbeads into designed fluidic traps and performing melting curve analysis controlled by a temperature control platform. The trapping mechanism was validated and optimized. | 03-20-2014 |
20140080723 | Method of Fast Tuberculosis Diagnosis and Efficacy Test - A method is provided for fast diagnosis of tubercle bacillus (TB). The method can be used for efficacy test at the same time. 13 specific TB genes and 6 drug-resistance genes are selected. Those genes are formed into a construction for diagnosing tuberculosis and testing drug resistance simultaneously. | 03-20-2014 |
20140080724 | Complexity Management of Genomic DNA - The presently claimed invention provides for novel methods and kits for reducing the complexity of a nucleic acid sample by providing non-gel based methods for amplification of a subset of the sequences in a sample. In a preferred embodiment, amplification of a subset can be accomplished by digesting a sample with two or more restriction enzymes and ligating adaptors to the fragments so that only a subset of the fragments can be amplified. The invention further provides for analysis of the above amplified sample by hybridization to an array, which may be specifically designed to interrogate the desired fragments for particular characteristics, such as, for example, the to presence or absence of a polymorphism. | 03-20-2014 |
20140080725 | METHOD FOR SEPARATION AND DETECTION OF DNA FRAGMENTS - A method of detecting nucleic acid fragments is provided. The method includes providing a plurality of chambers, each chamber separated from the other chambers of the plurality, each chamber having at least one set of probes disposed therein, each set of probes being capable of binding to a different target nucleic acid sequence relative to the other sets of probes. The method also includes providing a sample comprising a plurality of sets of nucleic acid fragments, placing at least a portion of the sample into each of the plurality of chambers and causing the at least one set of probes in each chamber to bind with complementary nucleic acid fragments of the sample, and detecting the binding of the nucleic acid fragments to the sets of probes in each chamber. | 03-20-2014 |
20140080726 | ENHANCED METHOD FOR PROBE BASED DETECTION OF NUCLEIC ACIDS - A method of detecting nucleic acid fragments is provided. The method includes providing a plurality of sets of probes, each set of probes having a nucleic acid sequence. A first portion of the sequence is complementary to a target nucleic acid sequence, which differs for each set of probes relative to the other sets of probes. A second portion of the sequence is a specified sequence, which is the same for each set of probes. Each probe has a fluorescent label joined to the second portion of the sequence. The first portion of the sequence binds with nucleic acid fragments of a sample having a sequence complementary to said first portion. A quenching compound that has a quenching moiety and a nucleic acid sequence complementary to the specified sequence of the second portion of the sets of probes quenches the fluorescence. | 03-20-2014 |
20140080727 | VARIANTS PREDICTIVE OF RISK OF GOUT - Markers on chromosome 19q13, in particular, markers in the ALDH16A1 gene, are associated with risk of gout in humans. Diagnostic applications using the markers, such as determining the susceptibility to Gout, are described. | 03-20-2014 |
20140080728 | METHODS AND COMPOSITIONS FOR THE SELECTION AND OPTIMIZATION OF OLIGONUCLEOTIDE TAG SEQUENCES - Methods for selecting tag-oligonucleotide sequences for use in an in vitro nucleic acid assay. The selected tag sequences are useful for nucleic acid assay wherein interference between the nucleic acid sequences is the assay is to be controlled. Selected tag sequences are incorporated into nucleic acid assay to improve the performance of and/or minimize any interference between nucleic acids in the assay compared to untagged assays. | 03-20-2014 |
20140080729 | OPTICAL SENSING DEVICE FOR SENSING ANALYTES AND RELATED APPARATUS AND METHODS - An optical sensing device and associated apparatus are configured for multiplexed detection of specific analytes in fluid samples. The device has a wavelength-tunable grating-coupler configuration in which a grating is disposed on a surface of a waveguide. Different regions of the grating may be functionalized with different receptors, and may form binding-specific sensors and reference sensors. The receptors are exposed to a fluid sample utilizing a fluidic structure mounted to the device. The device utilizes evanescent waves to sense analytes bound to the waveguide surface. The evanescent wave is sensitive to changes in refractive index at (or near) the waveguide surface. Changes in refractive index occur proportionally to the mass of the bound analyte. The apparatus utilizes a tunable light source to implement swept wavelength interrogation while the input beam is held at a fixed coupling angle relative to the waveguide and grating. | 03-20-2014 |
20140080730 | METHOD FOR PREDICTING SEVERITY OF ALLERGIC REACTION - The present invention provides methods for determining a likelihood of a degree of allergic reaction or a severity thereof using a threshold value rather than the binding activity number between the immunoglobulin of the subject and a test composition comprising a marker protein moiety of the allergy inducing material. In one particular embodiment of the invention, methods are provided for determining a likelihood of a degree of allergic reaction severity of a subject to peanuts using a threshold value of binding between immunoglobulin E (IgE) of the subject and Ara h 2 moiety and Ara h 6 moiety. | 03-20-2014 |
20140080731 | THYROID CANCER DIAGNOSTICS - Disclosed herein, in certain instances, are methods for the diagnosis, prognosis and determination of cancer progression of a cancer in a subject. Further disclosed herein, in certain instances, are methods for determining the treatment modality of a cancer in a subject. The methods comprise expression-based analysis of targets. Further disclosed herein, in certain instances, are probe sets for use in assessing a cancer status in a subject. | 03-20-2014 |
20140080732 | BLOOD TRANSCRIPTIONAL SIGNATURE OF ACTIVE VERSUS LATENT MYCOBACTERIUM TUBERCULOSIS INFECTION - The present invention includes methods, systems and kits for distinguishing between active and latent | 03-20-2014 |
20140080733 | Use of marker panels for stratifying drug treatment options - Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers. | 03-20-2014 |
20140080734 | IN VITRO METHOD FOR DETERMINING IMMUNOTOXICITY OF A COMPOUND - The invention is in the field of molecular diagnostics. More in particular it provides marker genes for determining the immunotoxicity of compounds. A method according to the invention employs samples obtained from a cell exposed to a potentially immunotoxic compound and determines expression levels of a number of marker genes in order to distinguish between immunotoxic compounds and non-immunotoxic compounds. More in particular, the invention relates to an in vitro method for determining whether a compound is immunotoxic wherein the expression level of at least one marker gene is determined in a sample obtained from a nucleated cell exposed to the compound, wherein the at least one marker gene is selected from the group consisting of ABCA1, CHAC1, CRIM1 and HMGCS1, and wherein it is concluded that the compound is immunotoxic if the expression level of said at least one marker gene is below or above a predetermined reference value. | 03-20-2014 |
20140080735 | METHOD FOR THE DETECTION AND/OR IDENTIFICATION OF A MICROORGANISM - The present invention relates generally to a method of identifying micro-organisms in a sample and in particular to the identification of prokaryotic micro-organisms. In some embodiments, the present invention relates to a method for the detection and/or identification of at least one microorganism or for the simultaneous detection and/or identification of several microorganisms in a test sample wherein the test sample is contacted with one or more probes derived from a tuf gene variable region. | 03-20-2014 |
20140080736 | TUMOUR MARKER PROTEINS AND USES THEREOF - Tumour marker proteins and their preparation from fluids from one or more cancer patients, wherein said fluids are those which collect in a body cavity or space which is naturally occurring or which is the result of cancer or medical intervention for cancer. The present application also relates to preparation of tumour marker proteins from excretions taken from patients with cancer. The tumour marker proteins are useful as immunoassay reagents in the detection of cancer-associated anti-tumour marker autoantibodies. | 03-20-2014 |
20140080737 | GENE EXPRESSION PROFILE FOR THERAPEUTIC RESPONSE TO VEGF INHIBITORS - The invention provides gene expression profiles (GEPs), protein expression profiles (PEPs) as well as gene/protein expression profiles (GPEPs) and methods for using them to identify metastatic breast cancer patients who are likely to respond to therapy with a VEGF inhibitor. The present invention allows a treatment provider to identify those patients who are most likely to respond to such treatment, and to initiate and/or adjust treatment options for such patients accordingly. | 03-20-2014 |
20140087957 | METHODS, ASSAYS AND KITS FOR CANCER DIAGNOSIS AND SCREENING UTILIZING GLYCAN-BINDING AND GLYCAN EPITOPES - The invention relates to the diagnosis, monitoring, prognosis, and/or prediction of cancer utilizing the detection or measurement of glycan-protein interactions, particularly glycan-antibody interactions. The invention relates to carbohydrate-containing molecules that are utilized in bioanalytical systems, methods and kits for detecting neoplasia and methods related thereto and based thereon. In an exemplary embodiment glycans or glycopolymers are carried in an array, on beads or in a microfluidic system for diagnostic screening for risk of neoplasia, the existence of neoplasia in a patient, or for treatment monitoring. In such an embodiment, the bioanalytic system identifies binding interactions between molecules in a patient test sample (e.g., glycan compositions) and the glycans or glycopolymers. The glycan-binding compositions may be used to generate an immune response against cancer cell epitopes. Alternatively, antibody therapeutics can be developed that are useful for binding to glycan compositions on a cell surface. | 03-27-2014 |
20140087958 | HONEYCOMB TUBE - A honeycomb tube with a planar frame defining a fluidic path between a first planar surface and a second planar surface. A fluidic interface is located at one end of the planar frame. The fluidic interface has a fluidic inlet and fluidic outlet. The fluidic path further includes a well chamber having an well-substrate with a plurality of wells. The well chamber is arranged in the planar frame between the first or second surface and the well-substrate. The well chamber is in fluidic communication between the pre-amplification chamber and the fluidic outlet. | 03-27-2014 |
20140087959 | Methods And Compositions Involving Intrinsic Genes - Disclosed are compositions and methods related intrinsic gene sets and methods and compositions related to detecting and classifying cancer. | 03-27-2014 |
20140087960 | Markers Related to Age-Related Macular Degeneration and Uses Therefor - Methods are provided of screening for age-related macular degeneration (AMD), including a risk of a subject devel - oping AMD or a risk of a subject progressing to an advanced fom of AMD. The methods can include analyzing a sample obtained from the subject for the presence of at least one single nucleotide polymorphism (SNP) selected from the group consisting of rs4711751, rs6982567, rs1999930, rs13278062, rs1912795, rs2270637, rs12040406, rs1367068, rs1079982, rs1443179, rs7720497, and/or rs6 1800454. | 03-27-2014 |
20140087961 | GENETIC VARIANTS USEFUL FOR RISK ASSESSMENT OF THYROID CANCER - The invention discloses genetic variants that have been determined to be susceptibility variants of thyroid cancer. Methods of disease management, including methods of determining susceptibility to thyroid cancer, methods of predicting response to therapy and methods of predicting prognosis of thyroid cancer using such variants are described. The invention further relates to kits useful in the methods of the invention. | 03-27-2014 |
20140087962 | Identification of Linkage Using Multiplex Digital PCR - This specification generally relates to methods of detecting the linkage between two or more targets in a sample using digital multiplex PCR. A method of identifying physical linkage between two or more nucleic acid targets in a sample is provided. The method includes diluting the sample via limiting dilution and aliquoting the diluted sample into wells. The method further includes performing multiplex PCR in each chamber, where a first dye is used for the first target and a second dye is used for the second target. The method includes identifying the presence of the first and second dyes in the wells, wherein a non-random distribution of the dyes identifies the targets as linked. | 03-27-2014 |
20140087963 | IMMUNOSIGNATURING: A PATH TO EARLY DIAGNOSIS AND HEALTH MONITORING - Health is a complex state that represents the continuously changing outcome of nearly all human activities and interactions. The invention provides efficient methods and arrays for health monitoring, diagnosis, treatment, and preventive care. The invention monitors a broad range of identifying molecules from a subject, such as circulating antibodies, and the invention evaluates a pattern of binding of those molecules to a peptide array. The characterization of the pattern of binding of such molecules to a peptide array with the methods of the invention provide a robust measure of a state of health of a subject. | 03-27-2014 |
20140087964 | COMPOSITIONS AND METHODS FOR DETECTING ABERRANT REGULATION, EXPRESSION, AND LEVELS OF HGH - Detection of human growth hormone use is very challenging due to the short half-life of circulating human growth hormone and the fact that the recombinant human growth hormone used is identical in protein sequence as the native, naturally produced growth hormone. The chief objective of this invention is to discover a marker(s) that will identify use of recombinant human growth hormone use. In the case of this invention, we have discovered specific circulating micro RNA (miRNA) that can be detected and quantified in plasma of individuals taking recombinant human growth hormone. | 03-27-2014 |
20140087965 | MARKER FOR DIAGNOSING DIABETIC RETINOPATHY AND USE THEREOF - The present invention relates to a marker which can be used to diagnose a diabetic retinopathy patient and determine the progression of diabetic retinopathy, a composition for diagnosing diabetic retinopathy, which comprises an agent for measuring the level of a gene or protein associated with the marker, and the use thereof. | 03-27-2014 |
20140087966 | Detection and Differentiation of Demodex Mites - Methods of detecting | 03-27-2014 |
20140087967 | METHODS AND COMPOSITIONS FOR DIAGNOSING COMPLICATIONS OF PREGNANCY - The present invention provides methods and compositions for identifying subjects at risk of developing a complication of pregnancy, such as preeclampsia or preterm labor. The compositions are microRNAs and associated nucleic acids. | 03-27-2014 |
20140087968 | MODIFIED RNASE H AND DETECTION OF NUCLEIC ACID AMPLIFICATION - A reversibly modified ‘hot start’ RNase H enzyme composition is described for the improved CATACLEAVE™ probe detection of nucleic acid sequences in a test sample. A key feature of the enzyme composition is the ability to regulate the catalytic activity of the RNase H during the course of a reverse transcription-PCR cycle. Thus, RNase H activity can be initially suppressed to minimize degradation of RNA:DNA primer heteroduplexes prior to reverse transcription. After cDNA synthesis is complete, RNase H activity is induced to promote the cleavage and fluorescent detection of CATACLEAVE™ probes that anneal to target DNA sequences within the reverse transcriptase-PCR products. The inducible RNase H enzyme is amenable to high throughput applications requiring one step reverse transcriptase CATACLEAVE™ PCR in a single reaction mix. | 03-27-2014 |
20140087969 | PIM-3 Kinase as a Target for Type 2 Diabetes Mellitus - The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus. | 03-27-2014 |
20140094377 | METHOD FOR MUTIPLEXED MICROFLUIDIC BEAD-BASED IMMUNOASSAY - A method for performing multiplexed bead-based immunoassays using a microfluidic cassette capable of detecting a particle passing in substantially single file through an interrogation zone and generating a Coulter effect signal responsive to a characteristic of the particle. A fluid sample may be prepared by associating antibody-coated beads of different sizes to particles of interest. A first multiplexing option may be based on bead size, in which case the intensity of the Coulter signal is used to sort or characterize the particles. A second multiplexing option may be based on detection of Stokes' shift phenomena, or even simply emission intensity, in which case particles may be characterized responsive to intensity of the signal resulting from detection of radiation. The first and second multiplexing options may be employed together to populate an array of particle characteristics. | 04-03-2014 |
20140094378 | MEANS AND METHODS FOR CLASSIFYING SAMPLES OF MULTIPLE SCLEROSIS PATIENTS - The invention in one aspect provides a method for classifying cells from a human individual said method comprising: providing a sample comprising cells from said individual that are typically responsive to exposure to a type I interferon; determining a level of activity of a pathway that is modulated by type I interferon; and classifying said cells on the basis of the determined level of activity. Cells present in said sample are preferably cultured said cells in the presence of a type I interferon prior to determining a level of activity of said pathway. This is activity is preferably compared to the activity of said pathway in cells in said sample prior to said culture. Preferably the sample is from an individual that is not treated with a type I interferon prior to collecting said sample. Preferably the method is used to determine, prior to initiating treatment with a type I interferon, whether said individual is likely to be a good, a normal or a poor responder to the contemplated treatment. | 04-03-2014 |
20140094379 | Colon Cancer Gene Expression Signatures and Methods of Use - A gene expression signature of colon cancer, microarrays including them and methods of using the colon gene expression signature are provided. The gene expression signature is especially useful for determining the prognosis of a patient diagnosed with colon cancer, such as stage II colon cancer. The gene signature described herein is also useful for determining effectiveness of surgical resection with or without adjuvant chemotherapy, and determining possibility of cancer recurrence in patients with colon cancer. | 04-03-2014 |
20140094380 | Methylation Biomarkers for Diagnosis of Prostate Cancer - Biomarkers for diagnosis and prognosis of prostate cancer are provided. The biomarkers are promoter sequences have altered methylation patterns relative to normal prostate tissue. Altered expression of DNA methyltransferases (DNMT) and proteins that interact with DNMT result in increased methylation at a subset of prostate tumor hypermethylation sites. | 04-03-2014 |
20140094381 | Predictive Biomarkers for Response to Exercise - A set of biomarkers have been identified that allows one to predict subjects who will respond to an exercise regime in term of cardiorespiratory fitness as assessed by maximal oxygen uptake. These predictions may be used, for example, to predict risk of cardiovascular disease, to design a more effective program for cardiac rehabilitation, to predict capacity for athletic performance or physically demanding occupation, and to predict ability to maintain functional capacity with aging using exercise. | 04-03-2014 |
20140094382 | METHODS AND AGENTS FOR MODULATING PROTOCADHERIN-18 ACTIVITY - Screening assays and methods of using same for screening to identify modulator agents or compounds that affect pcdh18 mediated inhibition of T cell effector function are described herein. Pharmaceutical and immunogenic compositions comprising agents or compounds that modulate pcdh18 mediated inhibition of T cell effector function are also encompassed. Methods for modulating pcdh18 mediated inhibition of T cell effector function using agents identified using assays described herein in pharmaceutical and immunogenic compositions are also envisioned. Adenocarcinoma is an exemplary tumor type that expresses pcdh18 and for which such pharmaceutical and immunogenic compositions would confer benefit to patients. Also encompassed are methods for reducing pcdh18 mediated inhibition of T cell effector function so as to achieve more effective T cell responses to pcdh18 expressing tumors. | 04-03-2014 |
20140094383 | Tethered Lipoplex nanoparticle Biochips And Methods Of Use - Disclosed are compositions and methods for the use of lipoplex nanoparticle chips and arrays in the detection of/diagnosis of a disease or condition. | 04-03-2014 |
20140094384 | STROMAL ANTIGEN 2 (STAG2) COMPOSITIONS AND METHODS - Compositions and methods related to stromal antigen 2 (STAG2) and its role in diverse human cancers, including nucleic acids, polypeptides, vectors, cells and cell lines. | 04-03-2014 |
20140094385 | SEQUENCE-SPECIFIC ENGINEERED RIBONUCLEASE H AND THE METHOD FOR DETERMINING THE SEQUENCE PREFERENCE OF DNA-RNA HYBRID BINDING PROTEINS - The subject of the invention is the ribonuclease which cleaves RNA strand in DNA-RNA hybrids, wherein ribonuclease comprises fusion protein comprising catalytic domain of RNase HI (RNase HI) or derivative thereof with a zinc finger DNA-RNA hybrid binding domain, and wherein the zinc finger binding domain has the ability to bind to specific sequences in the DNA-RNA hybrid. The invention also relates to new methods for determination of the sequence preference of DNA-RNA hybrid binding protein(s) or its domain(s) and allows determining the sequence recognized by sequence specific binding protein in the DNA-RNA hybrid. | 04-03-2014 |
20140094386 | METHODS OF DETERMINING A TREATMENT PROTOCOL FOR AND/OR A PROGNOSIS OF A PATIENT'S RECOVERY FROM A BRAIN INJURY RESULTING FROM A HYPOXIC EVENT - The present invention, in some embodiments, generally relates to methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury resulting from a hypoxic event. In some embodiments, methods are provided for determining a measure of the concentration of beta-amyloid peptide in a patient sample containing or suspected of containing beta-amyloid peptide. | 04-03-2014 |
20140094387 | SUV39H2 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS - Objective methods for detecting or diagnosing cancer, or determining a predisposition for developing cancer, particularly lung cancer, cervical cancer, bladder cancer, esophageal cancer, osteosarcoma, prostate cancer and soft tissue tumor, are described herein. In one embodiment, the diagnostic method involves determining an expression level of the SUV39H2 gene. The present invention further provides methods of screening for candidate substances useful in the treatment and/or prevention of an SUV39H2-associated cancer, such as lung cancer, cervical cancer, bladder cancer, esophageal cancer, osteosarcoma, prostate cancer and soft tissue tumor. The present invention further provides methods of inhibiting the cell growth and thereby treating or alleviating symptoms of an SUV39H2 associated cancer. The present invention also features double-stranded molecules against the SUV39H2 gene and vectors encoding thereof as well as compositions containing such components and their utility in connection with the treatment and prevention of an SUV39H2-associated cancer. | 04-03-2014 |
20140094388 | Engineered Cardiac Tissues and Methods of Using Them - Engineered cardiac tissues are provided herein. The tissues include cardiomyocyte cells derived from a pluripotent cell, fibroblast cells and extracellular matrix components. Methods of using the tissues described herein are also provided. | 04-03-2014 |
20140100124 | DIAGNOSTIC MIRNAS FOR DIFFERENTIAL DIAGNOSIS OF INCIDENTAL PANCREATIC CYSTIC LESIONS - Embodiments concern methods and compositions for characterizing or evaluating neoplastic pancreatic cells using miRNAs that are measured and used in calculations to determine a risk score for a patient. | 04-10-2014 |
20140100125 | Methods, Kits and Compositions for Determining Severity and Survival of Heart Failure in a Subject - The application provides a method of determining a severity of heart failure in a human test subject, by determining a level of RNA encoded by one or more heart failure marker genes in blood of the test subject compared to controls. The application also provides a method of determining survival outcome and allows the ranking of test subjects based on the level of RNA encoded by one or more survival associated genes. | 04-10-2014 |
20140100126 | Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data - Provided herein are methods for determining the ploidy state of one or more chromosome in a developing fetus. The subject methods provide for increase accuracy by utilizing information about the mosaicism level of one or more chromosomes of interest in the mother of fetus. The mosaicism level of one or more chromosomes of interest is determine for the maternal tissue that is used as the source of nucleic acid for genetic analysis that are used to determine the ploidy state of the fetal chromosome or chromosomes of interest. For example, if 5% white blood cells of mother are missing a copy of the X chromosome, this information can be used when determining fetal ploidy level, rather than operating under the assumption that the maternal X chromosome are present in two copies. Utilization of the mosaicism data can be used to increase the reliability and accuracy of the determination of the ploidy state of a chromosome of interest. | 04-10-2014 |
20140100127 | LIVER CANCER DIAGNOSIS MARKER AND USE THEREOF - A marker for the detection of liver cancer and application of the marker thereof. The application includes use of cytochrome p450 family 17 subfamily A polypeptide 1 (CYP17A1 protein) in the preparation of diagnostic reagents or kits for the detection of liver cancer kit. Studies have shown that CYP17A1 expression levels are higher in liver cancer tissues than in the adjacent healthy tissues, and the amount of CYP17A1 in sera of liver patients is significantly higher than that of healthy human population. Therefore, CYP17A1 can be used as a marker for the diagnosis of liver cancer (especially serological diagnosis). | 04-10-2014 |
20140100128 | USE OF MARKERS IN THE IDENTIFICATION OF CARDIOTOXIC AGENTS AND IN THE DIAGNOSIS AND MONITORING OF CARDIOMYOPATHY AND CARDIOVASCULAR DISEASE - The invention provides methods for the diagnosis and prognosis of cardiovascular disease, and for monitoring of the treatment of cardiovascular disease, including heart failure and cardiomyopathy. The invention further provides methods for identifying an agent for treating cardiomyopathy or heart failure, for identifying a cardiotoxic agent, and for identifying a rescue agent to reduce or prevent drug-induced toxicity, by using one or more biomarkers selelcted from the group consisting of CCDC47, HMOX1, PTX3, PAI1, IL27, IGFBP7, Emmprin, CFL2, EDIL3, NUCB1, PE D18:0-20:3/D18:1-20:2/D16:0-22:3; PE D18:0-22:5/D18:1-22:4; PE D16:1-22:6; PE P18:1-18:1/P18:0-18:2/P16:0-20:2; LPC 20:3; and PC-LI-183-D18:22-22:6, or any of the other biomarkers provided herein. The invention further provides kits for practicing the methods of the invention. | 04-10-2014 |
20140100129 | METHOD OF THERAPY AND DIAGNOSIS OF ATHEROSCLEROSIS - There is provided a method of therapy of atherosclerosis, by providing microRNA let-7g, an analogue thereof or modified let-7g to organisms to inhibit the expression of lectin-like oxidized low density lipoprotein receptor-1 (LOX-1), and the binding of LOX-1 and oxidized low-density lipoprotein (oxLDL), so as to block the pathogenesis of atherosclerosis. Also, a method of diagnosis of atherosclerosis comprises determining the levels of microRNA let-7g in serum or plasma samples of organisms, in which the levels of microRNA let-7g is estimated in individuals with atherosclerosis as compared to individuals without atherosclerosis. | 04-10-2014 |
20140100130 | Methods and Compositions for the Diagnosis of Ovarian Cancer - A diagnostic reagent or device comprises at least one ligand capable of specifically complexing with, binding to, or quantitatively detecting or identifying the biomarker chloride intracellular channel protein 4 (CLIC4) or an isoform, pro-form, modified molecular form including posttranslational modification, or unique peptide fragment or nucleic acid fragment thereof. An alternative diagnostic reagent or device comprises ligand or ligands capable of specifically complexing with, binding to, or quantitatively detecting or identifying multiple tropomyosin biomarkers. Optionally, such reagent or device includes a signaling molecule and/or a substrate on which the ligand is immobilized. Other reagents and methods of diagnosing ovarian cancer include use of CLIC4 ligands and/or multiple tropomyosin ligands with an additional ovarian cancer biomarker. For example, CLIC4 combined with one or more of CLIC1 and/or one or multiple members of the tropomyosin family, e.g., TPM1, TPM2, TPM3 or TPM4, and further optionally including CTSD-30 kDa and/or PRDX-6, among other ovarian cancer biomarkers can form a characteristic diagnostic pattern or profile of expression that is diagnostic of the disease. Still other embodiments are described. | 04-10-2014 |
20140100131 | Methods and Reagents for Target Isolation from a Sample - The present invention provides methods and kits for isolating a target of interest from a sample, where the methods involve use of nucleic acid strand displacement technology. | 04-10-2014 |
20140100132 | PROCESSES FOR DETECTING OR QUANTIFYING MORE THAN ONE NUCLEIC ACID IN A LIBRARY - This invention provides novel compositions and processes for analyte detection, quantification and amplification. Nucleic acid arrays and libraries of analytes are usefully incorporated into such compositions and processes. Universal detection elements, signaling entities and the like are employed to detect and if necessary or desirable, to quantify analytes. Amplification of target analytes are also provided by the compositions and processes of this invention. | 04-10-2014 |
20140100133 | Methods for Diagnosing Breast Cancer Using MicroRNAs - Described herein are methods for diagnosing breast cancer using microRNAs. Also described are methods and compositions for the diagnosis and treatment of solid cancers. Methods of identifying inhibitors of tumorigenesis are also provided. | 04-10-2014 |
20140100134 | METHODS FOR NON-INVASIVE PRENATAL PLOIDY CALLING - The present disclosure provides methods for determining the ploidy status of a chromosome in a gestating fetus from genotypic data measured from a sample of DNA from the mother of the fetus and from the fetus, and from genotypic data from the mother and optionally also from the father. The ploidy state is determined by using a joint distribution model to create a set of expected allele distributions for different possible fetal ploidy states given the parental genotypic data, and comparing the expected allelic distributions to the pattern of measured allelic distributions measured in the mixed sample, and choosing the ploidy state whose expected allelic distribution pattern most closely matches the observed allelic distribution pattern. In an embodiment, the mixed sample of DNA may be preferentially enriched at a plurality of polymorphic loci in a way that minimizes the allelic bias. | 04-10-2014 |
20140100135 | DETECTION OF NUCLEIC ACID SEQUENCE DIFFERENCES USING THE LIGASE DETECTION REACTION WITH ADDRESSABLE ARRAYS - The present invention describes a method for identifying one or more of a plurality of sequences differing by one or more single base changes, insertions, deletions, or translocations in a plurality of target nucleotide sequences. The method includes a ligation phase, a capture phase, and a detection phase. The ligation phase utilizes a ligation detection reaction between one oligonucleotide probe, which has a target sequence-specific portion and an addressable array-specific portion, and a second oligonucleotide probe, having a target sequence-specific portion and a detectable label. After the ligation phase, the capture phase is carried out by hybridizing the ligated oligonucleotide probes to a solid support with an array of immobilized capture oligonucleotides at least some of which are complementary to the addressable array-specific portion. Following completion of the capture phase, a detection phase is carried out to detect the labels of ligated oligonucleotide probes hybridized to the solid support. | 04-10-2014 |
20140100136 | ISOLATION AND CHARACTERIZATION OF PATHOGENS - Methods of the invention generally involve using magnetic particles to isolate low levels of pathogens from a samples and identifying genes expressed by those pathogen. In one aspect, the method includes obtaining a sample comprising a pathogen, forming magnetic particle/target complexes, separating the magnetic particle/target complexes using magnetic fields, and determining an expression profile of a nucleic acid derived from the target. | 04-10-2014 |
20140100137 | MARKERS FOR IMPAIRED BONE FRACTURE HEALING - The present application discloses particularly interleukin-8 (IL-8) as a novel biomarker for the prediction, diagnosis, prognosis and/or monitoring of impaired bone fracture healing; and related methods, uses and kits. | 04-10-2014 |
20140106976 | Compressed Sensing for Simultaneous Measurement of Multiple Different Biological Molecule Types in a Sample - A method and apparatus for simultaneously determining multiple different biological molecule types in a sample include labeling each different biological molecule type in a biological sample with a unique combination of a plurality of labels. Each different biological molecule type is selected from a population of M different biological molecules types. The plurality of labels is selected from a population of L different labels; and, M is greater than L. Measurements are obtained of relative abundances of the L different labels in the sample. Relative abundance of up to M different biological molecule types in the sample are determined based on the measurements and a method of compressed sensing. | 04-17-2014 |
20140106977 | SIMULTANEOUS DETECTION OF MULTIPLE MUTATIONS - Methods and compositions for simultaneous detection of polymorphisms at multiple loci in a target nucleic acid. | 04-17-2014 |
20140106978 | Automatic Threshold Setting and Baseline Determination for Real-Time PCR - The invention discloses a system and methods for quantitating the presence of nucleic acid sequences by evaluation of amplification data generated using real-time PCR. In one aspect, the methods may be adapted to identify a threshold and threshold cycle for one or more reactions based upon evaluation of exponential and baseline regions for each amplification reaction. The methodology used in the analysis may be readily automated such that subjective user interpretation of the data is substantially reduced or eliminated. | 04-17-2014 |
20140106979 | POLYMERS HAVING ORTHOGONAL REACTIVE GROUPS AND USES THEREOF - Polymers having orthogonal reactive groups and solid supports comprising polymers immobilized thereto are provided. The polymers find utility in any number of applications including immobilizing analyte molecules to solid supports for high throughput assays. | 04-17-2014 |
20140106980 | OPTICAL SENSING AND SEPARATION BASED ON ORDERED THREE-DIMENSIONAL NANOSTRUCTURED SURFACES - A sensor having a substrate is provided in which structures are disposed on a surface of the substrate. The structures can be, e.g., nanostructures. Polarized light is directed toward the sensor, and birefringence of the structures with respect to the light is measured. Target particles that interact with the structures are detected based on changes in the measured birefringence. | 04-17-2014 |
20140106981 | Organ-Specific Proteins and Methods of Their Use - The present invention relates generally to methods for identifying and using organ-specific proteins and transcripts. The present invention further provides compositions comprising organ-specific proteins and transcripts encoding the same, detection reagents for detecting such proteins and transcripts, and diagnostic panels, kits and arrays for measuring organ-specific proteins/transcripts in blood, biological tissue or other biological fluid. | 04-17-2014 |
20140106982 | PLASMIDS AND METHODS FOR PEPTIDE DISPLAY AND AFFINITY-SELECTION ON VIRUS-LIKE PARTICLES OF RNA BACTERIOPHAGES - The present invention relates to a system and method for controlling peptide display valency on virus-like particles (VLPs), especially including MS2 or PP7 VLPs. In this method, large amounts of wild-type and low quantities of single-chain dimer coat proteins may be produced from a single RNA. Valency is controlled in immunogen (vaccine) production by providing a system that allows the production of large amounts of wild-type and low quantities of single-chain dimer coating proteins from a single RNA, allowing facile adjustment of display valency levels on bacteriophage VLPs, especially MS2 or PP7 VLPs over a wide range, from few than one—on average—to as many as ninety per particle. This facilitates the production of immunogens and vaccines, including VLPs exhibiting low valency. Nucleic acid constructs useful in the expression of virus-like particles are disclosed, comprised of a coat polypeptide of bacteriophage such as MS2 or PP7 modified by insertion of a heterologous peptide, optionally comprising a carbohydrate mimotope, wherein the heterologous peptide is displayed on the virus-like particle and encapsidates bacteriphage mRNA. | 04-17-2014 |
20140106983 | Methods for Detecting and Measuring Specific Nucleic Acid Sequences - The invention provides novel oligonucleotides and methods of using the same for detection or measurement of specific nucleic acid molecules. The invention also features nucleic acid arrays comprising the oligonucleotides of the invention. An oligonucleotide of the invention comprises (1) a reporter-binding sequence capable of hybridizing to a fluorrophore-labeled reporter sequence and (2) a hairpin-forming sequence capable of forming a stem-loop. Formation of the stem-loop modifies (e.g., quenching) the fluorescence signals of the reporter sequence when the reporter sequence is hybridized to the oligonucleotide. This can be achieved, for example, by bringing one or more guanine based in the oligonucleotide into close proximity to the fluorophore(s) of the reporter sequence by virtue of the formation of the stem-loop. Disruption of the stem-loop, such as by hybridization of a target sequence to at least part of the hairpin-forming sequence, produces a detectable change in the fluorescence signals. | 04-17-2014 |
20140106984 | FLOW PASSAGE DEVICE AND TESTING SYSTEM USING THE SAME - A real time analysis in accordance with temperature change and highly sensitive detection are permitted. A flow passage device has a flow passage ( | 04-17-2014 |
20140106985 | MICRORNA BIOMARKERS FOR PROGNOSIS OF PATIENTS WITH PANCREATIC CANCER - The present invention relates to prognostic micro RNA (miRNA) biomarkers based on a specific miRNA expression pattern, which can prove as a valuable prognostic tool to predict the survival of patients being diagnosed with pancreas cancer. | 04-17-2014 |
20140106986 | METHODS AND DEVICES FOR PROGNOSIS OF CANCER RELAPSE - The present invention features microRNAs as biomarkers for prognosing cancer relapse in cancer patient. The present invention also features methods, devices, and kits for this purpose. | 04-17-2014 |
20140106987 | BIOMARKERS FOR AUTOIMMUNE LIVER DISEASES AND USES THEREOF - The present invention relates to a method for diagnosis or prognosis of liver autoimmune diseases by means of detecting specific biomarkers in biological samples. The invention refers also to a method of monitoring an autoimmune liver disease pathology status after treatment with surgery and/or therapy in a subject with autoimmune liver disease, to kits and microarrays to perform said methods. | 04-17-2014 |
20140113830 | Azoline Compound and Azole Compound Library and Method for Producing Same - An object of the present invention is to provide a method of efficiently constructing a library abundant in diversity and also usable for screening of a compound that binds to a target substance having protease activity. | 04-24-2014 |
20140113831 | ANTIBODY SCREENING METHODS - Provided are methods and compositions for the production of novel antibodies that bind specifically to a target anti gen. These methods and compositions are particularly useful for producing antibodies having the antigen binding specificity of a reference antibody but with improved properties (e.g., binding affinity, immunogenicity, and thermodynamic stability) relative to the reference antibody. | 04-24-2014 |
20140113832 | ENGINEERED THIOREDOXIN-LIKE FOLD PROTEINS - The invention features compositions based on thioredoxin-like fold protein domains described as engineered thioredoxin-like fold proteins (ETRXs). These proteins include one or more artificially diversified thioredoxin-like fold protein domains; each domain may be originated from the same or different thioredoxin-like fold protein domains. Features of the invention also include methods for identifying and preparing an enriched composition of target binding, loop-diversified ETRXs with additional sequence variations to improve affinity, stability, selectivity, or solubility. The invention also features compositions of ETRXs substituted with prosthetic groups, polymers, proteins, nucleic acids, carbohydrates, metals, natural or synthetic small molecules and toxins. | 04-24-2014 |
20140113833 | USE OF MULTIPLE RISK PREDICTORS FOR DIAGNOSIS OF CARDIOVASCULAR DISEASE - Methods and kits for characterizing the risk of developing cardiovascular disease are described. The methods include determining the levels of a plurality of risk predictors selected from the group consisting of B-type natriuretic peptide (BNP), myeloperoxidase (MPO), and high-sensitivity C-reactive protein (hsCRP) predictors in a biological sample from a subject. The levels of the plurality of risk predictors are then compared to corresponding control values to obtain a risk predictor differential for each risk predictor. The plurality of risk predictor differentials are then added to provide a cardiac biomarker score, and the cardiac biomarker score is compared to a reference biomarker score. A positive difference between the cardiac biomarker score and the reference biomarker score indicates the subject has an increased risk of developing cardiovascular disease compared to the risk of a reference population. The methods can be used for risk stratification. | 04-24-2014 |
20140113834 | HYBRIDOMA CLONES AND MONOCLONAL ANTIBODIES TO ING4 - The present invention is directed to a monoclonal antibody that recognizes human ING4 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody, and to methods of diagnosing cancer using the antibody. | 04-24-2014 |
20140113835 | CHEMICALLY-DEFINED ARRAYS FOR SCREENING CELL-SUBSTRATE INTERACTIONS - Patterned SAM arrays and methods of preparing patterned SAM arrays are disclosed. Advantageously, the methods used to prepare the patterned SAM arrays allow for controlling SAM spot-to-spot conditions such as ligand identity and ligand density, which allows for preparing a wide range of SAM spots in a single array format. Additionally, the patterned SAM arrays of the present disclosure support the culture of a range of cell types. The patterned SAM arrays offer the ability to rapidly screen substrate components for influencing cell attachment, spreading, proliferation, migration, and differentiation. | 04-24-2014 |
20140113836 | COMPOSITIONS, SYSTEMS AND METHODS FOR THE DIAGNOSIS, PREVENTION AND TREATMENT OF DISORDERS ASSOCIATED WITH AZETIDINE-2-CARBOXYLIC ACID - The present disclosure provides synthesized peptides containing azetidine-2-carboxylic acid (Aze), methods for detecting antibodies to peptides containing Aze, and methods for diagnosing conditions associated with misincorporation of Aze into host proteins. | 04-24-2014 |
20140113837 | SYSTEM AND METHOD FOR DETERMINING INDIVIDUALIZED MEDICAL INTERVENTION FOR A DISEASE STATE - A system and method for determining individualized medical intervention for a particular disease state, and especially for cancers, that includes the molecular profiling of a biological sample from the patient, determining whether any molecular findings including one or more genes, one or more gene expressed proteins, one or more molecular mechanisms, and/or combinations of such exhibit a change in expression compared to a reference, and identifying a non-specific disease therapy or agent capable of interacting with the genes, gene expressed proteins, molecular mechanisms, or combinations of such molecular findings that exhibited a change in expression. | 04-24-2014 |
20140121122 | Method for Detecting Transcription Factor-Protein Interactions - A method is provided for identifying complexes between a transcription factor and another protein, the method comprising: isolating from a biological sample transcription factor complexes based on whether the transcription factor complexes comprise a particular type of transcription factor; and identifying which of a plurality of different proteins are present in the isolated transcription factor complexes. | 05-01-2014 |
20140121123 | METHODS FOR DIVERSIFYING ANTIBODIES, ANTIBODIES DERIVED THEREFROM AND USES THEREOF - The invention provides methods of introducing diversity into antibody molecules comprising introducing or substituting at least one amino acid sequence in the CDR of the target antibody together with at least one amino acid in the FW region spanning the 3 amino acid adjoining the CRD on each side. The resulting diverse antibodies with variant CDRs and FW region sequences comprising diverse amino acid sequences are also described. These polypeptides regions, herein referred to as 3+CDR3+, that form the gist of the invention contribution described herein provide a flexible and simple source of sequence diversity that can be used as a source for expressing and identifying diverse antibodies or antigen binding polypeptides. Libraries comprising a plurality of these polypeptides are also provided. In addition, methods of and compositions for generating and using these polypeptides and libraries are provided. A method of producing diverse antibodies comprising amino acid substitutions in one of the CDR region and the FW region comprising 3 contiguous FW sequence amino acids adjacent to each CDR on either side is described herein. The substitutions are relative to database or germline sequences. Not all substitution are preserved in conservative regions. | 05-01-2014 |
20140121124 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION - Methods of identifying inhibitors of retroviral propagation, tRNA used in the methods, and kits, including the tRNA, which can be used in the methods, are disclosed. Methods of treating or preventing retroviral infections by administering an effective amount of the inhibitors, and pharmaceutical compositions including the inhibitors, are also disclosed. The methods involve forming a mixture comprising a linear sequence of a tRNA anticodon stem loop fragment that is not capable of forming a stem-loop, a target nucleic acid molecule capable of binding to the tRNA anticodon stem loop fragment, and a test compound. The mixture is incubated under conditions that allow binding of the tRNA anticodon stem loop fragment and the target nucleic acid molecule in the absence of the test compound. Assays can then be performed that detect whether or not the test compound inhibits the binding of the tRNA anticodon stem loop fragment and the target nucleic acid molecule. | 05-01-2014 |
20140121125 | PEPTIDES, DEVICES, AND METHODS FOR THE DETECTION OF EHRLICHIA ANTIBODIES - The invention provides peptide compositions and mixtures useful for the detection of antibodies that bind to | 05-01-2014 |
20140121126 | METHODS OF DETECTING AXL AND GAS6 IN CANCER PATIENTS - Described herein, inter alia, are compositions and methods for detecting levels of AXL and GAS6. | 05-01-2014 |
20140121127 | Methods and Compositions for Diagnosis of Ovarian Cancer - Methods and compositions are provided for diagnosing ovarian cancer in a mammalian subject, preferably in a serum or plasma sample of a human subject. The methods and compositions enable the detection or measurement in the sample or from a protein level profile generated from the sample, the protein level of one or more specified biomarkers. Comparing the protein level(s) of the biomarker(s) in the subject's sample or from protein abundance profile of multiple biomarkers, with the level of the same biomarker(s) or profile in a reference standard, permits the determination of a diagnosis of ovarian cancer, or the identification of a risk of developing ovarian cancer, or enables the monitoring of the status of progression or remission of ovarian cancer in the subject followed during a therapeutic protocol. | 05-01-2014 |
20140121128 | METHOD FOR THE PROGNOSIS OF BREAST CANCER BASED ON THE EXPRESSION OF THE GENE PIN1 IN COMBINATION WITH MUTATIONS IN THE GENE TP53 - It is described the influence of the presence of mutations in the TP53 gene in association with high levels of the enzyme prolyl isomerase Pin1 and a molecular signature of 10 genes expression correlated with the expression of Pin1 and p53 for the prognosis of breast tumors. The association between overexpression of Pin1 and the presence of protein p53 mutants induces transcriptional programs which promote tumor aggressiveness and in a cohort of patients the overexpression of Pin1 has proved to influence the prognostic value of the presence of mutations in the gene TP53. The assessment of the expression of Pin1 in the presence of mutations of the gene TP53, together with the detection of the expression of the genes forming the molecular signature can therefore be used for the prognosis of breast cancer. | 05-01-2014 |
20140121129 | Alkylamino BODIPY Dyes As Selective Fluorescent Probes For Proteins And Mouse Embryonic Stem Cells - The present invention discloses a series of alkylamino BODIPY dyes, methods for preparing a library of alkyl-amino BODIPY dyes via solid-phase synthesis, and the use of the alkyl-amino BODIPY dyes as fluorescent sensors for protein detection, cell imaging and cytometry applications, and staining of certain cell line. | 05-01-2014 |
20140121130 | METHOD OF DETERMINING THE PROGNOSIS OF HEPATOCELLULAR CARCINOMAS USING A MULTIGENE SIGNATURE ASSOCIATED WITH METASTASIS - Expression of MYC alone, in a conditional transgenic mouse model of Twist1- and MYC-induced hepatocellular carcinoma (HCC), resulted in tumors that failed to metastasize, whereas Twist1 co-expression with MYC resulted in tumors associated with extra-hepatic metastases to the lymph nodes, spleen, peritoneum, and lungs. Twist1 also caused a marked increase in circulating tumor cells. Combined inactivation of Twist1 and MYC resulted in sustained regression of both primary and metastatic tumors as shown by gross and microscopic pathology, X-ray computed tomography and bioluminescence imaging, as well as the suppression of circulating tumor cells. Through genomic analysis a 20-gene signature comprising 17 up-regulated genes and 3 down-regulated genes has been identified that is highly predictive of metastasis and overall survival in human patients with HCC. Another aspect of the disclosure methods of determining the metastatic status of an hepatocellular carcinoma of a patient, comprising obtaining a first differential gene expression profile from a carcinoma sample from a subject having an hepatocellular carcinoma and creating a report summarizing the normalized data obtained by the first gene expression analysis and including a determination of the metastatic status of the hepatic carcinoma. | 05-01-2014 |
20140121131 | METHOD OF PROTEIN DISPLAY - The present invention relates to methods for screening a polypeptide for desired activity against a target molecule. In particular, the present invention relates to methods for screening a polypeptide for desired activity against a target molecule by expressing the polypeptide in a Gram-negative bacterial cell and permeabilising the cell. The invention also relates to methods of packaging gene libraries in a bacterial cell. | 05-01-2014 |
20140128272 | Method for Inducing Dormancy of Cancer Tissue-Derived Cell Mass and Method for Evaluating Treating Means with the Use of Cancer-Tissue-Derived Cell Mass - Provided are a method for retaining in a dormant state a cancer tissue-derived cell mass that can reflect accurately the in vivo behavior of cancer cells, and an evaluation method for examining the sensitivity to various treatments including a drug sensitivity test by using a cancer tissue-derived cell mass in such a dormant state. The cancer tissue-derived cell mass is prepared from an individual. Such a cancer tissue-derived cell mass is cultured in vitro under the conditions of hypoxia and low levels of growth factors. Furthermore, a treatment with a drug, etc. is applied in vitro to the cancer tissue-derived cell mass in the dormant state so that evaluation is achieved by examination of its proliferation state, determination of life and death, and analysis of signals. | 05-08-2014 |
20140128273 | Metabolic Syndrome and HPA Axis Biomarkers for Major Depressive Disorder - Materials and methods for using combinations of metabolic syndrome and HPA axis biomarkers for monitoring major depressive disorder. | 05-08-2014 |
20140128274 | Methods for Microorganism Detection and Identification - Methods for detecting and identifying microorganisms in a biologic sample are provided. The methods utilize identifying rRNA from microorganisms to both show the presence and identity for the majority of infectious agents present in clinical samples. The methods are preferably adapted for use in a clinical setting. | 05-08-2014 |
20140128275 | COMPLEX OF NON-COVALENTLY BOUND PROTEIN WITH ENCODING NUCLEIC ACIDS AND USES THEREOF - A method of binding a protein to its encoding nucleic acid is disclosed wherein the method of binding is non-covalent at one or more locations between the protein and the encoding nucleic acids. | 05-08-2014 |
20140128276 | CYTOKINE PROFILES AS METHODS FOR DIAGNOSIS AND PROGNOSIS OF IRRITABLE BOWEL SYNDROME - Methods, devices, and kits for diagnosing or evaluating irritable bowel syndrome employ an analysis for the presence and amount of specific cytokines. The levels of such cytokines provide an index for diagnosis and/or evaluation of therapeutic response. Samples to be tested include peripheral blood, serum, plasma, or tissue from a human subject having or suspected of having Irritable Bowel Syndrome. | 05-08-2014 |
20140128277 | Method for Identifying a Subset of Polynucleotides from an Initial Set of Polynucleotides Corresponding to the Human Genome for the In Vitro Determination of the Severity of the Host Response of a Patient - The invention discloses a method for identifying a subset of polynucleotides from an initial set of polynucleotides corresponding to the human genome for the in vitro determination of severity of the host response of a patient having a severe infectious and/or inflammatory condition, in a sample, a measuring device comprising a plurality of different gene probes which represent the entire human genome, the test persons, depending on their infectious and/or inflammatory status, are divided into at least two clinically determined phenotype groups, changes of the gene expression signals between the phenotype groups are compared statistically, and gene probes are selected based on the gene expression signals which have significantly changed statistically between at least two phenotype groups. | 05-08-2014 |
20140128278 | Calibration of Nanostructure Sensors - The present invention relates to uniform nanostructure biosensors and methods of calibrating the response of nanostructure biosensors. The invention overcomes device to device variability that has made quantitative detection difficult. The described biosensors have uniform characteristics that allow for more reliable comparison across devices. The methods of the invention comprise normalizing the initial current rate, as measured by the nanostructure biosensor following the addition of an analyte, to device characteristics of the biosensor. The device characteristics of the biosensor which can be used to normalize the response include baseline current and transconductance. Calibration of responses allows for the generation of calibration curves for use in all devices to quantitatively detect an analyte, without the need for individual device calibration. | 05-08-2014 |
20140128279 | PRIMERS AND PROBES FOR DETECTION AND DISCRIMINATION OF TYPES AND SUBTYPES OF INFLUENZA VIRUSES - Methods of detecting influenza, including differentiating between type and subtype are disclosed, for example to detect, type, and/or subtype an influenza infection. A sample suspected of containing a nucleic acid of an influenza virus, is screened for the presence or absence of that nucleic acid. The presence of the influenza virus nucleic acid indicates the presence of influenza virus. Determining whether the influenza virus nucleic acid is present in the sample can be accomplished by detecting hybridization between an influenza specific probe, influenza type specific probe, and/or subtype specific probe and an influenza nucleic acid. Probes and primers for the detection, typing and/or subtyping of influenza virus are also disclosed. Kits and arrays that contain the disclosed probes and/or primers also are disclosed. | 05-08-2014 |
20140128280 | Synthetic Antibodies - The present invention provides methods for synthetic antibodies, methods for making synthetic antibodies, methods for identifying ligands, and related methods and reagents. | 05-08-2014 |
20140128281 | MICRO-REACTOR ARRAY - The present disclosure provides a cover sheet for a microarray reaction device. In one aspect, the present cover sheet or device ensures the reaction units/volumes are stable and/or consistent among assay samples and assay runs, allowing samples (e.g., reaction solutions) to be conveniently added and distributed uniformly. | 05-08-2014 |
20140128282 | IMMUNE FUNCTION BIOMARKERS - The invention provides biomarkers associated with age related immune function and the use of the biomarkers to identify compositions useful for strengthening immune function in animals and to determine if an animal is responding to treatment targeted to strengthen the immune system. | 05-08-2014 |
20140128283 | Method of Detecting Cancer through Generalized Loss of Stability of Epigenetic Domains, and Compositions Thereof - Provided herein is a method of detecting cancer through generalized loss of stability of epigenetic domains as well as compositions useful therein. The present invention is based on the discovery that generalized loss of stability of epigenetic domains was determined to be a characteristic across various cancer types. Genome-scale bisulfite sequencing of cancers revealed a surprising loss of methylation stability in the cancer methylome, involving both CpG islands and shores, as well as large (up to several megabases) blocks of hypomethylation affecting more than half of the genome, with concomitant stochastic variability in gene expression. | 05-08-2014 |
20140128284 | METHODS AND COMPOSITIONS FOR TREATMENT AND DIAGNOSIS OF FIBROSIS, TUMOR INVASION, ANGIOGENESIS, AND METASTASIS - Provided are methodology, compositions and kits to prevent and treat diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, using processed lysyl oxidase or lysyl oxidase-like protein inhibitors, LOX inhibitors and LOXL inhibitors, or synergistic combinations of such inhibitors with therapeutic agents. Provided are methods for selecting tumor invasion, angiogenesis and metastasis inhibiting agents, by contacting cells in EMT states with candidate agents and detecting changes in such states; and methods, compositions, and kits for diagnosing or monitoring diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, using molecules or agents specifically recognizing processed LOX or LOXL. Provided are methods, compositions, medical devices, systems and kits for preventing or treating diseases and conditions associated with fibrosis, including pathological cardiovascular conditions and diseases, e.g., hypertension, hypertensive heart disease, myocardial infarction, atherosclerosis, restenosis, liver fibrosis, kidney fibrosis, lung fibrosis, dermal scaring, keloid formation, and Alzheimer's disease, with LOX or LOXL inhibitors. | 05-08-2014 |
20140135224 | QUANTITATIVE DIAGNOSTIC METHODS USING MULTIPLE PARAMETERS - Materials and methods related to diagnosing a clinical condition in a subject, or determining the subject's predisposition to develop the clinical condition, using a multi-parameter system to measure a plurality of parameters and an algorithm to determine a disease score. | 05-15-2014 |
20140135225 | BIOMARKERS FOR DISEASE ACTIVITY AND CLINICAL MANIFESTATIONS SYSTEMIC LUPUS ERYTHEMATOSUS - This invention related to methods and assays for screening for, identifying, and predicting the severity and clinical manifestations of systemic lupus erythematosus (SLE). Specifically, this invention provides various biomarkers for the prediction of flares of the disease both in number and severity, as well as clinical manifestations of the disease, and methods of using these biomarkers to correctly subclassify patients with this disease, and prescribe appropriate treatment. The invention also provides for biomarkers of lupus disease activity, i.e., flares, as well as biomarkers for the prediction of future flares, and methods of using these biomarkers. The invention also provides, in these biomarkers, targets and methods for drug development and basic research for SLE. | 05-15-2014 |
20140135226 | DISPLAY LIBRARY PROCESS - Disclosed are methods for identifying desired members from a display libraries, including bacteriophage display libraries. Display library members can be amplified in the presence of a target compound so that cycles of selection can be rapidly completed. | 05-15-2014 |
20140135227 | USE OF PERIOSTIN AS A NOVEL BIOMARKER - The invention provides, in certain embodiments, a method of detecting an indicator of renal injury or renal disease. The method entails assaying a urine sample for periostin, wherein the presence of periostin at an elevated level indicates the presence and/or degree of renal injury or renal disease. Also provided, are methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment. | 05-15-2014 |
20140135228 | Method for the Cytological Analysis of Cervical Cells - The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose cervical cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3 and chromosome 5 using FISH analysis of probes targeted to 3q and/or 5p. | 05-15-2014 |
20140135229 | Method and System for Automated Image Analysis in Cancer Cells - A method of screening for the presence and/or extent of a pathology in a subject, the pathology characterized by an abnormal chromosomal component in a cell of the subject, comprising the steps of: contacting a biological sample comprising cell nuclei from said subject with, one or more distinguishable labeled probes directed to at least one chromosomal sequence that characterizes the abnormality under conditions that promote hybridization of the one or more probes to the at least one sequence, automatically obtaining a representation of the one or more distinguishable labels hybridized to the chromosomal sequences, automatically analyzing the distribution and intensity of binding of the one or more labels in the representation to determine the presence and/or extent of an abnormal chromosomal component; and automatically reporting results of the analysis; wherein the steps are carried out without intervention by a human. | 05-15-2014 |
20140135230 | Lipoparticles Comprising Proteins, Methods Of Making, And Using The Same - The present invention relates to lipoparticles. The invention also relates to producing lipoparticles. The invention further relates to lipoparticles comprising a viral structural protein. The invention further relates to a lipoparticle comprising a membrane protein, and the lipoparticle can be attached to a sensor surface. The invention further relates to methods of producing and using the lipoparticle to, inter alia, assess protein binding interactions. | 05-15-2014 |
20140135231 | Population Scale HLA-Typing and Uses Thereof - The present invention provides a portable system for real-time population-scale HLA genotyping and/or allelotyping in a field environment and methods of such population-scale HLA genotyping. The individual components of the system are portable to and operable within a field environment thereby providing high throughput with real-time geno- or allelotyping. Also provided are HLA gene-specific primers and HLA allele-specific or single nucleotide polymorphism-specific hybridization probes. In addition the present invention provides a microarray comprising the hybridization probes. Further provided is a kit comprising the HLA gene-specific primers and the microarray. | 05-15-2014 |
20140135232 | METHODS AND MATERIALS FOR DETERMINING THE EFFICACY OF PROSTATE CANCER THERAPIES - Methods for monitoring, and determining the efficacy of, a treatment for prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in biological samples obtained from the subject prior to, and during, a course of treatment. Specific patterns of changes in the expression of the polypeptide biomarkers are indicative of the effectiveness of the treatment in the subject. | 05-15-2014 |
20140135233 | COMPOSITIONS AND METHODS FOR PREPARING OLIGONUCLEOTIDE SOLUTIONS - The present invention is directed to methods and compositions for generating a pool of oligonucleotides. The invention finds use in preparing a population or subpopulations of oligonucleotides in solution. The pool of oligonucleotides finds use in a variety of nucleic acid detection and/or amplification assays. | 05-15-2014 |
20140141984 | System And Method For Authentication and Tamper Detection Using Nucleic Acid Taggants - Methods for authenticating and/or detecting tampering of an item of interest using a nucleic acid tag. A nucleic acid tag comprising a nucleotide-support platform attached to a nucleic acid molecule is created or obtained and then sealed within or on the item of interest. The surface of the item of interest is sampled for the presence of the seeded tag after the item of interest has been moved from one location to another or has been stored for a period of time, during which tampering can occur and/or authentication may necessary. The presence of the tag can indicate that tampering has occurred, or that the item of interest is authentic. | 05-22-2014 |
20140141985 | BIOMARKERS OF THERAPEUTIC RESPONSIVENESS - The present invention relates to methods of diagnosing a kidney disorder in a patient, as well as methods of monitoring the progression of a kidney disorder and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein. | 05-22-2014 |
20140141986 | CIRCULATING BIOMARKERS - Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease. Circulating biomarkers can be detected and optionally used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles. Biomarkers can be assessed for diagnostic, prognostic or theranostic purposes, e.g., to select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Examples of useful circulating biomarkers include polypeptides, nucleic acids (e.g., DNA, mRNA, microRNA) and vesicles. | 05-22-2014 |
20140141987 | METHOD FOR DIAGNOSING ARRHYTHMIA BASED ON SINGLE NUCLEOTIDE POLYMORPHISM IN CHROMOSOME 1Q24, NEURL GENE, OR CUX2 GENE - A method for diagnosing arrhythmia such as atrial fibrillation is provided. A single nucleotide polymorphism present in the region 24 of the long arm of the chromosome 1, NEURL gene, or CUX2 gene is analyzed, and the risk of developing arrhythmia and/or the presence or absence of the onset of arrhythmia is diagnosed on the basis of the analysis result. | 05-22-2014 |
20140141988 | Systems And Compositions For Diagnosing Barrett's Esophagus And Methods Of Using The Same - The invention provides a system, composition, and methods of using the systems and compositions for the analysis of a sample from a subject to accurately diagnose, prognose, or classify the subject with certain grades of or susceptibility to Barrett's esophagus. In some embodiments, the system of the present invention comprises a means of detecting and/or quantifying morphological features, the expression of protein, or the expression of nucleic acids in a plurality of cells and correlating that data with a subject's medical history to predict clinical outcome, treatment plans, preventive medicine plans, or effective therapies. In some embodiments, the invention relates to a method of classifying and compiling data taken from a cell sample from a subject analyzing the data, and converting the data from the system into a score by which a pathologist may calculate the likelihood that the subject develops cancer. | 05-22-2014 |
20140141989 | MULTIPLEXED IDENTIFICATION OF NUCLEIC ACID SEQUENCES - A method for the rapid identification of a target nucleic acid sequence is provided, as well as corresponding devices, products and kits. Such methods are useful for the rapid detection, identification and/or quantification of target nucleic acid sequences associated with, for example, a pathogen. | 05-22-2014 |
20140141990 | PERFORMANCE OF A BIOMARKER PANEL FOR IRRITABLE BOWEL SYNDROME - The present invention provides a method of using a panel of serological and genetic biomarkers to distinguish IBS subjects from healthy subjects and/or to differentiate IBS subtypes from each other. The present invention also provides a method of using one or more psychological measures of a subject in conjunction with a panel of serological and/or genetic biomarkers to further aid in diagnosing IBS or discriminating IBS subtypes from each other. | 05-22-2014 |
20140141991 | HIGH THROUGHPUT DETECTION OF FUSION PROTEINS - A method and related microfluidic chip and kit for high throughput detection of proteins of interest contained in a sample is disclosed. The method comprises of specifically labeling fusion proteins in a complex sample with fusion tag specific fluorophores that specifically bind the fusion tags coupled to the proteins of interest, and subjecting the sample to automated capillary electrophoresis, wherein the presence of the proteins of interest in the sample is detected by fluorescence signals associated with the fusion tag specific fluorophores. | 05-22-2014 |
20140141992 | NEOEPITOPE DETECTION OF DISEASE USING PROTEIN ARRAYS - A biosensor for use in detecting the presence of diseases, the biosensor comprising a detector for detecting a presence of at least one marker indicative of a specific disease. A method of determining efficacy of a pharmaceutical for treating a disease or staging disease by administering a pharmaceutical to a sample containing markers for a disease, detecting the amount of at least one marker of the disease in the sample, and analyzing the amount of the marker in the sample, whereby the amount of marker correlates to pharmaceutical efficacy or disease stage. Markers for gynecological disease. An immune-imaging agent comprising labeled antibodies, whereby the labeled antibodies are isolated and reactive to proteins overexpressed in vivo. Informatics software for analyzing the arrays, the software including analyzing means for analyzing the arrays. | 05-22-2014 |
20140141993 | METHOD FOR DETECTING FUNGI, REACTION SOLUTION FOR PCR, AND CARRIER FOR DETECTING FUNGI - A method for detecting fungi includes amplifying DNA fragments containing target regions in fungal DNA to confirm the presence or absence of an amplified product. As the target regions, both of the ITS region and the β-tubulin gene are used, and by using a primer set for amplifying the β-tubulin gene and a primer set for amplifying the ITS region in a reaction solution for PCR for amplifying the target regions, both of the target regions are simultaneously amplified according to one or two or more types of fungi. | 05-22-2014 |
20140141994 | Protein Scaffolds - The invention provides protein scaffolds and methods of preparing, screening, engineering and using such protein scaffolds. | 05-22-2014 |
20140141995 | IMMUNOASSAY - The invention provides a method of quantifying multiple antigen-specific immunoglobulins in a test sample, the method comprising utilising a serial dilution of anti-immunoglobulin antibodies, fragments or derivatives thereof, immobilised on a solid support in combination with a serial dilution of a reference sample of immunoglobulin to generate multiple binding capacity curves. Such binding capacity curves are matched to specific dose response curves generated for each specific antigen to be tested using serum samples of known reactivity to those antigens to provide a calibration system that enables more accurate analysis of antigen-specific immunoglobulin in a sample. The invention also provides methods for calibrating a device suitable for assaying multiple antigen-specific immunoglobulins binding to multiple antigens or fragments thereof immobilised on a solid support. A multi-allergen test system and kits for use in the methods are also provided. | 05-22-2014 |
20140141996 | Methods and Compositions for the Treatment and Diagnosis of Cancer - Embodiments of the disclosure are directed to methods of diagnosis, prognosis and treatment of cancer. In some embodiments, the methods include targeting a marker that is expressed at abnormal levels in bladder cancer tissue in comparison to normal somatic tissue. Some embodiments are directed to methods of treating cancer comprising administering a composition including a therapeutic that affects the expression or function of a target marker. Some embodiments are directed to methods of detecting cancer comprising detecting a level of a target marker associated with the cancer, | 05-22-2014 |
20140141997 | FOETAL NUCLEATED RED BLOOD CELL DETECTION - In one aspect, the invention is directed to methods of separating foetal nucleated red blood cells (FNRBCs) from a sample comprising contacting the sample with an agent that specifically recognizes CD147, thereby producing a mixture; maintaining the mixture under conditions in which a complex forms between the agent and the CD147 in the sample; and separating the complex from the mixture; thereby separating the FNRBCs from the sample. In other embodiments, the invention is directed to methods of detecting FNRBCs in a sample comprising contacting the sample with an antibody or antigen binding fragment thereof that specifically binds CD147, thereby producing a combination; maintaining the combination under conditions in which an immune complex forms between the antibody and FNRBCs present in the sample; and detecting whether the immune complex forms in the combination; wherein if the immune complex is detected then FNRBCs are present in the sample. In still other aspects, the invention further comprises methods of separating FNRBCs from anucleated RBCs, detecting prenatal disorders and/or the gender of a foetus. | 05-22-2014 |
20140141998 | NEOPLASIA SCREENING COMPOSITIONS AND METHODS OF USE - As described in more detail below, the present invention generally features compositions and non-invasive methods useful for the screening, identification, monitoring, or diagnosis of subjects having a neoplasia. The invention further provides highly accurate non-invasive methods for the staging or selection of treatment for a bladder, renal, or prostate cancer in a subject. | 05-22-2014 |
20140141999 | Method for Chip-Integrated Label-Free Detection and Absorption Spectroscopy with High Throughput, Sensitivity, and Specificity - Systems and methods for chip-integrated label-free detection and absorption spectroscopy with high throughput, sensitivity, and specificity are disclosed. The invention comprises packaged chips for multiplexing photonic crystal waveguide and photonic crystal slot waveguide devices. Other embodiments are described and claimed. | 05-22-2014 |
20140148350 | CIRCULATING BIOMARKERS FOR DISEASE - Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease. Circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles. Biomarkers can be used for theranostic purposes to select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. The biomarkers can be circulating biomarkers, including vesicles and microRNA. | 05-29-2014 |
20140148351 | Prediction of Clinical Outcome in Hematological Malignancies Using a Self-Renewal Expression Signature - Methods, compositions, and kits are provided for providing a diagnosis, a prognosis, or a prediction of responsiveness to a therapy for a patient with a hematological malignancy. In practicing the subject methods, the expression level of at least one leukemia stem cell (LSC) genes in a tissue sample is assayed to obtain an LSC expression representation. The LSC expression representation is then employed to determine if an individual has a hematological malignancy, to provide a prognosis to a patient with a hematological malignancy, and/or to provide a prediction of the responsiveness of a patient with a hematological malignancy to a therapy. Also provided are screening methods for identifying novel therapies for patients with a hematological malignancy, and compositions and kits for use in these screening methods. | 05-29-2014 |
20140148352 | MID-INFRARED IMAGING OF MICROARRAYS - Described herein are methods for mid-infrared imaging of nucleic acid microarrays by employing mid-infrared reflective labels combined with detection in the reflection mode. The methods described herein provide intrinsic image contrast, and permit detection of DNA microarray hybridization on infrared absorbing substrates such as glass slides. | 05-29-2014 |
20140148353 | PROTEIN EXPRESSION-BASED CLASSIFIER FOR PREDICTION OF RECURRENCE IN ADENOCARCINOMA - A method for making a prognosis for a patient afflicted with a type of cancer which comprises (a) determining in a sample of a tumor from the patient a level of expression for at least three biomarkers from the following group: thyroid transcription factor-1 (TTF1), signal transducer and activator of transcription-3 (STAT-3), beta-catenin and cyclin D1; (b) calculating a score based on the levels of expression determined in step (a); (c) correlating the score obtained in step (b) with a series of predetermined reference scores associated with a series of prognoses; so as to thereby make a prognosis for the patient. | 05-29-2014 |
20140148354 | METHODS AND COMPOSITIONS FOR IDENTIFYING MINIMAL RESIDUAL DISEASE IN ACUTE LYMPHOBLASTIC LEUKEMIA - This invention provides methods and kits for diagnosing, ascertaining the clinical course of minimal residual disease associated with acute lymphoblastic leukemia (ALL). Specifically the invention provides methods and kits useful in the diagnosis and determination of clinical parameters associated with diseases associated with ALL based on patterns of surface marker expression unique to ALL. | 05-29-2014 |
20140148355 | COMPOSITIONS AND METHODS FOR ANALYSIS OF H3K4 METHYLATED CHROMATIN - The present invention relates to polypeptides that bind to H3K4 methylated chromatin, and in particular to the use of reagents comprising such polypeptides for epigenetic/epigenomic analysis. | 05-29-2014 |
20140148356 | APPARATUS AND METHOD FOR SINGLE-CYCLE SELECTION OF APTAMERS - A method for single-cycle selection of aptamers is provided. More specifically, a method comprising single-cycle selection of aptamers for proteins blotted on a membrane is provided. In some embodiments, the present methods can comprise a deoxyribonuclease I (DNase I) mediated aptamers selection strategy that may be capable of isolating strong binding aptamers for target proteins from a crude protein extract. Aptamers selected using the present method are further provided. More specifically, the presently selected aptamers may be thermally stable, modifiable and easily produced through single-cycle synthesis process. The present aptamers may provide unique affinity reagents for use in diagnosing and detecting infectious disease (for example Hepatitis B), for research and biochemical studies (e.g. into molecular mechanisms). Further, the present aptamers may be utilized to develop unique assays or kits for clinical application, such as monitoring disease treatment and outcome. | 05-29-2014 |
20140148357 | Characterizing Gastro-Intestinal Disease - A method for characterizing a gastro-intestinal disease in a subject involves comparing ratios of expression levels of genes in a biological sample from a subject to references, wherein the gastro-intestinal disease is characterized based on a difference in the ratios of the expression values of genes in the biological sample from the subject as compared to the references. | 05-29-2014 |
20140148358 | SYSTEM AND METHOD FOR DETECTING ONE OR MORE ANALYTES IN A FLUID - Various embodiments provide a system for detecting one or more analytes in a fluid. The system comprises: a controller adapted to obtain one or more sample streams of the fluid. The controller is configured in use to form a plurality of output streams. Each output stream comprises at least part of one of the one or more sample streams. The system further comprises: a detector adapted to receive from the controller the plurality of output streams and comprising a plurality of sensors. Each sensor is operable to detect an interaction between a corresponding detecting agent and a corresponding analyte. The detector is configured in use to detect one or more said interactions using the plurality of output streams to determine if the fluid contains one or more said analytes. A corresponding method is also provided. | 05-29-2014 |
20140148359 | MULTI-NUCLEIC-ACID AMPLIFICATION REACTION TOOL - According to one embodiment, a multi-nucleic-acid amplification reaction tool includes a support and a plurality of types of primer sets. The support is configured to be able to support a reaction field of a liquid phase. A plurality of types of primer sets are fixed in a releasable state, for each type, on mutually independent fixing regions of at least a surface of the support, which is in contact with the reaction field, when the liquid phase forms the reaction field. A plurality of types of primer sets are configured to amplify the respectively corresponding target sequences. | 05-29-2014 |
20140155281 | Method of assessing infection status - The present invention relates to a method for assessing the infection status of a subject and in particular to a method for assessing the infection status of a subject by analysing the cellular and/or humoral composition of breastmilk from said subject. The invention has been developed primarily for use as a method for detecting infection in a breastfeeding mother and/or infant. | 06-05-2014 |
20140155282 | METHODS OF DETERMINING STABILIZATION COMPOUNDS FOR PREDICTIVE BIOMARKERS - Methods of determining stabilization compounds for predictive biomarkers. According to at least one embodiment of a method of the present disclosure, the method comprises introducing a diagnostic marker and a stabilization agent to a detection platform, mixing the diagnostic marker and stabilization agent, and determining their binding characteristics. Additionally, the method may further comprise generating a report based on the binding characteristics and delivering the report to a recipient. | 06-05-2014 |
20140155283 | MICROARRAY FOR DETECTING VIABLE ORGANISMS - A methodology of microarray using the fluorescent DNA intercalating agent propidium monoazide (PMA) to selectively block DNA of dead cells from amplification and its application in detecting and enumerating viable microbes in complex microbial communities is described. A phylogenetic array is used in the preferred embodiment to enhance the sensitivity of the method. The PMA-Microarray assay is particularly applicable for monitoring samples from environments with extremely low microbial burden such as spacecraft surfaces. | 06-05-2014 |
20140155284 | SYSTEM FOR IDENTIFICATION OF MICROORGANISM AND DETECTION OF INFECTIOUS DISEASE - Methods for the identification of microorganisms or infectious disorders are disclosed, comprising obtaining a suitable sample from sources such as persons, animals, plants, food, water or soil. The methods also comprise providing tailored nucleic acid substrate(s) designed to react with a type 1 topoisomerase from one or more microorganism(s) or infectious agent(s), and incubating said substrate with said sample, or extracts or preparations from the sample, so that the substrate is processed by said topoisomerase if said microorganism(s) or infectious agent(s) is present in the sample. Microfluidic-implemented methods of detecting an enzyme, in particular a DNA-modifying enzyme, are also provided, as well as methods for detecting a cell, or a microorganism expressing said enzyme. The enzyme is detected by providing a nucleic acid substrate, which is specifically targeted by that enzyme. | 06-05-2014 |
20140155285 | NOVEL CELL LINE SCREENING METHOD - The invention provides a novel cell line development method useful to screen for recombinant protein production. The method utilizes a membrane-anchored reporter or an intracellular reporter residing in the expression vector for a gene of interest to facilitate initial cell selection by FACS or MACS. A switching mechanism can be used to delete the reporter from the chromosome by providing an appropriate DNA recombinase, which turns the selected cells into production cells that secrete the protein of interest without co-expression of the reporter. | 06-05-2014 |
20140155286 | MODIFIED TYROSINE AMINO ACIDS, PEPTIDES CONTAINING THEM, AND THEIR USE FOR DETECTING HYDROLASE ENZYME ACTIVITY - The present invention relates to a method and tools which allow the kinetic monitoring of hydrolase enzyme activity. The present invention also aims to provide synthetic peptides and peptide residues modified such that they can be used in assays for monitoring hydrolase enzyme activity, and preferably phosphatase activity. Also claimed are modified tyrosine amino acid derivatives of formula (IV), wherein Y is chosen from —PO | 06-05-2014 |
20140155287 | METHODS AND COMPOSITIONS FOR ASSESSMENT OF PULMONARY FUNCTION AND DISORDERS - The present invention provides methods for the assessment of risk of developing lung cancer in smokers and non-smokers using analysis of genetic polymorphisms. The present invention also relates to the use of genetic polymorphisms in assessing a subject's risk of developing lung cancer, and the suitability of a subject for an intervention in respect of lung cancer. Nucleotide probes and primers, kits, and microarrays suitable for such assessment are also provided. | 06-05-2014 |
20140155288 | METHODS FOR DIAGNOSING CANCER - The invention provides cDNAs which encodes a signal peptide-containing proteins. It also provides for the use of a cDNA, protein, and antibody in the diagnosis, prognosis, treatment and evaluation of therapies for cancer. The invention further provides vectors and host cells for the production of the protein and transgenic model systems. | 06-05-2014 |
20140155289 | NUCLEIC ACID ANALYSIS METHOD - Embodiments relate to a method of analyzing nucleic acid. The nucleic acid analysis method includes subjecting a sample to an amplifying reaction using first and second primers, reacting an amplification product with a nucleic acid probe, measuring presence/absence of hybridization and/or a quantity thereof, and determining presence/absence of a target nucleic acid in the sample and/or a quantity of target nucleic acid. The amplification product obtained with the first or second primer forms a stem-and-loop structural body. With the detection of the presence/absence of the hybridization between a nucleic acid probe for the loop structure and the amplification product, and/or the amount thereof, the nucleic acid analysis is carried out on the sample. | 06-05-2014 |
20140155290 | HOST CELLS COMPRISING ALPHA 1, 2 MANNOSIDASE AND CULTURE METHODS THEREOF - Improved host cells and culture methods involving overexpression of MAN1C1 activity to improve protein production are provided. | 06-05-2014 |
20140155291 | Method for Identifying Lineage-Related Antibodies - In certain embodiments, the method may comprise: a) obtaining the antibody sequences from a population of B cells; b) grouping the antibody sequences to provide a plurality of groups of lineage-related antibodies; c) testing a single antibody from each of the groups in a bioassay and, after the first antibody has been identified, d) testing further antibodies that are in the same group as the first antibody in a second bioassay. In another embodiment, the method may comprise: a) testing a plurality of antibodies obtained from a first portion of an antibody producing organ of an animal; b) obtaining the sequence of a first identified antibody; c) obtaining from a second portion of said antibody producing organ the sequences of further antibodies that are related by lineage to said first antibody; and, c) testing the further antibodies in a second bioassay. | 06-05-2014 |
20140162888 | CIRCULATING BIOMARKERS FOR DISEASE - Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease. Circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles. Biomarkers can be used for theranostic purposes to select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. The biomarkers can be circulating biomarkers, including vesicles and microRNA. | 06-12-2014 |
20140162889 | COMPOSITION OR KIT FOR MAKING A PROGNOSIS OF LIVER CANCER, AND METHOD FOR MAKING A PROGNOSIS OF LIVER CANCER - The present disclosure provides a marker for predicting prognosis of liver cancer, a composition or kit for predicting prognosis of liver cancer, preferably, a composition or kit for predicting prognosis of liver cancer for predicting the prognosis according to the stage of liver cancer. The marker, composition or kit, and method of the present disclosure make it possible to effectively predict prognosis of liver cancer, preferably, prognosis of liver cancer according to stage. | 06-12-2014 |
20140162890 | METHODS FOR PREPARING MONOCLONAL ANTIBODIES RECOGNIZING GLYCAN BINDING SITE AS AN EPITOPE - The present disclosure relates to a method for producing a monoclonal antibody that binds to an epitope for the glycan binding site of a glycoprotein. According to the present disclosure, a monoclonal antibody that recognizes the glycan binding site of a glycoprotein as an epitope can be produced in a relatively simple and economic manner, and a monoclonal antibody having high sensitivity and specificity for the glycan binding site of a glycoprotein can be produced. The monoclonal antibody produced according to the present disclosure can be effectively used as an agent for diagnosing or treating various diseases associated with a change in glycan structure or glycan expression level. | 06-12-2014 |
20140162891 | METHODS AND MATERIALS FOR DETECTION, DIAGNOSIS AND MANAGEMENT OF OVARIAN CANCER - The subject invention concerns methods using a panel of proteins to detect, diagnose, and monitor therapy during treatment of ovarian cancer in a female patient. The proteins were identified using proteomics analyses of plasma samples obtained preoperatively from ovarian cancer patients versus those of healthy control women. Such a panel has utility for the diagnosis of ovarian cancer, screening for ovarian cancer and possibly therapeutic monitoring. | 06-12-2014 |
20140162892 | Parallel polymer sequencing mothods - The present invention relates to a method of sequencing a target polynucleotide by enzymatic and/or chemical means. The sequencing method includes a method for characterizing multiple alleles in a sample, a method of calculating confidence levels in ascertained sequences, a method for comparing polynucleotide sequences and a method of resolving ambiguities in a polynucleotide sequence. It also provides methods for appropriately preparing samples, for immobilising template molecules, for organising the template molecules and to conduct the sequencing of many molecules in parallel. The method involves analysing molecules as members of an array. Many target polynucleotides or many segments of a single target polynucleotide can be sequenced simultaneously. In a preferred embodiment the method involves analysing individual molecules within an array and base calls are based on the signals from two or more molecules. A method to prevent non-specific signal in sequencing is also provided. The invention is readily automated, both for small-scale and large-scale operation and relevant algorithms and the composition of kits and systems are provided. | 06-12-2014 |
20140162893 | Aptamer Coated Measurement and Reference Electrodes and Methods Using Same for Biomarker Detection - A device for identifying the presence of a specific target molecule or biomarker by the detection of a change in an electrical property includes a measurement sensor | 06-12-2014 |
20140162894 | METHODS AND COMPOSITIONS FOR SCREENING AND TREATING DEVELOPMENTAL DISORDERS - This document provides methods and materials related to genetic variations of developmental disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Autism Spectrum Disorder. | 06-12-2014 |
20140162895 | SYSTEM, COMPUTER PROGRAM AND METHOD FOR DETERMINING BEHAVIOR OF THYROID TUMOR - The invention provides a system adapted to a method for determining behavior of thyroid tumor. The system comprises a processor, and a memory, under control of said processor, including software instructions adapted to enable the system to perform operations. | 06-12-2014 |
20140162896 | COMPOSITIONS AND METHODS FOR GENOTYPING CES1 GENETIC VARIANTS AND USE THEREOF - The invention features compositions and methods that are useful for genotyping CES1 isoforms (CES1A1, CES1A2, CES1A3). The ability to specifically genotype one or more CES1 isoforms (e.g. CES1A1) is useful for assessing drug metabolism in a subject and guiding treatment selection. | 06-12-2014 |
20140162897 | TRANSPOSON END COMPOSITIONS AND METHODS FOR MODIFYING NUCLEIC ACIDS - The present invention provides methods, compositions and kits for using a transposase and a transposon end for generating extensive fragmentation and 5′-tagging of double-stranded target DNA in vitro, then using a DNA polymerase for generating 5′- and 3′-tagged single-stranded DNA fragments without performing a PCR amplification reaction, wherein the first tag on the 5′-ends exhibits the sequence of the transferred transposon end and optionally, an additional arbitrary sequence, and the second tag on the 3′-ends exhibits a different sequence from the sequence exhibited by the first tag. The method is useful for generating 5′- and 3′-tagged DNA fragments for use in a variety of processes, including processes for metagenomic analysis of DNA in environmental samples, copy number variation (CNV) analysis of DNA, and comparative genomic sequencing (CGS), including massively parallel DNA sequencing (so-called “next-generation sequencing.) | 06-12-2014 |
20140162898 | Method for Detecting Variations in Nucleic Acid Sequences - The present invention relates to a method and a kit for detecting nucleic acid sequence variation using melting curve analysis, especially relates to a method and a kit for detecting nucleic acid sequence variation by melting curve analysis using self-quenched probe. Said method provides the characteristics of the self-quenched probe employed, as well as the corresponding nucleic acid amplification conditions, so that the probe can bind to the amplified target sequence, and variations of the target sequence can be detected by melting curve analysis. The present invention also encompasses a kit assembled according to the method described. | 06-12-2014 |
20140162899 | CANCER PROGRESSION OBSERVATION INDEX GENE GROUP AND METHOD OF DETECTING THE GENE GROUP - Provided are a cancer progression observation index gene group and a method of detecting the gene group. The gene group includes cancer progression observation index genes increased or decreased when high- or low-dose radiation is performed on a mouse in which an oncogene is inserted into a thymocyte, for example, Itgb3 and Igf1 increased due to low-dose radiation to suppress the conversion of the thymocyte into a cancer cell, and Itga4, Itgb1, Itgav, Itga6, Itgb4, Raf, Myc, Fos, Trp53 and Apaf1 decreased due to high-dose radiation to stimulate the conversion of the thymocyte into a cancer cell. The gene group and the method may be used to clearly define a cancer progression observation index specifically responding to radiation. | 06-12-2014 |
20140171333 | METHOD TO OBTAIN OPTICAL MEANS ADAPTED TO A HUMAN INDIVIDUAL SUFFERING OR SUSCEPTIBLE TO SUFFER FROM ONE OR MORE GENETIC RELATED EYE DISORDER(S) OR DISEASE(S) - The present invention is related to a method comprising the step of performing a complete, partial or targeted sequencing of the genome or the epigenome of a biological sample obtained from the said individual, obtaining a genetic analysis by comparing every genetic modification present in the said sample genome or epigenome with the sequenced genome of individuals not affected by the genetic related eye disorder(s) or disease(s), and from the said previous genetic analysis, obtaining for the said individual, optical means able to prevent, correct or reduce the symptoms associated with the detected disorder(s) or disease(s). | 06-19-2014 |
20140171334 | GENE ANALYSIS METHOD USING SDL-PCR - The present invention relates to a method for analyzing genes using SDL-PCR (separation of displaced ligation probe-based PCR), and more particularly to a method for analyzing genes using SDL-PCR, in which probes comprising a nucleotide sequence complementary to the gene of interest are ligated with each other by ligase, and another probe capable of hybridizing to the probes is hybridized and extended, thereby preparing a template probe, and the template probe for the gene of interest is amplified using universal primers. | 06-19-2014 |
20140171335 | PREDICTIVE RENAL SAFETY BIOMARKERS AND BIOMARKER SIGNATURES TO MONITOR KIDNEY FUNCTION - Biomarker signatures were identified which can be used to diagnose or predict kidney or liver toxicity and more specifically renal tubular toxicity as a consequence of disease or drug treatment. | 06-19-2014 |
20140171336 | Methods and Kits Using Extended Rhodamine Dyes - Extended rhodamine compounds exhibiting favorable fluorescence characteristics having the structure | 06-19-2014 |
20140171337 | METHODS AND DEVICES FOR ASSESSING RISK OF FEMALE INFERTILITY - The invention generally relates to methods and devices for assessing risk of female infertility. In certain aspects, methods of the invention involve obtaining a sample, conducting an assay on at least one infertility-associated biomarker, and assessing risk to the patient of developing early-onset decrease in fertility based upon results of the assay. | 06-19-2014 |
20140171338 | METHODS AND COMPOSITIONS FOR DETECTING TARGET NUCLEIC ACIDS - The present invention provides compositions, apparatuses and methods for detecting one or more nucleic acid targets present in a sample. Methods of the invention include utilizing two or more ligation probes that reversibly bind a target nucleic acid in close proximity to each other and possess complementary reactive ligation moieties. When such probes have bound to the target in the proper orientation, they are able to undergo a spontaneous chemical ligation reaction that yields a ligation product that is directly detected or that is amplified to produce amplicons that are then detected. The present invention also provides methods to stabilize sample RNA so that degradation does not significantly affect the results of the analysis. | 06-19-2014 |
20140171339 | METHODS AND KITS FOR DETECTING ADENOMAS, COLORECTAL CANCER, AND USES THEREOF - This invention is directed to a novel method to detect adenomas and colorectal cancer (CRC) using a bacterial signature. Included in the invention are methods of (a) determining an individual's risk developing adenomas or CRC; (b) determine whether or not a patient should have a colonoscopy; (c) differential diagnosis; (d) staging; (e) selecting therapies; (f) monitoring therapies; (g) patient surveillance; and (h) drug screening. Kits and reagents for detecting adenomas and CRC and/or drug screening are also part of the invention. | 06-19-2014 |
20140171340 | METHODS FOR RAISING ANTIBODIES - The present invention generally relates to methods of generating antibodies against a species of pathogen that involve identifying the pathogen that is most genetically representative of member of pathogen species and using the identified pathogen to generate an antibody. | 06-19-2014 |
20140179540 | MODIFYING PROTEINS (GPCR), LIGANDS, AND NANOPORE SURFACES TO ALLOW THE DETECTION OF CREATE BINDING-INDUCED MOLECULAR CHANGES OF PROTEIN-LIGAND COMPLEXES WITH NANOCHANNEL TRANSLOCATION - A mechanism is provided for utilizing a nanodevice to distinguish molecules with different structure. The molecules translocate through or across a nanochannel filled with a electrolyte solution. An electrical signal through the nanochannel is measured for every translocation event. Inner surfaces of the nanochannel include a functional layer, which is a coating to functionalize the nanochannel, in which the functional layer is configured to interact with predetermined ones of the molecules during translocation events. It is determined that a combination of at least two different molecules is formed based on predetermined ones of the molecules interacting with the functional layer to change the electrical signal and/or change a translocation time for the translocation event. | 06-26-2014 |
20140179541 | MODIFYING SINGLE PROTEINS (GPCR), LIGANDS, AND NANOPORE SURFACES TO CREATE BINDING-INDUCED MOLECULAR CHANGES OF PROTEIN-LIGAND COMPLEXES DETECTED IN NANOCHANNEL TRANSLOCATION - A mechanism is provided for utilizing a nanodevice to distinguish molecules with different structure. The molecules translocate through or across a nanochannel filled with a electrolyte solution. An electrical signal through the nanochannel is measured for every translocation event. Inner surfaces of the nanochannel include a functional layer, which is a coating to functionalize the nanochannel, in which the functional layer is configured to interact with predetermined ones of the molecules during translocation events. It is determined that a combination of at least two different molecules is formed based on predetermined ones of the molecules interacting with the functional layer to change the electrical signal and/or change a translocation time for the translocation event. | 06-26-2014 |
20140179542 | METHODS FOR RAPIDLY IDENTIFYING SMALL ORGANIC MOLECULE LIGANDS FOR BINDING TO BIOLOGICAL TARGET MOLECULES - The present invention is directed to novel methods for rapidly and unambiguously identifying small organic molecule ligands for binding to biological target molecules. Small organic molecule ligands identified according to the methods of the present invention may find use, for example, as novel therapeutic drug lead compounds, enzyme inhibitors, labeling compounds, diagnostic reagents, affinity reagents for protein purification, and the like. Also presented are novel methods for identifying high affinity binding ligands for a biological target molecule of interest, wherein those methods comprise linking two or more small organic molecule ligands previously identified as being capable of binding to the biological target molecule of interest. Biological target molecules include, for example, polypeptides, nucleic acids, carbohydrates, nucleoproteins, glycoproteins, glycolipids and lipoproteins. | 06-26-2014 |
20140179543 | IDENTIFICATION OF SMALL-MOLECULE CANDIDATE THERAPEUTICS CAPABLE OF INHIBITING OR INTERFERING WITH A TARGET PROTEIN-PROTEIN INTERACTION - The present invention provides a method of screening method small-molecule candidate therapeutics capable of inhibiting or interfering with intracellular protein-protein interactions, such as cancer associated oncogenic protein interactions and in particular RAS and LMO2 protein-protein interactions. The present invention also provides methods and assays for rationalized drug design based on identifying small molecular weight protein-protein interaction inhibitor molecules that emulate antibody therapeutics products. | 06-26-2014 |
20140179544 | COMPOSITIONS, SYSTEMS AND METHODS FOR DROPLET FORMATION, SPACING AND DETECTION - The present disclosure provides assays and devices for forming, spacing, and/or detecting droplets. The droplets may be emulsions composed of two or more immiscible fluids. An emulsion can be a double emulsion, such as water-in-oil droplets that are present in a continuous aqueous phase. The double emulsion can be formed when the water-in-oil droplets are contacted with one or more streams of aqueous fluid(s). This disclosure also provides a variety of additives that can be added to the fluids. | 06-26-2014 |
20140179545 | Diagnosis, Prognosis and Identification of Potential Therapeutic Targets of Multiple Myeloma Based on Gene Expression Profiling - Gene expression profiling is a powerful tool that has varied utility. It enables classification of multiple myeloma into subtypes and identifying genes directly involved in disease pathogensis and clinical manifestation. The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myleoma. It is further contemplated that therapeutic strategies that directly target CKS1B or related pathways may represent novel, and more specific means of treating high risk myeloma and may prevent its secondary evolution. | 06-26-2014 |
20140179546 | GENETIC VARIANTS ON CHR 5P12 AND 10Q26 AS MARKERS FOR USE IN BREAST CANCER RISK ASSESSMENT, DIAGNOSIS, PROGNOSIS AND TREATMENT - The invention pertains to certain genetic variants on Chr5p12 and Chr10q26 as susceptibility variants of breast cancer. Methods of disease management, including diagnosing increased and/or decreased susceptibility to breast cancer, methods of predicting response to therapy and methods of predicting prognosis using such variants are described. The invention further relates to kits useful in the methods of the invention. | 06-26-2014 |
20140179547 | Methods For The Generation Of Multispecific And Multivalent Antibodies - The invention provides novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule and methods for producing novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule. The antibodies are composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other of a Lambda constant domain. The invention provides methods for the isolation of antibodies of different specificities but sharing a common heavy chain. The invention also provides methods for the controlled co-expression of two light chains and a single heavy chain leading to the assembly of monospecific and bispecific antibodies. The invention provides a mean of producing a fully human bispecific and bivalent antibody that is unaltered in sequence and does not involve the use of linkers or other non-human sequences, as well as antibody mixtures of two monospecific antibodies and one bispecific antibody. The invention also provides the means of efficiently purifying the bispecific antibody. | 06-26-2014 |
20140179548 | MOLECULAR PROGNOSTIC SIGNATURE FOR PREDICTING BREAST CANCER METASTASIS, AND USES THEREOF - The present invention is based on the discovery of a unique 14-gene molecular prognostic signature that is useful for predicting breast cancer metastasis. In particular, the present invention relates to methods and reagents for detecting and profiling the expression levels of these genes, and methods of using the expression level information in predicting risk of breast cancer metastasis. | 06-26-2014 |
20140179549 | METHODS FOR IDENTIFYING INFLAMMATORY BOWEL DISEASE PATIENTS WITH DYSPLASIA OR CANCER - The present invention provides methods for identifying IBD patients with dysplasia or cancer. In particular embodiments, the methods of the invention may comprise determining the presence or level of at least one or a panel of miRNAs in a sample obtained from an IBD patient to establish a miRNA expression profile, and comparing the miRNA expression profile with one or more pre-established model miRNA expression profiles. The present invention further provides methods for monitoring the efficacy of treatment of IBD patients with dysplasia or cancer. | 06-26-2014 |
20140179550 | IMMUNOGLOBULIN FC LIBRARIES - Methods and composition for the screening and isolation of aglycosylated antibody Fc domain polypeptides. For example, in certain aspects methods for identifying aglycosylated Fc domains that bind to Fc receptors or preferentially bind to particular Fc receptors are described. Furthermore, the invention provides aglycosylated Fc domains that bind to Fc receptors with high affinity. Enhanced methods and media for prokaryotic based interaction screening are also provided. | 06-26-2014 |
20140179551 | METHODS FOR THE SELECTION OF BINDING PROTEINS - This application provides an improved screening method for the selection of target-binding proteins having desirable biophysical properties. The method combines mRNA display and yeast surface display in a way that takes advantage of the desirable attributes of both processes. | 06-26-2014 |
20140179552 | METHODS AND COMPOSITIONS FOR DIAGNOSING OSTEOARTHRITIS IN A FELINE - Methods, compositions and kits for diagnosing osteoarthritis in a feline are disclosed. The methods of the invention comprise detecting differential expression of at least one biomarker in a body sample, preferably a blood sample, where the biomarker is differentially expressed in osteoarthritis. | 06-26-2014 |
20140179553 | MERCURY METHYLATION GENES IN BACTERIA AND ARCHAEA - Two genes required for this mercury methylation have been identified in bacteria and archaea. These genes are the hgcA gene and hgcB, a corrinoid protein that facilitates methyl group transfer to Hg, and a corrinoid protein-associated ferredoxin with two [4Fe-4S] binding motifs involved in generating cob(I)almin, respectively. The invention provides nucleic acid probes and primers for detecting methylmercury and or for assessing mercury methylation potential in environmental, clinical and other samples. The invention also provides antibodies against these proteins, antibodies against these proteins, methods of using the antibodies and methods of biocatalysis. | 06-26-2014 |
20140179554 | Microarrays - Provided herein are microarrays (protein and/or nucleic acid microarrays) containing an array of spots on a solid substrate, wherein the spots are arranged to reduce the risk of array misalignment and/or to facilitate the visual interpretation of an array image by a human operator. Also provided herein are methods of using such arrays and kits containing such arrays. | 06-26-2014 |
20140179555 | SELF-ENCODING SENSOR WITH MICROSPHERES - Disclosed herein are compositions and methods for combining the output obtained from redundant sensor elements in a sensor array. | 06-26-2014 |
20140179556 | Method for Identifying Lineage-Related Antibodies - In certain embodiments, the method may comprise: a) obtaining the antibody sequences from a population of B cells; b) grouping the antibody sequences to provide a plurality of groups of lineage-related antibodies; c) testing a single antibody from each of the groups in a bioassay and, after the first antibody has been identified, d) testing further antibodies that are in the same group as the first antibody in a second bioassay. In another embodiment, the method may comprise: a) testing a plurality of antibodies obtained from a first portion of an antibody producing organ of an animal; b) obtaining the sequence of a first identified antibody; c) obtaining from a second portion of said antibody producing organ the sequences of further antibodies that are related by lineage to said first antibody; and, c) testing the further antibodies in a second bioassay. | 06-26-2014 |
20140179557 | MARKER SEQUENCES FOR DIAGNOSING PROSTATE CANCER, AND USE THEREOF - The present invention relates to novel marker sequences for prostate carcinoma while excluding inflammatory prostate diseases or diabetes or polymorbidity and relates to their diagnostic use including a method for screening potential active substances for such prostate diseases by means of these marker sequences. The invention furthermore relates to a diagnostic device including such marker sequences for prostate carcinoma, in particular a protein biochip and its use. | 06-26-2014 |
20140179558 | METHOD FOR DETECTING PANCREATIC CANCER - This invention relates to a method for detecting pancreatic cancer using novel tumor markers. Specifically, the invention provides a method for detecting pancreatic cancer comprising measuring the presence or an amount of a polypeptide having an reactivity of binding via an antigen-antibody reaction to an antibody against CAPRIN-1 protein in a sample separated from a subject, and to a reagent or kit for detecting pancreatic cancer comprising a CAPRIN-1 protein or a fragment thereof, an antibody against the same, or a polynucleotide encoding the same. | 06-26-2014 |
20140187430 | Compositions and Methods for Identifying Autism Spectrum Disorders - The invention provides methods of identifying DNA methylation profiles for neurological and psychiatric conditions including autism spectrum disorders, methods of treating such conditions, and methods of identifying therapeutics for the treatment of such neurological and psychiatric conditions. | 07-03-2014 |
20140187431 | Method Using A Nonlinear Optical Technique for Detection of Interactions Involving A Conformational Change - A nonlinear optical technique, such as second or third harmonic or sum or difference frequency generation, is used to detect binding interactions, or the degree or extent of binding, that comprise conformational change. In one aspect of the present invention, the nonlinear optical technique detects a conformational change in a probe due to target binding. In another aspect of the invention, the nonlinear optical technique screens candidate probes by detecting a conformational change due to a probe-target interaction. In another aspect of the invention, the nonlinear optical technique screens candidate modulators of a probe-target interaction by detecting a conformational change in the presence of the modulator. | 07-03-2014 |
20140187432 | METHODS USING A NONLINEAR OPTICAL TECHNIQUE FOR DETECTION OF INTERACTIONS INVOLVING A CONFORMATIONAL CHANGE - A nonlinear optical technique, such as second or third harmonic or sum or difference frequency generation, is used to detect binding interactions, or the degree or extent of binding, that comprise conformational change. In one aspect of the present invention, the nonlinear optical technique detects a conformational change in a probe due to target binding. In another aspect of the invention, the nonlinear optical technique screens candidate probes by detecting a conformational change due to a probe-target interaction. In another aspect of the invention, the nonlinear optical technique screens candidate modulators of a probe-target interaction by detecting a conformational change in the presence of the modulator. | 07-03-2014 |
20140187433 | METHODS USING A NONLINEAR OPTICAL TECHNIQUE FOR DETECTION OF INTERACTIONS INVOLVING A CONFORMATIONAL CHANGE - A nonlinear optical technique, such as second or third harmonic or sum or difference frequency generation, is used to detect binding interactions, or the degree or extent of binding, that comprise conformational change. In one aspect of the present invention, the nonlinear optical technique detects a conformational change in a probe due to target binding. In another aspect of the invention, the nonlinear optical technique screens candidate probes by detecting a conformational change due to a probe-target interaction. In another aspect of the invention, the nonlinear optical technique screens candidate modulators of a probe-target interaction by detecting a conformational change in the presence of the modulator. | 07-03-2014 |
20140187434 | Nucleic Acid Labeling Compounds - Nucleic acid labeling compounds are disclosed. The compounds are synthesized by condensing a heterocyclic derivative with a cyclic group (e.g. a ribofuranose derivative). The labeling compounds are suitable for enzymatic attachment to a nucleic acid, either terminally or internally, to provide a mechanism of nucleic acid detection. | 07-03-2014 |
20140187435 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS - Methods of treating and evaluating subjects having neoactive mutants are described herein. | 07-03-2014 |
20140187436 | NANOPLASMONIC MOLECULAR RULER FOR NUCLEASE ACTIVITY AND DNA FOOTPRINTING - This invention provides a nanoplasmonic molecular ruler, which can perform label-free and real-time monitoring of nucleic acid (e.g., DNA) length changes and perform nucleic acid footprinting. In various embodiments the ruler comprises a nucleic acid attached to a nanoparticle, such that changes in the nucleic acid length are detectable using surface plasmon resonance. The nanoplamonic ruler provides a fast and convenient platform for mapping nucleic acid-protein interactions, for nuclease activity monitoring, and for other footprinting related methods. | 07-03-2014 |
20140187437 | Cross-Reactive Sensor Arrays And Methods of Use - Disclosed herein are methods and compositions directed to the construction of aptamer-based receptors and cross-reactive sensor arrays of such receptors and the use of the same in disease detection and management. | 07-03-2014 |
20140187438 | Methods and Compositions for the Diagnosis and Treatment of Epithelial Cancers - Methods for detecting, diagnosing and monitoring an epithelial cancer in a patient are described comprising measuring in a sample from the patient Ep-ICD polypeptides and Ep-ICD polynucleotides. Methods for prognosis of breast cancer comprising measurement of nuclear Ep-ICD polypeptides and optionally EpEx polypeptides are provided. The invention also provides kits and compositions for carrying out the methods of the invention. | 07-03-2014 |
20140187439 | METHOD FOR THE DIAGNOSIS OF GAUCHER'S DISEASE - The present invention is related to an in vitro method for diagnosing Gaucher's disease in a subject comprising a step of a) detecting a biomarker in a sample from the subject, wherein the biomarker is free lyso-Gb1. | 07-03-2014 |
20140187440 | SYSTEMATIC EVALUATION OF SEQUENCE AND ACTIVITY RELATIONSHIPS USING SITE EVALUATION LIBRARIES FOR ENGINEERING MULTIPLE PROPERTIES - The present invention provides methods for protein engineering. Specifically, the invention provides methods utilizing site evaluation libraries to design libraries that optimize two or more properties of a protein. | 07-03-2014 |
20140187441 | AMPLIFICATION OF CYP24 AND USES THEREOF - This invention pertains to the discovery that an amplification of the CYP24 gene or an increase in CYP24 activity is a marker for the presence of, progression of, or predisposition to, a cancer (e.g., breast cancer). Using this information, this invention provides methods of detecting a predisposition to cancer in an animal. The methods involve (i) providing a biological sample from an animal (e.g. a human patient); (ii) detecting the level of CYP24 within the biological sample; and (iii) comparing the level of CYP24 with a level of CYP24 in a control sample taken from a normal, cancer-free tissue where an increased level of CYP24 in the biological sample compared to the level of CYP24 in the control sample indicates the presence of said cancer in said animal. | 07-03-2014 |
20140194304 | PROCESS FOR ULTRA-SENSITIVE QUANTIFICATION OF TARGET ANALYTES IN COMPLEX BIOLOGICAL SYSTEMS - Antibody-free processes are disclosed that provide accurate quantification of a wide variety of low-abundance target analytes in complex samples. The processes can employ high-pressure, high-resolution chromatographic separations for analyte enrichment. Intelligent selection of target fractions may be performed via on-line Selected Reaction Monitoring (SRM) or off-line rapid screening of internal standards. Quantification may be performed on individual or multiplexed fractions. Applications include analyses of, e.g., very low abundance proteins or candidate biomarkers in plasma, cell, or tissue samples without the need for affinity-specific reagents. | 07-10-2014 |
20140194305 | INTEGRATED MULTIPLEX TARGET ANALYSIS - This invention provides biochip cartridges and instrument devices for the detection and/or analysis of target analytes from patient samples. | 07-10-2014 |
20140194306 | NUCLEIC ACID SEQUENCES FROM DIABROTICA VIRGIFERA VIRGIFERA LECONTE AND USES THEREOF - Expressed Sequence Tags (ESTs) isolated from the Western Corn Rootworm, | 07-10-2014 |
20140194307 | RECOGNITION OF CELLULAR TARGET BINDING BY A BIOACTIVE AGENT USING INTRACELLULAR BIOLUMINESCENCE RESONANCE ENERGY TRANSFER - The present invention provides compositions and methods for detection and analysis of intracellular binding of a bioactive agent to a cellular target. In particular, provided herein are bioactive agents tethered to fluorophores, cellular targets fused to bioluminescent reporters, or portions, components, or subunits of bioluminescent reporters, and methods of detecting and analyzing the interaction of bioactive agents with cellular targets therewith. | 07-10-2014 |
20140194308 | USE OF MYELIN BASIC PROTEIN AS A NOVEL GENETIC FACTOR FOR RHEUMATOID ARTHRITIS - A novel genetic factor for rheumatoid arthritis is searched for and used as a diagnostic marker. | 07-10-2014 |
20140194309 | IN VITRO METHOD FOR PREDICTING IN VIVO GENOTOXICITY OF CHEMICAL COMPOUNDS - The invention is in the field of genomics and it provides an in vitro method for predicting whether a compound is genotoxic in vivo. In particular, the invention provides a method for predicting the in vivo genotoxicity of a compound comprising the steps of performing an Ames test on the compound and determining if the result is positive or negative, followed by a step wherein the gene expression of at least 3 genes is determined in a HepG2 cell, compared to a reference value and predicting that the compound is in vivo genotoxic if the expression level of more than 2 of the genes is above a reference value. | 07-10-2014 |
20140194310 | GENES DYSREGULATED IN AUTISM AS BIOMARKERS AND TARGETS FOR THERAPEUTIC PATHWAYS - The disclosed invention comprises methods and materials for screening cells for genetic profiles associated with autism spectrum disorders. The methods typically involve isolating a cell from an individual and then observing the expression profile of one or more genes in the cell, wherein certain expression patterns of the genes observed are associated with autism spectrum disorders. | 07-10-2014 |
20140194311 | Multiplexed Proximity Ligation Assay - The present invention provides a method for detecting interactions between or with any two of at least three target substrates, or any two of at least three features of a target substrate, or a combination of interactions and features of target substrates, by a multiplexed proximity ligation assay, said method comprising: a) for each of the at least three target substrates or features, providing a proximity probe comprising a binding moiety with affinity for the feature or binding site on said substrate, and a proximity probe oligonucleotide coupled on the binding moiety; wherein each of the proximity probe oligonucleotide carries a unique tag sequence; b) mixing the proximity probes with a sample, under a condition to allow binding of each proximity probe to its respective binding site or feature on each of said substrates through the binding moiety, c) simultaneous with, or following step b), forming circularized DNA molecules where any two proximity probes bind sufficiently close to each other on the substrate, wherein each of the circularized DNA molecules comprise complementary sequences to the unique tag sequences from the two proximity probes oligo-nucleotides; d) amplifying the circularized DNA; and e) characterizing the amplified DNA. | 07-10-2014 |
20140194312 | COMPLEX SETS OF MIRNAS AS NON-INVASIVE BIOMARKERS FOR DILATED CARDIOMYOPATHY - The present invention relates to non-invasive methods, kits and means for diagnosing and/or prognosing of dilated cardiomyopathy in a body fluid sample from a subject. Further, the present invention relates to set of polynucleotides or sets of primer pairs for detecting sets of miRNAs for diagnosing and/or prognosing of dilated cardiomyopathy in a body fluid sample from a subject. In addition, the present invention relates to sets of miRNAs for diagnosing and/or prognosing of dilated cardiomyopathy in a body fluid sample from a subject. | 07-10-2014 |
20140194313 | MICROFLUIDIC DEVICE FOR EXTRACTING, ISOLATING, AND ANALYZING DNA FROM CELLS - The present invention relates to a microfluidic device for extracting and isolating DNA from cells. The device includes a support having an inlet port for receiving a sample containing a cell, an outlet port for dispensing DNA isolated from the cell, and a microfluidic channel disposed within the support and extending from the inlet port to the outlet port. The microfluidic channel includes a micropillar array, an inflow channel disposed between the inlet port and the micropillar array, and an outflow channel disposed between the micropillar array and the outlet port. The micropillar array includes micropillars spatially configured to entrap, by size exclusion, the cell, to immobilize DNA released from the cell, and to maintain the immobilized DNA in elongated or non-elongated form when hydrodynamic force is applied to the microfluidic channel. Systems and methods of making and using the device are also provided herein. | 07-10-2014 |
20140194314 | Multi-Color Nanoscale Imaging Based On Nanoparticle Cathodoluminescence - Multi-color CL images of nanoparticle samples may be generated, by irradiating with a scanning electron beam a nanoparticle sample that containing a plurality of spectrally distinct optical emitters configured to generate CL light at respective different color channels, then detecting the CL light from the nanoparticles to generate multi-color NP-CL images of the nanoparticle sample. In some embodiments, SE (secondary electron) images of the sample may be acquire, substantially simultaneously with the acquisition of the CL images, so as to generate correlative NP-CL and SE images of the nanoparticle sample. In some embodiments, the nanoparticles may be surface-functionalized so that the nanoparticles selectively bind only to particular structures of interest. | 07-10-2014 |
20140194315 | METHODS AND COMPOSITIONS FOR RAPID FUNCTIONAL ANALYSIS OF GENE VARIANTS - Methods and compositions are disclosed for rapid functional analysis of gene variants based on analysis of protein-protein and protein-nucleic acid interactions. | 07-10-2014 |
20140194316 | ENHANCED MULTIPLEX FISH - Subject of the present invention is a combination of nucleic acid molecules capable of hybridizing with a target nucleic acid sequence. In order to overcome problems with the reproducibility of FISH assays and to decrease assay time, hairpin probes are used in combination with helper probes annealing adjacent to the target site of the hairpin probe. | 07-10-2014 |
20140194317 | BIOMARKERS FOR THE DETECTION OF HEAD AND NECK TUMORS - A method of detecting the presence of specific human papilloma virus and host cell biomarkers associated with head and neck tumors in biological samples, like saliva, blood or biopsy tissue, obtained from a subject. | 07-10-2014 |
20140194318 | BIOMARKERS FOR DIAGNOSING ALZHEIMER'S DISEASE - A method for assessing the state of Alzheimer's disease in patients is disclosed. A method for monitoring the progression of Alzheimer's disease in patients is also disclosed. The method applies detection of specific peptide markers, e.g., using mass spectrometric analysis. | 07-10-2014 |
20140194319 | USE OF MICROVESICLES IN DIAGNOSIS AND PROGNOSIS OF MEDICAL DISEASES AND CONDITIONS - The presently disclosed subject matter is directed to methods of aiding diagnosis, prognosis, monitoring and evaluation of a disease or other medical condition in a subject by detecting a biomarker in microvesicles isolated from a biological sample from the subject. | 07-10-2014 |
20140194320 | METHOD FOR PREPARING NUCLEIC ACID APTAMER - An object of the present invention is to develop and provide a method for efficiently and conveniently producing a nucleic acid aptamer, particularly, a DNA aptamer, having high specificity for and high binding activity against a target substance. The present invention provides a method for producing a nucleic acid aptamer, comprising: a complex formation step of mixing a single-stranded nucleic acid library with a target substance in a solution to form a complex of a single-stranded nucleic acid and the target substance; an immobilization step of mixing the solution after the preceding step with a solid-phase support to immobilize the complex onto the solid-phase support via connector(s) adsorbed on the target substance and/or the solid-phase support; a recovery step of recovering the complex immobilized on the solid-phase support from the solution; an amplification step of recovering the single-stranded nucleic acid from the complex, followed by amplification by a nucleic acid amplification method; and a single-stranded nucleic acid preparation step of converting the double-stranded nucleic acids obtained in the amplification step into single strands and then forming an intramolecular conformation. | 07-10-2014 |
20140200149 | Methods and compositions for identification of source of microbial contamination in a sample - Herein are described 1058 different bacterial taxa that were unique to either human, grazing mammal, or bird fecal wastes. These identified taxa can serve as specific identifier taxa for these sources in environmental waters. Two field tests in marine waters demonstrate the capacity of phylogenetic microarray analysis to track multiple sources with one test. | 07-17-2014 |
20140200150 | BIOMARKERS - The invention relates to a method of differentially diagnosing schizophrenia, bipolar disorder and major depressive disorder. | 07-17-2014 |
20140200151 | BIOMARKERS - The invention relates to a method of differential diagnosis of schizophrenia or other psychotic disorder from a further psychiatric disorder. | 07-17-2014 |
20140200152 | METHOD FOR SCREENING ANTI-LIGAND LIBRARIES FOR IDENTIFYING ANTI-LIGANDS SPECIFIC FOR DIFFERENTIALLY AND INFREQUENTLY EXPRESSED LIGANDS - The present invention relates to screening methods and, in particular, to methods of screening anti-ligand libraries for identifying anti-ligands specific for differentially and/or infrequently expressed ligands. The method comprises the steps of providing a library of anti-ligands; providing a first subtractor ligand; providing a second target ligand; determining the amount of the first and second target ligands using one or more equations derived from the universal law of mass action; providing the determined amount of a first subtractor ligand; providing the determined amount of a second target ligand; providing separation means capable of use to isolate anti-ligand bound to the second target ligand from anti-ligand bound to the first subtractor ligand; exposing the library of to the first and second target ligands to permit binding of anti-ligands to ligands; and using the separation means to isolate the anti-ligand bound to second target ligand. | 07-17-2014 |
20140200153 | METHODS OF DETECTING LUNG CANCER - Methods of lung cancer in a sample from a patient are provided. Methods of detecting changes in expression of one or more target RNAs associated with lung cancer are also provided. Compositions and kits are also provided. | 07-17-2014 |
20140200154 | LOW-COST POINT-OF-CARE ASSAY DEVICE - The present disclosure provides methods and systems for analyzing a liquid sample. A micro-fluidic device to perform an assay of a liquid sample is described that includes a sample application site and a vent outlet in fluid communication with the capillary channel. A cap is provided that is configured to seal both the vent outlet and the sample application site in a shared volume and separate from an outside environment. | 07-17-2014 |
20140200155 | Prognostic marker for endometrial carcinoma - The present invention relates to a method for diagnosing or determining the status of endometrial carcinoma in an individual afflicted with or suspected to be afflicted with endometrial carcinoma based on the phosphorylated stathmin compound whereby said stathmin is phosphorylated at position Serine 38. Moreover, the present invention relates to a method for evaluating the probability of survival, the clinical outcome or the treatment course of an individual afflicted with or suspected to be afflicted with endometrial carcinoma. In another aspect, the present invention relates to the stratification of the therapeutic regimen of an individual with endometrial carcinoma. In particular, the present invention provides a method for diagnosing or identifying endomentrial carcinoma with high grade aggressive phenotype, in particular, having low response and susceptibility to chemotherapeutic regimen, in particular, with respect to microtubule stabilization based regimen including treatment with taxanes. Moreover, the present invention relates to a kit for use in any of the above-referenced methods comprising means for determining the level or amount of phosphorylated pStathmin(S38) as well as assays for conducting the method according to the present invention. In one embodiment, the methods according to the present invention include the combined determination of stathmin and phosphorylated stathmin (pStathmin(S38)). | 07-17-2014 |
20140200156 | GENES INDUCING AGONISTIC EFFECTS BY ANTI-C-MET ANTIBODY TREATMENT AND DRUG SCREENING METHOD USING THE GENES - Biomarkers for screening drugs reducing side effects of anti-c-Met antibodies and a method of screening using the biomarkers, and more particularly, biomarkers commonly enhancing or reducing gene expression and a method of screening anti-c-Met antibodies having reduced side effects using the biomarkers or a method of screening drugs that reduce side effects of anti-c-Met antibodies. | 07-17-2014 |
20140200157 | Array with Extended Dynamic Range and Associated Method - A system and method of quantitating the concentration of a molecule of interest in one embodiment includes establishing a plurality of test environments at a plurality of test sites, each of the plurality of test environments associated with one of a plurality of response curves, each of the plurality of response curves different from the other of the plurality of response curves, storing a combined response curve resulting from a summation of the plurality of response curves, exposing the plurality of test sites to a sample having a concentration of a molecule of interest, obtaining a plurality of quantitation signals, each of the plurality of quantitation signals associated with one of the plurality of test sites, associating a summation of the plurality of quantitation signals with the stored combined response curve, and generating a signal related to the concentration of the molecule of interest based upon the association. | 07-17-2014 |
20140200158 | MICROARRAY FABRICATION SYSTEM AND METHOD - A microarray is designed capture one or more molecules of interest at each of a plurality of sites on a substrate. The sites comprise base pads, such as polymer base pads, that promote the attachment of the molecules at the sites. The microarray may be made by one or more patterning techniques to create a layout of base pads in a desired pattern. Further, the microarrays may include features to encourage clonality at the sites. | 07-17-2014 |
20140200159 | IDENTIFYING ANTIGEN CLUSTERS FOR MONITORING A GLOBAL STATE OF AN IMMUNE SYSTEM - Method, system and an article of manufacture for clustering and thereby identifying predefined antigens reactive with undetermined immunoglobulins of sera derived from patient subjects in need of diagnosis of disease or monitoring of treatment. | 07-17-2014 |
20140200160 | MOLECULAR-BASED METHOD OF CANCER DIAGNOSIS AND PROGNOSIS - A gene profiling signature for diagnosis and prognosis of cancer patients is disclosed herein. In one embodiment, the gene signature includes 32 or 79 cancer survival factor-associated genes. Thus, provided herein is a method of determining the prognosis of a subject with a tumor by detecting expression of five of more cancer survival factor-associated genes in a tumor sample and comparing expression of the five or more cancer survival factor-associated genes in the tumor sample to a control. In some examples, an increase in expression of ABCF1, CORO1C, DPP3, PREB, UBE3A, and PTDSS1 in a tumor sample compared to a control sample indicates poor prognosis. Further provided are arrays including probes or antibodies specific for a plurality of cancer survival factor-associated genes or proteins. | 07-17-2014 |
20140200161 | METHOD OF PREPARING AN ADDUCT - A method for identifying one or several molecular structure(s) having a high-affinity for a target of interest, the molecular structure(s) each including one nucleotide chain onto which is hybridized at least one PNA-encoded molecule. | 07-17-2014 |
20140200162 | METHOD AND APPARATUS FOR NUCLEIC ACID ANALYSIS - A convenient method for nucleic acid analysis is provided, which enables 1000 or more types of nucleic acid to be analyzed collectively with high comprehensiveness and with a dynamic range of at least four digits. In particular, provided is a very effective analytical method especially for untranslated RNAs and microRNAs, of which the types of target nucleic acids is 10000 or lower. Nucleic acids can be analyzed conveniently and rapidly with high comprehensiveness and quantitative performance at single-molecule sensitivity and resolution by following the steps of: preparing a group of target nucleic acid fragments one molecule at a time and hybridizing the nucleic acid molecules, which have known base sequences and have been labeled with the fluorescence substances, with the group of the target nucleic acid fragments to detect the fluorescence substances labeling the hybridized nucleic acid molecules. | 07-17-2014 |
20140206556 | Systems and Methods for Identifying Replikin Scaffolds and Uses of Said Replikin Scaffolds - The present invention provides a new class of peptides related to rapid replication and high human mortality, and their use in diagnosing, preventing and treating disease including vaccines and therapeutics for emerging viral diseases and methods of identifying the new class of peptides and related structures. | 07-24-2014 |
20140206557 | Novel Reagents for Directed Biomarker Signal Amplification - Described herein are methods, compositions and articles of manufacture involving neutral conjugated polymers including methods for synthesis of neutral conjugated water-soluble polymers with linkers along the polymer main chain structure and terminal end capping units. Such polymers may serve in the fabrication of novel optoelectronic devices and in the development of highly efficient biosensors. The invention further relates to the application of these polymers in assay methods. | 07-24-2014 |
20140206558 | SYSTEM FOR PRODUCTION OF ANTIBODIES AND THEIR DERIVATIVES - The present disclosure provides methods and compositions for the production of chimeric antibodies that specifically bind an antigen of interest. | 07-24-2014 |
20140206559 | ASSAY FOR METASTATIC POTENTIAL OF TUMOR CELLS - The present invention relates to methods, compositions and kits related to a novel in vitro assay for a high-capacity and high-throughput method for measuring the ability of cancer cells to migrate in a three-dimensional cellular assay. The three-dimensional cellular invasion assay provides a method for determining and quantitating the metastatic potential and invasive capacity of a cancer cell. Other aspects of the invention further relate to the use of the in vitro assay to screen for agents and compounds capable of inhibiting intravasation, and thereby modulating the metastatic potential of cancer cells. The methods, compositions and three-dimensional assay provide a highly sensitive assay system capable of mimicking the in vivo cellular and molecular interactions required for successful completion of intravasation. | 07-24-2014 |
20140206560 | NUCLEIC ACID CONSTRUCT, NUCLEIC ACID-PROTEIN COMPLEX, AND USE THEREOF - Using a nucleic acid construct, association of a polypeptide with a sequence coding therefor and screening of a polypeptide that binds to a target substance are carried out, which nucleic acid construct comprises a 5′-untranslated region and a coding region, wherein the above-mentioned coding region comprises a sequence coding for a polypeptide subjected to be displayed, a sequence coding for a first nucleic acid binding polypeptide, and a sequence coding for a second nucleic acid binding polypeptide; the above-mentioned 5′-untranslated region comprises a first sequence capable of binding to a first nucleic acid binding polypeptide and a second sequence capable of binding to second nucleic acid binding polypeptide; and, when the above-mentioned nucleic acid construct is introduced in a translation system, a fusion protein translated from the coding region of the above-mentioned nucleic acid construct forms a complex with an RNA corresponding to the above-mentioned nucleic acid construct. | 07-24-2014 |
20140206561 | METHOD FOR PROVIDING INFORMATION ON ANTIDEPRESSANT THERAPEUTIC EFFECT USING SINGLE NUCLEOTIDE POLYMORPHISM - Disclosed is a method for providing information on the therapeutic effect of an SSRI antidepressant by identifying TPH2 gene polymorphism rs4760815, SLC6A4 gene polymorphism 5-HTTLPR, SLC6A4 gene polymorphism rs2066713, GAD1 gene polymorphism rs3828275, and GRIK2 gene polymorphism rs543196. Through the disclosed method, it is possible to select an antidepressant based on genetic information, to prevent the worsening or relapse of depression, and to establish customized depression treatment models which are effective in the development of customized new drugs, and appropriate for Korean people. Therefore, the base of domestic clinical trials can be expanded, which will enhance competitive power in the pharmaceutical market and preoccupy technology of drug prediction. | 07-24-2014 |
20140206562 | FABRICATION AND USE OF A MICROFLUIDICS MULTITEMPERATURE FLEXIBLE REACTION DEVICE - Fabrication of a microfluidic multi-temperature reaction device (MMR) and the design and fabrication of the equipment to drive various molecular biological methods on the device are provided. The device can be applicable, for example, to nucleic acid (DNA, RNA, cDNA, etc) amplification, cell lysis, reverse transcription and other enzymatic temperature sensitive and also temperature cycling reactions. | 07-24-2014 |
20140206563 | BIOMARKERS FOR PSORIASIS - A group of polypeptides that are modulated in a psoriatic sample as compared to a normal sample is provided. These polypeptides can be used as biomarkers for diagnosis and monitoring treatment of psoriasis. | 07-24-2014 |
20140206564 | REAGENTS FOR IMPROVING PCR ACCURACY - Provided herein are reagents for improving PCR accuracy. | 07-24-2014 |
20140206565 | Esophageal Cancer Markers - The present invention is directed to methods for diagnosing cancer in a subject. Morphologically normal epithelial cells of the esophagus are assayed for marker expression. Characteristic expression of the markers indicates the presence of cancer or the predisposition to cancer. A panel of eleven markers are particularly good at identifying cancer and the predisposition to cancer. | 07-24-2014 |
20140206566 | Methods and Compositions for Determining a Graft Tolerant Phenotype in a Subject - Methods are provided for determining whether a subject has a graft tolerant phenotype. In practicing the subject methods, the expression of at least one gene in a sample from the subject, e.g., a blood sample, is assayed to obtain an expression evaluation for the at least one gene. The obtained expression evaluation is then employed to determine whether the subject has a graft tolerant phenotype. Also provides are compositions, systems and kits that find use in practicing the subject methods. The methods and compositions find use in a variety of applications, including the determination of an immunosuppressive therapy regimen. | 07-24-2014 |
20140206567 | Method for Detecting Target Nucleic Acid - The disclosure of the present description provides a method for detecting a target nucleic acid, whereby probe hybridization can be accomplished efficiently. To that end, a target nucleic acid is amplified using a first primer having a tag sequence complementary to a detection probe pre-associated with the target nucleic acid and a first recognition sequence that recognizes a first base sequence in the target nucleic acid and also having a linking site capable of inhibiting or arresting a DNA polymerase reaction disposed between the tag sequence and the first recognition sequence, and a second primer having a second recognition sequence that recognizes a second base sequence in the target nucleic acid, the amplified fragment is brought into contact with a detection probe so as to allow hybridization, and the hybridization product is detected. | 07-24-2014 |
20140206568 | CHEMILUMINESCENCE COMPACT IMAGING SCANNER - Systems, devices, and methods for accurately imaging chemiluminescence and other luminescence are disclosed. A compact, flat-bed scanner having a light-tight enclosure, one or more detector bars of linear charge-coupled device (CCD) or complementary metal oxide semiconductor (CMOS) imaging chips, and high working numerical aperture (NA) optics scans closely over a sample in one direction and then the opposite direction. Averages or other combinations of intensity readings for each pixel location (x, y) between the two or more passes are averaged together in order to compensate for luminescence that varies over time. On-chip pixel binning and multiple clock frequencies can be used to maximize the signal to noise ratio in a CCD-based scanner. | 07-24-2014 |
20140206569 | ENCODING OF MICROCARRIERS - Encoded microcarriers, and more specifically microcarriers having codes written on them. Methods for writing the codes on the microcarriers, methods of reading the codes, and methods of using the encoded microcarriers. A preferred method of encoding the microcarriers involves exposing microcarriers containing a bleachable substance to a high spatial resolution light source to bleach the codes on the microcarriers. The encoded microcarriers may be used, for example, as support materials in chemical and biological assays and syntheses. | 07-24-2014 |
20140206570 | Characterization of biochips containing self-assembled monolayers - The present invention relates to a method of characterizing biochips with matrix-assisted laser desorption/ionization and time of flight mass spectrometry (MALDI-TOF MS). | 07-24-2014 |
20140206571 | Automatic Genechip Array Diagnosing Apparatus - A method of diagnosing a sample with an automated genechip array for a fast diagnosis having high accuracy, where the sample is processed through lysis, separation, purification, labeling, reacting in the genechip array, taking a photo thereafter and analyzing the photo. | 07-24-2014 |
20140206572 | OVARIAN MARKERS OF FOLLICULAR MATURITY AND USES THEREOF - The present invention relates to field of fertility. The invention identifies biological ovarian markers from follicular cells, from follicular fluid, from cumulus cells and from oocytes which are indicative of follicular maturity in mammals. Described are methods for improving ovarian stimulation, methods for assessing maturity of a mammalian ovarian follicle, methods for optimizing in vitro maturation (IVM) and methods for classifying an embryo, these methods being based on assessment of expression level of ovarian markers indicative of maturity. Also described are methods for screening compounds stimulatory of or inhibitory to mammalian follicular maturation, kits for evaluating follicular maturity. | 07-24-2014 |
20140206573 | METHOD FOR EVALUATING BACTERIAL CELL WALL INTEGRITY - The present invention relates to a method for evaluating the integrity of the cell wall of the bacteria present in a culture in the presence of an antibiotic acting on the bacterial cell wall which, from a practical point of view, allows quickly determining if a bacterium is sensitive or resistant to an antibiotic acting on the bacterial cell wall. Likewise, the present invention also relates to a lysis solution applicable in the preceding method, specifically affecting bacteria having the cell wall damaged by the action of an antibiotic acting on the bacterial cell wall, which allows distinguishing bacteria sensitive to said antibiotic from those resistant to said antibiotic. | 07-24-2014 |
20140206574 | Methods and Compositons for the Treatment and Diagnosis of Cancer - The invention relates to methods of detecting cancer in a sample obtained from a subject. The invention also provides kits and reagents for detecting cancer as well as therapeutics and methods of treating cancer. | 07-24-2014 |
20140206575 | Collection and Methods For Its Use - The present disclosure enables collections of variable heavy chain and variable light chain pairs comprising, in part, germline protein sequences that are pre-selected for functional properties relevant to developability, wherein the collections may be used to select against any antigen using, for example, phage display. | 07-24-2014 |
20140213465 | PLAQUE ARRAY METHODS AND COMPOSITIONS FOR FORMING AND DETECTING PLAQUES - Provided herein are methods and compositions for the in vitro formation of an array of plaque particles for use in biological assays, diagnosis, drug discovery and drug development. More specifically, the embodiments described herein relate to the in vitro synthesis of plaque particles when treated with biofluids and identification of such plaque particles by a variety of detection systems. In particular, the resulting in vitro plaque particles resemble atherosclerotic and amyloid plaques. The plaque embodiments described may be used to enable rapid, sensitive and/or efficient drug discovery, medical diagnostics and patient stratification. | 07-31-2014 |
20140213466 | HIGH-THROUGHPUT ASSESSMENT METHOD FOR CONTACT HYPERSENSITIVITY - The present invention provides methods for high-throughput assessment of in vivo skin sensitizing activity of chemical compounds through detection of secretion levels of cytokine markers implicated in skin sensitization in combination with a multivariate analysis, using support vector machine (SVM) for feature selection. The invention includes a computational algorithm that will provide unbiased analysis on the skin cell secretome data and predict the level of skin sensitization. The invention allows accurate assessment of the level sensitizing potency of any chemicals in a high-throughput manner, which can eliminate the needs for animal experiments, potentially saving money and time. | 07-31-2014 |
20140213467 | Mucin 5B as a Pancreatic Cyst Fluid Specific Biomarker for Accurate Diagnosis of Mucinous Cysts and Other Markers Useful for Detection of Pancreatic Malignancy - Compositions and methods which indicate an increased risk for pancreatic carcinoma in a test subject are disclosed. | 07-31-2014 |
20140213468 | DEVICE AND METHOD FOR PERFORMING A DIAGNOSTIC TEST - Devices and methods for performing a point of care diagnostic test for detecting and quantifying at least one analyte in a biological sample. The device may include an immunoassay apparatus and a holder with a variable angle stage for positioning the immunoassay apparatus relative to a light source and a detector device. In one embodiment, the device is based upon elastic light scattering, so the variation in the angle of incidence and angle of reflection are optimized to maximize signal generation due to elastic light scattering. The detector device may include a wired or wireless connection to a computer network for communicating with an electronic medical records system, uploading the amount or concentration of at least one analyte present in the sample to the electronic medical records system, or querying a decision support algorithm stored in a computer readable format. The detector device may further include an onboard interpretive algorithm. | 07-31-2014 |
20140213469 | Compositions and Methods for Identifying Autism Spectrum Disorders - The compositions and methods described are directed to gene chips having a plurality of different oligonucleotides with specificity for genes associated with autism spectrum disorders. The invention further provides methods of identifying gene profiles for neurological and psychiatric conditions including autism spectrum disorders, methods of treating such conditions, and methods of identifying therapeutics for the treatment of such neurological and psychiatric conditions. | 07-31-2014 |
20140213470 | METHODS FOR USE WITH BAFF ANTAGONISTS - BAFF plays a central role in acquired immunity. The disclosure identifies BAFF responsive genes that are substantially upregulated by administration of BAFF and substantially downregulated by treatment with a BAFF antagonist. Specific genes are NF-κB2, CD23, H2-Mβ (the beta chain of H2-DM), Fig-1, and OBF-1. The disclosure provides methods and compositions for monitoring the activity of a BAFF antagonist in a mammal; monitoring BAFF activity in a mammal; identifying a mammal to be treated with a BAFF antagonist; and related uses. Such methods include detecting one or more molecules selected from the group consisting of Fig-1 molecule, OBF-1 molecule, and H2-Mβ molecule in a biological sample of the mammal, and optionally further detecting NF-κB2 molecule and/or CD23 molecule in the biological sample. | 07-31-2014 |
20140213471 | CHROMOPHORE-BASED CHARACTERIZATION AND DETECTION METHODS - This disclosure provides methods, compositions and kits for the detection of a plurality of analytes in a sample. In some examples, this disclosure provides methods, compositions, and kits for detecting analytes, genetic variations, monitoring reaction process, and monitoring analyte-analyte interactions by measuring signals. In some examples, the presence of signals or changes in signals may be used to construct signal profiles which can be used to detect analytes. | 07-31-2014 |
20140213472 | Head and Neck Cancer Biomarkers - A method for predicting the response to treatment in a patient suffering from a head or neck cancer including: obtaining a biological sample for the patient; measuring the expression level of several gene and using the measurement to predict a patient's response to treatment. The methods may include predicting the treatment response in a patient having virally-induced head or neck cancer; and/or using the prediction to treat the patient. | 07-31-2014 |
20140213473 | APPLICATION OF REDUCED DYES IN IMAGING - The present invention provides novel compounds and methods for hydrocyanines derived from near-infrared cyanine dyes, as reactive oxygen species probes in imaging. In certain embodiments, the present invention provides reduced dyes as substrates for ELISA and Western blots. | 07-31-2014 |
20140213474 | GLUCOCORTICOID RECEPTOR ALLELES AND USES THEREOF - Provided here in are, inter alia, methods of determining whether a patient is resistant or sensitive to glucocorticoid therapy. | 07-31-2014 |
20140213475 | METHODS OF DIAGNOSING CANCER USING EPIGENETIC BIOMARKERS - The invention features methods of diagnosing cancer in a mammal (e.g., a human) by detecting a biomarker selected from a satellite II ribonucleic acid (RNA) molecule, a cancer-associated polycomb group (CAP) body, a cancer-associated satellite transcript (CAST) body, and UbH2A. Also featured is a method for identifying an agent for treating cancer in a mammal by contacting a cancer cell having a biomarker selected from a CAP body, a CAST body, and a satellite II RNA molecule with a test agent and determining whether the test agent reduces the level of the biomarker in the cancer cell. Other inventions featured are a method for determining whether a chemotherapeutic agent increases epigenetic imbalance of a cell and a method for detecting epigenetic imbalance by determining a copy number of a satellite II DNA locus at chromosome 1q12 in a cell. | 07-31-2014 |
20140213476 | COMPLEX SETS OF MIRNAS AS NON-INVASIVE BIOMARKERS FOR COLON CANCER - The present invention relates to non-invasive methods, kits and means for diagnosing and/or prognosing of colon cancer in a body fluid sample from a subject. Further, the present invention relates to set of polynucleotides or sets of primer pairs for detecting sets of miRNAs for diagnosing and/or prognosing of colon cancer in a body fluid sample from a subject. In addition, the present invention relates to sets of miRNAs for diagnosing and/or prognosing of colon cancer in a body fluid sample from a subject. | 07-31-2014 |
20140213477 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Heat shock 70 kDa protein 1, Alpha-1-antitrypsin Neutrophil elastase complex, Stromelysin-1:Metalloproteinase inhibitor 2 complex, 72 kDa type IV collagenase:Metalloproteinase inhibitor 2 complex, Insulin-like growth factor 1 receptor, Myeloid differentiation primary response protein MyD88, Neuronal cell adhesion molecule, and Tumor necrosis factor ligand superfamily member 10 as diagnostic and prognostic biomarkers in renal injuries. | 07-31-2014 |
20140213478 | SRM/MRM Assay for the Receptor Tyrosine-Protein Kinase erbB-4 Protein (HER4) - Specific peptides, and derived ionization characteristics of the peptides, from the Receptor Tyrosine-Protein Kinase erbB-4 Protein (HER4) protein are provided that are particularly advantageous for quantifying the HER4 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed where the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, | 07-31-2014 |
20140213479 | METHODS AND COMPOSITIONS FOR DETECTING IMMUNE RESPONSES - Methods and compositions for detecting immune responses and antigen-specific cells are described herein. | 07-31-2014 |
20140213480 | METHOD FOR THE SIMULTANEOUS DETERMINATION OF BLOOD GROUP AND PLATELET ANTIGEN GENOTYPES - RBC and platelet (Plt) alloimmunization requires antigen-matched blood to avoid adverse transfusion reactions. Some blood collection facilities use unregulated Abs to reduce the cost of mass screening, and later confirm the phenotype with government approved reagents. Alternatively, RBC and Plt antigens can be screened by virtue of their associated single nucleotide polymorphisms (SNPs). We developed a multiplex PCR-oligonucleotide extension assay using the GenomeLab SNPStream platform to genotype blood for a plurality of blood group antigen-associated SNPs, including but not limited to: RhD (2), RhC/c, RhE/e, S/s, K/k, Kp | 07-31-2014 |
20140213481 | METHOD FOR THE SIMULTANEOUS DETERMINATION OF BLOOD GROUP AND PLATELET ANTIGEN GENOTYPES - RBC and platelet (Plt) alloimmunization requires antigen-matched blood to avoid adverse transfusion reactions. Some blood collection facilities use unregulated Abs to reduce the cost of mass screening, and later confirm the phenotype with government approved reagents. Alternatively, RBC and Plt antigens can be screened by virtue of their associated single nucleotide polymorphisms (SNPs). We developed a multiplex PCR-oligonucleotide extension assay using the GenomeLab SNPStream platform to genotype blood for a plurality of blood group antigen-associated SNPs, including but not limited to: RhD (2), RhC/c, RhE/e, S/s, K/k, Kp | 07-31-2014 |
20140213482 | SIMPLE METHOD FOR DETCTING PLURIPOTENT STEM CELLS GENETICALLY MODIFIED BY HOMOLOGOUS RECOMBINATION - The present invention relates to a method for producing pluripotent stem cells, which comprises the steps of introducing an artificial chromosome having a genetically modified chromosome fragment as a targeting vector, and determining the number of some or all copies of the introduced artificial chromosome using an SNP array, so as to select pluripotent stem cells modified by homologous recombination, and, a method for detecting pluripotent stem cells genetically modified by homologous recombination. | 07-31-2014 |
20140221223 | Use of Probes for Mass Spectrometric Identification and Resistance Determination of Microorganisms or Cells - This invention pertains to identifying one or more hybridization probes sequestered within (or optionally released from the intact) cells or microorganisms by mass spectrometry to thereby determine a trait of the cells or microorganisms and/or to identify the cells or microorganisms themselves. The cells or microorganisms can come from a subject and the information obtained from the mass spectrometry analysis may, if clinically relevant, optionally be used to diagnose and/or treat the subject. | 08-07-2014 |
20140221224 | Single tube multiplex assay for detection and quantification of adulterants in basmati rice samples - The present invention provides a single tube multiplex assay for distinguishing basmati from non-basmati rice varieties, and thereby identifying the adulteration of basmati rice varieties. The present invention further provides a method for quantifying adulteration in basmati rice varieties. The present invention also provides a kit for performing a muliplex assay for distinguishing basmati from non-basmati rice varieties. The kit may comprise a primer directed to an SSR loci, appropriate reagents for PCR, and optionally, a package insert for conducting the assay. | 08-07-2014 |
20140221225 | METHOD FOR OBTAINING A MULTICELLULAR SPHEROID - The invention provides a method for producing a multicellular spheroid comprising injecting a cell suspension into a gel. The invention also provides a method of producing a gel comprising one or more multicellular spheroids, the method comprising injecting a cell suspension into a gel, as well as a gel obtainable by the method. Also provided is a method of assessing the effect of an agent on the property of a cell selected from any of survival, growth, proliferation, differentiation, migration, morphology, signalling, metabolic activity, gene expression and cell-cell interaction, the method comprising (i) producing a multicellular spheroid or gel according to the method of the invention, or providing a gel according to the invention; and (ii) assessing the effect of the agent on the property of a cell in the multicellular spheroid. | 08-07-2014 |
20140221226 | GENETIC DETERMINANTS OF PROSTATE AND BREAST CANCER RISK - Described are methods of determining if a subject has a genetic predisposition to developing prostate cancer (PCa) or aggressive PCa, or to developing breast cancer (BrCa). | 08-07-2014 |
20140221227 | AUTOMATED CANCER DIAGNOSTIC METHODS USING FISH - In various embodiments methods for automated screening for gene amplification in biological tissue samples using an automated fluorescence microscope to analyze fluorescence in situ hybridized samples are provided. Various additional embodiments provide methods of high throughput screening for gene amplification. | 08-07-2014 |
20140221228 | METHODS AND COMPOSITIONS FOR AMPLIFICATION AND DETECTION OF MicroRNAs - A method and system for amplifying non-coding RNA, microRNA, and small polynucleotide sequences through the generation of a pool of signature sequences to the target sequences. The target sequences can be amplified through DNA synthesis, RNA synthesis, or the combination of DNA and RNA synthesis. The amplification of signature sequences provides an efficient and reproducible mechanism to determine the presence or absence of the target miRNAs, to analyze the quantities of the miRNAs, and for miRNA profiling. The method may also be used for screening for unknown non-coding RNAs, including novel miRNAs. | 08-07-2014 |
20140221229 | GENOMIC SIGNATURES OF METASTASIS IN PROSTATE CANCER - A method of determining the risk of metastasis of prostate cancer in a human subject who has or had prostate cancer is disclosed herein. The method is based on detecting in a prostate sample from the subject the number of copies per cell of genes and/or genomic regions of a metastatic gene signature set disclosed herein, and determining alternations in the number of copies per cell of the genes and/or genomic regions in the signature set, as compared to the number of copies per cell in non-cancer cells, thereby determining the risk of prostate cancer metastasis. | 08-07-2014 |
20140221230 | THROMBOEMBOLIC DISEASE MARKERS - The invention relates to a method for a more appropriate thromboembolic event risk assessment based on the presence of different genetic variant. The invention also relates to a method for determining the risk of suffering a thromboembolism disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for thromboembolism as well as computer-implemented means for carrying out said method. | 08-07-2014 |
20140221231 | TH-17 DIFFERENTIATION MARKERS FOR ROSACEA AND USES THEREOF - A method is described that uses ROR gamma t, or ROR alpha to diagnose rosacea and/or to screen inhibitors of Th17 differentiation, notably in inhibiting ROR gamma t or ROR alpha. Also described is a method of using these screened inhibitors in rosacea treatment. | 08-07-2014 |
20140221232 | COMPUTER-IMPLEMENTED SYSTEM AND METHOD FOR THE PREDICTION OF CANCER RESPONSE TO GENOTOXIC CHEMOTHERAPY AND PERSONALISED NEOADJUVANT TREATMENTS (PCCP) - A method for predicting an individual's response to a treatment for cancer, the method comprising a step of assaying a biological sample from the individual to determine the abundance of a panel of two or more bio-markers comprising pro-apoptotic and/or anti-apoptotic biomarkers; inputting the abundance value for the two bio-markers into a computational model of a mitochondrial apoptosis pathway; and processing said abundance values using said computational model to provide a value to predict the individual's response to treatment. | 08-07-2014 |
20140221233 | MYOSITIS - The current invention relates to a method for identifying a subject at risk of developing an idiopathic inflammatory myopathy and/or diagnosing a subject suffering from an idiopathic inflammatory myopathy, preferably wherein said idiopathic inflammatory myopathy is Inclusion Body Myositis. The invention provides methods in diagnosis, use of specific antigens, and kits for use in studying the presence or absence of (auto)antibodies in samples derived from subjects. | 08-07-2014 |
20140221234 | Methods for Analyzing High Dimensional Data for Classifying, Diagnosing, Prognosticating, and/or Predicting Diseases and Other Biological States - A method of diagnosing, predicting, or prognosticating about a disease that includes obtaining experimental data, wherein the experimental data is high dimensional data, filtering the data, reducing the dimensionality of the data through use of one or more methods, training a supervised pattern recognition method, ranking individual data points from the data, wherein the ranking is dependent on the outcome of the supervised pattern recognition method, choosing multiple data points from the data, wherein the choice is based on the relative ranking of the individual data points, and using the multiple data points to determine if an unknown set of experimental data indicates a diseased condition, a predilection for a diseased condition, or a prognosis about a diseased condition. | 08-07-2014 |
20140221235 | BIOMARKER ALGORITHM FOR DETERMINING THE TIME OF STROKE SYMPTOM ONSET AND METHOD - A method of determining the time of stroke symptom onset is provided including obtaining a biological sample from an individual; contacting the biological sample with a detection composition comprising at least one expression mediator of a LY96, ARG1, CA4, and a TLR expression mediators, or a combination of these expression mediators, wherein at least one of the expression mediators is associated with an acute phase response of ischemic stroke, for forming a detectable response; and correlating the detectable response with a time of onset of one or more stroke symptoms. A composition is provided having a nucleic acid probe, an antibody, or a purified biomarker that is specific for at least one of a LY96, ARG1, CA4, and TLR expression mediators, or a combination of these expression mediators. | 08-07-2014 |
20140221236 | METABOLOMIC MARKERS FOR PRETERM BIRTH - Panels, kits, and methods for diagnosing or predicting the likelihood of occurrence of preterm birth (PTB) in a subject are disclosed. An exemplary panel includes at least one of a first marker from a first group of markers and a second marker from a second group of markers. A significant decrease in the first marker and a significant increase in the second marker measured in a sample taken from a subject during the second trimester of pregnancy are diagnostic or predictive of an increased risk of preterm birth for the subject. | 08-07-2014 |
20140221237 | MULTIPLEXED DIGITAL ASSAY WITH DATA EXCLUSION FOR CALCULATION OF TARGET LEVELS - Digital assay system, including methods and apparatus, for calculating a level of one or more targets. In an exemplary method, data for amplification of a plurality of targets including a first target may be collected from partitions. A level of the first target may be calculated from only a subset of the data that excludes partitions according to target content. | 08-07-2014 |
20140221238 | MULTIPLEXED DIGITAL ASSAY WITH SPECIFIC AND GENERIC REPORTERS - Digital assay system, including methods, apparatus, and compositions, for performing target assays in partitions each containing a generic reporter and a specific reporter for target amplification. | 08-07-2014 |
20140221239 | SYSTEM FOR DETECTION OF SPACED DROPLETS - System, including methods and apparatus, for spacing droplets from each other and for detection of spaced droplets. | 08-07-2014 |
20140221240 | PREDICTIVE MARKERS FOR OVARIAN CANCER - Methods are provided for predicting the presence, subtype and stage of ovarian cancer, as well as for assessing the therapeutic efficacy of a cancer treatment and determining whether a subject potentially is developing cancer. Associated test kits, computer and analytical systems as well as software and diagnostic models are also provided. | 08-07-2014 |
20140221241 | Mass Dots: Nanoparticle Isotope Tags - Compositions and methods are provided for the use of nanoparticles, which may be referred to herein as mass dots, as mass tags for probes such as antibodies, aptamers, nucleic acids, etc. in multiplexed bioassays with ICP-MS detection. | 08-07-2014 |
20140221242 | GENOME-WIDE METHYLATION ANALYSIS AND USE TO IDENTIFY GENES SPECIFIC TO BREAST CANCER HORMONE RECEPTOR STATUS AND RISK OF RECURRANCE - To better understand the biology of hormone receptor-positive and negative breast cancer and to identify methylated gene markers of disease progression, a genome-wide methylation array analysis was performed on 103 primary invasive breast cancers and 21 normal breast samples using the Illumina Infinium HumanMethylation27 array that queried 27,578 CpG loci. Forty CpG loci showed differential methylation specific to either ER-positive or ER-negative tumors. Each of the 40 ER-subtype-specific loci was validated in silico using an independent, publicly available methylome dataset from The Cancer Genome Atlas (TCGA). In addition, 100 methylated CpG loci were identified that were significantly associated with disease progression. Arrays containing the ER-subtype-specific loci and their use in methods of diagnosis and treatment of breast cancer are provided. | 08-07-2014 |
20140221243 | USE OF CCNE2 AS A STRATIFICATION MARKER IN THE TREATMENT OF BREAST TUMOURS WITH NOVEL PAN-CDK INHIBITORS - The invention relates to the use of CCNE2 as stratification marker in the treatment of breast tumours with novel pan-CDK inhibitors of the formula (I). | 08-07-2014 |
20140221244 | Methods and Compositions for the Treatment and Diagnosis of Colorectal Cancer - The invention provides methods, compositions and kits relating to the detection, diagnosis, treatment of colorectal cancer. | 08-07-2014 |
20140221245 | IMMUNOASSAY METHODS - The invention relates to a method of detecting a disease state or disease susceptibility in a mammalian subject which comprises detecting an antibody in a test sample comprising a bodily fluid from said mammalian subject wherein said antibody is a biological marker of a disease state or disease susceptibility, the method comprising: (a) contacting said test sample with a plurality of different amounts of an antigen specific for said antibody, (b) detecting the amount of specific binding between said antibody and said antigen, (c) plotting or calculating a curve of the amount of said specific binding versus the amount of antigen for each amount of antigen used in step (a) and (d) determining the presence or absence of said disease state or disease susceptibility based upon the amount of specific binding between said antibody and said antigen at each different antigen concentration used. | 08-07-2014 |
20140221246 | HUMAN RARE BLOOD GROUP MULTIPLEX PCR DETECTION METHOD AND KIT - Disclosed are a human rare blood type detection method, a kit, a rapid screening method and applications thereof. By using multiple pairs of PCR specific primers directing to the SNP loci of multiple rare blood types, the SNP loci of multiple rare blood types are simultaneously detected in the same PCR reaction system; and the multiplex PCR detection method and a Pool detection method are combined to rapidly screen the human rare blood types. | 08-07-2014 |
20140235464 | DETECTION AND QUANTIFICATION OF BIOMOLECULES USING MASS SPECTROMETRY - The present invention is directed in part to a method for detecting a target nucleic acid using detector oligonucleotides detectable by mass spectrometry. This method takes advantage of the 5′ to 3′ nuclease activity of a nucleic acid polymerase to cleave annealed oligonucleotide probes from hybridized duplexes and releases labels for detection by mass spectrometry. This process is easily incorporated into a polymerase chain reaction (PCR) amplification assay. The method also includes embodiments directed to quantitative analysis of target nucleic acids. | 08-21-2014 |
20140235465 | METHOD OF USING NEUTRILIZED DNA (N-DNA) AS SURFACE PROBE FOR HIGH THROUGHPUT DETECTION PLATFORM - A method of using Neutrilized DNA (N-DNA) as a surface probe for a high throughput detection platform is disclosed. FET and SPRi are used as high throughput detection platforms to demonstrate that the N-DNA surface probe produces good results and enhances detection sensitivity. The N-DNA modifies the charged oxygen ions (O | 08-21-2014 |
20140235466 | Tumor biomarkers for pancreatic marker - This invention pertains generally to the fields of molecular biology and medical diagnosis. More particularly this invention provides novel biomarkers for the detection of pancreatic cancer comprising at least one messenger RNA and/or up-regulated peptide in pancreatic cancer. The present invention provides biomarkers capable of discriminating between non-neoplastic pancreatic tissues and ductal adenocarcinoma tissues and can be correlated with a probable diagnosis of pancreatic cancer as well as assessing the efficacy of ongoing therapies for this disease. | 08-21-2014 |
20140235467 | Protease-Resistant Systems for Polypeptide Display and Methods of Making and Using Thereof - The present invention generally relates to bacterial polypeptide display systems, libraries using these bacterial display systems, and methods of making and using these systems, including methods for improved display of polypeptides on the extracellular surface of bacteria using circularly permuted transmembrane bacterial polypeptides that have been modified to increase resistance to protease degradation and to enhance polypeptide display characteristics. | 08-21-2014 |
20140235468 | HIGH THROUGHPUT MINIATURIZED ASSAY SYSTEM AND METHODS - The present invention provides an apparatus for conducting biological assays which employs “virtual wells” in lieu of the physical wells of conventional array plates. Also provided are methods of processing a sample and/or culturing cells using the apparatus and systems described herein. In some embodiments, the apparatus includes a first structure having a sheet layer with a plurality of discrete through holes; and a second structure coupled to the first structure, the second structure including a base layer. At least a portion of a first surface of the sheet layer of the first structure is exposed from the second structure, and a second surface of the sheet layer, opposite to the first surface of the sheet layer, is embedded in the base layer of the second structure adjacent the first surface of the base layer. | 08-21-2014 |
20140235469 | MIRNA BIOMARKERS OF PROSTATE DISEASE - This application describes miRNAs that may be used as serum or plasma biomarkers for characterizing prostate disease in a patient. These miRNA biomarkers may be used alone or in combination with other markers for the diagnosis, prognosis, or monitoring of diseases such as prostate cancer. | 08-21-2014 |
20140235470 | MULTIPLEX NUCLEIC ACID DETECTION METHODS - Methods for multiplex ligation-dependent probe amplification include (a) providing a sample tissue to query different target nucleic acids, (b) providing different probe sets for each of the target nucleic acids, each probe set including a first locus specific probe having a first adapter sequence and a first target specific portion and a second locus specific probe having a second adapter sequence, and a second target specific portion adjacent to the first target specific portion, (c) hybridizing the probe sets to the target sequences to form hybridization complexes, (d) ligating the hybridization complexes to form ligated probes, (e) amplifying the ligated probes to form amplicons, the amplifying step being carried out with a first universal primer including a region complementary to the first adapter sequence and a second universal primer including a region complementary to the second adapter sequence, and (f) detecting the amplicons in a detection system by sequencing each of the amplicons. | 08-21-2014 |
20140235471 | Global Proteomic Screening Of Random Bead Arrays Using Mass Spectrometry Imaging - Methods for proteomic screening on random protein-bead arrays by mass spec is described. Photocleavable mass tags are utilized to code a protein library (bait molecules) displayed on beads randomly arrayed in an array substrate. A library of probes (prey) can be mixed with the protein-bead array to query the array. Because mass spec can detect multiple mass tags, it is possible to rapidly identify all of the interactions resulting from this mixing. | 08-21-2014 |
20140235472 | METHODS AND COMPOSITIONS FOR THE DETECTION OF BALANCED RECIPROCAL TRANSLOCATIONS/REARRANGEMENTS - Disclosed are methods and compositions related to the detection of balanced reciprocal translocations/rearrangements and determination of the location of said balanced reciprocal translocations/rearrangements. Also disclosed are methods and compositions relating to the diagnosis of a disease or condition associated with uncontrolled cellular proliferation by the detection of balanced reciprocal translocation/rearrangement. Additionally, also disclosed are kits for the detection of balanced reciprocal translocations/rearrangements. | 08-21-2014 |
20140235473 | Diagnosis and/or Prognosis of Parkinson's Disease Dementia - The present Invention provides a method for diagnosing and/or prognosing Parkinson's disease dementia (PDD) comprising the step of detecting O-glycosylation. in a protein comprising a Ser/Thr motive, in particular Serpin A1, and/or the level of sialic acid on a protein comprising a Ser/Thr motive, in particular Serpin A1. Further, the present invention relates to a molecule for detecting O-linked glycomoieties in a protein comprising a Ser/Thr motive, in particular Serpin A1, and/or glycosylated i so forms of a Ser/Thr motive comprising protein, in particular Serpin A1, for use in the diagnosis and/or prognosis of Parkinson's disease dementia (PDD), Furthermore, the present invention relates to means for diagnosing and/or prognosing Parkinson's disease dementia (PDD) and a kit for diagnosing and/or prognosing Parkinson's disease dementia (PDD). | 08-21-2014 |
20140235474 | METHODS AND PROCESSES FOR NON INVASIVE ASSESSMENT OF A GENETIC VARIATION - Provided in part herein are methods and processes that can be used for non-invasive assessment of a genetic variation which can lead to diagnosis of a particular medical condition or conditions. Such methods and processes can, for example, identify dissimilarities or similarities for one or more features between a subject data set and a reference data set, generate a multidimensional matrix, reduce the matrix into a representation and classify the representation into one or more groups. Methods and processes described herein are applicable to data in biotechnology and other fields. | 08-21-2014 |
20140235475 | TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF - A method is described for using ROR gamma t or ROR alpha to diagnose acne and/or to screen inhibitors of Th17 differentiation. Specifically described are methods of inhibiting ROR gamma t or ROR alpha and use of the screened inhibitors in acne treatment. | 08-21-2014 |
20140235476 | MULTIVALENT BINDING PROTEIN COMPOSITIONS AND METHODS FOR IDENTIFYING VARIANTS OF SAME - Provided are protein, nucleic acid, and cellular libraries of multivalent binding proteins (e.g., DVD-Fab or DVD-Ig molecules) and the use of these libraries for the screening of multivalent binding proteins using cell surface display technology (e.g., yeast display). | 08-21-2014 |
20140235477 | Measurement and Monitoring of Cell Clonality - Methods are provided for the detection and analysis of clonality in a cell population, where parallel sequencing is applied to a nucleic acid sample obtained from the cell population, optionally a population of lymphocytes. Replicate samples are amplified, and sequenced, where identification of coincident sequences in two or more replicates is indicative of clonal expansion. | 08-21-2014 |
20140235478 | Measurement and Comparison of Immune Diversity by High-Throughput Sequencing - High-throughput long read sequencing is used to perform immunogenomic characterization of expressed antibody repertoires in the context of vaccination. Informatic analysis allows global characterizations of isotype distributions, determination of the lineage structure of the repertoire and measure age and antigen related mutational activity. Global analysis of the immune system's clonal structure provides direct insight into the effects of vaccination and provides a detailed molecular portrait of age-related effects. | 08-21-2014 |
20140235479 | SIGNATURES AND PCDETERMINANTS ASSOCIATED WITH PROSTATE CANCER AND METHODS OF USE THEREOF - The present invention provides methods of detecting cancer using biomarkers. | 08-21-2014 |
20140235480 | Ultra-sensitive Detection of Analytes - The present invention provides devices and methods for ultra-sensitive detection of analytes of interest in a rapid and convenient manner. A portable handheld device having replaceable cartridges adaptable for detection of a wide array of analytes (e.g., biological, environmental, and the like) is provided. Sample wells containing bound capture antibodies are provided with microelectrical circuits across each of the sample wells such that there is a nanoscale gap which prevents passage of electrical current. A sample potentially containing the analyte of interest is pumped into a sample well containing bound capture antibodies directed to an first epitope of the analyte of interest. After removal of unbound sample, a metal-labeled antibody directed to a second epitope of the analyte of interest thereby, if the analyte of interest was present in the sample, a metal-labeled antibody-analyte-capture antibody complex remains bound to the sample well. Passage of electrical current across the nanoscale gap (as indicated by a change in electrical resistance, capacitance, impedance and/or conductance, as well as combinations thereof, as compared to the blank control well) thereby reveals the presence of the metal-labeled antibody-analyte-capture antibody complex and, thus, the presence of the analyte of interest in the sample. | 08-21-2014 |
20140235481 | CANCER BIOMARKER AND METHODS OF USE THEREOF - Certain embodiments of the present invention provide methods for identifying subjects that have, or are at risk for developing, cancer. Certain embodiments of the present invention provide methods for determining the effectiveness of cancer treatments. | 08-21-2014 |
20140235482 | IMMUNOGLOBULIN FC POLYPEPTIDES - Methods and compositions involving polypeptides having an aglycosylated antibody Fc domain. In certain embodiments, polypeptides have an aglycosylated Fc domain that contains one or more substitutions compared to a native Fc domain. Additionally, some embodiments involve an Fc domain that is binds some Fc receptors but not others. For example, polypeptides are provided with an aglycosylated Fc domain that selectively binds FcγRI at a level within 2-fold of a glycosylated Fc domain, but that is significantly reduced for binding to other Fc receptors. Furthermore, methods and compositions are provided for promoting antibody-dependent cell-mediated toxicity (ADCC) using a polypeptide having a modified aglycosylated Fc domain and a second non-Fc binding domain, which can be an antigen binding region of an antibody or a non-antigen binding region. Some embodiments concern antibodies with such polypeptides, which may have the same or different non-Fc binding domain. | 08-21-2014 |
20140235483 | PARALLEL DETERMINATION OF COMPETITIVE BINDING AND TARGET SPECIFICITY OF A BINDING COMPOUND LIBRARY BY HIGH-THROUGHPUT DNA SEQUENCING - The invention is directed to a method for analyzing the competitive binding and target (or ligand) specificity of large numbers of candidate binding compounds with respect to a predetermined reference compound. That is, the invention provides a method for essentially conducting a massively parallel ELISA on each member of an entire library of candidate binding compounds at the same time. Instead of determining binding characteristics from a series of colorimetric or fluorometric readouts, such characteristics are determined from a series of frequencies of bound and unbound library members which, in turn, are determined by high-throughput sequencing of their encoding nucleic acids. In one aspect, predetermined reference compounds are proteins and candidate binding compounds are members of a mutant library based on or related to, the predetermined reference compound. | 08-21-2014 |
20140235484 | METHODS FOR DETECTION AND DIFFERENTIATION OF ORIGIN OF VIRAL DNA - The invention disclosed herein provides methods for identifying the origin of viral DNA in a sample by detecting the methylation state of at least one CpG site on a target site of the genome of a virus of interest, and determining whether the origin of the viral DNA is from a cell, such as a tumor cell, or a virion, wherein when the methylation state is positive for methylation, the viral DNA is from a cell, and wherein when the methylation state is negative for methylation, the viral DNA is from a virion. Use of these methods for diagnosis or monitoring, and/or treatment of a subject infected with a virus known to cause cancer and related disease are also provided. | 08-21-2014 |
20140235485 | Methods And Devices For Amplification Of Nucleic Acid - The present invention relates to methods and devices for amplifying nucleic acid, and, in particular, amplifying so as to generate products on a surface without the use of emulsions. In a preferred embodiment, a plurality of groups of amplified product are generated on the surface, each group positioned in different (typically predetermined) locations on said surface so as to create an array. | 08-21-2014 |
20140235486 | Methods and Compositions for the Treatment and Diagnosis of Breast Cancer - The invention provides for methods of diagnosis, prognosis and treatment of cancer including, but not limited to, breast cancer. | 08-21-2014 |
20140235487 | ORAL CANCER RISK SCORING - Neural net method of computing oral cancer risk based on inputs such as age, gender, smoking status, morphological characteristics of sampled cells, and levels of biomarkers in samples cells. | 08-21-2014 |
20140235488 | MICRORNA PATTERNS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF MELANOMA - The present invention relates to methods for diagnosing, staging, prognosticating and treating melanoma based on evaluating the expression of specific patterns of oncogenic or suppressive microRNA (miR) molecules in a patient in need thereof. | 08-21-2014 |
20140235489 | Integrated Membrane Sensor - An integrated microelectronic sensor is provided in a disposable flow membrane sensing device. The integrated sensors detect electromagnetic effect labels in flow detection zones above the sensor in the membrane. The labels are small particles that give off a detectable electromagnetic signal. They are commonly used for isolating and quantifying biochemical targets of interest. The sensors are fabricated using planar integrated circuit technologies. Sensors can detect labels of several types including magnetic, electric, and photonic. These types all have in common the fact that the sensor detects the label at a distance. Magnetoresistive sensors for detecting magnetic labels, and photodiodes for detecting photonic labels are described. | 08-21-2014 |
20140235490 | METHODS FOR DETECTION OF BOTULINUM NEUROTOXIN - Provided herein is a large immuno-sorbent surface area assay (ALISSA) for the rapid and sensitive detection of botulinum neurotoxins (BoNTs) and anthrax toxin. This assay is designed to capture a low number of toxin molecules and to measure their intrinsic protease activity via conversion of a fluorogenic or luminescent substrate. Also provided herein are novel peptides that can be specifically cleaved by BoNT and novel peptides that are resistant to cleavage by BoNT. The combination of these cleavable and control peptides can be used for implementation of an exemplary ALISSA used to specifically detect BoNT enzymatic activity. Furthermore, the ALISSA as described herein may also be used in a column based format for use in a high-throughput system for testing large quantities of samples. | 08-21-2014 |
20140235491 | METHOD OF APPLYING ETFB TO ABNORMAL PROLIFERATION OF CELL, AND ABNORMAL PROLIFERATION INHIBITOR - Provided is a method for identifying and suppressing abnormal growth of fibroblasts at an early stage. Provided is a method for identifying the growth state of fibroblasts using as an index the level of expression of ETFB (electron transfer flavoprotein beta subunit), comprising: judging, in cases where the level of expression of ETFB is high, that there is a high probability that fibroblasts are abnormally growing; and judging, in cases where the level of expression of ETFB is low, that there is a high probability that fibroblasts are normally growing. Further, by inhibition of ETFB, abnormal growth of fibroblasts can be suppressed. | 08-21-2014 |
20140235492 | METHODS FOR PREPARING SINGLE DOMAIN ANTIBODY MICROARRAYS - The present invention relates to a method for preparing sd Ab microarray comprising the step consisting of: —i) providing a host cell capable of expressing a biotinylation enzyme —ii) transforming said host cell with a nucleic acid encoding for a fusion protein wherein a single domain antibody is fused at its carboxy terminal end to a biotinylation peptide —iii) culturing said host cell in presence of biotin in such a way that said fusion protein and biotinylation enzyme are expressed, resulting in biotinylation of said fusion protein —iv) lysing said host cell as cultured at step iii) —v) spotting the lysate obtained at step iv) on a solid sup port coated with an agent selected from the group consisting of avidin, streptavidin and/or any art known derivative of these agents A further object of the invention relates to a sd Ab microarray obtainable by the method of the invention. | 08-21-2014 |
20140235493 | MULTIMODE PLATFORM FOR DETECTION OF COMPOUNDS - A muitimode gas sensor platform ( | 08-21-2014 |
20140235494 | Methods, Kits and Computer Program Products using Hepatocellular Carcinoma (HCC) Biomarkers - Methods of determining the presence or risk of liver disease or other diseases in a subject include measuring a level of a saccharide selected from N-acetylneuraminic acid, N-acetylglucosamine, N-acetylgalactosamine, or a combination thereof on one or more glycosylated proteins and the total amount of alpha-fetoprotein in a biological sample from the subject. Glycosylated proteins include but are not limited to vascular endothelial growth factor, lymphatic vessel endothelial hyaluronan receptor, E-cadherin, alpha 1 acid glycoprotein, glypican-3, galectin-3, and any combination thereof. The presence or risk of disease in the subject is determined responsive to a value based on the level of glycosylation and amount of alpha-fetoprotein. | 08-21-2014 |
20140235495 | CELL RESPONSE ASSAY FOR CANCER AND METHODS OF PRODUCING AND USING SAME - A cell response assay for cancer is provided. In the assay, the levels of a cancer cell type biomarker, a chemo resistance biomarker and a metastatic potential biomarker are simultaneously measured in a biological sample. | 08-21-2014 |
20140235496 | STIMULUS-ELICITED GENOMIC PROFILE MARKERS OF A NEURODEGENERATIVE CONDITION - The present disclosure is directed to methods of diagnosing a neurodegenerative condition, such as Alzheimer's disease, comprising contacting a cell sample from a subject with at least one stimulus, such as a protein and/or polysaccharide mixture, a protein kinase C activator, an Aβ oligomer, an agent, and combinations thereof; and detecting the expression of at least one gene in the cell sample. Methods may further comprise comparing the expression of the at least one gene in the cell sample to the expression of the same at least one gene in control cells; and determining whether the subject has the neurodegenerative condition (e.g., Alzheimer's disease), wherein a change in the expression of the at least one gene in the cell sample compared to the expression of the same at least one gene in the control cells indicates the subject has the neurodegenerative condition (e.g., Alzheimer's disease). | 08-21-2014 |
20140235497 | Identification of Antigen-Specific Adaptive Immune Responses Using ARM-PCR and High-Throughput Sequencing - Disclosed is a method for correlating at least one amino acid sequence from an antibody isolated from human or animal blood with at least one DNA sequence corresponding to the antibody in the immunorepertoire of the human or animal. The method also provides a means for pairing heavy and light chains to produce synthesized monoclonal antibodies. | 08-21-2014 |
20140243222 | MULTI-SPOT METAL-CAPPED NANOSTRUCTURE ARRAY NUCLEIC ACID CHIP FOR DIAGNOSING OF CORNEAL DYSTROPHY AND PREPARATION METHOD THEREOF PRODUCING SAME - A multi-spot metal-capped nanostructure array nucleic acid chip for diagnosing corneal dystrophy, and more particularly to a multi-spot metal-capped nanostructure array nucleic acid chip capable of employing LSPR (localized surface plasmon resonance) optical properties, a preparation method thereof, and a multi-spot metal-capped nanostructure array nucleic acid chip for diagnosing BIGH3 gene mutations, which can diagnose various corneal dystrophies. The metal-capped nanostructure array nucleic acid chip can be combined with analysis devices, including a light source, a detector, a spectrophotometer and a computer, to provide an LSPR optical property-based optical biosensor, and the use of the multi-spot metal-capped nanostructure array nucleic acid chip for diagnosing BIGH3 gene mutations allows the simultaneous diagnosis of various corneal dystrophies that are genetic ocular diseases. | 08-28-2014 |
20140243223 | ULTRA-SENSITIVE DETECTION OF MOLECULES ON SINGLE MOLECULE ARRAYS - The present invention relates to systems and methods for detecting analyte molecules or particles in a fluid sample and in some cases, determining a measure of the concentration of the molecules or particles in the fluid sample. Methods of the present invention may comprise immobilizing a plurality of analyte molecules or particles to form a plurality of complexes, releasing at least a portion of some of the plurality of complexes, determining at least a portion of the plurality of complexes released, and determining a measure of the concentration of the analyte molecules or particles in a fluid sample. | 08-28-2014 |
20140243224 | GEL PATTERNED SURFACES - Provided is an array including a solid support having a surface, the surface having a plurality of wells, the wells containing a gel material, the wells being separated from each other by interstitial regions on the surface, the interstitial regions segregating the gel material in each of the wells from the gel material in other wells of the plurality; and a library of target nucleic acids in the gel material, wherein the gel material in each of the wells comprises a single species of the target nucleic acids of the library. Methods for making and using the array are also provided. | 08-28-2014 |
20140243225 | Multiplex Compositions And Methods For Quantification Of Human Nuclear DNA And Human Male DNA And Detection of PCR Inhibitors - The invention relates to a method for simultaneous quantification of human nuclear DNA and human male DNA in a biological sample while also detecting the presence of PCR inhibitors in a single reaction. The multiplex quantification method also provides a ratio of human nuclear and male DNA present in a biological sample. Such sample characterization is useful for achieving efficient and accurate results in downstream molecular techniques such as genotyping. | 08-28-2014 |
20140243226 | SIGNATURES OF RADIATION RESPONSE - The present invention relates, in general, to gene expression profiles, and in particular, to a peripheral blood gene expression profile of an environmental exposure, ionizing radiation. The invention further relates to methods of screening patients for radiation exposure based on gene expression profiling and to kits suitable for use in such methods. | 08-28-2014 |
20140243227 | CULTURE MEDIA FOR STEM CELLS - Culture media and methods for expanding and differentiating populations of stem cells and for obtaining organoids. Expanded cell populations and organoids obtainable by methods of the invention and their use in drug screening, toxicity assays and regenerative medicine. | 08-28-2014 |
20140243228 | HIGH-THROUGHPUT SYSTEM AND METHOD FOR IDENTIFYING ANTIBODIES HAVING SPECIFIC ANTIGEN BINDING ACTIVITIES - System and methods are disclosed for identifying and isolating antibodies with specific affinity with an antigen of interest. Multiple DNA libraries encoding antibodies or their fragments are designed such that the encoded antibodies from different libraries are tagged differently. These libraries may be transformed into yeast cells. The variants of the antibodies are displayed on the surface of the yeast cells and flow cytometry may be used to sort the cells based on antigen affinity and the different tags on the antibodies. By allowing multiple libraries to be screened simultaneously, the disclosed methods help improve the efficiency of affinity. | 08-28-2014 |
20140243229 | METHODS AND PRODUCTS RELATED TO GENOTYPING AND DNA ANALYSIS - The invention encompasses methods and products related to genotyping. The method of genotyping of the invention is based on the use of single nucleotide polymorphisms (SNPs) to perform high throughput genome scans. The high throughput method can be performed by hybridizing SNP allele-specific oligonucleotides and a reduced complexity genome (RCG). The invention also relates to methods of preparing the SNP specific oligonucleotides and RCGs, methods of fingerprinting, determining allele frequency for a SNP, characterizing tumors, generating a genomic classification code for a genome, identifying previously unknown SNPs, and related compositions and kits. | 08-28-2014 |
20140243230 | GENE EXPRESSION SIGNATURE FOR CLASSIFICATION OF KIDNEY TUMORS - The present invention provides a method for classification of kidney tumors through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA expression framework allows optimization of treatment, and determination of specific therapy. | 08-28-2014 |
20140243231 | METHODS AND COMPOSITIONS FOR THE EFFICIENT REUSE OF MULTIPLY DYED PARTICLES - Provided herein are compositions and methods for reuse and/or recycling of internally dyed particles useful for multiplex assays of target analytes. | 08-28-2014 |
20140243232 | NUCLEIC ACID COMPLEXITY REDUCTION - In some embodiments, the present teachings provide compositions, systems, methods and kits for reducing the complexity of nucleotide sequences in a nucleic acid sample comprising the steps: hybridizing a plurality of polynucleotide constructs to at least one blocker oligonucleotide and to at least one capture oligonucleotide, wherein the plurality of polynucleotide constructs include a plurality of polynucleotides each joined to at least one nucleic acid adaptor, wherein the at least one nucleic acid adaptor can hybridize to the at least one blocker oligonucleotide, and wherein the at least one capture oligonucleotide can hybridize to at least a portion of target polynucleotides that are a sub-population of the plurality of polynucleotides, so as to produce a capture duplex. | 08-28-2014 |
20140243233 | METHODS FOR MEASURING HDL SUBPOPULATIONS - This invention provides a capture/detection antibody-based method for measuring the amount of a high density lipoprotein (HDL) subpopulation present in a sample, wherein each particle of the HDL subpopulation being measured is characterized by the presence of a plurality of defined protein epitopes. This invention also provides related analytical and diagnostic methods, as well as kits for performing same. | 08-28-2014 |
20140243234 | NUCLEIC ACID COMPOSITIONS, METHODS AND KITS FOR RAPID PAIRING OF AFFINITY AGENTS - The present inventions relate to the selection and production of specific proteins or peptides with desired properties. The inventions relate to the agents and methods of identifying select peptides or proteins with specific binding properties or greater enzymatic performance from vast numbers of variants. | 08-28-2014 |
20140243235 | PERIPHERAL NEUROPATHY DIAGNOSIS - Genes whose expression is correlated with the presence of CIDP or vasculitic neuropathy are disclosed. Probes and sets of nucleic acids and proteins specific for these genes are described, as are molecular and immunological methods for aiding in the diagnosis of these disease conditions in a subject. | 08-28-2014 |
20140243236 | POLYMERIC CARRIERS FOR IMMUNOHISTOCHEMISTRY AND IN SITU HYBRIDIZATION - Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays. | 08-28-2014 |
20140243237 | METHOD FOR EVALUATING DRUG SENSITIVITY AND DISEASE VULNERABILITY BY ANALYZING CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN GENE - The present invention provides a method for evaluating (predicting, etc.) an individual difference (the tendency of every individual) in terms of drug sensitivity and disease vulnerability, comprising using a gene polymorphism of a cyclic AMP responsive element binding protein gene or the like. The method for evaluating drug sensitivity and the method for evaluating disease vulnerability according to the present invention comprise associating a gene polymorphism of a cyclic AMP responsive element binding protein gene or a haplotype constituted by the gene polymorphism with the drug sensitivity and disease vulnerability of an individual. | 08-28-2014 |
20140243238 | METHODS OF CO-DETECTING MRNA AND SMALL NON-CODING RNA - Disclosed herein are methods of co-detecting presence of target messenger RNA (mRNA) and small non-coding RNA (for example, miRNA) in a sample. The disclosed methods can be used to simultaneously detect mRNA and small non-coding RNA in a single assay (for example in the same reaction or the same well of a multi-well assay). The methods can include contacting a sample with a plurality of nuclease protection probes including at least one probe which specifically binds to a target mRNA and at least one probe which specifically binds to a target small non-coding RNA, contacting the sample with a nuclease specific for single-stranded nucleic acids, and detecting the NPP, for example on a microarray. | 08-28-2014 |
20140243239 | MULTIPLEXED KINASE INHIBITOR BEADS AND USES THEREOF - This invention is directed to a multi-analyte column comprising two or more layers with a first solid support having specific binding affinity for kinases and a second solid support having non-specific binding affinity for kinases. Methods are also provided, including methods of detecting low abundance kinases, predicting resistance to chemotherapy, determining cancer prognosis, and improving the effectiveness of a treatment regimen. | 08-28-2014 |
20140243240 | microRNA EXPRESSION PROFILING OF THYROID CANCER - Methods of screening an individual for thyroid cancer or a potential for developing thyroid cancer, and for diagnosing thyroid cancer or a potential for developing thyroid cancer in an individual subject in need thereof includes: determining expression levels of at least one miRNA selected from a first group of specific miRNAs; compare the expression levels of the at least one miRNA from the first group with the expression levels of the corresponding miRNA established for a control individual not having thyroid cancer or nodular hyperplasia, and identifying differences in the miRNA expression levels between the at least one sample from said individual subject and miRNA expression levels established for a control individual not having thyroid cancer or nodular hyperplasia. Methods of treating an individual subject having thyroid cancer and/or a potential for developing thyroid cancer using these procedures in selecting the most appropriate method of treatment for the particular stage and/or type of thyroid cancer. | 08-28-2014 |
20140249040 | ULTRA SENSITIVE METHOD FOR IN SITU DETECTION OF NUCLEIC ACIDS - Disclosed is a method for in situ detection of one or more target nucleic acids based on a combination of RNAscope® method and a general ISH signal amplification method. This new method produces high signal intensity and while keeps low background noise of signal amplification. The result can be consistently reproduced and the method can be easily adopted for routine clinic diagnostic use. Further, the invention relates to a kit, comprising the components of RNAscope® assay and a general ISH signal amplification assay, for sensitive detection of one or more target nucleic acids. | 09-04-2014 |
20140249041 | Marker of Prostate Cancer - An SLC18A2 gene serves as a marker of prostate cancer. Methods are provided for diagnosing prostate cancer, predicting or prognosticating the disease outcome, predicting recurrence following surgery, and monitoring disease progression in an individual having prostate cancer. The methods relate to determining the methylation state of an SLC18A2 gene and/or determining the level of transcription or translation of the gene in a sample from the individual. Methods of treating prostate cancer are also provided. The invention also pertains to compositions and kits for use in the methods. | 09-04-2014 |
20140249042 | DETECTION OF BIOAGENTS USING A SHEAR HORIZONTAL SURFACE ACOUSTIC WAVE BIOSENSOR - Viruses and other bioagents are of high medical and biodefense concern and their detection at concentrations well below the threshold necessary to cause health hazards continues to be a challenge with respect to sensitivity, specificity, and selectivity. Ideally, assays for accurate and real time detection of viral agents and other bioagents would not necessitate any pre-processing of the analyte, which would make them applicable for example to bodily fluids (blood, sputum) and man-made as well as naturally occurring bodies of water (pools, rivers). We describe herein a robust biosensor that combines the sensitivity of surface acoustic waves (SAW) generated at a frequency of 325 MHz with the specificity provided by antibodies and other ligands for the detection of viral agents. In preferred embodiments, a lithium tantalate based SAW transducer with silicon dioxide waveguide sensor platform featuring three test and one reference delay lines was used to adsorb antibodies directed against Coxsackie virus B4 or the negative-stranded category A bioagent Sin Nombre virus (SNV), a member of the genus Hantavirus, family Bunyaviridae, negative-stranded RNA viruses. Rapid detection (within seconds) of increasing concentrations of viral particles was linear over a range of order of magnitude for both viruses, although the sensor was approximately 50×10 | 09-04-2014 |
20140249043 | Multiplexed Analyses of Test Samples - The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. The described methods, devices, kits, and reagents facilitate the detection and quantification of a non-nucleic acid target (e.g., a protein target) in a test sample by detecting and quantifying a nucleic acid (i.e., an aptamer). The methods described create a nucleic acid surrogate for a non-nucleic acid target, thus allowing the wide variety of nucleic acid technologies, including amplification, to be applied to a broader range of desired targets, especially protein targets. The disclosure further describes aptamer constructs that facilitate the use of aptamers in a variety of analytical detection applications. | 09-04-2014 |
20140249044 | Cell-Based Methods for Coupling Protein Interactions and Binding Molecule Selection and Diversification - The invention relates to cell-based methods for diversifying, expressing and selecting binding molecules, e.g., antibodies, and target molecules to which they bind, all of which are expressed in the same cell. The target molecule can be a member of a ligand binding pair comprising a cell-surface expressed ligand binding receptor molecule and its cognate ligand, which interact within the cell. The methods provide retaining either the antibody or its target in a cell organelle as the site of binding and interaction. By performance of the methods, the binding or non-binding of the antibody to its target molecule within the cell produces a cell phenotype that is detectable at the cell surface via high throughput assays, e.g., flow cytometry. The methods are particularly useful for generating, recovering and providing antibodies that have optimal target molecule binding properties or activities for potential therapeutic use. Methods for generating diversity in such antibodies are also provided. | 09-04-2014 |
20140249045 | NOVEL USE OF LEUCYL TRNA SYNTHETASE - Provided is a method of screening for agents for preventing or treating mTORC1 mediated diseases by screening test agents to determine test agents that inhibit the binding ability of LRS to RagD, or RagD GTPases, and a method of reducing cell size as compared to the control group, including inhibiting the expression of intracellular LRS in the cells. | 09-04-2014 |
20140249046 | SSR MARKERS FOR PLANTS AND USES THEREOF - Simple sequence repeat (SSR) markers identified in | 09-04-2014 |
20140249047 | GENETIC MARKER FOR THE DIAGNOSIS OF DEMENTIA WITH LEWY BODIES - Specific polymorphisms in BChE gene have been found which allow determining whether a patient suffers from dementia with Lewy bodies (DLB), and allow distinguishing it from Alzheimer's disease. The invention provides an in vitro method for the diagnosis of DLB comprising determining in a biological sample from a subject, the genotype of the following polymorphisms in butyrylcholinesterase (BChE) gene: the polymorphic site at position 3687 in NCBI Accession Number NG_009031 (i.e. SEQ ID NO: 1) the polymorphic site at position 4206 in SEQ ID NO: 1, the polymorphic site at position 4443 in SEQ ID NO: 1. and the polymorphic site at position 68974 in NCBI Accession Number NG_009031 (i.e. position 934 in SEQ ID NO: 26). | 09-04-2014 |
20140249048 | Novel Prostate Kallikrein Allergen - Methods for in vitro diagnosis of type I allergy comprises the steps of contacting an immunoglobulin-containing body fluid sample from a patient suspected of having type I allergy with a variant or fragment of the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, which variant or fragment shares epitopes for antibodies with the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1; and detecting the presence, in the sample, of IgE antibodies specifically binding to the variant or fragment. The presence of such IgE antibodies specifically binding to the variant or fragment is indicative of a type I allergy in the patient. | 09-04-2014 |
20140249049 | USE OF CD5 ANTIGEN-LIKE AS A BIOMARKER FOR DIABETIC NEPHROPATHY - Biomarkers for pre-Diabetes, Diabetes and/or a Diabetes related conditions, and methods of their use, including the biomarkers in Tables 1 and 2 such as peroxiredoxin-2, complement C1q subcomponent subunit B, sulfhydryl oxidase 1 and apolipoprotein A-IV. | 09-04-2014 |
20140249050 | METHOD AND DEVICE FOR THE MANIPULATION OF MICROCARRIERS FOR AN IDENTIFICATION PURPOSE - Disclosed is a method for the manipulation for an identification purpose of a microcarrier comprising the steps of: (a) an identification purpose step of the microcarrier; and (b) a positioning and orientation step prior to or during the identification purpose step. Also disclosed is an apparatus for the manipulation for identification purposes of a microcarrier comprising means for identification purposes such as a microscope or labelling means such as a high spatial resolution light source, and means for the positioning and orientation of the microcarriers. | 09-04-2014 |
20140249051 | METHOD AND SYSTEM FOR ABO ANTIBODY DETECTION AND CHARACTERIZATION - The present application discloses a system and method for ABO antibody detection and characterization that can provide an alternative means for assessment and management of ABO-incompatible and ABO-compatible transplants. The method and system comprises determining an anti-ABO blood group antigen subtype antibody profile of a subject using a biological sample from the subject. The method and system can be used to evaluate the suitability of a donor blood or tissue product for a recipient subject by comparing the determined anti-ABO antigen subtype antibody profile of the recipient subject with the ABO histo-blood group or ABO histo-blood subgroup of a donor blood or tissue product. In order to define the subject's ABO histo-blood subgroup, the determined antibody profile is compared to known ABO histo-blood group antigen subtype profiles and/or known anti-ABO antigen subtype antibody profiles for ABO histo-blood subgroups to identify the ABO histo-blood subgroup of the subject. Profiles can be established by applying a sample to an array of surface-bound ABO antigens selected from the group of type I to type VI antigens of each blood group A, B or H. | 09-04-2014 |
20140249052 | Polypeptides and their use - The present invention provides polypeptides that bind to inorganic solid surfaces, structures comprising such polypeptides, and methods of making such structures. | 09-04-2014 |
20140249053 | NANOPARTICLE PROBES, METHODS, AND SYSTEMS FOR USE THEREOF - Methods of identifying geological materials of interest comprising (i) providing a nanoprobe composition comprising one or more nanoprobes; wherein the nanoprobe includes (a) at least one tag; and (b) at least one signal generator; (ii) introducing the nanoprobes to a geological material; and (iii) detecting the presence of a signal generated by the signal generator on association of the tag with a target. Nanoprobe compositions identify geological materials, systems include such nanoprobe compositions, and methods use such nanoprobe compositions for the evaluation of geological materials. | 09-04-2014 |
20140256573 | RAPID QUANTIFICATION OF BIOMOLECULES IN A SELECTIVELY FUNCTIONALIZED NANOFLUIDIC BIOSENSOR AND METHOD THEREOF - A method and device for the rapid quantification of biomolecules ( | 09-11-2014 |
20140256574 | Compositions and Methods for Diagnosing Diseases and Disorders Associated with Beta Cell Death - The present invention relates to compositions and methods for detecting cell death by detecting cell DNA in a biological sample. The invention relates the discovery that the presence of hypomethylated β cell DNA outside of the pancreas of a subject is indicative of β cell death. Thus, in one embodiment, the invention is a method of detecting hypomethylated β cell insulin DNA in a biological sample of a subject including the steps of: obtaining a biological sample from the subject, where the biological sample is obtained from outside of the subject's pancreas and where the biological sample contains β cell insulin DNA; determining the methylation status of at least one of the CpG dinucleotides in the β cell insulin DNA, where when at least one of the CpG dinucleotides in the β cell insulin DNA is determined to be unmethylated, the hypomethylated β cell insulin DNA is detected. | 09-11-2014 |
20140256575 | SYNTHESIS OF LONG FISH PROBES - A method comprising: synthesizing a set of overlapping oligonucleotides that comprises probe sequences that hybridize to unique sequences in a chromosome, assembling the overlapping oligonucleotides in a way that produces one or more double stranded polynucleotides that each comprises multiple probe sequences, labeling the one or more double stranded polynucleotides to produce one or more labeled probes, and hybridizing the labeled probes to an intact chromosome, in situ, is provided. | 09-11-2014 |
20140256576 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 09-11-2014 |
20140256577 | SEQUENCE-SPECIFIC DETECTION OF NUCLEOTIDE SEQUENCES - A method for detecting the presence of a target nucleotide sequence in a sample of DNA is described herein in which a test sample comprising single stranded DNA is exposed to a DNA probe and a nicking endonuclease under conditions that would permit sequence-specific hybridization of the probe to a complementary target sequence. The probe comprises a sequence complementary to the target sequence to be detected and this sequence also includes a recognition sequence for the nicking endonuclease. If the sample contains the target sequence, the probe hybridizes to the target and is cleaved by the nicking endonuclease, which leaves the target intact. Observing the presence of probe cleaved by the nicking endonuclease indicates the presence of the target nucleotide sequence in the sample of DNA. | 09-11-2014 |
20140256578 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HUNTINGTON'S DISEASE - Methods and compositions for reducing expression of a mutant huntingtin (mHTT) protein in a cell are provided. Such methods include contacting the cell with an effective amount of a nucleic acid silencing agent targeting a differentiating polymorphism in RNA encoding the mHTT. | 09-11-2014 |
20140256579 | Protein Arrays - Protein arrays are provided comprising single domain antibodies obtainable from | 09-11-2014 |
20140256580 | ASSAY FOR DETECTING CLOSELY-RELATED SEROTYPES OF HUMAN PAPILLOMAVIRUS (HPV) - A real time Taq-Man PCR assay for detecting multiple serotypes of human papillomavirus (HPV) wherein the number of serotypes detected exceeds the number of colorimetric channels for detection. A biological sample is combined with three oligonucleotide primer/probe sets such that the probes and primers anneal to a target sequence. Each primer/probe set is at least preferential for a specific serotype of an organism. The first and second primer/probe sets are degenerate with respect to each other. The third primer/probe set is not degenerate with respect to the first and second primer/probe sets and discriminates for a third serotype. The third primer/probe set has a signal moiety that emits signal at a wavelength that is the same or different from the wavelength emitted by the signal moiety of the degenerate primer/probe set probes. The target sequences, if present, are amplified and detected. | 09-11-2014 |
20140256581 | VIRAL NANOARRYS AND SENSORS COMPRISING THE SAME - The present invention provides arrays comprising polypeptides associated with viruses that are immobilized to an electrode in a directional orientation such that the surface area of the electrode and the sensitivity of the electrode is increased. The invention also provides for methods of diagnosing and/or prognosing a certain disease or disorder through contacting a sample from a patient with an array comprising the polypeptides associated with viruses. | 09-11-2014 |
20140256582 | OPTIMIZED PROBES AND PRIMERS AND METHODS OF USING SAME FOR THE DETECTION, SCREENING, ISOLATION AND SEQUENCING OF MRSA, MSSA, STAPHYLOCOCCUS MARKERS, AND THE ANTIBIOTIC RESISTANCE GENE MEC A - Described herein are primers and probes useful for the detection, screening, isolation and sequencing of MRSA, MSSA, Staphylococci markers, MR-CoNS and the antibiotic resistance gene mecA. | 09-11-2014 |
20140256583 | DETECTION OF HUMAN ENDOGENOUS RETROVIRUS EXPRESSION IN CANCER AND NORMAL CELLS - The invention relates to human endogenous retrovirus env (HERV-WL) polypeptides, nucleotide sequences, HERV-WL antibodies, methods to detect cancer, and methods to determine the effectiveness of the treatment of cancer. | 09-11-2014 |
20140256584 | DIAGNOSIS OF MELANOMA AND SOLAR LENTIGO BY NUCLEIC ACID ANALYSIS - The present invention provides methods for diagnosing melanoma and/or solar lentigo in a subject by analyzing nucleic acid molecules obtained from the subject. The present invention also provides methods for distinguishing melanoma from solar lentigo and/or dysplastic nevi and/or normal pigmented skin. The methods include analyzing expression or mutations in epidermal samples, of one or more skin markers. The methods can include the use of a microarray to analyze gene or protein profiles from a sample | 09-11-2014 |
20140256585 | REPETITIVE REVERSE TRANSCRIPTION PARTITION ASSAY - Methods, compositions, and kits are provided for quantifying RNA molecules in a partitioned sample via multiple reverse transcription reactions. | 09-11-2014 |
20140256586 | METHODS AND COMPOSITIONS FOR DIAGNOSIS OF COLORECTAL CANCER - Methods and compositions are provided for diagnosing colorectal cancer in a mammalian subject, preferably in a serum or plasma sample of a human subject. The methods and compositions enable the detection or measurement in the sample or from a protein level profile generated from the sample, the protein level of one or more specified biomarkers. Comparing the protein level(s) of the biomarker(s) in the subject's sample or from protein abundance profile of multiple biomarkers, with the level of the same biomarker(s) or profile in a reference standard, permits the determination of a diagnosis of colorectal cancer, or the identification of a risk of developing colorectal cancer, or enables the monitoring of the status of progression or remission of colorectal cancer in the subject followed during a therapeutic protocol. | 09-11-2014 |
20140256587 | INDIRECT ANTIGEN-SPECIFIC T CELL RECOGNITION ASSAY - The present invention provides a method for analyzing simultaneously multiple human antigen-specific cell populations of a sample, the sample comprising B cells and antigen-specific cells, the method comprising a) separation of B cells from said sample, b) dividing the B cells into n sub-samples, c) differentially labeling the B cells of said sub-samples, wherein at least n-1sub-samples are labeled, d) pulsing of the B cells of each sub-sample with single or multiple peptides, e) pooling of the labeled and peptide-pulsed B cells with cells of said sample comprising said antigen-specific cells, f) co-cultivation of the cells of step e), g) flow cytometry analysis of the B cells with regard to their cell number and CD83 expression, thereby determining the potency of said antigen-specific cells in said sample. | 09-11-2014 |
20140256588 | METHODS FOR CONDUCTING MULTIPLEXED ASSAYS - The invention relates to methods for conducting solid-phase binding assays. One example is an assay method having improved analyte specificity where specificity is limited by the presence of non-specific binding interactions. | 09-11-2014 |
20140256589 | METHODS FOR ACCELERATED SELECTION OF POLYPEPTIDES - In certain embodiments, the disclosure provides a method for generating an mRNA-protein fusion molecule. In other embodiments, the disclosure provides a method for selecting a desired polypeptide. | 09-11-2014 |
20140256590 | METHOD OF ANALYSING A BLOOD SAMPLE OF A SUBJECT FOR THE PRESENCE OF A FOETAL DISEASE OR CONDITION MARKER - The present invention relates to a method of analysing a blood sample of a subject carrying a foetus for the presence of a foetal disease or condition marker, said method comprising the steps of a) extracting nucleic acid from anucleated blood cells, preferably thrombocytes, in said blood sample to provide an anucleated blood cell-extracted nucleic acid fraction, and b) analysing said anucleated blood cell-extracted nucleic acid fraction for the presence of a foetal disease or condition marker, wherein said foetal disease or condition marker is a nucleic acid of a foetus, or wherein said foetal disease or condition marker is a foetal disease or condition-specific expression profile of genes of a cell of said foetus. | 09-11-2014 |
20140256591 | MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Ovarian Cancer Using a Real-Time PCR Platform - Methods and compositions for the diagnosis, prognosis and/or treatment of ovarian cancer are disclosed. | 09-11-2014 |
20140256592 | DETERMINING RESPONSIVENESS OF AUTOIMMUNE PATIENTS TO DMARD TREATMENT - The invention is directed to a method of screening patients suffering from an autoimmune disease for responsiveness to treatment with a disease modifying anti-rheumatic drug, or DMARD. In some embodiments the method of the invention comprises the steps of (a) measuring an IgH clonotype profile from B-cells in a sample of tissue affected by the autoimmune disease, the IgH clonotype profile including IgH clonotypes, IgG clonotypes, and IgD clonotypes; and (b) classifying a patient as being more likely to respond to DMARD treatment, whenever the patient has, with respect to reference levels characteristic of normal tissue, elevated IgH concentration, elevated IgG fraction, and reduced IgD fraction. | 09-11-2014 |
20140256593 | PLASMONIC SUBSTRATES FOR METAL-ENHANCED FLUORESCENCE BASED SENSING, IMAGING AND ASSAYS - Techniques for metal enhanced fluorescence include determining a calibration curve that relates concentration of a particular analyte to at least one of intensity or lifetime of fluorescent emissions at a functionalized substrate in response to incident light, for a plurality of known concentrations of the particular analyte mixed with a reagent. The functionalized substrate comprises a plasmonic substrate and a bioactive target molecule that has an affinity for the particular analyte. The reagent comprises a detection molecule. A concentration of the particular analyte in a sample is determined directly from the calibration curve and measurements, in response to the incident light, of at least one of intensity or lifetime of fluorescent emissions at the functionalized substrate in contact with the sample and reagent. | 09-11-2014 |
20140274753 | EPIGENETIC BIOMARKER ZNF545 FOR DIAGNOSING AND PROGNOSIS OF GASTRIC CANCER - The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the ZNF545 gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating gastric cancer by increasing ZNF545 gene expression or activity | 09-18-2014 |
20140274754 | GENERATION OF pH/TEMPERATURE/IONIC GRADIENTS ON A LATERAL FLOW PLATFORM FOR MODULATING PROTEIN INTERACTIONS - Lateral flow assay devices for determining the concentration of a biomolecular analyte in a sample and methods for measuring analyte concentration in sample using such lateral flow assay devices. | 09-18-2014 |
20140274755 | ANTIGEN DERIVED FROM EXTRACELLULAR DOMAIN OF MULTI-TRANSMEMBRANE PROTEIN AND USES THEREOF - A multi-transmembrane protein antigen includes a polypeptide corresponding to an extracellular loop of the multi-transmembrane protein, the N-terminal and C-terminal of the polypeptide being fixed on a solid substrate or the N-terminal and C-terminal being attached to both ends of a linker to form a cyclic structure, an antibody specifically binding to the antigen or an antigen-binding fragment thereof, and a method for screening an antibody specifically binding to the antigen. The present invention may be usefully employed for effective production of antibodies for multi-transmembrane proteins that play important roles in disease-related phenomena such as cell signaling. | 09-18-2014 |
20140274756 | Detection of Nucleic Acids - This invention provides compositions, methods, and systems for characterizing, resolving, and quantitating single stranded and double stranded DNA and RNA in-situ. Paired sense and anti-sense probes can signal the presence of double stranded nucleic acids. DNA and RNA can be distinguished in cell and tissue samples by hybridizing with probe sets adapted to highlight differences in these targets in-situ. | 09-18-2014 |
20140274757 | Differential Methylation Level of CpG Loci That Are Determinative of a Biochemical Reoccurrence of Prostate Cancer - The present disclosure provides for and relates to the identification of novel biomarkers for diagnosis and prognosis of prostate cancer or the biochemical reoccurrence of prostate cancer. The biomarkers of the invention show altered methylation levels of certain CpG loci relative to normal prostate tissue, as set forth. | 09-18-2014 |
20140274758 | ANTIBODY PROFILING, METHODS AND APPARATUS FOR IDENTIFYING AN INDIVIDUAL OR SOURCE OF A BIOLOGICAL MATERIAL - A sample of a biological material having individual-specific antibodies is contacted with an array of less than about 200 proteins on a support to bind some of the individual-specific antibodies to the proteins of the array to form immune complexes. A detection agent with an interacting protein for conjugation to a marker is applied to the array to detect the immune complexes and obtain an antibody profile, which is compared to a known antibody profile obtained from an individual. The array may further include control spots including human IgG to form control complexes and volume assessment spots including volume determination proteins to form volume complexes. Intensity of the control complexes may be detected to determine if results of the identifying are complete. Intensity of the volume complexes may be detected to determine if a volume of the sample is sufficient for an accurate result. | 09-18-2014 |
20140274759 | MODIFICATION OF POLYPEPTIDES - The invention provides a method for conjugating a peptide displayed on a genetic display system to a molecular scaffold performed on an ion exchange resin. | 09-18-2014 |
20140274760 | SMART GLASS SLIDE FOR MICROARRAYS - Device for use in a biosensor comprising a multisite array of test sites, the device being useful for modulating the binding interactions between a (biomolecular) probe or detection agent and an analyte of interest from a biological by modulating the pH or ionic gradient near the electrodes in such biosensor. The device provides a biosensor which is more accurate, reliable and the results of which are more reproducible. Analytic methods for more accurately measuring an analyte of interest in a biological sample are also provided. | 09-18-2014 |
20140274761 | CONSTITUTIVE PROMOTER - The invention relates to an isolated nucleic acid sequence comprising a promoter, which is a native sequence of | 09-18-2014 |
20140274762 | MULTIPLEX IMMUNO SCREENING ASSAY - The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. This immunoassay involves the covalent and oriented coupling of fusion proteins comprising an AGT enzyme and a viral antigen on an identifiable solid support (e.g. fluorescent microspheres), said support being previously coated with an AGT substrate. This coupling is mediated by the irreversible reaction of the AGT enzyme on its substrate. The thus obtained antigen-coupled microspheres show enhanced capture of specific antibodies as compared to antigen-coupled microspheres produced by standard amine coupling procedures. The methods of the invention possess the ability to multiplex, minimize the amount of biological sample, and have enhanced sensitivity and specificity toward target antibodies as compared with classical ELISA or Radio-Immunoprecipitation assays. | 09-18-2014 |
20140274763 | METHOD AND SYSTEM TO PREDICT RESPONSE TO PAIN TREATMENTS - The present inventions relates to methods and assays to predict the response of an individual to an analgesic treatment and to a method to improve medical treatment of a disorder, which is responsive to treatment with an analgesic. | 09-18-2014 |
20140274764 | METHOD AND SYSTEM TO PREDICT RESPONSE TO TREATMENTS FOR MENTAL DISORDERS - The present inventions relates to methods and assays to predict the response of an individual to a psychiatric treatment and to a method to improve medical treatment of a disorder, which is responsive to treatment with a psychiatric treatment. | 09-18-2014 |
20140274765 | CARDIAC STEM CELL AND MYOCYTE SECRETED PARACRINE FACTORS AND USESTHEREOF - The invention relates to secreted proteins from cardiac stem cells (cardiospheres and cardiosphere-derived cells) or myocytes for diagnostic and/or therapeutic use | 09-18-2014 |
20140274766 | METHODS OF USING F-SPONDIN AS A BIOMARKER FOR CARTILAGE DEGENERATIVE CONDITIONS AND BONE DISEASES - Methods for identifying subjects having, or at risk for developing, osteoarthritis or other cartilage degenerative conditions by measuring levels of expression of F-spondin are provided. Assays, kits and methods for determining and assaying the presence of F-spondin in individual patients are disclosed. Oligonucleotide probes and primers for use in the assays, kits and methods are described. Assays and methods are disclosed for identifying candidate compounds that modulate F-spondin levels of expression and/or function or for determining and evaluating an individual's response to drugs and therapeutic agents, are provided. The invention further relates to the modulation of F-spondin, particularly the inhibition of F-spondin, for increasing or stimulating bone formation and/or growth and mediating the alleviation of bone disease, disorders or conditions. The use of F-spondin, an active fragment thereof, or a modulator thereof for enhancing cartilage repair or preventing or treating cartilage degeneration, degenerative diseases or arthritic conditions is also provided. | 09-18-2014 |
20140274767 | DNA METHYLATION MARKERS FOR METASTATIC PROSTATE CANCER - The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for assessing prostate cancer. In a specific embodiment, present inventors have developed and applied a new technology and associated computation methods enabling simultaneous genome-scale analysis of genetic (copy number) and epigenetic (total methylation (TM) and allele-specific methylation (ASM) alternation, This method, called MBD-SNP, features affinity enrichment or methylated genomic DNA fragments using a methyl-binding domain polypeptide. | 09-18-2014 |
20140274768 | Glycoforms of MUC5AC and Endorepellin and Biomarkers for Mucinous Pancreatic Cysts - The present invention relates to a method for diagnosing a subject with a malignant pancreatic cyst, the method comprising, obtaining a pancreatic cyst fluid sample from a pancreatic cyst lesion of the subject, detecting the level of MUC5AC, and endorepellin glycoforms present in the pancreatic cyst fluid sample, comparing the levels of MUC5AC and endorepellin glycoforms to a control pancreatic cyst sample level of MUC5AC and endorepellin glycoforms; and diagnosing the pancreatic cyst lesion as malignant if the levels of the MUC5AC and endorepellin glycoforms are differentially expressed compared to the levels of the MUC5AC and endorepellin glycans present in control pancreatic cyst samples. | 09-18-2014 |
20140274769 | METHODS AND COMPOSITIONS FOR TREATMENT OF BREAST CANCER - Provided are methods of treating breast cancer in a subject in need thereof comprising administering to the subject an effective amount of an inhibitor of miR-105 or an inhibitor of miR-122 are provided. Also provided herein are methods of determining a level of miR-105 or a level of miR-122 in a subject that has or is at risk for developing breast cancer. The method includes obtaining a biological sample from the subject and determining a level of miR-105 or a level of miR-122 or a combination thereof in the biological sample, wherein a higher level of miR-105 or miR-122 as compared to a control indicates that the subject has or is at risk of developing breast cancer. | 09-18-2014 |
20140274770 | PCR ASSAYS AND REAGENTS FOR MOLECULAR DETECTION OF INFECTIOUS AGENTS - The present disclosure is directed to PCR-based assays and compositions for use in molecular detection of viral, bacterial and parasitic infectious agents in body fluid or tissue samples, and in particular to multiplex assays, as well as to solid reagent compositions for use in such assays. | 09-18-2014 |
20140274771 | METHODS FOR MAKING MICROARRAYS AND THEIR USES - The present invention provides microarrays that can be analysed by more than one technique using a non-covalent ligand attachment strategy to solid supports such as indium tin oxide (ITO) covered transparent glass slides. This provides, inter alia, glycan arrays on a micrometer scale which allow multimodal readout by MALDI-Tof-MS, fluorescence and optical microscopy. Glycans functionalized with a C5-aminolinker were attached in situ on a picomolar scale to a hydrophobic tag bound to this surface, thus avoiding the wasteful off-chip ligand tagging of other approaches. Glycan arrays prepared using this methodology were analysed both with a fluorescence scanner and by on-chip MALDI-mass spectrometry in a series of glycomics experiments specifically requiring a multimodal readout. | 09-18-2014 |
20140274772 | BIOMARKER PANEL FOR DETECTING LUNG CANCER - A method and a kit for assessing risk of lung cancer versus benign disease in a subject are provided. The method includes obtaining a biological sample from the subject and determining a measurement for a panel of biomarkers in the biological sample. The panel includes at least two biomarkers selected from the group consisting of IL-6, IL-1ra, IL-10, SDF-1α+β, TNF-α, MIP-1α, sIL-2Rα, CA-125, sE-Selectin, Eotaxin, sEGFR, MMP-2, OPN, MCP-1, CRP, sICAM-1 and CYFRA 21.1. The method further includes comparing the measurement to a reference profile for the panel of biomarkers, sorting the subject into a group and determining whether the subject is at risk for lung cancer based on the group. | 09-18-2014 |
20140274773 | SYSTEMS AND METHODS FOR EMPLOYING PODOCALYXIN AND TRA HUMAN STEM CELL MARKERS AS PROGNOSTIC MARKERS FOR AGGRESSIVE AND METASTATIC CANCER - The invention relates to systems and methods to detect podocalyxin-expressing and TRA-expressing cancer stem cells or cancer cells with stem cell-like properties in a tissue cell sample obtained from a localized tumor of a patient, and to determine a diagnosis or prognosis of aggressive and metastatic cancer by employing podocalyxin and TRA human stem cell markers as prognostic markers. | 09-18-2014 |
20140274774 | UNIVERSAL REPORTER-BASED GENOTYPING METHODS AND MATERIALS - The present disclosure is drawn to methods for detection, quantitation and analysis of nucleotides of interest, for example SNPs, in nucleic acid sequences of interest using universal FRET-based reporter primers. | 09-18-2014 |
20140274775 | ASSAY METHODS - The present invention is directed to methods for reducing cross-reactivity between species employed in multiplexed immunoassays. | 09-18-2014 |
20140274776 | Porphyrin-Modified Antimicrobial Peptides for Application as Indicators of Microbial Targets - Porphyrin-modified antimicrobial peptides as described here may be used as indicators of the presence of microbial targets. Their application may be as (for example) (1) fluorescent indicators in a microarray format, (2) fluorescence or absorbance based indicators in traditional solution based applications, or (3) reflectance based indicators for use in reagent-less detection platforms. | 09-18-2014 |
20140274777 | LIPID DROPLET PROTEIN MARKERS FOR ALGAL OIL ACCUMULATION - The application relates to apparatuses, methods and kits for detecting and quantifying oil content in algal samples. | 09-18-2014 |
20140274778 | METHODS AND SYSTEMS FOR MULTIPLEX ASSAYS - Disclosed herein are compositions comprising beads with unique identifiers for storing information about a multiplex assay as well as methods for using the same in multiplex chemical and biological assays. | 09-18-2014 |
20140274779 | MULTIPLEX ALLELE DETECTION - Provided herein is technology relating to nucleic acid detection and particularly, but not exclusively, to methods and compositions for the simultaneous detection of multiple nucleic acids. | 09-18-2014 |
20140274780 | METHODS OF IMPROVING SURVIVAL IN CANCER - Methods of improving cancer therapy outcomes are provided. Diagnostics useful for evaluating patients based on microRNA signatures of cancer tissue are provided. | 09-18-2014 |
20140274781 | Methods for Immobilizing Target Nucleic Acids Utilizing Combinatorial Capture Probes - The present invention provides methods for immobilizing target nucleic acids on a solid support utilizing combinatorial capture probe pairs. These pairs contain first and second capture oligonucleotides that each comprise a target binding region, a capture region and a stem region positioned between the target binding and capture regions. The target binding regions comprise nucleic acid sequences that allow them to hybridize to adjacent regions on the target nucleic acid. The stem regions have nucleic acid sequences that are complementary to each other and the capture regions each comprise a sequence that when positioned adjacent to one another produce a combined nucleic acid sequence that is complementary to a portion of an oligonucleotide bound to a solid support. When the first and second capture oligonucleotides are annealed to the target nucleic acid, the stem regions are brought together allowing them to hybridize, which in turn brings the capture regions together to produce a combined nucleic acid sequence. This combined nucleic acid sequence is then able to hybridize to the oligonucleotide bound to the solid support thereby immobilizing the target nucleic acid. | 09-18-2014 |
20140274782 | AFFINITY REAGENTS AND METHODS FOR DETECTION, PURIFICATION, AND PROTEOMIC ANALYSIS OF METHYLATED PROTEINS - Methyl-lysine affinity reagents created by engineering the 3×MBT methyl-lysine binding domain repeat of lethal (3) malignant brain tumor-like protein 1 (L3MBTL1) are disclosed. In particular, the invention relates to affinity reagents and affinity chromatography media comprising the 3×MBT domain repeat and methods of using such affinity reagents in detection, purification, and proteomic profiling of methylated proteins and peptides. | 09-18-2014 |
20140274783 | CHLAMYDIA-SPECIFIC CD8+ T CELLS AND METHODS OF ISOLATING | 09-18-2014 |
20140274784 | AUTOMATED IMMUNOANALYZER SYSTEM FOR PERFORMING DIAGNOSTIC ASSAYS FOR ALLERGIES AND AUTOIMMUNE DISEASES - A quantitative method for performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate. | 09-18-2014 |
20140274785 | BIOMARKERS - The invention disclosed herein describes a novel therapeutic target for motoneuron diseases (altered dynamics of microtubules and microtubule-mediated axonal transport of cargo molecules in neurons), with or without dementia, and in dementia; methods for measuring the state of activity of this therapeutic target in subjects with established, incipient, or potential motoneuron disease, with or without dementia, and in dementia; the discovery of drug agents that modulate neuronal microtubule dynamics in living subjects with motoneuron diseases; the discovery that administration of such agents, alone or in combinations, can improve MT-mediated transport of cargo molecules along and through axons; the discovery that such modulation of altered microtubule dynamics and improvement in MT-transport of molecules along axons can provide marked neuroprotective therapy for living subjects with motoneuron diseases, including delay in symptoms and prolongation of survival; and the discovery that monitoring of microtubule-mediated axonal transport of cargo molecules in response to therapeutic interventions in subjects with motoneuron diseases, with or without dementia, and in dementia allows diagnostic monitoring, to optimize therapeutic regimens and treatment strategies in individual subjects or in drug trials. | 09-18-2014 |
20140274786 | DIGITAL ASSAYS WITH ASSOCIATED TARGETS - System, including methods, apparatus, and compositions, for performing a digital assay with associated targets. In some embodiments, the assay of associated targets in partitions may lower the limit of detection (LOD) or otherwise increase assay sensitivity, accuracy, and/or specificity. The targets may represent spaced or overlapping regions of the same template and/or each may represent a region from a different complementary strand of the same template. In some embodiments, the associated targets may be provided by a type of biological particle, and the target content of partitions may be used to identify and quantify the type of biological particle in a sample. | 09-18-2014 |
20140274787 | BIOMARKER FOR OVARIAN CANCER CTAP3-RELATED PROTEINS - The present invention provides a protein-based biomarker that is useful in qualifying ovarian cancer status in a patient. In particular, the biomarker of this invention is useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarker can be detected by SELDI mass spectrometry. | 09-18-2014 |
20140274788 | LEUKEMIA STEM CELL MARKERS - The invention provides a test method for predicting the initial onset or a recurrence of acute myeloid leukemia (AML) comprising (1) measuring the expression level of human leukemic stem cell (LSC) marker genes in a biological sample collected from a subject for a transcription product or translation product of the gene as an analyte and (2) comparing the expression level with a reference value; an LSC-targeting therapeutic agent for AML capable of suppressing the expression of a gene selected from among LSC marker genes or a substance capable of suppressing the activity of a translation product of the gene; a method for producing a sample containing hematopoietic cells for autologous transplantation or allogeneic transplantation for AML patients, comprising obtaining an LSC-purged sample with at least 1 kind of LSC marker as an index; and a method of preventing or treating AML. | 09-18-2014 |
20140274789 | COMPLEX SETS OF MIRNAS AS NON-INVASIVE BIOMARKERS FOR PSORIASIS - The present invention relates to non-invasive methods, kits and means for diagnosing and/or prognosing of psoriasis in a body fluid sample from a subject. Further, the present invention relates to set of polynucleotides or sets of primer pairs for detecting sets of miRNAs for diagnosing and/or prognosing of psoriasis in a body fluid sample from a subject. In addition, the present invention relates to sets of miRNAs for diagnosing and/or prognosing of psoriasis in a body fluid sample from a subject. | 09-18-2014 |
20140274790 | IgG-BINDING PEPTIDE AND METHOD FOR DETECTING AND PURIFYING IgG USING SAME - Provided is a peptide that specifically or selectively binds to human IgG. This peptide comprises an amino acid sequence consisting of 13 to 17 amino acid residues and is capable of binding to human IgG, wherein the amino acid sequence is represented by formula I: (X | 09-18-2014 |
20140274791 | miRNA BIOMARKERS OF LUNG DISEASE - This application describes miRNAs that may be used as serum or plasma biomarkers for characterizing lung disease in a patient. These miRNA biomarkers may be used alone or in combination with other markers for the diagnosis, prognosis, or monitoring of diseases such as lung cancer. | 09-18-2014 |
20140274792 | PEPTIDE AND PROTEIN BIOMARKERS FOR TYPE 1 DIABETES MELLITUS - A method for identifying persons with increased risk of developing type 1 diabetes mellitus, or having type I diabetes mellitus, utilizing selected biomarkers described herein either alone or in combination. The present disclosure allows for broad based, reliable, screening of large population bases. Also provided are arrays and kits that can be used to perform such methods. | 09-18-2014 |
20140274793 | NT-proANP AND NT-proBNP FOR THE DIAGNOSIS OF STROKE - The present invention relates to a method for diagnosing a transitory ischemic attack (TIA) in a subject who is suspected to have exhibited a transitory ischemic attack, but who did not exhibit a stroke. The method is based on the determination of the amount of NT-proANP in a sample from said subject. Moreover, the present invention is directed to a method for diagnosing an acute cerebral ischemic event in a subject based on the determination of the amounts of NT-proBNP and NT-proANP in a sample from a subject. The method further comprises the step of calculating a ratio of the amounts of NT-proBNP and NT-proANP. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention. | 09-18-2014 |
20140274794 | Methods and Compositions for Diagnosis of Ovarian Cancer - Methods and compositions are provided for diagnosing ovarian cancer in a mammalian subject, preferably in a serum or plasma sample of a human subject. The methods and compositions enable the detection or measurement in the sample or from a protein level profile generated from the sample, the protein level of one or more specified biomarkers. Comparing the protein level(s) of the biomarker(s) in the subject's sample or from protein abundance profile of multiple biomarkers, with the level of the same biomarker(s) or profile in a reference standard, permits the determination of a diagnosis of ovarian cancer, or the identification of a risk of developing ovarian cancer, or enables the monitoring of the status of progression or remission of ovarian cancer in the subject followed during a therapeutic protocol. | 09-18-2014 |
20140274795 | DETECTION UNITS AND METHODS FOR DETECTING A TARGET ANALYTE - Detection units and methods for detecting one or more target analytes in a sample are disclosed. The detection unit provides a first and second surface connected by a filament which is capable of binding the target analyte in the sample. The methods provide for the detection of the target analyte through the generation of a detectable signal following the binding of the target analyte to the filament. | 09-18-2014 |
20140287939 | Biomarker(s) for early detection / diagnosis/ prognosis of gastric cancer - The present invention discloses the nine biomarkers including HIF1A, FAM84B, CRIP2, GSN, RPL15, DLG1, MAT2A, PGBD2 and ID3 are respectively selected according to their specific and unique expression profile in the gastric cancer cells or gastric cancer tissue. Therefore, the nine biomarkers are related to diagnose gastric cancer, such as detecting early gastric cancer, staging gastric cancer, predicting prognosis of gastric cancer and diagnosing lymph node metastasis. By analyzing the expression value of at least one biomarker of a sample from a subject, the subject can be precisely diagnose the risk about gastric cancer. | 09-25-2014 |
20140287940 | METHOD OF DIAGNOSING NEOPLASMS - II - The present invention relates generally to nucleic acid molecules in respect of which changes to the DNA or to the RNA or protein expression profiles are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to the DNA or to the RNA or protein expression profiles are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or an adenocarcinoma. The DNA or the expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening a subject for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in the DNA or the RNA or protein expression profile of one or more nucleic acid molecule markers. | 09-25-2014 |
20140287941 | OPTICAL MICROSCOPY WITH PHOTOTRANSFORMABLE OPTICAL LABELS - Imaging a sample that includes phototransformable optical labels (“PTOLs”) with an optical system having a diffraction-limited resolution volume (DLRV), includes providing activation radiation to the PTOLs to activate a statistical subset of the PTOLs. A density of the PTOLs of the activated subset is less than an inverse of the DLRV. Excitation radiation is provided to the activated subset to excite activated PTOLs. Radiation emitted from the activated and excited PTOLs located at different focal planes of the optical system within the sample is detected with the optical system. The preceding steps are repeated one or more times, each time activating a different statistical subset of the plurality of PTOLs. Three-dimensional locations within the sample are determined, with a sub-diffraction-limited accuracy, of the activated and excited PTOLs based on the radiation emitted from the activated and excited PTOLs that is detected from the different focal planes of the optical system. | 09-25-2014 |
20140287942 | Methods and Devices for Detection and Acquisition of Biomarkers - The present invention provides devices and methods for detecting and capturing molecular biomarkers from a subject in situ. Specifically, the devices contain an array of microneedles to which are attached probes specific for one or more biomarkers of interest. The devices can be used directly on a subject (e.g., via skin piercing) in detecting the biomarkers in the body of the subject (e.g., tissues, blood stream). | 09-25-2014 |
20140287943 | ASSAY FOR SHIP1 EXPRESSION, ACTIVITY AND SEQUENCE ALTERATIONS AS A PREDICTOR OF INFLAMMATORY BOWEL DISEASE RISK - The present disclosure is directed to detecting colon disorders by measuring the expression of SHIP1 in a sample of PBMCs. One method includes the following steps, obtaining a sample including peripheral blood mononuclear cells (PBMCs) from a subject and determining whether SHIP1 is underexpressed in the PBMCs or lacks normal enzymatic activity. The present disclosure is also directed to a method of determining the expression of SHIP1 protein expression and SHIP1 enzyme activity in PBMCs. This method includes the following steps, obtaining a sample comprising PBMCs from a subject and determining the amount of SHIP1 in the PBMCs. | 09-25-2014 |
20140287944 | MARKERS FOR FUNCTIONALLY MATURE BETA-CELLS AND METHODS OF USING THE SAME - Markers for functionally mature β-cells and methods of using these markers are disclosed. | 09-25-2014 |
20140287945 | SURFACE OXIDATION FOR SEQUESTERING BIOMOLECULES AND RELATED METHODS - Solid supports comprising polymers covalently bound to a solid substrate are provided. The polymers find utility in any number of applications including immobilizing analyte molecules to solid supports for high throughput assays. | 09-25-2014 |
20140287946 | NUCLEIC ACID CONTROL PANELS - Provided herein is technology relating to detecting nucleic acids in a sample and particularly, but not exclusively, to systems and methods related to panels that are used to evaluate sequencing efficacy. | 09-25-2014 |
20140287947 | BIOMARKERS AND METHODS FOR PREDICTING PREECLAMPSIA - The disclosure provides biomarker panels, methods and kits for determining the probability for preeclampsia in a pregnant female. The present disclosure is based, in part, on the discovery that certain proteins and peptides in biological samples obtained from a pregnant female are differentially expressed in pregnant females that have an increased risk of developing in the future or presently suffering from preeclampsia relative to matched controls. The present disclosure is further based, in part, on the unexepected discovery that panels combining one or more of these proteins and peptides can be utilized in methods of determining the probability for preeclampsia in a pregnant female with relatively high sensitivity and specificity. These proteins and peptides dislosed herein serve as biomarkers for classifying test samples, predicting a probability of preeclampsia, monitoring of progress of preeclampsia in a pregnant female, either individually or in a panel of biomarkers. | 09-25-2014 |
20140287948 | BIOMARKERS AND METHODS FOR PREDICTING PRETERM BIRTH - The disclosure provides biomarker panels, methods and kits for determining the probability for preterm birth in a pregnant female. The present disclosure is based, in part, on the discovery that certain proteins and peptides in biological samples obtained from a pregnant female are differentially expressed in pregnant females that have an increased risk of developing in the future or presently suffering from preterm birth relative to matched controls. The present disclosure is further based, in part, on the unexepected discovery that panels combining one or more of these proteins and peptides can be utilized in methods of determining the probability for preterm birth in a pregnant female with relatively high sensitivity and specificity. These proteins and peptides disclosed herein serve as biomarkers for classifying test samples, predicting a probability of preterm birth, monitoring of progress of preterm birth in a pregnant female, either individually or in a panel of biomarkers. | 09-25-2014 |
20140287949 | MULTIPLEX ASSAY FOR MEMBERS OF BINDING PAIRS - The invention provides an efficient multiplex method for identifying binding partners of small molecules and proteins. The small molecules and proteins are tagged with a nucleic acid barcode that can be used to identify the protein or small molecule, and thereby its partner. | 09-25-2014 |
20140287950 | BIOMARKERS AND METHODS FOR PREDICTING PRETERM BIRTH - The disclosure provides biomarker panels, methods and kits for determining the probability for preterm birth in a pregnant female. The present disclosure is based, in part, on the discovery that certain proteins and peptides in biological samples obtained from a pregnant female are differentially expressed in pregnant females that have an increased risk of developing in the future or presently suffering from preterm birth relative to matched controls. The present disclosure is further based, in part, on the unexepected discovery that panels combining one or more of these proteins and peptides can be utilized in methods of determining the probability for preterm birth in a pregnant female with relatively high sensitivity and specificity. These proteins and peptides disclosed herein serve as biomarkers for classifying test samples, predicting a probability of preterm birth, monitoring of progress of preterm birth in a pregnant female, either individually or in a panel of biomarkers. | 09-25-2014 |
20140287951 | Detection of Auto-Antibodies to Specific Glycans as Diagnostic Tests for Autoimmune Diseases - The invention provides uses, methods, and kits for diagnosing an autoimmune disease, particularly scleroderma and systemic lupus erythematosus, in a subject by detecting the presence of one or more antibodies that specifically bind to one or more glycans in a subject sample. | 09-25-2014 |
20140287952 | PROTOCOL FOR IDENTIFYING AND ISOLATING ANTIGEN-SPECIFIC B CELLS AND PRODUCING ANTIBODIES TO DESIRED ANTIGENS - Methods of identifying antigen-specific antibody-secreting and antibody-forming cells, such as antigen-specific B cells, and methods for cloning the antigen-specific antibody sequences of the antibody produced by these cells are provided. In particular, the methods include enriching B cells for antigen-specific B cells, culturing the antigen-specific B cells to generate clonal B cell populations, detecting clonal B cells that produce a single antigen-specific antibody, optionally screening the clonal B cell populations for functional activity, staining and sorting the cells to isolate the antigen-specific B cells, sequencing the nucleic acids encoding the antigen-specific antibody sequences, expressing the sequences to produce an antibody, isolating the antibody and screening the antibody for antigen recognition. The methods provide improved enrichment and selection of antigen-specific antibody-secreting and antibody-forming cells, which enhances recovery of antigen-specific antibodies. | 09-25-2014 |
20140287953 | LASER ABLATION CELL - A laser ablation cell ( | 09-25-2014 |
20140287954 | MICROARRAY BASED SAMPLE DETECTION SYSTEM - A microarray assembly for detection of a target molecule is disclosed. The microarray assemblies comprise an array chamber having a microarray located therein and features that facilitate liquid movement within the array chamber. Also disclosed are methods for making the microarray assembly using rollable films and methods for detecting microarray spots using an internal control fluorophore in the array spot. | 09-25-2014 |
20140287955 | SAMPLE PROCESSING METHOD AND SAMPLE PROCESSING CARTRIDGE - The present invention pertains inter alia to a method for analysing a sample comprising biomolecules, which comprises the following steps:
| 09-25-2014 |
20140287956 | Biomarkers of Cancer - Methods for diagnosing cancer and monitoring treatment efficacy based on detecting the presence of increased levels of expression of satellite correlated genes. | 09-25-2014 |
20140296086 | SYSTEM AND METHOD FOR CELL-TYPE SPECIFIC COMPARATIVE ANALYSES OF DIFFERENT GENOTYPES TO IDENTIFY RESISTANCE GENES - L. Merr. (soybean) resistance to | 10-02-2014 |
20140296087 | NUCLEIC ACID BINDING OLIGONUCLEOTIDES - The present application pertains to products and methods related to the ability of short nucleotide oligomers to bind the tertiary or globular structure of nucleic acids. This application discloses libraries of short oligomers and methods for using these libraries. | 10-02-2014 |
20140296088 | Spectral Imaging for Measurement of Nuclear Pathology Features in Cancer Cells Prepared for In Situ Analysis - In general, the presently disclosed technology relates to identification of cancer subtypes. More specifically, the technology relates to methods for determining molecular drivers of cancer and/or progression using a multivariate image data and statistical analysis of in-situ molecular markers and morphological characteristics in the same cells of a biological sample suspected of b cancer. This analysis takes place after a single acquisition that obtains the molecular and anatomic morphology data in parallel. The analysis compares specific morphological and molecular markers to known samples exhibiting particular genetic drivers of the cancer. This method provides statistical information that allows for an increased confidence in the identification of specific molecular drivers of the cancer. | 10-02-2014 |
20140296089 | SYSTEMS AND METHODS FOR MULTI-ANALYSIS - Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample. | 10-02-2014 |
20140296090 | ASSAY METHODS FOR INCREASED THROUGHPUT OF SAMPLES AND/OR TARGETS - The present invention provides assay methods that increase the number of samples and/or target nucleic acids that can be analyzed in a single assay. | 10-02-2014 |
20140296091 | Mycobacterium Antigens - There is provided a diagnostic reagent for use in the detection of | 10-02-2014 |
20140296092 | Methods, Reagents and Kits for Detection of Nucleic Acid Molecules - Methods, reagents and kits are provided for the production and use in detection assays of labeled nucleic acid molecules wherein a labeling molecule is attached directly to the 3′ end of the nucleic acid molecules. | 10-02-2014 |
20140296093 | USE OF MULTIPLE RECOMBINATION SITES WITH UNIQUE SPECIFICITY IN COMBINATIONAL CLONING - The present invention provides compositions and methods for recombinational cloning. The compositions include vectors having multiple recombination sites with unique specificity. The methods permit the simultaneous cloning of two or more different nucleic acid molecules. In some embodiments the molecules are fused together while in other embodiments the molecules are inserted into distinct sites in a vector. The invention also generally provides for linking or joining through recombination a number of molecules and/or compounds (e.g., chemical compounds, drugs, proteins or peptides, lipids, nucleic acids, carbohydrates, etc.) which may be the same or different. Such molecules and/or compounds or combinations of such molecules and/or compounds can also be bound through recombination to various structures or supports according to the invention. | 10-02-2014 |
20140296094 | SYSTEMS AND METHODS FOR DETECTION OF GENOMIC COPY NUMBER CHANGES - The present invention relates to systems and methods for detecting genomic copy number changes. In particular, the present invention relates to next generation sequencing methods for detection of copy number changes. | 10-02-2014 |
20140296095 | Spatially Selective Release of Aptamer-Captured Cells by Temperature Mediation - Methods and systems are provided for capturing and releasing target cells. The system includes a microdevice having a microchamber including surface-patterned aptamers capable of binding with the target cells. A sample including target cells is introduced to the microchamber, where the target cells bind to the aptamers at locally regulated temperatures. The captured target cells can be selectively released when the temperature of a region is changed to a second temperature. | 10-02-2014 |
20140296096 | PROSTATE CANCER MARKERS AND USES THEREOF - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to polypeptides found in extracellular microvesicles as diagnostic and screening markers, and clinical targets for cancer (e.g., prostate cancer). | 10-02-2014 |
20140296097 | MARKER FOR DETERMING EFFECTS OF ANTI-C-MET ANTIBODY AND METHOD OF DETERMING EFFECTS OF ANTI-C-MET ANTIBODY USING THE MARKER - There are provided a composition for determining the efficacy of a c-Met antibody including marker genes and a method for determining the efficacy of a c-Met antibody using the marker genes. | 10-02-2014 |
20140296098 | Diagnostic and Prognostic Markers for Cancer - Compositions and methods useful for diagnosis and prognosis of cancer are provided. | 10-02-2014 |
20140296099 | Use of MicroRNA for Assessing Embryos Grown in Vitro and Improving Culture Media - Disclosed are methods of detecting miRNA expression by an embryo. The methods may be utilized for assessing embryo viability and chromosomal makeup and selecting the embryo for subsequent implantation into a patient. The methods also may be utilized for modifying and optimizing culture media to improve embryo viability via adding one or more miRNAs to culture media for the embryo or depleting one or more miRNAs from the culture media for the embryo. Kits for performing the disclosed methods are also disclosed. | 10-02-2014 |
20140296100 | METHODS FOR TREATING CANCER RESISTANT TO ERBB THERAPEUTICS - Provided herein are methods for treating cancer that is resistant to treatment with an anti-ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti-ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell. | 10-02-2014 |
20140296101 | SECRETED PROTEINS AND USES THEREOF - The invention provides isolated nucleic acid molecules, designated TANGO 228 nucleic acid molecules, which encode secreted proteins with homology to the rat MCA-32 protein, isolated nucleic acid molecules, designated TANGO 240 nucleic acid molecules, which encode secreted proteins with homology to the | 10-02-2014 |
20140296102 | Nucleic Acid Ligand Diagnostic Biochip - A nucleic acid ligand “biochip” is disclosed, consisting of a solid support to which one or more specific nucleic acid ligands is attached in a spatially defined manner. Each nucleic acid ligand binds specifically and avidly to a particular target molecule contained within a test mixture, such as a bodily fluid. The target molecules include, but are not limited to, proteins (cellular, viral, bacterial, etc.) hormones, sugars, metabolic byproducts, cofactor, and intermediates, drugs, and toxins. Contacting the test mixture with the biochip leads to the binding of a target molecule to its cognate nucleic acid ligand. The biochip may then be contacted with a reagent(s) that reacts covalently with proteins and not with nucleic acids. Each protein target in the test mixture may then detected by detecting the presence of the reagent at the appropriate address on the biochip. | 10-02-2014 |
20140296103 | TOPOGRAPHIC GENOTYPING FOR DETERMINING THE DIAGNOSIS, MALIGNANT POTENTIAL, AND BIOLOGIC BEHAVIOR OF PANCREATIC CYSTS AND RELATED CONDITIONS - The application relates to a method of a predicting the presence of invasive pancreatic cancer or high grade dysplasia, pre-cancerous pancreatic states and non-neoplastic conditions comprising detailed molecular analysis incorporating DNA quality and quantity, K-ras mutational analysis and a broad spectrum of tumor suppressor gene linked microsatellite LOH. Methods of diagnosing, determining prognosis of and determining a course of treatment for pancreatic cancer or high grade dysplasia, pre-cancerous pancreatic states and non-neoplastic conditions are also provided. | 10-02-2014 |
20140296104 | Genes Differentially Expressed by Cumulus Cells and Assays Using Same to Identify Pregnancy Competent Oocytes - A genetic means of identifying “pregnancy competent” oocytes is provided. The means comprises detecting the level of expression of one or more genes that are expressed at characteristic levels (upregulated or downregulated) in cumulus cells derived from pregnancy competent oocytes. This characteristic gene expression level, or pattern referred to herein as the “pregnancy signature”, also can be used to identify subjects with underlying conditions that impair or prevent the development of a viable pregnancy, e.g., pre-menopausal condition, other hormonal dysfunction, ovarian dysfunction, ovarian cyst, cancer or other cell proliferation disorder, autoimmune disease and the like. In preferred embodiments the pregnancy signature will comprise one or more of FG-F12, (Hs00374427_m1), GPR137B (Hs00162803_m1), SLC2A9 (Hs00417125_m1), ARID IB (Hs00368175_m1), NR2F6 (Hs00172870_m1), ZNF132 (Hs01036387_m1), FAM36A (Hs00831105_s1), ZNF93 (Hs01656246,,s1), RHBDL2 (Hs00384848_m1), DNAJC15 (Hs00387763_m1), MTUS1 (Hs00826834_m1), ND NUP133 (Hs00217272_m1), or their orthologs, splice or allelic variants. | 10-02-2014 |
20140296105 | Antibody Response Phenotyping - Disclosed herein are methods, systems, mediums, and kits for use in phenotyping antibody responses via devices such as surface plasmon resonance devices. Such phentypes can include total target-specific antibody titers, quantitative isotype distribution of the target-specific antibodies, and/or epitope specificity of the target-specific antibodies. Other methods, systems, mediums, and kits are also disclosed. | 10-02-2014 |
20140303012 | EXTRACTION AND DETECTION OF PATHOGENS USING CARBOHYDRATE-FUNCTIONALIZED BIOSENSORS - The disclosure relates to the extraction and detection of pathogens using carbohydrate-functionalized biosensors. Immobilized carbohydrate moieties on the biosensor provide a means for non-specific binding of a plurality of target analytes. When a sample containing the target analyte is applied or otherwise transported to the biosensor detection surface, non-specific binding interactions between the carbohydrate moiety and the analyte immobilize/retain the analyte at the detection surface. The carbohydrate moiety is a stable binding pair member that allows on-sensor rinsing of a sample to enhance detection of an analyte in the sample. Specific analyte identification can be achieved with an analyte probe having a detection moiety and a binding pair member specific to the target analyte of interest. | 10-09-2014 |
20140303013 | METHODS OF DIAGNOSING AND TREATING VASCULAR ASSOCIATED MACULOPATHY AND SYMPTOMS THEREOF - Disclosed herein are methods and compositions for the diagnosis and treatment of Vascular Associated Maculopathy, or a symptom thereof, in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of one or more symptoms associated with Vascular Associated Maculopathy Disclosed in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of severe maculopathy or last stage maculopathy in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of resolving aberrant choriocapillaris lobules in a subject. | 10-09-2014 |
20140303014 | MULTIPLEXED DETECTION WITH ISOTOPE-CODED REPORTERS - Some aspects of this invention provide reagents and methods for the sensitive, quantitative and simultaneous detection of target analytes in complex biological samples by liquid chromatography tandem mass spectrometry (LC MS/MS). Some aspects of this invention provide affinity reagents encoded with mass reporters for the sensitive and quantitative translation of an analyte of interest into a mass tag. The reagents and methods provided herein have general utility in analyte detection and encoding, for example, in biomolecular profiling, molecular diagnostics, and biochemical encoding. | 10-09-2014 |
20140303015 | Molecular Constructs for Differentiating a Target Molecule from an Off-Target Molecule - Molecular constructs, populations thereof, arrays, compositions, methods and kits for differentiating a target molecule from an off-target molecule are provided. | 10-09-2014 |
20140303016 | Methods and Processes for Calling Bases in Sequence by Incorporation Methods - Computer implemented methods, and systems performing such methods for processing signal data from analytical operations and systems, and particularly in processing signal data from sequence-by-incorporation processes to identify nucleotide sequences of template nucleic acids and larger nucleic acid molecules, e.g., genomes or fragments thereof. | 10-09-2014 |
20140303017 | Multiplexed Amplification of Short Nucleic Acids - The present teachings provide methods, compositions, and kits for reverse transcribing and amplifying small nucleic acids such as micro RNAs. High levels of multiplexing are provided by the use of a zip-coded stem-loop reverse transcription primer, along with a PCR-based pre-amplification reaction that comprises a zip-coded forward primer. Detector probes in downstream decoding PCRs can take advantage of the zip-code introduced by the stem-loop reverse transcription primer. In some embodiments, further amplification is achieved by cycling the reverse transcription reaction. The present teachings also provide compositions and kits useful for performing the reverse transcription and amplification reactions described herein. | 10-09-2014 |
20140303018 | NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NONALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKERS AND USES THEREOF - Methods, compositions, and kits for determining whether a subject has non-alcoholic fatty liver disease (NAFLD) are provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatosis are also provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatohepatitis (NASH) are also provided. | 10-09-2014 |
20140303019 | Calorimetric Microfluidic Sensor - A microfluidic sensor includes a microchannel that includes a reaction site with a reagent and a sample inlet. A liquid substance is received at the sample inlet and travels by capillary action to the reaction site. A temperature sensor measures a temperature as a result of a reaction between the reagent and a chemical in the liquid substance. A controller is communicatively connected to the temperature sensor, receives the temperature measured by the temperature sensor, and derives a concentration of the chemical in the liquid substance from the temperature. | 10-09-2014 |
20140303020 | Method for Assessing Myelodysplastic Syndrome or Myeloid Tumor Predisposition, Polypeptide and Antibody Therefor, and Candidate Screening Method for Therapeutic Drug or Prophylactic Drug Therefor - [Problem] To provide a method for assessing myelodysplastic syndrome or myeloid tumor predisposition, on the basis of a genetic diagnosis using massively parallel sequencing technology, as well as a peptide and antibody therefor, and a method for screening for candidate therapeutic drugs or prophylactic drugs for myelodysplastic syndrome or myeloid tumor. | 10-09-2014 |
20140303021 | METHODS AND DEVICES FOR DETECTING OBSTRUCTIVE UROPATHY AND ASSOCIATED DISORDERS - Methods and devices for diagnosing, monitoring, or determining obstructive uropathy or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining obstructive uropathy or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described. | 10-09-2014 |
20140303022 | Magnetic-nanoparticle conjugates and methods of use - The present invention provides novel compositions of binding moiety-nanoparticle conjugates, aggregates of these conjugates, and novel methods of using these conjugates, and aggregates. The nanoparticles in these conjugates can be magnetic metal oxides, either monodisperse or polydisperse. Binding moieties can be, e.g., oligonucleotides, polypeptides, or polysaccharides. Oligonucleotide sequences are linked to either non-polymer surface functionalized metal oxides or with functionalized polymers associated with the metal oxides. The novel compositions can be used in assays for detecting target molecules, such as nucleic acids and proteins, in vitro or as magnetic resonance (MR) contrast agents to detect target molecules in living organisms. | 10-09-2014 |
20140303023 | METHOD OF DIAGNOSING RENAL DISORDERS - The invention refers to an in vitro method of determining the risk of renal disorders, in a patient, by measuring a VCAN parameter, characterized in that at least one of the isoforms V0 and V1 are specifically determined in a sample of said patient and compared to a reference level. | 10-09-2014 |
20140303024 | MARKERS OF ACUTE KIDNEY FAILURE - The present invention relates to a method of determining the risk of acute kidney injury comprising determining the amount of a marker selected from VCAN, NRP1, CCL2, CCL19, COL3A1, GZMM or any combination thereof in a sample. | 10-09-2014 |
20140303025 | METHODS FOR THE DIAGNOSIS AND PROGNOSIS OF NEURODEGENERATIVE DISEASES - The present invention provides methods of making determinations regarding the state of cognition within a subject by determining whether a plurality of miRNAs has deregulated biological expression in a sample from the subject. The present invention also provides methods of making determinations regarding the potential severity of pathologies associated with neurodegenerative disorders by determining whether a plurality of miRNAs has deregulated biological expression in a sample from the subject. | 10-09-2014 |
20140303026 | Compounds for Modulating Integrin CD11B/CD18 - The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency. | 10-09-2014 |
20140303027 | GENE EXPRESSION PROFILING FOR THE DIAGNOSIS OF PROSTATE CANCER - Methods for diagnosing the presence of a disorder, such as prostate cancer, in a subject are provided, such methods including detecting the relative frequency of expression of RNA biomarkers in a biological sample obtained from the subject using NGS technology and comparing the relative levels of expression with predetermined threshold levels. Levels of expression of at least two of the RNA biomarkers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Also provided is a method for preparing a reference standard for quantitating the relative frequency of expression of RNA biomarkers in a biological sample obtained from the subject with a prostate cancer lesion using, for example, NGS technology. | 10-09-2014 |
20140303028 | GENOMIC DIAGNOSTICS USING CIRCULATING ENDOTHELIAL CELLS - Circulating Endothelial Cells are isolated from patient blood and gene expression of the cells is analyzed to assess a medical condition or the tissue of origin of the cell. Kits for conducting the method are also provided. | 10-09-2014 |
20140303029 | GENETIC ALTERATIONS IN GLIOMA - Methods and genetic sequences are described for use in determining the diagnosis, subtype, prognosis, and disease course of high-grade gliomas, such as glioblastoma multiforme. One such method includes determining increased expression of at least one gene on a chromosome segment in cells of the glioma, the segment being 17:57,851,812-17:57,973,757; 7:127,892,509-7:127,947,649; 12:33,854-12:264,310; or 19:33,329,393-19:35,322,055; and estimating, based on the expression, a predicted length of survival, a probability of survival, or a predicted response to a therapy for the glioma. | 10-09-2014 |
20140303030 | METHOD FOR IDENTIFYING APTAMERS - The invention relates to a method for identifying aptamers, having the following steps bringing a mixture of oligonucleotides into contact with an aptamer target structure and binding at least some of the oligonucleotides to the target structure, separating the oligonucleotides which have been bound to the aptamer target structure from the aptamer target structure and from oligonucleotides that are not bound to the aptamer target structure, amplifying individual oligonucleotides which were bound to the aptamer target structure in a physically separate manner and producing a plurality of physically separate amplicons, each amplicon predominantly containing one type of oligonucleotides, specifying a specific marker for a plurality of the physically separate amplicons such that each of the marked amplicons can be uniquely identified using the specified marker of the amplicon, sequencing oligonucleotides in a plurality of marked amplicons and assigning the marker that is specific for the amplicon to the sequence of the type of oligonucleotides in the amplicon for each amplicon examined by means of the sequencing process analyzing the binding properties of the types of oligonucleotides to the aptamer target structure and assigning the analyzed binding properties to the specific markers of the amplicons and to the sequences of the types of oligonucleotides. | 10-09-2014 |
20140303031 | METHODS AND COMPOSITIONS FOR CHARACTERIZING AUTISM SPECTRUM DISORDER BASED ON GENE EXPRESSION PATTERNS - The invention relates to methods and kits for characterizing and diagnosing autism spectrum disorder in an individual based on gene expression levels. | 10-09-2014 |
20140303032 | SYSTEMS AND METHODS FOR DETERMINING GENETIC DATA - Systems and methods of polynucleotide sequencing are provided. Systems and methods optimize control, speed, movement, and/or translocation of a sample (e.g., a polynucleotide) within, through, or at least partially through a nanopore or a type of protein or mutant protein in order to accumulate sufficient time and current blocking information to identify contiguous nucleotides or plurality of nucleotides in a single-stranded area of a polynucleotide. | 10-09-2014 |
20140303033 | Devices and Methods for Detection of Panton-Valentine Leukocidin (PVL) - The present invention provides methods and devices for detecting the presence of biomolecules in a biological sample, such as PVL, PBP2 | 10-09-2014 |
20140303034 | PREDICTING PROGNOSIS IN CLASSIC HODGKIN LYMPHOMA - Predictor genes and methods for determining prognosis in classic Hodgkin's lymphoma (cHL) are described herein. Expression levels of predictor genes ALDH1A1, APOL6, B2M, CD300A, CD68, CXCL11, GLUL, HLA-A, HLA-C, IFNG, IL15RA, IRF1, LMO2, LYZ, PRF1, RAPGEF2, RNF144B, STAT1, TNFSF10, WDR83, CCL17, COL6A1, and PDGFRA are used to derive a score within a prognostic model. Measurement of expression levels may involve counting RNA molecules using digital profiling, such as the NanoString™ platform. The score is compared to a threshold indicative of outcome. Associated kits, commercial packages, panels of biomarkers, and uses are also provided. | 10-09-2014 |
20140309123 | METHODS FOR LUNG CANCER CLASSIFICATION - The present invention provides specific nucleic acid sequences for use in the identification, classification and diagnosis of various sub-types of lung cancers. The present invention permits one to accurately classify lung cancers based on their miR expression profile without further manipulation. Using microRNA microarray data generated from over two hundred formalin-fixed paraffin-embedded (FFPE) resection samples, fine needle aspiration (FNA) samples and fine needle biopsy (FNB) samples of primary lung cancer, microRNA expression profiles were identified that differ significantly for various sub-types of lung cancer. | 10-16-2014 |
20140309124 | METHODS FOR ASSESSING ATHEROGENESIS BY DETERMINING OXIDIZED PHOSPHOLIPID TO APOLIPOPROTEIN B RATIOS - The present invention provides methods to analyze oxidized phospholipids (OxPL) on apolipoprotein B-100 in patients at high risk or with documented coronary artery disease (CAD) or acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction or suspected of being at risk for ACS. Such methods are useful for diagnostic purposes and for monitoring the effects of dietary interventions or with drugs such as statins. More particularly, the disclosure provides methods for determining OxPL/apoB ratios as indices of atherosclerosis regression and plaque stability. | 10-16-2014 |
20140309125 | MARKERS RELATED TO AGE-RELATED MACULAR DEGENERATION AND USES THEREFOR - Described herein are compositions, kits and methods for diagnosing and tracking the progression of AMD in a subject by detecting the presence or absence of particular lipid metabolism markers associated with AMD. Predictive computer models of disease risk are also disclosed. | 10-16-2014 |
20140309126 | PEPTIDE BINDING TO GRAPHITIC MATERIALS AND PHAGE INCLUDING SAME - The present disclosure provides a peptide including one or more amino acid sequence selected from a group consisting of SEQ ID NO 1 and SEQ ID NO 2 and binding specifically to a graphitic material, a phage including same, and a graphitic material including a graphitic surface on which the peptide or the phage is arranged. | 10-16-2014 |
20140309127 | METHODS OF DETECTING BLADDER CANCER - Compositions and methods for detecting bladder cancer are provided. In some embodiments, methods of detecting low grade bladder cancer are provided. In some embodiments, methods of monitoring recurrence of bladder cancer are provided. In some embodiments, the methods comprise detecting androgen receptor (AR) and/or uroplakin 1B (UPK1B). | 10-16-2014 |
20140309128 | DIGITAL ASSAYS FOR MUTATION DETECTION - Provided herein are methods, compositions, and kits for detecting alleles using a single probe or a single primer set. Also, provided herein are methods, compositions, and kits for detecting allelic variants using a single probe or a single primer set. Also, provided herein are methods, compositions, and kits for determining a polymerization error rate. | 10-16-2014 |
20140309129 | Encoded Nanopore Sensor for Multiplex Nucleic Acids Detection - The present invention provides a new and improved multiplexed oligonucleotide detection method based on the nanopore technology with one or more probes containing a sequence with complementarity to the target oligonucleotide, a terminal extension at the probe's 3′ terminus, 5′ terminus, or both termini and a label attached to the terminus. The improved probes and probe sets enable sensitive, selective, and direct multiplex detection, differentiation and quantification of distinct target oligonucleotides such as miRNAs. The inventive detection method may also be employed as a non-invasive and cost-effective diagnostic method based on miRNA levels in the patient's tissue sample. | 10-16-2014 |
20140309130 | Use of MicroRNAs for Screening and Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia - Disclosed are microRNA biomarkers and use thereof for screening and diagnosis of prostate cancer and benign prostatic hyperplasia. This invention provides a method for screening for prostate cancer in a subject involving the steps of: (a) assaying the miRNA expression level in a test sample from the subject to be screened for prostate cancer; (b) comparing the assayed miRNA expression level of the subject to the miRNA expression level in a normal sample providing a control relative to the test sample of the subject; and (c) computing the differential expression of the miRNA from the subject, wherein the over-expression of miR-1825 or under the expression of miR-484 is indicative of prostate cancer. In another aspect, provided is a method for screening for benign prostatic hyperplasia in a subject involving the steps of: (a) assaying the miRNA expression level in a test sample from the subject to be screened for benign prostatic hyperplasia; (b) comparing the assayed miRNA expression level of the subject to the miRNA expression level in a normal sample providing a control relative to the test sample of the subject; and (c) computing the differential expression of the miRNA from the subject, wherein the under expression of miR-498 is indicative of benign prostatic hyperplasia. | 10-16-2014 |
20140309131 | METHOD FOR SCREENING INDUCED PLURIPOTENT STEM CELLS - The present invention provides a method for screening for iPS cells exhibiting differentiation resistance using a marker identified as lincRNA or mRNA that is specifically expressed in an iPS cell line exhibiting differentiation resistance, and such markers. | 10-16-2014 |
20140309132 | METHOD FOR QUANTITATIVELY SENSING AND EFFECTIVELY MARKING INTERACTION WITH TARGET MATERIAL BY USING ENERGY TRANSFER AND SIGNAL CHANGE BASED ON HIGH-DENSITY DISPLAY OF MATERIAL - The present invention relates to methods of quantitatively analyzing and detecting interactions, which effectively occur between detector materials displayed on a nano-assembly matrix at high density, and sensitively labeling and isolating a target material that effectively interacts with the detector materials, by the use of energy transfer and signal changes that effectively occur in label molecules displayed at high density. Specifically, the present invention relates to a method of quantitatively detecting the interactions between various bioactive materials, which occur in vitro or in vivo, based on high-density displays of molecules, and to a method of sensitively labeling a target material that interacts with these bioactive materials. | 10-16-2014 |
20140309133 | Novel Method for Diagnosis of High-Affinity Binders and Marker Sequences - The present invention relates to a novel method for diagnosing high-affinity binders, in particular antibodies or autoantibodies, and the identification, characterisation and selection of marker sequences and diagnostic use thereof, in particular in the form of a panel. The invention also relates to a singleplex assay in which the discovered selection of marker sequences is used in the form of a panel and high-affinity binders are detected using a single signal. | 10-16-2014 |
20140309134 | EXCHANGE-INDUCED REMNANT MAGNETIZATION FOR LABEL-FREE DETECTION OF DNA, MICRO-RNA, AND DNA/RNA-BINDING BIOMARKERS - A method of using an exchange-induced remnant magnetization (EXIRM) technique for label free detection of short strands of nucleotides and cancer biomarkers, such as DNA and microRNA strands, DNA/RNA-binding biomarkers, and cancer-specific antigens, with high sensitivity, high specificity, and broad dynamic range. The method may provide a label-free approach aimed to facilitate high reliability, and to require a minimum amount of biochemical reagents. | 10-16-2014 |
20140309135 | REMEDY FOR DIABETES - A method of screening a compound having a hypoglycemic effect (hereinafter referred to as “hypoglycemic compound”), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the β subunit of a trimeric GTP-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the β subunit of a trimeric GTP-binding protein, as the active ingredient, etc. | 10-16-2014 |
20140309137 | GENE EXPRESSION PROFILES ASSOCIATED WITH LEAN PHENOTYPE AND USES THEREOF - Gene expression profiles associated with improved or maintained lean body mass or reduced body fat are disclosed. The gene expression profiles were determined in adipose, liver, and muscle tissue of animals subjected to lean-promoting regimens such as consumption of a high protein diet, ingestion of conjugated linolenic acid, and/or increased exercise. Methods of using such profiles for the identification of pharmaceutical substances, nutraceutical substances, dietary substances, or treatment regimens that modulate or contribute to desired phenotypes in animals are also disclosed | 10-16-2014 |
20140309138 | COMPOSITIONS AND METHODS OF DETECTING RESPIRATORY PATHOGENS USING NUCLEIC ACID PROBES AND SUBSETS OF BEADS - The present disclosure is instructional for a multiplex nucleic acid amplification assay to detect and identify multiple respiratory pathogens. | 10-16-2014 |
20140309139 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS IN WOMEN, METHODS OF DETECTION AND USES THEREOF - Methods and kits for identifying a woman having an increased risk of developing venous thrombosis, requiring prophylactic or therapeutic treatment are provided, and methods for identifying an agent useful in prophylactically or therapeutically treating venous thrombosis in women, said methods comprising genotyping the woman with respect to the F9 G32023A (rs440051) polymorphism and/or the F9 5:32164:6/4 polymorphism (rs35599944). | 10-16-2014 |
20140309140 | METHOD FOR THE DIAGNOSIS OF NIEMANN-PICK DISEASE - The present invention is related to a method for diagnosing Niemann-Pick disease in a subject comprising a step a), wherein the step a) comprises detecting a biomarker in a sample from the subject. | 10-16-2014 |
20140315732 | CANCER DIAGNOSIS AND TREATMENT - A diagnostic assay for cancer such as lung cancer is disclosed. The assay can also be used to follow patients during treatment and for assessment of disease relapse after treatment. The assay utilizes biomarkers for tumor formation identified in a transgenic mouse model. The assay is used to identify a therapeutic indication for a patient based on the patient's biomarker expression. The biomarker and fragments thereof are also useful for treating cancer, for example lung or colon cancer. | 10-23-2014 |
20140315733 | Methods and Compositions For Sorting and/or Determining Organisms - This invention is directed to methods and compositions for sorting and/or determining microscopic organisms or cells. The methods and compositions are directed to the use of molecular probes to selectively stain the organisms or cells in combination with the use of binding partners to selectively immobilize the stained organisms or cells to a solid carrier. By combining the selectivity of both molecular probes and binding partners in an orthogonal method for staining and immobilization, these methods and compositions increase both the discriminating power of the assays and/or the certainty of the result obtained therefrom. | 10-23-2014 |
20140315734 | METHODS AND COMPOSITIONS FOR ASSIGNING LIKELIHOOD OF ACUTE KIDNEY INJURY PROGRESSION - The invention encompasses diagnosis and prognosis in the context of heart or renal failure, particularly in subjects who exhibit a normal body fluid level of a natriuretic peptide. The invention also relates to methods of assigning an increased likelihood that a subject having AKI is susceptible to AKI progression. The invention relates in part to assigning a diagnosis of heart and/or renal failure, and/or an outcome risk (e.g., worsening cardiac and/or renal function or a mortality risk) to a subject based, at least in part, on the result(s) obtained from an assay that detects WAP four-disulfide core domain protein 2 performed on a body fluid sample obtained from a subject. | 10-23-2014 |
20140315735 | CANCER ANTIGEN-SPECIFIC T-CELL RECEPTOR GENE, PEPTIDE ENCODED BY THE GENE, AND USE OF THEM - Disclosed are: a nucleotide sequence and an amino acid sequence for CDR3 region of T-cell receptor (TCR) gene of WT1-specific cytotoxic T-cell (CTL) for WT1 protein; a method for the detection or treatment of cancer using the nucleotide sequence or the amino acid sequence; and a chip, a primer set, a kit, an apparatus and the like for use in the detection of cancer, each of which comprises the nucleotide sequence or the amino acid sequence. | 10-23-2014 |
20140315736 | DIAGNOSTIC BIOMARKER PROFILES FOR THE DETECTION AND DIAGNOSIS OF ALZHEIMER'S DISEASE - The present invention provides methods, compositions and kits for the detection of Alzheimer's disease (AD) diagnostic biomarkers, for the diagnosis of AD, for the identification of a subject at risk for developing AD, and for the generation of patient-specific AD diagnostic biomarker profiles. | 10-23-2014 |
20140315737 | BIOMARKERS FOR EPILEPSY - The present invention relates to a group of epilepsy biomarkers comprising (i) SNP rs2740574; (ii) SNP rs1799735; (iii) SNP rs1695; (iv) SNP rs6280; and the locus of the human glutathione S-transferase theta-1 (GSTT1) gene. The invention particularly relates to this group of biomarkers as marker for protection against drug-resistant epilepsy. The group of biomarkers may additionally comprise at least one clinical marker selected from the group comprising (i) a focal seizure with secondary generalization; (ii) age at confirmed diagnosis of epilepsy; (iii) atrophy of hippocampus or medial temporal sclerosis; and (iv) the presence of a brain tumor. The present invention further relates to a method for detecting protection against drug-resistant epilepsy in a subject, a method for monitoring epilepsy therapy, a method of identifying an individual as eligible for an aggressive epilepsy therapy, a composition for detecting protection against drug-resistant epilepsy in a subject, a corresponding kit and a microarray for the analysis of protection against drug-resistant epilepsy. | 10-23-2014 |
20140315738 | MARINE MEDAKA GENES RESPONDING TO THE EXPOSURE OF ENDOCRINE-DISRUPTING CHEMICALS, AND METHOD FOR DIAGNOSING AN AQUATIC ECO-SYSTEM CONTAMINATION USING SAME - The present invention relates to marine medaka genes responding to the exposure of endocrine-disrupting chemicals, and a method for diagnosing an aquatic eco-system contamination using the marine medaka genes. Specifically, the method for diagnosing an aquatic eco-system contamination, according to the present invention, makes use of marine medaka genes of which the expression amount changes according to 17β-estradiol, or marine medaka genes of which the expression amount changes according to bisphenol A. Since it was verified that genes of marine medaka exposed to 17β-estradiol are changed or genes of marine medaka exposed to bisphenol A are changed, the present invention can be used in a useful manner for a microarray chip in which marine medaka genes responding to 17β-estradiol or marine medaka genes responding to bisphenol A are integrated, for a diagnosis using same, and for a method for diagnosing health or detecting stress of a marine eco-system by applying a kit having the microarray chip. | 10-23-2014 |
20140315739 | GENE EXPRESSION SIGNATURE FOR CLASSIFICATION OF TISSUE OF ORIGIN OF TUMOR SAMPLES - The present invention provides a process for classification of cancers and tissues of origin through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA tree-based expression framework allows optimization of treatment, and determination of specific therapy. | 10-23-2014 |
20140315740 | ANTIGEN ARRAY AND DIAGNOSTIC USES THEREOF - A method of diagnosing an immune disease, or a predisposition thereto, in a subject is disclosed. The method comprises determining a capacity of immunoglobulins of the subject to specifically bind each antigen probe of an antigen probe set, wherein the antigen probe set comprises a plurality of antigen probes selected from the group consisting of at least a portion of a cell/tissue structure molecule, at least a portion of a heat shock protein, at least a portion of an immune system molecule, at least a portion of a homopolymeric polypeptide, at least a portion of a hormone, at least a portion of a metabolic enzyme, at least a portion of a microbial antigen, at least a portion of a molluscan antigen, at least a portion of a nucleic acid, at least a portion of a plant antigen, at least a portion of plasma molecule, and at least a portion of a tissue antigen, wherein the capacity is indicative of the immune disease or the predisposition thereto, thereby diagnosing the immune disease, or the predisposition thereto, in the subject. | 10-23-2014 |
20140315741 | METHODS AND MATERIALS FOR MODULATING DEUBIQUITINASES AND UBIQUITINATED POLYPEPTIDES - This document relates to methods and materials involved in modulating deubiquitinases (e.g., USP10 polypeptides) and/or ubiquitinated polypeptides (e.g., tumor suppressor polypeptides or mutant versions of tumor suppressor polypeptides). For example, methods and materials for increasing deubiquitinase (e.g., a USP10 polypeptide) expression or activity, methods and materials for decreasing deubiquitinase (e.g., a USP10 polypeptide) expression or activity, methods and materials for stabilizing tumor suppressor polypeptides (e.g., wild-type p53 polypeptides), methods and materials for de-stabilizing mutant versions of tumor suppressor polypeptides (e.g., mutant p53 polypeptides), and methods and materials for reducing cancer cell proliferation, increasing cancer cell apoptosis, and/or treating cancer (e.g., cancers having reduced levels of wild-type p53 polypeptides or cancers having increased levels of mutant p53 polypeptides) are provided. This document also provides methods and materials for identifying agonists or antagonists of USP10 polypeptide mediated stabilization of p53 polypeptides. | 10-23-2014 |
20140315742 | BIODOSIMETRY PANELS AND METHODS - The present invention relates to methods and kits to assess an absorbed dose of ionizing radiation and/or the severity of tissue injury from radiation in a patient. The invention also relates to algorithms used to calculate an absorbed dose of radiation based on biomarker measurements of a plurality of biomarkers that are altered relative to a normal control in the event of radiation exposure. | 10-23-2014 |
20140315743 | Methods and Compositions for the Treatment and Diagnosis of Ovarian Cancer - The invention relates to methods, compositions and kits for the diagnosis, detection, and treatment of ovarian cancer. | 10-23-2014 |
20140315744 | ASSESSMENT OF OOCYTE COMPETENCE BY DETECTING SPSB2 AND/OR TP53I3 GENE EXPRESSION - Methods are provided for evaluating an oocyte for fertilization and implantation comprising analysis of gene expression in cumulus cells wherein the detected genes or polypeptides include at least SPSB2 and TP53I3. For example, methods are provided for determining whether a cumulus cell expresses, or does not express, one or more of a group of markers identified as differently expressed between cumulus cells associated with chromosomally normal oocytes and cumulus cells associated with chromosomally abnormal oocytes. Methods are provided for the detection of marker expression of differentially expressed genes at the RNA level, as well as at the protein level. | 10-23-2014 |
20140315745 | BROAD DETECTION OF DENGUE VIRUS SEROTYPES - Processes for detecting Dengue virus (DENV) nucleic acid in a sample are provided including producing an amplification product by amplifying DENV nucleotide sequence and detection of an amplification by hybridization of a probe or other technique. The processes use primers or probes with introduced mutations and or degenerate bases that provide excellent superiority in detection and serotyping of DENV in a sample. | 10-23-2014 |
20140315746 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROSTATE CARCINOMA - Compositions and methods for the diagnosis, treatment and prevention of prostate cancer, well as for treatment selection. | 10-23-2014 |
20140315747 | BIFUNCTIONAL OLIGONUCLEOTIDE PROBE FOR UNIVERSAL REAL TIME MULTIANALYTE DETECTION - The invention relates to a mediator probe comprising a probe region and a mediator region. Furthermore, the invention relates to a system comprising a mediator probe and a detection molecule, use of that system and a method for detection of at least one target molecule. | 10-23-2014 |
20140315748 | DETECTION, ISOLATION AND ANALYSIS OF RARE CELLS IN BIOLOGICAL FLUIDS - The invention provides a method for isolating or enriching a rare cell from a biological fluid of a mammal employing an antibody that binds a cell-surface antigen of the rare cell. The immobilized antibody is incubated with a sample of biological fluid that includes the rare cells and a plurality of other cells so as to form an antibody-rare cell complex. The complex can be detected or isolated and subsequently analyzed by any of a variety of physical, chemical and genetic techniques. | 10-23-2014 |
20140315749 | METHODS AND KITS FOR DETECTING IGE-EXPRESSING B CELLS - The invention relates to the field of medical diagnostics. In particular, it relates method and kits for identification and classification of IgE-related diseases, e.g. Type I hypersensitivity, as well as for monitoring of treatment efficacy, for instance anti-IgE therapy. Provided is a multi-color flow cytometric method for analyzing memory B cell and plasma cell subsets in a biological sample, comprising staining the sample with a panel of fluorochrome-conjugated antibodies comprising antibodies against IgM, IgA, IgG, IgD and IgE; an antibody against a B cell marker and an antibody against the CD38 antigen; subjecting the sample to flow cytometry and gating for lymphocytes based on forward scatter and side scatter pattern; gating the lymphocytes for expression of the B cell specific marker and CD38 to discriminate between CD38 | 10-23-2014 |
20140315750 | SELECTIVE DETECTION OF NOROVIRUS - A process for detecting norovirus nucleic acid in a sample is provided including producing an amplification product by amplifying a norovirus nucleotide sequence using a forward primer of SEQ ID NO: 1, 4, or 10 and a reverse primer of SEQ ID NO: 2, 5, or 11, and detecting the amplification product to detect norovirus in the sample. Also provided are reagents and methods for detecting and distinguishing GI or Gil norovirus from other infectious agents. A kit is provided for detecting and quantifying norovirus in a sample. | 10-23-2014 |
20140315751 | High Throughput Selection of Specific Cell Binding and Lytic Polypeptides - The invention provides methods for identifying cell binding and/or lytic polypeptides that permit production of specific polypeptide therapeutics in a high throughput manner. | 10-23-2014 |
20140315752 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Stanniocalcin-1, Antithrombin-III, Toll-like receptor 2, Triiodothyronine (T3), Thyroxine (T4), Extracellular matrix protein 1, Coagulation factor XIII A chain, Coagulation factor XIII B chain, Interleukin-17F, Interleukin-22, Vitronectin, Progesterone, Estradiol, Growth/differentiation factor 15, and Proprotein convertase subtilisin/kexin type 9 as diagnostic and prognostic biomarkers in renal injuries. | 10-23-2014 |
20140323322 | METHOD AND APPARATUS FOR CHEMICAL SENSING USING 2D PHOTONIC CRYSTAL ARRAYS - A chemical sensor comprising: a hydrogel layer, comprising one or more molecular recognition agents and a 2DPC self-assembling array; and a mirror layer. A method for analyzing a sample or bodily fluid, comprising: obtaining a sample or bodily fluid; placing an amount of the sample or bodily fluid onto a chemical sensor, comprising: a hydrogel layer, comprising a molecular recognition agent and a 2DPC self-assembling array; a tethering hydrogel layer; a mirror layer; and a membrane filter layer, allowing the bodily fluid to interact with the hydrogel layer; and allowing ambient or artificial light to pass through the hydrogel layer onto the mirror layer and observing a change in diffraction versus a control. | 10-30-2014 |
20140323323 | Silicon-Based Photonic Crystal Fluorescence Enhancement and Laser Line Scanning Instrument - A silicon-based photonic crystal includes a silicon substrate, a first dielectric with a grating structure formed therein, and a second dielectric with a higher index of refraction that covers at least a portion of the grating structure. The first dielectric can be formed on the silicon substrate, or a Fabry-Perot optical cavity can be formed between the silicon substrate and the first dielectric. An instrument can excite a fluorophore coupled to the photonic crystal by focusing collimated incident light that includes the fluorophore's excitation wavelength to a focal line on the surface of the photonic crystal such that the focal line is substantially parallel to the grating direction and can detect fluorescence radiation emitted by the fluorophore in response to the incident light. To provide for fluorescence enhancement, the excitation wavelength and/or emission wavelength of the fluorophore can couple to an optical resonance of the photonic crystal. | 10-30-2014 |
20140323324 | Method for Enrichment and Separation of Spinal Fluid Glycoprotein, Method for Searching for Marker for Central Nervous System Diseases Which Utilizes the Aforementioned Method, and Marker for Central Nervous System Diseases - The purpose of the present invention is to develop: a method for selectively separating a glycoprotein derived from the central nervous system from a body fluid or a central nervous system cell; and a method for searching for an index marker for central nervous system diseases, which utilizes the aforementioned method. A protein derived from the central nervous system, which occurs in a trace amount in a body fluid or a central nervous system cell, can be selectively enriched by a two-stage separation procedure comprising removing a glycoprotein having sialic acid at a non-reducing terminal thereof from the body fluid or the central nervous system cell and then separating a glycoprotein having N-acetylglucosamine at a non-reducing terminal thereof. | 10-30-2014 |
20140323325 | Molecular imaging and related methods - The present invention generally relates to imaging single molecules, or one or more collections of single molecules, and methods related to the imaging. In a method aspect, the present invention provides a method of imaging single molecules. The method comprises the steps of: a) exposing a test sample to a probe, wherein the probe comprises a first portion that specifically binds to a target molecule and a second portion that is detectable as the result of one or more chemical groups that interact with light at one or more wavelengths, wherein the probe binds to a target molecule to provide a complex; b) exposing the complex to one or more wavelengths of light that interact with the one or more chemical groups; c) detecting a result from the interacting of one or more wavelengths of light that interact with the one or more chemical groups to provide an image of one or more single molecules. The image possesses a resolution better than 450 nm over a view field area of at least 1×10 | 10-30-2014 |
20140323326 | METHODS FOR THE ELECTROCHEMICAL TREATMENT OF SELF-ASSEMBLED MONOLAYERS - The present invention provides compositions and methods directed to an electrode initialization step for the electrochemical treatment of monolayers used in electrochemical detection of target analytes on the surface of a monolayer. Electrode initialization creates a more stable monolayer, and resolves variability within the electrochemical signal detected on the monolayer. | 10-30-2014 |
20140323327 | ANIMALS, REPERTOIRES & METHODS - The present invention is directed to the concept of sectoring antibody gene segment repertoires in order to enable the development of novel, synthetic antibody chain repertoires not seen in nature. The present invention is also directed to the realisation of the inventors that sectoring can also alter gene segment expression by providing new arrangements of gene segment clusters relative to other gene segments and regulatory elements in transgenic immunoglobulin loci, thereby providing for new synthetic antibody chain sequence repertoires. The invention also relates to gene segment inversion. | 10-30-2014 |
20140323328 | METHOD - The invention provides a method of measuring the affinity of first and second biomolecules in which a first biomolecule is tethered by a first tether portion having a first tether portion length and a second biomolecule is tethered by a second tether portion having a second tether portion length, the method comprising determining binding of adjacent first and second biomolecules to each other, varying at least one of the first and second tether lengths and determining binding of the first and second biomolecules. The invention also provides apparatus suitable for use in the method of the invention. | 10-30-2014 |
20140323329 | Gene Fusion - The disclosure provides gene fusion variants and novel associations with disease states, as well as kits, probes, and methods of using the same. | 10-30-2014 |
20140323330 | MICROARRAY COMPOSITIONS AND METHODS OF THEIR USE - Microarray compositions suitable for analysis by one or several spectrographic methods are disclosed. In an embodiment, a microarray composition includes a three-dimensional solid support and a plurality of reactive microbeads positioned on the solid support in spatially distinct and addressable locations. | 10-30-2014 |
20140323331 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ACNE VULGARIS - Described herein are methods, systems, platforms, and kits for the characterization, assessment, diagnosis and treatment of acne vulgaris. Among the methods provided are methods of identifying a gene expression profile for acne vulgaris and biomarkers for monitoring treatment. Also provided are methods, systems, platforms, and kits for monitoring efficacy of a treatment and methods for selecting a treatment regimen. | 10-30-2014 |
20140323332 | MULTIPLEX HEPATITIS B ASSAY - Provided herein are multiplex assays for determining whether an individual is or has been infected with Hepatitis B virus, and the stage of infection or resolution. In addition, the multiplex system can discriminate between vaccinated subjects and subjects susceptible to Hepatitis B infection. | 10-30-2014 |
20140323333 | FLOW CYTOMETRY ASSAY METHODS - This document provides methods and materials involved in performing flow cytometry assay methods. For example, flow cytometry assay methods and kits are provided. | 10-30-2014 |
20140323334 | Interference Control Panel for Evaluation of Analytical Assays For Samples Derived from Blood - The invention relates to quality control of analytical assays, particularly NAT assays of blood samples containing nucleic acids. A control panel containing quantified amounts of substances known to interfere with an analytical assay is used and compared with a reference sample in the analytical assay. A comparison of the assay results interference panel validates the assay and can serve as a periodic quality control check for the analytical assay as well as related methods and protocols. The use of the control panel of the invention can also determine whether interfering substances are present and establish under what conditions the analytical assay reliable. | 10-30-2014 |
20140323335 | Methods of Novel Therapeutic Candidate Identification Through Gene Expression Analysis in Vascular-Related Diseases - The present invention discloses multiple treatment regimens for vascular-related diseases and disorders. The present invention provides for methods of treating vascular-related disorders based on gene expression studies from samples collected from individuals having symptoms of vascular-related disorders. Additionally, methods are disclosed involving diagnostic techniques to focus treatment regimens. Finally, methods of treating vascular-related disorder involving targeting microRNAs are also disclosed. | 10-30-2014 |
20140323336 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE - A method for performing a multiplexed diagnostic assay, such as for two or more different targets in a sample, is described. One embodiment comprised contacting the sample with two or more specific binding moieties that bind specifically to two or more different targets. The two or more specific binding moieties are conjugated to different haptens, and at least one of the haptens is an oxazole, a pyrazole, a thiazole, a nitroaryl compound other than dinitrophenyl, a benzofurazan, a triterpene, a urea, a thiourea, a rotenoid, a coumarin, a cyclolignan, a heterobiaryl, an azo aryl, or a benzodiazepine. The sample is contacted with two or more different anti-hapten antibodies that can be detected separately. The two or more different anti-hapten antibodies may be conjugated to different detectable labels. | 10-30-2014 |
20140323337 | MONOLITHIC DEVICE COMBINING CMOS WITH MAGNETORESISTIVE SENSORS - A monolithic device comprises a substrate. An array of sensing elements is coupled to the substrate, and each sensing element includes a magnetoresistive sensor. An analog electric drive generator is coupled to the substrate, and the electric drive generator produces a sensor-biasing signal that biases the magnetoresistive sensors of the array. An analog multiplexer is coupled to the substrate, and outputs of the array are coupled to inputs of the multiplexer. An analog signal conditioning circuit is coupled to the substrate, wherein at least one output of the multiplexer is coupled to at least one input of the signal conditioning circuit. The monolithic device is fabricated using both complementary metal-oxide semiconductor (i.e., CMOS) technology and thin film technology. For example, the electric drive generator, the multiplexer, and the signal conditioning circuit may be fabricated with CMOS technology, while the magnetoresistive sensors of the array are fabricated with thin film technology. | 10-30-2014 |
20140323338 | BIOMARKERS FOR PREDICTION, DIAGNOSIS, AND MONITORING OF ALZHEIMER'S DISEASE - A method for the risk detection, early diagnosis, prognosis, and monitoring of Alzheimer's disease in an individual by measuring the amount of specific biomarkers present in a bodily fluid and comparing them to a reference level of biomarkers in a sample from a healthy person, a person previously diagnosed with Alzheimer's disease, or an earlier sample from the individual of interest. | 10-30-2014 |
20140323339 | METHODS TO ASSAY KINASE ACTIVITY - Methods and kits for enzymes involved in post-translational modifications are provided. The methods employ elemental analysis, including ICP-MS. The methods allow for the convenient and accurate analysis of post-translation modifications of substrates by enzymes involved in post-translational modifications, including kinase and phosphatase enyzmes | 10-30-2014 |
20140323340 | SENSITIVE AND RAPID DETERMINATION OF ANTIMICROBIAL SUSCEPTIBILITY - The present invention relates to moving microorganisms to a surface, where they are grown in the presence and absence of antimicrobials, and by monitoring the growth of the microorganisms over time in the two conditions, their susceptibility to the antimicrobials can be determined. The microorganisms can be moved to the surface through electrophoresis, centrifugation or filtration. When the movement involves electrophoresis, the presence of oxidizing and reducing reagents lowers the voltage at which electrophoretic force can be generated and allows a broader range of means by which the target can be detected. Monitoring can comprise optical detection, and most conveniently includes the detection of individual microorganisms. The microorganisms can be stained in order to give information about their response to antimicrobials. | 10-30-2014 |
20140323341 | SYSTEMS AND METHODS FOR ASSESSMENT OF BIOSIMILARITY - A method of determining biosimilarity of a sample composition to a reference composition, including: exposing a test cell system to a sample composition so that the test cell system responds to the sample composition by change in transcription factor activity in the test cell system; generating from the test cell system response an output correlative to the change of transcription factor activity in the test cell system; and determining from comparison of said output with a transcription factor activity reference standard for the reference composition, the biosimilarity of the sample composition to the reference composition. Computer systems and kits for carrying out the determination of biosimilarity of compositions are also described, in which biosimilarity of compositions ranging from simple molecules to complex mixtures can be readily and accurately determined by transcription factor activity analysis. | 10-30-2014 |
20140323342 | Methods and Compositions for the Treatment and Diagnosis of Bladder Cancer - The invention provides methods, compositions and kits for the detection and treatment of bladder cancer. | 10-30-2014 |
20140323343 | BIOMARKERS FOR ASSESSING IDIOPATHIC PULMONARY FIBROSIS - Disclosed are methods are kits for evaluating predicting whether an individual IPF has slowly or rapidly progressive IPF. | 10-30-2014 |
20140323344 | Differential Identification of Pancreatic Cysts - More than 2% of adults harbor a pancreatic cyst, a subset of which progress to invasive lesions with lethal consequences. To assess the genomic landscapes of neoplastic cysts of the pancreas, we determined the exomic sequences of DNA from the neoplastic epithelium of eight surgically resected cysts of each of the major neoplastic cyst types: serous cystadenomas (SCAs), intraductal papillary mucinous neoplasms (IPMNs), mucinous cystic neoplasms (MCNs) and solid pseudo-papillary neoplasms (SPNs). SPNs are low-grade malignancies, and IPMNs and MCNs, but not SCAs, have the capacity to progress to cancer. We found that SCAs, IPMNs, MCNs, and SPNs contained 10=4.6, 27=12, 16=7.6, and 2.9=2.1 somatic mutations per tumor, respectively. Among the mutations identified, E3 ubiquitin ligase components were of particular note. Four of the eight SCAs contained mutations of VHL, a key component of the VHL ubiquitin ligase complex that has previously been associated both with renal cell carcinomas, SCAs, and other neoplasms. Six of the eight IPMNs and three of the eight MCNs harbored mutations of RNF43, a gene coding for a protein with intrinsic E3 ubiquitin ligase activity that has not previously been found to be genetically altered in any human cancer. The preponderance of inactivating mutations in RNF43 unequivocally establish it as a suppressor of both IPMNs and MCNs. SPNs contained remarkably few genetic alterations, but always contained mutations of CTNNB1, previously demonstrated to inhibit degradation of the encoded protein (β-catenin) by E3 ubiquitin ligases. These results highlight the essential role of ubiquitin ligases in these neoplasms and have important implications for the diagnosis and treatment of patients with cystic tumors. | 10-30-2014 |
20140323345 | NOVEL MARKERS OF PAPILLARY AND RETICULAR FIBROBLASTS AND USES THEREOF - An in vitro method for screening for candidate compounds for preventing and/or attenuating skin ageing, and/or hydrating skin, includes: a) contacting a test compound with a sample of papillary fibroblasts; b) measuring the expression of a gene selected from PDPN, CCRL1 and NTN1, in the papillary fibroblasts; and c) selecting compounds for which an activation of at least 1.5 fold of the expression of at least one of the genes is measured in the treated papillary fibroblasts compared with untreated papillary fibroblasts. Another in vitro method includes: a) contacting a test compound with a sample of reticular fibroblasts; b) measuring the expression of a gene selected from MGP, PPP1R14A and TGM2, in the reticular fibroblasts; and c) selecting compounds for which an activation of at most 1.0 fold of the expression of at least one of the genes is measured in the treated reticular fibroblasts compared with untreated reticular fibroblasts. | 10-30-2014 |
20140323346 | BINDING AGENT - The present disclosure generally relates to protein binding agents, such as protein kinase binding agents of general Formula (I). The protein binding agents may be provided attached to a solid support and may be used, for example, to detect the presence of a broad range of proteins in a sample. Methods of synthesizing the protein binding agents, and kits comprising the protein binding agents, are also disclosed. | 10-30-2014 |
20140323347 | POINT OF CARE IMMUNIZATION TESTING SYSTEM - A point of care immunization system based upon microfluidics and micro-titration technologies to rapidly test a patient in order to ascertain an immunization profile so that vaccinations can be administered to address identified gaps. A point of care system comprised of uniquely shaped and color distinguishing sample and test cartridges, with said test cartridges configured to meet healthcare requirements of national governing bodies. A point of care system including an easy access vaccine storage device with indicators to provide data on viability of stored vaccines. | 10-30-2014 |
20140323348 | EXPRESSION OF G-PROTEIN COUPLED RECEPTORS (GPCRs) - Disclosed are methods of promoting and/or enhancing G-Protein Coupled Receptor (GPCR) localization to the cell membrane and/or cell surface; methods of promoting and/or enhancing GPCR functional expression; and methods and assays for screening or identifying ligands (e.g., agonists or antagonists) that bind GPCRs. Also provided are vectors, recombinant cells, and stable cell lines for use in the methods and assays. | 10-30-2014 |
20140323349 | COMPOSITIONS AND METHODS FOR MONITORING AND DETECTING CANCEROUS CONDITIONS - A method for monitoring or detecting a prostate condition in a subject comprises determining Engrailed-2 (EN2) gene, Paired Box 2 (PAX2) gene, and/or β defensin-1 (DEFB1) gene expression levels in a biological sample from the subject. The expression levels of EN2, PAX2 and/or DEFB1 gene are correlated with cancerous, pre-cancerous, or non-cancerous prostate conditions. | 10-30-2014 |
20140323350 | ELECTRONIC LATERAL FLOW TEST ARRANGEMENT AND METHOD - A lateral test flow arrangement for a test molecule is disclosed, comprising: a test strip for transporting an analyte away from a sampling region and towards an absorbing region, the test strip having therein and remote from the sampling region, a test region for functionalization with a molecule which binds to the test molecule or to a conjugate of the test molecule; a sensing test capacitor having electrodes extending across the test strip at least partially aligned with the test region and being physically isolated therefrom; a reference test capacitor having electrodes extending across the test strip and being physically isolated therefrom; and an electronic circuit configured to measure a time-dependant capacitance difference between the sensing test capacitor and the reference test capacitor. A method for carrying out that lateral flow tests is also disclosed, as are test systems and in particular pregnancy test systems | 10-30-2014 |
20140329701 | KIAA1456 EXPRESSION PREDICTS SURVIVAL IN PATIENTS WITH COLON CANCER - The invention relates to methods for deciding on the therapy in a subject suffering from colorectal cancer as well as for predicting the clinical outcome of a patient which suffers from colorectal cancer based on the expression level of KIAA1456 comprising determining the expression level of the KIAA1456 gene. The invention relates as well to kits and uses thereof comprising reagents adequate for the determination of the expression level of the KIAA1456 gene. | 11-06-2014 |
20140329702 | METHOD OF AMPLIFYING A NUCLEIC ACID - A nucleic acid amplification method is provided, along with kits useful in performing the amplification method. | 11-06-2014 |
20140329703 | METHODS AND COMPOSITIONS FOR PREPARING RNA FROM A FIXED SAMPLE - The present invention provides improved methods and compositions for RNA isolation. In particular embodiments the present invention concerns the use of methods and compositions for the isolation of full-length RNA from fixed tissue samples. The present invention provides methods for digesting and extracting RNA from a fixed tissue sample. | 11-06-2014 |
20140329704 | MARKERS FOR MATURE BETA-CELLS AND METHODS OF USING THE SAME - Markers for mature β-cells and methods of using these markers are disclosed. | 11-06-2014 |
20140329705 | SALIVA COLLECTION, PROCESSING, STABILIZATION, AND STORAGE METHOD - Provided herein is an all-in-one saliva collection apparatus that collects saliva to allow for the filtration of saliva in order to separate saliva components, such as extracellular proteins and nucleic acids that are not present in intact cells, from the intact cells and debris remaining in the extracted sample. The filtered saliva samples can be aliquoted into two fractions for protein and/or nucleic acid analysis. The present invention further describes long term storage at ambient temperatures of filtered salivary nucleic acids, and long term storage at ambient temperatures of filtered salivary proteins added to an ethanol solution. The filtered cell-free saliva samples have diagnostic usefulness. | 11-06-2014 |
20140329706 | AFFINITY TAGS, AND RELATED AFFINITY LIGANDS, ENGINEERED PROTEINS, MODIFIED SUPPORTS, COMPOSITIONS, METHODS AND SYSTEMS - Affinity tags and ligands comprising a PDZ domain peptide and a PDZ binding carboxy terminal peptide and related engineered protein, engineered labels, compositions, methods and systems. | 11-06-2014 |
20140329707 | NANOSCALE COAXIAL ELECTRODE ARRAYS AND METHODS THEREOF - The invention provides novel devices and methods that enable ultrahigh spatial and temporal resolution interfaces that allow access and intervention to local (intra- and proximate extra-neuronal) neuroelectronic and neurotransmitter molecular signatures associated with aberrant cell function and cell death leading to neurodegenerative diseases. Scalable devices based on a unique nanocoaxial electrode array of the invention offer neural recording and control at unprecedented levels of precisions. | 11-06-2014 |
20140329708 | Methods and Compositions for Determining a Graft Tolerant Phenotype in a Subject - Methods are provided for determining whether a subject has a graft tolerant phenotype. In practicing the subject methods, the expression of at least 5 genes in a sample from the subject, e.g., a blood sample, is assayed to obtain a gene expression result for the at least 5 genes. The obtained gene expression result for the at least 5 genes is then employed to determine whether the subject has a graft tolerant phenotype. Also provided are compositions, systems and kits that find use in practicing the subject methods. The methods and compositions find use in a variety of applications, including the determination of an immunosuppressive therapy regimen. | 11-06-2014 |
20140329709 | METHOD FOR DETECTING A TARGET PARTICLE - The present invention provides a method for indirectly and with high sensitivity detecting a particle dispersed and moving randomly in a solution using a luminescent probe. In the present invention, (a) a solution is prepared that contains a target particle and one or more types of a luminescent probe that directly or indirectly binds to the target particle, (b) a complex is formed that contains the target particle and the luminescent probe in the solution, (c) the complex is recovered by separating luminescent probe not bound to the target particle from the solution containing the complex, followed by (d) dissociating the luminescent probe from the recovered complex and mutually separating and separately recovering the free luminescent probe and target particle, (e) again binding a luminescent probe to the recovered target particle followed by dissociating the luminescent probe and mutually separating and recovering free luminescent probe and the target particle are repeated, followed by preparing a single measurement sample solution containing the total amount of the recovered free luminescent probe, and (f) the number of molecules of the luminescent probes in the measurement sample solution is calculated. | 11-06-2014 |
20140329710 | TRANSCRIPTOMIC BIOMARKERS FOR INDIVIDUAL RISK ASSESSMENT IN NEW ONSET HEART FAILURE - A novel transcriptomic biomarker for prognosis in heart failure has a direct clinical application in prediction of prognosis in new onset heart failure, heart disease, heart disorders and associated heart conditions. This approach should improve individualization of cardiac care and help identify patients at highest risk for circulatory collapse within the first years of presentation with heart failure. | 11-06-2014 |
20140329711 | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same - A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of pH dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses a single light chain variable domain derived from a single rearranged light chain variable region gene in the germline of the non-human animal, wherein the single rearranged light chain variable region gene comprises a substitution of at least one non-histidine encoding codon with a histidine encoding codon. Methods of making non-human animals that express antibodies comprising a histidine-containing universal light chain are provided. | 11-06-2014 |
20140329712 | DNA SAMPLE PREPARATION AND SEQUENCING - This disclosure describes, in one aspect, a method for preparing DNA molecule for sequencing. Generally, the method includes fragmenting the DNA molecule into double-stranded fragments; amplifying at least a portion of the double-stranded fragments; circularizing the fragments so that the first end of the fragment comprises a first loop connecting the strands and the second end of the fragment comprises a second loop connecting the strands; annealing a first sequencing primer to the first loop oriented to sequence at least a portion of one strand of the fragment; and annealing a second sequencing primer to the second loop oriented to sequence at least a portion of the other strand of the fragment. In another aspect, this disclosure describes a method for sequencing a DNA molecule. Generally, the method includes fragmenting the DNA molecule into double-stranded fragments; amplifying at least a portion of the double-stranded fragments; circularizing the fragments so that the first end of the fragment comprises a first loop connecting the strands and the second end of the fragment comprises a second loop connecting the strands; and sequencing at least one of the DNA strands. | 11-06-2014 |
20140329713 | GEL-TETHERED MOLECULAR BEACONS - The present invention relates to surface-patterned microgels to which molecular beacon probes are immobilized. The immobilized molecular beacon probes exhibit both low non-specific background and high specific fluorescence. Also disclosed are related arrays, related detection methods, and preparation methods. | 11-06-2014 |
20140329714 | STAT3 ACTIVATION AS A MARKER FOR CLASSIFICATION AND PROGNOSIS OF DLBCL PATIENTS - Methods are disclosed for determining classification and prognosis of patients with diffuse large B-cell lymphoma (DLBCL) using activation of signal transducer and activator of transcription 3 (STAT3). | 11-06-2014 |
20140329715 | Water Treatment and Monitoring - The present invention relates to the provision of polymers that are selected to have either; surface properties that allow protozoa, in particular | 11-06-2014 |
20140336063 | Windowed Sequencing - In one implementation, a method is described. The method includes determining an operational characteristic of sensors of a sensor array. The method further includes selecting a group of sensors in the array based on the operational characteristic of sensors in the group. The method further includes enabling readout of the sensors in the selected group. The method further includes receiving output signals from the enabled sensors, the output signals indicating chemical reactions occurring proximate to the sensors of the sensor array. | 11-13-2014 |
20140336064 | MULTIVOLUME DEVICES, KITS AND RELATED METHODS FOR QUANTIFICATION AND DETECTION OF NUCLEIC ACIDS AND OTHER ANALYTES - Provided are devices comprising multivolume analysis regions, the devices being capable of supporting amplification, detection, and other processes. Also provided are related methods of detecting or estimating the presence nucleic acids, viral levels, and other biological markers of interest. | 11-13-2014 |
20140336065 | DETECTION OF HUMAN SOMATIC CELL REPROGRAMMING - The methods and kits described herein are based, in part, to the discovery of a phenotype representing a fully-reprogrammed iPS cell and several reprogramming intermediates. The methods and kits described herein permit identification of fully-reprogrammed iPS cells and further permits one of skill in the art to monitor the emergence of iPS cells during the reprogramming process. The methods/kits can also be performed using real time using live cell imaging. Also described herein are methods for screening candidate reprogramming agents by monitoring the emergence of fully-reprogrammed iPS cells in the presence and absence of such an agent. | 11-13-2014 |
20140336066 | DRG11-RESPONSIVE (DRAGON) GENE AND USES THEREOF - This invention features methods and compositions useful for treating and diseases caused by a dysregulation of the BMP/GDF branch of the TGF-β signaling pathway. Also disclosed are methods for identifying compounds useful for such therapy. | 11-13-2014 |
20140336067 | METHOD FOR FINDING BIOACTIVE PEPTIDES - The present invention relates to a method for discovering bioactive peptides, and a use thereof. The present invention relates to a method for discovering a peptide which has an effect on tissue regeneration or a peptide which adheres to a biomaterial, by searching the smallest bioactive domain from a protein. This method for discovering a peptide is named PEPscovery (PEPtide Discovery). According to the present invention, it is possible to discover peptides comprising 20 or more amino acids more rapidly than conventional techniques for discovering a peptide, and to discover bioactive peptides effective in tissue regeneration and capable of being adhered to a specific biomaterial through PEPscovery, thereby developing medical supplies and medical equipment and applying the same to the development of a diagnostic chip. | 11-13-2014 |
20140336068 | MAGNETIC IMMUNO DIGITAL PCR ASSAY - The present invention provides methods of detecting an antigen in a sample comprising contacting the sample with affinity agents to form an antigen-affinity agent-label complex, separating the antigen-affinity agent-label complex from uncomplexed components, partitioning label from the separated sample into multiple partitions, and detecting the presence of the label in one or more partitions. Compositions and kits for detecting an antigen in a sample are also provided. | 11-13-2014 |
20140336069 | METHOD OF DETECTING AUTO-ANTIBODIES FROM PATIENTS SUFFERING FROM RHEUMATOID ARTHRITIS, A PEPTIDE AND AN ASSAY KIT - Peptides useful in determining the presence of autoantibodies in patients suffering from rheumatoid arthritis are disclosed. | 11-13-2014 |
20140336070 | ASSAY BUFFER, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME - The invention relates to improved electrochemiluminescence assay methods for phosphorylated peptides or proteins employing phospho-specific antibodies and buffer compositions that are substantially free of inorganic phosphate. | 11-13-2014 |
20140336071 | DEVICES, COMPOSITIONS, AND METHODS FOR MEASURING MOLECULES AND FORCES - This disclosure relates to compositions, devices and methods of detecting the presence of molecules and optionally quantifying forces associated with molecular interactions on the surface of cells and other lipids. In certain embodiments, devices disclosed herein can be used to detect forces through cell surface receptors. In other embodiments, the devices can be used to detect the presence or absence of molecules on cells or other particles or detect the changes in cell morphology after ligand receptor binding. | 11-13-2014 |
20140336072 | Deformable Platforms for Biological Assays - A platform for biological assays includes a base substrate providing structural support to the platform, at least one surface of the base substrate coated with position markers, a first deformable layer positioned on top of the base substrate, and a second deformable layer positioned on top of the first deformable layer, the second deformable layer embedded with deformation markers. | 11-13-2014 |
20140336073 | METHOD OF DETERMINATION OF CANCER CELL DRUG SENSITIVITY TOWARDS AURORA KINASE INHIBITORS - A method for determining the sensitivity and/or resistance of a patient suffering from a cancer disease to Aurora kinase inhibitor therapy, which comprises determining in vitro in the cancer cells or body fluids taken from the patient the expression of at least one gene selected from a particular group and/or determining in vitro in the cancer cells or body fluids taken from the patient the level of at least one protein selected from a particular group. | 11-13-2014 |
20140336074 | METHOD FOR PREPARING IMPROVED CARDIOMYCOCYTE-LIKE CELLS - The present invention relates to the field of cell differentiation. In particular, the present invention relates to a method for preparing improved cardiomyocyte-like cells differentiated from at least one multipotent or pluripotent cell, comprising a step of contacting the cardiomyocyte-like cell(s) with at least one agent to promote and/or induce integrin subunit alpha-V (integrin α | 11-13-2014 |
20140336075 | METHOD AND SYSTEM FOR DETERMININING WHETHER GENOME IS ABNORMAL - The present invention provides a method and system for determining whether a genomic abnormality exists. The method for determining whether a genomic abnormality exists includes the steps of: separating fetal nucleated red blood cells from a sample from a pregnant woman; sequencing at least a part of the genome of the nucleated red blood cells, so as to obtain a sequencing result; and on the basis of the sequencing result, determining whether a genomic abnormality exists in the nucleated red blood cells. | 11-13-2014 |
20140336076 | METHOD FOR DIAGNOSING AND TREATING FIBROMYALGIA - The invention provides methods, kits and reagents for diagnosing fibromyalgia (FM) in an individual by determining whether the levels of one or more cytokines in the individual are altered, as compared to control levels. The altered level(s) or patterns of expression of the cytokines measured in the affected individual compared to the level from the control is predictive/indicative of FM in the | 11-13-2014 |
20140336077 | MEANS AND METHODS FOR RECOGNIZING THE DEVELOPMENT OF CARDIOVASCULAR DISEASE IN AN INDIVIDUAL - A method of recognizing the development of an Acute Myocardial Infarction (AMI) process in an individual, wherein the method comprises steps of: profiling specific antibody reactivities or biomarkers associated with AMI susceptibility, the profiling comprises steps of: attaching a set of defined antigens to a substrate; obtaining a biological fluid derived specimen from an individual, the specimen containing a specific antibody repertoire; and binding said antibodies of the biological fluid specimen to the attached antigens thereby forming bound antibody antigen complexes; and analyzing results obtained, wherein the presence of the complexes is indicative of AMI. | 11-13-2014 |
20140342923 | BIOMARKER TEST FOR ACUTE CORONARY SYNDROME - The present invention relates to biomarker signatures and associated methods for identifying patients that are not likely to manifest significant coronary artery disease. It is based, at least in part, on a study performed on serum samples of 239 patients with clinical symptoms of cardiac distress, some of whom required invasive intervention (stent placement or bypass graft surgery). A set of biomarkers was identified as exhibiting different levels of expression in subjects that did, or did not, require invasive intervention. Further, an algorithm was developed which, using serum levels of these biomarkers, assigned a score to a given patient that was indicative of whether that patient required invasive intervention. | 11-20-2014 |
20140342924 | Molecular Diagnostic Test for Cancer - Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that are responsive to anti-angiogenesis therapeutics and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. | 11-20-2014 |
20140342925 | METHOD FOR PREDICTING A MANIFESTATION OF AN OUTCOME MEASURE OF A CANCER PATIENT - The invention pertains to a method for predicting a manifestation of an outcome measure of a cancer patient based on a tumor DNA containing tissue sample from the cancer patient, comprising, firstly, determining an existence of a sequence variation within segments of at least two genes of the tumor DNA as Present, if at least one significant sequence variation can be determined, or as Absent, if no significant sequence variation can be determined, wherein the at least two genes of the tumor DNA are associated with the outcome measure of the patient; secondly, combining the existence of sequence variations of the at least two genes using a logical operation (prediction function), and thirdly, predicting based on the results of the logical operation the manifestation of an outcome measure of the patient. | 11-20-2014 |
20140342926 | Methods for Assessing Risk for Cardiac Dysrythmia in a Human Subject - The present invention relates to methods for assessing the risk of a patient for developing a potentially fatal cardiac dysrhythmia and for diagnosing Andersen's Syndrome. A tissue sample from a patient is obtained and the DNA or proteins of the sample isolated. From the DNA and protein isolates the sequence of the KCNJ2 gene or the Kir2.1 polypeptide can be obtained. The KCNJ2 gene or the Kir2.1 can be screened for alteration as compared to the wile-type sequence. An alteration in a copy of the KCNJ2 gene or a Kir2.1 polypeptide indicates that the patient has a high risk for developing a cardiac dysrhythmia and can be diagnosed with Andersen's Syndrome. The invention also related to isolated nucleic acid molecules with one or more alterations as compared to the wild-type sequence. | 11-20-2014 |
20140342927 | METHODS AND COMPOSITIONS FOR DETECTING FUNGI AND MYCOTOXINS - The invention relates to a method of identifying a specific fungal species in patient tissue or body fluid. The method comprises the steps of extracting and recovering DNA of the fungal species from the patient tissue or body fluid, amplifying the DNA, hybridizing a probe to the DNA to specifically identify the fungal species, and specifically identifying the fungal species. The invention also relates to a method of identifying a mycotoxin in patient tissue or body fluid. The method comprises the steps of extracting and recovering the mycotoxin from the patient tissue or body fluid, contacting the mycotoxin with an antibody directed against the mycotoxin, and identifying the myocotoxin. Both of these methods can be used to determine if a patient is at risk for or has developed a disease state related to a fungal infection, and to develop an effective treatment regimen for the patient. | 11-20-2014 |
20140342928 | MEASURING METHOD FOR NUCLEIC ACID SAMPLES - A measuring method for nucleic acid samples is provided. The measuring method provides qualitative and quantitative analyses of different types of templates of divergent concentration ranges in one experiment. Hence, the same test panel of various assays may be performed in a single test slide. | 11-20-2014 |
20140342929 | BIOMARKERS OF HIGH-GRADE SERIOUS OVARIAN CARCINOMAS - The present disclosure provides biomarkers useful for determining the prognosis of conditions such as ovarian cancer. The presently disclosed subject matter provides angiogenic biomarkers and methods and compositions for predicting overall survival (OS) in women with high-grade serious carcinomas (HGSCs). The presently disclosed subject matter provides compositions and methods that enable rationally directed therapies to improve outcome in women with HGSC. | 11-20-2014 |
20140342930 | METHODS FOR SELECTIVE TARGETING - A selective targeting method is disclosed comprising contacting a library of ligands, particularly a peptide library, with an anti-target to allow the ligands to bind to the anti-target; separating the non-binding ligands from the anti-target bound ligands, contacting the non-binding anti-target ligands with a target allowing the unbound ligands to bind with the target to form a target-bound ligand complex; separating the target-bound ligand complex from ligands which do not bind to the target, and identifying the target-bound ligands on the target-bound ligand complex wherein the target-bound ligands have a K | 11-20-2014 |
20140342931 | METHOD FOR PREDICTING RESPONSE TO ENDOCRINE THERAPY - The present invention relates to a method for predicting the response of a patient diagnosed with breast cancer to treatment with an endocrine therapy drug, comprising the steps of: (a) measuring the binding of the estrogen receptor, obtained from a breast cancer tumor from said patient, generating a binding profile, said binding profile comprising the binding of the estrogen receptor from said patient on one or more co-regulator proteins or functional parts thereof in the presence and absence of one or more added phosphatases, (b) measuring the binding of the estrogen receptor, obtained from a breast cancer tumor from said patient, generating a binding profile, said binding profile comprising the binding of the estrogen receptor from said patient on one or more co-regulator proteins or functional parts thereof in the presence and absence of added estradiol, and, (c) predicting from said binding profiles the response of said patient to endocrine drug therapy. The present invention also relates to variant methods hereof and methods for predicting the response of a patient diagnosed with breast cancer to drug treatment and methods for individualized endocrine therapy of a patient diagnosed with an endocrine related disease. The invention also relates to arrays and kits for carrying out these methods. | 11-20-2014 |
20140342932 | FUNCTIONAL CELL SURFACE DISPLAY OF LIGANDS FOR THE INSULIN AND/OR INSULIN GROWTH FACTOR 1 RECEPTOR AND APPLICATIONS THEREOF - Systems for making, identifying, and selecting recombinant cells that express a ligand for the insulin receptor (IR) or insulin growth factor I (IGF-1) receptor are described. In general, libraries of recombinant cells are constructed that are capable of displaying a plurality of ligand molecules on the cell surface. Recombinant cells that display a ligand in a form accessible for binding to the IR and/or IGF-1 receptor can be detected and the recombinant cells displaying said ligands can be selected and isolated using cell sorting technologies. In particular aspects, the system is useful for constructing and screening libraries of recombinant cells that express and displaying insulin analogue precursors molecules to identify and select recombinant cells in the library that bind the IR and/or IGF-1 receptor with a desired affinity and/or avidity. | 11-20-2014 |
20140342933 | METHODS AND COMPOSITIONS FOR MULTIPLEXED AND ULTRASENSITIVE MICRORNA DETECTION - Provided herein are methods and compositions for detection and quantification of one or multiple target miRNA(s) in biological fluids and/or tissue samples using alternating laser excitation (ALEX) single molecule fluorescence spectroscopy, and employing such methods and compositions for diagnostic, prognostic, therapeutic, and/or research applications. | 11-20-2014 |
20140342934 | METHODS FOR DIAGNOSING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS - Provided is a method for identifying human immunodeficiency virus (HIV) in a sample. The invention involves use of a plurality of fluorescently labeled oligonucleotide probes and flow cytometry to detect the presence or absence of HIV in macrophages that are obtained from a mucosal surface. The invention is particularly useful for detecting HIV infection prior to seroconversion. | 11-20-2014 |
20140342935 | BASE FOR USE IN AMPLIFICATION OF NUCLEIC ACID AND METHOD FOR AMPLIFYING NUCLEIC ACID - The present invention is to provide a base for use in the amplification of a nucleic acid, which makes it possible to accurately and effectively amplify and detect a plurality of target nucleic acid sequences that are subjects for detection. A base for use in the amplification of a nucleic acid according to the present invention is a base in which a hydrophilic gel is held and which has arrayed plural zones, and the zones contain different kinds of primer or the like for amplifying nucleic acids. | 11-20-2014 |
20140342936 | METHODS AND KITS FOR DIAGNOSING LATENT TUBERCULOSIS INFECTION - The present invention relates to a method for diagnosing latent tuberculosis infection in a subject comprising the step i) consisting of incubating a biological sample obtained from the subject with at least one | 11-20-2014 |
20140342937 | METHODS FOR DIAGNOSIS AND THERAPEUTIC FOLLOW-UP OF MUSCULAR DYSTROPHIES - The invention relates to the diagnosis, the follow-up and the evaluation of the efficacy of a treatment of a muscular dystrophy by detection of microRNA in a body fluid, in particular in the urine. | 11-20-2014 |
20140342938 | Compositions and Methods for Functional Quality Control for Human Blood-Based Gene Expression Products - Methods for assessing the integrity of an RNA sample from a given tissue or blood type are disclosed. | 11-20-2014 |
20140342939 | DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS - The present invention relates to methods and kits for diagnosing systemic lupus erythematosus (SLE) in a subject. Particularly, the present invention relates to a specific antibody profile useful in diagnosing SLE in a subject. | 11-20-2014 |
20140342940 | Detection of Target Nucleic Acids using Hybridization - The present invention provides detection systems and methods for detection of loci and genomic regions in a sample, including mixed samples, using hybridization to an array. | 11-20-2014 |
20140342941 | METHOD FOR USING PERMUTED NUCLEIC ACID PROBES - The present disclosure provides nucleic acid probes, as well as kits that include such probes. Methods for producing and using (for example in chromosomal in situ hybridization) the probes are also provided. Such probes in some examples are used to detect chromosomal abnormalities or the presence of a pathogen. | 11-20-2014 |
20140342942 | SENSING DEVICE FOR SENSING A GFLUID - The invention relates to a sensing device for sensing a fluid. The sensing device comprises an inlet port ( | 11-20-2014 |
20140349862 | METHODS AND COMPOSITIONS FOR THERAPEUTIC DRUG MONITORING AND DOSING BY POINT OF CARE PHARMACOKINETIC PROFILING - Disclosed are methods and kits for pharmacokinetic profiling employing point-of-care or point of service self-sampling and allowing for dosage adjustments based on the pharmacokinetic profiles. | 11-27-2014 |
20140349863 | Assay for Diagnosing Streptococcus Pneumoniae - Assays for detecting anti-streptococcal antibodies in biological samples using one or more streptococcal antigens are described herein. Various combinations of antigens may be used in the assays. For example, one or more of Ply, PhtD, PhtE, LytB and PcpA may be utilized. Additional streptococcal antigens may also be used. The assays may also be used in combination with assays that detect streptococcal nucleic acids. | 11-27-2014 |
20140349864 | METHODS AND COMPOSITIONS OF MOLECULAR PROFILING FOR DISEASE DIAGNOSTICS - The present invention relates to compositions, kits, and methods for molecular profiling and cancer diagnostics, including but not limited to gene expression product markers, alternative exon usage markers, and DNA polymorphisms associated with cancer. In particular, the present invention provides molecular profiles associated with thyroid cancer, methods of determining molecular profiles, and methods of analyzing results to provide a diagnosis. | 11-27-2014 |
20140349865 | DRUG SELECTION FOR BREAST CANCER THERAPY USING ANTIBODY-BASED ARRAYS - The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments. | 11-27-2014 |
20140349866 | NEW TH-17 DIFFERENTIATION MARKERS FOR ROSACEA AND USES THEREOF - Methods are described for using genes crucial in TH17 differentiation, IL-12Rbeta 1/IL-23R, CCR6, BATF, AHR, STAT3 and IRF4 as new markers for rosacea. Also described, are methods of their use to diagnose rosacea, to screen inhibitors of Th17 differentiation. In particular, method are described for inhibiting at least one of these genes and using the screened inhibitors in rosacea treatment. | 11-27-2014 |
20140349867 | SYSTEM AND METHOD FOR CAPTURING AND ANALYZING CELLS - A system and method for capturing and analyzing a set of cells, comprising: an array including a set of parallel pores, each pore including a chamber including a chamber inlet and a chamber outlet, and configured to hold a single cell, and a pore channel fluidly connected to the chamber outlet; an inlet channel fluidly connected to each chamber inlet of the set of parallel pores; an outlet channel fluidly connected to each pore channel of the set of parallel pores; a set of electrophoresis channels fluidly coupled to the outlet channel, configured to receive a sieving matrix for electrophoretic separation; and a set of electrodes including a first electrode and a second electrode, wherein the set of electrodes is configured to provide an electric field that facilitates electrophoretic analysis of the set of cells. | 11-27-2014 |
20140349868 | METHODS AND COMPOSITIONS FOR MONITORING AND RISK PREDICTION IN CARDIORENAL SYNDROME - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function. | 11-27-2014 |
20140349869 | METHODS OF DETECTING LUNG CANCER - Methods of detecting lung cancer, such as non-small cell lung cancer, including squamous cell carcinoma and adenocarcinoma, are provided. Methods of detecting changes in the levels of one or more small RNAs associated with lung cancer are also provided. Compositions and kits are also provided. | 11-27-2014 |
20140349870 | SELF-REGULATING CHEMO-MECHANO-CHEMICAL SYSTEMS - A chemo-mechano-chemical (C | 11-27-2014 |
20140349871 | REAL-TIME ANALYSIS FOR CROSS-LINKED PEPTIDES - Disclosed herein are methods for large-scale, high-throughput identification of protein-protein interactions and the topologies thereof under physiologically relevant conditions. In one aspect, the disclosure provides methods for identifying one or a plurality of interacting peptides within a biological system comprising obtaining a population of proteins cross-linked with a cleavable protein interaction reporter (PIR) cross-linker, cleaving the PIR crosslinker to produce released peptides and cleaved reporter ions, and analyzing the population of released peptides to identify interacting peptides. Also disclosed are methods for identifying candidate drug compounds, as well as methods of data processing and visualization of protein-protein interactions. | 11-27-2014 |
20140349872 | Systems and Methods for Immunosorbent Assay for Single and Multiple Analytes - Systems and methods for minimizing or eliminating steps in immunosorbent assays for single and multiple analytes by eliminating the need to attach target molecules to test well and the need to remove unbound antibodies through rinsing. Immunosorbent assay (ISA) is utilized for a single analyte and includes the step of mixing the immunologic molecules with the sample and detection. Immunosorbent assay for multiple analytes for testing a plurality of analytes in a single well is disclosed using a modified ISA test wherein different tags are attached to different antibody pairs. Alternate embodiments use multiple types of scavenger antigens with corresponding elimination of the need for scavenger antibodies. Various types of test wells are disclosed for rapid and simultaneous testing of fluids for a plurality of components and methodology for continuous immunosorbent assay. Method for immunosorbent assay of an analyte object having a plurality of distinct target antigens is also disclosed. | 11-27-2014 |
20140349873 | Methods of Producing Competitive Aptamer FRET Reagents and Assays - Methods are described for the production and use of fluorescence resonance energy transfer (FRET)-based competitive displacement aptamer assay formats. The assay schemes involve FRET in which the analyte (target) is quencher (Q)-labeled and previously bound by a fluorophore (F)-labeled aptamer such that when unlabeled analyte is added to the system and excited by specific wavelengths of light, the fluorescence intensity of the system changes in proportion to the amount of unlabeled analyte added. Alternatively, the aptamer can be Q-labeled and previously bound to an F-labeled analyte so that when unlabeled analyte enters the system, the fluorescence intensity also changes in proportion to the amount of unlabeled analyte. The F or Q is covalently linked to nucleotide triphosphates (NTPs), which are incorporated into the aptamer by various nucleic acid polymerases, such as Taq or Deep Vent Exo | 11-27-2014 |
20140349874 | DIAGNOSTIC POLYMORPHISMS FOR CARDIAC DISEASE - One or more polymorphisms, including single nucleotide polymorphisms (SNPs), or combinations thereof, for diagnosis of cardiac disease, such as heart failure and atrial fibrillation. | 11-27-2014 |
20140349875 | METHOD FOR THE IN VITRO DIAGNOSIS OR PROGNOSIS OF TESTICULAR CANCER - A method for in vitro diagnosis of testicular cancer includes (i) obtaining a biological sample from a patient suspected of having testicular cancer, (ii) performing an assay to determine the methylation status of CpG dinucleotides in a genomic DNA target sequence, the DNA target sequence being the 5′ LTR U3 promoter sequence of the ERVWE1 locus, optionally further including an activator sequence directly upstream of the 5′ LTR U3 promoter sequence, and (iii) diagnosing the patient with testicular cancer when the DNA target sequence is hypomethylated as compared to a methylation status indicative of the absence of testicular cancer. | 11-27-2014 |
20140349876 | SUGARCANE-STALK=SUGAR-CONTENT-RELATED MARKER AND THE USE THEREOF - According to the present invention, a sugarcane-stalk-sugar-content-related marker linked to a sugarcane quantitative trait is provided. Such marker is a sugarcane-stalk-sugar-content-related marker, which comprises a continuous nucleic acid region existing in a region sandwiched between the nucleotide sequence shown in SEQ ID NO: 1 and the nucleotide sequence shown in SEQ ID NO: 8 or a region sandwiched between the nucleotide sequence shown in SEQ ID NO: 9 and the nucleotide sequence shown in SEQ ID NO: 16. | 11-27-2014 |
20140349877 | METHODS AND COMPOSITIONS FOR DIAGNOSING NEURODEGENERATIVE DISEASE - Methods and compositions for detecting and diagnosing Parkinson's disease are disclosed. | 11-27-2014 |
20140349878 | PACLITAXEL RESPONSE MARKERS FOR CANCER - Cancer marker sets consisting of particular genes differentially expressed in tumours provide improved accuracy of predicting effectiveness of paclitaxel or paclitaxel-like drug treatment against a cancer. These sets are further useful for screening drug candidates for paclitaxel-like cancer treatment activity. The cancer marker sets may be used in a clinical setting to provide information about the likelihood that a cancer patient would or would not respond to paclitaxel or paclitaxel-like drug treatment. | 11-27-2014 |
20140349879 | METHOD FOR DETECTING NUCLEOTIDE MUTATION, AND DETECTION KIT - Provided are a detection method and detection kit for detecting a nucleotide mutation simply, with highly sensitivity and high specificity, which allow a plurality of samples to be simultaneously detected in a single measurement. The detection method includes the steps of: amplifying a nucleic acid to be tested to obtain a DNA amplification product; subjecting the DNA amplification product, a first nucleic acid probe having a region complementary to a first region of the DNA amplification product, a second nucleic acid probe having a region complementary to a second region of the DNA amplification product, and a plurality of kinds of signal amplification probes to be used in a PALSAR method to a reaction to form a complex for detection including a probe polymer; and detecting the probe polymer bound in the complex for detection to detect the presence or absence of a mutation in a nucleotide mutation site of the DNA amplification product, the first region of the DNA amplification product including the nucleotide mutation site, the nucleotide mutation site being located at a portion other than both end portions of the first region, the second nucleic acid probe having a base sequence identical to part or all of the base sequence of one of the signal amplification probes. | 11-27-2014 |
20140349880 | NOVEL ANTIBIOTIC PREPARATION METHOD AND PLATFORM SYSTEM BASED ON SAME - Provided are a novel antibiotic preparation method and platform system based on the method, belonging to a novel drug development method. The method is based on a fixed structural formula: F—R, wherein F is an effect area, and R is an identification area. At the prior art level, the present invention can quickly develop a specific novel antibiotic for most pathogenic microorganisms or biological cells. Also provided is a platform for implementing the method, ensuring that the novel antibiotic is developed in an efficient streamlined process. | 11-27-2014 |
20140349881 | BIOMARKERS AND PARAMETERS FOR PREECLAMPSIA - The application discloses new test panels comprising biomarkers and clinical parameters, for the prediction, diagnosis, prognosis and/or monitoring of hypertensive disorders of pregnancy and particularly preeclampsia; and related methods, uses, kits and devices. | 11-27-2014 |
20140349882 | METHOD FOR THE DIAGNOSIS OF ROSACEA - A method is described for the diagnosis of rosacea. The method can include a step of measuring the expression of at least one peptide from the galanin family in a sample of biological fluid from a patient. Also described, is a related diagnostic kit. | 11-27-2014 |
20140349883 | MONITORING TRANSFORMATION OF FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA BY IMMUNE REPERTOIRE ANALYSIS - The invention is directed to a method of prognosing in an individual a transformation from follicular lymphoma to diffuse large B-cell lymphoma (DLBCL) by measuring changes and/or lack of changes in certain groups of related clonotypes, referred to herein as “clans,” in successive clonotype profiles of the individual. A clan may arise from a single lymphocyte progenitor that gives rise to many related lymphocyte progeny, each possessing and/or expressing a slightly different immunoglobulin receptor due to somatic mutation(s), such as base substitutions, inversions, related rearrangements resulting in common V(D)J gene segment usage, or the like. A higher likelihood of transformation from follicular lymphoma to DLBCL is correlated with the persistence of clans in successive clonotype profiles whose clonotype membership fails to undergo diversification over time. | 11-27-2014 |
20140357504 | SOURCE CONTROLLED DECODABLE MICROARRAY SYSTEM AND METHODS FOR USE - A system and methods for consumer use of a microarray product are provided. A method includes obtaining a microarray product and contacting the microarray product with a sample and performing bioassays. The method further includes obtaining a decoding information data package from a manufacturer of the microarray product for correlating bioassay signals from the bioassays with respective analytes, wherein the microarray product is obtained at a first time different and discrete from a second time that the decoding information data package is obtained. | 12-04-2014 |
20140357505 | System And Method Of Cytomic Vascular Health Profiling - The present invention relates to a method of determining vascular health in a subject. The method includes the steps of obtaining a biological sample from the subject, obtaining microparticle data based on the level of at least one set of microparticles in the biological sample, obtaining progenitor cell data based on the level of at least one set of progenitor cells in the biological sample, generating a cytometric fingerprint of the biological sample based on the microparticle and progenitor cell data, and determining the vascular health of the subject based on the generated cytometric fingerprint. | 12-04-2014 |
20140357506 | ADHESIVE SIGNATURE-BASED METHODS FOR THE ISOLATION OF STEM CELLS AND CELLS DERIVED THEREFROM - The present invention provides for methods of isolating a stem cell or cell derived therefrom from a mixture of cells, for example, a mixture of adherent cells in culture. Cell isolation is achieved by the application of selective detachment forces. | 12-04-2014 |
20140357507 | METHODS OF USING SMALL RNA FROM BODILY FLUIDS FOR DIAGNOSIS AND MONITORING OF NEURODEGENERATIVE DISEASES - Described are methods for detection of neuronal pathologies using quantitative analysis in bodily fluids of synapse and/or neurite small RNAs and application of these methods to early diagnosis and monitoring of neurodegenerative diseases and other neurological disorders. | 12-04-2014 |
20140357508 | Cell Surface Display, Screening and Production of Proteins of Interest - Aspects of the invention provide compositions and methods for displaying engineered polypeptides on a cell surface. According to aspects of the invention, immobilized polypeptides can be screened to identify one or more variants having one or more functional or structural properties of interest. Aspects of the invention provide composition and methods for producing engineered protein or protein variants having a functional or a structural property of interest. | 12-04-2014 |
20140357509 | DIFFERENTIATION BETWEEN TRANSIENT AND PERSISTENT HIGH-RISK HPV INFECTION BY IN SITU HYBRIDIZATION - The invention relates to methods of categorizing a cervical tissue or cytology sample by performing an in situ hybridization assay using an antisense E6 or E7 probe on a cervical tissue sample, wherein the antisense E6 or E7 probe can simultaneously detect HPV DNA and HPV RNA; detecting the presence of HPV nucleic acid; and categorizing the cervical tissue sample based on HPV nucleic acid expression. | 12-04-2014 |
20140357510 | Compositions for Diagnosis and Therapy of Diseases Associated with Aberrant Expression of Futrins (R-Spondins) and/or Wnt - The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4 (=R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein. | 12-04-2014 |
20140357511 | SYSTEM AND METHOD FOR ISOLATING AND ANALYZING CELLS - A system and method for isolating cells, comprising: a substrate having a broad surface; an array comprising a set of wells defined at the broad surface of the substrate, each well including: a base surface, an open surface directly opposing the base surface, defined at the broad surface of the substrate, and configured to receive one of a single cell and a single cluster of cells from a direction perpendicular to the broad surface of the substrate, and a set of channels that fluidly couple each well to at least one adjacent well; wherein the set of wells includes an interior subset and an exterior subset fluidly coupled to and surrounding the interior subset by way of the set of channels; and a fluid delivery module surrounding the array and fluidly coupled to each well in the set of wells. | 12-04-2014 |
20140357512 | HISTONE DEACETYLASE (HDAC) BIOMARKERS IN MULTIPLE MYELOMA - The invention relates to histone deacetylase (HDAC) biomarkers in multiple myeloma. Specifically, the biomarkers are drug specific, histone deacetylase (HDAC) or HDAC6 biomarker peptides, which are acetylated, for multiple myeloma. Alternatively, the biomarkers are drug specific, HDAC6 biomarker peptides, which are acetylated or unacetylated, for multiple myeloma. The invention also relates to a kit comprising a detection agent and instructions for identifying a biomarker peptide of the invention. The invention further relates to a method for monitoring treatment efficiency of an HDAC inhibitor in a subject. | 12-04-2014 |
20140357513 | ASSAY METHODS - The invention provides an assay method for detection and/or quantification of a plurality of nucleic acid or protein targets in a sample. In the method probes are used to associate a detectable tag sequence with each of the selected targets present in the sample. Probes or primers sufficient to identify at least 25, and preferably at least 500, different targets are used. The method involves segregating aliquots of the sample from each other and detecting the tag sequences in each aliquot. | 12-04-2014 |
20140357514 | GENERAL STRATEGY FOR ANTIBODY LIBRARY SCREENING - A generally applicable method for the selective covalent attachment of a reporter molecule to a replicating entity that allows one to obtain specific binders from a single round of library screening is disclosed. For example, selective biotinylation of phage particles and yeast cells displaying a binder to any given target can be achieved via application of a coupled enzyme reaction that includes a peroxidase, an oxidase and a catalase. | 12-04-2014 |
20140357515 | Method and Kit for Identification and Quantification of Single-Strand Target Nucleic Acid - A method for identification and quantification of at least one single-stranded target nucleic acid and a kit for detection of at least one single-stranded target nucleic acid in a sample are described. The method includes contacting at least one solid carrier that includes at least one capture oligonucleotide immobilized thereon with at least one complementary-strand oligonucleotide, at least one single-stranded target nucleic acid, and at least one reporter oligonucleotide that includes a label. The target nucleic acid is identified by reading the label of the reporter oligonucleotide on the carrier. | 12-04-2014 |
20140357516 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING CANCER - The invention provides assays, methods, systems, compositions, and kits for diagnosing and treating cancer. | 12-04-2014 |
20140357517 | RADIATION EXPOSURE DIAGNOSTIC MARKER IGFBP-5, COMPOSITION FOR RADIATION EXPOSURE DIAGNOSIS BY MEASURING THE EXPRESSION LEVEL OF THE MARKER, RADIATION EXPOSURE DIAGNOSTIC KIT COMPRISING THE COMPOSITION, AND METHOD FOR DIAGNOSING RADIATION EXPOSURE USING THE MARKER - The present disclosure provides a composition for radiation exposure diagnosis including an agent for measuring an expression level of an insulin-like growth factor-binding protein-5 (IGFBP-5) gene at an mRNA or the protein and a kit for radiation exposure diagnosis. Methods of diagnosing radiation exposure as well as methods for screening an agent for enhancing radiation sensitivity or for radiation protection are disclosed. Also provided are compositions for enhancing radiation sensitivity and/or radiation protection. | 12-04-2014 |
20140357518 | Methods and Compositions for the Treatment and Diagnosis of Thyroid Cancer - The invention provides methods, compositions and kits for the detection and treatment of thyroid cancer. | 12-04-2014 |
20140357519 | METHODS OF SCREENING MONOCLONAL ANTIBODY POPULATIONS - The present invention concerns methods and compositions for screening primary hybridoma cultures to generate monoclonal antibodies that are useful in a variety of methods, including for in situ cellular imaging by immunocytochemical assays or in vivo applications, for example. Embodiments of the methods concern the use of automated high-throughput immunofluorescence (for example) to identify subcellular in vivo patterns that are expected based on the antigen or that may be unforeseen. | 12-04-2014 |
20140357520 | MYCOBACTERIUM TUBERCULOSIS SPECIFIC PEPTIDES FOR DETECTION OF INFECTION OR IMMUNIZATION IN NON-HUMAN PRIMATES - The present invention relates to novel peptides that may be used in whole or in combination for the detection of | 12-04-2014 |
20140357521 | TOOLS AND METHODS FOR EXPRESSION OF MEMBRANE PROTEINS - The disclosure relates cells or cellular systems that express both a membrane protein and a binding domain directed to the membrane protein. Also, methods are provided that use such cells or cellular systems to produce higher amounts of the membrane proteins. Further, the cells or cellular systems can be used as tools for the structural and functional characterization of membrane proteins, as well as for screening and drug discovery efforts targeting membrane proteins. | 12-04-2014 |
20140357522 | Simultaneous Assay of Target and Target-Drug Binding - Whole cell, simultaneous target and drug-target assay using differentially labeled antibodies and flow cytometry. First antibody binds to total target and second antibody binds to the drug binding site of the target, thus drug binding will competitively inhibit the second antibody allowing for a competitive inhibition assay of drug-target binding. The assay allows for whole cell analysis and even analysis of mixed populations of cells, yet provides detailed kinetic assessment of drug activity. | 12-04-2014 |
20140364326 | COMBINATORIAL BIOMARKERS FOR CLINICAL APPLICATIONS IN LUNG CANCER PATIENT MANAGEMENT - The present invention relates to compositions and methods for detecting, managing or monitoring cancer. The invention also relates to antibodies specific for cancer markers, compositions and chips containing the same, as well as their uses for cancer detection, managing, monitoring, imaging or treatment, as well as for drug development. The invention is particularly suited for detecting, managing or monitoring lung cancer in human subjects. | 12-11-2014 |
20140364327 | Compositions and Methods for the Systemic Treatment of Arthritis - The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β. | 12-11-2014 |
20140364328 | Diagnostic Biomarker Profiles for the Detection and Diagnosis of Parkinsons Disease - The present invention provides methods, compositions and kits for the detection of Parkinson' disease (PD) diagnostic biomarkers, for the diagnosis of PD, for the identification of a subject at risk for developing PD, and for the generation of patient-specific PD diagnostic biomarker profiles. | 12-11-2014 |
20140364329 | METHODS FOR IDENTIFYING PROTEIN-PROTEIN INTERACTIONS - The invention generally relates to methods for identifying protein-protein interactions. In certain aspects, methods of the invention involve conducting a protein-fragment complementation assay on a sample to form a protein-protein complex between two proteins in the sample that only transiently interact under physiological conditions, separating the complexes from the sample, and analyzing a protein of the complex using a mass spectrometry technique. | 12-11-2014 |
20140364330 | Multiplexed Olfactory Receptor-Based Microsurface Plasmon Polariton Detector - The invention provides a bio-sensing nanodevice comprising: a stabilized G-protein coupled receptor on a support, a real time receptor-ligand binding detection method, a test composition delivery system and a test composition recognition program. The G-protein coupled receptor can be stabilized using surfactant peptide. The nanodevice provides a greater surface area for better precision and sensitivity to odorant detection. The invention further provides a microfluidic chip containing a stabilized G-protein coupled receptor immobilized on a support, and arranged in at least two dimensional microarray system. The invention also provides a method of delivering odorant comprising the step of manipulating the bubbles in complex microfluidic networks wherein the bubbles travel in a microfluidic channel carrying a variety of gas samples to a precise location on a chip. The invention further provides method of fabricating hOR17-4 olfactory receptor. | 12-11-2014 |
20140364331 | RECURRENT GENE FUSIONS IN PROSTATE CANCER - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusions as diagnostic markers and clinical targets for prostate cancer. | 12-11-2014 |
20140364332 | PEPTIDES AND METHODS FOR THE DETECTION OF LYME DISEASE ANTIBODIES - The invention provides compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to | 12-11-2014 |
20140364333 | Methods for Live Imaging of Cells - The present invention relates to methods of hybridizing nucleic acid probes to genomic DNA. | 12-11-2014 |
20140364334 | CONGESTIVE HEART FAILURE BIOMARKERS - The invention provides gene and protein markers for cardiac disease and methods for using them to identify patients at risk for developing heart failure, or patients in an early stage of heart failure whose disease is likely to advance to a later stage. The present invention allows a treatment provider to identify those patients whose disease is most likely to develop and/or advance, and to initiate and/or adjust treatment options for such patients accordingly. | 12-11-2014 |
20140364335 | METHOD FOR SCREENING FOR NRF1 REGULATOR - The present invention provides a method for screening a test compound for a compound regulating Nrf1 activity, comprising using Nrf1 and Lipin1 and/or PGC-1β. A method for screening for a compound regulating Nrf1 activity is provided by the invention. | 12-11-2014 |
20140371080 | HIGH-THROUGHPUT RNA INTERACTION ASSAY - The present invention is directed to a method for detecting an interaction between a ribonucleic acid (RNA) molecule and a second molecule. This method involves providing a nucleic acid construct that contains a promoter sequence, a nucleotide sequence encoding the RNA molecule, and an RNA polymerase blocking site. The nucleotide sequence encoding the RNA molecule is transcribed in vitro to produce an RNA transcript corresponding to the RNA molecule. Transcription is halted by the RNA polymerase blocking site under conditions effective for the RNA transcript to remain tethered to the nucleic acid construct. The tethered RNA transcript is contacted with the second molecule and any interaction between the tethered RNA transcript and the second molecule is detecting and identified based on said contacting. | 12-18-2014 |
20140371081 | Compositions for and Methods of Detecting, Diagnosing, and Prognosing Thymic Cancer - Biomarkers are provided for detecting, diagnosing and prognosing thymic cancer in individuals having or suspected of having thymic cancer. In addition, kits are provided for measuring expression levels or the presence of the biomarkers associated with thymic cancer for detecting, diagnosing and prognosing thymic cancer. Furthermore, methods are provided for detecting, diagnosing and prognosing thymic cancer in individuals having or suspected of having thymic cancer via the biomarkers. | 12-18-2014 |
20140371082 | PROCESS AND APPARATUS FOR QUANTIFYING NUCLEIC ACID IN A SAMPLE - In one aspect, the present invention concerns methods and kits for quantifying a target nucleic acid in a sample. In embodiments, a method comprises sequestrating the target nucleic acid by one or more interactors to form a sequestered conjugate that will be further labeled to form a labeled conjugate. The signal produced by the labeled conjugate is measured and correlated to the amount of the target nucleic acid. In another aspect, the present invention concerns a method for quantifying a target nucleic acid in a sample by a reaction of the nucleic acids in the sample with a nucleic acid interactor or set of interactors to form a conjugate. The conjugate is then sequestered from the rest of the sample with a molecule bound to a support, to form a sequestered conjugate. The sequestered conjugate is labeled to form a labeled conjugate. The signal produced by the labeled conjugate is measured and correlated to the amount of the target nucleic acid. In some embodiments, the target nucleic acid is cell free nucleic acids. In embodiments, the interactor binds to nucleic acids in the sample in a nonsequence specific manner. | 12-18-2014 |
20140371083 | SYSTEMS, APPARATUS AND METHODS FOR BIOCHEMICAL ANALYSIS - Systems, apparatus and methods are provided for biochemical analysis of a sample (e.g., a cell or nucleic acids). Samples are analyzed for molecular information and remain accessible for subsequent analysis or testing. The systems, apparatus and methods and systems provided are useful for performing quantitative and highly parallel biochemical reactions on biological samples in a high-throughput manner. | 12-18-2014 |
20140371084 | SNRNA RNU2-1 AS A TUMOR MARKER - The invention relates to a method for the diagnosis of malignant diseases comprising the steps
| 12-18-2014 |
20140371085 | T CELL RECEPTOR DISPLAY - A proteinaceous particle, for example a bacteriophage, ribosome or cell, displaying on its surface a T-cell receptor (TCR). The displayed TCR is preferably a heterodimer having a non-native disulfide bond between constant domain residues. Such display particles may be used for the creation of diverse TCR libraries for the identification of high affinity TCRs. Several high affinities are disclosed. | 12-18-2014 |
20140371086 | Compositions and methods for the treatment of immune related diseases - The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases. | 12-18-2014 |
20140371087 | MIXED FORMAT MICROARRAYS - The invention provides methods, database and information management system for using mixed format microarrays to identify and validate biomarkers in target samples. The present invention provides highly accurate diagnostic assays and methods. | 12-18-2014 |
20140371088 | MULTIPLEXABLE TAG-BASED REPORTER SYSTEM - The present invention relates to compositions and methods for the detection and quantification of individual target molecules in biomolecular samples. In particular, the invention relates to coded, labeled compositions comprising at least two probes hybridized to each other that are capable of binding to and identifying target molecules based on the probes' label codes. Methods of making and using such compositions are also provided. The compositions can be used in diagnostic, prognostic, quality control and screening applications. | 12-18-2014 |
20140371089 | METHOD FOR DIGANOSING ATHEROSCLEROTIC PLAQUES BY MEASUREMENT OF CD36 - The present invention relates to diagnosis, classification and monitoring of atherosclerotic plaques in an individual using measurement of the concentration of CD36 in a body fluid and/or the plaque as such. The present invention also relates to diagnosing the burden of atherosclerotic plaques in an individual. Furthermore, the invention relates to a method for diagnosing stenosis caused by atherosclerotic plaques. Within the scope of the present invention are also methods for determining the treatment regime of an individual. Kits and oligonucleotides for use in the methods are claimed. | 12-18-2014 |
20140371090 | METHOD AND KIT FOR DETERMINING- ANTIBODY SENSITIVITY AND CLONE CELL STRAIN - A method and kit for determining antibody sensitivity and quality of a clone cell stain. The method comprises: obtaining a solid-phase carrier, cells and an antibody; adsorbing the antibody on the solid-phase carrier; incubating the cells and the antibody; preserving cells bound with the antibody; and dyeing and counting the cells bound with the antibody, so as to determine the antibody sensitivity or the quality of the clone cell stain based on the cell count. The kit comprises components used in the method. | 12-18-2014 |
20140371091 | Programmable Arrays - Biomolecule arrays on a substrate are described which contain a plurality of biomolecules, such as coding nucleic acids and/or isolated polypeptides, at a plurality of discrete, isolated, locations. The arrays can be used, for example, in high throughput genomics and proteomics for specific uses including, but not limited molecular diagnostics for early detection, diagnosis, treatment, prognosis, monitoring clinical response, and protein crystallography. | 12-18-2014 |
20140371092 | METHODS FOR ASSESSING ENDOMETRIAL RECEPTIVITY OF A PATIENT AFTER CONTROLLED OVARIAN HYPERSTIMULATION - The present invention relates to methods and kits for assessing the endometrial receptivity of a patient after controlled ovarian hyperstimulation. More particularly, the invention relates to a method for assessing the endometrial receptivity of a patient after controlled ovarian hyperstimulation, comprising a step consisting of measuring the expression level of at least one gene selected from fifteen genes in an endometrial biopsy sample obtained from said patient wherein said genes are FGFBP1, MUC20, TM-PRSS3, PRUNE2, HES2, MGST1, ERRFI1, EDN1, SLC17A7, MET, CPT1B, DCDC2, LRRC39, IL18RAP, and FOXP1. | 12-18-2014 |
20140371093 | MICROSTRUCTURED CHIP FOR SURFACE PLASMON RESONANCE ANALYSIS, ANALYSIS DEVICE CONTAINING SAID MICROSTRUCTURED CHIP AND USE OF SAID DEVICE - A microstructured chip ( | 12-18-2014 |
20140371094 | METHODS FOR TREATING, DIAGNOSING AND MONITORING ALZHEIMER'S DISEASE - The invention provides methods of diagnosis and prognosis of Alzheimer' disease (AD) in a subject comprising detecting the presence or absence of one or more genetic variations in a sample from the subject, wherein the presence of the genetic variation indicates that the subject is afflicted with, or at risk of developing, AD. Methods of predicting the response of a subject to therapeutic agents for the treatment of AD are also provided. | 12-18-2014 |
20140371095 | NOVEL METHOD FOR IDENTIFYING SPECIFIC MARKER SEQUENCES FOR PROSTATE CANCER - The present invention relates to a novel method for identifying specific marker sequences for diagnosis of prostate cancer and/or for prognosis in prostate cancer, and to the use of the specific marker sequences identified with the aid of this method. | 12-18-2014 |
20140371096 | COMPOSITIONS AND METHODS FOR CHARACTERIZING THYROID NEOPLASIA - The present invention features compositions and methods for characterizing thyroid lesions (e.g., benign follicular adenomas (FAs), papillary thyroid carcinomas (PTC) and follicular variant papillary thyroid carcinomas (FVPTCs)). | 12-18-2014 |
20140371097 | NON-INVASIVE METHODS FOR ASSESSING OOCYTE QUALITY FOR IN VITRO FERTILIZATION - The present invention provides methods of selecting oocytes for in vitro fertilization comprising determining the level of translation products in medium in which the oocyte is incubate. | 12-18-2014 |
20140371098 | MARKER SEQUENCES FOR BREAST CANCER AND THE USE THEREOF - The present invention relates to a method for identifying marker sequences for breast cancer, the marker sequences identified with the aid of this method and diagnostic use thereof, diagnostic devices containing marker sequences for breast cancer, in particular an arrangement and a protein array, and use thereof. The invention also relates to method for the screening of potential active agents for the treatment and prevention of breast cancer by means of these marker sequences. | 12-18-2014 |
20140371099 | BIOMARKER FOR CHRONIC INFLAMMATORY LUNG DISEASES - The invention relates to an in vitro method for the diagnosis and/or prognosis and/or evaluation of the progression of a chronic inflammatory lung disease in a subject, using the level of expression of the GPR15 G protein-coupled receptor gene as a biomarker for the disease. | 12-18-2014 |
20140371100 | METHOD OF NUCLEIC ACID AMPLIFICATION - A nucleic acid molecule can be annealed to an appropriate immobilized primer. The primer can then be extended and the molecule and the primer can be separated from one another. The extended primer can then be annealed to another immobilized primer and the other primer can be extended. Both extended primers can then be separated from one another and can be used to provide further extended primers. The process can be repeated to provide amplified, immobilized nucleic acid molecules. These can be used for many different purposes, including sequencing, screening, diagnosis, in situ nucleic acid synthesis, monitoring gene expression, nucleic acid fingerprinting, etc. | 12-18-2014 |
20140371101 | PARP Substrates and Biomarkers - PARylated proteins are enriched by treating cell lysates comprising PARylated proteins and DNA/RNA with an endonuclease that cleaves the DNA/RNA but not the PAR; and separating the PARylated proteins from the cleaved DNA/RNA. PARylation sites are labeled by eluting PARylated proteins from a PAR-affinity substrate with a nucleophilic amine exchange reactant, wherein the reactant labels PARylation sites of the proteins. Specific binding agents are identified by screening compounds for specific binding to a PARylated protein disclosed herein; and identifying one of the compounds as a specific binder of the protein. Antibodies which specifically bind PARylation sites are also disclosed. | 12-18-2014 |
20140371102 | SYSTEM AND METHOD FOR AUTOMATED BIOPARTICLE RECOGNITION - Disclosed are embodiments of methods, apparatus, systems, compositions, and articles of manufacture relating to identifying the source of bioparticles, such as bioparticles shed by an organism. In embodiments, a method may include collecting a sample of bioparticles from the environment, selecting from that sample the bioparticles most informative for identifying their source, and gathering data from those bioparticles to form bioparticle signatures; the bioparticle signatures may be processed into a multi-dimensional vector which may be compared to a multi-dimensional vector derived from a standard using a pattern recognition strategy. In embodiments, an apparatus may include a particle collection device to collect a sample, a transfer device to select bioparticles, and a detector that restricts the movement of the bioparticles; the restricted movement may be used to produce a bioparticle signature. | 12-18-2014 |
20140371103 | METHODS AND REAGENTS FOR EVALUATING AUTOIMMUNE DISEASE AND DETERMINING ANTIBODY REPERTOIRE - The invention provides methods and kits for determining an antibody or T-cell receptor repertoire in a sample containing B-cells and/or T-cells, and provides a method for evaluating a patient for the presence of an autoimmune disorder. | 12-18-2014 |
20140371104 | SEQUENCES AND THEIR USE FOR DETECTION AND CHARACTERIZATION OF E. COLI 0157:H7 - This invention relates to a rapid method for detection and characterization of | 12-18-2014 |
20140378324 | RAF DIMERS AND USES THEREOF - Disclosed herein are mutated RAF and KSR nucleic acids and polypeptides. Also disclosed are methods of using the mutated RAF and KSR to inhibit the dimerization of RAF/RAF and RAF/KSR. Also disclosed are methods of using the mutated RAF and KSR to screen for inhibitors of dimerization. | 12-25-2014 |
20140378325 | BIOMARKER FOR MENTAL DISORDERS INCLUDING COGNITIVE DISORDERS, AND METHOD USING SAID BIOMARKER TO DETECT MENTAL DISORDERS INCLUDING COGNITIVE DISORDERS - Methods are provided that detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence. Novel biomarkers are also provided for cognitive impairment and non-psychiatric disease, as well as methods for detecting cognitive impairment using such biomarkers. Specifically, a biomarker for diagnosis is provided that comprises a protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of an amino acid sequence expressed by SEQ ID NO: 1, 3, 6, 8, 10, 13, 15, 18, or 20 and selected from the group of partial peptide in these proteins consisting of an amino acid sequence expressed by SEQ ID NO: 2, 4, 5, 7, 9, 11, 12, 14, 16, 17, 19, or 21. | 12-25-2014 |
20140378326 | Methods, Kits and Compositions Pertaining to the Suppression of the Detectable Probe Binding to Randomly Distributed Repeat Sequences Genomic Nucleic Acid - This invention is directed to methods, kits, non-nucleotide probes as well as other compositions pertaining to the suppression of binding of detectable nucleic acid probes to undesired nucleotide sequences of genomic nucleic acid in assays designed to determine target genomic nucleic acid. | 12-25-2014 |
20140378327 | REAL-TIME MULTIPLEXED HYDROLYSIS PROBE ASSAY USING SPECTRALLY IDENTIFIABLE MICROSPHERES - Methods and compositions for the detection and quantification of nucleic acids are provided. In one embodiment, a sample is contacted with a primer and a quencher-probe complementary to a target nucleic acid. The quencher-probe is complementary to an anti-probe that comprises a reporter and is attached to a solid support. Thus, hybridized probe is cleaved with a nucleic acid polymerase having exonuclease activity to release the quencher from the probe. The presence of the target nucleic acid is then detected and/or optionally quantified by detecting an increase in signal from the fluorescent reporter on the solid support. | 12-25-2014 |
20140378328 | Two-Dimensional Photonic Crystal MicroArray Measurement Method and Apparatus for Highly-Sensitive Label-Free Multiple Analyte Sensing, Biosensing, and Diagnostic Assay - Methods and systems for highly-sensitive label-free multiple analyte sensing, biosensing, and diagnostic assay are disclosed. The systems comprise an on-chip integrated two-dimensional photonic crystal sensor chip. The invention provides modulation methods, wavelength modulation and intensity modulation, to monitor the resonance mode shift of the photonic crystal microarray device and further provides methods and systems that enable detection and identification of multiple species to be performed simultaneously with one two-dimensional photonic crystal sensor chip device for high throughput chemical sensing, biosensing, and medical diagnostics. Other embodiments are described and claimed. | 12-25-2014 |
20140378329 | Animal Colony Monitoring Using Fecal Samples - A library of fecal samples from animals populations for analysis of disease in the population and methods for collection and analysis of the samples. Methods for managing a population of animals using the library and methods. | 12-25-2014 |
20140378330 | Multi-primer Assay for Mycoplasma Detection - Disclosed is a multi-primer amplification assay, method and kits for detecting | 12-25-2014 |
20140378331 | MULTIPLEXED BIOMARKER QUANTITATION BY NANOPORE ANALYSIS OF BIOMARKER-POLYMER COMPLEXES - Devices and methods for detecting a target molecule are provided herein. The methods entail contacting a sample with a polymer scaffold, the polymer comprising at least one association site configured to associate with the target molecule. The sample is brought into contact with the polymer to determine whether the target molecule is present in the sample under conditions allowing the target molecule, if present, to associate with the polymer scaffold. The methods further involve loading the polymer into a device comprising a pore or channel that connects two volumes, configuring the device to pass the polymer through the pore or channel from one volume to the other volume, and determining, with a sensor configured to detect objects passing through the pore or channel, whether the target molecule is associated with the association site, and thereby detecting the presence or absence of the target molecule in the sample. | 12-25-2014 |
20140378332 | Health Test for a Broad Spectrum of Health Problems - Provided herein are methods and devices for the detection of conditions or disorders by detecting altered levels of stress response pathway biomarkers. Also provided are methods and reagents for identifying panels of biomarkers associated with a condition or disorder. | 12-25-2014 |
20140378333 | DIGITAL BRIDGE PCR - The present disclosure, among other things, provides methodologies for quantifying targets of interest in samples by 1) capturing single target entities on individual solid phase particles in a manner that permits that those particles that contain captured targets to be optically distinguished from those that do not, and 2) optically analyzing the particles so that those with captured target entities are “counted”. In some embodiments, provided methods and compositions in the present application comprise a population of particles including one or more sub-populations distinguishable from one another. | 12-25-2014 |
20140378334 | METHOD FOR QUANTIFYING RENAL MARKERS BY ASSAYING URINE - The invention pertains to a method of in vitro diagnosis of pathologies in a patient. According to the invention, the method comprises the following steps:
| 12-25-2014 |
20140378335 | METHOD FOR THE DIAGNOSIS AND/OR PROGNOSIS OF ACUTE RENAL DAMAGE - The invention relates to miRNAs: miR-26b, miR-29a, miR-454, miR-146a, miR-27a, mi-R93 and miR-10a, as markers of acute renal damage, and to a method and kit for the diagnosis and/or prognosis of acute renal damage using said markers. | 12-25-2014 |
20140378336 | DIAGNOSIS OF CELL PROLIFERATIVE DISEASES - The method of the present disclosure is directed towards a method and a kit for diagnosing a cell proliferative disease. This method includes the following steps; gathering a sample from a subject, measuring the fibulin expression level or measuring the fibulin activity level in the sample, comparing the measured fibulin expression level or measured fibulin activity level to a baseline level of fibulin expression or activity and assigning the subject to a normal or abnormal group based on the measured fibulin expression level or activity level in the sample. The present disclosure is also directed towards a kit for diagnosing a cell proliferative disease. The kit includes a sampler, a measurer, a comparor and an assignor. | 12-25-2014 |
20140378337 | COMPOSITIONS AND METHODS FOR DETECTING AND IDENTIFYING BACTERIA - The present invention relates to compositions and methods for using nucleic acid sequences present in the genome of a bacterium to rapidly identify the Gram-stain status of an unknown bacterium present in a biological sample. The invention also relates to compositions and methods for using nucleic acid sequences present in the genome of a bacterium to rapidly determine the species of an unknown bacterium present in a sample. | 12-25-2014 |
20140378338 | SIGNATURE FOR THE DIAGNOSIS OF LUNG CANCER AGGRESSIVENESS AND GENETIC INSTABILITY - The present invention relates to a method for diagnosing aggressiveness of a lung cancer in a patient from a lung cancer sample of said patient, comprising: a) detecting in vitro an expression profile of the DNA replication stress signature, said signature comprising the CDC6, CLASPIN, PLK1, and POLQ genes, as well as, optionally, RAD51; b) comparing the said expression profile to a reference expression profile, and d) diagnosing cancer aggressiveness and from the said comparison. Dedicated microarrays and kits are also described, as well as a method of selecting or adapting a suitable treatment. | 12-25-2014 |
20140378339 | PATTERNING DEVICE - A novel miniaturized and highly automated method for the controlled printing of large arrays of nano- to femtoliter droplets is presented by actively transporting mother droplets over hydrophilic-in-hydrophobic micropatches. The proposed technology consists of single plate or double-plate devices where mother droplets can be actuated and hydrophilic-in-hydrophobic micropatches on one or both plates of the device where nano- to femtoliter droplets are printed. Due to the selective wettability of the more wettable hydrophilic micropatches in a hydrophobic matrix, large nano- to femtoliter droplet arrays are created when mother droplets are transported over these arrays. The parent droplets can be moved by different droplet actuation principles, for example, by using the principle of electrowetting-on-dielectric droplet actuation. We propose another method that uses two plates that are placed on top of each other while being separated by a spacer. One plate is dedicated to confirming and guiding of parent droplets by using hydrophilic patches in a hydrophobic matrix, while the other plate contains hydrophilic-in-hydrophobic arrays dedicated to the printing of nano- to femtoliter droplets. When the plate dedicated to parent droplet guiding is rotated over the plate dedicated to printing of nano- to femtoliter droplets, nano- to femtoliter droplets are dispensed inside the hydrophilic-in-hydrophobic array due to their selective wettability. All these proposed methods allow the parent droplets to be moved over the hydrophilic-in-hydrophobic arrays many times, providing unique advantages for performing bio-assays or miniaturized materials synthesis in nano- to femtoliter sized droplets. Upon the controlled evaporation of the dispensed droplets of solution, large arrays of the printed material can be generated on an automated way in seconds of time on a very flexible way. The method disclosed herein provides a distinct nano- to femtoliter droplet printing technique for a wide variety of applications such as protein- or cell-based bio-assays or printing of crystalline structures, suspensions of nanoparticles or components for microelectronics. | 12-25-2014 |
20140378340 | Methods for Genotyping - Novel methods and kits are disclosed for reducing the complexity of a nucleic acid sample to interrogate a collection of target sequences, for example, to discriminating between alleles at polymorphic positions in a genome. Complexity reduction can be accomplished by extension of a capture probes followed by amplification of the extended capture probe using common primers. The capture probes may be locus specific and allele-specific. The amplified sample may be hybridized to an array designed to interrogate the desired fragments for the presence or absence of a polymorphism. In some aspects the methods employ allele-specific extension of oligonucleotides that are complementary to one of the alleles at the 3′ end of the oligonucleotide. The allele-specific oligonucleotides are resistant to proof reading activity from a polymerase and may be extended in an allele-specific manner by a DNA polymerase with a functional 3′ to 5′ exonuclease activity. | 12-25-2014 |
20140378341 | ASSAY CARTRIDGES AND METHODS OF USING THE SAME - Assay modules, preferably assay cartridges, are described as are reader apparatuses which may be used to control aspects of module operation. The modules preferably comprise a detection chamber with integrated electrodes that may be used for carrying out electrode induced luminescence measurements. Methods are described for immobilizing assay reagents in a controlled fashion on these electrodes and other surfaces. Assay modules and cartridges are also described that have a detection chamber, preferably having integrated electrodes, and other fluidic components which may include sample chambers, waste chambers, conduits, vents, bubble traps, reagent chambers, dry reagent pill zones and the like. In certain preferred embodiments, these modules are adapted to receive and analyze a sample collected on an applicator stick. | 12-25-2014 |
20140378342 | IRRIGATION AND ASPIRATION DEVICE AND METHOD - Irrigation and/or aspiration devices and methods may be configured to aspirate and irrigate alone, sequentially, or concurrently. The devices and methods may provide a base with a removable head, and adapted for partial or complete separation of the irrigation and aspiration functions. The devices and methods can be configured to aspirate and/or irrigate the nasal and sinus cavities. The devices and methods may be manually and/or automatically controlled. The devices and methods may include removable, and/or replaceable, and/or refillable, and easily cleanable reservoirs for aspirant and irrigant. The device head and/or aspirant reservoir may comprise a diagnostic device, i.e., test device and/or container after use of the devices and methods. | 12-25-2014 |
20150011405 | Use of Nanoexpression to Interrogate Antigen Repertoires - Disclosed herein are methods and compositions for using nanoexpression to interrogate antigen specificity within antibody repertoires. Also disclosed herein is an antibody display system composition comprising one or more recombinant nucleic acid sequences comprising a first nucleic acid sequence encoding a heavy chain variable region sequence or fragment thereof operatively linked to a first identification region sequence and a second nucleic acid sequence encoding a light chain variable region sequence or fragment thereof operatively linked to a second identification region sequence. | 01-08-2015 |
20150011406 | MULTIPLE-PULSE PUMPING FOR ENHANCED FLUORESCENCE DETECTION AND MOLECULAR IMAGING IN CELLS AND TISSUE - The present invention includes a method and system for enhancing the signal-to-noise ratio in emission detection comprising: selecting a probe capable of at least one of fluorescence, phosphorescence, or delayed fluorescence in or about a sample that comprises interfering background signal; and exposing the probe to one or more controllable bursts, each burst comprising two or more pulses, wherein the one or more controllable bursts of high repetition energy pulses enhance the signal from the probe above that of the background signal. | 01-08-2015 |
20150011407 | Bidirectional Promoter - The invention refers to a library of bidirectional expression cassettes or expression vectors comprising a repertoire of bidirectional promoter sequences, each expression cassette comprising a promoter sequence operably linked to a first gene in one direction, and operably linked to an oppositely oriented second gene in the other direction which is different from the first gene, and bidirectional | 01-08-2015 |
20150011408 | TANDEM SEQUENCING TOP AND BOTTOM STRANDS OF DOUBLE STRANDED NUCLEIC ACID USING ARRAYS CONFIGURED FOR SINGLE MOLECULE DETECTION - The present invention relates to compositions, methods and systems for analyzing the methylation state of nucleic acids. Some embodiments relate to a compositions, methods and systems for analyzing the methylation state of DNA with a gene array. | 01-08-2015 |
20150011409 | Phased Genome Sequencing - The present disclosure provides methods for determining phased nucleic acid sequence for a single chromosome of interest and/or a single chromosomal fragment of interest. The present disclosure also provides methods for determining phased nucleic acid sequence for a plurality of single chromosomes of interest and/or a plurality of single chromosomal fragments of interest. The plurality of single chromosomes of interest may be of one chromosome type or of two or more chromosome types. The present disclosure also provides a method for isolating a plurality of chromosomal fragments of a specified size range, where the chromosomal fragments are from one or more specified regions of the genome. The plurality of chromosomal fragments may be separated into single chromosomal fragments and sequenced to provide phased nucleic acid sequence for the single chromosomal fragments. Alternatively, the plurality of chromosomal fragments may be sequenced together to provide unphased nucleic acid sequence for the chromosomal fragments. | 01-08-2015 |
20150011410 | METHODS AND KITS FOR DETECTING SUBJECTS AT RISK OF HAVING CANCER - The present invention relates to agents and methods for screening, diagnosis and surveillance of cancer, in particular pancreatic cancer. | 01-08-2015 |
20150011411 | BIOMARKERS OF CANCER - The present invention relates to identification of a transcriptional signature of RalA and RalB GTPase proteins that is present in human cancer cells, and methods of treating the cancer, methods of diagnosis of the cancer, methods of determining predisposition to the cancer, methods of monitoring progression/regression of the cancer, methods of assessing efficacy of compositions for treating the cancer, methods of screening compositions for activity in modulating biomarker of the cancer, as well as other methods and assay systems based on the signature. | 01-08-2015 |
20150011412 | SYSTEM FOR DETECTING INFECTION IN SYNOVIAL FLUID - The invention provides methods and systems for detecting a biomarker in a synovial fluid wherein the system also includes a control to ensure that the test sample is indeed synovial fluid. The biomarkers and the control for synovial fluid can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay. | 01-08-2015 |
20150011413 | INTERNAL REFERENCE GENES FOR MICRORNAS NORMALIZATION AND USES THEREOF - Disclosed are standardized reference genes for microRNAs and the use thereof. The reference gene is microRNA let-7d, let-7g, let-7i or a combination thereof. The reference genes have extremely high stability and accuracy compared to the currently most commonly used reference genes in microRNA quantitation. | 01-08-2015 |
20150011414 | MICRORNA FOR DIAGNOSIS OF PANCREATIC CANCER AND/OR PROGNOSIS OF PATIENTS WITH PANCREATIC CANCER BY BLOOD SAMPLES - The present invention relates to methods for improving the diagnosis and prognosis of patients with pancreatic carcinoma by making use of specific miRNA biomarkers associated with pancreatic carcinoma that may be identified based on a blood sample, in particular a whole blood, serum or plasma sample, from an individual. | 01-08-2015 |
20150011415 | METHOD FOR CALCULATING A DISEASE RISK SCORE - The present disclosure relates to a general method for converting complex gene expression data into a simple, composite disease risk score which can be used for the development of rapid diagnostic tests suitable for clinical use for the determination of the presence of an infection or disease in a host. | 01-08-2015 |
20150011416 | MULTIMODAL PCR TARGET DETECTION - The technology described herein relates to detecting the presence of one or more specific nucleic acids, e.g. determining the genotype of one or more allelic target site loci. | 01-08-2015 |
20150011417 | MEMBRANE SPAN-KINASE FUSION PROTEIN AND THE USES THEREOF - The disclosure relates to a recombinant membrane span protein complex, comprising (1) a fusion protein, comprising a membrane span protein fused to a kinase domain, preferably a constitutive kinase and (2) a reporter construct comprising a polypeptide, interacting with the membrane span protein, fused to a reporter phosphorylation domain. The disclosure relates further to the uses of such membrane span protein complex for the detection of compounds that interact with the membrane span protein and for the screening and/or detection of inhibitors of the compound-membrane span protein interactions. In a preferred embodiment, the membrane span protein is a G protein coupled receptor (GPCR) and the method is used for the screening and/or detection of inhibitors of the ligand-receptor binding. | 01-08-2015 |
20150011418 | METHOD FOR DETERMINING THE IMMUNE STATUS OF A SUBJECT - The present invention is a method for using levels of soluble Clusters of Differentiation (CD) proteins, or cell surface-localized CD proteins extracted from T lymphocytes for determining the immune status of a subject. The present invention also a kit containing a CD protein extraction means and at least one antibody which specifically binds a CD protein for use in carrying out the method of the invention. | 01-08-2015 |
20150011419 | SYSTEMS AND METHODS FOR CHARACTERIZING LUPUS ERYTHEMATOSUS - The present invention provides systems and methods for characterizing biological markers in the urine of systemic lupus erythematosus (SLE) subjects. In particular, the present invention relates to the detection of cytokines and chemokines in urine of SLE subjects for determining nephritic disease states and kidney damage in SLE subjects and the efficacy of agents and interventions used to treat lupus nephritis. | 01-08-2015 |
20150018223 | METHODS OF DIAGNOSING TAU-ASSOCIATED NEURODEGENERATIVE DISEASES - This invention provides methods and kits for the detection of tau-associated neurodegenerative diseases, such as Alzheimer's disease, prior to the onset of clinical symptoms. The method generally involves determining the amount of one or more tau protein isoforms in a biological sample relative to a suitable control, where an altered amount of the tau isoform(s) relative to the control identifies the presence of a tau-associated neurodegenerative disease. Such methods can also be applied more generally for the detection of tau abnormalities in any biological sample. | 01-15-2015 |
20150018224 | REAGENTS AND METHODS FOR DETECTING PROTEIN LYSINE 2-HYDROXYISOBUTYRYLATION - The invention provides an isolated peptide comprising a lysine 2-hydroxyisobutyrylation site, a lysine 2-hydroxyisobutyrylation specific affinity reagent that specifically binds to the peptide, and a method for detecting protein lysine 2-hydroxyisobutyrylation in a sample using the reagent. | 01-15-2015 |
20150018225 | CELL ADHESION INHIBITOR, CELL PROLIFERATION INHIBITOR, AND METHOD AND KIT FOR EXAMINING CANCER | 01-15-2015 |
20150018226 | Microfluidic Cell Trap and Assay Apparatus for High-Throughput Analysis - Microfluidic devices are provided for trapping, isolating, and processing single cells. The microfluidic devices include a cell capture chamber having a cell funnel positioned within the cell capture chamber to direct a cell passing through the cell capture chamber towards one or more a cell traps positioned downstream of the funnel to receive a cell flowing. The devices may further include auxiliary chambers integrated with the cell capture chamber for subsequent processing and assaying of the contents of a captured cell. Methods for cell capture and preparation are also provided that include flowing cells through a chamber, funneling the cells towards a cell trap, capturing a predefined number of the cells within the trap, interrupting the flow of cells, flowing a wash solution through the chamber to remove contaminants from the chamber, and sealing the predefined number of cells in the chamber. | 01-15-2015 |
20150018227 | MICRORNA BIOMARKERS - The presently disclosed subject matter provides methods for characterization of and evaluation of treatment and/or progression of a lung cancer or a head and neck cancer by measuring amounts of one or more RNAs present in microvesicles isolated from a biological sample from the subject. | 01-15-2015 |
20150018228 | ENZYME DETECTION BY MICROFLUIDICS - Microfluidic-implemented methods of detecting an enzyme, in particular a DNA-modifying enzyme, are provided, as well as methods for detecting a cell, or a microorganism expressing said enzyme. The enzyme is detected by providing a nucleic acid substrate, which is specifically targeted by that enzyme. | 01-15-2015 |
20150018229 | POLYMORPHISMS IN THE HUMAN GENE FOR THE MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1 (MRP-1) AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS - The present invention relates to a polymorphic MRP-1 polynucleotide, genes or vectors comprising the polynucleotides and a host cell genetically engineered with the polynucleotide or gene. Also provided are methods for producing molecular variant polypeptides, cells capable of expressing a molecular variant polypeptide and a polypeptide encoded by the polynucleotide or the gene or obtainable by the method or cells produced herein. Also provided is an antibody to the polypeptide, a transgenic animal, and a solid support comprising one or a plurality of the provided polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or drug or an inhibitor are also provided. In addition, the invention relates to methods for producing a pharmaceutical composition, diagnosing a disease and detection of the polynucleotide. Furthermore, provided herein are uses of the polynucleotides, genes, vectors, polypeptides or antibodies herein. | 01-15-2015 |
20150018230 | PLASMA miRNA SIGNATURE FOR THE ACCURATE DIAGNOSIS OF PANCREATIC DUCTAL ADENOCARCINOMA - The differential expression of select miRNA in plasma and bile among patients with PDAC, chronic pancreatitis (CP), and controls were measured. Patients (n=215) with treatment-naïve PDAC (n=77), CP with bile or pancreatic duct pathology (n=67), and controls (n=71) that had been prospectively enrolled in a Pancreatobiliary Disease Biorepository at the time of endoscopic retrograde cholangiopancreatography (ERCP) or endoscopic ultrasound (EUS) were identified. Controls were patients with choledocholithiasis but normal pancreata. The sample was separated into training (n=95) and validation (n=120) cohorts to establish and then test the performance of PDAC Signature Panels in diagnosing PDAC. The training cohort (n=95) included age-matched patients with CP and controls. Panels were derived from the differential expression of 10-candidate miRNA in plasma or bile. Differential expression of miR-10b, -155, and -106b in plasma and bile accurately distinguishes individuals with PDAC from those having CP or normal pancreata. | 01-15-2015 |
20150018231 | METHOD AND SYSTEM FOR TRACKING SPECIFIC IN SITU HYBRIDIZATIONS IN BIOLOGICAL SAMPLES USING MOLECULAR BARCODES - A method for tracking specific in situ hybridizations in biological samples using molecular barcodes is disclosed. Present invention specifically addresses the in suspension in situ hybridization protocols and makes it possible to track a mixed sample processed on a high throughput flow cytometer. Since the DNA probes selected for the molecular barcodes are naturally existing sequences on the chromosomes, each cell will have two copies of the molecular barcode as opposed to the single barcode provided by the other systems. Tracking is accomplished by following the florescence patterns emitted by the two, three, four or five fluorescent tags attached to the DNA probes. Alternatively, colorimetric system can be used for tracking by employing non-fluorescent tags and subsequent specific enzyme-substrate reactions. | 01-15-2015 |
20150018232 | ELECTROCHEMICAL SUBSTRATE PATTERNING AND ANALYTE DETECTION ON A TWO-ELECTRODE PLATFORM - A two-electrode detection system having target substrates including nucleic acids, proteins, and/or small molecules on specifically defined regions of a single surface. The spatial distribution of the target substrate on the surface allows for more accurate substrate interactions and analysis. Additionally, the detection system of the present invention allows for patterning of different target substrates, thereby affording more accurate analysis of multiple substrate targets. | 01-15-2015 |
20150018233 | METHODS AND G PROTEINS FOR SCREENING AND IDENTIFYING LIGANDS OF G PROTEIN-COUPLED RECEPTORS - Abstract of the Disclosure Disclosed herein are methods and compounds for screening and identifying ligands of G protein-coupled receptors (GPCRs). Also disclosed are chimeric G proteins and methods for detecting the activation or inhibition of GPCRs. | 01-15-2015 |
20150018234 | BIOMARKERS FOR DIAGNOSING ISCHEMIA - The present invention provides methods and compositions for diagnosing and predicting the occurrence of ischemia. For example, the present invention provides methods and compositions for diagnosing and predicting the risk and cause of transient neurological events (TNE) as ischemic or non-ischemic. | 01-15-2015 |
20150018235 | Methods and Compositions for the Treatment and Diagnosis of Pancreatic Cancer - The invention provides methods, compositions and kits for the detection and treatment of pancreatic cancer. | 01-15-2015 |
20150018236 | HIGH THROUGHPUT SCREEN FOR BIOLOGICALLY ACTIVE POLYPEPTIDES - Methods for screening libraries of polypeptides for biologically activity on cells. For example, polypeptides can be synthesized and encapsulated along with their coding sequences in microcapsules of an emulsion. Emulsion microcapsules can then be fused with microcapsules comprising test cells and biological activity on the cells is assessed to identify biologically active polypeptides and nucleic acid molecules encoding the same. | 01-15-2015 |
20150018237 | MEANS AND METHODS FOR ASSESSING BONE DISORDERS - The present invention pertains to the field of diagnostics for bone disorders and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing a bone disorder. It also relates to a method for determining whether a compound is capable of inducing such a bone disorder in a subject and to a method of identifying a drug for treating a bone disorder. Furthermore, the present invention relates to a device and a kit for diagnosing a bone disorder. | 01-15-2015 |
20150018238 | MULTI-BIOMARKER-BASED OUTCOME RISK STRATIFICATION MODEL FOR PEDIATRIC SEPTIC SHOCK - Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to septic shock in pediatric patients. In particular, the invention relates to identifying one or more biomarkers associated with septic shock in pediatric patients, obtaining a sample from a pediatric patient having at least one indication of septic shock, then quantifying from the sample an amount of one or more of said biomarkers, wherein the level of said biomarker correlates with a predicted outcome. The invention further relates to diagnostic kits, tests, and/or arrays that can be used to quantify the one or more biomarkers associated with septic shock in pediatric patients. | 01-15-2015 |
20150018239 | BIOMARKER SET FOR IDENTIFYING A SEVERE FORM OF CANCER - The present invention relates to a method for differentiating between i) a severe form of cancer and ii) a mild form of cancer, comprising a) determining the amounts of gene product of at least the genes coding for ribosomal protein S6 (RPS6), nucleoside diphosphate kinase (NME/NDKA), and caveolin-1, in a sample from a subject, b) comparing the amounts obtained in step a) to reference amounts, and c) differentiating between a severe form of cancer and a mild form of cancer, wherein an increased amount of products of the genes coding for RPS6 and NME/NDKA and a decreased amount of product of the gene coding for caveolin-1 are indicative of a severe form of cancer. The invention further relates to the use of antibodies specifically recognizing a polypeptide selected from the list consisting of RPS6, NME/NDKA, and caveolin-1, for differentiating between a severe form of cancer and a mild form of cancer. Furthermore, the invention relates to a detection agent specifically recognizing a polypeptide selected from the list consisting of RPS6, NME/NDKA, and caveolin-1, for use in diagnosing, a device and a kit for differentiating between a severe form of cancer and a mild form of cancer. | 01-15-2015 |
20150018240 | THERANOSTICS PLATFORM AND METHODS OF USE - Theranostics platforms for identifying drugs and nutraceuticals for treatment of rare disease are described. The platforms comprise (a) a cell-phenotype image-enhancing instrument; (b) a drug/nutraceutical library; and (c) a computer-implemented system for analyzing a response of an optically-visible rare-disease cell phenotype to a drug or nutraceutical from the drug/nutraceutical library. | 01-15-2015 |
20150018241 | FC-RECEPTOR BASED AFFINITY CHROMATOGRAPHY - Herein is reported the use of an immobilized non-covalent complex of a neonatal Fc receptor (FcRn) and beta-2-microglobulin (b2m) as affinity chromatography ligand in general and, for example, for the determination of the in vivo half-live of an antibody by determining the ratio of the retention times of the antibody and a reference antibody. | 01-15-2015 |
20150018242 | METHODS AND BIOMARKERS FOR DETECTION AND PROGNOSIS OF CERVICAL CANCER - The present invention relates to methods and biomarkers for detection of cervical cancer in biological samples, and in particular to markers associated with hypoxia related to the cervical cancer. | 01-15-2015 |
20150018243 | Plant Tissue Sampling Method and Plant Gene Analysis Method - To provide a means and a method of quickly sampling a tissue fragment from a plant tissue, quickly preserving a gene expression state within the tissue fragment, and comprehensively analyzing the gene expression state. The present invention relates to a method of sampling a plant tissue section, comprising: inserting a first gel layer into a needle; arranging a plant tissue on a second gel layer; and passing the needle through the plant tissue together with the second gel layer, and sampling a section of the plant tissue in the needle. | 01-15-2015 |
20150024952 | MOLECULAR PROFILING FOR CANCER - Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease. The cancer can be an ovarian cancer. | 01-22-2015 |
20150024953 | METHODS FOR IDENTIFYING EUBACTERIA - This invention relates, e.g., to methods for detecting a | 01-22-2015 |
20150024954 | APTAMER REGULATED NUCLEIC ACIDS AND USES THEREOF - The invention relates to aptamer-regulated, ligand-responsive nucleic acids, or “ampliSwitches,” and uses thereof. Particular embodiments include a ligand-responsive nucleic acid that comprises a primer sequence domain and an aptamer domain that is responsive to a ligand. | 01-22-2015 |
20150024955 | Methods of Identifying Modulators of Dephosphorylation of Histone Deacetylase - The present invention relates to screening methods that make use of a histone deacetylase interacting with a myosin phosphatase for the identification of novel therapeutics useful for inhibiting or inducing apoptosis and for the treatment of pathological conditions, such as smooth muscle cell disorder, cardiac hypertrophy or asthma. Also disclosed are methods for inhibiting or inducing apoptosis and for treatment of a pathological condition by administering to a mammal a therapeutically effective amount of a compound that inhibits or increases the dephosphorylation of a histone deacetylase by a myosin phosphatase or inhibits or increases the binding of a histone deacetylase to a myosin phosphatase. | 01-22-2015 |
20150024956 | METHODS FOR DIAGNOSIS AND/OR PROGNOSIS OF GYNECOLOGICAL CANCER - Ovarian, cervical cancer, endometriosis, clear cell renal carcinoma cancers are very heterogeneous diseases which lack robust diagnostic, prognostic and predictive clinical biomarkers. Conventional clinical biomarkers (stages, grades, tumor mass etc) and molecular biomarkers (CA125, KRAS, p53 etc) are not appropriate for early diagnostics, differential diagnostics, prediction and prognosis of the disease outcome for individual patients. The most common type of the human ovarian cancers is human epithelial ovarian cancer (EOC). This cancer is characterized with one of the lowest survival rates compared to other cancers. The present invention relates to an in vitro method for diagnosing epithelial ovarian cancer, cervical cancer, endometriosis, dear cell renal carcinoma and/or predisposition to epithelial ovarian cancer in a subject, the method comprising determining in a sample of the subject gene expression level of at least one gene in the MDS1 and EVI1 complex (MECOM) locus; and/or copy number of at least one gene in the MECOM locus; wherein the level against at least one expression cutoff value and/or copy number against at least one copy number cutoff value are indicative of the subject having epithelial ovarian cancer, cervical cancer, endometriosis, clear cell renal carcinoma and/or a predisposition to epithelial ovarian cancer, cervical cancer, endometriosis, dear cell renal carcinoma and/or determining whether the ovarian cancer in the subject is primary or secondary ovarian cancer and/or a risk of the disease progression after surgery treatment, and/or an effectiveness of post-surgery chemotherapy. | 01-22-2015 |
20150024957 | Methods and Devices for Detection and Measurement of Analytes - Sensors for target entities having functionalized thereon, at least one aptamer specific to the target entity, and methods of making and using the same are described for use in glycated protein monitoring and/or biomarkers. | 01-22-2015 |
20150024958 | METHOD OF QUANTIFYING PEPTIDE-DERIVATIVE LIBRARIES USING PHAGE DISPLAY - The present application provides a method of quantifying an amount of a derivatized peptide displayed on a phage by phage display, the method comprising: providing a phage containing the target peptide thereon; reacting the phage containing the target peptide with a first reagent to derivatize the target peptide to form a derivatized peptide, reacting the derivatized peptide with a capture agent comprising a detection marker, thereby incorporating the detection marker within the derivatized peptide; and determining an amount of the detection marker, thereby quantifying the amount of the derivatized peptide displayed on the phage. A kit comprising a capture agent comprising a detection marker for quantifying the phage displayed derivatized peptides is also provided. | 01-22-2015 |
20150024959 | METHOD FOR AMPLIFYING cDNA DERIVED FROM TRACE AMOUNT OF SAMPLE - The problem to be solved by the present invention is to provide a method for preparing a sample for comprehensively and accurately analyzing gene expression in a single cell or a few cells, for example, by a large-scale DNA sequencer. The present invention relates to a method for amplifying cDNA from mRNA in a cell, comprising: (1) capturing mRNA derived from the cell by a first DNA probe containing a first tag sequence and a poly T sequence and being immobilized to a solid carrier in a single reaction vessel, and synthesizing a first strand cDNA from the mRNA by a reverse transcription reaction; (2) removing a reaction reagent from the reaction vessel while keeping the first strand cDNA synthesized onto the solid carrier in the reaction vessel; (3) adding a polynucleotide sequence consisting of one type of nucleotides to 3′ terminal of the first strand cDNA on the solid carrier; (4) hybridizing a second DNA probe containing a second tag sequence and a complementary sequence to the polynucleotide sequence with the cDNA to which the polynucleotide sequence is added, and synthesizing a second strand cDNA; and (5) performing a DNA amplification reaction using the second strand cDNA synthesized on the solid carrier as a template. | 01-22-2015 |
20150024960 | MULTIPLE BIOMARKER SET FOR BREAST CANCER DIAGNOSIS, METHOD OF DETECTING THE SAME, AND DIAGNOSIS KIT FOR BREAST CANCER USING ANTIBODY AGAINST THE SAME - The present invention relates to a biomarker set for diagnosing breast cancer comprising two or more protein markers of: apolipoprotein C1, apolipoprotein (a), neural cell adhesion molecule L1-like protein, carbonic anhydrase 1, and fibronectin; a method for detecting the biomarker set in a blood sample through a multiple reaction monitoring; a kit for diagnosing breast cancer comprising antibodies specific to each of the proteins of the biomarker set; and a method for detecting proteins of the marker set in a blood sample through an antigen-antibody binding reaction. The method for detecting the protein marker set in a blood sample by the MRM method or antigen-antibody binding reaction and the diagnostic kit can provide very high accuracy and sensitivity in comparison with the diagnosis method using a single marker and can very conveniently diagnose breast cancer using blood from patients, thereby being effectively used for early diagnosis of breast cancer. | 01-22-2015 |
20150024961 | METHODS AND SYSTEMS OF USING BIOMARKERS FOR DETERMINING PHENOTYPES - Biomarkers such as exosomes and/or RNA, e.g., microRNA, can be used for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Such biomarkers can be used in profiling of physiological states or determining phenotypes. Biomarkers can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Biomarkers can also be used to identify conditions of diseases of unknown origin. | 01-22-2015 |
20150024962 | MARKER SEQUENCES FOR MULTIPLE SCLEROSIS AND USE THEREOF - The present invention relates to new marker sequences for multiple sclerosis and the diagnostic use thereof together with a method for screening of potential active substances for multiple sclerosis by means of these marker sequences. Furthermore, the invention relates to a diagnostic device containing such marker sequences for multiple sclerosis, in particular a protein biochip and the use thereof. | 01-22-2015 |
20150024963 | microRNA Signatures in Human Ovarian Cancer - Described herein are methods and compositions for the diagnosis, prognosis and treatment of ovarian cancer. Also described are methods of identifying anti-cancer agents. | 01-22-2015 |
20150024964 | USES OF SYSTEMS WITH DEGREES OF FREEDOM POISED BETWEEN FULLY QUANTUM AND FULLY CLASSICAL STATES - Disclosed herein are systems and uses of systems operating between fully quantum coherent and fully classical states. Such systems operate in what is termed the “Poised realm” and exhibit unique behaviors that can be applied to a number of useful applications. Non-limiting examples include drug discovery, computers, and artificial intelligence | 01-22-2015 |
20150024965 | USE OF MICROFLUIDIC SYSTEMS IN THE DETECTION OF TARGET ANALYTES USING MICROSPHERE ARRAYS - The invention relates generally to methods and apparatus for conducting analyses, particularly microfluidic devices for the detection of target analytes. | 01-22-2015 |
20150031561 | BIOMARKER PANELS, DIAGNOSTIC METHODS AND TEST KITS FOR OVARIAN CANCER - Methods are provided for predicting the presence, subtype and stage of ovarian cancer, as well as for assessing the therapeutic efficacy of a cancer treatment and determining whether a subject potentially is developing cancer. Associated test kits, computer and analytical systems as well as software and diagnostic models are also provided. | 01-29-2015 |
20150031562 | BIOMARKERS FOR MULTIPLE SCLEROSIS AND METHODS OF USE THEREOF - Biomarkers useful for identifying treatments for and monitoring treatment of patients with multiple sclerosis (MS) are provided, as well as methods for their identification, methods of diagnosing MS, relapse of MS patients and disease progression in MS patients. | 01-29-2015 |
20150031563 | Multi Component Antibody Based Detection Technology - The disclosure provides methods for detecting the concurrent presence of at least two targets within a biological sample. The method includes contacting said biological sample with a first binding agent, said first binding agent operably linked to a first sortase molecule, wherein said first binding agent specifically binds to a first target; contacting said biological sample with a second binding agent, said second binding agent operably linked to a first sortase recognition sequence peptide, wherein said second binding agent specifically binds to a second target; adding a sortase substrate under conditions where a first sortase-mediated ligation of the sortase substrate to the first sortase recognition sequence will produce a ligation product, and detecting the ligation product, wherein detection of said ligation product indicates the concurrent presence of the first target and the second target in the biological sample. Also disclosed are kits comprising reagents for performing the methods as claimed. | 01-29-2015 |
20150031564 | LIGAND HAVING THREE FINGER STRUCTURE AND A METHOD FOR DETECTING A MOLECULE BY USING THEREOF - The present invention improves in vitro virus synthesis efficiency and stability of mRNA derived from screened cDNA in a cDNA display method to improve the efficiency and reliability of the production of a peptide by a molecular evolutionary engineering technique. Provided is a ligand which comprises three fingers formed from antiparallel β-sheets and a loop region intercalated between the antiparallel β-sheets, wherein at least a fingertip part formed by the loop region of each of the fingers is bound to the target molecule, and wherein the ligand comprises the amino acid sequence of SEQ ID NO: 1. In the amino acid sequence of SEQ ID NO: 1, X7 represents an arbitrary amino acid residue that constitutes the fingertip part of each of the fingers, each numeric character represents the number of amino acid residues, and X7 and X4 are not composed of the same amino acid residues as each other. | 01-29-2015 |
20150031565 | DETERMINATION OF THE IDENTITIES OF SINGLE NUCLEOTIDE POLYMORPHISMS, POINT MUTATIONS AND CHARACTERISTIC NUCLEOTIDES IN DNA - A method of genotyping single nucleotide polymorphisms (“SNP”) and point mutations in nucleic acid based on chain extension by polymerase. This invention is based on the fact that the neighboring sequence immediately 3′ adjacent to the site is known, and the nucleoside immediately 5′ adjacent to any SNP/point mutation site is also known. An extension primer complementary to the sequence directly adjacent to the SNP on the 3′ side of a target polynucleotide is used for chain extension. Up to four different polymerase reaction mixtures are provided in separate reaction containers, each containing one different potentially chain-extending Bridging Nucleotide. A Reporting Nucleotide having a base complementary to the nucleotide directly adjacent to the SNP on the 5′ side of the target polynucleotide may also be added to each reaction container. | 01-29-2015 |
20150031566 | BIOTINYLATED MHC COMPLEXES AND THEIR USES - The invention demonstrates an improved choice of biotinylation peptide to be used in a combination or fusion with an MHC molecule for immobilizing or multimerising such MHC molecules for a variety of purposes. | 01-29-2015 |
20150031567 | miRNA Biomarkers For Ulcerative Colitis - Methods for diagnosing inflammatory bowel disease and ulcerative colitis using miRNA biomarkers for these diseases are provided. Differential expression of the miRNA biomarkers in blood fractions, e.g., platelets, of diseased individuals as compared to expression levels in normal individuals indicates the presence of IBD or ulcerative colitis. Also provided are microarrays for use in the diagnostic methods, wherein the features of the microarray consist essentially of nucleic acid sequences that hybridize to the miRNA biomarkers and normalization controls. | 01-29-2015 |
20150031568 | METHOD FOR MEASURING PHYSIOLOGICALLY ACTIVE SUBSTANCE OF BIOLOGICAL ORIGIN, AND MICROPARTICLES AND EXTRACT FOR USE IN THE METHOD - Provided is a technique which can detect a physiologically active substance of biological origin or measure the concentration of the physiologically active substance of biological origin with higher accuracy or within a shorter period even when a sample that contains the physiologically active substance of biological origin at an extremely low concentration or a sample that contains a component capable of interfering with an AL is used. Microparticles capable of adsorbing a specific physiologically active substance, e.g., an endotoxin, is dispersed in a sample containing the specific physiologically active substance to cause the adsorption of the specific physiologically active substance onto the microparticles, thereby concentrating the specific physiologically active substance in the sample. Subsequently, the microparticles are separated and collected, then are reacted with an AL to cause an aggregation reaction, and the aggregation is detected by an optical means. In this manner, the measurement of the specific physiologically active substance can be carried out. | 01-29-2015 |
20150031569 | Mutations of the GPR179 Gene in Congenital Stationary Night Blindness - The present invention relates to an in vitro method for diagnosing a complete congenital stationary night blindness (cCSNB) in a subject, which method comprises determining the presence of an alteration in the GPR179 gene in a biological sample of said subject. Screening methods and therapeutic applications are further described. | 01-29-2015 |
20150031570 | METHOD AND APPARATUS FOR RAPID, HIGH SENSITIVITY ANALYSIS OF LOW VOLUME SAMPLES OF BIOLOGICAL MATERIALS - A high throughput biological sample processing system includes a sample carrier with a plurality of wells that progresses through the high throughput biological sample processing system. The system further includes a sample dispensing module, a reagent dispensing module, an accumulation/incubation module, and a detection module. The detection module employs an optical measuring device to encapsulate a biological sample in one of the plurality of wells of the sample carrier and detect energy from the chemistry of the biological sample to determine the amount of an analyte in the biological sample. | 01-29-2015 |
20150031571 | CHEMILUMINESCENT NANOPARTICLES AND USES THEREOF - Gold nanoparticles having luminol covalently linked thereto and optionally functionalized with an oligonucleotide and bacterial or viral detection assays. In one aspect, the detection system for detecting an analyte in a sample comprises a light-shielding container having a fiberoptic cable for transmitting light generated within the light-shielding container to a photodetector; a plurality of functionalized nanoparticles deposited in solid form on or within a support, such that the support is located within the light-shielding container; wherein the functionalized nanoparticles comprise nanoparticles covalently attached to one or more chemiluminescent moieties; and a reagent system which causes the chemiluminescent moieties to produce light in the presence of the reagent system and the analyte in the sample. | 01-29-2015 |
20150031572 | MEANS AND METHODS FOR ASSESSING NEURONAL TOXICITY - The present invention pertains to the field of diagnostics for neuronal toxicity and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing neuronal toxicity. It also relates to a method for determining whether a compound is capable of inducing such neuronal toxicity in a subject and to a method of identifying a drug for treating neuronal toxicity. Furthermore, the present invention relates to a device and a kit for diagnosing neuronal toxicity. | 01-29-2015 |
20150031573 | MIRNA ANALYSIS METHODS - The present invention provides a PCR-free, multiplexed ligation assay for miRNA expression analysis that produces highly quantitative, 10-100 plex miRNA profiling in a single reaction. The inventive methods use a 2-step ligation assay to generate an array of miRNA specific ligation products that can be decoded and quantified by a size discrimination method such as gel electrophoresis or single molecule separation. One embodiment is a low-cost assay that can be performed using standard tools available in nearly all molecular biology laboratories. This assay requires nothing more than a gel apparatus and reader for detection. Other embodiments include use of magnetic beads and other size exclusion apparatus which give increasingly higher sensitivity, lower sample consumption, and reduced processing steps. | 01-29-2015 |
20150031574 | METHOD FOR CLASSIFICATION OF TEST BODY FLUID SAMPLE - A method for classifying test body fluid samples into either of two groups selected from four groups consisting of chronic hepatitis C, chronic hepatitis B, non-alcoholic steatohepatitis (NASH) and normal liver, is provided. In one or plural embodiment(s), it relates to a method for classifying test body fluid samples into either of two groups selected from four groups consisting of chronic hepatitis C, chronic hepatitis B, non-alcoholic steatohepatitis (NASH) and normal liver. The method includes a measurement of an expression level of the one or plural non-coding RNA(s) in the test body fluid sample. | 01-29-2015 |
20150031575 | USES OF IDED NANOSTRUCTURES IN NUCLEIC ACID TECHNOLOGY - The present invention relates to compositions comprising a porous nanostructure of a known characteristics and a fragment of nucleic acid having a known sequence. Methods of use of the compositions were also provided, for example in DNA amplification, detection, and DNA sequencing. | 01-29-2015 |
20150031576 | REAL TIME PCR DETECTION OF M. TUBERCULOSIS RESISTANT/SUSCEPTIBLE TO RIFAMPICIN AND/OR ISONIAZID - The present invention relates to assays, diagnostic kits and methods for the real-time PCR detection of nucleic acids that are indicative of rifampicin and/or isoniazid susceptible and/or resistant | 01-29-2015 |
20150031577 | NUCLEIC ACID DETECTION METHOD COMPRISING TARGET SPECIFIC INDEXING PROBES (TSIP) COMPRISING A RELEASABLE SEGMENT TO BE DETECTED VIA FLUORESCENCE WHEN BOUND TO A CAPTURE PROBE - Reagents, systems and methods for the detection of nucleic acids are described herein, including such methods which may be performed in a single reaction. Such reagents include a target specific indexing probe (TSIP) synthetic DNA structure comprising a detectable moiety and a quencher thereof, wherein in the presence of a target nucleic acid a portion (a tag) of the (TSIP) synthetic DNA structure comprising the detectable moiety is released, thereby increasing the signal emitted therefrom. The tag may in turn bind to a capture probe, facilitating signal detection. | 01-29-2015 |
20150031578 | DEVICES AND METHODS FOR PROGNOSIS PREDICTION FOR MELANOMA CANCER - The invention relates to prognostic markers and prognostic signatures, and compositions and methods for determining the prognosis of cancer in a patient, particularly for melanoma. Specifically, the invention relates to the use of genetic and protein markers for the prediction of the risk of progression of a cancer, such as melanoma, based on markers and signatures of markers. In various aspects, the invention provides methods, compositions, kits, and devices based on prognostic cancer markers, specifically melanoma prognostic markers, to aid in the prognosis and treatment of cancer. | 01-29-2015 |
20150031579 | Aza-Benzazolium Containing Cyanine Dyes - Unsymmetrical cyanine dyes that incorporate an aza-benzazolium ring moiety are described, including cyanine dyes substituted by a cationic side chain, monomeric and dimeric cyanine dyes, chemically reactive cyanine dyes, and conjugates of cyanine dyes. The subject dyes are virtually non-fluorescent when diluted in aqueous solution, but exhibit bright fluorescence when associated with nucleic acid polymers such as DNA or RNA, or when associated with detergent-complexed proteins. A variety of applications are described for detection and quantitation of nucleic acids and detergent-complexed proteins in a variety of samples, including solutions, electrophoretic gels, cells, and microorganisms. | 01-29-2015 |
20150038347 | SURFACE ENHANCED RAMAN SPECTROSCOPY - Rapid surface enhanced Raman spectroscopy (SERS) assays for ultratrace pathogen detection are provided. One-particle and two-particle sensor assays (e.g., biosensor assays) are provided. In one implementation, for example, an assay forms and concentrates a DNA hybridization complex incorporating paramagnetic particles and Raman active noble metal (e.g., gold, silver and/or copper) nanoparticles (two-particle sensor) or noble metal coated paramagnetic particles that provide both a SERS substrate and magnetic capture ability in a single sensor particle via a noble metal-coated paramagnetic particle, such as a gold-coated paramagnetic particle (one-particle sensor). | 02-05-2015 |
20150038348 | MICROBIAL BIOINDICATORS OF HYDROCARBONS IN WATER AND IN MARINE SEDIMENTS AND METHODS FOR MAKING AND USING THEM - In alternative embodiments, the invention provides products of manufacture and compositions, e.g., nucleic acid probes, for use as identifying agents or indicators to detect the presence of a hydrocarbon in a sample, e.g., in marine sediments, muds, sands and the like, or in a solution, e.g., an aqueous solution, such as a production water, fresh water, underground water or seawater. In alternative embodiments, the invention provides compositions, e.g., nucleic acid probes or primers or primer pairs, for use as sensors and/or identifying agents to detect the presence of a hydrocarbon in a sample (e.g., in fresh water, underground water or seawater, or a marine mud, sand or sediment), where the presence of the hydrocarbon indicates e.g., the presence of a subsurface oil, petroleum or gas accumulation or deposit. In alternative embodiments, the invention provides compositions and methods for use as tools for offshore oil exploration activities. | 02-05-2015 |
20150038349 | Methods and Molecular Pharmacodynamic Biomarkers for Multiple Signaling Pathways in Response to Carboxyamidotriazole Orotate - This invention provides methods, pharmacodynamics biomarker signatures for multiple signaling pathways in a cell sample such as anagen hair, in response to carboxyamidotriazole orotate (CTO) from a subject. CTO has demonstrated response in several cancers having different genomic mutations in clinical studies. This invention provides a diagnostic and prognostic assay for monitoring response to CTO ranging from −100 fold to +25 fold differential expression in several transcriptional signatures associated with tumor inhibition including EGFR, MEK, HDAC, RAS, GFS, WNT, HSP90 or non-voltage dependent calcium signaling, while inducing tumor suppressors signatures such as P53 or EGR1 in the anagen hair assay. | 02-05-2015 |
20150038350 | Method for Determining Condition of Oral Cavity and Analytical Tool, Apparatus, and Program Used for the Method - Means of determining the condition of the oral cavity in a subject is provided. The condition of the oral cavity in the subject is determined by using an analytical tool comprising the following (A), (B), and (C):
| 02-05-2015 |
20150038351 | Gene Signatures That Predispose Or Protect Individuals From Low-Dose Radiation Induced Breast Cancer Or Are Associated with Disease-Free Survival - A method for identifying sensitivity to low-dose ionizing radiation and cancer patient prognosis. Several predictor panels of genes that are predictive for increased or decreased susceptibility for LD-induced cancer and predictor panel that are predictive for increased or decreased disease free survival in women who are newly diagnosed with breast cancer. | 02-05-2015 |
20150038352 | ANALYSIS OF METHYLATION USING NUCLEIC ACID ARRAYS - Arrays for genome-wide analysis of methylation are disclosed. In a preferred aspect arrays comprising a plurality of probes complementary to a plurality of identified CpG islands in the human, mouse and rat genome are disclosed. The arrays may be used to detect methylation within CpG islands in samples from human, mouse and rat genomes. | 02-05-2015 |
20150038353 | MOLECULAR MARKERS FOR DETECTING NOSEMA INFECTION - The present invention provides a molecular marker for detecting | 02-05-2015 |
20150038354 | FULL LENGTH ANTIBODY DISPLAY SYSTEM FOR EUKARYOTIC CELLS AND ITS USE - Herein is reported a method of selecting a cell expressing a bispecific antibody comprising the steps of (a) generating a population of eukaryotic cells by transduction with a population of lentiviral virus particles, whereby each cell of the population of cells displays a membrane-bound full length antibody which is encoded by the lentiviral nucleic acid, and which specifically binds to two or more antigens or two or more epitopes on the same antigen, and (b) selecting from the population of eukaryotic cells a cell depending on the properties of the displayed membrane-bound full length antibody, whereby each lentiviral virus particle of the population of lentiviral virus particles comprises a bicistronic expression cassette comprising the EV71-IRES for the expression of the membrane-bound antibody. | 02-05-2015 |
20150038355 | MULTIPLEX BLOCKER BEADS FOR IMMUNOASSAYS - Provided are methods and compositions for immunoassay with improved specificity. The presently disclosed bead-based blocking agents reduce the interference associated with the samples and reagents of such assays. | 02-05-2015 |
20150038356 | GENETIC ASSAYS - Provided herein are methods, compositions, systems, and kits for recombination assays, many of which involve amplification reactions such as PCR or droplet digital PCR. | 02-05-2015 |
20150038357 | PROGNOSIS FOR GLIOMA - Disclosed is a method of determining the survival prognosis of a patient afflicted by a glioma. The method includes assessing the level of expression of one or more specific gene in cells of the glioma. | 02-05-2015 |
20150038358 | METHODS FOR DETECTING TRISOMY 21 - Methods for determining whether a subject, such as a fetus, has Down syndrome are described. In one embodiment, the methods include detecting one or more biomarkers in a biological sample, and determining whether the expression of the biomarkers is altered when compared to expression of the biomarkers in one or more subjects that do not have trisomy 21. In one embodiment, the biological sample is a blood sample, and the biomarkers are cell free plasma RNAs. | 02-05-2015 |
20150038359 | METHOD OF PREDICTING OUTCOME IN CANCER PATIENTS - A method of prognosis for a mammal with cancer is provided. The method includes the steps of determining in a biological sample obtained from the mammal the expression level of each biomarker of the group DSTN, TDRD3, RGS4, MYO1E, RPL3, Hypothetical FLJ13769, ANP32C, MC2R, DKFZp434L092, GPR27, HPS and LCP1; comparing the expression level of each biomarker with the expression level of a housekeeping gene; and rendering a prognosis for the mammal of a greater than 50% survival for an extended period of time when the expression level of DSTN, TDRD3, RGS4, MYO1E, RPL3(1), RPL3(2), RPL3(3), Hypothetical FLJ13769 and ANP32C is decreased in comparison to the expression of the housekeeping gene, and the expression level of MC2R, DKFZp434L092, GPR27, HPS5 and LCP1 is increased in comparison to the expression of the housekeeping gene. | 02-05-2015 |
20150038360 | Method for Multiplex-Detecting Chronic Myelogenous Leukemia Gene Using Cleavable Probe - One embodiment of the present invention provides a detection kit for detecting a chronic myelogenous leukemia (CML) gene expression, wherein the detection kit includes a primer set which is specifically bound to the CML gene; and a cleavable probe which is specifically bound to the inside of a CML gene amplification product which is amplified by the primer set. Another embodiment of the present invention provides a method of measuring the CML gene expression by using the detection kit according to one embodiment of the present invention. The method according to one embodiment of the present invention is used to efficiently detect a low CML gene expression for CML diagnosis and prognosis diagnosis. | 02-05-2015 |
20150038361 | APPARATUS, METHODS, AND APPLICATIONS FOR POINT OF CARE MULTIPLEXED DIAGNOSTICS - Methods and systems for colorimetric detection of a target. Nucleic acid is obtained from a sample potentially containing two pathogens of interest, and is contacted with a plurality of nanoparticles. A first portion of the plurality of nanoparticles are functionalized with oligonucleotides complementary to a first region of the first target and oligonucleotides complementary to a second region of the first target, and a second portion of the plurality of nanoparticles are functionalized with oligonucleotides complementary to a first region of the second target and oligonucleotides complementary to a second region of the second target. The presence of the target nucleic acid causes a detectable colorimetric change, thereby diagnosing the presence of the pathogen. | 02-05-2015 |
20150038362 | High-Throughput Method For Sialic Acid Quantitation - The present invention relates to a method for specifically measuring sialylation of a biomolecule of interest without the interference of other biomolecules present in the sample. | 02-05-2015 |
20150038363 | Method for Stimulating T Cell and Use Thereof - An object of the present invention is to stimulate a T cell without using a peptide/MHC tetramer. In the present invention, the step of supplying an antigen peptide to a T cell having a T cell receptor (TCR) that can recognize the antigen peptide on cell surface to form a complex of a major histocompatibility complex (MHC) molecule on the cell surface of the T cell and the antigen peptide is used, and the T cell is stimulated through recognition by TCR of the antigen peptide as the MHC molecule-antigen peptide complex on the cell surface of the same T cell. Such a stimulating and activating method would be applicable to not only T cells, but also various cells. According to the present invention, an antigen-specific T cell can be identified without establishing any antigen-specific T cell strain, and without using such a reagent as MHC/peptide tetramer. That is, a cancer-specific T cell can be efficiently and conveniently identified. | 02-05-2015 |
20150038364 | MICROARRAY SUBSTRATE, MICROARRAY, MICROFLUIDIC SYSTEM AND METHODS FOR PREPARING THE SAME - A microarray substrate including a piece of fluoropolymer whose surface is modified with polydopamine, in which the polydopamine forms an array of microspots on the surface of the fluoropolymer piece, and allows immobilization of molecules or cells. A microarray including the substrate, a microfluidic system designed for dispensing reagents onto selected locations on the surface of substrates, and a method for preparing the substrate and the microarray, in which a dopamine solution is dispensed onto the fluoropolymer piece using the microfluidic system, and forms an array of polydopamine microspots serving as the reaction sites for microarray analysis. | 02-05-2015 |
20150038365 | LUNG CANCER BIOMARKERS - The present invention relates to methods of diagnosing lung cancer in a patient, as well as methods of monitoring the progression of lung cancer and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein. | 02-05-2015 |
20150038366 | Immunoassay for Phenethylamines of the 2C and DO Sub-Families - Immunoassay methods and their requisite components for the detection and determination of phenethylamines of the 2C and DO sub-families are described. | 02-05-2015 |
20150038367 | METHODS FOR DETECTING GENE DYSREGULATIONS - Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g., translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5′ and 3′ regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5′ portion of a target gene relative to the 3′ region of the target gene. | 02-05-2015 |
20150038368 | Biomolecule Immobilization On A Surface via Hydrophobic Interactions - A method, apparatus, or system for generating a pattern of polynucleotides on a substrate. The method includes providing a substrate having a hydrophobic surface. The method further includes conjugating a polystyrene moiety to a polynucleotide and applying a polystyrene-polynucleotide conjugate to create a plurality of reaction spots on the hydrophobic surface of the substrate. An apparatus includes a substrate with at least one polystyrene-polynucleotide conjugate on a surface of the substrate. A system can analyze a polystyrene-polynucleotide conjugate and the system may perform PCR. | 02-05-2015 |
20150038369 | Method and Kit for Diagnosing Autism Using Gene Expression Profiling - This invention relates to DNA microarray technology, and more specifically to methods and kits for identifying autism and autism spectrum disorders in humans. | 02-05-2015 |
20150038370 | Methods for Antibody Engineering - The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications. | 02-05-2015 |
20150045239 | MULTIPLE- ANALYTE ASSAY DEVICE AND SYSTEM - Provided herein is technology relating to testing biological samples and particularly, but not exclusively, to devices, systems, and kits for performing multiple, simultaneous real-time assays on a sample in a single-use disposable format. For example, the technology relates to an apparatus that finds use, for example, for point-of-care diagnostics, including use at accident sites, emergency rooms, in surgery, in intensive care units, as well as for non-medical applications. | 02-12-2015 |
20150045240 | Methods of Diagnosing or Treating Prostate Cancer Using the ERG Gene, Alone or in Combination with Other over or Under Expressed Genes in Prostate Cancer - The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and/or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene. | 02-12-2015 |
20150045241 | GLOBAL DNA HYPOMETHYLATION AND BIOMARKERS FOR CLINICAL INDICATIONS IN CANCER - The present invention provides methods of determination of a global DNA methylation index (GDMI) in a sample from a subject, using a variety of methods which can detect global, genome-wide, and gene-specific DNA methylation to create methylation portraits that can be used for early detection, diagnosis, and clinical management in the personalized medicine space. Further, the invention provides methods of diagnosis of cancer, including gastric cancer and hepatocellular cancer in a subject, by comparing the GDMI in a sample obtained from a subject to the methylation index of standard controls. These methods allow diagnosis of gastric carcinoma and liver cancer in patients who may be asymptomatic or have inconclusive pathology, and allowing earlier treatment of the subject. | 02-12-2015 |
20150045242 | DETECTION OF LISTERIA SPECIES IN FOOD AND ENVIRONMENTAL SAMPLES, METHODS AND COMPOSITIONS THEREOF - Embodiments of the disclosure relate to isolated nucleic acid sequences, methods of use thereof, and workflows for detection of several | 02-12-2015 |
20150045243 | MIRNAS AS NON-INVASIVE BIOMARKERS FOR DIAGNOSIS - The present invention relates to non-invasive methods, kits and means for diagnosing and/or prognosing of a disease in a body fluid sample from a subject. Further, the present invention relates to set of polynucleotides or sets of primer pairs for detecting sets of miRNAs for diagnosing and/or prognosing of a disease in a body fluid sample from a subject. | 02-12-2015 |
20150045244 | METHOD FOR DETERMINING RHEUMATOID ARTHRITIS ACTIVITY INDICATOR, AND BIOMARKER USED THEREIN - The object of the invention is to find a simple biomarker with high reproducibility with regard to a method for evaluating the activity of the condition and progression of rheumatoid arthritis disease and provide an effective evaluation method therefor. The invention is to provide a method for determining the value of a rheumatoid arthritis-linked indicator in a subject, the method being characterized by comprising a step for measuring the amount of expression of the FAM20A gene in blood collected from the subject, a step for analyzing the measured amount of expression using a gene expression profile that is prepared in advance and correlates with the indicator and a step for estimating the value of the indicator in the subject on the basis of the analysis results. | 02-12-2015 |
20150045245 | BIOMARKERS AND TEST PANELS USEFUL IN SYSTEMIC INFLAMMATORY CONDITIONS - The application discloses new biomarkers or test panels useful in systemic inflammatory conditions such as sepsis; methods for the diagnosis, prediction, prognosis and/or monitoring systemic inflammatory conditions such as sepsis based on measuring said biomarkers or test panels; and related kits and devices. | 02-12-2015 |
20150045246 | METHOD FOR THE QUANTIFICATION, QUALITATIVE GENETIC CHARACTERIZATION AND GENE EXPRESSION CHARACTERIZATION OF PREDETERMINED CELLS - In the present invention, a method for the qualitative genetic characterization and/or gene expression characterization of predetermined cells in a fluid sample containing such cells is provided. The inventive method for the qualitative genetic and/or gene expression characterization of predetermined cells in a fluid sample containing such cells, comprises: a) selectively extracting at least a part of the predetermined cells from the sample forming a cell suspension cs | 02-12-2015 |
20150045247 | USE OF miR-199a-5p, TARGETS AND/OR INHIBITORS THEREOF FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF FIBROPROLIFERATIVE DISORDERS - The present invention relates to the use of the miRNA expression profile, particularly of miR-199a-5p, and the target genes regulated thereby for the diagnosis, prognosis and use of miR-199a-5p inhibitors for treating fibroproliferative disorders. | 02-12-2015 |
20150045248 | METHOD FOR IDENTIFYING DISEASE ASSOCIATED WITH ABUNDANCE OF TDP-43 IN CELL - The present invention aims to develop and provide a method for identifying a disease associated with the abundance of TDP-43 in cells and a method for producing a TDP-43 binding inhibitor. By measuring the abundance of a measurement substance, the amount of binding between a measurement substance and TDP-43, etc. in cells obtained from a subject, it is identified whether or not the subject is suffering from a disease associated with the abundance of TDP-43 in cells. Also, a drug which can significantly reduce the binding between a measurement substance and TDP-43 is produced by adding a drug candidate substance. | 02-12-2015 |
20150045249 | NUCLEIC ACID DETECTION METHOD - A method detects nucleic acid with high sensitivity even when the target nucleic acid is detected by sandwich hybridization using neither nucleic acid amplification nor a sensitization technique. The method includes sequentially or simultaneously bringing a target nucleic acid or fragmentation product thereof, a plurality of detection probes, and a capture probe immobilized on a support, into contact with each other to hybridize the capture probe with the target nucleic acid or fragmentation product thereof and to hybridize the target nucleic acid or fragmentation product thereof with the plurality of detection probes, thereby binding the plurality of detection probes to the support through the capture probe and the target nucleic acid or fragmentation product thereof; and then detecting the plurality of detection probes bound to the support. | 02-12-2015 |
20150045250 | METHOD FOR STIRRING SOLUTION - A method of stirring a test substance-containing solution injected into an analysis chip, wherein said analysis chip includes a recess to which said test substance-containing solution is injected; and a selective binding substance, which selectively binds to said test substance, is immobilized on the entirety or a part of the bottom surface of said recess, said method including injecting said test substance-containing solution to the space in said recess of said analysis chip such that said space is partially left unfilled; and rotating said analysis chip to which said test substance-containing solution is injected applying a centrifugal acceleration of not less than 1×g. | 02-12-2015 |
20150045251 | DUPLEX CHROMOGENIC ASSAY FOR IN SITU DETECTION OF NUCLEIC ACIDS - The disclosure provides methods of detecting two or more target nucleic acids. The methods can include the steps of contacting a sample with two or more label probes having distinct enzyme labels and targeting distinct nucleic acid targets, binding the two or more label probes to the target nucleic acids by hybridization; contacting the sample with a first substrate for the first enzyme of the first label probe; reacting the first substrate with the first enzyme, thereby producing a first detectable signal; contacting the sample with a second substrate for the second enzyme of the second label probe; reacting the second substrate with the second enzyme, thereby producing a second detectable signal; and detecting the first detectable signal and the second detectable signal, thereby detecting the first and second target nucleic acids in the sample. | 02-12-2015 |
20150045252 | Systems and Methods for Assessing of Biological Samples - A system for determining the number of target nucleotide molecules in a sample includes a sample holder, an excitation optical system, an optical sensor, and an emission optical system. The sample holder is configured to receive an article comprising at least 20,000 separate reaction sites. The excitation optical system comprises a light source configured to simultaneously illuminate the at least 20,000 separate reaction sites. The optical sensor comprises a predetermined number of pixels, the predetermined number of pixels being at least 20 times the number of separate reaction sites. The emission optical system comprises a system working distance from the sample holder, wherein the working distance is less than or equal to 60 millimeters. | 02-12-2015 |
20150045253 | METHOD FOR DETERMINING THE ABILITY OF AN ANTIBODY TO KEEP CELLS CLOSE TO ONE ANOTHER - The invention relates to a method for determining the ability of a candidate antibody to keep a first cell and a second cell close to one another, said method comprising the following steps:
| 02-12-2015 |
20150045254 | SYSTEMS, METHODS AND DEVICES FOR ELECTROCHEMICAL DETECTION USING HELPER OLIGONUCLEOTIDES - Disclosed herein are systems, devices, and methods for the electrochemical detection of a target using a helper oligonucleotide (each a helper oligo, or collectively, helper oligos). | 02-12-2015 |
20150045255 | Endometrial Phase or Endometrial Cancer Biomarkers - Methods for detecting endometrial diseases or an endometrium phase in a subject are described comprising measuring endometrial markers or polynucleotides encoding the markers in a sample from the subject. The invention also provides localization or imaging methods for endometrial diseases, and kits for carrying out the methods of the invention. The invention also contemplates therapeutic applications for endometrial diseases employing endometrial markers, polynucleotides encoding the markers, and/or binding agents for the markers. | 02-12-2015 |
20150051091 | METHODS OF SELECTING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) BINDING AGENTS - The present application relates to methods of selecting EGFr binding agents. In certain embodiments, such EGFr binding agents bind to at least a portion of a panitumumab epitope on an EGFr. In certain embodiments, such EGFr binding agents do not bind to a panitumumab epitope on an EGFr. | 02-19-2015 |
20150051092 | COMPOSITIONS AND METHODS FOR DETECTION OF HEPATITIS A VIRUS NUCLEIC ACID - Nucleic acid oligomeric sequences and in vitro nucleic acid amplification and detection methods for detecting the presence of HAV RNA sequences in samples are disclosed. Kits comprising nucleic acid oligomers for amplifying and detecting HAV nucleic acid sequences are disclosed. | 02-19-2015 |
20150051093 | Reagents And Methods for Detecting Protein Lysine 3-Hydroxybutyrylation - The invention provides an isolated peptide comprising a lysine 3-hydroxybutyrylation site, a lysine 3-hydroxybutyrylation specific affinity reagent that specifically binds to the peptide, and a method for detecting protein lysine 3-hydroxybutyrylation in a sample using the reagent. | 02-19-2015 |
20150051094 | Biomarkers of immune dysfunction in response to chronic stress, methods of use and diagnostic kits - Diagnostic biomarkers for diagnosing immune suppression/dysfunction. The diagnostic biomarkers are genes and/or transcripts that are up or down regulated compared to normal expression when a subject has been stressed either mentally and/or physically. The invention also relates to a method of detecting comprised or suppressed immune response in a subject by comparing certain diagnostic biomarkers in the subject to a control set of diagnostic biomarkers. | 02-19-2015 |
20150051095 | METHOD OF USING DNA STRUCTURE - A method of using a DNA structure includes forming a DNA structure including a plurality of spaces; attaching a DNA building block to the spaces; contacting the DNA building block with a clinical specimen; and separating the DNA building block from the DNA structure. After the DNA building block is separated from the DNA structure, the method may further include attaching a new DNA building block to the spaces. The DNA building block includes a first DNA strand attached to the spaces; and a second DNA strand attached to the first DNA strand. | 02-19-2015 |
20150051096 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS - Provided in certain embodiments are new methods for forming azido modified biomolecule conjugates of reporter molecules, carrier molecules or solid support. In other embodiments are provided methods for enzymatically labeling a biomolecules with an azide group. | 02-19-2015 |
20150051097 | Methods for Screening Inhibitors of Tau Phosphorylation By Casein Kinase I - Methods of screening for candidate compounds capable of inhibiting activity of fyn in phosphorylating tau protein at Y394 or binding to fyn to inhibit interaction with tau protein at Y394, including determining whether, and optionally the extent, the candidate compounds have these capabilities under conditions where fyn has these capabilities in the absence of the candidate compound. Methods of screening for substances capable of promoting dephosphorylation of tau protein by a phosphatase at a site of tau protein including contacting a candidate substance, the tau protein and a phosphatase capable of dephosphorylating the tau protein under conditions where the phosphatase is capable of dephosphorylating the site in absence of the candidate substance, where the kinase is fyn; determining whether, and optionally the extent, the candidate substance promotes dephosphorylation of the tau protein at the site; and selecting the candidate substance which promotes dephosphorylation of the tau protein the sites. | 02-19-2015 |
20150051098 | METHOD OF SCREENING A PLURALITY OF SINGLE SECRETING CELLS FOR FUNCTIONAL ACTIVITY - This invention generally relates to methods, devices and kits for screening a plurality of single secreting cells for functional activity of the secreted molecules by measuring the amount of reporter gene mRNA produced in one or more reporter cells in response to the secreted molecules. | 02-19-2015 |
20150051099 | METHODS OF CONSTRUCTING SMALL RNA LIBRARIES AND THEIR USE FOR EXPRESSION PROFILING OF TARGET RNAS - Methods, compositions, and kits comprising target-specific oligonucleotides (TSOs) are disclosed herein. Methods, compositions, and kits comprising target-specific oligonucleotides (TSOs) can be used to attach adapters and/or linkers to target RNAs. Methods, compositions, and kits comprising target-specific oligonucleotides (TSOs) can be used in reactions, including, but not limited to, ligation reactions, amplification reactions, and sequencing reactions. Additionally, methods, compositions, and kits comprising target-specific oligonucleotides (TSOs) can be used for reducing and/or preventing the formation of secondary structures in target RNAs. These methods, compositions, and kits can also find use in a number of applications, for example, any application that benefits from stabilizing primary RNA structure, such as detecting and quantifying target RNAs in a sample, in the construction of small RNA libraries, in microarray and RT-qPCR applications, etc. | 02-19-2015 |
20150051100 | DNA HYPERMETHYLATION OF PROMOTERS OF TARGET GENES AND CLINICAL DIAGNOSIS AND TREATMENT OF HPV RELATED DISEASE - The present invention provides arrays for gene loci that allow diagnosis of cervical cancer in patients who may be asymptomatic or have inconclusive Pap smears or cytology, and allowing earlier diagnosis and treatment of the subject. The present invention also provides methods of determination of a global promoter DNA methylation in a cervical tissue sample from a subject, using a variety of methods which can detect DNA methylation. Further, the invention provides methods of diagnosis of cervical cancer in a subject, by comparing the global promoter DNA methylation in a cervical tissue sample obtained from a subject to the global promoter DNA methylation of standard controls. In addition, the present invention also provides a method of diagnosis of cervical cancer in a subject suspected of having cervical cancer after obtaining a biological sample of cervical tissue comprising DNA from the subject and detecting the amount of promoter methylation on at least one or more DNA target sites selected from the group consisting of ZN-F516, INTS1, and FKBP6; and comparing the amount of promoter methylation on at least one or more DNA target sites in the sample of the subject. These methods allow diagnosis of cervical cancer in patients who may be asymptomatic or have inconclusive Pap smears or cytology, and allowing earlier diagnosis and treatment of the subject | 02-19-2015 |
20150051101 | DETECTION METHOD FOR BIOLOGICAL SUBSTANCE - It is an object of the present invention to provide a detection method in which background noise is not increased even if a high-luminance fluorescent labeling material is used and which has an improved S/N ratio and high quantitativity and is advantageous for an immunohistological staining method. The present invention provides a detection method which is a method for detecting a specific biological substance using, as a color former, fluorescent substance-encapsulated nanoparticles to whose particle surfaces biological substance-recognizing molecules that specifically recognize a specific biological substance have been bonded, and which has an improved S/N ratio and high quantitativity and is advantageous for an immunohistological staining method because nanoparticles encapsulating no fluorescent substance are used as a blocking agent for preventing the fluorescent substance-encapsulated nanoparticles from being non-specifically adsorbed on a biological substance other than the specific biological substance. | 02-19-2015 |
20150051102 | MULTIFUNCTIONAL NANOPARTICLES FOR MOLECULAR AND CELLULAR SEPARATION, DETECTION AND QUANTIFICATION - The present disclosure provides compositions and methods useful for molecular and cellular separation, detection and quantification. The compositions provided herein comprise a nanostructure having magnetic property operably linked to an analyte-binding member. | 02-19-2015 |
20150051103 | Methods of Detecting Cervical Cancer - Methods of detecting cervical dysplasia, such as cervical dysplasia likely to progress to carcinoma in a sample of human cervical cells, are provided. Methods of detecting changes in expression of one or more microRNAs or mRNAs associated with cervical dysplasia or cervical cancer are also provided. Compositions and kits are also provided. | 02-19-2015 |
20150051104 | PHARMACEUTICAL COMPOSITION AND METHOD FOR IDENTIFYING A CANCEROUS AND/OR AN INFLAMMATORY DISEASE IN A PATIENT - The invention relates to a method for identifying prostate cancer in a patient that includes at least the step of examining if at least a protein cluster (CMP) or a group of CMPs containing at least CD26 and CD29 can be identified on the cell surfaces of cells from a part of the body of the patient, wherein the part of the body is prostate tissue and is suspected to be affected by prostate cancer. | 02-19-2015 |
20150051105 | NUCLEIC ACID DETECTION METHOD, DETECTION PROBE, DETECTION PROBE SET, AND NUCLEIC ACID QUANTIFICATION METHOD - A method for detecting a target nucleic acid, comprising: (a) contacting a nucleic acid sample comprising a target nucleic acid, comprising a first portion and a second portion, with: (i) a detection probe, wherein the detection probe is labeled with a labeling substance and comprises a nucleic acid sequence that forms a stem-loop structure and having a 5′ protruding end or a 3′ protruding end that is capable of hybridizing to the second portion, and (ii) a capture probe comprising a nucleic acid sequence capable of hybridizing to the first portion, wherein the capture probe is immobilized to a substrate, under conditions to form a target nucleic acid-detection probe-capture probe complex by hybridizing the second portion to the detection probe and hybridizing the first portion to the capture probe; (b) ligating a first end of the detection probe with an end of the target nucleic acid and ligating a second end of the detection probe with an end of the capture probe; and (c) detecting the labeling substance of the nucleic acid-detection probe-capture probe complex formed on the substrate. | 02-19-2015 |
20150051106 | Human Serum Biomarkers of Prostate Cancer and SARS-CoV - Anti-carbohydrate antibodies are detected by (a) contacting an array of oligomannose-serum albumin conjugates immobilized on a substrate with an antibody-containing serum sample under conditions wherein TM10 antibodies bind the oligomannose of the conjugates at at least micromolar affinity; and (b) detecting resultant binding of specific antibodies of the sample to the oligomannose of the conjugates, as indicative of the anti-carbohydrate antibodies. | 02-19-2015 |
20150051107 | ANTIBODY-BASED ARRAYS FOR DETECTING MULTIPLE SIGNAL TRANSDUCERS IN RARE CIRCULATING CELLS - The present invention provides antibody-based arrays for detecting the activation state and/or total amount of a plurality of signal transduction molecules in rare circulating cells and methods of use thereof for facilitating cancer prognosis and diagnosis and the design of personalized, targeted therapies. | 02-19-2015 |
20150051108 | KIT FOR MONITORING IMMUNE STATUS AFTER TRANSPLANT AND METHOD FOR MONITORING IMMUNE STATUS USING SAME - The present invention relates to a method and a kit for monitoring an immune status after transplant. The kit for monitoring an immune status after transplant and the method for monitoring an immune status of an individual after transplant as provided in the present invention make it easy and accurate to determine an immune status in the individual after transplant and thus have an effect of reducing overuse of an immunosuppressive agent prescribed after transplant and also have an effect of conveniently managing an immune status of each patient. | 02-19-2015 |
20150057167 | SYSTEM, METHOD, AND PRODUCT FOR IMAGING PROBE ARRAYS WITH SMALL FEATURE SIZES - An embodiment of a method for resolving features on a probe array is described that, comprises acquiring a plurality of micro-shifted images of a region of a probe array; reconstructing an image of the probe array using the micro-shifted images; and deriving intensity values for one or more probe features disposed on the probe array from the reconstructed image. | 02-26-2015 |
20150057168 | Primers for Detecting Serotypes of Shigella Flexneri and Multiplex Amplifications Using the Same - The present inventions relates to primers for identifying | 02-26-2015 |
20150057169 | Biomarkers for Head-and-Neck Cancers and Precancers - The invention provides markers and methods for detecting head-and-neck precancers, (including OPLs), cancers and related disease conditions in a subject. The invention also provides localization and imaging methods for head-and-neck precancers (including OPLs) and cancers, along with kits for carrying out methods of the invention. The invention further provides therapeutic applications for head-and-neck precancers (including OPLs) and cancers which employ head-and-neck precancer and cancer markers, polynucleotides encoding the markers, and binding agents for the markers. | 02-26-2015 |
20150057170 | METHOD FOR DIAGNOSING PRIMARY BILIARY CIRRHOSIS (PBC) USING NOVEL AUTOANTIGENS - Methods and compositions are described for the diagnosis of primary biliary cirrhosis. Novel autoantigens are described for use in assays which employ test samples from individuals. | 02-26-2015 |
20150057171 | OLIGONUCLEOTIDES AND METHODS FOR DETERMINING A PREDISPOSITION TO SOFT TISSUE INJURIES - A method of determining in a subject a predisposition to, or increased risk for, developing a tendon, ligament, or other soft tissue injury or pathology, the method comprising the step of screening the subject for the presence of at least one polymorphism in at least one gene selected from the group comprising: a) the collagen V gene COL5A1; wherein the COL5A1 gene is rs71746744, rs16399 and/or rs1134170 within the 3′-untranslated region (UTR) of the alpha 1 chain of the COL5A1 gene; b) the MIR608 gene which encodes a miRNA which binds to a recognition sequence within the 3′-UTR of the collagen V gene COL5A1; and c) the CASP8 gene; wherein the presence of the polymorphism is indicative of a predisposition to, or increased risk for, developing a musculoskeletal soft tissue injury in the subject. | 02-26-2015 |
20150057172 | REAL-TIME PCR DETECTION OF MYCOBACTERIUM TUBERCULOSIS COMPLEX - The present invention relates to assays, diagnostic kits and methods for the simultaneous real-time PCR detection of bacteria belonging to the MTR and/or | 02-26-2015 |
20150057173 | METHODS FOR DETERMINING THE TROPISM AND RECEPTOR USAGE OF A VIRUS, IN PARTICULAR HIV, IN BODY SAMPLES TAKEN FROM THE CIRCULATION - The present invention relates to microarrays, sets of primers and methods for determining the co-receptor usage of a virus, in particular whether HIV uses CXCR4 or CCR5 as co-receptor. The methods and compositions of the invention are based on microRNA analysis. The invention can be used to determine virus tropism in any species or organism that expresses microRNAs, particularly in human beings. | 02-26-2015 |
20150057174 | DIFFERENTIAL DIAGNOSTIC METHOD AND KIT FOR INFECTIOUS AND PARASITIC DISEASES, USING FLOW CYTOMETRY - The present invention relates to a differential diagnostic method using flow cytometry, performed by means of differential fluorescent marking of biological agents, such as cells and pathogens of interest, with fluorescent substances. The diagnostic method generally consists in performing fluorescent marking of biological agents with gradual concentrations of fluorescent substances, and in analysing the reactivity profile of IgG1 to the biological agents. The present invention further relates to a diagnostic kit. | 02-26-2015 |
20150057175 | METHOD FOR MONITORING HIV SPECIFIC T CELL RESPONSES - The invention relates to a method and a diagnostic kit for monitoring HIV specific T cell responses and identifying subjects capable of controlling HIV progression or preventing HIV infection altogether. The method is based on the combined use of boosted flow cytometry and toggle peptides and can cover a vastly larger set of effector functions than standard assays. The method is also suitable to detect T cell responses of any desirable cytokine or combination of cytokines to any pathogen | 02-26-2015 |
20150057176 | CELLULAR MARKERS FOR DIAGNOSIS OF ALZHEIMER'S DISEASE AND FOR ALZHEIMER'S DISEASE PROGRESSION - The present invention provides methods for early diagnosis of Alzheimer's disease and for determining the efficacy of a treatment for Alzheimer's disease in an Alzheimer's patient, i.e., monitoring Alzheimer's disease progression, utilizing cellular blood markers; as well as kits for carrying out these methods. | 02-26-2015 |
20150057177 | METHODS FOR DETERMINING A BREAST CANCER-ASSOCIATED DISEASE STATE AND ARRAYS FOR USE IN THE METHODS - The present invention provides a method for determining a breast cancer-associated disease state comprising the steps of: a) providing a sample to be tested; and b) determining a biomarker signature of the test sample by measuring the presence and/or amount in the test sample of one or more biomarker selected from the group defined in Table 1; wherein the presence and/or amount in the test sample of the one or more biomarker selected from the group defined in Table 1 is indicative of the breast cancer-associated disease state. The invention further provides arrays and kits fir use in the same. | 02-26-2015 |
20150057178 | SIGNAL ENCODING AND DECODING IN MULTIPLEXED BIOCHEMICAL ASSAYS - This disclosure provides methods, systems, compositions, and kits for the multiplexed detection of a plurality of analytes in a sample. In some examples, this disclosure provides methods, systems, compositions, and kits wherein multiple analytes may be detected in a single sample volume by acquiring a cumulative measurement or measurements of at least one quantifiable component of a signal. In some cases, additional components of a signal, or additional signals (or components thereof) are also quantified. Each signal or component of a signal may be used to construct a coding scheme which can then be used to determine the presence or absence of any analyte. | 02-26-2015 |
20150057179 | Methods and Compositions for hte Diagnosis and Treatment of Thyroid Cancer - Methods for detecting thyroid cancer or thyroid cancer status in a subject are described comprising measuring novel markers or polynucleotides encoding the markers in a sample from the subject. The invention also provides localization or imaging methods for thyroid cancer, and kits for carrying out the methods of the invention. The invention also contemplates therapeutic applications for thyroid cancer employing the novel markers, polynucleotides encoding the markers, and/or binding agents for the markers. | 02-26-2015 |
20150057180 | Methods and Kits for Analyzing Biomarkers in a Signal Transduction Pathway - Provided are methods and kits for analyzing biomarkers in one or more signal transduction pathways in a cell. In some embodiments, the methods and kits of the invention permit simultaneous analysis of more than one biomarker and/or more than one signal transduction pathway. In some embodiments, the invention provides methods for detecting whether a cell treated with an agent targeting a targeted biomarker is responding to the agent, or whether the cell is developing resistance to the agent. In some embodiments, the invention provides methods for determining which biomarker to target in a diseased or damaged cell, or which pathway an agent is targeting in an agent-treated cell. The invention provides kits for carrying out the described methods. | 02-26-2015 |
20150057181 | MICRORNA SIGNATURES INDICATIVE OF IMMUNOMODULATING THERAPY FOR MULTIPLE SCLEROSIS - The present invention provides methods, systems, and kits for evaluating multiple sclerosis (MS) in a patient. Particularly, the invention provides convenient miRNA-based tests for evaluating a patient for MS, including for diagnosing MS, for excluding MS as a diagnosis, and for monitoring the course of disease or efficacy of treatment, including evaluation of immunomodulating therapy. | 02-26-2015 |
20150057182 | METHODS FOR ANALYSIS OF DNA FRAGMENTS - A method of genotyping includes applying a sample solution including a plurality of copies of a sample polynucleotide to an array of sensors. The sample polynucleotide includes a region associated with an allele. The method further includes measuring using a plurality of sensors of the array of sensors a characteristic of the region of the plurality of copies of the sample polynucleotide and determining using a computational circuitry and the measured characteristics a statistical value indicative of the allele. | 02-26-2015 |
20150057183 | METHOD FOR THE DETERMINATION OF THE DNA METHYLATION LEVEL OF A CPG POSITION IN IDENTICAL CELLS WITHIN A TISSUE SAMPLE - Aspects of the present invention relate to the determination of the DNA methylation level at one or more CpG position within cells of a defined type in a tissue sample. This methylation level is deduced from the total DNA methylation level of all cells of the sample and from the content of said cells of interest. In aspects of the invention, the cell content is determined by means of histopatholoy, staining methods, antibodies, expression analysis or DNA methylation analysis. | 02-26-2015 |
20150065363 | BIOMIMETIC CHEMICAL SENSORS USING NANOELECTRONIC READOUT OF OLFACTORY RECEPTORS - The present invention provides biomimetic sensor devices that utilize proteins—such as G-protein coupled receptors—and are useful in high-sensitivity analysis of analyte-containing samples. These sensors may be used to determine the presence or concentration of one or more analytes in a sample. The invention also includes methods of fabricating the devices and methods of using the devices to assay samples. | 03-05-2015 |
20150065364 | SELF-SENSING ARRAY OF MICROCANTILEVERS FOR CHEMICAL DETECTION - The invention provides a chemical detection system for detecting at least one target chemical species, including a self-sensed cantilevered probe array having a plurality of self-sensed cantilevered probes, at least one chemical-sensitive coating material applied to at least one cantilevered probe in the cantilevered probe array, and an interface circuit that is coupled to the cantilevered probe array. At least one cantilevered probe in the cantilevered probe array exhibits a shifted cantilevered probe response when the cantilevered probe array is exposed to the target chemical species and the interface circuit actuates the cantilevered probe. A handheld chemical detection system and a method of operation are also disclosed. | 03-05-2015 |
20150065365 | THERMOELECTRIC SENSOR FOR ANALYTES IN A GAS AND RELATED METHOD - An apparatus is provided for sensing an analyte in a fluid. The apparatus includes a fluid collecting device configured to collect the fluid containing the analyte; a fluid input in fluid communication with the fluid collecting device configured to input the fluid containing the analyte into the fluid collecting device, an analyte interactant in fluid communication with the fluid collecting device, wherein the analyte interactant, when contacted by the analyte, reacts to cause a first change in thermal energy within the fluid collecting device; a modulator that causes a second change in thermal energy; a thermal sensing device comprising at least one pyroelectric device thermally coupled to the fluid collecting device to generate a first signal in response to at least one of the first change in thermal energy and the second change in thermal energy; a control device operatively coupled to the thermal sensing device and the modulator that generates a second signal, wherein the second signal comprises information useful in characterizing the analyte. A related method also is disclosed. | 03-05-2015 |
20150065366 | Biomarkers for Bladder Cancer and Methods Using the Same - Methods for identifying and evaluating biochemical entities useful as biomarkers for bladder cancer, target identification/validation, and monitoring of drug efficacy are provided. Also provided are suites of small molecule entities as biomarkers for bladder cancer. | 03-05-2015 |
20150065367 | POLYOMAVIRUS PEPTIDE SEQUENCES - The current invention concerns the identification of B-cell epitopes (as linear peptides) from human polyoma virus proteins and their use in an immune diagnostic assay. | 03-05-2015 |
20150065368 | METHOD FOR THE IN VITRO DIAGNOSIS OR PROGNOSIS OF OVARIAN CANCER - The present invention relates to a method for the in vitro diagnosis or prognosis of ovarian cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, once isolated, as one or more molecular marker(s) and a kit including at least one specific binding partner of at least one of the expression products of the HERV nucleic acid sequences. | 03-05-2015 |
20150065369 | METHOD FOR THE DIAGNOSIS OR PROGNOSIS, IN VITRO, OF TESTICULAR CANCER - The subject matter of the present invention is a method for the diagnosis or prognosis, in vitro, of testicular cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, which have been isolated, as a molecular marker or molecular markers, and a kit including at least one binding partner specific for at least one of the expression products of the HERV nucleic acid sequences. | 03-05-2015 |
20150065370 | METHOD FOR MEASURING RADIOACTIVITY - The present invention provides a method for determining radioactivity in an ion-sensitive field effect transistor array, the method comprising the steps of incubating the array with electron-sensitive silver-halide material and then incubating the array with a developer solution reducing the silver halides that have been exposed to radioactivity to elemental silver and simultaneously measuring pH at each separate reaction chambers, wherein decrease of the pH indicates the presence of radioactivity in a reaction chamber. | 03-05-2015 |
20150065371 | IMMUNOFLUORESCENCE AND FLUORESCENT-BASED NUCLEIC ACID ANALYSIS ON A SIMGLE SAMPLE - A method for providing a composite image of a single biological sample, comprising the steps of generating a first image of the biological sample, generating a second image of the biological sample, and generating a composite image that provides the relative location of both the target protein and the target nucleic acid. Also provided is a method of analyzing a biological sample, comprising providing a composite image of the biological sample according to the method for providing a composite image, and analyzing the expression of the protein and the nucleic acid sequences of interest from the composite image. Further provided are system and kit that comprise the means for executing the novel methods. | 03-05-2015 |
20150065372 | DEVICE AND METHOD FOR DETECTION OF ANALYTES - A detection device and associated systems and methods for detecting analytes from a multiplex reaction are described. In particular, a device for conducting at least one detection reaction using a modified ELISA method including a surface with a detection region and a reference region, a detection sensor, and a light source. The detection device may include a complementary metal-oxide-semiconductor (CMOS) image sensor. The device may be used to measure and report discrete quantities or combinations of discrete analytes, providing information to aid in the prognosis and/or diagnosis of altered states of health in vertebrates. | 03-05-2015 |
20150065374 | Detection of Platelet-Derived Shed CD31 - The present invention relates to various soluble forms of CD31, including a novel form which is shed by activated platelets and released into the circulation. Methods for detecting said soluble forms of CD31 are disclosed, as are methods of specifically 1 detecting said platelet-derived shed CD31 and the use of such methods as a diagnostic tool. | 03-05-2015 |
20150065375 | ACQUIRED IMMUNITY BIOMARKERS AND USES THEREOF - The present invention relates to a biomarker of immunity response for use in monitoring the acquired immunity of an immunized subject, to an in vitro method and a kit for monitoring the acquired immunity of an immunized subject. | 03-05-2015 |
20150065376 | EXPRESSION CONSTRUCTS ENCODING G PROTEIN COUPLED RECEPTORS AND METHODS OF USE THEREOF - Expression vectors comprising a first nucleic acid sequence encoding a G protein coupled receptor (GPCR), wherein the GPCR encoded thereby is expressed as a fusion protein with a first detectable marker/signal, and a second nucleic acid sequence encoding a second polypeptide that is or comprises a second detectable marker/signal, wherein the second polypeptide is expressed as a fusion protein with a membrane localizing sequence are encompassed herein. The first nucleic acid sequence encoding the GPCR and the second nucleic acid sequence encoding the second polypeptide are under the transcriptional control of the same promoter and are operably linked via, for example, an internal ribosomal entry site (IRES). The first and second detectable markers, moreover, emit distinct detectable signals. Cells comprising these expression vectors are also encompassed herein, as are methods of using same to screen for G protein coupled receptor modulators. | 03-05-2015 |
20150065377 | NUCLEIC ACID SEQUENCE MEASURING METHOD, NUCLEIC ACID SEQUENCE MEASURING DEVICE, MANUFACTURING METHOD FOR NUCLEIC ACID SEQUENCE MEASURING DEVICE, AND NUCLEIC ACID SEQUENCE MEASURING APPARATUS - A nucleic acid sequence measuring method includes measuring fluorescence from the nucleic acid sequence measuring device supplied with a sample solution. The device includes a fluorescent probe added with a fluorescent molecule, and a quenching probe added with a quenching substance. The fluorescent probe and/or the quenching probe has a detection part detecting a particular nucleic acid sequence. Fluorescence from the fluorescent molecule is quenched by the quenching substance coupled with the fluorescent molecule when the hybridization between the detection target nucleic acid and the detection part has not occurred, and fluorescence is emitted from the fluorescent molecule separated from the quenching substance when the hybridization has occurred. | 03-05-2015 |
20150065378 | SYNTHETIC OLIGONUCLEOTIDES FOR DETECTION OF NUCLEIC ACID BINDING PROTEINS - Synthetic oligonucleotides that comprise a nucleic acid binding protein binding site, PCR primer sequences, and tag sequences that do not bind to nucleic acid binding proteins, with a total length of 85-130 nucleotides are disclosed herein. Also disclosed are libraries and kits comprising the synthetic oligonucleotides as well as methods of detecting nucleic acid binding proteins in a sample using the synthetic oligonucleotides. | 03-05-2015 |
20150065379 | Retrieval of Biological Materials from the Human Uterus, Ovary and Cervix by Suction - The invention provides devices and methods for self-administered noninvasive retrieval of biological materials of the uterus and/or cervix. The cervical device comprises a receptacle with a variable volume receptacle cavity, a controller configured to change the volume of the receptacle cavity, a surface for collection of biological materials, and a flexible pouch for generation of suction to facilitate efficient retrieval of biological materials. The biological materials retrieved include various biomarkers of diseases and disorders of reproduction, are directly isolated from a site of pathology, and are not metabolized or diluted. Information generated by analyzing these biological materials permits early diagnosis and prognosis assessments of disease and disorders of the female reproductive organs, irregularities of pregnancy, anomalies of the fetus in utero, and microbial infections. | 03-05-2015 |
20150065380 | Brain somatic mutations associated to epilepsy and uses thereof - The present invention relates to epilepsy-inducing brain somatic mutations which are associated with intractable epilepsy caused by malformations of cortical development, and uses thereof. More particularly, the present invention relates to an mTOR (Mammalian target of rapamycin) gene having mutations in a nucleotide sequence or an mTOR protein having mutations in an amino acid sequence resulting from the mutations in the nucleotide sequence. Further, the present invention relates to a technique for diagnosing intractable epilepsy caused by malformations of cortical development using the gene or the protein. | 03-05-2015 |
20150065381 | METHODS OF IDENTIFYING NOVEL HIV-1 IMMUNOGENS - The present application relates to identifying one or more components of HIV envelope glycoprotein which bind to broadly neutralizing antibodies, which may be utilized as research tools for developing HIV-1 vaccine immunogens, antigens for crystallization and/or for identifying of broad neutralizing antibodies. | 03-05-2015 |
20150065382 | Method for Producing and Identifying Soluble Protein Domains - Methods for producing and identifying fragments of proteins, and more particularly to methods for generating and identifying soluble protein domains are disclosed based on a method for generating a library of nucleic acid fragments from nucleic acid encoding a desired polypeptide, and more especially a library of essentially, randomly sampled fragments of coding DNA sequence predominantly of defined size range and a method for selecting cloned gene fragments from the library that encode soluble protein domains. | 03-05-2015 |
20150065383 | METHOD FOR DETECTING CERVICAL DYSPLASIA - This invention provides methods and kits for improved diagnosis of medically relevant conditions by solution based biochemical testing procedures performed in solutions of test samples. The invention provides a method to substitute the cell based morphological information contained within the cytological and/or histological data of the test sample by molecular information obtainable from the solution, wherein the original test sample is dissolved and thus enables for accurate and reproducible assessment of medically relevant diagnosis from dissolved test samples. The method according to the invention comprises the steps of determining the levels of one or more disease markers associated with the condition to be diagnosed, determining the level of one or more normalization markers suitable to substitute the information related to morphological aspects of the sample, comparing and/or combining the data of the disease and normalization markers, and assessing diagnosis of a medically relevant condition. | 03-05-2015 |
20150065384 | SEQUENCES ASSOCIATED WITH TDP-43 PROTEINOPATHIES AND METHODS OF USING THE SAME - The present invention provides nucleic acids and peptides, and methods of using the nucleic acids and peptides to identify subjects at risk for a TDP-43 proteinopathy. The invention also provides for an array comprising the nucleic acids and peptides of the invention. | 03-05-2015 |
20150065385 | REAGENTS AND METHODS FOR DETECTING PROTEIN CROTONYLATION - The invention provides an isolated peptide comprising a crotonylation site, a Kcr-specific affinity reagent that specifically binds to the peptide, and a method for detecting protein crotonylation in a sample using the reagent. | 03-05-2015 |
20150065386 | METHODS FOR ASSESSING ADJUSTED CANCER STAGE OR PROGNOSIS OF SUBJECT WITH HEPATOCELLULAR CARCINOMA - Disclosed herein is a method for assessing an adjusted cancer stage of a subject suffered from hepatocellular carcinoma. The subject has been assigned with a preliminary cancer stage based on the result of a clinical staging and/or pathological staging assessment, and the assessment is made based on both the preliminary cancer stage and the expression level of a cancer stem cell marker gene, Lin-28 homolog B (LIN28B) gene, in the blood of the subject. When the cancer stem cell marker gene is detected in the subject's blood, it is determined that the adjusted cancer stage of the subject is at least one stage advanced than the preliminary cancer stage, whereas when the cancer stem cell marker gene is not detected in the subject's blood, it is determined that the adjusted cancer stage of the subject is the same as the preliminary cancer stage. | 03-05-2015 |
20150065387 | COMPOSITIONS AND METHODS FOR REPRESENTATIONAL SELECTION OF NUCLEIC ACIDS FROM COMPLEX MIXTURES USING HYBRIDIZATION - The invention provides a method of selecting a representational sample of nucleic acid sequences from a complex mixture. The method includes: (a) contacting a complex mixture of nucleic acids under conditions sufficient for hybridization with a population of capture probes complementary to one or more nucleic acids comprising a predetermined portion of the sequence collectively present in the complex mixture to form hybridization complexes of the one or more nucleic acids with the population of probes, the population of capture probes being attached to a solid support, and (b) removing unhybridized nucleic acids to select a representational sample of nucleic acids having a complexity of less than 10% but more than 0.001% of the complex mixture, wherein the representational sample comprises a nucleic acid copy having a proportion of each sequence in the copy relative to all other sequences in the copy substantially the same as the proportions of the sequences in the predetermined portion of one or more nucleic acids within the complex mixture. A method of selecting a representational sample of genomic sequences from a complete genome also is provided. The invention further provides a nucleic acid population that includes a representational sample having a complexity of less than 10% but more than 0.001% of a complex mixture, the representational sample comprising a nucleic acid copy having a proportion of each sequence in the copy relative to all other sequences in the copy substantially the same as the proportions of sequences in a predetermined portion of a sequence collectively present in one or more nucleic acids within the complex mixture. | 03-05-2015 |
20150065388 | ANTI-MESOTHELIN ANTIBODIES AND IMMUNOCONJUGATES - The invention provides anti-mesothelin antibodies and immunoconjugates and methods of using the same. | 03-05-2015 |
20150072877 | COMPOSITION FOR TREATMENT OF PANCREATIC CANCER - Disclosed is a composition for treating pancreatic cancer. The composition comprises a pharmaceutically effective amount of an antisense nucleic acid or siRNA that inhibits expression of at least one gene selected from the group consisting of SON gene, MCM5 gene, WDR5 gene, PBK gene and CENPA gene. The composition inhibits the expression of a specific gene to provide the effect of inhibiting the proliferation, survival and tumorigenicity of pancreatic cancer cells. | 03-12-2015 |
20150072878 | Stratification of Left-Side and Right-Side Colon Cancer - Compositions/methods for employing fresh-frozen or FFPE colon cancer tissue in left side colon cancer (LCC) and right-side colon cancer (RCC) disease patients for risk of relapse assessment/stratification is provided (3 strata and a 4 strata methodology). An RCC gene panel of 4 genes (FAM69A, CDX2, FAM84A, ITGA3), and 9 genes (FAM69A, CDX2, ITGA3, FAM84A, ITPRIP, RAB3B, SMAD3, PCSK5, MMP28), is provided. An LCC gene panel of 4 genes (NOX4, WNT5A, MMP3, IBSP), and a 9 genes (MMP3, WINT5A, NOX4, IBSP, SLC16A6, CYPIBI, TFAP2C, MATN3, ANKRD6), is provided. A microchip-based clinical tool, and a kit including a microchip, is presented. The invention also describes a computer-implemented method for assessing relative risk of relapse in LCC and/or RCC disease. An individual patient scoring method that presents a continuous stratification score useful in the post-surgical colon cancer management of LCC and/or RCC patient is also presented. | 03-12-2015 |
20150072879 | METHODS FOR IMPROVING INFLAMMATORY BOWEL DISEASE DIAGNOSIS - The present invention provides methods and systems to predict and diagnose inflammatory bowel disease (IBD) and subtypes such as ulcerative colitis (UC) and Crohn's disease (CD) by detecting the presence, absence, level, and/or genotype of one or more sero-genetic-inflammation markers. Advantageously, with the present invention, it is possible to provide a diagnosis of IBD versus non-IBD, to rule out IBD that is inconclusive for CD and UC, and to differentiate between CD and UC with increased accuracy. | 03-12-2015 |
20150072880 | RAPID DETECTION OF ANALYTES IN LIQUID SAMPLES - A device for detecting at least one analyte generally comprises (i) a support having a chamber for receiving a biological fluid therein, wherein said chamber is an elongate chamber having a length axis; (ii) a carrier or agitator in said elongate chamber, said carrier or agitator having opposite end portions and a side portion, the carrier or agitator dimensioned to travel in said chamber along said length axis and/or permit said liquid sample to flow in the chamber therearound, either (or both) thereby agitating the liquid sample; and (iii) at least one anti-analyte antibody coupled to either the carrier and/or the chamber side wall. Methods of using the device are also described. | 03-12-2015 |
20150072881 | Methods to Assess Treatment Outcomes in Reward Deficiency Syndrome (RDS) Behaviors Utilizing Expression Profiling - The present invention relates to methods to objectively assess treatment outcomes in Reward Deficiency Syndrome (RDS) behaviors by obtaining expression profiles (e.g., mRNA expression and/or protein expression profiles) for one or more genes at two or more different time points, for example, before and after treating a subject known to have or suspected of having an RDS affliction. Analysis, for example, of mRNA and/or protein expression levels and/or patterns can be conducted before admission to a treatment facility, followed by testing at one or more various designated times during and after a subject's treatment. Such methods may also be combined with other tests, and can be used in diagnosis and treatment of RDS and RDS behaviors, including drug and/or alcohol abuse and addiction, overeating, gambling, sexual addiction, etc. | 03-12-2015 |
20150072882 | METHOD OF DETECTING NUCLEIC ACIDS - A method of detecting a target nucleic acid, and a polynucleotide and a composition for detecting a target nucleic acid. | 03-12-2015 |
20150072883 | Detection and quantification of microRNAs in the circulation and the use of circulating microRNAs as biomarkers in cancer - The present invention relates to the identification of biomarkers suitable for use in the diagnosis and prognosis of a number of cancers. In addition, the invention relates to improved methods for the identification and quantification of such biomarkers in samples taken from patients. | 03-12-2015 |
20150072884 | METHOD AND PROBE SET FOR DETECTING CANCER - Methods for detecting cancer that include hybridizing a set of chromosomal probes to a biological sample obtained from a patient, and identifying if aneusomic cells are present in a selected subset of cells obtained from the biological sample are described. A set of chromosomal probes and kits for detecting cancer that include sets of chromosomal probes, are also described. | 03-12-2015 |
20150072885 | ANTIBODIES AND METHOD FOR DETERMINING DELETIONS IN HBV PRE-S2 REGION - A HBS-specific antibody, a LHBS-specific antibody, a WT LHBS-specific antibody, an immunoassay kit comprising the antibodies, and a method of detecting pre-S | 03-12-2015 |
20150072886 | Methods and Systems for Detecting MHC Class I Binding Peptides - The present invention is based on the discovery that MHC heavy chain monomers immobilized to a solid surface are still capable of forming detectable conformational epitopes and being detected by conformation-dependent antibodies. Methods for detecting peptide binding to HLA monomers, and methods for measuring the relative degree of binding between two MHC-binding peptides as well as a method of measurement for the rate of dissociation of peptides from MHC complexes are provided. The present invention also provides systems and kits useful for conducting the methods of the present invention. | 03-12-2015 |
20150072887 | DETECTION OF TARGET NUCLEIC ACID SEQUENCE BY PTO CLEAVAGE AND EXTENSION-DEPENDENT SIGNALING OLIGONUCLEOTIDE HYBRIDIZATION ASSAY - The present invention relates to the detection of a target nucleic acid sequence by a PCE-SH (PTO Cleavage and Extension-Dependent Signaling Oligonucleotide Hybridization) assay. The present invention does not use probes to be hybridized with target nucleic acid sequences for providing target signals. Interestingly, the present invention uses probes (signaling oligonucleotides) to be hybridized with the extended strand formed in a target-dependent manner in which the extended strand is synthesized using the CTO artificially selected as templates. | 03-12-2015 |
20150072888 | Biomarkers For Diagnosis Of Diabetes And Monitoring Of Anti-Diabetic Therapy - The present invention relates to the use of N-linked glycan profiles of blood or blood component proteins as biomarkers for diagnosing diabetes mellitus and for monitoring the efficacy of anti-diabetic therapy. Specifically, the present invention relates to detecting changes in the amounts of N-linked glycans as diagnostic biomarkers for diabetes mellitus and as indicators of the efficacy of anti-diabetic therapy over time. | 03-12-2015 |
20150072889 | SYSTEMS AND METHODS FOR DETECTING INFECTIOUS DISEASES - Systems, methods, and devices for detecting infections in a clinical sample are provided. Small-volume clinical samples obtained at a point-of-service (POS) location and may be tested at the POS location for multiple markers for multiple diseases, including upper and lower respiratory diseases. Samples may be tested for cytokines, or for inflammation indicators. Dilution of samples, or levels of detection, may be determined by the condition or past history of a subject. Test results may be obtained within a short amount of time after sample placement in a testing device, or within a short amount of time after being obtained from the subject. A prescription for treatment of a detected disorder may be provided, and may be filled, at the POS location. A bill may be automatically generated for the testing, or for the prescription, may be automatically sent to an insurance provider, and payment may be automatically obtained. | 03-12-2015 |
20150072890 | METHODS AND COMPOSITIONS FOR AIDING IN THE DETECTION OF LUNG CANCER - A lung cancer biomarker panel comprising an microRNA (miRNA) lung cancer biomarker and at least one additional lung cancer biomarker selected from a tumor protein (TP) lung cancer biomarker and/or a autoantibody (AAB) lung cancer biomarker is provided herein and methods for screening patients for lung cancer. The present lung cancer biomarker panel provides an improvement in sensitivity and diagnostic accuracy for lung cancer as compared to a lung cancer biomarker panel without the miRNA biomarkers. | 03-12-2015 |
20150072891 | METHOD FOR DETECTION OF L523S EXPRESSION IN BIOLOGICAL SAMPLES - The present invention discloses methods for differentiating between normal or reactive cells and malignant cells in biological samples comprising: exposing the biological sample to an antibody to L523S protein and detecting the presence of the antibody bound to L523S protein within the malignant cells, in embodiments, such methods may further comprise: exposing the biological sample to an antibody to a second protein that is a marker of cell lineage and detecting the presence of the antibody to the second protein within cells corresponding to a particular ceil lineage and/or may comprise: exposing the biological sample to an antibody to a third protein which is a marker of cells that are normal or reactive and detecting the presence of the antibody to the third protein within cells that are normal or reactive. | 03-12-2015 |
20150080239 | Classification and Actionability Indices for Cancer - The disclosure provides compositions, kits, and methods for detecting a plurality of genes and associated variants in a sample from a subject with cancer. The compositions, kits, and methods include a set of oligonucleotides, typically primers and/or probes that can hybridize to identify a gene variant. The methods disclosed herein provide for a mutation status of a tumor to be determined and subsequently associated with a report comprising an actionable treatment recommendation. | 03-19-2015 |
20150080240 | Methods and systems for using built-in standard curve to measure molecular numbers of biological components - Methods and devices are disclosed, which perform absolute quantification assay of functional components of biological specimens. The present application relates to manufacture built-in standard curve(s) and computational analysis. The present application further relates to methods for the measurements of such biological components, for example, biochips, PCR arrays, microarrays, and ELISA array. | 03-19-2015 |
20150080241 | POLYNUCLEOTIDE AND USE THEREOF - A polynucleotide comprising a first region the 5′ end of which is complementary to a portion of a target nucleic acid, a cleavable second region, a third region having a stem-loop structure, and a fourth region complementary to the 3′ end of the first region, and use of the polynucleotide, as well as a composition comprising two such polynucleotides each of which hybridize different strands of a double-stranded target nucleic acid, and methods and kits using the same for amplifying targets. | 03-19-2015 |
20150080242 | NANOPORE SENSORS AND USES THEREOF - Aspects of the invention relate to nanopores useful as sensors for detecting intermolecular interactions. | 03-19-2015 |
20150080243 | METHODS AND COMPOSITIONS FOR DETECTING CANCER BASED ON MIRNA EXPRESSION PROFILES - The disclosure in some aspects provides methods of determining the likelihood that a subject has lung cancer based on the expression of informative miRNAs. In other aspects, the disclosure provides methods for determining a treatment course for a subject based on the expression of informative-miRNAs. The disclosure also provides computer implemented methods for processing genomic information relating to miRNA expression. Related compositions and kits are provided in other aspects of the disclosure. | 03-19-2015 |
20150080244 | BIOMARKERS USEFUL FOR DETECTION OF TYPES, GRADES AND STAGES OF HUMAN BREAST CANCER - The present invention relates to biomarkers useful for detection of types, grades and stages of human breast cancer. The present invention particularly relates to the development of these identified biomarkers as a miRNA chip for the early and accurate diagnosis of human breast cancer. This patent application highlights the novelty in the utility of these miRNAs, that they could be used as a diagnostic kit (miRNA chip) for early and accurate detection of breast cancer grades, stages and subtypes. Few to hundreds of samples can be checked within a span of 2 to 3 hrs and hence this becomes an easy, fast, robust and high throughput technology for screening program for early detection of breast cancer. | 03-19-2015 |
20150080245 | RHEUMATOID ARTHRITIS DIAGNOSIS KIT - The present invention aims to diagnose rheumatoid arthritis more accurately and rapidly, and relates to a method and a kit for diagnosing rheumatoid arthritis, based on the detection of citrullinated autoantigens in a test sample. | 03-19-2015 |
20150080246 | PREDICTION OF OUTCOME IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE - The present invention relates to a method for the prognosis and/or risk assessment and/or monitoring of therapy and/or management of patients with COPD the method comprising the steps of: i) providing a sample of a bodily fluid from said patient, ii) determining in said sample the level of at least one biomarker, selected from the group consisting of pro-adrenomedullin (proADM), pronatriuretic peptide, pro-Vasopressin (proAVP) and Procalcitonin (PCT) or fragments thereof of at least 12 amino acids in length, iii) determining one, two or three of the BODE-index parameters body-mass index (BMI, parameter B), degree of airflow obstruction (FEV | 03-19-2015 |
20150080247 | Systems and Methods for Biological Analysis - A system for performing biological reactions is provided. The system includes a chip including a substrate and a plurality of reaction sites. The plurality of reaction sites are each configured to include a liquid sample of at most one nanoliter. Further, the system includes a control system configured to initiate biological reactions within the liquid samples. The system further includes a detection system configured to detect biological reactions on the chip. According to various embodiments, the chip includes at least 20000 reaction sites. In other embodiments, the chip includes at least 30000 reaction sites. | 03-19-2015 |
20150080248 | METHODS FOR ISOLATING PROTEINS - The invention generally relates to methods for isolating proteins. In certain aspects, methods of the invention involve preparing a plurality of sample preparations, each preparation including one or more intact cells. A capture unit is introduced to a plurality of the preparations. The capture unit includes a member that transiently interacts with one or more proteins in the cells and a reactive functional group. The sample preparations are incubated, and a reaction is initiated at a different time in a plurality of the preparation. In this manner, a protein within the cell that specifically interacts with the member of the capture unit becomes bound to the capture unit via the reactive functional group to form protein/capture unit complexes. The cells are lysed and the protein/capture unit complexes are isolated. | 03-19-2015 |
20150080249 | O-GLYCAN PATHWAY OVARIAN CANCER SIGNATURE - Biomarkers, methods, assays, and kits are provided for determining the prognosis of and treating a patient with ovarian cancer. Also disclosed are biomarkers, methods, assays, and kits for predicting the sensitivity of ovarian cancer cells to chemotherapy. | 03-19-2015 |
20150080250 | SOLID SUPPORT AND METHOD FOR DETECTING AN ANALYTE IN A SAMPLE - A solid support for detecting the presence of an analyte in a sample at or above a predetermined threshold comprises: a competitive analyte within said solid support, wherein said competitive analyte is coupled to a first member of a binding pair; a labelled conjugate within said solid support, downstream of said competitive analyte, wherein said analyte and said competitive analyte compete for binding to said conjugate; and a capture reagent immobilized within said solid support, downstream of said conjugate, wherein said capture reagent comprises a second member of the binding pair; wherein the affinity of the first and second members of the binding pair for one another and the distance between the conjugate and the capture reagent and/or the conjugate and the competitive analyte within the solid support are selected so as to increase the threshold of the solid support for the analyte. | 03-19-2015 |
20150080251 | COMPOSITION FOR DETECTING NUCLEIC ACID AND METHOD FOR DETECTING NUCLEIC ACID USING SAME - The present invention relates a composition, including an RNA probe which contains a fluorescence material absorbed in graphene oxide, for detecting a nucleic acid, and to a method for detecting a nucleic acid using the composition. By means of the composition and the method, the presence and expression pattern of a target nucleic acid in a sample or a cell can be observed in real time, and a plurality of target nucleic acids can be detected in multitude. | 03-19-2015 |
20150080252 | GENE EXPRESSION SIGNATURES ASSOCIATED WITH RESPONSE TO IMATINIB MESYLATE IN GASTROINTESTINAL STROMAL TUMORS AND USE THEREOF FOR PREDICTING PATIENT RESPONSE TO THERAPY AND IDENTIFICATION OF AGENTS WHICH HAVE EFFICACY FOR THE TREATMENT OF CANCER - Compositions and methods are disclosed for identifying agents useful for the treatment of malignancy, particularly GISTs which are resistant to imatinib mesylate (IM). In a preferred embodiment, agents which sensitize cancer cells to IM are provided. | 03-19-2015 |
20150080253 | LABEL-FREE SENSING CHIP AND APPLICATION THEREOF - The present invention provides a label-free sensing chip for identifying a chemical substance, comprising: (a) a transparent substrate comprising a base and first periodic ridges; and (b) a metal layer covering said transparent substrate, comprising second periodic ridges and third periodic ridges, in which said second periodic ridges has a height equal to or greater than the height of the first periodic ridges, and each ridge of the second periodic ridges fits into the space between each ridge of the first periodic ridges, and said third periodic ridges correspondingly located on said first periodic ridges. The present invention also provides a method for identifying a chemical substance by using the foresaid label-free sensing chip. | 03-19-2015 |
20150080254 | LATERAL FLOW ASSAYS USING TWO DIMENSIONAL TEST AND CONTROL SIGNAL READOUT PATTERNS - The present invention relates to novel lateral flow devices using two dimensional features, preferably, uniform two dimensional test and control signal readout patterns, and the methods for detecting an analyte using the lateral flow devices. | 03-19-2015 |
20150080255 | MPL MUTATIONS IN JAK2 V617F NEGATIVE PATIENTS WITH MYELOPROLIFERATIVE DISEASE - The invention provides compositions and methods for diagnosing a patient as having a myeloproliferative disease by identifying mutations in the MPL gene or gene products. | 03-19-2015 |
20150080256 | LUMINESCENCE DETECTING APPARATUSES AND METHODS - A luminescence detecting apparatus and method for analyzing luminescent samples is disclosed. Luminescent samples are placed in a plurality of sample wells in a tray, and the tray is placed in a visible-light impervious chamber containing a charge coupled device camera. The samples may be injected in the wells, and the samples may be injected with buffers and reagents, by an injector. In the chamber, light from the luminescent samples pass through a collimator, a Fresnel field lens, a filter, and a camera lens, whereupon a focused image is created by the optics on the charge-coupled device (CCD) camera. The use of a Fresnel field lens, in combination with a collimator and filter, reduces crosstalk between samples below the level attainable by the prior art. Preferred embodiments of the luminescence detecting apparatus and method disclosed include central processing control of all operations, multiple wavelength filter wheel, and robot handling of samples and reagents. Preferred embodiments of processing software integrated with the invention include elements for mechanical alignment, outlier shaving, edge detection and masking, manipulation of multiple integration times to expand the dynamic range, crosstalk correction, dark subtraction interpolation and drift correction, multi-component analysis applications specifically tailored for luminescence, and uniformity correction. | 03-19-2015 |
20150080257 | METHOD FOR EVALUATING URATE TRANSPORT-RELATED DISEASE FACTOR AND INFLAMMATION-RELATED DISEASE FACTOR - A method and evaluation kit are provided, in which a high-capacity urate transporter is identified to assist in the early treatment and prevention of urate transport-related disease and inflammation-related disease. The method can include a step for detecting variations in genes that encode ABCG2 protein. When a subject has an SNP of V12M, R113X, Q126X, Q141K, F2085, G268R, E334X, S441N, L447V, S486N, F506SfsX4, R575X, and/or C608X, it can be concluded that the subject has a factor that is capable of inducing urate transport failure, or a state or disease attributable to that failure. When a subject has an SNP of V12M, it can be concluded that, unlike the other SNPs, there is a possibility that the subject does not possess such a factor because, although this variation itself does not lead to a change in urate transport capability, said variation is related to linkage disequilibrium with other SNPs. | 03-19-2015 |
20150080258 | NUCLEIC ACIDS AND METHODS FOR THE DETECTION OF ENTEROBACTER SAKAZAKII (CRONOBACTER SPP.) - Provided are detection means and method specific for the genus | 03-19-2015 |
20150080259 | SYSTEMS AND METHODS FOR PERFORMING AMPLICON RESCUE MULTIPLEX POLYMERASE CHAIN REACTION (PCR) - Embodiments of the present disclosure generally pertain to systems and methods for performing amplicon rescue multiplex polymerase chain reaction (arm-PCR). In one embodiment, the system comprises a processor and a reader coupled to a control element. The control element is configured to control the operation of the processor and the reader based on a variety of settings. The processor is configured to receive a self-contained cassette for performing PCR amplification of DNA and/or RNA obtained from an organic specimen. The processor engages with the cassette and manipulates reagents within the cassette in order to amplify and detect the DNA from the specimen. The processor also causes the cassette to deposit the DNA on a microarray within the cassette. The reader is configured to receive the cassette after it has been processed by the processor and to capture an image of the microarray for transmission to the control element as test data. The control element is further configured to analyze the test data received from the reader and to produce an output indicative of a comparison of the test data to predefined data. | 03-19-2015 |
20150080260 | METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY - This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided. | 03-19-2015 |
20150087539 | METHOD FOR PREDICTING OUTCOME OF CANCER IN A SUBJECT - The invention relates to a method for predicting the outcome of a subject suffering from cancer, based on the copy number of the CHKA gene in a sample from said subject. The invention also relates to a BAC composition and a method for detecting the number of copies of the CHKA gene. | 03-26-2015 |
20150087540 | Composition for Diagnosing Sepsis, and Method and Kit Therefor - A composition for diagnosing sepsis, and a method and a kit therefor. The kit includes a primer composition containing specific individual primers for amplifying: a segment of a 16s rRNA gene; a segment of an ITS gene; a segment of a Nuc gene; a segment of a MecA gene; segments of a VanA and a VanB; a segment of an invA gene; a segment of an ipaH gene; and a segment of a Cps gene. The kit also includes a probe composition containing specific individual probes for detecting: gram-negative bacteria; gram-positive bacteria; a Nuc gene; a MecA gene for checking whether or not MRSA has antibiotic resistance; a VanA and a VanB, for checking whether or not VRE have antibiotic resistance; and a gene for identifying a fungus. | 03-26-2015 |
20150087541 | Derivation of Neural Stem Cells and Dopaminergic Neurons from Human Pluripotent Stem Cells - The present invention is based in part on a chemically defined method of generating neural stem cells (NSCs) and dopaminergic (DA) neurons from human pluripotent stem cells (hPSCs). The DA neurons of the invention can be derived from hPSCs and NSCs. The present invention also provides reagents and kits useful for the derivation of neural stem cells and dopaminergic neurons from human pluripotent stem cells. | 03-26-2015 |
20150087542 | SCREENING METHOD FOR THE DETECTION OF CLOSTRIDIUM DIFFICILE - The invention concerns a screening method for the detection of | 03-26-2015 |
20150087543 | Device, Array, And Methods For Disease Detection And Analysis - A device and array coupled to capture molecules are provided. Specifically, the device and array can be used for detecting the presence and concentration of biomarkers in a sample from a subject. The device and array can also allow the use of a method for scoring a sample for, e.g., the purpose of diagnosing a disease. The method can also be advantageous to applications where there is a need to accurately determine the disease stage of a subject for the purpose of making therapeutic decisions. | 03-26-2015 |
20150087544 | Methods and Systems for Manufacture of Microarray Assay Systems, Conducting Microfluidic Assays, and Monitoring and Scanning to Obtain Microfluidic Assay Results - A method of flowing a fluid with a tracer in a microfluidic channel of an assay device and detecting the tracer for determining the channel location or condition of the channel. | 03-26-2015 |
20150087545 | DETECTION OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN BIOLOGICAL SAMPLES - Disclosed are methods of identifying a methicillin-resistant | 03-26-2015 |
20150087546 | SEQUENCE, TECHNIQUE PLATFORM, AND METHOD FOR IN VITRO DETECTING CLOSTRIDIUM DIFFICILE RIBOTYPE 027 - The invention relates to a sequence, a technique platform, and a method for in vitro detecting | 03-26-2015 |
20150087547 | METHOD FOR SEALING SUBSTANCES, METHOD FOR DETECTING TARGET MOLECULE, ARRAY, KIT, AND TARGET MOLECULE DETECTION DEVICE - [Problem to be Solved] | 03-26-2015 |
20150087548 | MARKER SEQUENCES FOR RHEUMATOID ARTHRITIS AND USE THEREOF - The present invention relates to new marker sequences for rheumatoid arthritis and the diagnostic use thereof together with a method for screening of potential active substances for rheumatoid arthritis by means of these marker sequences. Furthermore, the invention relates to a diagnostic device containing such marker sequences for rheumatoid arthritis, in particular a protein biochip and the use thereof. | 03-26-2015 |
20150087549 | METHODS OF USING TISSUE BIOMARKERS FOR INDICATION OF PROGRESSION FROM BARRETTS ESOPHAGUS TO ESOPHAGEAL ADENOCARCINOMA - A method of diagnosing progression from Barrett's esophagus toward esophageal dysplasia can include: obtaining miRNA from a test subject having Barrett's esophagus; assaying for miRNA biomarker selected from one or more of miR-15b or miR-486-5p; and determining whether one or more of miR-15b or miR-486-5p provide an indication of progression toward esophageal dysplasia in the test subject. The method can include determining an amount of one or more of miR-15b or miR-486-5p. The method can include determining a modulation in amount of one or more of miR-15b or miR-486-5p. The method can include comparing the one or more of miR-15b or miR-486-5p with a positive control or a negative control. | 03-26-2015 |
20150087550 | Apparatus and Methods for Parallel Processing of Micro-Volume Liquid Reactions - Disclosed herein are apparatuses and methods for conducting multiple simultaneous micro-volume chemical and biochemical reactions in an array format. In one embodiment, the format comprises an array of microholes in a substrate. Besides serving as an ordered array of sample chambers allowing the performance of multiple parallel reactions, the arrays can be used for reagent storage and transfer, library display, reagent synthesis, assembly of multiple identical reactions, dilution and desalting. Use of the arrays facilitates optical analysis of reactions, and allows optical analysis to be conducted in real time. Included within the invention are kits comprising a microhole apparatus and a reaction component of the method(s) to be carried out in the apparatus. | 03-26-2015 |
20150094215 | MODULATION OF LINE-1 REVERSE TRANSCRIPTASE - A reverse transcriptase encoded by L-1 (LINE-1) has been identified as a target molecule for treating or preventing cancers induced or mediated by this molecule. Method of treating or preventing such cancers in patients involves administration of a therapeutically effective amount of a composition having an inhibitor or antagonist of the reverse transcriptase in cells of the patients. The inhibitor or antagonist blocks lengthening of telomeres in telomerase negative cells. Methods and kits for detecting pathologically proliferating cells expressing L1RT are also disclosed. | 04-02-2015 |
20150094216 | SYSTEMS AND METHODS FOR IDENTIFYING PROTEIN STABILIZERS - A device for studying protein conformation transformation can include a macroscopic substrate, and chaperonin proteins bound to the substrate, each chaperonin protein being capable of binding to a protein of interest during or after undergoing protein conformation transformation. The device may also include the proteins of interest bound to the substrate, where the substrate is included in a label-free assay system. A method of studying protein conformation transformation can include: providing a macroscopic substrate bound with the chaperonin protein and immersing the chaperonin protein in a study composition having the protein of interest, or include providing a macroscopic substrate bound with the protein of interest; and immersing the protein in a study composition having the chaperonin. Such a method can be done with and without a potential stabilizer in order to determine whether the potential stabilizer stabilizes the protein of interest. | 04-02-2015 |
20150094217 | TEST FOR DIAGNOSING RESISTANCE TO AZACITIDINE - The invention relates to an in vitro analysis method for predicting resistance to azacitidine treatment in a patient, using the BCL2L10 protein contained in a sample of biological fluid taken from said patient, and also biological molecules which specifically bind the BCL2L10 protein. It is characterized in that a sample of biological fluid is recovered from a patient; the percentage of total cells in said biological fluid expressing the BCL2L10 protein is calculated; this calculated percentage is compared with a reference threshold value, this threshold value being between 20% and 60%; and resistance to azacitidine treatment is diagnosed in a patient who has a percentage of cells expressing the BCL2L10 protein in said biological fluid which is greater than said reference value. | 04-02-2015 |
20150094218 | METHOD AND KIT FOR DETECTION OF ANTI-BETA AMYLOID ANTIBODIES - An in vitro method and a kit for the quantification of antibodies anti-beta amyloid protein in a sample of cerebrospinal fluid comprising the following steps a) concentrating the quantity of said antibodies of said sample with magnetic micro beads coated with macromolecules capable of binding said antibodies b) analysing the concentrated sample obtained in step a) by immunoenzyme assay or by radioimmunoassay; c) analysing a sample comprising antibodies anti-beta amyloid protein having a known titre with the same assay used in step b) and elaborating the related calibration curve, wherein said antibody having a known titre is a murine antibody belonging to the IgG | 04-02-2015 |
20150094219 | METHODS AND SYSTEMS FOR DETECTING AN ANALYTE OR CLASSIFYING A SAMPLE - The present invention relates to methods and systems for detecting one or more analytes in a sample and/or for classifying a sample. In particular, the present invention relates to methods and systems which can be used to detect the analytes in real time and which rely on flowing through a microfluidic device one or more types of sensor molecule each comprising a domain that binds one or more analytes, a chemiluminescent donor domain and an acceptor domain, wherein the separation and relative orientation of the chemiluminescent donor domain and the acceptor domain, in the presence and/or the absence of analyte, is within +50% of the Forster distance. | 04-02-2015 |
20150094220 | METHOD TO PREDICT THE SAFETY OF THE TREATMENT WITH A NICOTINIC CHOLINERGIC RECEPTOR AGONIST - The present invention generally relates to methods for predicting the safety of a nicotinic cholinergic receptor agonist drug-based pharmacological treatment, such as one based on varenicline, based on determining at least one allele of one or more of single-nucleotide polymorphisms (SNPs) rs9479757, rs7930792, rs12423809, rs4251417, rs7146, rs477292, rs495491, rs3778151, rs763132, rs4474069 and rs1183035, or of any SNP of the corresponding linkage groups thereof, in a biological sample of a subject. | 04-02-2015 |
20150094221 | Method for Indicating the Presence or Non-Presence of Prostate Cancer - The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to determine if it is likely that the patient suffers from prostate cancer. | 04-02-2015 |
20150094222 | QUANTITATIVE MULTIPLEX METHYLATION SPECIFIC PCR METHOD- cMethDNA, REAGENTS, AND ITS USE - The cMethDNA method of the present invention is a novel modification of the QM-MSP method (U.S. Pat. No. 8,062,849), specifically intended to quantitatively detect tumor DNA (or other circulating DNAs) in fluids such as serum or plasma at the lowest copy number yet reported. Unique compared to any other PCR-based assay, a small number of copies of a synthetic polynucleotide standard (STDgene) is added to an aliquot of patient serum. In a standard procedure, a cocktail of standards for a plurality of genes of interest (TARGETgene) is added to a sample of serum. Once total DNA is purified and processed, a PCR (multiplex step) is performed wherein the STDgene and the TARGETgene are co-amplified with the same external primer set. In the N second nested PCR step, amplicons present in a dilution of the first PCR reaction are subjected to real time PCR, and quantified for each gene in one well by two-color real-time PCR. Products are calculated by absolute quantitation with internal primer sets specific for the methylated TARGETgene and associated STDgene. Methods of making the STDgene standards and the use of the cMethDNA methods and kits containing the same are disclosed. | 04-02-2015 |
20150094223 | METHODS AND APPARATUSES FOR DIAGNOSING CANCER BY USING GENETIC INFORMATION - A method and apparatus for diagnosing cancer by using genetic information, the method comprising acquiring first gene expression data of a subject, for whom cancer is to be diagnosed, for a gene marker set including at least one gene marker; and determining a possibility of a presence of the cancer of the subject by using the acquired first gene expression data and pre-stored second gene expression data of a normal person group and a cancer patient group, wherein the gene marker set includes gene markers such as pyrroline-5-carboxylate reductase 1 (PYCR1), phosphoglycerate dehydrogenase (PHGDH), glutaminase 2 (liver, mitochondrial) (GLS2), and glutaminase (GLS) among others. | 04-02-2015 |
20150094224 | METHODS FOR THE DIAGNOSIS OR PROGNOSIS OF BREAST CANCER - Methods for detecting, diagnosing and monitoring an epithelial cancer in a patient are described comprising measuring in a sample from the patient Ep-ICD polypeptides and Ep-ICD polynucleotides. Methods for prognosis of breast cancer comprising measurement of nuclear Ep-ICD polypeptides and optionally EpEx polypeptides are provided. The invention also provides kits and compositions for carrying out the methods of the invention. The invention also provides a unique scoring system using immunohistochemical analysis to arrive at an Ep-ICD Subcellular Localization Index (ESLI) score, which is used to arrive at a diagnosis of cancer in a patient, or, more particularly, to identify patients that are in need of aggressive clinical treatment. | 04-02-2015 |
20150094225 | METHOD OF OBTAINING INFORMATION FOR IDENTIFYING TUMOR CELL UNDERGOING EPITHELIAL-MESENCHYMAL TRANSITION IN SAMPLE, METHOD OF IDENTIFYING TUMOR CELL UNDERGOING EPITHELIAL-MESENCHYMAL TRANSITION IN SAMPLE, METHOD OF DIAGNOSING SUBJECT HAVING TUMOR CELL UNDERGOING EPITHELIAL-MESENCHYMAL TRANSITION AND COMPOSITION OR KIT FOR IDENTIFYING TUMOR CELL UNDERGOING EPITHELIAL-MESENCHYMAL TRANSITION IN SAMPLE - Provided are a method of obtaining information for identifying tumor cells undergoing epithelial-mesenchymal transition in a sample, a method of identifying tumor cells undergoing epithelial-mesenchymal transition in a sample, a method of diagnosing a subject having a tumor, and a composition or kit for identifying tumor cells undergoing epithelial-mesenchymal transition in a sample. | 04-02-2015 |
20150094226 | Crystal Structure of a NEF/SdAb19 Complex and Uses Thereof - The present invention provides detailed three-dimensional structural information for the complex formed by the Nef protein and the sdAb19 antibody fragment. In addition, the present invention also provides residues which mediate the interaction between the Nef protein and the sdAb19 antibody fragment. The present invention also provides methods for identifying compounds modulating the interaction of the Nef protein and the sdAb19 antibody. | 04-02-2015 |
20150094227 | PREGNANCY TEST DEVICE AND METHOD - Disclosed is a test device to detect pregnancy in a human female subject, the test device comprising:
| 04-02-2015 |
20150094228 | ANURAN CROSS-SPECIES MOLECULAR SENSORS - Described herein are DNA primer sequences designed for the determination of gene or transcript information from Anuran species, and which may be used in studies for developmental and/or toxicity testing and for environmental toxicology or ecological assessment. Also described herein is a rapid, sensitive, high-throughput assay useful for supporting potential risk assessment across vertebrate clades, and that is also useful for evaluation of complex contaminant mixtures. | 04-02-2015 |
20150094229 | METHODS FOR THE SCREENING OF ANTIBACTERIAL SUBSTANCES - The present invention concerns a method for the screening of antibacterial substances comprising a step of determining the ability of a candidate substance to inhibit the activity of a purified enzyme selected from the group consisting of: (i) a D-aspartate ligase comprising a polypeptide having an amino acid sequence possessing at least 50% amino acid identity with an amino acid sequence selected from the group consisting of SEQ ID No 1 to SEQ ID No 10, or a biologically active fragment thereof; and (ii) a L,D-transpeptidase comprising a polypeptide having an amino acid sequence possessing at least 50% amino acid identity with the amino acid sequence of SEQ ID No 11, or a biologically active fragment thereof. | 04-02-2015 |
20150094230 | Method And System For Detecting and Differentiating Cancer and Sepsis in Mammals Using Biomarkers - The invention provides a method and system for developing and using diagnoses of cancer and sepsis in canine subjects using thymidine kinase (TK), c-reactive protein (CRP), and C-type natriuretic peptide (CNP) as biomarkers. The level of each biomarker may be measured and an index may be computed using a two- or a three-biomarker method. The invention provides a predefined scale for the index where each range of the index matches a health condition. The latter allows a practitioner, through computing an index value of a patient, to determine the health status of the patient by comparing the index value to the predefined scale. | 04-02-2015 |
20150094231 | Oligonucleotides and Methods for Detecting KRAS and PIK3CA Mutations - Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences. | 04-02-2015 |
20150099650 | PROBING OF BIOLOGICAL SAMPLES - Disclosed are high throughput methods of probing multiple targets in a biological sample where the recurrent time-consuming antibody incubation steps and individual signal modification and activation steps are replaced by simultaneous hybridization of biomarkers and sequential detection by combining signal removal and activation into a single step. Also disclosed are images obtained by such methods. | 04-09-2015 |
20150099651 | METHOD FOR PREDICTION OF THE PROGRESSION RISK OF TUMORS - The present invention concerns a method for predicting the potential for aggressive growth and/or the risk to progress to high grade cancer for tumors in cell based detection procedures. In one aspect the invention concerns the detection of overexpression of cyclin-dependent kinase inhibitor gene products as a tool for predicting the progression risk and/or potential for aggressive growth of tumors. In a second aspect the invention concerns predicting the progression risk and/or potential for aggressive growth in tumors on the basis of the simultaneous co-detection of the presence of overexpression of cyclin-dependent kinase inhibitor gene products together with the expression of markers for active cell proliferation. Further the invention concerns preparations of probes for diagnosis namely for predicting the progression risk and/or the potential for aggressive growth of tumors. | 04-09-2015 |
20150099652 | IN VITRO PROCESS FOR THE QUICK DETERMINATION OF A PATIENT'S STATUS RELATING TO INFECTION WITH MYCOBACTERIUM TUBERCULOSIS - An in-vitro process for the quick determination of the infection status of a | 04-09-2015 |
20150099653 | PROCESS OF DIAGNOSTIC, PROGNOSTIC AND THERAPEUTIC MONITORING OF SOLID TUMORS - A process of diagnostic, prognostic and therapeutic monitoring of solid tumors, and new biological markers of tumor. | 04-09-2015 |
20150099654 | REAL TIME PCR DETECTION OF RESPIRATORY SYNCYTIAL VIRUS - The present invention relates to assays, diagnostic kits and methods for real-time PCR detection of RSV, preferably for the detection of both human pathogens RSV A and RSV B at the same time. | 04-09-2015 |
20150099655 | Methods and Compositions for Providing a Preeclampsia Assessment - Preeclampsia markers, preeclampsia marker panels, and methods for obtaining a preeclampsia marker level representation for a sample are provided. These compositions and methods find use in a number of applications, including, for example, diagnosing preeclampsia, prognosing a preeclampsia, monitoring a subject with preeclampsia, and determining a treatment for preeclampsia. In addition, systems, devices and kits thereof that find use in practicing the subject methods are provided. | 04-09-2015 |
20150099656 | Multiplex Immuno Screening Assay - The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. This immunoassay involves the covalent and oriented coupling of fusion proteins comprising an AGT enzyme and a viral antigen on an identifiable solid support (e.g. fluorescent microspheres), said support being previously coated with an AGT substrate. This coupling is mediated by the irreversible reaction of the AGT enzyme on its substrate. The thus obtained antigen-coupled microspheres show enhanced capture of specific antibodies as compared to antigen-coupled microspheres produced by standard amine coupling procedures. The methods of the invention possess the ability to multiplex, minimize the amount of biological sample, and have enhanced sensitivity and specificity toward target antibodies as compared with classical ELISA or Radio-Immunoprecipitation assays. | 04-09-2015 |
20150099657 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF SEPSIS USING GAMMA PEPTIDE NUCLEIC ACIDS - The present disclosure provides for composition of γPNA probes. Additionally, the present disclosure provide for methods and kits using γPNA probes for the prognosis of sepsis. In some embodiments, wherein the γPNA capture probes and γPNA reporter probes comprise one or more functional moiety selected from the group consisting of: a binding molecule, a spacer group, a linker group, a hydrophobicity-changing group, a charge-inducing group, and a structural charge-inducing group. | 04-09-2015 |
20150099658 | ANTI-GP41 ANTIBODY-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING - The present application provides stable peptide-based anti-gp41 antibody capture agents and methods of use as detection and diagnosis agents. The application further provides methods of manufacturing anti-gp41 antibody capture agents using iterative on-bead in situ click chemistry. | 04-09-2015 |
20150099659 | MULTIPLEX PROBES - Methods and reagents suitable for conducing polymerase chain reaction are described. In particular, the disclosure provides probes and primers that are suitable in dynamic flux amplification procedures. In aspects, the disclosure provides long oligonucleotide probes and primers, as well as triplex forming probes and primers, which function within the narrow Tm ranges used with dynamic flux amplification. However, embodiments are also provided wherein the probes and primers taught herein can be utilized in standard PCR. | 04-09-2015 |
20150099660 | MULTI-DIRECTIONAL MICROFLUIDIC DEVICES COMPRISING A PAN-CAPTURE BINDING REGION AND METHODS OF USING THE SAME - Microfluidic devices and methods for using the same are provided. Aspects of the invention include microfluidic devices that include a separation medium and a pan-capture binding medium. The microfluidic devices are configured to subject a sample to two or more directionally distinct electric fields. Also provided are methods of using the devices as well as systems and kits that include the devices. The devices, systems and methods find use in a variety of different applications, including diagnostic and validation assays. | 04-09-2015 |
20150099661 | DIGITAL COUNTING OF INDIVIDUAL MOLECULES BY STOCHASTIC ATTACHMENT OF DIVERSE LABELS - Compositions, methods and kits are disclosed for high-sensitivity single molecule digital counting by the stochastic labeling of a collection of identical molecules by attachment of a diverse set of labels. Each copy of a molecule randomly chooses from a non-depleting reservoir of diverse labels. Detection may be by a variety of methods including hybridization based or sequencing. Molecules that would otherwise be identical in information content can be labeled to create a separately detectable product that is unique or approximately unique in a collection. This stochastic transformation relaxes the problem of counting molecules from one of locating and identifying identical molecules to a series of binary digital questions detecting whether preprogrammed labels are present. The methods may be used, for example, to estimate the number of separate molecules of a given type or types within a sample. | 04-09-2015 |
20150099663 | BIOMARKERS - The invention relates to biomarkers and a method of diagnosing or monitoring depression, anxiety disorder or other psychotic disorder. | 04-09-2015 |
20150099664 | PROTEIN BIOMARKERS AND THERAPEUTIC TARGETS FOR AUTOIMMUNE AND ALLOIMMUNE DISEASES - A method for characterizing the risk a subject will develop an autoimmune and/or alloimmune disease following tissue transplant includes obtaining a biological sample from the subject, wherein the subject has received the tissue transplant determining in the biological sample a level of at least one protein selected from Tables 1-4, comparing the measured level of the at least one protein to a control value, and characterizing a subject as at greater risk of developing an autoimmune disease and/or alloimmune disease if the level of at least one protein determined is increased or decreased compared to the control value. | 04-09-2015 |
20150099665 | METHODS FOR DISTINGUISHING BETWEEN SPECIFIC TYPES OF LUNG CANCERS - The present invention provides nucleic acid sequences that are used for identification, classification and diagnosis of lung cancers. The present invention further provides microRNA molecules, as well as various nucleic acid molecules relating thereto or derived therefrom, associated with specific types of lung cancers. | 04-09-2015 |
20150099666 | Method And Device For Combined Detection Of Viral And Bacterial Infections - A lateral flow assay detects and differentiates between viral and bacterial infections. A combined point of care diagnostic device tests markers for viral infection and markers for bacterial infection, to effectively assist in the rapid differentiation of viral and bacterial infections. In one preferred embodiment, the bacterial marker is CRP. In another preferred embodiment, the viral marker is MxA. In some embodiments, it is unnecessary to lyse the cells in the sample prior to applying it to the device. | 04-09-2015 |
20150105275 | Small RNA Capture, Detection and Quantification - Methods, compositions and kits for capturing, detecting and quantifying mature small RNAs are provided herein. Embodiments of the methods comprise ligating 5′ and 3′ ligation adaptors to the 5′ and 3′ ends of the mature small RNAs, respectively, in the presence of 5′ and 3′ semi-degenerate ligation splints to generate a ligation product. Other embodiments comprise reverse transcribing polyadenylated mature small RNA with a universal reverse transcription primer and ligating an adaptor to the 3′ end of the cDNA in the presence of a semi-degenerate ligation splint to generate a cDNA ligation product. | 04-16-2015 |
20150105276 | BLOOD-BASED GENE DETECTION OF NON-SMALL CELL LUNG CANCER - The present invention provides a method for early detection of non-small cell lung cancer based on the abundance of RNAs from blood samples as well as diagnostic tools such as kits and arrays suitable for such method. | 04-16-2015 |
20150105277 | DETECTION OF VIRAL INFECTION - The present invention relates to methods of detecting an increased likelihood of virus infection in a subject. In particular, the present invention relates to methods of detecting an increased likelihood of virus infection in a subject by detecting an altered level of at least one microRNA (miRNA), as well as methods of treating or preventing virus infection. The present invention also relates to nucleotide arrays, oligonucleotides and kits useful for the detection of miRNAs associated with an increased likelihood of virus infection in a subject. | 04-16-2015 |
20150105278 | METHODS OR RISK ASSESSMENT OF PML AND RELATED APPARATUS - The invention provides a method of assessing the risk of occurrence of progressive multifocal leukoencephalopathy (PML) in a subject as well as a method of stratifying a subject undergoing VLA-4 blocking agent treatment for suspension of VLA-4 blocking agent treatment. These methods comprise detecting the level of L-selectin (CD62L) and optionally LFA-1 expressing T cells in a sample from the subject. | 04-16-2015 |
20150105279 | PRODUCT SELECTION USING GENETIC ANALYSIS - A method of assessing the suitability of a set of cosmetic and/or nutricosmetic and/or skin care products for an individual. The method comprises testing a sample of genetic material for an individual to identify the presence or absence of single-nucleotide polymorphisms at a predefined set of single-nucleotide locations. One or more weights for each location are identified in dependence upon the presence or absence of a single-nucleotide polymorphism at the location and the single-nucleotide location weights used in order to determine a product score for each of said products, a score being indicative of the suitability of a product to the individual. | 04-16-2015 |
20150105280 | SELECTOR BASED RECOGNITION AND QUANTIFICATION SYSTEM AND METHOD FOR MULTIPLE ANALYTES IN A SINGLE ANALYSIS - A multi-dimensional method is provided for simultaneously analyzing multiple analytes within a sample solution, the method including: adding affinity selectors to a sample solution containing analytes to be measured, the affinity selectors having an affinity for one or more of the analytes within the sample solution; allowing immune complexes to form between the affinity selectors and the analytes; partially or totally resolving the formed immune complexes from non-analyte substances within the sample solution in a first dimension of separation using a selective adsorption technique; dissociating the resolved immune complexes; separating the analytes and the affinity selectors of the dissociated immune complexes from one another in a second dimension of separation using a selective adsorption technique; and resolving the analytes in accordance with their mass-to-charge ratios. | 04-16-2015 |
20150105281 | Method for the Selection of Serum Biomarkers of Epigenetic Alterations, Particularly of Global Hypomethylation and Their Uses - The present invention provides a novel method for the selection of serum biomarkers of epigenetic alterations, particularly of global hypomethylation, and the use of said biomarkers in a method for screening, diagnosing and following a pathology associated to epigenetic alterations of cell in an individual, such as placental-related pathology or cancer. The present invention also relates to a method of detecting a predisposition to placental-related pathology or cancer based on the presence or the level of said biomarker in a serum or plasma sample of said patient. The present invention also relates to a method for predicting and following the effect of drugs targeting epigenetic modifications and in particular the effect of demethylating agents. The present invention is directed to a kit comprising such serum biomarkers of epigenetic alterations, particularly of global hypomethylation. | 04-16-2015 |
20150105282 | SCREENING METHOD FOR THE DETECTION OF CLOSTRIDIUM DIFFICILE - The invention concerns a screening method for the detection of | 04-16-2015 |
20150105283 | MULTIPLEXED DIAGNOSIS METHOD FOR CLASSICAL HODGKIN LYMPHOMA - A method for providing a composite image of a single biological sample from a patient suspected of having classical Hodgkin lymphoma, comprising the steps of generating a first image of the biological sample including the presence, absence and/or expression level of a first biomarker, generating a second image of the biological sample including the presence, absence and/or expression level of a second biomarker, and generating a composite image that provides the relative location or expression of both biomarkers. Also provided is a method of analyzing a biological sample, comprising providing a composite image of the biological sample according to the method for providing a composite image, and analyzing the expression of the biomarkers of interest from the composite image. Further provided are method for diagnosing classical Hodgkin lymphoma, as well as system and kit that comprise the means for executing the novel methods. | 04-16-2015 |
20150105284 | PHOSPHORESCENT REPORTERS - In some embodiments, the present disclosure pertains to new compositions of matter that comprise phosphorescent reporters. In some embodiments, the phosphorescent reporters of the present disclosure comprise strontium aluminate. In some embodiments, the strontium aluminate is doped with europium and dysprosium (SrAl | 04-16-2015 |
20150105285 | SPECIFIC AND HIGH AFFINITY BINDING PROTEINS COMPRISING MODIFIED SH3 DOMAINS OF FYN KINASE - The present invention relates to a method for the production of a library comprising recombinant derivatives of the SH3 domain of the Fyn kinase of SEQ ID NO: 1 as well as a method for selecting from a library comprising recombinant derivatives of the SH3 domain of the Fyn kinase of SEQ ID NO: 1 one or more of said derivatives having a specific binding affinity to a protein or peptide. | 04-16-2015 |
20150105286 | BLID; a novel protein domain for interaction with the Bcl-2 family of proteins. Applications in Oncology - In this invention, a novel protein interaction domain is provided along with several of its variants. This domain is involved in protein-protein interactions with the Bcl-2 family of proteins. It is named BLID (Bcl2 family of proteins Like Interaction Domain). Several BLID peptides that could be useful for discovery of drugs to help fight pathological states like cancer are presented. | 04-16-2015 |
20150105287 | Microfluidic Systems and Methods for Chromatin Immunoprecipitation (ChIP) - An integrated microfluidic chromatin immunoprecipitation assay dramatically improves the collection efficiency of ChIP DNA from cells. Immunoprecipitation of chromatin fragments is conducted in a microfluidic chamber with a large fraction of its volume (e.g., ˜15-40%) occupied by magnetic immunoprecipitation (IP) beads. Oscillating washing of the beads, enabled by, e.g., solenoid valves (controlled by a computer) and high pressure attached to both ends of the microfluidic chamber, effectively removes unbound chromatin and produces high-quality ChIP DNA. ChIP DNA produced by an example device generates excellent results in the subsequent DNA library preparation. The ChIP-seq (i.e., ChIP followed by next-generation sequencing) results match very well with public data generated using much larger cell sample sizes and a conventional approach. | 04-16-2015 |
20150105288 | GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS RELATING TO INNATE IMMUNE SYSTEM RESPONSE DETECTION - Described herein are immunodeficient non-human animals lacking expression of toll-like receptor 4 (TLR4) by endogenous autogeneic innate immune cells, as well as methods and compositions for engraftment of xenogeneic hematopoietic stem cells in the immunodeficient non-human animal lacking expression of toll-like receptor 4 (TLR4), thereby creating an innate immune system in the animal derived from the xenogeneic hematopoietic stem cells. Further described are immunodeficient mice lacking expression of toll-like receptor 4 by endogenous autogeneic innate immune cells, as well as methods and compositions for engraftment of xenogeneic hematopoietic stem cells in the immunodeficient mouse lacking expression of toll-like receptor 4, thereby creating an innate immune system in the animal derived from the xenogeneic hematopoietic stem cells. | 04-16-2015 |
20150105290 | Infectious Hepatitis C Viruses of Genotype 3A and 4A and Uses Thereof - The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis C virus. In particular, the invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis C viruses of either genotype 3a (strain S52) or genotype 4a (strain ED43). The invention therefore relates to the use of the nucleic acid sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and in the development of screening assays for the identification of antiviral agents for HCV. The invention therefore also relates to the use of viral particles derived from laboratory animals infected with S52 and ED43 viruses. | 04-16-2015 |
20150105291 | METHOD, KIT, AND APPARATUS FOR EVALUATING ISCHEMIC HEART DISEASE - It is intended to evaluate an ischemic heart disease with high accuracy by convenient operation. The method for evaluating an ischemic heart disease according to the present invention comprises the steps of: assaying complement factor H and/or complement factor D in a sample derived from the blood of a test subject; and comparing the concentration of the complement factor H and/or the concentration of the complement factor D assayed in the preceding step with a reference value(s), wherein it is determined that the seriousness of the ischemic heart disease is high when the concentration falls below the reference value. | 04-16-2015 |
20150105292 | METHOD FOR ANALYSIS OF COMPOUND-BINDING ABILITY OF PROTEIN - A method for analyzing a binding ability of protein to a compound, involves fractionating first and second groups of proteins into plural fractions using a carrier having the compound immobilized thereon; combining fractions, analyzing the combined fractions with mass spectrometry; based on the mass spectrometry information, obtaining, regarding each fraction, an intensity ratio between peaks derived from a protein in each of the groups of fractions; and comparing degrees of the binding ability of the plural kinds of proteins to the compound. | 04-16-2015 |
20150105293 | CLINICAL DIAGNOSIS OF HEPATIC FIBROSIS USING A NOVEL PANEL OF LOW ABUNDANT HUMAN PLASMA PROTEIN BIOMARKERS - The inventors have proposed a novel panel of human plasma protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis. A 2D-PAGE based proteomics study was used to identify potential fibrosis biomarkers. Plasma from patients with hepatic cirrhosis induced by infection with the hepatitis C virus (HCV) were analysed. Several proteins associated with liver scarring and potentially also related to viral infection were identified. These proteins include 14-3-3 protein zeta/delta, adiponectin, afamin, alpha-1-antitrypsin, alpha-2-HS-glycoprotein, apolipoprotein C-M, apolipoprotein E, C4b-binding protein beta chain, intact/cleaved complement C3dg, corticosteroid-binding globulin, fibrinogen gamma chain, beta haptoglobin at pH 5.46-5.49, haptoglobin-related protein, hemopexin, immunoglobulin J chain, leucine-rich alpha-2-glycoprotein, lipid transfer inhibitor protein, retinol-binding protein 4, serum paraoxonase/arylesterase 1, sex hormone-binding globulin and zinc-alpha-2-glycoprotein. | 04-16-2015 |
20150105294 | PIEZOELECTRIC MICROCANTILEVER SENSORS FOR BIOSENSING - A piezoelectric microcantilever for sensing compounds or molecules. The piezoelectric microcantilever, may include at least one electrode, an insulation layer, a receptor, an immobilization layer, a non-piezoelectric layer and a piezoelectric layer The sensor is capable of self actuation and detection. The piezoelectric layer may be constructed from a highly piezoelectric thin lead magnesium niobate-lead titanate film, a highly piezoelectric thin zirconate titanate film, a highly piezoelectric lead-free film. Methods of using the sensors and flow cells and arrays including the sensors are also described. | 04-16-2015 |
20150105295 | MULTIPLEXED FLOW ASSAY BASED ON ABSORPTION-ENCODED MICRO BEADS - Analysis of a system and/or sample involves the use of absorption-encoded micro beads. Each type of micro bead is encoded with amounts of the k dyes in a proportional relationship that is different from proportional relationships of the k dyes of others of the n types of absorption-encoded micro beads. A system and/or a sample can be analyzed using information obtained from detecting the one or more types of absorption-encoded micro beads. | 04-16-2015 |
20150111764 | POLYMERIZED MICROARRAYS - Micropatterns of glycan-bearing brush polymers generated by the initiation of oligomerization of acrylate and methacrylate monomers from thiol-terminated surfaces. Chain lengths are controlled in situ by varying exposure time, and these multivalent glycan scaffolds detect glycan binding proteins at sub-micromolar concentrations. | 04-23-2015 |
20150111765 | BIOCOATED PIEZOELECTRIC BIOSENSOR PLATFORM FOR POINT-OF-CARE DIAGNOSTIC USE - Biosensor components (chips) are described based on direct biocoating processes that result in the tenacious and stable, noncovalent (believed to be chemisorptive) binding of anchor substances such as avidin(s) other proteins having specific binding partners or oligo- or poly-nucleotides onto any piezo-electrically active crystal surface. The resulting platform technology can be developed for a variety of biosensors with specific applications in biological assays. The table mono layers of the anchor substances forms reactive layers, ready to bind a capture reagent such as a biot-inylated antibody for capture and detection of analytes in biologic fluid samples. Although the processes described herein can be performed on any type of piezoelectric material in any number of configurations, some embodiments are directed to a biosensor with the foregoing biocoating onto a particular acoustic plate mode biosensor and where the interdigitated transducers (IDTs) are present on the opposite side of the crystal's biocoated film. | 04-23-2015 |
20150111766 | FLUORESCENT NEUTRALIZATION AND ADHERENCE INHIBITION ASSAYS - The present invention comprises rugged, inexpensive, reliable, and sensitive laboratory assays of antibody-based viral neutralization activity and antibody-based viral adherence inhibition activity. The assays use inactivated, fluorescently-labeled virus, allowing the tests to be performed without extensive safety precautions. The interaction of the labeled virus with target cells is monitored using flow cytometric methods. A preferred embodiment uses simple and inexpensive flow cytometry methodologies and equipment, such as bead array readers used as simplified flow cytometers. The assays are rapid, taking no longer than a few hours and are readily conducted by a trained technician. The assays are sensitive because they use labeled viruses at low concentrations and determine neutralizing and blocking capacity of sera and antibody at low concentrations. The methods are appropriate for high-throughput screening of large panels of samples. | 04-23-2015 |
20150111767 | METHOD AND KIT FOR THE DETECTION OF HEPATITIS-SPECIFIC ANTIBODIES - The present invention relates to an improved method for detecting antibodies to a hepatitis virus in a tissue sample from individuals, which can reliably detect antibodies in recently infected individuals and which provides much lower false positive results in individuals that have cleared their hepatitis infections. More particularly, the present invention relates to an improved method and kit which utilizes an activator of (i) hepatitis virus-primed lymphocytes, (ii) memory cells specific for said hepatitis virus, (iii) hepatitis virus-specific antibody production, or (iv) a combination thereof in a tissue sample to stimulate the production of antibodies from newly primed B cells, if present. | 04-23-2015 |
20150111768 | METHODS FOR GENERATION OF PLURIPOTENT AND MULTIPOTENT CELLS - This disclosure relates to methods of producing induced pluripotent (iPS), multipotent, and/or lineage-committed stem cells from differentiated cells, maintaining iPS, multipotent, and/or lineage-committed cells in culture, and re-differentiating the iPS and multipotent stem cells into any desired lineage-committed cell type. | 04-23-2015 |
20150111769 | METHOD FOR ASSESSING ENDOMETRIAL CANCER SUSCEPTIBILITY - The present invention aims to provide an assessment method of corpus uteri cancer susceptibility, in which a human chromosomal region consisting of a nucleotide sequence of approximately 100 bps that exhibits a DNA copy number polymorphism associated with corpus uteri cancer susceptibility is identified and assessment is made based on an increase or decrease in the DNA copy number polymorphism. Corpus uteri cancer susceptibility can be assessed by: first, isolating a chromosomal region exhibiting the DNA copy number polymorphism specific for corpus uteri cancer by screening using a microarray derived from the peripheral blood, and subsequently, identifying DNA in a human chromosomal region consisting of a nucleotide sequence shown in any of SEQ ID NOs: 1 to 7, which is associated with corpus uteri cancer susceptibility, from a vast number of chromosomal regions including not only the chromosomal regions isolated by the above screening, but also regions not covered by the microarray, and then detecting a decrease in DNA copy number in the human chromosomal region consisting of the nucleotide sequence shown in any of SEQ ID NOs: 1 to 7. | 04-23-2015 |
20150111770 | QUANTITATIVE DETERMINATION OF BIOMARKERS IN THE ERYTHROCYTE MEMBRANE - This invention relates to determination of quantitative expression of plasma membrane proteins as biomarkers in the erythrocytes. The invention includes simple, quantitative assay platforms which can be made available in most diagnostic laboratories. The platform allows performing personalized, quantitative tests for the direct expression level of a wide range of membrane proteins from small volume blood samples and connecting them to individual genetic variability, disease conditions, disease stages and complications, treatment protocols, pharmacological responses, or toxic side effects. | 04-23-2015 |
20150111771 | Method for Identifying Agents Capable of Inducing Respiratory Sensitization and Array and Analytical Kits for Use in the Method - The present invention relates to an in vitro method for identifying agents capable of inducing respiratory sensitization in a mammal and arrays and diagnostic kits for use in such methods. In particular, the methods include measurement of the expression of the biomarkers listed in Table 1A, Table 1B and/or Table 1C in MUTZ-3 cells exposed to a test agent. | 04-23-2015 |
20150111772 | DIAGNOSTIC MIRNA PROFILES IN MULTIPLE SCLEROSIS - The invention relates to methods for diagnosing multiple sclerosis with miRNA markers. Diagnosis of multiple sclerosis (MS) can be challenging in patients with atypical presentations and during a first neurological deficit possibly related to inflammatory demyelination. Towards the identification of biomarkers for diagnosis of MS, a comprehensive analysis of miRNA expression patterns was obtained. Significantly deregulated miRNAs were identified, which have previously not been related to MS according to the microRNA disease database. These miRNAs could potentially serve as future diagnostic biomarkers for MS and help in diagnosis, monitoring disease activity, and evaluation of treatment responses in patients with MS. | 04-23-2015 |
20150111773 | Rapid Affinity Measurement of Peptide Ligands and Reagents Therefor - The present invention provides methods for rapidly screening and measuring the ligand binding affinity of in vitro selected peptides to the cognate and off-target proteins. This general strategy is amenable to high throughput analysis because the peptides are synthesized by cell-free translation, as opposed to solid-phase synthesis required by traditional assays, and affinities can be readily measured in standard formats. | 04-23-2015 |
20150111774 | Method for Detecting Target Nucleic Acid - The disclosure of this Description includes: a step of preparing a solid-phase body provided with a detection probe having a predetermined nucleotide sequence; a step of preparing a signaling target nucleic acid having a signal generating part for detecting the target nucleic acid; a step of bringing the signaling target nucleic acid, the detection probe, and an oligonucleotide being a mediator having a first site that hybridizes specifically with the target nucleic acid and a second site (preferably 20 to 50 nucleotides or more preferably 20 to 25 nucleotides in length) that hybridizes specifically with a part having the predetermined nucleotide sequence of the detection probe into contact with one another so that a hybridization product of these components can be formed; and a step of obtaining data based on the signal generating part of the signaling target nucleic acid on the solid-phase body. | 04-23-2015 |
20150111775 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual having a cardiovascular disorder to treatment of the disorder with statin. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 04-23-2015 |
20150111776 | IMMUNOASSAYS USING OVER-LABELED FLUORESCENT PROBES - The present disclosure provides immunoassays using one or more over-labeled fluorescent probes, which provides for rapid, accurate and quantitative detection of one or more target analytes in sample, reading fluorescent intensity. The disclosed immunoassays provide multiplexing capability with low cross-reactivity. | 04-23-2015 |
20150111777 | BIOMARKER FOR EARLY NEURODEGENERATION DETECTION - The present invention relates to compositions, methods, and kits that can be used to assess neurodegeneration associated diseases and conditions in a subject by detecting the level of TDP-43 protein in platelets. The compositions, methods, and kits are suitable for neurodegeneration associated disease diagnosis, prognosis and treatment evaluation. | 04-23-2015 |
20150111778 | BIO-NANO-CHIP FOR ANTICONVULSANT DRUG SALIVARY ASSAY - This disclosure describes portable bio-nano-chip (BNC) assays of antiepileptic drugs (AED) using salivary samples. The BNC technology results in a more convenient, less expensive, and less time consuming sampling and analysis. | 04-23-2015 |
20150111779 | High Speed Molecular Sensing with Nanopores - Described herein are methods and devices for capturing and determining the identity of molecules using nanopores. The molecules can be counted, sorted and/or binned rapidly in a parallel manner using a large number of nanopores (e.g., 132,000 nanopores reading 180 million molecules in 1 hour). This fast capture and reading of a molecule can be used to capture probe molecules or other molecules that have been generated to represent an original, hard to detect molecule or portions of an original molecule. Precise counting of sample molecules or surrogates for sample molecules can occur. The methods and devices described herein can, among other things, replace flow cytometers and other counting instruments (e.g., while providing increased precision and throughput relative to a flow cytometer). In some cases, the devices and methods capture and hold particular molecules or surrogates of molecules in the nanopores and then eject them into clean solution to perform a capture, sorting, and binning function similar to flow cytometers. | 04-23-2015 |
20150111780 | NUCLEIC ACID-BASED AUTHENTICATION CODES - This invention relates to a nucleic-acid based product authentication by determining authentication codes comprising target nucleic acids using oligonucleotide probes immobilized on particulate and non-particulate substrates. The presence of the authentication code is determined using detection methods, such as flow cytometric methods, capable of particle discrimination based on the light scattering or fluorescence properties of the particle, or by spatial resolution of oligonucleotides immobilized at specific loci on a substrate. Target-correlated fluorescence signal, originating from a target nucleic acid hybridized to substrate-immobilized oligonucleotide is determined as an indicator of the presence of the authentication code. | 04-23-2015 |
20150111781 | ANALYZING SEMAPHORIN7A (Sema7A) LEVELS FOR ASSESSING CANCER METASTATIC POTENTIAL - Methods, assays, and kits for determining a cancer's (e.g., breast cancer) metastatic potential and tumor aggressiveness in a subject (e.g., a human patient) and for measuring a subject's response to cancer therapy involve analyzing expression of Sema7A in a biological sample from the subject, and correlating increased expression of Sema7A in the biological sample compared to a control sample with metastatic potential of the cancer, wherein the expression of Sema7A is linearly proportional to the metastatic potential of the cancer in the subject. These methods, kits and assays provide for individualized diagnosis and treatment options for cancer (e.g., breast cancer) patients. They can be used independently, or can be combined with additional diagnostic tests and/or prognostic methods. Compositions, kits and methods for treating a subject having cancer (e.g., breast cancer) include administering a composition for inhibiting Sema7A expression or activity to the subject. | 04-23-2015 |
20150111782 | Methods for Diagnosing and Treating Eye-Length Related Disorders - The invention provides to methods for diagnosing eye-length related disorders, including myopia. The invention also provides methods for treating and limiting eye-length related disorders, including myopia. In addition, the invention provides certain haplotypes associated with eye-length related disorders, including myopia and Bornholm Eye Disease. | 04-23-2015 |
20150111783 | COMPOSITIONS AND METHODS FOR THE DETECTION OF ANTIBODIES TO NATIVE HUMAN LEUKOCYTE ANTIGEN - Provided herein are compositions comprising native and denatured human leukocyte antigens (HLA) and methods of making said compositions. Also provided herein are methods and kits for the detection of antibodies to native HLAs. | 04-23-2015 |
20150111784 | Detecting Cells Secreting A Protein of Interest - In some cases, the described systems and methods include obtaining a cell sample containing multiple antibody-producing cells. In such cases, the cells can be tagged with a cross-linking reagent having a first portion configured to bind to a marker on the antibody-producing cells and a second portion configured to bind to an antigen of interest. In some instances, the tagged antibody-producing cells are exposed to the antigen of interest such that the antigen becomes bound to the cells. In some such instances, the antibody-producing cells are also allowed to produce an antibody, such that a portion of the antibody-producing cells produce an antigen-specific antibody that binds to the antigen of interest. To identify cells that produce the antigen-specific antibody, the tagged cells can be exposed to a labeled secondary antibody that is configured to bind to the antigen-specific antibody. Other implementations are also described. | 04-23-2015 |
20150119263 | CARBON NANOTUBE BIOSENSORS AND RELATED METHODS - Disclosed are devices that comprise a protein, such as an antibody, placed into electronic communication with a semiconductor material, such as a carbon nanotube. The devices are useful in assessing the presence or concentration of analytes contacted to the devices, including the presence of markers for prostate cancer and Lyme disease. | 04-30-2015 |
20150119264 | DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE - The invention relates to novel variants that associate with Alzheimer's disease AD and their use in kits as a means for diagnosing AD; and also their use in nucleic acid molecules or cells/cell lines for identifying novel therapeutic, label of identification means. | 04-30-2015 |
20150119265 | METHOD FOR THE DIAGNOSIS OR PROGNOSIS, IN VITRO, OF LUNG CANCER - The subject matter of the present invention is a method for the diagnosis or prognosis, in vitro, of lung cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, a method for use of said nucleic acid sequences, which have been isolated, as a molecular marker or molecular markers, and a kit including at least one binding partner specific for at least one of the expression products of the HERV nucleic acid sequences. | 04-30-2015 |
20150119266 | ANTIBODY ARRAY USED FOR THE ANALYSIS OF THE THREE-DIMENSIONAL STRUCTURE OF PROTEIN THERAPEUTICS AND ITS PRODUCTION - This invention relates to an antibody array for the analysis of the three-dimensional structure of a protein. It includes the development and production of the antibody array and methods of using the array to analyze the three-dimensional structure of a protein as well as to compare the three-dimensional structure of two proteins, for example, a therapeutic protein and a biosimilar, to determine if the two proteins are similar. | 04-30-2015 |
20150119267 | INHIBITION OF COLONY STIMULATING FACTOR-1 RECEPTOR SIGNALING FOR THE TREATMENT OF BRAIN CANCER - The present invention provides a method of screening brain tumor patients for treatment with inhibitor of CSF-1R, based on differential gene expression including adrenomeduUin (ADM), arginase 1 (ARG1), clotting factor F13A1, mannose receptor C type 1 (MRC1/CD206), and protease inhibitor SERPINB2 after treatment with the inhibitor. Based on the same differential gene expression profile, the present invention also provides a method of screening a compound to treat brain cancer. | 04-30-2015 |
20150119268 | APPARATUS WITH HETEROGENEOUS PROCESSING MODULES - A biological sample processing apparatus having an enclosure. A plurality of sample processing modules are held by the enclosure. Each sample processing module is configured to hold a removable sample cartridge and to only perform sample processing on a sample within the corresponding removable sample cartridge. Each sample processing module is configured to perform at least one of a plurality of testing processes on the sample within the removable sample cartridge. At least one module in the apparatus is configured to perform nucleic acid amplification and detection. | 04-30-2015 |
20150119269 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF STROKE OR OTHER CEREBRAL INJURY - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in stroke patients and in patients at risk for stroke. In particular, the invention relates to using assays that detect one or more biomarkers as diagnostic and prognostic biomarker assays in such patients. | 04-30-2015 |
20150119270 | METHODS FOR DETECTING ALLOSTERIC MODULATORS OF PROTEIN - The present invention discloses, inter alia, methods for labeling a target protein with an SHG-active probe for detection by second harmonic or sum-frequency generation in order to identify agents which bind to an allosteric site on the target protein thereby altering its structural conformation | 04-30-2015 |
20150119271 | BIOMARKERS FOR THE DIAGNOSIS, PROGNOSIS, ASSESSMENT AND THERAPY STRATIFICATION OF SYNCOPE - The present invention relates to a method for the diagnosis and/or prognosis and/or assessment and/or therapy stratification of syncope in a patient the method comprising: determining the level of at least one biomarker selected from the group consisting of proET-1, pro ADM, proANP, proBNP, proAVP and PCT or a fragment of at least 12 amino acids thereof, in a sample of a bodily fluid of said patient, correlating said level of at least one biomarker or fragments thereof with the diagnosis and/or prognosis and/or assessment and/or therapy stratification of syncope. | 04-30-2015 |
20150119272 | DOSE-RESPONSE MEDICAL OUTCOME MODEL PREDICTOR SYSTEM AND METHOD - The invention provides a computer-implemented method and system for predicting quantitatively whether an adjuvant or neoadjuvant chemotherapeutic treatment will be or is being successful in treating an individual suffering from cancer. | 04-30-2015 |
20150119273 | Chronic Traumatic Encephalopathy in Blast-Exposed Individuals - The invention is based on the surprising discovery that as few as one episode of blast exposure increases the risk of CTE. Blast exposure is associated with chronic traumatic encephalopathy, impaired neuronal function, and persistent cognitive deficits in blast-exposed military veterans and experimental animals. Early diagnosis and assessment of risk permits physicians to prescribe treatment to reduce or slow progression of impairment before the onset of overt symptoms that become apparent decades after an initial insult or trauma to brain tissue. The invention provides methods and compositions for diagnosis and prognosis of individuals at risk of long term complications related to blast injury or concussive injury. | 04-30-2015 |
20150119274 | Microplates with Enhanced Immobilisation Capabilities Controlled by Magnetic Field - The present invention describes microplates with arrays of wells containing magnetic inserts in the form of disks, cylinders or otherwise shaped materials with apertures in the centre for optical interrogation of the contacting solution. These inserts are capable of capturing ferro- and paramagnetic nano- and microparticles. The subject microplates find use in a variety of applications, including clinical and environmental assays, high throughput screening for genomics, proteomics and pharmaceutical applications, point-of-care in vitro diagnostics, molecular genetic analysis and nucleic acid diagnostics, cell separations, and bioresearch generally and high-throughput screening of materials for separation and catalysis. | 04-30-2015 |
20150119275 | Methods for Diagnosing, Staging, Predicting Risk for Developing and Identifying Treatment Responders for Rheumatoid Arthritis - Disclosed are methods for diagnosing, staging, and predicting risk for developing rheumatoid arthritis and other inflammatory diseases, and methods for identifying treatment responders and non-responders. | 04-30-2015 |
20150119276 | IMMUNOREACTIVE EHRLICHIA P120/P140 EPITOPES AND USES THEREOF - Provided herein are immunoreactive peptides which can selectively bind | 04-30-2015 |
20150119277 | CANDIDA TROPICALIS OLIGONUCLEOTIDES, DETECTION METHOD, AND KIT THEREOF - The invention discloses an in vitro method for the identification of | 04-30-2015 |
20150119278 | BIOMARKERS AND DIAGNOSTIC METHODS FOR ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS - The present invention relates to biomarkers and diagnostic and prognostic methods for Alzheimer's disease and other neurodegenerative disorders. The invention also provides compositions for detecting the biomarker as well as compositions and methods useful for treating Alzheimer's disease and other neurodegenerative disorders. | 04-30-2015 |
20150119279 | SALIVARY BIOMARKERS FOR PREDIABETES AND TYPE 2 DIABETES - The present invention provides for the first time the identification of salivary protein and RNA factors that can be used in the detection of diabetes. The present invention therefore provides methods of diagnosing and providing a prognosis for diabetes, by examining relevant proteins and RNA in a patient's saliva. | 04-30-2015 |
20150119280 | Hydrogel Microstructures with Immiscible Fluid Isolation for Small Reaction Volumes - Techniques for hydrogel microstructures with oil isolation for small reaction volumes include providing a hydrogel microstructure that has a plurality of pores and a hydrogel frame surrounding the pores. The microstructure has a volume in a range from about 1 picoliter to about 10,000 picoliters and is configured to repel an immiscible fluid. Each pore of the plurality of pores has a pore size configured to pass the target molecule in a first solution. The microstructure is contacted with the first solution, and with a second solution that includes a reactant molecule that reacts with the target molecule to produce an observable product molecule. The microstructure is encompassed with the immiscible fluid for an extended observation duration from about 1 to about 10,000 seconds, wherein the immiscible fluid does not pass into the pores but traps the product in the microstructure. The observable product molecule is measured at some time during the observation duration. | 04-30-2015 |
20150119281 | PHOSPHINE DERIVATIVES OF FLUORESCENT COMPOUNDS - A phosphine derivative of DyLight dyes modified with ethylene glycol or (poly)ethylene glycol groups. In one embodiment, the compounds are useful in chemoselective ligation reactions. | 04-30-2015 |
20150119282 | MARKERS FOR THE DETECTION OF HUMAN EMBRYO DEVELOPMENTAL QUALITY - Markers are provided for genetic and epigenetic diagnosis of embryos to determine those of which are more likely to be chromosomally normal and advance in development. | 04-30-2015 |
20150119283 | METHOD AND SYSTEM FOR THE ANALYSIS OF HIGH DENSITY CELLS SAMPLES - Methods for forming cell arrays of multiple cell samples arranged substantially in a monolayer on a single substrate particularly suited for diagnostic analysis are disclosed. The cell arrays are formed with a high-speed dispensing apparatus capable of dispensing small volumes in precise, complex patterns. Also disclosed are substrates upon which cell arrays may be formed, and methods for conducting diagnostic analyses on the formed cell arrays. | 04-30-2015 |
20150126383 | Sensitive and Rapid Method for Candidatus Liberibacter Species Detection - DNA amplification methods using novel primers obtained from the novel genes for hyvI and hyvII s from the | 05-07-2015 |
20150126384 | Prognostic Biomarkers in Patients with Ovarian Cancer - The present invention provides methods for assessing an ovarian cancer patient's survival status. Also, methods for evaluating the ovarian cancer state of a patient are described herein. These methods involve the detection, analysis, and classification of biological patterns in biological samples. The biological patterns are obtained using, for example, mass spectrometry systems and other techniques. | 05-07-2015 |
20150126385 | BIOMARKER-BASED METHODS AND BIOCHIPS FOR AIDING THE DIAGNOSIS OF STROKE - The present invention provides biomarker-based methods for diagnosing stroke in a patient suspected of having suffered a stroke, and also for discriminating between ischemic stroke and transient ischemic attack. Substrates comprising probes for specific combinations of biomarkers useful in the methods of the invention are also described. | 05-07-2015 |
20150126386 | METHOD FOR THE IN VITRO PREDICTION OF THE PROBABILITY OF A PATIENT DEVELOPING SEVERE DENGUE, BASED ON A BLOOD SAMPLE - The present invention relates to a method for the in vitro prediction of the probability of a patient developing severe dengue, based on a blood sample, which involves: a) determining the quantity of at least one marker, and b) comparing the quantity with a reference quantity obtained from a group of individuals who have been diagnosed with non-severe dengue, and if the quantity determined in step a) is greater than the reference quantity established in step b), predicting that the patient will develop severe dengue, and also to the use of predictive marker(s) and to a kit to predict the development of severe dengue. | 05-07-2015 |
20150126387 | AMPK ACTIVATOR SCREENING METHOD, AND AMPK ACTIVATOR - A method for screening an AMPK activator, wherein inhibition of an interaction between prohibitin and AMPK is used as an index is provided. Besides, an AMPK activator comprising, as an active ingredient, a compound inhibiting an interaction between prohibitin and AMPK, and a prohibitin-AMPK complex are also provided. | 05-07-2015 |
20150126388 | SURFACE ENHANCED RAMAN SPECTROSCOPY (SERS) MARKER CONJUGATES AND METHODS OF THEIR PREPARATION - A surface enhanced Raman spectroscopy (SERS) marker conjugate is provided. The SERS marker conjugate comprises a metallic nanoparticle and an organometallic material attached to a surface of the metallic nanoparticle. A biosensor comprising a plurality of the SERS marker conjugates and a method of forming the SERS marker conjugate is also provided. | 05-07-2015 |
20150126389 | PROBE DENSITY CONSIDERATIONS AND ELONGATION OF SELF-COMPLEMENTARY LOOPED PROBES WHERE PROBES ARE ATTACHED TO A SOLID PHASE - In a multiplexed assay method carried out in solution, wherein the solution contains nucleic acid targets and, wherein several different types of oligonucleotide probes, each type having a different sequence in a region designated as a target binding domain, are used to detect the nucleic acid targets, said assay method including a method for increasing the effective concentration of the nucleic acid targets at the surface of a bead to which the oligonucleotide probes are bound, by one or more of the following steps: | 05-07-2015 |
20150126390 | MULTIPLEX AVIDITY PROFILING OF PROTEIN AGGREGATES - The present invention relates to methods for classifying conformationally-distinct aggregates of the same protein (i.e. “conformers”) by measuring minor differences in the binding avidity of a plurality of epitope-binding agents for each conformer and performing a multivariate analysis that evaluates the avidity of various antibodies for the confomers. | 05-07-2015 |
20150126391 | SIGNAL DETECTION TECHNIQUES FOR THE DETECTION OF ANALYTES - The invention relates to the use of signal processing methods in order to achieve higher signal to noise ratios, to increase the detection limits of target analytes. These techniques include the monitoring of the output signal at higher harmonic frequencies. | 05-07-2015 |
20150126392 | METHOD, SYSTEM, AND KIT FOR CHARACTERIZING A CANCER - A method for characterizing a cancer in a subject, comprising:
| 05-07-2015 |
20150126393 | NANOSTRUCTURED ARRAYS ON FLEXIBLE POLYMER FILMS - The present invention relates to nanocones and nanomaterials. In one embodiment, the present invention provides a method of fabricating an array of nanostructures on a flexible film, comprising self-assembling a layer of particles on a film, and fabricating an array of nanostructures by etching and/or modifying the film. In another embodiment, the present invention provides a microarray comprising a nanomaterial comprising a film configured for an array of one or more nanocones. | 05-07-2015 |
20150126394 | DETECTING CANCER WITH ANTI-CXCL13 AND ANTI-CXCR5 ANTIBODIES - Methods for diagnosing cancer in a subject are disclosed. The method includes detecting the level of expression of one or more cancer markers in a biological sample obtained from the subject; and comparing the level of expression of the one or more cancer markers in the biological sample to a normal level of expression of the one or more cancer markers. The one or more cancer markers comprises CXCL13 or CXCR5 or both CXCL13 and CXCR5. Also disclosed is a kit for detecting cancer or monitoring cancer progression. | 05-07-2015 |
20150126395 | Methods and Kits for Detecting a Prostate Carcinoma and Predicting Disease Outcomes for Prostate Cancers - The present invention provides methods for diagnosing whether a human subject has a prostate carcinoma, methods for differentiating a high grade prostate cancer from a low grade prostate cancer in a human subject having a prostate carcinoma, and kits for detecting prostate cancer cells in a sample from a human subject. | 05-07-2015 |
20150126396 | Method for Identification, Selection and Analysis of Tumour Cells - The present invention relates to a method for the diagnosis of tumoural conditions and/or of the corresponding state of advance, wherein a sample from a patient comprising at least one tumour cell is obtained. According to the invention, a purified specimen of the at least one tumour cell is obtained by individually selecting and isolating single cells in a microfluidic device the purified specimen having a purity of at least 90%. On the purified specimen thus obtained there is subsequently performed a molecular analysis such as to highlight a characteristic thereof suited to enabling diagnosis. | 05-07-2015 |
20150126397 | DETECTION OF DIGESTIVE ORGAN CANCER, GASTRIC CANCER, COLORECTAL CANCER, PANCREATIC CANCER, AND BILIARY TRACT CANCER BY GENE EXPRESSION PROFILING - The present invention provides a method and a reagent for detecting a digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, or biliary tract cancer patient by analyzing genes with expression levels (in peripheral blood) that vary in association with digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, or biliary tract cancer cases, compared with normal healthy subjects. Specifically, the method for detecting a digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, or biliary tract cancer patient based on expression profiles comprises obtaining the expression profile of at least one gene selected from the group consisting of probes corresponding to genes with expression levels (in peripheral blood) that vary in digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, and biliary tract cancer cases, compared with normal healthy subjects. The reagent for detecting digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, or biliary tract cancer contains nucleotides or partial sequences thereof consisting of the nucleotide sequence of at least one gene selected from the group consisting of probes with expression levels that vary in digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, or biliary tract cancer, or nucleotides containing sequences complementary thereto. | 05-07-2015 |
20150126398 | Methods for Dendritic Cell Precursor Populations, Dendritic Cell Populations Derived Therefrom, and Uses Thereof - Dendritic cell precursor populations, dendritic cell populations derived therefrom, methods for isolating, expanding and using are disclosed. | 05-07-2015 |
20150126399 | DIAGNOSIS AND PROGNOSIS OF VARIOUS TYPES OF CANCERS - The present invention provides nucleic acid sequences that are used for identification, classification and diagnosis of specific types of cancers. The nucleic acid sequences can also be used for prognosis evaluation of a subject based on the expression pattern of a biological sample. | 05-07-2015 |
20150126400 | MOLECULAR DIAGNOSTIC SCREENING ASSAY - The invention generally relates to method for screening for a condition in a subject. In certain embodiments, methods of the invention involve obtaining a pool of nucleic acids from a sample, incubating the nucleic acids with first and second sets of binders, in which the first set binds uniquely to different regions of a target nucleic acid in the pool, the second set binds uniquely to different regions of a reference nucleic acid in the pool, and the first and second sets include different detectable labels, removing unbound binders, detecting the labels, and screening for a condition based upon results of the detecting step. | 05-07-2015 |
20150126401 | CALPROTECTIN AND HEMOGLOBIN/HAPTOGLOBIN COMPLEX FROM STOOL SAMPLE TO ASSESS COLORECTAL CANCER - The present invention relates to a method aiding in the assessment of colorectal cancer. The method especially is used in assessing the absence or presence of colorectal cancer in vitro. The method is for example practiced by analyzing biochemical markers, comprising measuring in a stool sample the concentration of the hemoglobin/haptoglobin complex and calprotectin and correlating the concentrations determined to the absence or presence of colorectal cancer. To further improve the assessment of colorectal cancer based on a method of this invention the level of one or more additional marker may be determined together with the hemoglobin/haptoglobin complex and calprotectin in a stool sample and be correlated to the absence or presence of colorectal cancer. The invention also relates to the use of a marker panel comprising the hemoglobin/haptoglobin complex and calprotectin in the early diagnosis of colorectal cancer and it teaches a kit for performing the method of the invention. | 05-07-2015 |
20150133321 | QUANTITATIVE IN SITU CHARACTERIZATION OF BIOLOGICAL SAMPLES - The present disclosure relates to characterization of biological samples. By way of example, a biological sample may be contacted with a plurality of probes specific for targets in the sample, such as probes for immune markers and segmenting probes. Acquired image data of the sample may be used to segment the images into epithelial and stromal regions to characterize individual cells in the sample based on the binding of the probes. Further, the biological sample may be characterized by a distribution, location, and type of a plurality of the characterized cells. | 05-14-2015 |
20150133322 | METHOD FOR THE DIAGNOSIS OF EARLY RHEUMATOID ARTHRITIS - The present invention relates to biomarkers that are specifically recognized by autoantibodies present in a biological of patients with Rheumatoid Arthritis (RA). The invention provides methods and kits using these biomarkers for the diagnosis of RA, in particular for the diagnosis of early RA. | 05-14-2015 |
20150133323 | METHOD FOR CHARACTERIZING CIRCULATING TUMOR CELLS, AND USE THEREOF IN DIAGNOSIS - Disclosed is a method for characterization, in a biological sample, of circulating tumour cells (CTCs) bearing at least one marker characteristic of the tumorous nature of the cell, the marker being selected from the groups constituted by: the oncogenic proteins characteristic of the CTCs, and the tumour markers. Also disclosed is the use of this method for deciding on the implementation of a treatment for a cancer patient. | 05-14-2015 |
20150133324 | MULTIPLEX REAL-TIME PCR DETECTION OF INFLUENZA VIRUSES 2009 H1N1, INFLUENZA A AND INFLUENZA B - The present invention relates to assays, diagnostic kits and methods for the simultaneous real-time PCR detection of influenza viruses selected from influenza A subtypes H1 and/or H3 and/or influenza 2009 H1N1 and/or influenza B. | 05-14-2015 |
20150133325 | METHODS OF DETECTING BLADDER CANCER - Compositions and methods for detecting bladder cancer are provided. In some embodiments, methods of monitoring recurrence of bladder cancer are provided. In some embodiments, the methods comprise detecting a set of markers consisting of CRH, IGF2, KRT20, and ANXA10. | 05-14-2015 |
20150133326 | BIOMARKERS FOR RECOVERED HEART FUNCTION - Disclosed herein is a method for determining recovered heart function in a subject based in the biomarker ceruloplasmin in patient samples. Also disclosed are computer systems, kits and software. | 05-14-2015 |
20150133327 | METHOD FOR DETECTING OR MONITORING PROSTATE CANCER - The present invention provides methods identifying subjects having prostate cancer (PCa) by detecting in micro-particles a pair of biomarkers. The methods disclosed can be used to distinguish subjects having PCa from those having non-malignant prostate pathologies, including benign prostatic hyperplasia. Methods for monitoring prostate cancer and assessing efficacy of prostate cancer therapies are also disclosed. Kits for detecting prostate cancer using the methods disclosed are also provided. | 05-14-2015 |
20150133328 | PROBE OR PROBE SET FOR EVALUATING INFLUENCE OF ULTRAVIOLET RAY ON SKIN AND NUCLEIC ACID MICROARRAY - Provided are a probe or a probe set which can evaluate what the skin condition or a skin cell is, and what kind of influence an external stimulation (particularly ultraviolet ray) to the skin or a skin cell has on the skin condition, such as elasticity and wrinkles, and a nucleic acid microarray which is loaded with the probe or the probe set. The invention is an invention related to a probe or a probe set for evaluating the influence of ultraviolet ray on the skin, which comprises nucleic acids of (a), (b) or (c) described below. (a) Nucleic acids comprising a base sequence constituting at least one kind of gene selected from the group consisting of GBA, GLB1, CAT, OLFM1, ASAH1, MMP14, MMP17 and COL18A1; (b) Nucleic acids comprising a base sequence complementary to the nucleic acids of aforesaid (a); (c) Nucleic acids which hybridize with nucleic acids comprising a base sequence complementary to the nucleic acids of aforesaid (a) or (b) under stringent conditions, and can detect a skin constitution-related gene. | 05-14-2015 |
20150133329 | METHODS OF DETECTING INFLUENZA VIRUS - Disclosed herein are methods of detecting influenza virus in a sample from a subject. In some embodiments, the disclosed methods include contacting a sample with at least one primer 10-40 nucleotides in length wherein the at least one primer is capable of hybridizing to an influenza virus polymerase basic protein 1 (PB1) nucleic acid at least 70% identical to the nucleic acid sequence set forth as any one of SEQ ID NOs: 1-3, amplifying the PB1 nucleic acid or a portion thereof to produce an amplified PB1 nucleic acid, and detecting the amplified PB1 nucleic acid, wherein presence of the amplified PB1 nucleic acid indicates presence of influenza virus in the sample from the subject. In some examples, the primers comprise or consist of the nucleic acid sequence set forth as one of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 9, or SEQ ID NO: 10. | 05-14-2015 |
20150133330 | METHODS AND COMPOSITIONS USEFUL FOR DIAGNOSING INFLAMMATORY BOWEL DISEASE-ASSOCIATED NEOPLASIA - The present invention relates to the field of biomarkers. More specifically, the present invention relates to the use of microRNAs to diagnose and monitor various diseases such as cancer. In particular embodiments, microRNA expression levels can serve as diagnostic biomarkers in inflammatory bowel disease-associated neoplasia (IBDN). More specifically, in certain embodiments, the present invention can be used to differentiate or distinguish IBDN from sporadic colorectal cancer (S-CRC), IBD-Dysplasia, IBD and/or normal. | 05-14-2015 |
20150133331 | METABOLITE BIOMARKERS FOR THE DETECTION OF LIVER CANCER - Methods for the detection and screening of hepatocellular carcinoma (HCC) patients and for the monitoring of HCC treatment using a panel or panels of small molecule metabolite biomarkers are disclosed. In other aspects, methods for detection and screening for the progression of high-risk conditions, such as HCV infections, to HCC and to monitoring treatment using a panel or panels of small molecule metabolite biomarkers are disclosed. The biomarkers are sensitive and specific for the detection of HCC, and can also be used to classify HCV infections that are regarded as precursors of HCC. | 05-14-2015 |
20150133332 | DETECTION, ISOLATION AND ANALYSIS OF RARE CELLS IN BIOLOGICAL FLUIDS - The invention provides a method for isolating or enriching a rare cell from a biological fluid of a mammal employing an antibody that binds a cell-surface antigen of the rare cell. The immobilized antibody is incubated with a sample of biological fluid that includes the rare cells and a plurality of other cells so as to form an antibody-rare cell complex. The complex can be detected or isolated and subsequently analyzed by any of a variety of physical, chemical and genetic techniques. | 05-14-2015 |
20150133333 | COMPOSITIONS AND METHODS FOR DETECTING COMPLICATED SARCOIDOSIS - Disclosed are kits and methods for diagnosing a person with, or assessing a person's risk for developing, sarcoidosis and/or complicated sarcoidosis. | 05-14-2015 |
20150133334 | DETECTION OF DIGESTIVE ORGAN CANCER, GASTRIC CANCER, COLORECTAL CANCER, PANCREATIC CANCER, AND BILIARY TRACT CANCER BY GENE EXPRESSION PROFILING - The present invention provides a method and a reagent for detecting a digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, or biliary tract cancer patient by analyzing genes with expression levels (in peripheral blood) that vary in association with digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, or biliary tract cancer cases, compared with normal healthy subjects. Specifically, the method for detecting a digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, or biliary tract cancer patient based on expression profiles comprises obtaining the expression profile of at least one gene selected from the group consisting of probes corresponding to genes with expression levels (in peripheral blood) that vary in digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, and biliary tract cancer cases, compared with normal healthy subjects. The reagent for detecting digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, or biliary tract cancer contains nucleotides or partial sequences thereof consisting of the nucleotide sequence of at least one gene selected from the group consisting of probes with expression levels that vary in digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, or biliary tract cancer, or nucleotides containing sequences complementary thereto. | 05-14-2015 |
20150133335 | DETECTION OF DIGESTIVE ORGAN CANCER, GASTRIC CANCER, COLORECTAL CANCER, PANCREATIC CANCER, AND BILIARY TRACT CANCER BY GENE EXPRESSION PROFILING - The present invention provides a method and a reagent for detecting a digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, or biliary tract cancer patient by analyzing genes with expression levels (in peripheral blood) that vary in association with digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, or biliary tract cancer cases, compared with normal healthy subjects. Specifically, the method for detecting a digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, or biliary tract cancer patient based on expression profiles comprises obtaining the expression profile of at least one gene selected from the group consisting of probes corresponding to genes with expression levels (in peripheral blood) that vary in digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, and biliary tract cancer cases, compared with normal healthy subjects. The reagent for detecting digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, or biliary tract cancer contains nucleotides or partial sequences thereof consisting of the nucleotide sequence of at least one gene selected from the group consisting of probes with expression levels that vary in digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, or biliary tract cancer, or nucleotides containing sequences complementary thereto. | 05-14-2015 |
20150133336 | METHODS FOR DETERMINING LIGAND BINDING TO A TARGET PROTEIN USING A THERMAL SHIFT ASSAY - The present invention concerns a method of determining whether a non-purified sample contains a target protein bound to a ligand of interest comprising the steps of a) exposing the non-purified sample to a temperature which is capable of causing or enhancing precipitation of the unbound target protein to a greater extent than it is capable of causing or enhancing precipitation of the target protein bound to the ligand; and b) analysing said sample for the presence of soluble or native target protein using two or more affinity reagents capable of binding to said soluble or native target protein with a higher affinity than to an unfolded and/or insoluble form of said target protein. The invention particularly concerns the use of two affinity reagents (e.g. antibodies) which are capable of distinguishing between soluble or native, and unfolded and/or insoluble forms of a target protein and whose detection e.g. by FRET based technology, allows the performance of the method without a separation step. | 05-14-2015 |
20150133337 | SYSTEMS AND METHODS FOR DETECTION AND QUANTIFICATION OF ANALYTES - Devices, systems, and methods for detecting molecules of interest within a collected sample are described herein. In certain embodiments, self-contained sample analysis systems are disclosed, which include a reusable reader component, a disposable cartridge component, and a disposable sample collection component. In some embodiments, the reader component communicates with a remote computing device for the digital transmission of test protocols and test results. In various disclosed embodiments, the systems, components, and methods are configured to identify the presence, absence, and/or quantity of particular nucleic acids, proteins, or other analytes of interest, for example, in order to test for the presence of one or more pathogens or contaminants in a sample. | 05-14-2015 |
20150133338 | HYDROLYSIS PROBES - Methods and compositions for the detection and quantification of nucleic acids are provided. In one embodiment, a sample is contacted with a primer complementary to a first region of a target nucleic acid and a probe complementary to a second region of the target nucleic acid downstream of the first region under conditions suitable for hybridization of the target nucleic acid with the primer and the probe. The probe in this embodiment comprises a fluorophore and is attached to a solid support. The hybridized probe is cleaved with a nucleic acid polymerase having exonuclease activity to release the reporter from the solid support. The presence of the target nucleic acid is then detected and optionally quantified by detecting a decrease in signal from the reporter on the solid support. | 05-14-2015 |
20150141272 | ULTRA-SENSITIVE DETECTION OF EXTREMELY LOW LEVEL BIOLOGICAL ANALYTES USING ELECTROCHEMICAL SIGNAL AMPLIFICATION AND BIOSENSOR - This invention allows ultra-low levels of virtually any biological analyte to be detected and quantified rapidly, simply and inexpensively with an electrochemical biosensor using a novel electrochemical signal amplification technique. The invention amplifies detection signals from low level analytes using an innovative sandwich ELISA structure that replaces optical labels with a massive amount of electrochemically detectable guanine rich oligonucleotide tags. Selective binding is achieved with matched pairs of either commercial or custom analyte binding materials such as monoclonal antibodies or single stand DNA. The guanine tags are eluted from the sandwich structures and hybridize with complementary cytosine rich oligonucleotide recognition probes attached to the surface of a biosensor working electrode. An electrochemical technique generates a signal in proportion to the guanine level on the working electrode which is also proportional to the analyte level in the sample. Magnetic separation and a nanosensor are used to improve the signal-to-noise ratio for measuring analyte levels 1,000,000 times lower than enzyme-linked immunosorbent assay (ELISA). | 05-21-2015 |
20150141273 | BIOMARKERS - The invention provides a method for screening for colorectal cancer, the method comprising: screening a biological sample from an individual for one or more biomarkers selected from the group defined in Table 1 and/or Table 6, wherein the presence of or increased expression of the one or more biomarkers relative to a control sample is indicative that the individual is at risk of suffering from or is suffering from colorectal cancer. The invention also provides an array and kit suitable for use in the methods of the invention, methods of treating colorectal cancer and therapeutic agents for use in methods of treating cancer. | 05-21-2015 |
20150141274 | Methods and Compositions for Activity Dependent Transcriptome Profiling - Disclosed herein are methods, compositions, and kits for isolating actively translated mRNA from heterogeneous cell populations. Also disclosed herein are methods, compositions, and kits for identifying cell types that respond to stimuli in heterogeneous cell populations. | 05-21-2015 |
20150141275 | DIAGNOSTIC GENE MARKER PANEL FOR COLORECTAL CANCER - The present invention relates generally to a method of screening for the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention relates to a method of screening for the onset, predisposition to the onset and/or progression of a neoplasm by screening for changes to the methylation levels of a panel of gene markers including BCAT1, IKZF1, IRF4, GRASP and/or CAHM. The method of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinosis. | 05-21-2015 |
20150141276 | IN VITRO METHOD FOR DIAGNOSIS OF ENDOMETRIOSIS - The present description relates to an in vitro method for the diagnosis of endometriosis, an in vitro method for the monitoring of endometriosis and a kit for the diagnosis of endometriosis and/or for the monitoring of endometriosis in a subject. | 05-21-2015 |
20150141277 | METHODS OF QUANTIFYING OF NUCLEIC ACIDS CAPTURED ON A SOLID SUPPORT - A method for the measurement of the amount or difference in the amounts of 2 or more nucleic acid targets in a sample, the method comprising the steps of attaching to nucleic acids present in the sample (1) a tag which allows the nucleic acids to be captured to a solid support; and (2) a labelled probe for a first nucleic acid target present in the sample and a labelled probe for second nucleic acid target present in the sample, and then measuring the amount of each labelled probe or difference in the amount of labelled probes; wherein the probe is not a single labelled nucleotide. | 05-21-2015 |
20150141278 | MULTIPLEXED ASSAY METHOD FOR LUNG CANCER CLASSIFICATION - A method for providing a composite image of a single biological sample from a patient suspected of having lung cancer, comprising the steps of generating a first image of the biological sample, generating a second image of the biological sample, and generating a composite image that provides the relative location of both the targeted proteins. Also provided is a method of analyzing a biological sample, comprising providing a composite image of the biological sample according to the method for providing a composite image, and analyzing the expression of the protein of interest from the composite image. Further provided are method for classification of lung cancer, as well as system and kit that comprise the means for executing the novel methods. | 05-21-2015 |
20150141279 | Method for Diagnosing Tuberculosis Disease by Detecting Induced Markers After Stimulation of T-Cells With Antigens - A method of diagnosing | 05-21-2015 |
20150141280 | MIRNA ONCOLOGIC BIOMARKER OF BREAST CANCER - The invention provides methods of and diagnostic kits for the detection of breast cancer, in particular luminal A breast cancer, or to assist in assessing the prognosis, or determine the efficacy of a treatment regimen for breast cancer comprising at least one oligonucleotide probe capable of binding to at least a portion of a circulating miRNA selected from the group comprising the miR-181a and miR-652 biomarkers. The invention also provides methods of identifying a therapeutic agent capable of preventing or treating cancers, including breast cancer, comprising testing the ability of the potential therapeutic agent to enhance the expression of at least one protein selected from the group comprising miR-181a and miR-652. | 05-21-2015 |
20150141281 | METHOD AND DEVICE FOR PERFORMING BIOLOGICAL AND/OR CHEMICAL ASSAYS - The present invention relates to a method for performing a chemical and/or a biological assay comprising the following successive steps of: a) providing an assay device with a microchannel having an inlet and an outlet and further comprising restricting means designed to restrict the movement toward the outlet of microparticles introduced in the microchannel while letting a fluid to flow through the restricting means, b) introducing microparticles in the microchannel via the inlet, c) restricting the movement of said microparticles in the microchannel toward the outlet using restricting means, d) flowing a fluid sample through the microchannel, e) performing a biological and/or chemical read-out on each microparticle, the method further comprising the steps of: f) moving the microparticles in the microchannel, and g) repeating successively the steps d) and e). | 05-21-2015 |
20150141282 | RNA SEQUENCES THAT INDUCE FLUORESCENCE OF SMALL MOLECULE FLUOROPHORES - The present invention relates to novel nucleic acid molecules, called aptamers, that bind specifically to a small molecule fluorophore and thereby enhance the fluorescence signal of the fluorophore upon exposure to radiation of suitable wavelength. Molecular complexes formed between the novel fluorophores, novel nucleic acid molecules, and their target molecules are described, and the use of multivalent aptamer constructs as fluorescent sensors for target molecules of interest are also described. | 05-21-2015 |
20150141283 | IL-17 HOMOLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF - The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases. | 05-21-2015 |
20150141284 | HUMAN T CELL LINE ASSAY FOR EVALUATING THE IMMUNOLOGIC IDENTITY OF GLATIRAMER ACETATE PREPARATIONS - The invention relates to the field of medicine. The invention provides methods for generating glatiramer-acetate-specific human T-cell lines, and assays that use these T-cell lines for demonstrating immunological identity between glatiramer acetate preparations. These assays allow sensitive and accurate comparison of glatiramer acetate preparations, and find utility as lot-release assays. | 05-21-2015 |
20150141285 | Detection of Unlabeled Nucleic Acids by Changing Solubility of Surface-Associating Probes - Provided are methods and devices for detection of unlabeled nucleic acids. The detection methods are based on change of solubility of hydrophobic probes upon hybridization with a polynucleotide. In one embodiment, the probes are morpholino probes, having a fluorophore attached thereto. The morpholino probes are immobilized on a substrate that has fluorescence quenching functionality. | 05-21-2015 |
20150141286 | METHOD AND APPARATUS FOR DETERMINING A PROBABILITY OF COLORECTAL CANCER IN A SUBJECT - A method of determining a probability that a human test subject has colorectal cancer as opposed to not having colorectal cancer is disclosed. The method comprises, for each gene of a set of one or more genes selected from the group consisting of ANXA3, CLEC4D, IL2RB, LMNB1, PRRG4, TNFAIP6 and VNN1: determining a level of RNA encoded by the gene in blood of the test subject, thereby generating test data; providing positive control data representing levels of RNA encoded by the gene in blood of human control subjects having colorectal cancer, and providing negative control data representing levels of RNA encoded by the gene in blood of human control subjects not having colorectal cancer; and determining a probability that the test data corresponds to the positive control data and not to the negative control data, where the probability that the test data corresponds to the positive control data and not to the negative control data represents the probability that the test subject has colorectal cancer as opposed to not having colorectal cancer. | 05-21-2015 |
20150141287 | GENETIC MARKERS ASSOCIATED WITH INTELLECTUAL DISABILITY - Genetic markers associated with intellectual disability as well as compositions, methods and kits for screening for genetic markers of intellectual disability, diagnosing intellectual disability and identifying individuals with a predisposition for offspring suffering from intellectual disability are provided. | 05-21-2015 |
20150141288 | LONGITUDINAL ASSAY - Embodiments of the invention relate generally to macro and small molecule detection and, more particularly, to methods for detecting macro and small molecules, including bio-molecules, in a liquid or gaseous sample. Methods according to embodiments of the invention are useful in the identification, discovery, and validation of biomarkers, as well as the screening of individuals for such biomarkers for diagnostic, therapeutic, and forensic purposes. In one embodiment, the invention provides a method of detecting an analyte in a fluid sample, the method comprising: passing a fluid sample containing a labeled analyte across at least one assay surface containing a capture agent for the analyte; detecting the labeled analyte; repeating the passing and detecting steps at least once; and creating a binding curve for the analyte based on the detecting of the labeled analyte. | 05-21-2015 |
20150148243 | METHOD FOR REVERSIBLE FIXATION OR SELECTIVE LYSIS OF CELL USING PHOTOCLEAVABLE POLYMER - A photocleavable polymer comprising a photocleavable linker and a polymer having a functional group that binds to a protein, lipid, sugar of a cell, or any combination thereof, as well as a method of selectively lysing cells by incubating a sample comprising two or more cells with the photocleavable polymer to reversibly fix the cells; selectively irradiating the fixed cells or a target or non-target cell among the fixed cells to cleave the photocleavable polymer; and adding a cell lysis solution to selectively lyse the irradiated cells. | 05-28-2015 |
20150148244 | METHODS FOR DETERMINING RESPONSIVENESS TO A DIHYDROFOLATE REDUCTASE INHIBITOR - The present disclosure provides methods for predicting or determining the sensitivity of a cell and/or biological sample obtained from a subject to a DHFR inhibitor including, for example, an antifolate such as Methotrexate or Pemetrexed. Such methods may comprise determining the expression level of one or more miRNAs (e.g., one or more members of the miR-181 and/or miR-143 families) in a cell or biological sample. The methods may be used to determine the responsiveness of a subject to treatment with a DHFR inhibitor. | 05-28-2015 |
20150148245 | Methods of Monitoring Responsiveness to Anti-SMAD7 Therapy - Methods for monitoring whether a subject will be sensitive or resistant to treatment with an anti-SMAD7 therapy are disclosed. The methods are based on the determining of the amount of CCR9+ FOXP3+ T cells, CCR9+ IFN-gamma+ T cells, CCR9+ IL17A+ T cells, FOXP3+ T cells, IFN-gamma+ T cells, and/or IL17A+ T cells in a sample from the subject. Measurement of T cell populations may be determined by flow cytometry, immunohistochemistry, and/or ELISA. | 05-28-2015 |
20150148246 | SURFACE ANCHORED LIGHT CHAIN BAIT ANTIBODY DISPLAY SYSTEM - The present invention provides, in part, an antibody display system that simultaneously uses a secretion and a display mode. Embodiments of the invention provide a system in which a bait complexed with a monovalent antibody fragment can be captured prior to secretion in a host cell by virtue of surface displaying an antibody light chain and utilizing the covalent interaction of this light chain with the heavy chain of an antibody molecule that is co-expressed in the same host. Polypeptides, polynucleotides and host cells useful for making the antibody display system are also provided along with methods of using the system for identifying antibodies that bind specifically to an antigen of interest. | 05-28-2015 |
20150148247 | METHODS AND DEVICES FOR TUBERCULOSIS DIAGNOSIS USING BIOMARKER PROFILES - The invention relates to tuberculosis diagnostic methods and devices that measure particular biomarker profiles in subjects and identify a subject having tuberculosis based on such profiles. | 05-28-2015 |
20150148248 | MMP2 AS A PREDICTIVE BIOMARKER OF RESPONSE TO ANTIANGIOGENIC THERAPY AND SURVIVAL AFTER THERAPY IN CANCER PATIENTS - The present invention relates to the use of matrix metalloproteinase-2 (MMP2) as a predictive biomarker of response to antiangiogenic therapy and survival after antiangiogenic therapy in cancer patients, and to related methods for predicting or monitoring the response to an antiangiogenic treatment and the survival after said treatment of a cancer patient. | 05-28-2015 |
20150148249 | METHOD OF IMPROVING THE SENSITIVITY OF COMPETITIVE IMMUNOASSAY - The present invention discloses a method improving the sensitivity of competitive immunoassay, mainly, the small molecular substances for detection first react with the antibody/receptor sufficiently, then react with the second molecules, which locates on the solid phase and participates the competitive reactions, in a short time, which may greatly improve the sensitivity of competitive immunoassay. The present invention owns an easy operation method and a low cost, does not require expensive equipments or professional technological personnel, also, it owns a high sensitivity and adapts to a plurality of immunoassay methods. | 05-28-2015 |
20150148250 | AMPLIFICATION REPORTER WITH BASE-PAIRING OLIGOMERS - System, including methods, apparatus, and compositions, for performing amplification assays with an amplification reporter including a first oligomer and a second oligomer capable of base-pairing with one another below a melting temperature of the reporter. The reporter may have a detectable photoluminescence that is affected, such as reduced, by base-pairing of the first and second oligomers with one another. A target, such as a nucleic acid target sequence, may be amplified in at least one volume, such as a plurality of partitions, above the melting temperature, and photoluminescence of the reporter may be detected from the at least one volume below the melting temperature. A property of the target, such as a concentration of the target, may be determined based on the photoluminescence detected. | 05-28-2015 |
20150148251 | AUTISM ASSOCIATED GENETIC MARKERS - The present disclosure relates to the identification of a subject that is affected with, or predisposed to, autism or to one or more autism spectrum disorders (ASD). The present disclosure includes methods related to the association of certain genetic markers with autism and/or ASD. More particularly, the present disclosure is related to methods and diagnostic tests for diagnosing or predicting ASD in an individual. | 05-28-2015 |
20150148252 | MULTIPLEX TARGET DETECTION ASSAY - Provided herein are reagents and kits for detection of multiple target sequences in a single-tube, single-color assay, and methods of use thereof. In particular, multiplex assays are provided for the detection of | 05-28-2015 |
20150148253 | CELL WITH SURFACE COATED WITH ANXA1 AND USE THEREOF - A cell having a surface coated with Annexin A1 (ANXA1), a method of detecting a substance binding to ANXA1 using the cell, and a method of preparing the cell are provided. | 05-28-2015 |
20150148254 | Diffuse Large B-Cell Lymphoma Markers and Uses Therefor - The present invention provides methods and compositions for prognosing treatment outcome in DLBCL patients, diagnosing DLBCL and monitoring efficacy of DLBCL treatment. | 05-28-2015 |
20150148255 | APPARATUS, SYSTEM, AND METHOD FOR COLLECTING A TARGET MATERIAL - This disclosure is directed to an apparatus, system and method for retrieving a target material from a suspension. A system includes a plurality of processing vessels and a collector. The collector funnels portions of the target material from the suspension through a cannula and into the processing vessels. Sequential density fractionation is the division of a sample into fractions or of a fraction of a sample into sub-fractions by a step-wise or sequential process, such that each step or sequence results in the collection or separation of a different fraction or sub-fraction from the preceding and successive steps or sequences. In other words, sequential density fractionation provides individual sub-populations of a population or individual sub-sub-populations of a sub-population of a population through a series of steps. | 05-28-2015 |
20150291995 | HIGH-THROUGHPUT MUTAGENIZED CELL SCREENING SYSTEM FOR SELECTIVE SINGLE CELL EXTRACTION - The subject invention pertains to a microfluidic apparatus and methods for screening and isolating a target cell from a population of cells. The apparatus comprises a first microfluidic layer comprising microfluidic channels; a second microfluidic layer comprising microfluidic channels; and a microfluidic cell analysis layer comprising a top hanging blocking structure located directly below each location where the first layer microfluidic channels overlap with the second layer microfluidic channels and a cell trap juxtaposed to each of the top hanging blocking structures. The top hanging blocking structures can close or open the juxtaposed cell trap when either or both the first or second layer microfluidic channels located directly above the top hanging blocking structure are sufficiently pressurized and/or sufficiently depressurized. The methods for screening and isolating a target cell from a population of cells comprise screening the population of cells using the apparatus and isolating the target cell interest therefrom. | 10-15-2015 |
20150292000 | CONTROL FOR DIAGNOSTIC ASSAY - A method for determining whether a lysate contains sufficient biological sample material for a nucleic acid amplification reaction that includes preparing the lysate in the presence of at least one compound that inhibits the amplification reaction if insufficient biological sample material was present during preparation of the lysate, but does not inhibit the amplification reaction if sufficient biological sample material was present during preparation of the lysate, subjecting the lysate to the amplification reaction, and analyzing a result of the amplification reaction. Due to the presence of the compound in the amplification reaction, no amplification signal is obtained if insufficient biological sample material was present during preparation of the lysate but an amplification signal is obtained if sufficient biological sample material was present during preparation of the lysate. The invention allows for reliable identification of false negatives that occur because insufficient sample material was subjected to the amplification assay. | 10-15-2015 |
20150292005 | NUCLEIC ACID MOLECULES FOR HIGHLY SENSITIVE DETECTION OF LIGANDS, SCREENING METHOD FOR NUCLEIC ACID MOLECULES, AND OPTIMIZATION METHOD FOR SENSITIVITY OF NUCLEIC ACID MOLECULES - It is an object of the present invention to provide nucleic acid molecules that enable highly sensitive detection of ligands (e.g., patulin). It is another object of the present invention to provide a screening method for nucleic acid molecules that enable highly sensitive detection of ligands (e.g., patulin), and a method for screening for nucleic acid molecules used for the optimization of nucleic acid molecules that enable highly sensitive detection of ligands (e.g., patulin). It is a further object of the present invention to provide a method for effectively removing ligands from samples containing ligands (e.g., patulin). According to the present invention, there is provided a loop-structured nucleic acid molecule for detection of ligands (e.g., patulin) having a DNA aptamer and a DNAzyme, wherein the sequence is modified between the DNA aptamer region and the DNAzyme. | 10-15-2015 |
20150292006 | MULTIPLEX DECODING OF ARRAY SENSORS WITH MICROSPHERES - The invention relates to compositions and methods for multiplex decoding of microsphere array sensors. | 10-15-2015 |
20150292024 | BIOMARKERS FOR BREAST CANCER PREDICTION AND DIAGNOSIS - This invention provides the applications of CST1 gene and its splice variants (sequence shown in SEQ ID No.48) and cystatin SN protein coded by CST1 gene (sequence shown in SEQ ID No.52) for the predictions and diagnoses of human breast cancers. The invention can be used for the diagnosis of breast cancer and breast cancer metastasis, for the analysis for the susceptibility for breast cancer, for the evaluation of the treatments, medicine, efficacy and prognosis for original or metastatic breast cancer patients, and for the risk assessment for breast cancer or its metastasis. The methods described in this invention are of significant sensitivity, specificity and reliability. The invention provides the capturers of CST1 gene, its splice variants and cystatin SN and their applications in manufacturing diagnostic reagents, kits and chips for breast cancers. The diagnostic reagents, kits and chips for breast cancer are included in this invention. | 10-15-2015 |
20150292025 | METHYLATION BIOMARKERS FOR PROSTATE CANCER - Different combinations of methylation status based biomarkers can be used to test for prostate cancer with high sensitivity and high specificity. | 10-15-2015 |
20150292029 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING GASTRIC CANCER - The present invention relates to the field of gastric cancer. More specifically, the present invention provides methods and compositions for diagnosing and treating gastric cancer. In a specific embodiment, a method for diagnosing gastric cancer or a likelihood thereof in a patient comprises the steps of (a) providing a sample from the patient; (b) measuring the methylation levels of one or more biomarkers in the sample collected from the patient; and (c) predicting gastric cancer in the patient if the biomarkers are hypermethylated. In a more specific embodiment, the one or more biomarkers comprises tight junction protein claudin-1 1 (CLD-N11), the transcription factor BarH-like homeobox (BARX1), basonuclin1 (BNC1), Coagulation factor C homolog (COCH), filamin C gamma (FLNC), cytoglobin B (CYGB), glutamine-fructose-6-phospahe-transaminase-2 (GFPT2), heat-shock-70 kDa protein-6 (HSPA6), snail homolog 1(SNAL1), skin calmodulin-related factor (SCARF), and tumor protein p53 binding protein 2 (TP53BP2). | 10-15-2015 |
20150292031 | TREATMENT OF ANGIOGENESIS DISORDERS - This invention concerns pathological angiogenesis and cancer, related treatment methods, and related compositions. Also disclosed are related diagnosis kits and methods. | 10-15-2015 |
20150292034 | RECEPTOR GENE FOR PEPTIDE CANCER ANTIGEN-SPECIFIC T CELL - The invention provides the nucleotide sequence and amino acid sequence of the CDR3 domain of the T cell receptor (TCR) gene of a WT1-specific cytotoxic T cell (CTL) against WT1 protein. Also provided are a method for testing for and treating cancer using the nucleotide sequence and amino acid sequence, and a chip, primer set, kit, and device for testing for cancer comprising the nucleotide sequence and amino acid sequence. | 10-15-2015 |
20150292039 | METHOD TO AMPLIFY NUCLEIC ACIDS OF FUNGI TO GENERATE FLUORESCENCE LABELED FRAGMENTS OF CONSERVED AND ARBITRARY PRODUCTS - Disclosed herein are methods for the identification of the species, serotype, and strain of a fungi. Also disclosed are primers for use in detecting such fungi and kits comprising such primers. | 10-15-2015 |
20150292046 | DETECTION OF NUCLEIC ACIDS FROM MULTIPLE TYPES OF HUMAN PAPILLOMAVIRUS - Nucleic acid oligonucleotide sequences are disclosed which include amplification oligomers and probe oligomers which are useful for detecting multiple types of human papillomaviruses (HPV) associated with cervical cancer. Methods for detecting multiple HPV types in biological specimens by amplifying HPV nucleic acid sequences in vitro and detecting the amplified products are disclosed. | 10-15-2015 |
20150292047 | DETECTION OF NUCLEIC ACIDS FROM MULTIPLE TYPES OF HUMAN PAPILLOMAVIRUS - Nucleic acid oligonucleotide sequences are disclosed which include amplification oligomers and probe oligomers which are useful for detecting multiple types of human papillomaviruses (HPV) associated with cervical cancer. Methods for detecting multiple HPV types in biological specimens by amplifying HPV nucleic acid sequences in vitro and detecting the amplified products are disclosed. | 10-15-2015 |
20150293022 | Use of Modular Nucleic Acid Scaffolds to Create Nanoscale Energy Harvesting and Focusing Arrays - The invention relates to a nanoscale antenna including a nucleic acid scaffold having a structure selected from the group consisting of a Holliday junction, a star, and a dendrimer; and a plurality of fluorophores attached to the scaffold and configured as a FRET cascade comprising at least three different types of fluorophores, arranged with (a) a plurality of initial donor fluorophores fixed in exterior positions on the structure, (b) a terminal acceptor fluorophore fixed in a central position on the structure, and (c) a plurality of intermediate fluorophores fixed in positions on the scaffold between the initial acceptor fluorophores and the terminal acceptor fluorophores. | 10-15-2015 |
20150293057 | FUNCTIONALIZED NANOTUBE SENSORS AND RELATED METHODS - Functionalized nanotube arrays, sensors, and related methods of detecting target compounds are presented. A functionalized nanotube array ( | 10-15-2015 |
20150293085 | QUANTITATIVE LATERAL FLOW ASSAY - The present invention relates to devices, kits, instruments and methods for quantitatively detecting multiple analytes in a sample. More specifically, the present invention relates to devices, kits, instruments and methods for quantitatively detecting multiple analytes with desired or targeted precision, and the uses thereof. | 10-15-2015 |
20150293089 | Electrophoretic Bar Code Assay Devices and Methods for Making and Using the Same - A microfluidic device for determining whether an analyte is present in a sample is provided. The microfluidic device includes an elongated flow path having a polymeric medium, where the polymeric medium includes a first analyte detection domain having a first immobilized capture member that specifically binds to a first analyte and a second analyte detection domain having a second immobilized capture member that specifically binds to a second analyte. Also provided are methods, systems and kits in which the subject microfluidic devices find use, as well as methods of producing the same. | 10-15-2015 |
20150293093 | VITRO ASSAYS FOR DETECTING SALMONELLA ENTERICA SEROTYPE TYPHI - Provided are assays, kits and compositions for testing subjects, particularly asymptomatic subjects, to ascertain whether or not they are carriers of | 10-15-2015 |
20150293096 | COMPOSITIONS AND METHODS RELATING TO LYME DISEASE - Compositions and methods of the present invention relating to | 10-15-2015 |
20150293098 | METHODS FOR HEAD AND NECK CANCER PROGNOSIS - This invention is directed to improved methods for determining the prognosis of patients with head and neck cancer. The invention is also directed to kits comprising reagents useful for determining head and neck cancer prognosis. | 10-15-2015 |
20150293120 | MARKER SEQUENCES FOR RHEUMATOID ARTHRITIS - The present invention relates to a novel method for identifying marker sequences for rheumatoid arthritis, the novel marker sequences discovered with the aid of the method, and the diagnostic use thereof. The invention also relates to diagnostic devices containing such marker sequences for rheumatoid arthritis, in particular a protein biochip or beads (pellets), and use thereof. | 10-15-2015 |
20150293127 | ARGININE VASOPRESSIN PRO-HORMONE AS PREDICTIVE BIOMARKER FOR DIABETES - Subject of the present invention are assays and in vitro methods for the prediction of the risk of a subject for contracting metabolic syndrome and/or diabetes mellitus and for diagnosing metabolic syndrome, comprising determining the level of arginine vasopres sin pro-hormone or fragments thereof in a sample of a subject. | 10-15-2015 |
20150293128 | METHOD OF SCREENING MHC MOLECULES - The invention relates to a method for screening the binding properties of constituent peptides of MHC molecules by providing in solution MHC molecules or their constituent peptides for a set of MHC molecules including a plurality of subsets of MHC molecules, wherein the MHC molecules of each subset differ from MHC molecules of at least one other subset in at least one of the putative MHC binding peptide, an MHC alpha chain and an MHC beta chain, and loading said MHC molecules with an MHC binding peptide by (i) refolding of the MHC alpha chain and beta chain peptides in presence of said MHC binding peptide or (ii) by peptide exchange or loading with an unlabelled MHC binding peptide in the absence of any labelled MHC binding peptide, (b) taking of at least one sample from each subset, and (c) determining loading efficiency for the sample of step (b). | 10-15-2015 |
20150293131 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF SEPSIS - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in sepsis patients and in patients at risk for sepsis. In particular, the invention relates to using assays that detect one or more biomarkers as diagnostic and prognostic biomarker assays in such patients. | 10-15-2015 |
20150299767 | COMPOSITIONS AND METHODS FOR NEGATIVE SELECTION OF NON-DESIRED NUCLEIC ACID SEQUENCES - The present invention provides methods, compositions and kits for the generation of next generation sequencing (NGS) libraries in which non-desired nucleic acid sequences have been depleted or substantially reduced. The methods, compositions and kits provided herein are useful, for example, for the production of libraries from total RNA with reduced ribosomal RNA and for the reduction of common mRNA species in expression profiling from mixed samples where the mRNAs of interest are present at low levels. The methods of the invention can be employed for the elimination of non-desired nucleic acid sequences in a sequence-specific manner, and consequently, for the enrichment of nucleic acid sequences of interest in a nucleic acid library. | 10-22-2015 |
20150299774 | METHOD FOR DETERMINING THE PRESENCE OF DIARRHOEA CAUSING PATHOGENS - This invention relates to the field of detection of diarrhoea causing pathogens from patient, food or environmental samples. Particularly, the present invention provides a polymerase chain reaction (PCR) based assay method for detection of diarrhoea causing pathogens. The present invention further provides materials such as primers, primer pairs and probes for use in the method of the invention. Preferably, the method of the invention is a multiplex real-time PCR (RT-PCR) assay for rapid determination of clinically important pathogens related to traveller's diarrhoea. | 10-22-2015 |
20150299775 | PCR PRIMERS FOR DETECTION OF VIBRIO PARAHAEMOLYTICUS THERMOSTABLE DIRECT HEMOLYSIN (TDH) AND TDH-RELATED HEMOLYSIN GENES - Disclosed are PCR primers as may be utilized in detection of the genes encoding the thermostable direct hemolysin (tdh) and the TDH-related hemolysin (trh). The PCR primers can be utilized to detect the presence of pathogenic | 10-22-2015 |
20150299777 | SYSTEMS AND METHODS FOR DETECTING INFECTIOUS DISEASES - Systems, methods, and devices for detecting infections in a clinical sample are provided. Small-volume clinical samples obtained at a point-of-service (POS) location and may be tested at the POS location for multiple markers for multiple diseases, including upper and lower respiratory diseases. Samples may be tested for cytokines, or for inflammation indicators. Dilution of samples, or levels of detection, may be determined by the condition or past history of a subject. Test results may be obtained within a short amount of time after sample placement in a testing device, or within a short amount of time after being obtained from the subject. A prescription for treatment of a detected disorder may be provided, and may be filled, at the POS location. A bill may be automatically generated for the testing, or for the prescription, may be automatically sent to an insurance provider, and payment may be automatically obtained. | 10-22-2015 |
20150299782 | METHODS AND MATERIALS USING SIGNALING PROBES - Methods of isolating cells or generating cell lines comprising the step of exposing the cells to signaling probes that produce a signal upon hybridization to a target sequence, as well as methods of quantifying the level of expression of an RNA of interest, methods for identifying genetic recombinational events in living cells and methods of generating a transgenic animal using the isolated cells. Methods for isolating a plurality of cells encoding a plurality of different RNAs associated with a same nucleic acid tag sequence, comprising the step of exposing the cells to a same signaling probe that produces a detectable signal upon hybridization to the same nucleic acid tag sequence, are also provided. Signaling probes and protease probes that form stem-loop structures, three-arm junction structures, and dumbbell structures may be used in the above methods. | 10-22-2015 |
20150299788 | RNA DETECTION METHOD AND DETECTION KIT - Provided are a method and kit for detecting RNA, which allow RNA such as microRNA and messenger RNA to be detected with high sensitivity and simply, and signal amplification probes to be used in the method. Specifically, provided is a method of detecting target RNA, the method including: (A) a capturing step of capturing RNA by a capture substance for capturing the RNA; (B) a complex-for-detection forming step of subjecting the captured RNA and signal amplification probes capable of self-assembling to a reaction to form a complex for detection including the RNA, the capture substance, and a probe polymer formed from the signal amplification probes; and (C) a detecting step of detecting the probe polymer bound in the complex for detection to detect the RNA, one of the signal amplification probes including a poly(T) sequence. | 10-22-2015 |
20150299790 | NOVEL ASSAY FOR MONITORING GLUCOSE BALANCE AND OXIDATIVE STRESS - The invention relates to diagnostic and prognostic assays, particularly to methods of determining the metabolic state of a subject. More specifically, the invention provides assays and methods comprising determining the level of m RNA of uncoupling protein 2 (UCP2) specifically in platelets of the subject. The invention is useful in determining or adjusting the treatment of conditions associated with an unbalanced metabolic state manifested by elevated blood levels of glucose, reactive oxygen species (ROS) and/or free fatty acids (FFA). In particular embodiments, the assays and methods of the invention are useful in prognosing and monitoring subjects diagnosed with diabetes, particularly type II diabetes. | 10-22-2015 |
20150299794 | Quantitative Reverse Transcription Polymerase Chain Reaction Kit for Breast Cancer Drug Screening Test and Early Diagnosis Using Tissue and Blood - A method for a breast cancer drug screening including separating a full-length RNA from a cell obtained from a tissue or blood of a suspected cancer patient; synthesizing a cDNA from the full-length RNA; performing a PCR with the synthesized cDNA by using a composition including sets of a Pair of primers and a probe, each set independently able to amplify human epidermal growth factor receptor 2 (HER2), cytokeratin 19, EpCAM, a hTERT, Ki67, vimentin, and a GAPDH. The method further includes comparing an amount of the amplification with an expression amount to a normal person. A kit for performing methodology of the invention. | 10-22-2015 |
20150299797 | COMPOSITIONS AND METHODS RELATING TO BLOOD-BASED BIOMARKERS OF BREAST CANCER - The present invention relates generally to the field of breast cancer. More specifically, the invention concerns methods and compositions useful for diagnosing treating breast cancer. | 10-22-2015 |
20150299806 | GENE EXPRESSION PROFILE IN DIAGNOSTICS - The present invention provides a method for diagnosing, identifying or monitoring proliferative disorders due to e.g cancer preferably breast cancer in a subject by measuring the change of gene expression in a sample e.g. a blood sample. The present invention also encompasses oligonucleotide probes and primers corresponding to genes differentially expressed compared to the expression pattern in a normal cell. The use of such oligonucleotides is also an aspect of the invention together with a kit comprising said oligonucleotides. | 10-22-2015 |
20150301015 | QUADRUPLEX METHOD - The invention relates to a new method of determining in a sample the presence, absence or concentration of one or more target analytes, such as micro-ribonucleic acids (microRNAs or miRNAs). The invention may therefore relate to a multiplex assay for determining the presence or absence of each target analyte in a group of multiple analytess. The invention uses one or more probes comprising a quadruplex and transmembrane pores. | 10-22-2015 |
20150301032 | METHODS AND COMBINATIONS OF SIGNALING MARKERS FOR ASSESSMENT OF DISEASE STATES - Methods for preparation of cells for analysis of biomarkers are disclosed. In one aspect, the method for preparation of cells for analysis of biomarkers includes contacting a sample that contains a population of cells with at least one modulating substance at a first temperature, thereby producing a modulated cell population; contacting the modulated cell population with at least one antibody that is directed to a cell surface biomarker at a second temperature that is lower than the first temperature, thereby producing an extracellularly stained cell population; and contacting the extracellularly stained cell population with one or more reagents that fixes and permeabilizes the cells, thereby producing a fixed and permeabilized cell population. | 10-22-2015 |
20150301033 | MICROFLUIDIC DEVICES FOR AUTOMATED ASSAYS - Provided herein are cartridges, devices, and methods for carrying out multistep assays on a microfluidic scale. A cartridge includes a block frame comprising a well, wherein the well comprises an outlet, at least one inlet, and a bottom surface; a plurality of containers, wherein each container is connected to the well via a microchannel leading to the at least one inlet; and an openable cover, which cover when closed is configured to enclose an assay surface and form a gap between (i) the assay surface and the bottom surface of the well or (ii) the assay surface and the cover. The gap can be formed by a spacer that extends from the bottom surface of the well or from the outer edge of the cover. Methods include flowing liquid into the gap and/or through an opening adjacent to the assay surface. | 10-22-2015 |
20150301034 | LABEL-FREE DETECTION OF NANOPARTICLES AND BIOLOGICAL MOLECULES USING MICROTOROID OPTICAL RESONATORS - Systems and methods are provided for detecting one or more particles such as individual unlabeled molecules or single nanoparticles. In examples described herein, optical energy is introduced into a microtoroid or other microcavity to generate an evanescent field. The microcavity has a functionalized outer surface that has been functionalized with a chemically or biologically active substance such as an antibody, antigen or protein. An indication of a particle bound to the functionalized outer surface of the microcavity is then detected based on a reactive interaction between the particle and the evanescent field while using frequency locking, balanced detection and various filtering techniques. The frequency locking, balanced detection and filtering techniques reduce the signal-to-noise ratio (SNR) of the detection system so that single nanoparticles (e.g. 2.5 nanometers (nm) in radius) and individual molecules (e.g. 15.5 kilo-Dalton (kDa) in size) can be detected in aqueous solution in some examples. | 10-22-2015 |
20150301040 | IDENTIFICATION OF MODULATORS OF BINDING PROPERTIES OF ANTIBODIES REACTIVE WITH A MEMBER OF THE INSULIN RECEPTOR FAMILY - The present invention relates to methods and kits useful in the identification of modulators of the binding properties of antibodies reactive with one or more members of the insulin receptor family selected from the insulin receptor (IR), the insulin-like growth factor 1 receptor (IGF1R), the insulin-like growth factor 2 receptor (IGF2R), the insulin-IGF1 hybrid receptor (IIHR), and the insulin receptor-related receptor (IRRR) and methods for the detection of such antibodies. | 10-22-2015 |
20150301041 | ASSAY METHOD - A method of determining the likelihood of a patient developing rheumatoid arthritis (RA) is provided, which relies on the use of AdipoR1 and/or AdipoR2 in leukocytes as prognostic markers. The method may comprise determining the expression of A dipoR1 and/or AdipoR2 in leukocytes in a sample from said patient. The method may be used for screening, within a population, one or more patients likely to develop RA. | 10-22-2015 |
20150301045 | NON-B-LINEAGE CELLS CAPABLE OF PRODUCING ANTIBODY - Disclosed herein are kits for detection and isolation of antibody-producing cells and cells capable of producing antibodies, antibody-producing cells and cells capable of producing antibodies, including V cells, a non-B-cell-lineage class of cells capable of producing antibody. Disclosed herein are methods of identifying and methods of isolating antibody-producing cells and cells capable of producing antibodies. Disclosed herein are methods of making antibodies. | 10-22-2015 |
20150301054 | ANTIBODY COCKTAIL - The present invention relates to a composition comprising at least three primary antibodies or fragments thereof, wherein the at least three antibodies or fragments thereof binds specifically to at least three different proteins, and wherein the at least three different proteins are AMCAR, CK 5/6, and HMWC. Methods for using the composition in diagnosis, prognosis, and assessing efficacy of treatment is further included as well as kits comprising said composition, and optionally, instructions of its use. | 10-22-2015 |
20150301055 | CIRCULATING BIOMARKERS FOR DISEASE - Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease. Circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles. Biomarkers can be used for theranostic purposes to select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. The biomarkers can be circulating biomarkers, including vesicles and microRNA. | 10-22-2015 |
20150301062 | METHOD FOR DIAGNOSING AND TREATING FIBROMYALGIA - The invention provides methods, kits and reagents for diagnosing fibromyalgia (FM) in an individual by determining whether the levels of one or more cytokines in the individual are altered, as compared to control levels. The altered level(s) or patterns of expression of the cytokines measured in the affected individual compared to the level from the control is predictive/indicative of FM in the individual. | 10-22-2015 |
20150301063 | SALIVARY INFLAMMATORY BIOMARKERS ASSOCIATED WITH GLYCEMIC CONTROL AND ORAL HEALTH - The present invention provides non-invasive diagnostic methods and kits for determining and/or monitoring oral health and glycemic control in subjects with Type 1 diabetes. | 10-22-2015 |
20150302713 | SECURITY SYSTEM AND METHOD OF MARKING AN INVENTORY ITEM AND/OR PERSON IN THE VICINITY - A method of marking an inventory item includes providing an activatable smoke generator and a reservoir for holding a smoke fluid and adapted to provide a flow of smoke fluid to the generator. The reservoir contains a smoke fluid including a carrier nucleic acid having a uniquely identifiable sequence, and upon activation of the smoke generator, marker smoke is generated and targeted to flow over the inventory item. The method further includes activating the smoke generator to produce the marker smoke including the carrier nucleic acid so as to cause the marker smoke to flow over the inventory item and thereby to detectably mark the inventory item with carrier nucleic acid. | 10-22-2015 |
20150307918 | INVERSE MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION (iMLPA), AN IN VITRO METHOD OF GENOTYPING MULTIPLE INVERSIONS - It is described here a new method for improvement genotyping of a large number of inversions mediated by inverted repeats through a fast and high-throughput assay. The assay is based on Multiplex Ligation-dependent Probe Amplification, adapted for the detection of genomic structural variants, particularly adapted to inversions detection (iMLPA). By comparison with other techniques used to genotype inversions one by one, like inverse PCR, iMLPA has shown a very high sensibility, reproducibility and accuracy. Besides, iMLPA is the fastest method to determine the inversion genotypes in large sets of samples. | 10-29-2015 |
20150307919 | MULTIPLEXED DIGITAL ASSAY - Method of performing a multiplexed digital assay. The method may include (1) partitioning a sample containing at least two distinct targets into droplets; (2) amplifying the at least two distinct targets within the droplets; (3) detecting light from the droplets indicative of the presence or absence of each distinct target in each droplet; and (4) calculating a level of each distinct target based on the detected light. | 10-29-2015 |
20150307921 | SELF-CONTAINED BIOLOGICAL ASSAY APPARATUS, METHODS, AND APPLICATIONS - A self-contained, fully automated, biological assay-performing apparatus includes a housing; a dispensing platform including a controllably-movable reagent dispensing system, disposed in the housing; a reagent supply component disposed in the housing; a pneumatic manifold removably disposed in the housing in a space shared by the dispensing platform, removably coupled to a fluidic transport layer and a plurality of reservoirs, wherein the fluidic transport layer, the reservoirs, and a test sample to be introduced therein are disposed in the housing in the space separate from the dispensing platform; a pneumatic supply system removably coupled to the pneumatic manifold in the housing in a space separate from the dispensing platform; and a control system coupled to at least one of the dispensing platform and the pneumatic supply system, disposed in the housing. | 10-29-2015 |
20150307924 | METHODS FOR DIAGNOSING IRRITABLE BOWEL SYNDROME - The present invention discloses a method for diagnosing Irritable Bowel Syndrome (IBS) in a test sample by determining the level of several bacterial taxa in the test sample, comparing this level with the levels of those bacterial taxa in a control sample, and relating the level to a diagnosis of IBS. Additionally, the present invention provides a method for treatment of IBS based on said diagnosis. Also, the invention provides a method for subtyping IBS in a test sample. | 10-29-2015 |
20150307944 | KIT COMPRISING PRIMERS FOR AMPLIFYING ALK KINASE DOMAIN NUCLEIC ACIDS - Disclosed are methods and kits for detecting the presence of a cancer in a subject and assessing the efficacy of treatments for the same. The disclosed method use reverse transcription polymerase chain reaction (RT-PCR) techniques to detect the presence of point mutations, truncations, or fusions of anaplastic lymphoma kinase. | 10-29-2015 |
20150307946 | EPIGENETIC METHOD FOR THE IDENTIFICATION OF SUBPOPULATIONS OF CD8+ T LYMPHOCYTES, IN PARTICULAR CD8 ALPHA AND BETA T LYMPHOCYTES - The present invention relates to a method, in particular an in vitro method, for identifying CD8 positive subpopulations of a mammal, wherein said method comprises analyzing the bisulfite convertibility of at least one CpG position in the CD8 beta and CD8 alpha cell specific bisulfite convertibility gene region according to SEQ ID No. 1 and 2, wherein a bisulfite convertibility of at least one CpG position in said gene regions is indicative for a CD3+CD8+ and/or CD3+/−CD8+ cell. The analyses according to the invention can identify CD3+CD8+ and/or CD3+/−CD8+ cells on an epigenetic level and distinguish them from all other cells in complex samples, such as, for example, other blood cells. | 10-29-2015 |
20150308988 | Antibody Coformulations - This invention relates to stable formulations of multiple antibodies comprising a plurality of antibodies and an effective amount of a succinate buffer wherein the pH of the formulation is between about 4.5 and about 7.0. | 10-29-2015 |
20150309016 | Fluorescent Methods and Materials for Directed Biomarker Signal Amplification - Methods and compositions are provided that include a multichromophore and/or multichromophore complex for identifying a target biomolecule. A sensor biomolecule, for example, an antibody can be covalently linked to the multichromophore. Additionally, a signaling chromophore can be covalently linked to the multichromophore. The arrangement is such that the signaling chromophore is capable of receiving energy from the multichromophore upon excitation of the multichromophore. Since the sensor biomolecule is capable of interacting with the target biomolecule, the multichromophore and/or multichromophore complex can provide enhanced detection signals for a target biomolecule. | 10-29-2015 |
20150309021 | Advanced Drug Development and Manufacturing - X-ray fluorescence (XRF) spectrometry has been used for detecting binding events and measuring binding selectivities between chemicals and receptors. XRF may also be used for estimating the therapeutic index of a chemical. For estimating the binding selectivities of a chemical versus chemical analogs, for measuring post translational modification of proteins, and for drug manufacturing. | 10-29-2015 |
20150309023 | USE OF AMINO ACID SEQUENCES FROM MYCOBACTERIUM TUBERCULOSIS OR CORRESPONDING NUCLEIC ACIDS FOR DIAGNOSIS AND PREVENTION OF TUBERCULAR INFECTION, DIAGNOSTIC KIT AND VACCINE THEREFROM - The present invention refers to the use of gene sequences or portions thereof characterized in that the same belong to the classes of in vitro and ex vivo induced, repressed or conserved genes in | 10-29-2015 |
20150309026 | METHODS OF SCREENING FOR CELL PROLIFERATION OR NEOPLASTIC DISORDERS - The invention relates to methods and compositions for identifying subjects having, or predisposed to having, a neoplastic or cell proliferation or neoplastic disorder. The methods are applicable to any type of tissue sample and can be conducted on otherwise normal tissue. | 10-29-2015 |
20150309034 | BIOMARKER PANEL FOR PREDICTION OF RECURRENT COLON CANCER - The present invention provides a biomarker panel predictive of whether colorectal cancer is likely to recur or metastasize in an afflicted patient. By identifying the likelihood of recurrence, a treatment provider may determine in advance those patients who would benefit from certain types of treatment. The present invention further provide methods of identifying gene and protein expression profiles associated with the likelihood of recurrence/metastasis of colorectal cancer in a patient sample. | 10-29-2015 |
20150309036 | Diagnostic Markers of Indolent Prostate Cancer - A 3-gene prognostic panel has been identified that together accurately predicted the outcome of low Gleason score prostate tumors as either truly indolent or at a high risk of becoming aggressive. The 3-gene prognostic panel was validated on independent cohorts confirmed its independent prognostic value, as well as its ability to improve prognosis with currently used clinical nomograms. Expression of the 3-gene prognostic panel was determined by quantifying mRNA or protein encoded by the panel (collectively referred to as “prognostic biomarkers”). The prognostic biomarkers were discovered to be up-regulated in indolent tumors and down-regulated in aggressive forms of prostate cancer. | 10-29-2015 |
20150309039 | Polymeric Carriers for Immunohistochemistry and In Situ Hybridization - Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays. | 10-29-2015 |
20150309044 | DIAGNOSTIC METHOD BASED ON LARGE SCALE IDENTIFICATION OF POST-TRANSLATIONAL MODIFICATION OF PROTEINS - Methods for the large scale identification of post-translational modification states of proteins and enzyme activities for carrying out post-translational modification reactions involve the analysis of functional extracts from fresh and frozen samples using protein arrays. The methods and kits of the present invention can be used to analyze and characterize compounds for their effects on post-translational modifications and their pathways. The methods and kits can also be used to diagnose and characterize a wide variety of diseases and medical conditions, including cancer, neurodegenerative diseases, immune diseases, infectious diseases, genetic diseases, metabolic conditions, and drug effects using cells or body fluids of a patient. | 10-29-2015 |
20150309047 | CIRCULATING PROTEOLYTIC BIOMARKERS OF CELL DEATH AND METHODS FOR THE USE THEREOF - Provided herein are peptides useful, inter alia, for determining a level of apoptosis in a cancer patient. Further provided are complexes including said peptides bound to a binding reagent and antibodies specifically binding said peptides. | 10-29-2015 |
20150309050 | DIAGNOSTIC AND THERAPEUTIC METHODS AND PRODUCTS RELATED TO ANXIETY DISORDERS - The present invention relates to diagnostic, prognostic and therapeutic methods related to anxiety, as well as related products. In particular examples the anxiety is post-traumatic stress disorder. | 10-29-2015 |
20150309052 | ACUTE KIDNEY INJURY - The present invention relates to a method of predicting the severity of acute kidney injury following cardiac surgery. | 10-29-2015 |
20150309053 | TEST METHOD AND TEST KIT FOR PSYCHIATRIC AILMENTS - A novel test method for testing for the presence or absence of a predisposition to autistic spectrum disorder or the presence or absence of development of autistic spectrum disorder is provided. The test method includes a test step of determining an amount of at least one of the fatty acid binding proteins FABP3, FABP4, FABP5, and FABP7 in a sample prepared from the living body of a human or determining an expression level of at least one of the FABP3, FABP4, FABP5, and FABP7 genes in the sample. | 10-29-2015 |
20150309062 | HIGH THROUGHPUT FLOW CYTOMETRY SYSTEM AND METHOD - The invention provides systems, compositions, kits and methods for automated processing of biological samples and analysis using a flow cytometer. | 10-29-2015 |
20150315295 | DUAL TARGETING - The present invention relates to antibody-based dual targeting molecules, and to methods for generating such dual targeting molecules, including a library-based approach. | 11-05-2015 |
20150315565 | METHODS FOR IDENTIFYING AND ISOLATING CELLS EXPRESSING A POLYPEPTIDE - The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies. | 11-05-2015 |
20150315631 | MICROFLUIDIC SYSTEM FOR AMPLIFYING AND DETECTING POLYNUCLEOTIDES IN PARALLEL - The present technology provides for an apparatus for detecting polynucleotides in samples, particularly from biological samples. The technology more particularly relates to microfluidic systems that carry out PCR on nucleotides of interest within microfluidic channels, and detect those nucleotides. The apparatus includes a microfluidic cartridge that is configured to accept a plurality of samples, and which can carry out PCR on each sample individually, or a group of, or all of the plurality of samples simultaneously. | 11-05-2015 |
20150315632 | RATIOMETRIC PRE-rRNA ANALYSIS - Disclosed are compositions and methods for detecting the presence of viable cells in a sample. Included are compositions and methods for increasing the sensitivity of a nucleic acid amplification test for determining the presence of at least one target microorganism in a sample. Also disclosed are compositions and methods for detecting ribosomal RNA precursors (pre-rRNA) as dynamic indicators of viable microorganisms in a sample. | 11-05-2015 |
20150315634 | Calibration of High Resolution Melting - The present invention refers to a method and a kit for performing temperature calibration in high resolution melting PCR experiments. The present invention further refers to a method for optimal calibration allowing read-out of identical or similar melting temperatures for target and calibrator. The present invention further refers to an apparatus for performing the method and a computer program for executing the method. | 11-05-2015 |
20150315644 | METHODS AND COMPOSITIONS FOR SCD, CRT, CRT-D, OR SCA THERAPY IDENTIFICATION AND/OR SELECTION - Compositions, polynucleotides, probes, kits, methods, computer systems, treatment methods and genetic markers useful for assessing the risk of Sudden Cardiac Death (SCD), Sudden Cardiac Arrest (SCA), Ventricular Arrhythmia (VA), or Heart Failure (HF) are provided herein. The compositions, polynucleotides, probes, kits, methods, computer systems, treatment methods and genetic markers of the invention can provide patients selection for those that can be treated with an ICD or CRT-D based on assessing the presence of one or more Single Nucleotide Polymorphisms (SNPs) associated with any one of Sudden Cardiac Death (SCD), Sudden Cardiac Arrest (SCA), Ventricular Arrhythmia (VA), or Heart Failure (HF), and can indicate treatment with certain drugs such as beta-blockers. | 11-05-2015 |
20150315652 | Method for Determining Coronary Artery Disease Risk - Markers and methods useful for assessing coronary artery disease in a subject are provided, along with kits for measuring their expression. Also provided are predictive models, based on the markers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. | 11-05-2015 |
20150315655 | PROSTATE CANCER TESTING AND DIAGNOSIS METHOD - A molecular assay of prostate cancer testing and diagnosis method is provided. The tests of the present invention include a broad spectrum analysis of testing molecular values for prostate cancer management. The tests of the present invention may include a three part series of testing which includes distinguishing benign prostate hyperplasia from a potential prostate cancer diagnosis. The present invention further examines recurrent values for prostate cancer patients and in addition measures values for metastatic prostate cancer. | 11-05-2015 |
20150315658 | METHODS FOR DETECTING GENE DYSREGULATIONS - Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g., translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5′ and 3′ regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5′ portion of a target gene relative to the 3′ region of the target gene. | 11-05-2015 |
20150315660 | METHODS AND COMPOSITIONS FOR DETERMINING RESPONSIVENESS TO ANTIBODY THERAPY - Methods and compositions are provided for determining whether a subject suffering from a neoplastic condition is responsive to an antineoplastic therapy, such as antibody therapy, e.g., Rituximab. In practicing the subject methods, the subject is genotyped to determine whether the subject has a least one favorable FcγR polymorphism, e.g., the131 H/H genotype or the158 VN genotype. In addition, reagents, devices and kits thereof, that find use in practicing the subject methods are provided. | 11-05-2015 |
20150316482 | PHOTOACTIVATED CHEMICAL BLEACHING OF DYES - Methods comprising the use of photoactivated chemical bleaching for detecting multiple targets in a biological sample are provided. The methods include the steps of providing a biological sample including multiple targets, binding at least one probe to one or more target present in the sample, and detecting a signal from the probe. The method further includes the steps of contacting the sample comprising the bound probe with an electron transfer reagent, as well as an optional additive which prevents target modification during photoactivated chemical bleaching, and irradiating the sample, thereby initiating a photoreaction that substantially inactivates the probe by photoactivated chemical bleaching. The method further includes the steps of binding at least one probe to one or more target present in the sample, and detecting a signal from the probe. The process of binding, defecting and bleaching may be iteratively repeated. | 11-05-2015 |
20150316545 | ULTRASENSITIVE DETECTION OF A BIOLOGICAL TARGET BY APTAMER-CONJUGATED GOLD NANOPARTICLES - Methods of assaying a biological target are disclosed. The method comprises: (a) providing a sample containing the biological target; (b) providing biotin-labeled first aptamers conjugated to a gold nanoparticle (GNP), and second aptamers conjugated to a magnetic bead, wherein the first and the second aptamers exhibit specific binding affinities to the target; (c) incubating the sample with the first and the second aptamers to obtain target-bound aptamers; (d) separating the target-bound aptamers from unbound aptamers; (e) eluting the first aptamers from the GNP; (f) incubating the eluted biotin-labeled first aptamers with streptavidin-magnetic beads and reporter gold nanoparticles (GNPs) to obtain a complex comprising: the bead, the first aptamers, attached to the bead; and the reporter GNPs captured by the bead through the first aptamers; (g) eluting the reporter GNPs captured; and (h) detecting the target by measuring and analyzing a light-scattering signal of the eluted reporter GNPs. | 11-05-2015 |
20150316550 | Method of Determining the Probability of a Therapeutic Response in Cancer Chemotherapy with Cardiac Glycoside - A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the α subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside. | 11-05-2015 |
20150316554 | Diagnostic Biomarkers and Therapeutic Targets for Pancreatic Cancer - We identified >40 proteins that elicited at least a 2-fold increase in antibody response post-pancreatic-cancer vaccination, from each of three patients' sera. The antibody responses detected against these proteins in patients with >3 years disease-free survival indicates the anti-tumor potential of targeting these proteins. We found that tissue expression of proteins PSMC5, TFRC and PPP1R12A increases during tumor development from normal to pre-malignant to pancreatic tumor. In addition, these proteins were shown to be pancreatic cancer-associated antigens that are recognized by post-vaccination antibodies in the sera of patients that received the vaccine and have demonstrated a favorable disease free survival. | 11-05-2015 |
20150316556 | SSEA4 AND ST3GAL2 AS CHEMOTHERAPEUTIC DRUG RESPONSE BIOMARKERS - The present invention provides the use of the biomarkers SSEA4 and/or ST3GAL2 for assessing the outcome for chemotherapeutic treatment of a cancer in an individual and methods thereof. | 11-05-2015 |
20150316558 | Fluorescent Chemical Compounds Having High Selectivity for Double Stranded DNA, and Methods for Their Use - Chemical compounds having a high selectivity for double stranded DNA over RNA and single stranded DNA are disclosed. The chemical compounds are stains that become fluorescent upon illumination and interaction with double stranded DNA, but exhibit reduced or no fluorescence in the absence of double stranded DNA. The compounds can be used in a variety of biological applications to qualitatively or quantitatively assay DNA, even in the presence of RNA. | 11-05-2015 |
20150316560 | PREDICTION AND PROPHYLACTIC TREATMENT OF TYPE 1 DIABETES - An in vitro method for predicting the onset of type 1 diabetes (T1D) in a subject, comprises the steps of: (a) measuring the concentration of at least one amino acid, amino acid derivative or amino acid metabolite in a biological sample taken from the subject; (b) determining the subject's HLA genotype; (c) assigning the subject's genetic risk of developing T1D on the basis of the subject's HLA genotype; (d) combining the information obtained in step (a) with the information in step (c); and (e) predicting the likelihood of onset of T1D based upon the combination of step (d). The diagnostic method can be used to select target subjects for T1D prophylactic treatment, and as part of a T1D preventative treatment regime for neonates having a likelihood of developing childhood T1D. | 11-05-2015 |
20150316561 | METHODS AND COMPOSITIONS RELATED TO MODULATORS OF EUKARYOTIC CELLS - Methods for Identifying protein modulators of eukaryotic cells by expressing a combinatorial library of potential agonists inside a eukaryotic cell and then directly selecting for an agonist of a target molecule. Some methods involve co-culturing a cell expressing a combinatorial library of potential agonists and a second cell, and then selecting agents that modulate a phenotype of or a desired cellular response in the second cell. Preferably, the agonists are antibodies introduced into and expressed in the starting cells, such as agonist anti-EpoR, anti-TpoR, or G-CSFR antibodies. Also disclosed are methods for selecting from combinatorial antibody libraries bispecific antibodies that can regulate cell phenotypes. | 11-05-2015 |
20150316563 | METHOD FOR THE DIAGNOSIS OF METACHROMATIC LEUKODYSTROPHY - The present invention is related to a method for diagnosing metachromatic leukodystrophy in a subject comprising a step a), wherein the step a) comprises detecting a biomarker in a sample from the subject, wherein the sample is selected from the group consisting of blood, dried blood, serum and plasma and wherein the biomarker is different from an enzyme. | 11-05-2015 |
20150317431 | Method for Indicating a Presence or Non-Presence of Aggressive Prostate Cancer - The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to determine if it is likely that the patient suffers from aggressive prostate cancer. The present invention is particularly applicable only for patients having a body mass index value greater than 25. | 11-05-2015 |
20150322132 | T1R TASTE RECEPTORS AND GENES ENCODING SAME - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular taste stimulus in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed. | 11-12-2015 |
20150322395 | METHODS AND DEVICES FOR MICRO-ISOLATION, EXTRACTION, AND/OR ANALYSIS OF MICROSCALE COMPONENTS - Provided herein are devices and methods for the micro-isolation of biological cellular material. A micro-isolation apparatus described can comprise a photomask that protects regions of interest against DNA-destroying illumination. The micro-isolation apparatus can further comprise photosensitive material defining access wells following illumination and subsequent developing of the photosensitive material. The micro-isolation apparatus can further comprise a chambered microfluidic device comprising channels providing access to wells defined in photosensitive material. The micro-isolation apparatus can comprise a chambered microfluidic device without access wells defined in photosensitive material where valves control the flow of gases or liquids through the channels of the microfluidic device. Also included are methods for selectively isolating cellular material using the apparatuses described herein, as are methods for biochemical analysis of individual regions of interest of cellular material using the devices described herein. Further included are methods of making masking arrays useful for the methods described herein. | 11-12-2015 |
20150322426 | DNA Based Bar Code for Improved Food Traceability - Food distributed to consumers through a distribution chain may be traced by tagging the food with DNA tags that identify the origin of the food, such as the grower, packer and other points of distribution, and their attributes. This makes it much quicker and easier to trace the food in case of food contamination or adulteration. Preferably these attributes indicate the field, location, crew and machine used to grow and process the food, and the dates of the various steps of food harvesting, processing and distribution. Natural or synthetic DNA pieces may be used to tag items, including food items. Multidigit binary or other types of bar codes may be represented by multiple types of DNA. Each digit of the bar code may be represented by one, two or more unique DNA pieces. | 11-12-2015 |
20150322500 | Multiplexed diagnostic platform for point-of care pathogen detection - The invention provides a system for high-throughput multiplex analysis of target samples. A sample and reagent delivery unit is operatively connected to a thermal cycler for amplification of target nucleic acids. Microspheres are hybridized to the resulting amplicons in the thermal cycler. A flow cytometer is operatively connected to the thermal cycler or optionally a bead trap for washing the microspheres. | 11-12-2015 |
20150322510 | TWO-PRIMER PCR FOR MICRORNA MULTIPLEX ASSAY - The present invention provides method for amplifying a specific RNA molecule in a sample, the method comprising: (a) adding a poly(ribonucleotide) sequence to RNA molecules in the sample; (b) reverse transcribing the poly-adenylated RNA molecules using a reverse primer comprising a sequence that anneals to said poly(ribonucleotide) sequence; and (c) amplifying and detecting the cDNA molecule(s) using the same reverse primer and using a forward primer specific for the RNA molecule to be detected; wherein at least one of the forward and reverse primers comprises a hairpin primer. The invention also provides kits useful for practicing this method. | 11-12-2015 |
20150322511 | DETECTION OF DNA THAT ORIGINATES FROM A SPECIFIC CELL-TYPE - The present invention relates to methods to detect an amount of DNA that originates from cells of a given type, where the sample comprising such DNA in admixture with DNA that does not originate from such cells. Such methods are based on differential methylation, at certain regions, of the DNA that originates from the given type of cells compared to the admixed DNA. Such methods have particular application in the detection, from a biological fluid from a pregnant female, of cell free DNA that originates from a foetus or the placenta of a foetus, or the detection, from a biological fluid from an individual, of cell free DNA that originates from cells of a tumour. Accordingly, such methods have diagnostic, prognostic and/or predictive utility for detecting an increased risk of an individual suffering from or developing a medical condition such as preeclampsia or cancer, and/or to aid subsequent diagnostic, prognostic and/or predictive methods such as the detection of chromosomal trisomy in a foetus, including for twin-pregnancies. The present invention also relates to compositions, kits, computer program products and other aspects that are used in, useful for or related to the practice of such methods. | 11-12-2015 |
20150322512 | MULTIPLEX DETECTION OF DNA THAT ORIGINATES FROM A SPECIFIC CELL-TYPE - The present invention relates to methods to detect an amount of DNA that originates from cells of a given type, where the sample comprising such DNA in admixture with DNA that does not originate from such cells. Such methods are based on different methylation, at certain regions of the DNA that originates from the given type of cells compared to the admixed DNA. Such methods have particular application in the detection, from a biological fluid from a pregnant female, of cell free DNA that originates from a foetus or the placenta of a foetus, or the detection, from a biological fluid from an individual, of cell free DNA that originates from cells of a tumour. Accordingly, such methods have diagnostic, prognostic and/or predictive utility for detecting an increased risk of an individual suffering from or developing a medical condition such as preeclampsia or cancer, and/or to aid subsequent diagnostic, prognostic and/or predictive methods such as the detection of chromosomal trisomy in a foetus, including for twin-pregnancies. The present invention also relates to compositions, kits, computer program products and other aspects that are used in, useful for or related to the practice of such methods. | 11-12-2015 |
20150322513 | MULTIPLEX DETECTION OF DNA THAT ORIGINATES FROM A SPECIFIC CELL-TYPE - The present invention relates to methods to detect an amount of DNA that originates from cells of a given type, where the sample comprising such DNA in admixture with DNA that does not originate from such cells. Such methods are based on differential methylation, at certain regions, of the DNA thst originates from the given type of cells compared to the admixed DNA. Such methods have particular application in the detection, from a biological fluid from a pregnant female, of cell free DNA that originates from a foetus or the placenta of a foetus, or the detection, from a biological fluid from an individual, of cell free DNA that originates from cells of a tumour. Accordingly, such methods have diagnostic, prognostic and/or predictive utility for detecting an increased risk of an individual suffering from or developing a medical condition such as preeclampsia or cancer, and/or to aid subsequent diagnostic, prognostic and/or predictive methods such as the detection of chromosomal trisomy in a foetus, including for twin-pregnancies. The present invention also relates to compositions, kits, computer program products and other aspects that are used in, useful for or related to the practice of such methods. | 11-12-2015 |
20150322515 | METHODS AND COMPOSITIONS FOR DETECTING TARGET SNP - The present invention provides methods and compositions, and uses thereof, for simultaneously detecting one target SNP locus or multiple target SNP loci in a sample. In exemplary embodiments, the present invention also provides a multiplex SNP assay technique, which can simultaneously detect up to 20 SNP loci (40 alleles) with high level of specificity (e.g., >99.9%), sensitivity (e.g. 100%) and accuracy, high throughput, cost-effective and time-saving, reduced or no false-negative results. The present invention further provides certain isolated polynucleotides that can be used as primers or primer pairs in the present methods and composition for simultaneously detecting one target SNP locus or multiple target SNP loci in a sample. | 11-12-2015 |
20150322516 | UV Associated mtDNA Fusion Transcripts and Methods and Uses Thereof - The present invention provides novel mitochondrial fusion transcripts and related deletion molecules that are associated with UV exposure. Methods for in vivo and in vitro detection of mtDNA molecules and associated fusion transcripts is also provided, as is their use in the screening and testing of skin care products. | 11-12-2015 |
20150322527 | TRANSCRIPTIONAL PROFILING AND BIOMARKER-BASED METHODS FOR IDENTIFYING AND EVALUATING AGENTS FOR ANTIOXIDANT EFFICACY IN COSMETIC SKIN CARE FORMULATIONS - Gene panels, microarrays and biomarker panels relating to genes and gene products associated with age-related oxidative damage to skin, and transcriptional profiling-based methods for identification and evaluation of cosmetic agents for prevention, reversal, or reduction of oxidative damage to skin. Cosmetic agents and compositions comprising the cosmetic agents, capable of inducing nrf2-mediated activation of the antioxidant response element to increase expression of Phase 2 enzymes, methods for restoring optimal redox status to skin employing the agents, and methods for identifying and evaluating cosmetic agents acting via the nrf2-mediated mechanism. | 11-12-2015 |
20150322538 | RISK STRATIFICATION IN INFLUENZA - The present invention relates to methods for the identification of clinical risk in patients having, or suspected of having, influenza. The invention also relates to methods for distinguishing between patients having influenza or viral pneumonia from patients having a symptomatically similar condition. The methods of the invention comprise determination of the level of expression of interferon alpha inducible protein 27 (IF127) in a biological sample from a patient having, or suspected of having, influenza. Kits comprising suitable components for the performance of the methods are also provided by the invention. The invention allows stratification of patients into groups defining clinical risk, for example groups based on the severity of risk to the long-term health of the subject. | 11-12-2015 |
20150323461 | WIRELESS COMMUNICATION DEVICE-BASED DETECTION SYSTEM - The invention combines recent advances in barcode technology with portable wireless communication devices to engineer a simple and low-cost chip-based multiplex wireless detection system. The system can analyze multiple targets of interest simultaneously in minutes and is applicable to detection of pathogens or contaminants in a wide range of fields including medicine, agriculture and the environment. | 11-12-2015 |
20150323525 | METHODS AND MEANS FOR DETECTING CELLS USING SURFACE PLASMON RESONANCE - The invention relates to means and methods for detecting a cell surface molecule in a cell sample. The invention further relates to a method for blood group typing and screening and to SPR sensors and SPR measuring systems suitable for use in such methods. The method includes steps of allowing a liquid cell sample to flow to and along the sensor surface, temporarily reducing the shear rate of the liquid sample to allow cells in the sample to sediment by binding to a binding compound immobilised on a metal film on the sensor surface, and removing unbound cells or non-specifically bound cells or fragments thereof. Moreover, the ratio of the magnitude of the specific total signal response to the signal response during sedimentation is determined. | 11-12-2015 |
20150323529 | MARKER SEQUENCES FOR NEUROMYELITIS OPTICA (NMO) AND USE THEREOF - The present invention relates to new markers for Neuromyelitis Optica (NMO), a method for identifying markers for NMO, the use of the markers identified by the method, diagnostic devices, panels of markers, assays, protein arrays comprising markers for NMO and a method for detecting NMO. | 11-12-2015 |
20150323530 | QUANTUM DOT-PROTEIN COMPLEXES, FILMS, AND METHODS OF USE - The present application relates to protein-conjugated quantum dot compositions. The compositions may comprise, for example, zein proteins, and may be configured as films, for example on the sample-contacting surface of a sample well. Methods, kits, and an apparatus for the detection of food-borne microorganisms, for example, are also disclosed. | 11-12-2015 |
20150323541 | METHODS AND REAGENTS FOR ANALYTE DETECTION - The present invention relates to chemiluminescent method and regent to detect analyte. One aspect of the current invention relates to using chemiluminescent and fluorescent molecule/enzyme coupled with analyte binding molecules to detect specific analyte molecules. Another aspect of the current invention is to use gold nanoparticle triggered chemiluminescent reaction to detect analyte. | 11-12-2015 |
20150323544 | Drug Discovery and Protein-Protein Interaction Assay Using Fluorescent Protein Exchange - A novel assay for determining a molecular process using a fluorescent protein exchange assay, and a composition for use thereof, are provided. The assay provides first and second signalling proteins and an exchange protein, wherein the exchange protein interacts with the first signalling protein to form a complex, then introducing the second signalling protein, wherein in response to the molecular process, the exchange protein dissociates from the first protein and associates with the second protein. The change in signal in response to the exchange of the proteins is measured to indicate a molecular process. | 11-12-2015 |
20150328639 | GENETIC TESTING KIT - A kit of parts comprising a set of two or more components and a substantially rigid box having provided on a surface thereof a visual representation of a sequence of ordered steps in a biological testing procedure. The box is provided with formations, coinciding with respective steps in said visual representation, adapted to permit insertion of said components through the surface of the box to allow the components to be supported in an upright position. | 11-19-2015 |
20150329856 | METHODS AND SYSTEMS FOR THE GENERATION OF A PLURALITY OF SECURITY MARKERS AND THE DETECTION THEROF - This invention pertains to methods for generating large quantities of DNA security markers by combinatorial variation techniques using polymorphic fragment length DNA for unique identification security marker applications such as explosive ink used in dye/smoke pack and cash carrying boxes. | 11-19-2015 |
20150329915 | COMPOSITIONS AND METHODS FOR CLASSIFYING THYROID NODULE DISEASE - A system for classifying thyroid nodule tissue as malignant or benign is provided that is based on the identification of sets of gene transcripts, which are characterized in that changes in expression of each gene transcript within a set of gene transcripts can be correlated to with either malignant or benign thyroid nodule disease. The thyroid classification system provides for sets of “thyroid classifying” target sequences and further provides for combinations of polynucleotide probes and primers derived there from. These combinations of polynucleotide probes can be provided in solution or as an array. The combination of probes and the arrays can be used for diagnosis. The invention further provides further methods of classifying thyroid nodule tissue. | 11-19-2015 |
20150329916 | METHODS AND KITS USED IN CLASSIFYING ADRENOCORTICAL CARCINOMA - The invention encompasses methods and kits used to detect biomarkers that may be used to predict disease outcome in adrenocortical carcinoma patients. | 11-19-2015 |
20150329921 | DETERMINING TUMOR ORIGIN - The disclosure provides methods for the use of gene expression measurements to classify or identify among 54 cancer types in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples. | 11-19-2015 |
20150330974 | Digital Analysis of Molecular Analytes Using Single Molecule Detection - Methods and systems are provided for small molecule analyte detection using digital signals, key encryption, and communications protocols. The methods provide detection of a large numbers of proteins, peptides, RNA molecules, and DNA molecules in a single optical or electrical detection assay within a large dynamic range. | 11-19-2015 |
20150330979 | PREPARATION OF FETAL NUCLEATED RED BLOOD CELLS (NRBCs) FOR DIAGNOSTIC TESTING - The disclosure relates to methods of preparation of fetal nucleated red blood cells (NRBCs) from biological samples for diagnostic testing. | 11-19-2015 |
20150330981 | PGC-1beta-Protein-Function Regulator, Mitochondria-Function Regulator, Anti-Obesity Agent, And Screening Method Therefor | 11-19-2015 |
20150330985 | GALECTIN-7 AS A BIOMARKER FOR DIAGNOSIS, PROGNOSIS AND MONITORING OF OVARIAN AND RECTAL CANCER - Methods, kits and systems for the diagnosis, prognosis and monitoring of ovarian cancer and rectal cancer are described. The methods, kits and systems are based on the detection of the lectin Galectin-7 in samples obtained from subjects. | 11-19-2015 |
20150330990 | METHOD OF SCREENING CANDIDATE BIOCHEMICAL ENTITIES TARGETING A TARGET BIOCHEMICAL ENTITY - Described herein are methods useful for screening candidate biochemical entities targeting a target biochemical entity and methods useful for identifying a binding moiety for a target biochemical entity. The invention provides methods of screening drug candidates targeting a target biomolecule, comprising selecting a drug candidate based on a signal difference between a first signal and a second signal. The signal difference indicates a difference in an in vivo or in vitro pharmacological property. The first signal is produced upon binding between the target biomolecule and a first candidate by contacting the target biomolecule with the first candidate, and the second signal is produced upon binding between the target biomolecule and a second candidate by contacting the target biomolecule with the second candidate. | 11-19-2015 |
20150330993 | Diagnostic, prognostic, therapeutic and screening protocols - The specification describes an antibody capture process comprising (i) obtaining a biological sample comprising antibodies, (ii) contacting the biological sample with recombinant pIgR or a dIgA-binding variant, wherein the pIgR or variant binds dIgA and forms a pIgR-dIgA complex. The process may further comprise (iii) directly or indirectly assessing the level of the pIgR-dIgA complex or the level of a complex between pIgR-dIgA and an antigen of interest. There is also an antibody capture process for determining gut wall integrity in a test subject, wherein the level or ratio of SIgA to dIgA is compared to a corresponding level or ratio from a control subject. The specification provides kits embodying the process and recombinant pIgR when used for, or for use, in capturing or detecting dIgA and/or IgM. | 11-19-2015 |
20150330994 | IMMUNOASSAY - The present invention relates to an improved immunoassay which increases the sensitivity of detection of substance specific immunoglobulin from a sample. A method of the invention relates to the provision of a plurality of forms of a substance, at least one of which forms includes the natural extract of that substance. The other forms present may be recombinant or natural antigenic components of the substance. | 11-19-2015 |
20150330996 | DETECTION OF HISTONE MODIFICATION IN CELL-FREE NUCLEOSOMES - This invention relates to the diagnosis of disease conditions, such as cancer and autoimmune disease, by the analysis of cell-free nucleosomes in samples from individuals. Methods of the invention may include contacting cell-free nucleosomes from a biological fluid sample obtained from the individual with an antibody that binds specifically with a modified histone protein. Binding of the antibody to the nucleosomes is indicative that the individual has the disease condition. | 11-19-2015 |
20150330997 | TYPE 2 DIABETES BIOMARKERS AND USES THEREOF - The present invention provides biomarkers, methods and kits for diagnosing and prognosing the development of impaired glucose tolerance in a subject and the progression of diabetes in a subject, as well as methods for identifying a compound that can inhibit the development of impaired glucose tolerance and/or type 2 diabetes; reduce or slow down the progression of normal glucose tolerance to impaired fasting glycaemia, to impaired glucose tolerance, and/or to diabetes; and/or reduce or inhibit the development of complications associated with the disease in a subject, and methods for inhibiting the development of impaired glucose tolerance and/or type 2 diabetes; reducing or slowing down the progression of normal glucose tolerance to impaired fasting glycaemia, to impaired glucose tolerance, and/or to diabetes; and/or reducing or inhibiting the development of complications associated with the disease in a subject. | 11-19-2015 |
20150331000 | COMPOSITIONS AND METHODS FOR PURIFICATION AND DETECTION OF HDL AND APOA1 - The present invention provides methods, kits, and compositions for purifying HDL molecules from a sample (e.g., blood sample) using HDL tagging molecules comprising an HDL lipophilic core binding peptide (e.g., portion of ApoA1) and an affinity tag. The present invention also provides methods, kits, and compositions for detecting non-fragmented ApoA1 with mass spectrometry. The present invention further provides methods, kits, and compositions for tagging HDL molecules in a sample with detectably labeled ApoA1 molecules such that the ratio of detectably labeled ApoA1 molecules to native ApoA1 proteins may be determined. | 11-19-2015 |
20150337372 | METHODS AND APPARATUS FOR SELECTIVELY PROCESSING EGGS ACCORDING TO GENDER AND OTHER CHARACTERISTICS - Methods and apparatuses for processing eggs based upon a characteristic such as gender are provided. Sample material is extracted from each of a plurality of live eggs. The extracted sample material is deposited on a liquid-immobilizing assay template and then assayed to identify eggs having the characteristic. The eggs identified as having the characteristic are processed accordingly. | 11-26-2015 |
20150337374 | ASSESSMENT AND REDUCTION OF RISK OF GRAFT-VERSUS-HOST DISEASE - Methods of assessing and reducing risk of graft versus host disease (GVHD) based on gene expression profiling are described, as well as methods of selecting a suitable transplant donor. Corresponding reagents and kits are also described. | 11-26-2015 |
20150337377 | METHOD OF DIAGNOSIS OF COMPLEMENT-MEDIATED THROMBOTIC MICROANGIOPATHIES - A method for identifying a patient's risk for developing complement-mediated thrombic microangiopathy is described. A sample of genetic material is obtained from a patient. The genetic material is amplified using primers specific for complement-mediated thrombic microangiopathy. After amplification, the genetic sequence of the amplicon is determined. The genetic sequence of the amplicon is compared to a reference sequence, and variations are identified between the sample amplicon and the reference sequence. A variation between the sample amplicon and the reference sequence is indicative of a risk for the patient for developing complement-mediated thrombic microangiopathy. | 11-26-2015 |
20150337380 | Compositions and Methods for Diagnosing and Assessing Inflammatory Myopathies - The present invention is directed to assay methods for inflammatory myopathies and microarray plates that can be used in carrying out these assays. | 11-26-2015 |
20150337381 | ASSESSMENT OF RISK OF ANEUPLOIDY - The present disclosure relates generally to methods and materials for use in detecting abnormalities of the number of whole chromosomes or chromosome regions (aneuploidy). It has particular utility for assessing the risk of aneuploidy of eggs (i.e., oocytes), fertilised eggs or embryos developed therefrom in the context of in vitro fertilisation. | 11-26-2015 |
20150337391 | METHOD AND PROBE SET FOR DETECTING CANCER - Methods for detecting cancer that include hybridizing a set of chromosomal probes to a biological sample obtained from a patient, and identifying if aneusomic cells are present in a selected subset of cells obtained from the biological sample are described. A set of chromosomal probes and kits for detecting cancer that include sets of chromosomal probes, are also described. | 11-26-2015 |
20150337392 | MARKERS FOR ENDOMETRIAL CANCER - The invention relates to the surprising finding that biomarkers corresponding to ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, SOCS2, and DCN are differentially expressed in control samples as compared to samples from patients having endometrial cancer and are therefore useful for detecting endometrial cancer. In particular these biomarkers having excellent sensitivity, specificity, and/or the ability to separate affected from non affected individuals. Furthermore, the inventors found that the differential expression of these biomarkers in primary endometrial cancer tumor tissue is correlated to their expression level in uterine fluid samples as compared to control values. Thus these biomarkers are robust in that they are found to be differentially expressed in several different types of samples from affected and individuals. | 11-26-2015 |
20150337393 | miRNA FINGERPRINT IN THE DIAGNOSIS OF PROSTATE CANCER - MicroRNAs (miRNA) are a recently discovered class of small non-coding RNAs (17-14 nucleotides). Due to their function as regulators of gene expression they play a critical role both in physiological and in pathological processes, such as cancer. The present invention provides novel methods for diagnosing prostate cancer based on the determination of specific miRNAs that have altered expression levels in different conditions, e.g. disease states compared to healthy controls | 11-26-2015 |
20150337397 | Methods and Compositions for Selecting Soybean Plants Resistant to Brown Stem Rot - The present invention is in the field of plant breeding and disease resistance. More specifically, the invention includes methods and compositions for breeding soybean plants containing quantitative trait loci that are associated with resistance to Brown Stem Rot (BSR), a fungal disease associated with | 11-26-2015 |
20150338399 | METHODS FOR DIAGNOSING AND MONITORING DISEASE BY DIRECTLY QUANTIFYING DISEASE MODIFIED BIOMOLECULES - Assays for diagnosing or monitoring a disease of interest are provided. The assays detect disease modified bjomolecules (DMBs) in a direct manner by the sequential use of agents with differing specificities. In an exemplary embodiment, the agents are antibodies and the first antibody is specific for a biomolecule that may be modified during the course of 10 the disease, and detects such biomolecules, whether modified or not The second antibody detects only biomolecules that have been modified. | 11-26-2015 |
20150338401 | MULTIPLEXED BIOASSAY TECHNIQUES - Techniques for multiplexed bioassays include a substrate in which is formed a microchannel in fluid communication between an entry port and an exit port. A first portion of the microchannel is configured to supply multiple different labeled probes, each selected to complex with one of a corresponding plurality of different analytes. A second portion of the microchannel comprises multiple corresponding different supplementary probes covalently bound to the substrate. A supplementary probe is selected to bind to a part of a corresponding analyte, which part is exposed when the corresponding analyte is complexed with a corresponding labeled probe. The techniques include a sensor configured to detect signals emitted from the labeled probes in the second portion of the microchannel. | 11-26-2015 |
20150338402 | Tamm Structures for Enhanced Fluorescence Based Sensing, Imaging and Assays - Techniques for enhanced fluorescence include a Tamm substrate for a target optical frequency comprising a metal nanoscale layer deposited on a Bragg grating. The Bragg grating includes multiple dielectric layers including multiple high index of refraction layers alternating with multiple low index of refraction layers. The dielectric layers are parallel to the metal nanoscale layer; and, the thickness of each dielectric layer is about a fourth of a wavelength of the target optical frequency in the layer. The metal nanoscale layer is configured to host a fluorophore such that an S polarized emission from the fluorophore at the target optical frequency propagates out of the substrate perpendicular to the plurality of dielectric layers. | 11-26-2015 |
20150338410 | COMPETITION BASED-DETECTION ASSAYS - Disclosed herein are methods and kits which are useful for detecting presence of an enzyme and the relative amount of glycan associated with the enzyme in a test sample based upon the enzyme's ability to competitively inhibit the binding of a ligand in such test sample. The present invention provides the ability to evaluate cell culture conditions and optimize the desired glycoform content of recombinantly prepared enzymes. | 11-26-2015 |
20150338411 | BIOMARKER FOR THE PREDICTION OF RESPONSIVENESS TO AN ANTI-TUMOUR NECROSIS FACTOR ALPHA (TNF) TREATMENT - The invention refers to a method for diagnosing an individual who is to be subjected to or is being subjected to an anti-tumour necrosis factor alpha (TNFα or TNF) treatment to asses the responsiveness to an anti-TNF treatment which comprises the detection of immunoglobulin(s) against one or more biomarker proteins in a bodily fluid or an excrement of said patient, and sorting the individual into one of two categories based on detection of said immunoglobulin(s), wherein individuals are classified as NON-responder or responder. The invention refers to diagnostic kits comprising said one or more biomarker proteins and the use of these kits for assessing the responsiveness to an anti-TNF treatment of an individual who is to be subjected to or is being subjected to an anti-TNFα treatment. | 11-26-2015 |
20150338412 | COMPOSITION FOR DIAGNOSIS OF LUNG CANCER AND DIAGNOSIS KIT FOR LUNG CANCER - A method of diagnosing small cell lung cancer comprises: measuring an expression level of serum paraoxonase 1 protein and a fucosylation level of the serum paraoxonase 1 protein in a biological sample from a small cell lung cancer patient and in a same biological sample from a normal person, and determining the expression level of the serum paraoxonase 1 protein is decreased in the biological sample of the small cell lung cancer patient as compared to the biological sample of a normal person, and the fucosylation level of the serum paraoxonase 1 protein is increased in the biological sample of the small cell lung cancer patient as compared to the biological sample of a normal person. The measuring of the fucosylation of the serum paraoxonase 1 protein comprises using a biotinylated lectin which binds specifically to fucose on the serum paraoxonase 1 protein and HRP-conjugated streptavidin in a hybrid ELISA. | 11-26-2015 |
20150338415 | MEANS AMD METHODS APPLYING sFlt-1/PIGF OR ENDOGLIN/PIGF RATIO TO RULE OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD - The present invention concerns the field of diagnostic assays for prenatal diagnosis of preeclampsia. In particular, it relates to a method for diagnosing whether a pregnant subject is not at risk for preeclampsia within a short window of time comprising a) determining the amount of at least one angiogenesis biomarker selected from the group consisting of sFlt-1, Endoglin and PlGF in a sample of said subject, and b) comparing the amount with a reference, whereby a subject being not at risk for developing preeclampsia within a short period of time is diagnosed if the amount is identical or decreased compared to the reference in the cases of sFlt-1 and Endoglin and identical or increased in the case of PlGF, wherein said reference allows for making the diagnosis with a negative predictive value of at least about 98%. Further contemplates are devices and kits for carrying out said method. | 11-26-2015 |
20150338416 | ORDERED TWO- AND THREE-DIMENSIONAL STRUCTURES OF AMPHIPHILIC MOLECULES - The invention pertains, at least in part, to a method for forming an ordered structure of amphiphilic molecules, such as proteins. The method includes contacting a population of amphiphilic molecules with an interface; compressing said population laterally to an appropriate pressure, such that an ordered structure at the interface is formed. The invention also pertains to the two- and three-dimensional ordered structures that are formed using the planar membrane compression method of the invention. | 11-26-2015 |
20150338422 | METHOD FOR OBTAINING DATA THAT ARE USEFUL FOR THE DIAGNOSIS, PROGNOSIS AND CLASSIFICATION OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND/OR LUNG CANCER - The invention describes a method for obtaining data useful for the diagnosis, prognosis and classification of individuals with chronic obstructive pulmonary disease (COPD) and/or lung cancer, diagnostic kit, device and uses thereof for the diagnosis, prognosis and classification of patients as a) individuals with no COPD or lung cancer, b) individuals with COPD, c) individuals with adenocarcinoma, d) individuals with COPD and adenocarcinoma, or e) individuals with COPD and squamous carcinoma | 11-26-2015 |
20150344552 | ANTIBODY AGAINST THE PROTEIN TRIO AND ITS METHOD OF PRODUCTION - Disclosed are specific antibodies against the protein Trio, their method of production, and their use in in vitro cancer prognostic method. Also described are the antigens enabling production of the antibodies. | 12-03-2015 |
20150344874 | Screening method for drug target gene using heterozygous deletion fission yeast strain - The present invention relates to a screening method for a drug target gene by using chemical-genetic profile compendium of the heterozygous deletion fission yeast strain and the comparative genetic analysis using the same. More precisely, the present inventors constructed the chemical-genetic profile compendium for drug candidates from the heterozygous deletion fission yeast strain of | 12-03-2015 |
20150344937 | OLIGONUCLEOTIDE-MEDIATED QUANTITATIVE MULTIPLEXED IMMUNOASSAYS - Methods and compositions for quantitative immunoassays are provided, in which ligand-conjugated probes are used to label samples and ligand-surfaced microspheres are used as quantitative reference standards. Certain embodiments provide a method of quantitative flow cytometry where ligands are oligonucleotides, and a sample comprising one or more cells is contacted with a hybridized antibody::fluorophore labeled targeting construct to label the cells, and the labeled cells are analyzed. In some embodiments, a population of quantitative labeled oligospheres labeled with the same fluorescent label as the cells is analyzed using the flow cytometer and used to create a quantitative standard curve of cytometer intensity versus molecules fluorescent label per oligosphere event. A standard curve trendline is established and used to determine the molecules of fluorescent label per cellular event for the antigen-positive cell populations. Based on molecules of fluorescent label per cell, the amount of Antibody Binding per Cell (ABC) is quantified. | 12-03-2015 |
20150344939 | Methods and Compositions For Sorting and/or Determining Organisms - This invention is directed to methods and compositions for sorting and/or determining microscopic organisms or cells. The methods and compositions are directed to the use of molecular probes to selectively stain the organisms or cells in combination with the use of binding partners to selectively immobilize the stained organisms or cells to a solid carrier. By combining the selectivity of both molecular probes and binding partners in an orthogonal method for staining and immobilization, these methods and compositions increase both the discriminating power of the assays and/or the certainty of the result obtained therefrom. | 12-03-2015 |
20150344949 | COMBINED METHODOLOGY USED TO DETECT THE PRESENCE OF POSSIBLE CONTAMINATING EVENTS - Disclosed herein are methods for determining if a contaminating integration of a nucleotide sequence is present in a set of nucleic acids. Further disclosed herein are methods for determining the copy number/zygosity of a nucleic acid sequence of interest. The methods disclosed herein may be performed using quantitative PCR. | 12-03-2015 |
20150344951 | PRE-IMPLANTATION GENDER SCREENING KIT AND METHOD - A kit and method for determining the gender of a human's or other mammal's pre-implantation embryo with increased accuracy. The method comprises exposing genetic material from one or more cells removed from the embryo to multiple labeled hybridization agents that will detect markers associated with (1) the Y chromosome, but not the X chromosome, (2) the X chromosome, but not the Y chromosome, and (3) both X and Y chromosomes. The gender is determined by detecting the presence or absence of labeled hybridized agents in the sample after washing, or indicates that the test results are not reliable. The kit contains labeled hybridization agents for conducting the pre-implantation gender screening method. | 12-03-2015 |
20150344952 | DNA MARKERS FOR BEEF TENDERNESS IN CATTLE - The present invention provides genetic polymorphisms and methods for identifying said genetic polymorphisms associated with desired beef tenderness in cattle, as well as kits for identifying said polymorphisms in beef cattle. The invention also provides methods of predicting the tenderness of beef in a head of cattle before slaughter based on the presence of a hapblock conferring tenderness. In other embodiments, the invention provides methods of determining a breeding value for a head of cattle involving detection of such polymorphisms. | 12-03-2015 |
20150344959 | COMPOSITIONS AND METHODS FOR GENOTYPING CANINES - Provided are compositions and methods for use in genotyping canines. The compositions and methods are useful for determining canine genotypes related to certain canine phenotypes, including shedding and/or long hair, body size, and ear type. The compositions and methods involve determining single nucleotide polymorphisms in biological samples obtained from canines. | 12-03-2015 |
20150344961 | Sera Based miRNAs as Non-Invasive Biomarkers in Melanoma - The present invention relates to serum marker microRNAs (miRNAs) which are associated with cancer, particularly melanoma, and to the assessment thereof in the prognosis, treatment and management of cancer. Embodiments include methods, compositions, kits and isolated nucleic acids. The present invention is directed to methods and compositions for prognosing melanoma and monitoring for recurrence by monitoring serum miRNAs, and the use of miRNAs and antagonists thereof, particularly antagomirs, for predicting and assessing risk and/or likelihood of recurrence in a melanoma patient. The present invention relates to biomarkers for melanoma, particularly serum markers and sets thereof which are relevant and significant as prognostic indicators of melanoma disease and patient risk for recurrence. | 12-03-2015 |
20150344962 | METHODS FOR EVALUATING BREAST CANCER PROGNOSIS - Methods for diagnosing and for evaluating the prognosis of a cancer patient, particularly a breast cancer patient, are provided. The methods include determining expression levels of at least five biomarkers in a body sample including a cancer cell from the patient, where expression levels of the biomarkers are indicative of cancer prognosis. Overexpression of the biomarkers of the invention is indicative of a poor prognosis. In some embodiments, the body sample is a breast tissue sample, particularly a primary breast tumor sample. The methods of the invention can be used in combination with assessment of conventional clinical factors and permit a more accurate evaluation of breast cancer prognosis. | 12-03-2015 |
20150344964 | PREDICTION OF THE TREATMENT RESPONSE TO AN ANTI-EGFR MOLECULE IN COLORECTAL CANCER PATIENTS - The present invention relates to a method for predicting the treatment response to an anti-epidermal growth factor receptor (EGFR) molecule in a patient suffering from colorectal cancer. Furthermore, the present invention relates to an anti-EGFR molecule for use in the treatment of a patient suffering from colorectal cancer. | 12-03-2015 |
20150344969 | COMPOSITIONS AND METHODS FOR DETECTING NEOPLASIA - Compositions and methods for the diagnosis, treatment, and prevention of neoplasia (e.g., colorectal cancer). | 12-03-2015 |
20150344973 | Method and System for Detection of an Organism - The invention provides, inter alia, systems, compositions, kits and methods for detecting an organism, such as a microbe, microorganism, pathogen, or organism associated with Hospital Associated Infections (HAIs). The systems, compositions, kits and methods can comprise one or more probes for detecting a strain with high sensitivity, high specificity, or both. The systems, compositions, kits and methods can also be used to detect the strain within a short time frame. | 12-03-2015 |
20150344974 | DNA MARKERS FOR FEED EFFICIENCY IN CATTLE - The present invention provides genetic polymorphisms and methods for identifying said genetic polymorphisms associated with feed efficiency in cattle, as well as kits for identifying said polymorphisms in beef cattle. The invention also provides methods of predicting the feed efficiency of beef in a head of cattle based on the presence of a hapblock conferring feed efficiency. In other embodiments, the invention provides methods of determining a breeding value for a head of cattle involving detection of such polymorphisms. | 12-03-2015 |
20150346192 | Intracellular Phenotypic Screening - The present invention relates to a method for identifying a cellular target involved in a cell phenotype comprising identifying an intrabody which can modify a cell phenotype and identifying a direct or indirect cellular target of the intrabody. The present invention also relates to intrabodies 3H2-1, 3H2-VH and 5H4 which are capable of inhibiting the degranulation reaction in mast cells triggered by an allergic stimulus, and especially to intrabodies 3H2-1 and 5H4 which are capable of directly or indirectly targeting a protein of the ABCF1 family and of the C120RF4 family respectively. The present invention also relates to ABCF1 and C120RF4 inhibitors for use in therapy, in particular for treating allergic and/or inflammatory conditions. | 12-03-2015 |
20150346199 | METHODS AND COMPOSITIONS FOR HYBRID MICROFLUIDIC DEVICES INTEGRATED WITH NANO-BIOSENSORS - Certain embodiments are directed to paper/polymer hybrid microfluidic devices integrated with nano-biosensors for pathogen detection and infectious disease diagnosis. | 12-03-2015 |
20150346200 | ANTIBODIES TO MICROBIOME, STRESS FACTORS AND MAST CELL MARKERS AS DIAGNOSTIC MARKERS FOR IBS - The present invention provides methods for aiding in the diagnosis of irritable bowel syndrome (IBS) in an individual. In particular, the present invention is useful for determining whether a sample from an individual is an IBS sample or a healthy control sample using a statistical algorithm. Thus, the present invention provides an accurate diagnostic prediction of IBS and is useful for guiding treatment decisions. | 12-03-2015 |
20150346201 | SYSTEM AND METHOD FOR PICOLITER VOLUME MICROFLUIDIC DIAGNOSTICS - The present invention provides a method for a picoliter volume microfluidic assay. The method includes the steps of providing a first solution comprising a sensor, preparing a sample comprising at least one analyte, and combining the sample with an indicator, thereby forming a second solution. The method further includes co-encapsulating the first solution and the second solution in a plurality of droplets with a microfluidic device, incubating the plurality of droplets, thereby forming at least one complex comprising the sensor, at least one analyte and indicator, and detecting the at least one complex. A primary signal associated with the at least one complex is distinguishable from a background signal associated with at least one of the sensor, at least one analyte and indicator individually. | 12-03-2015 |
20150346205 | METHODS OF SUBCLASSIFICATION OF DUCTAL CARCINOMA IN SITU OF THE BREAST - Provided herein are methods of determining the aggressiveness or indolence of a ductal carcinoma in situ lesion. Also provided are methods of development treatment plans for subjects with a ductal carcinoma in situ lesion based on the aggressiveness of the lesion. | 12-03-2015 |
20150346213 | PLASMA CYTOCHROME C AS A BIOMARKER FOR MITOCHONDRIAL TOXICITY DURING ANTIRETROVIRAL THERAPY - The present invention relates to the discovery that measurement of the level of cytochrome c (Cyt-C) in the plasma can be used as a diagnostic signature to predict antiretroviral therapy (ART) toxicity in human immunodeficiency virus (HIV) infected patients. Thus, in various embodiments described herein, the methods of the invention relate to methods of diagnosing a HIV patient with ART toxicity, methods of predicting a patient's risk of having or developing toxicity for ART, methods of assessing if a patient will benefit from a change in the treatment strategies by adjusting the dosage and/or changing the medication or even terminating of ART, and methods of predicting antiretroviral drugs propensity for causing mitochondrial toxicity. Furthermore, the invention encompasses a diagnostic kit for carrying out the aforementioned methods. | 12-03-2015 |
20150346216 | DEVICES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF WOUNDS USING BIOMARKERS - The present invention provides for devices and methods for determining the healing phase of a wound. In some aspects, the present invention provides a wound diagnosis device comprising a surface and at least one agent that is specific to a desired biomarker. In another aspect, the present invention provides a method of determining the phase of wound healing. In still other aspects, the present invention provides methods of determining the phase of wound healing using the disclosed devices. | 12-03-2015 |
20150346217 | USE OF sCD14 OR ITS FRAGMENTS OR DERIVATIVES FOR RISK STRATIFICATION, DIAGNOSIS AND PROGNOSIS - The present invention relates to a method for diagnosis of a cardiovascular disease or condition or atherosclerosis and for a method for evaluating the risk of a subject of developing the same. Methods are further provided for evaluating a subject's risk of mortality, for evaluating whether a subject will benefit from a certain treatment or whether a subject needs to be hospitalized or whether a subject may be discharged. The present invention provides sCD14 or a fragment or derivative thereof (including in particular sCD14-ST) as a novel marker for cardiovascular risk in general, more specifically as a marker for cardiovascular disease or condition, or atherosclerosis. | 12-03-2015 |
20150346218 | MARKERS ASSOCIATED WITH ARTERIOVASCULAR EVENTS AND METHODS OF USE THEREOF - Disclosed are methods of identifying subjects with arteriovascular disease, subjects at risk for developing arteriovascular disease, methods of differentially diagnosing diseases associated with arteriovascular disease from other diseases or within sub-classifications of arteriovascular disease, methods of evaluating the risk of arteriovascular events in patients with arteriovascular disease, methods of evaluating the effectiveness of treatments in subjects with arteriovascular disease, and methods of selecting therapies for treating arteriovascular disease. | 12-03-2015 |
20150346222 | FASTING LEVELS OF GROWTH HORMONE AS A PREDICTIVE MARKER OF CARDIOVASCULAR RISK - Subject matter of the present invention is a method for predicting the cardiovascular risk or the total mortality risk in a subject comprising:
| 12-03-2015 |
20150346227 | IMMUNOASSAY FOR SYNTHETIC CANNABINOIDS OF THE ADAMANTYL INDAZOLE/INDOLE-3-CARBOXAMIDE FAMILY - An immunoassay method for detecting and determining adamantane substituted indazole and indole synthetic cannabinoids is described. Also described are components for use in implementing the method, namely, antibodies, detection agents, solid state devices and kits as well as immunogens used to raise the antibodies. | 12-03-2015 |
20150347672 | ASSESSMENT OF CELLULAR SIGNALING PATHWAY ACTIVITY USING LINEAR COMBINATION(S) OF TARGET GENE EXPRESSIONS - The present application mainly relates to specific methods for inferring activity of a cellular signaling pathway in tissue and/or cells of a medical subject based at least on expression levels of one or more target gene(s) of the cellular signaling pathway measured in an extracted sample of the tissue and/or cells of the medical subject, an apparatus comprising a digital compressor configured to perform such methods and a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such methods. | 12-03-2015 |
20150352512 | BIOLOGICAL SAMPLE ANALYTICAL INSTRUMENT - A method for processing a biological material sample includes dispensing a sample into wells of an array tape from a sample plate, dispensing a reagent into the wells of the array tape from a reagent plate, and sealing the sample and the reagent in the array tape. The method further includes cooling the array tape and detecting biological material in the wells of the array tape. | 12-10-2015 |
20150353632 | SIGNAL BIOMARKERS - Diagnostics relating to C-type natriuretic and erythropoietin signal peptides and fragments, and kits, uses and applications therefore. | 12-10-2015 |
20150353927 | Templates, Libraries, Kits and Methods for Generating Molecules - The present invention is directed to collections of templates for molecules such as RNA, as well as templates, devices, kits and methods for generating molecules from these collections. Through the use of various embodiments of the present invention one may efficiently and effectively obtain selected RNA molecules such as siRNA, shRNA, miRNA mimics and inhibitors, lncRNA, antisense RNA, aptamers, ribozymes, and sgRNA and sets of those molecules. | 12-10-2015 |
20150353990 | Test Cartridge with Integrated Transfer Module - A system that includes a cartridge housing and a hollow transfer module, according to an embodiment is described herein. The cartridge housing further includes at least one sample inlet, a plurality of storage chambers, a plurality of reaction chambers, and a fluidic network. The fluidic network is designed to connect the at least one sample inlet, a portion of the plurality of storage chambers and the portion of the plurality of reaction chambers to a first plurality of ports located on an inner surface of the cartridge housing. The hollow transfer module includes a second plurality of ports along an outer surface of the transfer module that lead to a central chamber within the transfer module. The transfer module is designed to move laterally within the cartridge housing. The lateral movement of the transfer module aligns at least a portion of the first plurality of ports with at least a portion of the second plurality of ports. | 12-10-2015 |
20150353995 | ECF-BINDING AGENTS AND USES THEREOF - The invention features a method for isolating a population of pathogenic | 12-10-2015 |
20150353997 | DETECTION OF DNA OR RNA USING SINGLE MOLECULE ARRAYS AND OTHER TECHNIQUES - Described herein are methods and systems for detecting DNA or RNA using single molecules array or other techniques. DNA or RNA from the sample may be fragmented and exposed to a first type of binding ligand and a second type of binding ligand that comprise nucleic acid sequences complimentary at least a portion of a sequence contained in the target DNA or RNA. At least a portion of the fragmented DNA or RNA associates with at least one of the first type of binding ligand and/or the second type of binding ligand, wherein the first type of binding ligand and second type of binding ligand comprises nucleic acid sequences complimentary to a different portions of a sequence contained in the DNA or RNA. A portion of the sample exposed to the binding ligands is analyzed to determine the number of fragmented DNA or RNA sequences. | 12-10-2015 |
20150353998 | COMPOSITIONS AND METHODS FOR REPRESENTATIONAL SELECTION OF NUCLEIC ACIDS FROM COMPLEX MIXTURES USING HYBRIDIZATION - The invention provides a method of selecting a representational sample of nucleic acid sequences from a complex mixture. The method includes: (a) contacting a complex mixture of nucleic acids under conditions sufficient for hybridization with a population of capture probes complementary to one or more nucleic acids comprising a predetermined portion of the sequence collectively present in the complex mixture to form hybridization complexes of the one or more nucleic acids with the population of probes, the population of capture probes being attached to a solid support, and (b) removing unhybridized nucleic acids to select a representational sample of nucleic acids having a complexity of less than 10% but more than 0.001% of the complex mixture, wherein the representational sample comprises a nucleic acid copy having a proportion of each sequence in the copy relative to all other sequences in the copy substantially the same as the proportions of the sequences in the predetermined portion of one or more nucleic acids within the complex mixture. A method of selecting a representational sample of genomic sequences from a complete genome also is provided. The invention further provides a nucleic acid population that includes a representational sample having a complexity of less than 10% but more than 0.001% of a complex mixture, the representational sample comprising a nucleic acid copy having a proportion of each sequence in the copy relative to all other sequences in the copy substantially the same as the proportions of sequences in a predetermined portion of a sequence collectively present in one or more nucleic acids within the complex mixture. | 12-10-2015 |
20150354005 | METHOD FOR PREDICTING THE ONSET OF EXTRAPYRAMIDAL SYMPTOMS (EPS) INDUCED BY AN ANTIPSYCHOTIC-BASED TREATMENT - The invention relates to methods for predicting the onset of extrapyramidal symptoms (EPS) induced by an antipsychotic-based treatment as well as methods for providing personalized medicine to patients based on the sequence of several SNPs associated with the onset of EPS. The invention relates as well to kits for carrying out the diagnostic and predictive medicine methods. | 12-10-2015 |
20150354008 | DIAGNOSTIC FOR LUNG DISORDERS USING CLASS PREDICTION - The present invention provides methods for diagnosis and prognosis of lung cancer using expression analysis of one or more groups of genes, and a combination of expression analysis with bronchoscopy. The methods of the invention provide far superior detection accuracy for lung cancer when compared to any other currently available method for lung cancer diagnostic or prognosis. The invention also provides methods of diagnosis and prognosis of other lung diseases, particularly in individuals who are exposed to air pollutants, such as cigarette or cigar smoke, smog, asbestos and the like air contaminants or pollutants. | 12-10-2015 |
20150355079 | Spatial Positioning of Spectrally Labeled Beads - Devices, systems, kits, and methods for detecting and/or identifying a plurality of spectrally labeled bodies well-suited for performing multiplexed assays. By spectrally labeling the beads with materials which generate identifiable spectra, a plurality of beads may be identified within the fluid. Reading of the beads is facilitated by restraining the beads in arrays, and/or using a focused laser. | 12-10-2015 |
20150355132 | METHOD FOR THE DETECTION AND QUANTIFICATION OF ANALYTES USING THREE-DIMENSIONAL PAPER-BASED DEVICES - Described herein are three-dimensional (3-D) paper fluidic devices. The entire 3-D device is fabricated on a support layer formed from a single sheet of material and assembled by folding the support layer. The folded structure may be enclosed in an impermeable cover or package. Chemically sensitive particles may be disposed in the support layer for use in detecting analytes. | 12-10-2015 |
20150355133 | NANO-WELL BASED ELECTRICAL IMMUNOASSAYS - In some embodiments, the compositions and methods relate to nano-well sensors and methods for using the same to detect target molecules in samples. In some embodiments, the nano-well chip comprises three parts: (a) a solid substrate, (b) a nanoporous nylon membrane situated on the top surface of the solid substrate, and (c) a polymer on top of and surrounding the nano-porous nylon membrane. | 12-10-2015 |
20150355169 | MODULAR POINT-OF-CARE DEVICES, SYSTEMS, AND USES THEREOF - The present invention provides devices and systems for use at the point of care. The methods devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device are modular to allow for flexibility and robustness of use with the disclosed methods for a variety of medical applications. | 12-10-2015 |
20150355182 | METHODS AND SYSTEMS FOR EXTENDING DYNAMIC RANGE IN ASSAYS FOR THE DETECTION OF MOLECULES OR PARTICLES - Described herein are systems and methods for extending the dynamic range of assay methods and systems used for determining the concentration of analyte molecules or particles in a fluid sample. In some embodiments, a method comprises spatially segregating a plurality of analyte molecules in a fluid sample into a plurality of locations. At least a portion of the locations may be addressed to determine the percentage of said locations containing at least one analyte molecule. Based at least in part on the percentage, a measure of the concentration of analyte molecules in the fluid sample may be determined using an analog, intensity-based detection/analysis method/system and/or a digital detection/analysis method/system. In some cases, the assay may comprise the use of a plurality of capture objects. | 12-10-2015 |
20150355195 | METHODS FOR PREDICTING AND MONITORING MUCOSAL HEALING - The present invention provides methods for predicting the likelihood of mucosal healing in an individual with a disease such as inflammatory bowel disease (IBD). In addition, the present invention provides methods for monitoring the progression of mucosal healing in an individual with a disease such as IBD. Information on mucosal healing status derived from the use of the present invention can also aid in optimizing therapy and/or monitoring the therapeutic efficiency of an anti-TNFα inhibitor drug. | 12-10-2015 |
20150355199 | AGENTS, KITS AND METHODS FOR COMPLEMENT FACTOR H-RELATED PROTEIN 1 DETECTION - The present invention relates to an assay for specific detection of complement factor H-related protein 1 (CFHR1) in a sample from a subject, as well as kits and agents related thereto. | 12-10-2015 |
20150355200 | Method for Selecting Agents that Bind to Transmembrane Receptors in a Conformationally-Selective Manner - Provided herein are several methods for selecting agents that bind to transmembrane receptors in a conformationally-selective way. In some embodiments, the method may comprise producing: a transmembrane receptor in an active conformation; and said transmembrane receptor in an inactive conformation and using cell sorting to select, from a population of cells comprising a library of cell surface-tethered extracellular capture agents, cells that are specifically bound to either the transmembrane receptor in its active conformation or the transmembrane receptor in its inactive conformation, but not both. In other embodiments, the method may comprise: contacting a GPCR with a population of cells that comprise a library of surface-tethered extracellular proteins; labeling the cell population with a conformationally-specific binding agent, e.g., a G-protein or mimetic thereof; and using cell sorting to select from the cell population cells that bind to the agent. | 12-10-2015 |
20150360195 | DEVICE FOR RECOVERY AND ISOLATION OF BIOMOLECULES - The present invention relates to a device for isolating and recovering a biomolecule from a test sample. The device includes a support and at least one peelable layer deposited on at least a portion of the support. The peelable layer includes a substrate having a target component immobilized on the substrate. The device is effective for isolating and recovering a biomolecule having affinity to the target component. The present invention also relates to systems and methods of using the device. The present invention also relates to a biomolecule elution strip and related methods. | 12-17-2015 |
20150361159 | FIBRONECTIN BASED SCAFFOLD PROTEINS - Fibronectin type III ( | 12-17-2015 |
20150361420 | Methods for Screening Proteins Using DNA Encoded Chemical Libraries as Templates for Enzyme Catalysis - Disclosed are methods, compositions and devices for screening a protein library for proteins having a desired activity, such as capable of catalyzing the formation of a bond between two reactants. In an exemplary embodiments, a plurality of proteins are expressed in vitro from a plurality of nucleic acids, the plurality of proteins are exposed with two single stranded oligonucleotides having complementary sequences, each oligonucleotide having a reactant and a fluorophore, the fluorescence of the protein-reactant-oligonucleotide-fluorophore complexes is detected and the complexes showing detectable fluorescence energy transfer are isolated, thereby isolating proteins having the desired enzymatic activity. | 12-17-2015 |
20150361480 | DETECTION OF ANALYTES AND NUCLEIC ACIDS - Methods of detecting at least one analyte and at least one nucleic acid in a sample are provided. Reagents for carrying out the methods are also provided. | 12-17-2015 |
20150361491 | miRNA-124 AS A BIOMARKER - A use of at least one miRNA, said at least one miRNA being miR-124, as a biomarker, in particular of a viral infection, or of an efficacy of a therapeutic treatment of said viral infection. | 12-17-2015 |
20150361493 | MULTIPLEX COMPOSITIONS AND METHODS FOR QUANTIFICATION OF HUMAN NUCLEAR DNA AND HUMAN MALE DNA AND DETECTION OF PCR INHIBITORS - The invention relates to a method for simultaneous quantification of human nuclear DNA and human male DNA in a biological sample while also detecting the presence of PCR inhibitors in a single reaction. The multiplex quantification method also provides a ratio of human nuclear and male DNA present in a biological sample. Such sample characterization is useful for achieving efficient and accurate results in downstream molecular techniques such as genotyping. | 12-17-2015 |
20150361500 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ACNE VULGARIS - Described herein are methods, systems, platforms, and kits for the characterization, assessment, diagnosis and treatment of acne vulgaris. Among the methods provided are methods of identifying a gene expression profile for acne vulgaris and biomarkers for monitoring treatment. Also provided are methods, systems, platforms, and kits for monitoring efficacy of a treatment and methods for selecting a treatment regimen. | 12-17-2015 |
20150362411 | MICROFLUIDIC DEVICES, SYSTEMS, AND METHODS FOR IMAGING TISSUE SAMPLES - One aspect of the present disclosure can include a microfluidic device for imaging a tissue sample. The device can include a tissue chamber, a liquid inlet channel, and a liquid outlet channel. The tissue chamber can be defined by a plurality of walls, at least one of which is transparent. The liquid inlet channel can be fluid communication with the tissue chamber. The liquid outlet channel can be in fluid communication with the tissue chamber. The tissue chamber can be sized and dimensioned to completely immobilize the tissue sample during imaging. | 12-17-2015 |
20150362433 | CHEMICAL SENSING DEVICE - The present disclosure is drawn to chemical sensing devices and associated methods. In an example, a chemical sensing device can include a substrate and an elongated nanostructure having an attachment end and a free end opposite the attachment end, the attachment end affixed to the substrate and the free end comprising a metal having a potential sensing ligand attached thereto via a covalent bond. | 12-17-2015 |
20150362434 | System and Method for Evaluating Biological Samples Remotely - Disclosed herein is a healthcare system and method for analyzing a biological sample having a data acquisition unit, a field unit for obtaining and storing visualized biomarkers; an optical lens adapter configured to adapt to an imaging device capable of taking images of the visualized biomarkers; a data analysis unit having an analyzing unit to receive and evaluate the image to determine the presence or absence of preset values that are above or below an arbitrarily set threshold level; and an output device providing a graphic or textual output according to the presence or absence of the preset values. | 12-17-2015 |
20150362486 | CHEMICAL-ANALYSIS DEVICE INTEGRATED WITH METALLIC-NANOFINGER DEVICE FOR CHEMICAL SENSING - A chemical-analysis device integrated with a metallic-nanofinger device for chemical sensing. The chemical-analysis device includes a metallic-nanofinger device, and a platform. The metallic-nanofinger device includes a substrate, and a plurality of nanofingers coupled with the substrate. A nanofinger of the plurality includes a flexible column, and a metallic cap coupled to an apex of the flexible column. At least the nanofinger and a second nanofinger of the plurality of nanofingers are to self-arrange into a close-packed configuration with at least one analyte molecule. A morphology of the metallic cap is to generate a shifted plasmonic-resonance peak associated with amplified luminescence from the analyte molecule. A method for using, and a chemical-analysis apparatus including the chemical-analysis device are also provided. | 12-17-2015 |
20150362487 | Multi-Diagnosis Parallel-Type Linear Biochip - The present invention is related to a parallel line biochip for multiplex diagnosis. The parallel line biochip for multiplex diagnosis includes a plurality of line strips disposed in parallel, and a well configured to immobilize the line strips. Since the parallel line biochip for multiplex diagnosis can be used to connect two or more line strips in parallel, the parallel line biochip for multiplex diagnosis has an effect of measuring various materials present in a biological test sample at the same time. | 12-17-2015 |
20150362490 | PROTEIN BIOSENSORS, CROSS REACTIVE SENSOR ARRAYS AND METHODS OF USE THEREOF - The present invention is directed to fluorescent protein biosensors based on oligonucleotide cross reactive sensor arrays including a selective and a non-selective protein surface binding domain for protein detection. Interaction of different protein isoforms with the sensors of this invention yields a unique optical signature for each protein. The unique optical signature allows differentiating between closely related protein isoforms and diagnosing diseases and disorders associated with the proteins also in biofluids. | 12-17-2015 |
20150362496 | METHODS AND PRODUCTS FOR IN VITRO DIAGNOSIS, IN VITRO PROGNOSIS AND THE DEVELOPMENT OF DRUGS AGAINST INVASIVE CARCINOMAS - The present invention relates to in vitro methods and products for detecting the presence of an invasive carcinoma in an individual, for determining and/or predicting the stage and/or invasiveness of said carcinoma in an individual, or for monitoring the effect of the therapy administered to an individual who has said carcinoma based on col11a1 gene and proCOL11A1 protein expression. The invention also relates to the search for, identification, development and evaluation of the efficacy of compounds for therapy for said carcinoma, for the purpose of developing new medicinal products. The invention also relates to agents inhibiting proCOL11A1 protein expression and/or activity, and/or the effects of this expression. | 12-17-2015 |
20150362497 | Autoantibody Signature for the Early Detection of Ovarian Cancer - Methods for identifying antigens as potential biomarkers for the early detection of ovarian cancer, as well as kits for utilizing said antigens as biomarkers and in personalized medicine/therapeutics assessment. Protein microarrays displaying full-length candidate antigens were developed and sequentially screening to select candidate autoantibody biomarkers to limit the false discovery rate inherent to large-scale proteomic screening. | 12-17-2015 |
20150362503 | REAL-TIME ANALYTICAL METHODS AND SYSTEMS - The present invention is generally directed to compositions, methods, and systems for performing single-molecule, real-time analysis of a variety of different biological reactions, and for determining various characteristics of the different biological reactions. The ability to analyze such reactions provides an opportunity to study those reactions as well as to potentially identify factors and/or approaches for impacting such reactions, e.g., to stimulate, enhance, or inhibit such reactions. | 12-17-2015 |
20150362505 | INHIBITION OF PHOSPHORYLATION OF PRAS40, GSK3-BETA OR P70S6K1 AS A MARKER FOR TOR KINASE INHIBITORY ACTIVITY - Provided herein are methods for treating a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3β or p70S6K1, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3β or p70S6K1. | 12-17-2015 |
20150362509 | Method for Differentiating Sepsis and Systemic Inflammatory Response Syndrome (SIRS) - A method of characterizing sepsis in a subject involves determining an amount in a biological sample from the subject of each biomarker in a biomarker panel including at least two biomarkers; and calculating a risk index or sepsis probability score using the amounts of biomarkers in the biomarker panel. Exemplary biomarker panels include TNF-alpha, interleukin-6, interleukin-10, lipopolysaccharide binding protein, and C-reactive protein; IL-1beta, procalcitonin, absolute neutrophil count, and immature granulocyte count; and Interleukin-8, GM-CSF, MCP1, and INF-gamma. The method can further involve determining one or more clinical parameters about the subject, and calculating the risk index using the amounts of the biomarkers in the biomarker panel and the clinical parameters. | 12-17-2015 |
20150367347 | MOLECULAR ANALYSIS SYSTEM AND USE THEREOF - A molecular testing device comprises a heating and cooling module having a thin-film thermoelectric heating and cooling device, and a removable test module having a combined amplification and hybridization reaction chamber. The reaction chamber comprises a thermo-conductive exterior surface and a microarray on an interior surface. The thin-film thermoelectric heating and cooling device has a heat transfer surface that is adapted to make contact with the thermo-conductive exterior surface of the reaction chamber. The molecular testing device may be used to perform a PCR in the reaction chamber. | 12-24-2015 |
20150368697 | ON-SLIDE STAINING BY PRIMER EXTENSION - A method for analyzing planar sample is provided. In some cases the method comprises: (a) incubating the planar sample with a capture agent that is linked to an oligonucleotide, wherein the capture agent specifically binds to complementary sites in the planar sample; (b) reading a fluorescent signal caused by extension of a primer that is hybridized to the oligonucleotide, using fluorescence microscopy. Several implementations of the method, and multiplexed versions of the same, are also provided. | 12-24-2015 |
20150368698 | PROCESSES FOR DETECTING OR QUANTIFYING NUCLEIC ACIDS USING AN ARRAY OF FIXED OR IMMOBILIZED NUCLEIC ACIDS - This invention provides novel compositions and processes for analyte detection, quantification and amplification. Nucleic acid arrays and libraries of analytes are usefully incorporated into such compositions and processes. Universal detection elements, signaling entities and the like are employed to detect and if necessary or desirable, to quantify analytes. Amplification of target analytes are also provided by the compositions and processes of this invention. | 12-24-2015 |
20150368699 | PROCESSES FOR DETECTING OR QUANTIFYING NUCLEIC ACIDS USING AN ARRAY OF FIXED OR IMMOBILIZED NUCLEIC ACIDS - This invention provides novel compositions and processes for analyte detection, quantification and amplification. Nucleic acid arrays and libraries of analytes are usefully incorporated into such compositions and processes. Universal detection elements, signaling entities and the like are employed to detect and if necessary or desirable, to quantify analytes. Amplification of target analytes are also provided by the compositions and processes of this invention. | 12-24-2015 |
20150368700 | PROCESS FOR DETECTING OR QUANTIFYING NUCLEIC ACIDS IN A LIBRARY - This invention provides novel compositions and processes for analyte detection, quantification and amplification. Nucleic acid arrays and libraries of analytes are usefully incorporated into such compositions and processes. Universal detection elements, signaling entities and the like are employed to detect and if necessary or desirable, to quantify analytes. Amplification of target analytes are also provided by the compositions and processes of this invention. | 12-24-2015 |
20150368713 | METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs) - High efficiency methods for producing retinal pigment epithelial cells from induced pluripotent stem cells (iPSCs) are disclosed herein. The iPSCs are produced from somatic cells, including retinal pigment epithelial (RPE) cells, such as fetal RPE stem cells. In some embodiments, the iPSC include a tyrosinase promoter operably linked to a marker. Methods are disclosed for using the RPE cells, such as for treatment. Methods for screening for agents that affect RPE differentiation are also disclosed. | 12-24-2015 |
20150368724 | METHODS AND MATERIALS FOR CLASSIFICATION OF TISSUE OF ORIGIN OF TUMOR SAMPLES - The present invention provides a process for classification of cancers and tissues of origin through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA tree-based expression framework allows optimization of treatment, and determination of specific therapy. | 12-24-2015 |
20150368726 | NUCLEOPHOSMIN PROTEIN (NPM) MUTANTS, CORRESPONDING GENE SEQUENCES AND USES THEREOF - The invention relates to new nucleophosmin protein (NPM) mutants, corresponding gene sequences and relative uses thereof for diagnosis, monitoring of minimal residual disease, prognostic evaluation and therapy of acute myeloid leukaemia (AML). | 12-24-2015 |
20150369778 | CHEMICAL SENSOR ARRAY AND METHODS OF MAKING AND USING THE SAME - Chemicals sensor arrays are disclosed for detecting analytes in a sample. The chemical sensor array may include two or more vibration detection units. In some embodiments, the vibration detection units each independently include: a piezoelectric element having a first side and a second side; a first electrode disposed on the first side of the piezoelectric element; a second electrode disposed on the first side of the piezoelectric element, wherein the second electrode is spaced apart from the first electrode; and a conductive layer disposed on the piezoelectric element. The conductive layer is spaced apart from the first electrode and the second electrode. Methods of making and using the chemical sensor array are also disclosed. | 12-24-2015 |
20150369801 | Method for Detecting and/or Quantifying the Binding Affinities of a Target Molecule to a Plurality of Different Binding Partners by Plasmon Resonance of Nanoparticles and a Position-Encoded Sensor Therefor - A method for detecting and/or quantifying the binding affinities of one sort of target molecule to a plurality of different binding partners includes using plasmon resonance of nanoparticles, and a position-encoded sensor to measure shifts in the plasmon resonance of the nanoparticles when the target molecule is bound thereto. | 12-24-2015 |
20150369802 | Biomolecule Binding Composite Surfaces, Methods Of Making Such Surfaces, Devices Incorporating Such Surfaces, And Methods Of Using Such Surfaces In Biomolecule Binding Assays, And Devices Therefor - The present invention relates to novel microporous, biomolecule binding composite surfaces. It also relates to processes for making such surfaces. It also relates to processes for incorporating such surfaces into assay devices, and the resulting assay devices. It also relates to readable biomolecule binding assay devices and methods of using such devices in protein microarrays or immunoassays. | 12-24-2015 |
20150369804 | CAPTURE AND RELEASE OF PARTICLES FROM LIQUID SAMPLES - Systems, methods, and devices for selective capture and release of target particles, e.g., living cells, from liquid samples, e.g., blood, are provided. The particle capture systems include a substrate; a first layer of gelatin bound to the substrate by physical adsorption, wherein the gelatin is functionalized with a plurality of first members of a binding pair; a second layer of gelatin wherein the gelatin is functionalized with a plurality of the first members of the binding pair and the second layer is bound to the first layer via a plurality of second members of the binding pair that are associated with the first members of the binding pair on both the first and the second layers; and a plurality of nanostructures bound to the second members of the binding pair and to one or more particle-binding moieties that selectively bind to the target particles. | 12-24-2015 |
20150369808 | METHODS AND PRODUCTS FOR PROGNOSING THE CLINICAL EVOLUTION, OR PREDICTING THE RECURRENCE RISK, OF A PAPILLARY LESION OF THE BREAST - The present invention relates to in vitro methods and products for prognosticating clinical progression or predicting the risk and type of recurrence of a papillary lesion of the breast based on proCOL11A1 protein expression, for the purpose of determining the treatment and follow-up regimen that are most suited to each patient. | 12-24-2015 |
20150369817 | PLATELET BIOMARKERS IN CANCER DIAGNOSIS - The present embodiments relate generally to the field of cancer diagnostics. More specifically the embodiments relate to platelet derived biomarkers used for diagnosis of cancer or cancer progression, as well as prognosis and improved treatment. | 12-24-2015 |
20150369822 | METHOD T0 MAKE AN AQUEOUS POUR POINT DEPRESSANT DISPERSION COMPOSITION - The present invention relates to an aqueous pour point depressant dispersion composition comprising a thermoplastic polymer, preferably ethylene vinyl acetate (EVA); a dispersing agent; water; optionally an aqueous freezing point depressant; and optionally a stabilizing agent wherein the volumn average particle size of the dispersed thermoplastic polymer is equal to or less than 1 micrometers and a method to make and use said composition. | 12-24-2015 |
20150369823 | METHOD TO IDENTIFY PATIENTS THAT WILL LIKELY RESPOND TO ANTI-TNF THERAPY - The present invention identifies various methods for the identification of patients that suffer from an immune system disorder and are likely to benefit from anti-TNF therapy. Because of the significant cost of anti-TNF therapy and the high rate of ineffectiveness of anti-TNF therapy for treating immune disorders such as rheumatoid and psoriatic arthritis, the present invention will improve the delivery of effective therapies to patients in need of either anti-TNF therapy or alternative therapies. | 12-24-2015 |
20150376575 | PODOCYTE CULTURES AND USES THEREOF - The following disclosure generally relates to methods of culturing podocytes in vitro. The cultures can be used for drug screening (such as medium or high throughput drug screening), and for studying molecular pathways involved in glomerular diseases. The disclosure also provides methods for analyzing the healthiness of podocytes in a cell culture. The disclosure also relates to diagnosis of kidney diseases. | 12-31-2015 |
20150376604 | Scaffolded Peptidic Libraries and Methods of Making and Screening the Same - Scaffolded peptidic libraries and methods of screening the same for specific binding to a target protein are provided. Each library includes distinct peptidic compounds that include a scaffold domain and a distinct variable domain. A variety of libraries are provided where each library is based on an underlying peptidic scaffold having a structural motif. In some embodiments, the peptidic scaffold is a small protein having a protein-protein interaction surface. Libraries of polynucleotides that encode a variety of peptidic compounds are provided. These libraries find use in a variety of applications in which specific binding to target molecules, e.g., target proteins is desired. Also provided are methods of making the libraries and methods of screening the libraries for binding to a target. | 12-31-2015 |
20150376681 | NUCLEIC ACID TARGET IDENTIFICATION BY STRUCUTRE BASED PROBE CLEAVAGE - The present invention provides for novel methods and compositions for nucleic acid sequence detection. Unique, identifying cleavage fragments from probes, bound to target nucleic acids, are produced during PCR by the 5′-nuclease activity of the polymerase. The identity of the targets can be determined by identifying the unique cleavage fragments. | 12-31-2015 |
20150376683 | METHODS OF DETECTING CHLAMYDIA AND GONORRHEA AND OF SCREENING FOR INFECTION/INFLAMMATION BASED ON GENOMIC COPY NUMBER - Compositions and methods for detecting | 12-31-2015 |
20150376688 | PROCESS FOR DETECTING OR QUANTIFYING NUCLEIC ACIDS IN A LIBRARY - This invention provides novel compositions and processes for analyte detection, quantification and amplification. Nucleic acid arrays and libraries of analytes are usefully incorporated into such compositions and processes. Universal detection elements, signaling entities and the like are employed to detect and if necessary or desirable, to quantify analytes. Amplification of target analytes are also provided by the compositions and processes of this invention. | 12-31-2015 |
20150376697 | METHOD AND SYSTEM TO DETERMINE BIOMARKERS RELATED TO ABNORMAL CONDITION - A method and system to determine biomarkers related to abnormal condition in a subject are provided, comprising:sequencing nucleic acid samples from a first and a second subject in order to obtain multiple sequences respectively consisting of the first and the second sequencing results, wherein the first subject is in the abnormal condition; and the second subject is not in the abnormal condition; and the nucleic acid samples from the first and the second subject are both isolated from the samples of the same type; and the first and the second subject belong to the same species; and determining the biomarkers related to the abnormal condition in the subject based on the difference between the first and the second sequencing results. | 12-31-2015 |
20150376702 | METHODS FOR ASSESSING THE RISK OF CANINE ATOPIC DERMATITIS - The present invention relates to methods for assessing the risk of a dog to develop canine atopic dermatitis. The methods comprise detecting in a sample of DNA obtained from a dog the presence or absence of at least one genetic marker, wherein said at least one genetic marker is located on dog ( | 12-31-2015 |
20150376708 | PROBES AND METHODS FOR DETERMINING THE PRESENCE OR ABSENCE OF GENETIC SEGMENTS - A method for determining the presence or absence of a genetic segment of interest, such as an exon, an intron or a promoter, in a DNA-containing sample, and probe sets for use in such methods, including probe sets comprising oligonucleotide probes having nucleotides sequences selected from those of SEQ ID NOS: 1-101. | 12-31-2015 |
20150376709 | METHOD FOR PREDICTION OF SPONTANEOUS PRETERM BIRTH BY MEASURING CELL FREE NUCLEIC ACIDS IN MATERNAL BLOOD - A nucleic acid normalization kit can include a nucleic acid having a normalization sequence including or complementary to one or more of SEQ ID NOs: 1-4 and 301-303 or unique segment thereof, the nucleic acid being present in an amount sufficient for use in a nucleic acid normalization protocol. The normalization kit can be used in a method of identifying a pregnancy normalization nucleic acid sequence. A nucleic acid diagnostic kit for diagnosing susceptibility to preterm birth (PTB) can include a nucleic acid having a CFP RNA PTB biomarker sequence including or complementary to one or more of SEQ ID NOs: 5-300 or unique segment thereof, the nucleic acid being present in an amount sufficient for use in a nucleic acid diagnostic protocol for diagnosing susceptibility to PTB. The diagnostic kit can be used in a method for predicting susceptibility of a pregnant woman to preterm birth (PTB). | 12-31-2015 |
20150376714 | METHOD FOR PREDICTING THE BENEFIT FROM INCLUSION OF TAXANE IN A CHEMOTHERAPY REGIMEN IN PATIENTS WITH BREAST CANCER - A method for predicting a benefit from inclusion of taxane in a chemotherapy regimen in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer. Said method comprises the steps of: a) determining in a tumor sample from said patient the expression levels of the marker genes S100P and PCSK6, and b) mathematically combining the expression level values of the genes PCSK6 and S100P to yield a combined score and comparing said combined score to a reference-value, including a cutoff, wherein a high combined score is indicative of a benefit from including a taxane in a chemotherapy regimen of said patient and a low combined score is indicative of not having a benefit from including a taxane in a chemotherapy regimen of said patient or c) mathematically combining the expression level value of PCSK6 and S100P with the expression values of other genes to yield a combined score and comparing said combined score to a reference-value, including a cutoff, wherein a high combined score is indicative of a benefit from including a taxane in a chemotherapy regimen of said patient and a low combined score is indicative of not having a benefit from including a taxane in a chemotherapy regimen of said patient. | 12-31-2015 |
20150376718 | IDENTIFICATION OF TUMOR-ASSOCIATED CELL SURFACE ANTIGENS FOR DIAGNOSIS AND THERAPY - The present invention provides agents with tumor-inhibiting activity, and which are selective for cells expressing or abnormally expressing a tumor-associated antigen. Said tumor-associated antigen has a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence selected from the specific sequences set forth herein, or a 6-50 contiguous nucleotide residue portion thereof; (b) a nucleotide sequence of a nucleic acid which hybridizes with a nucleic acid having the nucleotide sequence of (a) under stringent conditions; (c) a nucleotide sequence which is degenerate with respect to the nucleotide sequence of (a) or (b); and (d) a nucleotide sequence which is complementary to the nucleotide sequence of (a), (b) or (c). Pharmaceutical compositions and kits comprising the agents are also provided, as well as methods treating, diagnosing or monitoring a disease characterized by expression or abnormal expression of the tumor-associated antigen. | 12-31-2015 |
20150376719 | QUALITY CONTROL OF AGRICULTURAL PRODUCTS BASED ON GENE EXPRESSION - The invention relates to the field of quality testing of fresh plant-based and mushroom based products. Methods, carriers and kits for determining the quality stage are provided. | 12-31-2015 |
20150376723 | PROGNOSTIC BIOMARKERS FOR INFLUENZA - Described are biomarkers and associated methods for identifying a subject having, or at risk of developing, severe illness from influenza. The level of one or more biomarkers in a test sample from the subject is determined and compared to a control level. Optionally, the subject has or is suspected of having H1N1 influenza. In some embodiments the biomarkers may include IL23R, IL10, TNFRSF13B, CX3CR1, CCR2, MAP2K3 and/or IRF1. In some embodiments, the biomarkers include a combination of IL2 and IL23R or IL10 and IL23R. Also described are methods which include determining the level of two or more biomarkers in a sample and multivariate methods are used for comparing the levels in the test sample to the level in a control sample. | 12-31-2015 |
20150376725 | HPV Detection in Urine - The disclosure provides compositions and methods for the detection of human papillomavirus (HPV) nucleic acids in a urine sample from a human subject. The nucleic acids may be from one or more high risk forms of HPV. The urine sample is minimally processed, without fractionation into cell-free and cell-containing portions, before preparation of the nucleic acids for detection of HPV sequences. | 12-31-2015 |
20150377861 | CELL CULTURE DEVICE WITH AN ARRAY OF MICROFLUIDIC NETWORKS - A cell culture assay device can include: a substrate having a plurality of discrete microfluidic networks and a plurality of wells over the discrete microfluidic networks, each discrete microfluidic network having one or more wells fluidly coupled thereto, the wells extending upward from the discrete microfluidic networks; and a manifold body coupled with the substrate and having at least one fluid conduit pair for each microfluidic network and/or each well, each fluid conduit pair including a fluid inlet conduit and a fluid outlet conduit fluidly coupled to a corresponding microfluidic network and/or well. The substrate can be formed from a substrate base having the microfluidic networks coupled to a well plate having the wells associated with the microfluidic networks. | 12-31-2015 |
20150377864 | HIGH THROUGHPUT SCREENING OF AGENTS ON DOPAMINERGIC NEURONS - A method of determining whether an agent is a neuroeffector is disclosed. The method comprises:
| 12-31-2015 |
20150377871 | MODULAR POINT-OF-CARE DEVICES, SYSTEMS, AND USES THEREOF - The present invention provides devices and systems for use at the point of care. The methods devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device are modular to allow for flexibility and robustness of use with the disclosed methods for a variety of medical applications. | 12-31-2015 |
20150377879 | PEPTOIDS THAT BIND SPECIFIC ANTIGENS - Combinatorial libraries were generated providing a vast number of diverse peptoid ligands. From these libraries, ligands were identified which specifically bind molecules associated with autoimmune diseases, such as antibodies specific to aquaporin-4 (AQP4), binding of which to AQP4 causes the autoimmune disease, Neuoromyelitis Optica. Methods of generating peptoid libraries and for diagnosing Neuromyelitis Optica are also provided. | 12-31-2015 |
20150377880 | CELL-FREE BIOFRAGMENT COMPOSITIONS AND RELATED SYSTEMS, DEVICES, AND METHODS - The present disclosure relates to biofragment compositions that comprise bioparticle fragments and at least one heterologous antigen-binding molecule. In some embodiments, the biofragment is typically derived from a larger, intact bioparticle that express the at least one heterologous antigen-binding molecule at the surface, and the biofragment has increased solubility to facilitate assays for antigen detection. The disclosure also relates the related methods of using and making the biofragment compositions, as well as systems and devices implementing the biofragment compositions. In some embodiments, the related methods, systems and devices do not require additional detection reagents, such as animal derived detection antibodies. | 12-31-2015 |
20150377883 | BIOMARKERS OF ACUTE LIVER INJURY - Provided herein are biomarkers of acute liver injury (ALI), which includes acute liver failure, and methods of diagnosing ALI and/or monitoring treatment and prognosis therewith. In particular, serum levels of carbamoyl phosphate synthatase-1 (CPS1) are detected to diagnose and/or monitor treatment and prognosis of ALI. | 12-31-2015 |
20150377889 | GALECTIN-3 AS A MARKER FOR PROSTATE CANCER - Provided are methods and kits for the use of galectin-3, alone or in combination with prostate specific antigen (PSA), as a marker for the presence or absence of and/or activity of prostate cancer. | 12-31-2015 |
20150377893 | SYSTEMS AND METHODS FOR HIGH-THROUGHPUT DETECTION OF AN ANALYTE IN A SAMPLE - Provided are high-throughput detection systems. The systems include a magnetic sensor device, a magnetic field source and a reservoir plate that includes a plurality of fluid reservoirs. The magnetic sensor device includes a support with two or more elongated regions each having a magnetic sensor array disposed at a distal end. Also provided are methods in which the subject high-throughput detection systems find use. | 12-31-2015 |
20150377897 | METHODS FOR IDENTIFYING ARTHROPOD REPELLENTS BASED ON MODULATION OF SPECIFIC IONOTROPIC RECEPTORS, AND COMPOUNDS AND COMPOSITIONS IDENTIFIED BY SUCH METHODS - Provided herein are screening methods for identifying arthropod repellent compounds based on modulation of ionotropic receptors, including an Ir40a receptor, an Ir93a receptor and an Ir25a receptor. Further provided are screening systems related to these methods. Such systems may include a sample that has one or more of the ionotropic receptors; and one or more compounds that each is a repellent for at least one arthropod species, wherein the one or more compound each modulates the activity of such ionotropic receptor(s). Further provided are one or more compounds identified using the screening methods described herein, and compositions containing such compounds. | 12-31-2015 |
20150377899 | MOLECULE LIBRARY CONSTRUCTED ON THE BASIS OF BACKBONE STRUCTURE OF MICROPROTEIN - Disclosed is a molecular library comprising a group of a plurality of molecules, wherein each member of the library is a polypeptide having a randomized sequence moiety and a microprotein moiety. The microprotein is a protein comprising an amino acid sequence of 30 or less amino acid residues having the ability to form a particular conformation by spontaneous folding in a solution and is, for example, chignolin comprising the amino acid sequence represented by SEQ ID NO: 1. Also, disclosed is a method for identifying a novel functional molecule using the library of the present invention. | 12-31-2015 |
20150377900 | SYSTEMS AND METHODS FOR HIGH THROUGHPUT ANALYSIS OF CONFORMATION IN BIOLOGICAL ENTITIES - Methods, devices, and systems are disclosed for performing high throughput analysis of conformational change in biological molecules or other biological entities using surface-selective nonlinear optical detection techniques. | 12-31-2015 |
20150377901 | POINT OF CARE IMMUNIZATION TESTING SYSTEM - DETECTION METHODS - A point of care immunization system based upon a range of detection methods to rapidly test a patient in order to ascertain an immunization profile so that vaccinations can be administered to address identified gaps. A point of care system comprised of sample and test strips/cartridges, with said test strips/cartridges configured to meet healthcare requirements of national governing bodies. A point of care system that can function as a stand-alone diagnostic system, stand-alone kit or with a device. | 12-31-2015 |
20150377906 | BIOMARKERS FOR RADIATION EXPOSURE - Panels of 1-, 2-, 3-, and 4 protein-biomarker for diagnostic and prognostic methods to determine a subject's radiation exposure and discriminates between persons who have been exposed to various levels of radiation, 1-5 days after exposure. | 12-31-2015 |
20150377909 | BIOMARKERS AND METHODS FOR MEASURING AND MONITORING INFLAMMATORY DISEASE ACTIVITY - Biomarkers useful for diagnosing and assessing inflammatory disease are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. The biomarkers include at least two biomarkers selected from the DAIMRK group and the score is a disease activity index (DAI). | 12-31-2015 |
20150377910 | Biomarkers for Fatty Liver Disease and Methods Using the Same - The present invention provides various biomarkers of fatty liver disease, including steatosis and steatohepatitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of fatty liver disease, methods of determining predisposition to fatty liver disease, methods of monitoring progression/regression of fatty liver disease, methods of assessing efficacy of compositions for treating fatty liver disease, methods of screening compositions for activity in modulating biomarkers of fatty liver disease, methods of treating fatty liver disease, as well as other methods based on biomarkers of fatty liver disease. | 12-31-2015 |
20160002622 | METHODS FOR CAPTURING NUCLEIC ACIDS - A method is provided herein, wherein the method of capturing a target nucleic acid, comprises applying a nucleic acid capture probe to a capture zone of a needs definition, wherein the nucleic acid capture probe having a first molecular weight comprises at least a sequence that is complimentary to at least a portion of the target nucleic acid sequence and the nucleic acid capture probe is substantially immobilized at the capture zone of the substrate. The method further comprises applying a sample comprising the target nucleic acid having a second molecular weight to a sample application zone of the substrate; wherein the sample comprising the target nucleic acid flows across a length of the substrate from the sample application zone to the capture zone by lateral flow, and the target nucleic acid is captured by the nucleic acid capture probes by hybridization to the capture zone. | 01-07-2016 |
20160002623 | GENES EXPRESSED IN MENTAL ILLNESS AND MOOD DISORDERS - The present invention relates to a composition comprising a plurality of cDNA molecules for use in methods of detecting changes in expression of genes encoding proteins that are associated with mental illnesses and which are differentially expressed in patients with mental illnesses, such as bipolar I disorder, bipolar II disorder, unipolar disorder, schizophrenia, attention deficit hyperactive disorders, obsessive compulsive disorders, anxiety disorders or other related mood disorders. The composition and the cDNA molecules may be used in their entirety or in part as to diagnose, to stage, to treat, and/or to monitor the treatment of a subject with mental illness. | 01-07-2016 |
20160002704 | MUTLIPLEXED IN SITU MOLECULAR ANALYSES AND PROGRAMMABLE MOLECULAR PROBES FOR REGULATED AMPLIFICATION - The present invention generally relates to methods for detecting a target in a sample; methods for modulating the reporting intensity of a labeled target in a sample of fixed cells or tissues; methods for detecting the location of at least two targets in a sample; and related compositions. | 01-07-2016 |
20160002706 | ISOLATION OF NUCLEIC ACIDS - Improved compositions for and methods of processing and analyzing samples are described. In particular, the compositions and methods liberate nucleic acids from a biological sample allowing direct downstream processing of the nucleic acids in microfluidic systems. These compositions, methods and kits are useful in diagnosing, staging or otherwise characterizing various biological conditions. | 01-07-2016 |
20160002709 | MULTIPHASE NUCLEIC ACID AMPLIFICATION - Improved methods for use in nucleic acid amplification, including multiplex amplification, where the amplification is carried out in two or more distinct phases are disclosed. The first phase amplification reaction preferably lacks one or more components required for exponential amplification. The lacking component is subsequently provided in a second, third or further phase(s) of amplification, resulting in a rapid exponential amplification reaction. The multiphase protocol results in faster and more sensitive detection and lower variability at low analyte concentrations. Compositions for carrying out the claimed methods are also disclosed. | 01-07-2016 |
20160002714 | AUTOMATED ANALYSIS OF MULTIPLEXED PROBE-TARGET INTERACTION PATTERNS: PATTERN MATCHING AND ALLELE IDENTIFICATION - Disclosed are methods and algorithms (and their implementation) supporting the automated analysis and interactive review and refinement (“redaction”) of the analysis within an integrated software environment, for automated allele assignments. The implementation, preferably with a software system and a program referred to as the Automated Allele Assignment (“AAA”) program, provides a multiplicity of functionalities including: data management by way of an integrated interface to a portable database to permit visualizing, importing, exporting and creating customizable summary reports; system configuration (“Set-up”) including user authorization, training set analysis and probe masking; Pattern Analysis including string matching and probe flipping; and Interactive Redaction combining real-time database computations and “cut-and-paste” editing, generating “warning” statements and supporting annotation. It also includes a thresholding function, a method of setting thresholds, a method of refining thresholds by matching an experimental binary string (“reaction pattern”) setting for that probe, probe masking of signals produced by probes which do not contribute significantly to discriminating among alleles. | 01-07-2016 |
20160002717 | DETERMINING MUTATION BURDEN IN CIRCULATING CELL-FREE NUCLEIC ACID AND ASSOCIATED RISK OF DISEASE - The invention generally relates to methods of assessing an individual's risk of developing a disease associated with accumulation of DNA mutations by determining the mutation burden in their circulating cell-free nucleic acid relative to a reference sequence. The invention further relates to establishing a score indicative of the individual's risk by assessing the individual's mutation burden against a mutation burden continuum containing various thresholds associated with different degrees of risk. The reference sequence and the continuum may be constructed from a variety of sources. In certain aspects, methods of the invention relate to compilation of a database of mutation burdens for individuals along with population characteristics for each individual. | 01-07-2016 |
20160002732 | MOLECULAR DIAGNOSTIC TEST FOR CANCER - Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that have an up-regulation or a down-regulation in biomarker expression related to angiogenesis and vascular development. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. | 01-07-2016 |
20160002735 | MATERIALS AND METHODS FOR ASSESSING PROGRESSION OF PROSTATE CANCER - Methods of distinguishing and identifying a patient with aggressive/indolent, prostatic adenocarcinoma comprising contacting a sample from the patient with a set of detectably labeled probes under hybridization conditions and determining the presence of chromosomal abnormalities in the sample; sets of probes for use in such methods; and kits comprising a set of probes and instructions for distinguishing or identifying a patient as having aggressive/indolent, prostatic adenocarcinoma. | 01-07-2016 |
20160002736 | USE OF MICROVESICLES IN ANALYZING NUCLEIC ACID PROFILES - The invention concerns gene signatures obtained from microvesicles and a method of applying these gene signatures in helping to determine a biological condition. The determination of a biological condition may aid, for example, the diagnosis, prognosis, and therapy treatment selection for disease in a subject. | 01-07-2016 |
20160003786 | Methods Of Detecting Cancer - The present disclosure is directed toward methods and kits for detecting cancer, and in particular breast cancer, in a subject by measuring the levels of at least one of the identified markers, as compared to a control. The expression of the markers in Table 2A is increased in samples from subjects with cancer as compared to the expression level in subjects without cancer and the expression of the markers in Table 2B are decreased in samples from subjects with cancer as compared to the expression level in subjects without cancer. The sample may be lacrimal secretions or eye wash fluid, saliva, or other biological fluids. The kits may include an eye wash kit, collection tubes and protease inhibitors, or protein stabilizers. | 01-07-2016 |
20160003799 | Means and Methods for Assessing the Quality of a Biological Sample - The present invention relates to the field of diagnostic methods. Specifically, the present invention relates to a method for assessing the quality of a biological sample comprising the steps of determining in a sample the amount of at least one biomarker from Tables 1, 1′, 2, 2′, 3, 3′, 4, 5, 5′, 6, 7, and/or 8 and comparing the said amount of the at least one biomarker with a reference, whereby the quality of the sample is assessed. The invention also relates to tools for carrying out the aforementioned method, such as devices and kits. | 01-07-2016 |
20160003809 | PROTEIN DETECTION VIA NANOREPORTERS - The invention provides methods, compositions, kits and devices for the detection of proteins. In some embodiments, the invention allows for multiplexed protein detection. | 01-07-2016 |
20160003811 | NUCLEIC ACID ELEMENT CANDIDATE MOLECULE AND SCREENING METHOD FOR SCREENING FOR NUCLEIC ACID ELEMENT FOR TARGET ANALYSIS USING THE SAME - The present invention provides a novel nucleic acid element candidate molecule for use in screening for a nucleic acid element for target analysis and a novel screening method for screening for a nucleic acid element for target analysis using the same. The candidate molecule according to the present invention is a molecule for screening for a nucleic acid element for target analysis, being the following single-stranded nucleic acid (I): (I) a single-stranded nucleic acid comprising a catalyst sequence (D), a blocking sequence (B), and a binding sequence (A) that binds to a target, linked in this order. The blocking sequence (B) is complementary to a partial region (Dp) in the catalyst sequence (D). A terminal region (Ab) on the blocking sequence (B) side in the binding sequence (A) is complementary to a flanking region (Df) of the partial region (Dp) in the catalyst sequence (D) and is complementary to a terminal region (Af) on the side opposite to the blocking sequence (B) side in the binding sequence (A). | 01-07-2016 |
20160003815 | METHOD, SYSTEM, AND DEVICE FOR ANALYTE DETECTION AND MEASUREMENT USING LONGITUDINAL ASSAY - Embodiments of the invention provide methods, systems, and devices for detection and measurement of an analyte or analytes. In one embodiment, the invention provides an assay system comprising a cartridge device including: one or more reservoir portions for holding one or more liquids; and at least one assay portion for receiving the one or more liquids from the at least one reservoir portion, the at least one assay portion having a plurality of binding sites over which the one or more liquids from the one or more reservoirs can be flowed repeatedly (more than one time); and a measurement device for measuring binding of one or more analytes in the one or more liquids to the plurality of binding sites. | 01-07-2016 |
20160003816 | Methods, Systems, and Arrays for Biomolecular Analysis - Disclosed herein are formulations, substrates, and arrays. Also disclosed herein are methods for manufacturing and using the formulations, substrates, and arrays. Also disclosed are methods for identifying peptide sequences useful for diagnosis and treatment of disorders, and methods for using the peptide sequences for diagnosis and treatment of disorders, e.g., celiac disorder. In certain embodiments, substrates and arrays comprise a porous layer for synthesis and attachment of polymers or biomolecules. | 01-07-2016 |
20160003818 | Analytical Measuring and Evaluation Method for Molecular Interactions - The invention relates to an analytical measuring and evaluation method for determining the interaction parameters between an analyte and a ligand, preferably in a biosensor. According to the inventive method, the concentration of the analyte is gradually changed at defined intervals ti and the initial association or dissociation rates or association and dissociation rate constants are determined. The invention further relates to a device for carrying out the inventive method. | 01-07-2016 |
20160003819 | RAPID TESTS FOR INSURANCE UNDERWRITING - The present invention relates to rapid test devices, kits and systems comprising the rapid test devices for assessing at least two analytes in a sample derived from a life or health insurance applicant, said at least two analytes being selected from the group consisting of a human immunodeficiency virus (HIV) antigen (e.g., a HIV polypeptide), a HIV polynucleotide, an anti-HIV antibody, a hepatitis C virus (HCV) antigen (e.g., a HCV polypeptide), a HCV polynucleotide, an anti-HCV antibody, a liver enzyme alanine transaminase (ALT), a liver enzyme aspartate transaminase (AST), nt-probnp (or NT-proBNP), probnp (or proBNP), cotinine, nicotine, cocaine, a metabolite of cocaine (e.g., benzoylecgonine), pro state-specific antigen (PSA), apolipoprotein A-1 (ApoA1), apolipoprotein B (ApoB), Hemoglobin Ale and high-sensitivity C-reactive protein (hsCRP). The present invention also relates to methods for using the rapid test devices, kits and systems as part of the assessment of the life or health insurance applications. | 01-07-2016 |
20160003822 | BIODOSIMETRY PANELS AND METHODS - The present invention relates to methods and kits to assess an absorbed dose of ionizing radiation and/or the severity of tissue injury from radiation in a patient. The invention also relates to algorithms used to calculate an absorbed dose of radiation based on biomarker measurements of a plurality of biomarkers that are altered relative to a normal control in the event of radiation exposure. | 01-07-2016 |
20160003825 | USE OF PKC-ZETA AS A BREAST CANCER TUMORIGENIC BIOMARKER AS WELL AS A TARGET FOR TREATMENT OF BREAST CANCER - The present invention provides use of protein kinase C-zeta (PKC-ζ) as a diagnostic biomarker for breast cancer tumorigenesis. Also provided are uses of PKC-zeta inhibitors for inhibiting breast cancer tumorigenesis and for treatment of breast cancer. | 01-07-2016 |
20160003827 | METHOD AND APPARATUS OF AIDING DETECTION OF SURFACE ABNORMALITY IN THE OESOPHAGUS - The invention relates to a method of aiding detection of a surface abnormality in the oesophagus of a subject, wherein said surface abnormality is selected from the group consisting of low-grade dysplasia (LGD), high-grade dysplasia (HGD), asymptomatic oesophageal adenocarcinoma (OAC) and intra-mucosal cancer (IMC), the method comprising:
| 01-07-2016 |
20160003829 | METHODS FOR DETERMINING PROGNOSIS OF COLORECTAL CANCER - Provided herein are methods for determining the risk that a subject diagnosed with colorectal cancer will develop a recurrence of colorectal cancer and methods of predicting clinical outcome for a subject diagnosed with colorectal cancer by a) determining the level of expression for each marker of a panel of markers in a panel of tumor compartments in a tumor tissue sample from the subject, wherein the panel of markers comprises at least two of TEM1, HIF2α, CAIX, PDGFRβ, fibronectin, collagen I, collagen IV, and CD31 and wherein the panel of tumor compartments comprises at least three tumor compartments of pure stroma, tumor, stromal vessel, and tumor vessel; b) determining the TAPPS score for said subject; and c) comparing the TAPPS score of the subject to the TAPPS score of a population of subjects diagnosed with colorectal cancer. Also provided are related computer-implemented methods and systems, kits, and tumor microarrays. | 01-07-2016 |
20160003830 | MULTIPLEX COLON CANCER MARKER PANEL - The present invention provides a specific combination of colon cancer markers based on statistical knowledge, which is capable of detecting a larger number of colon cancer patients in an earlier stage while maintaining high specificity. A multiplex colon cancer marker panel comprising a combination of five colon cancer markers of Carcinoembryonic antigen-related cell adhesion molecule 5, Carbohydrate antigen 19-9, Galectin-4, APEX nuclease and Actin-related protein 2. A method for analyzing colon cancer markers using multiplex colon cancer marker panel. | 01-07-2016 |
20160003832 | SPECIFIC BIOMARKER SET FOR NON-INVASIVE DIAGNOSIS OF LIVER CANCER - Cells within liver tumour mass comprise a unique set of proteins/tumour antigens when compared to the normal liver tissues epithelial cells juxtaposed to the tumour. The presence of tumour antigens couples the production of auto-antibodies against these tumour antigens. The present invention relates to the identification and elucidation of a protein set that can act as a novel marker set for liver cancer diagnosis and prognosis. Specifically, it relates to a kit that enables diagnostic and prognostic measurement of auto-antibodies in serum of liver cancer patients. The present invention provides a non-invasive, specific, sensitive, and cost effective detection and quantification method by evaluating a set of validated liver cancer proteins/tumour antigens, which includes Bmi-1, VCC1, SUMO-4, RhoA, TXN, ET-1, UBE2C, HDGF2, FGF21, LECT2, SOD1, STMN4, Midkine, IL-17A or IL26, to complement the conventional diagnostic methods. | 01-07-2016 |
20160003835 | APTAMERS AND USES THEREOF - Methods and compositions are provided for specific aptamers and aptamer pools that bind biomarkers of interest such as microvesicle surface antigens or functional fragments of microvesicle surface antigens. In various embodiments, aptamers of the invention are used in diagnostic, prognostic, or theranostic processes to screen a biological sample for the presence or levels of biomarkers such as microvesicles that are determined to provide a diagnostic, prognostic, or theranostic readout. The diagnosis, prognosis, or theranosis may be related to cancer or other diseases and disorders. The invention also provides methods and composition to facilitate aptamer library screening and aptamer detection methods. | 01-07-2016 |
20160003836 | PHOTO OR CHEMOLABILE CONJUGATES FOR MOLECULES DETECTION - The present invention relates to the field of the detection of molecules of interest in a sample, preferably by mass spectrometry. The present invention concerns a label compound, a molecule labeled with said compound (a conjugate), a method of detection of a molecule of interest (a target molecule) in a sample involving said conjugate, a kit to implement said method and a process for the preparation of the label. | 01-07-2016 |
20160003838 | METHODS AND COMPOSITIONS FOR DIAGNOSING PREECLAMPSIA - Provided herein are methods, compositions, and kits for using binding agents to detect the presence of PEE proteins and/or PEE autoantibodies in a biological sample from a pregnant woman. Such methods and compositions are useful for predicting the onset of preeclampsia, monitoring the progression of preeclampsia, monitoring the regression of preeclampsia, assessing efficacy of treatment for preeclampsia, identifying a sub-population of patients who should be treated for preeclampsia and/or identifying a sub-population of patients who should be monitored for preeclampsia symptoms. | 01-07-2016 |
20160003840 | Methods and Compositions for Detecting Receptor Clustering and Activation Events in Single Cells - The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state. | 01-07-2016 |
20160003843 | ENGINEERED ANTIBODY SCAFFOLDS - The invention described herein features methods and compositions for generating an antibody specific to post-translational modifications (PTMs). The methods and compositions provide a renewable synthetic antibody strategy that installs a novel motif-specific hot spot into an antibody scaffold that functions independently of the surrounding scaffold. Such antibodies provide a rapid and robust development of antibodies for signaling, diagnostic, and therapeutic applications. | 01-07-2016 |
20160007906 | METHODS FOR ASSESSING VAGINAL ATROPHY | 01-14-2016 |
20160008809 | METHODS AND COMPOSITIONS FOR PAPER-BASED AND HYBRID MICROFLUIDIC DEVICES INTEGRATED WITH NUCLEIC ACID AMPLIFICATION FOR DISEASE DIAGNOSIS | 01-14-2016 |
20160010082 | Methods for Enhancing Bacterial Cell Display of Proteins and Peptides | 01-14-2016 |
20160010083 | OB-Fold Used As Scaffold For Engineering New Specific Binders | 01-14-2016 |
20160010152 | Dual Probe:Antiprobe Compositions for DNA and RNA Detection | 01-14-2016 |
20160010153 | NOVEL COMPOSITIONS, METHODS AND KITS FOR BLOOD TYPING | 01-14-2016 |
20160010156 | DETECTION OF ORGAN REJECTION | 01-14-2016 |
20160010162 | BIOMARKER PANELS FOR PREDICTING PROSTATE CANCER OUTCOMES | 01-14-2016 |
20160011112 | Sample Plate and Analyzing Method | 01-14-2016 |
20160011183 | MULTIANALYTE ASSAY | 01-14-2016 |
20160011185 | MULTI-ANALYTE ASSAY | 01-14-2016 |
20160011189 | ARRAYS, SUBSTRATES, DEVICES, METHODS AND SYSTEMS FOR DETECTING TARGET MOLECULES | 01-14-2016 |
20160011190 | Microfluidic Devices and Methods for Separating and Detecting Constituents in a Fluid Sample | 01-14-2016 |
20160011193 | Method for Diagnosing a Viral Infection | 01-14-2016 |
20160011195 | Method of Forming Fragment Ligated Inhibitors | 01-14-2016 |
20160011197 | Methods and Compositions for the Diagnosis of a Thyroid Condition | 01-14-2016 |
20160011204 | METHODS FOR HIGH THROUGHPUT RECEPTOR:LIGAND IDENTIFICATION | 01-14-2016 |
20160011214 | QUANTITATIVE DIAGNOSTIC METHODS USING MULTIPLE PARAMETERS | 01-14-2016 |
20160016166 | MOLECULAR DIAGNOSTIC DEVICES WITH MAGNETIC COMPONENTS - The invention provides disposable microfluidic devices that incorporate magnetic media and methods of using such devices to perform diagnostic assays on a sample. One exemplary microfluidic device comprises a first magnetic layer, a second magnetic layer, and a substantially planar member containing at least one hydrophilic region, where the substantially planar member is disposed between the first magnetic layer and the second magnetic layer, and the magnetic layers provide an attractive force useful for reducing the loss of fluid and/or s reagent from the device. | 01-21-2016 |
20160016171 | Systems and Methods for Mobile Device Analysis of Nucleic Acids and Proteins - A portable system for extracting, optionally amplifying, and detecting nucleic acids or proteins using a compact integrated chip in combination with a mobile device system for analyzing detected signals, and comparing and distributing the results via a wireless network. Related systems and methods are provided. | 01-21-2016 |
20160017406 | METHOD FOR DETECTING HELICOBACTER PYLORI DNA IN A STOOL SAMPLE - The present invention provides a PCR based method for detecting chronic gastritis causing bacterium, namely | 01-21-2016 |
20160017407 | Methods for Microorganism Detection and Identification - Methods for detecting and identifying microorganisms in a biologic sample are provided. The methods utilize identifying rRNA from microorganisms to both show the presence and identity for the majority of infectious agents present in clinical samples. The methods are preferably adapted for use in a clinical setting. | 01-21-2016 |
20160017408 | METHODS AND KITS TO DETERMINE THE SENSITIVITY OF STRAINS OF LACTOCOCCUS LACTIS BACTERIA TO PHAGE INFECTION - A kit useful for determining the phage susceptibility of one or more strains of | 01-21-2016 |
20160017411 | ASSAY FOR DETECTING A NUCLEIC ACID ANALYTE IN A BIOLOGICAL SAMPLE - An assay for detecting an analyte in a biological sample. The assay comprises a surface probe linked to the surface of a measuring electrode and the surface probe has a nucleic acid sequence complementary to a first target nucleic acid sequence. The assay also comprises a signal probe, having a nucleic acid sequence complementary to a second target nucleic acid sequence and a binding element capable of binding a ligand. The ligand is associated with a catalytic element or precursor thereof capable of reacting with a substrate to alter electrical potential of the measuring electrode. | 01-21-2016 |
20160017418 | METHOD OF DETECTING METHYLATION - The present invention relates to a method of screening for the presence of methylated DNA in a biological sample by using multiple methylation-sensitive restriction endonucleases. More particularly, the present invention relates to a method of quantitatively screening for the level of one or more methylated genes of interest without the requirement that an undigested internal reference sample is used as a point of reference against which relative quantification is calculated. The present invention is useful in a range of applications including, but not limited to, providing a simpler and more accurate means to determine DNA methylation status, such as in the context of diagnosing or monitoring conditions characterised by changes to DNA methylation. | 01-21-2016 |
20160017423 | METHOD AND KIT FOR MAKING AN IN VITRO PROGNOSIS OF SEVERITY FOR A PATIENT IN SEPTIC SHOCK - The subject of the invention is a method for making an in vitro prognosis of severity for a patient in septic shock, including the following steps: (i) the level of expression of the expression product of at least one gene chosen from the lilrb2 and lilrb1 genes is measured in vitro on the basis of a biological sample taken from the patient, (ii) the level of expression of the expression product of the at least one gene is compared with a control level of expression, of the expression product of the same gene, with a good prognosis of severity, in which a level of expression of the expression product of the at least one gene below the control level of expression indicates a poor prognosis of severity for the patient, and also a kit for implementing the method. | 01-21-2016 |
20160017424 | COLLECTION OF PROBES FOR AUTISTIC SPECTRUM DISORDERS AND THEIR USE - The present invention relates to collections of probes or their complements that recognize a set of biomarkers related to autism spectrum disorders (ASDs), as well as to methods utilizing these probes for diagnosing whether a subject has an ASD or has a predisposition for developing an ASD. | 01-21-2016 |
20160017429 | METHOD FOR PROGNOSING THE SURVIVAL OF PATIENTS SUFFERING FROM CHRONIC MYELOMONOCYTIC LEUKAEMIA - The present invention relates to a method of prognostic of the survival of human subject suffering from chronic myelomonocytic leukemia (CMML) based on the differential expression of six genes in a test sample of PBMC cells obtained from said human subject and in a control sample of normal cells, wherein said expression level indicates if the human subject from which the test sample has been obtained will have long-term or short-term survival. | 01-21-2016 |
20160017433 | NON-INVASIVE DIAGNOSTIC METHOD FOR DIAGNOSING BLADDER CANCER - Non-invasive diagnostic methods for diagnosing bladder cancer are based on determining the expression level of one or more markers. The one of the markers comprises the IGF2 gene in a sample from the subject to be studied. Other suitable markers include MAGEA3, ANXAIO, AHNAK2, CTSE, CRH, KLF9, KRT20, POSTN, PPP1R14D, SLCIA6, TERT, ASAM, MCMIO, EBF1, CFH and MMP12 and possibly FOXM1, KIF20A, MELK, CDK1. | 01-21-2016 |
20160017434 | MOLECULAR MARKERS IN BLADDER CANCER - The Present invention relates methods for establishing the presence, or absence, of a bladder tumour and/or classification of the tumor according to the aggressiveness and/or establishing the prediction of prognosis and disease outcome for a human individual suffering from bladder cancer. Specifically, the present invention relates to methods for establishing the presence, or absence, of a bladder tumour in a human individual comprising: determining the expression of one or more genes chosen from the group consisting of ADAMTS12, ASPN, CDC20, COL10A1, CTHRC1, FAP, SFRP4, FOXM1, KRT6A, ANLN, CHI3L1, TPX2, CCNB2, IGF2BP2, INHBA, PDCD1LG2, transcript cluster 2526893, and transcript cluster 2526896 in a biological sample (tissue or bodyfluid) originating from said human individual; establishing up regulation of expression of said one or more genes as compared to expression of said respective one or more genes in a sample originating from said human individual not comprising tumour cells or tissue. | 01-21-2016 |
20160017435 | Differential Methylation Level of CpG Loci That Are Determinative of a Biochemical Reoccurrence of Prostate Cancer - The present disclosure provides for and relates to the identification of novel biomarkers for diagnosis and prognosis of prostate cancer or the biochemical reoccurence of prostate cancer. The biomarkers of the invention show altered methylation levels of certain CpG loci relative to normal prostate tissue, as set forth. | 01-21-2016 |
20160017438 | METHODS OF TREATING BREAST CANCER WITH TAXANE THERAPY - The application describes methods for screening subjects with breast cancer to determine if the breast cancer will be responsive to a breast cancer therapy including a taxane or a taxane derivative. The application also describes methods for treating subjects with breast cancer by screening them for the likelihood of the effectiveness of treating the cancer with a therapy including a taxane or a taxane derivative and administering the therapy in subjects when it is found that a taxane or a taxane derivative is likely to be effective. | 01-21-2016 |
20160017439 | MARKER OF BREAST TUMORS FROM THE LUMINAL-B SUBTYPE - An in vitro method for diagnosing a breast cancer from the luminal-B subtype in a female, includes the steps of analyzing a biological sample from the female by (i) determining the copies number of the ZNF703 gene, and/or (ii) determining the expression of the ZNF703 gene, wherein an increased copies number and/or an over-expression of the ZNF703 gene is indicative of a luminal B tumor; to a kit for diagnosing a breast cancer from the luminal-B subtype in a female including at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a method as defined previously, for determining the copies number of the ZNF703 gene, and/or determining the expression of the ZNF703 gene; and to the use of such a kit. | 01-21-2016 |
20160017441 | METHOD FOR IDENTIFYING CELLS - It is an object of the present invention to provide a method for analyzing, in detail, the epigenetic state of stem cells. | 01-21-2016 |
20160018304 | LIQUID TISSUE PREPARATION FROM HISTOPATHOLOGICALLY PROCESSED BIOLOGICALLY SAMPLES, TISSUES AND CELLS - The current invention provides a method for directly converting histopathologically processed biological samples, tissues, and cells into a multiuse biomolecule lysate. This method allows for simultaneous extraction, isolation, solubilization, and storage of all biomolecules contained within the histopathologically processed biological sample, thereby forming a representative library of said sample. This multi-use biomolecule lysate is dilutable, soluble, capable of being fractionated, and used in any number of subsequent experiments. | 01-21-2016 |
20160018331 | BIOSENSORS INCLUDING METALLIC NANOCAVITIES - A biomolecular assay includes a substrate with a metallic layer on at least one surface thereof. The metallic film includes nanocavities. The nanocavities are configured to enhance signals that are representative of the presence or amount of one or more analytes in a sample or sample solution, and may be configured to enhance the signal by a factor of about two or more or by a factor of about three or more. Such signal enhancement may be achieved with nanocavities that are organized in an array, randomly positioned nanocavities, or nanocavities that are surrounded by increased surface area features, such as corrugation or patterning, or nanocavities that have quadrilateral or triangular shapes with tailored edge lengths, or with a plurality of nanoparticles. Methods for fabricating biomolecular substrates and assay techniques in which such bimolecular substrates are used are also disclosed. | 01-21-2016 |
20160018394 | Assay Device Having Multiplexing - An assay device for determining the concentration of multiple analytes or controls, where the device is capable of determining the presence or concentration of at least six analytes or controls includes: a fluid flow path; a liquid sample addition zone; a reagent zone downstream and in fluid communication with the sample addition zone containing one or more reagents; multiple detection zones in fluid communication with the reagent zone. The fluid flow path, which extends through the detection zones, has a length capable of having at least six detection zones linearly spaced at least a sufficient distance apart in order to discriminate each signal peak from its adjacent signal peak. The device further includes a wicking zone in fluid communication with the detection zones having a capacity to receive liquid sample flowing from the detection zone. The fluid flow path extends from the sample zone to the wicking zone, and at least a part of the fluid flow path has a substrate and projections which extend substantially vertically from the substrate. The projections have a height, cross-section and a distance between one another that defines a space between the projections capable of generating capillary flow parallel to the substrate surface. | 01-21-2016 |
20160018397 | RECOMBINANT PHAGES AND PROTEINS - The present disclosure provides recombinant phages, a Wip1 p23 receptor binding protein and a Wip1 p24 receptor binding protein that bind to | 01-21-2016 |
20160018408 | PEPTIDE ARRAY QUALITY CONTROL - The present application provides arrays for use in immunosignaturing and quality control of such arrays. Also disclosed are peptide arrays and uses thereof for diagnostics, therapeutics and research. | 01-21-2016 |
20160018413 | Methods of Prognosing Preeclampsia - Preeclampsia peptide biomarkers are provided. Also provided are methods for using these biomarkers, including in prognosing or diagnosing preeclampsia in a pregnant individual by detecting these biomarkers in a sample from the pregnant individual. Reagents, devices and kits thereof that find use in practicing the subject methods are also provided. | 01-21-2016 |
20160018417 | ASSAY AND METHOD FOR IDENTIFYING COMPOUNDS TO TREAT TAUOPATHIES - The invention relates to methods and assays for identifying compounds as candidates in the development of a drug for the treatment of various diseases including those associated with pathological Tau. The invention also relates to methods and assays for identifying compounds for the treatment of various diseases including those associated with pathological Tau. The invention also relates to cell lines and constructs for use in an assay of the invention. The methods and assays identify a compound as useful in the treatment of a tauopathy if said compound modulates Sil1 expression or activity. | 01-21-2016 |
20160023206 | SAMPLE COLLECTION AND TRANSFER DEVICE - An integrated device for a sample collection and transfer is provided. The integrated device comprises a capillary channel disposed between a first layer and a second layer, wherein the first layer comprises a hydrophilic layer comprising a fluid inlet for receiving a sample fluid to the capillary channel, wherein the capillary channel comprises an inner surface and an outer surface and an outlet for driving out the sample fluid. The device further comprises an interface assembly comprising: a third layer, a fourth layer, a fifth layer, and a flow path. The interface assembly is disposed on the outer surface of the capillary, at a determining position relative to the outlet, such that the capillary is in contact with the third layer of the interface assembly and the outlet is in contact with the flow path of the interface assembly for driving out the sample fluid from the integrated device. | 01-28-2016 |
20160023209 | SAMPLE COLLECTION AND TRANSFER DEVICE - An integrated device for a sample collection and transfer is provided. The integrated device comprises a capillary channel disposed between a first layer and a second layer, wherein the first layer comprises a hydrophilic layer comprising a fluid inlet for receiving a sample fluid to the capillary channel, wherein the capillary channel comprises an inner surface and an outer surface; and an outlet for driving out the sample fluid. The device further comprises a third layer comprising an adhesive material such as a patterned adhesive material, and a flow path, wherein the third layer is disposed on the outer surface of the capillary, at a determining position relative to the outlet, such that the capillary is in contact with the third layer and the outlet is in contact with the flow path of the third layer for allowing the sample fluid out from the integrated device. | 01-28-2016 |
20160024491 | Method for Isolation of Nucleic Acid Containing Particles and Extraction of Nucleic Acids Therefrom - A method for extracting nucleic acids from a biological sample by isolating nucleic acid-containing particles from the biological sample by one or more centrifugation procedures, performing one or more steps to mitigate adverse factors that prevent or might prevent high quality nucleic acid extraction, and extracting nucleic acids from the isolated particles. The centrifugation procedures are performed at a speed not exceeding about 200,000 g. The extracted nucleic acids contain both 18S and 28S rRNA. | 01-28-2016 |
20160024581 | METHODS AND COMPOSITIONS FOR ASSESSING RENAL STATUS USING URINE CELL FREE DNA - The present invention relates to non-invasive tools and methods for evaluating renal status and renal health using urine cell free DNA. | 01-28-2016 |
20160024582 | MICROARRAY FOR EVALUATING EYE DISEASE, AND EVALUATION METHOD OF EYE DISEASE - The purpose of the present invention is to provide a method for objectively evaluating the state of eye disease in a test organism. Provided is a microarray for evaluating the state of eye disease. Further, this method for evaluating the state of eye disease in a test organism is characterized by detecting, from a sample taken from the test organism, at least one gene from a prescribed gene group and comparing the obtained detection result with a control. | 01-28-2016 |
20160024583 | METHODS FOR EVALUATING COPD STATUS - The invention in some aspects provides methods of determining the likelihood that a subject has COPD based on the expression of informative-genes. In other aspects, the invention provides methods for determining an appropriate diagnostic intervention plan for a subject based on the expression of informative-genes. Related compositions and kits are provided in other aspects of the invention. | 01-28-2016 |
20160024591 | METHODS AND COMPOSITIONS FOR CORRELATING GENETIC MARKERS WITH RISK OF AGGRESSIVE PROSTATE CANCER - The present invention provides a method of identifying a subject as having an increased risk of having or developing aggressive prostate cancer, comprising detecting in the subject the presence of various genetic markers associated with an increased risk of having or developing aggressive prostate cancer. | 01-28-2016 |
20160024596 | Prognostic and Predictive Gene Signature for Non-Small Cell Lung Cancer and Adjuvant Chemotherapy - The application provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups and for determining the benefit of adjuvant chemotherapy by way of a multigene signature. The application also includes kits and computer products for use in the methods of the application. | 01-28-2016 |
20160025603 | AIRBORNE AGENT COLLECTORS, METHODS, SYSTEMS AND DEVICES FOR MONITORING AIRBORNE AGENTS - Air flow systems, devices and methods for monitoring airborne agents include airborne agent collectors. Airborne agent collectors for collecting and detecting the presence and/or identification of an airborne agent(s) include a soluble and hydrophilic polycaprolactone (PCL) that has been treated with a base (e.g., a base having a pH greater than 8 (e.g., NaOH, NaHCO | 01-28-2016 |
20160025630 | ANALYTICAL INSTRUMENT SYSTEMS - The invention provides optical instrument systems and methods for analyzing signals from biological arrays, and performing analytical amplification reactions for identifying the presence or absence of a target nucleic acid sequence in a sample to be analyzed. | 01-28-2016 |
20160025705 | PROCESS FOR ASSESSING RISK OF SUBSTANCE ADMINISTRATION - A process for assessing risk that administration of a substance will suppress immune competence in a population of subjects is provided. Such a substance may be a substance related to, contained in or derived from a tobacco product or, more generally, a substance concerning which it is desired to assess risk of administration of the substance. | 01-28-2016 |
20160025715 | MULTIPLEXING WITH SINGLE SAMPLE METERING EVENT TO INCREASE THROUGHPUT - An assay device includes a support, test elements arranged thereover, and a diverter defining a common sample addition area of the device. The diverter conducts respective portions of a fluidic sample from the area to each of the test elements. Another assay device includes the test elements, one a dry slide element, disposed over the support at least partly in proximity to each other to define a common sample addition area. Apparatus for analyzing a sample includes an assay device having the test elements, one a dry slide element. A controller operates a metering mechanism, to apply the sample to the assay device, an incubator, and a measurement device per a timing protocol to determine a characteristic of the sample. Methods for enabling an assay device to perform multiple tests based upon a single sample metering event include are also described. | 01-28-2016 |
20160025729 | Systems And Methods For Early Detection Of Cervical Cancer By Multiplex Protein Biomarkers - Method for diagnosis and prognosis of premalignant and malignant cervical disease by using multiple neoplastic protein biomarkers are provided. In particular, methods and systems for screening cervical cells for the expression of proteins, which occur as a result of premalignant cervical disease and progression to invasive cervical cancer. | 01-28-2016 |
20160025730 | METHODS OF SELECTING COMBINATION THERAPY FOR COLORECTAL CANCER PATIENTS - The present invention provides methods for selecting a subject as suitable for combination therapy with EGFR and HER2 inhibitors. The present invention also provides methods for predicting whether a subject will benefit from the combination therapy. In some embodiments, the present invention provides methods for determining whether to administer a combination therapy in a subject receiving EGFR inhibitor therapy. In other embodiments, the present invention provides methods for monitoring a subject on EGFR inhibitor therapy to determine whether to administer a combination therapy of EGFR and HER2 inhibitors. The present invention is particularly useful to facilitate the design of personalized therapies for colorectal cancer patients with EGFR inhibitor sensitivity. | 01-28-2016 |
20160025731 | POLYMER BACKBONE ELEMENT TAGS - Element tags based on novel metal-polymer conjugates are provided for elemental analysis of analytes, including ICP-MS. A polymer backbone is functionalized to irreversibly bind metals that are selected prior to use by the user. The polymer is further functionalized to attach a linker which allows for attachment to antibodies or other affinity reagents. The polymer format allows attachment of many copies of a given isotope, which linearly improves sensitivity. The metal-polymer conjugate tags enable multiplexed assay in two formats: bulk assay, where the average biomarker distribution in the sample is diagnostic, and single cell format to distinguish a rare (for example a diseased) cell in a complex sample (for example, blood). | 01-28-2016 |
20160025732 | COMPOSITIONS AND METHODS RELATED TO DIAGNOSIS OF PROSTATE CANCER - Aspects of the disclosure relate to improved methods for predicting whether a prostate tissue biopsy obtained from a subject will contain detectable prostate cancer. | 01-28-2016 |
20160025737 | BIOMARKERS FOR ASSESSMENT OF PREECLAMPSIA - Disclosed herein are screening tools for fetal/maternal wellness, such as biomarkers for assessing preeclampsia. More specifically, methods are disclosed for assessing the risk of preeclampsia in a subject, the methods including obtaining a first serum sample from the subject, determining a level of glycosylated fibronectin (GlyFn) in the first serum sample, and comparing the determined level of GlyFn with a control value, wherein an elevation in the determined level of GlyFn in the first serum sample relative to the control value indicates that the subject is at increased risk of preeclampsia. Also disclosed are methods of determining the risk of preeclampsia in a subject during a first, second, or third trimester, methods of assessing severity and progression of preeclampsia and complications of a risk of low birth weight or HELLP syndrome. | 01-28-2016 |
20160025744 | PLASMONIC SUBSTRATE FOR MULTIPLEX ASSESSMENT OF TYPE 1 DIABETES - Disclosed are methods and materials providing fluorescence detection of autoantibodies present in individuals who have developed or are at risk for type 1 diabetes. Provided is a plasmonic chip capable of fluorescence-enhancement of >100-fold. The fluorescent signal is generated by an anti-human antibody antibody, such as an anti-IgG antibody that is coupled to a fluorophore selected to emit at a wavelength enhanced by the plasmonic chip, for example in the NIR. | 01-28-2016 |
20160025746 | METHODS OF SCREENING COMPOUNDS THAT CAN MODULATE NR2F6 BY DISPLACEMENT OF A REFERENCE LIGAND - The current invention discloses compositions of matter, protocols and methods of screening test compounds to identifying agonists and antagonists of the orphan nuclear receptor NR2F6 by measuring the ability of a test compound to occupy the active site of NR2F6, in the presence of a reference compound. | 01-28-2016 |
20160025753 | ASSAY FOR CANNABINOIDS AND METHODS OF USE THEREOF - Immunoassays, methods, and kits for qualitative and/or quantitative detection of cannabinoids in specimens including, without limitation, bodily fluids (e.g., blood, urine, oral fluid or sweat) or other biological specimens and potential drug samples. | 01-28-2016 |
20160025763 | SYSTEMS AND METHODS FOR MULTI-ANALYSIS - Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample. | 01-28-2016 |
20160032279 | Polypeptide Display Libraries and Methods of Making and Using Thereof - Disclosed herein are expression vectors which display a passenger polypeptide on the outer surface of a biological entity. As disclosed herein the displayed passenger polypeptide is capable of interacting or binding with a given ligand. Also disclosed are methods of making and using the expression vectors. N/C terminal fusion expression vectors and methods of making and using are also disclosed. | 02-04-2016 |
20160032364 | Ribosomal Ribonucleic Acid Hybridization for Organism Identification - The present disclosure relates to method of distinguishing between two or more species of one or more organisms in a sample, by contacting a biological sample comprising ribosomal ribonucleic acid (rRNA) with a set of antisense probes, wherein the set of probes contains at least one detectable probe that is specific for a target rRNA sequence of each species to be tested, and wherein the individual probes specific for each species comprises less than about 85% sequence identity; and, detecting hybridization between one or more of the probes and the rRNA, thereby distinguishing between two or more species in a sample. | 02-04-2016 |
20160032366 | MULTIPLEX ASSAY FOR DETECTION OF BACTERIAL SPECIES IN BIOLOGICAL SAMPLES - The invention provides a rapid, accurate, sensitive, and low-cost detection method for screening a biological sample for one or more desired bacterial species. The inventive method employs a two-step multiplex real-time PCR assay that comprises an internal amplification control and specific primer sets to detect and discriminate bacterial species based the unique melting temperatures of specific DNA sequences of each strain. | 02-04-2016 |
20160032372 | NOVEL COMPOSITIONS AND PROCESSES FOR ANALYTE DETECTION, QUANTIFICATION AND AMPLIFICATION - This invention provides novel compositions and processes for analyte detection, quantification and amplification. Nucleic acid arrays and libraries of analytes are usefully incorporated into such compositions and processes. Universal detection elements, signaling entities and the like are employed to detect and if necessary or desirable, to quantify analytes. Amplification of target analytes are also provided by the compositions and processes of this invention. | 02-04-2016 |
20160032373 | SYSTEMS AND METHODS FOR MULTIPLEX ANALYSIS OF PCR IN REAL TIME - The present invention provides methods and systems for real-time measurements of PCR with multiplexing capability. Certain embodiments relate to methods and systems that use fluorescently encoded superparamagnetic microspheres for the immobilization of amplification products during the PCR process, and an imaging chamber of a measurement device that is also capable of controllable thermal cycling for assisting the PCR process. | 02-04-2016 |
20160032381 | GENES AND POLYMORPHISMS ASSOCIATED WITH AMD - There is provided a method of screening for susceptibility to complement dysregulation in an individual, the method including screening for the presence or absence of a genetic profile characterized by polymorphisms in the genome of the individual associated with complement dysregulation. The presence of a genetic profile is indicative of the individual's risk of complement dysregulation. | 02-04-2016 |
20160032385 | METHOD FOR DETECTING CYSTIC FIBROSIS - The present invention relates to methods for simultaneously determining the presence or absence of mutations, deletions, duplications and single nucleotide polymorphisms in a cystic fibrosis transmembrane regulator (CFTR) nucleic acid. Oligo nucleotide primers and kits used to amplify regions of a CFTR nucleic acid for high throughput, massively parallel sequencing and methods of determining an individual's cystic fibrosis status are also disclosed. | 02-04-2016 |
20160032391 | METHOD OF ESTABLISHING A GENETIC RISK STRATIFICASTION FOR GENETIC ADDICTION RISK ANALYSIS - Methods and kits for assessing severity index for alcohol abuse, drug abuse, and other reward deficiency syndromes. It has been discovered that a multifaceted non-specific RDS behaviors should be considered as the true “reward” phenotype (endophenotype) instead of a single subset RDS behavior such as alcoholism. In an embodiment of the present invention, it has been discovered that there are at least eleven risk alleles associated with ten candidate genes. The methods and kits of the present invention satisfy the need to classify patients at genetic risk for drug/alcohol seeking behavior prior to or upon entry to residential and or non-residential chemical dependency and pain programs. | 02-04-2016 |
20160032407 | PROGNOSTIC AND PREDICTIVE GENE SIGNATURE FOR NON-SMALL CELL LUNG CANCER AND ADJUVANT CHEMOTHERAPY - The application provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups and for determining the benefit of adjuvant chemotherapy by way of a multigene signature. The application also includes kits and computer products for use in the methods of the application. | 02-04-2016 |
20160032408 | Polynucleotide Primers For Detecting PIK3CA Mutations - A polynucleotide comprising at least the final six nucleotides of one of the following primer sequences, or a sequence complementary thereto: SEQ. ID NOS. 3 to 16, 18, 20 to 33, 35 or 37 to 39. A method of detecting the presence or absence of a mutation in the PIK3CA gene, wherein the mutation is one of H1047R, H1047L, E542K and E545K, and preferably ARMS primers are combined with Scorpion primers. | 02-04-2016 |
20160033417 | HETEROGENEOUS LUMINESCENT OXYGEN CHANNELING IMMUNOASSAYS - A chemiluminescent detection system, kits and microfluidics devices containing same, and methods of use thereof, are disclosed. | 02-04-2016 |
20160033491 | MULTIPHASE MICROARRAYS AND USES THEREOF - The present invention relates to solution microarrays. In particular, the present invention relates to an aqueous two-phase system for solution microarrays and uses thereof. Additional embodiments are described herein. | 02-04-2016 |
20160033509 | DIAGNOSTIC AND PROGNOSTIC MARKER FOR PROSTATE CANCER - Provided herein are methods for determining a diagnosis and/or prognosis for prostate cancer using the ratio of FOXC1:FOXA1 in a sample obtained from a subject. | 02-04-2016 |
20160033514 | BIOMARKERS OF IMMUNOMODULATORY EFFECTS IN HUMANS TREATED WITH ANTI-CD200 ANTIBODIES - The present disclosure relates to anti-CD200 antibodies (e.g., variant anti-CD200 antibodies having decreased or no effector function) and to biomarkers for use in a variety of diagnostic and therapeutic methods, e.g., determining whether a human has been administered one or more of the antibodies at a dose sufficient to induce a desired immunomodulatory effect in the human and/or selecting an appropriate dosing schedule for a patient. | 02-04-2016 |
20160033525 | IMMUNOASSAY STANDARDS AND MEASUREMENT OF TAU USING INTRA-ASSAY CALIBRATION STANDARDS - The present invention provides novel peptides, compositions, and methods for creating quantitative novel compositions, as well as methods for creating quantitative standards to calibrate analytes. These peptides, compositions, and methods enable the creation of standards and calibrators for analyzing analytes and measuring clinical biomarkers (e.g., Tau). Also provided are kits comprising the peptides or compositions described herein, for use in assays (e.g., sandwich immunoassays). | 02-04-2016 |
20160033528 | Methods for Selecting Peptides that Bind to Disease Specific Antibodies, Disease Specific Peptides and Uses Thereof - Provided herein is a method for selecting and expanding polypeptide epitopes against disease-specific antibodies present in blood across a wide variety of antibody-mediated infectious and autoimmune diseases. In particular, high-throughput selection methods are provided for selecting and expanding disease-relevant polypeptide epitopes against disease-specific antibodies present in a sample from a subject using polypeptide epitope libraries. Also provided are polypeptide epitope sequences, which accurately discriminate subjects with active and remitting Celiac Disease compared to non-Celiac subjects for diagnostic or therapeutic purposes. These peptide epitopes can be employed in methods for diagnosing a subject with Celiac disease. Kits useful in the disclosed methods are also provided. | 02-04-2016 |
20160033535 | Methods for the Diagnosis of Amyotrophic Lateral Sclerosis - The present invention is directed to systems and methods for diagnosing amyotrophic lateral sclerosis (ALS) by assessing the expression level of a marker, FGGY. In other aspects, the present invention is also directed to systems and methods of establishing a prognosis of ALS disease severity by assessing the expression level of FGGY. | 02-04-2016 |
20160033536 | NOVEL GROUPS OF BIOMARKERS FOR DIAGNOSING ALZHEIMER'S DISEASE - The inventors have discovered sets of proteinaceous biomarkers which can be measured in biological fluid samples to diagnosis or aid in the diagnosis of Alzheimer's disease and distinguish AD samples from non-demented samples. | 02-04-2016 |
20160033544 | SYSTEMS AND METHODS FOR MULTI-ANALYSIS - Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample. | 02-04-2016 |
20160038903 | SOL-GEL KIT FOR PREPARING BIOCHIP AND METHODS FOR PREPARING BIOCHIP USING THE SAME - A method of preparing a protein chip by gelation of a sol composition. In the method, a mixture of specific silicate monomers, such as SolB | 02-11-2016 |
20160039891 | CONSTITUTIVE PROMOTER - The invention relates to an isolated nucleic acid sequence comprising a promoter, which is a native sequence of | 02-11-2016 |
20160040158 | PROTEIN SCREENING METHODS - The invention provides methods and compositions useful for identifying polypeptides with desired characteristics in vitro. | 02-11-2016 |
20160040216 | SYSTEMS AND METHODS TO ASSES MICROBIOMES AND TREATMENTS THEREOF - Systems and methods to assess the health of various microbiomes and to identity species therein are disclosed. Described assessments and identifications can inform treatment decisions if a microbiome is determined to have a less than optimal balance of bacterial species within it; the presence of one or more negative species; and/or the absence of one or more positive species. | 02-11-2016 |
20160040232 | METHODS AND COMPOSITIONS FOR DETECTING NON-HEMATOPOIETIC CELLS FROM A BLOOD SAMPLE - The present invention recognizes that diagnosis and prognosis of many conditions can depend on the enrichment of rare cells, especially tumor cells, from a complex fluid sample such as a blood sample. In particular, the present invention is directed to methods and compositions for detecting a non-hematopoietic cell, e.g., a non-hematopoietic tumor cell, in a blood sample via, inter alia, removing red blood cells (RBCs) from a blood sample using a non-centrifugation procedure, removing white blood cells (WBCs) from said blood sample to enrich a non-hematopoietic cell, if any, from said blood sample; and assessing the presence, absence and/or amount of said enriched non-hematopoietic cell. | 02-11-2016 |
20160040235 | Methods for Diagnosing and Treating Diseases Caused by Genetic Copy Number Variants of Ultra-Conserved Elements - Methods for inducing cell apoptosis by cellular comparison of genetic copy number variants of ultra-conserved elements. | 02-11-2016 |
20160040237 | KIR3DL1 ALLELE CLASSIFICATION KIT AND METHOD - Disclosed herein are single nucleotide polymorphisms (SNPs) characteristic of functional subgroups of KIR3DL1. Also disclosed herein are methods for classifying KIR3DL1 alleles by using a series of oligonucleotide primers and PCR reaction conditions uniquely designed to identify group-specific SNPs from genomic DNA. The compositions and methods disclosed herein are useful in clinical settings and research laboratories, and enable prospective assessment of prognoses of various diseases and selection of most appropriate donors for HCT. | 02-11-2016 |
20160040241 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CORONARY HEART DISEASE - The invention pertains to a method of determining a statin dosage for an individual in need of treatment with a statin, comprising determining a SLCO1B1 genotype from a nucleic acid sample of the individual, said genotype comprising the presence or absence of the SLCO1B1-056 polymorphism, and determining an ApoE genotype or phenotype identifying an ApoE polymorphism selected from the group consisting of ApoE2, ApoE3, ApoE4, and any combination thereof, wherein the combination of a SLCO1B1 genotype identifying the presence of the SLCO1B1-056 C polymorphism and the ApoE genotype or phenotype identifying one of the ApoE3/4 or ApoE4/4 genotypes indicates the statin dosage. | 02-11-2016 |
20160040245 | CIRCULATING TUMOR CELL DIAGNOSTICS FOR DETECTION OF NEUROENDOCRINE PROSTATE CANCER (NEPC) - The present invention describes a method for detecting NEPC in a patient afflicted with prostate cancer comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characterization of nucleated cells in a blood sample obtained from the patient to detect circulating tumor cells (CTC), and (b) determining presence or absence of a CTC subpopulation associated with NEPC comprising detecting a measurable feature of each biomarker in a panel of morphological and protein biomarkers, wherein the presence of the CTC subpopulation associated with NEPC is indicative of NEPC. In other embodiments, the biomarkers for the CTC subpopulation associated with NEPC comprise small size, absence of Androgen Receptor (AR | 02-11-2016 |
20160040247 | METHOD FOR THE DIAGNOSIS, PROGNOSIS, AND TRATMENT OF CANCER METASTASIS - This study describes a method to determine the likelihood of the development of metastasis in a subject suffering from cancer, in addition to a method to design a customized therapy in a subject suffering from cancer, in particular breast, colon, lung, kidney and thyroid cancer, based on the determination of the expression level of one or more genes whose expression is modulated by an increase in c-MAF expression. It also describes a method for the identification of marker genes with a propensity for metastatic cancer based on inducing the modulation of the c-MAF expression Finally, the use of PTHLH and PODXL inhibitors and RERG activators in the treatment and/or prevention of the cancer, in particular breast, colon, lung, kidney and thyroid cancer. | 02-11-2016 |
20160040249 | METHODS FOR THE DETECTION OF SEQUENCE AMPLIFICATION IN THE BRCA1 LOCUS - Methods for detecting the amplifications of sequences in the BRCA1 locus, which sequences have ends consisting of or are framed with sequence stretches present at least twice in the BRCA1 locus, and which amplification results in at least two or at least three, especially three, tandem copies of the amplified sequence; methods for determining a predisposition to diseases or disorders associated with these amplifications, including predisposition to ovarian cancer or breast cancer and methods for detecting amplifications with similar features in other loci. | 02-11-2016 |
20160040251 | BIOMARKERS FOR THE IDENTIFICATION OF CHEMOSENSITIVITY - The instant application provides biomarkers for the identification of chemosensitivity in patient having cancer, in a particular embodiment the invention provides MST for the identification of chemosensitivity in breast cancer patient, wherein a reduced expression of XIST in the breast cancer cells of the patient indicates that the breast cancer stem cells in the patient may be successfully treated with HDAC inhibitor. | 02-11-2016 |
20160040253 | METHOD FOR MANUFACTURING GASTRIC CANCER PROGNOSIS PREDICTION MODEL - The present invention relates to a novel model for predicting a prognosis capable of predicting the prognosis of gastric cancer, and more specifically, to manufacturing a prediction model for predicting a clinical result after a resection during gastric cancer surgery through genetic mutation comparative analysis. | 02-11-2016 |
20160041148 | PLACEBO-CONTROLLED GLUTEN CHALLENGE METHOD - Provided herein are placebo-controlled methods for identifying Celiac disease in a subject, and related compositions and kits. | 02-11-2016 |
20160041158 | NON-CONVALENT PATTERNED CHEMICAL FEATURES AND USE THEREOF IN MALDI-BASED QUALITY CONTROL - The present application provides arrays for use in immunosignaturing and quality control of such arrays. Also disclosed are peptide arrays and uses thereof for diagnostics, therapeutics and research. | 02-11-2016 |
20160041159 | BIOSENSOR MICROARRAY COMPOSITIONS AND METHODS - Described herein are biosensor microarrays comprising detector polypeptide monolayers substantially free of contaminants. Also provided are methods for generation of such biosensor microarrays by capture of polypeptides by arrays comprising capture moieties and associated sensors. | 02-11-2016 |
20160041165 | A BLOOD BIOMARKER THAT PREDICTS PERSISTENT COGNITIVE DYSFUNCTION AFTER CONCUSSION - The invention relates to methods for providing prognosis, diagnosis, and treatment of a mild traumatic brain injury (mTBI) in a computed tomography (CT)-negative subject. The invention further relates to monitoring the severity of brain damage resulting from TBI in a subject and determining the prognosis of a subject that has suffered from mTBI. This invention also relates to methods of predicting who is at risk for developing brain damage and long-term dysfunction. | 02-11-2016 |
20160041168 | ARRAYED DETECTOR SYSTEM FOR MEASUREMENT OF INFLUENZA IMMUNE RESPONSE - A sensor chip for detecting an immune response against an influenza virus, the sensor chip including a substrate having a surface and a plurality of hemagglutinin polypeptides bound to discrete locations on the surface of the substrate, each hemagglutinin polypeptide having a hemagglutinin epitope. Detection devices containing the sensor chip and methods of detecting influenza immune responses are also described herein. | 02-11-2016 |
20160041173 | METHODS AND ARRAYS FOR USE IN THE SAME - The invention provides a method for determining prostate cancer-associated disease state in an individual comprising or consisting of the steps of: (a) providing a sample to be tested from the individual; and (b) determining a biomarker signature of the test sample by measuring the expression in the test sample of one or more biomarkers selected from the group defined in Table 1; wherein the expression in the test sample of the one or more biomarkers selected from the group defined in Table 1 is indicative of one or more prostate cancer-associated disease state in the individual. The invention also provides arrays and kits for use in the same. | 02-11-2016 |
20160041174 | USING PHAGE EPITOPES TO PROFILE THE IMMUNE RESPONSE - The present disclosure provides compositions and methods for using one or more polypeptide probes to profile an immune response. The polypeptide probe can be used to detect one or more antibodies from a sample. Furthermore, the present disclosure provides methods and compositions for characterizing a cancer based on the detection of one or more antibodies, such as autoantibodies. | 02-11-2016 |
20160041178 | ARRAY-BASED PROXIMITY LIGATION ASSOCIATION ASSAYS - Embodiments of this disclosure encompass methods, systems and probes for the detection of a target analyte in a sample. The method uses of the detection of at least two distinct sites on an analyte molecule, or the pairing of two distinct sites on two adjacent and contacting molecules, the sites being integral to the structure of a single molecule or positioned near one another due to the three-dimensional structure of the polypeptide. At least one of the detectable sites may be formed by a modification of a larger molecule. The methods of detecting a target analyte comprise contacting a sample with a pair of probes, each probe comprising a binding moiety capable of specifically binding to a target analyte o a tag thereon, and an oligonucleotide tail that comprises a PCR initiator region proximal to the target analyte binding moiety, a barcoding region uniquely associated with the target analyte binding moiety, and a connector-hybridizing region complementary to a region of a connector oligonucleotide; hybridizing a connector oligonucleotide to the connector-hybridizing regions of the probes and ligating the connector-hybridizing regions of the probes; PCR amplifying the ligated oligonucleotide tails; hybridizing the amplification product with a substrate-immobilized oligonucleotide that as regions complementary to the barcoding regions of the probes; digesting any single-strand DNA molecule; hybridizing a signaling oligonucleotide to the product of the previous step; and detecting the signal, thereby detecting the presence of the analyte in the sample. | 02-11-2016 |
20160041182 | Fibronectin Type III Repeat Based Protein Scaffolds with Alternative Binding Surfaces - Protein scaffolds and scaffold libraries based on a fibronectin type III (FN3) repeat with an alternative binding surface design, isolated nucleic acids encoding the protein scaffolds, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders. | 02-11-2016 |
20160041185 | Methods of Detecting Complement Fixing and Non-Complement Fixing Antibodies and Systems for Practicing the Same - Provided are methods for simultaneously determining the presence or absence of complement-fixing antibody (CFAb) and non-complement-fixing antibody (non-CFAb) in a biological sample in a single reaction. The methods include mixing a cellular sample from a donor, a biological sample from a recipient, isolated human complement component C1q (C1q), and a labeled C1q binding agent (CBA), under conditions sufficient for recipient CFAb and non-CFAb, if present, to bind to donor cell surface antigen (Ag) to form antibody-Ag (Ab-Ag-C1q-CBA) complexes. The methods further include contacting the mixture with labeled an-ti-hIgG antibodies and labeled anti-CD antibodies, and detecting (e.g., semi-quantitatively) the presence or absence of the detectable labels bound to the antibody-Ag complexes to determine the presence or absence of CFAb and non-CFAb in a biological sample from the recipient. Systems and kits for practicing the subject methods are also provided. | 02-11-2016 |
20160046990 | GENETIC MARKERS ASSOCIATED WITH ASD AND OTHER CHILDHOOD DEVELOPMENTAL DELAY DISORDERS - The present invention relates generally to genetic markers for autism spectrum disorders and other childhood developmental delay disorders, in particular to copy number variant genetic markers for autism spectrum disorders. | 02-18-2016 |
20160046995 | CLEAVABLE HAIRPIN PRIMERS - Nucleic acid constructs and methods that provide superior prevention of primer-dimers and other artifacts of false priming events are disclosed. In particular, there is disclosed a hairpin primer having a target-specific primer region, wherein the target-specific region comprises a target-binding dependent cleavage sequence; a first stem forming region 5′ of the target-specific primer region; and a second stem forming region 3′ of the target-specific primer region, wherein the second stem forming region is complementary to the first stem forming region. Methods of using the hairpin primer to amplify a target nucleic acid are also disclosed. | 02-18-2016 |
20160046998 | METHDS AND COMPOSITION TO GENERATE UNIQUE SEQUENCE DNA PROBES, LABELING OF DNA PROBES AND THE USE OF THESE PROBES - The invention relates generally to the field of the identification of DNA sequences, genes or chromosomes. Methods and composition to obtain Unique Sequence DNA probes are provided. Compositions comprises of and double stranded DNA containing Unique Sequences from which the repetitive sequences are eliminated according to the method described in this invention. The invention also relates to the preservation of cells that have been identified after immunomagnetic selection and fluorescent labeling in order to further interrogate the cells of interest. Furthermore the invention relates to genetic analysis of cells that have been identified after immunomagnetic selection and fluorescent labeling. | 02-18-2016 |
20160047000 | METHODS AND SYSTEMS FOR TREATMENT OF OVARIAN CANCER - As described herein, the inventors have identified gene signatures which permit the identification of patients who will benefit from (e.g. have optimal outcomes) cytoreductive surgery as treatment for ovarian cancer. Accordingly, provided herein are methods of treatment, assays, and systems relating to ovarian cancer and the administration of cytoreductive surgery. In one aspect, the technology described herein relates to a method of treatment comprising, detecting, in a sample obtained from a subject in need of treatment for ovarian cancer, the level of activation of at least one pathway, and administering cytoreductive surgery to the subject if the level of activation is not increased relative to a reference level. | 02-18-2016 |
20160047005 | DEVICES FOR THE DETECTION OF MULTIPLE ANALYTES IN A SAMPLE - The present invention relates generally to an assay for detecting and differentiating multiple analytes, if present, in a single fluid sample, including devices and methods therefore. | 02-18-2016 |
20160047793 | CARTRIDGE FOR STORING BIOSAMPLE PLATES AND USE IN AUTOMATED DATA STORAGE SYSTEMS - In one embodiment, a method of using a biosample storage cartridge includes performing bioanalysis on one or more biosamples in one or more biosample plates in a holder of a biosample storage cartridge, the biosample storage cartridge having an enclosure having a same form factor as a data tape cartridge that is configured for use in an automated tape library, the holder being disposed in the enclosure, wherein the holder comprises a plurality of slots, each slot being configured to receive a biosample plate. In another embodiment, a computer program product for using a biosample storage cartridge, the computer program product including a computer readable storage medium having program instructions embodied therewith, the program instructions executable by an analytical system to cause the analytical system to perform the foregoing method. | 02-18-2016 |
20160047813 | INTERGRIN ALPHA V BETA 6 FOR DIAGNOSIS/PROGNOSIS OF COLORECTAL CARCINOMA - The invention relates to a method for diagnosis of colorectal carcinoma in a patient, comprising detecting, in a blood sample obtained from said patient, an indicator protein selected from the group comprised of integrin subunit alpha (v) and integrin subunit beta (6) or their heterodimer. | 02-18-2016 |
20160047815 | METHOD OF DIAGNOSING OR PROGNOSING EPITHELIAL OVARIAN CANCER - The present invention provides a binding moiety which selectively binds to Sox11 protein and/or mRNA for imaging, diagnosis or prognosis of epithelial ovarian cancer (EOC). Optionally, the moiety is an antibody or antigen binding fragment thereof. Advantageously, moiety comprises a further, readily detectable moiety. The invention also provides methods of imaging EOC cells as well as methods of diagnosing or prognosing EOC in an individual. A further aspect of the present invention provides a method of identifying cells associated with EOC, the method comprising analysing the pattern of gene expression in a sample of cells to be tested and comparing it to the pattern of gene expression in a sample of known lymphomas cells. | 02-18-2016 |
20160047816 | ASSAY METHODS INVOLVING DISSOCIABLE NANOPARTICLES - Among other things, the present invention provides assay methods for detecting or quantifying one or more analytes in a sample, which involve the use of dissociable nanoparticles that comprise one or more signaling agents (e.g., the nanoparticles conceal or partially conceal the signaling agents). | 02-18-2016 |
20160047820 | COMPOSITIONS, METHODS AND KITS FOR DIAGNOSIS OF LUNG CANCER - Methods are provided for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. Also provided are compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC). | 02-18-2016 |
20160047823 | FKBP52-Tau Interaction as a Novel Therapeutical Target for Treating the Neurological Disorders Involving Tau Dysfunction - Candidate compounds for use in neuro-protection and repair in neurological disorders involving Tau dysfunction (including Alzheimer's disease) are identified from a direct interaction between proteins FKBP52 and Tau. The method for screening a drug for the prevention and treatment of neurological disorders involving Tau dysfunction includes determining the ability of a candidate compound, to modulate binding between a Tau polypeptide and a FKBP52 polypeptide, and selecting positively the candidate compound that modulates binding. | 02-18-2016 |
20160052993 | ALBUMIN VARIANTS BINDING TO FCRN - The invention relates to methods of identifying albumin variants having improved pharmacokinetics, albumin variants having improved pharmacokinetics, and therapeutic uses of albumin variants having improved pharmacokinetics. | 02-25-2016 |
20160053301 | METHODS FOR QUANTITATIVE GENETIC ANALYSIS OF CELL FREE DNA - The invention provides a method for genetic analysis in individuals that reveals both the genetic sequences and chromosomal copy number of targeted and specific genomic loci in a single assay. The present invention further provides methods for the sensitive and specific detection of target gene sequences and gene expression profiles. | 02-25-2016 |
20160053309 | SET OF PRIMERS AND PROBES TO BE USED FOR IDENTIFICATION OF GENE POLYMORPHISM AND USE THEREOF - By establishing a simple method for extracting a nucleic acid from a human specimen, and using the LAMP method, which is an isothermal gene amplification method showing superior quickness and convenience, with a concept of measurement different from the conventional ones, there is established a test method including steps up to detection with a measurement apparatus. There is provided a method for detecting a target site, which is an LAMP method using four kinds of primers, FIP, F3 primer, BIP, and B3 primer, which are designed on the basis of six regions of a template polynucleotide, F1 region, F2 region, F3 region, B1 region, B2 region, and B3 region, wherein: the template polynucleotide contains the target site, the four kinds of primers are designed so that the target site exists between the F1 region and the F2 region, or between the B1 region and the B2 region; a loop primer designed on the basis of a region between the F1 region and the F2 region or between the B1 region and the B2 region on the side on which the target site exists, and an oligonucleotide probe that can associate with a region including the target site are used, the loop primer and the probe are designed so that the 5′ end of the loop primer and the 3′ end of the probe associate with the template polynucleotide at positions close to each other, one of the loop primer and the probe is modified with a fluorescent molecule around the 5′ end in the case of the loop primer or the 3′ end in the case of the probe, and the other is modified with a quenching molecule. | 02-25-2016 |
20160053320 | NON-INVASIVE PRENATAL SCREENING - The present invention is concerned with prenatal screening and in particular non-invasive prenatal screening, as well as primers, primer sets and kits. In one instance, the invention provides a method of prenatal screening comprising: (a) amplifying a region encompassing the site of a mutation site responsible for the disorder, the amplification being performed on a DNA sample obtained from a pregnant female which comprises both maternal and fetal DNA; (b) sequencing a plurality of products from the amplification and determining whether or not the mutant allele is represented at a different frequency to that expected from the genotype of the pregnant female alone. | 02-25-2016 |
20160053327 | COMPOSITIONS AND METHODS FOR PREDICTION OF CLINICAL OUTCOME FOR ALL STAGES AND ALL CELL TYPES OF NON-SMALL CELL LUNG CANCER IN MULTIPLE COUNTRIES - Lung cancer is one of the most commonly diagnosed cancers in the world. While numerous predictive genetic models of non-small cell lung cancer (NSCLC) have been proposed, but many current models fail to accurately predict patient survival when verified by other multiple datasets. Here, we successfully eliminated institutional variations and merged twelve datasets from different institutions to generate a training cohort of 1073 and a testing cohort of 659. From the training cohort, we identified 129 deferentially expressed probes or 95 genes (Table1-2) associated with Lung Cancer. | 02-25-2016 |
20160053329 | MEAN DNA COPY NUMBER OF CHROMOSOMAL REGIONS IS OF PROGNOSTIC SIGNIFICANCE IN CANCER - Methods for predicting a disease free time interval (DFI) for a cancer patient under consideration for initial or further chemotherapy treatment are disclosed. The methods include obtaining a biological sample from a patient and detecting a copy number of chromosome region A1 and/or C2. The mean copy number per cell is correlated with a DFI for the subject. The chemotherapy can include doxorubicin and/or L-asparaginase treatment. Also provided are kits for predicting DFI in a subject with cancer and computer readable storage media for performing the presently disclosed methods. | 02-25-2016 |
20160053330 | COMPOSITIONS AND METHODS FOR DETECTING CANCER METASTASIS - The present invention encompasses compositions and methods for detecting cancer metastasis. | 02-25-2016 |
20160054207 | Low Resource Sample Processor Containing Heat-Activated Surface Tension Valves - Systems and methods are described for isolation, separation and detection of a molecular species using a low resource device for processing of samples. Methods include isolation, separation and detection of whole cells as well as biomolecules including viruses, proteins, nucleic acids, carbohydrates and lipids. | 02-25-2016 |
20160054313 | PEPTIDES, DEVICES, AND METHODS FOR THE DETECTION OF EHRLICHIA ANTIBODIES - The invention provides peptide compositions and mixtures useful for the detection of antibodies that bind to | 02-25-2016 |
20160054316 | SYSTEM AND APPARATUS FOR POINT-OF-CARE DIAGNOSTICS - A system comprised of an apparatus and a test device is described. The test device and the apparatus are designed to interact to determine the presence or absence of an analyte of interest in a sample placed on the test device. | 02-25-2016 |
20160054318 | METHOD FOR THE DIAGNOSIS OF NEUROMYELITIS OPTICA - The present invention relates to a method for the diagnosis and/or risk stratification of neuromyelitis optica (abbreviated NMO), wherein a determination from a body sample of a patient/test subject is performed by means of artificial aquaporin-4 peptides. The invention further relates to a kit and to new artificial aquaporin-4 peptides as such. | 02-25-2016 |
20160054331 | METHOD FOR THE DETECTION AND/OR ENRICHMENT OF ANALYTE PROTEINS AND/OR ANALYTE PEPTIDES FROM A COMPLEX PROTEIN MIXTURE - The present invention relates to a method for the detection and/or enrichment of a large number of different analyte proteins and/or analyte peptides from a sample mixture which includes proteins and/or peptides. The method includes the following steps: a) provision of the sample mixture and, where appropriate, fragmentation of the proteins contained therein into defined peptides, b) provision of first binding molecules which are specific for a peptide epitope of at least one of the various analyte proteins and/or analyte peptides, whereby the peptide epitope includes up to a maximum of five, preferably two to three, amino acids, c) incubation of the first binding molecules with the sample mixture, and d) detection and/or enrichment of the analyte proteins and/or analyte peptides bound to the first binding molecules. The invention also relates to binding molecules which are specific for the terminal peptide epitope of various peptide analytes, whereby the terminal peptide epitope includes the free NH | 02-25-2016 |
20160054333 | METHOD FOR DETECTING ASYN-SPECIFIC ANTIBODIES IN A BIOLOGICAL SAMPLE - Disclosed is a method for detecting aSyn-specific antibodies in a biological sample, comprising the following steps: contacting the sample with aSyn-comprising-aggregates and allowing the aSyn-specific antibodies to bind to the aSsyn-comprising-aggregates, and detecting the aSyn-specific antibodies bound to the aSyn-comprising-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (FACS). | 02-25-2016 |
20160054334 | FUTURE CARDIAC EVENT BIOMARKERS - The present invention relates to the identification of chemokine biomarkers predictive of future acute coronary syndromes including unstable angina pectoris (UAP). The present invention also identifies particular chemokines as potential therapeutic targets for intervention in cardiovascular diseases. | 02-25-2016 |
20160054335 | MARKER FOR DIAGNOSING AGE-RELATED MACULAR DEGENERATION, AND METHOD FOR DIAGNOSING AGE-RELATED MACULAR DEGENERATION BY USING SAME - A biomarker for diagnosing age-related macular degeneration includes a vinculin protein, and a diagnostic kit, a diagnostic method, and a method of screening a therapeutic material for age-related macular degeneration use the biomarker. The diagnostic kit and the diagnostic method of age-related macular degeneration are novel immunological diagnostic tools using the plasma of a patient, and have remarkable sensitivity that enables simple analysis of plasma without a biopsy, and thus can be useful for diagnosing age-related macular degeneration. | 02-25-2016 |
20160054337 | Method for Determining Radiosensitivity - The present invention relates to a method for the in vitro determination of the radiosensitivity of a subject. More particularly, the invention relates to a method comprising a step of inducing an exogenous stress on a biological sample from a subject, followed by the comparison of the presence or level of at least one compound chosen in a group of defined compounds, in said biological sample and in a reference sample. The present invention also relates to the use of said at least one compound as predictive biomarker of the radio-sensitivity of a subject. The invention also relates to a kit for the detection of the presence or level of at least one of said compounds, usable in a method according to the invention. | 02-25-2016 |
20160059201 | BIOCHIP FIXING METHOD, BIOCHIP FIXING DEVICE, AND SCREENING METHOD FOR BIOMOLECULE ARRAY - A biochip fixing method includes: arranging a biochip on an object with a predetermined material interposed therebetween; and irradiating the predetermined material with energy waves via the object to fix the biochip to the object. | 03-03-2016 |
20160060620 | THE USE OF LAMBDA-GAM PROTEIN IN RIBOSOMAL DISPLAY TECHNOLOGY - Methods and systems for increasing the stability of a nucleic acid template that encodes a protein of interest in a cell free translation system or a ribosomal display reaction system are described. In some embodiments, the nucleic acid template is an RNA or mRNA. The stability of the RNA template is increased by adding the bacteriophage lambda protein Gam to the cell free extract used in the transalation system. The addition of Gam protein increases the longevity of the reaction system, thereby increasing the efficiency of the ribosomal display reaction system. | 03-03-2016 |
20160060642 | G Protein Coupled Receptor Libraries - The present invention relates to a yeast cell expressing a nematode G protein coupled receptor (GPCR), whereby ligand binding to the GPCR results in a detectable signal. In particular, the present invention relates to a yeast library expressing a range of different GPCRs, and to methods of screening said library. | 03-03-2016 |
20160060680 | METHOD FOR ANALYZING PLURALITY OF SAMPLES - A diagnostic system performs a first nucleic acid amplification reaction and a second, different nucleic acid amplification reaction. The diagnostic system includes a compartment configured to store at least a first bulk reagent container comprising a first bulk reagent for performing a sample preparation process, and a second bulk reagent container comprising a second bulk reagent for performing the first reaction. The system including a compartment configured to store at least one unit-dose pack comprising a plurality of unit-dose reagents for performing the second reaction. The diagnostic system is configured to perform the sample preparation process using the first bulk reagent on each of a plurality of samples provided to the diagnostic system. The system is configured to perform the first reaction using the second bulk reagent on a first sample subset, and perform the second reaction using the plurality of first unit-dose reagents on a second sample subset. | 03-03-2016 |
20160060682 | MULTIPLEXED ANALYSIS OF TARGET NUCLEIC ACIDS - The present invention provides, among other things, methods of detecting target nucleic acid, comprising steps of: a) contacting a sample with one or more capturing probes, each comprising at least one target capturing sequence, under conditions that permit the one or more capturing probes to capture one or more target nucleic acids in the sample; b) amplifying the captured one or more target nucleic acids in a reaction mixture comprising a detectable entity such that the amplified one or more target nucleic acids are labeled with the detectable entity; c) incubating amplification product with a plurality of re-capturing probes such that the amplified one or more target nucleic acids are re-captured by the plurality of the re-capturing probes; and d) detecting signal generated by detectable entity associated with the re-captured amplified one or more target nucleic acids, wherein the presence and/or abundance of the detectable signal indicates the presence and/or abundance of the one or more target nucleic acids in the sample. | 03-03-2016 |
20160060685 | COMPOSITIONS AND METHODS FOR DETECTING NUCLEIC ACID FROM MOLLICUTES - Compositions, reaction mixtures, kits and methods used in amplifying and detecting nucleic acids from various species of the class Mollicutes. Particular regions of the 23S rRNA or its gene have been identified as preferred targets for nucleic acid amplification reactions of a sample suspected containing at least one species of Mollicutes. Some oligomers comprise tag regions, target closing regions, promoter sequences, and/or binding moieties. Samples can be from any source suspected of containing a species of the class Mollicutes. Preferred sample sources include bioreactors, cell lines, cell culture wares and pharmaceutical manufacturing wares. | 03-03-2016 |
20160060688 | USE OF PROBES FOR MASS SPECTROMETRIC IDENTIFICATION OF MICROORGANISMS OR CELLS AND ASSOCIATED CONDITIONS OF INTEREST - This invention pertains to identifying one or more hybridization probes sequestered within (or optionally released from the intact) cells or microorganisms by mass spectrometry to thereby determine a trait of the cells or microorganisms and/or to identify the cells or microorganisms themselves. The cells or microorganisms can come from a subject and the information obtained from the mass spectrometry analysis may, if clinically relevant, optionally be used to diagnose and/or treat the subject. | 03-03-2016 |
20160060690 | DETECTION OF TARGET NUCLEIC ACID SEQUENCE BY PTO CLEAVAGE AND EXTENSION-DEPENDENT NON-HYBRIDIZATION ASSAY - The present invention relates to the detection of a target nucleic acid sequence by a PCE-NH (PTO Cleavage and Extension-Dependent Non-Hybridization) assay. The present invention adopts the occurrence of the inhibition of the hybridization between the HO with the CTO by the formation of the target-dependent extended duplex. Therefore, the present invention may detect target sequences even when the HO is not cleaved. In this regard, the design of the 5′-tagging portion of PTO, CTO and HO sequences may be readily performed and the conditions for reactions may be also easily established. In addition, the detection of the hybrid between the CTO and the HO may be performed in a different vessel from that for the extension of the CTO. | 03-03-2016 |
20160060694 | OLIGONUCLEOTIDES FOR CONTROLLING AMPLIFICATION OF NUCLEIC ACIDS - Methods and oligonucleotides are provided for detecting an internal control nucleic acid for qualitative and/or quantitative purposes. | 03-03-2016 |
20160060701 | METHODS FOR PREDICTING RISK OF INTERSTITIAL PNEUMONIA - Disclosed are biomarkers, methods and assay systems for the identification of poor prognosis of interstitial pneumonia (pulmonary fibrosis) in an individual diagnosed with suspected of having interstitial pneumonia. | 03-03-2016 |
20160060704 | Methods and Compositions for Diagnosis of Glioblastoma or a Subtype Thereof - An isoform-level gene panel is disclosed that can accurately classify a glioblastoma subtype from a tumor sample. Such an isoform level gene panel comprises the 121 to 214 target isoforms identified in Table 1. Also disclosed are reagents for quantitatively detecting the expression or activity of the target isoforms of Table 1 in a patient sample. For example, such ligands can be PCR primer and probes sets. This isoform-level gene panel and reagents for detection of the isoforms are useful in an isoform-level assay for diagnosis of the molecular subtype of a glioblastoma in a patient. The assay employs algorithms and a novel computer program that performs the functions of FIG. | 03-03-2016 |
20160060706 | METHODS FOR CANCER SCREENING IN LATIN AMERICAN/HISPANIC POPULATIONS - Provided herein are novel methods for diagnosing ovarian and breast cancer risk in a Latin American/Hispanic population based on the presence of specific BRCA1 and/or BRCA2 mutations. | 03-03-2016 |
20160060708 | Method for detecting the risk of early gastric cancer - The present invention discloses the nine biomarkers including HIF1A, FAM84B, CRIP2, GSN, RPL15, DLG1, MAT2A, PGBD2 and ID3 are respectively selected according to their specific and unique expression profile in the gastric cancer cells or gastric cancer tissue. Therefore, the nine biomarkers are related to diagnose gastric cancer, such as detecting early gastric cancer, staging gastric cancer, predicting prognosis of gastric cancer and diagnosing lymph node metastasis. By analyzing the expression value of at least one biomarker of a sample from a subject, the subject can be precisely diagnose the risk about gastric cancer. | 03-03-2016 |
20160060712 | SYSTEMS AND METHODS FOR PERICARP GENOTYPING - The invention includes methods for obtaining samples of maternal tissue from seeds, obtaining genetic material from the maternal seed tissue, and performing a molecular analysis on the genetic material from the maternal seed tissue to determine maternal lineage of a single seed. The invention also includes methods for establishing a consensus maternal genotype from maternal seed tissues obtained from multiple seeds as well as methods for determining paternal lineage. | 03-03-2016 |
20160060713 | Systems and Methods for Genotyping Seed Components - The invention provides methods for obtaining genetic material from plant embryos while preserving their viability as well as methods for performing a molecular analysis of plant embryos, particularly with small quantities of genetic material. The methods may include the steps of collecting shed cellular material from one or more embryos; obtaining DNA from the shed cellular material; performing a molecular analysis of the DNA; and germinating at least one of said one or more embryos. A further extension of this method includes determining whether to germinate and grow the embryo or to discard the embryo based on its genotype as part of a breeding process. | 03-03-2016 |
20160060716 | GeXP Detection Kits for Identification of 11 Kinds of Duck Virus Diseases - Provided herein is a GeXP detection kit for identification of 11 kinds of duck virus diseases. The detection kit includes a primer set for identifying or auxiliarily identifying pathogens of duck communicable diseases, including one or more of primer pair A, primer pair B primer pair C, primer pair D, primer pair E, primer pair F, primer pair G, primer pair H, primer pair I, primer pair J, primer pair K and primer pair L. The can kit detect, simultaneously avian influenza virus, subtype H5, H7 and H9 of avian influenza virus, duck hepatitis virus, duck enteritis virus, duck Tembusu virus, Newcastle disease virus, egg drop syndrome virus, Muscovy duck reovirus, Muscovy duck parvovirus and duck circovirus with the primer set, PCR reagent or primer pairs provided in the present invention. | 03-03-2016 |
20160060718 | EPSTEIN BARR VIRUS GENOTIPIC VARIANTS AND USES THEREOF AS RISK PREDICTORS, BIOMARKERS AND THERAPEUTIC TARGETS IN MULTIPLE SCLEROSIS - The present invention relates to a nucleic acid coding for a variant of the Epstein Barr nuclear antigen 2 (EBNA2) for use as a biomarker for predicting the risk of developing multiple sclerosis and/or for screening and/or for the diagnosis and/or prognosis of multiple sclerosis, and to an in vitro method for predicting the risk of developing and/or for screening for multiple sclerosis and/or for the diagnosis and/or prognosis of multiple sclerosis in a subject, comprising the detection of the presence of said nucleic acid. | 03-03-2016 |
20160061815 | PDGF AS A BIOMARKER FOR PREDICTING RESISTANCE OR EFFECT OF C-MET TARGETING DRUGS - Provided is a method for evaluating efficacy of, or resistance to, a c-Met targeting agent including measuring a level of a PDGF protein and/or a PDGF coding gene. | 03-03-2016 |
20160061833 | RATIONALE, METHODS, AND ASSAYS FOR IDENTIFYING HUMAN AND NON-HUMAN PRIMATE TASTE SPECIFIC GENES AND USE THEREOF IN TASTE MODULATOR AND THERAPEUTIC SCREENING ASSAYS - This invention relates to novel rationale and methods for identifying human and primate taste-specific genes, including genes involved in salty taste perception, especially human salty taste perception, but also genes involved in sweet, bitter, umami, and sour taste perception, and genes involved in other taste cell or taste receptor related activities such as digestive function and digestive related diseases, taste cell turnover, immunoregulation of the oral and digestive tract, and metabolic regulation such as in diabetes and obesity, the genes identified using these methods, and assays for identifying taste modulators (enhancers or blockers) and potential therapeutics using these genes. These compounds have potential application in modulating (enhancing or blocking) taste perception, especially salty taste perception and as potential therapeutics. In addition, this invention relates to novel methods for identifying taste-specific genes that can be used as markers for different taste cell types, including sweet, bitter, umami, sour, salty, and other taste cells in mammals as well as assays that measure the activity of the sweet, bitter, umami, or sour receptor in the presence of these genes to identify modulators of sweet, bitter, umami, and sour taste and to identify therapeutics especially for treating digestive or metabolic disorders, taste loss, and oral infections. Particularly, the genes identified herein and antibodies or oligos thereto can be used as markers to identify and/or purify specific taste cells e.g., from taste cell suspensions by use of FACS or magnetic bead cell selection or other known cell purification and isolation procedures. | 03-03-2016 |
20160061839 | Methods of Determining Patient Response by Measurement of HER-3 - The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3. | 03-03-2016 |
20160061845 | COMPOSITIONS AND METHODS FOR TREATING STEROID RESISTANT NEPHROTIC SYNDROME AND/OR STEROID SENSITIVE NEPHROTIC SYNDROME - Disclosed are methods of determining whether a patient diagnosed with nephrotic syndrome has steroid sensitive nephrotic syndrome (SSNS) or steroid resistant nephrotic syndrome (SRNS) by determining the levels of one or more biomarkers in a biofluid from the patient. Also disclosed are methods of treating a patient diagnosed with nephrotic syndrome, and kits and substrates related to the disclosed methods. | 03-03-2016 |
20160061846 | Method for Evaluating Atherosclerotic Lesion, and Kit - The present invention provides a method and a means for evaluating atherosclerotic lesions by identifying a protein (marker protein) group, the expression level of which varies according to the progression of the atherosclerotic lesion, and using the proteins. Specifically, the present invention relates to a method for evaluating atherosclerotic lesions, comprising the steps of detecting a marker protein exhibiting an expression pattern (expression variation) characteristic at a specific disease stage of atherosclerotic lesions in a subject, and evaluating the atherosclerotic lesions in the subject based on the detection result. | 03-03-2016 |
20160063179 | SYSTEM FOR PREDICTING PROGNOSIS OF LOCALLY ADVANCED GASTRIC CANCER - The present invention relates to a novel system for predicting a prognosis capable of predicting the prognosis of locally advanced gastric cancer, and more specifically, capable of predicting a clinical result after a resection during gastric cancer surgery through gene set enrichment comparative analysis. | 03-03-2016 |
20160067308 | USE OF HUMAN SMALL LEUCINE ZIPPER PROTEIN IN OSTEOGENESIS PROCEDURE - The present invention relates to a use of a human small leucine zipper protein in the osteogenesis procedure. More specifically, sLZIP increases the transcriptional activity of Runx2 and inhibits the transcriptional activity of PPARγ2, thereby increasing the osteoblast differentiation, so that sLZIP performs an important role in the osteogenesis procedure, and thus can be used as a marker for treating bone disease and developing new medicines. | 03-10-2016 |
20160068808 | METHODS FOR STIMULATING ANTIGEN-SPECIFIC T CELL RESPONSES - The present invention relates to methods for stimulating antigen-specific T cell responses. In particular, the invention relates to a method for stimulating antigen (Ag)-specific T cell responses in a blood sample or PBMC sample isolated from a subject comprising the step consisting in culturing said blood or PBMC sample in a appropriate culture medium which comprises an amount of IL-1beta and an amount of a least one antigen. | 03-10-2016 |
20160068817 | IN VITRO MODEL OF METASTATIC CANCER - The present invention relates to drug discovery and development. More specifically, the present invention provides methods and composition useful for screening anti-cancer agents. In a specific embodiment, a method for screening candidate anti-cancer agents comprises the steps of (a) contacting a monolayer of reversible spheroid cancer cells with a candidate anti-cancer agent; and (b) measuring the response of the reversible spheroid cancer cells to the candidate anti-cancer agent. | 03-10-2016 |
20160068861 | METHOD FOR DETECTING PROTEIN STABILITY AND USES THEREOF - Provided in the present invention is a genetic construct having a structure as represented by 5′-A+B+C+D+E-3′, wherein A indicates a promoter; B indicates a coding sequence of a fusion protein consisting of a target protein and a first labeled protein; C indicates a coding sequence of a connecting peptide; D indicates a coding sequence of a second labeled protein; and E indicates a terminator. Also provided in the present invention is a polypeptide having a structure as represented by B1+C1+D1, wherein B1 indicates the fusion protein consisting of the target protein and the first labelled protein; C1 indicates the connecting peptide; and D1 indicates a second labelled protein. Also provided in the present invention are a vector containing the genetic construct, a mammalian cell containing the genetic construct or the vector, a library consisting of the cell and a method for detecting protein stability and uses thereof. The method of the present invention not only has a high sensitivity and specificity for detecting protein stability, but also is simple and convenient in operation. | 03-10-2016 |
20160068887 | COMPOSITIONS AND METHODS OF NUCLEIC ACID-TARGETING NUCLEIC ACIDS - This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof. | 03-10-2016 |
20160068891 | OLIGONUCLEOTIDE PROBE SET AND METHODS OF MICROBIOTA PROFILING - Described herein is a set of oligonucleotide probes. Also included are methods of using the oligonucleotide probes in profiling the microbiota of the GI tract of a subject and methods of diagnosing or monitoring a disease or condition in a subject or predicting or assessing the risk of a subject developing a disease or condition. Kits comprising the oligonucleotide probe set described herein are also provided | 03-10-2016 |
20160068893 | Method for Detection of KRAS Mutations - The present invention is based on a detection method of the 9 KRAS mutations Gly12Ser, Gly12Arg, Gly12Cys, Gly12Asp, Gly12Ala, Gly12Val, Gly13Asp, Gln61His and Gln61Leu, in a sample susceptible of containing one or more of such mutations, based on amplification of the sample with the primers of the present invention. Further, the present invention relates to (i) a kit which comprises, amongst its components, reagents for ARMS amplification including one or more of the primers of the present invention; (ii) the primers themselves; and (iii) use of the method, kit and primers of above, for the diagnosis/prognosis of a pathological condition in a patient, particularly, of cancer. | 03-10-2016 |
20160068894 | RNA Microchip Detection Using Nanoparticle-Assisted Signal Amplification - Disclosed are methods and materials for detecting RNA in a sample. In some forms, the method involves (a) bringing into contact the sample and a probe array, (b) bringing into contact the probe array and a ribonuclease specific for RNA/DNA hybrids (such as RNase H), (c) bringing into contact the probe array, labeled nucleotides, and a nucleic acid polymerase capable of extending a RNA strand using a DNA template and capable of incorporating the labeled nucleotides in the extension from the RNA strand (such as Klenow fragment DNA polymerase), and (d) detecting the labeled nucleotides in the extended nucleic acid strand. The probe array comprises one or more chimeric probes. The chimeric probes comprise a DNA region and a RNA region, where the DNA region and the RNA region are contiguous and where the DNA region is 5′ of the RNA region. The chimeric probe can also include a second DNA region. The second DNA region can also be contiguous with the RNA region and can be 3′ of the RNA region. | 03-10-2016 |
20160068905 | Method for Studying V(D)J Combinatory Diversity - The present invention pertains to a method of visualizing an immunological status of an individual, by combining the degree of immunoglobulin and/or TCR diversity and another biological marker linked to the immunological status of said individual in a two- or three-dimensional graph. | 03-10-2016 |
20160068907 | Profiling Expression at Transcriptome Scale - Ligation assays for detecting and profiling expression products at transcriptome scale. | 03-10-2016 |
20160068909 | MARKERS FOR DIAGNOSIS OF PULMONARY INFLAMMATION AND METHODS RELATED THERETO - The present invention is related to the novel discovery of a number of genes that were identified as systemic markers of pulmonary inflammation. This discovery allows for development of a novel tool for reliable, rapid and efficient assessment of therapeutic responses and enables design of novel therapies targeted against diseases associated with pulmonary inflammation. In one embodiment, the present invention allows quantification of therapeutic response in patients who have a disease associated with pulmonary inflammation. In preferred embodiments, the genes are CD64, ADAM9, CD36, IL32, HPSE, PLXND1, | 03-10-2016 |
20160069782 | METHODS OF ANALYZING AN H&E STAINED BIOLOGICAL SAMPLE - Methods comprising probing multiple targets in an H&E stained biological sample are provided. The methods include the steps of providing a hematoxylin and eosin stained biological sample containing multiple targets, optionally detecting H&E staining of the sample, removing the hematoxylin and eosin signals, and detecting additional features or targets in the biological sample. The detecting step may include performing the steps of binding at least one probe to one or more targets to the sample, detecting a signal from the probe and contacting the sample with a bleaching agent. The process of binding, detecting and bleaching may be iteratively repeated. | 03-10-2016 |
20160069872 | METHODS FOR CONDUCTING MULTIPLEXED ASSAYS - The invention relates to methods for conducting solid-phase binding assays. One example is an assay method having improved analyte specificity where specificity is limited by the presence of non-specific binding interactions. | 03-10-2016 |
20160069881 | METHODS FOR DETECTING MOLECULES IN A SAMPLE - The present invention relates to a method for detecting molecules. The method employs: at least two primary antibodies, wherein the first primary antibody binds to a first site on a molecule and the second primary antibody binds to a second site on a molecule, wherein the second site is different from the first site and wherein the first and second primary antibodies are immunologically distinct; at least two secondary antibodies, wherein the first secondary antibody is labelled with a fluorescence resonance energy transfer (FRET) donor and binds to the first primary antibody; and the second secondary antibody is conjugated or fused to an enzyme and binds the second primary antibody, wherein the first secondary antibody does not bind the second primary antibody and the second secondary antibody does not bind the first primary antibody; a conjugate comprising a FRET acceptor and a substrate specific for the enzyme, wherein when the substrate reacts with the enzyme, an activated conjugate forms, which activated conjugate binds to electron rich moieties on a molecular surface adjacent to the enzyme; wherein the method comprises: contacting a sample with the at least two primary antibodies; contacting the sample with the at least two secondary antibodies; performing a wash step; contacting the sample with the conjugate; and detecting any FRET signal generated by the FRET acceptor. | 03-10-2016 |
20160069889 | COMPOSITIONS AND METHODS FOR APTAMER SCREENING - Methods are provided for selecting aptamers that are specific to a target of interest from amongst a library of potential aptamer sequences. Aptamers disclosed can be used to detect and/or characterize biological entities of interest, e.g. microvesicles and/or surface antigens. Further disclosed are biomarkers that can be used for diagnosing different disorders including different types of cancer. | 03-10-2016 |
20160069891 | DIAGNOSTIC BIOMARKER TO IDENTIFY WOMEN AT RISK FOR PRETERM DELIVERY - The invention relates to biomarkers associated with preterm delivery. More specifically, the invention provides methods of measuring biomarkers found in women that are at risk for preterm delivery. | 03-10-2016 |
20160069896 | DIAGNOSIS OF AUTOIMMUNE DISEASES USING A SPECIFIC ANTIBODY PROFILE - Methods and kits for diagnosing systemic lupus erythematosus (SLE) or scleroderma in a subject are provided. Particularly, the present invention relates to a specific antibody reactivity profile useful in diagnosing SLE or scleroderma in a subject. | 03-10-2016 |
20160069897 | SELECTION OF FAB FRAGMENTS USING RIBOSOMAL DISPLAY TECHNOLOGY - The invention relates to a method for generating and selecting Fab fragments using ribosomal display and cell-free protein synthesis. The invention also provides a ribosomal display reaction system for generating Fab fragment complexes. The compositions of a Fab fragment complex and a library thereof are also provided. | 03-10-2016 |
20160069904 | Methods for Early Diagnosis of Kidney Disease - The invention provides reagents and methods for diagnosing kidney disease in a human or animal. | 03-10-2016 |
20160069906 | HEALTH TEST FOR A BROAD SPECTRUM OF HEALTH PROBLEMS - Provided herein are methods and devices for the detection of conditions or disorders by detecting altered levels of stress response pathway biomarkers. Also provided are methods and reagents for identifying panels of biomarkers associated with a condition or disorder. | 03-10-2016 |
20160069920 | SYSTEMS AND METHODS FOR MULTI-ANALYSIS - Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample. | 03-10-2016 |
20160070884 | SYSTEMS AND METHODS FOR DETECTING INFECTIOUS DISEASES - Systems, methods, and devices for detecting infections in a clinical sample are provided. Small-volume clinical samples obtained at a point-of-service (POS) location and may be tested at the POS location for multiple markers for multiple diseases, including upper and lower respiratory diseases. Samples may be tested for cytokines, or for inflammation indicators. Dilution of samples, or levels of detection, may be determined by the condition or past history of a subject. Test results may be obtained within a short amount of time after sample placement in a testing device, or within a short amount of time after being obtained from the subject. A prescription for treatment of a detected disorder may be provided, and may be filled, at the POS location. A bill may be automatically generated for the testing, or for the prescription, may be automatically sent to an insurance provider, and payment may be automatically obtained. | 03-10-2016 |
20160076021 | APTAMER METHODS AND COMPOSITIONS - Methods of selecting an aptamer that specifically binds to a target molecule complexed with a derivatization agent. Also disclosed are specific aptamers and methods of use thereof. | 03-17-2016 |
20160076022 | NUCLEIC ACID LINKER - The present invention relates to a nucleic acid linker for producing a complex of mRNA, and a protein or a peptide which is encoded by the mRNA, the linker comprising: a spacer portion at the 5′-terminal; a polynucleotide portion hybridizable with at least a part of a sequence of the mRNA; and an arm portion which has a connection portion for the protein or the peptide at the 3′-terminal, in which the spacer portion, the polynucleotide portion, and the arm portion form a single strand, and in which the polynucleotide portion contains a photoreactive base derivative. | 03-17-2016 |
20160076083 | METHODS AND DEVICES RELATED TO TOEHOLD-BASED STRAND DISPLACEMENT WITH LOOP-MEDIATED ISOTHERMAL AMPLIFICATION - Disclosed are compositions and methods for isothermal nucleic acid amplification and detection. | 03-17-2016 |
20160076087 | Assays for Single Molecule Detection and Use Thereof - The invention relates to methods of detecting a genetic variation in a genetic sample from a subject using labeled probes and counting the number of labels in the probes. | 03-17-2016 |
20160076090 | METHODS, COMPOSITIONS, AND KITS FOR DETECTING ALLELIC VARIANTS - In some embodiments, the present inventions relates generally to compositions, methods and kits for use in discriminating sequence variation between different alleles. More specifically, in some embodiments, the present invention provides for compositions, methods and kits for quantitating rare (e.g., mutant) allelic variants, such as SNPs, or nucleotide (NT) insertions or deletions, in samples comprising abundant (e.g., wild type) allelic variants with high specificity and selectivity. In particular, in some embodiments, the invention relates to a highly selective method for mutation detection referred to as competitive allele-specific TaqMan PCR (“cast-PCR”). | 03-17-2016 |
20160076099 | ANALYSIS OF NUCLEIC ACIDS - Provided herein are improved methods, compositions, and kits for analysis of nucleic acids. The improved methods, compositions, and kits can enable copy number estimation of a nucleic acid in a sample. Also provided herein are methods, compositions, and kits for determining the linkage of two or more copies of a target nucleic acid in a sample (e.g. whether the two or more copies are on the same chromosome or different chromosomes) or for phasing alleles. | 03-17-2016 |
20160076107 | METHOD FOR DETECTING T-CELL LYMPHOMA - A method for detecting T-cell lymphoma characterized in that gene mutations of at least one base selected from a group comprising base numbers 50, 331, 334, and 482 or gene mutations of base numbers 49 to 51 in the base sequence of an RHOA gene collected from a subject are analyzed, and the analysis results and T-cell lymphoma are associated with each other. | 03-17-2016 |
20160076108 | SYSTEMS AND METHODS FOR EXPRESSION-BASED CLASSIFICATION OF THYROID TISSUE - A system for classifying thyroid nodule tissue as malignant or benign is provided that is based on the identification of sets of gene transcripts, which are characterized in that changes in expression of each gene transcript within a set of gene transcripts can be correlated to with either malignant or benign thyroid nodule disease. The thyroid classification system provides for sets of “thyroid classifying” target sequences and further provides for combinations of polynucleotide probes and primers derived there from. These combinations of polynucleotide probes can be provided in solution or as an array. The combination of probes and the arrays can be used for diagnosis. The invention further provides further methods of classifying thyroid nodule tissue. | 03-17-2016 |
20160076109 | ALLOGENEIC AUTOPHAGOSOME-ENRICHED COMPOSITION FOR THE TREATMENT OF DISEASE - A method is presented for screening cells that produce allogeneic autophagosome enriched compositions able to induce expression of a selective marker on a subpopulation of peripheral blood mononuclear cells, the method comprising contacting a cell with a proteasome inhibitor, contacting the cell with a lysosome inhibitor, harvesting the resulting autophagosomes, determining a molecular signature of the harvested autophagosomes, and selecting cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes. By screening for cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes, enriched populations of autophagosomes may be generated which may illicit a specific immune response against numerous cancer types. In this way, an allogeneic, off-the-shelf cancer vaccine may be produced and made available to be administered in order to stimulate a targeted immune response in patients bearing different tumor types. | 03-17-2016 |
20160076110 | METHODS FOR PATHOGEN DETECTION AND DISEASE MANAGEMENT ON MEATS, PLANTS, OR PLANT PARTS - Provided are methods for detecting pathogens affecting meats, plants, or plant parts. Also provided are methods for predicting disease and/or disease management for meats, plants, or plant parts. In some embodiments, methods provided comprise nucleic acid based amplification. Examples of such nucleic acid based amplification methods include quantitative polymerase chain reaction (qPCR) and recombinase polymerase amplification (RPA). | 03-17-2016 |
20160077015 | SYSTEMS AND METHODS FOR MULTI-ANALYSIS - Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample. | 03-17-2016 |
20160077046 | SYSTEMS AND METHODS FOR MULTIPLEXED ELECTROCHEMICAL DETECTION - Contemplated methods and devices comprise performing electrochemical sample analysis in a multiplexed electrochemical detector having reduced electrical cross-talk. The electrochemical detector includes electrodes that share a common lead from a plurality of leads. The sample, which may be a liquid sample, is introduced into one or more sample wells and a signal is applied to at least one of the electrodes. A response signal is measured while simultaneously applying a substantially fixed potential to each of a remainder of the plurality of leads. | 03-17-2016 |
20160077082 | COMPOSITIONS AND METHODS FOR INHIBITING HMGB1 ACTIVATION OF MELANOCYTES - A method of identifying a test agent as a skin tone agent. The method includes determining the level of high-mobility group protein B1 (HMGB1), messenger RNA associated with the expression and/or regulation of HMGB1 (HMGB1 mRNA), and/or micro-RNA associated with the expression and/or regulation of HMGB1 (HMGB1 miRNA) present in the test sample, and identifying the test agent as a skin tone agent when there is no increase in HMGB1 level, a downregulation in transcription of HMGB1 mRNA, and/or an upregulation of HMGB1 miRNA. The method also includes identifying a test agent as a skin tone agent when the test agent inhibits or prevents an increase in melanocyte dendricity and/or body size caused by HMGB1. | 03-17-2016 |
20160077084 | AMPHIBIAN OOCYTE OR EMBRYO BIOASSAY - The present invention provides in vivo methods for screening compounds of interest. The methods rely on readily-observable phenotypic changes in amphibian oocytes or early embryos. | 03-17-2016 |
20160077085 | MULTIPLE- ANALYTE ASSAY DEVICE AND SYSTEM - Provided herein is technology relating to testing biological samples and particularly, but not exclusively, to devices, systems, and kits for performing multiple, simultaneous real-time assays on a sample in a single-use disposable format. For example, the technology relates to an apparatus that finds use, for example, for point-of-care diagnostics, including use at accident sites, emergency rooms, in surgery, in intensive care units, as well as for non-medical applications. | 03-17-2016 |
20160077094 | Media Elaborated with Newly Synthesized Antibodies (MENSA) and Uses Thereof - Disclosed are methods and kits for early detection of antigen exposure through the presence or absence of antigen-specific antibodies. | 03-17-2016 |
20160077101 | DETECTION OF INTRAAMNIOTIC AND/OR INFECTION - The present invention concerns the identification of biomarkers and groups or combinations of biomarkers that can be used for non-invasive diagnosis of intra-amniotic infection, and diagnostic assays using such biomarkers. | 03-17-2016 |
20160077102 | Diagnostic Biomarker to Predict Women at Risk for Preterm Delivery - The invention relates to biomarkers associated with preterm delivery. More specifically, the invention provides methods of measuring biomarkers including but not limited to cytokines, cytokine receptors, cytokine receptor antagonists, chemokines, chemokine receptors, and/or chemokine receptor antagonists found in women that are at risk for preterm delivery. The diagnostic methods may be performed on whole blood. | 03-17-2016 |
20160077104 | MEANS AND METHODS FOR PRODUCING ANTI-PROTEOME ANTIBODIES AND IDENTIFYING CONSERVED UNIQUE OR DIFFERENTIALLY EXPRESSING MOLECULES OF ORGANISMS - Disclosed are methods for identifying one or more amino acid molecules and nucleic acid molecules encoding such amino acid molecules of at least two proteomes that are conserved, unique or express at higher or lower levels in at least one of the proteomes. Expression libraries are used that produce the proteome, and in one embodiment, may produce the proteome from at least one cDNA expression library in one to five reactions. Anti-proteome antibodies are prepared that selectively bind to one of the proteomes and binding with at least one second proteome compared. | 03-17-2016 |
20160077105 | POLYSPECIFICITY REAGENTS, METHODS FOR THEIR PREPARATION AND USE - The present invention relates, inter alia, to polyspecificity reagents, methods of making the same, and methods of using the same in, inter alia, the selection, screening, enrichment, and identification of non-polyspecific, and thus developable, polypeptides. | 03-17-2016 |
20160077108 | Collagen Type VI Alpha-1 Assay - Provided is an antibody which binds to an epitope of collagen type VI alpha 1 comprised in the N-terminal globular domain internal amino acid sequence -ADWGQSRDAEEAISQ- (SEQ ID NO: 1). Also provided is a method of immunoassay for detecting in a biological sample an epitope comprised in the N-terminal globular domain internal amino acid sequence -ADWGQSRDAEEAISQ- (SEQ ID NO: 1) of collagen type VI alpha 1, by contacting the sample with the antibody, and determining the amount of binding of the antibody. | 03-17-2016 |
20160077114 | METHODS FOR PREDICTING AMOUNTS OF OSTEOACTIVITY MARKERS - Various embodiments describe methods of predicting an amount of a target osteoactivity marker. The methods include measuring an initial concentration of the target osteoactivity marker at a time t | 03-17-2016 |
20160078168 | FUSION TRANSCRIPT DETECTION METHODS AND FUSION TRANSCRIPTS IDENTIFIED THEREBY - This present disclosure generally relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure provides a computerized method for detecting fusion transcripts from RNA-seq data and provides the fusion transcripts identified thereby in human cancers. Compositions and methods for identifying the fusion transcripts are also provided. | 03-17-2016 |
20160083434 | DIVALENT NUCLEOBASE COMPOUNDS AND USES THEREFOR - Described herein are novel divalent nucleobases that each bind two nucleic acid strands, matched or mismatched when incorporated into a nucleic acid or nucleic acid analog backbone (a genetic recognition reagent, or genetic recognition reagent). In one embodiment, the genetic recognition reagent is a peptide nucleic acid (PNA) or gamma PNA (?PNA) oligomer. Uses of the divalent nucleobases and monomers and genetic recognition reagents containing the divalent nucleobases also are provided. | 03-24-2016 |
20160083719 | Method for Producing Compound Containing Heterocycle - An object of the present invention is to provide a method of stably introducing a heterocycle into a substrate peptide by using an azoline backbone introducing enzyme. | 03-24-2016 |
20160083779 | Novel Gene Normalization Methods - Measurement of gene expression relative to an endogenous control gene is prone to excessive variability between samples and even replicates. The disclosure provides methods for normalizing expression levels of a gene by scaling gene expression levels to that of the most highly expressed gene in the set of genes whose expression levels are measured, rather than a house-keeping gene. | 03-24-2016 |
20160083787 | DIGITAL PCR FOR NON-INVASIVE PRENATAL TESTING - Techniques are provided for determining settings of a dPCR experiment for the detection of a chromosomal aneuploidy in a plasma sample from a female pregnant with a fetus. Data about the sample, the dPCR process, and a desired accuracy can be used to determine the settings. Such settings can include a minimal input number of control chromosome molecules for the dPCR experiment, a minimal number of control chromosome molecules for a pre-amplification procedure, and a number of PCR cycles in the pre-amplification procedure. These settings can be used to satisfy the accuracy specified by the accuracy data. Thus, the dPCR experiment can be designed to achieve the desired accuracy while reducing cost, e.g., by not using more of a sample than needed and not performing more pre-amplification than needed or performing more manipulations than needed. | 03-24-2016 |
20160083794 | Predicting AMD With SNPS Within or Near C2, Factor B, PLEKHA1, HTRA1, PRELP, or LOC387715 - The invention relates to gene polymorphisms and genetic profiles associated with an elevated or a reduced risk of a complement cascade dysregulation disease such as AMD. The invention provides methods and reagents for determination of risk, diagnosis and treatment of such diseases. In an embodiment, the present invention provides methods and reagents for determining sequence variants in the genome of an individual which facilitate assessment of risk for developing such diseases. | 03-24-2016 |
20160083800 | MONOCLONAL AND OLIGOCLONAL ANTI-EGFR ANTIBODIES FOR USE IN THE TREATMENT OF TUMORS EXPRESSING PREDOMINANTLY HIGH AFFINITY EGFR LIGANDS OR TUMORS EXPRESSING PREDOMINANTLY LOW AFFINITY EGFR LIGANDS - Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-EGFR monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations. | 03-24-2016 |
20160083806 | SEQUENCE SPECIFIC PRIMER POOL FOR MULTIPLEX PCR AND METHOD OF DETECTING MICROBIAL INFECTIONS IN THALASSEMIA PATIENTS - Reagents and methods for the fast, accurate and early detection of infections in thalassemia major patients. Reagents include a primer pool containing a mixture of primer pairs for the specific recognition and simultaneous amplification of targeted gene sequences of pathogens from a biological sample collected from a patient in a multiplex PCR reaction. Pathogens may include at least one Fungi species, | 03-24-2016 |
20160084823 | METHODS AND KITS FOR TESTING THE GENOTOXICITY OF AN AGENT - The present invention relates to methods and kits for testing the genotoxicity of an agent. In particular, the present invention provides a global assay for the measurement of genotoxic stress based on p53 target gene induction. In particular, the present invention relates to a method for testing the genotoxicity of an agent comprising the steps consisting of i) providing a population of test cells, ii) exposing the populations of test cells with the agent to be tested, iii) determining the expression level of at least one p53 target gene selected from the group consisting of ATF3, BBC3, CABYR, C10ORF10; EMX1; FHL2, GLS2; GRHL3; HES2; IGF-BP4; KIAA0284; PODXL1; RRAD; TP53I3, and XPC in the population of test cells exposed to the agent to be tested iv) comparing the expression level determined at step iii) with the expression level determined when the population of test cells was not exposed to the agent to be tested, and v) concluding that the agent is genotoxic when the expression level determined at step iii) is higher than the level determined when the population of test cells was not exposed to the agent to be tested. | 03-24-2016 |
20160084832 | Method and Device for Combined Detection of Viral and Bacterial Infections - A lateral flow assay is capable of detecting and differentiating viral and bacterial infections. A combined point of care diagnostic device tests markers for viral infection and markers for bacterial infection, to effectively assist in the rapid differentiation of viral and bacterial infections. In some preferred embodiments, bimodal methods and devices determine if an infection is bacterial and/or viral. A dual use two strip sample analysis device includes a first lateral flow chromatographic test strip to detect MxA and a low level of C-reactive protein and a second lateral flow chromatographic test strip to detect high levels of C-reactive protein. In some preferred embodiments, the sample is a fingerstick blood sample. | 03-24-2016 |
20160084849 | BIOMARKER COMPOSITE TEST FOR HEPATIC VEIN PRESSURE GRADIENT AND CIRRHOSIS TREATMENT - Diagnostic biomarker panel, method, kit, and device for diagnosing the severity and/or prognosis of cirrhosis are provided. More specifically, the invention provides a novel biomarker panel correlating to HVPG and esophageal varices. The invention further provides a biomarker panel and non-invasive test methods that predict non-clinically significant portal hypertension HVPG and non-clinically significant esophageal varices when the expression of the biomarker panel correlates with HVPG of less than 12 mmHg. The invention further provides that the patients with the expression of the biomarker panel correlating to non-clinically significant HVPG and esophageal varices can be excluded from undergoing esophagogastroduodenoscopy (EGD) screening and those correlating to HVPG equal to or greater than 12 mmHg are indicated for EGD. | 03-24-2016 |
20160090589 | COMPOSITIONS FOR AND METHODS OF IDENTIFYING ANTIGENS - Replicable libraries having discrete members in defined locations for screening for antigens to a pathogenic organism are provided. Also provided are methods for using such libraries as well as a specific antigen, CT788, which induces T-cell activation during a | 03-31-2016 |
20160090626 | METHOD FOR DIAGNOSING MYOTONIC DYSTROPHY TYPE 1 - The present invention relates to a method for diagnosing myotonic dystrophy type 1 or a method for identifying myotonic dystrophy type 1 patients by using a computer processor. According to the method of the present invention, it is possible to take suitable measures related to symptoms, which will occur later, by classifying a genetic carrier and first to third risk groups according to the repetition number of the CTF sequence of 3′-noncoding region of the DMPK gene. Particularly, the method of the present invention numerically provides a genetic carrier or the approximate prevalence of a disease with respect to an unborn baby, thereby allowing the risk of disorders to be accurately understood. | 03-31-2016 |
20160090627 | COMPOSITIONS FOR DETECTING HUMAN INTERFERON-ALPHA SUBTYPES AND METHODS OF USE - The invention provides highly sensitive, specific and efficient quantitative real-time PCR compositions, methods and assay kits to detect at least one IFN subtype and/or IFN subtype allotypic variants. Primer/probe sets complementary to the coding sequence of an IFN subtype of interest avoid spurious detection of degraded mRNA and enhances the correlation between the IFN subtype that is measured by the assays of the invention and the protein that is actually expressed. The invention also provides methods for designing primers and methods of using the compositions and assay kits. The compositions, kits, and methods of the invention may be used, for example, to monitor vaccine efficacy, autoimmune disease, chronic infections, or tumor therapy. | 03-31-2016 |
20160090636 | MicroRNA-129 AS A BIOMARKER FOR COLORECTAL CANCER - The current disclosure describes methods for identifying subjects that would benefit from treatment with a chemotherapeutic agent. The disclosure is based in part on the observation that miR-129 expression levels are reduced in colorectal cancer. Accordingly, the current disclosure provides therapeutic compositions and methods for altering the expression of a miR-129 effector. Described herein are methods for characterizing the stage of colorectal cancer in a subject, based on the levels of miR-129 expression. The disclosure also identifies miR-129 as a predictive biomarker for cancer diagnosis and the subsequent treatment with directed therapeutic agents including but not limited to miR-129 nucleic acid molecules and/or a chemotherapeutic agent. The current disclosure also identifies novel therapeutic agents that modulate the level of BCL2, TS and/or E2F3 expression, as well as sensitize a subject to treatment with a chemotherapeutic agent. | 03-31-2016 |
20160091488 | CELLS AS A MODEL TO IDENTIFY POTENTIAL TASTE MODULATORS - Co-expression of T1R2 and T1R3 results in a taste receptor that responds to sweet taste stimuli, including naturally occurring and artificial sweeteners. Cells such as U2-OS, which express a functional sweet receptor, can be used in cell-based assays to detect cellular responses to tastants. | 03-31-2016 |
20160091490 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS OF RHEUMATOID ARTHRITIS - The present disclosure relates to the field of molecular biology and more specifically to methods for detecting anti-carbamylated protein (anti-CarP) antibodies in the serum of rheumatoid arthritis (RA) patients. | 03-31-2016 |
20160091493 | METHOD FOR PREDICTING THE RESPONSE TO HER2-DIRECTED THERAPY - This invention provides methods for determining or predicting response to HER2-directed therapy in an individual. | 03-31-2016 |
20160091497 | Highly Sensitive Biomarker Panels - Cardiovascular disease, e.g., congestive heart failure, is often first diagnosed after the onset of clinical symptoms, eliminating potential for early intervention. The invention provides a multi-marker immunoassay, including cardiac pathology and vascular inflammation biomarkers, yielding a more sensitive assay for early detection of CHF in plasma. A panel consisting of cardiac pathology (cTnI, BNP) and vascular inflammation (IL-6, TNFα, IL-17a) biomarkers provided a sensitivity of 94% for association with CHF. | 03-31-2016 |
20160091498 | METHODS FOR THE TREATMENT OF DISORDERS RELATED TO PHOSPHORYLATION OF HISTONES - Methods for disease diagnosis, prognosis and therapy selection. Compositions for use in these methods and selected therapies for treatment are also disclosed. | 03-31-2016 |
20160091499 | CARDIOVASCULAR RISK EVENT PREDICTION AND USES THEREOF - Biomarkers, methods, devices, reagents, systems, and kits used to assess an individual for the prediction of risk of developing a Cardiovascular (CV) Event over a 1 to 5 year period are provided. | 03-31-2016 |
20160091500 | CHONDROADHERIN FRAGMENTS AS INDICATORS OF INTERVERTEBRAL DISC DEGENERATION - The present disclosure concern fragments of the chondroadherin (CHAD) polypeptide which are generated during the proteolytic cleavage of the third leucine repeat motif of the CHAD polypeptide. Such fragments are generated and thus associated with the onset and progression of intervertebral disc degeneration and can be used to assess the risk of a subject to develop intervertebral disc degeneration or to determine if the subject is afflicted by intervertebral disc degeneration. The fragments can also be used to screen for potential therapeutic agents for preventing, treating and/or alleviating the symptoms associated with intervertebral disc degeneration. | 03-31-2016 |
20160097089 | Methods of Using Inductively Coupled Plasma Mass Spectroscopy Systems for Analyzing a Cellular Sample - The invention relates to the use of inductively coupled plasma mass spectroscopy for cellular sample analysis. In some embodiments a method of performing mass spectroscopy analysis using an inductively coupled plasma mass spectroscopy system is provided. The method may include introducing a cellular sample comprising one or more cells or cellular particles into an inductively coupled plasma of the inductively coupled plasma mass spectroscopy system. The method may further include using the inductively coupled plasma mass spectroscopy system to assess the cellular sample by detecting and measuring one or more element tags in the cellular sample based on the element or isotopic compositions of the one or more element tags. | 04-07-2016 |
20160097090 | Methods for Multiplexing Recombinase Polymerase Amplification - This disclosure provides for methods and reagents for rapid multiplex RPA reactions and improved methods for detection of multiplex RPA reaction products. In addition, the disclosure provides new methods for eliminating carryover contamination between RPA processes. | 04-07-2016 |
20160097104 | RECURRENT GENE FUSIONS IN PROSTATE CANCER - Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided. | 04-07-2016 |
20160097105 | METHOD FOR USING GENE EXPRESSION TO DETERMINE PROGNOSIS OF PROSTATE CANCER - Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein. | 04-07-2016 |
20160097767 | MULTIPLEXED VOLUMETRIC BAR CHART CHIP FOR POINT OF CARE BIOMARKER AND ANALYTE QUANTITATION - Apparatus for determining the quantity of a target protein and other types of biomarkers or analytes present in a sample, the apparatus comprising:
| 04-07-2016 |
20160097769 | MATERIALS AND METHODS FOR ASSAYING LIVING CELLS - The present invention provides a device for assaying living cells comprising a substrate, wherein the substrate comprises one or more tethering molecules which adhere to the substrate and are capable of interacting with cell membranes of the cells, wherein the cells maintain a free-floating, non-adherent character when bound to the one or more tethering molecules. | 04-07-2016 |
20160097770 | METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT - This invention is directed to methods and compositions for diagnosis, prognosis and for determining methods of treatment. The physiological status of cells present in a sample (e.g. clinical sample) can be used in diagnosis or prognosis of a condition (e.g. Chronic Lymphocytic Leukemia), in patient selection for therapy, to monitor treatment and to modify or optimize therapeutic regimens. The physiological status of a cell can be determined by comparing the intracellular status of one or more activation elements (e.g. the phosphorylation status of a signaling molecule) in a cell (e.g. a cancer cell) to that of another cell (e.g. a normal cell). The physiological status of a cell can be further classified by adding one or more modulators (e.g. an inhibitor or activator) to the cell in question. In some embodiments, the invention is directed to methods of determining a phenotypic profile of a population of cells. | 04-07-2016 |
20160097771 | USE OF TENASCIN-C AS AN EXTRACELLULAR MARKER OF TUMOR-DERIVED MICROPARTICLES - The present disclosure provides methods for isolating tumor-derived microparticles from a subject for analysis, specifically by isolating Tenascin-C positive microparticles from a sample from the subject to obtain tumor-derived microparticles. Methods for determining the expression status of biomarkers in the tumor-derived microparticles and methods for determining additional characteristics of the tumor-derived microparticles are also provided. | 04-07-2016 |
20160097772 | METHOD FOR DETECTING NUCLEOSOME ADDUCTS - The invention relates to a method for detecting and measuring the presence of nucleosome-protein adducts and the use of such measurements for the detection and diagnosis of disease. The invention also relates to a method of identifying nucleosome adduct biomarkers for the detection and diagnosis of disease and to biomarkers identified by said method. | 04-07-2016 |
20160097773 | INTERCELLULAR LABELING OF LIGAND-RECEPTOR INTERACTIONS - An sortase-mediated intercellular labeling method allowing for tracking ligand-receptor interaction both in vitro and in vivo; and uses thereof for tracking molecule interactions both in vitro and in vivo, identifying modulators of ligand-receptor interaction, identifying potential binding partners of a protein of interest, identifying B cells expressing high affinity B cell receptors to antigens, and identifying the antigen to which a T cell of interest binds. | 04-07-2016 |
20160097780 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE - The present invention relates to methods for the diagnosis of subjects that have or are at risk of having Alzheimer's disease (AD). In particular the present invention identifies individuals who have or are at risk of having AD through measurement of the levels of Afamin in combination with at least one other biomarker such as Alpha-1-antichymotrypsin, Alpha-2-macroglobulin, ApoB100, Complement C5, Serine threonine protein kinase TBK1 or Complement C3 in a fluid sample taken from a subject. Furthermore, genotype (Apolipoprotein E or glutathione S-transferase Omega) may also be taken into consideration and used within classification algorithms to determine the probability of a subject having or being at risk of having AD. | 04-07-2016 |
20160101418 | METHOD AND SYSTEM FOR ULTRA-HIGH DYNAMIC RANGE NUCLEIC ACID QUANTIFICATION - A method of quantifying nucleic acids in a sample includes generating a plurality of droplets in oil within a microfluidic device, wherein at least some of the droplets comprise a nucleic acid, amplification reagents, and a fluorescent probe or dyes contained therein. The droplets are delivered to a collection chamber to form an array of droplets. The droplets are subject to thermal cycling within the collection chamber a plurality of times to perform nucleic acid amplification within the droplets. The array of droplets is imaged during the plurality of thermal cycles as well as at a thermal cycle endpoint. An initial concentration of nucleic acid in the sample is calculated based on at least one of: a ratio of aqueous phase droplets exhibiting fluorescence within the array at the thermal cycle endpoint or a cycle threshold (Ct) of one or more aqueous phase droplets within the array. | 04-14-2016 |
20160101421 | APPARATUS AND METHODS FOR INTEGRATED SAMPLE PREPARATION, REACTION AND DETECTION - An apparatus includes a housing, a reaction vial and a transfer mechanism. The housing defines a first flow path and a second flow path. The housing has transfer port defining an opening in fluid communication with the second flow path and a volume outside of the housing. The transfer port includes a flow control member to limit flow through the opening. The reaction vial is coupled to the housing and defines a reaction volume, which is in fluid communication with the transfer port via the second flow path. The transfer mechanism is configured to transfer a sample from an isolation chamber of an isolation module to the reaction chamber via at least the first flow path when the transfer mechanism is actuated. The transfer mechanism configured to produce a vacuum in the reaction vial to produce a flow of a sample from the isolation chamber to the reaction volume. | 04-14-2016 |
20160102152 | IMMUNOGLOBULIN VARIABLE REGION CASSETTE EXCHANGE - The invention provides methods for generating human antibodies with the specificity of a reference antibody by replacement of portions of the V | 04-14-2016 |
20160102215 | INCORPORATING SOLUBLE SECURITY MARKERS INTO CYANOACRYLATE SOLUTIONS - Methods for authenticating an article with a cyanoacrylate solution comprising a water soluble security marker compound are described. The methods for producing a nucleophilic security marker/cyanoacrylate solution as well as methods for labeling an item and detecting the nucleophilic security marker/cyanoacrylate from an item being authenticated are also described. A method for using a nucleophilic cyanoacrylate security marker for antitheft purposes is also described. | 04-14-2016 |
20160102304 | METHODS AND COMPOSITIONS FOR ISOLATING SMALL RNA MOLECULES - The present invention concerns the use of methods and compositions for the isolation of small RNA molecules (100 nucleotides or fewer), such as microRNA and siRNA molecules. Such molecules are routinely lost in commonly used isolation procedures and therefore the present invention allows for a much higher level of enrichment or isolation of these small RNA molecules. | 04-14-2016 |
20160102342 | System and Method for Rapid Detection and Identification of Nucleic Acid Labeled Tags - A system for identifying which of a plurality of nucleic acid tag varieties are present on an item of interest. The system includes nucleic acid tag varieties each including a nucleotide-support platform attached to a nucleic acid molecule, the nucleic acid molecule including a first and a second universal primer region common to all nucleic acid tag varieties, and a first and a second unique primer region unique to each nucleic acid tag variety. The system also includes a first primer set with a first primer complementary to the first universal primer region and a second primer complementary to the second universal primer region, as well as a second primer set with a first primer complementary to the first unique primer region of one of the nucleic acid tag varieties and a second primer complementary to the second unique primer region of the same nucleic acid tag variety. | 04-14-2016 |
20160102344 | Site-Specific Immobilization of DNA Origami Structures on Solid Substrates - The present invention relates to methods for the site-specific immobilization of DNA origami structures on solid substrates, as well as to respective assemblies comprising DNA origami structures immobilized on a solid substrate and uses thereof. | 04-14-2016 |
20160102353 | Polymorphisms Associated With Age-Related Macular Degeneration and Methods for Evaluating Patient Risk - The present invention provides for certain polynucleotide sequences that have been correlated to AMD. These polynucleotides are useful as diagnostics, and are preferably used to fabricate an array, useful for screening patient samples. The array is used as part of a laboratory information management system, to store and process additional patient information in addition to the patient's genomic profile. As described herein, the system provides an assessment of the patient's risk for developing AMD, risk for disease progression, and the likelihood of disease prevention based on patient controllable factors. | 04-14-2016 |
20160102368 | TEST KITS AND METHODS FOR THEIR USE - This invention relates to test kits and methods for their use in determining the expression levels of genetic markers. Additionally, this invention relates to kits and uses thereof for the determination of ratios of genetic markers. Ratios of genetic markers can be used to assist in analysis of bladder cancer from samples of urine. | 04-14-2016 |
20160102369 | DETECTION OF ECHINOCANDIN-RESISTANT CANDIDA GLABRATA - Probes and primers are disclosed for detecting a | 04-14-2016 |
20160103066 | Measuring System, Such as an Interaction Measuring System and a Measuring Method - The present invention relates to a method for the measurement of at least one sample by the interaction with the surface in the field of at least one sensor surface, such as surface plasmon resonance measurement, comprising the steps of: i) sampling the sample and a buffer; ii) transporting the sample and the buffer to at least one flow cell which is in liquid contact with the sensor surface of at least one sensor for measuring a parameter of a sample by interaction of the sample at the sensor surface in the field of the sensor surface; iii) transporting the sample into the flow cell into contact with the sensor surface; iv) handling a separation fluidim by inserting and/or removing the separation fluidim between the sample and the buffer upstream and/or downstream of the sensor surface; v) measuring the interaction of the sample at the sensor surface; and vi) dispensing the sample from the flow cell, and to a measuring system for such method. | 04-14-2016 |
20160103120 | CONSTRUCTION OF MITOCHONDRIAL UQCRB MUTANT EXPRESSING CELLS AND UTILIZATION OF THE CELLS FOR UQCRB ASSAY SYSTEM THEREOF - The present invention relates to a mitochondrial UQCRB mutant cell line expressing the UQCRB mutant protein. The present invention is directed to a novel research method for UQCRB activity evaluation using a novel mitochondrial UQCRB mutant cell line, and provides a method for anticancer activity evaluation, a method for angiogenesis inhibitory activity evaluation, and a method for screening a UQCRB activity inhibitor. In particular, the cell line of the present invention is a novel cell line having cell proliferative and angiogenesis inducing activities, and provides a method for screening an angiogenesis inhibitor or an anticancer material through the UQCRB activity inhibitory mechanism, and thus can be applied in the development of therapeutic agents against angiogenesis or mitochondria-mediated diseases and various cancers. | 04-14-2016 |
20160106813 | CGRP RECEPTOR AGONIST FOR HIV TREATMENT OR PREVENTION - A first object of the invention is CGRP or an agonist of the CGRP receptor for use in the prevention of an HIV infection in a human subject. A second object of the invention is a method for selecting an active compound for the prevention of an HIV infection in a human subject, comprising the steps of: a) contacting Langerhans cells with a candidate compound; b) in vitro infecting of Langerhans cells from step a) by at least one HIV variant, c) measuring of at least one of the following parameters: HIV content, adhesive potential of Langerhans cells, in particular to TCs, secretion of anti-HIV chemokines by Langerhans cells. A third object of the invention is therefore a composition comprising CGRP or agonist of the CGRP receptor for use in the prevention of an HIV infection in a human subject. A fourth object of the invention is a method for the in vitro diagnosis of an HIV infection in a human subject, characterized in that it comprises determining the level of CGRP from a biological sample from said subject. A fifth object of the invention is a method for assaying the efficiency of HAART in the treatment of HIV infection in a subject, characterized in that it comprises determining the level of CGRP from a biological sample from said subject. | 04-21-2016 |
20160108458 | MULTIPLEXED DETECTION AND QUANTIFICATION OF NUCLEIC ACIDS IN SINGLE-CELLS - Proximity Ligation Assay for RNA (PLAYR) provides cost-efficient detection of specific nucleic acids in single cells, and may be combined with flow cytometry to simultaneously analyze large numbers of cells for a plurality of nucleic acids, e.g. at least one, to up to 5, up to 10, up to 15, up to 20 or more transcripts can be simultaneously analyzed, at a rate of up to about 50, 100, 250, 500 or more cells/second. An advantage of PLAYR includes the ability to simultaneously analyze multiple nucleic acids and proteins in single cells, as the method is compatible with conventional antibody staining for proteins, intracellular phosphorylation sites, and other cellular antigens. This enables the simultaneous detection of multiple nucleic acid molecules in combination with additional cellular parameters. | 04-21-2016 |
20160108460 | METHODS FOR DETECTION AND QUANTIFICATION OF NUCLEIC ACID OR PROTEIN TARGETS IN A SAMPLE - The invention provides an assay method for detection and/or quantification of a plurality of nucleic acid or protein targets in a sample. In the method probes are used to associate a detectable tag sequence with each of the selected targets present in the sample. Probes or primers sufficient to identify at least 25, and preferably at least 500, different targets are used. The method involves segregating aliquots of the sample from each other and detecting the tag sequences in each aliquot. | 04-21-2016 |
20160108463 | Biological Specimen Collection and Transport System - Disclosed are compositions for isolating populations of nucleic acids from biological, forensic, and environmental samples. Also disclosed are methods for using these compositions as one-step formulations for killing pathogens, inactivating nucleases, and releasing polynucleotides from other cellular components within the sample, and stabilizing the nucleic acids prior to further processing or assay. The disclosed compositions safely facilitate rapid sample collection, and provide extended storage and transport of the samples at ambient or elevated temperature without contamination of the sample or degradation of the nucleic acids contained therein. This process particularly facilitates the collection of specimens from remote locations, and under conditions previously considered hostile for preserving the integrity of nucleic acids released from lysed biological samples without the need of refrigeration or freezing prior to molecular analysis. | 04-21-2016 |
20160108464 | MULTIPLEXED DIGITAL ASSAYS WITH COMBINATORIAL USE OF SIGNALS - System, including methods, apparatus, and compositions, for performing a multiplexed digital assay on a greater number of targets through combinatorial use of signals. | 04-21-2016 |
20160108465 | CATALYTIC NUCLEIC ACID AND GOLD NANOPARTICLES FOR DETECTION OF BIOMOLECULES - The present invention relates to catalytic nucleic acid molecule signal amplification combined with surface plasmon properties of gold nanoparticles to achieve simple and sensitive colorimetric detection of biological targets. The assays of the present invention have about 50 pM sensitivity without the need for purification steps, can detect multiple targets in parallel, and is easily adaptable to new targets. The methods of the present invention are capable of rapid detection of genetic targets for gonorrhea, syphilis, malaria, and hepatitis B infections. | 04-21-2016 |
20160108466 | PRIMERS AND METHODS FOR THE DETECTION AND DISCRIMINATION OF NUCLEIC ACIDS - The present invention provides novel primers and methods for the detection of specific nucleic acid sequences. The primers and methods of the invention are useful in a wide variety of molecular biology applications and are particularly useful in allele specific PCR. | 04-21-2016 |
20160108467 | HIGH THROUGHPUT TESTING FOR PRESENCE OF MICROORGANISMS IN A BIOLOGICAL SAMPLE - Provided are methods and apparatus for high throughput testing of biological samples that may or may not comprise microorganisms. The methods include the use of a diagnostic multiplexing panel (DMP) specifically designed for the simultaneous identification of a plurality of potential microorganisms that may be present in the biological sample via a primer extension reaction directed a highly conserved nucleic acid sequences in the microorganisms under test. The biological sample is typically immobilised on a solid substrate at a first location before being transferred to a second location for analysis using the DMP. The methods and apparatus of the invention are particularly suited to diagnosis of the presence of infectious pathogens in the biological sample, for example for diagnosis of sexually transmitted infection. | 04-21-2016 |
20160108474 | LIGATION-BASED DETECTION OF GENETIC VARIANTS - The present invention provides assays systems and methods for detection of genetic variants in a sample, including copy number variation and single nucleotide polymorphisms. The invention preferably employs the technique of tandem ligation, e.g., the ligation of two or more fixed sequence oligonucleotides and one or more bridging oligonucleotides complementary to a region between the fixed sequence oligonucleotides—combined with detection of levels of particular genomic regions using array hybridization. | 04-21-2016 |
20160108477 | Traceability of Cellular Cycle Anomalies Targeting Oncology and Neurodegeneration - The present invention relates to the field of medicine and biology. It concerns a novel test for screening and for therapeutic follow-up in oncology. More particularly, it relates to diagnostic and/or therapeutic tests in oncology and on neurodegenerative diseases. It is a diagnostic test and a prognostic test for various cancers (breast cancer, bladder cancer, ovarian cancer, lung cancer, skin cancer, prostate cancer, colon cancer, liver cancer, glioblastoma, sarcoma, leukemia, etc.) and therapeutics solutions for specific neurodegenerative diseases. More particularly, the invention concerns the use of the LIV21 protein, LIV21 gene and of derivatives thereof as diagnostic and prognostic markers for cancers. The invention therefore concerns the detection of the LIV21 protein with a kit comprising LIV21-specific antibodies. | 04-21-2016 |
20160108478 | METHODS OF DETECTING LUNG CANCER - Methods of detecting lung cancer, such as non-small cell lung cancer, including squamous cell carcinoma and adenocarcinoma, are provided. Methods of detecting changes in the levels of one or more small RNAs associated with lung cancer are also provided. Compositions and kits are also provided. | 04-21-2016 |
20160108479 | COMPOSITIONS AND METHODS FOR MULTIPLEX ANALYSIS OF NRAS AND BRAF NUCLEIC ACIDS - Described herein are methods and assays relating to the detection of NRAS and/or BRAF alterations (e.g. variations in copy number and expression level, and/or the presence of mutations, including point mutations). Existing methods are limited in their clinical usefulness by, e.g., limited sensitivity, inter-lab discordance, or inability to provide the necessary multiplex ability. The methods and assays provided herein permit multimodal, multiplex assaying for faster, more cost-effective testing and screening of patients, permitting improved healthcare. | 04-21-2016 |
20160109434 | SOLID SUPPORTED ARTIFICIAL CELL MEMBRANE SYSTEM - The present invention relates to an artificial cell membrane system comprising at least one membrane protein carrier associated with at least one membrane protein, wherein the at least one membrane protein carrier comprises or consists of a polymeric vesicle or a polymeric planar structure, and a solid support freely suspended in a fluid medium, wherein the at least one membrane protein carrier is attached to a surface of the solid support. A method of forming the artificial cell membrane system, and use of the artificial cell membrane system as a reagent are also provided. | 04-21-2016 |
20160109443 | DETECTION OF GLUTEN-SPECIFIC T-CELLS - The present invention relates to compositions and methods for visualizing disease-specific T-cells. In particular, the present invention relates to compositions and methods for use in the diagnosis, monitoring of progression, monitoring of response to therapy, and selection of patients for therapy of autoimmune diseases characterized by selective expansion of disease-specific effector memory T-cells. | 04-21-2016 |
20160109446 | PEPTIDES AND METHODS FOR THE DETECTION OF LYME DISEASE ANTIBODIES - The invention provides compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to | 04-21-2016 |
20160109447 | Reagents For HCV Antigen-Antibody Combination Assays - The present invention is directed to combination immunoassays, reagents and kits for simultaneous detection of HCV antigens and anti-HCV antibodies in a sample. The combination immunoassays of the present invention employ a non-ionic detergent that effectively exposes or releases the HCV core antigen from virions in a sample without interfering with the performance of other reagents such as the capture of anti-HCV antibodies by recombinant HCV antigens. | 04-21-2016 |
20160109453 | Lung Cancer Diagnostic Method and Means - The present invention discloses a method of diagnosing lung cancer by using specific markers from a set, having diagnostic power for lung cancer diagnosis and distinguishing lung cancer types in diverse samples. | 04-21-2016 |
20160109455 | COMPOSITIONS FOR OVARIAN CANCER ASSESSMENT HAVING IMPROVED SPECIFICTY - The present invention provides compositions and methods that provide a high degree of sensitivity and a high degree of specificity for the preoperative assessment of ovarian tumors in a variety of subject's (e.g., pre- and post-menopausal women) having a variety of ovarian cancer types (e.g., clear cell/mucinous, low malignant potential, high malignant potential) and at a variety of disease states (e.g., early and late stage). | 04-21-2016 |
20160109462 | Tuberculosis Biomarkers and Uses Thereof - The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection, treatment and diagnosis of tuberculosis (TB). In one aspect, the present application includes the identification of biomarkers that can be used alone or in various combinations for the detection of TB, including those set forth in Tables 1, 2, 4, 5, and 8 to 12. In another aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose or prognose TB or follow treatment response. In another aspect, methods are provided for diagnosing TB in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Tables 1, 2, 4, 5, and 8 to 12, wherein the individual is classified as having TB, or the likelihood of the individual having TB is determined, based on the at least one biomarker value. | 04-21-2016 |
20160114321 | MICROREACTOR WITH VENT CHANNELS FOR REMOVING AIR FROM A REACTION CHAMBER - A microreactor for performing chemical reactions, includes a body, a first chamber and a second chamber, both formed in the body. Interconnections are provided for fluidly coupling the first chamber and the second chamber through the body. The microreactor also includes a venting passage formed in the body and having a venting outlet in the second chamber and at least one venting inlet in the first chamber, at a location where formation of bubbles is expected upon introduction of a liquid in the first chamber. | 04-28-2016 |
20160114322 | PARALLELIZED SAMPLE HANDLING - Provided herein are methods, compositions, and devices for the parallel handling of samples, such as cells or other biological samples. The methods, compositions, and devices are suited for multiple levels of analysis, including genetic and functional assays, of samples. | 04-28-2016 |
20160115206 | Treponema Pallidum Triplet Antigen | 04-28-2016 |
20160115220 | PROTEOLYTIC RELEASE OF CELL SURFACE ANTIGENS FOR PHAGE BIOPANNING - The invention described herein features methods of isolating monoclonal antibodies or polypeptides that bind to a cell surface expressed antigen. The method of catch and release utilizes engineered protease site for cleavage antigen-antibody or antigen-polypeptide complexes. In some embodiments the protease cleavage site to cleave the complexes is an exogenous protease to mammalian cell. In various embodiments the protease cleavage site to cleave the complexes is an endogenous protease to mammalian cell. | 04-28-2016 |
20160115250 | Synthetic Oligosaccharide Subunits Of The PSL Exopolysaccharide Of Pseudomonas Aeruginosa And Uses Thereof - This disclosure relates to synthetic oligosaccharide subunits of the | 04-28-2016 |
20160115526 | MULTIPLEX AMPLIFICATION AND DETECTION - The invention relates to the field of multiplex amplification. In particular, the invention relates to methods for assaying a sample for one or more nucleic acid targets in a single reaction based on the distinct melting temperatures or melting profiles of primers and/or probes. The invention also provides probes and kits for use in such methods. | 04-28-2016 |
20160115538 | Methods and Systems for Using Photoswitchable Nucleic Acids to Control Hybridization Stringency - Compositions, methods and systems are provided that enable light-controlled hybridization between two nucleic acid sequences and further enable the characterization of one or more sequence variations between the nucleic acids. | 04-28-2016 |
20160115541 | DETECTION AND QUANTIFICATION OF DONOR CELL-FREE DNA IN THE CIRCULATION OF ORGAN TRANSPLANT RECIPIENTS - This invention provides methods, compositions, and kits relating to detecting donor cell-free DNA in the circulation of an organ transplant recipient for the early identification of transplant rejection | 04-28-2016 |
20160115543 | Neurosurgical Genomics - Ten (10) genes and seven (7) RNA probes are disclosed, the relative expressions of which, hold predictive value with regard to seizure-free surgical outcomes for epilepsy patients. Whole genome and targeted gene expression analyses demonstrate that (a) specific biological process pathways existing in brain tissue of patients with medically intractable temporal lobe epilepsy, and (b) temporal cortical gene expression, differ between patients rendered seizure-free compared to non-seizure-free patients following anterior temporal lobectomy with amygdalohippocampectomy (ATL/AH). | 04-28-2016 |
20160115546 | MICRORNAS EXPRESSION SIGNATURE FOR DETERMINATION OF TUMORS ORIGIN - The present invention provides a process for classification of specific cancers and tumors origin through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA expression framework allows optimization of treatment, and determination of specific therapy. | 04-28-2016 |
20160115547 | USE OF FREE CIRCULATING DNA FOR DIAGNOSIS, PROGNOSIS, AND TREATMENT OF CANCER - A method of detecting circulating DNA in a body fluid. The method comprises identifying a subject suffering from or at risk for developing cancer, obtaining a body fluid sample from the subject, and determining the sequence integrity of circulating DNA in the sample, wherein the circulating DNA is not purified from the sample. | 04-28-2016 |
20160115551 | METHODS TO PREDICT RISK OF RECURRENCE IN NODE-POSITIVE EARLY BREAST CANCER - The present invention provides methods for classifying and for evaluating the prognosis of a subject having breast cancer are provided. The methods include prediction of breast cancer subtype using a supervised algorithm trained to stratify subjects on the basis of breast cancer intrinsic subtype. The prediction model is based on the gene expression profile of the intrinsic genes listed in Table 1. This prediction model can be used to accurately predict the intrinsic subtype of a subject diagnosed with or suspected of having breast cancer. | 04-28-2016 |
20160115552 | MEANS AND METHODS FOR MOLECULAR CLASSIFICATION OF BREAST CANCER - The invention relates to a method of typing a sample from a breast cancer patient. More specifically, the invention relates to a method for classification of breast cancer according to the presence or absence of Estrogen Receptor (ER), Progesterone Receptor (PR) and Human Epidermal growth factor Receptor 2 (ERBB2; HER2). More specifically, the invention provides methods and means to classify breast cancer as ER positive, triple negative (ER | 04-28-2016 |
20160115555 | BIOMARKERS FOR DIFFERENTIATING MELANOMA FROM BENIGN NEVUS IN THE SKIN - Disclosed is a method for diagnosing melanoma in a human subject, as well as a method for providing a prognosis to a human subject who is at risk of developing melanoma recurrence, and a method for determining the stage of melanoma in a human subject, comprising the step of determining the level of expression of phosphatase and actin regulator 1 (PHACTR1) gene, or fragments thereof, either alone or in combination with the level of expression of secreted integrin-binding phosphoprotein (SPP1), preferentially expressed antigen in melanoma (PRAME), growth differentiation factor 15 (GDF15), and chemokine C-X-C motif ligand 10 (CXCL10) genes. Further, the invention relates to a diagnostic kit, comprising at least one substance for detection of the expression of PHACTR1, or fragments thereof, either alone or in combination with the detection of SPP1, PRAME, GDF15, and CXCL10, for the diagnosis or prognosis of melanoma. | 04-28-2016 |
20160116456 | METHODS FOR IDENTIFYING AGENTS USEFUL FOR MODULATING THE EXPRESSION AND AGGREGATION OF CAG-EXPANDED GENE PRODUCT IN CELLS - This invention provides a method for modulating the expression of a first gene in a cell wherein the first gene is one containing more than 36 CAG trinucleotide repeats and encoding a protein that form polyglutamine-mediated protein aggregation. Suppression of the first gene is achieved by reducing the expression of SPT4 gene or SUPT4H gene. It can also be achieved by inhibiting the formation of a Spt4/Spt5 complex or a Supt4h/Supt5h complex. Also provided is a method for identifying an agent useful for modulating the expression and aggregation of CAG-expanded gene product, or treating a polyglutamine disease such as Huntington's disease. | 04-28-2016 |
20160116462 | ANTIBODY-NANOPARTICLE CONJUGATES AND METHODS FOR MAKING AND USING SUCH CONJUGATES - Disclosed herein are antibody-nanoparticle conjugates that include two or more nanoparticles (such as gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof) directly linked to an antibody or fragment thereof through a metal-thiol bond. Methods of making the antibody-nanoparticle conjugates disclosed herein include reacting an arylphosphine-nanoparticle composite with a reduced antibody to produce an antibody-nanoparticle conjugate. Also disclosed herein are methods for detecting a target molecule in a sample that include using an antibody-nanoparticle conjugate (such as the antibody-nanoparticle conjugates described herein) and kits for detecting target molecules utilizing the methods disclosed herein. | 04-28-2016 |
20160116479 | AMPLIFYING RARE CELL SURFACE MARKERS - This invention relates generally to a microfluidic device for encapsulation, incubation, and analysis of cell surface markers or secreted molecules from a single cell. | 04-28-2016 |
20160116482 | Target Binding Molecules Identified by Kinetic Target-Guided Synthesis - Methods of identifying target binding molecules by target guided synthesis are provided. The methods include providing two or more fragments capable of reacting to form the target binding molecule and mixing the fragments with the target. The methods can be used to identify target binding molecules that bind targets such as proteins or nucleic acids, including those that bind shallow binding pockets on the surface of such targets. The methods are applied to the Bcl-XL and Mcl-1 proteins from the Bcl-2 family of proteins. Using thio acid and sulfonyl azide fragments capable of reacting through sulfo-click chemistry, new acyl sulfonamides are identified that bind one or both of the Bcl-XL and Mcl-1 proteins. Pharmaceutical formulations of these target binding molecules are also provided. | 04-28-2016 |
20160116485 | COMPOSITIONS, METHODS, AND ASSAYS FOR ANALYZING THE STRUCTURE, FUNCTION, AND ACTIVITY OF MEMBRANE PROTEINS - Compositions and methods for reconstituting a protein of interest in the plasma membrane of a | 04-28-2016 |
20160116486 | BIOMARKERS RELATED TO KIDNEY FUNCTION AND METHODS USING THE SAME - Biomarkers of kidney function and methods for using said biomarkers for assessing kidney function, monitoring kidney function, diagnosing acute kidney injury, and diagnosing chronic kidney disease are provided. Also provided are suites of small molecule entities as biomarkers for chronic kidney disease. | 04-28-2016 |
20160116488 | Method of In Vitro Diagnosis of a Neurological Disorder - The present invention relates to a new method for the in vitro diagnosis of a neurological disorder, more particularly of Alzheimer's disease (AD) and of mild cognitive impairment (MCI). The present invention also relates to the use of orexin-A (hypocretin-1), a specific fragment thereof, a nucleotide encoding the same or a combination thereof, as a biomarker for the in vitro diagnosis of a neurological disorder, more particularly of Alzheimer's disease (AD), alone or in combination with other known bio markers for the diagnosis of AD. The present invention finally relates to kits for the in vitro diagnosis of a neurological disorder, more particularly of AD, comprising means for the detection of orexin-A. | 04-28-2016 |
20160116489 | LATERAL FLOW IMMUNOASSAY METHOD OF SIMULTANEOUSLY DETECTING HEMOGLOBIN S, HEMOGLOBIN C, AND HEMOGLOBIN A IN NEWBORNS, INFANTS, CHILDREN, AND ADULTS - Screening methods and devices for detecting and diagnosing hemoglobinopathies for sickle cell disease and related phenotypes. Lateral flow immunoassay devices for the detection of hemoglobinopathies. Methods for screening for hemoglobinopathies. Kits for the detection of a hemoglobinopathy in a sample. Immunogenic peptides for producing antibodies against hemoglobin variants. | 04-28-2016 |
20160116490 | METHODS AND DEVICES FOR IMMUNODIAGNOSTIC APPLICATIONS - Methods and devices for evaluating a sample, e.g., a plasma sample, from a subject, for detecting a target red blood cell protein or antibody are disclosed. In one embodiment, optimized antibody screening methods and devices significantly reduce the level of non-specific binding to a surface (e.g., a test surface bound with a red blood cell (rbcm) preparation), thus allowing for more efficient detection and reduced test time. In one embodiment, the optimized antibody screening method includes an immunoglobulin G (IgG) binding moiety that binds selectively and specifically to the plasma IgG present relative to the binding to the lysed rbcm preparation. In another embodiment, an optimized antibody screening method is disclosed whereby non-specific binding caused by lysed red blood cell membrane preparations can be reduced by an agent that specifically cleaves a human IgG in the hinge region. In other embodiments, the invention provides methods and devices for target capturing that include a substantially planar surface, optionally having an optimized angle, for capture. Alternative solid phase geometries for capture are disclosed. Optimized methods for cell deposition are also disclosed. Thus, optimized methods, devices, kits, assays for evaluating a sample are disclosed. | 04-28-2016 |
20160116494 | Lp(a) SUBFORM SIZE IDENTIFICATION BY CAPILLARY ISOTACHOPHORESIS ELECTROPHORESIS WITH LASER-INDUCED-FLUORESCENCE - The application describes methods for determining the concentration and/or particle number of a lipoprotein(a) subform in a biological sample using capillary isotachophoresis laser induced fluorescence (CE-ITP-LIF) and compositional analysis of lipoprotein(a) particles. The ability to measure the concentration and/or particle number of a lipoprotein(a) subform in a biological sample provides a useful diagnostic tool for assessing cardiovascular risk in a subject. | 04-28-2016 |
20160122754 | Arrays and Methods of Use - Methods are provided for producing a molecular array comprising a plurality of molecules immobilized to a solid substrate at a density which allows individual immobilised molecules to be individually resolved, wherein each individual molecule in the array is spatially addressable and the identity of each molecule is known or determined prior to immobilization. The use of spatially addressable low density molecular arrays in single molecule detection and analysis techniques is also provided. Novel assays and methods are also provided. | 05-05-2016 |
20160122803 | EARLY DEVELOPMENTAL GENOMIC ASSAY FOR CHARACTERIZING PLURIPOTENT STEM CELL UTILITY AND SAFETY - The present invention generally relates to a set of early developmental reference data or “lineage scorecard” for stem cells, and methods, systems and kits to generate a lineage scorecard for predicting the functionality and suitability of stem cell lines. In some aspects, methods for generating a scorecard comprises measuring the gene expression of a plurality of early developmental genes, such as pluripotent, early ectoderm, early mesoderm and early endoderm genes to predict the pluripotency and differentiation potential of the stem cell line and its functionality and/or suitability for a desired use. In some embodiments, a reference scorecard can be compared with the test stem cell line scorecard to accurately predict the utility and/or identify specific characteristics of the stem cell line, e.g., to determine its suitability for downstream applications, e.g., therapeutic use, drug screening, toxicity assays, differentiation into a desired cell lineage, etc. | 05-05-2016 |
20160122805 | PRIMERS FOR THE DETECTION AND TYPING OF CARBAPENEMASE-PRODUCING BACTERIAL STRAINS, AND DETECTION METHOD AND KIT - Some pairs of primers are provided, being used for detection of carbapenemase genes and carbapenemase-producing bacterial strains, and a diagnosis method using said set of primers. Furthermore, there is also disclosed, preferably, the use of probes within each amplification reaction, more preferably multiplex PCR, for selective identification and detection of carbapenemase genes from a biological sample. The primers object of this invention may be used for preparing a kit for carbapenemase genes identification and detection, preferably carbapenemases contained in bacterial strains producing said enzymes. | 05-05-2016 |
20160122810 | SYSTEMS AND METHODS FOR NUCLEIC ACID CAPTURE - Provided herein are methods for improving the detection sensitivity of amplification reaction products. In particular, provided herein are methods of improving sensitivity of detection of amplification products by introducing modified and degradable nucleotides into amplification primers. | 05-05-2016 |
20160122824 | METHODS FOR DETECTION OF DEPRESSIVE DISORDERS - The present invention relates generally to the detection or diagnosis of depressive disorders, and provides methods and compositions useful for this purpose. In particular, the present invention provides biomarkers for the detection or diagnosis of major depressive disorder, and methods of use thereof. | 05-05-2016 |
20160122835 | REAL-TIME PCR POINT MUTATION ASSAYS FOR DETECTING HIV-1 RESISTANCE TO ANTIVIRAL DRUGS - Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase, protease, or integrase of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS: 1-89, 96-122, and 124-151. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS: 1-89, 96-122, and 124-151. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV simultaneously or sequentially. Mutations in the reverse transcriptase, protease, or integrase of HIV can be detected using the methods described herein. | 05-05-2016 |
20160123853 | METHOD, SYSTEMS AND KIT FOR FORENSIC IDENTIFICATION, POST MORTEM INTERVAL ESTIMATION AND CAUSE OF DEATH DETERMINATION BY RECOVERY OF DENTAL TISSUE IN PHYSIOLOGICAL CONDITIONS - The present invention is related to a method for obtaining dental pulp and root cement in the forensic dentistry field, wherein the method comprises the steps of: (a) obtaining a tooth; (b) taking a digital radiography to the tooth; (c) external rehydrating of the tooth; (d) perforating the rehydrated tooth; (e) internal rehydrating of dentin pulp complex (f) obtaining rehydrated root cement; (g) obtaining rehydrated dental pulp content with a low speed rotation tool; and (h) storing, preservation, processing and/or analyses of the rehydrated dental pulp content and rehydrated root cement, and the use of this method and kits thereof for forensic identification, estimation of post mortem interval (early and late) and determination of possible causes of death. | 05-05-2016 |
20160123958 | APPARATUS AND METHODS FOR CONDUCTING ASSAYS AND HIGH THROUGHPUT SCREENING - The present invention provides microfluidic devices and methods for using the same. In particular, microfluidic devices of the present invention are useful in conducting a variety of assays and high throughput screening. Microfluidic devices of the present invention include elastomeric components and comprise a main flow channel; a plurality of branch flow channels; a plurality of control channels; and a plurality of valves. Preferably, each of the valves comprises one of the control channels and an elastomeric segment that is deflectable into or retractable from the main or branch flow channel upon which the valve operates in response to an actuation force applied to the control channel. | 05-05-2016 |
20160123968 | DEVICE AND METHOD FOR DETECTING AN ANALYTE - A detection device detects an analyte that may be contained in a specimen. The detection device includes a plurality of gold nanoparticles, an optical trapping light source, an illumination light source, an objective lens, an image pick-up device, and a computation unit. The plurality of gold nanoparticles are each modified with a probe DNA allowing the analyte to specifically adhere thereto. The optical trapping light source emits polarized light for assembling the plurality of gold nanoparticles together. The objective lens focuses and introduces the polarized light into a liquid containing a specimen and the plurality of gold nanoparticles. The image pick-up device receives light from the liquid. The computation unit detects an analyte based on a signal received from the image pick-up device. | 05-05-2016 |
20160123973 | MULTIMODAL BIOSENSOR - Multimodal biosensor devices are disclosed. A device may include at least two sensors selected from: (i) a nanomechanical resonator; (ii) plasmonic nanodisk antennae; and (iii) a field effect transistor. The biosensor device is capable of transducing the adsorption of biomolecules onto the biosensor device into optical, electrical and/or mechanical signals. | 05-05-2016 |
20160123978 | BIOCHIP, ANTIGEN BOUQUET, OPTICAL READER AND METHOD FOR DETECTING AND MONITORING DISEASES - The present invention comprises a biochip with specifically-designed configuration and microfluidic properties that increases the speed and effectiveness of the whole process of detection and monitoring diseases. This biochip is to be read in a specifically adapted optical reader for which an algorithm was developed and implemented to provide faster and more selective results, with a revealing method using quantum dots. The present invention is applicable to medical and diagnostic technical fields. | 05-05-2016 |
20160123979 | BIOMARKERS FOR EARLY DIAGNOSIS AND DIFFERENTIATION OF MYCOBACTERIAL INFECTION - Mycobacterial-specific biomarkers and methods of using such biomarkers for diagnosis of mycobacterial infection in a mammal are disclosed. | 05-05-2016 |
20160123980 | MULTICOLOR FLOW CYTOMETRY METHOD FOR IDENTIFYING A POPULATION OF CELLS, IN PARTICULAR MESENCHYMAL STEM CELLS - This invention is in the field of the identification and even isolation of mesenchymal stem cells (MSCs) and other cell types by means of differential specific fluorescence activated cell sorting (FACS). | 05-05-2016 |
20160123983 | HCV ANTIGEN-ANTIBODY COMBINATION ASSAY AND METHODS AND COMPOSITIONS FOR USE THEREIN - The present invention generally relates to combination immunoassays, reagents and kits for simultaneous detection of HCV antigens and anti-HCV antibodies in a test sample. | 05-05-2016 |
20160123984 | DRUG SELECTION FOR BREAST CANCER THERAPY USING ANTIBODY-BASED ARRAYS - The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments. | 05-05-2016 |
20160123985 | HEMATOPOIETIC CELL PHENOTYPING USING CIRCULATING CELL-FREE MARKERS - The present invention provides methods of classifying cluster of differentiation (CD) marker phenotype for hematopoietic cancer cells using multiple circulating cell-free CD markers in bodily fluid. In other aspects, treatment and disease progression of particular hematopoietic cancers can be monitored by measuring the levels of CD and other markers in bodily fluids of a patient. | 05-05-2016 |
20160123988 | METHOD OF TRACELESS LABELING GLYCOPROTEINS ON SURFACE AND APPLICATION THEREOF - The present invention relates to a method of traceless labeling glycoproteins on a surface and an application thereof. A test glycoprotein can be immobilized on a surface using a BA-tosyl probe and the BA-tosyl probe is then released using a releasing agent, so as to expose a glycan residue of the test glycoprotein. The exposed glycan residue of the test glycoprotein can be detected without altering native glycan structures. Moreover, the present invention further provides a detection kit of traceless labeling glycoproteins on a surface in the study of glycoprotein-protein interactions, which is suitable for using the aforementioned method. | 05-05-2016 |
20160123992 | METHODS FOR PREDICTING RHEUMATOID ARTHRITIS TREATMENT RESPONSE - The invention relates to methods and means for predicting rheumatoid arthritis treatment response. | 05-05-2016 |
20160123996 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Prostatic acid phosphatase, Lactotransferrin, Soluble erythropoietin receptor, Von Willebrand factor, Soluble endothelial protein C receptor, and Beta-2-glycoprotein 1 as diagnostic and prognostic biomarkers in renal injuries. | 05-05-2016 |
20160123997 | MATERIALS AND METHODS RELATING TO ALZHEIMER'S DISEASE - The invention relates to methods and compositions relating Alzheimer's disease. There is provided a panel of optimal biomarkers which allow diagnosis of Alzheimer's disease and discrimination between Alzheimer's disease and its earlier precursor, mild cognitive impairment (MCI). | 05-05-2016 |
20160125130 | METHOD FOR ASSIGNING TARGET-ENRICHED SEQUENCE READS TO A GENOMIC LOCATION - Provided herein, among other things, is a computer-implemented method for assigning a sequence read to a genomic location, the method including: a) accessing a file containing a sequence read, wherein the sequence read is obtained from a nucleic acid sample that has been enriched by hybridization to a plurality of capture sequences; and b) assigning the sequence read to a genomic location by: i) identifying a capture sequence as being a match with the sequence read if the sequence read contains one or more subsequences of the capture sequence; ii) calculating, using a computer, a score indicating the degree of sequence similarity between each of the matched capture sequences and the sequence read; and iii) assigning the sequence read to the genomic location if the calculated score for a matched capture sequence is above a threshold. | 05-05-2016 |
20160130279 | PATHWAY SPECIFIC ASSAYS FOR PREDICTING IRRITABLE BOWEL SYNDROME DIAGNOSIS - The present invention provides antibodies and methods for preparing antibodies to metabolites in the serotonin, tryptophan, kynurenine pathways. The prepared antibodies have low cross-reactivity to related metabolites, and are useful reagents for specific and sensitive immunoassays The present invention also provides stable derivatives of various metabolites and short chain fatty acids. The derivative can be conjugated to a biomolecule such as a carrier protein and combined with an adjuvant to stimulate an immune response. The derivatives can also be conjugated to other biomolecules. | 05-12-2016 |
20160130329 | COMPOSITIONS AND METHODS RELATED TO RECOMBINANT ANTIBODIES TO HISTONE POSTTRANSLATIONAL MODIFICATIONS - Embodiments concern compositions and methods involving recombinant antibodies to histone post-translational modifications. The invention provides compositions and methods for histone methyltransferase assays. In certain embodiments, the compositions and methods involve a recombinant antibody that binds histone H3 fragment harboring biomarkers such as H3K9me3 mark, H3K4me3 mark, H3K36me3 mark, H3K27me3, H3K9me3 and H3S10phos or a recombinant antibody that binds histone H4 fragment harboring H4K20me3 mark. | 05-12-2016 |
20160130553 | PREPARATION OF FETAL NUCLEATED RED BLOOD CELLS (NRBCs) FOR DIAGNOSTIC TESTING - The disclosure relates to methods of preparation of fetal nucleated red blood cells (NRBCs) from biological samples for diagnostic testing. | 05-12-2016 |
20160130636 | QUANTITATING HIGH TITER SAMPLES BY DIGITAL PCR - The present invention provides systems, devices, methods, kits, and compositions for nucleic acid analysis using digital PCR. In particular, methods are provided to analyze high titer samples that cannot be divided into a sufficient number of partitions containing zero nucleic acid molecules per partition to allow for Poisson analysis (digital PCR analysis). | 05-12-2016 |
20160130638 | METHODS FOR THE DIAGNOSIS OF BACTERIAL VAGINOSIS - The present invention relates to methods for the diagnosis of bacterial vaginosis based on an analysis of a patient sample. For example, patient test samples are analyzed for the presence or absence of one or more lactobacilli and two or more pathogenic organisms. The presence or absence of one or more lactobacilli and two or more pathogenic organisms may be detected using PCR analysis of nucleic acid segments corresponding to each target organism. The quantity of the target organisms can then be used to determine a score which is indicative of a diagnosis of bacterial vaginosis. | 05-12-2016 |
20160130642 | METHOD, MICROREACTOR AND APPARATUS FOR CARRYING OUT REAL-TIME NUCLEIC ACID AMPLIFICATION - A method for carrying out nucleic acid amplification, includes providing a reaction chamber, accommodating an array of nucleic acid probes at respective locations, for hybridizing to respective target nucleic acids; and introducing a solution into the reaction chamber, wherein the solution contains primers, capable of binding to target nucleic acids, nucleotides, nucleic acid extending enzymes and a sample including nucleic acids. The a structure of the nucleic acid probes and of the primers so that a hybridization temperature of the probes is higher than an annealing temperature of the primers, whereby hybridization and annealing take place in respective separate temperature ranges. | 05-12-2016 |
20160130655 | MUTATIONS IN THE BCR-ABL TYROSINE KINASE ASSOCIATED WITH RESISTANCE TO STI-571 - The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bu-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS. | 05-12-2016 |
20160130656 | METHODS FOR EVALUATING LUNG CANCER STATUS - The disclosure in some aspects provides methods of determining the likelihood that a subject has lung cancer based on the expression of informative-genes. In other aspects, the disclosure provides methods for determining an appropriate diagnostic intervention plan for a subject based on the expression of informative-genes. Related compositions and kits are provided in other aspects of the disclosure. | 05-12-2016 |
20160130657 | METHOD OF DIAGNOSING NEOPLASMS - The present invention relates generally to a nucleic acid molecule, the RNA and protein expression profiles of which are indicative of the onset, predisposition to the onset and/or progression of a large intestine neoplasm. More particularly, the present invention is directed to a nucleic acid molecule, the expression profiles of which are indicative of the onset and/or progression of a colorectal neoplasm, such as an adenoma or an adenocarcinoma. The expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenomas and adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening a subject for the onset, predisposition to the onset and/or progression of a large intestine neoplasm by screening for modulation in the expression profile of said nucleic acid molecule markers. | 05-12-2016 |
20160130660 | COMPOSITIONS AND METHODS FOR MULTIMODAL ANALYSIS OF CMET NUCLEIC ACIDS - Described herein are methods and assays relating to the detection of cMET alterations (e.g. variations in copy number and expression level, and/or the presence of mutations, including point mutations). Existing methods are limited in their clinical usefulness by, e.g., limited sensitivity, inter-lab discordance, or inability to provide the necessary multiplex ability. The methods and assays provided herein permit multimodal, multiplex assaying for faster, more cost-effective testing and screening of patients, permitting improved healthcare. | 05-12-2016 |
20160130665 | PROGNOSTIC METHODS AND SYSTEMS FOR CHRONIC LYMPHOCYTIC LEUKEMIA - The present invention provides systems useful for risk stratification of chronic lymphocytic leukemia (CLL) patients. The systems can include a microarray and a decision tree having steps for stratification of one or more CLL patients into prognostic groups. The invention further provides methods for risk stratification of CLL patients. The methods can include detecting the presence of alterations, such as copy number alterations, in sample genetic material from each of one or more CLL patients and then stratifying the one or more CLL patients into prognostic groups. | 05-12-2016 |
20160130666 | SIMULTANEOUS DETECTION OF MUTATIONAL STATUS AND GENE COPY NUMBER - The present invention provides compositions and methods for simultaneously detecting mutational status and gene copy number. In particular, the present invention provides simultaneous measurement of gene copy number and detection of the L858R and Exon 19 del mutations in a tissue sample. | 05-12-2016 |
20160130669 | RECOMBINASE POLYMERASE AMPLIFICATION (RPA) METHOD FOR LEISHMANIA SPP. AND TRYPANOSOMA CRUZI - Certain embodiments are directed to a sensitive isothermal amplification test based on the recombinase polymerase amplification (RPA) method that is capable of detecting <2 parasites in a biological sample. | 05-12-2016 |
20160130672 | COMPOSITIONS AND ASSAYS TO DETECT SWINE H1N1 INFLUENZA A VIRUS, SEASONAL H1 INFLUENZA A VIRUS AND SEASONAL H3 INFLUENZA A VIRUS NUCLEIC ACIDS - Methods for detecting the presence or absence of the swine H1N1 influenza A virus, seasonal H1 influenza A virus and/or seasonal H3 influenza A virus nucleic acids in biological samples are disclosed. Compositions that are target-specific nucleic acid sequences and kits comprising target-specific nucleic acid oligomers for amplifying in vitro the swine H1N1 influenza A virus, seasonal H1 influenza A virus and/or seasonal H3 influenza A virus nucleic acid and detecting amplified nucleic acid sequences are disclosed. | 05-12-2016 |
20160131613 | FLOATING GATE BASED SENSOR APPARATUS AND RELATED FLOATING GATE BASED SENOR APPLICATIONS - A floating gate based sensor apparatus includes at least two a separate electrical bias components with respect to a floating gate based sensor surface within the floating gate based sensor apparatus. By including the at least two electrical bias components, the floating gate based sensor apparatus provides enhanced capabilities for biomaterial and non-biomaterial detection and manipulation while using the floating gate based sensor apparatus. | 05-12-2016 |
20160131615 | HIGH PERFORMANCE QUARTZ CRYSTAL MICROBALANCE ENHANCED BY MICROSTRUCTURES FOR BIOLOGICAL APPLICATIONS - Quartz crystal microbalance resonators are described, as are methods of making them using micron sized pillar array of polymethyl methacrylate fabricated on a QCM surface using a nanoimprint lithography process. Their use in any applications, including for example gas and liquid sensors and biosensors as well as other measurement applications, is also discussed. | 05-12-2016 |
20160131638 | IMMUNITY TO FOLATE RECEPTORS - This document provides methods and materials related to assessing immunity to folate receptors. For example, methods and materials for assessing FRα immunity in a mammal are provided. This document also provides methods and materials related to stimulating immunity to folate receptors. | 05-12-2016 |
20160131643 | MICROFLUIDIC COLLABORATIVE ENZYME ENHANCED REACTIVE CEER IMMUNOASSAY - The present invention provides methods for diagnosing a disease state in a patient by detecting the presence, expression level and/or activation level of a target analyte in a patient sample using a proximity dual detection assay on a microcarrier. The present invention also provides an assay device for performing the methods described herein. | 05-12-2016 |
20160131651 | Gamma-Secretase Substrates and Methods of Use - Polypeptide substrates based on modifications or fragments of the various APP isoforms, assay methods based on the use of these substrates, and screening methods directed toward identifying inhibitors of γ-secretase activity. The assay methods and the screening methods are adapted for use in high throughput multi-well plate assay apparatuses. In many embodiments the substrate polypeptides are labeled for ease of detection, and/or may bind specific ligands that themselves are labeled. Generally the labels promote high specificity as well as high sensitivity of detection. These features render the assay and screening methods that employ the labeled substrates especially suited for use in high throughput assay formats. This disclosure further identifies small polypeptides based on a subsequence motif of Aβ that are shown herein to be potent inhibitors of the activity of γ-secretase. | 05-12-2016 |
20160131660 | Risk Stratification for Acute Coronary Syndrome by Means of Fragments/Partial Peptides of Provasopressin, Especially Copeptin or Neurophysin II - The invention relates to a method for risk stratification for acute coronary syndrome (ACS), in particular acute myocardial infarction (AMI) and angina pectoris (AP), wherein provasopressin (proAVP) or fragments and partial peptides thereof, in particular copeptin or neurophysin II, is determined by an in vitro diagnosis. | 05-12-2016 |
20160131662 | PROTEIN AND ANTIBODY PROFILING USING SMALL MOLECULE MICROARRAYS - Aspects of the present invention describe methodology by which arrays of synthetic molecules can be created and employed for various types of proteomics profiling experiments. The most important of these from a clinical standpoint are the visualization of antibody and T cell binding patterns, which could be employed as a tool for monitoring the state of the immune system of a patient. This may be a generally useful tool for the diagnosis of many types of disease states. Similar techniques are employed to detect the post-translational modification of specific proteins, a tool for the visualization of induction of signal transduction pathways in cells and tissues treated with drugs. Finally, aspects of the invention teach a method for the creation of simpler arrays with less than 100 features that are, nonetheless, effective for protein profiling experiments. | 05-12-2016 |
20160131669 | VISUALIZED BIOCHIP AND METHOD FOR SIMULTANEOUSLY DETECTING A VARIETY OF ANTIBIOTICS, ILLEGAL ADDITIVES AND BIOTOXINS - The present invention provides a biochip for simultaneously detecting a variety of antibiotics, illegal additives and biotoxins in a visualized manner, wherein the biochip comprises a chip carrier fixed with a group of detection target antigens, the detection targets are the antibiotics, the illegal additives and the biotoxins, and the biochip is prepared by the following method: enabling the bovine serum albumin and the detection target antigens to perform sample application operation on the chip carrier through a biochip preparation system by taking bovine serum albumin as blank control, and then fixing in a water bath at 20-37° C. for 0.5-4 h for preparation. The invention further provides a method for simultaneously detecting a variety of antibiotics, illegal additives and biotoxins by using the biochip. The biochip has the advantages of simple structure, simple preparation process, low cost, multiple targets, high accuracy, high sensitivity, high precision, short detection time, simpleness and easiness in operation and no need of expensive detection instruments and is applicable to on-site large-scale primary screening of samples. | 05-12-2016 |
20160135722 | METHODS FOR ASSESSING VAGINAL ATROPHY - An array of methods for assessing vaginal atrophy are disclosed. The methods may be used alone or in combination with a treatment or as part of a kit. | 05-19-2016 |
20160137864 | SUPRAMOLECULAR ENCRYPTED FLUORESCENT SECURITY INK COMPOSITIONS - Fluorescent dyes, ink compositions comprising the dyes, methods and devices for printing the ink compositions, images printed using the ink compositions and methods for authenticating the printed images are provided. The fluorescent dyes are heterorotaxanes that include large macrocyclic rings around fluorophores and are capable of emitting solid-state fluorescence. When the heterorotaxanes are combined with encapsulating agents and competitive binding agents in aqueous solution, the resulting ink composition exhibits a complex, dynamic equilibrium that provides a tunable fluorescence emission spectrum with a non-linear response to the dye concentration. | 05-19-2016 |
20160137981 | INDUCED PLURIPOTENT STEM CELL SELECTION METHOD AND METHOD FOR INDUCING DIFFERENTIATION TO BLOOD CELLS - A method for producing hematopoietic stem cells and/or hematopoietic progenitor cells from pluripotent stem cells is described. The method includes a step of culturing pluripotent stem cells in the presence of IGF2. A method is described for selecting an induced pluripotent stem cell(s) having high capacity to differentiate into hematopoietic stem cells and/or hematopoietic progenitor cells, or into blood cells, based on the expression level(s) of one or more genes such as TRIM58, CTSF, FAM19A5, and TCERG1L genes, or on the DNA methylation state(s) of the TRIM58, CSMD1, and/or FAM19A5 gene(s). | 05-19-2016 |
20160138009 | NUCLEIC ACID EXTRACTION USING ORGANIC SOLVENTS TO REMOVE INHIBITORS - Nucleic acid amplification tests have been widely used in clinical laboratories. Nucleic acid extraction from biological materials is challenging because different unfavorable substances may co-extract and inhibit downstream applications. The present invention relates to a composition of and a method for treating the sample prior, during or post extraction of nucleic acid. More specifically, the claimed invention relates to a composition of and a method for using low concentrations of common organic solvents to remove inhibitors of nucleic acid amplification. The present invention can be used for extracting nucleic acids (DNA/RNA) from bacteria, viruses, parasites, and other biological materials or matrices, including but not limit to, stool samples, body fluids, plants and cultures. The method is rapid, low-cost, and easy to use in a laboratory setting. The nucleic acid extracted in accordance with the invention can be used for nucleic acid amplification reactions. | 05-19-2016 |
20160138072 | METHODS OF TARGETED ANTIBIOTIC SUSCEPTIBILITY TESTING - Methods are provided for performing antibotic susceptibility testing based on the detection of RNA, such as tmRNA, from microbial cells after exposure to antibiotics. In some embodiments, aliquots are obtained from a sample, one of which contains a selected antibiotic. The aliquots, which include growth media, are incubated under conditions suitable for microbial growth, and the microbial cells in each aliquot are removed and lysed, and the lysate is subjected to reverse transcription and amplification in infer the effect of the selected antibiotic on the microbial cells. In one embodiment, a sample containing microbial cells is incubated in the pressence of a selected antibiotic and a stimulus is provided to induce the production on m RNA within the microbial cells. The microbial cells are subsequently lysed without substantial degradation of the m RNA within the lysate, and the m RNA is detected to determine the effect of the antibiotic on the microbial cells. | 05-19-2016 |
20160138081 | METHOD FOR ISOLATING SPECIFIC GENOMIC REGION USING MOLECULE BINDING SPECIFICALLY TO ENDOGENOUS DNA SEQUENCE - Provided is a method comprising
| 05-19-2016 |
20160138083 | DETERMINATION OF VARIANTS PRODUCED UPON REPLICATION OR TRANSCRIPTION OF NUCLEIC ACID SEQUENCES - A method of determining whether or not a nucleic acid having an expected sequence or one or more variants of the expected sequence are present in a sample containing nucleic acids after replication, transcription or editing (or other transformation) of a substrate nucleic acid. The method involves deciding an expected sequence likely to be formed in the sample upon the replication, transcription or editing of the substrate nucleic acid, and possible variants of the expected sequence, providing primer pairs for a polymerase chain reaction, reverse transcriptase polymerase chain reaction or ligase chain reaction, carrying out the polymerase chain reaction or reverse transcriptase polymerase chain reaction in one or more steps to form amplicons, and analyzing the amplicons to determining whether or not a nucleic acid having the expected sequence and/or variants are present in the sample. The primers of the primer pairs are designed to anneal to regions of the nucleic acid of the expected sequence and the variants, the regions being selected to reveal unambiguously the presence or absence in the sample of the nucleic acid of the expected sequence or the variants thereof according to the presence or absence of specific amplicons amplified by the primers. | 05-19-2016 |
20160138088 | OPTIMIZED PROBES AND PRIMERS AND METHODS OF USING SAME FOR THE DETECTION, SCREENING, ISOLATION AND SEQUENCING OF VANCOMYCIN RESISTANCE GENES AND VANCOMYCIN RESISTANT ENTEROCOCCI - Described herein are primers and probes useful for detecting, screening, isolating, and sequencing of the vancomycin resistance genes and vancomycin resistant Enterococci and methods of using the described primers and probes. | 05-19-2016 |
20160138093 | Charge Perturbation Detection System for DNA and Other Molecules - Methods and apparatus for direct detection of chemical reactions are provided. Electric charge perturbations of the local environment during enzyme-catalyzed reactions are sensed by an electrode system with an immobilized target molecule. The charge perturbation caused by the polymerase reaction can uniquely identify a DNA sequence. The polymerization process generates local perturbations of charge in the solution near the electrode surface and induces a charge in a polarazible gold electrode. This event is detected as a transient current by a voltage clamp amplifier. Detection of single nucleotides in a sequence can be determined by dispensing individual dNTPs to the electrode solution and detecting the charge perturbations. Alternatively, multiple bases can be determined at the same time using a mix of all dNTPs with subsequent analysis of the resulting signal. This technique may be adapted to other reaction determinations, such as enzymatic reactions, other electrode configurations, and other amplifying circuits. | 05-19-2016 |
20160138095 | MOLECULAR MANIPULATION SYSTEM AND METHOD - A molecular manipulation system for investigating molecules, having a sample holder constructed to hold a sample comprising a plurality of molecules attached on one side to a surface in the sample holder and on another side attached to a microbead of a plurality of microbeads. The system having; an acoustic wave generator to generate an acoustic wave exerting a force on the microbeads in the sample; and a detector device to detect a response of the plurality of microbeads in the sample on the force exerted by the acoustic wave to investigate the molecules attached to the microbeads. | 05-19-2016 |
20160138096 | KIT FOR DETECTING NUCLEIC ACID AND METHOD FOR DETECTING NUCLEIC ACID - The present invention relates a kit for detecting a nucleic acid and a method of detecting a nucleic acid for enabling a multiplexed-detection and real-time detection of a target nucleic acid by using properties of a graphene oxide. | 05-19-2016 |
20160138103 | DIAGNOSTIC BIOMARKERS OF DIABETES - Methods are disclosed for the identification of gene sets that are differentially expressed in PBMCs of patients diagnosed with a pre-diabetic disease state and overt type II diabetes. 3 gene and 10 gene signatures are shown to accurately predict a diabetic disease state in a patient. The application also described kits for the rapid diagnosis of diabetic disease states in patients at a point of care facility. | 05-19-2016 |
20160138105 | SYSTEM AND METHODS FOR DETERMINING A WOMAN'S RISK OF ANEUPLOID CONCEPTION - The present invention provides methods and systems for determining a woman's risk of carrying an aneuploid embryo based on the maternal genotype, maternal age and optionally paternal age. | 05-19-2016 |
20160138108 | STROMA BIOMARKERS FOR THE DIAGNOSIS OF PROSTATE CANCER - The invention described herein relates in part to compositions, biomarkers and methods for diagnosis and prognosis of prostate lesions, including prostate cancer, including a tissue-based assay providing diagnostic and prognostic information related to prostate cancer. In some embodiments, the invention further relates to improvements in the ability to accurately diagnose prostate cancer, detect early-stage prostate cancer, and localize prostate lesions within the three-dimensional space of the prostate. | 05-19-2016 |
20160138110 | GLIOMA BIOMARKERS - Provided herein are biomarkers for evaluating malignant glioma. | 05-19-2016 |
20160138117 | COMPLEX SETS OF MIRNAS AS NON-INVASIVE BIOMARKERS FOR COLON CANCER - Described herein are non-invasive methods, kits and means for diagnosing and/or prognosing of colon cancer a body fluid sample from a subject. Further described herein are sets of polynucleotides or sets of primer pairs for detecting sets of miRNAs for diagnosing and/or prognosing of colon cancer in a body fluid sample from a subject. In addition, described herein are sets of miRNAs for diagnosing and/or prognosing of colon cancer in a body fluid sample from a subject. | 05-19-2016 |
20160139113 | Methods and Compositions for Phototransfer - Methods are described for phototransferring a compound from a first surface to a second surface. Compounds are described with photocleavable linkers. Compounds attached to a first surface through a photocleavable linker are put in proximity (or contact) with a second surface, and then phototransferred to the second surface upon exposure to electromagnetic radiation. Illuminating the compound with radiation photocleaves the compound from the first surface and transfers the compound to the second surface. | 05-19-2016 |
20160139114 | Rapid Test for Detecting Pathogen Material, in Particular in Order to Support the Diagnosis of Sepsis, and Kit and Device for Performing a Sepsis Test - A rapid test is provided for detecting pathogenic material, particularly for supporting the diagnosis of sepsis, as well as a kit and a device for the implementation of a sepsis test. | 05-19-2016 |
20160139115 | DEVICE FOR USE IN THE DETECTION OF BINDING AFFINITIES | 05-19-2016 |
20160139121 | Methods for Assaying Cellular Binding Interactions - There are provided methods, and devices for assaying for a binding interaction between a protein, such as a monoclonal antibody, produced by a cell, and a biomolecule. The method may include retaining the cell within a chamber having an aperture; exposing the protein produced by the cell to a capture substrate, wherein the capture substrate is in fluid communication with the protein produced by the cell and wherein the capture substrate is operable to bind the protein produced by the cell; flowing a fluid volume comprising the biomolecule through the chamber via said aperture, wherein the fluid volume is in fluid communication with the capture substrate; and determining a binding interaction between the protein produced by the cell and the biomolecule. | 05-19-2016 |
20160139129 | BIOMARKERS FOR THE DIAGNOSIS AND THE RESPONSE TO TREATMENT OF PANCREATIC CANCER - The invention related to biomarkers, a method and a kit for early diagnosis of pancreatic cancer, in particular of pancreatic ductal adenocarcinoma (PDAC); and to biomarkers, a method and a kit or device for predicting or prognosticating an individual's response to combination treatment with a nucleoside analogue (preferably gemcitabine) and with a growth factor receptor (preferably erlotinib) in patients with pancreatic ductal adenocarcinoma. | 05-19-2016 |
20160139130 | DETECTING CANCER WITH ANTI-CXCL16 AND ANTI-CXCR6 ANTIBODIES - Methods for detecting cancer or monitoring cancer progression in a subject are disclosed. The method includes detecting the level of expression of one or more cancer markers in a biological sample obtained from the subject; and comparing the level of expression of the one or more cancer markers in the biological sample to a normal level of expression of the one or more cancer markers. The one or more cancer markers comprises CXCL16 or CXCR6 or both CXCL16 and CXCR6. Also disclosed is a kit for detecting cancer or monitoring cancer progression. | 05-19-2016 |
20160139138 | MODULAR POINT-OF-CARE DEVICES, SYSTEMS, AND USES THEREOF - The present invention provides devices and systems for use at the point of care. The methods devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device are modular to allow for flexibility and robustness of use with the disclosed methods for a variety of medical applications. | 05-19-2016 |
20160139139 | Systems and Methods for Developing Diagnostic Tests Based on Biomarker Information from Legacy Clinical Sample Sets - Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 μL. or less of a legacy clinical sample. | 05-19-2016 |
20160139147 | Method for Aiding Differential Diagnosis of Stroke - The present invention provides a method of aiding the differential diagnosis of haemorrhagic stroke, ischemic stroke and a transient ischemic attack in a patient who has suffered or is suffering a stroke. The method comprises: (i) determining the concentration of the biomarkers VCAM-1, GFAP and CRP in an ex vivo sample obtained from the patient; and (ii) establishing the statistical significance of the concentration of the biomarkers. Optionally, the method further comprises steps of (iii) determining the concentration of the biomarkers IL-6 and sTNFR1 in an ex vivo sample obtained from the patient; (iv) determining the gender of the patient; and (v) establishing the statistical significance of the concentration of the five biomarkers, in conjunction with the patient's gender. The present invention also provides substrates comprising probes for VCAM-1, GFAP and CRP for use in a method for aiding the differential diagnosis of stroke. | 05-19-2016 |
20160139148 | PATHWAY SPECIFIC MARKERS FOR DIAGNOSING IRRITABLE BOWEL SYNDROME - The present invention provides methods for aiding in the diagnosis of irritable bowel syndrome (IBS) in an individual. In particular, the present invention is useful for determining whether the individual does not have either celiac disease or inflammatory bowel disease (IBD), and has IBS and/or a subtype thereof. Thus, the present invention provides an accurate diagnostic prediction of IBS and is useful for guiding treatment decisions. | 05-19-2016 |
20160139153 | BIOMARKERS FOR SEIZURES - The application relates to markers for seizures and epilepsy. Polypeptide expression panels or arrays are provided, comprising one or more probes capable of binding specific polypeptides in blood plasma or blood serum of a mammalian subject. Also provided are methods for detecting seizure, methods for predicting seizure, use of sICAM-5 in the treatment of seizure, methods for assessing the effectiveness of a treatment of seizure, and diagnostic kits. | 05-19-2016 |
20160140382 | CELLULAR ACTIVITY QUANTIFICATION USING LABELED PROBES - Methods and systems for quantifying cellular activity using labeled probes, e.g., quantum dots, are disclosed. In one example approach, a method for quantifying cellular activity in a sample containing intact cells having labeled complexes comprises receiving images of the sample at a plurality of depths and detecting individual intact cells in the images of the sample at the plurality of depths. For each detected cell, discrete labels may be detected and localized in the cell at each depth, a total number of detected and localized labels may be calculated in the cell, and an activity level of the target molecule for the labeled probe in the cell determined. | 05-19-2016 |
20160144331 | METHOD FOR GENERATING AN AFFINITY REAGENT LIBRARY - The present disclosure provides a method for generating an affinity reagent library against a target protein which interacts with a ligand, which comprises the following steps; i) determining one or more structural element(s) of the ligand which are involved in ligand: target protein interaction; ii) producing a library of peptides which retain these structural element(s); and iii) grafting each peptide from the library of peptides into a portion of the affinity reagent molecule such that it may interact with the target protein, in order to produce an affinity reagent library. | 05-26-2016 |
20160144332 | Microfluidic Devices and Methods for Gene Synthesis - Certain aspects of the present invention provide devices and methods for preparing oligonucleotides and for assembling nucleic acid molecules using microfluidic devices. | 05-26-2016 |
20160144368 | PLATE, METHOD FOR MANUFACTURING PLATE, METHOD FOR OBSERVING BIOCHIP, AND METHOD FOR SCREENING - This plate ( | 05-26-2016 |
20160145586 | AAD-1 EVENT DAS-40278-9, RELATED TRANSGENIC CORN LINES, AND EVENT-SPECIFIC IDENTIFICATION THEREOF - This invention relates in part to plant breeding and herbicide tolerant plants. This invention includes a novel aad-1 transformation event in corn plants comprising a polynucleotide sequence, as described herein, inserted into a specific site within the genome of a corn cell. In some embodiments, said event/polynucleotide sequence can be “stacked” with other traits, including, for example, other herbicide tolerance gene(s) and/or insect-inhibitory proteins. Additionally, the subject invention provides assays for detecting the presence of the subject event in a sample (of corn grain, for example). The assays can be based on the DNA sequence of the recombinant construct, inserted into the corn genome, and on the genomic sequences flanking the insertion site. Kits and conditions useful in conducting the assays are also provided. | 05-26-2016 |
20160145602 | METHODS AND APPARATUSES FOR GENE PURIFICATION AND IMAGING - The present disclosure is directed to systems, devices and methods for nucleic acid or protein purification and imaging. A system is provided including a cartridge comprising a sample input area configured to hold a sample, comprising a plurality of hybridized complexes comprising a plurality of target molecules each hybridized with probes and a plurality of non-hybridized probes. The cartridge may also include a first binding chamber configured with first magnetic beads to receive and bind the sample, a first elution channel configured to receive the first magnetic beads and elute the sample from the first magnetic beads, a second binding chamber configured with second magnetic beads to receive and bind the sample, a second elution channel configured to receive the second magnetic beads and elute the sample from the second magnetic beads, and a binding area configured to receive the eluted sample and hold molecules for imaging. | 05-26-2016 |
20160145605 | PEPTIDE-PRESENTING PROTEIN AND PEPTIDE LIBRARY USING SAME - The object of the present invention is to provide a method for screening peptide(s) highly specific to a target molecule. The object can be solved by a peptide-presenting protein wherein a peptide is presented in a presentation region consisting of the 131st to 139th amino acids in the amino acid sequence of the SEQ ID NO: 54, wherein the peptide consisting of 4 to 15 amino acids is inserted in the 131st to 139th amino acids sequence, or substituted for any of 1 to 9 amino acid(s) sequence in the 131st to 139th amino acids sequence; and a total length of an amino acid sequence corresponding to the 131st to 139th amino acids sequence is 15 or less. | 05-26-2016 |
20160145654 | POLYMER PARTICLES AND USES THEREOF - The present invention relates to polymer particles and uses thereof. The polymer particle may comprise a polymer selected from poly-beta-amino acids, polylactates, polythioesters and polyesters. In particular the present invention relates to functionalised polymer particles, processes of production and uses thereof. The methods, polymer particles and fusion proteins of the present invention have utility in diagnostics, protein production, biocatalyst immobilisation, and drug delivery. | 05-26-2016 |
20160145678 | MULTIPLEX ASSAY FOR THE DETECTION OF AT LEAST TWO CITRUS PATHOGENS - The present invention provides methods and compositions for detecting multiple citrus pathogens using a multiplex branched DNA signal amplification reaction. | 05-26-2016 |
20160145686 | BIOMARKER FOR SENESCENCE AND USE THEREOF - A biomarker for diagnosing senescence, a composition and a kit for diagnosing a senescence level to detect the same, a method of diagnosing a senescence level in a cell or subject, and a method of screening a senescence inhibitor. | 05-26-2016 |
20160145688 | Methods and Compositions for Diagnosing Disease - The present invention relates to methods and compositions for diagnosing a disease or disorder in a subject by introducing into cells of the subject a diagnostic gene switch construct and monitoring expression of a reporter gene. The invention further relates to methods and compositions for monitoring the progression of a disease or disorder or the effectiveness of a treatment for a disease or disorder. | 05-26-2016 |
20160146733 | METHOD FOR MANUFACTURING NANOPARTICLE ARRAY, SURFACE PLASMON RESONANCE-BASED SENSOR AND METHOD FOR ANALYZING USING SAME - The present invention relates to a method for manufacturing a nanoparticle array, a surface plasmon resonance-based sensor, and a method for analyzing using the same. According to one embodiment of the present invention, after a mixed solution of an ionized binder and conductive nanoparticles is prepared, a substrate is dipped into the mixed solution. Thereafter, by applying an electric field to the mixed solution into which the substrate is dipped so as to induce coating of the conductive nanoparticles on the substrate, it is possible to manufacture, by a wet method, a nanoparticle array in which the conductive nanoparticles are quickly coated on the substrate with high density. | 05-26-2016 |
20160146796 | HIGH SENSITIVITY QUANTITATION OF PEPTIDES BY MASS SPECTROMETRY - The instant invention provides an economical flow-through method for determining amount of target proteins in a sample. An antibody preparation (whether polyclonal or monoclonal, or any equivalent specific binding agent) is used to capture and thus enrich a specific monitor peptide (a specific peptide fragment of a protein to be quantitated in a proteolytic digest of a complex protein sample) and an internal standard peptide (the same chemical structure but including stable isotope labels). Upon elution into a suitable mass spectrometer, the natural (sample derived) and internal standard (isotope labeled) peptides are quantitated, and their measured abundance ratio used to calculate the abundance of the monitor peptide, and its parent protein, in the initial sample. | 05-26-2016 |
20160146798 | BIOSENSOR BASED ON THE MEASUREMENTS OF CLUSTERING DYNAMICS OF MAGNETIC PARTICLES USING A DOUBLE PASS SETUP - Disclosed herein is a biosensor for optical detection of Brownian relaxation dynamics of magnetic particles measured by light transmission. The magnetic particles can be functionalized with biological ligands for the detection of target analytes in a sample. The setup may be implemented in a disc and optical pick-up head configuration. | 05-26-2016 |
20160146800 | APERTURE ARRAY SUBSTRATE DEVICE, A DETECTION SYSTEM AND A METHOD FOR DETECTING ANALYTES IN A SAMPLE - There is provided an optical detection system ( | 05-26-2016 |
20160146804 | DNA-CONJUGATED ANTIBODIES FOR IMPROVED ANTIBODY AFFINITY AND REDUCED ANTIBODY CROSS REACTIVITY - Disclosed are specific binding molecules (e.g. antibodies) that are provided in a set of conjugates, where each conjugate comprises an antibody linked to an oligonucleotide (oligo), such as a DNA oligonucleotide. The antibodies in each set are to the same target antigen. One antibody is preferably immobilized so that it remains in the sample reaction after a wash step. One antibody is used for detection since it will remain in the sample after washing only if there is a specific antibody-target antigen. The oligos in a given set hybridize to each other when both antibodies bind to a target with immuno-specificity. However, if the binding is not immune specific, such as in the case of cross-reactivity, the oligos do not hybridize. | 05-26-2016 |
20160146805 | FLOW-THROUGH SENSOR - In one general aspect, a flow-through sensor can include a carbon nanotube structure including a parallel array of micro-channels, a catalyst coupled to an inner surface of at least one of the micro-channels, and a functionalizing material disposed within the micro-channels. | 05-26-2016 |
20160146810 | ASSAYS FOR ANTIMICROBIAL ACTIVITY AND APPLICATIONS THEREOF - The disclosure provides methods, compositions, and kits for enhanced detection of microbes in samples and monitoring of antimicrobial activity in a subject. | 05-26-2016 |
20160146818 | BLADDER CANCER DETECTION COMPOSITION, KIT, AND ASSOCIATED METHODS - Compositions, kits, and methods for the diagnosis, prognosis, and monitoring of bladder cancer in a subject are provided by detecting in a urine sample a combination of biomarkers. In one embodiment of the invention, biomarker panels consisting of individual targets listed in Tables 4 through 10 may be detected. In another embodiment of the invention, multiplex biomarker panels of various composition, but including those biomarkers listed above may be detected. | 05-26-2016 |
20160146823 | METHODS, COMPOSITIONS AND SYSTEMS FOR MICROFLUIDIC ASSAYS - Provided herein, among other aspects, are methods and apparatuses for analyzing particles in a sample. In some aspects, the particles can be analytes, cells, nucleic acids, or proteins and contacted with a tag, partitioned into aliquots, detected by a ranking device, and isolated. The methods and apparatuses provided herein may include a microfluidic chip. In some aspects, the methods and apparatuses may be used to quantify rare particles in a sample, such as cancer cells and other rare cells for disease diagnosis, prognosis, or treatment. | 05-26-2016 |
20160146831 | Antibody and Cytokine Biomarker Profiling for Determination of Patient Responsiveness - Compositions and methods are provided for prognostic classification of autoimmune disease patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of circulating blood levels of serum autoantibodies and/or cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness. Additionally, serum autoantibody and/or cytokine signature patterns can be utilized to monitor responses to therapy. Assessment of this signature pattern of autoantibodies and/or cytokines in a patient thus allows improved methods of care. In one embodiment of the invention, the autoimmune disease is rheumatoid arthritis. | 05-26-2016 |
20160146832 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - It is an object of the present invention to provide a combination of a functional assessment of renal function together with biomarker results in order to improve assessment of patient at risk of or having, an acute kidney injury. A loop diuretic such as furosemide inhibits luminal active chloride transport throughout the thick ascending limb of Henle, thereby preventing sodium reabsorption and resulting in natriuresis and increased urine flow. Loop diuretic-induced increases in urine output might be a method to assess the integrity of the renal tubular function in the setting of early AKI, and so a kidney's response, or lack thereof, to a diuretic challenge as a clinical assessment of tubular function can identify patients with severe tubular injury before it is clinically apparent (e.g. a rise in creatinine). | 05-26-2016 |
20160146833 | STRESS AND INFLAMMATION BIOMARKER URINE PANEL FOR DAIRY COWS AND BEEF CATTLE - A panel for monitoring levels of biomarkers in ruminants, including an assay having at least one inflammation monitoring test, at least one oxidative stress monitoring test, and at least one antioxidant activity monitoring test. A method of monitoring the health of ruminants, by collecting a sample from the ruminant, applying the sample to an assay panel, performing at least one inflammation monitoring test, at least one oxidative stress monitoring test, and at least one antioxidant activity monitoring test in the panel, and determining levels of biomarkers related to inflammation, oxidative stress, and antioxidant activity and therefore providing information regarding the ruminant's relative health and/or risk of developing one or more diseases. | 05-26-2016 |
20160146836 | USE OF ALPHA-CRYSTALLIN B (CRYAB) IN THE ASSESSMENT OF HEART FAILURE - The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker CRYAB, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure selected from the group consisting of a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation, and of assessing heart failure by comparing the concentration determined in for CRYAB and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of CRYAB as a marker protein in the assessment of heart failure, a marker combination comprising CRYAB and a kit for measuring CRYAB. | 05-26-2016 |
20160146837 | DIAGNOSTIC TESTING IN DEMENTIA AND METHODS RELATED THERETO - This disclosure relates to diagnostic testing for subjects with or at risk of dementia and methods related thereto. In certain embodiments, the disclosure relates to methods of diagnosing a frontotemporal lobar degeneration subtype comprising measuring total Tau and Tau phosphorylated at threonine 181 in a sample from a subject, calculating a ratio of Tau phosphorylated at threonine 181 to total Tau, and making a diagnosis of the subtype based on said ratios. Typically, the sample is of cerebrospinal fluid and the frontotemporal lobar degeneration subtypes are selected from frontotemporal lobar degeneration with immunoreactive lesions to Tau and frontotemporal lobar degeneration with immunoreactive lesions to TAR DNA binding protein of 43 kD. | 05-26-2016 |
20160146840 | AUGURIN IMMUNOASSAY - The present invention relates to an immunoassay method for the detection of augurin or a precursor or fragment thereof comprising contacting a sample suspected of comprising augurin or a precursor or fragment thereof with a first and second antibody specific for augurin or a precursor or fragment thereof, wherein said first and second antibodies or antigen-binding fragments or derivatives thereof are specific for epitopes comprised in the sequence spanning amino acids 71 to 107 of pre-augurin according to SEQ ID NO:1. | 05-26-2016 |
20160152971 | Method for Selecting Polynucleotides Encoding Antigen-Specific Immunoglobulin Subunits | 06-02-2016 |
20160153026 | Dynamic Array Assay Methods | 06-02-2016 |
20160153027 | Sensitive and Rapid Method for Candidatus Liberibacter Species Detection | 06-02-2016 |
20160153030 | CYANOBACTERIA SAXITOXIN GENE CLUSTER AND DETECTION OF CYANOTOXIC ORGANISMS | 06-02-2016 |
20160153032 | METHOD FOR PREDICTING A MANIFESTATION OF AN OUTCOME MEASURE OF A CANCER PATIENT | 06-02-2016 |
20160153033 | Detection of Nucleic Acids | 06-02-2016 |
20160153034 | Rapid Epidemiologic Typing of Bacteria | 06-02-2016 |
20160153036 | SPECIFIC NUCLEIC ACID AMPLIFICATION WITH COMPOUNDED SELECTIVITY | 06-02-2016 |
20160153037 | METHODS TO DETECT A SILENT CARRIER GENOTYPE | 06-02-2016 |
20160153047 | CELL CULTURE ISOLATION AND EXPANSION OF CIRCULATING TUMOR CELLS (CTC) FROM CANCER PATIENTS OR ANIMALS TO DERIVE PROGNOSTIC AND PREDICTIVE INFORMATION AND TO PROVIDE A SUBSTRATE FOR SUBSEQUENT GENETIC, METABOLIC, IMMUNOLOGIC, AND OTHER CELLULAR CHARACTERIZATIONS. | 06-02-2016 |
20160153048 | Method for the Cytological Analysis of Cervical Cells | 06-02-2016 |
20160153050 | METHOD FOR DETECTING PRECANCEROUS LESIONS | 06-02-2016 |
20160153051 | GENE EXPRESSION PROFILES TO PREDICT BREAST CANCER OUTCOMES | 06-02-2016 |
20160153052 | MARKER TO PREDICT AND MONITOR RESPONSE TO AURORA KINASE B INHIBITOR THERAPY | 06-02-2016 |
20160153053 | CANCER-RELATED BIOLOGICAL MATERIALS IN MICROVESICLES | 06-02-2016 |
20160153973 | DEVICE AND METHOD OF RAPID LINKER MEDIATED LABEL-BASED IMMUNOASSAYS | 06-02-2016 |
20160153980 | METHOD AND DEVICE FOR BIOASSAYS | 06-02-2016 |
20160153983 | BIOMARKERS, METHODS AND KITS FOR THE DIAGNOSIS OF RHEUMATOID ARTHRITIS | 06-02-2016 |
20160153985 | COMPLEMENT ASSAYS AND USES THEREOF | 06-02-2016 |
20160153989 | SELECTION OF BIOLOGICAL OBJECTS | 06-02-2016 |
20160153991 | Synbodies for Detection of Human Norovirus | 06-02-2016 |
20160153992 | MUTATED PARVOVIRUS STRUCTURAL PROTEINS AS VACCINES | 06-02-2016 |
20160153994 | EBV PROTEINS AS MARKERS IN METHODS OF DIAGNOSING CHRONIC FATIGUE SYNDROME (CFS) | 06-02-2016 |
20160153998 | BIOMARKERS FOR PREDICTING THE SENSITIVITY OF CELLS TO IMMUNOMODULATORY COMPOUNDS DURING TREATMENT OF NON-HODGKIN'S LYMPHOMA | 06-02-2016 |
20160154005 | TUBERCULOSIS BIOMARKERS AND USES THEREOF | 06-02-2016 |
20160154008 | METHODS AND APPARATUS FOR ASSESSMENT OF RISK FOR JOINT INJURY | 06-02-2016 |
20160154010 | BLOOD-BASED SCREEN FOR DETECTING NEUROLOGICAL DISEASES IN PRIMARY CARE SETTINGS | 06-02-2016 |
20160154012 | MEANS AND METHODS FOR DIAGNOSING HEART FAILURE IN A SUBJECT | 06-02-2016 |
20160160265 | DEVICES AND METHODS FOR THERMALLY-MEDIATED CHEMICAL REACTIONS - One aspect of the invention provides container for thermal cycling a plurality of samples in a microfluidic array. The container includes a plurality of walls defining an interior volume and a conductive member for heating the interior volume. Another aspect of the invention provides container for thermal cycling a plurality of samples in a microfluidic array. The container includes a plurality of walls defining an interior volume and a plurality of conductive members for heating an interior volume. Another aspect of the invention provides a container for thermal cycling a plurality of samples in a microfluidic array. The container includes a plurality of walls defining an interior volume and a first conductive member located in the interior volume and adapted to contact a first end of the microfluidic array. | 06-09-2016 |
20160160268 | AMDINOCILLIN FOR RAPID DETERMINATION OF SUSCEPTIBILITY TO BETA-LACTAM ANTIBIOTICS - Described are methods for detecting susceptibility of a specimen to antibiotics, and particularly for enhancing such susceptibility testing for beta lactam antibiotics and antibiotics that bind to penicillin-binding proteins. The method comprises contacting the specimen with an oligonucleotide probe that specifically hybridizes with a target nucleic acid sequence region of ribosomal RNA. The target sequence is mature ribosomal RNA or at the splice site between a pre-ribosomal RNA tail and mature ribosomal RNA. Performing the method in the presence and absence of an antibiotic permits determination of antibiotic susceptibility. Rapid susceptibility testing is enabled by the addition of the PBP2-specific antibiotic, amdinocillin. | 06-09-2016 |
20160160271 | Real Time Microarrays - This invention provides methods and systems for measuring the binding of analytes in solution to probes bound to surfaces in real-time. | 06-09-2016 |
20160160272 | Arrays and Methods of Use - Methods are provided for producing a molecular array comprising a plurality of molecules immobilised to a solid substrate at a density which allows individual immobilised molecules to be individually resolved, wherein each individual molecule in the array is spatially addressable and the identity of each molecule is known or determined prior to immobilization. The use of spatially addressable low density molecular arrays in single molecule detection and analysis techniques is also provided. Novel assays and methods are also provided. | 06-09-2016 |
20160160280 | METHODS OF PREDICTING TOXICITY - Described herein are compounds useful for the treatment and investigation of diseases, methods for the prediction of in vivo toxicity of compounds useful for the treatment and investigation of diseases, and methods of discovering and identifying compounds useful for the treatment and investigation of diseases that have reduced in vivo toxicity. | 06-09-2016 |
20160160282 | Neprilysin Gene Polymorphism and Amyloid Beta Plaques in Traumatic Brain Injury - The invention relates to methods of diagnosing risk of amyloid β deposition following traumatic brain injury. The invention further relates to the discovery of a specific single nucleotide polymorphism in the neprilysin gene that is linked to an increased risk of amyloid β deposition after traumatic brain injury. | 06-09-2016 |
20160160285 | METHOD FOR DETECTING GENES SENSITIVE TO LOW-LEVEL IONIZING RADIATION, AND GENE DETECTED BY THE METHOD - A method for detecting genes sensitive to low-level ionizing radiation and genes detected by the method. More specifically, genes sensitive to low-level ionizing radiation and related to suppressing thymic cancer, discovered in a carcinogenic entity and verified in a normal entity are detected by subjecting a cancerous AKR/J mouse and a normal ICR mouse to low-level radiation. Thymus is collected therefrom, immunogenic and apoptotic genes are classified via microarray processing of the thymus. The genes are amplified and the levels of gene expression are measured. Thus, a gene having a specific reaction to radiation to be accurately detected by preventing the interference of confounding variables. | 06-09-2016 |
20160160288 | METHOD FOR DETERMINING NUCLEIC ACID COMPOSITION OF NUCLEIC ACID MIXTURE - The present invention provides a method for determining the nucleic acid composition in a total nucleic acid mixture comprising a first nucleic acid and a second nucleic acid. The method comprises: 1) treating the total nucleic acid mixture with a bisulfate, to convert the non-methylated cytosine in the total nucleic acid mixture into uracil, and obtain a converted total nucleic acid mixture; 2) subjecting the converted total nucleic acid mixture to multiplexed fluorescent quantitative PCR using a first set of amplification primers and a second set of amplification primers; and 3) based on the ratio R of the methylated amplification product to the non-methylated amplification product of the predetermined nucleic acid fragment, a methylation proportion M | 06-09-2016 |
20160160298 | DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER - Disclosed are methods for identifying early-stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery that chromosomal copy number gains at Chr19, 34.7 Mb-35.6 Mb can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of this genetic locus. | 06-09-2016 |
20160161392 | METHODS AND APPARATUS FOR THE MANIPULATION OF PARTICLE SUSPENSIONS AND TESTING THEREOF - Apparatus and methods are provided for analysis of individual particles in a microfluidic device. The methods involve the immobilization of an array of particles in suspension and the application of experimental compounds. Such methods can also include electrophysiology studies including patch clamp recording, electroporation, or both in the same microfluidic device. The apparatus provided includes a microfluidic device coupled to a multi-well structure and an interface for controlling the flow of media within the microchannel device. | 06-09-2016 |
20160161455 | ELUCIDATION OF ION EXCHANGE CHROMATOGRAPHY INPUT OPTIMIZATION - The present invention provides methods for determining chromatography separation conditions; for example, separation of a polypeptide and its charge variants. The invention also provides methods to determine a buffer condition for chromatography separation conditions. The invention also provides a robust method to analyze multiple polypeptide products. | 06-09-2016 |
20160161472 | QUANTITATIVE DNA-BASED IMAGING AND SUPER-RESOLUTION IMAGING - The present disclosure provides, inter alia, methods and compositions (e.g., conjugates) for imaging, at high spatial resolution, targets of interest. | 06-09-2016 |
20160161474 | METHODS AND DEVICES FOR PERFORMING HIGH DYNAMIC RANGE IMMUNOASSAYS - A method for performing a high dynamic range immunoassay includes (a) measuring a first signal from a sandwich immunoassay to detect a target analyte in a fluidic sample in a fluidic channel and a second signal from a competitive immunoassay associated with the target analyte in the same fluidic sample in the fluidic channel, and (b) determining ratio of the first signal to the second signal to provide a measure of concentration of the target analyte in the fluidic sample, wherein the measure is applicable to a high dynamic range of concentrations of the target analyte. | 06-09-2016 |
20160161475 | HYBRID SEMICONDUCTING POLYMER NANOPARTICLES AS POLARIZATION-SENSITIVE FLUORESCENT PROBES - Compositions of, methods of making, and methods of using hybrid nanoparticles comprise at least one semiconducting polymer and at least one nonsemiconducting polymer. Compositions of, methods of making and methods of using hybrid nanoparticles comprise at least one semiconducting polymer and non-semiconducting polymers wherein the non-semiconducting polymer comprises more than one non-semiconducting polymer such that at least one non-semiconducting polymer is functionalized for bioconjugation. The hybrid nanoparticles are polarization-sensitive and have low mass ratios with large fluorescence. | 06-09-2016 |
20160161479 | OPTOELECTRONIC DETECTION SYSTEM - The invention relates to optoelectronic systems for detecting one or more target particles. The system includes a reaction chamber, a specimen collector, an optical detector, and a reservoir containing cells, each of the cells having receptors which are present on the surface of each cell and are specific for the target particle to be detected, where binding of the target particle to the receptors directly or indirectly activates a reporter molecule, thereby producing a measurable optical signal. | 06-09-2016 |
20160161481 | METHOD FOR DETECTING INDICATORS FOR DETERMINING DISEASES - The invention concerns a method for detecting indicators for determining diseases (disease indicators), in which aggregates of misfolded proteins play a role, and a method for selective quantitation and/or characterization of these disease indicators. | 06-09-2016 |
20160161492 | Methods Of Detecting Cancer - Method and kits for detecting cancer, and in particular breast cancer, in a subject by measuring the levels of at least one of a series of biomarkers, as compared to a control sample lacking cancer. The expression of the biomarker either increases or decreases in samples from subjects with cancer, as compared to the expression level in subjects without cancer. The sample is optimally an ocular sample, such as an isolated tear sample or ocular wash, but can also be from saliva, or other bodily fluid. Kits can include a collection tube and protease inhibitors or protein stabilizers. | 06-09-2016 |
20160161501 | NOVEL INFLAMMATORY BOWEL DISEASE MARKERS AND THERAPIES FOR COLITIS-ASSOCIATED INTESTINAL FIBROSIS - Method of diagnosing and treating inflammatory bowel disease are disclosed herein. Inflammatory bowel disease can be treated and diagnosed using cathelicidin peptides and detection agents thereof. Specifically, method of treating and diagnosing Crohn's disease and ulcerative colitis are disclosed herein. | 06-09-2016 |
20160161508 | METHOD FOR DIAGNOSING NEURO-DEGENERATIVE DISEASE - A method for the diagnosis of Alzheimer's Disease (AD) or Parkinson's Disease (PD), including measuring the level of expression of one or more AD markers (Table 1) or PD markers (Table 2) in a sample of platelets isolated from a person suspected of having AD or PD, and determining whether the levels of expression are altered compared to a control. | 06-09-2016 |
20160161513 | MODULAR POINT-OF-CARE DEVICES, SYSTEMS, AND USES THEREOF - The present invention provides devices and systems for use at the point of care. The methods devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device are modular to allow for flexibility and robustness of use with the disclosed methods for a variety of medical applications. | 06-09-2016 |
20160161514 | Simultaneous Assay of Target and Target-Drug Binding - Whole cell, simultaneous target and drug-target assay using differentially labeled antibodies and flow cytometry. First antibody binds to total target and second antibody binds to the drug binding site of the target, thus drug binding will competitively inhibit the second antibody allowing for a competitive inhibition assay of drug-target binding. The assay allows for whole cell analysis and even analysis of mixed populations of cells, yet provides detailed kinetic assessment of drug activity. | 06-09-2016 |
20160168621 | METHODS AND RELATED DEVICES FOR SINGLE MOLECULE WHOLE GENOME ANALYSIS | 06-16-2016 |
20160168622 | IMMEDIATE CHROMATIN IMMUNOPRECIPITATION AND ANALYSIS | 06-16-2016 |
20160168623 | ANALYSIS | 06-16-2016 |
20160168625 | METHODS AND COMPOSITIONS FOR DETECTING ANTIBIOTIC RESISTANT BACTERIA | 06-16-2016 |
20160168637 | GENETIC MARKERS OF MENTAL ILLNESS | 06-16-2016 |
20160168645 | GENE EXPRESSION PROFILES TO PREDICT BREAST CANCER OUTCOMES | 06-16-2016 |
20160168650 | CELLULAR ARRAYS AND METHODS OF DETECTING AND USING GENETIC DISORDER MARKERS | 06-16-2016 |
20160168651 | METHOD FOR DETECTING CHIKUNGUNYA VIRUS | 06-16-2016 |
20160169801 | Target Characterization Based on Persistent Collocation of Multiple Specks of Light in Time Series Imagery | 06-16-2016 |
20160169877 | PATTERNING SILICA ISLANDS ONTO THERMOPLASTIC SHRINK FILM | 06-16-2016 |
20160169878 | DETECTION OF ANALYTES USING METAL NANOPARTICLE PROBES AND DYNAMIC LIGHT SCATTERING | 06-16-2016 |
20160169880 | SYSTEMS AND METHODS FOR MULTI-ANALYSIS | 06-16-2016 |
20160169885 | DETECTION OF DEGRADATIVE ENZYMES AND BIOMOLECULES IN BODILY FLUIDS | 06-16-2016 |
20160169886 | ASSAY STRUCTURES AND ENHANCEMENT BY SELECTIVE MODIFICATION AND BINDING ON AMPLIFICATION STRUCTURES | 06-16-2016 |
20160169895 | FLAP ENDONUCLEASE-1 AS A MARKER FOR CANCER | 06-16-2016 |
20160169897 | ASSAY METHODS FOR THE DETERMINATION OF FKBPL EXPRESSION LEVEL IN THE CONTEXT OF BREAST CANCER | 06-16-2016 |
20160169899 | METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF CANCER | 06-16-2016 |
20160169900 | COMPOSITIONS, METHODS AND KITS FOR DIAGNOSIS OF LUNG CANCER | 06-16-2016 |
20160169901 | METHODS FOR DIAGNOSIS OF CUTANEOUS T-CELL LYMPHOMA | 06-16-2016 |
20160169903 | METHODS AND COMPOSITIONS RELATING TO SUPER-RESOLUTION IMAGING AND MODIFICATION | 06-16-2016 |
20160169904 | Secretome Profile-Facilitated In Vitro Fertilization | 06-16-2016 |
20160169907 | METHOD FOR PROGNOSIS OF THE EFFICACY OF ORAL IMMUNOTHERAPY FOR THE TREATMENT OF ALLERGY TO PROTEINS IN COW'S MILK | 06-16-2016 |
20160169912 | Diagnosis and Risk Assessment of Pancreatic Diabetes Using MR-proADM | 06-16-2016 |
20160175800 | COVALENTLY-IMMOBILIZED HYDROGEL ARRAYS IN MULTI-WELL PLATES | 06-23-2016 |
20160176853 | Benzocyanine Compounds | 06-23-2016 |
20160177375 | METHODS AND SYSTEMS FOR DETECTING BIOLOGICAL COMPONENTS | 06-23-2016 |
20160177377 | COMPOSITIONS AND METHODS FOR DETECTION OF DRUG RESISTANT MYCOBACTERIUM TUBERCULOSIS | 06-23-2016 |
20160177378 | METHOD FOR SIMULTANEOUS DETECTION OF BACTERIA AND FUNGI IN A BIOLOGICAL PREPARATION BY PCR, PRIMERS AS WELL AS BACTERIA AND FUNGI DETECTION KIT | 06-23-2016 |
20160177381 | Base-Pair Specific Inter-Strand Locks for Genetic and Epigenetic Detection | 06-23-2016 |
20160177382 | DEVICES AND METHODS FOR CONTROLLING REVERSIBLE CHEMICAL REACTIONS AT SOLID-LIQUID INTERFACES BY RAPID PRECONCENTRATION AND PHASE REPLACEMENT | 06-23-2016 |
20160177394 | ESOPHAGEAL MICRORNA EXPRESSION PROFILES IN EOSINOPHILIC ESOPHAGITIS | 06-23-2016 |
20160177395 | BIOMARKERS FOR THE PREDICTION OF RENAL INJURY | 06-23-2016 |
20160177396 | COMPREHENSIVE AND COMPARATIVE FLOW CYTOMETRY-BASED METHODS FOR IDENTIFYING THE STATE OF A BIOLOGICAL SYSTEM | 06-23-2016 |
20160177401 | URINE BIOMARKER COHORTS, GENE EXPRESSION SIGNATURES, AND METHODS OF USE THEREOF | 06-23-2016 |
20160178520 | Multiplexed Single Molecule Analyzer | 06-23-2016 |
20160178614 | CELL-BASED CONTROL AND METHOD | 06-23-2016 |
20160178616 | T1R HETERO-OLIGOMERIC TASTE RECEPTORS AND CELL LINES THAT EXPRESS SAID RECEPTORS AND USE THEREOF FOR IDENTIFICATION OF TASTE COMPOUNDS | 06-23-2016 |
20160178620 | Biomarkers for Pre-Diabetes, Cardiovascular Diseases, and other Metabolic-Syndrome Related Disorders and Methods Using the Same | 06-23-2016 |
20160178624 | DEVICE AND METHOD TO PERFORM MULTIPLEX ASSAYS AND TARGET ENRICHMENT | 06-23-2016 |
20160178626 | HUMAN STREPTOCOCCUS PNEUMONIAE ANTIBODIES AND USES THEREFOR | 06-23-2016 |
20160178641 | BIOMARKERS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION | 06-23-2016 |
20160178642 | BIOMARKERS FOR COGNITIVE DYSFUNCTION DISEASES AND METHOD FOR DETECTING COGNITIVE DYSFUNCTION DISEASE USING BIOMARKERS | 06-23-2016 |
20160178643 | MULTI-PROTEIN BIOMARKER ASSAY FOR BRAIN INJURY DETECTION AND OUTCOME | 06-23-2016 |
20160178648 | MARKER FOR DETECTING PROLIFERATION AND TREATMENT CAPACITIES OF ADIPOSE-DERIVED STEM CELL CULTURED IN MEDIUM CONTAINING EGF OR BFGF, AND USE THEREOF | 06-23-2016 |
20160178649 | METHOD AND SYSTEM FOR SENSING AND DETECTING A TARGET MOLECULE | 06-23-2016 |
20160186236 | REAL TIME QUANTITATIVE AND QUALITATIVE ANALYSIS METHOD FOR BIOSUBSTANCE - A method of quantitatively and qualitatively analyzing a biomaterial in real-time, the method comprising preparing a device for detecting a biomaterial, feeding a complex of first and second probes, a forward primer, a reverse primer, a sample comprising deoxynucleotide triphosphate, a polymerase having exonuclease activity, and a sample comprising target genes, and a reaction solution comprising a buffer into the reaction container, performing polymerase chain reaction comprising denaturation of the target genes in the sample, hybridization of the target genes, the complex, and the forward and reverse primers in the sample, and elongation of the primers through the polymerase having exonuclease activity, allowing for elongation of the second probe on the third probe by the polymerase after hybridizing the released second probe and the third probe fixed to the biochip, detecting a first fluorescence signal by the first phosphor and a second fluorescence signal by the second phosphor. | 06-30-2016 |
20160186237 | METHODS AND COMPOSITIONS TO ENABLE ENRICHMENT OF MINOR DNA ALLELES BY LIMITING DENATURATION TIME IN PCR OR SIMPLY ENABLE ENRICHMENT OF MINOR DNA ALLELES BY LIMITING THE DENATURATION TIME IN PCR - The present invention is directed to methods, compositions and reaction mixtures for conducting COLD-PCR, by controlling and varying a preferential denaturation time. | 06-30-2016 |
20160186238 | REACTIVITY-DEPENDENT AND INTERACTION-DEPENDENT PCR - Methods, reagents, compositions, and kits for reactivity-dependent polymerase chain reaction (RD-PCR) and interaction-dependent polymerase chain reaction (ID-PCR) are provided herein. RD-PCR is a technique useful for determining whether a reactive moiety can form a covalent bond to a target reactive moiety, for example, in screening a library of candidate reactive moieties for reactivity with a target reactive moiety, and in identifying an enzyme substrate, for example, in protease substrate profiling. ID-PCR is a technique useful for determining whether a ligand can non-covalently bind to a target molecule, for example, in screening a library of candidate ligands for non-covalent interaction with a target molecule. RD-PCR and ID-PCR are also useful in detecting the presence of an analyte or an environmental condition. | 06-30-2016 |
20160186239 | MULTIPLEXED ASSAY FOR QUANTITATING AND ASSESSING INTEGRITY OF CELL-FREE DNA IN BIOLOGICAL FLUIDS FOR CANCER DIAGNOSIS, PROGNOSIS AND SURVEILLANCE - A retrotransposable element based multiplexed qPCR assay to robustly quantitate and distinguish cell free DNA integrity and concentration in blood plasma and serum is described. The multiplexed system for characterizing cancer in humans includes a sample of serum, plasma, urine, or other biological fluid, the sample comprising cell free DNA, the cell free DNA comprising long and short retrotransposable element targets and an added internal positive control, the long and short targets being independent of each other, a distinctly labeled TaqMan probe corresponding to each target, a forward primer and a reverse primer corresponding to each target, a DNA standard for generating standard curves, a qPCR system for amplifying the targets and a qPCR data analysis system. The assay provides an accurate, minimally-invasive, rapid, high-throughput, and cost-effective method with the potential to complement or replace existing methods for detection, diagnosis, prognosis, treatment monitoring and/or surveillance of cancer, thereby improving patient outcomes. | 06-30-2016 |
20160186242 | COMPOSITIONS AND METHODS FOR DETECTION OF MYCOBACTERIUM AVIUM PARATUBERCULOSIS - Disclosed are compositions, assays, methods, diagnostic methods, kits and diagnostic kits for the specific and differential detection of | 06-30-2016 |
20160186245 | MULTIPLEX DETECTION OF NUCLEIC ACIDS - Methods of detecting nucleic acids, including methods of detecting two or more nucleic acids in multiplex branched-chain DNA assays, are provided. Nucleic acids captured on a solid support are detected, for example, through cooperative hybridization events that result in specific association of a label with the nucleic acids. Compositions, kits, and systems related to the methods are also described. | 06-30-2016 |
20160186246 | PROCESS FOR DETECTING OR QUANTIFYING NUCLEIC ACIDS IN A LIBRARY - This invention provides novel compositions and processes for analyte detection, quantification and amplification. Nucleic acid arrays and libraries of analytes are usefully incorporated into such compositions and processes. Universal detection elements, signaling entities and the like are employed to detect and if necessary or desirable, to quantify analytes. Amplification of target analytes are also provided by the compositions and processes of this invention. | 06-30-2016 |
20160186258 | DETECTION OF RNA-INTERACTING REGIONS IN DNA - The present invention provides methods and kits for detecting RNA-interacting regions in genomic DNA. | 06-30-2016 |
20160186265 | Methods for Typing HLA Alleles - This disclosure relates to the typing of human leucocyte antigen (HLA) alleles. More particularly, the present invention relates to HLA typing as a method of identify patients at risk of a hypersensitivity reaction to drugs such as abacavir and/or to diagnose disease (e.g., Behçet's disease). | 06-30-2016 |
20160186270 | SIGNATURE OF CYCLING HYPOXIA AND USE THEREOF FOR THE PROGNOSIS OF CANCER - The present invention relates to a signature comprising at least 2 cycling hypoxia markers. The present invention also relates to a non-invasive method for the prognosis of cancer in a subject, wherein said method comprises assessing the expression of markers of a signature of the invention in a sample from said subject; and to a kit for implementing this non-invasive method. | 06-30-2016 |
20160186271 | COMPOSITIONS AND METHODS FOR DETERMINING THE PROGNOSIS OF BLADDER UROTHELIAL CANCER - Described herein are compositions and methods for the prediction of bladder cancer risk of invasiveness. The compositions are microRNA molecules associated with the prognosis of bladder cancer, as well as various nucleic acid molecules relating thereto or derived therefrom. | 06-30-2016 |
20160187273 | PHOTOMETRIC ENTHALPY CHANGE DETECTION SYSTEM AND METHOD - A method for detecting an enthalpy change includes providing a first mixture and a second mixture to a drop generator. The first mixture includes a ligand. The second mixture contains a target molecule. The method further includes generating a drop in the drop generator. The drop includes the target molecule, a temperature-sensitive reporter compound, and the ligand. The method also includes measuring a property of the temperature-sensitive reporter compound in the drop to determine an amount of enthalpy change that has occurred. | 06-30-2016 |
20160187321 | INDUCED EXPRESSION OF PROTEINS IN INSECT CELLS - The present invention concerns insect cells that have been induced to express one or more proteins by contact with one or more insect hormones or one or more modulators of the G protein-coupled receptor signaling pathway, compositions comprising such insect cells, a method for inducing protein expression in insect cells, and a screening method using such insect cells. | 06-30-2016 |
20160187327 | DIAGNOSTIC ASSAY USING PARTICLES WITH MAGNETIC PROPERTIES - A novel system for the analysis of molecules and cells, comprising clusters where a non-magnetic particle is supplemented with magnetic particles to form a characteristic pattern, fingerprint or bar code. Methods and devices for formation of such particles are also disclosed. | 06-30-2016 |
20160187333 | PLANAR WAVEGUIDE BASED CARTRIDGES AND ASSOCIATED METHODS FOR DETECTING TARGET ANALYTE - A cartridge for processing a sample includes (a) a planar waveguide with upper and lower planar surfaces defining an optical axis therebetween, wherein the upper planar surface has a plurality of capture molecules bound thereto, (b) a lens portion, coupled to the planar waveguide, for focusing and refracting a light beam propagating parallel to, but offset from, the optical axis such that the light beam couples into the planar waveguide and propagates therein along the optical axis at a non-zero, internal propagation angle β relative to the upper planar surface, and (c) a sample chamber for positioning the sample in contact with the plurality of capture molecules such that a target analyte of the sample is detectable through (i) an assay involving the target analyte and the capture molecules and (ii) evanescent illumination of the assay using the light beam within the planar waveguide. | 06-30-2016 |
20160187341 | KERATINS AS BIOMARKERS FOR CERVICAL CANCER AND SURVIVAL - The current disclosure provides methods for detecting and analyzing KRT4 and KRT17 expression in a sample obtained from a test subject. The current disclosure pertains to methods and kits for identifying a mammalian subject with cervical cancer or non-cancerous lesions of the cervix. The current disclosure further provides methods and kits for determining the likelihood of survival or treatment outcome of a subject having cervical cancer by determining the expression level of KRT17 in a sample. | 06-30-2016 |
20160187356 | METHOD FOR ENRICHMENT AND SEPARATION OF SPINAL FLUID GLYCOPROTEIN, METHOD FOR SEARCHING FOR MARKER FOR CENTRAL NERVOUS SYSTEM DISEASES WHICH UTILIZES THE AFOREMENTIONED METHOD, AND MARKER FOR CENTRAL NERVOUS SYSTEM DISEASES - The purpose of the present invention is to develop: a method for selectively separating a glycoprotein derived from the central nervous system from a body fluid or a central nervous system cell; and a method for searching for an index marker for central nervous system diseases, which utilizes the aforementioned method. A protein derived from the central nervous system, which occurs in a trace amount in a body fluid or a central nervous system cell, can be selectively enriched by a two-stage separation procedure comprising removing a glycoprotein having sialic acid at a non-reducing terminal thereof from the body fluid or the central nervous system cell and then separating a glycoprotein having N-acetylglucosamine at a non-reducing terminal thereof. | 06-30-2016 |
20160194626 | Universal Fibronectin Type III Bottom-Side Binding Domain Libraries | 07-07-2016 |
20160194627 | COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF | 07-07-2016 |
20160194628 | METHODS FOR PRODUCING STRANDED cDNA LIBRARIES | 07-07-2016 |
20160194688 | DIAGNOSTIC METHOD | 07-07-2016 |
20160194693 | PROCESSES FOR DETECTING OR QUANTIFYING NUCLEIC ACIDS IN A LIBRARY | 07-07-2016 |
20160194707 | 3' BIASED DETECTION OF NUCLEIC ACIDS | 07-07-2016 |
20160194719 | A BIOMARKER OF BREAST CANCER | 07-07-2016 |
20160195466 | MASS CYTOMETRY APPARATUS AND METHODS | 07-07-2016 |
20160195516 | Methods of Detecting Signatures of Disease or Conditions in Bodily Fluids | 07-07-2016 |
20160195519 | FLUORESCENT MOLECULAR ROTORS | 07-07-2016 |
20160195524 | Automated Assay | 07-07-2016 |
20160195545 | ASSAY FOR NITRATED AND TOTAL HEMOPEXIN IN FLUID SAMPLES | 07-07-2016 |
20160195546 | Type 1 Diabetes Biomarkers | 07-07-2016 |
20160195547 | DIAGNOSTIC TOOLS FOR ALZHEIMER'S DISEASE | 07-07-2016 |
20160195549 | BIOMARKERS FOR SEIZURES | 07-07-2016 |
20160195552 | MULTIPLEXED DIAGNOSTIC TO RECOGNIZE CONCENTRATIONS OF RELATED PROTEINS AND PEPTIDES | 07-07-2016 |
20160200773 | Molecule Detection Using Boronic Acid Substituted Probes | 07-14-2016 |
20160200847 | CLICKABLE POLYMERS AND GELS FOR MICROARRAY AND OTHER APPLICATIONS | 07-14-2016 |
20160201116 | SEQUENCES AND THEIR USE FOR DETECTION OF SALMONELLA ENTERITIDIS AND/OR SALMONELLA TYPHIMURIUM | 07-14-2016 |
20160201117 | ULTRA SENSITIVE METHOD FOR IN SITU DETECTION OF NUCLEIC ACIDS | 07-14-2016 |
20160201119 | Digital Analysis of Molecular Analytes Using Electrical Methods | 07-14-2016 |
20160201120 | STABLE NANOREPORTERS | 07-14-2016 |
20160201121 | MICROVESICLE-BASED ASSAYS | 07-14-2016 |
20160201127 | METHODS AND PROBES FOR MONITORING MARINE WATER | 07-14-2016 |
20160201133 | METHODS OF MONITORING CONDITIONS BY SEQUENCE ANALYSIS | 07-14-2016 |
20160201136 | BIOMARKERS FOR USE IN COLORECTAL CANCER | 07-14-2016 |
20160201138 | METHOD AND MARKERS FOR ASSESSING THE RISK OF HAVING COLORECTAL CANCER | 07-14-2016 |
20160201139 | METHOD AND MARKERS FOR ASSESSING THE RISK OF HAVING COLORECTAL CANCER | 07-14-2016 |
20160201142 | USING SIZE AND NUMBER ABERRATIONS IN PLASMA DNA FOR DETECTING CANCER | 07-14-2016 |
20160201145 | MARKER ASSOCIATED WITH ANTHRACNOSE RESISTANCE IN PLANT OF THE GENUS FRAGARIA AND USE THEREOF | 07-14-2016 |
20160202163 | PORTABLE DIFFRACTION-BASED IMAGING AND DIAGNOSTIC SYSTEMS AND METHODS | 07-14-2016 |
20160202195 | A QUANTUM METHOD FOR FLUORESCENCE BACKGROUND REMOVAL IN DNA MELTING ANALYSIS | 07-14-2016 |
20160202234 | METHOD FOR EVALUATING, VIA BIODOSIMETRY, THE IRRADIATION DOSE RECEIVED BY A PERSON SUBJECTED TO IONIZING RADIATION | 07-14-2016 |
20160202241 | NANOFIBROUS PHOTOCLICKABLE HYDROGEL MICROARRAYS | 07-14-2016 |
20160202244 | Method for Preparing Topographically Structured Microarrays | 07-14-2016 |
20160202248 | ImmunoLipoplex Nanoparticle Biochip Containing Molecular Probes for Capture and Characterization of Extracellular Vesicles | 07-14-2016 |
20160202252 | Devices and Methods Related to Airway Inflammation | 07-14-2016 |
20160202253 | DETECTION OF BIOLOGICAL MOLECULES USING SURFACE PLASMON FIELD ENHANCED FLUORESCENCE SPECTROSCOPY (SPFS) COMBINED WITH ISOTACHOPHORESIS (ITP) | 07-14-2016 |
20160202260 | BIOMARKERS FOR PROSTATE CANCER | 07-14-2016 |
20160202267 | METHOD FOR OBTAINING APRIL-BINDING PEPTIDES, PROCESS FOR PRODUCING THE PEPTIDES, APRIL-BINDING PEPTIDES OBTAINABLE WITH SAID METHOD/PROCESS AND USE OF THE APRIL-BINDING PEPTIDES | 07-14-2016 |
20160202273 | BIOMARKERS ASSOCIATED WITH DIABETES AND FIBROSIS | 07-14-2016 |
20160203262 | System and Method for Determining Quality of Stem Cell Derived Cardiac Myocytes | 07-14-2016 |
20160251631 | DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES | 09-01-2016 |
20160251651 | CELL FREE CLONING OF NUCLEIC ACIDS | 09-01-2016 |
20160251698 | Analysis Unit for Carrying Out a Polymerase Chain Reaction, Analysis Device, Method for Operating such an Analysis Unit, and Method for Producing such an Analysis Unit | 09-01-2016 |
20160251701 | MULTIPLEX SLIDE PLATE DEVICE AND OPERATION METHOD THEREOF | 09-01-2016 |
20160251702 | Process and Kit for Predicting Antibiotic Resistance and Susceptibility of Bacteria | 09-01-2016 |
20160251705 | GENETIC ANALYSIS SYSTEM | 09-01-2016 |
20160251706 | COMPOSITIONS AND METHODS FOR REPRESENTATIONAL SELECTION OF NUCLEIC ACIDS FROM COMPLEX MIXTURES USING HYBRIDIZATION | 09-01-2016 |
20160251707 | KARYOTYPING ASSAY | 09-01-2016 |
20160251709 | DIRECT QUANTIFICATION OF UNPROCESSED NUCLEIC ACID SAMPLES | 09-01-2016 |
20160251716 | METHODS AND KITS FOR MONITORING THE EFFECTS OF IMMUNOMODULATORS ON ADAPTIVE IMMUNITY | 09-01-2016 |
20160251726 | HYPERMETHYLATION BIOMARKERS ASSOCIATED WITH POOR SURVIVAL OUTCOMES FOR HEAD AND NECK SQUAMOUS CELL CANCER | 09-01-2016 |
20160251731 | MICROBIAL BIOINDICATORS OF HYDROCARBONS IN WATER AND IN MARINE SEDIMENTS AND METHODS FOR MAKING AND USING THEM | 09-01-2016 |
20160251732 | COMPOSITIONS AND METHODS FOR DETECTION AND DISCRIMINATION OF INFLUENZA VIRUSES | 09-01-2016 |
20160251733 | SUGARCANE BACILLIFORM VIRAL (SCBV) ENHANCER AND ITS USE IN PLANT FUNCTIONAL GENOMICS | 09-01-2016 |
20160252459 | SPECTROSCOPIC APPARATUS AND METHODS FOR DETERMINING COMPONENTS PRESENT IN A SAMPLE | 09-01-2016 |
20160252494 | MICROSCALE MICROPATTERNED ENGINEERED IN VITRO TISSUE | 09-01-2016 |
20160252495 | Microfluidic Devices and Methods for Use Thereof in Multicellular Assays of Secretion | 09-01-2016 |
20160252500 | METHOD FOR DETERMINING THE TOTAL AMOUNT AND/OR CONCENTRATION OF AN ANALYTE IN THE PRESENCE OF A BINDING MOLECULE AS WELL AS KITS, COMPOSITIONS AND USES RELATING THERETO | 09-01-2016 |
20160252501 | ENZYME COUPLED ASSAY FOR QUANTIFICATION OF PROTEIN AND PEPTIDE BINDING BY SAMDI MASS SPECTROMETRY | 09-01-2016 |
20160252510 | METHODS OF DIAGNOSING PROLIFERATIVE DISORDERS | 09-01-2016 |
20160252512 | COMPOSITION FOR DIAGNOSING PANCREATIC CANCER AND METHOD FOR DIAGNOSING PANCREATIC CANCER USING SAME | 09-01-2016 |
20160252513 | METHOD, ARRAY AND USE THEREOF | 09-01-2016 |
20160252514 | METHOD FOR CANCER DETECTION, DIAGNOSIS AND PROGNOSIS | 09-01-2016 |
20160252517 | BIOMOLECULAR INTERACTION DETECTION DEVICES AND METHODS | 09-01-2016 |
20160252531 | Biomarkers of Alzheimer's Disease Progression | 09-01-2016 |
20160252535 | Detection and Quantification of Analytes in Bodily Fluids | 09-01-2016 |
20160376632 | KINASE ACTIVITY DETECTION METHODS - The invention provides a method for detecting the activities of two or more kinases. The method enables multiplexed detection with high signal to noise in a high-throughput-compatible format and a platform that could be applied to other lanthanide metal and fluorophore combinations to achieve even greater multiplexing without the need for phosphospecific antibodies. | 12-29-2016 |
20160376637 | SPECIFIC DETECTION OF ORGANISMS DERIVED FROM A SAMPLE - Methods, materials, and kits for distinguishing a population of cells or organisms truly present in a clinical specimen from contaminating cells or organisms is disclosed. The methods and kits use a suppressor to avoid false positive detection of contaminants in nucleic acid amplification reactions. | 12-29-2016 |
20160376638 | QUANTITATIVE ANALYSIS METHOD USING MICROORGANISM 16S RDNA GENE HAVING SINGLE NUCLEOTIDE POLYMORPHISM - The present invention relates to utilization of an artificially synthesized nucleic acid, and more particularly, to a quantitative analysis method capable of quantitatively adjusting gene-based microbial community analysis results by preparing a microorganism 16S rDNA gene, which has a single nucleotide polymorphism (SNP) at a particular location so as to be differentiated from a gene of a target microorganism on the nucleotide sequence, and then using the microorganism 16S rDNA gene as an internal standard material which is quantifiable through nucleotide sequencing. | 12-29-2016 |
20160376639 | METHOD AND SYSTEM FOR MULTIPLEX PROFILING OF CHROMOSOMES IN BIOLOGICAL SAMPLES USING TARGET-SPECIFIC DNA PROBES - The present invention comprises methods and systems to profile individual chromosomes using target-specific DNA probes in biological samples. The invention relates to generation of chromosome profiles either singly or in combination (multiplex). The invention can refer to the generation of chromosome profiles using target-specific DNA probes for various biological samples such as cell free DNA from the peripheral blood of a pregnant woman or from a cancer patient. The invention further involving generation of chromosome profiles using target-specific DNA probes for individual intact cells from the peripheral blood of a pregnant woman, from a cancer patient or from an embryo created using artificial reproductive technologies. The invention further involving detection of target-specific DNA hybridizations through direct fluorescence by special spectral filters or fluorescence intensity by fluorimeters. Alternatively, chemiluminescent system can be used for detecting target-specific DNA hybridizations indirectly through enzyme-substrate reactions using poly-HRP as enzyme and enhanced luminol as substrate. | 12-29-2016 |
20160376641 | Automated RNA Detection Using Labeled 2'-O-Methyl RNA Oligonucleotide Probes and Signal Amplification Systems - Disclosed herein are methods and compositions for detecting differential expression of certain miRNAs in cancer cells or their surrounding normal tissues in the tumor microenvironment. The disclosure describes an automated, highly sensitive and specific method for detection of any cellular RNA molecule, including microRNA, messenger RNA and non-coding RNA. The technology includes probe design as well as probe use in an automated fashion for detection of RNA molecules in formalin-fixed paraffin-embedded tissue (FFPET) samples. | 12-29-2016 |
20160376653 | Biomarkers for Determining an Allograft Tolerant Phenotype - Methods are provided for determining whether a subject has a graft tolerant phenotype. In practicing the subject methods, the expression level of one or more gene in a sample from the subject, e.g., a blood sample, is assayed to obtain a gene expression result, where the gene expression result includes a result for a biomarker of graft tolerance. The obtained gene expression result is then employed to determine whether the subject has a graft tolerant phenotype. Also provided are compositions, systems and kits that find use in practicing the subject methods. The methods and compositions find use in a variety of applications, including the determination of an immunosuppressive therapy regimen. | 12-29-2016 |
20160376654 | Temporal Pediatric Sepsis Biomarker Risk Model - Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to septic shock in pediatric patients. In particular, the invention relates to identifying one or more biomarkers associated with septic shock in pediatric patients, obtaining a sample from a pediatric patient having at least one indication of septic shock, then quantifying from the sample an amount of one or more of said biomarkers, wherein the level of said biomarker correlates with a predicted outcome. | 12-29-2016 |
20160376660 | 3.4 KB MITOCHONDRIAL DNA DELETION FOR USE IN THE DETECTION OF CANCER - A method for detecting cancer in an individual comprising detecting a deletion in the nucleic acid sequence between residues 10743 and 12125 in mitochondrial DNA, obtaining a biological sample from the individual, extracting the mitochondrial DNA (mtDNA) from the sample, quantifying the amount of mtDNA in the sample having a deletion in the nucleic acid sequence between residues 10743 and 14125 of the mtDNA genome, and comparing the amount of mtDNA in the sample having the deletion to at least one known reference sample. | 12-29-2016 |
20160376662 | IMPROVED CERVICAL CANCER DIAGNOSING METHOD AND DIAGNOSTIC KIT FOR SAME - There are provided an improved cervical cancer diagnosing method and a diagnostic kit for same. According to the present invention, it is possible to more rapidly and accurately provide a patient group requiring a clinical treatment and a prevention treatment in terms of a technical aspect to predict that the limitation of the existing HPV DNA test method can be overcome, automate the RNA extraction from eliminated cells, and more rapidly provide more objective and accurate results because the result analysis can be performed by software by using the real-time RT-PCR. | 12-29-2016 |
20160376665 | EGFR ASSAY - Provided herein is technology relating to detecting molecular markers relevant to cancer and particularly, but not exclusively, to methods and compositions for quantifying and/or detecting EGFR mRNA and/or EGFRvIII mRNA in biological samples. | 12-29-2016 |
20160376667 | QUALITY CONTROL OF AGRICULTURAL PRODUCTS BASED ON GENE EXPRESSION - The invention relates to the field of quality testing of fresh plant-based and mushroom based products. Methods, carriers and kits for determining the quality stage are provided. | 12-29-2016 |
20160376668 | GENETIC LOCI ASSOCIATED WITH SOYBEAN CYST NEMATODE RESISTANCE AND METHODS OF USE - Various methods and compositions are provided for identifying and/or selecting soybean plants or soybean germplasm with improved resistance to soybean cyst nematode. In certain embodiments, the method comprises detecting at least one marker locus that is associated with resistance to soybean cyst nematode. In other embodiments, the method further comprises detecting at least one marker profile or haplotype associated with resistance to soybean cyst nematode. In further embodiments, the method comprises crossing a selected soybean plant with a second soybean plant. Further provided are markers, primers, probes and kits useful for identifying and/or selecting soybean plants or soybean germplasm with improved resistance to soybean cyst nematode. | 12-29-2016 |
20160377608 | METHOD AND ARRANGEMENT FOR DETECTING BINDING EVENTS OF MOLECULES - Method and arrangement for detecting binding events of molecules, in which, to at least one first molecule which is immobilised on a bioactive surface by a covalent bond, at least one second molecule has been bonded or is bonded, with formation of at least one specific non-covalent bond, the second molecule being bonded or having been bonded chemically covalently to a ligand. The bioactive surface can be contacted with at least one analyte molecule, binding events between the analyte molecule and the ligand being able to be detected by means of an analytical measuring method. The at least one specific non-covalent bond between the first and second molecule is breakable again by supplying a buffer solution. According to the invention, a third molecule is bonded to the second molecule, the third molecule also having a ligand. A specific ligand, or two specific ligands which are different from each other, can hence be available on the bioactive surface in an easily reversible manner, | 12-29-2016 |
20160377609 | TEST SYSTEM AND METHOD - The present invention relates to an apparatus for detecting compounds, the apparatus having a device defining a disk-shaped geometry, the device having a centre, a plurality of fluid channels each comprising a fluid inlet positioned at a first distance from the centre and a fluid channel end at a second distance from the centre, the second distance being larger than the first distance, one or more sensors arranged at each fluid channel, wherein the sensors each comprise at least one optical detectable member, the test apparatus further comprising one or more optical sensing devices arranged for sensing the at least one optical detectable member of the one or more sensors, and a rotation device adapted for rotating the device so that the sensors pass over the one or more optical sensing devices. Further the present invention relates to a method for determining compounds comprising providing an apparatus for detecting compounds having a device defining a disk-shaped geometry, the device having a centre, a plurality of fluid channels each comprising a fluid inlet positioned at a first distance from the centre and a fluid channel end at a second distance from the centre, the second distance being larger than the first distance, one or more sensors arranged at each fluid channel, wherein the sensors each comprise at least one optical detectable member, the test apparatus further comprising one or more optical sensing devices arranged for sensing the at least one optical detectable member of the one or more sensors, and a rotation device adapted for rotating the device so that the sensors pass over the one or more optical sensing devices, the method comprising: providing a fluid at an inlet near the centre of the device, rotating the device, and obtaining properties of the sensors using the optical sensing devices. | 12-29-2016 |
20160377610 | FUNCTIONALIZED BIOCHIPS FOR SPR-MS COUPLING - The invention relates to a method for coupling in-line the analysis of molecular interactions by surface plasmon resonance (SPR) with a structural identification by mass spectrometry using the same functionalized support for both types of analysis. | 12-29-2016 |
20160377612 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF BIOLOGICAL PREPARATION ON RHEUMATOID ARTHRITIS - The objective of the present invention is to provide a method for simply, inexpensively and accurately assessing, before administering a biological preparation, the therapeutic effect thereof (in particular whether there will be a complete response) or the improvement of symptoms in patients having rheumatoid arthritis. | 12-29-2016 |
20160377620 | COMBINATION HEPATITIS C VIRUS ANTIGEN AND ANTIBODY DETECTION METHOD - An in vitro method that allows detection of hepatitis C by detecting hepatitis C virus (HCV) core protein and antibodies to HCV core protein (anti-core antibodies) in a single assay is provided. Cross-reactivity is eliminated in the method preferably by utilizing short peptides, each of which has an amino acid sequence that corresponds to an immunodominant region of the native core protein but which does not wholly encompass the epitope bound by the antibodies utilized in the method. The method can be used to detect the presence of HCV in a subject, and/or to determine the suitability of donor blood or blood products for transfusion purposes. Also provided are diagnostic kits for carrying out the method and a process for selecting suitable capture peptides and monoclonal antibodies for use in the combination method. | 12-29-2016 |
20160377627 | METHODS APPARATUSES AND SYSTEMS FOR DETECTING AND QUANTIFYING PHOSPHOPROTEINS - Embodiments herein provide methods, apparatuses, and systems for detecting, monitoring, measuring, and/or characterizing the activity of phosphoproteins such as tyrosine kinases (TKs) and downstream proteins in TK signal transduction pathways (e.g., TK pathway proteins). In various embodiments, the methods, apparatuses, and systems may use nanoparticles, such as quantum dots (QD), to detect and/or characterize the abnormally overactive TK signaling pathways that underlie tumorgenesis and tumor progression. In various embodiments, the QD-based methods, apparatuses, and systems may have a sufficiently high degree of sensitivity to enable the identification of new TK signaling pathway markers, for example for use in diagnosing, staging, monitoring, and/or prognosing cancers, or in evaluating the efficacy of cancer therapeutics. | 12-29-2016 |
20160377640 | SYSTEMS AND METHODS FOR MULTI-ANALYSIS - Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample. | 12-29-2016 |
20170233496 | AFFINITY PROTEINS AND USES THEREOF | 08-17-2017 |
20170233726 | Method for Making an Enriched Library | 08-17-2017 |
20170233790 | NUCLEIC ACID INTRODUCTION METHOD, NUCLEIC ACID DETECTION METHOD, BIOMOLECULE ANALYSIS METHOD, ARRAY DEVICE FOR BIOMOLECULE QUANTIFICATION, AND BIOMOLECULE ANALYSIS KIT | 08-17-2017 |
20170233791 | METHODS AND COMPOSITIONS FOR PCR USING BLOCKED AND UNIVERSAL PRIMERS | 08-17-2017 |
20170233797 | Microfluidic Devices, Solid Supports for Reagents and Related Methods | 08-17-2017 |
20170233799 | METHOD AND APPARATUS FOR ULTRASENSITIVE QUANTIFICATION OF MICRORNA | 08-17-2017 |
20170233811 | DNA ARRAY FOR DETECTING CANINE TOLL-LIKE RECEPTOR GENE MUTATIONS | 08-17-2017 |
20170233814 | MICRORNAS CHARACTERIZING ROSACEA AND THE USES THEREOF | 08-17-2017 |
20170233815 | HEALTHCARE DIAGNOSTIC | 08-17-2017 |
20170233824 | SYSTEMS AND METHODS OF DETECTING SOLID TUMOR CANCER | 08-17-2017 |
20170233827 | METHODS AND COMPOSITIONS FOR PROGNOSTIC AND/OR DIAGNOSTIC SUBTYPING OF PANCREATIC CANCER | 08-17-2017 |
20170233828 | GLYCOSYLTRANSFERASE GENE EXPRESSION PROFILE TO IDENTIFY MULTIPLE CANCER TYPES AND SUBTYPES | 08-17-2017 |
20170234854 | FRIZZLED-BINDING AGENTS AND USES THEREOF | 08-17-2017 |
20170234866 | MULTIPLEXED LATERAL FLOW ASSAY | 08-17-2017 |
20170234867 | QUANTITATIVE LATERAL FLOW ASSAY | 08-17-2017 |
20170234882 | METHODS OF DETERMINING A PATIENT'S PROGNOSIS FOR RECURRENCE OF PROSTATE CANCER AND/OR DETERMINING A COURSE OF TREATMENT FOR PROSTATE CANCER FOLLOWING A RADICAL PROSTATECTOMY | 08-17-2017 |
20170234886 | MULTIPLES IMMUNOHISTOCHEMICAL ASSAY USING PRIMARY ANTIBODIES OF THE SAME HOST SPECIES | 08-17-2017 |
20180023116 | METHOD FOR PREPARING SINGLE-STRANDED DNA PRODUCT | 01-25-2018 |
20180023120 | Methods for Preparative In Vitro Cloning | 01-25-2018 |
20180023129 | MULTIPLEXED ANALYSIS OF NUCLEIC ACID HYBRIDIZATION THERMODYNAMICS USING INTEGRATED ARRAYS | 01-25-2018 |
20180023138 | Assays for Single Molecule Detection and Use Thereof | 01-25-2018 |
20180023140 | ARTICLES FOR DIAGNOSIS OF LIVER FIBROSIS | 01-25-2018 |
20180024030 | DETECTION OF LOW CONCENTRATION BIOLOGICAL AGENTS | 01-25-2018 |
20180024055 | Optical Sensing and Separation Based on Ordered 3D Nanostructured Surfaces | 01-25-2018 |
20180024125 | SUBSTRATE/PEPTIDE/LIPID BILAYER ASSEMBLY, PREPARATION METHODS AND ASSOCIATED DETECTION METHODS | 01-25-2018 |
20180024130 | DETECTOR AND RELATED, DEVICES, METHODS AND SYSTEMS | 01-25-2018 |
20180024134 | IMMOBILIZATION OF CELLS OR VIRUS PARTICLES ON PROTEIN STRUCTURES USING A MICROFLUIDIC CHAMBER | 01-25-2018 |
20180024143 | PROTEIN AND LIPID BIOMARKERS PROVIDING CONSISTENT IMPROVEMENT TO THE PREDICTION OF TYPE 2 DIABETES | 01-25-2018 |
20180024146 | ALZHEIMER'S DISEASE-SPECIFIC ALTERATIONS OF THE ERK1/ERK2 PHOSPHORYLATION RATIO-ALZHEIMER'S DISEASE-SPECIFIC MOLECULAR BIOMARKERS (ADSMB) | 01-25-2018 |
20180024152 | HDL-ASSOCIATED PROTEIN BIOMARKER PANEL DETECTION | 01-25-2018 |
20190144853 | TARGETED IN SITU PROTEIN DIVERSIFICATION BY SITE DIRECTED DNA CLEAVAGE AND REPAIR | 05-16-2019 |
20190144927 | METHODS FOR GENOTYPING SELECTED POLYMORPHISM | 05-16-2019 |
20190144930 | ENHANCED METHODS OF RIBONUCLEIC ACID HYBRIDIZATION | 05-16-2019 |
20190144946 | MUTATIONS IN THE BCR-ABL TYROSINE KINASE ASSOCIATED WITH RESISTANCE TO STI-571 | 05-16-2019 |
20190145971 | Lateral Flow Analyte Detection | 05-16-2019 |
20190145986 | REAGENTS AND METHODS FOR DETECTING PROTEIN LYSINE 2-HYDROXYISOBUTYRYLATION | 05-16-2019 |
20220136034 | MICROFLUIDIC SYSTEM FOR AMPLIFYING AND DETECTING POLYNUCLEOTIDES IN PARALLEL - The present technology provides for an apparatus for detecting polynucleotides in samples, particularly from biological samples. The technology more particularly relates to microfluidic systems that carry out PCR on nucleotides of interest within microfluidic channels, and detect those nucleotides. The apparatus includes a microfluidic cartridge that is configured to accept a plurality of samples, and which can carry out PCR on each sample individually, or a group of, or all of the plurality of samples simultaneously. | 05-05-2022 |